<SEC-DOCUMENT>0001558370-24-003436.txt : 20240315
<SEC-HEADER>0001558370-24-003436.hdr.sgml : 20240315
<ACCEPTANCE-DATETIME>20240315171321
ACCESSION NUMBER:		0001558370-24-003436
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		150
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240315
DATE AS OF CHANGE:		20240315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		24755904

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>chrs-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:chrs="http://www.coherus.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" xs:nil="true" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_t6jFhJBbhkKHfxOGu1jTgA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" xs:nil="true" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_BjE3iFxCZkGPiWaFAMkLBg"></ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_LHX0qd3ip0i6d6fhQPx3CQ">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_Vr8K8LWppE6G3mquOm9drQ">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_Moa6JZuMv0mJTSdRd1DFlg">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_BVLNcymS4EaV3DJ3plJTVg">http://www.coherus.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_c5lAcKOcVkil8kEMNgNApQ">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_11BhQSEL3km5vBJeD_RAsQ">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityCentralIndexKey" id="Tc_DwcuEkqWB0mqmuX8ExLV9w_2_1">0001512762</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:CurrentFiscalYearEndDate" id="Tc_btjtpCePKk2-v5ikv70FRA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentFiscalYearFocus" id="Tc_vE_F7BUjlESZrg-lq84LFg_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentFiscalPeriodFocus" id="Tc_QwKca6CpGUSPCfLSDTRSXg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:AmendmentFlag" id="Tc_R-ikeEMa50SHTZi_r4tvbA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_--szY9Mda0qUwes4reSEXw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_OYWDmfmE_EWMGnJd8jiObQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" id="Hidden_rRMf5nysqEO0xgC7AyVmnA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" id="Hidden_V9mVERuzDUyFPQ0FF4cI4Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" id="Hidden_ifXNjsyJr0WWF5FEEv1GQg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_v4oTsv095Ua3rj9SnG6xIw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_tWVxfTC3cUmEtX68kvPusw">78851516</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_mr4oREKsHEmMwylrOmO9ow">112215260</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="0" name="us-gaap:DerivativeLiabilities" id="Hidden_YgjkhDQ6bEeOg5gUe8O-fQ">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="Hidden_-IH_mKjA6U6bK5tk5yUUQQ">http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" name="chrs:CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" id="Hidden_RNOKr2yfgEaTSaGdgRnfUQ">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA" name="chrs:MandatoryPrepaymentTerm" id="Hidden_9sZZOOI5Ik6UXQMv7GKoqA">P10D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_QSE5TXfKi0yFbPvOeiAHDw" name="us-gaap:LeaseExpirationDate1" id="Hidden_fHNXk8VMLECyy9jYAF_Fdw">2024-09-01</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_QSE5TXfKi0yFbPvOeiAHDw" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Hidden_VkjnRAfIcEy-ZaCcc2AiFA">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_NewCamarilloLeaseMember_1n1rY0uyP0KFXFjXo3Ns4Q" name="us-gaap:LeaseExpirationDate1" id="Hidden_2eeuHZDPwkuwZhYvkItgaQ">2027-05-01</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_NewCamarilloLeaseMember_1n1rY0uyP0KFXFjXo3Ns4Q" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Hidden_TfxsXMoIkUuAjOrWK1_x9w">true</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_-mf-ZxnNGEipJwEpza_71w">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_WgpZY07_p0GbKqCO5gEf4g">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_liJO04hsZUOJwgNDIHYjyw">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_TFQ5qkqFP0exAVaWIavjVw">http://www.coherus.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_ieMrVFi9_UGwUiP2AK3LZQ">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_wCWMjCewb0K1TBEZgR53KQ">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_4_2023_To_10_4_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_HOqnw3R6o0K280PJUueNGA" name="chrs:NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" id="Hidden_I67Wh2887EWvSltZhszIEw">P10D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gK5gYMN5WUG2uYVdwePLuA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_AKrDviHwTEWrO6-oIS4MzA">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_31_2014_To_10_31_2014_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_pTatCpQza0uNROYRLjt8pg" name="chrs:EmployeeServiceShareBasedCompensationOfferingPeriodOne" id="Hidden_VnDr0p6zgkaCQAXWjop8Wg">--05-16</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_31_2014_To_10_31_2014_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_pTatCpQza0uNROYRLjt8pg" name="chrs:EmployeeServiceShareBasedCompensationOfferingPeriodTwo" id="Hidden_y3PMsjUAX0CNLgPeFQI8aw">--11-16</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A" name="ecd:Rule10b51ArrTrmntdFlag" id="Hidden_DILPxNagiE2rs6ISbTZ4RA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_6muBIslFhk2zKGVekJX6QA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A" name="ecd:NonRule10b51ArrTrmntdFlag" id="Hidden_YgjPL260ZU2HOBfFy0NsgA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A" name="ecd:NonRule10b51ArrAdoptedFlag" id="Hidden_6Ta87eBqSEq-2bamScPPEQ">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="chrs-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_-SnhX9CP50mp8ATn7g01-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5guUqMGHzkGsdOQekHmiiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_942S1mhLyka6ZkBmZenXDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IqHD8wCCtk-Oe0InVzTD9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_kZ0HsUuPOkSNL1EUtnGJbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_sWN29oXoPUKV6kz5vOqq8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_e1HpM3V8pkO34aP3JnxjLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_X0KeVsHZyUSbmqBiyMUPOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_DuLOSPFfNUakKw9YrfEp6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">chrs:ChiefMarketingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-09</xbrli:startDate><xbrli:endDate>2023-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_sKhnfgNtxkaJ97AXUGzpNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_0oZWQSLFL0e-jivOJv3aGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IWhFYTVSXEG3Qc-xyQ609A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2ZR7usP3sE6lA9rxzLUIRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF-Oa2qAakqTeMwji5pTSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wRFs1JzPGkC_zfkTJLKIXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6C9ecxQ_QEG8bE7IGXl6xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8tkQ9GUbnkaeOclpHWkaYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zxmvh3LGk0mrm79pZRE9ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-x0yoCYUqUKXgofi_PW4rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JlI5BNiMwkCobaOJnCtF4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_js5PyUWww0i7olNWi5CL6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T9fLg1zdZUuTqPJFq3Ewmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EqOtkI14-kOGNRiKyN0UaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OvQzecJ6mUOHxhU6qoAvsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_bovPFj58gkCF6OVAq9cZrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">chrs:ChiefMarketingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_1ztFg0EZYE-MyDgGu8F23A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_BTKj2cvojU24AiFKRX3zBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_14_2020_lOYMm8IewEGa7ecW7rCQ6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange5.86To10.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange19.85To46.38Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange17.30To19.40Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange14.03To17.17Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange10.37To13.63Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange1.67To5.44Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange5.86To10.05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange19.85To46.38Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange17.30To19.40Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange14.03To17.17Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange10.37To13.63Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange1.67To5.44Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2014_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_9Fk-bFLoyEefRodmTzt7Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandTenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gK5gYMN5WUG2uYVdwePLuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZaEeUbUKZ0m5v1ED2M0RTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_z6Il8N4kPkqJ7o0Wx5ZYXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_yD1xE6Kl5kOzUlgXuDoYKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_YusimryMember_Aem49C8g_EO-UPcinAmbWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:YusimryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_UdenycaMember_SS-iB5-1RkODBPDHZukxAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:UdenycaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_ToripalimabMember_fUCqK5DU-kekHTnpp0vwtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_CimerliMember_kv6U35_BGUWQFIX2et6tLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:CimerliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_KNuuvD7dxEO2mjwTXA6LtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_f8r-3G-5Wk-nnxPCHpt2WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_UdenycaMember_OBt5e09w-U23AKziLIjkeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:UdenycaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_CimerliMember_Yi451Ksh7ku2qLqz_SNLxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:CimerliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yRtnhYcLKki9OALzaJd-_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_JMBKRfq1M06yP1UncYP2wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_chrs_UdenycaMember_YyirJnaG_EuVQxR4eipeHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:UdenycaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_PdGnVstbm0yndk6laylDZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2023_To_3_10_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_4wHJPeiz5EGGZlHVcqOJhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iP1gAk8B10WNqliDVtY6VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_tM3Ef_Mpak6Ub3zq_1vXxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_bli3D_4p8Eu4TDVPspP6-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_cWwUSInfWk6DbOgC8phq1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0Z36Will8EWLyeJWTqBk6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_R1ZNIhTdtU6PTDnnezToVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_CmUnXGsYHU-xLi_OavbKiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_6mauAg9SEkCGnWzdOVcIUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_q4XQKvn7hUuMY-hLmFDudw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_YjMCSisOdUGXZi2xqln_Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_XQIUc6d-XUmksooC86ywXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qgwSy_5jP0WkljoCN5grsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lMgSkORl9USZXjMIwMYQHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_0z3z_qR8HkiyEEOaFlpNTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_jucBH5LjrUK46koXbkAVgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_oL0nzgyjPkiv7bL6dvw4Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_NxhQ8-y-vE-qqYM8KM5CLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:Chs2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_5VUKYAUWS0WOL1uTbEXYnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-18</xbrli:startDate><xbrli:endDate>2023-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_RpO-Vx6ls0enT64RbZm2Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_chrs_JunshiBiosciencesMember_3vcTLYS0gkekD3G2uhqorw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_drbbzBbCqEO7LriCD-yj_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZLR_IWpbikGexBZ7BUjpdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_S-PFsrc-YEyD32_Z5ut0iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Pnm4g_v2k6bFQvlK9UGDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_PoW1P6R9s0CVYOhvmiJS7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_trchcL8ElUmTtWSY92BZ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsFNWbdr7UWhpxeQGE8rJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VcpbTyhPOkKFIXTOT5V2DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_2TW5nZJ8wUWRYttn81wTMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedRebatesFeesAndReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_u0BIpPgozk2LV-saZBzeXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedRebatesFeesAndReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_l7MKURXDWkyyeEGasiZroA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_12_31_2023_Oq6suCh5tUWT6TFeG9xafw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_IkAU-wbfW06hNr0VdkRc-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:VehiclesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_NewCamarilloLeaseMember_1n1rY0uyP0KFXFjXo3Ns4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:NewCamarilloLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_QSE5TXfKi0yFbPvOeiAHDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:CorporateHeadquartersLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_YusimryProductMember_-J7VNgvVG0G6bkwKupKhUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:YusimryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_UdenycaMember_couIVXZw9U2OdgPC4e_wMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:UdenycaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_Loyb6ABkV0CqKB-V5_uHvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JoIcCfI8pEKowyCw3vvEBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yPqNV7UizkyOlrp2llCvgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_v9SRmwDa7E2QVcIw31qKkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_Pb1Z3ozRJkOA77OkYuNphw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_s5c_u_nwN0uYnEawr_ZR3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_fo0yiw1iyUiG0i_wC4e7wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_Plan401KMember_GZqVTPVTJESoNA_KLec_Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_Plan401KMember_vkpLaKLvgkiXZssii_XeDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember__qTNMulPqkyLxoNEOq3P_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_Z0wbfOYnWk6X7ZFZMIo1Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-u8VFwKaq0W-VpOwOG1Tug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-07</xbrli:startDate><xbrli:endDate>2019-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2019_To_1_7_2019_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ESE6x74w_0eBsyYKVq7Vhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-07</xbrli:startDate><xbrli:endDate>2019-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_IYOtI7t0s06IRoQfEZsvfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-29</xbrli:startDate><xbrli:endDate>2016-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4w3mHtTbxUO8oH0eEffh_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_DixWwtQqF0uRVadXYuAfNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2020_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_9RhPVS_PkUqmSIIeRzY6ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_cTMkGi5D4E2X87OVhy9Ppg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheDLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_M-uRNszAXEi9r-8LL3xQhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bYNDamUcsk2slttHQRFDdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_UbIxb6J1Y0GS_zqAinL_8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_4dYZePFHI0uh8xLaZDgW8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_2LOhPFc_bEyFVajuBKg_hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:KKRBiosimilarLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_MXIIAssociatesLLCMember_dlXABsWvD0ytszx5uH9T9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:MXIIAssociatesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KMGCapitalPartnersLLCMember_gM38q0-qfkqM70dI2BG3iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:KMGCapitalPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_VEix4k9_P0C5vL3mOkva7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:KKRBiosimilarLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_chrs_ThreeMonthLiborMember_SFCa5VQ500OXf47jZb2Inw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">chrs:ThreeMonthLiborMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mz08bJgB4EaXuGX2fTgvhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pmdNhIdK2kyIctMI_ST38Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hcVA_aikGUy_-SUX6FtLgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">chrs:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dUP-XGp_40W0Jk2_k2_aaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">chrs:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_bG3CyRk7Ckyq7Y946J92rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_JgK6Pnltr0iCDbO6eeuWPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sysHEkDeMUeiH_xQmMEqHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Ip4i_KQKSEGmi48UbBbU4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RLQcDbciHU-31RTWPiRddA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R15nhg7ueUmpYAw1PVmVYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_awtJ_xuQLE-3TKhXeZPfnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_rgJ5WsHKGE6cmgscswHw3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_2Jb4uL_RpUq98xojm1NbWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QFSyxqW7LU6FdbrdJ_hL6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_86rzXe3xOEmTHUqRT8IxuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jT2bvCGQeUqvA48e-rmNXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_5TOTwxrkukmWntYx2iyH2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandTenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_Hh7T20nqkUe4hvfBDJLy5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EmploymentCommencementIncentivePlanMember_PYQsmuC8gEmAkSzwx_wKQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EmploymentCommencementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_zLRTOCdaDkGr-Wlc6H94QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_BPCdvDMynEyiPHvB9x6iQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_pOfVd5Rj4Eum4N-4rVrphQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithNovartisInstitutesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_aK8ibHz1PEqs0z1M6Yn7Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithGrkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf388Member_2lO8XAyg6UKhnOMI1Zafnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">chrs:InProcessResearchAndDevelopmentSrf388Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf114Member_MCpWdvb_hUWv00leqUKNEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">chrs:InProcessResearchAndDevelopmentSrf114Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_9_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_rkk2bVd2PEWq4HB48Bymrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-09</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_x0b6Pn8B7UCsaUPMe0v01g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_jcZy0wFZJEaEwLSiKmitHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Q3N2Kq2ULUiYN4xUaP-tWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_GPeCZEn7kE-kP1gzmLw43A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_frQuFnuBxEq5QXwcCjbX7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uqXRAvtuPU-XGMoUQjrc2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LA2YAsqsu0CpSSrrZHjsug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M7126HnRO0qaXeQIsFj8pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uGXcRbQazkuREy28y8WrtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:PrepaidExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_2BjSULWChEWs710kn9cfgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VSDrzPQUwUu7_hzLLjkspg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_mU8Xaof7xEm7Zbk_ZFo9-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__89KIdAh-kybMMe17Uup0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ms9aAG7KIkGkwghMFQVoVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nz62sO_ud0WlWk86bTugEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TO8ess3RJkWPdTQJVaqKPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__TxWSJDseUuXN-WFeLop7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:PrepaidExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bSSUTn6bQUCMiUY_ocTL-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_8fbTc7hIa0utRNZd1eRxfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_TwVcSvlCtEijskcFydA41w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_prYGlg4f4U63CuX4vjb7Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LQWs2-eMdE2bcCcsGBh6vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_v32YInlozkipoEXkDWXGJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_qVO9cnI0VUC56AJulEuw6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_rEMXEsXhaEWSunlNBcnl4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_LaboratoryFacilitiesLeaseAgreementMember_eWCVJY2d0Uy0fzrMJb295g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:LaboratoryFacilitiesLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_4-NTVWKntkKpLY2m9obR2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:CorporateHeadquartersLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_24_2023_us-gaap_LeaseContractualTermAxis_chrs_OfficeSpaceRemainingPremisesMember_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_1ikJXPlaT0qaIZD07NCcJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">chrs:OfficeSpaceRemainingPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SixthAmendmentToLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_24_2023_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_2VupKf10C0ysFKHcmA-N7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SixthAmendmentToLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_trJKeZ-blEWFIlIsmGdHcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_AYPPQ8ihj0mbo87bSd2xhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_CTwRAY9QGkWlaOjDUS3erA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6-wHjlrUb0eK7XFKJFi0cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lJUaials20Ozgd2f9R3-Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8C3aK0xQf0Go0f8lJiI49A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_w5gYK5ZD10mxWUfBk3mCAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nDHklqDsSkqnJXBtDs4Nbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_7tgQKK_EDUasryLtCO67SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pQgsHAcxhEiHaH9C5c3xTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_yimB1PocVk6HJoJLxYsOcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jItQvbGTK0Sy8MYmJwHtDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wrjDrMYWnEG3vQ3_hGdwAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_V7Ntz2koqkOY3qfjC84Z6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rdMdgsUj7kOwcgAE94-32g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_yPWVLupjLUC-LrZ0QvW9YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_NvtDoX2JKU-V8xqMiC3p8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_X4a12fHdGkKcfkBHCiHSBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Lv-W7pNdHEiIdf02okAMpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_i6sG_wGq0kGSogKwmLXRFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_08hF26t1CE220LggkCbdaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithNovartisInstitutesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_Db9iHsTjOk2dnST6JR1wPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithGrkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_81rW7yIWNEmb6m_5_UL_5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2024__Ij5iegjlE6VjA_i4djOuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_rO5PqjjHM061tAOT8W_pJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_n-FydJrePEuzzIDzlXSx6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_bjX_QmuqBUiNiIM7YQU9cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_4fiZbKl1c0-rDjVdhAf4iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_7mQuJY0wwEqgj61CikPPcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_oW7u_hLkakKhdnoyoEmKmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_RCrhOsC4rUSwHbQXRXofbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Y1Km_JnNyku-WuF69J4RdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-16</xbrli:startDate><xbrli:endDate>2023-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_15_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_xIobUuv7xkaTn4Q-FI1LMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_11_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_D_dyxc-7bk6FZ7_nraT6IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_t94RIbg44kqe6E07Ycbe0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_15_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_f9ef-yFAYEWYmhIzUHYLVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_N0EdjlOAy0Sqb92Q_d-eKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IQec6wbqNkyXTV-ONWSp-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_1_2019_peTS_V4r30KWdrPrMS7BCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JuDeIjk7WEOxnh8sAqvA9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_CPtilZC0L0K1V6_IsNLFKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_fqcHXPJqtUOZjDirZssjWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_PmryB88z9UeGYuVn9_eCHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fLywbKoRN0OM9lBXBdTjtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ahBUQTlFkUCSXShSrIOSkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUQLjzgmQ0O_aiicO1YWSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_DPP_6bC4Yk26dzFhoz_XuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_Ayc2h31NhkepkMrVbtGURA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUbaaM5xv06IKYj90EnrjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_TQp5WTVb9EWxY7FxWuYu-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_-COT1WJ3EUuvoamMLm5fRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2014_To_10_31_2014_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_Y3ICWQYaSEa4JfXz8gYGiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-31</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_7crZcL4mN0ypA7JbGnmqqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_13eeoeTRfk2iZ3H7ofLzJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_1_31_2016_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_0C2GDS067kqyEScTv50pUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_LoqtorziMember_z2kc3sXj-0-3-XUzY_VHZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:LoqtorziMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_2_2019_To_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_iS0ub3fSH06yefAa2ICMew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-02</xbrli:startDate><xbrli:endDate>2019-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_gVOkBFt9vUSNT22wfjVu6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v-ug3g3l80mlObh8LcgInw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_tLJFKpYaNUKKGQtoFUHYZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Mozz1GcMBEOZ4p50-Yzzeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_AndqifxXsEG2Tfoo9es73w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:VehiclesLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_4_2023_To_10_4_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_HOqnw3R6o0K280PJUueNGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">chrs:ChiefMarketingOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_0bsmQzQVxkiRBstBPBwZjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rrL79xCbSEKm0OK1XTANMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2024_To_2_5_2024_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_otbpUOnq8EKYMPXpah8q6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_yd1vkuCA00aL3Hm8mfet-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-04</xbrli:startDate><xbrli:endDate>2019-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2023_To_9_11_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_wNY0LcAqy0m5BY-y3yR8Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-11</xbrli:startDate><xbrli:endDate>2023-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uXbjzY_AUkS5DM3UL80JAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2014_To_10_31_2014_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_pTatCpQza0uNROYRLjt8pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-31</xbrli:startDate><xbrli:endDate>2014-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_H5jjpUn1Hkae89daAw6YHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_aM31ORVDHEOXDbOoQGO-Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_OaNk_89S-kO2L5QxklSuhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_G4zeUvb2AkiJrpZxrWkJfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wOrFEBBx0kqCfY3Jfb9mmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_F3uuUNoynEGVqfaLmbmpNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_MV06IYXPdkmqFzBkwhBAXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_5_2024_To_2_5_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_F3gEcw2SlkGZ3F3ZhhXOuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_hK4XJ0wrhk2gRd8IsFyEIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_hh8Bb6a9E0Co_wILfDg5zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_GKvVg5Ic6ES4-RDKrSHttg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:NovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_K1geY-rGLEiNymNh_P6jTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_-QTpVgOnZUGGQfnOSlwd1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_zOQpf9YQJEWfttgbnzt7Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_HSE0jmg2IUOdXIECBGmidA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_dei_LegalEntityAxis_chrs_SurfaceMember_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_gfCoLb-ssE-NI0WQHzEhdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">chrs:SurfaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:GskAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_QfB80gafZEu1g-1S9zIihw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:AntiTigitAntibodyAndIl2CytokineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_5YqDtd4hEUeB-HOMwGXqCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_23_2021_To_3_23_2021_us-gaap_TypeOfArrangementAxis_chrs_VaccinexLicenseAgreementMember_WDAN8bKZtkOa0CTw_Zz0iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:VaccinexLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:AdimabDevelopmentAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:GskAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_2WiqeL2ms06O_McAP8cV_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_RzvldwJEbE2sTE9gTKsnIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rVWYKaHlykapW6Ik8MkDUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_wPWUD9JeY06Jz0STfXnoNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:CoherusOphthalmologyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">chrs:CimerliDivestitureTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_XCQ--7iqDkm-4Cxl9nIn8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceSrf388ProprietaryDrugProductAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_dcELaaK_i0Oi3XQ1ke-MNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceSrf114ProprietaryDrugProductAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceNovartisAgreementMember_gPSalh4re0SjsDIBtluNVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceNovartisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceGlaxosmithklineAgreementMember_HFnWjX4pcU-dEYSrnOgYsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceGlaxosmithklineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-08</xbrli:startDate><xbrli:endDate>2023-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rKbabCHH6U2-QciM6M39Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_1YkpEyUoQUqaZRiv-_dAXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-04</xbrli:startDate><xbrli:endDate>2019-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_v--BLMYsNkKl0zxMmYmYEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_position_Q8MGuTzVYkuWPpfxSr2J5Q"><xbrli:measure>chrs:position</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_AAmVcdTDXkmNakyN2ltl5g"><xbrli:measure>chrs:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ"><xbrli:measure>chrs:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_ZKmzrBOMS0eN5e6PQhEzOA"><xbrli:measure>chrs:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_SdGd84au20GyPZXZYh-a9w"><xbrli:measure>chrs:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:12.21pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_92cdf6a9_548e_4c74_b704_8a364536553d"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentType" id="Narr_PRVSSd-3MUm0WgggZSgpZg"><b style="font-size:8pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentAnnualReport" id="Narr_8u75Aw1WhkaFjLDwyIZjPA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentPeriodEndDate" id="Narr_4kZe8V7nQ0KYEHHYp0QYnw"><b style="font-size:8pt;font-weight:bold;">December 31, 2023</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentTransitionReport" id="Narr_J9dvC0PieUGUPso3MnIsZg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">For the transition period from&#160;_________ to _________</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityFileNumber" id="Narr_9ev_Ep2aJEqyUO4yGWZxtA"><b style="font-size:8pt;font-weight:bold;">001-36721</b></ix:nonNumeric></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityRegistrantName" id="Narr_B1ulcpQ_UUCZeLDvbMMnVw"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:4.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_ba17ef22_755c_456a_9087_002033fdfbe0"></a><a id="Tc_Tt1QAWe59UKJIUoJnUaMTA_2_0"></a><a id="Tc_oi9Lt4tNq0KvaqsfcGrC_g_2_2"></a><a id="Tc_eMcs89XE30yG4YZwHWgplg_4_0"></a><a id="Tc_KNz-S2cMkU2gXtfP-hjnzw_4_2"></a><a id="Tc_cRTXtjU8eEGHp62sDim3JA_5_1"></a><a id="Tc_ky4zUVqmgkacC9_kDb509g_6_0"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:45.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:45.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityIncorporationStateCountryCode" id="Tc_KASEaoOMg060DHV46PEc2w_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:45.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityTaxIdentificationNumber" id="Tc_vk7Rrw4TZ0OppGSyvjpmwg_1_2"><b style="font-size:8pt;font-weight:bold;">27-3615821</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:45.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:45.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:top;width:45.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:45.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressAddressLine1" id="Narr__5gTzCILyEab1S8LO7sh0w"><b style="font-size:8pt;font-weight:bold;">333 Twin Dolphin Drive</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressAddressLine2" id="Narr_8jRDPDdnmkm25Bao3x28Xg"><b style="font-size:8pt;font-weight:bold;">Suite 600</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressCityOrTown" id="Narr_UkfxB5K8n0SbknGrJ0YMeA"><b style="font-size:8pt;font-weight:bold;">Redwood City</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressStateOrProvince" id="Narr_R2FgLZlAXEeR9NDB7VhxFA"><b style="font-size:8pt;font-weight:bold;">California</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressPostalZipCode" id="Narr_57DqluQ1CUe-5TOPcHD_oA"><b style="font-size:8pt;font-weight:bold;">94065</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressPostalZipCode" id="Narr_aA5zs6Wr10y9OhOqBFE3Qw"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityAddressPostalZipCode" id="Narr_PZOo7dMla0iaEo0bGkNqKQ"><b style="font-size:8pt;font-weight:bold;">94065</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr><tr><td style="vertical-align:top;width:45.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:CityAreaCode" id="Narr_i4uAxyk0r0ueDURIBERhEQ"><b style="font-size:8pt;font-weight:bold;">650</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)</b><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:LocalPhoneNumber" id="Narr_JoEjqgi4rkGPwn5Qv36vUA"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:LocalPhoneNumber" id="Narr_4LfqbZoDHUCHXWwmIDMkiw"><b style="font-size:8pt;font-weight:bold;">649-3530</b></ix:nonNumeric></ix:nonNumeric></p></td><td style="vertical-align:top;width:45.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_538417b9_f0b5_44a1_812f_c2db3375bc37"></a><a id="Tc_sg2bLL6cd0-A6TQ5HyWUdg_1_0"></a><a id="Tc_Zig7-Uoyw0OyBLsVdrI0EA_1_2"></a><a id="Tc_htRPJDoIfE2VNG_Q0oJBdw_1_4"></a><a id="Tc_ppPc5RLzLEubR6dwWMVxtg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.69%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.72%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.69%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:37.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:44.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:37.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:Security12bTitle" id="Tc_HuYj8c6uXkipD5xnHhcjBQ_2_0"><span style="font-size:9pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:TradingSymbol" id="Tc_UMJJY9ToikmDeoRhonmZUw_2_2"><span style="font-size:9pt;">CHRS</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:SecurityExchangeName" id="Narr_VmXrZgJ69U63ZL1COQuF9Q"><span style="font-size:9pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:9pt;"> Global Market</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities Registered Pursuant to Section&#160;12(g)&#160;of the Act: None</b></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:3.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_SeZs3MIl00u_2NKTS-Yjzg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityVoluntaryFilers" id="Narr_8uapNHMne0yYkrQB0u8ogw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period than the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityCurrentReportingStatus" id="Narr_EGUfIQVd-kul_Mz9KUR0kg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityInteractiveDataCurrent" id="Narr_PtTMGTxYgUa36F9pjAedVg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_44693648_a5e7_4ad0_83d7_b30256a5ad26"></a><a id="Tc_EcCJAtUzT0WfHAZhdILg5A_0_0"></a><a id="Tc_MMge5YthwUawInMLjDOqpg_0_1"></a><a id="Tc_cn_oo1nwyke6gZZywDsDgw_0_4"></a><a id="Tc_JCyi-9_yRE6bSC3rsWwxpA_2_0"></a><a id="Tc_G-v_5tdbxEKbGE8PKZ4i8A_2_1"></a><a id="Tc_ZhsjZCgMG0yjM7N3dekLgQ_2_3"></a><a id="Tc_vUJkiTIL_0uV0E5jIDIrcw_4_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99%;"><tr><td style="vertical-align:bottom;width:22.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityFilerCategory" id="Tc_hmBl9QwsqEexM3kX8E5uTA_0_3"><span style="font-size:8pt;">Accelerated&#160;filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">Non-accelerated filer</p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntitySmallBusiness" id="Tc_rhJb_N8pikW4LBEDDxZ6xw_2_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:22.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.76%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-indent:0pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityEmergingGrowthCompany" id="Tc_1TrXdcIAl0KLmgUqlcyqnw_4_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#8217;</span><span style="font-size:8pt;">s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:IcfrAuditorAttestationFlag" id="Narr_bULlMqenvUeQIdhOxa_kXg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements</span><span style="font-size:8pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_Kr5GVaPE1ESWUOPpd_Vw3Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).<span style="font-family:'Segoe UI Symbol';"> </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:EntityShellCompany" id="Narr_-05lcIOeZkaLbB_8fMfgGQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">The aggregate market value of the registrant&#8217;s common stock, held by non-affiliates of the registrant as of June&#160;30, 2023 (which is the last business day of registrant&#8217;s most recently completed second fiscal quarter) based upon the closing market price of such stock on the Nasdaq Global Market on that date, was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2023_81rW7yIWNEmb6m_5_UL_5Q" decimals="INF" name="dei:EntityPublicFloat" id="Narr_A04NvsmG5E21GgN31I_Jig">324,137,955</ix:nonFraction>. For purposes of this disclosure, shares of common stock held by each officer and director have been excluded in that such persons may be deemed to be &#8220;affiliates&#8221; as that term is defined under the Rules&#160;and Regulations of the Securities Exchange Act of 1934, as amended. This determination of affiliate status is not necessarily conclusive.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">The number of shares of the registrant&#8217;s common stock issued and outstanding as of February 29, 2024 was <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_29_2024__Ij5iegjlE6VjA_i4djOuA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr__MubSohvDkWvsr1Iam5xqw">112,714,488</ix:nonFraction>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_kZ7hIZY6okOCTTItU63dsA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Part&#160;III of this annual report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive proxy statement for the 2024 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2023.</p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_834252b4_4dcd_4e8a_9178_f506c755c3d8"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">COHERUS BIOSCIENCES,&#160;INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</b></p><a id="TOC"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.01%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:6.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTI_789821"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1Business_217063"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1Business_217063"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">3</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_350560"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1A.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1ARiskFactors_350560"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">25</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUnresolvedStaffComments_157284"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1B.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item1BUnresolvedStaffComments_157284"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">71</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_1C._"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1C.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_1C._"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">71</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties_55198"><b style="font-style:normal;font-weight:bold;">ITEM&#160;2.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item2Properties_55198"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">72</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM1LegalProceedings_470595"><b style="font-style:normal;font-weight:bold;">ITEM&#160;3.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#ITEM1LegalProceedings_470595"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">72</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MineSafetyDisclosures_762796"><b style="font-style:normal;font-weight:bold;">ITEM&#160;4.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item4MineSafetyDisclosures_762796"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">72</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTII_514324"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><b style="font-style:normal;font-weight:bold;">ITEM&#160;5.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">73</span></p></td></tr><tr><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6"><b style="font-style:normal;font-weight:bold;">ITEM 6.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item6"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">74</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><b style="font-style:normal;font-weight:bold;">ITEM&#160;7.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="display:inline-block;width:3.73pt;"></span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">74</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7AQuantitativeandQualitativeDisclosu"><b style="font-style:normal;font-weight:bold;">ITEM&#160;7A.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">90</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8ConsolidatedFinancialStatementsandS"><b style="font-style:normal;font-weight:bold;">ITEM&#160;8.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item8ConsolidatedFinancialStatementsandS"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">91</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span><span style="display:inline-block;width:1.61pt;"></span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">135</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsandProcedures_21407"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9A.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9AControlsandProcedures_21407"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">135</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOtherInformation_597802"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9B.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOtherInformation_597802"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">137</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item9BOtherInformation_597802"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9C.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#_Item_9C._"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">137</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTIII_837998"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><b style="font-style:normal;font-weight:bold;">ITEM&#160;10.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">138</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11ExecutiveCompensation_746019"><b style="font-style:normal;font-weight:bold;">ITEM&#160;11.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item11ExecutiveCompensation_746019"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">138</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item12SecurityOwnershipofCertainBenefici"><b style="font-style:normal;font-weight:bold;">ITEM&#160;12.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">138</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CertainRelationshipsandRelatedTran"><b style="font-style:normal;font-weight:bold;">ITEM&#160;13.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">138</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PrincipalAccountingFeesandServices"><b style="font-style:normal;font-weight:bold;">ITEM&#160;14.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">138</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#PARTIV_110740"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15ExhibitsandFinancialStatementSched"><b style="font-style:normal;font-weight:bold;">ITEM&#160;15.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">139</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_259502"><b style="font-style:normal;font-weight:bold;">ITEM&#160;16.</b></a></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:9pt;" href="#Item16Form10KSummary_259502"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">139</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:bottom;width:84.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a style="font-size:9pt;" href="#SIGNATURES_311562"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">144</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">UDENYCA&#174;, YUSIMRY&#174; <span style="background:#ffffff;">and LOQTORZI</span>&#174;, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. Trademarks and trade names of other companies appearing in this Annual Report on Form 10-K are, to the knowledge of Coherus, the property of their respective owners.</p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">As used in this Annual Report on Form 10-K, unless the context requires otherwise, references to &#8220;Coherus,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar references refer to Coherus BioSciences, Inc. and its wholly owned subsidiaries.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Annual Report on Form&#160;10-K contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Any statements that are not statements of historical facts contained in this Annual Report on Form&#160;10-K may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by words such as </i>&#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;attempt,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strive,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; <i style="font-style:italic;">and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</i></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">whether we will be able to continue to maintain or increase sales for our products;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">our expectations regarding our ability to develop and commercialize our product candidates in the United States and Canada; </i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to maintain regulatory approval for our products and our ability to obtain and maintain regulatory approval of our product candidates, if and when approved;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations regarding government and third-party payer coverage and reimbursement;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to manufacture our product candidates in conformity with regulatory requirements and to scale up manufacturing capacity of these products for commercial supply;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our reliance on third-party contract manufacturers to supply our product candidates and products for us;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations regarding the potential market size and the size of the patient populations for our products and product candidates, if approved for commercial use;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations about making required future interest and principal payments as they become due in connection with our debt obligations;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our financial performance, including, but not limited to, projected future performance of our gross margins, research and development expenses and selling and general administrative expenses;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the implementation of strategic plans for our business, products and product candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the initiation, timing, progress and results of future preclinical and clinical studies and our research and development programs;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our products and product candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our expectations regarding the scope or enforceability of third-party intellectual property rights, or the applicability of such rights to our products and product candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the cost, timing and outcomes of litigation involving our products and product candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our reliance on third-party contract research organizations to conduct clinical trials of our product candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the benefits of the use of our products and product candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the rate and degree of market acceptance of our current or any future products product candidates;</i></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">our ability to compete with companies currently producing competitor products, including Neulasta and Humira and other biosimilar products made by other companies;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">developments and projections relating to our competitors, our market opportunity and our industry; and</i></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">the potential impact of COVID-19 and the continuation of the war in Ukraine and conflicts in the Middle East on our business and prospects.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">We have based </i>these<i style="font-style:italic;"> forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K under the heading &#8220;Risk Factors.&#8221; Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. Except as required under federal securities laws and the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;), we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Annual Report on Form&#160;10-K also contains estimates, projections, market opportunity estimates and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, publicly filed reports and similar sources.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_945a1f22_d231_486f_93a6_fcae1e549724"></a><a id="PARTI_789821"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_217063"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;&#160;<span style="font-style:italic;">Business</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><a id="_Hlk86746797"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of our portfolio of United States Food and Drug Administration (&#8220;FDA&#8221;)-approved oncology products, including LOQTORZI&#174; (toripalimab-tpzi). Our strategy is to build a leading immuno-oncology business funded with cash generated from our diversified portfolio of FDA-approved therapeutics.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 15, 2024, our commercial portfolio includes two FDA-approved biosimilar products. Our first product, UDENYCA&#174;, a biosimilar to Neulasta, a long-acting G-CSF, was launched commercially in the United States in January 2019. The FDA approved the prior approval supplement (&#8220;PAS&#8221;) for an autoinjector (&#8220;AI&#8221;) presentation of UDENYCA on March 3, 2023, and on May 22, 2023 we announced the availability of UDENYCA AI for commercial sale. On December 26, 2023 we announced that the FDA approved the PAS for our third pegfilgrastim presentation, the UDENYCA&#174; on-body injector (&#8220;UDENYCA ONBODY&#8221;). UDENYCA ONBODY became commercially available in the first quarter of 2024. Our second product, YUSIMRY&#174; (adalimumab-aqvh), a biosimilar to Humira (adalimumab), was launched in the United States in July 2023. Another product, CIMERLI&#174; (ranibizumab-eqrn), was approved by the FDA in August 2022 as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. We launched CIMERLI commercially in the United States in October 2022. On January 19, 2024, we entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) by and between us and Sandoz Inc., a Delaware corporation (&#8220;Sandoz&#8221;). Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz (the &#8220;Sale Transaction&#8221;) for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial portfolio includes LOQTORZI, a novel PD-1 inhibitor that we developed in collaboration with Shanghai Junshi Biosciences Co., Ltd. (&#8220;Junshi Biosciences&#8221;). On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (&#8220;NPC&#8221;), and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. We announced the launch of LOQTORZI in the U.S. on January 2, 2024. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have a pipeline of earlier stage clinical and preclinical immuno-oncology programs. On September 8, 2023, we acquired Surface Oncology, Inc. (&#8220;Surface&#8221;) and took ownership of its assets, including its portfolio of product candidates. The lead clinical stage product candidate from our acquisition of Surface (the &#8220;Surface Acquisition&#8221;) is casdozokitug (CHS-388, formerly SRF388), an investigational antibody targeting <span style="background:#ffffff;">interleukin 27 (&#8220;IL-27&#8221;)</span>, an immune regulatory cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. IL-27 is a cytokine secreted by macrophages and antigen presenting cells that plays an important physiologic role in suppressing the immune system, as evidenced by its ability to resolve tissue inflammation. In addition, both IL-27 subunits, EBI3 and p28, are highly expressed during pregnancy in the placenta and their expression is associated with maternal-fetal tolerance. Due to its immunosuppressive nature, there is a rationale for inhibiting IL-27 to treat cancer, as this approach will influence the activity of multiple types of immune cells that are necessary to recognize and attack a tumor. Casdozokitug received orphan drug designation and fast track designation from the FDA for the treatment of hepatocellular carcinoma (&#8220;HCC&#8221;) in November 2020. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Casdozokitug is currently in two on-going clinical studies, a Phase 1/2 study in patients with advanced solid tumors (clinicaltrials.gov identifier# NCT04374877) and a Phase 2 study in HCC (clinicaltrials.gov identifier# NCT05359861). Our second clinical-stage product candidate from the Surface Acquisition, CHS-114 (formerly SRF114), is an investigational afucosylated <span style="background:#ffffff;">immunoglobulin isotype G1 (&#8220;</span>IgG1&#8221;) antibody targeting CCR8, a chemokine receptor highly expressed on regulatory T cells (&#8220;Treg cells&#8221;) in the tumor microenvironment (&#8220;TME&#8221;). CHS-114 is designed to cause depletion of intra-tumoral CCR8 expressing Treg cells, important regulators of immune suppression, through antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), or antibody-dependent cellular phagocytosis (&#8220;ADCP&#8221;), or both, and CCR8 cytolytic antibodies have shown anti-tumor activity in preclinical cancer models. We are enrolling patients with advanced solid tumors in North America in a clinical trial evaluating safety and pharmacokinetics of CHS-114 (clinicaltrials.gov identifier# NCT05635643). We are also pursuing an early-stage development candidate that is in investigational new drug application-enabling studies, CHS-1000, an antibody targeting human ILT4, designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition to our internally developed portfolio of product candidates that we obtained in the Surface Acquisition, we also own two product candidates, NZV930 and GSK4381562, which are exclusively licensed to <span style="background:#ffffff;">Novartis Institutes for Biomedical Research, Inc. (&#8220;Novartis Institutes&#8221;) and GlaxoSmithKline Intellectual Property No. 4 Limited (&#8220;GSK&#8221;), respectively</span>. We will pay 70% of all milestone- and royalty-based payments that we or our affiliates actually receive from the product candidates licensed to Novartis Institutes and GSK during the ten-year period following the entry into the <span style="background:#ffffff;">Contingent Value Rights Agreement, dated September 8, 2023, by and among us and &#160;Computershare Inc. and its affiliate Computershare Trust Company, N.A., together, as the rights agent thereunder (the &#8220;CVR Agreement&#8221;) </span>to the holders of contingent value rights (&#8220;CVRs&#8221;). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Products and Product Candidates </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our portfolio includes the following products and product candidates:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Oncology </b></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">UDENYCA, a biosimilar to Neulasta, a long-acting G-CSF, was launched commercially in the United States in January 2019. The FDA approved the PAS for an AI presentation of UDENYCA on March 3, 2023, and on May 22, 2023 we announced the availability of UDENYCA AI for commercial sale. We announced on December 26, 2023 that the FDA approved the PAS for our third pegfilgrastim presentation, UDENYCA ONBODY</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#8482;, the first and only pegfilgrastim biosimilar on-body injector novel in its design</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">. UDENYCA ONBODY became commercially available in the first quarter of 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">LOQTORZI was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. We believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune system&#8217;s ability to attack and kill tumor cells.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is an anti-PD-1 antibody that we developed in collaboration with Junshi Biosciences. We announced the launch of LOQTORZI in the U.S. on January 2, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 54pt;">On December 11, 2023 we announced that the National Comprehensive Cancer Network (&#8220;NCCN&#8221;) updated the clinical practice guidelines for NPC to include LOQTORZI as a preferred, category 1 first-line treatment option for adults with metastatic or recurrent locally advanced NPC when used in combination with cisplatin and gemcitabine. The guidelines also recommend LOQTORZI monotherapy as the only preferred treatment in subsequent lines of therapy if disease progression on or after a platinum-containing therapy.</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Casdozokitug (CHS-388, formerly SRF388), is an investigational recombinant human IgG1 monoclonal antibody targeting IL-27, an immune regulatory cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. IL-27 is a cytokine secreted by macrophages and antigen presenting cells that plays an important physiologic role in suppressing the immune system, as evidenced by its ability to resolve tissue inflammation. In addition, IL-27 is highly expressed during pregnancy and its expression is correlated with maternal-fetal tolerance. Due to its immune regulatory nature, there is a rationale for inhibiting IL-27 to treat cancer, as this approach will influence the activity of multiple types of immune cells that are necessary to recognize and attack a tumor. Casdozokitug received orphan drug designation and fast track designation from the FDA for the treatment of HCC in November 2020. Casdozokitug is currently in two on-going clinical studies, a Phase 1/2 study in advanced solid tumors (clinicaltrials.gov identifier# NCT04374877) and a Phase 2 study in HCC (clinicaltrials.gov identifier# NCT05359861). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-114 (formerly SRF114), is an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the TME. CHS-114 is designed as a cytolytic antibody to cause depletion of intra-tumoral Treg cells, important regulators of immune suppression and tolerance, through ADCC, or ADCP or both. CHS-114 has shown anti-tumor activity as monotherapy or in combination with anti-PD-1 antibodies in preclinical models. We are enrolling patients with advanced solid tumors in North America in a clinical trial evaluating safety and pharmacokinetics of CHS-114 (clinicaltrials.gov identifier# NCT05635643).</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are pursuing a development candidate, CHS-1000, an antibody targeting human ILT4, designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. We plan to submit an investigational new drug application (&#8220;IND&#8221;) to the FDA in the second quarter of 2024 for CHS-1000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition to our internally developed portfolio of product candidates that we obtained in the Surface Acquisition, we also own NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes and GSK, respectively. NZV930 is an antibody designed to inhibit CD73, which is a critical enzyme involved in the production of extracellular adenosine, a key metabolite with strong immunosuppressive properties within the TME. NZV930 aims to reduce the production of immunosuppressive adenosine within the TME. GSK4381562 is an antibody targeting CD112R, also known as PVRIG, an inhibitory protein expressed on natural killer (&#8220;NK&#8221;) and T cells. GSK4381562 is designed to block the interaction of CD112R with CD112, its binding partner that is expressed on tumor cells. GSK4381562 is designed to promote the activation of both NK and T cells, with potential to elicit a strong anti-tumor response and promote immunological memory. We will pay 70% of all milestone- and royalty-based payments that we or our affiliates receive from the product candidates licensed to Novartis Institutes and GSK during the ten-year period following the entry into the </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">CVR Agreement</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> to the holders of the CVRs. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Immunology</b></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">YUSIMRY, a biosimilar of Humira (adalimumab), is a monoclonal antibody that can bind to tumor necrosis factor (&#8220;TNF&#8221;). YUSIMRY provides certain therapeutic benefits for treatment of patients with certain inflammatory diseases characterized by increased production of TNF in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#8217;s disease, psoriasis and ulcerative colitis. In December 2021, the FDA approved YUSIMRY, which we launched in the United States in July 2023. The list price of YUSIMRY at launch represented an approximately 85% discount to the list price of Humira. YUSIMRY is now available for sale nationwide through select retail, mail order, and specialty pharmacy channels, including Mark Cuban Cost Plus Drug Company, PBC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Ophthalmology &#8211; Sold to Sandoz pursuant to the Sale Transaction</b></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CIMERLI is a Lucentis biosimilar. On November 4, 2019, we entered into a license agreement (the &#8220;Bioeq Agreement&#8221;) with Bioeq IP AG (&#8220;Bioeq&#8221;) for the commercialization of CIMERLI in certain dosage forms in both a vial and </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-filled syringe (&#8220;PFS&#8221;) </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">presentation. Under the Bioeq Agreement, Bioeq granted to us an exclusive royalty-bearing license to commercialize CIMERLI in the field of ophthalmology (and any other approved labelled indication) in the United States. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="background:#ffffff;">On August 2, 2022, the FDA approved CIMERLI as a biosimilar product interchangeable with Lucentis for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. The FDA also granted CIMERLI 12 months of first interchangeable exclusivity. On October 3, 2022, we launched CIMERLI commercially in the United States in both 0.3 mg and 0.5 mg dosage forms. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 54pt;">On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Oncology Franchise Market Opportunity</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">LOQTORZI Opportunity</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">According to Clarivate/Decision Resource Group, the Squamous Cell Carcinoma of the Head and Neck (&#8220;SCCHN&#8221;) therapy market was expected to increase 9% annually over the 2022-2032 forecast period. In 2022, sales of SCCHN therapies in the major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) totaled $1.5 billion, and sales were expected to increase to almost $3.5 billion in 2032. Fueling this growth are the continued uptake of pembrolizumab in the recurrent or metastatic first-line setting, its label expansion into the locoregionally advanced setting, and the expected approval of four new therapies.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD-1 inhibitors are expected to be the sales-leading drug class in 2032, garnering major-market sales of over $1.7 billion, and we expect these agents to be approved for both non-nasopharyngeal and nasopharyngeal drug-treatable patient populations. By the end of 2032, we expect them to be prescribed mostly in the large and commercially lucrative locoregionally advanced and recurrent or metastatic first-line setting.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Immuno-oncology agents, and the PD-1/PD-L1 class in particular, have shifted the treatment paradigm across a broad range of tumors, and across the continuum of cancer settings (metastatic to early stage). Clinical adoption of PD-1/PD-L1 therapies has been driven by the proven versatility of certain therapies within the class to be used as a monotherapy, as well as combination therapy with targeted agents such as tyrosine kinase inhibitors, chemotherapy, or other immunotherapy agents to achieve durable tumor responses and improved survival benefits, with acceptable toxicity profiles. The improved safety profile observed for approved PD-L1 therapies versus chemotherapy enables these therapies to be used as a backbone therapy in a broad array of combination regimens.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is an anti-PD-1 antibody that we developed in collaboration with Junshi Biosciences. We announced the launch of LOQTORZI in the U.S. on January 2, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">LOQTORZI is a next-generation programmed death receptor-1 (&#8220;PD-1&#8221;) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NPC is a type of aggressive cancer that starts in the nasopharynx, the upper part of the throat behind the nose and near the base of the skull. NPC is rare in the United States, with an annual incidence of fewer than one per 100,000 people. The five-year survival rate for all patients diagnosed with NPC is approximately 60%, however, those who are diagnosed with advanced disease have a five-year survival rate of approximately 49%. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the location of the primary tumor, surgery is rarely an option, and, before the launch of LOQTORZI, patients with localized disease were treated primarily with radiation and chemotherapy. Patients treated with chemotherapy alone experience poor prognosis: only 20% experience one-year progression-free survival; up to 50% developed distant metastasis during their disease course; and low median overall survival (&#8220;OS&#8221;) of 29 months.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on SEER and DRG models, we estimate that the annual drug-treatable population in the United States for NPC is approximately 2,000 patients annually. Of this group, 60% have relapsed/metastatic disease and would be candidates for LOQTORZI. 40% have localized disease that can progress to relapsed/metastatic within a 12-24 month timeframe.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On Dec. 11, 2023 we announced that the NCCN updated the clinical practice guidelines for NPC to include LOQTORZI as a preferred, category 1 first-line treatment option for adults with metastatic or recurrent locally advanced NPC when used in combination with cisplatin and gemcitabine. The guidelines also recommend LOQTORZI monotherapy as the only preferred treatment in subsequent lines of therapy if disease progression on or after a platinum-containing therapy.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NCCN recommendations were based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study. In the JUPITER-02 Phase 3 study, LOQTORZI combined with chemotherapy significantly improved progression-free survival, reducing the risk of disease progression or death by 48% compared to chemotherapy alone. LOQTORZI also demonstrated a statistically significant and clinically meaningful improvement in OS, with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone. In the POLARIS-02 clinical study, LOQTORZI demonstrated durable anti-tumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an objective response rate of 20.5%, a disease control rate of 40%, and a median OS of 17.4 months with an acceptable safety profile.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">LOQTORZI is the first FDA-approved therapy for NPC, and we believe could represent a new standard of care for treating the disease when used in combination with cisplatin and gemcitabine in the first line setting or as monotherapy in the second line or greater setting. On November 27, 2023, we announced that we established a wholesale acquisition cost for LOQTORZI of $8,892.03 per single-use vial.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">UDENYCA Biosimilar</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We initiated United States sales of UDENYCA in January&#160;2019, and in 2023 we recorded UDENYCA net product sales of $127.1 million. UDENYCA is currently approved by the FDA in both PFS and AI presentation, and as we announced on December 26, 2023, the FDA approved the PAS for our third pegfilgrastim presentation, UDENYCA ONBODY. UDENYCA ONBODY became commercially available in the first quarter of 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PFS products currently account for approximately 56% of the overall pegfilgrastim market, which annually comprises sales of approximately 1.4 million units. Prior to the launch of UDENYCA ONBODY, approximately 43% of the remaining market was held by Neulasta Onpro&#174;, an on-body presentation of pegfilgrastim owned by Amgen Inc. and Amgen USA Inc. (collectively &#8220;Amgen&#8221;). UDENYCA ONBODY could potentially expand the UDENYCA market opportunity into a portion of the market held by Neulasta Onpro.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Immunology Franchise Market Opportunity</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">YUSIMRY </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, Humira revenue in the United States was approximately $12.2 billion. In December 2021, the FDA approved YUSIMRY, which we launched in the United States in July 2023. The list price of YUSIMRY at launch represented an approximately 85% discount to the list price of Humira. This pricing strategy provides physicians, patients, payers, and employers with access to low-cost, high-quality, safe and effective treatment. YUSIMRY Solutions&#8482;&#8212;our patient services platform&#8212;facilitates improved access and fast and seamless experience as patients start or switch to YUSIMRY based on a determination by their healthcare provider.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">YUSIMRY is now available for sale nationwide through select retail, mail order, and specialty pharmacy channels and was the first biologic offered by Mark Cuban Cost Plus Drug Company, PBC.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our commercial strategy with YUSIMRY, we believe that payor coverage policies and formularies dictate provider access to both Humira and adalimumab biosimilars and that a combination of factors influence formulary decision making. With the implementation of the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), in 2025 the Part D benefit will be restructured and liability for all Part D plans will significantly increase. This change in liability will shift plan costs into Part D plan bids, as opposed to costs being primarily paid through reinsurance, as is the case under the benefit today. Therefore, Part D plans may re-structure formularies to include products with low WAC prices, creating potential opportunity for YUSIMRY in 2025 to achieve broader payer coverage. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Ophthalmology Franchise &#8211; Sold to Sandoz pursuant to the Sale Transaction</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CIMERLI </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On August 2, 2022, the FDA approved CIMERLI as a biosimilar product interchangeable with Lucentis for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. On October 3, 2022, we launched CIMERLI commercially in the United States in both 0.3 mg and 0.5 mg dosage forms.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales and Marketing</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to build a leading immuno-oncology franchise funded with cash generated from our diversified portfolio of FDA-approved therapeutics. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Following the FDA approval of LOQTORZI for NPC, the commercial launch commenced in January 2024 with our existing Oncology commercial and medical affairs teams. There are approximately 2,200 Oncologists that treat 80% of patients in the United States with NPC and 90% of these physicians practice in existing UDENYCA accounts creating significant synergies in our commercial execution. Our </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Oncology commercial team was built to scale and meet the needs of our existing Oncology portfolio, as well as new indications for LOQTORZI that could come in the future, pending FDA approval.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the field facing teams, Coherus has a team of strategic account managers that support the portfolio of products and work directly with the largest accounts including group purchasing organizations, integrated delivery networks, and large clinic customers. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have an experienced market access and patient services team that support the portfolio of Coherus&#8217; products. This team is responsible for negotiating payer coverage with national and regional health plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimbursement of Coherus&#8217; products (via a team of Field Reimbursement Managers), and managing our Coherus Solutions patient services hub which provides product specific coverage, reimbursement and co-pay support for patients and providers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a discussion of risks related to sales and marketing, please see &#8220;Risk Factors&#8212;Risks Related to Launch and Commercialization of our Products and our Product Candidates.&#8221; </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into agreements with several contract manufacturing organizations (&#8220;CMOs&#8221;) for the manufacture and clinical drug supply of our commercial products and product candidates. We continue to screen other contract manufacturers to meet our clinical, commercial and regulatory supply requirements on a product-by-product basis. We have and may be required again to take inventory write-downs and incur other charges and expenses for products that are manufactured in reliance on a forecast that proves to be inaccurate because we do not sell as many units as forecasted. For example, during the fourth quarter of 2023, we recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. For a discussion of risks related to our sources and availability of supplies, please see &#8220;Risk Factors&#8212;Risks Related to Our Ability to Hire and Retain Highly Qualified Personnel&#8221; and &#8220;Risk Factors&#8212;Risks Related to Manufacturing and Supply Chain.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we believe that our biologics platform, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from many different sources. We operate in a highly competitive environment.&#160;Such competition includes larger and better-funded pharmaceutical, generic pharmaceutical, specialty pharmaceutical and biotechnology companies commercializing and developing immuno-oncology and biosimilar products that would compete with our products and the product candidates in our pipeline. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">LOQTORZI, following its recent launch, faces a competitive market in the United States where a number of anti-PD-1 or PD-L1 antibody drugs have been approved by the FDA including the following marketed products from several competitors: Keytruda&#174;&#160;(pembrolizumab) from Merck &amp; Company, Inc. (&#8220;Merck&#8221;), Opdivo&#174;&#160;(nivolumab) from Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Tecentriq&#174;&#160;(atezolizumab) from Genentech, Inc. (&#8220;Genentech&#8221;), Imfinzi&#174;&#160;(durvalumab) from AstraZeneca plc (&#8220;AstraZeneca&#8221;), Bavencio&#174;&#160;(avelumab) from EMD Serono Inc. and Pfizer Inc. (&#8220;Pfizer&#8221;), Libtayo&#174;&#160;(cemiplimab-rwlc) from Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) and Sanofi S.A. (&#8220;Sanofi&#8221;), and Jemperli (dostarlimab-gxly) from GlaxoSmithKline plc (&#8220;GlaxoSmithKline&#8221;). In addition to LOQTORZI, multiple other competitors are seeking to develop and approve novel anti-PD-1 or PD-L1 antibody drugs in the United States in the coming years, including but not limited to BeiGene, Ltd. (in collaboration with Novartis International AG (&#8220;Novartis&#8221;)). As the only immunotherapy approved by the FDA for the treatment of NPC, we believe LOQTORZI addresses a potentially high unmet need. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CHS-114, if approved, faces competition from programs in development specifically targeting CCR8, including those by BMS, Gilead/Jounce, Shionogi, AbbVie, Bayer, LaNova and Immunophage.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">UDENYCA faces competition in the United States from Amgen, Viatris Inc. (&#8220;Viatris&#8221;), Sandoz, Pfizer and Spectrum Pharmaceuticals, Inc. (&#8220;Spectrum&#8221;), and also faces competition from Amneal Pharmaceuticals, Inc. (&#8220;Amneal&#8221;) and Fresenius Medical Care AG &amp; Co. KGaA (&#8220;Fresenius&#8221;), each of which has announced the approval of a pegfilgrastim biosimilar and have launched their products for sale in the United States.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">YUSIMRY faces competition in the United States from AbbVie (the holder of rights to Humira), Amgen (Amjevita<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-atto)), Sandoz (Hyrimoz<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-adaz)), Samsung Bioepis (Hadlima<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-bwwd)), Pfizer (Abrilada<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-afzb)), Boehringer Ingelheim GmbH (&#8220;Boehringer Ingelheim&#8221;) (Cyltezo<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-adbm)) as well as Viatris / Biocon (&#8220;Biocon&#8221;) (Hulio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (adalimumab-fkjp)), Alvotech Holdings S.A. and Fresenius, each a company that has disclosed development plans for a Humira biosimilar </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">candidate. As a result of continued expected competition from Humira and a large number of potential adalimumab (Humira) biosimilar competitors, we may not be able to achieve substantial topline sales for YUSIMRY in the United States.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect any products that we develop and commercialize directly or with partners to compete on the basis of, among other things, price and the availability of reimbursement from government and other third-party payers. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For a discussion of risks related to our competition, please see &#8220;Risk Factors&#8212; Risks Related to Competitive Activity.&#8221; </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration and License Agreements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Distribution Agreement with Orox Pharmaceuticals B.V. (&#8220;Orox&#8221;)</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2012, we entered into a distribution agreement with Orox, for the commercialization of biosimilar versions of our internally developed biosimilars. Under this agreement, we granted to Orox an exclusive license to commercialize UDENYCA in Latin America, except Brazil and Argentina, and YUSIMRY and CHS-0214 (our etanercept (Enbrel<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) biosimilar candidate, for which we discontinued development in 2020) in Latin America, except Brazil. Under this agreement, Orox has an option, exercisable within a defined time period, to obtain an exclusive license to commercialize certain additional biosimilar products in the same field and territory. We are obligated to manufacture and supply licensed products to Orox.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are obligated to develop licensed products and achieve regulatory approval for such products outside of the Caribbean and Latin American countries covered by the agreement by specified dates in order to support Orox&#8217;s activities under the agreement in its licensed territory. We are eligible to receive from Orox a share of gross profits in the low twenty&#160;percent range from the sale of licensed products, on a product-by-product basis.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our agreement with Orox will expire on a product-by-product and country-by-country basis ten&#160;years after regulatory approval of such product in such country, subject to automatic three-year extensions unless Orox notifies us in writing at least 18&#160;months in advance of the date upon which the term would otherwise expire that it does not wish to extend the term for such product in such country. Either party may terminate the agreement for material breach by the other party that is not cured within a specified time period. Orox may terminate the Agreement for convenience on a product-by-product basis at any time upon 12-months prior written notice. Each party may terminate the agreement upon bankruptcy or insolvency of the other party, and we may terminate the agreement immediately upon written notice to Orox if Orox challenges the licensed patents or commits a breach of specified provisions of the agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Settlement and License Agreements with AbbVie</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2019, we entered into three settlement and license agreements with AbbVie that grant Coherus global, royalty-bearing, non-exclusive license rights under AbbVie&#8217;s intellectual property to commercialize YUSIMRY. The global settlements resolve all pending disputes between the parties related to YUSIMRY. Under the United States settlement, our license period in the United States commenced on July&#160;1, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Settlement and License Agreements with Pfizer</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2019, we entered into a license and settlement agreement with Pfizer relating to Coherus&#8217; patents and applications for patents directed to Humira (adalimumab) formulations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement with Bioeq</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2019, we entered into the Bioeq Agreement with Bioeq for the commercialization of a biosimilar version of ranibizumab (Lucentis) in certain dosage forms in both a vial and pre-filled syringe presentation (the &#8220;Bioeq Licensed Products&#8221;). Under this agreement, Bioeq granted to us an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. Bioeq will supply us the Bioeq Licensed Products in accordance with terms and conditions specified in the agreement and a manufacturing and supply agreement to be executed by the parties in accordance therewith.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the Bioeq Agreement, Bioeq must use commercially reasonable efforts to develop and obtain regulatory approval of the Bioeq Licensed Products in the United States in accordance with a development and manufacturing plan, and we must use commercially </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Bioeq will manufacture and supply the Bioeq Licensed Products to us in accordance with terms and conditions specified in the Bioeq Agreement and a manufacturing and supply agreement between us and Bioeq dated as of September 29, 2022 (the &#8220;Bioeq Manufacturing Agreement&#8221;). The Bioeq Manufacturing Agreement will remain in force until the first to occur of the following: (1) the termination of the Bioeq Agreement; (2) the exercise of a right to termination by us or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement. Additionally, we must commit certain post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the Bioeq Agreement. The development, manufacturing, and commercialization of the Bioeq Licensed Products in the United States is governed by a governance committee as described in more detail in the Bioeq Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We paid Bioeq an upfront payment of &#8364;5.0 million and a milestone payment of &#8364;5.0 million in 2019. In 2022, we paid Bioeq a &#8364;2.5 million milestone payment related to the FDA approval of the CIMERLI Section 351(k) BLA. We share a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Bioeq Agreement&#8217;s initial term continues in effect for ten&#160;years after the first commercial sale of a Bioeq Licensed Product in the United States, which occurred on October 3, 2022, and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. Either party may terminate the Bioeq Agreement for the other party&#8217;s material breach which is not cured within a specified time period or for the other party&#8217;s bankruptcy or insolvency-related events. Bioeq may terminate the Bioeq Agreement in certain limited circumstances for failure to obtain specified minimum market share requirements during certain windows of time, if we conduct certain commercial or advanced pre-commercial activities with respect to certain competitive products, if we challenge the validity or enforceability of the patent rights licensed to us under the Bioeq Agreement, or if we undergo a change of control with a competitor of Bioeq and do not divest certain competitive products in connection therewith. We may terminate the Bioeq Agreement if Bioeq receives certain adverse regulatory feedback from the FDA for the Bioeq Licensed Products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The FDA approval of CIMERLI occurred on August 2, 2022, and we commercially launched CIMERLI in the United States on October 3, 2022. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Bioeq and Genentech</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 22, 2022, we entered into a license agreement with Genentech, Inc. (&#8220;Genentech&#8221;) and our partner Bioeq (the &#8220;Genentech Agreement&#8221;). Under the agreement, Genentech granted us and Bioeq a non-exclusive, royalty-bearing, license under certain of its patent rights to commercially launch and sell CIMERLI in the United States which started on the launch date on October 3, 2022. Pursuant to the terms of the Genentech Agreement, the royalty is a low single-digit percentage of net sales of CIMERLI that must be paid through the end of 2023. In addition, we obtained the right to make non-binding offers to sell and engage in manufacturing and stockpiling activities during specified time periods prior to the launch date pursuant to the terms of the Genentech Agreement. The term of the Genentech Agreement will expire when all of the valid claims in the patent rights licensed under the agreement expire. The agreement may be terminated by either party if a party materially breaches one or more of its material obligations, subject to customary cure period. If we, Bioeq or either party&#8217;s respective affiliates initiate, participate, or assist any other person in bringing or prosecuting any challenge to the validity of any patent rights licensed under the Genentech Agreement, Genentech may terminate the licenses granted under such licensed patent rights or terminate the Genentech Agreement in its entirety, unless we, Bioeq, or the applicable affiliates withdraw all such challenges or stop assisting in any such challenges. Genentech may also terminate the agreement in the event of our insolvency. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement with Junshi Biosciences</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On February 1, 2021, we entered into the Collaboration Agreement with Junshi Biosciences for the co-development and commercialization of toripalimab, Junshi Biosciences&#8217; anti-PD-1 antibody in the United States and Canada (the &#8220;Collaboration Agreement&#8221;). </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the Collaboration Agreement, we paid&#160;$150.0 million&#160;upfront for exclusive rights to LOQTORZI in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug candidates. We have the right to conduct all commercial activities of LOQTORZI in the United States and Canada. We are obligated to pay Junshi Biosciences up to a 20% royalty on net sales of LOQTORZI and up to an aggregate&#160;$380.0 million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In March 2022, we paid $35.0 million for the exercise of our option to license the TIGIT Program (as defined in the Collaboration Agreement). Subsequent joint development consistent with the Collaboration Agreement commenced. On January 10, 2024, we announced that we had delivered a notice of termination of the TIGIT Program to Junshi Biosciences pursuant to the Collaboration Agreement. Under the Collaboration Agreement, we retain the right to collaborate in the development of LOQTORZI and the other licensed compounds and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, we are responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The $35.0 million payment for the option to license CHS-006 was reflected in our first quarter of 2022 financial statements. We recorded research and development expense of $145.0 million during the first quarter of 2021, related to an upfront payment for exclusive rights to LOQTORZI in the United States and Canada. We had entered into a Right of First Negotiation agreement with Junshi Biosciences and paid a fee of $5.0 million which was expensed as research and development expense in the fourth quarter of 2020. The Right of First Negotiation fee was fully credited against the total upfront license fee obligation under the Collaboration Agreement. As of December 31, 2023, we recorded $26.3 million in accrued and other current liabilities, inclusive of the $25.0 million milestone payment to Junshi Biosciences. Additionally, we recorded $6.3 million in accounts payable related to the co-development, regulatory and technology transfer costs related to these programs, as well as an immaterial royalty obligation.&#160;The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Adimab Development and Option Agreement</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018, Surface and Adimab LLC (&#8220;Adimab&#8221;), entered into an amended and restated development and option agreement, (as amended by the amendments dated as of December 16, 2020, June 1, 2022 and July 18, 2022, &#8220;the A&amp;R Adimab Agreement&#8221;), which amended and restated the development and option agreement with Adimab dated July 2014, as amended, (&#8220;the Original Adimab Agreement&#8221;), for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the A&amp;R Adimab Agreement, we will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. The A&amp;R Adimab Agreement, among other things, extended the discovery term of the Original Adimab Agreement, provided access to additional antibodies, and expanded our right to evaluate and use antibodies that were modified or derived using Adimab technology for diagnostic purposes. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon our selection of a target, we and Adimab will initiate a research plan and the discovery term begins. During the discovery term, Adimab will grant us a non-exclusive, non-sublicensable license under its technology with respect to the target, to research, design and preclinically develop and use antibodies that were modified or derived using Adimab technology, solely to evaluate such antibodies, perform our responsibilities under the research plan, and use such antibodies for certain diagnostic purposes. We also will grant Adimab a non-exclusive, nontransferable license with respect to the target under our technology that covers or relates to such target, solely to perform its responsibilities under the research plan during the discovery period. We are required to pay Adimab at an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adimab granted us an exclusive option to obtain a non-exclusive, worldwide, fully paid-up, sublicensable license under Adimab&#8217;s platform patents and other Adimab technology solely to research up to ten antibodies, chosen by us against a specific biological target for a specified period of time (the &#8220;Research Option&#8221;). In addition, Adimab granted us an exclusive option to obtain a worldwide, royalty-bearing, sublicensable license under Adimab platform patents and other Adimab technology to exploit, including commercially, 20 or more antibodies against specific biological targets (the &#8220;Commercialization Option&#8221;). Upon the exercise of a Commercialization Option, and payment of the applicable option fee to Adimab, Adimab will assign us the patents that cover the antibodies selected by such Commercialization Option. We will be required to use commercially reasonable efforts to develop, seek market approval of, and commercialize at least one antibody against the target covered by the Commercialization Option in specified markets upon the exercise of a Commercialization Option.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the A&amp;R Adimab Agreement, we are obligated to make milestone payments and to pay specified fees upon the exercise of the Research Option or Commercialization Option. During the discovery term, we may be obligated to pay Adimab up to $0.3 million for technical milestones achieved against each biological target. Upon exercise of a Research Option, we are obligated to pay a nominal research maintenance fee on each of the next four anniversaries of the exercise. Upon the exercise of each Commercialization Option, we will be required to pay an option exercise fee of a low seven-digit dollar amount, and we may be responsible for milestone payments of up to an aggregate of $13.0 million for each licensed product that receives marketing approval. For any licensed product that is commercialized, we are obligated to pay Adimab tiered royalties of a low to mid single-digit percentage on worldwide net sales of such product. We may also partially exercise a Commercialization Option with respect to ten antibodies against a biological target by paying 65% of the option fee and later either (i) paying the balance and choosing additional antibodies for commercialization, up to the maximum number under the Commercialization Option, or (ii) foregoing the Commercialization Option entirely. For any Adimab diagnostic product that is used with or in connection with any compound or product other than a licensed antibody or licensed product, we are obligated to pay Adimab up to a low seven digits in regulatory milestone payments and low single-digit royalties on net sales. No additional payment is due with respect to any companion diagnostic or any diagnostic product that does not contain any licensed antibody. Any payments payable to Adimab as a result of any product candidates being developed pursuant to the license agreement between Surface and GSK, dated December 16, 2020, which was subsequently amended in August 2021 (as amended, the &#8220;GSK Agreement&#8221;), will be payable to Adimab directly by GSK. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The A&amp;R Adimab Agreement will remain in effect until (a) the earlier of (i) the expiration of the Research and Commercialization Options (if they expire without exercise) and (ii) 12 months from the effective date without us providing materials that pass Adimab&#8217;s quality control; or (b) if a Research Option is exercised but the Commercialization Option is not, then upon the expiration of the last to expire research license term; or (c) upon commercialization of a product, until the end of the royalty term, which will vary on a product-by-product and country-by-country basis, ending on the later of (y) the expiration of the last valid claim covering the licensed product in such country as the product is manufactured or sold, or (z) ten years after the first commercial sale of the licensed product in such country.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Either party may terminate the A&amp;R Adimab Agreement for material breach if such breach remains uncured for a specified period of time, however, if a Research Option or Commercialization Option has been exercised and the breach only applies to the applicable target of such Research Option or Commercialization Option, then the termination right will only apply to such target. We may also terminate the A&amp;R Adimab Agreement for any reason with prior notice to Adimab. If Adimab is bankrupt, we will be entitled to a complete duplicate of, or complete access to, all rights and licenses granted under or pursuant to the A&amp;R Adimab Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis Institutes Out-licensing Agreement</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2016, Surface entered into the collaboration agreement between Surface and Novartis Institutes dated January 9, 2016 which was subsequently amended in May 2016, July 2017, September 2017, and October 2018 (as amended, the &#8220;Novartis Agreement&#8221;). Pursuant to the Novartis Agreement, Surface granted Novartis Institutes a worldwide exclusive license to research, develop, manufacture and commercialize antibodies that target cluster of differentiation 73 (&#8220;CD73&#8221;). Under the Novartis Agreement, we are currently entitled to potential development milestones of $325.0 million and sales milestones of $200.0 million, as well as tiered royalties on annual net sales by Novartis Institutes ranging from high single-digit to mid-teens percentages upon the successful commercialization of NZV930. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, we may not receive any milestone payments or any royalty payments under the Novartis Agreement. We did not recognize any revenue relating to the Novartis Agreement from September 8, 2023 through December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Novartis Agreement will continue in effect until neither us nor Novartis Institutes is researching, developing, manufacturing or commercializing NZV930. Novartis Institutes may terminate the Novartis Agreement for any or no reason upon prior notice to the Company within a specified time period. Either party may terminate the Novartis Agreement in full if an undisputed material breach is not cured within a certain period of time or upon notice of insolvency of the other party. To the extent Novartis Institutes terminates for convenience, or we terminate for Novartis Institutes&#8217; uncured material breach, Novartis Institutes will grant us, on mutually agreeable financial terms, an exclusive, worldwide, irrevocable, perpetual and royalty-bearing license with respect to intellectual property controlled by Novartis Institutes that is reasonably necessary to research, develop, manufacture or commercialize NZV930.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">GSK Out-licensing Agreement</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target CD112R, also known as PVRIG, including the antibody GSK4381562 (the &#8220;Licensed Antibodies&#8221;). GSK is responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee was formed to facilitate information sharing. GSK is responsible for all costs </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and expenses of such development, manufacturing and commercialization and is obligated to provide us with updates on its development, manufacturing and commercialization activities through the joint development committee. In March 2022, Surface earned a $30.0 million milestone payment from GSK upon the dosing of the first patient in the Phase 1 trial of GSK4381562. We are eligible to receive up to $60.0 million in additional clinical milestones and $155.0 million in regulatory milestones. In addition, we may receive up to $485.0 million in sales milestone payments. We are also eligible to receive royalties on global net sales of any approved products based on the Licensed Antibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, we may not receive any milestone payments or any royalty payments under the GSK Agreement. We did not recognize license-related revenue under the GSK Agreement from September 8, 2023 through December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. We may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, we would regain worldwide rights to the terminated program.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License Agreement with Vaccinex</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 23, 2021, Surface and Vaccinex, Inc. (&#8220;Vaccinex&#8221;) entered into an exclusive product license agreement (the &#8220;Vaccinex License Agreement&#8221;) to exclusively license certain antibodies, including CHS-114. Pursuant to the terms of the Vaccinex License Agreement, we have a worldwide, exclusive, sublicensable license to make, have made, use, sell, offer to sell, have sold, import and otherwise exploit licensed products that incorporate certain Vaccinex intellectual property which covers certain antibodies (each, a &#8220;Vaccinex Licensed Product&#8221;), including the antibody CHS-114 targeting CCR8.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Vaccinex License Agreement, we are obligated to use commercially reasonable efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at least one Vaccinex Licensed Product and have the sole right to develop, manufacture and commercialize the licensed products worldwide. We are responsible for all costs and expenses of such development, manufacturing and commercialization. Pursuant to the Vaccinex License Agreement, Surface paid Vaccinex a one-time fee of $0.9 million. Vaccinex is eligible to receive up to an aggregate of $3.5 million based on achievement of certain clinical milestones and up to an aggregate of $11.5 million based on achievement of certain regulatory milestones per Vaccinex Licensed Product. We also owe low single-digit royalties on global net sales of any approved licensed products. Commencing on the third anniversary of the date of the Vaccinex License Agreement and continuing until the first dosing of a Vaccinex Licensed Product in a clinical trial, we will be required to pay Vaccinex a nominal yearly maintenance fee. Since a patient was dosed with a Vaccinex Licensed Product, CHS-114, in January 2023, no yearly maintenance fees are due under the Vaccinex License Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We may terminate the Vaccinex License Agreement for convenience upon the notice period specified in the Vaccinex License Agreement. Either party may terminate the agreement for an uncured material breach by the other party. Vaccinex may terminate the Vaccinex License Agreement if we default on any payments owed to Vaccinex under the agreement, if we are in material breach of, and fail to cure, our development obligations, or institute certain actions related to the licensed patents. In the event of termination, all rights in the licensed intellectual property would revert to Vaccinex.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Term Sheet with Klinge Biopharma</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 9, 2023, we announced that we entered<span style="background:#ffffff;"> into a term sheet (the &#8220;Term Sheet&#8221;) with Klinge Biopharma GmbH (&#8220;Klinge Biopharma&#8221;) for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea&#174; (aflibercept), in the United States. We notified Klinge Biopharma that we do not intend to pursue the transaction contemplated by the Term Sheet.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our commercial success depends in part on our ability to avoid infringing the proprietary rights of third parties. Additionally, our commercial success may depend on our ability to obtain and maintain proprietary protection for our technologies where applicable and to prevent others from infringing our proprietary rights. We seek to protect our proprietary technologies by, among other methods, filing United States and international patent applications on these technologies, inventions and improvements that are important to our </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term of the patents in countries in which they are obtained. In most countries, including the United States, the patent term is generally 20&#160;years from the earliest date of filing a non-provisional patent application in the applicable country. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the normal course of business, we pursue patent protection for inventions related to our product candidates. Each patent family includes United States patent applications and/or issued patents, and some include foreign counterparts to certain of the United States patents and patent applications. Our patent portfolio includes issued or pending claims directed to formulations, methods of manufacturing biological proteins, and drug products and devices, including their methods of use and methods of manufacture.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a discussion of risks related to our proprietary technology and processes, please see &#8220;Risk Factors&#160;&#8212; Risks Related to Intellectual Property.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations and activities are subject to extensive regulation by numerous government authorities in the United States, the European Union (the &#8220;E.U.&#8221;) and other countries, including laws and regulations governing the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product development and product approval processes are very expensive and time consuming. The regulatory requirements applicable to drug development and approval are subject to change. Any legal and regulatory changes may impact our operations in the future. A country&#8217;s regulatory agency, such as the FDA in the United States, must approve a drug before it can be sold in the respective country or countries. The general process for biosimilar approval in the United States is summarized below. Many other countries, including countries in the E.U., have similar regulatory structures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">FDA Approval Process for Drugs and Biologics</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our products and product candidates are subject to regulation in the United States by the FDA as biological products or as drug product candidates. The FDA subjects drugs and biologics to extensive pre- and post-market regulation pursuant to the Federal Food, Drug and Cosmetic Act (&#8220;FFDCA&#8221;) and its implementing regulations, and in the case of biologics, the FFDCA and the Public Health Service Act (&#8220;PHSA&#8221;) and their implementing regulations. In addition, we are subject to other federal and state statutes and regulations. These laws and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of drugs and biologics. Failure to comply with applicable United States requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve a pending biologics license application (&#8220;BLA&#8221;) or new drug application (&#8220;NDA&#8221;), withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal penalties.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a new biologic or drug may be marketed in the United States is long, expensive and inherently uncertain. Biologic and drug development in the United States typically involves the completion of certain preclinical laboratory and animal tests in accordance with good laboratory practices (&#8220;GLP&#8221;), the submission to the FDA of an IND, which must become effective before clinical testing may commence, the performance of adequate and well-controlled clinical trials to establish the safety and effectiveness of the biologic or drug for each indication for which FDA approval is sought in compliance with good clinical practice (&#8220;GCP&#8221;) requirements, the submission to the FDA of an original BLA under Section&#160;351(a)&#160;of the PHSA (&#8220;original BLA&#8221;) or an NDA, as appropriate, satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced, and FDA approval and review of the original BLA or NDA. Developing the data to satisfy FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as, when applicable, animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. An IND is a request for allowance from the FDA to administer an investigational drug or biologic to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s)&#160;for human studies, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">although the IND must also include the results of preclinical testing and animal testing assessing the toxicology, pharmacokinetic, pharmacology and pharmacodynamic characteristics of the product along with other information, including information about product chemistry, manufacturing and controls and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If during the 30-day waiting period the FDA raises concerns or questions related to the proposed clinical studies, the sponsor and the FDA must resolve any outstanding concerns or questions before clinical studies can begin. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients with the condition under investigation, all under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with GCP requirements, which are designed to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on United States patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials for novel drugs and biologics are typically conducted in three sequential phases that may overlap or be combined.</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1&#8212;The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the product candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2&#8212;Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3&#8212;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of such &#8220;Phase 4&#8221; clinical trials.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (&#8220;IRB&#8221;), for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or may impose other conditions. The study sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health risk.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product candidate. To help reduce the risk of the introduction of adventitious agents with use of </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. Additionally, for both NDA and BLA products, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its proposed shelf-life.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed information regarding the investigational product is submitted to the FDA in the form of a BLA or NDA requesting approval to market the product for one or more indications. The BLA or NDA must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. Under the PDUFA as amended, each original BLA or NDA must be accompanied by a significant user fee. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, where the product candidate has received orphan drug designations for the sought indication or where the applicant is a small business submitting its first human therapeutic application for review.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within 60&#160;days following submission of the application, the FDA reviews an original BLA or NDA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any original BLA or NDA that it deems incomplete or not properly reviewable at the time of submission, and may request additional information. In this event, the original BLA or NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the original BLA or NDA. The FDA reviews the original BLA to determine, among other things, whether the proposed product is safe, pure and potent for its intended use, and has an acceptable purity profile, and in the case of an NDA, whether the product is safe and effective for its intended use, and in each case, whether the product is being manufactured in accordance with cGMP. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for Priority Review, six months after the FDA accepts the application for filing. A BLA or NDA is eligible for Priority Review if the product or the product candidate has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. In both standard and Priority Reviews, the review process may also be extended for a three-month period by the FDA to review additional information deemed a major amendment to the application.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) is necessary to assure the safe use of the product. If the FDA concludes a REMS plan is needed, the sponsor of the original BLA or NDA must submit a proposed REMS plan. The FDA will not approve an original BLA or NDA without a REMS plan, if required. In determining whether a REMS plan is necessary, the FDA must consider the size of the population likely to use the drug or biologic, the seriousness of the disease or condition to be treated, the expected benefit of the drug or biologic, the duration of treatment, the seriousness of known or potential adverse events, and whether the drug or biologic is a new molecular entity. A REMS plan may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate health care providers of the risks, limitations on who may prescribe or dispense the drug or biologic, or other measures that the FDA deems necessary to assure the safe use of the drug or biologic. In addition, the REMS plan must include a timetable to assess the strategy at 18&#160;months, three&#160;years, and seven&#160;years after the strategy&#8217;s approval, or at another frequency specified in the REMS.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA will not approve the application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an original BLA or NDA, the FDA will typically inspect one or more clinical sites to ensure compliance with cGCP. After the FDA evaluates an original BLA or NDA and conducts any inspections in the U.S. or internationally that it deems necessary, the FDA may issue an approval letter or a CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application is not ready for approval. A CRL may require additional clinical data and/or an additional clinical trial or trials, and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical trials or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the original BLA or NDA does not satisfy the criteria for approval.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Abbreviated Licensure Pathway of Biological Products as Biosimilar under Section 351(k)</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;) amended the PHSA and created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological product. The BPCIA attempts to minimize duplicative testing and thereby lower development costs and increase patient access to affordable treatments. Thus, an application for licensure of a biosimilar product pursuant to a Section&#160;351(k)&#160;BLA must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">animal studies (including the assessment of toxicity); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">two clinical study phases: first, a clinical study or studies (generally termed &#8220;Phase 1&#8221;) that demonstrate the PK and PD similarity (e.g., bioequivalence study) of the proposed biosimilar to the originator molecule, and second, a clinical study or studies (generally termed &#8220;Phase 3&#8221;) that demonstrate the safety (including immunogenicity), purity and that potency is statistically not inferior to that of the originator in one or more conditions for which the reference product is licensed and intended to be used.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, an application submitted under the Section 351(k)&#160;pathway must include information demonstrating that:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s)&#160;of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s)&#160;of action are known for the reference product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure and potent.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biosimilarity is defined to mean that the proposed biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. In addition, a biosimilar may also be determined to be &#8220;interchangeable&#8221; with the reference products, whereby the biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the proposed product is biosimilar to the reference product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the proposed product is expected to produce the same clinical result as the reference product in any given patient; and</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA approval is required before a biosimilar may be marketed in the United States. The FDA has discretion over the kind and amount of scientific evidence&#160;&#8212; laboratory, preclinical and/or clinical&#160;&#8212; required to demonstrate biosimilarity to a licensed biological product. The FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity, and recommends that sponsors use a stepwise approach in the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to establish the underlying safety and effectiveness of the reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that any impurities or differences in active ingredients do not affect the safety, purity or potency of the biosimilar product. In addition, as with original BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological product&#8217;s safety, purity and potency.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The submission of an application via the Section 351(k)&#160;pathway does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it finds are incomplete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any applicable user fees have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to conduct further analytical, preclinical or clinical studies to demonstrate such biosimilarity under Section&#160;351(k)&#160;or submit an original BLA for licensure as a new biological product under Section 351(a)&#160;of the PHSA.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for 12&#160;years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application under the Section 351(k)&#160;pathway for four&#160;years from the date of first licensure of the reference product. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent and thus block the Section&#160;351(k)&#160;BLA from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six&#160;months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The first biological product determined to be interchangeable with a branded product for any condition of use is also entitled to a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: (1)&#160;one&#160;year after the first commercial marketing of the first interchangeable product; (2)&#160;18&#160;months after resolution of a patent infringement suit instituted under 42 U.S.C. &#167;&#160;262(l)(6)&#160;against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3)&#160;42&#160;months after approval of the first interchangeable product, if a patent infringement suit instituted under 42 U.S.C. &#167;&#160;262(l)(6)&#160;against the applicant that submitted the application for the first interchangeable product is still ongoing; or (4)&#160;18&#160;months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued under 42 U.S.C. &#167;&#160;262(l)(6).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">FDA Regulation of Combination Products</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain products or product candidates, such as the OBI presentation of UDENYCA we developed, may be composed of components, such as drug components and device components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a product composed of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">two or more separate products packaged together in a single package or as a unit and composed of drug and device products, device and biological products, or biological and drug products;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a drug, or device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, or device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any investigational drug, or device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the FFDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA component for combination products, although it does not preclude consultations by the lead center with other components of the FDA. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A combination product with a biologic primary mode of action generally would be reviewed and approved pursuant to the biologic licensure processes under the PHSA. In reviewing the BLA or Section 351(k) BLA for such a product, however, FDA reviewers in the drug center could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding safety, purity, potency, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality System regulations applicable to medical devices.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Advertising and Promotion</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an NDA, original BLA, or Section 351(k)&#160;BLA is approved, a product will be subject to continuing post-approval regulatory requirements, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with these regulations can result in significant penalties, including the issuance of warning letters directing a company to correct deviations from FDA standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA and federal and state civil and criminal investigations and prosecutions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biologics and drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. After approval, most changes to the approved product, including changes in indications, labeling or manufacturing processes or facilities, require submission and FDA approval of a new marketing application or supplement to the approved marketing application before the change can be implemented. A supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing original application. There are also continuing annual program user fee requirements for marketed products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Adverse Event Reporting and GMP Compliance</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Adverse event reporting and submission of periodic reports are required following FDA approval of a marketing application. The FDA also may require post-market testing, including Phase 4 testing, implementation of a REMS, and/or surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, manufacturing, packaging, labeling, storage and distribution procedures must continue to conform to cGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">request product recalls or impose marketing restrictions through labeling changes or product removals if a company fails to comply with regulatory standards, if it encounters problems following initial marketing or if previously unrecognized problems are subsequently discovered.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and transparency laws and regulations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statutes or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases, may apply to items or services reimbursed by any third-party payer, including commercial insurers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, federal civil and criminal false claims laws, including the civil False Claims Act, prohibit knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the United States government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Violations of the False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of Medicare or Medicaid payable items or services. Noncompliance with such beneficiary inducement provision of the federal Civil Monetary </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Penalties Law can result in civil money penalties for each wrongful act, assessment of three times the amount claimed for each item or service and exclusion from the federal healthcare programs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Federal and state government price reporting laws require manufacturers to calculate and report complex pricing metrics to government programs. Such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products. Participation in these programs and compliance with the applicable requirements subject manufacturers to potentially significant discounts on products, increased infrastructure costs, and potentially limit the ability to offer certain marketplace discounts.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), among other things, imposed new reporting requirements on drug manufacturers for payments made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors, certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties for any payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission, and additional penalties for &#8220;knowing failures.&#8221; Certain states also mandate implementation of commercial compliance programs, impose restrictions on pharmaceutical manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third<span style="font-family:'Cambria Math';">&#8209;</span>party payers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti<span style="font-family:'Cambria Math';">&#8209;</span>Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some states also require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require manufacturers to report information related to payments and other transfers of value to healthcare providers and institutions as well as marketing expenditures and pricing information.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. A violation of any of such laws or any other applicable governmental regulations may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, additional reporting obligations and oversight if the government requires a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and/or imprisonment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Data Privacy and Security </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts and can result in investigations, proceedings or actions that lead to significant civil or criminal penalties or both and restrictions on data processing.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pharmaceutical Coverage, Pricing and Reimbursement</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the United States and other countries, sales of UDENYCA, YUSIMRY, LOQTORZI and any other products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payers, including government health administrative authorities, managed care providers, private health insurers and other organizations. Third-</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">party payers are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. In addition, the United States government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our net revenue and results. <span style="background:#ffffff;">A significant portion of our sales are subject to substantial discounts to list price, including rebates we may be required to pay to Medicaid agencies or discounts we may be required to pay to 340B covered entities. </span>Decreases in third-party reimbursement for UDENYCA, YUSIMRY, LOQTORZI or other products for which we receive regulatory approval or a decision by a third-party payer to not cover our products could reduce physician utilization of our products and have a material adverse effect on our sales, results of operations and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Price Reporting </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Medicaid is a joint federal and state program for low-income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Under the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;), as a condition of having federal funds available for our covered outpatient drugs under Medicaid and under Medicare Part B, we must enter into, and have entered into, an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of our covered outpatient drugs dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid rebates are based on pricing data that we are required to report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price (&#8220;AMP&#8221;) for each drug and, in the case of innovator products, the Best Price, which represents the lowest price available from us to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. In connection with Medicare Part B, we must provide CMS with Average Sales Price (&#8220;ASP&#8221;) information on a quarterly basis. CMS uses this information to compute Medicare Part B payment rates, which consist of ASP plus a specified percentage. If we become aware that our MDRP submissions for a prior period were incorrect or have changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. If we fail to provide information timely or are found to have knowingly submitted false information to CMS, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;) and requires us to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs when used in an outpatient setting. 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, a manufacturer must also participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA FSS program, we must report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers for the untimely, inaccurate, or incomplete reporting of drug pricing information or for otherwise failing to comply with drug price transparency requirements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform, including the IRA</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The United States federal and state governments continue to propose and pass legislation designed to regulate the healthcare industry, including legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing. Most significantly, on August 16, 2022, the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. In particular, if a product becomes subject to the IRA negotiation provision and related price cap, that may significantly alter the economic rationale for developing and commercializing a biosimilar.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Environment</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to a number of laws and regulations that require compliance with federal, state, and local regulations for the protection of the environment. The regulatory landscape continues to evolve, and we anticipate additional regulations in the near future. Laws and regulations are implemented and under consideration to mitigate the effects of climate change mainly caused by greenhouse gas emissions. Our business is not energy intensive. Therefore, we do not anticipate being subject to a cap and trade system, carbon emissions tax or other mitigation measure that would materially impact our capital expenditures, operations or competitive position. The building where our headquarters is located in Redwood City, California, has been awarded LEED Gold Certification from the United States Green Building Council. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Management</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 3, 2023, we committed to a plan to reduce our workforce to focus resources on strategic priorities including the commercialization of our diversified product portfolio and development of innovative immuno-oncology product candidates. We initiated a reduction in force impacting approximately 50 full-time and part-time employees effective March 10, 2023 for most of these employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had 306 full-time and part-time employees. All were located in the United States and none of our employees were represented by a labor union. We have not experienced any work stoppages and believe we have good relations with our employees and contractors. Our guiding principles are anchored on the goals of being able to recruit, incentivize, retain and integrate talented employees who can develop, implement, and drive long-term value creation strategies. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Compensation and Benefits&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe our base salaries are fair and competitive with the external labor markets in which our employees work and are reviewed on a regular basis. We offer incentive programs that provide bonus opportunities to encourage and reward participants for our achievement of financial and other key performance metrics and strengthen the<i style="font-style:italic;"> </i>connection between pay and performance. We also grant equity compensation awards that vest over time through our long-term incentive plan to employees to align such employees&#8217; incentives with our long-term strategic objectives and the interests of our stockholders.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We also offer competitive benefits to our employees, including paid vacation and holidays, family leave, disability insurance, life insurance, healthcare, dental and vision coverage, dependent care flexible spending accounts, a 401(k) plan with a company match, and an Employee Stock Purchase Plan. Additionally, we offer an Employee Assistance Program (&#8220;EAP&#8221;) that includes professional support for employees to balance the stress of personal and professional demands.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Inclusion and Diversity</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">People are a critical component of our efforts to drive growth and deliver value for stockholders. One of the ways we have put people at the center of our business is by continuing to work toward a more inclusive and diverse workplace where each person feels respected, valued and seen and can be the best version of themselves. We believe that having a truly diverse workplace helps our company to achieve the best results, including by striving for diversity in terms of gender, ethnicity, nationality, disability status, veteran status and other factors. We launched our Diversity and Inclusion Program to our employees in 2020 and intend to continue implementation of the program in 2024. As of December 31, 2023, ethnically diverse employees represented approximately 37% of our employees and women composed 49% of our employees. We donate to non-profit organizations such as Life Science Cares, an organization focused on eliminating the impact of poverty on our neighbors. Our Chief Executive Officer also serves on the Board of Advisors of Life Science Cares.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Health and Safety</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are committed to a safe workplace for our employees and have implemented health and safety management processes, including training and awareness, into our operations. In response to the COVID-19 pandemic, we implemented additional safety measures for the protection of our employees, including work-from-home measures for applicable employees and additional cleaning and protective measures. We require that all employees are fully vaccinated for COVID-19 and recommend they get all booster shots recommended by the United States Centers of Disease Control and Prevention. We react to emergencies on an ongoing basis to protect our employees.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Training, Development and Engagement</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Through our online learning platform, we deliver a variety of required learning modules, including those modules tied to our Code of Business Conduct, unlawful harassment and anti-corruption policies, which are completed periodically by all team members. We also have Performance Management Training and Interview Training programs for our managers. We have a highly collaborative, engaging company environment.<span style="font-family:'Times New Roman','Times','serif';"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Additional Information</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We view our operations and measure our business as one reportable segment operating primarily in the United States. See &#8220;Note&#160;1. Organization and Significant Accounting Policies&#8221; in the Notes to Consolidated Financial Statements contained in Part II, Item 8 of this Annual Report on Form&#160;10-K for additional information. Additional information required by this item is incorporated herein by reference to Part&#160;I, Item&#160;1A &#8220;Risk Factors.&#8221; </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in September&#160;2010. We completed the initial public offering of our common stock in November&#160;2014. Our common stock is currently listed on The Nasdaq Global Market under the symbol &#8220;CHRS.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 333 Twin Dolphin Drive, Suite&#160;600, Redwood City, CA 94065, and our telephone number is (650) 649-3530.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">You may find electronic copies of our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934 on our website at https://www.coherus.com free of charge. We also periodically release and publicize press releases to the public that are also available on our website&#8217;s section entitled &#8220;News&#8221; which we use as a recognized channel of distribution for our investors and other people interested in our company. The SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. Such filings are placed on our website as soon as reasonably possible after they are filed with the SEC. Our most recent charter for our audit, compensation, and nominating and corporate governance committees and our Code of Business Conduct and Ethics are available on our website as well. Any waiver of our Code of Business Conduct and Ethics may be made only by our board of directors. Any waiver of our Code of Business Conduct and Ethics for any of our directors or executive officers must be disclosed on a Current Report on Form&#160;8-K within four business&#160;days, or such shorter period as may be required under applicable law.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cdbab9e7_f6f0_4482_91b2_d96f8c68047f"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;&#160;<span style="font-style:italic;">Risk Factors</span></p><a id="Item1ARiskFactors_350560"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Risk Factor</span><span style="font-style:italic;"> Summary</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:18pt 0pt 0pt 0pt;"><i style="font-style:italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report on Form 10-K, </i><i style="font-style:italic;">including our financial statements and related notes thereto, </i><i style="font-style:italic;">before making investment decisions regarding our common stock.</i></p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited history of profitability, which we have not maintained and may not achieve again, and only three products that have been approved and marketed, with multiple products that are not approved and still in development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The commercial success of our existing products or any future products will depend upon the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining placement on national and/or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">As we have in-licensed development and/or commercial rights to LOQTORZI, we rely on prior and ongoing preclinical, clinical, regulatory and manufacturing expertise of our collaborators in order to advance this product candidate through regulatory approvals in the United States and other licensed territories.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products and our product candidates, even if approved, will remain subject to regulatory scrutiny.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages, government shut-downs or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and conduct inspections of manufacturing facilities, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our biosimilar products face significant competition from the reference products and from other biosimilar products or pharmaceuticals approved for the same indication as the originator products. LOQTORZI faces significant competition from other immuno-oncology biologics. If we fail to compete effectively, we may not achieve significant market penetration and expansion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If an improved version of an originator product, such as Neulasta or Humira, is developed or if the market for the originator product significantly declines, sales of our biosimilar products may suffer. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare reform measures, including the IRA, may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to a multitude of manufacturing risks and the risks of inaccurately forecasting sales of our products. We also need to make a determination of excess or obsolete inventory that requires significant judgment and may result in write-downs of </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inventory, charges related to firm purchase commitments, or both. Any adverse developments affecting the manufacturing operations of our products and product candidates could substantially increase our costs and limit supply for our products and product candidates. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The continuation of the war between Russia and Ukraine and conflicts in the Middle East may exacerbate certain risks we face.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products or our product candidates may cause undesirable side effects or have other properties that could, as applicable, delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the development, clinical success, regulatory approval and commercial success of our product candidates. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Risk Factors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:normal;">Investing in the common stock of a biopharmaceutical company, including one with significant international partnerships and multiple products in development, is a highly speculative undertaking and involves a substantial degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">We have a limited history of profitability, which we have not maintained and may not achieve again, and only three products that have been approved and marketed, with multiple products that are not approved and still in development.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">With the exception of generating net income of $132.2 million and $89.8 million in 2020 and 2019, respectively, we incurred net losses in each year from our inception in September 2010 through December&#160;31, 2023, including net losses of $237.9 million, $291.8 million and $287.1 million in 2023, 2022 and 2021, respectively. It is uncertain that we will be profitable in future periods as research and development is expensive and risky. The amount of our future net losses or any future net income will depend, in part, on the amount of our future expenditures offset by the amount of future product sales, including sales of our current products or any other products that may receive regulatory approval. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">For example, as of December 31, 2023, we had an accumulated deficit of $1.6 billion. The losses and accumulated deficit were primarily due to the substantial investments we made to identify, develop or license our product candidates, including conducting, among other things, analytical characterization, process development and manufacturing, formulation and clinical studies and providing general and administrative support for these operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk106783503"></a><a id="_Hlk106782865"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We have incurred and anticipate we will continue to incur certain development and commercial expenses for LOQTORZI, the anti-PD-1 antibody we licensed from Junshi Biosciences in 2021, and have agreed to pay up to $90.0 million for the achievement of certain regulatory approvals and up to $290.0 million for the attainment of certain sales thresholds. The recent launch of this product and future work to advance our product candidates through clinical development will be expensive and could result in us continuing to experience future net losses.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">For YUSIMRY, UDENYCA and LOQTORZI which are launched products, and if we obtain regulatory approval to market any other product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payers, and adequate market share for our product candidates which include all product candidates for which we obtained commercial rights, in those markets. However, even </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">if additional product candidates in addition to our current products gain regulatory approval and are commercialized, we may not remain profitable.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our expenses will increase substantially if and as we: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">further develop our sales, marketing and distribution infrastructure for our current products and develop such infrastructure for new products once they are launched;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure to commercialize any of our product candidates for which we may obtain marketing approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">make upfront, milestone, royalty or other payments under any license agreements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our nonclinical and clinical development of our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate additional nonclinical, clinical or other studies for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expand the scope of our current clinical studies for our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">advance our programs into more expensive clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">change or add contract manufacturers, clinical research service providers, testing laboratories, device suppliers, legal service providers or other vendors or suppliers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for our product candidates that successfully complete clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify, assess, acquire and/or develop other product candidates or products that may be complementary to our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to create, maintain, protect and expand our intellectual property portfolio; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">engage legal counsel and technical experts to help us evaluate and avoid infringing any valid and enforceable intellectual property rights of third parties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in litigation, including patent litigation, and Inter Partes Review (&#8220;IPR&#8221;) proceedings with originator companies or others that may hold patents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to attract and retain skilled personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">experience any delays or encounter issues with any of the above, including but not limited to failed studies, conflicting results, safety issues, manufacturing delays, litigation or regulatory challenges that may require longer follow-up of existing studies, additional major studies or additional supportive studies or analyses in order to pursue marketing approval. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 49pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Further, the net loss or net income we achieve may fluctuate significantly from quarter-to-quarter and year-to-year such that a period-to-period comparison of our results of operations may not be a good indication of our future performance quarter-to-quarter and year-to-year due to factors including the timing of clinical trials, any litigation that we may initiate or that may be initiated against us as well as any settlements or judgments from such litigation, the execution of collaboration, licensing or other agreements and the timing of any payments we make or receive thereunder.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We continue to be dependent on the ability to raise funds. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization efforts or other operations. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As of December 31, 2023, our cash, cash equivalents and marketable securities were $117.7 million. We expect that our existing cash and cash equivalents, investments and cash collected from our product sales will be sufficient to fund our current operations for the foreseeable future. We have financed our operations primarily through the sale of equity securities, convertible notes, credit facilities, license agreements and through recent product sales of our products.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">However, our operating or investing plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue to successfully commercialize our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, results and cost of any clinical studies, nonclinical testing and other related activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical drug supplies and establishing commercial supplies, of our product candidates and any products that we may develop; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of regulatory approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully integrate the business of Surface following consummation of the Surface Acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of establishing sales, marketing and distribution capabilities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any licensing or other arrangements to acquire intellectual property rights that we may establish, including any milestone and royalty payments thereunder; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of conversion in common shares or repayment in cash of our convertible debt, or the timing of repayment in cash, whether due or not, of our long-term debt; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of any litigation that we may file against third parties or that may be filed against us by third parties. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The sale of additional equity or convertible securities, such as the sales from time to time through our sales agreement dated November 8, 2022 (&#8220;Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;TD Cowen&#8221;) pursuant to which we may issue and sell from time to time up to $150.0 million of our common stock through or to TD Cowen as our sales agent or principal in an at-the-market offering (&#8220;ATM Offering&#8221;), may dilute the share ownership of our existing stockholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as those contained in the loan agreement we entered into in January 2022 (as amended to date, the &#8220;Loan Agreement&#8221;) with BioPharma Credit PLC, (as the &#8220;Collateral Agent&#8221;), BPCR Limited Partnership, (as a &#8220;Lender&#8221;) and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#8220;Lender&#8221;) that provides for a senior secured term loan facility of up to $300.0 million, including limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. For more information on our restrictive covenants please read the Loan Agreement, the First Amendment to Loan Agreement, the Second Amendment and Waiver to Loan Agreement, and Consent, Partial Release and Third Amendment dated February 5, 2024 (the &#8220;Consent and Amendment&#8221;) among us, the Collateral Agent and the Lenders &#160;filed as exhibits to our public filings. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage or for a lower price than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or for specific strategic considerations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage or for a lower price than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or for specific strategic considerations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we are unable to obtain funding on a timely basis or at all, stay profitable or generate any net profits, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any products or product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our financial condition and results of operations. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Launch and Commercialization of our Products and our Product Candidates</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We have a limited operating history in an emerging regulatory environment on which to assess our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We are a biopharmaceutical company with a limited operating history in an emerging regulatory environment of biosimilar and immuno-oncology products. Although we have received upfront payments, milestone and other contingent payments and/or funding for development from some of our collaboration and license agreements, our only approved products include UDENYCA, YUSIMRY and LOQTORZI which are approved for commercialization in the United States, and we have no products approved in any other territories.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our ability to generate meaningful revenue and remain profitable depends on our ability, alone or with strategic collaboration partners, to successfully market and sell our products, and to complete the development of, and obtain the regulatory approvals necessary to commercialize, one or more of our product pipeline candidates, which include: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-1000</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">casdozokitug; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-114.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We may not be able to continue to generate meaningful revenue from product sales, as this depends heavily on our success in many areas, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue to successfully commercialize all three UDENYCA product presentations and LOQTORZI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize YUSIMRY in a very competitive adalimumab market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competing against numerous current and future pegfilgrastim, ranibizumab and adalimumab products with significant market share; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare providers, payers, and patients adopting our products and product candidates once approved and launched;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to procure and commercialize our in-licensed biosimilar candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining additional regulatory approvals for product candidates for which we complete clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining adequate third-party coverage and reimbursements for our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of our products and product candidates as viable treatment options; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">completing nonclinical and clinical development of our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and testing of our product formulations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">developing a sustainable and scalable manufacturing process for our products and any approved product candidates and establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our products and product candidates, if approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, assessing and developing (or acquiring/in-licensing on favorable terms) new product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">defending against any litigation including patent or trade secret infringement lawsuits, which may be filed against us, or achieving successful outcomes of IPR petitions that we have filed, or may in the future file, against third parties.</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs to commercialize any such product. Our expenses could increase beyond our expectations if we are required by the FDA, the European Medical Agency (the &#8220;EMA&#8221;), other regulatory agencies, domestic or foreign, or by any unfavorable outcomes in intellectual property litigation filed against us, to change our manufacturing processes or assays or to perform clinical, nonclinical or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining additional regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the number of biosimilar or immuno-oncology competitors in such markets, the accepted price for the product, the ability to get reimbursement at any price, the nature and degree of competition from originators and other biosimilar or immuno-oncology companies (including competition from large pharmaceutical companies entering the biosimilar market or possessing large established positions in the immuno-oncology market that may be able to gain advantages in the sale of biosimilar or immuno-oncology products based on brand recognition and/or existing relationships with customers and payers) and whether we own (or have partnered with companies owning) the commercial rights for that territory. If the market for our products and product candidates (or our share of that market) is not as significant as we expect, the price of our products is not what we project, the indication approved by regulatory authorities is narrower than we expect or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are unable to successfully complete development and obtain additional regulatory approval for our products, our business may suffer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The commercial success of our existing products or any future products will depend upon the degree of market acceptance and adoption by prescribing physicians, healthcare providers and the patients to whom our medicines are prescribed. Additionally, obtaining placement on national and/or local clinical guidelines/pathways, as well as coverage on third-party payor formularies, can impact our short and long-term financial performance</span><span style="font-style:italic;">. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Even with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products or product candidates, if approved, will depend in part on the medical community, patients and third-party payers accepting our products and product candidates as medically useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payers and others in the medical community. The degree of market acceptance of our recently launched product, LOQTORZI, or any of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety and efficacy of the product, as demonstrated in clinical studies, and potential advantages over competing treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects and any limitations or warnings contained in a product&#8217;s approved labeling; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which approval is granted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for our immuno-oncology product candidates, our ability to compete in a competitive immuno-oncology market that may differ from the biosimilar market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inclusion, in either parity or better position, on commonly accepted clinical guidelines or pathways that influence prescribing patterns and/or affect reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience, ease of administration and any real or perceived benefit from administration at home as opposed to in the clinic; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prevalence of the disease or condition for which the product is approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment, particularly in relation to competing treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support and timing of market introduction of competitive products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which the product is approved for inclusion on formularies of hospitals, integrated delivery networks and managed care organizations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products or competing products and treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which third-party payers (including government and national/regional commercial plans) provide adequate third-party coverage and reimbursement for our products and product candidates, if approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the price at which we sell our products; </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential impact of the IRA on the pharmaceutical industry and the market for biosimilars;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the actions taken by current and future competitors to delay, restrict or block customer usage of the product; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain compliance with regulatory requirements. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Market acceptance of any future product candidates, if approved, will not be fully known until after they are launched and may be negatively affected by a potential poor safety experience and the track record of other biosimilar and immuno-oncology products and product candidates. Further, continued market acceptance of UDENYCA, LOQTORZI and YUSIMRY, and any future product candidates that may be approved, depends on our efforts to educate the medical community and third-party payers on the benefits of our products and product candidates and will require significant resources from us and we have significantly less resources compared to large, well-funded pharmaceutical entities. Given the resource disparity, our outreach may have little success or may never be successful. If our products or any future product candidates that are approved fail to achieve an adequate level of acceptance by physicians, patients, third-party payers and others in the medical community, we will not be able to generate sufficient revenue to sustain profitability.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The third-party coverage and reimbursement status of our products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Pricing, coverage and reimbursement of our products, or any of our product candidates, if approved, may not be adequate to support our commercial infrastructure. The prices required to successfully compete may not continue to be sufficient to recover our development and manufacturing costs, and as a result, we may not be profitable in the future. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and commercial payers are essential to enable provider/patient access to our products and our patient support services must be sufficiently scaled to meet the needs of patients receiving our products. Sales will depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations or reimbursed by government authorities, private health insurers and other third-party payers. If coverage and reimbursement are not available, or are available only to limited levels, or become unavailable, we may not be able to successfully commercialize our products or any of our product candidates, if approved. Even if coverage is provided, the approved reimbursement amount may not be adequate to allow us to establish or maintain pricing sufficient to realize a return on our investment. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payers, including private and governmental payers such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older or those who are disabled or suffering from end-stage renal disease. The Medicaid program, which varies from state to state, covers certain individuals and families who have limited financial means. The Medicare and Medicaid programs increasingly are used as models for how private payers and other governmental payers develop their coverage and reimbursement policies for drugs and biologics. It is difficult to predict what third-party payers will decide with respect to the coverage and reimbursement for any newly approved product. In addition, in the United States, no uniform policy of coverage and reimbursement for biologics exists among third-party payers. Therefore, coverage and reimbursement for biologics can differ significantly from payer to payer. As a result, the process for obtaining favorable coverage determinations often is time-consuming and costly and may require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be obtained. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Effective January 2019, CMS assigned a product specific Q-Code to UDENYCA, which is necessary to enable providers to separately bill for UDENYCA to have its own reimbursement rate with Medicare or other third-party payers. However, reimbursement is not guaranteed, and rates may vary based on product life cycle, site of care, type of payer, coverage decisions, and provider contracts. Furthermore, while payers have adopted the Q-Codes assigned by CMS for UDENYCA, there remains uncertainty as to whether such payers will continue to cover and pay providers for the administration and use of the product with each patient or may favor competing products. If our products or any of our future product candidates, are not covered or adequately reimbursed by third-party payers, including Medicare, then the cost of the relevant product may be absorbed by healthcare providers or charged to patients. If this is the case, our expectations of the pricing we expect to achieve for such product and the related potential revenue, may be significantly diminished.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Outside of the United States, pharmaceutical businesses are generally subject to extensive governmental price controls and other market regulations. We believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Increasing efforts by governmental and third-party payers in the United States and abroad to control healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or any of our product candidates. While cost containment practices generally benefit biosimilars, severe cost containment practices may adversely affect our product sales. Furthermore, the impact of the IRA on our business and the pharmaceutical industry generally is currently unknown. We expect to experience pricing pressures in connection with the sale of our products and any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our products and our product candidates, even if approved, will remain subject to regulatory scrutiny.</span></p><a id="_cp_text_1_36"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our products and our product candidates, even If approved, will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to &#8220;cGMP&#8221; regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, original BLA submitted under Section 351(a) of the Public Health Service Act PHSA, Section 351(k) BLA or MAA. Accordingly, we and others with whom we work must continue to spend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any regulatory approvals that we or our collaboration partners receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or may contain requirements for potentially costly additional clinical trials and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse events and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization or increased costs to ensure compliance. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. If our product candidates are approved, we must submit new or supplemental applications and obtain approval for certain changes to the approved products, product labeling or manufacturing process. We or our collaboration partners could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval is obtained via an accelerated biosimilar approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other possibilities: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impose civil or criminal penalties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a product recall. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </p><a id="_cp_text_1_34"></a><a id="_cp_text_1_35"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States, China or other foreign countries.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages, government shut-downs or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, and conduct inspections of manufacturing facilities, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:12pt 0pt 0pt 0pt;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, government shut-downs, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.&#160;For example, over the last several years, the United States government has periodically shut down and certain regulatory agencies, such as the&#160;FDA, had to furlough critical&#160;FDA&#160;employees and stop critical activities.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations, any resurgence of the virus or emergence of new variants may lead to further administrative or inspectional delays. If a prolonged government shutdown occurs it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Competitive Activity</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our biosimilar products face significant competition from the reference products and from other biosimilar products or pharmaceuticals approved for the same indication as the originator products. Our product LOQTORZI and product candidate CHS-114, if approved, will face significant competition from other immuno-oncology biologics. If we fail to compete effectively, we may not achieve significant market penetration and expansion.</span></p><a id="_Hlk151972096"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"> We operate in highly competitive pharmaceutical markets. Successful competitors in the pharmaceutical market have demonstrated the ability to effectively discover molecules, obtain patents, develop, test and obtain regulatory approvals for products, as well as an ability to effectively commercialize, market and promote approved products. Numerous companies, universities and other research institutions are engaged in developing, patenting, manufacturing and marketing of products competitive with those that we are developing. Many of these potential competitors are large, experienced multinational pharmaceutical and biotechnology companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, legal, governmental affairs, manufacturing, personnel, and marketing resources, with additional benefits of mergers and acquisitions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">LOQTORZI recently entered a competitive market in the United States where a number of anti-PD-1 or PD-L1 antibody drugs have been approved by the FDA including the following marketed products from several competitors: Keytruda&#174; (pembrolizumab) from Merck, Opdivo&#174; (nivolumab) from BMS, Tecentriq&#174; (atezolizumab) from Genentech, Imfinzi&#174; (durvalumab) from AstraZeneca, Bavencio&#174; </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">(avelumab) from EMD Serono Inc. and Pfizer, and Libtayo&#174; (cemiplimab-rwlc) from Regeneron and Sanofi, and Jemperli (dostarlimab-gxly) from GlaxoSmithKline. In addition to LOQTORZI, multiple other competitors are seeking to develop and approve novel anti-PD-1 or PD-L1 antibody drugs in the United States in the coming years, including but not limited to BeiGene, Ltd. (in collaboration with Novartis). As the only immunotherapy approved by the FDA for the treatment of NPC, we believe LOQTORZI addresses a potentially high unmet need.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">CHS-114, if approved, faces competition from programs in development specifically targeting CCR8, including those by Bristol-Myers Squibb Company, Gilead/Jounce, Shionogi, AbbVie, Bayer, LaNova and Immunophage;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">UDENYCA faces competition in the United States from Amgen, Viatris, Sandoz, Pfizer, and Spectrum, and is expected to face competition from Amneal and Fresenius, each of which has announced the approval of a pegfilgrastim biosimilar<span style="background:#ffffff;"> and have launched their products for sale in the United States.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">YUSIMRY, following our launch in July 2023, faces competition in the United States from AbbVie (the holder of rights to Humira), Amgen (Amjevita<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-atto)), Sandoz (Hyrimoz<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-adaz)), Samsung Bioepis (Hadlima<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-bwwd)), Pfizer (Abrilada<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-afzb)), Boehringer Ingelheim (Cyltezo<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (adalimumab-adbm)) as well as Viatris / Biocon (Hulio&#174; (adalimumab-fkjp)), Alvotech Holdings S.A. and Fresenius, each a company that has disclosed development plans for a Humira biosimilar candidate. As a result of continued expected competition from Humira and a large number of potential adalimumab (Humira) biosimilar competitors, we may not be able to achieve substantial topline sales for YUSIMRY in the United States.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">These companies may also have greater brand recognition and more experience in conducting preclinical testing and clinical trials of product candidates, obtaining FDA and other regulatory approvals of products and marketing and commercializing products once approved. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, many manufacturers of originator products have increasingly used legislative, regulatory and other means, such as litigation, to delay regulatory approval and to seek to restrict competition from manufacturers of biosimilars. These efforts may include or have included: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">settling, or refusing to settle, patent lawsuits with biosimilar companies, resulting in such patents remaining an obstacle for biosimilar approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">submitting Citizen Petitions to request the FDA Commissioner to take administrative action with respect to prospective and submitted biosimilar applications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">appealing denials of Citizen Petitions in United States federal district courts and seeking injunctive relief to reverse approval of biosimilar applications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restricting access to reference brand products for equivalence and biosimilarity testing that interferes with timely biosimilar development plans; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">attempting to influence potential market share by conducting medical education with physicians, payers, regulators and patients claiming that biosimilar products are too complex for biosimilar approval or are too dissimilar from originator products to be trusted as safe and effective alternatives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing payer market access tactics that benefit their brands at the expense of biosimilars; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 49pt;">seeking state law restrictions on the substitution of biosimilar products at the pharmacy without the intervention of a physician or through other restrictive means such as excessive recordkeeping requirements or patient and physician notification;</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking federal or state regulatory restrictions on the use of the same non-proprietary name as the reference brand product for a biosimilar or interchangeable biologic; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking changes to the United States Pharmacopeia, an industry recognized compilation of drug and biologic standards; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining new patents covering existing products or processes, which could extend patent exclusivity for a number of years or otherwise delay the launch of biosimilars; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">influencing legislatures so that they attach special patent extension amendments to unrelated federal legislation. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our products and our product candidates, if approved, could face price competition from other products or biosimilars of the same reference products for the same indication. This price competition could exceed our capacity to respond, detrimentally affecting our market share and revenue as well as adversely affecting the overall financial health and attractiveness of the market for the biosimilar.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Competitors in the biosimilar market have the ability to compete on price through PBMs, payers and their third-party administrators, IDNs and hospitals who exert downward pricing pressure on our product offerings. It is possible our biosimilar competitors&#8217; compliance with price discounting demands in exchange for market share or volume requirements could exceed our capacity to respond in kind and reduce market prices beyond our expectations. There could be similar price competition in the immuno-oncology market that could adversely affect our results in the future. Such practices may limit our ability to increase market share and may also impact profitability.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, less costly, easier to administer or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop; they may also obtain patent protection that could block our products; and they may obtain regulatory approval, product commercialization and market penetration earlier than we do. Our competitors may have products that are easier to administer than our products, which could adversely affect our results, such as due to the observed trend that a large number of patients demonstrate a preference to administer medication at home due to COVID-19 or other factors. Biosimilar or immuno-oncology product candidates developed by our competitors may render our potential product candidates uneconomical, less desirable or obsolete, and we may not be successful in marketing our product candidates against competitors. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If other competitors to LOQTORZI (in indications besides NPC), casdozokitug and CHS-114 are approved and successfully commercialized before LOQTORZI (in indications besides NPC), casdozokitug and CHS-114, our business would suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">There are a number of companies that currently commercialize PD-1/PD-L1 blocking antibodies or are developing such compounds for commercialization in the United States. If other competitors to LOQTORZI (in indications besides NPC), casdozokitug and CHS-114 are successfully commercialized before LOQTORZI (in indications besides NPC), casdozokitug and CHS-114, we may never achieve meaningful market share for these products, our revenue would be reduced and, as a result, our business, prospects and financial condition could suffer. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">If an improved version of an originator product, such as Neulasta or Humira, is developed or if the market for the originator product significantly declines, sales of our biosimilar products may suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Originator companies may develop improved versions of a reference product as part of a life cycle extension strategy and may obtain regulatory approval of the improved version under a new or supplemental BLA submitted to the applicable regulatory authority. Should the originator company succeed in obtaining an approval of an improved biologic product, it may capture a significant share of the collective reference product market in the applicable jurisdiction and significantly reduce the market for the reference product and thereby the potential size of the market for our biosimilar products. In addition, the improved product may be protected by additional patent rights that may subject our follow-on biosimilar to claims of infringement. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Biologic reference products may also face competition as technological advances are made that may offer patients a more convenient form of administration or increased efficacy or as new products are introduced. External developments can also result in changing preferences for convenient forms of administration of products that may impact our business. As new products are approved that compete with the reference product to our biosimilar products, sales of the reference originator product may be adversely impacted or rendered obsolete. If the market for the reference product is impacted, we may lose significant market share for our approved biosimilar products. As a result of the above factors, our business, prospects and financial condition<b style="font-weight:bold;"> </b>could suffer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates for which we intend to seek approval as original biologic products may face competition sooner than anticipated.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our development of novel biologic product candidates, such as casdozokitug and CHS-114, subjects us to additional risks relating to biosimilar competition. In particular, under the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We believe that LOQTORZI and any of our future product candidates approved under an original BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:18pt 0pt 12pt 0pt;">Risks Related to Our Ability to Hire and Retain Highly Qualified Personnel </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, product development and scientific personnel, our business will suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We are highly dependent on the principal members of our management and scientific and technical staff. The loss of service of any of our management or key scientific and technical staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, product development and scientific personnel. If we are not able to retain our management, particularly our President and Chief Executive Officer, Mr.&#160;Lanfear, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We will need to expand and effectively manage our managerial, scientific, operational, financial, commercial and other resources in order to successfully pursue our product development and commercialization efforts. Our success also depends on our continued ability to attract, retain and motivate highly qualified management and technical personnel. We may not be able to attract or retain qualified management and scientific and product development personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly those located in the San Francisco Bay Area. We also use equity compensation as a part of a comprehensive compensation package for our personnel. The majority of our outstanding options have exercise prices that are above our current stock price. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We may need to expand our organization, particularly due to employee turnover, and we may experience difficulties in managing this turnover, which could disrupt our operations. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As of December 31, 2023, we had 306 full-time and part-time employees. As our development and commercialization plans and strategies develop and evolve from time to time, and as we experience turnover, we may need to hire additional people in the future. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these hiring activities. We may not be able to effectively manage during a period of employee turnover, which </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future product candidates. If our management is unable to effectively manage our turnover, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Reliance on Third Parties</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We have relied upon and plan to continue to rely upon third-party clinical research organizations (&#8220;CROs&#8221;) to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with cGMP, GCP, and GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections or remote regulatory assessments (&#8220;RRAs&#8221;) of study sponsors, principal investigators, study sites and other contractors. If we, any of our CROs, service providers or investigators fail to comply with applicable regulations or GCPs, the data generated in our nonclinical and clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional nonclinical and clinical studies before approving our marketing applications. There can be no assurance that upon inspection or conclusion of an RRA by a given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must be conducted with product generated under cGMP regulations. Failure to comply by any of the participating parties or ourselves with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process. Moreover, our business may be implicated if our CRO or any other participating parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our clinical studies may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, a transition period is necessary when a new CRO commences work, which can materially impact our ability to meet our desired clinical development timelines. Though we strive to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, prospects and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We rely on third parties, and in some cases a single third party, to manufacture nonclinical, clinical and commercial drug supplies of our product candidates and to store critical components of our product candidates for us. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product candidates or fail to do so at acceptable quality levels or prices. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We do not currently have the infrastructure or capability internally to manufacture supplies of our product candidates for use in our nonclinical and clinical studies, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on third-party manufacturers to manufacture and supply us with our product candidates for our preclinical and clinical studies as well as to establish commercial supplies of our product candidates. Successfully transferring complicated manufacturing techniques to contract manufacturing organizations and scaling up these techniques for commercial quantities is time consuming and we </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">may not be able to achieve such transfer or do so in a timely manner. Moreover, the availability of contract manufacturing services for protein-based therapeutics is highly variable and there are periods of relatively abundant capacity alternating with periods in which there is little available capacity. If our need for contract manufacturing services increases during a period of industry-wide production capacity shortage, we may not be able to produce our product candidates on a timely basis or on commercially viable terms. Although we will plan accordingly and generally do not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete such study, any significant delay or discontinuation in the supply of a product candidate for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates, which could harm our business and results of operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third-party manufacturers may not be able to comply with cGMP or similar regulatory requirements outside the United States. Our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or any other product candidates or products that we may develop. Any failure or refusal to supply the components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected products or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If any of our product candidates are approved, in order to produce the quantities necessary to meet anticipated market demand, any contract manufacturer that we engage may need to increase manufacturing capacity. If we are unable to build and stock our product candidates in sufficient quantities to meet the requirements for the launch of these candidates or to meet future demand, our revenue and gross margins could be adversely affected. Although we believe that we will not have any material supply issues, we cannot be certain that we will be able to obtain long-term supply arrangements for our product candidates or materials used to produce them on acceptable terms, if at all. If we are unable to arrange for third-party manufacturing, or to do so on commercially reasonable terms, we may not be able to complete development of our product candidates or market them. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are dependent on Junshi Biosciences and Orox for the commercialization of our product candidates in certain markets and we intend to seek additional commercialization partners for major markets, and the failure to commercialize in those markets could have a material adverse effect on our business and operating results. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We have exclusive licenses from Junshi Biosciences to develop and commercialize LOQTORZI in the United States and Canada. Our licensors are responsible for supplying us with drug substance and final drug products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our exclusive licensee, Orox, is responsible for commercialization of certain of our products and product candidates, including UDENYCA and YUSIMRY in certain Caribbean and Latin American countries (excluding Brazil, and in the case of UDENYCA, also excluding Argentina). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Our licenses with Junshi Biosciences, Bioeq, Orox, or other future license or collaboration agreements, may not result in positive outcomes. Factors that may affect the success of our licenses and collaborations include, but are not limited to, the following:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential collaboration partners may fail to provide sufficient amounts of commercial products, including because of import restrictions, or they may be ineffective in doing so;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential collaboration partners may fail regulatory inspections or RRAs which may preclude or delay the delivery of commercial products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential collaboration partners may fail to exercise commercially reasonable efforts to market and sell our products in their respective licensed jurisdictions or they may be ineffective in doing so; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential licensees and collaboration partners may incur financial, legal or other difficulties that force them to limit or reduce their participation in our joint projects;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential licensees and collaboration partners may terminate their licenses or collaborations with us, which could make it difficult for us to attract new partners or adversely affect perception of us in the business and financial communities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our existing and potential licensees and collaboration partners may choose to pursue alternative, higher priority programs, which could affect their commitment to us. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Moreover, any disputes with our licensees and collaboration partners will substantially divert the attention of our senior management from other business activities and will require us to incur substantial costs associated with litigation or arbitration proceedings. If we cannot maintain successful license and collaboration arrangements, our business, financial condition and operating results may be adversely affected.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Manufacturing and Supply Chain </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We are subject to a multitude of manufacturing risks and the risks of inaccurately forecasting sales of our products. We also need to make a determination of excess or obsolete inventory that requires significant judgment and may result in write-downs of inventory, charges related to firm purchase commitments, or both. Any adverse developments affecting the manufacturing operations of our products and product candidates could substantially increase our costs and limit supply for our products and product candidates. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product loss due to contamination, equipment failure or improper installation or operation of equipment or vendor or operator error; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">equipment failures, labor shortages, natural disasters, power failures and numerous other factors associated with the manufacturing facilities in which our product candidates are produced, and potentially exacerbated by climate change; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of supply chains for critical and specialized raw materials, delays in regulatory inspections of manufacturing and testing facilities, and reduced manufacturing capacities created by global events such as the COVID-19 pandemic and the ongoing conflict in Ukraine. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We have experienced reduced production yields, product defects and other supply disruptions. For example, we have experienced failures with respect to the manufacturing of certain lots of each of our product candidates resulting in delays prior to our taking corrective action. Additionally, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any adverse developments affecting manufacturing operations for our products and product candidates, including due to sudden or long-term changes in weather patterns or conflicts in particular geographic areas, may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of our product candidates. We also need to make a determination of excess or obsolete inventory that requires significant judgment and includes consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information and potential product obsolescence, among others. Although we believe that the assumptions we use in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by us, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in our consolidated statements of operations. Adverse developments affecting our assumptions of the level and timing of demand for our products include those that are outside of our control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors. We may have to take inventory write-downs and incur other charges and expenses, such as charges related to firm purchase commitments, for products that are manufactured in reliance on a forecast that proves to be inaccurate because we do not sell as many units as forecasted. For example, during the third quarter of 2022, we recorded a $26.0 million write-down of UDENYCA inventory that was at risk of expiration and during the fourth quarter of 2023, we recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. Although we believe that the assumptions that we use in estimating inventory write-downs are reasonable, additional write-downs of inventory may be required in the future if actual market conditions are less favorable than our projections, which could materially and adversely impact our financial results. In addition to such write-downs, we may also have to incur charges and expenses related to firm purchase commitments or for product candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">We currently engage single suppliers for manufacture, clinical trial services, formulation development and product testing of our product candidates. The loss of any of these suppliers or vendors could materially and adversely affect our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">For our products and our product candidates, we currently engage a distinct&#160;vendor or service provider for each of the principal activities supporting our manufacture and development of these products, such as manufacture of the biological substance present in each of the products, manufacture of the final filled and finished presentation of these products, as well as laboratory testing, formulation development and clinical testing of these products.&#160;Because we currently have engaged a limited number of back-up suppliers or vendors for these single-sourced services, and although we believe that there are alternate sources that could fulfill these activities, we cannot assure you that identifying and establishing relationships with alternate suppliers and vendors would not result in significant delay in the development of our product candidates. Additional delays or cost increases could occur due to the direct or indirect effects of the COVID-19 pandemic and the ongoing conflict in Ukraine.&#160;Additionally, we may not be able to enter into arrangements with alternative service providers&#160;on commercially reasonable terms or at all.&#160;A delay in the development of our product candidates, or having to enter into a new agreement with a different third party on less favorable terms than we have with our current suppliers, could have a material adverse impact on our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We and our collaboration partners and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We, our collaboration partners, or our contract manufacturers must supply all necessary documentation in support of a Section 351(k) BLA, original BLA, NDA or MAA on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our contract manufacturers may have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our collaboration partners and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The regulatory authorities also may, at any time following approval of a product for sale, inspect, audit or initiate an RRA of the manufacturing facilities of our collaboration partners and third-party contractors. If any such inspection, audit or RRA identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection, audit or RRA, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we, our collaboration partners or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate, withdrawal of an approval or suspension of production. As a result, our business, financial condition and results of operations may be materially harmed. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through a PAS, NDA supplement or MAA variation or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">These factors could cause us to incur additional costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenue. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The structure of complex proteins used in protein-based therapeutics is inherently variable and highly dependent on the processes and conditions used to manufacture them. If we are unable to develop manufacturing processes that achieve a requisite degree of biosimilarity to the originator drug, and within a range of variability considered acceptable by regulatory authorities, we may not be able to obtain regulatory approval for our biosimilar products. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Protein-based therapeutics are inherently heterogeneous and their structures are highly dependent on the production process and conditions. Products from one production facility can differ within an acceptable range from those produced in another facility. Similarly, physicochemical differences can also exist among different lots produced within a single facility. The physicochemical complexity and size of biologic therapeutics create significant technical and scientific challenges in the context of their replication as biosimilar products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The inherent variability in protein structure from one production lot to another is a fundamental consideration with respect to establishing biosimilarity to an originator product to support regulatory approval requirements. For example, the glycosylation of the protein, meaning the manner in which sugar molecules are attached to the protein backbone of a therapeutic protein when it is produced in a living cell, is critical to therapeutic efficacy, half-life, efficacy and even safety of the therapeutic and is therefore a key consideration for biosimilarity. Defining and understanding the variability of an originator molecule in order to match its glycosylation profile requires significant skill in cell biology, protein purification and analytical protein chemistry. Furthermore, manufacturing proteins with reliable and consistent glycosylation profiles at scale is challenging and highly dependent on the skill of the cell biologist and process scientist. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">There are extraordinary technical challenges in developing complex protein-based therapeutics that not only must achieve an acceptable degree of similarity to the originator molecule in terms of characteristics such as the unique glycosylation pattern, but also the ability to develop manufacturing processes that can replicate the necessary structural characteristics within an acceptable range of variability sufficient to satisfy regulatory authorities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Given the challenges caused by the inherent variability in protein production, we may not be successful in developing our biosimilar products if regulators conclude that we have not achieved a sufficient level of biosimilarity to the originator product, or that the processes we use are unable to generate our products within an acceptable range of variability. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:18pt 0pt 12pt 0pt;">Risks Related to Adverse Events </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our products or our product candidates may cause undesirable side effects or have other properties that could, as applicable, delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if granted. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As with most pharmaceutical products, use of our products or our product candidates could be associated with side effects or adverse events, which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our product candidates may be observed at any time, including in clinical trials or when a product is commercialized. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our studies could reveal a high and unacceptable severity and prevalence of side effects such as toxicity or other safety issues and could require us or our collaboration partners to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business. In such an event, we may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our product candidates, which we have not planned or anticipated or our studies could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any other regulatory agency in a timely manner, if ever, which could harm our business, prospects and financial condition. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, product quality characteristics have been shown to be sensitive to changes in process conditions, manufacturing techniques, equipment or sites and other such related considerations, hence any manufacturing process changes we implement prior to or after regulatory approval could impact product safety and efficacy. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Drug-related side effects could affect patient recruitment for clinical trials, the ability of enrolled patients to complete our studies or result in potential product liability claims. We currently carry product liability insurance and we are required to maintain product liability insurance pursuant to certain of our license agreements. We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we receive approval for our product candidates, regulatory agencies including the FDA and foreign regulatory agencies, regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or foreign regulatory agencies could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or extended delay in approval or clearance of future products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Adverse events involving an originator product, or other biosimilars of such originator product, may negatively affect our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In the event that use of an originator product, or other biosimilar for such originator product, results in unanticipated side effects or other adverse events, it is likely that our biosimilar product will be viewed comparably and may become subject to the same scrutiny and regulatory sanctions as the originator product or other biosimilar, as applicable. Accordingly, we may become subject to regulatory supervisions, clinical holds, product recalls or other regulatory actions for matters outside of our control that affect the originator product, or other biosimilar, as applicable, if and until we are able to demonstrate to the satisfaction of our regulators that our biosimilar product is not subject to the same issues leading to the regulatory action as the originator product or other biosimilar, as applicable. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed. Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our commercial success depends in large part on avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the pharmaceutical industry, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. The companies that originated the products for which we introduced biosimilar versions, such as Amgen, AbbVie and Genentech, as well as other competitors (including other companies developing biosimilars) have developed, and are continuing to develop, worldwide patent portfolios of varying sizes and breadth, many of which are in fields relating to our business, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. We are aware of third-party patents or patent applications with claims, for example, to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. While we have conducted freedom to operate analyses with respect to our products and our product candidates, including our in-licensed biosimilar candidates, as well as our pipeline candidates, we cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents covering our product candidates. With respect to products we are evaluating for inclusion in our future product pipeline, our freedom to operate analyses, including our research on the timing of potentially relevant patent expirations, are ongoing. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">There may also be patent applications that have been filed but not published and if such applications issue as patents, they could be asserted against us. For example, in most cases, a patent filed today would not become known to industry participants for at least 18 months given patent rules applicable in most jurisdictions, which do not require publication of patent applications until 18 months after filing. Moreover, some United States patents may issue without any prior publication in cases where the patent applicant does not also make a foreign filing. We may also face claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may have no deterrent effect. In addition, coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid and/or unenforceable, and we may not be able to do this. Proving that a patent is invalid or unenforceable is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Also, in proceedings before courts in Europe, the burden of proving invalidity of the patent usually rests on the party alleging invalidity. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial monetary damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on commercially acceptable terms or at all. If, as a result of patent infringement claims or to avoid potential claims, we choose or are required to seek licenses from third parties, these licenses may not be available on acceptable terms or at all. Even if we are able to obtain a license, the license may obligate us to pay substantial license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would likely involve substantial litigation expense and would likely be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may, in addition to being blocked from the market, have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On May 10, 2017, Amgen Inc. and Amgen Manufacturing Inc. filed an action against us in the United States District Court for the District of Delaware alleging infringement of one or more claims of Amgen&#8217;s US patent 8,273,707 (the &#8220;&#8216;707 patent&#8221;) under 35 U.S.C. &#167; 271. The complaint seeks injunctive relief, monetary damages and attorney fees. On December&#160;7, 2017, the United States Magistrate Judge issued under seal a Report and Recommendation to the District Court recommending that the District Court grant, with prejudice, our pending motion to dismiss Amgen&#8217;s complaint for failure to state a claim pursuant to Federal Rule of Civil Procedure 12(b)(6). On March 26, 2018, Judge Stark of the District Court adopted the United States Magistrate Judge&#8217;s Report and Recommendation to grant our motion pursuant to Federal Rule of Civil Procedure 12(b)(6) to dismiss with prejudice the patent infringement complaint alleging infringement of the &#8216;707 patent on the grounds that such complaint failed to state a claim upon which relief may be granted. In May 2018, Amgen filed a Notice of Appeal in the United States Court of Appeals for the Federal Circuit. We and Amgen filed briefs in this matter and oral argument </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">was held on May 8, 2019. On July 29, 2019, the Federal Circuit issued a precedential opinion affirming the District Court&#8217;s judgment in our favor. The Federal Circuit held that the doctrine of prosecution history estoppel barred Amgen from succeeding on its infringement claim and affirmed the District Court&#8217;s dismissal. In a Joint Status Report, dated September 20, 2019, Amgen stated that it does not intend to further appeal the Federal Circuit&#8217;s decision. On October 11, 2019, we filed a Motion for Attorneys&#8217; Fees with the District Court. Amgen filed its Answering Brief in Opposition on November 8, 2019. On November 22, 2019, we filed our Reply Brief with the District Court. On November 30, 2020, the District Court issued an order denying our motion.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On January 24, 2019, we entered into settlement and license agreements with AbbVie, which grant us global, royalty-bearing, non-exclusive license rights under AbbVie&#8217;s intellectual property to commercialize YUSIMRY. The global settlements resolved all the pending disputes between the parties related to YUSIMRY. Under the United States settlement, our license period in the United States commenced on July 1, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, IPR, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. An unfavorable outcome in any such proceeding could require us to cease using the related technology or to attempt to license rights to it from the prevailing party or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Third parties may submit applications for patent term extensions in the United States or other jurisdictions where similar extensions are available and/or Supplementary Protection Certificates in the E.U. states and Switzerland seeking to extend certain patent protection, which, if approved, may interfere with or delay the launch of one or more of our products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Patent litigation and other proceedings may fail, and even if successful, may result in substantial costs and distract our management and other employees. The companies that originated the products for which we intend to introduce biosimilar versions, as well as other competitors (including other biosimilar companies) may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We do not know whether any of our pending patent applications will result in the issuance of any patents or whether the rights granted under any patents issuing from these applications will prevent any of our competitors from marketing similar products that may be competitive with our own. Moreover, even if we do obtain issued patents, they will not guarantee us the right to use our patented technology for commercialization of our product candidates. Third parties may have blocking patents that could prevent us from commercializing our own products, even if our products use or embody our own, patented inventions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The validity and enforceability of patents are generally uncertain and involve complex legal and factual questions. Any patents that may be issued on our pending applications may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing products similar to ours. Furthermore, our competitors may develop similar or alternative technologies not covered by any patents that may issue to us.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">For technologies for which we do not seek patent protection, we may rely on trade secrets to protect our proprietary position. However, trade secrets are difficult to protect. We seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, advisors, contractors or collaborators. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, advisors, contractors and collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits or IPR proceedings to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We may discover that competitors are infringing our issued patents. Expensive and time-consuming litigation may be required to abate such infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including but not limited to lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone involved in the prosecution of the patent withheld relevant or material information related to the patentability of the invention from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if we cannot obtain a license from the prevailing party on commercially reasonable terms. Third parties may request an IPR of our patents in the USPTO. An unfavorable decision may result in the revocation of our patent or a limitation to the scope of the claims of our patents. Our defense of litigation, interference or IPR proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during any litigation we initiate to enforce our patents. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We employ individuals, retain independent contractors and consultants and members on our board of directors or scientific advisory board who were previously employed at universities or other pharmaceutical companies, including our competitors or potential competitors. For example, our Chief Executive Officer, Dennis&#160;M. Lanfear, is a former employee of Amgen. Mr.&#160;Lanfear was employed at Amgen during periods when Amgen&#8217;s operations included the development and commercialization of Neulasta. Senior members of our commercial team and medical affairs team who were responsible for the launch of additional presentations of UDENYCA formerly held positions at Amgen. Our board of directors and scientific advisory board include members who were former employees of Genentech, Amgen and Abbott Laboratories. Although we have procedures in place to try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On March 3, 2017, Amgen filed an action against us, KBI Biopharma, our employee Howard S. Weiser and Does 1-20 in the Superior Court of the State of California, County of Ventura. The complaint, which was amended, alleged that we engaged in unfair competition and improperly solicited and hired certain former Amgen employees in order to acquire and access trade secrets and other confidential information belonging to Amgen. The complaint, as amended, sought injunctive relief and monetary damages. On May 2, 2019, we and Amgen settled the trade secret action brought by Amgen. The details of the settlement are confidential, but we will continue to market UDENYCA and began paying a mid-single digit royalty to Amgen for five years starting on July 1, 2019.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We are a party to certain non-exclusive intellectual property license agreements with certain vendors (pertaining to mammalian cell lines) and with AbbVie (pertaining to AbbVie&#8217;s intellectual property related to YUSIMRY) that are important to our business, and we expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the license or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In the event we breach any of our obligations related to such agreements, we may incur significant liability to our licensing partners. Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patents and other rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and that could have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to our products and product candidates through acquisitions and in-licenses. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We currently have rights to certain intellectual property, through licenses from third parties and under patent applications that we own, to develop and commercialize our products and product candidates. Because we may find that our programs require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. We may also get into disputes or litigation with third parties from whom we license intellectual property rights necessary for the sale of our products. For example, on June 6, 2023 we received a notice letter from AbbVie alleging that we breached our settlement and license agreement with AbbVie (the &#8220;AbbVie Agreement&#8221;), which grants us a royalty-bearing, non-exclusive license under AbbVie&#8217;s intellectual property rights to commercialize YUSIMRY in the United States commencing on July 1, 2023, because of our announcement on June 1, 2023 of our pricing agreement with Mark Cuban Cost Plus Drug Company, PBC and its plans to offer YUSIMRY to its customers beginning in July 2023. The parties engaged in discussions to resolve the dispute and on June 14, 2023 entered into a stipulation resolving our motion for temporary restraining order, whereby AbbVie agreed that it will not seek to terminate the AbbVie Agreement based on its June 6, 2023 notice and that it will not terminate the AbbVie Agreement unless it first serves a new notice of breach and affords us an opportunity to cure any alleged breach. While we remain in discussion with AbbVie, the litigation is ongoing and there can be no guarantee we will reach resolution.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">If we are unable to successfully obtain required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to market our biosimilar products in the United States may be significantly delayed or prevented by the BPCIA patent dispute resolution mechanism. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The BPCIA created an elaborate and complex patent dispute resolution mechanism for biosimilars that, if we choose to implement it, could prevent us from launching our product candidates in the United States or could substantially delay such launches. However, even if we elect not to implement this mechanism, the launch of our products in the United States could still be prevented or substantially delayed by intellectual property disputes with originator companies that market the reference products on which our biosimilar products are based.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The BPCIA establishes a patent disclosure and briefing process between the biosimilar applicant and the originator that is demanding and time-sensitive. While certain aspects of this process are still being tested in the federal courts, the United States Supreme Court, as discussed further below, ruled in 2017 that this process is not mandatory, such that a biosimilar applicant may elect to engage in this process, but is not required to do so. The following is an overview of the patent exchange and patent briefing procedures established by the BPCIA for biosimilar applicants that elect to employ them: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosure of the Biosimilar Application. Within 20 days after the FDA publishes a notice that its application has been accepted for review, a Section 351(k) biosimilar applicant may elect to provide a copy of its application to the originator if it chooses to engage in the BPCIA patent exchange mechanism. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Identification of Pertinent Patents. Within 60 days of the date of receipt of the application the originator must identify patents owned or controlled by the originator, which it believes could be asserted against the biosimilar applicant. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Statement by the Biosimilar Applicant. Following the receipt of the originator&#8217;s patent list, the biosimilar applicant must state either that it will not market its product until the relevant patents have expired or alternatively provide its arguments that the patents are invalid, unenforceable or would not be infringed by the proposed biosimilar product candidate. The biosimilar applicant may also provide the originator with a list of patents it believes the brand-name firm could assert against the reference product. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Statement by the Originator. In the event the biosimilar applicant has asserted that the patents are invalid, unenforceable or would not be infringed by the proposed follow-on product, the originator must provide the biosimilar applicant with a response within 60 days. The response must provide the legal and factual basis of the opinion that such patent will be infringed by the commercial marketing of the proposed biosimilar. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent Resolution Negotiations. If the originator provides its detailed views that the proposed biosimilar would infringe valid and enforceable patents, then the parties are required to engage in good faith negotiations to identify which of the discussed patents will be the subject of a patent infringement action. If the parties agree on the patents to be litigated, the brand-name firm must bring an action for patent infringement within 30 days. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Simultaneous Exchange of Patents. If those negotiations do not result in an agreement within 15 days, then the biosimilar applicant must notify the originator of how many patents (but not the identity of those patents) that it wishes to litigate. Within five days, the parties are then required to exchange lists identifying the patents to be litigated. The number of patents identified by the originator may not exceed the number provided by the biosimilar applicant. However, if the biosimilar applicant previously indicated that no patents should be litigated, then the originator may identify one patent. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Commencement of Patent Litigation. The originator must then commence patent infringement litigation within 30 days. That litigation will involve all of the patents on the originator&#8217;s list and all of the patents on the follow-on applicant&#8217;s list. The follow-on applicant must then notify the FDA of the litigation. The FDA must then publish a notice of the litigation in the Federal Register. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:42.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Notice of Commercial Marketing. The BPCIA requires the biosimilar applicant to provide notice to the originator 180 days in advance of its first commercial marketing of its proposed follow-on biologic. The originator is allowed to seek a preliminary injunction blocking such marketing based upon any patents that either party had preliminarily identified but were not subject to the initial phase of patent litigation. The litigants are required to &#8220;reasonably cooperate to expedite such further discovery as is needed&#8221; with respect to the preliminary injunction motion. The federal courts have not yet settled the issue as to when, or under what circumstances, the biosimilar applicant must provide the 180-day notice of commercial marketing provided in the BPCIA.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">On June 12, 2017, the Supreme Court issued its decision in <i style="font-style:italic;">Amgen v. Sandoz</i>, holding that (i) the &#8220;patent dance&#8221; is optional; and (ii) the 180-day pre-marketing notification may be given either before or after receiving FDA approval of the biosimilar product. The Supreme Court declined to rule whether a state injunctive remedy may be available to the originator and remanded that question to the Federal </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Circuit for further consideration. On December 14, 2017, the Federal Circuit decided that state law claims are preempted by the BPCIA on both field and conflict grounds. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">A significant legal risk for a biosimilar applicant that pursues regulatory approval under the Section 351(k) regulatory approval route and also elects to engage in the above-described BPCIA patent exchange mechanism, is that the process could result in the initiation of patent infringement litigation prior to FDA approval of a Section 351(k) application, and such litigation could result in blocking the market entry of the biosimilar product. However, even if biosimilar applicants opt out of the BPCIA patent exchange process, originators will still have the right to assert patent infringement as a basis to enjoin a biosimilar product launch. Thus, whether or not we engage in the BPCIA patent exchange process, there is risk that patent infringement litigation initiated by originators could prevent us indefinitely from launching our biosimilar products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The legal and strategic considerations weighing for or against a decision to voluntarily engage in the BPCIA patent exchange process are complex and will differ on a product-by-product basis. If we decide to engage in the BPCIA patent exchange process, preparing for and conducting the patent exchange, briefing and negotiation process outlined above will require extraordinarily sophisticated legal counseling and extensive planning, all under extremely tight deadlines. Moreover, it may be difficult for us to secure or retain such legal support if large, well-funded originators have already entered into engagements with highly qualified law firms or if the most highly qualified law firms choose not to represent biosimilar applicants due to their long-standing relationships with originators. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">Under the complex, and uncertain rules of the BPCIA patent provisions, coupled with the inherent uncertainty surrounding the legal interpretation of any originator patents that might be asserted against us in this new process, we see substantial risk that the BPCIA process may significantly delay or defeat our ability to market our biosimilar products in the United States, or may result in us incurring substantial legal settlement costs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Discovery and Development of Our Product Candidates </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We are heavily dependent on the development, clinical success, regulatory approval and commercial success of our product candidates. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We invested substantially all of our efforts and financial resources to identify, acquire and develop our product candidates. Our future success is dependent on our ability to develop, obtain regulatory approval for, and then commercialize and obtain adequate third-party coverage and reimbursement for one or more of our product candidates. We currently have three approved products: UDENYCA, YUSIMRY and LOQTORZI.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Our product candidates are in varying stages of development and will require additional clinical development, management of nonclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supplies, commercial organization and significant marketing efforts before we generate any revenue from product sales. Other than certain pharmacokinetic bridging studies, we have not initiated phase 3 clinical trials for other product candidates in our pipeline. It may be some time before we file for market approval with the relevant regulatory agencies for these product candidates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we and our existing or future collaboration partners do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We, together with our collaboration partners, generally plan to seek regulatory approval to commercialize our product candidates in the United States, the E.U., and additional foreign countries where we or our partners have commercial rights. To obtain regulatory approval, we and our collaboration partners must comply with numerous and varying regulatory requirements of such countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, and pricing and distribution of our product candidates. Even if we and our collaboration partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we and our collaboration partners are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and the regulatory approval requirements for biosimilars are evolving. If we and our collaboration partners are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, marketing, distribution, post-approval monitoring and reporting and export and import of biologic and biosimilar products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, by the EMA and EEA Competent Authorities in the European Economic Area (&#8220;EEA&#8221;), and by other regulatory authorities in other countries, where regulations differ from country to country. Neither we nor any existing or future collaboration partners are permitted to market our product candidates in the United States until we and our collaboration partners receive approval from the FDA, or in the EEA until we and our collaboration partners receive EC or EEA Competent Authority approvals. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The time required to develop new products or obtain approval for new products by the FDA and comparable foreign authorities is unpredictable, may take many years following the completion of clinical studies and depends upon numerous factors. Further, applications to the Human Genetic Resources Administration of China (HGRAC) required for any activities, including development activities and data sharing with our partners in China, may result in product development delays. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Neither we nor any collaboration partner has obtained regulatory approval for any of our products and product candidates, other than UDENYCA, which has received approval from the FDA and EMA, YUSIMRY, which has received approval from the FDA, and LOQTORZI, which has received approval from the FDA and is also approved for use in China, and it is possible that none of our other current or future product candidates will ever obtain additional regulatory approvals.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an original BLA, an NDA, a Section 351(k) BLA, a biosimilar marketing authorization under Article 6 of Regulation (EC) No.&#160;726/2004 and/or Article 10(4) of Directive 2001/83/EC in the EEA or other submission or to obtain regulatory approval in the United States, the EEA or elsewhere; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may determine that the population studied in the clinical program may not be sufficiently broad or representative to assure safety and efficacy in the full population for which we seek approval, or that conclusions of clinical trials conducted in a single country or region outside the United States may not be generalizable to the patient population in the United States; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from analytical and bioanalytical studies, nonclinical studies or clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of our collaborators or third-party manufacturers with which we contract for clinical and commercial supplies; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">This approval process, as well as the unpredictability of the results of clinical studies, may result in our failure to obtain regulatory approval to market any of our product candidates, which would significantly harm our business. Any delays in the commencement or completion of clinical testing could significantly impact our product development costs and could result in the need for additional financing.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Clinical drug development involves a lengthy and expensive process and we may encounter substantial delays in our clinical studies or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we or our collaboration partners, or both, as the case may be, must conduct clinical studies to demonstrate the safety and efficacy of the product candidates in humans. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent registration clinical studies. There is a high failure rate for product candidates proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical studies. A&#160;number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Nonclinical and clinical data are also often susceptible to varying interpretations and analyses. We do not know whether any clinical studies we may conduct for our product candidates will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval. Furthermore, biosimilar clinical studies must use originator products as comparators, and such supplies may not be available on a timely basis to support such trials.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited to: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to generate sufficient preclinical, toxicology or other </span><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> or </span><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> data to support the initiation of human clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory agencies on study design; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable terms with prospective CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining required IRB approval at each clinical study site; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory agencies, after review of an IND or amendment or equivalent application or amendment, or an inspection of our clinical study operations or study sites or as a result of adverse events reported during a clinical trial; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in recruiting suitable patients to participate in our clinical studies sponsored by us or our partners; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty collaborating with patient groups and investigators; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by our CROs, other third parties or us to adhere to clinical study requirements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to perform in accordance with the FDA&#8217;s good clinical practices requirements or applicable regulatory guidelines in other countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in patients completing participation in a study or return for post-treatment follow-up, or patients dropping out of a study; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical studies of our product candidates being greater than we anticipate; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical studies of our product candidates producing negative or inconclusive results, which may result in us deciding or regulators requiring us to conduct additional clinical studies or abandon product development programs; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in manufacturing, testing, releasing, validating or importing/exporting and/or distributing sufficient stable quantities of our product candidates and originator products for use in clinical studies or the inability to do any of the foregoing. </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Any inability to successfully complete nonclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials will depend, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or other comparable regulatory authorities. Some of the conditions for which we may plan to evaluate our product candidates are rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Patient enrollment in clinical trials may be affected by other factors, including: </p><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">size and nature of the targeted patient population; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">severity of the disease or condition under investigation; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">availability and efficacy of approved therapies for the disease or condition under investigation; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">patient eligibility criteria for the trial in question as defined in the protocol; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">perceived risks and benefits of the product candidate under study; </p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any products that may be approved for, or any product candidates under investigation for, the indications we are investigating; </span></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">efforts to facilitate timely enrollment in clinical trials; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">patient referral practices of physicians; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">the ability to monitor patients adequately during and after treatment; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">proximity and availability of clinical trial sites for prospective patients; </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;text-align:justify;">continued enrollment of prospective patients by clinical trial sites; and </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:24.5pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:6pt;text-align:justify;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:6pt;text-align:justify;">the risk that patients enrolled in clinical trials will drop out of such trials before completion.</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll any clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain regulatory approval for the sale of our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The development, manufacture and commercialization of biosimilar products under various global regulatory pathways pose unique risks. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We and our collaboration partners intend to pursue market authorization globally. In the United States, an abbreviated pathway for approval of biosimilar products was established by the BPCIA, enacted on March&#160;23, 2010, as part of the ACA. The BPCIA established this abbreviated pathway under Section 351(k) of the PHSA. Subsequent to the enactment of the BPCIA, the FDA issued guidance documents regarding the demonstration of biosimilarity and interchangeability as well as the submission and review of biosimilar applications. Moreover, market acceptance of biosimilar products in the United States is unclear. Numerous states are considering or have already enacted laws that regulate or restrict the substitution by state pharmacies of biosimilars for originator products already licensed by the FDA. Market success of biosimilar products will depend on demonstrating to patients, physicians, payers and relevant authorities that such products are similar in quality, safety and efficacy as compared to the reference product. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">We will continue to analyze and incorporate into our biosimilar development plans any final regulations issued by the FDA, pharmacy substitution policies enacted by state governments and other applicable requirements established by relevant authorities. The costs of development and approval will be dependent upon the application of any laws and regulations issued by the relevant regulatory authorities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Biosimilar products may also be subject to extensive originator-controlled patent portfolios and patent infringement litigation, which may delay and could prevent the commercial launch of a product. Moreover, the BPCIA prohibits the FDA from accepting an application for a biosimilar candidate to a reference product within four years of the reference product&#8217;s licensure by the FDA. In addition, the BPCIA provides innovative biologics with 12&#160;years of exclusivity from the date of their licensure, during which time the FDA cannot approve any application for a biosimilar candidate to the reference product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Under current E.U. regulations, an application for regulatory approval of a biosimilar drug cannot be submitted in the E.U. until expiration of an eight-year data exclusivity period for the reference (originator) product, measured from the date of the reference product&#8217;s initial marketing authorization. Furthermore, once approved, the biosimilar cannot be marketed until expiration of a ten-year period following the initial marketing authorization of the reference product, such ten-year period being extendible to 11 years if the reference product received approval of an additional therapeutic indication, within the first eight years following its initial marketing authorization, representing a significant clinical benefit in comparison with existing therapies. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In Europe, the approval of a biosimilar for marketing is based on an opinion issued by the EMA and a decision issued by the EC. Therefore, the marketing approval will cover the entire EEA. However, substitution of a biosimilar for the originator is a decision that is made at the national level. Additionally, a number of countries do not permit the automatic substitution of biosimilars for the originator product. Therefore, even if we obtain marketing approval for the entire EEA, we may not receive substitution in one or more European nations, thereby restricting our ability to market our products in those jurisdictions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Other regions, including Canada, Japan and South Korea, also have their own legislation outlining a regulatory pathway for the approval of biosimilars. In some cases, other countries have either adopted European guidance (Singapore and Malaysia) or are following guidance issued by the World Health Organization (Cuba and Brazil). While there is overlap in the regulatory requirements across regions, there are also some areas of non-overlap. Additionally, we cannot predict whether countries that we may wish to market in which do not yet have an established or tested regulatory framework could decide to issue regulations or guidance and/or adopt a more conservative viewpoint than other regions. Therefore, it is possible that even if we obtain agreement from one health authority to an accelerated or optimized development plan, we will need to defer to the most conservative view to ensure global harmonization of the development plan. Also, for regions where regulatory authorities do not yet have sufficient experience in the review and approval of a biosimilar product, these authorities may rely on the approval from another region (e.g., the United States or the E.U.), which could delay our approval in that region. Finally, it is possible that some countries will not approve a biosimilar without clinical data from their population or may require that the biosimilar product be manufactured within their region, or some countries may require both. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">If other biosimilars of pegfilgrastim (Neulasta) or adalimumab (Humira) are determined to be interchangeable and our biosimilar products are not, our business could suffer. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The FDA or other relevant regulatory authorities may determine that a proposed biosimilar product is &#8220;interchangeable&#8221; with a reference product, meaning that the biosimilar product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, if the application includes sufficient information to show that the product is biosimilar to the reference product and that it can be expected to produce the same clinical result as the reference product in any given patient. If the biosimilar product may be administered more than once to a patient, the applicant must demonstrate that the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar product and the reference product is not greater than the risk of using the reference product without such alternation or switch. To make a final determination of interchangeability, regulatory authorities may require additional confirmatory information beyond what we plan to initially submit in our applications for approval, such as more in-depth analytical characterization, animal testing or further clinical studies. Provision of sufficient information for approval may prove difficult and expensive. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We cannot predict whether any of our biosimilar products and product candidates will meet regulatory authority requirements for approval not only as a biosimilar product but also as an interchangeable product in any jurisdiction. Furthermore, legislation governing interchangeability could differ by jurisdiction on a state or national level worldwide. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The labelling of &#8220;interchangeability&#8221; is important because, in the United States for example, the first biosimilar determined to be interchangeable with a particular reference, or originator, product for any condition of use is eligible for a period of market exclusivity that </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">delays an FDA determination that a second or subsequent biosimilar product is interchangeable with that originator product for any condition of use until the earlier of: (1)&#160;one year after the first commercial marketing of the first interchangeable product; (2)&#160;18 months after resolution of a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; (3)&#160;42 months after approval of the first interchangeable product, if a patent infringement suit instituted under 42 U.S.C. &#167; 262(l)(6) against the applicant that submitted the application for the first interchangeable product is still ongoing; or (4)&#160;18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued under 42&#160;U.S.C.&#160;&#167;&#160;262(l)(6). Thus, a determination that another company&#8217;s product is interchangeable with the originator biologic before we obtain approval of our corresponding biosimilar product candidates may delay the potential determination that our products are interchangeable with the originator product, which could materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Failure to obtain regulatory approval in any targeted regulatory jurisdiction would prevent us from marketing our products to a larger patient population and reduce our commercial opportunities.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We are marketing LOQTORZI, UDENYCA and YUSIMRY in the United States, and subject to product approvals and relevant patent and settlement agreement expirations, we intend to market our other biosimilar products in the United States and outside the United States on our own or with future collaboration partners. We entered into a distribution agreement with our licensee Orox for the commercialization of biosimilar versions of etanercept (Enbrel) (for which we discontinued development), rituximab (Rituxan) (for which we discontinued development), adalimumab (Humira) and pegfilgrastim (Neulasta) in certain Caribbean and Latin American countries. We intend to market our products in the United States and may seek to partner commercially all products outside the United States. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In order to market our products in the E.U., the United States and other jurisdictions, we and our collaboration partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The EMA is responsible for the centralized procedure for the regulation and approval of human medicines. This procedure results in a single marketing authorization that is valid in all E.U. countries, as well as in Iceland, Liechtenstein and Norway. The time required to obtain approval abroad may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and we may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We or our collaboration partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. Failure to obtain these approvals would materially and adversely affect our business, financial condition and results of operations. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify, develop or commercialize additional product candidates. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of our existing product candidates, the success of our business also depends upon our ability to identify, develop and commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our development efforts may fail to yield additional product candidates suitable for clinical development and commercialization for a number of reasons, including but not limited to the following: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be successful in identifying potential product candidates that pass our strict screening criteria; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to overcome technological hurdles to development or a product candidate may not be capable of producing commercial quantities at an acceptable cost or at all; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may not succeed in nonclinical or clinical testing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential product candidates may fail to show sufficient biosimilarity to originator molecules; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our product candidates obsolete or less attractive or the market for a product candidate may change such that a product candidate may not justify further development. </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs or we may not be able to identify, develop or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Compliance with Applicable Laws</b> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Healthcare reform measures, including the IRA, may increase the difficulty and cost for us to obtain marketing approval for and commercialize our products, affect the prices we may set, and have a material adverse effect on our business and results of operations. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA, was passed, which substantially changed the way health care is financed by both governmental and private insurers and has impacted and continues to impact the United States pharmaceutical industry. The ACA, among other things, modified the AMP definition under the MDRP for drugs that are inhaled, infused, instilled, implanted or injected and not generally distributed through the retail channel; expanded rebate payments under the MDRP to include utilization by individuals enrolled in Medicaid managed care organizations; added a provision to increase the Medicaid rebate for line extension drugs; established annual fees and taxes on manufacturers of certain branded prescription drugs; expanded the entities eligible for discounts under the Public Health Service 340B drug pricing program; and established the Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the United States Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include the American Rescue Plan Act of 2021, which eliminated the statutory cap on the Medicaid drug rebate beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s AMP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Most significantly, on August 16, 2022, the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. For that and other reasons, the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined. If a product becomes subject to the IRA negotiation provision and related price cap, that may significantly alter the economic rationale for developing and commercializing a biosimilar. Additionally, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The cost of prescription pharmaceuticals in the United States is likely to remain the subject of considerable discussion. There have been several Congressional inquiries and proposed and enacted legislation designed to, among other things, reform government program reimbursement methodologies. The likelihood of implementation of these and other reform initiatives is uncertain. In the coming years, additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the success of our product candidates. We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Individual states in the United States have also proposed and enacted legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and other transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures, such as a single reimbursement code for biosimilar products.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In the E.U., similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the E.U. or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the E.U., including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than E.U., law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most E.U. member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing E.U. and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and E.U., reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We may be subject, directly or indirectly, to federal and state healthcare laws, including fraud and abuse, false claims and physician payment transparency laws. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our operations are directly or indirectly through our customers subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws impact, among other things, sales, marketing and education programs. The laws that may affect our ability to operate include: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or in return for the purchase, recommendation, order or furnishing of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented claims for payment from Medicare, Medicaid or other third-party payers that are false or fraudulent and which may apply to entities that provide coding and billing advice to customers. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician &#8220;sunshine&#8221; requirements under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services information related to payments and other transfers of value made by such manufacturers to physicians (defined to include doctors, dentists, optometrists, podiatrists, chiropractors, and certain non-physician practitioners (physician assistants, nurse practitioners, </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives)), and teaching hospitals and ownership and investment interests held by physicians and their immediate family members; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Efforts to ensure that our operations and business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:11.5pt;"></span>We participate in governmental programs that impose drug price reporting, payment, and other compliance obligations on pharmaceutical manufacturers. Medicaid is a joint federal and state program for low-income and disabled beneficiaries. Medicare is a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain disabilities. Medicare Part B reimburses physicians who administer our products. Under the MDRP, as a condition of having federal funds available for our covered outpatient drugs under Medicaid and under Medicare Part B, we must enter into, and have entered into, an agreement with the Secretary of Health and Human Services to pay a rebate to state Medicaid programs for each unit of our covered outpatient drugs dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid rebates are based on pricing data that we are required to report on a monthly and quarterly basis to CMS, the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the AMP for each drug and, in the case of innovator products, the Best Price, which represents the lowest price available from us to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity in the United States in any pricing structure, calculated to include all applicable sales and associated rebates, discounts and other price concessions. In connection with Medicare Part B, we must provide CMS with ASP information on a quarterly basis. CMS uses this information to compute Medicare Part B payment rates, which consist of ASP plus a specified percentage. If we become aware that our MDRP submissions for a prior period were incorrect or have changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. Pursuant to the IRA, the AMP and ASP figures we report will also be used to compute rebates under Medicare Part D and Medicare Part B triggered by price increases that outpace inflation. If we fail to provide information timely or are found to have knowingly submitted false information to CMS, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program is administered by the HRSA and requires us to agree to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered drugs when used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, a pharmaceutical manufacturer must also participate in VA FSS pricing program. Under the VA FSS program, we must report the Non-FAMP for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If a manufacturer participating in the FSS program fails to provide timely information or is found to have knowingly submitted false information, the manufacturer may be subject to civil monetary penalties.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers for the untimely, inaccurate, or incomplete reporting of drug pricing information or for otherwise failing to comply with drug price transparency requirements. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or underage in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of ASP, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our submissions will not be found by CMS or other governmental agencies to be incomplete or incorrect.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Common Stock </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">The market price of our common stock may be highly volatile, and purchasers of our common stock could incur substantial losses. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The market price of our common stock has been highly volatile since our Initial Public Offering (&#8220;IPO&#8221;) and the intraday sales price per share has ranged from $1.43 to $38.10 per share during the period from November 6, 2014 through December 31, 2023 and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K and others such as: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in preclinical or clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk of deterioration in our financial conditions, such as reduced collection of cash and increased costs in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any inability to obtain additional funding; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in filing an IND, NDA, BLA, Section 351(k) BLA or other regulatory submission for any of our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory agency&#8217;s review of that IND, NDA, BLA, Section 351(k) BLA or other regulatory submission; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of limited market sizes or pricing for our products and product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize our product candidates; </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-marketing safety issues relating to our product candidates or biosimilars generally; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to maintain our existing strategic collaborations or enter into new collaborations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">future outbreaks of COVID-19 and other viral pandemics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we may provide to the public; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial projections of the investment community; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, dispositions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">lawsuits, including but not limited to complaints initiated by stockholders, customers and collaboration partners, and litigation filed by us or filed against us pertaining to patent infringement or other violations of intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcomes of any citizen petitions filed by parties seeking to restrict or limit the approval of biosimilar products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about our business or if they issue an adverse or misleading opinion regarding our stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general market or macroeconomic conditions, including rising interest rates and inflation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issuance of patents to third parties that could prevent our ability to commercialize our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reductions in the prices of originator products that could reduce the overall market opportunity for our product candidates intended as biosimilars to such originator products; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in biosimilar regulatory requirements that could make it more difficult for us to develop our product candidates. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, biopharmaceutical companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As of December 31, 2023, our executive officers, directors, five percent stockholders and their affiliates beneficially owned approximately 30.6% of our voting stock (assuming no exercise of outstanding options or conversion of our outstanding convertible notes). These stockholders have the ability to influence us through their ownership positions, which may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our financial condition, our ability to raise additional capital to fund our operations, our ability to operate our business, our ability to react to changes in the economy or our industry and our ability to pay our debts and could divert our cash flow from operations for debt payments.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our leverage and debt service obligations could adversely impact our business, including by:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impairing our ability to generate cash sufficient to pay interest or principal, including periodic principal payments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increasing our vulnerability to general adverse economic and industry conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increasing our need to meet minimum net sales requirements when our future sales are uncertain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring the dedication of a portion of our cash flow from operations to service our debt, thereby reducing the amount of our cash flow available for other purposes, including funds for clinical development or to pursue future business opportunities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring us to sell debt or equity securities or to sell some of our core assets, possibly on unfavorable terms, to meet payment obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limiting our flexibility in planning for, or reacting to, changes in our business and the industries in which we compete; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">placing us at a possible competitive disadvantage with less leveraged competitors and competitors that may have better access to capital resources.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Any of the foregoing factors could have negative consequences on our financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">This indebtedness could be due sooner upon the triggering of certain covenants in our debt agreements and or upon the occurrence of an event of default. If and when our indebtedness becomes due, if we do not have sufficient cash or access to capital to pay such indebtedness, we will default on our obligations which will adversely harm our business. We entered into a Loan Agreement that contains affirmative and negative covenants that restrict our operations, including, among other restrictions, the requirement to maintain minimum trailing twelve-month net sales in an amount that began at $200.0 million in the first quarter of 2022 and increases to $210.0 million for the quarter ended March 31, 2024. Beginning in the second quarter of 2024 and continuing through the quarter ended December 31, 2026, the requirement is to maintain minimum trailing twelve-month net sales of $125.0 million. In addition, there is a requirement to maintain a minimum trailing twelve-month net sales for LOQTORZI tested quarterly at the end of each quarter commencing with the quarter ended December 31, 2024. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict our ability to incur liens, incur additional indebtedness, make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. We may need to request additional waivers from time to time with respect to the Loan Agreement and if we are unable to obtain a waiver that we need it could materially impact our business and financial results.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">If our existing stockholders sell or indicate an intention to sell substantial amounts of our common stock in the public market the market price of our common stock could decline. In addition, we may authorize our sales agent to sell our common stock from time to time as part of the ATM Offering. As of December 31, 2023, there were 112.2 million shares of common stock outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In addition, as of December 31, 2023, approximately 30.6 million shares of common stock that are either subject to outstanding options and restricted stock units or reserved for future issuance under our equity incentive plans were eligible or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule&#160;144 and Rule&#160;701 under the Securities Act. Certain of our outstanding options have exercise prices that are above our current stock price. See the tables describing our outstanding stock options in Note 12. Stock-Based Compensation and Employee Benefits to our financial statements included in this report. If these additional shares of common stock are sold or if it is perceived that they will be sold in the public market, the market price of our common stock could decline. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans and convertible notes, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We have needed and anticipate we will need additional capital in the future to continue our planned operations. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. Similar to prior or ongoing financing transactions like the ATM Offering or the exchange of our shares for shares of outstanding stock of Surface as part of the acquisition of Surface, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. In addition, if we raise additional funds through licensing arrangements, it may be necessary to grant potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Pursuant to our 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2014 Plan will be increased by (i)&#160;the number of shares pursuant to outstanding awards under the 2010 Plan that are forfeited or lapse unexercised and which following the effective date are not issued under the 2010 Plan and (ii)&#160;an annual increase on the first day of each fiscal year beginning in 2015 and ending in 2024, equal to 4% of the shares of stock outstanding as of the last day of the preceding fiscal year, or such smaller number of shares as determined by our board of directors. Pursuant to our 2014 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), eligible employees are able to acquire shares of our common stock at a discount to the prevailing market price, and an aggregate of 320,000&#160;shares are initially available for issuance under the ESPP. The number of shares available for issuance under the ESPP will automatically increase on the first day of each fiscal year beginning in 2015 and ending in 2024, equal to 1% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year or such smaller number of shares as determined by our board of directors. If our board of directors elects to increase the number of shares available for future grant under the 2014 Plan or the ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall<b style="font-weight:bold;">. </b>Pursuant to our 2016 Employment Commencement Incentive Plan (the &#8220;2016 Plan&#8221;), our management is authorized to grant stock options and other equity-based awards to our new employees. The 2016 Plan is designed to comply with the inducement exemption contained in Nasdaq&#8217;s Rule 5635(c)(4), which provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director, or following a bona fide period of non-employment, as an inducement material to the individual&#8217;s entering into employment with us. As of December 31, 2023, we reserved for future issuance under the 2016 Plan a total of 1.8 million shares of common stock for new employees. The 2016 Plan does not provide for any annual increases in the number of shares available.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In April 2020, we issued and sold $230.0 million aggregate principal amount of our 1.5% senior convertible notes due April 2026 (the &#8220;2026 Convertible Notes&#8221;). The holders may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the second scheduled trading day immediately before April 15, 2026. Upon conversion of the 2026 Convertible Notes by a holder, the holder will receive shares of our common stock, together, if applicable, with cash in lieu of any fractional share. Since inception, the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our business operations, financial condition, results of operations and prospects.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="font-weight:normal;">Our cash and cash equivalents are deposited or invested with several banks and other financial institutions. Actual events involving reduced or limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank was closed and taken over by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) and subsequently had all of its customer deposits and other liabilities and substantially all loans and other assets acquired by First-Citizens Bank &amp; Trust Company. We had approximately $117.7 million of cash, cash equivalents and marketable securities as of December 31, 2023 with the majority held by custodians or in money market mutual funds that are not bank deposits. Our bank deposits are primarily held in accounts at three large banks that we believe to be stable at this time. Actual and perceived stability of banks can change from time to time and adverse perceptions by customers or investors about the banks where we deposit money could result in a material and adverse effect on our ability to access necessary cash. Investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including </span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources, could, among other risks, adversely impact our ability to access funds for our basic operating expenses, financial obligations, payroll or fulfill our other important obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity, business operations, financial condition, results of operations and prospects.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation of their stock. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions that: </p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">create a classified board of directors whose members serve staggered three-year terms; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">specify that special meetings of our stockholders can be called only by our corporate secretary pursuant to a resolution adopted by a majority of our board of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors other than nominations made by or at the direction of the board of directors or a committee of the board of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our directors may be removed only for cause or without cause by the holders of 66&#160;2/3% of the voting power of all then outstanding shares of voting stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">specify that no stockholder is permitted to cumulate votes at any election of directors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">require holders of 66&#160;2/3% of the voting power of all then outstanding shares of voting stock to amend specified provisions of our amended and restated certificate of incorporation except for the provision making it possible for our board of directors to issue &#8220;blank check&#8221; preferred stock, and amended and restated bylaws. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">These provisions, alone or together, could delay, deter or prevent hostile takeovers and changes in control or changes in our management. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The international aspects of our business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We currently have limited international operations of our own and have and may have in the future a number of international collaborations, including our significant collaboration with Junshi Biosciences in China. Doing business internationally involves a number of risks, including but not limited to: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses, including those that affect our work with a collaboration partner in China; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us or our collaboration partners to obtain and maintain regulatory approvals for the use of our products in various countries; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations by us or our collaboration partners;</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems by our collaboration partners; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our or our collaboration partners&#8217; ability to penetrate international markets; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expose us to sanctions, such as the sanctions levied by United States, E.U. and Russian regulatory bodies in connection with Russia&#8217;s invasion of Ukraine in February 2022; and</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the United States Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Investors&#8217; expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt;">There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance (or &#8220;ESG&#8221;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers and if we are perceived as lagging with respect to ESG initiatives, certain investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our board of directors accountable. In addition, the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We may face reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. We also face significant costs from complying with new ESG regulations, for example, the SEC&#8217;s proposed climate disclosure rule would result in significant costs of compliance if it is approved as proposed in the future.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt;">We may face reputational damage in the event our corporate responsibility initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchange or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt;">Because we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaboration partners, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">So called &#8220;submarine&#8221; patents may be granted to our competitors that may significantly alter our launch timing expectations, reduce our projected market size, cause us to modify our product or process or block us from the market altogether. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The term &#8220;submarine&#8221; patent has been used in the pharmaceutical industry and in other industries to denote a patent issuing from an application that was not published, publicly known or available prior to its grant. Submarine patents add substantial risk and uncertainty to our business. Submarine patents may issue to our competitors covering our pipeline candidates and thereby cause significant market entry delay, defeat our ability to market our products or cause us to abandon development and/or commercialization of a molecule. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Examples of submarine patents include Brockhaus, et al., United States patents 8,063,182 and 8,163,522 (controlled by Amgen), which are directed to the fusion protein in Enbrel. On July 1, 2020, the United States Court of Appeals for the Federal Circuit issued a decision that affirmed the lower court&#8217;s decision upholding the validity of these patents. As a result, we discontinued the development of CHS-0214 (our etanercept (Enbrel) biosimilar candidate). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The issuance of one or more submarine patents may harm our business by causing substantial delays in our ability to introduce a biosimilar candidate into the United States market. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which might adversely affect our ability to develop and market our products. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete and thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products or pipeline molecules. We may incorrectly determine that our products are not covered by a third-party patent. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Many patents may cover a marketed product, including but not limited to the composition of the product, methods of use, formulations, cell line constructs, vectors, growth media, production processes and purification processes. The identification of all patents and their expiration dates relevant to the production and sale of an originator product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to prevent competitors from using technologies we consider important in our successful development and commercialization of our product candidates, resulting in loss of any potential competitive advantage our patents may have otherwise afforded us.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">While our principal focus in matters relating to intellectual property is to avoid infringing the valid and enforceable rights of third parties, we also rely upon a combination of patents, trade secret protection and confidentiality agreements to protect our own intellectual property related to our product candidates and development programs. Our ability to enjoy any competitive advantages afforded by our own intellectual property depends in large part on our ability to obtain and maintain patents and other intellectual property protection in the United States and in other countries with respect to various proprietary elements of our product candidates, such as, for example, our product formulations and processes for manufacturing our products and our ability to maintain and control the confidentiality of our trade secrets and confidential information critical to our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our products that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no guarantee that any patent application we file will result in an issued patent having claims that protect our products. Additionally, while the basic requirements for patentability are similar across jurisdictions, each jurisdiction has its own specific requirements for patentability. We cannot guarantee that we will obtain identical or similar patent protection covering our products in all jurisdictions where we file patent applications. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The patent positions of biopharmaceutical companies generally are highly uncertain and involve complex legal and factual questions. As a result, the patent applications that we own or license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries for many reasons. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, considered or cited during patent prosecution, which can be used to invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patent claims being narrowed, found unenforceable or invalidated. Our patents and patent applications, even if they are unchallenged, may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competitors from using the technologies claimed in any patents issued to us, which may have an adverse impact on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In addition, changes to United States patent laws provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after March 15, 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is challenged, then it could threaten our ability to prevent competitive products using our proprietary technology. Further, because patent applications in the United States and most other countries are confidential for a period of time, typically for 18 months after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013 or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications claiming the same invention are filed by different parties. A third party that files a patent application in the USPTO before we do, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to &#8220;first-to-file&#8221; from &#8221;first-to-invent&#8221; is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), signed into law on September 16, 2011. Among some of the other significant changes to the patent laws are changes that limit </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. It is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to prevent third parties from using the same technologies that we use in our product candidates. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We have issued patents and have filed patent applications, which are currently pending, covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened or infringed by third parties. Any successful actions by third parties to challenge the validity or enforceability of any patents, which may issue to us could deprive us of the ability to prevent others from using the technologies claimed in such issued patents. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">While our biosimilar business is based primarily on the timing of our biosimilar product launches to occur after the expiration of relevant patents and on avoiding infringing valid and enforceable rights of third parties, we have filed a number of patent applications seeking patents that cover various proprietary elements of our product candidates when we have believed securing such patents may afford a competitive advantage. Our patent portfolio includes pending patent applications and issued patents, in the United States and globally, covering our biosimilar products and methods of making them. We cannot guarantee that our proprietary technologies will avoid infringement of third-party patents. Moreover, because competitors may be able to develop their own proprietary technologies, it is uncertain whether any of our issued patents or pending patent applications directed to etanercept and adalimumab would cover the etanercept and adalimumab products of any competitors. The product and patent landscape is highly uncertain and we cannot predict whether our patent filings will afford us a competitive advantage against third parties or if our etanercept and adalimumab products will avoid infringement of third-party patents. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We do not consider it necessary for us or our competitors to obtain or maintain a proprietary patent position in order to engage in the business of biosimilar development and commercialization. Hence, while our ability to secure patent coverage on our own proprietary developments may improve our competitive position with respect to the product candidates we intend to commercialize, we do not view our own patent filings as a necessary or essential requirement for conducting our business nor do we rely on our own patent filings or the potential for any commercial advantage they may provide us as a basis for our success. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural requirements, document submissions, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Filing, prosecuting, defending and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may choose not to file patent applications in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or importing products made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but the ability to enforce our patents is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Governments of foreign countries may force us to license our patents to third parties on terms that are not commercially reasonable or acceptable to us. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to maintain effective (non-patent) proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">While we have filed patent applications to protect certain aspects of our own proprietary formulation and process developments, we also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. However, confidential information and trade secrets can be difficult to protect. Moreover, the information embodied in our trade secrets and confidential information may be independently and legitimately developed or discovered by third parties without any improper use of or reference to information or trade secrets. We seek to protect the scientific, technical and business information supporting our operations, as well as the confidential information relating specifically to our product candidates by entering into confidentiality agreements with parties to whom we need to disclose our confidential information, for example, our employees, consultants, scientific advisors, board members, contractors, potential collaborators and investors. However, we cannot be certain that such agreements have been entered into with all relevant parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. Our confidential information and trade secrets thus may become known by our competitors in ways we cannot prove or remedy. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. We cannot guarantee that our employees, former employees or consultants will not file patent applications claiming our inventions. Because of the &#8220;first-to-file&#8221; laws in the United States and the EU, such unauthorized patent application filings may defeat our attempts to obtain patents on our own inventions. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship of our patent filings and other intellectual property.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:31.5pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">Although we are not currently aware of any claims challenging the inventorship of our patent applications or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patent applications or patents we may be granted or other intellectual property as an inventor or co-inventor. For example, we may have inventorship or ownership disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We or the third parties upon whom we depend on may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Our corporate headquarters and laboratory are located in the San Francisco Bay Area and in Southern California (Camarillo), respectively. These locations have in the past experienced severe earthquakes, floods and other natural disasters. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaboration partners and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure (such as the manufacturing facilities of our third-party contract manufacturers) or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The continuation of the war in Ukraine and conflicts in the Middle East may exacerbate certain risks we face.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The war between Russia and Ukraine and the global response, including the imposition of sanctions by the United States and other countries, could create or exacerbate risks facing our business. Conflicts in the Middle East may also increase the risks facing our business. We have evaluated our operations and partner contracts, and we currently do not expect either conflict to directly have a significant effect on our financial condition or results of operations. However, if the war between Russia and Ukraine or conflicts in the Middle East escalate or expand, risks that we have identified in this Annual Report on Form 10-K may be materially increased. For example, if our supply arrangements or clinical operations are disrupted due to expanded sanctions or involvement of, and adverse impacts on, countries where we have operations or relationships, our business could be materially disrupted. Further, the use of cyberattacks could expand as part of the ongoing conflicts, which could adversely affect our ability to maintain or enhance our cyber security measures. These and other risks are described more fully in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act, and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel must devote a substantial amount of time to ensure that we maintain compliance with all of these requirements. Moreover, the reporting requirements, rules and regulations have increased our legal and financial compliance costs and make some activities more time consuming and costly. Any changes we have made, and may make in the future to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, may also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">manner in which we operate our business in ways we cannot currently anticipate. For example, the SEC&#8217;s proposed climate disclosure rule would result in significant costs of compliance if final rules that are similar to the proposed rules are approved in the future. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our information technology systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches and geopolitical tensions or conflicts, such as the ongoing war in Ukraine or conflicts in the Middle East, may create a heightened risk of cyberattacks.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk151979846"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, preclinical and clinical trial data, and personal information (collectively, &#8220;Confidential Information&#8221;) of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Despite the implementation of security measures, our information technology systems as well as those of our third-party collaborators, consultants, contractors, suppliers, and service providers, may be vulnerable to damage from physical or electronic break-ins, computer viruses, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, &#8220;phishing&#8221; attacks, malware, ransomware, denial of service and other cyberattacks or disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of Confidential Information and could subject us to significant liabilities and regulatory and enforcement actions, and reputational damage. In addition, geopolitical tensions or conflicts, such as the war between Russia and Ukraine or conflicts in the Middle East, may create a heightened risk of cyberattacks. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our Confidential Information. If we or any of our third-party collaborators or service providers were to experience any material failure or security breach, it could result in a material disruption of our development programs, reputation, and business operations. For example, the loss of clinical study data from completed or ongoing clinical studies could result in delays in any regulatory approval or clearance efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize the product.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of Confidential Information, we may have to notify individuals, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on our third-party CROs and other third parties to conduct clinical studies, and similar events relating to their computer systems could also have a material adverse effect on our business. There can also be no assurance that our and our service providers&#8217; cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Further, the continued hybrid working environment has generally increased the attack surface available to criminals, as more companies and individuals work online and work remotely, and as such, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate or unauthorized access to or disclosure or use of Confidential Information, we could incur liability and suffer reputational harm, and the development and commercialization of our products could be delayed. Federal, state and international laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties, fines and significant legal liability, if our information technology security efforts fail. We may also be exposed to a risk of loss or litigation and potential liability, which could materially and adversely affect our business, results of operations or financial condition. Our insurance policies may not be </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">adequate to compensate us for the potential losses arising from such disruptions, failure, or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to governmental regulation and other legal obligations related to privacy, data protection and information security. Compliance with these requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. Compliance with these privacy and data security requirements is rigorous and time-intensive and may increase our cost of doing business. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, fines and penalties, litigation and reputational harm, which could materially and adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In the United States, we and our partners may be subject to numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Even when HIPAA does not apply, according to the Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. The FTC has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. Additionally, federal and state consumer protection laws are increasingly being applied by the FTC and states&#8217; attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;) on June 28, 2018, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with, data breach litigation. Further, the California Privacy Rights Act (&#8220;CPRA&#8221;) generally went into effect on January 1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">In addition, the regulatory framework for the receipt, collection, processing, use, safeguarding, sharing and transfer of personal and confidential data is rapidly evolving and is likely to remain uncertain for the foreseeable future as new global privacy rules are being enacted and existing ones are being updated and strengthened. For example, on May 25, 2018, the General Data Protection Regulation (&#8220;GDPR&#8221;) took effect. The GDPR is applicable in each EEA member state and applies to companies established in the EEA as well as companies that collect and use personal data to offer goods or services to, or monitor the behavior of, individuals in the EEA, including, for example, through the conduct of clinical trials. GDPR introduces more stringent data protection obligations for processors and controllers of personal data. Among other things, the GDPR requires the establishment of a lawful basis for the processing of data, includes requirements relating to the consent of the individuals to whom the personal data relates, including detailed notices for clinical trial subjects and investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. The GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (&#8220;CJEU&#8221;) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;) rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames. Penalties and fines for failure to comply with GDPR are significant, including fines of up to &#8364;20 million or 4% of total worldwide annual turnover, whichever is higher. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Further, since the beginning of 2021, we have also been subject to the &#160;United Kingdom General Data Protection Regulation and Data Protection Act 2018, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK government), as a UK GDPR data transfer mechanism from the U.K. to U.S. entities self-certified under the DPF. Other foreign jurisdictions are increasingly implementing or developing their own privacy regimes with complex and onerous compliance obligations and robust regulatory enforcement powers. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be negatively impacted by continued inflation.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be adversely impacted by continued increases in inflation. Current and future inflation may be driven by the following factors: supply chain disruptions, increased costs of transportation, increased input costs such as the cost of fuel, shortages, and governmental stimulus or fiscal policies. Continuing increases in inflation could impact the overall demand for our products, our costs for labor and materials and the size of any margins we are able to realize on our revenues. This would have a material and adverse impact on our business, financial position, results of operations and cash flows. Inflation may also result in higher interest rates, which in turn would result in higher interest expense related to our variable rate indebtedness.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2e1ca834_0f5b_43c3_800c_f300c33d6643"></a><a id="Item1BUnresolvedStaffComments_157284"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;<span style="font-style:italic;">Unresolved Staff Comments</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Item_1C._"></a><a id="_a9a4b4bc_ee18_4e76_9f7f_2b3ee888613a"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1C.&#160;&#160;&#160;<span style="font-style:italic;">Cybersecurity </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cybersecurity Risk Management and Strategy </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program is designed to align with industry standards and incorporates best practices such as the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have also established an interdisciplinary Cybersecurity Incident Response Team (&#8220;CIRT&#8221;), which is responsible for our incident response plan, our security controls, and for assessing incidents reported by our information technology security team. In addition, our cybersecurity risk management program includes: </span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Monitoring and evaluation of our vulnerability performance. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Implementation of processes to oversee and identify risks from cybersecurity threats associated with our use of third-party service providers that have access to our critical systems and information. For any agreements with service providers that do not contain acceptable protections, we are working to put them in place on an ongoing basis. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment. We use a third-party consultant to provide us with advisory, project execution, and operational support in connection with cybersecurity and to conduct NIST assessments and vulnerability evaluations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cybersecurity awareness training of our employees, incident response personnel, and senior management. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#8220;Risk Factor&#8212; Our information technology systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches and geopolitical tensions or conflicts, such as the ongoing war in Ukraine or conflicts in the Middle East, may create a heightened risk of cyberattacks.&#8221;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cybersecurity Governance </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Risk assessment and oversight are an integral part of our governance and management processes. Our Board of Directors encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Our Board considers cybersecurity risk as part of its risk oversight function and oversees management&#8217;s implementation of our cybersecurity risk management program. </span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Management discusses strategic and operational risks at regular management meetings and conducts specific strategic planning and review sessions throughout the year. Throughout the year, senior management reviews these risks, including with respect to cybersecurity, with the Board of Directors at board meetings from time to time as part of management presentations that focus on particular business functions, operations or strategies and presents the steps taken by management to mitigate or eliminate such risks. We have implemented a risk-based approach to identify and assess the cybersecurity threats that could adversely affect our business, data or information systems that we use or own. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our Vice President of Information Technology, as head of our information technology team, leading our cybersecurity efforts, oversees the day-to-day administration of our cybersecurity program. Our CIRT has members that include our Chief Executive Officer, Chief Financial Officer, and Vice President of Information Technology. As key members of our management team, our Chief Executive Officer, Interim Chief Financial Officer, and Vice President of Information Technology have approximately a combined 45 years of risk management experience and are responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Key members of our information technology management team collectively possess over 15 years of hands-on experience in implementing a diverse array of cybersecurity initiatives. Their expertise spans both cloud and on-premise IT infrastructure and applications/systems, cultivated through extensive engagement across various regulated environments. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment</span><span style="font-weight:normal;">.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b29739a9_0594_414e_a1d4_199769840d67"></a><a id="Item2Properties_55198"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;<span style="font-style:italic;">Properties</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our headquarters are located in Redwood City, California, where we occupy office space under a lease that was amended in October 2023. Pursuant to the amendment, we extended the term of the lease through September 30, 2027 for approximately 27,532 square feet of office space and for 20,257 square feet of previously-leased office space, the term of the lease expired on December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our analytical and process development laboratory is located in Camarillo, California under a lease that expires in May&#160;2027, and contains a one-time option to extend the lease term for five&#160;years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe that our existing facilities are adequate for our current needs.&#160;When our leases expire, or if we need to hire more employees, we may exercise our renewal option or look for additional or alternate space for our operations and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8b214086_8c46_4060_98cd_685b5aeaf44a"></a><a id="ITEM1LegalProceedings_470595"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;<span style="font-style:italic;">Legal Proceedings</span></p><a id="_Hlk93418752"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information called for by this Item is incorporated herein by reference to Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note&#160;9. &#8220;Commitments and Contingencies.&#8221;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0de0948a_d574_4a71_b557_6d051a0cd772"></a><a id="Item4MineSafetyDisclosures_762796"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;<span style="font-style:italic;">Mine Safety Disclosures</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:298.7pt;"><a id="_33ced371_0b20_454e_87ad_38b3f2660e2e"></a><a id="PARTII_514324"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;<span style="font-style:italic;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock has been listed on The Nasdaq Global Market under the symbol &#8220;CHRS&#8221; since November&#160;6, 2014. As of February&#160;29, 2024, there were approximately 85 stockholders of record of our common stock.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our capital stock and do not anticipate paying cash dividends in the foreseeable future. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Performance Graph</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following graph shows the total stockholder&#8217;s return on an investment of $100 in cash at market close on December 31, 2018 through December 29, 2023 (the last trading day at the end of our fifth fiscal year) for (i)&#160;our common stock, (ii)&#160;the Nasdaq Composite Index and (iii)&#160;the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder return. This graph shall not be deemed &#8220;soliciting material&#8221; or be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="chrs-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:298.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:497.81pt;"/></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Equity Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">F</span>rom January 1, 2023 through December 31, 2023, there were no sales or issuances of unregistered securities that were not otherwise reported on a Quarterly Report on Form 10-Q or Current Report on Form 8-K. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We did not repurchase any of our equity securities during the fourth quarter ended December&#160;31, 2023. &#160;A total of 96,047 <span style="background:#ffffff;">shares were surrendered to Coherus in the fourth quarter of 2023, to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards</span>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item6"></a><a id="_b696e0a7_cad6_455f_8e64_79c383f243f9"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;[Reserved]</p><a id="_fd87f1d5_056f_4d60_b05b_c0b24db5ac1d"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K (&#8220;Form&#160;10-K&#8221;). This Form&#160;10-K, including the following sections, contains forward-looking statements within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see the &#8220;Risk Factors&#8221; section in Item&#160;1A of this Form&#160;10-K. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis only as of the date of this Form&#160;10-K. We undertake no obligation to update forward-looking statements, which reflect events or circumstances occurring after the date of this Form&#160;10-K.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">This MD&amp;A section generally discusses 2023 and 2022 items and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 that are not included in this Form 10-K can be found in &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 6, 2023.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of our portfolio of FDA-approved oncology products, including LOQTORZI. Our strategy is to build a leading immuno-oncology business funded with cash generated from our diversified portfolio of FDA-approved therapeutics.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 15, 2024, our commercial portfolio includes two FDA-approved biosimilar products. Our first product, UDENYCA, a biosimilar to Neulasta, a long-acting G-CSF, was launched commercially in the United States in January&#160;2019. <span style="background:#ffffff;">The FDA approved the PAS for an AI presentation of UDENYCA on March 3, 2023, and on May 22, 2023 we announced the availability of UDENYCA AI for commercial sale. On December 26, 2023 we announced that the FDA approved the PAS for our third pegfilgrastim presentation, UDENYCA ONBODY. UDENYCA ONBODY became commercially available in the first quarter of 2024. Our second product, YUSIMRY (adalimumab-aqvh), a biosimilar to Humira (adalimumab), was launched in the United States in July 2023. Another product, CIMERLI (ranibizumab-eqrn), was approved by the FDA in August 2022 as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. We launched CIMERLI commercially in the United States in October 2022. On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">O<span style="background:#ffffff;">ur commercial portfolio includes LOQTORZI, a novel PD-1 inhibitor</span>. <span style="background:#ffffff;">On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is an anti-PD-1 antibody that we developed in collaboration with Junshi Biosciences. We announced the launch of LOQTORZI in the U.S. on January 2, 2024.</span> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">We also have a pipeline of earlier stage clinical and preclinical immuno-oncology programs. On September 8, 2023, we acquired Surface and took ownership of its assets, including its portfolio of product candidates. The lead clinical stage product candidate from the Surface Acquisition is casdozokitug (CHS-388, formerly SRF388), an investigational antibody targeting IL-27, an immune regulatory cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. IL-27 is a cytokine </span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">secreted by macrophages and antigen presenting cells that plays an important physiologic role in suppressing the immune system, as evidenced by its ability to resolve tissue inflammation. In addition, one of the subunits of IL-27, EBI3, is highly expressed during pregnancy and its expression is correlated with maternal-fetal tolerance. Due to its immunosuppressive nature, there is a rationale for inhibiting IL-27 to treat cancer, as this approach will influence the activity of multiple types of immune cells that are necessary to recognize and attack a tumor. Casdozokitug received orphan drug designation and fast track designation from the FDA for the treatment of HCC in November 2020. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Casdozokitug is currently in two on-going clinical studies, a Phase 1/2 study in patients with advanced solid tumors (clinicaltrials.gov identifier# NCT04374877) and a Phase 2 study in HCC (clinicaltrials.gov identifier# NCT05359861). Our second clinical-stage product candidate from the Surface Acquisition, CHS-114 (formerly SRF114), is an investigational IgG1 antibody targeting CCR8, a chemokine receptor highly expressed on Treg cells in the&#160;TME. CHS-114 is designed to cause depletion of intra-tumoral Treg cells, important regulators of immune suppression and tolerance, through ADCC, or ADCP, or both, that has shown anti-tumor activity in preclinical models. We are enrolling patients with advanced solid tumors in North America in a clinical trial evaluating safety and pharmacokinetics of CHS-114 (clinicaltrials.gov identifier# NCT05635643). We are also pursuing an early-stage development candidate that is in investigational new drug application-enabling studies, CHS-1000, an antibody targeting human ILT4, designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.</span> <span style="background:#ffffff;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In addition to our internally developed portfolio of product candidates that we obtained in the Surface Acquisition, we have two product candidates, NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes and GSK, respectively. We will pay 70% of all milestone- and royalty-based payments that we or our affiliates actually receive from the product candidates licensed to Novartis Institutes and GSK during the ten-year period following the entry into the CVR Agreement to the holders of the CVRs. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have built an experienced and robust oncology market access, key account management and medical affairs capability in the United States, <span style="background:#ffffff;">which have supported</span> the successful commercialization of UDENYCA across its three FDA-approved presentations. We expect to leverage these capabilities as we build and launch our immuno-oncology franchise.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We primarily operate in the United States and partner with companies that operate in other countries. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Business Update</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Surface Acquisition</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">On September 8, 2023 (the &#8220;Acquisition Date&#8221;), in accordance with the Agreement and Plan of Merger dated June 15, 2023 (the &#8220;Merger Agreement&#8221;) by and among us, Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of the Company (&#8220;Merger Sub I&#8221;), Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of the Company (&#8220;Merger Sub II,&#8221; and together with Merger Sub I, the &#8220;Merger Subs&#8221;), and Surface, we completed the acquisition of Surface, a clinical-stage I-O company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The Surface Acquisition expanded our I-O pipeline with the following: casdozokitug (CHS-388, formerly SRF388), an investigational, novel IL-27-targeted antibody currently being evaluated in a Phase 2 clinical trial in HCC, and CHS-114 (formerly SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On September 8, 2023, we issued to the holders of all outstanding Surface common stock (other than treasury shares, any shares of Surface common stock held directly by us or the Merger Subs immediately prior to the Acquisition Date and shares of Surface common stock issued and outstanding immediately prior to the Acquisition Date and held by any holder properly demanding appraisal for such shares in accordance with Section 262 of the Delaware General Corporation Law) 0.1960 shares of our common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on a $5.2831 per share price of our common stock and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also received one CVR for each share of Surface common stock and employee equity award converted. Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at our discretion during the ten-year period following September 8, 2023, for the sum of the following, less any permitted deductions (in accordance with the CVR Agreement):</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">70% of all milestone- and royalty-based payments actually received by us or our affiliates under the GSK Agreement related to the existing program (GSK4381562);</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">70% of all milestone- and royalty-based payments actually received by us or our affiliates under the Novartis Agreement related to the existing program (NZV930);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">25% of any upfront payment actually received by us or our affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">50% of any upfront payment actually received by us or our affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:11.5pt;text-align:justify;text-indent:-11.5pt;margin:0pt 0pt 0pt 24.5pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">We expensed $5.1 million of acquisition-related costs during 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">CIMERLI Divestment Transaction</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Other Updates</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is an anti-PD-1 antibody that we developed in collaboration with Junshi Biosciences. We announced the launch of LOQTORZI in the U.S. on January 2, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, we donated approximately 36,000 units of UDENYCA in the PFS presentation to the nonprofit organization Direct Relief to benefit cancer patients in low- and middle-income countries requiring increased access for vulnerable patients. The carrying value of this inventory was written down to zero in the third quarter of 2022, thus there was no charge associated with the donation.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On October 9, 2023, in accordance with the terms of an Optional Stock Purchase Agreement entered with a CMO on September 28, 2023 (the &#8220;Optional Stock Purchase Agreement&#8221;), we issued&#160;2,225,513&#160;shares of our common stock to the CMO for a price of $3.675&#160;per share, representing an aggregate value of $8.2&#160;million.&#160;The Optional Stock Purchase Agreement gave us the option, in our sole discretion to elect to pay for certain manufacturing services provided by the CMO by either paying cash or issuing shares of our common stock in a private placement offering (the &#8220;Stock Service Fee Payment&#8221;). On October 4, 2023, we notified the CMO of our election of the Stock Service Fee Payment. The price per share of common stock was equal to the volume-weighted average closing trading price per share of common stock on the Nasdaq Global Market over the&#160;ten-trading day period ending on and including October 6, 2023.&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 8, 2022, we filed a registration statement on Form S-3, which was declared effective on November 17, 2022 (the &#8220;Registration Statement&#8221;)<span style="background:#ffffff;">. Under the Registration Statement, we could offer and sell up to $150.0 million in the aggregate of our common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.</span> Also on November 8, 2022, we entered into the Sales Agreement with TD Cowen pursuant to which we may issue and sell from time to time up to $150.0 million of our common stock in the ATM Offering<span style="background:#ffffff;">. On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement, we reduced the number of shares that could be issued and sold pursuant to the ATM Offering by $86.25 million, lowering the aggregate offering price under the Sales Agreement from $150.0 million to $63.75 million. On September 11, 2023, pursuant to Amendment No. 2 to Sales Agreement, we increased the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $28.75&#160;million, increasing the aggregate offering price under the Sales Agreement from $63.75&#160;million to $92.5&#160;million. For the ATM Offering program to date as of December 31, 2023, we sold 4,476,645 shares of common stock at a weighted-average price per share of $5.81 for gross proceeds of $26.0 million pursuant to the ATM Offering and received net proceeds of $25.4 million, net of $0.6 million of commissions and fees. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On January 10, 2024, we announced that we had delivered a notice of termination for the TIGIT Program (as defined in the Collaboration Agreement) to Junshi Biosciences pursuant to the Collaboration Agreement. We had previously notified Junshi Biosciences on January 9, 2022 of our election to exercise the license option for the TIGIT program CHS-006 described in the Collaboration Agreement (the &#8220;TIGIT Program&#8221;). After our acquisition of Surface Oncology, Inc. in September 2023, we disclosed that we would conduct a portfolio prioritization process to allocate resources towards the most promising and competitively positioned product candidates in our pipeline. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We believed it would be in our best interests to terminate future work with Junshi Biosciences on the TIGIT Program. We plan to continue to wind down work with Junshi Biosciences on the TIGIT Program pursuant to the termination. Despite the termination of the work with Junshi BioSciences on the TIGIT Program, we will continue to support patients in its current studies involving CHS-006 (clinicaltrials.gov identifier# NCT05061628 and clinicaltrials.gov identifier# NCT05757492). The Collaboration Agreement remains effective and active for all other purposes as we continue to work together with Junshi Biosciences on the development of LOQTORZI.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On February 5, 2024, we entered into the Consent and Amendment with the Collateral Agent and the Lenders, pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Loan Agreement and the other loan documents in connection therewith, and the parties thereto agreed to amend the previously disclosed Loan Agreement. Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the Purchase Agreement, and released certain subsidiary of us from our obligation and certain assets subject to the transactions contemplated thereby, (2) the Lenders and the Collateral Agent required us to make a partial prepayment of the principal of the loans outstanding under the Loan Agreement in the amount of $175.0 million upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions and (3) the parties thereto agreed to adjust the minimum net sales covenant level under the Loan Agreement. Other terms of the Loan Agreement, as amended by the Consent and Amendment, remain generally identical to those under the Loan Agreement. Upon the closing of the Sale Transaction we became liable to repay $175.0 million of the existing principal balance of $250.0 million of the loans outstanding under the Loan Agreement on April 1, 2024 and we plan to repay $175.0 million and the prepayment premium and makewhole amount of $6.8 million to the Lenders on or before April 1, 2024 pursuant to the Consent and Amendment. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Products and Product Candidates</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our portfolio includes the following products and product candidates:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Oncology </span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">UDENYCA, a biosimilar to Neulasta, a long-acting G-CSF, was launched commercially in the United States in January&#160;2019. The FDA approved the PAS for an AI presentation of UDENYCA on March 3, 2023, and on May 22, 2023 we announced the availability of UDENYCA AI for commercial sale. On December 26, 2023 we announced that the FDA approved the PAS for our third pegfilgrastim presentation, UDENYCA ONBODY. UDENYCA ONBODY became commercially available in the first quarter of 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">LOQTORZI </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. We believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune system&#8217;s ability to attack and kill tumor cells.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 48.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 49.5pt;">On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is an anti-PD-1 antibody that we developed in collaboration with Junshi Biosciences. We announced the launch of LOQTORZI in the U.S. on January 2, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:23.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Casdozokitug (</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-388, </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">formerly SRF388), is an investigational recombinant human IgG1 monoclonal antibody targeting IL-27, an immune regulatory cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. IL-27 is a cytokine secreted by macrophages and antigen presenting cells that plays an important physiologic role in suppressing the immune system, as evidenced by its ability to resolve tissue inflammation. In addition, IL-27 is highly expressed during pregnancy and its expression is correlated with maternal-fetal tolerance. Due to its immune regulatory nature, there is a rationale for inhibiting IL-27 to treat cancer, as this approach will influence the activity of multiple types of immune cells that are necessary to recognize and attack a tumor. Casdozokitug received orphan drug designation and fast track designation from the FDA for the treatment of HCC in November 2020. Casdozokitug is currently in two on-going clinical studies a Phase 1/2 study in advanced solid tumors (clinicaltrials.gov identifier# NCT04374877) and a Phase 2 study in HCC (clinicaltrials.gov identifier# NCT05359861). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:23.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CHS-114 (formerly SRF114), is an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the TME. CHS-114 is designed as a cytolytic antibody </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:23.75pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to cause depletion of intra-tumoral Treg cells, important regulators of immune suppression and tolerance, through ADCC, and/or ADCP. CHS-114 has shown anti-tumor activity as monotherapy or in combination with anti-PD-1 antibodies in preclinical models. </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are enrolling patients with advanced solid tumors in North America in a clinical trial evaluating safety and pharmacokinetics of CHS-114 (clinicaltrials.gov identifier# NCT05635643).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:23.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">&#160;are pursuing an early-stage development candidate, CHS-1000, an antibody targeting human ILT4, designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. We plan to submit an IND to the FDA in the second quarter of 2024 for CHS-1000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition to our internally developed portfolio of product candidates that we obtained in the Surface Acquisition, we also own NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes and GSK, respectively. NZV930 is an antibody designed to inhibit CD73, which is a critical enzyme involved in the production of extracellular adenosine, a key metabolite with strong immunosuppressive properties within the TME. NZV930 aims to reduce the production of immunosuppressive adenosine within the TME. GSK4381562 is an antibody targeting CD112R, also known as PVRIG, an inhibitory protein expressed on NK and T cells. GSK4381562 blocks the interaction of CD112R with CD112, its binding partner that is expressed on tumor cells. GSK4381562 can promote the activation of both NK and T cells, with potential to elicit a strong anti-tumor response and promote immunological memory. We will pay 70% of all milestone- and royalty-based payments that we or our affiliates actually receive from the product candidates licensed to Novartis Institutes and GSK during the ten-year period following the entry into the CVR Agreement to the holders of the CVRs. </span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immunology</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">YUSIMRY, </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">a biosimilar of Humira (adalimumab), is a monoclonal antibody that can bind to TNF. YUSIMRY provides certain therapeutic benefits for treatment of patients with certain inflammatory diseases characterized by increased production of TNF in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#8217;s disease, psoriasis and ulcerative colitis.&#160;In December 2021, the FDA approved YUSIMRY, which we launched in the United States in July 2023. The list price of YUSIMRY at launch represented an approximately 85% discount to the list price of Humira. YUSIMRY is now available for sale nationwide through select retail, mail order, and specialty pharmacy channels.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ophthalmology franchise &#8211; sold to Sandoz pursuant to the Sale Transaction</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:25.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CIMERLI is a Lucentis biosimilar. In November 2019, we entered into a license agreement with Bioeq for the commercialization of CIMERLI in certain dosage forms in both a vial and </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-filled syringe (&#8220;PFS&#8221;) </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">presentation. Under the Bioeq Agreement, Bioeq granted to us an exclusive royalty-bearing license to commercialize CIMERLI in the field of ophthalmology (and any other approved labelled indication) in the United States. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 49.5pt;">On August 2, 2022, the FDA approved CIMERLI as a biosimilar product interchangeable with Lucentis for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. The FDA also granted CIMERLI 12 months of first interchangeable exclusivity. On October 3, 2022, we launched CIMERLI commercially in the United States in both 0.3 mg and 0.5 mg dosage forms.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 49.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 49.5pt;">On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the divestiture of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 49.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;">License Agreement with Junshi Biosciences </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On February 1, 2021, we entered into the Collaboration Agreement with Junshi Biosciences for the co-development and commercialization of LOQTORZI, Junshi Biosciences&#8217; anti-PD-1 antibody in the United States and Canada. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the Collaboration Agreement, we paid $150.0 million upfront for exclusive rights to LOQTORZI in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug candidates. We will have the right to conduct all commercial activities of LOQTORZI in the United States and Canada. We are obligated to pay Junshi Biosciences up to a 20% royalty on net sales of LOQTORZI and up to an aggregate&#160;$380.0 million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><a id="_Hlk106699310"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In March 2022, we paid $35.0 million for the exercise of our option to license CHS-006. Subsequent joint development consistent with the Collaboration Agreement commenced. On January 10, 2024, we announced that we had delivered a notice of termination of the TIGIT Program (as defined in the Collaboration Agreement) to Junshi Biosciences pursuant to the Collaboration Agreement. Under the Collaboration Agreement, we retain the right to collaborate in the development of LOQTORZI and the other licensed compounds and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, we are responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The $35.0 million payment for the option to license CHS-006 was reflected in our first quarter of 2022 financial statements. As of December 31, 2023, we have accrued a $25.0 million milestone payment to Junshi Biosciences, of which we expect to pay $12.5 million in the second quarter of 2024 and $12.5 million in the first quarter of 2025, as well as an immaterial royalty obligation. The additional milestone payments and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our first FDA-approved product, UDENYCA, was approved in November&#160;2018, and we initiated United States sales of UDENYCA on January&#160;3, 2019. In December 2021, the FDA-approved YUSIMRY, which we launched in the United States in July 2023. On August 2, 2022, the FDA approved CIMERLI, which we launched in the United States in October 2022. On October 27, 2023, we announced that LOQTORZI was approved by the FDA, and we subsequently launched LOQTORZI in the United States in January 2024. Total net revenues were $257.2 million and $211.0 million in 2023 and 2022, respectively. On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the Sale Transaction of our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Goods Sold </p><a id="_Hlk161068038"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cost of goods sold consists primarily of third-party manufacturing, distribution, certain overhead costs, and royalties on certain products. In the fourth quarter of 2023, </span>we recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments in cost of goods sold in the consolidated statements of operations.<span style="background:#ffffff;"> </span><span style="background:#ffffff;">On May&#160;2, 2019, we settled a trade secret action brought by Amgen. As a result, cost of goods sold reflects a mid-single digit royalty on UDENYCA net product revenue, which began July&#160;1, 2019 and continues for five years from then. Additionally, w</span>e share a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range, and pursuant to the Genentech Agreement we incur a royalty that is a low single-digit percentage of net sales of CIMERLI that was incurred through the end of 2023 but that is no longer owed.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Research and development expense represents costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred. We currently track research and development costs incurred on a product candidate basis only for external research and development expenses. Our external research and development expense consists primarily of:</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expense incurred under agreements with collaborators, consultants, third-party CROs, and investigative sites where a substantial portion of our preclinical studies and all of our clinical trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with manufacturing process development activities, analytical activities and </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-launch inventory manufactured prior to regulatory approval being obtained or </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">deemed to be probable</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">upfront and certain milestone payments related to licensing and collaboration agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Internal costs are associated with activities performed by our research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expense, which include salaries, benefits and stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The largest component of our total operating expense has historically been our investment in research and development activities, including the licensing and collaboration costs, clinical development and manufacturing process development of our product candidates.<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming. Furthermore, in the past, we have entered into collaborations with third parties to participate in the development and commercialization of our product candidates, and we may enter into additional collaborations in the future. In situations in which third parties have substantial influence over the development activities for product candidates, the estimated completion dates are not fully under our control. For example, our partners in licensed territories may exert considerable influence on the regulatory filing process globally. Therefore, we cannot forecast with any degree of certainty the duration and completion costs of these or other current or future clinical trials of our product candidates. We may never succeed in achieving regulatory approval for any of our pipeline product candidates. In addition, we may enter into other collaboration arrangements for our other product candidates, which could affect our development plans or capital requirements.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The following table summarizes our research and development expense incurred during the respective periods: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Development&#160;Status as&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External costs incurred by product candidate:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">UDENYCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Approved<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,358</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">YUSIMRY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Approved <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,273</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,309</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">LOQTORZI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Approved <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,192</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36,871</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CHS-006 (option terminated)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical Trials <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,833</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,650</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CHS-1000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,671</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Development <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CHS-114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Development <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,429</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other discontinued projects</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discontinued <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,007</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other research and development expenses<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,838</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Internal costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 73,654</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 109,436</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 199,358</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">Expenses related primarily to development efforts to obtain PAS for additional presentations of UDENYCA.</span></td></tr></table><a id="_Hlk126939715"></a><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">YUSIMRY, formerly CHS-1420, was approved by the FDA in December 2021. Expenses in 2023 and 2022 primarily related to manufacturing efforts for new formulations and clinical studies. </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">In October 2023, LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for LOQTORZI as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">In March 2022, we paid $35.0 million to exercise our option to license CHS-006, a TIGIT-targeted antibody, in the United States and Canada from Junshi Biosciences. Expenses in 2023 and 2022 included our reimbursement for certain costs related to an ongoing CHS-006 clinical trial being conducted by Junshi Biosciences. On January 10, 2024, we announced that we delivered a notice of termination of the TIGIT Program (as defined in the Collaboration Agreement) to Junshi Biosciences pursuant to the Collaboration Agreement. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">We acquired casdozokitug and CHS-114 in connection with the Surface Acquisition in September 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">The $1.0 million of expense in 2022 relates to CHS-3318 and CHS-305 which were both discontinued during 2022. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;">Amount consists of expenses for other pipeline candidates and CIMERLI, which was approved by the FDA in August 2022.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:6pt 0pt 12pt 0pt;">Selling, General and Administrative Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expense consists primarily of personnel costs, allocated facilities costs and other expense for outside professional services, including legal, insurance, human resources, outside marketing, advertising, audit and accounting services, acquisition-related costs, as well as costs associated with establishing commercial capabilities in support of the commercialization of UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. Personnel costs consist of salaries, benefits and stock-based compensation.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and debt issuance costs associated with our outstanding debt agreements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss on Debt Extinguishment</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Loss on debt extinguishment consists of losses incurred related to the early repayment of debt obligations</span>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists primarily of interest earned on our cash and cash equivalents, non-cash accretion of discount on our investments in marketable securities, foreign exchange gains (losses) resulting from currency fluctuations, and gains (losses) from disposal of long-lived assets. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of&#160;Years Ended December&#160;31, 2023 and 2022 </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 257,244</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 211,042</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,202</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The increase in net revenue was primarily due to our three new products: CIMERLI launched in October 2022 and contributed $118.4 million more in 2023 as compared to 2022, YUSIMRY launched in July 2023 contributing $3.6 million, and LOQTORZI sales to distributors began in December ahead of the January 2024 launch, contributing $0.6 million of net revenue. This was partially offset by a $76.8 million</span><span style="color:#00b050;background:#ffffff;"> </span><span style="background:#ffffff;">decline in UDENYCA net revenue as compared to 2022, primarily related to the decline in the average net selling price per unit.&#160;Our net revenue and market penetration may continue to be adversely impacted by pricing trends and competitive dynamics in the overall pegfilgrastim market.&#160;In addition, the COVID-19 pandemic has negatively impacted the pre-filled syringe pegfilgrastim market due to preferences to administer medication at home.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our net revenue to decrease during 2024, as a result of the CIMERLI Sale Transaction that closed on March 1, 2024. However, we believe this will be partially offset by the continued market share growth of UDENYCA, considering its multiple presentations, as well as the launch of LOQTORZI in the U.S. as announced on January 2, 2024, and a full year of sales of YUSIMRY. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cost of Goods Sold</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 158,992</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,083</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 88,909</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The increase in cost of goods sold in 2023 compared to 2022 was due to a $47.0 million charge in the fourth quarter of 2023 for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments, a $47.5 million increase in royalty costs and $25.0 million increase in product costs, both driven primarily by CIMERLI sales, $3.0 million in contract modification fees with one of our manufacturers for reducing the number of UDENYCA batches to be produced, and $2.3 million in write-downs, net of recoveries for inventory that was damaged during processing. These unfavorable factors were offset by the $26.0 million write-down in the third quarter of 2022 of inventory at risk of expiration and due to the sale in the second half of 2023 of certain of those UDENYCA units having no carrying value following the write-down and a total original cost of $9.9 million.</span></p><a id="_Hlk127469295"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our gross margin to increase during 2024 primarily because 2023 results included a $47.0 million charge for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments, as well as 2023 had a full year of sales of CIMERLI, which was divested March 1, 2024 and had a gross profit share in the low- to mid-fifty&#160;percent range reflected in COGS. &#160;Sales generated from our other products after the closing of the Sale Transaction will have a higher average gross margin. In addition, the mid-single digit royalty on UDENYCA net product revenue expires on June 30, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 109,436</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 199,358</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (89,922)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decrease in research and development expense was primarily due to:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the first quarter of 2022 including an upfront payment of $35.0 million to exercise our option to license CHS-006, a TIGIT-targeted antibody, in the United States and Canada;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $19.0 million in YUSIMRY costs primarily due to certain manufacturing costs for YUSIMRY being capitalized since mid-2022, as well as completion of key studies in the second half of 2022; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $18.5 million in co-development costs for LOQTORZI and CHS-006 resulting from reducing the scope of the development plan for LOQTORZI in the United States beginning in 2023;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $12.9 million in costs to develop additional presentations of UDENYCA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $10.0 million in personnel and stock-based compensation expense primarily due to fewer employees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $4.5 million in facilities, supplies and materials and other infrastructure related expenses to support our research and development programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"></p><a id="_Hlk126772617"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decrease was partially offset by<span style="background:#ffffff;">&#160;increases of $4.4 million for development of CHS-1000 and $4.1 million for development of </span>casdozokitug.<span style="color:#00b0f0;background:#ffffff;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expense in 2024 to be lower than in 2023, as CHS-006 co-development with Junshi Biosciences has been terminated and we continue our focus on cost containment across multiple functions.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Selling, General and Administrative Expense  </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 192,015</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 198,481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,466)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decrease in selling, general and administrative expense was primarily due to <span style="background:#ffffff;">lower average headcount, including reductions of $9.9 million in employee and consultant costs and&#160;$3.1 million in stock-based compensation. These decreases were partially offset by increases of $5.9 million in professional services&#160;driven by the Surface Acquisition and third-party processing fees.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Excluding the potential impact of any acquisitions or business development transactions that have not been consummated, we expect our selling, general and administrative expense for the full year 2024 to be lower than the full year 2023 primarily as a result of the CIMERLI Sale Transaction, reduced headcount and decreased commercial costs.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,542</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,474</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,068</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The increase in interest expense in 2023 was primarily due to a higher average outstanding debt balance and a higher average interest rate for the 2027 Term Loans. This was partially offset by $3.9 million of interest expense in 2022 related to the 2027 Term Loans discount and debt issuance costs that were allocated to unfunded tranches and subsequently amortized over the respective commitment periods for tranches, including $2.3 million allocated to Tranche B that was fully amortized in the first quarter of 2022.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our 2027 Term Loans have a variable interest rate component that resets at the beginning of every quarter, and the total interest rate ranged from 9.25% to 12.00% during 2022 and from 13.03% in the first quarter of 2023 to 13.91% in the fourth quarter of 2023. The interest rate on the 2027 Term Loans decreased to 13.84% for the first quarter of 2024. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Due to the expected partial prepayment of $175.0 million </span>of principal under the 2027 Term Loans as a result of the CIMERLI <span style="background:#ffffff;">Sale Transaction, we expect interest expense to decrease in 2024 compared to 2023.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss on Debt Extinguishment </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6,222)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $6.2 million loss on debt extinguishment recorded in 2022 resulted from voluntarily prepaying all amounts outstanding under the loan agreement between us and affiliates of Healthcare Royalty Partners dated as of January 7, 2019 (the &#8220;2025 Term Loan&#8221;) in January 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Other income (expense), net  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,822</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,647</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span>In 2023, other income (expense), net<span style="background:#ffffff;"> changed favorably compared to 2022 primarily due to higher income from investments in marketable securities.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Income Tax Provision (Benefit)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Income tax provision (benefit) consists of the change in deferred tax balances resulting from the recognition of a deferred tax liability related to the Surface Acquisition. We recognized $0.4 million of income tax benefit for the year ended December 31, 2023. No income tax provision or benefit was recognized for the year ended December 31, 2022.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Certain relevant measures of our liquidity and capital resources are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       Total Cash, cash equivalents and marketable securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 117,748</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 191,681</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Debt obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       2027 Term Loans</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 246,481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 245,483</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">       2026 Convertible Notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 226,888</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 225,575</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">            Total debt obligations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 473,369</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 471,058</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Although we were profitable in 2020 and 2019, due to our research and development expenditures and decline in revenue beginning in 2021, we have generated significant operating losses in all other years since our inception, including in 2023 and 2022. We have funded our operations primarily through sales of our common stock, issuance and incurrence of convertible and term debt and sales of our products.</span> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 19, 2024, we entered into the Purchase Agreement by and between us and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, we completed the Sale Transaction for our CIMERLI ophthalmology franchise through the sale of our subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2024, we entered into a Consent, Partial Release and Third Amendment to the 2027 Term Loans (the &#8220;Consent and Amendment&#8221;), that among other things: (1) provided consent to consummation of the transactions contemplated by the Purchase Agreement, and released certain of our subsidiary from our obligation and certain assets subject to the transactions contemplated thereby, (2) required us to make a partial prepayment of $175.0 million of the principal of the 2027 Term Loans outstanding upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions and (3) adjusted the minimum net sales covenant level under the 2027 Term Loans. Upon the closing of the Sale Transaction we became liable to repay $175.0 million of the existing principal balance of $250.0 million of the loans outstanding under the Loan Agreement on April 1, 2024 and we plan to repay $175.0 million and the prepayment premium and makewhole amount of $6.8 million to the Lenders on or before April 1, 2024 pursuant to the Consent and Amendment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On September 8, 2023, we obtained $28.8 million of cash, cash equivalents and marketable securities as part of the Surface Acquisition.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On May 16, 2023, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), pursuant to which we issued and sold an aggregate of 11,764,706 shares (the &#8220;Firm Shares&#8221;) of our common stock, par value $0.0001 per share, to the Underwriters (the &#8220;Public Offering&#8221;). Additionally, under the terms of the Underwriting Agreement, we granted the Underwriters an option, for 30 days from the date of the Underwriting Agreement, to purchase up to an additional 1,764,705 shares of common stock (the &#8220;Option Shares,&#8221; and together with the Firm Shares, the &#8220;Shares&#8221;), which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $4.25 per share. The Underwriters agreed to purchase the Shares from us pursuant to the Underwriting Agreement at a price of $3.995 per share. On May 18, 2023, we completed the sale and issuance of an aggregate of 13,529,411 Shares, including the exercise in full of the Underwriters&#8217; option to purchase the Option Shares. We received net proceeds of approximately $53.6 million, after deducting the Underwriters&#8217; discounts and commissions and offering expenses payable by us.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On November 8, 2022, we entered into the Sales Agreement related to the ATM Offering pursuant to which we may issue and sell from time to time up to $150.0 million of our common stock. On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, we reduced the number of shares that could be issued and sold pursuant to its ATM Offering with TD Cowen by $86.25 million, lowering the aggregate offering price under the Agreement from $150.0 million to $63.75 million. On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, we increased the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $28.75&#160;million, increasing the aggregate offering price under the Sales Agreement from $63.75&#160;million to $92.5&#160;million. During the year ended December 31, 2023, 3,559,761 shares were sold pursuant to the ATM Offering. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">For the ATM Offering program to date as of December 31, 2023, we sold 4,476,645 shares of common stock at a weighted-average price per share of $5.81 for gross proceeds of $26.0 million and received net proceeds of $25.4 million, net of $0.6 million of commissions and fees. As of December 31, 2023, we had approximately $66.5 million of our common stock remaining available for sales under the ATM Offering. The ability to elect to sell shares of our common stock in the ATM Offering from time to time adds to our financial flexibility.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, we had an accumulated deficit of $1.6 billion and cash, cash equivalents, and marketable securities of $117.7 million. We believe that our available cash, cash equivalents, marketable securities, cash collected from product sales and ATM Offering and Public Offering proceeds received to date will be sufficient to fund our planned expenditures and meet our obligations for at least the twelve&#160;months following our financial statement issuance date.<span style="color:#ff0000;background:#ffff00;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional agreements with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated research and development activities, and on-going and future licensing and collaboration obligations. We may need to raise additional funds in the future; however, there can be no assurance that such efforts will be successful or that, if they are successful, the terms and conditions of such financing will be favorable. Our future funding requirements will depend on many factors, including the following:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">cash proceeds from product sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing, distributing and marketing our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical supplies and any products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any other collaborative, licensing and other arrangements that we have established or may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales, profit sharing or royalties, if any, from any product candidates that are approved in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, results and cost of our clinical trials, preclinical testing and other related activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in businesses, products or technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of general economic conditions on our business, including but not limited to increased interest rates and high inflation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of the impact from the COVID-19 pandemic and future outbreaks.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For further discussion of risks related to our financial condition and capital requirements, please see &#8220;Risk Factors&#8212;Risks Related to Our Financial Condition and Capital Requirements.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing arrangements</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2027 Term Loans</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="display:inline-block;text-align:left;width:36pt;"></span>In January 2022, we entered into the 2027 Term Loans which provide for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $100.0 million that was funded on January 5, 2022; (ii) a Tranche B Loan in an aggregate principal amount of $100.0 million that was funded on March 31, 2022, in connection with the full repayment of our $100.0 million aggregate principal amount 8.2% Convertible Senior Notes due in March 2022 (&#8220;2022 Convertible Notes&#8221;); (iii) a Tranche C Loan in an aggregate principal amount of $50.0 million that was not funded; and (iv) a Tranche D Loan </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in an aggregate principal amount of $50.0 million that was funded on September 14, 2022. We have the right to request an uncommitted additional facility amount of up to $100.0 million that is subject to new terms and conditions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2027 Term Loans mature on either (i) January 5, 2027; or (ii) October 15, 2025, if the outstanding aggregate principal amount of our 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans accrued interest from inception through March 31, 2023 at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.0%; and, starting April 1, 2023, accrue interest at 8.25% plus the Adjusted Term SOFR, with a floor on Adjusted Term SOFR of 1.0%. Interest is payable quarterly in arrears. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, we paid to the Lenders of the 2027 Term Loans $6.0 million for a funding fee equal to 2.00% of the Lenders&#8217; total committed amount to fund all four tranches.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Loan agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were and will be used to fund our general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to voluntarily repay in full all amounts outstanding under the 2025 Term Loan, as well as all associated costs and expenses; and proceeds of the Tranche B Loan were drawn in connection with the full repayment of our 2022 Convertible Notes due in March 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2023, we were in full compliance with these covenants, and there were no events of default under the 2027 Term Loans.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2024, we entered into the Consent and Amendment, that among other things: (1) provided consent to consummation of the transactions contemplated by the Purchase Agreement, and released certain of our subsidiary from our obligation and certain assets subject to the transactions contemplated thereby, (2) required us to make a partial prepayment of $175.0 million of the principal of the 2027 Term Loans outstanding upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions and (3) adjusted the minimum net sales covenant level under the 2027 Term Loans. Upon the closing of the Sale Transaction we became liable to repay $175.0 million of the existing principal balance of $250.0 million of the loans outstanding under the Loan Agreement on April 1, 2024 and we plan to repay $175.0 million and the prepayment premium and makewhole amount of $6.8 million to the Lenders on or before April 1, 2024 pursuant to the Consent and Amendment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">2026 Convertible Notes</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the carrying amount of our $230.0 million aggregate principal amount convertible senior subordinated notes due 2026 was $226.9 million. The 2026 Convertible Notes accrue interest at a rate of 1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, and will mature on April 15, 2026, unless earlier repurchased or converted at the option of holders. Since inception, the conversion price has been 51.9224 shares of common stock per $1,000 principal amount of the 2026 Convertible Notes, which represents a conversion price of approximately $19.26 per share of common stock. The initial conversion price represents a premium of approximately 30.0% over the last reported sale of $14.82 per share of our common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. The 2026 Convertible Notes are not redeemable at our election before maturity. If the 2026 Convertible Notes were converted on December 31, 2023, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $39.8 million based on our closing stock price of $3.33 as of December 29, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the pricing of the 2026 Convertible Notes, we entered into privately negotiated capped call transactions with certain of the initial purchasers of the 2026 Convertible Notes and other financial institutions. Since inception, the cap price has been $25.93 per share, which represents a premium of approximately 75.0% over the last reported sale price of our common stock of $14.82 per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Milestones </span></p><a id="_Hlk161181489"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">We have obligations to make future payments to third parties that become due and payable upon the achievement of certain development, regulatory and commercial milestones (such as clinical trial achievements, the filing of a BLA, approval by the FDA or product launch). These milestone payments and other similar fees are contingent upon future events and therefore are only recorded when it becomes probable that a milestone will be achieved, or other applicable criteria will be met. With the exception of $25.0 million for a milestone payment to Junshi Biosciences, of which we expect to pay $12.5 million in the second quarter of 2024 and $12.5 million in the first quarter of 2025, as of December 31, 2023, no other milestones were accrued because their probability of achievement had not reached the threshold for recognition.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.75pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.75pt;background:#ffffff;margin:0pt;">The following table presents a summary of our active partnerships and collaborations that have contingent regulatory and sales milestones as of December 31, 2023:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.75pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.75pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Counterparty</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Potential Aggregate Milestone Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.03%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LOQTORZI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$355.0 million<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:24.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHS-006 anti-TIGIT antibody</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$255.0 million <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:24.03%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adimab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;background:#cceeff;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$13.0 million</p></td></tr><tr><td style="vertical-align:bottom;width:24.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vaccinex</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CHS-114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.24%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$15.0 million</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$290.0 million relates to sales milestones and $65.0 million relates to regulatory milestones, excluding the $25.0 million milestone payment to Junshi Biosciences, of which we expect to pay $12.5 million in the second quarter of 2024 and $12.5 million in the first quarter of 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(2)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">On January 10, 2024, we announced we delivered a notice of termination of the TIGIT Program so the Potential Aggregate Milestone Amount for CHS-006 anti-TIGIT antibody became $0 as of that date.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Value Rights</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">We have recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement in connection with the&#160;Surface Acquisition. These potential payments during the ten-year period following September 8, 2023 are only due if we first receive milestone- or royalty-based payments under certain license agreements or upfront payments pursuant to ex-U.S. licensing agreements. Payments to CVR holders can be in the form of cash, stock or a combination of cash and stock. As of December 31, 2023, no payments are due to CVR holders.&#160;For further details, see &#8220;Note 6. Surface Acquisition&#8221; in the Notes to Consolidated Financial Statements contained in Part II, Item 8 of this Annual Report on Form 10-K.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">Other Commitments  </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Non-cancelable purchase commitments</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We enter into contracts in the normal course of business with CROs for preclinical research studies and clinical trials, research supplies and other services and products for operating purposes.&#160;We have also entered into agreements with several CMOs for the manufacture and clinical drug supply of our commercial and product candidates. Our non-cancelable purchase commitments as of December 31, 2023 were $73.1 million, as outlined in &#8220;Note 9. Commitments and Contingencies&#8221; in the Notes to Consolidated Financial Statements contained in Part II, Item 8 of this Annual Report on Form 10-K. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease office and laboratory facilities through arrangements treated as operating leases, and we lease vehicles through finance leases. Refer to &#8220;Note 10. Leases&#8221; in the Notes to Consolidated Financial Statements contained in Part II, Item 8 of this Annual Report on Form 10-K for additional information to our leases. Our total non-cancelable contractual obligations arising from these agreements as of December 31, 2023 was $9.1 million, with $2.9 million of these obligations due within twelve months.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary Statement of Cash Flows </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (174,884)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (241,124)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144,640</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (166,850)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 69,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,326</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39,356</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (353,648)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash used in operating activities of $174.9 million for the year ended December 31, 2023 was primarily due to the net loss of $237.9 million adjusted for non-cash items including net inventory write-downs of $52.6 million, stock-based compensation expense of $43.1 million and other non-cash adjustments of $4.1 million, partially offset by the changes in our operating assets and liabilities of $36.8 million.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash used in operating activities of $241.1 million in 2022 was primarily due to the net loss of $291.8 million adjusted for the classification of the cash option payment to Junshi Biosciences of $35.0 million to investing activities, non-cash items including stock-based compensation expense of $50.7 million, net inventory write-downs of $26.0 million and other non-cash adjustments of $18.2 million, partially offset by the changes in our operating assets and liabilities of $79.3 million.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net cash provided by (used in) investing activities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash provided by investing activities of $144.6 million in 2023 was primarily due to proceeds from maturities of investments in marketable securities of $144.4 million, proceeds from sale of investments in marketable securities of $13.3 million, and $7.0 million of cash acquired from the Surface Acquisition, partially offset by&#160;purchases&#160;of investments in marketable securities of $19.5 million and a $1.1 million upfront milestone payment due to the first commercial sale of YUSIMRY.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash used in investing activities of $166.9 million in 2022 was primarily due to purchases of investments in marketable securities of $127.4 million, the option fee payment of $35.0 million&#160;to license CHS-006&#160;from Junshi Biosciences, a $2.4 million milestone payment to Bioeq related to the launch of CIMERLI, and purchases of property and equipment of $2.0 million. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash provided by financing activities of $69.6 million in 2023 was primarily due to proceeds of $53.6 million from the Public Offering, net of issuance costs, $18.1 million proceeds from the ATM Offering, net of issuance costs, and $1.8 million proceeds from purchase under the ESPP. These were partially offset by $3.6 million in tax payments related to net share settlement.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Cash provided by financing activities of $54.3 million in 2022 was primarily due to proceeds of $240.7 million under the 2027 Term Loans, net of debt discount and issuance costs, proceeds of $6.4 million from the ATM Offering, net of issuance costs, and $2.3 million proceeds from purchase under the ESPP. These were partially offset by fully repaying $109.0 million on the 2022 Convertible Notes and $81.8 million on the 2025 Term Loan (excluding interest which is presented as an operating activity), and $3.7 million in tax payments related to net share settlement of RSUs.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of our consolidated financial statements in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated and expense incurred during the reporting periods. &#8220;Note 1. Organization and Significant Accounting Policies&#8221; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K describes the significant accounting policies and methods used in the preparation of our consolidated financial statements. Our estimates are based on our historical experience and on various other factors that we believe to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination Accounting and Valuation of Acquired Assets</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">We completed the Surface Acquisition on September 8, 2023, which was accounted for as a business combination. We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. Judgment was required in assessing whether the acquired processes or activities, along with their inputs, met the criteria to constitute a business, as defined by U.S. GAAP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The acquisition method of accounting requires the recognition of assets acquired and liabilities assumed at their acquisition date fair values.&#160;The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill, or when there is an&#160;excess of the fair values of these identifiable assets and liabilities over the fair value of purchase consideration, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">a&#160;bargain purchase gain is recorded&#160;in the consolidated statements of operations.&#160;The estimations of fair values are based on non-observable inputs that are included in valuation models. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including the estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">During the measurement period, which occurs before finalization of the purchase price allocation, changes in assumptions and estimates that result in adjustments to the fair values of assets acquired and liabilities assumed, if based on facts and circumstances existing at the acquisition date, are recorded on a retroactive basis as of the acquisition date, with the corresponding offset to goodwill or bargain purchase gain.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Product Sales Discounts and Allowances</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="color:#0070c0;font-size:11pt;font-style:italic;"> </i><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue when a customer obtains control of the product, which generally occurs upon delivery to and acceptance by the customer. The amount recognized in net revenue reflects the consideration which we expect to receive in exchange for product sold, which includes adjustments to gross sales amounts for estimated chargebacks, rebates, discounts for prompt payment, co-payment assistance, product returns and other allowances. The actual amount of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, the estimates will be adjusted, which will affect net product revenue in the period that such variances become known.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The most significant and judgmental gross to net revenue adjustments are for chargebacks and rebates we provide to customers, hospitals, clinics, and payers under commercial and government programs. Amounts payable are provided for under various programs and vary by payer and individual payer plans. In developing our estimates of chargebacks and rebates, we use our historical claims experience and also consider payer mix, statutory discount rates and expected utilization, contractual terms, market events and trends, customer and commercially available payer data, as well as data collected from the healthcare providers, channel inventory data obtained from our customers and other relevant information. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021, total sales deductions to gross product sales were 77%, 73% and 67%, respectively.&#160;Adjustments to provisions for rebates and chargebacks related to sales made in prior periods were less than 3% of the actual payments and customer credits issued in each of the years 2023 and 2022. A change of 10% in our total provisions for product sales discounts and allowances as of December 31, 2023, would have resulted in a change of our pre-tax earnings in 2023 by approximately $24.5&#160;million. A summary of the activities and ending reserve balances for each significant category of discounts and allowances, can be found in &#8220;Note 2. Revenue&#8221; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory Valuation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information and potential product obsolescence, among others. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe that the assumptions we use in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by us, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in our consolidated statements of operations. Adverse developments affecting our assumptions of the level and timing of demand for our products include those that are outside of our control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021, cost of goods sold included inventory write-downs, net of $52.6 million, $26.0 million and $5.1 million, respectively. <span style="background:#ffffff;">As of December&#160;31, 2023, a 10% reduction in the carrying value of </span>inventory we expect to sell in 2024 would be approximately $6.3 million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a description of the impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Significant Accounting Policies&#8221; in the Notes to Consolidated Financial Statements contained in Part II, Item 8 of this Annual Report on Form 10-K.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_565f0026_1b18_485a_b64e_747fff26fac5"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are exposed to market risk related to changes in interest rates. </span>As of December 31, 2023, we had cash and cash equivalents and marketable securities of $117.7 million, primarily invested in U.S. treasuries and government agency securities, commercial paper, corporate bonds and money market funds. Our primary exposure to market risk is interest rate sensitivity. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe that our exposure to interest rate risk on these investments is not significant and a 1% movement in market interest rates would not have a material impact to our financial results. We do not enter into investments for trading or speculative purposes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments and accounts receivables. We attempt to minimize the risks related to cash, cash equivalents and investments by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. There were no material losses from credit risks on such accounts during any of the periods presented. We are not exposed to any significant concentrations of credit risk from these financial instruments.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also subject to credit risk from trade receivables related to product sales, and we monitor the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers. We have not experienced significant losses with respect to the collection of trade receivables. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to interest rate risk with respect to variable rate debt. As of December 31, 2023, we had $250.0 million principal outstanding on our 2027 Term Loans that starting April 1, 2023, accrue interest at 8.25% plus the Adjusted Term SOFR, with a floor on Adjusted Term SOFR of 1.0%. We currently do not hedge our variable interest rate debt. The interest rate for our variable rate debt during the quarter ended December 31, 2023 was 13.91%, and the interest rate during the first quarter of 2024 will be 13.84%. A hypothetical 100 basis point increase in the interest rate on our variable rate debt could result in up to a $2.5 million increase in the annual interest expense as of December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, we issued $230.0 million aggregate principal amount of 2026 Convertible Notes with a fixed interest rate of 1.5%. Since the notes have a fixed annual interest rate, we have no financial or economic interest exposure associated with changes in interest rates. However, the fair value of fixed rate debt fluctuates when interest rates change. Additionally, the fair value of the 2026 Convertible Notes can be impacted when the market price of our common stock fluctuates. We carry the 2026 Convertible Notes on our balance sheet at face value less the unamortized discount and issuance costs, and we present the fair value for required disclosure purposes only.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Substantially all of our sales are denominated in U.S. dollars. We had exposure to the exchange rate between the U.S. Dollar and the Euro because we made purchases of CIMERLI inventory from and paid royalties to our partner Bioeq that were denominated in Euros, and we were therefore subject to fluctuations due to changes in foreign currency exchange rates. Accordingly, fluctuations in the exchange rate between the U.S. Dollar and the Euro may have impacted our consolidated statements of operations. In the first quarter of 2023, we started utilizing euro currency contracts to manage euro currency risk in purchasing inventory and future settlement of euro denominated assets and liabilities. The volume of our foreign currency contract activity is limited by the amount of transaction exposure in each foreign currency and our election whether to hedge the transactions. There are no derivative instruments entered into for speculative or trading purposes. Since our derivatives all matured and settled by December 31, 2023, there were no derivative assets or derivative liabilities as of December 31, 2023.<span style="color:#e46c0a;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_be05a6cd_8817_49d1_8188_72042a87e53a"></a><a id="Item8ConsolidatedFinancialStatementsandS"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;&#160;&#160;<span style="font-style:italic;">Consolidated Financial Statements and Supplementary Data</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">COHERUS BIOSCIENCES,&#160;INC.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNUAL REPORT ON FORM&#160;10-K</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">INDEX TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:91.05%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th></tr><tr><td style="vertical-align:top;width:91.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:AuditorFirmId" id="Narr_VFN7T-MBlUO313tZoD6_Bg">42</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:91.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">Audited Consolidated Financial Statements</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:91.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><a href="#ConsolidatedBalanceSheets_984525"><span style="font-style:normal;font-weight:normal;">Consolidated Ba</span><span style="font-style:normal;font-weight:normal;">lance Sheets</span></a></p></td><td style="vertical-align:bottom;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">95</p></td></tr><tr><td style="vertical-align:top;width:91.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><a href="#ConsolidatedStatementsofOperations_85420"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">96</p></td></tr><tr><td style="vertical-align:top;width:91.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><a href="#ConsolidatedStatementsofComprehensiveInc"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Comprehensive Loss </span></a> </p></td><td style="vertical-align:bottom;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:91.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></a></p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr><td style="vertical-align:top;width:91.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><a href="#ConsolidatedStatementsofCashFlows_928221"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">99</p></td></tr><tr><td style="vertical-align:top;width:91.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt 0pt 0pt 24pt;"><a href="#NotestoConsolidatedFinancialStatements_4"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk161396171"></a><a id="_f0982b75_cd03_4843_a1b2_d1d976d4cef8"></a><a id="ReportofIndependentRegisteredPublic"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:21.0pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:21.0pt;margin:0pt 0pt 9pt 0pt;">To the Stockholders and the Board of Directors of Coherus BioSciences, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:21.0pt;margin:0pt 0pt 9pt 0pt;"><b style="font-family:'EYInterstate Light';font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">We have audited the accompanying consolidated balance sheets of Coherus BioSciences, Inc., (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders' equity (deficit), and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;">-</span><span style="font-family:'EYInterstate Light';">Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 15, 2024 expressed an unqualified opinion thereon.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to </span><span style="font-family:'EYInterstate Light';">those</span><span style="font-family:'EYInterstate Light';"> risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'EYInterstate Light';font-weight:bold;">Critical Audit Matters</b></p><div style="margin-left:-4.75pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100.93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:99.2%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:-4.75pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100.93%;"><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;font-weight:bold;">Estimate of Reserves for Chargebacks and Rebates </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="color:#ffffff;font-family:'EYInterstate Light';font-style:italic;font-weight:bold;">&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><i style="font-family:'EYInterstate Light';font-style:italic;">Description of the Matter</i></p></td><td colspan="2" style="vertical-align:top;width:85.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';white-space:pre-wrap;">As described in Note 1 to the consolidated financial statements, the Company recognizes revenues from product sales at the net sales price, which includes estimates of reserves for chargebacks and rebates it provides to hospitals, clinics, and payers under commercial and government programs. These reserves are recorded in the period when sales occur and are based on the amounts to be claimed on the related sales which may not be known at the point of sale. Chargebacks and rebates are estimated based on expected channel and payer mix, and contracted discount rates, adjusted for current period assumptions. Estimated chargebacks are recorded as a reduction of trade receivables on the consolidated balance sheet and totaled $74.0 million at December 31, 2023. Estimated rebates are presented within accrued rebates, fees and reserves and other liabilities, non-current on the consolidated balance sheet and totaled $121.1 million at December 31, 2023.    </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">Auditing the estimates for chargebacks and rebates was complex due to the judgmental nature of the assumptions used. In particular for product that remains in the distribution channel at December 31, 2023, management is required to estimate the portion of product that is expected to be subject to a chargeback and rebate as well as the applicable discount rate.</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><i style="font-family:'EYInterstate Light';font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';white-space:pre-wrap;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls over the Company's estimates of chargebacks and rebates, which are accounted for as reductions to revenue.  This included controls over management&#8217;s review of significant assumptions used in the estimates such as expected channel and payer mix and contractual discount rate. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';"> </span><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">To test the Company's estimated reserves for chargebacks and rebates, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the Company&#8217;s analyses and evaluating the significant assumptions stated above. Specifically, for estimated chargebacks and rebates, we obtained third-party channel inventory reports and reviewed the remaining inventory in the distribution channel, tested historical channel and payer mix data, and compared applicable contractual chargeback or rebate percentages applied against executed chargeback and rebate agreements. We also assessed the completeness and accuracy of current and historical channel and payer mix and discount rate data used in management&#8217;s estimates and performed sensitivity analyses to determine the effect of changes in assumptions, where appropriate.</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;font-weight:bold;">Excess and Obsolete Inventory Reserve</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><i style="font-family:'EYInterstate Light';font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">As of December 31, 2023, the Company had $130.1 million of inventory which included $13.0 million of raw materials, $82.6 million of work in progress and $34.5 million of finished goods. As disclosed in Note 1 to the Company&#8217;s consolidated financial statements, inventories are stated at the lower of cost or estimated net realizable value. The Company assesses its inventory levels along with its purchase commitments each reporting period and writes down inventory that is either expected to be at risk of expiration prior to sale or has a cost basis in excess of its expected net realizable value. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">Auditing management's estimates for excess inventory involved subjective auditor judgment because the estimates rely on a number of factors that are affected by market and economic conditions outside the Company's control. In particular, the excess inventory calculations are sensitive to significant assumptions, including the expected demand for the Company&#8217;s products, the effect on demand of competitive products and the Company's purchase commitments.</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-left:-4.75pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100.93%;"><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><i style="font-family:'EYInterstate Light';font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company's excess and obsolete inventory reserve process including management&#8217;s review of the significant assumptions described above and controls over the completeness and accuracy of the information used to develop the estimate. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">Our substantive audit procedures included, among others, evaluating methodologies used and data utilized in the analysis for inventory expected to be at risk for expiration or excess, or has a cost basis in excess of its expected net realizable value. We evaluated purchase commitments or alternative uses, compared forecasted demand and expected net realizable value to historical trends, compared actual inventory levels to forecasted demand requirements and expected net realizable value, and evaluated the sensitivity of sales forecast assumptions on the amount of inventory reserves recorded.</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;font-weight:bold;">Business Combination</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><i style="font-family:'EYInterstate Light';font-style:italic;">Description of the Matter</i></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">During the year ended December 31, 2023, the Company completed its acquisition of Surface Oncology, Inc. (&#8220;Surface&#8221;) for consideration of $64.6 million in net assets, as disclosed in Note 6 to the consolidated financial statements. The transaction was accounted for as a business combination.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">Auditing the Company&#8217;s accounting for its acquisition of Surface was complex due to the significant estimation required by management to determine the fair value of certain identified finite and indefinite-lived intangible assets, principally consisting of out-license intangible assets of $13.5 million and in-process research and development intangible assets of $26.2 million, respectively. The significant estimation uncertainty was primarily due to the sensitivity of the respective fair values to underlying assumptions about the future performance of the acquired business. The significant assumptions used to estimate the fair value of these intangible assets included certain assumptions including estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, and discount rates. These significant assumptions are forward looking and could be affected by future economic and market conditions.</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><i style="font-family:'EYInterstate Light';font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:84.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s accounting for the acquisition. This included testing controls over the estimation process supporting the recognition and measurement of the out-license assets and in-process research and development, including the valuation models and underlying assumptions used to develop such estimates. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'EYInterstate Light';white-space:pre-wrap;">To test the estimated fair value of the in-process research and development and out-license assets, we performed audit procedures that included, among others, evaluating the Company's selection of the valuation methodology, evaluating the methods and significant assumptions used by the Company, and evaluating the completeness and accuracy of the underlying data supporting the significant assumptions and estimates. For example, we compared the significant assumptions to current industry, market and economic trends and to the Company's forecasts. We involved our valuation specialists to assist with our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates. Our valuation specialists&#8217; procedures included, among others, developing a range of independent estimates for the discount rates used in the valuation models and comparing those to the discount rates selected by management.  </span></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:AuditorName" id="Narr_A2YIi7VWl0KrOYmInSpdWg">Ernst &amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2012.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="dei:AuditorLocation" id="Narr_Nli90iUWxUOo1y1xKESqUA">San Mateo, California</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;">March 15, 2024</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 108pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d45438ca_3116_4c6b_8efc_3f184ef45212"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="ConsolidatedBalanceSheets_984525"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ec21e0c5_6c89_40ab_b636_7a8b42cc93ba"></a><a id="Tc_Xs-ik4MnZEKH5o2CqAn-7w_1_2"></a><a id="Tc_eThej5HS1kCesqoiLS1YOw_1_5"></a><a id="Tc_jYTOnwqsBkO78KNBA8Nb0g_2_2"></a><a id="Tc_rLMKAPW03km6izAMnCE4ZQ_2_5"></a><a id="Tc_qRgAAieX50KjAyh8nhD04w_3_0"></a><a id="Tc_d1F2rvRXHEi0Fe2tf6e6ZQ_4_0"></a><a id="Tc_scv4NPI72kmn2c4G0iwvjQ_5_0"></a><a id="Tc_d5bxoeZzFE-nsotpOg_-YQ_5_2"></a><a id="Tc_Ms8J7GIUrkOncCtEUfB0oQ_5_5"></a><a id="Tc_P-0D-mn_EEmVeNBvhlHVlQ_6_0"></a><a id="Tc_eq7AUC0-Pk-Vsh1jEBDGDA_7_0"></a><a id="Tc_Mx3FSgt6UEyz9n33Qf1FFA_8_0"></a><a id="Tc_CREU5LnpXE6dM7MHE_lYrg_9_0"></a><a id="Tc_01R9UBqZFkSl8nr98FLpFQ_10_0"></a><a id="Tc_O5E8EDhN_0WBHt2TuwZang_11_0"></a><a id="Tc_DqoLHf8_o0iD_I5rt81cKg_12_0"></a><a id="Tc_tTCJZ7NI00eZlVXFcjm4iQ_13_0"></a><a id="Tc_dGlo_q9DuE2M6bYXjWjYRQ_14_0"></a><a id="Tc_qr9CdYAvdUCCgSBPrpQePA_15_0"></a><a id="Tc_fZjQCL7-xU2gTKY-6GE0Fg_16_0"></a><a id="Tc_MIVPcFK-y0KkN3OZytPS5Q_16_2"></a><a id="Tc_6JTG_OAmcUSs24ALaW0L7g_16_5"></a><a id="Tc_F2f2SS25Y0WtfvDBeEs7Rg_18_0"></a><a id="Tc_1wSqO3yuSE-1V2ugsnCJ1Q_19_0"></a><a id="Tc_e8VV46cx-kCosZH8rpDmiA_20_0"></a><a id="Tc_6yC_2ahQdEi6xOSYv5Z5Rg_20_2"></a><a id="Tc_pVU4OLpovECCkoPVw0p0hg_20_5"></a><a id="Tc_15_3PMoYs0CrBl09eoIyZw_21_0"></a><a id="Tc_b1auFKDh50S8VUfTbuBYxg_22_0"></a><a id="Tc_TWw5b1VBnE-cljEVho8pdg_23_0"></a><a id="Tc_htxqdCxYQkG8OM0jspwW2A_24_0"></a><a id="Tc_wpNLor7yAk-9dKbk0h1n0A_25_0"></a><a id="Tc_Q9tMZmg6uUmi6RQCa_KlFg_26_0"></a><a id="Tc_xL19W03R40e7-DMBEtVuIw_27_0"></a><a id="Tc_Ab7C3mvrskSk58BuQ8Z2cg_28_0"></a><a id="Tc_fwlYOPqhtEOBv-gjHIVjRQ_29_0"></a><a id="Tc_xTBkKtMk7U6-QDNNamDmBA_30_0"></a><a id="Tc_y0-dUta2N0yWEiSPT2q0GA_31_0"></a><a id="Tc_clfTKk2oBk6iOgCl5biQ9w_32_0"></a><a id="_87993594_a0c7_4884_a71f_96fd63071629"></a><a id="_87993594_a0c7_4884_a71f_96fd63071629_2"></a><a id="_87993594_a0c7_4884_a71f_96fd63071629_3"></a><a id="Tc_RR4IONXVE0id3t2ituzvnA_32_3"></a><a id="Tc_Jzhaa-iNJ02ElZKEgWKUlA_32_6"></a><a id="Tc_aBbwA6p43E-votD5GDYysA_33_0"></a><a id="Tc_9DX7v1Jd9kWnR481tmKUqQ_34_0"></a><a id="Tc_zJm0uGV1skWLijSJ7QOKrA_35_0"></a><a id="Tc_zGiosuWQskKd3IWcr92Ngg_36_0"></a><a id="Tc_tSPzQA8agUCxpn-xwTvmLQ_37_0"></a><a id="Tc_V29qw1M52EO4qd2BMk-IwA_38_0"></a><a id="Tc_yc8vF0O620OvcmvzzRoikg_38_2"></a><a id="Tc_0hy_dAqg9kSIF-KrZM6O2Q_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_S4YsZ0wJ50muadCE1zUhlA_5_3">102,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_XtUqqh49dUKAuV11EYvSZA_5_6">63,547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_nCFIdHRKF0KfGwQD8ht3bQ_6_3">14,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_cl_VBkbgMUGhzGx-gKHqFQ_6_6">128,134</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Trade receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_92v2oqrGUUK3FdO8sXlfMw_7_3">260,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_6sbx5GoaiUu73sFauvp1HQ_7_6">109,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_iqQjmLDqi0WJTWGkdcS61A_8_3">62,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_CX4kK-RGA0OGdGqg4v_pGA_8_6">38,791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="3" id="Tc_9s7zkNrAFE-oduuV2HnbVw_9_3">23,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="3" id="Tc_mYsR0zO9JUmKseY4_fPMcQ_9_6">17,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Other prepaids and current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_K5CafLcX5UqwwpV4TLaLDw_10_3">11,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_aI9Gfo2ZAkiwRm9nV2us0Q_10_6">22,918</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_hY4BV_50gUSCDuWjcgHWeA_11_3">475,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_u2Hv7saUL0CBVEyKRFTNuw_11_6">381,234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_K--I-Sk_nk2pscRHZlWYoA_12_3">5,119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_pfdWp_1B6k64TA98_Lce5g_12_6">8,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_5fo5cPomxEGGCmLQlNHs5A_13_3">67,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_f8IcKumQckWklPwfjmK9sw_13_6">76,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_dGrFGG_W80W1YOBwU0SMug_14_3">71,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_hfJRq3j640SM1Wf7nwKNdw_14_6">5,931</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other assets, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc__7qbwMbzgU2viorUEZn_0A_15_3">9,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_4SEQ9c1nNEu65cqSahETCw_15_6">8,668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_j6YWZCWrkU2uFvrZUQW8Ug_16_3">629,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_0VhAR2X0zU2C7KyB1K9KAw_16_6">480,847</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_eXXeA8Vbb0i4618OpksCKQ_20_3">35,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_kJCrEIimaUOK_dzfW_6iiw_20_6">11,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued rebates, fees and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedRebatesFeesAndReserveCurrent" scale="3" id="Tc_V25S2N1gH0GD0EfEYLpJOA_21_3">169,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedRebatesFeesAndReserveCurrent" scale="3" id="Tc_f3rsroLNkkyOIphBCsUFKQ_21_6">54,461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_lyhQONpLik2rmKQdbqRi2g_22_3">21,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_VCTpIsU-Qk-PzhpmKsmAyw_22_6">22,610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_PN-JgyiIn0y9idFqKhcg_Q_23_3">105,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_XWcjO8AtQ0K3BS6jgTc1sw_23_6">50,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_xIu7uU3-0kG9yXthUbF-JA_24_3">331,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_jY-5XFl5I0WgZD9GnUt_rw_24_6">138,694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Term loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:TermLoansPayableNoncurrent" scale="3" id="Tc_TxMI-ZKyYEqLaleEvlu-Aw_25_3">246,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:TermLoansPayableNoncurrent" scale="3" id="Tc_F9CQiGEgcEaVmgLJ2CQP4Q_25_6">245,483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" scale="3" id="Tc_wBygOSRqHUWvYozBssWQyA_26_3">226,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" scale="3" id="Tc_1sctoLG8X02f3TmI6BCDmw_26_6">225,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_1HC1apC510OvJeW1_iOZtw_27_3">5,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_HUZ30JwWF0eQ-rDPNP_AYw_27_6">5,046</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_4e65xBl4BUey7rXAJXu88w_28_3">12,561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_0P2_EcmbqEeb1lBb2DAMSQ_28_6">3,467</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_rEsyA54NTE2XPfB9ckQJOA_29_3">823,029</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_A0XDQtUepECpAEHEZVb2dw_29_6">618,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and contingencies (Note 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Preferred stock (</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_aJiERKpi6UyqczDv1Fkiug"><ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_g7EmZBo33U2mWgcSEmp7-g">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; shares authorized: </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_P2FLuQd2-Uyi0Dpy73y3Xw"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_LYSohQ1bG0K1caCPkHCosA">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;">; shares </span><span style="-sec-ix-hidden:Hidden_v4oTsv095Ua3rj9SnG6xIw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;">outstanding</span><span style="font-size:8pt;">: </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ok6IX3rk9U6c5vKTgCx0Lw"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_TaLgHH20fkiakV4AMA3Mfg">0</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> at December 31, 2023 and 2022)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Common stock (</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_JIVayFbwaE-MMee3vzKfXQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_874vkR9XlEi0k933XLszHw">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; shares authorized: </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_l_0kikA35kmB7rqiSsJvug"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3PAPHUONIkSMRCRNxg9E9w">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;">; shares </span><span style="-sec-ix-hidden:Hidden_tWVxfTC3cUmEtX68kvPusw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_mr4oREKsHEmMwylrOmO9ow;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;">: </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_YdVVzuxV3U6xdT4KVCiHCg">112,215,260</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_URSlstLuFU65ecm3FQRKkw">78,851,516</ix:nonFraction></span><span style="font-size:8pt;"> at December 31, 2023 and 2022, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Q9mCChbtM0W5IZ-P2U4EHA_33_3">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_GFu6g05kLkSHHqnnOQHn0A_33_6">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_yLO5ZrhTwUW8SufDm8mITw_34_3">1,386,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_6A_Ap2pAdUmRC8Ny4f_snw_34_6">1,204,431</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_i5V-LzxhPUyOM2I7ToX6oQ_35_3">248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_ZXIA-J3JyUqzBAcU41PhbA_35_6">249</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_XGxsb5uh1UiLJM7xonrBaQ_36_3">1,579,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_T7--AeuplkGtN2MfEEefuA_36_6">1,341,608</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders' deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_14fmchV7VU6YX99hceVRBQ_37_3">193,425</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KoKIC81-Z0m9vxLeBbjnGQ_37_6">137,418</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities and stockholders&#8217; deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_WcG_G1N3OUee6av8zjZpZw_38_3">629,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_OzLsDzRlfUygRzBeJ0vg7w_38_6">480,847</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ca5e6364_ecdb_467c_8a2a_6eba3faa000f"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="ConsolidatedStatementsofOperations_85420"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><a id="_bb1f81e9_f529_4ce3_bf6b_29c31fbe66b2"></a><a id="_517d08b7_509e_45d1_820c_eda6d126b2e4"></a><a id="Tc_nq9uFG2zSEi3wlLTPJ6yBg_1_2"></a><a id="Tc_Os2LQAge90S3q4KHCxpyGQ_2_2"></a><a id="Tc_Z2j_3OHVok2JhLh_6kYMfw_2_5"></a><a id="Tc_kVxcc9hiwUKYWllSKMTZ1g_2_8"></a><a id="Tc_3XTmMuH1l0CNqceJb2C24g_3_0"></a><a id="Tc_agJf3Tor8Eqz6Rn5XGG5pg_3_2"></a><a id="Tc_knS6FQfuT0uwwDvZ8LB5tw_3_5"></a><a id="Tc_M2SxdLPy3UeBV0D-QlD9BA_3_8"></a><a id="Tc_BIvQntSDkkOEYS5Yzn97lQ_4_0"></a><a id="Tc_GIia6QTKQk2QjMCX4fVcew_5_0"></a><a id="Tc_UCKnEpXXFUy56MUbQcC1oQ_6_0"></a><a id="Tc_82K9RYlqH0WV3ZCjqE534w_7_0"></a><a id="Tc_kiywwu3pWk2CDKabmDpt-w_8_0"></a><a id="Tc_yKaCDLGLB0SVPjbmgSCU3Q_9_0"></a><a id="Tc_oMb2S4KvKk-8Yg2bTSm0lg_10_0"></a><a id="Tc_Y7ZwfbbVa0evjJvE7qZw9g_11_0"></a><a id="Tc_qieVzG6lGkm_9V_iKJwavA_11_3"></a><a id="Tc_9atMhP-8q0e-8SP1b9ivMw_11_9"></a><a id="Tc_2vQuam13Y0i-3Yn2vIe3BA_12_0"></a><a id="Tc_87pL_xRASEaNo0KCjE6kpQ_13_0"></a><a id="Tc_4Ta7FO-NNkOfzPWkog-zsg_14_0"></a><a id="Tc_ZC4207cXUkuKNW59VOIgsw_14_6"></a><a id="Tc_xHXpcEbBbEugj9uG4c53lw_14_9"></a><a id="Tc_0xIw84g7n0mryvrSnMJgjw_15_0"></a><a id="Tc_fCkusrf3ZEyt19mfchQ4Kw_15_2"></a><a id="Tc_2MyPanv-IEeb24R4vuXw9w_15_5"></a><a id="Tc_NsdlryahCEC6AM42Rocv9Q_15_8"></a><a id="Tc_Zw7pF37qlUmoj_VCJDWtcg_17_0"></a><a id="Tc_rAt8wVINC0C_Dg6sxt4ojQ_17_2"></a><a id="Tc_73mF5HKJ80edFGE0v0kcbA_17_5"></a><a id="Tc_I9AZnSCZJESSYqgQSshfvA_17_8"></a><a id="Tc_IU15C_XYO0Kc1d6EAq3qTA_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_TtcantlobUWMp7frPhNsVg_3_3">257,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_f_egLoShp0GFS5xMlNe58g_3_6">211,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_kkQvuhyUskqxeupx7rve9g_3_9">326,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_pqvdIT47ZUanvquVwNYmkQ_5_3">158,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_TWLnJ30XPEKmQ5ARlLjSXQ_5_6">70,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_2gHVUz1yW0u9MZzoBOiuLw_5_9">57,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_0eYQR375QEmnVgXr1f2wJg_6_3">109,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ywfERAcTqkSqjYot9b8b_A_6_6">199,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_jnaY-ChWbEywsK-yAK0faA_6_9">363,105</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_4LdP-f5AxUe-9X_vpm21oA_7_3">192,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_hw_0Yb5pxESNevkzIaH0PQ_7_6">198,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_UsDQ4LyUPUu1SRsLt9fR9w_7_9">169,713</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_8MpnuQxhtEWH8gO0G5eW1A_8_3">460,443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_lCI5Ov5bzUCE07wRcxLZDA_8_6">467,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_Ah_2ZBq2cEuKBnMDeJt62w_8_9">590,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_h906MC-a2U-fgYu36bv42Q_9_3">203,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_cuHXi-q_XEiVBTlnhCntVA_9_6">256,880</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_EkPrsX401E6Y8c-zZeWLrQ_9_9">263,858</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_ZmZ4gMgF3US6zN31kA_11g_10_3">40,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_kwq7h9Esi0WQ5u-TVR8nKA_10_6">32,474</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_05Hu1pt5gky2zmDipJpKPA_10_9">22,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_yCw10z1Qm0aZN9oNIocWEA_11_6">6,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_ScXuC3_5MkysL586mmqRcw_12_3">5,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_gk43YvNveEW_mgmltBjjFA_12_6">3,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_kyud0aduw0i555h5YSS6Rg_12_9">283</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_0EwqDyU4REeeCui6xTK1Ww_13_3">238,272</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_DJqhH4MAz0aJwBddebO3Kg_13_6">291,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_h01HFgJpFU6G2POzKkVIPg_13_9">287,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Lx2sd-d0LEORvkGS9jmTHg_14_3">380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WpwvCXIlzEW5S9Ov9NkDVw_15_3">237,892</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7YM0lp2enUChJXQoP8gijQ_15_6">291,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__jYIoOHMx0aZ86bnBO8nNg_15_9">287,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_0ygXb8-f_UefKj4QkERu8Q_17_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_0ygXb8-f_UefKj4QkERu8Q_17_3_2">2.53</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_Y4sX3IWvUUW5Rhs5OXx1YA_17_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Y4sX3IWvUUW5Rhs5OXx1YA_17_6_2">3.76</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_p_Tw229Olk2BSkK76q0Q9w_17_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_p_Tw229Olk2BSkK76q0Q9w_17_9_2">3.81</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Weighted-average number of shares used in computing basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_-tGmNMGiE0ep0hMtO-kUqQ_19_3"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_-tGmNMGiE0ep0hMtO-kUqQ_19_3_2">94,162,637</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_S81P8FSU8EGedeqbOpf6yQ_19_6"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_S81P8FSU8EGedeqbOpf6yQ_19_6_2">77,630,020</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_3HvpDOrkHE2A-y7ymLNirw_19_9"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_3HvpDOrkHE2A-y7ymLNirw_19_9_2">75,449,632</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8d512f7a_4ece_4c92_8c36_04f1dedef788"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="ConsolidatedStatementsofComprehensiveInc"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Comprehensive Loss </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_43c1ff9a_538c_4500_bcd1_40a6a2cb1508"></a><a id="Tc_WTC5VPbdPkCBIzSO1v8JOg_1_2"></a><a id="Tc_RRKmI5mI7EO-f08ejJjzSw_2_2"></a><a id="Tc_tXC_EPYR-k6T4DkZU9TKVQ_2_5"></a><a id="Tc_vFO8o2goEkGONxkrDO6VzA_2_8"></a><a id="Tc_94xomznUJ0CQGIDFJmX3IQ_3_0"></a><a id="Tc_-cgrgxJJEU2ukcxcd8jcUA_3_2"></a><a id="Tc_cKIf8B5ujUOEUcD5gVsrsQ_3_8"></a><a id="Tc_1HIPBY97bEW2I8yX4CmcWg_4_0"></a><a id="Tc_qS1FmACtKUS5GecJVnBPAQ_5_0"></a><a id="Tc_1khIS8siPUexZFdobnwyAA_5_9"></a><a id="Tc_ZhwvFKw_eEiGSzXoeQgAbg_6_0"></a><a id="Tc_rh6OPAkTlEe1ze_Ub7P1jQ_6_9"></a><a id="Tc_4TR6UfpYlUe6kUG_-xfXiw_7_0"></a><a id="Tc_bjpNevx-60KPAChHY87HxA_7_2"></a><a id="Tc__6hpLyhxJ0uQibj_AL-QUA_7_5"></a><a id="Tc_6ehQfIRn30ufWLTO2ybQzA_7_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_lKL--kYpv0SUFEg72-dkbA_3_3">237,892</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_ky3l7MP5Dk21ktPditamnw_3_6">291,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Sy6UCvkLDk-cd6IB-dn2DQ_3_9">287,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Unrealized gain on available-for-sale securities, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_zA68baDY6EWu2Lrovs1lYQ_5_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_sep9iVm98UW6lnQid0KuuA_5_6">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency translation adjustments, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_tElBI1ZjP0GiPxIF-Np9zQ_6_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_FzSrIFphtke17xGtrGrPHA_6_6">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_MhcMe15YNUiI49QFSueKnQ_7_3">237,891</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_DTuW1VKv2U-F1x8OvXYA8w_7_6">291,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_ZGNLWI8w30CBRP6CA-IHyA_7_9">287,100</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes.</p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:3.45%;padding-right:3.45%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d16db920_9060_4d7d_b110_003fbc377586"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="Equity"></a><a id="ConsolidatedStatementsofStockholdersEqui"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><a id="_08b9a669_1777_45bc_a308_4575e93d693f"></a><a id="Tc_Q5k2l0YTJ0-F9WVX30Dosg_1_10"></a><a id="Tc_WXYsonVg8EWXdofJTnsc6Q_2_7"></a><a id="Tc_4VVsAx69M0qdEzii-n8fng_2_10"></a><a id="Tc_rdxUeCayyku030oU9xR8Hg_2_16"></a><a id="Tc_5sohMzCEmEWZodgjN_wYow_3_2"></a><a id="Tc_87OGv4t8a02mDDn-RdfOVQ_3_7"></a><a id="Tc_f99drt_BQ0q5H8K1jSq7sQ_3_10"></a><a id="Tc_Bc5j5ybbPE2Soqq5G7Ajyg_3_13"></a><a id="Tc_nUjXcHHRBEid2aeG1tLxSQ_3_17"></a><a id="Tc_7pObStqApUyL0onBPuCHIA_4_2"></a><a id="Tc_-LCcYnxwMUugpx9imdO5qQ_4_5"></a><a id="Tc_c2ZU7vHOA0W_wM0WZJZKpg_4_7"></a><a id="Tc_pWcK5LOq80udzhIB_oAnqA_4_10"></a><a id="Tc_m0BtCqJbYE2pA-cdTZWTSg_4_13"></a><a id="Tc_az9uO760uE6Sj3VcrDl8Yw_4_17"></a><a id="Tc_o65-FVaTGk2Xn8oPMstGug_5_0"></a><a id="Tc_HhsCzXs560mD6-ek97kFjA_5_4"></a><a id="Tc_jWeQupgL8kmoj6g85mOaMw_5_7"></a><a id="Tc_8f27NpyJFEqg3xBhNVHr2w_5_10"></a><a id="Tc_RU-h0zKyBUKpqj6p-xAYOQ_5_13"></a><a id="Tc_IaS8kDltpEOXqFec1nde6w_5_16"></a><a id="Tc_QGgmX8VIIECWSRYF1VCoLQ_6_0"></a><a id="Tc_jV2jJFa6aUCEgyhUqW0kJg_6_2"></a><a id="Tc_Pz_B3OF6sEemDKUz7sBlcQ_6_5"></a><a id="Tc_N6Xt9fcFdkOpavtYSAwa_g_6_8"></a><a id="Tc_PL_ImgyDn0uTGz_q8fF6fA_6_11"></a><a id="Tc_T0Yfwyi92EWyFKosGDderA_7_0"></a><a id="Tc_HkZW-6qGcEiQITCglXcZlQ_7_5"></a><a id="Tc_7q0QZ-69MUaW8orx6Imbaw_7_11"></a><a id="Tc_v_15mpr0j0S_eBUcTDoDpQ_7_14"></a><a id="Tc_yaNLSZe8JEOwQ7ZCBnOggw_8_0"></a><a id="Tc_iEJQjApEP0maQIOE7ItD7w_8_5"></a><a id="Tc_pkpfpT6Lz0exnTqYQqTk_Q_8_8"></a><a id="Tc_QvDnBqru9EC8RAPtgVqoAA_8_11"></a><a id="Tc_5D5XCKaRykiqSGt2nfXuAg_8_14"></a><a id="Tc_EidFK1MXZkWXBryw-dzv5g_8_17"></a><a id="Tc_J624iFP7Z0O82J04Jqe4xg_9_0"></a><a id="Tc_Qx4X0FS5k0CVVCVVnjD6Dg_9_5"></a><a id="Tc_-sZd-v2W402BnJBgaXTFdA_9_11"></a><a id="Tc_3uezzgugv0uCkmwltQbadA_9_14"></a><a id="Tc_A6SoWdYkskCh3bb8iMqLMw_10_0"></a><a id="Tc_tA9kbi5J7EC57WPcY_b31w_10_5"></a><a id="Tc_fAF6Mu8dvUi1iP9beK9Mbw_10_11"></a><a id="Tc_SKjVfph50Ue902Brt05wWA_10_14"></a><a id="Tc_2f2cPyBKnEytix_6Z0fvQw_11_0"></a><a id="Tc_0pb5hlEi50OOgJJyw2SE5Q_11_5"></a><a id="Tc_aXYu76nqO0uHflQUxEjnPQ_11_11"></a><a id="Tc_yxiBj5ukkUSK2HAZG6Ydxg_11_14"></a><a id="Tc_OiMxHRR2AkySAj60Fap5jA_12_0"></a><a id="Tc_4mZTxoFag0S9jtYIGz2lsQ_12_2"></a><a id="Tc_v9ul5HgHNEijp5vGEyM8Cw_12_5"></a><a id="Tc_nItchrZY9EWTs7DI8PDIuA_12_11"></a><a id="Tc_KaJOoo28wEimdhhl0HkQsw_12_14"></a><a id="Tc_6rK1RrbmP0CrthcIuOR9XA_13_0"></a><a id="Tc_Syba0P4kRUiev24koQa_hQ_15_0"></a><a id="Tc_eAlIGHbWB0a1BVe4rNWQ5w_15_2"></a><a id="Tc_pve15BgJY0eGiyCKGg0Tbg_15_5"></a><a id="Tc_rVPbpgJzGEKsnxVIYooK7g_15_8"></a><a id="Tc_vAJMTQ09bEGoPeR35D5Ifw_15_11"></a><a id="Tc_zaZB1TVIckyihogjt-rr5Q_16_0"></a><a id="Tc_SrbucrrBWkGoOlUbWkK0Bw_16_5"></a><a id="Tc_CWT6FDiKm0aHD842udC6Cg_16_11"></a><a id="Tc_UHyPmMUYUEq5GX64A-L5XA_16_14"></a><a id="Tc_ACtUUacdDk6aFkqRpUZkzw_17_0"></a><a id="Tc_MR86eBEIokmY8m5dntBcJQ_17_5"></a><a id="Tc_Yxkl0vZynkWE7IAToHOECQ_17_8"></a><a id="Tc_OS_BoYOOo0ujXwakKWBFDg_17_11"></a><a id="Tc_KSXemyragkSzLpywB52ECw_17_14"></a><a id="Tc_HJsV6RW2BUKUGXwGudjotg_17_17"></a><a id="Tc_PQH3lQULeUyq83LaBJE2pQ_18_0"></a><a id="Tc_YjxL2H3EDkKX28MQbcRVLA_18_5"></a><a id="Tc_4-O3xHbF5UWpdn_chzcgDQ_18_11"></a><a id="Tc_DBX2OE4DmE27IimeWM4q3A_18_14"></a><a id="Tc_Mjqh5PMllEqMgaSQrcIrqA_19_0"></a><a id="Tc_8j23F0jSrU6cg1iDBQ3RYg_19_11"></a><a id="Tc_zTO6evp9qEiVBmSVfdo0pg_19_14"></a><a id="Tc_9WPpZKIVA0KiQxWLzCxT-Q_20_0"></a><a id="Tc_dlPDkfuMmkG6V6Au36YVmA_20_5"></a><a id="Tc_vSZVk5Mav0evn7cl-FqjXA_20_11"></a><a id="Tc_cZGUWiozF064XpxJSOcxMw_20_14"></a><a id="Tc_sKJcTwsQr029RT8O9ogOnQ_21_0"></a><a id="Tc_mP3otYPm5EebPnKCLO7umA_21_2"></a><a id="Tc_XuMXfTgQsk2Aj4Z8MNdq3w_21_5"></a><a id="Tc_O5nA4eRcV0mnhLWM5KXKVg_21_11"></a><a id="Tc_bakdloFDWU6ZOihuJpSiJQ_21_14"></a><a id="Tc_StT5UXMH7UOH6pdIEZPNVw_22_0"></a><a id="Tc_MoRVuD6Ri06IVo1BKS7USw_22_2"></a><a id="Tc_Nj61NjXk10qeQcj7_oY3hA_22_5"></a><a id="Tc_-Ag9nlaDIkGALsRkNHpceQ_22_8"></a><a id="Tc_inHxaCwArEKcifPC15-x6Q_22_14"></a><a id="Tc_D9Q9pBsftEau6CpytG4Duw_23_0"></a><a id="Tc_TIgyOFvtV0WR7PnOUZ3-0g_25_0"></a><a id="Tc_nJRxY5VONk68CH7M0UmEUA_25_2"></a><a id="Tc_0LU76zpe-kqOdMxhr5fnQg_25_5"></a><a id="Tc_PoehvrjuFUCWENub2z3qTw_25_8"></a><a id="Tc_PFCAeNjyt0ONCScLAjNS3w_25_11"></a><a id="Tc_a7T5Y4XhEUKNS0RGP0wN0w_26_0"></a><a id="Tc_41M7bcs92kS5v-HJxYNZOw_26_5"></a><a id="Tc_FmmjAf519UOB631rUWzd3g_26_11"></a><a id="Tc_P01L2gzNLU6bGuo3dmV2xg_26_14"></a><a id="Tc_s6WrdJzYeE-KoDDLIPt03w_27_0"></a><a id="Tc_2uOnR7nq2kOYDKGW9EJ7Dg_27_5"></a><a id="Tc_b8fSwybvykuUyKeTrziskA_27_8"></a><a id="Tc_2Tqia5keLEucp6khHwIvow_27_11"></a><a id="Tc_OUmQvI3lGUqDuLUMcmRBDA_27_14"></a><a id="Tc_fHirTS9O_ECwKkJrjq3QAA_27_17"></a><a id="Tc_iNS32TAlOEmW2Yl2XfMV2Q_28_0"></a><a id="Tc_yhyjkO0mz0it4SUUvL0GdQ_28_5"></a><a id="Tc_U4gSBNIHXkmwWWkQY-b_-w_28_11"></a><a id="Tc_M91Y-Nafb0Ce6ymWIx21lg_28_14"></a><a id="Tc_MdoixdeOqEifP8xug8_uHA_29_0"></a><a id="Tc_KQq2tmuayk2tNpLgCQ7j7w_30_0"></a><a id="Tc_lAezzLTDa0KKYeKqXwZidQ_30_11"></a><a id="Tc_XNkJkkJQG0-aaVHfaLscwg_30_14"></a><a id="Tc_hKuBmYio8UWu4C1ABPsaxw_31_0"></a><a id="Tc_ePMJkc0Oh0Olixut5a9rPw_31_5"></a><a id="Tc_JKzEpdyzBEiYvF3_Dwdn5Q_31_11"></a><a id="Tc_KrqQeNRzZU-2dLmglSiTAQ_31_14"></a><a id="Tc_ce9dNUKLSEOcb4A4M5z9sg_32_0"></a><a id="Tc_E23TeCQR90qgveyC_iKBeA_32_5"></a><a id="Tc_0k0x9B19_0mvi1bmo1_4kg_32_11"></a><a id="Tc_tJpjKvAUuE28ikf_COdBfA_32_14"></a><a id="Tc_xluq78XNNEykqSjexRPC0g_33_0"></a><a id="Tc_Dj3b0j2SmEOkH5upv4Iidw_33_11"></a><a id="Tc_V7q23JB9hk-Q5oXSyzi5Hg_33_14"></a><a id="Tc_trhwdJpg3kaezZ6li0dreg_34_0"></a><a id="Tc_Em9LT6FsG0aKfqP_5-vGNw_34_11"></a><a id="Tc_SMySPubbzkuNJMtoB0BXAQ_34_14"></a><a id="Tc_nWq_ClOr60ubpS-fpRBgqA_35_0"></a><a id="Tc_1k6VgcyJi0WL_rxFjD4zIQ_35_5"></a><a id="Tc_Kxt2JJdJ90ayzWIiRt2pLQ_35_11"></a><a id="Tc_g2HZ8ImyVEaoTD_Tcnf-aA_35_14"></a><a id="Tc_A6IUlbxy4UO_4myc6PqMAg_36_0"></a><a id="Tc_-RMWfS493E-cKtlTe9BLSA_36_5"></a><a id="Tc_iwJt2Qz9Sk-kJwqqbEubuw_36_11"></a><a id="Tc_ErQ-HcgnyUe40MBcxuwKSg_36_14"></a><a id="Tc_n2nAEoJVeUaFMrdSQWQlXQ_37_0"></a><a id="Tc_CdhPYv3TeESAv8UHlLGZjw_37_2"></a><a id="Tc_QUjdt2uRZEydJDdl6AgUWQ_37_5"></a><a id="Tc_Irjay_19OUqrLGtA5SJDNA_37_11"></a><a id="Tc_hgu_qrTs1EakSHj-Zg5HKQ_37_14"></a><a id="Tc_09ZONwIrF0OnBslS-j3fCA_38_0"></a><a id="Tc_7uDLQyZgbUKUV_nj_K4FXA_38_2"></a><a id="Tc_XTM_Z3a450ui-93xB655gQ_38_5"></a><a id="Tc_IFepwEuAXUOSo_XwAw8luw_38_8"></a><a id="Tc_V6_U3RZen0W31ewY23nOPg_38_14"></a><a id="Tc_77LoYK_uYEyp2LMasmP-ig_39_0"></a><a id="Tc_5xMoxAA_U02mekFOS87q-A_39_4"></a><a id="Tc_zse9FAuDJki4Cs3mbp-V4A_39_7"></a><a id="Tc_vxaYkasEpESVyr6GSfZOIQ_39_10"></a><a id="Tc_u5Jazqh-GE23jOWPudmrVQ_39_13"></a><a id="Tc_jqqlFXSplE-M1M3MPNoUJA_39_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Stockholders'</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;"> </span><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at December&#160;31,&#160;2020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_LixgjHqC2UCTZUP3Hln0Cw_5_2">72,513,348</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EhMBh0kggkCU2PK0gcrq9Q_5_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EqOtkI14-kOGNRiKyN0UaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LmRKQY0Ti0-x1Na-8ByaGA_5_8">1,043,991</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OvQzecJ6mUOHxhU6qoAvsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7nwoiIkaaU-9Fr4WE0kITg_5_11">270</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T9fLg1zdZUuTqPJFq3Ewmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_TGXULbuJYUGHNqmjX9pB6A_5_14">762,754</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Jg4BhQkVxkyx6Oq1IrNV_A_5_17">280,974</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VcpbTyhPOkKFIXTOT5V2DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_z7SP4o4QaU2UiRw7mySo2Q_6_14">287,100</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6qELkY8Z3UWiXGp2W8B5LQ_6_17">287,100</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_USVSrVHQtk2WzY-4GZUm3Q_7_2">1,316,361</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_H1ofS6EpBUa3bKTC7CR31A_7_8">10,410</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_AX7o94M3tUezkeb7j-zlOQ_7_17">10,410</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_Hm39PPSPwUmib_38HT_lmQ_8_2">465,930</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under the ESPP</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_yxJwfdh_rUydsRSK6Slcgw_9_2">238,934</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc__HPHI7rlIEWR1rLEPAriww_9_8">3,002</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_i8IMbyswN0epwI1uqHxLWg_9_17">3,002</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock to Junshi Biosciences, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_VIhDrfTVD0yddQLDmINGsg_10_2">2,491,988</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_5irjdxskgU-TrAWlGJX9_g_10_8">40,903</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_s2wVQ_qIXkCZzDVLEZW2nQ_10_17">40,903</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_HAotFQ5hTEy4TTgDeqsaUA_11_2">96,465</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_F6vK57T-ykOQIIJj9ZpGrQ_11_8">1,753</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_TCNiUuQyRU295IhjTsP3Kg_11_17">1,753</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_PtzgSrgB4Ui9ElRlWB15lw_12_8">51,290</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Uw_l-R0DtEmJxU0Wlvg4sg_12_17">51,290</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at December&#160;31,&#160;2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jT2bvCGQeUqvA48e-rmNXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_Je5wjN4wYUiLN9hIgxt04A_13_2">76,930,096</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jT2bvCGQeUqvA48e-rmNXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9uRL71DArU6tRHl6tBPWYA_13_5">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JlI5BNiMwkCobaOJnCtF4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NnqH4bLN-kSlmaZaC2Xx4A_13_8">1,147,843</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_js5PyUWww0i7olNWi5CL6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5kHzKj8nWk6DVdOP-LxYgQ_13_11">270</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-x0yoCYUqUKXgofi_PW4rA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hXBdaiqzb0q6YT8haHBY8g_13_14">1,049,854</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_znvYTcdhYkaoVPp86FFwWg_13_17">97,726</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsFNWbdr7UWhpxeQGE8rJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_t0s-Wm8kckujvAtuDjE1sg_15_14">291,754</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3lDbfEmem0SxfdlNnCeQSg_15_17">291,754</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_3f13j0KS6kC2HsoF_Doo6g_16_2">141,897</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_5Wqk3FOZfEKclfvUWTBmag_16_8">691</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_UzIGdYu5hUSpC9c6sE4qlQ_16_17">691</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_zgMDjVcu6kySGwcGipq2Kw_17_2">806,854</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under the ESPP</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_CvPw9SYBJkqM6IFyGCsPDw_18_2">347,883</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_1sm_ZSItdkK8yZXS5rxnBQ_18_8">2,320</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_hKDwjEka9kOqCkaD-klWtw_18_17">2,320</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under ATM Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IWhFYTVSXEG3Qc-xyQ609A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_cuhUDvlIOUesgdc_pd-L3Q_19_2">916,884</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IWhFYTVSXEG3Qc-xyQ609A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="Tc_wyMrWq-2O0GSzKdf5tE6BA_19_5">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_942S1mhLyka6ZkBmZenXDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="Tc_7jN4iY2dRkKiJBPeb_Ro-Q_19_8">6,133</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="Tc_bqlBd1Ec30iSMB3gIceu2Q_19_17">6,134</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_uImW0kjSjEySH88uWcT5FA_20_2">292,098</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_juaCEp6x6UOJKPa9wDvj5Q_20_8">3,744</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_aIaiDVfw5ES5OX_cQ5R4mg_20_17">3,744</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_o0-oQ7ZVMk2Gvn02VTvO3Q_21_8">51,188</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_tXHMcaJ-8kOfgtFDfgWVGg_21_17">51,188</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Other comprehensive gain, net of tax</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZLR_IWpbikGexBZ7BUjpdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_k9j6R-MeNEW_g3RijMVqoA_22_11">21</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_eMyEQ7cuBEO6xFbcSn0MdA_22_17">21</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at December&#160;31,&#160;2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_86rzXe3xOEmTHUqRT8IxuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_Ek50jG2X8U-iCtppr88yWA_23_2">78,851,516</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_86rzXe3xOEmTHUqRT8IxuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RQE87JBrkkugnIiBWUZakw_23_5">8</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8tkQ9GUbnkaeOclpHWkaYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xfBwWVuTFkyWikTYIY3AVA_23_8">1,204,431</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zxmvh3LGk0mrm79pZRE9ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jMPy3Rk1Q0-_3-jOx1EXPQ_23_11">249</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6C9ecxQ_QEG8bE7IGXl6xA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_JEy2DWoi506htfE6J_hlcw_23_14">1,341,608</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s-VrK6VuZkCPTPIBiVhbCg_23_17">137,418</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_trchcL8ElUmTtWSY92BZ4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_By-KSF_iukqHJSiv_5NUmQ_25_14">237,892</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fBml9fCg_ke7v-pEOcDyxA_25_17">237,892</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon exercise of stock options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EGwaWadCfEmKTWRl0yrAfA_26_2">430,504</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fRqqpgEnm0WsKEwpegsjjw_26_8">694</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_eURP41SgM0u1_-BYlMyoVQ_26_17">694</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock upon vesting of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_o47CQscFukmfmu8G64fTDw_27_2">1,280,901</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under the ESPP</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_jqw8nL-TxEO424nA5EsaPg_28_2">630,348</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_YKB3CdrfzEyFkA4H5Jipnw_28_8">1,809</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_cdZcDecPJk2dgv4TnJeHfA_28_17">1,809</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock in connection with Surface Acquisition:</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;">   Issuance to Surface shareholders for acquisition</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Tc_RJkHT2y9QEW_3XsipyBJbQ_30_2">11,971,460</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_XmQLmzfgRUCf8VIamD_yWA_30_5">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_Sy-TZtCIRU-nns0AB01mqQ_30_8">58,540</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="Tc_AwxHa_OOp0uZ8PwzYb5aMw_30_17">58,541</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;">   Accelerated vesting of equity awards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="chrs:StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" scale="0" id="Tc_l5REvHBgnke9SAAtAG64RA_31_2">261,239</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="chrs:StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" scale="3" id="Tc_gy1FCzOR7UC8cVjzBKLqUQ_31_8">1,053</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" scale="3" id="Tc_oATRrm1N3USgP9fBo26Tlg_31_17">1,053</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;white-space:pre-wrap;">   Taxes paid related to net share settlement of equity awards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="chrs:StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" scale="0" id="Tc_AhIYvlq02kacXyvtnTeZ-g_32_2">65,732</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="chrs:StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" scale="3" id="Tc_Qj3agB410EunT3LKEfDD5w_32_8">347</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" scale="3" id="Tc_DAhQQ4K7vkqQkstUNAcH-A_32_17">347</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under ATM Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IqHD8wCCtk-Oe0InVzTD9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="0" id="Tc_gH8iiRGKW02Gjq89tyZq1w_33_2">3,559,761</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IqHD8wCCtk-Oe0InVzTD9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Fgr-nnzr_kiuGqHUnfdtkQ_33_5">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_e1HpM3V8pkO34aP3JnxjLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_X1Y9rcP0VUGFmRSMWPR51Q_33_8">18,316</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Vpd0Qk05QUuB6BLFYp1Qdg_33_17">18,317</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under Public Offering, net of issuance costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_sKhnfgNtxkaJ97AXUGzpNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_68BFwSjnDkunaj51V6PtVQ_34_2">13,529,411</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_sKhnfgNtxkaJ97AXUGzpNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_j_ycIz9_XEC0SYrxJE461w_34_5">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_kZ0HsUuPOkSNL1EUtnGJbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_eD31HLE-YEi5SU2Cv0uPbQ_34_8">53,624</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_RpO-Vx6ls0enT64RbZm2Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_wIlvI6s5pkWk9sCmIyqe6g_34_17">53,625</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Issuance of common stock under Optional Stock Purchase Agreement</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_0oZWQSLFL0e-jivOJv3aGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_bpdUm2lvRU-lBnryL2z5FQ_35_2">2,225,513</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_sWN29oXoPUKV6kz5vOqq8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_9CvkhziDj0evZGIqppVoKQ_35_8">8,179</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_X0KeVsHZyUSbmqBiyMUPOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__4oIK36JAUmQHm10rU7WxA_35_17">8,179</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Taxes paid related to net share settlement of RSUs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="Tc_LZEOl-_KLEG-q_7jMR0oJw_36_2">459,661</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_b2Ad0Q2U_02r5N7t8m7gXQ_36_8">3,527</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_6wHNBI12HUOATcFsVLyKwA_36_17">3,527</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stock-based compensation expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_dw8K35Ti0UeUNqYLtkwugg_37_8">43,540</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_NIQb4gPy60e00he4dWmYqg_37_17">43,540</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Other comprehensive gain, net of tax </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_drbbzBbCqEO7LriCD-yj_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_z3NudOV8pkqzREIyWzUKiA_38_11">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_VXdo0GNY0EegBxRMHHSI7Q_38_17">1</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:48.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Balances at December&#160;31,&#160;2023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QFSyxqW7LU6FdbrdJ_hL6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_YPU_TUTp0EKqFCmGQVYkeQ_39_2">112,215,260</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QFSyxqW7LU6FdbrdJ_hL6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HKSDrF03p0KJKJGnMtVmXw_39_5">11</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF-Oa2qAakqTeMwji5pTSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3J5FxFzRjU-qBjAB-lB29g_39_8">1,386,312</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wRFs1JzPGkC_zfkTJLKIXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GizNo7Xtm0eFvkYlKJxNrA_39_11">248</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2ZR7usP3sE6lA9rxzLUIRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8EuatHlAwEKaxIaRRZ8ygg_39_14">1,579,500</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_FHtcecLIpE29yDwQ9wE8bw_39_17">193,425</ix:nonFraction>)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;background:#ffffff;">See Note 6 for further discussion.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:93.09%;border:0;margin:30pt 3.45% 30pt 3.45%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_75a0705c_2ad9_45c2_951a_8c38b3a98454"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Coherus BioSciences,&#160;Inc.</b></p><a id="ConsolidatedStatementsofCashFlows_928221"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><a id="_b00941fc_c271_4d8f_8a7e_f301790a59d1"></a><a id="Tc_7uOsfZ8bK0q4UmjIP4-cfA_1_2"></a><a id="Tc_HGQz4E8y9UCyOU4-2M6m8A_2_2"></a><a id="Tc_XOQ8ip2zWEucSf_HYsHA4A_2_5"></a><a id="Tc_dCfIQJU2vUSaTlbkYBc9hw_2_8"></a><a id="Tc_rFpF5kLQ_Uye9H9W0J71tQ_3_0"></a><a id="Tc_46IrdO-LX0G08y-niVUQrw_4_0"></a><a id="Tc_h_QEBm_M-kCGwScN_JaxvA_4_2"></a><a id="Tc_PJr1qLJuu0W6ZGLJ3u_1hQ_4_5"></a><a id="Tc_zJwARAo-s0ewrbw69A6Ogw_4_8"></a><a id="Tc_5haygF3BikyUYr7DWhlFxw_5_0"></a><a id="Tc_T95ELnf1jEubEcpXPXIRmA_6_0"></a><a id="Tc_c-e7scIs3EOgBVdc_Gy8rg_7_0"></a><a id="Tc_rXAkmOXXbkWwmP8rmn1Pzw_8_0"></a><a id="Tc_1uRi1cb5HEGOrrwZ_26LYg_8_3"></a><a id="Tc_MAsQfFK9L0iTXlnGBupANg_8_6"></a><a id="Tc_BA7bO7rlMUGv9ADKgew8cg_9_0"></a><a id="Tc_6-IYecPsu06McgqBkLUHUQ_10_0"></a><a id="Tc_tX4LmuSmiESfe_Yy6hvBwQ_11_0"></a><a id="Tc_cE4-NA6huU-hQJ98KwH0iQ_12_0"></a><a id="Tc_8Ua7QWKp_UCBqTxKlXOSbQ_13_0"></a><a id="Tc_aWvk3QvW6U6lXADrAb5vAA_13_3"></a><a id="Tc_S_jxYilcqEKF1QhEi9tF9Q_14_0"></a><a id="Tc_e-3FKX2h2EKb2IdCXQ_-mw_14_3"></a><a id="Tc_qyEnNdIpNUKCkp1o_LQrqw_14_9"></a><a id="Tc_lP1PGT_OhkyOJbZiZaUqEQ_15_0"></a><a id="Tc_ZHtpOffna0iczi_WHrxYVw_16_0"></a><a id="Tc_lglvDUaQT02H5RKB-rJQpw_17_0"></a><a id="Tc_mKs3W7YcO0W1A_iILBMyhw_18_0"></a><a id="Tc_9UuQoW0c1E2icx6f8FbUhA_19_0"></a><a id="Tc_bqeqPAdJj0SKkmdvqTZRZQ_20_0"></a><a id="Tc_BMQigAs6FU-Ae3E5-1TZRQ_21_0"></a><a id="Tc_5ubf-8aK3UCjx9BwT_1jPQ_22_0"></a><a id="Tc_jX37j5LXskaZugxh6i0qUg_23_0"></a><a id="Tc_UHPIu4R1SESQcks_gNDgGQ_24_0"></a><a id="Tc_Ep2DtCS3nk6cnYR4Y7WRxQ_25_0"></a><a id="Tc_xR2BlARAxEi1Bqr9RAz5-g_27_0"></a><a id="Tc_IZ7sx4nAEE-Yxfz6ZXPaxQ_28_0"></a><a id="Tc_esrKwsA0yke1lwlvrAQqEg_29_0"></a><a id="Tc_yYJM1ofmeEqjNWpUgtAOGQ_29_6"></a><a id="Tc_kXOXrNBZSEen7iQh5QFdcw_29_9"></a><a id="Tc_jgeQ8ruFaEajn-zkDxHHPA_30_0"></a><a id="Tc_0ux9WQwsBUekv7yiivMT0w_31_0"></a><a id="Tc_aj-nvozvyEOhzlyYKi-J5w_31_6"></a><a id="Tc_PZkYylN6Ik68UmsAjTc_gA_32_0"></a><a id="Tc_b2EMCzFUbkeCqNcuupzfyA_32_6"></a><a id="Tc_plovYghg_0eSEdR_JB1Yjw_33_0"></a><a id="Tc_7EMwDW3cgUaZqfOt58SyWQ_33_6"></a><a id="Tc_Z9L9Et0G5Ee6y9-w1OjvHw_33_9"></a><a id="Tc_RYz5KOnZbUOkfXJ5Y4eKkQ_34_0"></a><a id="Tc_mNJ87L7BuUyolss-hsf2LA_34_3"></a><a id="Tc_QvR9E2IBkUWFGB67pnNTHg_35_0"></a><a id="Tc_4LzmY8C01EqrBMyp9eay4w_35_9"></a><a id="Tc_ZGapUBfuDkiRKxwcgoxKFw_36_0"></a><a id="Tc_VtPUGjvCxU-dtmgdCsT0hw_38_0"></a><a id="Tc_wmmfzL-lzkSm7-2F1bvoFQ_39_0"></a><a id="Tc_EKQG2WlsCkSzFFp-Vhld1A_39_3"></a><a id="Tc_B4OOd1F6xUC3rsiSEabljg_39_9"></a><a id="Tc_1sfnuX_RyE6oJ246UMSY0w_40_0"></a><a id="Tc_sq5y4m-W3U-7kL5ki6jqzg_40_3"></a><a id="Tc_CJi0j4WyOEKs683iE05YOg_40_6"></a><a id="Tc__hVurN6LskiAUvWsqy1Kvg_41_0"></a><a id="Tc_dwTcoNsB_ESnBgOWcErw0Q_41_9"></a><a id="Tc_zzmZlpvLjk6iRb7SrB1T6g_42_0"></a><a id="Tc_RchNASQDPkqE4eEYwJh65g_42_6"></a><a id="Tc_IBwn1U0f0EKcsneousIjAA_42_9"></a><a id="Tc_WWcNX0CgP0ynEitXlKMDEg_43_0"></a><a id="Tc_yigLtouQ2EKFI_An-MUw4Q_44_0"></a><a id="Tc_m4eRPrIQBUyqlnsaoPkZRA_45_0"></a><a id="Tc_Ga28fdhI10-rwz-uGDCPXg_46_0"></a><a id="Tc_Q2uJu3jowE6lxVEEvkP84g_46_3"></a><a id="Tc_6c8DKza9VkCcqDlbvYuSVg_46_9"></a><a id="Tc_8ubnPyqmckOLr5i5ZIFtvw_47_0"></a><a id="Tc_CL5_mfOSzUSYprFymy76fw_47_3"></a><a id="Tc_agfAlI2lnUKa8F_HBYvMng_47_9"></a><a id="Tc_Y6Q7oBlTv0mk9TKuxDghtw_48_0"></a><a id="Tc_rPNJ2S-yQECfNI4-Ms0oiA_49_0"></a><a id="Tc_uPQbQxOWEkGx35rBWhvEpA_51_0"></a><a id="Tc_4Ca9GMdNzEu0oCLs8rfU3Q_52_0"></a><a id="Tc_uyWglBXArk6w-EsUMvu0Gw_53_0"></a><a id="Tc_CElkSYOmnE-5FuyxBKFj-A_53_2"></a><a id="Tc_wEFewnn-7Ue-Lh8_0b1K-A_53_5"></a><a id="Tc_or7hNDrQXkqDEFjbt2Imsg_53_8"></a><a id="Tc_0nPYenF7xEmsbtYbqNyUMw_55_0"></a><a id="Tc_YQdEoSWd4UuTYOwE_EdyaQ_56_0"></a><a id="Tc_A-miN7S2uUOFsbkRvaAbjw_56_2"></a><a id="Tc_5uLChMmooUaIIB2gtEpheA_56_5"></a><a id="Tc_Ot0DZdm8o02mHJsafuGbHA_56_8"></a><a id="Tc_hjH4me0CVEWy1JlWhN2Mkw_57_0"></a><a id="Tc_IgBKTU_QjUyW1mxtTTxiBA_57_2"></a><a id="Tc_MrxVLkYaO0CuHbZrquEUtw_57_5"></a><a id="Tc_Qr3HYHXYKkGepxgW_I6p5w_57_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:39.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc__Ly-9xUFOE26KCMgs5Snug_4_3">237,892</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_kJ8dlel23kq8FjJRx8fXrQ_4_6">291,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_rwltKR7hkEGeb4gvwGA_Vg_4_9">287,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_iORpqpcnb0q_M8k__UUbFQ_6_3">3,791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_u1ltpybfukGUGT_pGmiP9A_6_6">3,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_df8wBpJS4Ui7rhZb-t69vQ_6_9">3,454</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_wi4hHyG3ZkGBBxxG1p2yiA_7_3">43,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_dXG4FfE28Ei51jpI0-ESFg_7_6">50,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_rYzKBVY8-kGEe0f8TsA02Q_7_9">51,364</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Write-off of prepaid manufacturing services related to the termination of CHS-2020</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnContractTermination" sign="-" scale="3" id="Tc_SljIvLxcw0-K4y1iJ-Ss4w_8_9">3,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Inventory write-downs, net</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_VkQzY1WUvUy42vQv0Hu6GQ_9_3">52,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_c7C0UvAAY0iCb5ETKrXn9Q_9_6">26,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc__YMo1QFoHkaZHPgfM_OpQw_9_9">5,133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Non-cash amortization of premium (accretion of discount) on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_7bY0WErkDkGsoC6SMTc9kw_10_3">3,052</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_bm7b2t8Rg0mT9pWn2g4vEg_10_6">730</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="3" id="Tc_NbJsLV789E6-s5IVy-LQ4w_10_9">1,095</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Non-cash interest expense from amortization of debt discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_GbMF6AKAhUaoLMUgbfMzAg_11_3">2,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_0-kJ8bnIOkauZ6khMWtIqg_11_6">6,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_uZo0yFvrCE--ROcH7_W3Yw_11_9">4,257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Non-cash operating lease expense</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:NoncashOperatingLeaseExpense" scale="3" id="Tc_nqCWGQwhHEmEgvQn3RDzOw_12_3">2,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:NoncashOperatingLeaseExpense" scale="3" id="Tc_3ATCUvghfki2Y3sZYMJYxQ_12_6">2,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:NoncashOperatingLeaseExpense" scale="3" id="Tc_gCo1qfg93EGq8GNp5sEOaA_12_9">2,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Upfront and option payments to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" scale="3" id="Tc_cXZ0Rv2OTUiUNzmQ1EY2fQ_13_6">35,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" scale="3" id="Tc_ZpSNEMmsgUi8TcUzXeg4Lg_13_9">136,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_OcO5c2pymkiE0DO4uQ5fmw_14_6">6,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Other non-cash adjustments, net</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" sign="-" scale="3" id="Tc_1qgNsOaQuEG0BSauZyz69A_15_3">1,493</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="Tc_kZYHDw_riUGoEv6TRHp1qw_15_6">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="Tc_5p8Bi1noJESiHiC65ZH4nQ_15_9">588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Trade receivables, net</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="Tc_UYYpWEPj3kqFjBAxq-3hAQ_17_3">150,683</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="3" id="Tc_VKONCYl_TEutOz2laCJT7g_17_6">13,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="3" id="Tc_yGjj2Zk4JEudBCOzWtrR-g_17_9">34,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_NLr348IimU63Df8oMWANWg_18_3">46,734</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_Jv1iXAO0l0-5RQ7B57WBHQ_18_6">47,348</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_inAMF5gB2UWJ0ZtQVbgnxg_18_9">6,253</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Prepaid manufacturing</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_IRWrqJg-XEmqLCzefVmN5Q_19_3">2,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_dX7ZiTjurEaIf9h5u_WUTw_19_6">4,214</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_uSa0XFQjY0CzS9mEkGbKBA_19_9">3,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Other prepaid, current and non-current assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_z2jySnAYXESc3YD8GUvO-w_20_3">16,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_HlIRiWlTsE25b5TpxpGAoA_20_6">13,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_6qkWuMWt_0-d0G-cmXDxpw_20_9">5,351</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_VSQQZdY7o0iNSBfmD9MNzg_21_3">23,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc_LMqzyiDMNkewrEi6KULhEw_21_6">4,548</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_ZsZAiHW9UEKr46w0ogHrFw_21_9">874</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued rebates, fees and reserves</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve" scale="3" id="Tc_1f9IA5KK6Ee76HYvdJgSPg_22_3">113,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve" sign="-" scale="3" id="Tc_GBvC_kknSkCITjfh5nQGmw_22_6">24,566</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve" sign="-" scale="3" id="Tc_FRKCn-MYbkuS8nE0ONR-_A_22_9">2,502</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedCompensation" sign="-" scale="3" id="Tc_pgemMxSkZUarLetqTN4jpA_23_3">5,373</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedCompensation" scale="3" id="Tc_dGtBKwtRakWMLKLIV_31Yg_23_6">596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:IncreaseDecreaseInAccruedCompensation" sign="-" scale="3" id="Tc_5DPiQAPS-EWDoxidNm1c1Q_23_9">230</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 24pt;">Accrued and other current and non-current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_irY1w14JS0C8jn2lSI5ptw_24_3">10,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_2JXGi2SOFU-cboPQ4B3O2A_24_6">1,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_c3OwWb10H0enTiuKQ-GwmQ_24_9">17,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 36pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_bL-DPGMRik-VgnT_db-5NQ_25_3">174,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_eEUcvMajxkWZsikBP4DlWw_25_6">241,124</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_7LdMcHUTq0CifI4CvHubrw_25_9">37,432</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_gZvuREeWP0WZYGAOY7iMew_28_3">286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_8GXyo_0PIUKD9K3_Rsp12A_28_6">2,039</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_QzlD5fsB1kKldSlPlpYQBg_28_9">1,289</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="Tc_JjbHOfMTvEmtl8Lyyh26iQ_29_3">845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Purchases of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_ua59lnUWtE24CQYrsVxjrw_30_3">19,507</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_8hwNK9yIikuBhppQH-aufw_30_6">127,382</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_YjlbhMiUZ02TGc-LIiboUQ_30_9">182,485</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from maturities of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_Sc3i0IBPzUWbGL4ZQM6Sow_31_3">144,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_12DttWyOuEm9jm70UQ-KAA_31_9">99,692</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from sale of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_R9PkVy40kkyFfqY8X7Kgpg_32_3">13,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_m1IMTJmOv0mZlBxEOrTL1A_32_9">81,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash and cash equivalents acquired from Surface Acquisition</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="3" id="Tc_NA94VrPRzkCfR0k5RW9K5Q_33_3">6,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Upfront and option payments to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" scale="3" id="Tc_PYjSBrX-BUCpRrwRWh0k4g_34_6">35,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" scale="3" id="Tc_unB976Ds8kagh0ff9uRs8g_34_9">136,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Milestone based license fee payments</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" scale="3" id="Tc_Ujodr_a5ckqpPpZ7zhS7Iw_35_3">1,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" scale="3" id="Tc_MbLNJyRB1kuP7pl3u4CuoA_35_6">2,429</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 36pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_vC-6D4rr_kWT-cuWBvIFbg_36_3">144,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_5Hq_Ci66wkmsA58wxpbDqw_36_6">166,850</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Ol_HSml8_E-3cjYJNqH0hQ_36_9">138,410</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="Tc_4Mg6m1yZr0ijoM56MKqRJg_39_6">240,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_chrs_JunshiBiosciencesMember_3vcTLYS0gkekD3G2uhqorw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_7WcVEYaIH06D-ZBufQMAFw_40_9">40,903</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_QlBj-0uhxU6OiHT3BsaHKg_41_3">18,093</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_NdNUhelPiECZLreAWl2vOw_41_6">6,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from issuance of common stock under Public Offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_RpO-Vx6ls0enT64RbZm2Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_m1fWtU5La0OWTSec_dwYew_42_3">53,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_Dp69KyPkPEWHT5oCSLjxxw_43_3">694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_ok-6jdyguki9qwm7n2hD7g_43_6">691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_KgEdVYlmCU6oiulM-UIBfg_43_9">10,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Proceeds from purchase under the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_JyUa4P4S-kamVVmNK5A8aA_44_3">1,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_TztGz6ChlUmi4bk45OZSpA_44_6">2,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_BOwdMyNoBES2Hg2Er_N8Hw_44_9">3,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Taxes paid related to net share settlement</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_LApXDlmupkOaM0v60Q74EQ_45_3">3,587</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_zzHSclcrH0SWrSjADKsgGg_45_6">3,744</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_AF1w7nmqokqCfVCKZF3ZRQ_45_9">1,753</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Repayment of 2022 Convertible Notes and premiums</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_wFDH3Cmbkkun6sjdOalsrg_46_6">109,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Repayment of 2025 Term Loan, premiums and exit fees</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_-O5t1yoR50iDKXf0N-fi8Q_47_6">81,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Other financing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="3" id="Tc_SxICRom8m0K7A2Ia3kurqQ_48_3">1,034</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="3" id="Tc_Uv0UHLX_jkKR8z-xqjOkyA_48_6">1,228</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="3" id="Tc_QYKS0G_uI0K8ge6li_xOaQ_48_9">672</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_FrF0ug_AX0abp5hjv6dLMw_49_3">69,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_zbeBfYoYVUKocziDEq3S9g_49_6">54,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_9TIIH-EZZka50eDQuD1h5A_49_9">51,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_eKe-I7EJi0Se_KWJMkVV1A_51_3">39,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_1H3Go8t-oE2WekNcBTQ3nQ_51_6">353,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_8X5yDwO_fkq7fRstdsJG7w_51_9">123,963</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RGpGgwn_9EGE4e_yijQPVw_52_3">63,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_4R2r03upWEGrNBHRQmSgIQ_52_6">417,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__7hVyKHGoEqNHAM8czjAWw_52_9">541,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_597MVqv7CUe1kNrHStuN7w_53_3">103,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_iV-NaibUbUuJ6ujp3K4CXw_53_6">63,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_-pktdKOAC0WOmcAaahN8Wg_53_9">417,635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_rSaQz015ZU61zCgP53b6vQ_56_3">37,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_6jdUL2pXBUqUwD4ftS7XMA_56_6">34,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_t70vg_qYNkix0peKs6e_4g_56_9">18,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Income taxes paid (refunded), net</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" sign="-" scale="3" id="Tc_FkBwc4B8qkKcae24zStFXg_57_3">118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_mV2CWE41GUaDMyW8X02Fwg_57_6">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_HOFBWV-r7EWlDTfd1DSMnQ_57_9">1,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NotestoConsolidatedFinancialStatements_4"></a><a id="_Hlk124843768"></a><a id="_Hlk124843841"></a><a id="_Hlk124843752"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_XdVJRy2iR0qG9qSEbFS9oA" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;"> Coherus BioSciences,&#160;Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span>Organization and Significant Accounting Policies</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Coherus BioSciences,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Coherus&#8221;) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The Company&#8217;s strategy is to build a leading immuno-oncology business funded with cash generated from its diversified portfolio of FDA-approved therapeutics. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company sells UDENYCA <span style="background:#ffffff;">(pegfilgrastim-cbqv)</span>, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. On August 2, 2022, the FDA approved CIMERLI&#174;&#160;<span style="background:#ffffff;">(ranibizumab-eqrn)</span>, a biosimilar to Lucentis, and commercial launch commenced in October 2022 in the United States. The Company launched YUSIMRY&#174;&#160;<span style="background:#ffffff;">(adalimumab-aqvh), a biosimilar to Humira (adalimumab),&#160;</span>in the United States in July 2023. On October 27, 2023, the Company announced that LOQTORZI&#8482; (toripalimab-tpzi) was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a novel PD-1 inhibitor that the Company developed in collaboration with Junshi Biosciences. The Company announced the launch of LOQTORZI in the U.S. on January 2, 2024. On January 19, 2024, the Company entered into the Purchase Agreement by and between the Company and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, the Company completed the Sale Transaction for its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="Narr_BHM7yfVlUUuAXppuPO2ZnQ">170.0</ix:nonFraction> million plus an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA" decimals="-5" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" scale="6" id="Narr_AdxuPe0rP0S0PrSK_YWXuw">17.8</ix:nonFraction> million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s product pipeline comprises&#160;the following <ix:nonFraction unitRef="Unit_Standard_product_SdGd84au20GyPZXZYh-a9w" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt-sec:numwordsen" name="chrs:ProductPipelineNumberOfDrugCandidates" scale="0" id="Narr_R83QhID_xECZq6XpIYhhnw">three</ix:nonFraction> product candidates: <span style="background:#ffffff;">CHS-1000, an antibody targeting ILT4; casdozokitug (CHS-388, formerly SRF388), an antibody targeting IL-27; and CHS-114 (formerly SRF114), a highly specific afucosylated IgG1 antibody targeting CCR8. In addition to the Company&#8217;s internally developed portfolio of product candidates, the Company has two product candidates, NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes and GSK, respectively.&#160;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_Kh12U6QVdEydDLPI8FurzA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of Coherus and its wholly-owned subsidiaries. The Company does not have any significant interest in variable interest entities. All material intercompany transactions and balances have been eliminated upon consolidation.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:UseOfEstimates" id="Tb_1daHQQKyB0eQ5ONvCs7WzA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" id="Tb_kmqi1l1y1U2ExwQN7LJbww" continuedAt="Tb_kmqi1l1y1U2ExwQN7LJbww_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Reporting and Revenue by Geographic Region</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as <ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="INF" format="ixt-sec:numwordsen" name="chrs:NumberOfOperatingAndReportableSegments" scale="0" id="Narr_1jb4qmkTIUiN710biluIJw">one</ix:nonFraction> reportable and operating segment, which is the business of developing and commercializing human pharmaceutical products. The Company&#8217;s chief executive officer, as the chief operating decision maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the Company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions. Primarily, all revenue is generated and all long-lived assets are maintained in the United States. </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_rWlcHXnXZESujo4YRPAstg_1_0"></a><a id="Tc_RkxcVsm_wEqBa-hnUgteJg_1_2"></a><a id="Tc_Ht5uEwUFvE2HZnF8BUzU5g_2_0"></a><a id="Tc_rk36HIE9F0mLUbzoL8GF5Q_2_2"></a><a id="Tc_WlX679I0MUqhWAvW0f9CtQ_2_5"></a><a id="Tc_ygoCuHO4LU-Oy0Q2DCtD2Q_2_8"></a><a id="Tc_UtfpqmxoZkeSTgGKeFKLJA_3_0"></a><a id="Tc_U9ucFbo33EOUPhtvWZW0mw_3_2"></a><a id="Tc_faXG7811M0Wp-osjjC9xag_3_5"></a><a id="Tc_XpvMWLKVR0uQjLjJco6uAA_3_8"></a><a id="Tc_tJ1m_CqNtkutg20tuzZi_w_4_0"></a><a id="Tc_DLfFjxrAtUuPTFVEPdWI_w_5_0"></a><a id="Tc_4OpHOPMYSkioiHtsC2kXhA_5_2"></a><a id="Tc_zQxmjNN68UO7ub88NMKs1Q_5_5"></a><a id="Tc_-tW6SypzPUW_cX4xUOhH1A_5_8"></a><a id="Tc_KQQmt8mwwEaW1YCXYPP9WA_7_2"></a><a id="Tc_TdpcEe_oF0aBcUXn_aaBow_8_0"></a><a id="Tc_rTBAign6PkmiaD4V1Xidyg_8_2"></a><a id="Tc_SeThZyBAlk2Oo8X7-2KNsg_8_5"></a><a id="Tc_S_LY45_nREG0LRvVfKnE4A_8_8"></a><a id="Tc_icVZNKRWsEqEuZWDi01uLg_9_0"></a><a id="Tc_aNW_fVbw40-FkA1C9cCHKw_9_2"></a><a id="Tc_gTN_aQYTVUeWPVbFw01y2Q_9_5"></a><a id="Tc_kosLrBiRWE-_FOknDufRdQ_9_8"></a><a id="Tc_YKyIMcrszUyBHSRhmf2LPQ_10_0"></a><a id="Tc_iOS1j87tiU-3pQWfjXRWPw_11_0"></a><a id="Tc_JWumx8w620uE775Sxx1qmA_11_2"></a><a id="Tc_-ulYQk6GH0-CvF8Ut2cMaA_11_5"></a><a id="Tc_14RrtIH89ECoH08MK0DbDg_11_8"></a><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont1" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont2"><ix:continuation id="Tb_kmqi1l1y1U2ExwQN7LJbww_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_v_n2Xz8GUEOdr0KYFFb24Q" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash comprise cash and highly liquid investments with original maturities of 90&#160;days or less.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets and which, in aggregate, represent the amount reported in the consolidated statements of cash flows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="Tb_GVtZFdPwmEenLWQI_00UcA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_INGwya90d06CSRtzo8M4-w_3_3">63,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_CHUkRyQnp0-NZ8JauSgGlQ_3_6">417,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_VsxuDgVtf0GeKplz-H8p8w_3_9">541,158</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_yGa7Dqq5J0aDiUX2uxcWeQ_4_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_Dqjg_joiFkKBdfp5g6PoAA_4_6">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_iTHHZ3D8g0iPFTyOxvKUTg_4_9">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_OSLcC37knkCGPAY_3FSSgA_5_3">63,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Bdiq6ouT8kSqIlcqob550Q_5_6">417,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3us_AziQD0CqLPhFS2NVsQ_5_9">541,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_cTZrIhThzkSCU7dHQ173Xg_9_3">102,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gfVRoTRCMEiep8mbQpxqLQ_9_6">63,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_zc4dMXlQeUCZw_S28X4Dcg_9_9">417,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_O3kD8vmxNEadnaR0OeUgGw_10_3">452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_1rXBK7BdAUaNGyh4qV9E4w_10_6">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="Tc_j72IyphJgEOCZG1K5VzndA_10_9">440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_l1Q3iNdIvUC0qhavI6HsXQ_11_3">103,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_1gq6emoLWUaXD50VUi465w_11_6">63,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FzuMnEiG6U-qwniVA8-KLQ_11_9">417,635</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company classifies the up-front and milestone payments related to licensing arrangements as cash flows used in investing activities in its consolidated statements of cash flows.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_JFW0XS8DjEqGDT53hiqmMA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Receivables</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are recorded net of allowances for chargebacks, chargeback prepayments, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses and was not material during the periods presented. The Company believes that its allowance for expected credit losses was adequate and immaterial as of December 31, 2023 and 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_wxwNFeAavUKPbdMtEfNxQg" continuedAt="Tb_wxwNFeAavUKPbdMtEfNxQg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investments in Marketable Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in marketable securities primarily consist of U.S. Treasury securities, government agency securities, commercial paper, corporate bonds and market money funds. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#8217;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#8217;s investment policy requires that it only invests in highly rated securities and limits its exposure to any single issuer, except for securities issued by the U.S. government. All investments in marketable debt securities are held as &#8220;available-for-sale&#8221; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. The Company regularly reviews its investments for declines in fair value below the amortized cost basis to determine whether the impairment, if any, is due to credit-related or other factors. This review includes the credit worthiness of the security issuers, the severity of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of the amortized cost basis. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an available-for-sale debt investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. There were <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="Narr_ihch3Ieg80GCKsBIhwBu4Q"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="Narr_jx8UAL4MrESCb8SP9QAyqQ"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="Narr_E2yEMrabPkSlforgr6PyaA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments related to credit losses during any of the periods presented. Realized gains and losses, if any, on available-for-sale securities </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk124844693"></a><a id="_Hlk124848217"></a><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont2" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont3"><ix:continuation id="Tb_wxwNFeAavUKPbdMtEfNxQg_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are included in other income (expense), net, in the consolidated statements of operations based on the specific identification method. During 2023, 2022 and 2021, interest income from marketable securities was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="Narr_nfGQLPRXfEyaqhb6Mx52Jw">2.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="Narr_W_zkyK-rfU6hIcTGwIWe3w">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="6" id="Narr_dZofCyJrSUa65fFCDDHCeA">1.4</ix:nonFraction> million, respectively, and is included in other income (expense), net, in the consolidated statements of operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_hfHPqP0VCUS93zJ8wMXjTQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Risk</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments in marketable securities and trade receivables. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company&#8217;s revenues are in the United States to three&#160;wholesalers. During 2023, the products sold by the Company were UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. During 2022, UDENYCA and CIMERLI were the only products sold by the Company, and in 2021 UDENYCA accounted for all of the Company&#8217;s revenues.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company enters into a strategic commercial supply agreement for each of its products. The Company currently has not engaged back-up suppliers or vendors. If any of the Company&#8217;s current vendors are not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_2ffmr95FcE2G81ZmWp_ILA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Instruments </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2023, the Company commenced using derivative contracts (foreign exchange option contracts) for the purpose of economically hedging exposure to changes in currency fluctuations between the U.S.&#160;Dollar and the Euro. The Company recognizes all derivatives at fair value on the consolidated balance sheets, and corresponding gains and losses are recognized in other income (expense), net in the consolidated statements of operations. The estimated fair value of derivative financial instruments represents the amount required to enter into similar contracts with similar remaining maturities based on quoted market prices. During the periods presented, the Company did not apply hedge accounting to these instruments. There are no derivative instruments entered into for speculative or trading purposes.&#160;Since the Company's foreign exchange derivatives all matured and settled by December 31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DerivativeAssets" scale="0" id="Narr_LA0djUehLE61pD8ve2CD-Q">no</ix:nonFraction> derivative assets or <span style="-sec-ix-hidden:Hidden_YgjkhDQ6bEeOg5gUe8O-fQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">derivative liabilities</span></span> as of December 31, 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" id="Tb_VNvtN_nmO0-MZo_z-1HF1g" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combination Accounting &amp; Valuation of Acquired Assets </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations.&#160;Judgment is required in assessing whether the acquired processes or activities, along with their inputs, meet the criteria to constitute a business, as defined by U.S. GAAP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquisition method of accounting requires the recognition of assets acquired and liabilities assumed at their acquisition date fair values.&#160;The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill, or when there is an&#160;excess of the fair values of these identifiable assets and liabilities over the fair value of purchase consideration, a&#160;bargain purchase gain is recorded in&#160;the consolidated statements of operations.&#160;The estimations of fair values based on non-observable inputs that are included in valuation models. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including the estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the measurement period, which occurs before finalization of the purchase price allocation, changes in assumptions and estimates that result in adjustments to the fair values of assets acquired and liabilities assumed, if based on facts and circumstances existing at the acquisition date, are recorded on a retroactive basis as of the acquisition date, with the corresponding offset to goodwill or bargain purchase gain (See Note 6. Surface Acquisition).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_Y32oWoW2REq4SBLuwB1X1A" continuedAt="Tb_Y32oWoW2REq4SBLuwB1X1A_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in&#160;foreign currencies are remeasured at historical rates.&#160;Translation gains and losses are included in </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ns5ketJPM0qhlOASWn-vCg_1_0"></a><a id="Tc_6TMD90Ic6UeiF6gq6r162w_1_2"></a><a id="Tc_JdDo-wlkqEqHrGuVheGijw_2_0"></a><a id="Tc_68OJZMw_B0y2EgQJdxyU4Q_3_0"></a><a id="Tc_NmK_35YAgEiXkNzCetqGYw_4_0"></a><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont3" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont4"><ix:continuation id="Tb_Y32oWoW2REq4SBLuwB1X1A_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accumulated other comprehensive loss in stockholders&#8217; equity (deficit).&#160;Revenue and expense accounts are translated to U.S. dollars at average exchange rates in effect during the period with resulting transaction gains and losses recognized in other income (expense), net in the consolidated statements of operations. The Company has not experienced material foreign currency transaction gains and losses for any of the years presented.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:InventoryPolicyTextBlock" id="Tb_SXR8CPGCBEK1eBnlaZN23Q" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. The Company primarily uses actual costs to determine the cost basis for inventory. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_76lFkIl1n0KUe6bC9lILgg">52.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_UdenycaMember_couIVXZw9U2OdgPC4e_wMw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_XCt6JuV2_kiL8XaOc-pAwg">26.0</ix:nonFraction> million in inventory write-downs, respectively, within cost of goods sold in the consolidated statements of operations. The 2023 charge was primarily for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. The 2022 charge was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company believes the assumptions used in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by management, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in the consolidated statements of operations. Adverse developments affecting the Company&#8217;s assumptions of the level and timing of demand for its products include those that are outside of the Company&#8217;s control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the regulatory approval of product candidates, the Company incurs expenses for the manufacture of drug products that could potentially be available to support the commercial launch of the products. I<span style="background:#ffffff;">nventory costs are capitalized when future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment. &#160;A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, viability of commercialization and marketplace trends. Inventory in the consolidated balance sheets as of December 31, 2023 was related to UDENYCA, YUSIMRY, CIMERLI and LOQTORZI.</span> The Company began to capitalize inventory costs associated with UDENYCA, CIMERLI and LOQTORZI after receiving final regulatory approval in November&#160;2018, August 2022, and October 2023, respectively, and capitalization of YUSIMRY inventory costs began in the second quarter of 2022 when sales were deemed probable. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_3kxyTGQ0FkKL_v-wUY71vg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment is stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the capitalized interest costs are amortized as depreciation or amortization expense over the life of the underlying asset. When the Company disposes of property and equipment, it removes the associated cost and accumulated depreciation from the related accounts in the consolidated balance sheets and include any resulting gain or loss in the consolidated statements of operations. Eligible costs of internal use software and implementation costs of certain hosting arrangements are capitalized and amortized over the estimated useful life of the software or associated hosting arrangement, as applicable. Depreciation and amortization are recognized using the straight-line method over the following estimated useful lives:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="Tb_hI231IkCR0S25ZXlTismuw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_cWwUSInfWk6DbOgC8phq1g" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_9fgELSEmx06Gs1LNmIFbMA">3</ix:nonNumeric> - <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0Z36Will8EWLyeJWTqBk6Q" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_tfxEulXxzkSNARdD7fBeVg">7 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_iMXY0L5gN06S5kClx8qFYg_2_2">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_R1ZNIhTdtU6PTDnnezToVQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_I6Mg3UVRFUqj2i6puowOwg_3_2">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life</span></span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_d4HuKo249EqSUh2NgRCG-g" continuedAt="Tb_d4HuKo249EqSUh2NgRCG-g_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill and Intangible Assets</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company&#8217;s single reporting unit below its carrying amount.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont4" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont5"><ix:continuation id="Tb_d4HuKo249EqSUh2NgRCG-g_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquired in-process research and development&#160;(&#8220;IPR&amp;D&#8221;) that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company <span style="background:#ffffff;">will commence amortization over the useful life of the intangible asset, which will generally be determined by the period in which the substantial majority of the cash flows are expected to be generated. </span>The Company evaluates IPR&amp;D for impairment on an annual basis, during the fourth quarter, or more frequently if impairment indicators exist.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finite-lived intangible assets are generally amortized on a straight-line basis over their estimated economic life and are reviewed periodically for impairment. The amortization expense related to capitalized milestone payments under license agreements and the amortization expense from out-licenses are recorded as a component of cost of goods sold in the consolidated statements of operations. The estimated life for capitalized milestone payments is&#160;<ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_Pb1Z3ozRJkOA77OkYuNphw" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_5XuQ7osEbkKOXgseCbd-gQ">ten years</ix:nonNumeric>,&#160;and the life for acquired out-licenses is&#160;<ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_v9SRmwDa7E2QVcIw31qKkg" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_khg3wsyu2UqsW_86tqvoFg">fifteen years</ix:nonNumeric>. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Tb_s20nfE8l0kqNSS2D9ND2Sg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" id="Tb_BIUsKfR4Y0eNJz_-rVimiQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ContingentConsiderationPolicyTextBlock" id="Tb_PPyD7qIfRkeXDuOXvXkQig" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Contingent consideration relates to the potential payments to holders of&#160;the CVRs&#160;that are contingent upon the achievement of the Company and certain third-parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within loss from operations in the consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts.</p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_8YuAv9NQMUWScSH24-seSA" continuedAt="Tb_8YuAv9NQMUWScSH24-seSA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Net Revenues </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sells to wholesalers and distributors, (collectively, &#8220;Customers&#8221;). The Customers then resell to hospitals and clinics (collectively, &#8220;Healthcare Providers&#8221;) pursuant to contracts with the Company. In addition to distribution agreements with Customers and contracts with Healthcare Providers, the Company enters into arrangements with group purchasing organizations (&#8220;GPOs&#8221;) that provide for United States government-mandated or privately negotiated rebates, chargebacks and discounts. The Company also enters into rebate arrangements with payers, which consist primarily of commercial insurance companies and government entities, to cover the reimbursement of products to Healthcare Providers. The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. Revenue from product sales is recognized at the point when a Customer obtains control of the product and the Company satisfies its performance obligation, which generally occurs at the time product is shipped to the Customer. <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="Narr_lrG1nuGQfEi4lCVGUYNJVA">Payment terms differ by jurisdiction and customer, but payment terms typically range from <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_gVOkBFt9vUSNT22wfjVu6g" format="ixt-sec:durday" name="chrs:PaymentTermsPeriodFromDateOfShipment" id="Narr_Iun9rdjIcU2zNQR_ND_30w">30</ix:nonNumeric> to approximately <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v-ug3g3l80mlObh8LcgInw" format="ixt-sec:durwordsen" name="chrs:PaymentTermsPeriodFromDateOfShipment" id="Narr_StOmpgvop0y4Mn_f80Xqpg">90 days</ix:nonNumeric> from date of shipment and may be extended during the launch period of a new product.</ix:nonNumeric> </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Product Sales Discounts and Allowances</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue from product sales is recorded at the net sales price (&#8220;transaction price&#8221;), which includes estimates of variable consideration for which reserves are established and that result from chargebacks, rebates, co-pay assistance, prompt-payment discounts, </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont5" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont6"><ix:continuation id="Tb_8YuAv9NQMUWScSH24-seSA_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">returns and other allowances that are offered within contracts between the Company and its Customers, Healthcare Providers, payers and GPOs. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions in trade receivables (if the amounts are payable to a Customer) or current and non-current liabilities (if the amounts are payable to a party other than a Customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specifically known market events and trends, industry data and forecasted Customer buying and payment patterns. Overall, these reserves reflect the best estimates of the amount of consideration to which the Company is entitled based on the terms of its contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The actual amount of consideration ultimately received may differ. If actual results in the future vary from the Company&#8217;s estimates, the estimates will be adjusted, which will affect net product revenue in the period that such variances become known.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: </i>Chargebacks are discounts that occur when Healthcare Providers purchase directly from a Customer. Healthcare Providers, which belong to Public Health Service institutions, non-profit clinics, government entities, GPOs, and health maintenance organizations, generally purchase the product at a discounted price. The Customer, in turn, charges back to the Company the difference between the price initially paid by the Customer and the discounted price paid by the Healthcare Providers to the Customer. The allowance for chargebacks is based on an estimate of sales through to Healthcare Providers from the Customer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discounts for Prompt Payment:</i> The Company provides for prompt payment discounts to its Customers, which are recorded as a reduction in revenue in the same period that the related product revenue is recognized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates:</i> Rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with these public sector benefit providers. The accrual for rebates is based on statutory or contractual discount rates and expected utilization. The estimates for the expected utilization of rebates are based on Customer and commercially available payer data, as well as data collected from the Healthcare Providers, Customers, GPOs, and historical utilization rates. Rebates invoiced by payers, Healthcare Providers and GPOs are paid in arrears. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenue in the period of adjustment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Returns:</i> The Company offers its Customers limited product return rights, which are principally based upon whether the product is damaged or defective, or the product&#8217;s expiration date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Allowances:</i> The Company pays fees to Customers and GPOs for account management, data management and other administrative services. To the extent that the services received are distinct from the sale of products to the customer, these payments are classified in selling, general and administrative expense in the Company&#8217;s consolidated statements of operations, otherwise they are included as a reduction in product revenue.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenue from licensees, which is based on sales to third parties of licensed products, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty revenue was immaterial for all periods presented and is included in net revenue. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:CostOfSalesPolicyTextBlock" id="Tb_MPXOtx_H_kOJOx5OrjjIpw" continuedAt="Tb_MPXOtx_H_kOJOx5OrjjIpw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold consists primarily of third-party manufacturing, distribution, certain overhead costs, royalties on certain products, and charges for inventory write-downs. <span style="background:#ffffff;">Through March 31, 2021, a portion of the costs of producing UDENYCA&#160;sold was expensed as research and development before the FDA approval of UDENYCA&#160;and therefore is not reflected in cost of goods sold. All the inventory expensed prior to approval of UDENYCA was fully utilized by March 31, 2021; thus, the costs of producing UDENYCA&#160;are fully reflected in cost of goods sold beginning April 1, 2021.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk94021387"></a><a id="_Hlk94261436"></a><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont6" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont7"><ix:continuation id="Tb_MPXOtx_H_kOJOx5OrjjIpw_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;2, 2019, the Company and Amgen settled a trade secret action brought by Amgen. As a result, cost of goods sold reflects a mid-single digit royalty on UDENYCA net product revenue, which began on July&#160;1, 2019. The royalty cost will continue for <ix:nonNumeric contextRef="Duration_7_1_2019_To_7_1_2019_peTS_V4r30KWdrPrMS7BCQ" format="ixt-sec:durwordsen" name="chrs:RoyaltyPaymentTerm" id="Narr_vcqihw1VlUm1ZuJJlQUWlw">five years</ix:nonNumeric> pursuant to the settlement. Additionally, the Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_5_2_2019_To_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_iS0ub3fSH06yefAa2ICMew" decimals="2" format="ixt-sec:numwordsen" name="chrs:PercentageOfGrossProfitsOnSales" scale="-2" id="Narr_sPovj_MP0kqoL0y3WDWfMA">fifty</ix:nonFraction>&#160;percent range. The Company incurs royalties on net sales of LOQTORZI in the low- to mid-<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_LoqtorziMember_z2kc3sXj-0-3-XUzY_VHZg" decimals="2" format="ixt-sec:numwordsen" name="chrs:PercentageOfRoyaltiesOnNetSales" scale="-2" id="Narr_NmnIaJ_P_kCNcduafRG_qQ">twenty</ix:nonFraction> percent range and on net sales of YUSIMRY in the mid-single digit range. Pursuant to the Genentech Agreement, the Company incurred a royalty that was a low single-digit percentage of net sales of CIMERLI through the end of 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021, cost of goods sold included inventory write-downs, net of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_4KVEG243LkuvNze54VMR2A">52.6</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_8BPrKZRCrEuUsjxRunWf-A">26.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_DoR0wyJ4X0mMDBMacWPZ1Q">5.1</ix:nonFraction> million, respectively. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_qisk_F9wSk-r35eZqu37RA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Research and development expense represents costs incurred to conduct research, such as the discovery and development of product candidates. The Company recognizes all research and development costs as they are incurred. The Company currently tracks research and development costs incurred on a product candidate basis only for external research and development expenses. The Company&#8217;s external research and development expense consists primarily of:</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expense incurred under agreements with collaborators, consultants, third-party CROs, and investigative sites where a substantial portion of the Company&#8217;s preclinical studies and all of its clinical trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with manufacturing process development activities, analytical activities and pre-launch inventory manufactured prior to regulatory approval being obtained or deemed to be probable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">upfront and milestone payments related to licensing and collaboration agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Internal costs are associated with activities performed by the Company&#8217;s research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expense, which include salaries, benefits and stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:LicenseAgreementsPolicyTextBlock" id="Tb_PbNYNrCETUezC936JHqpeg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered and may continue to enter into license agreements to access and utilize certain technology. To determine whether the licensing transactions should be accounted for as a business combination or as an asset acquisition, the Company makes certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an asset acquisition and therefore, any acquired IPR&amp;D that does not have an alternative future use is charged to expense at the acquisition date. To date none of the Company&#8217;s license agreements have been considered to be the acquisition of a business.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Tb_p4b4mhbGr06-dxiH9hXUUw" continuedAt="Tb_p4b4mhbGr06-dxiH9hXUUw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Selling, General and Administrative Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expense comprises primarily compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="6" id="Narr_DWhn8AhurUaEg48ntTUSEg">10.9</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="6" id="Narr_OkIIls00UE-oV3Ouhy51VA">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="6" id="Narr_T8SY2rVPTkW1o_koAE6HzA">8.7</ix:nonFraction> million in 2023, 2022 and 2021, respectively.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont7" continuedAt="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont8"><ix:continuation id="Tb_p4b4mhbGr06-dxiH9hXUUw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_C4eYDCFUXEukSn1tiuOBrw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s compensation programs include stock-based awards, and the related grants under these programs are accounted for at fair value. The fair values are recognized as compensation expense on a straight-line basis over the vesting period with the related costs recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company&#8217;s common stock on the date of issuance. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_nKhefH4xgEKApj6KSZM7vQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as income tax expense.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. The Company does not expect its unrecognized tax benefits from prior years to change significantly in 2024. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_kK7nNR4p8kigJyXi3bduoA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Operating and Finance Leases</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:45pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines at an arrangement&#8217;s inception whether it is a lease. The Company does not recognize right-of-use assets and lease liabilities related to short-term leases. The Company also does not separate lease and non-lease components for its facility and vehicle leases. Operating leases are included in accrued and other current liabilities, other assets, non-current, and lease liabilities, non-current in the consolidated balance sheets. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. The Company recognizes operating lease expense for these leases on a straight-line basis over the lease term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of vehicles leased under the Company&#8217;s fleet agreement (&#8220;Vehicle Lease Agreement&#8221;) are <ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Narr_qvqmNUL2zkazaUG5mXjaxg">36 months</ix:nonNumeric>. The vehicles leased under this arrangement were classified as finance leases. Finance leases are included in property and equipment, net, accrued and other current liabilities, and lease liabilities, non-current in the consolidated balance sheets. Assets under finance leases are depreciated to operating expenses on a straight-line basis over the lease term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The operating and finance lease right-of-use assets and the lease liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. The Company uses its incremental borrowing rate based on the information available at the commencement date or the lease modification date, as applicable, in determining the lease liabilities as the Company's leases generally do not provide an implicit rate.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_GeyP0OGaRUy3ITXSesp9IQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares.</span> <span style="background:#ffffff;">Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive</span> (see Note 14. Net Loss Per Share).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_2SOItWh6KEGqd7UZpCsisQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes the following two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that are recorded as an element of stockholders&#8217; equity (deficit), but are excluded from net loss. The Company&#8217;s other comprehensive income (loss) includes unrealized gains on available-for-sale securities and foreign currency translation adjustments in 2023, 2022 and 2021. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_XdVJRy2iR0qG9qSEbFS9oA_cont8"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ReclassificationsPolicyPolicyTextBlock" id="Tb_mB7E7AoIbU27vflBMuQ5jg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain amounts in prior years&#8217; financial statements have been reclassified to conform with the current year presentation in 2023, including amounts in the consolidated statements of cash flows. There were <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="0" id="Narr_ydheMdsufkaRbLCsPS0NHQ">no</ix:nonFraction> changes to net cash used in operating activities in the consolidated statements of cash flows for the prior years as a result.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_Xd0bGOoWSkm6_QBpGf72xA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following are recent accounting pronouncements that the Company has not yet adopted:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280) Improvements to Reportable Segment </i><i style="font-style:italic;">Disclosures</i>, which enhances the disclosures required for operating segments by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, among other expanded. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued&#160;ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.</p></ix:nonNumeric></ix:continuation><a id="Tc_ybmCaRJ6W0OuSZKOn20ifw_1_2"></a><a id="Tc_HrqwwiTNh0WsAG7F5Cw8Jg_2_0"></a><a id="Tc_A2rVAjp8b0qmQrmlEVmasg_2_2"></a><a id="Tc_3RCb2Tlk3EeESWTOfppz-g_2_5"></a><a id="Tc_ko6mO311SECm7iDvf9zSyw_2_8"></a><a id="Tc_VpOiOFbN0UWwVdngHZQTsA_3_0"></a><a id="Tc_iZuL1VDfj0uaMWhR3wlqjg_4_0"></a><a id="Tc_tMPcasx4m06v04v4t5RnPg_4_2"></a><a id="Tc_NU8Vf6ugsEaAl1lkEGh_0Q_4_5"></a><a id="Tc_CzV_6s1ktUqem38_iSWLng_4_8"></a><a id="Tc_EcKaaN5oO06gd1D8bp1guw_5_0"></a><a id="Tc_iqZbcuuFlkWFMMGFQcgTfg_5_9"></a><a id="Tc_DN4DLVUf2kqBYKeUwd1hkw_6_0"></a><a id="Tc_PBTl3KkWv0CyPHLJ67TedQ_6_6"></a><a id="Tc_oxwO8x22iUqJs1A_HRkrNA_6_9"></a><a id="Tc_OD_doVIF5EuoBfjSGSi4BA_7_0"></a><a id="Tc__duheJ6WD0aixd8WtqddOw_7_6"></a><a id="Tc_1uNVTpgICkieVKK0GIER0w_7_9"></a><a id="Tc_i_QbVLAD8ka99kxkchew1g_8_0"></a><a id="Tc_z6JsmphtokGcZU5ORRTbxg_9_0"></a><a id="Tc_6kwofXH8jEmkwFs6MlYqqQ_10_0"></a><a id="Tc_X6JjE1Hfk0unx-Y0NSNIJg_10_2"></a><a id="Tc_7QBgtXaD0E6nuaF3-lwc8g_10_5"></a><a id="Tc_-J4OAz42SEmGCkUiNZ3xtw_10_8"></a><a id="_b4e544ae_7240_4e92_9df7_ec458ec20237"></a><a id="Tc_EEraoDxLXkufzcs_wiSVkg_1_1"></a><a id="Tc_jDAGnTXc706vK8FZkx_D4A_2_1"></a><a id="Tc_Qx3WVkM9VkmznDP0VssUyQ_2_4"></a><a id="Tc_yTpXchlFfk6VsmG-MVAUIA_2_7"></a><a id="Tc_AjtT53REvEWYfRdC9p_Ofg_3_0"></a><a id="Tc_ee1qSXXfvEeQfUy5c1_K9w_3_2"></a><a id="Tc_83nSEjVLmESaS2ySbmGYIw_3_5"></a><a id="Tc_5AoozlzS3UatYuAEssZtqg_3_8"></a><a id="Tc_e3d7ux_fc0SSbDAfEqafxA_4_0"></a><a id="Tc_4QXKjtdvXkykab75HeXotg_4_2"></a><a id="Tc_LJVAr_wlMUaDjFTkUrU8Aw_4_5"></a><a id="Tc_yOfU89aU50G6O_ePDtcyqg_4_8"></a><a id="Tc__dXIh6t69EqFJJhPrMKEIg_5_0"></a><a id="Tc_k7fwMLcFaUuwUu3-oXAUFQ_5_2"></a><a id="Tc_KPO8vjKiaUexTvxuuH1z7Q_5_5"></a><a id="Tc_XbH3xL_Md0GTUUp-A1dlJg_5_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_tAlnwL9t70uuZu7lgXnVAg" continuedAt="Tb_tAlnwL9t70uuZu7lgXnVAg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company launched LOQTORZI and YUSIMRY in the United States in December and July 2023, respectively, and initiated sales of CIMERLI on October 3, 2022. All net product revenue was generated in the United States, and the Company&#8217;s net revenue was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_ZYqMiYD8CU-JU5LQCpN31Q" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   UDENYCA</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_UdenycaMember_SS-iB5-1RkODBPDHZukxAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_1nlPkw0AWU2ghP88My6SBA_4_3">127,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_UdenycaMember_OBt5e09w-U23AKziLIjkeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_pxq9QrS59UiQl4GzcCuH9w_4_6">203,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_chrs_UdenycaMember_YyirJnaG_EuVQxR4eipeHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_j7E1niXe20W4RXz_sPTP1w_4_9">326,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   CIMERLI</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_CimerliMember_kv6U35_BGUWQFIX2et6tLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_JWVAHlnzdEGTCDvHb80-Lg_5_3">125,388</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_CimerliMember_Yi451Ksh7ku2qLqz_SNLxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_G37Sx6g3c0urndqqMQlyNQ_5_6">6,946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   YUSIMRY</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_YusimryMember_Aem49C8g_EO-UPcinAmbWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_7O3vbqgnFkeDYoVu0fiEjA_6_3">3,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   LOQTORZI</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_ToripalimabMember_fUCqK5DU-kekHTnpp0vwtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_xUrDx4OyH0WSVl45-SMZ5Q_7_3">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_z6Il8N4kPkqJ7o0Wx5ZYXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_LK1kT-EsFEyNDioXSN5fsg_8_3">256,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_KNuuvD7dxEO2mjwTXA6LtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_VY_WwdQKk0SbGGp32IEegg_8_6">210,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yRtnhYcLKki9OALzaJd-_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_P1ridq-V1U6b-_te5n4c1Q_8_9">326,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_yD1xE6Kl5kOzUlgXuDoYKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_PhGoEx24BUaEtM0CwZGpHw_9_3">664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_f8r-3G-5Wk-nnxPCHpt2WA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_BLzqZN4xxUm1jvXLrBa8pQ_9_6">282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_JMBKRfq1M06yP1UncYP2wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_e-Uh4zyJakSrZQLtZAgjPw_9_9">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Total net revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_ekGCgHXd-kuPx7irw3sl3A_10_3">257,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_yMjgil7NqkuFXg3yt2wEgw_10_6">211,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="Tc_mqjPeuKepkeVVnFYF2h1gA_10_9">326,551</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Gross product revenues by significant customer as a percentage of total gross product revenues were as follows</span>:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Tb__mZwxnciDEeyxhkdgqDsJg" continuedAt="Tb__mZwxnciDEeyxhkdgqDsJg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_bG3CyRk7Ckyq7Y946J92rQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_9NPhF3OoyUiGaGAnatF9dQ_3_1">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Ip4i_KQKSEGmi48UbBbU4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_QJOlMw3sOUeqweGtndzlJw_3_4">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_awtJ_xuQLE-3TKhXeZPfnQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_Q2peBtiB8E-K1TZGcAMuew_3_7">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cencora (previously known as AmeriSource-Bergen Corporation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sysHEkDeMUeiH_xQmMEqHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_rkHfqq1zGE6wQsBmdV31dw_4_1">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R15nhg7ueUmpYAw1PVmVYw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc__3b7t4vD7U-YdG8N2hhjgA_4_4">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_2Jb4uL_RpUq98xojm1NbWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_CWR2mFDnSEW9hYd6uVef1Q_4_7">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_JgK6Pnltr0iCDbO6eeuWPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_hajnRqq16U-FdmKr13-_iA_5_1">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RLQcDbciHU-31RTWPiRddA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_G4_FFg1thkeNMq5MqYQnmA_5_4">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_rgJ5WsHKGE6cmgscswHw3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_HLLTP0yiN0mf4L4i8zrkNQ_5_7">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_eTA8C7QLc02NQrw4WyKxRA_1_2"></a><a id="Tc_NFphPX7zgkeDN14XoeKl-Q_1_8"></a><a id="Tc_s2JsTKoIBkOtTnEoMB-Xwg_2_2"></a><a id="Tc_QJFaX-ai0U6-7PWTW9PacA_2_8"></a><a id="Tc_cz3HgWeCwUexYfYU_Q4GYQ_3_2"></a><a id="Tc_Kfq1lkGeckeZqyT0pqVj8A_3_8"></a><a id="Tc_z8kjNv2dpEWbK5wvtntF-Q_4_0"></a><a id="Tc_joVt76wpHUuS_iYIvYRPnw_4_2"></a><a id="Tc_UEzu2NcaZk-46MBHG8gl0g_4_5"></a><a id="Tc_VBmJStitIEKB2P7HEU8mCw_4_8"></a><a id="Tc_gcfSKR3SMEazc7KCT9YNag_4_11"></a><a id="Tc_QIXjswVxSk-wgQGwK55m1g_5_0"></a><a id="Tc_pGODiG8gHUaIQ6hzldu9Nw_5_2"></a><a id="Tc_nENv256M-0qLXq473niwlQ_5_5"></a><a id="Tc_kBUp9N-tiU6P17mv3bVaVg_5_8"></a><a id="Tc_kP3G5nWe1U6mG3bk4-02_w_5_11"></a><a id="Tc_nDTB8Ikf6UOOdjLqQbOYgA_6_0"></a><a id="Tc_6uciWMKVEEWdLza1GT3rCA_7_0"></a><a id="Tc_9YG-nzuAAU-J5rJh95pPUA_8_0"></a><a id="Tc_VfOh9Wc7X0OZLtuy40pz7Q_9_0"></a><a id="Tc_tkW1wZZgXkyu6vy8PwQ8Tw_10_0"></a><a id="Tc_oGtK4QYG60ejNLet7UCrVg_11_0"></a><a id="Tc_tKn-UWpEWkS1bEyxdZSGpQ_12_0"></a><a id="Tc_Fyq84RhBH06_tcHQhCF2PA_13_0"></a><a id="Tc_u76_45ipw0GI_Mwj4gzxqA_14_0"></a><a id="Tc_L_dt-F3itUOZnVIiKsVVNA_15_0"></a><a id="Tc_54VxsS9bZUm-MPfETLp24A_16_0"></a><a id="Tc__7kyKb9r4UWjm3PzZOCObQ_17_0"></a><a id="Tc_xHneno-e2k2xq3N1nsW0lQ_18_0"></a><a id="Tc_RulMl-ifLEeA8-OqXxAM1w_19_0"></a><a id="Tc_CnN5pNKEyUeXDOft-ino6w_20_0"></a><a id="Tc_vLqpfPaJb02ucr25VUxxVA_20_2"></a><a id="Tc_4KXcl1Z90UWhev5wsYF4Pw_20_5"></a><a id="Tc_b2I6Xo40qk6jtQXDAaeX3g_20_8"></a><a id="Tc_KTI7Nk23K0q1mDxhYz221w_20_11"></a><ix:continuation id="Tb_tAlnwL9t70uuZu7lgXnVAg_cont1"><ix:continuation id="Tb__mZwxnciDEeyxhkdgqDsJg_cont1"></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Product Sales Discounts and Allowances  </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Provisions that reduce net revenue include chargebacks and discounts for prompt payment, which are recorded as a reduction in trade receivables, and rebates, other fees, co-pay assistance and returns, which are recorded as current liabilities and other liabilities, non-current in the accompanying consolidated balance sheets. The activities and ending reserve balances for each significant category of sales discounts and allowances, which constitute variable consideration, are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" id="Tb_mi4-ly2e90albYJFI22Idw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_-COT1WJ3EUuvoamMLm5fRA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_zBI8o7CWvU2ily2Gt38ZHA_5_3">40,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUbaaM5xv06IKYj90EnrjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_CLximu-u_0Ktr0eB6lNZQA_5_6">54,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_TQp5WTVb9EWxY7FxWuYu-Q" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_l-O8W7pfTUmV-gHU_dz-tw_5_9">28,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_EsKjtW_gWkCe0SvaZEkZYA_5_12">123,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_ulBTBPpm4EmjggpqtsUx0w_7_3">470,791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_JKEbz-i3sUqz-NaHXt34ng_7_6">113,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_9xU9ixwhK0u5sd3uxEnhLA_7_9">94,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_wVj40XtuqkS3WYu7FrcivQ_7_12">679,199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_PHZym18mekOtN5a0Bfwt8g_8_3">2,876</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_o_vgNQ-0q0qblbUp3BtmvQ_8_6">4,976</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_SyqYjFE0aEW_nwiB15MS0g_8_9">3,555</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_6V9HGDZOf0S8cit9BIIqIg_8_12">11,407</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_9ClFIR9S2UWU9bqZSH_5Ng_9_3">478,830</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_J3UkKhgTXkuPQa7co0Igsg_9_6">108,783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_FP4exD4WoE6N9NBD7IS9Gg_9_9">93,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_H9eN5Nbr0UWESTVcfwyzHg_9_12">681,467</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_Ayc2h31NhkepkMrVbtGURA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_ru_bC0rgPEy249HGCLGI8g_10_3">29,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUQLjzgmQ0O_aiicO1YWSA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc__zDo8NPCUk2SqHau6tuO5Q_10_6">54,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_DPP_6bC4Yk26dzFhoz_XuA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_aNNDpyUTokyoVsCwolVGdg_10_9">26,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_gYQd2w3YD0Cg2NJR8aWGzA_10_12">109,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_mCe1xCJp5kiyst7_K6otAg_12_3">436,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_YeuZeq6Bp02K2jRiOXYGLA_12_6">68,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_dDkZw12G30y62GpTTMwq_w_12_9">73,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_7TbPIZItXEC1fW8dadPpyA_12_12">578,699</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_zTWloSryekO1l9Uxli33Ng_13_3">2,090</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_fM2g_myUAU24Zdyh8hhCKA_13_6">1,050</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" scale="3" id="Tc_YX7PUZYTYki7kMBEFABQ9w_13_9">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_fwqDIRBxj0uW0WDbWBGHiw_13_12">3,108</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_Kn63x61KZkWqwVMO5CXOIw_14_3">421,763</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_ffzu_8idVEWJCoesrOoQHw_14_6">82,640</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_xlofzqnwlUOU3k0xebSgUA_14_9">80,408</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_cPmX4ecgWUqckZZ_SfHINQ_14_12">584,811</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ahBUQTlFkUCSXShSrIOSkA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_PahjM9xS1U6ZCT2dilCTRg_15_3">42,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_PmryB88z9UeGYuVn9_eCHw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_1UT1khRB7UqP1pBYiJiXqA_15_6">38,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fLywbKoRN0OM9lBXBdTjtw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_z-Zlh3qpnECKo9Vj3aXRLw_15_9">19,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_4CI288hFxkGd-Vel_j1qAg_15_12">100,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_J7viUmf4NkqqGpn0pdKRaQ_17_3">590,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_ty1_V0S2KU-oevcOYcV5qg_17_6">143,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc__2EmZ-xNhUOf9nvXwS_89Q_17_9">110,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_2Wusre3UsEONSfqhK_munA_17_12">844,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" sign="-" scale="3" id="Tc_WFX3mDFC6kCPPSyX30INbg_18_3">1,361</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" scale="3" id="Tc_XJCLRUUDPkWJf9hozn9qBA_18_6">1,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" scale="3" id="Tc_V0e4EE_5lUaHEamIfHRcZQ_18_9">3,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProvisionRelatedToSalesMadeInPriorPeriod" scale="3" id="Tc_uFqaG2pdUUi1IWFZ7czLEQ_18_12">3,807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_b8pIWWawj0-_AlnNp0wTwg_19_3">558,135</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_mAVlkB86UE-z3n9GeKsXTw_19_6">62,370</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_DmHhNpIGv0yjZl4FjES_PQ_19_9">83,245</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_-JjsZisEL0WXxuyPM5yHFg_19_12">703,750</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_fqcHXPJqtUOZjDirZssjWg" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_6rhBmQXZjU2x0jnioBuhTw_20_3">73,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JuDeIjk7WEOxnh8sAqvA9w" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_omzznJndN0CyNgBJwcnvZg_20_6">121,137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_CPtilZC0L0K1V6_IsNLFKw" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_-qDTxjz9R0-joyqX9Gslng_20_9">49,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration" scale="3" id="Tc_iztln31YiUu-LhT2FxqkEg_20_12">244,885</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_AwOS7XAj2UWDT2l1VZH3yg" continuedAt="Tb_AwOS7XAj2UWDT2l1VZH3yg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>Fair Value Measurements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of financial instruments are classified into one of the following categories <span style="background:#ffffff;">based upon the lowest level of input that is significant to the fair value measurement</span>:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In connection with the Surface Acquisition on September 8, 2023 (see Note 6. Surface Acquisition), the Company acquired money market funds and marketable securities and recorded&#160;a contingent consideration liability related to the CVRs. At the end of each reporting period, the fair value of the CVR liability is determined using a financial model representing a Level 3 measurement within the fair value hierarchy. Assumptions used in this calculation include estimated revenue, discount rate and various probability factors. If different assumptions were used for the various inputs, the estimated fair value could be significantly higher or lower than the fair value the Company determined. For example, increases in discount rates and the time to payment may result in lower fair value measurements. There is no assurance that any of the conditions for payment of the CVR liability will be met. As of December 31, 2023, the CVR liability was reduced by a fair value adjustment of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_8_2023_To_12_31_2023_Oq6suCh5tUWT6TFeG9xafw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" sign="-" scale="6" id="Narr_CC99ZfTkb0KGqeeIRsM_2Q">0.9</ix:nonFraction></span><span style="background:#ffffff;"> million which was recorded within selling, general and administrative expense in the </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f5bc74c7_1301_4632_af59_7fdefcdc47a2"></a><a id="Tc_UmwBkn42zUOJ01tq6mnoBQ_1_2"></a><a id="Tc_421QzU_ao0-0dDKjxWoisQ_2_2"></a><a id="Tc_4cnYQXuNXUCeV5aL6qPUiQ_3_0"></a><a id="Tc_pXtDWw94PEyEtAwFuxo6EA_3_2"></a><a id="Tc_GU8-OrlIHU2GBh9rpL2ceg_3_5"></a><a id="Tc_gTHKZ12oVU2w1yg5zA0y3g_3_8"></a><a id="Tc_VTmC5AefqEKVCPYm2VtW8w_3_11"></a><a id="Tc_EIHLHYCR8UmKbz1Yq97zaw_4_0"></a><a id="Tc_1_H9Uj9JqUKWdVB43iWJbQ_5_0"></a><a id="Tc_6ZtjUyhOK0aAdfazDI8Ezg_5_2"></a><a id="Tc_vjPmfd9wY06OilJ7T1GIzw_5_5"></a><a id="Tc_3N8wbjkNfE-ih0g_ghqDQA_5_8"></a><a id="Tc_NScporGNLUGrz2l4oyrQvQ_5_9"></a><a id="Tc_M_wXqWuP-EGTrePC6mHm1A_5_11"></a><a id="Tc_QSHJT3cmhkGBf9AoYWaOpw_6_0"></a><a id="Tc_IOy95bjdokqFBh8ZHTmIfw_7_0"></a><a id="Tc_5QSuY1TTkEea0WBy4pCBKw_7_6"></a><a id="Tc_IZ61suq1SEiqSzFagwX0CA_7_9"></a><a id="Tc_rEo0DPPjoEeLoN2O_4Zlgg_8_0"></a><a id="Tc_GNMa5m6y4ECqC5UKwl8qWA_8_6"></a><a id="Tc_dcUf0tf5O0m5llTXkP3CVQ_8_9"></a><a id="Tc_aHii3bUUwUefROG36KbKvg_9_0"></a><a id="Tc_aKFj44S0F0ql3kUa5kmIAg_9_3"></a><a id="Tc_ZxubsBThzk-sglrqHPA3SQ_9_9"></a><a id="Tc_Tugxh0R5RUqpU8-qiI67zg_10_0"></a><a id="Tc_2DQkRAVI-EaBgkhVS71pbA_10_3"></a><a id="Tc_ECZt3-q7h02HkV1nZ860Lw_10_6"></a><a id="Tc_ib87Y5DKSkeAogbK51uenw_11_0"></a><a id="Tc_3Tfx9c0PbEaMEKe6P89ojw_11_2"></a><a id="Tc_bPm8mAKAWEuSe6lnRkmssQ_11_5"></a><a id="Tc_hC6crT3zf0G3gxulB_OjRg_11_8"></a><a id="Tc_ujLK9z2Nz0i8l6mtvRd5Uw_11_11"></a><a id="Tc_RxC1xR69YE6WuettcRRuiw_12_0"></a><a id="Tc_5rr1x-FCNEWpIaMAQNnfEg_13_0"></a><a id="Tc_mHk23N_dnE-X5c53YUY0Pw_13_2"></a><a id="Tc_f4iJm_frSEqJjkD54ArCXQ_13_3"></a><a id="Tc_18_h_FQOO0iaES0bcEMiwg_13_5"></a><a id="Tc_8dtFvKJB_0eM8YT-8FROtA_13_6"></a><a id="Tc_PvToY6CoFESqcS423C94Zw_13_8"></a><a id="Tc_F9zymvktDEiLs9Mp7ys3GA_13_11"></a><a id="_3b9c7c1c_7597_40cf_ad3b_253d3214f7ac"></a><a id="Tc_tu6ChYRFnkGou8R7eM_0bg_1_2"></a><a id="Tc_VkcYWqoCfEqOBRpxv2ZoJw_2_2"></a><a id="Tc_NjpyiYUilkuiiBiPRjaJZA_3_0"></a><a id="Tc_bfRtKuoBnkuzKcOG1r0PRA_3_2"></a><a id="Tc_tzW4O21XM0GTt4HVhRzJeQ_3_5"></a><a id="Tc_iUw2mO4EukCIOFgvN_f8hw_3_8"></a><a id="Tc__fDSgfttE0KSfZVrJO8tVQ_3_11"></a><a id="Tc_9WfsrSkonEiccsMkkXdStw_4_0"></a><a id="Tc_eGxeasRzjEWRk0_2JaJDgw_5_0"></a><a id="Tc_UiE1jSZyPUCPsUZHaMxz0g_5_2"></a><a id="Tc_VizmnWfyGUajZ4Nridm1nw_5_5"></a><a id="Tc_3hrxkEv2z0KPNkquDHGH6g_5_6"></a><a id="Tc_Xp6W-coOPkC0OTSMTASOLw_5_8"></a><a id="Tc_k4zdZHngeUqhxQcmkFESGg_5_9"></a><a id="Tc_DMP5f_tudEqc5vXH9uMhDA_5_11"></a><a id="Tc_0jA_m6hhZkugER8EiVv9MQ_6_0"></a><a id="Tc_3mLkFGtoIkm31m-kDSpF6w_7_0"></a><a id="Tc_zWvmxuTn9USxchn-tqvaSA_7_6"></a><a id="Tc_SgSt5FJa2k23bpogO2dSiA_7_9"></a><a id="Tc_431Bwp9UnUSodj7m33frCA_8_0"></a><a id="Tc_2jzipsr2h0qr6lMW7uy5eQ_8_6"></a><a id="Tc_L5YD5jSkUkycPKzmtf0GRg_8_9"></a><a id="Tc_88HlyFHfd0qkWeGwXTltOA_9_0"></a><a id="Tc_WUm4yV85tECvioJM9DiOGA_9_3"></a><a id="Tc_bIcoe3jTg0OeYj0ZyrBTtQ_9_9"></a><a id="Tc_LnWeib592Uq_qxzJW70dNA_10_0"></a><a id="Tc_Qwm3ruHfzk2DZCMbWpL7WQ_10_2"></a><a id="Tc_jhLGSGP2-EqGd4MJJslHKw_10_5"></a><a id="Tc_npJv16KCSEWRzOLqpuFWHg_10_8"></a><a id="Tc_GVGHeBkx70eXsUc4TPa4Cg_10_9"></a><a id="Tc_gwKgv7O0LEK_d17L0Fi0Dw_10_11"></a><ix:continuation id="Tb_AwOS7XAj2UWDT2l1VZH3yg_cont1" continuedAt="Tb_AwOS7XAj2UWDT2l1VZH3yg_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">consolidated statements of operations. The CVR liabilities were recorded in accrued and other current liabilities and other liabilities, non-current on the consolidated balance sheets.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Financial liabilities related to long-term debt obligations are summarized in Note 8. Debt Obligations. &#160;Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_086_rJS1d0OxNpPweXdXYw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M7126HnRO0qaXeQIsFj8pQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_hyUScfVwCE2f0e5J4JQo2w_5_3">88,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LA2YAsqsu0CpSSrrZHjsug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_bHQnohiW1kOKSPv2xIaaZA_5_6">998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TO8ess3RJkWPdTQJVaqKPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_PAF_PTktAkyY0HSBqx2RDg_5_12">89,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uqXRAvtuPU-XGMoUQjrc2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_0V7xOkTu1USNRCbv5aq0Iw_7_3">5,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VSDrzPQUwUu7_hzLLjkspg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_8Hi21q-os0CJqI7WhsG4NQ_7_12">5,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_frQuFnuBxEq5QXwcCjbX7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_jsAo0DepH0OqJpMytnKBCg_8_3">2,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_2BjSULWChEWs710kn9cfgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_MmOh2dWbhU2zWM7g9oATew_8_12">2,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_GPeCZEn7kE-kP1gzmLw43A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_6PAXALrGmkmoNIlZmb389A_9_6">6,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_mU8Xaof7xEm7Zbk_ZFo9-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_LO1qaiz1BkSPctdmjJwaug_9_12">6,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid financial instrument in Prepaid manufacturing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uGXcRbQazkuREy28y8WrtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_vIwVjo4qE0-KRhBrmRgoAg_10_9">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__TxWSJDseUuXN-WFeLop7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Lcn1xdNDh0CXiwXydhaadA_10_12">625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nz62sO_ud0WlWk86bTugEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_SrNGZYeEo06yMnI62h97YA_11_3">96,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ms9aAG7KIkGkwghMFQVoVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_RN_BZWaDVUuiLEa9kL-dRg_11_6">7,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__89KIdAh-kybMMe17Uup0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_c3gD3_SqW0iue83WgEryTg_11_9">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bSSUTn6bQUCMiUY_ocTL-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_JBuA8k0u2UmdHM8TGbsXZg_11_12">104,940</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hcVA_aikGUy_-SUX6FtLgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" scale="3" id="Tc_qLcHaKcZeUu_fBntlh6kRA_13_9">4,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dUP-XGp_40W0Jk2_k2_aaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" scale="3" id="Tc_v8jnzDq11UeRftEG4yPoRg_13_12">4,472</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LQWs2-eMdE2bcCcsGBh6vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_kfCEFNcKx02OgD9yMZxrmA_5_3">55,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_rEMXEsXhaEWSunlNBcnl4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Q-LUvodUv0ePCgUHDzkNow_5_12">55,060</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_prYGlg4f4U63CuX4vjb7Nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_SnWS23TgREyeZU3Y-u0M0A_7_3">19,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_nMQf0ixR90S0XMZzwxaW5w_7_12">19,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_TwVcSvlCtEijskcFydA41w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_BhSPiDBKn0iVxi0zh9f0sw_8_3">68,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_EtcR0c2iBkuoeggOJEW4pw_8_12">68,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_8fbTc7hIa0utRNZd1eRxfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_xANocsncYECD-dD5PQmBoQ_9_6">48,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_2W3hPCOAIEahptvzn8frHA_9_12">48,203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_qVO9cnI0VUC56AJulEuw6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_CFOiUibzSUOlBXJNWPd38g_10_3">143,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_v32YInlozkipoEXkDWXGJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_0OuAofmMhUy-4hErNrjjIQ_10_6">48,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_hMudSVa9Ikm-1nYaoNer1Q_10_12">191,645</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;">Cash equivalents consist of money market funds, U.S treasury securities, and commercial paper and corporate notes with original maturities of 90 days or less.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;">Relates to Optional Stock Purchase Agreement.</span></td></tr></table><div style="margin-top:9pt;"></div></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_854486d3_ca91_4cf2_acc5_b83c279b548d"></a><a id="Tc_ltlxAeY37UeOCRqAxuNmKw_1_2"></a><a id="Tc_qi9RUG7mu0qvd_wzWptrjw_2_0"></a><a id="Tc_2OYLeJIrPU6D4WCt61YUBQ_2_2"></a><a id="Tc_1-DVfecfh0SNTFI4BKcz6Q_2_5"></a><a id="Tc_iAlD9I5nHkSPizKtVvH8fQ_2_8"></a><a id="Tc_jEL8o1jmfUKGl5-sAm0gHQ_2_11"></a><a id="Tc_eMlj1QnhBUCTXCjX2-GnUg_3_0"></a><a id="Tc_g--Hamu3ykWTn-6wM_6ONw_3_2"></a><a id="Tc_pkglD9hG6k6Vq6N4KMcF-A_3_5"></a><a id="Tc_lzkCNLdtE0q-8Bznnka3iA_3_6"></a><a id="Tc_-2hjHtBY00-wZ0MztjBEug_3_8"></a><a id="Tc_MBOP8bABKkKHPozL4JvI7Q_3_9"></a><a id="Tc_DI8H7clvGkCBtlYja99SRg_3_11"></a><a id="Tc_lyL5jX0aEUWOHsdt0qzVwA_4_0"></a><a id="Tc_62XX1GIQbkGm2qNA9IzmEQ_4_6"></a><a id="Tc_uTc1VhdtV0eWnAfaqsOtHA_5_0"></a><a id="Tc_IiKDUbj4-EucGPPsNPhGoA_5_9"></a><a id="Tc_Nx7YKVLTMUWM2gN_kR-M9w_6_0"></a><a id="Tc_wSbMDNqSMk6kB5g6bwDCOA_6_6"></a><a id="Tc_Puoj2MUlmESbXCy93QU0_w_7_0"></a><a id="Tc_WwTFjqBRAky0RHcNjHhaxQ_7_2"></a><a id="Tc_EgjaKcvoOkuc41dENNrIFQ_7_5"></a><a id="Tc_SeH0jlcC3UKwv_2BPk10Bg_7_8"></a><a id="Tc_sleFDd99bU2vTnEysjmTaw_7_11"></a><a id="_e4f51ae0_da2b_458a_a2ae_f1fdee89c689"></a><a id="Tc_-GT3ZsEDcUeDm8F-4TFRVg_1_2"></a><a id="Tc_a-edsgr_UUS3cvHZzjjzAw_2_0"></a><a id="Tc_kZbnDoIFLk6pYjV9SvuSTA_2_2"></a><a id="Tc_jPOD5jBgS0-BTAxOcotBPQ_2_5"></a><a id="Tc_veWL3y-be027SqxwKDnRTg_2_8"></a><a id="Tc_DcNGYJCIzUqrN7WbxFnIJw_2_11"></a><a id="Tc_QFkRsG3qZkKlTGap1r3C2A_3_0"></a><a id="Tc_c2l8BEyGWkeqxN-s7TVFcw_3_2"></a><a id="Tc_qVb7Usxg7kCtyrjkfoUIwQ_3_5"></a><a id="Tc_k90zn7AUp0aAzg9BaxxfLw_3_6"></a><a id="Tc_LxDDLVOoPkCV8_7m2lt69g_3_8"></a><a id="Tc_HwpViMhXTkS2EpKS8sZrGQ_3_9"></a><a id="Tc_uve3Y3W400CMiVRo6Y78ZA_3_11"></a><a id="Tc_rbGNS5Ly2UWPKwk6L3GsCw_4_0"></a><a id="Tc_cClIvzmQo0WZ83qlqjZYkA_4_9"></a><a id="Tc_8J97hZlAkkymTCJswX47Vg_5_0"></a><a id="Tc_4pg_PMIDfE6yTTFc62EH4w_6_0"></a><a id="Tc_Sso7fz7xkkOJj7HCxMRQ1A_6_6"></a><a id="Tc_3xMPwAqkPEe0zaxiOhDyug_6_9"></a><a id="Tc_hEc1FJoAlUCYHJx4reaD3Q_7_0"></a><a id="Tc_WkYP08IcGUCdTo4ucousSA_7_2"></a><a id="Tc_Zi3-yxjAQ0W_EVKu1MLpXA_7_5"></a><a id="Tc_fVfjpBcd70OfkctaAsgbwg_7_8"></a><a id="Tc_eSw-dgfwNkCdUJ6pi-V24w_7_11"></a><ix:continuation id="Tb_AwOS7XAj2UWDT2l1VZH3yg_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="background:#ffffff;">The cost, unrealized gains or losses, and fair value by investment type are summarized as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="Tb__pjmJ2DpUU26DNu73kr17Q" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th colspan="11" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Gain</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized (Loss)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Money market funds</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_jcZy0wFZJEaEwLSiKmitHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_EZ9OPxAQukyroLQU52dq0Q_3_3">79,484</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_jcZy0wFZJEaEwLSiKmitHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_EXjXw-iMpU6UtmWpmhjk3g_3_12">79,484</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. government agency securities</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_Wf3zJtHR90eUeERNhXndNQ_4_3">5,200</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_s68FND4iPE2jr5HRiF2Icg_4_9">5</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_KL5DlogwpkKzTcCxxDuLPg_4_12">5,195</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. treasury securities</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_5E3PmJxP5kyjFSiuP9hElA_5_3">11,967</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_eXJB-NJIB02IdND0YxLC6w_5_6">2</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_aABl4CZAeUWFpUNcWeqlag_5_12">11,969</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Commercial paper and corporate notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_RPnIq_CoHUekRewxF8oGcA_6_3">7,673</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_4CR1CBkRlkeBV0X-yOGybw_6_9">6</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_7RWK3NIQHk6MqCai6IqbLw_6_12">7,667</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_J98f1Wkkqk--yBPb1DC5Mw_7_3">104,324</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_vPJVjkPRFE6gSsxdLaSlxw_7_6">2</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_o8Oflvx1MUKwsAqw91cY9w_7_9">11</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_pJ6xxc7ECkKORwJIByUTiQ_7_12">104,315</ix:nonFraction></p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Q3N2Kq2ULUiYN4xUaP-tWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_n-eM6HbBZkKVOp7euS_Vnw_3_3">55,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Q3N2Kq2ULUiYN4xUaP-tWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_XJ4fmHzXhUm_K8Zj8_cM4w_3_12">55,060</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_LqFOt7p6gU2xfVJb_KMgMQ_4_3">19,929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_GeI0nEDFPkm8Z02wb3JeQQ_4_6">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_jYEfkX5ty0GOWX1sRfTRLg_4_12">19,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_UF46yOC5DkKo8w0ILv8UrA_5_3">68,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Z_ksMgE5SEq_PBhQ6UVDZA_5_6">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_m76YmKet9Uu2tlwbWYNmLA_5_9">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_CDeETeH4g0et8CSXHiUlrA_5_12">68,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_vNOtehnu-0ibWfefhv7Ffg_6_3">48,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_8AgyReVkk0afT5hXtPe0jg_6_12">48,203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_F-odSc4SmEqeD-nTVYo5-Q_7_3">191,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_XH2TDPUoq0KGHT4a3d0u-Q_7_6">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_lPTRacosGEedpkRFfePSiA_7_9">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_3D7xLtyt0U-KvCky9Gj4qQ_7_12">191,645</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company held </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_position_Q8MGuTzVYkuWPpfxSr2J5Q" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="Narr_bN6u8wVxqECGDux5argEYA">9</ix:nonFraction></span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_position_Q8MGuTzVYkuWPpfxSr2J5Q" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="Narr_o_Hz0_IrQ0GHLV53dGHA-g">13</ix:nonFraction></span><span style="background:#ffffff;"> positions that were in unrealized loss positions as of December 31, 2023 and 2022, respectively. </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="Narr_4hDr1lriv0it1OEP0N0c1Q"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="Narr_t5jrLErLUUSCBaRjJ78lXQ">No</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;"> impairment was recognized in 2023 or 2022. As of December 31, 2023 and 2022, the remaining contractual maturities of available-for-sale securities were less than&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" format="ixt-sec:durwordsen" name="chrs:ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" id="Narr_P3Y6yR6jkUmHvvImCCgAuA"><span style="background:#ffffff;">one year</span></ix:nonNumeric><span style="background:#ffffff;">, and the average maturity of investments upon acquisition was approximately&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" format="ixt-sec:durmonth" name="chrs:RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" id="Narr_q5jTpBO7mUeMqLYcxuJU0g"><span style="background:#ffffff;">9</span></ix:nonNumeric><span style="background:#ffffff;"> and </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" format="ixt-sec:durwordsen" name="chrs:RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" id="Narr_bKHCjvuG8UqlMftDS1Qstg"><span style="background:#ffffff;">7 months</span></ix:nonNumeric><span style="background:#ffffff;">, respectively. The accrued interest receivable on available-for-sale marketable securities was immaterial at December 31, 2023 and 2022.</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_BvHSvHv_T0qX3NTzFGLePw_1_2"></a><a id="Tc_sCOY89epbkC3Y01ouN4G3A_2_0"></a><a id="Tc_gsZSSgbfj0SdsNoD6vW4iA_2_2"></a><a id="Tc_1hJLStOx8kimAHgoFRysww_2_5"></a><a id="Tc_A5ecC3kpYEO0RbqdPOwb0A_3_0"></a><a id="Tc_sezUWM6POUSYqncwOID3ZQ_3_2"></a><a id="Tc_CWD51XXgDUipp5sBd7YxyQ_3_5"></a><a id="Tc_IuqSrwDE5EC6_hpUE_cA6g_4_0"></a><a id="Tc_xR1E9FkBRkix9dnTH8KusQ_5_0"></a><a id="Tc_tAgPSKYvN06wMxqfbJYyCQ_6_0"></a><a id="Tc_n_X4JDM2nUyD0f5SzCi5Qg_6_2"></a><a id="Tc_jLCixrBGbU6SdzTEWm_m1A_6_5"></a><a id="_Hlk161180846"></a><a id="_0b4999df_4b61_4e8f_9c1e_158538bd2690"></a><a id="Tc_ymepfPl5GE21ZLozeGxqHg_1_2"></a><a id="Tc_B8L35w8XoE2paNw1fV0HYw_2_0"></a><a id="Tc_fPuxZKmcY0CZwzfcM0bPlQ_2_2"></a><a id="Tc__iGz3jbk1EGzleu3QxKQLA_2_5"></a><a id="Tc_p1vZJxP5FEGk_8TzRYP3wA_3_0"></a><a id="Tc__fy-bPF7YEGcSr2VNlhqvA_3_2"></a><a id="Tc_Ze3obO2naUe8EtnFnhZepw_3_5"></a><a id="Tc_6vg3xE60jUutAlewbBR-qA_4_0"></a><a id="Tc_UzG1c451SU-1pM16BZRQ1g_5_0"></a><a id="Tc_PXPvQpou3kGbl_my4WQXEQ_5_2"></a><a id="Tc_DMV_dwETuEWerYwq6oc7gQ_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_GducaB4Gbke308921JO0qA" continuedAt="Tb_GducaB4Gbke308921JO0qA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span>Inventory</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventory consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfInventoryTableTextBlock" id="Tb_csA8wovWF0yQ7FFEDV5fmA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_IiPvU5jAw0u-sULp-jEykw_3_3">12,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_ZqQBBFAX0EaV3TCZQESJAA_3_6">10,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_Bb0R2k_Mrk2s98NXXeeduQ_4_3">82,588</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_uQHF8A8Wp0KSct1LqwEjUA_4_6">86,712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_nKxWG5adqkmvLheoeFANnw_5_3">34,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_iASKZ2-euEi53gQzrb8PWA_5_6">18,077</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="Tc_ekrC40pbB0Gr-zjGMb77Kg_6_3">130,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="Tc__04xMKYV-0GqPfZFL0PxBw_6_6">115,051</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">During 2023, the Company recorded a $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_YusimryProductMember_-J7VNgvVG0G6bkwKupKhUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_MSPBRK8NmEyacYJn1Z889A">47.0</ix:nonFraction> million charge for the write-down of slow moving YUSIMRY inventory, inclusive of the related partial recognition of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA" decimals="-5" format="ixt:numdotdecimal" name="chrs:LongTermAndShortTermPurchaseCommitmentsAmount" scale="6" id="Narr_UNy5V7X39ECJGACUKlIGAQ">20.5</ix:nonFraction> million in certain firm purchase commitments in cost of goods sold in the consolidated statements of operations. The Company has presented the partial recognition of these certain firm purchase commitments in the amounts of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_RCrhOsC4rUSwHbQXRXofbg" decimals="-5" format="ixt:numdotdecimal" name="chrs:ShortTermPurchaseCommitmentAmount" scale="6" id="Narr_aCJR1eIrrUCzwpszlCWoxA">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_l7MKURXDWkyyeEGasiZroA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="Narr_5IRAjiu2sEiwl9UXdtScOA">9.0</ix:nonFraction> million in accrued and other current liabilities and other liabilities, non-current, respectively, in the consolidated balance sheets as of December 31, 2023. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current in the consolidated balance sheets. As of December 31, 2023 and 2022, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following table presents the inventory balance sheet classifications: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" id="Tb_bBCCLH6gD0W4Br3K1fe4Pg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_GJvPZjlLq0ukxrFzlptU7w_3_3">62,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_g37X-Dybs02Q1YUV6ig0QQ_3_6">38,791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_GvxwgndMuk-Bs3WF9DbQDw_4_3">67,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_nFc-iBI31EiBjrUMifuUkA_4_6">76,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:InventoryCurrentAndNoncurrent" scale="3" id="Tc_Yo4Kj-VDikiYAd7pZkQP0w_5_3">130,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:InventoryCurrentAndNoncurrent" scale="3" id="Tc_6EochILi6U-88S-ZGqadkg_5_6">115,051</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Prepaid manufacturing of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="6" id="Narr_NI6ihpnIskSdPzWLRRNBHQ">23.7</ix:nonFraction> million as of December 31, 2023 includes prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForManufacturingServices" scale="6" id="Narr_n_nUI9wKz0GNpuqi0tEaAQ">12.6</ix:nonFraction> million to CMOs for manufacturing services of the Company&#8217;s products, which the Company expects to be converted into inventory during 2024, and prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" scale="6" id="Narr_EALxozxTAkyDaZCSbHHHlg">11.1</ix:nonFraction> million to various CMOs for research and development pipeline programs<i style="font-style:italic;">.</i> Prepaid manufacturing of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaidManufacturingExpenseCurrent" scale="6" id="Narr_0OwdVCzwkkOUMd-wsph47A">17.9</ix:nonFraction> million </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GducaB4Gbke308921JO0qA_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">as of December 31, 2022 included prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForManufacturingServices" scale="6" id="Narr_Bgfj_SBxYEaiv1KWH1QpHw">13.0</ix:nonFraction> million to CMOs for manufacturing services of the Company&#8217;s products and prepayments of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" scale="6" id="Narr_Za0H6vz-dE-DtMrzxwP9nA">4.9</ix:nonFraction> million to various CMOs for research and development pipeline programs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea as part of a realignment of research and development resources toward other development programs. As a result, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_NxhQ8-y-vE-qqYM8KM5CLQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_5CzJuPgj2kqPnk4CrdvBeA">11.2</ix:nonFraction> million within research and development expense in the consolidated statements of operations in 2021, which included an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_NxhQ8-y-vE-qqYM8KM5CLQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProductionRelatedImpairmentsOrCharges" scale="6" id="Narr_Wt2voCUR4U-37-U0d3LFxA">3.2</ix:nonFraction> million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="0" id="Narr_OGTPuU76Qk-JUY0Q2Yfdlw">No</ix:nonFraction> material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021.</p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f214da61_a85f_49f0_a7c9_eda906a7ddb8"></a><a id="Tc_YY6NwrBPSkGhSlLeZbTUdA_1_2"></a><a id="Tc_sP-C2EzMwkOy2lZDpm9CTA_2_0"></a><a id="Tc_AO_FWZQBBUKAAqRaOVpxGg_2_2"></a><a id="Tc_1UXv115ZtUqJKnMSo-4ZKg_2_5"></a><a id="Tc_u2c6ltaA-0uSND9xup1ocA_3_0"></a><a id="Tc_j8hRRbLdaUSbYxX-d_1FtQ_3_2"></a><a id="Tc_R_kYGwQmbkOlNhYlfDkMpg_3_5"></a><a id="Tc_WWyTaRIKQkCNHti_6Uz3oQ_4_0"></a><a id="Tc_YCWYm55t-EC13I1nN1GQNA_5_0"></a><a id="Tc_JI861rvq-UmZ2AhRSQjFKQ_6_0"></a><a id="Tc_ykxYEPJtY06VszsfP4OAIA_7_0"></a><a id="Tc_lBciAacnB0-nJdcmeWnWww_8_0"></a><a id="Tc_VQiyATJ2DUGU6tBCwrSdFQ_8_3"></a><a id="Tc_NItEK2TKhUG-FtnmWlHn1Q_9_0"></a><a id="Tc_SI5tEcrWHUCbZQWy5PM3Bw_10_0"></a><a id="Tc_isbMFVNiKkqQ0VLI-1fFLA_11_0"></a><a id="Tc_-h_35KVs50SnQE9xMplVHQ_11_2"></a><a id="Tc_KFMpxVsyIEuFDCTmTRah8w_11_5"></a><a id="Tc_aPxWncA_VEixc-kVE-_3dw_1_2"></a><a id="Tc_Lnu1Egif00GedVu2ChWrsw_2_0"></a><a id="Tc_iY4Lmu73xUK-4R59jYNJnQ_2_2"></a><a id="Tc_bJO8EBXjrkOCZVnkN5S1mw_2_5"></a><a id="Tc_wZr5FsQJW0mz8aHQg-JdyA_3_0"></a><a id="Tc_DRUbQ906XEaEAogw2JtHsQ_3_2"></a><a id="Tc_m1sUEG_SaEqI7K0jvSZlMA_3_5"></a><a id="Tc_zY9p76Ln6EmTzrw_QlNr7w_4_0"></a><a id="Tc_0ZLFopoJuUO5DRnY95I8tA_5_0"></a><a id="Tc_YuAAe6Wi20yAKHdlstC7_g_6_0"></a><a id="Tc_R0BLIrVFE0-5N27349w2sA_6_2"></a><a id="Tc_5luFnBnpT0ijhYFmuwbLcQ_6_5"></a><a id="_f6808628_4650_417d_bb76_2aac95029209"></a><a id="_f6808628_4650_417d_bb76_2aac95029209_2"></a><a id="_f6808628_4650_417d_bb76_2aac95029209_3"></a><a id="_f6808628_4650_417d_bb76_2aac95029209_4"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_YoOCIfxl_UGFJx2q8AbLRA" continuedAt="Tb_YoOCIfxl_UGFJx2q8AbLRA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span>Balance Sheet Components</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_VtBvd52zwEG28z3zbUsYpw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_R1ZNIhTdtU6PTDnnezToVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_MkQ9pSg2dku44pnYuRR3kw_3_3">13,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_YjMCSisOdUGXZi2xqln_Mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_mWfw-0AkrUiCYvooKbQkQQ_3_6">12,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_q4XQKvn7hUuMY-hLmFDudw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_qnJox0WZdU22QnMhe4EFaw_4_3">3,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_jucBH5LjrUK46koXbkAVgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_l7a5ItDbUEKxpxTHsyrXmQ_4_6">3,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_1sqZX3sEC0ybe4z7SnzBqQ_5_3">1,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lMgSkORl9USZXjMIwMYQHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_dOAtgGgGFEe6EeKzhAWj2w_5_6">1,258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_6mauAg9SEkCGnWzdOVcIUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_81U4tcLWkke2owFwaOUeuA_6_3">5,751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qgwSy_5jP0WkljoCN5grsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_r4UBYzG6eUeDY6EaiIshdA_6_6">6,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_CmUnXGsYHU-xLi_OavbKiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_zVqrmuNhtUuOwO9gCuvjDg_7_3">2,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_XQIUc6d-XUmksooC86ywXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_3b0u7QWkOEKTX4-kpKYLhQ_7_6">4,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_0z3z_qR8HkiyEEOaFlpNTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_jFBx6UU54UG2NaA876fERA_8_6">696</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_zjn1M99dcUe-AVg8xc98rg_9_3">25,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_Zp2VciFPPU2lmGFa-vtABA_9_6">28,911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_5zGE5d5iIEaSyIlR6xS9UA_10_3">20,651</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_KKnmojE2IUSbE5THZ8PWGg_10_6">20,157</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_1FoMH743J06ajvFLNr07aQ_11_3">5,119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_FCm_95t4UkekjQoxf5QckA_11_6">8,754</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense related to property and equipment, net was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_wGfA-Hg660SHjpUX6TNSMQ">3.2</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_mjAdY5gGZkK-j8KhwPM3Gw">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_LkxlTk8sy0KaYsGOeM7aUg">3.5</ix:nonFraction> million in 2023, 2022 and 2021, respectively. There were <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Narr_Ohuh8YsMTEWbpk4TOUDqLw"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Narr_l7qlIpFYEky1Q2KUmUbCCQ"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Narr_L9z6DLS3rUeyUwxod7Eytw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> material impairments of property and equipment in 2023, 2022 and 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the net book value of software implementation costs related to hosting arrangements was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="Narr_kjRlY0PKWkmfJfym7f1FdA">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="Narr_sjBiVGpYRUmMjVQQloZw9A">3.5</ix:nonFraction> million, respectively, and the amortization expense was immaterial for all periods presented.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets, Net</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Goodwill and intangible assets, net consisted of the following:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="Tb_MMVzH1udA0uBPV_MGn0iqw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finite-lived assets, net of accumulated amortization of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Narr_PRwDrYkAEkeXfGyTP29RpA">639</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Narr_EbDjRmrTv02lqghs7cc3oQ">61</ix:nonFraction>, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_jQrFPAIPs0OcL-uHfVSh1g_3_3">41,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_YDCXJ4penkqxocXBhDj1qA_3_6">2,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite-lived assets - IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc__ZjlN4R79EegxtV2bAnUfg_4_3">28,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_vBe8YNYJ606-cINZzu12Ew_4_6">2,620</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_lrf1iyFcrUuRifNB3ktiRA_5_3">943</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_9vZeBRzyQkCVwmJYmVRFVw_5_6">943</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc__XdqB9LYb0yfCghZR6SLgA_6_3">71,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="Tc_eGbxtkDPt0WounzQU3Ewrw_6_6">5,931</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization expense related to finite-lived intangible assets was immaterial in all periods presented. As of December 31, 2023, amortization expense related to finite-lived assets for each of the five succeeding fiscal years will be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="chrs:FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" scale="6" id="Narr_3naxq05z7UKLZAc9qHikDw">3.8</ix:nonFraction>&#160;million. The weighted average remaining life of the finite-lived assets is <ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_2seIXHRiPE-w5SWfi70Qhg">11.4</ix:nonNumeric> years on December 31, 2023. <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Narr_GbocUJydskOC8a1xpcvSGw"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Narr_zSdo_rTvEUqRRztlZ1ms5A"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Narr_RHH42lUZjU2g80UayUTY5A">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges were recognized for goodwill or intangible assets during 2023, 2022 or 2021. During 2023, the Company&#8217;s intangible assets increased due to assets acquired in the Surface Acquisition (see Note 6. Surface Acquisition) and capitalized milestone payments, including $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr_6D1YK9OeyEqVt3G8H0y3GQ">25.0</ix:nonFraction> million to Junshi Biosciences (see Note 7. Collaborations and Other Arrangements). </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e3653604_1b51_40c3_ac13_609593be4d77"></a><a id="Tc_sqMX_kqPGESjhNw9BiMp5A_1_2"></a><a id="Tc_3DeF1nfK50mb7r4vs6RFmA_1_5"></a><a id="Tc_0StIfW3MG0C17EiiDghqdQ_2_0"></a><a id="Tc__yV8aM4X9kOjGAt7pbb0OA_2_2"></a><a id="Tc_Y6kYzquj_k-VzQYWZIjmTQ_2_5"></a><a id="Tc_fL0lbqjGEkSAFY7Q3dDbFA_3_0"></a><a id="Tc_0aLK4qP7Rky9cCLVgqfgRg_3_2"></a><a id="Tc_z7wR6OT1C0y0hVANoHtw2g_3_5"></a><a id="Tc_jFCPd9Le40CSGiMZvYXbrA_4_0"></a><a id="Tc_0dDlnHTKxEqTz1-I78YdJQ_5_0"></a><a id="Tc_67cUpeeweUOhfVZbBYfTUg_6_0"></a><a id="Tc_yXqq6Dga1EOEjaC_e_50LQ_7_0"></a><a id="Tc_9ptvGTH-v0O8Gbmkc8p1mg_8_0"></a><a id="Tc_rISX_mjeLEKSwuU6myP4wg_8_6"></a><a id="Tc_Wn21EHU95E2ewFzzdmgU6Q_9_0"></a><a id="Tc_VQrdsjXjkkC6BxmVt4defg_9_2"></a><a id="Tc_QX60C_mYXkCxZ2aPX2P8Ww_9_5"></a><a id="Tc_tBnOStXfuU-Pn2TdrK22jw_1_2"></a><a id="Tc_skH3DUtqeEO5OGcs2Qny4w_1_5"></a><a id="Tc_U1i1Ocou4kWrKdM14ZYJ2w_2_0"></a><a id="Tc_gPMRdVaCekGDzRPICZbIew_2_2"></a><a id="Tc_s5jcGnmywkG0B2bCcdI1bQ_2_5"></a><a id="Tc_gdaULwzNxkO5ihwd9aJdfQ_3_0"></a><a id="Tc_uMHvx3cqtEWN-4rGneMzmQ_3_2"></a><a id="Tc_-GbNuH8560qiFEW1VM-14w_3_5"></a><a id="Tc_q6J4u4YBBU62ZZySjp_CAg_4_0"></a><a id="Tc_I9AvT6t_1E-K5Qr_JsryjA_4_6"></a><a id="Tc_SAGoFrzK1kCIL2iP3cNU-g_5_0"></a><a id="Tc_8vqDFVjtnkK4M52iwCQfTw_6_0"></a><a id="Tc_Xh_DE0VekEi5G6mJvCBppw_6_2"></a><a id="Tc_q0PUCV57M0Oz7Xk14sLcPg_6_5"></a><ix:continuation id="Tb_YoOCIfxl_UGFJx2q8AbLRA_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Current Liabilities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Accrued and other current liabilities consisted of the following:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_3uYYk1dfg02nxIJVc5--cw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued commercial and research and development manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" scale="3" id="Tc_JLJwEoJ7m0S8oWCYT3VNyA_3_3">23,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" scale="3" id="Tc_JGLW1t7jeE2R4DvaaWmpPw_3_6">21,774</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued co-development costs and milestone payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCoDevelopmentCostsAndMilestonePayments" scale="3" id="Tc_y2Qp5q5DY0eLP_gnj8ER1g_4_3">26,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:AccruedCoDevelopmentCostsAndMilestonePayments" scale="3" id="Tc_Jf1tI0TVkkqNlfn91aSzVw_4_6">8,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_iaWEZ5jwzE-JrJTxdr5rLQ_5_3">42,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_gN_odPho7kOtoaUAx-gdqA_5_6">5,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_UV9YaQ2nNk6PrOHYyOCFAw_6_3">7,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_PT_gUXtAT0GH9h1HLKxy-g_6_6">10,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:LeaseLiabilitiesOperatingAndFinancing" scale="3" id="Tc_th3PeZc5cE69QBZEndUH5Q_7_3">2,145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:LeaseLiabilitiesOperatingAndFinancing" scale="3" id="Tc_WAFE-rs7P06cZVDlBIC6Pg_7_6">4,318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="Tc_TUSXU9FF50CZxhhIQ9YFjw_8_3">3,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_5AIveHiilkOKL4JSBSfGHA_9_3">105,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_JUi6KGBGqkOozpttaYVD5Q_9_6">50,097</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Liabilities, Non-current</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other liabilities, non-current consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="Tb_pLo0DrfI_Ue7U2aycFvVNA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="Tc_0nfghXhBT0apFNixNxDKWA_3_3">1,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="Tc_qWmnneJvhEO4IdP29YEtHQ_3_6">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_fUzI9f5Jx0GXUlTzPdx1zw_4_3">1,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="3" id="Tc_lZPWaoVqYEqxI2zg1WtFHA_5_3">10,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="3" id="Tc_YBJySZV0kkuF0P7KQX80Dg_5_6">3,365</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Other liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_06NblY8XhUOzN0DBx4bUuQ_6_3">12,561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_gRM9_KMm8Euaul9i47-zhA_6_6">3,467</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Tb_xiB7_d6_G0eKlhr-Ybed2Q" continuedAt="Tb_xiB7_d6_G0eKlhr-Ybed2Q_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">6. Surface Acquisition</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On September 8, 2023, in accordance with Merger Agreement by the Merger Subs, and Surface, the Company completed the Surface Acquisition. Surface is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment&#160;for the development of next-generation cancer therapies. The Surface Acquisition expanded the Company&#8217;s immune-oncology pipeline with the following: casdozokitug (CHS-388,&#160;formerly SRF388), an investigational, novel&#160;IL-27-targeted&#160;antibody currently being evaluated in a Phase 2 clinical trial in HCC, and CHS-114 (formerly SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On the Acquisition Date, and in accordance with the Merger Agreement, the Company issued to the holders of all outstanding Surface common stock (other than treasury shares, any shares of Surface common stock held directly by the Company or the Merger Subs immediately prior to the Acquisition Date and shares of Surface common stock issued and outstanding immediately prior to the Acquisition Date and held by any holder properly demanding appraisal for such shares in accordance with Section 262 of the Delaware General Corporation Law)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="INF" format="ixt:numdotdecimal" name="chrs:BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" scale="0" id="Narr_g4NTZ9xGKEi2AqEwbYHiJQ">0.1960</ix:nonFraction>&#160;shares of Coherus common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on a&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_zTWwW2Bx40WnIFKHnF6tvw">5.2831</ix:nonFraction>&#160;per share price of Coherus common stock&#160;and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also received&#160;<ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="INF" format="ixt-sec:numwordsen" name="chrs:BusinessCombinationConsiderationContingentValueRightPerShare" scale="0" id="Narr_6ngbuvWiI0GxhPdArTvbTA">one</ix:nonFraction>&#160;CVR for each share of Surface common stock and employee equity award converted.&#160;Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at the Company&#8217;s discretion during the&#160;<ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" format="ixt-sec:durwordsen" name="chrs:BusinessCombinationConsiderationContingentValueRightPaymentPeriod" id="Narr_9Fhmz0kwI0WGjztj-xRW-Q">ten-year</ix:nonNumeric>&#160;period following September 8, 2023, for the sum of the following, less any permitted deductions in accordance with the CVR Agreement:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceGlaxosmithklineAgreementMember_HFnWjX4pcU-dEYSrnOgYsA" decimals="2" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" scale="-2" id="Narr_6UaTdjD4IkiPJplxnggUgA">70</ix:nonFraction>%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of all milestone- and royalty-based payments actually received by the Company or its affiliates under the GSK Agreement related to the existing program (GSK4381562);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceNovartisAgreementMember_gPSalh4re0SjsDIBtluNVw" decimals="2" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" scale="-2" id="Narr_k1kErWmqxkCHdz1DQIae4A">70</ix:nonFraction>%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of all milestone- and royalty-based payments actually received by the Company or its affiliates under the Novartis Agreement related to the existing program (NZV930);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_dcELaaK_i0Oi3XQ1ke-MNg" decimals="2" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" scale="-2" id="Narr_V8x7z4LNv0qBWhcGci33lQ">25</ix:nonFraction>%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; and</span></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_eea61549_f202_48dc_97e2_95d3bcbec358"></a><a id="Tc_iTrLEV2wuke01JLW5nsd_A_1_0"></a><a id="Tc_bJdF9H6A-UKjUBrNvyDdUw_1_2"></a><a id="Tc_7Q0lg5hixEa65ORewG0IJw_2_0"></a><a id="Tc_5xWMc282gEi5CJ6mbjk3KA_3_0"></a><a id="Tc_hbo8FgdPn0Od_KeNMB6lFg_3_2"></a><a id="Tc_jpRNS5Ul60iSxRm2OzQ9OA_5_0"></a><a id="Tc_Bsw_sLeKkUC3pZ_V18oH4Q_6_0"></a><a id="Tc_HkMuemORe02bT4YC62hdoA_6_2"></a><a id="Tc_zTs-c4W3qU-mXoQ1TYycIg_7_0"></a><a id="Tc_2QLmjVpfpU-dmLRi9he35g_8_0"></a><a id="Tc_ZfSQX7I0Z0imsWjxhkN8bA_9_0"></a><a id="Tc_8wZvfV7a1k25UQQhIIG3Lw_9_2"></a><a id="Tc_6FCo274GsUSZQOPvJAl6cA_1_0"></a><a id="Tc_zbY-P5zdskqJWuP3pA9xkA_1_2"></a><a id="Tc_kevTSr0ExUGLR8IoImTdCw_2_0"></a><a id="Tc_gur6SnUnEkypB40EfxbGJQ_3_0"></a><a id="Tc_3HXb3_2Wx0a7oPV3h-35kQ_3_2"></a><a id="Tc_e4lJcRZFv0uvgT6fYPq0Hg_4_0"></a><a id="Tc_F0WLrjDagE-9EuAhfRhx7Q_5_0"></a><a id="Tc_ImudRbXoc0-czQWi56kUXQ_6_0"></a><a id="Tc_wWxsiYHc2kekvGgBChtJKA_7_0"></a><a id="Tc_tJtZPd66rUGEpauOasTKvQ_8_0"></a><a id="Tc_KU7fOEFWc02Op6-uBZmLSw_8_2"></a><a id="Tc_tOid1lMRpEOjY8ggmE9YCQ_9_0"></a><a id="Tc_9VbbfaQAlEyAcjEQM57Qyw_10_0"></a><a id="Tc_Z6iQFXaxTEGSSOhJAPiy-Q_10_2"></a><a id="Tc_KJjyuRmu0Em7Yzn3EN85Jg_11_0"></a><a id="Tc_b6s97ggvCUWFsv0dKGktug_12_0"></a><a id="Tc_lTEgttRM6kqVB5vpQHloYg_13_0"></a><a id="Tc_MrXMUpktJUe0p5Nj5ihjEg_13_2"></a><ix:continuation id="Tb_xiB7_d6_G0eKlhr-Ybed2Q_cont1" continuedAt="Tb_xiB7_d6_G0eKlhr-Ybed2Q_cont2"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_XCQ--7iqDkm-4Cxl9nIn8w" decimals="2" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" scale="-2" id="Narr_qEJO0MVYJkOeTgSyhwYEGg">50</ix:nonFraction>%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">The Company has recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement described above.&#160;The Company is unable to estimate a range of outcomes for potential royalty and milestone payments&#160;for CHS-114 and&#160;casdozokitug.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The total consideration paid for the Surface Acquisition of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="Narr_mWgpt3Edv0m5wpE8HSrv2g">64.6</ix:nonFraction>&#160;million consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="Tb_gAUR-wi8i0SHsc6JiztGLA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coherus common stock issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="Tc_Q9fPaEK6dkeny3UZyk4ajw_2_3">11,971,460</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coherus common stock share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="Tc_KCpEN340hE6Y8fKB-r7efg_3_3">4.89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value of components of purchase price consideration at closing:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity of combined company owned by Surface equity holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" scale="3" id="Tc_caY4lm4QTEKlTNsgthEy8w_6_3">58,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent CVR liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="3" id="Tc_DjEi4lYZ-ES9ICZUre99kQ_7_3">5,290</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity of combined company owned by Surface former employees <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" scale="3" id="Tc_ByeR_D4G9UC_0HeDjjKOdg_8_3">766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="3" id="Tc_dTDCTnVFG0eM9Rw2cXcYqQ_9_3">64,596</ix:nonFraction></p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="INF" format="ixt:numdotdecimal" name="chrs:BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" scale="0" id="Narr_dfuIHoEa4kGxJE39iBZYTg">161,100</ix:nonFraction></span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Coherus common stock, net of shares withheld for taxes, issued to Surface&#8217;s former employees on the Acquisition Date.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company has accounted for the Surface Acquisition as a business combination which requires, among other things, that the assets acquired and liabilities assumed generally be recognized at their fair value on the Acquisition Date. Fair value estimates are based on management&#8217;s estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company&#8217;s results of operations. The purchase price allocation for the Surface Acquisition is preliminary and subject to revisions as additional information about fair value of assets and liabilities becomes available. This is primarily related to the Company&#8217;s deferred tax liabilities assumed in connection with the Surface Acquisition, as the 2023 short period tax returns have not yet been filed. The following table below sets forth the purchase price allocation to the estimated fair value of the net assets acquired:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Tb_Mh1kx0d-4UeZrjo63463Ag" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amounts Recognized at Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="Tc_txnsXkrLgE21RQGQXU6uOQ_3_3">6,997</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="Tc_oxPW-EqNck6ipwyH32cbJg_4_3">21,791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other prepaids and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="Tc_LjZtIQ8XSU2CRdp0z_SM1g_5_3">5,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_BPCdvDMynEyiPHvB9x6iQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_hZv_Dp2fYEm7k611aEdrtg_6_3">26,239</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_zLRTOCdaDkGr-Wlc6H94QA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_3gVhSsS4AE-DA790W_Gf5g_7_3">13,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="Tc_l0avfVyNa0yDb5HXjzsxSw_8_3">73,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="chrs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" scale="3" id="Tc_9_XOl9PcHkGiJgIOrvcRdA_10_3">7,722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="Tc_FgN2X5014EmhSay_mKom0A_11_3">1,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="Tc_lTgwlhpIDk2po5VzfjdMfQ_12_3">9,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="Tc_1VwYaSjNk0O350J55WBixA_13_3">64,596</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Company believes that, even after reassessing its identification of all assets acquired and liabilities assumed, it was able to acquire Surface for a price that was completely allocable to identifiable assets acquired and liabilities assumed with&#160;<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Goodwill" scale="6" id="Narr_LkVyjinDCkilqRh1Vr5SRA">no</ix:nonFraction>&#160;residual attributable to goodwill primarily due to Surface&#8217;s need to raise additional capital to finance its operations, the challenging biotech funding environment at the time the transaction was initially announced, and the value of the acquired net assets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Llv9rz6KwUmIAd96B6QZxQ_1_0"></a><a id="Tc_6IqWTfKxe0CzMTQZSzSDiQ_1_2"></a><a id="Tc_zPU7NfXZREGvSjfdywmYMw_1_5"></a><a id="Tc_1RaVI0BVJEOjGRUOGBGBiA_2_0"></a><a id="Tc_LVsf39AlZUmFic9LvSRmZg_2_2"></a><a id="Tc_SuRr8MM3-k2rVSP0jdPx0g_2_4"></a><a id="Tc_OlqCy0mV8UKGMzAS2sJDGA_3_0"></a><a id="Tc_wHkNtyTOw0OaAsTAvEAbBA_3_2"></a><a id="Tc_FBgeN6YXt0SOqL1Zo19f2w_4_0"></a><a id="Tc_ssgN-HtHzEWXZRfbE7zdEw_5_0"></a><a id="Tc_8449tGS_fUSnm8oS9jt8cQ_6_0"></a><a id="Tc_q6uCEP08mUuUwvU-JOhsNw_6_4"></a><a id="Tc_Asl45gDOukWpg7BYixIjWA_1_2"></a><a id="Tc_yeoHmmNyBkiFxh_pUCYiYg_2_0"></a><a id="Tc_a_RIzV97aUyBYpZ-TuYIjg_2_2"></a><a id="Tc_TGKIXMUaqUu1UK46E9vy3g_2_5"></a><a id="Tc_y_p0o_my3EyMP1Fy0MVSFg_3_0"></a><a id="Tc_GxDyU2RWkE6NtP87Srhtow_3_2"></a><a id="Tc_cLpEBPsyeUSQD2C5VCgEmg_3_5"></a><a id="Tc_1oKzPWjS6kG2KlYbhYjGsQ_4_0"></a><a id="Tc_JvU163W9zkm8DT18e9xz6g_4_2"></a><a id="Tc_CtOF_yzpEkal62Kb4_oKjQ_4_5"></a><ix:continuation id="Tb_xiB7_d6_G0eKlhr-Ybed2Q_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The amount allocated to identifiable intangible assets has been attributed to the following assets:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" id="Tb_Cl6LTCZQ8kGBn7ZOHf6bqw" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf388Member_2lO8XAyg6UKhnOMI1Zafnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_TnNfxFFv10yU7ASX-9qFtg_2_5">25,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - CHS-114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf114Member_MCpWdvb_hUWv00leqUKNEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_UvLRiIQwvkye6cIR3_A8lQ_3_5">340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-license - GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_Db9iHsTjOk2dnST6JR1wPA" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Tc_EVRnr5XH6ky-f6VXsBylNw_4_2">15 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_aK8ibHz1PEqs0z1M6Yn7Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_h3FTHMGPAkKn3wHrwNmA7w_4_5">2,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-license - Novartis Institutes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_08hF26t1CE220LggkCbdaQ" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Tc_3ZB4cc9rZEyIZSPfT-QT_A_5_2">15 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_pOfVd5Rj4Eum4N-4rVrphQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_s0aLkyw9NE6MS_iPtA7sVw_5_5">11,024</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total identifiable intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_wyYUenSLA0WfoiJn26c0Tw_6_5">39,769</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Surface had&#160;<ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A" decimals="INF" format="ixt-sec:numwordsen" name="chrs:BusinessCombinationNumberOfOutLicensedPartnershipProgram" scale="0" id="Narr_momAkZe3jUScVwdzw1_eaw">two</ix:nonFraction>&#160;out-licensed&#160;partnership programs, with Novartis Institutes (NZV930) and GSK (GSK4381562), to advance certain next-generation cancer therapies. The out-license intangible assets represent potential milestone and royalty-based payments to be received in the future.&#160;Surface shareholders received CVRs for certain percentages of these milestone and royalty-based payments on existing programs with Novartis Institutes (NZV930) and GSK (GSK4381562), as further explained above. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Following the Acquisition Date, the operating results of Surface have been included in the consolidated financial statements. For the period September 8, 2023 through December 31, 2023, there was&#160;<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_9_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_rkk2bVd2PEWq4HB48Bymrw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="Narr_Gp0yqniICEu7Kg23VZRT2A">no</ix:nonFraction>&#160;revenue attributable to Surface and operating losses attributable to Surface for such period were $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_9_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_rkk2bVd2PEWq4HB48Bymrw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" sign="-" scale="6" id="Narr_AN6hNygMz0uWjzzA5lmV8w">5.9</ix:nonFraction>&#160;million, excluding acquisition-related costs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unaudited Pro Forma Summary of Operations</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table shows the unaudited pro forma summary of operations for the years ended December 31, 2023 and 2022, as if the Surface Acquisition had occurred on January 1, 2022. This pro forma information does not purport to represent what the Company&#8217;s actual results would have been if the acquisition had occurred as of January 1, 2022, and it is not indicative of what such results would be expected for any future period: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="Tb_1UzZ6ftxxEOEczsEtdoOiA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="Tc_ChvAf39RbUGhUfLt6HPp7Q_3_3">257,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_x0b6Pn8B7UCsaUPMe0v01g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="Tc_OKoxqy64NEuHaKI_iYrS2g_3_6">241,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" sign="-" scale="3" id="Tc_o0JBRnj5OEW7sK6MfcvgmA_4_3">284,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_x0b6Pn8B7UCsaUPMe0v01g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" sign="-" scale="3" id="Tc_r7gLEcMya0ei_lxC8tfOeQ_4_6">369,442</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and Surface. In order to reflect the Surface Acquisition as if it had occurred on January 1, 2022, the summary pro forma financial information includes adjustments to reflect&#160;Surface&#8217;s severance expense, the early termination and related amortization expense of Surface&#8217;s corporate headquarters operating lease, the loss on debt extinguishment and historical interest expense related to the cash settlement of Surface&#8217;s convertible note as if it had occurred on January&#160;1, 2022, and&#160;amortization expense on the acquired finite-lived intangible&#160;assets.&#160;The unaudited pro&#160;forma summary of operations does not reflect the income tax effects, if any, of the pro&#160;forma adjustments, given the combined entity incurred significant losses during the historical periods presented.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Acquisition-related costs of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="Narr_KFa2zp62xEOSrxWN_Rrudg">5.1</ix:nonFraction>&#160;million were recorded in selling, general and administrative expense in the consolidated statements of operations during the year ended December 31, 2023.</p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_w_qQcpZTHES3MUqrG0SmdA" continuedAt="Tb_w_qQcpZTHES3MUqrG0SmdA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">Collaborations and Other Arrangements</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">In-Licensing Agreements</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Junshi Biosciences</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On February 1, 2021, the Company entered into the Collaboration Agreement with Junshi Biosciences for the co-development and commercialization of LOQTORZI, Junshi Biosciences&#8217; anti-PD-1 antibody, in the United States and Canada.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the Collaboration Agreement, the Company paid&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_K1geY-rGLEiNymNh_P6jTA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationCosts" scale="6" id="Narr_PCnZ8wccZkumAb4xQARqWg">150.0</ix:nonFraction>&#160;million&#160;upfront for exclusive rights to LOQTORZI in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to&#160;two&#160;undisclosed preclinical immuno-oncology drug candidates. The Company will have the right to conduct all commercial activities of LOQTORZI in the United States and Canada. The </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk126843225"></a><a id="_Hlk106783636"></a><ix:continuation id="Tb_w_qQcpZTHES3MUqrG0SmdA_cont1" continuedAt="Tb_w_qQcpZTHES3MUqrG0SmdA_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Company will be obligated to pay Junshi Biosciences up to a&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_K1geY-rGLEiNymNh_P6jTA" decimals="2" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSales" scale="-2" id="Narr_g-GR5_x17kmWuMZZGCQujg">20</ix:nonFraction>% royalty on net sales of LOQTORZI and up to an aggregate&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_5YqDtd4hEUeB-HOMwGXqCw" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" scale="6" id="Narr_YqWb5k4C7EWZBQRj7cxQ-w">380.0</ix:nonFraction>&#160;million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In March 2022, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_zOQpf9YQJEWfttgbnzt7Ag" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementOptionExerciseFeePerProgram" scale="6" id="Narr_MfrfKiOL80Cfyd8kFXyvsQ">35.0</ix:nonFraction> million for the exercise of its option to license CHS-006. Junshi Biosciences and the Company were jointly developing CHS-006 with each party responsible for the associated development costs as set forth in the Collaboration Agreement, however on January 10, 2024, the Company announced that it had delivered a notice of termination of the TIGIT Program (as defined in the Collaboration Agreement) to Junshi Biosciences pursuant to the Collaboration Agreement. The Company plans to continue to wind down work with Junshi Biosciences on the TIGIT Program pursuant to the termination. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay Junshi Biosciences an additional option exercise fee of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_HSE0jmg2IUOdXIECBGmidA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementOptionExerciseFeePerProgram" scale="6" id="Narr_l77mpJrU4EO9qTXLgyd1RA">35.0</ix:nonFraction> million and an <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_HSE0jmg2IUOdXIECBGmidA" decimals="2" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" scale="-2" id="Narr_JzduuBTFCEC69SoGsnXJ8A">18</ix:nonFraction>% royalty on net sales, up to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_hh8Bb6a9E0Co_wILfDg5zQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" scale="6" id="Narr_tIjbOeH4l0ScZqVinddMBw">85.0</ix:nonFraction> million&#160;for the achievement of certain regulatory approvals, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_QfB80gafZEu1g-1S9zIihw" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" scale="6" id="Narr_zMt26-1A50uKGDb9Rt0YbA">170.0</ix:nonFraction> million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of LOQTORZI and the other licensed compounds and will pay for a portion of these co-development activities up to a maximum of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rrL79xCbSEKm0OK1XTANMw" decimals="-5" format="ixt:numdotdecimal" name="chrs:MaximumAmountPaidCoDevelopmentActivities" scale="6" id="Narr_zOOrOPbM-UWLG030Ss2uzw">25.0</ix:nonFraction> million&#160;per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. Research and development expenses recognized for obligations to Junshi Biosciences were $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_-QTpVgOnZUGGQfnOSlwd1A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_YiLYe2ViiUavkrlbja6d4g">8.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iP1gAk8B10WNqliDVtY6VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_lgO5_fbfoESczyDuaMvSmA">68.5</ix:nonFraction> million (inclusive of the $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_-QTpVgOnZUGGQfnOSlwd1A" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementOptionExerciseFeePerProgram" scale="6" id="Narr_dM84M1FhMEaoSxAj0y3_KQ">35.0</ix:nonFraction> million option fee) and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_tM3Ef_Mpak6Ub3zq_1vXxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_M3kNeeWYpkS5_O4lWRd2QQ">175.4</ix:nonFraction> million (inclusive of the upfront fee) in 2023, 2022, and 2021 respectively. In the consolidated balance sheets as of December 31, 2023 and 2022, the Company classified $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_RzvldwJEbE2sTE9gTKsnIg" decimals="-5" format="ixt:numdotdecimal" name="chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts" scale="6" id="Narr_kSmaCp0tXEmkBPjcYiUgBw">26.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_wPWUD9JeY06Jz0STfXnoNg" decimals="-5" format="ixt:numdotdecimal" name="chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts" scale="6" id="Narr_L6UBUVVKFEO-Xf-nY7DaFg">8.4</ix:nonFraction> million, respectively, in accrued and other current liabilities and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_2WiqeL2ms06O_McAP8cV_g" decimals="-5" format="ixt:numdotdecimal" name="chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts" scale="6" id="Narr_HkWpDNUlzEqs4N1AAegnng">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rVWYKaHlykapW6Ik8MkDUA" decimals="-6" format="ixt:numdotdecimal" name="chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts" scale="6" id="Narr_zRqBIEp7tEyBvKWQtTtZAQ">0</ix:nonFraction> in accounts payable, respectively, related to the co-development, regulatory and technology transfer costs related to these programs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">On October 27, 2023, LOQTORZI was approved by the FDA in</span><span style="color:#0a0a0a;background:#ffffff;">&#160;combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. </span>As of December 31, 2023, the Company has accrued a<span style="background:#ffffff;"> </span>$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_v--BLMYsNkKl0zxMmYmYEA" decimals="-5" format="ixt:numdotdecimal" name="chrs:AccruedMilestonePayment" scale="6" id="Narr_t4bxq-yIHEeSflgatoERAQ">25.0</ix:nonFraction> million milestone payment to Junshi Biosciences, of which it expects to pay $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_4fiZbKl1c0-rDjVdhAf4iA" decimals="-5" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr_a0Mv7ZNFuUqKq7OrUURMxQ">12.5</ix:nonFraction> million in the second quarter of 2024 and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_bjX_QmuqBUiNiIM7YQU9cw" decimals="-5" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr_RY2X1wphrkywjRuNuUkgXg">12.5</ix:nonFraction> million in the first quarter of 2025. This amount is a non-cash transaction which the Company has recognized in intangible assets, net and accrued and other current liabilities as of December 31, 2023<span style="background:#ffffff;">. The accrued royalty obligation to Junshi Biosciences is immaterial as of December 31, 2023. </span>The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In connection with the Collaboration Agreement, the Company entered into a stock purchase agreement dated February 1, 2021 (the &#8220;Stock Purchase Agreement&#8221;) with Junshi Biosciences agreeing, subject to customary conditions, to acquire certain equity interests in the Company. Pursuant to the Stock Purchase Agreement, on April 16, 2021, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ" decimals="INF" format="ixt:numdotdecimal" name="chrs:StockPurchaseAgreementSharesAgreedToBeIssued" scale="0" id="Narr_u9aYHA4cwEuW-RenjgsW9w">2,491,988</ix:nonFraction>&#160;unregistered shares of its common stock to Junshi Biosciences, at a price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_oaRRmEbooE6uheOeSOw-Fg">20.06</ix:nonFraction>, for an aggregate amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:StockPurchaseAgreementSharesAgreedToBeIssuedValue" scale="6" id="Narr_MWlJYp5a8UWUn0IGnsiBjw">50.0</ix:nonFraction>&#160;million in cash. Under the terms of the Stock Purchase Agreement, Junshi Biosciences was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of the common stock for the <ix:nonNumeric contextRef="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_13eeoeTRfk2iZ3H7ofLzJg" format="ixt-sec:durwordsen" name="chrs:PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" id="Narr_ycIyAQdzs0ajnOX-HIwFlQ">two-year</ix:nonNumeric> period following its effective date. The Collaboration Agreement and the Stock Purchase Agreement were negotiated concurrently and were therefore evaluated as a single agreement. The Company used the &#8220;Finnerty&#8221; and &#8220;Asian put&#8221; valuation models and determined the fair value for the discount for lack of marketability (&#8220;DLOM&#8221;) was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uXbjzY_AUkS5DM3UL80JAA" decimals="-5" format="ixt:numdotdecimal" name="chrs:FairValueForDiscountForLackOfMarketability" scale="6" id="Narr_uej47OIMPUKew5UBHjUc9Q">9.0</ix:nonFraction> million at the date the shares were issued. The fair value of the DLOM was attributable to the Collaboration Agreement and was included as an offset against the research and development expense in the consolidated statements of operations for the year ended December 31, 2021.<span style="background:#ffffff;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Bioeq</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On November&#160;4, 2019, the Company entered into the Bioeq Agreement with Bioeq for the commercialization of a biosimilar version of ranibizumab (Lucentis) in certain dosage forms in both a vial and pre-filled syringe presentation. Under this agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. Bioeq will supply to the Company the Bioeq Licensed Products in accordance with terms and conditions specified in the agreement and a manufacturing and supply agreement to be executed by the parties in accordance therewith. The agreement&#8217;s initial term continues in effect for<ix:nonNumeric contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_yd1vkuCA00aL3Hm8mfet-Q" format="ixt-sec:durwordsen" name="chrs:InitialTermOfAgreement" id="Narr_G790GjothEe6ivwUR4Vyvw"> ten years </ix:nonNumeric>after the first commercial sale of a Bioeq Licensed Product in the United States, and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Bioeq will manufacture and supply the Bioeq Licensed Products to the Company in accordance with terms and conditions specified in the Bioeq Agreement and the Bioeq Manufacturing Agreement and will remain in force until the first to occur of the following: (1) the </p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk124324288"></a><ix:continuation id="Tb_w_qQcpZTHES3MUqrG0SmdA_cont2" continuedAt="Tb_w_qQcpZTHES3MUqrG0SmdA_cont3"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">termination of the Bioeq Agreement; (2) the exercise of a right to termination by the Company or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Under the agreement, Bioeq was required to use commercially reasonable efforts to develop and obtain regulatory approval of the Bioeq Licensed Products in the United States in accordance with a development and manufacturing plan, and the Company was required to use commercially reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Additionally, the Company was required to commit certain pre-launch and post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The Company paid Bioeq an upfront and a milestone payment aggregating to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_7mQuJY0wwEqgj61CikPPcw" decimals="-6" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr__Axr2EQq0UGfxCzeep0E_w">10</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_7mQuJY0wwEqgj61CikPPcw" decimals="-5" format="ixt:numdotdecimal" name="chrs:UpfrontAndMilestonePayment" scale="6" id="Narr_lnXgjpbXxkaroq1wXR4_5g">11.1</ix:nonFraction>&#160;million), which was recorded as research and development expense in the Company&#8217;s consolidated statements of operations in 2019. The terms of the Bioeq Agreement include an aggregate of up to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg" contextRef="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_1YkpEyUoQUqaZRiv-_dAXg" decimals="-5" format="ixt:numdotdecimal" name="chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" scale="6" id="Narr_mlpn4ycQykS0ECzrkYAwpw">12.5</ix:nonFraction>&#160;million in additional milestone payments in connection with the achievement of certain development and regulatory milestones with respect to the Bioeq Licensed Products in the United States including a &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rKbabCHH6U2-QciM6M39Sw" decimals="-5" format="ixt:numdotdecimal" name="chrs:AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" scale="6" id="Narr_NSETKAWkSkObraL1pTcFYw">2.5</ix:nonFraction> million milestone related to the FDA approval of the CIMERLI Section 351(k) BLA that was paid in 2022. The Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_yd1vkuCA00aL3Hm8mfet-Q" decimals="2" format="ixt-sec:numwordsen" name="chrs:PercentageOfGrossProfitsOnSales" scale="-2" id="Narr_YWHiogo06UikeP7FoynEbw">fifty</ix:nonFraction>&#160;percent range. Royalties due to Bioeq were $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_OO5lQg6WOEqa5rle5GaCfQ">38.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_RcbOLK6Tr02V9KadOJHYFw">2.9</ix:nonFraction> million as of December 31, 2023 and 2022, respectively. The remaining milestone payments are contingent upon future events and, therefore, will be recorded when it becomes probable that a milestone will be achieved. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Adimab Development and Option Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In October 2018, Surface and Adimab entered into the A&amp;R Adimab Agreement, which amended and restated the Original Adimab Agreement, for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the A&amp;R Adimab Agreement, the Company will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. The A&amp;R Adimab Agreement, among other things, extended the discovery term of the Original Adimab Agreement, provided access to additional antibodies, and expanded the Company&#8217;s right to evaluate and use antibodies that were modified or derived using Adimab technology for diagnostic purposes.&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Upon the Company&#8217;s selection of a target, the Company and Adimab will initiate a research plan and the discovery term begins. During the discovery term, Adimab will grant the Company a non-exclusive, non-sublicensable license under its technology with respect to the target, to research, design and preclinically develop and use antibodies that were modified or derived using Adimab technology, solely to evaluate such antibodies, perform the Company&#8217;s responsibilities under the research plan, and use such antibodies for certain diagnostic purposes. The Company also will grant to Adimab a non-exclusive, nontransferable license with respect to the target under the Company&#8217;s technology that covers or relates to such target, solely to perform its responsibilities under the research plan during the discovery period. The Company is required to pay Adimab at an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Adimab granted the Company the Research Option. In addition, Adimab granted the Company the Commercialization Option. Upon the exercise of a Commercialization Option, and payment of the applicable option fee to Adimab, Adimab will assign the Company the patents that cover the antibodies selected by such Commercialization Option. The Company will be required to use commercially reasonable efforts to develop, seek market approval of, and commercialize at least&#160;<ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" decimals="INF" format="ixt-sec:numwordsen" name="chrs:MinimumAntibodiesToBeCommercializedUnderCommercializationOption" scale="0" id="Narr_1oCyBn_yzUC60twQknFsjw">one</ix:nonFraction>&#160;antibody against the target covered by the Commercialization Option in specified markets upon the exercise of a Commercialization Option.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the A&amp;R Adimab Agreement, the Company is obligated to make milestone payments and to pay specified fees upon the exercise of the Research Option or Commercialization Option. During the discovery term, the Company may be obligated to pay Adimab up to&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" scale="6" id="Narr_q-Th8oUHbk6_Nk9Rab2FTg">0.3</ix:nonFraction>&#160;million&#160;for technical milestones achieved against each biological target. Upon exercise of a Research Option, the Company is obligated to pay a nominal research maintenance fee on each of the next <span style="-sec-ix-hidden:Hidden_RNOKr2yfgEaTSaGdgRnfUQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span>&#160;anniversaries of the exercise. Upon the exercise of each Commercialization Option, the Company will be required to pay an option exercise fee of a low seven-digit dollar amount, and the Company may be responsible for milestone payments of up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" scale="6" id="Narr_4k8dv76eykyYVnlz-eNaXw">13.0</ix:nonFraction>&#160;million&#160;for each licensed product that receives marketing approval. For any licensed product that is commercialized, the Company is obligated to pay Adimab tiered royalties of a low to mid single-digit percentage on worldwide net sales of such product. The Company may also partially exercise a Commercialization Option with respect to&#160;<ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" decimals="INF" format="ixt-sec:numwordsen" name="chrs:MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" scale="0" id="Narr_1C6JyOhaFE2SECbnJvoHHg">ten</ix:nonFraction>&#160;antibodies against a biological target by paying&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" decimals="2" format="ixt:numdotdecimal" name="chrs:PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" scale="-2" id="Narr_vz--7yNCi0WFnuI4-DpQKA">65</ix:nonFraction>% of the option fee and later either (i)&#160;paying the balance and choosing additional antibodies for commercialization, up to the maximum number under the Commercialization Option, or (ii)&#160;foregoing the Commercialization Option entirely. For any Adimab diagnostic product that is used with or in connection with any compound or product other than a licensed antibody or licensed product, the Company is obligated to pay Adimab up to a low seven digits in regulatory milestone payments and low </p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_w_qQcpZTHES3MUqrG0SmdA_cont3" continuedAt="Tb_w_qQcpZTHES3MUqrG0SmdA_cont4"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">single-digit royalties on net sales.&#160;<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" decimals="-5" format="ixt-sec:numwordsen" name="chrs:CollaborationAgreementAdditionalPaymentToBeMade" scale="6" id="Narr_5yQmxQUZT0m_uuZqSp6rZw">No</ix:nonFraction>&#160;additional payment is due with respect to any companion diagnostic or any diagnostic product that does not contain any licensed antibody.&#160;Any payments payable to Adimab as a result of any product candidates being developed pursuant to the GSK Agreement, will be payable to Adimab directly by GSK.&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The A&amp;R Adimab Agreement will remain in effect until (a)&#160;the earlier of (i)&#160;the expiration of the Research and Commercialization Options (if they expire without exercise) and (ii)&#160;<ix:nonNumeric contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" format="ixt-sec:durwordsen" name="chrs:CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" id="Narr_kv0p4zwYYU6FBvEacynlQg">12 months</ix:nonNumeric>&#160;from the effective date without the Company providing materials that pass Adimab&#8217;s quality control; or (b)&#160;if a Research Option is exercised but the Commercialization Option is not, then upon the expiration of the last to expire research license term; or (c)&#160;upon commercialization of a product, until the end of the royalty term, which will vary on a product-by-product and country-by-country basis, ending on the later of (y)&#160;the expiration of the last valid claim covering the licensed product in such country as the product is manufactured or sold, or (z)&#160;<ix:nonNumeric contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w" format="ixt-sec:durwordsen" name="chrs:CollaborationAgreementTerm" id="Narr_ikJCUFBFM06kURL8nPAXuw">ten&#160;years</ix:nonNumeric> after the first commercial sale of the licensed product in such country.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Either party may terminate the A&amp;R Adimab Agreement for material breach if such breach remains uncured for a specified period of time, however, if a Research Option or Commercialization Option has been exercised and the breach only applies to the applicable target of such Research Option or Commercialization Option, then the termination right will only apply to such target. The Company may also terminate the A&amp;R Adimab Agreement for any reason with prior notice to Adimab. If Adimab is bankrupt, the Company will be entitled to a complete duplicate of, or complete access to, all rights and licenses granted under or pursuant to the A&amp;R Adimab Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Vaccinex License Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On March 23, 2021, Surface and Vaccinex entered into the Vaccinex License Agreement which provides the Company a worldwide, exclusive, sublicensable license to make, have made, use, sell, offer to sell, have sold, import, and otherwise exploit Vaccinex Licensed Products, including the antibody CHS-114 targeting CCR8. Under the Vaccinex License Agreement, the Company is obligated to use commercially reasonable efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at least one Vaccinex Licensed Product.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company is responsible for all costs and expenses of such development, manufacturing and commercialization. Vaccinex is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_23_2021_To_3_23_2021_us-gaap_TypeOfArrangementAxis_chrs_VaccinexLicenseAgreementMember_WDAN8bKZtkOa0CTw_Zz0iA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" scale="6" id="Narr_Iv_ui31oU0yJyc6MEddLcw">3.5</ix:nonFraction> million based on achievement of certain clinical milestones, up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_23_2021_To_3_23_2021_us-gaap_TypeOfArrangementAxis_chrs_VaccinexLicenseAgreementMember_WDAN8bKZtkOa0CTw_Zz0iA" decimals="-5" format="ixt:numdotdecimal" name="chrs:RegulatoryMilestonesEligibleToPay" scale="6" id="Narr_yISJa1AYikeVI-RMXOCknw">11.5</ix:nonFraction> million based on achievement of certain regulatory milestones per Vaccinex Licensed Product, and low single-digit royalties on global net sales of any approved licensed products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company may terminate the Vaccinex License Agreement for convenience upon the notice period specified in the Vaccinex License Agreement. Either party may terminate the agreement for an uncured material breach by the other party. Vaccinex may terminate the Vaccinex License Agreement if we default on any payments owed to Vaccinex under the agreement, if the Company is in material breach of, and fails to cure, its development obligations, or institute certain actions related to the licensed patents. In the event of termination, all rights in the licensed intellectual property would revert to Vaccinex.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Out-Licensing Agreements Acquired as part of the Surface Acquisition</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;">On September 8, 2023, at the closing of the Surface Acquisition, all the assets, liabilities, rights and obligations of Surface were assumed by the Company&#8217;s direct, wholly-owned subsidiary, Surface Oncology, LLC. See further details in Note 6. Surface Acquisition above.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Novartis Institutes</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;">In January 2016, Surface entered into the&#160;Novartis Agreement. Pursuant to the Novartis Agreement, Surface granted Novartis Institutes a worldwide exclusive license to research, develop, manufacture and commercialize antibodies that target cluster of differentiation 73 (&#8220;CD73&#8221;). Under the Novartis Agreement, the Company is currently entitled to potential development milestones of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_0C2GDS067kqyEScTv50pUg" decimals="-5" format="ixt:numdotdecimal" name="chrs:PotentialDevelopmentMilestonesEntitled" scale="6" id="Narr_jW9q7N5mX0Clq54sv_Ayhg">325.0</ix:nonFraction>&#160;million&#160;and sales milestones of&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_0C2GDS067kqyEScTv50pUg" decimals="-5" format="ixt:numdotdecimal" name="chrs:SalesMilestonesEntitled" scale="6" id="Narr_n784x_CcmEq1pdCNtTOqDA">200.0</ix:nonFraction>&#160;million, as well as tiered royalties on annual net sales by Novartis Institutes ranging from high single-digit to mid-teens percentages upon the successful commercialization of NZV930. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the Novartis Agreement. The Company did&#160;not&#160;recognize any revenue relating to the Novartis Agreement from September 8, 2023 through December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;">Unless terminated earlier, the Novartis Agreement will continue in effect until neither the Company nor Novartis Institutes is researching, developing, manufacturing or commercializing NZV930. Novartis Institutes may terminate the Novartis Agreement for any or </p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_w_qQcpZTHES3MUqrG0SmdA_cont4"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">no reason upon prior notice to the Company within a specified time period. Either party may terminate the Novartis Agreement in full if an undisputed material breach is not cured within a certain period of time or upon notice of insolvency of the other party. To the extent Novartis Institutes terminates for convenience, or the Company terminates for Novartis Institutes&#8217; uncured material breach, Novartis Institutes will grant the Company, on mutually agreeable financial terms, an exclusive, worldwide, irrevocable, perpetual and royalty-bearing license with respect to intellectual property controlled by Novartis Institutes that is reasonably necessary to research, develop, manufacture or commercialize NZV930.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">GSK Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"><span style="color:#231f20;">In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies. GSK is responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee was formed to facilitate information sharing. GSK is responsible for all costs and expenses of such development, manufacturing and commercialization and is obligated to provide the Company with updates on its development, manufacturing and commercialization activities through the joint development committee.&#160;</span>In March 2022, Surface earned a&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2022_To_3_31_2022_dei_LegalEntityAxis_chrs_SurfaceMember_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_gfCoLb-ssE-NI0WQHzEhdQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementMilestonePaymentsEarned" scale="6" id="Narr_N7FpAsw1M0iv9OR-EbNGvA">30.0</ix:nonFraction>&#160;million&#160;milestone payment from GSK upon the dosing of the first patient in the Phase 1 trial of GSK4381562. The Company is eligible to receive up to&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" scale="6" id="Narr_VTIHWcypCkuEf_EzUtaMDw">60.0</ix:nonFraction>&#160;million&#160;in additional clinical milestones and&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CollaborationAgreementRegulatoryMilestonesEligibleToReceive" scale="6" id="Narr_nN0FwtxS4kKvg1_PlLJjIw">155.0</ix:nonFraction>&#160;million&#160;in regulatory milestones. In addition, the Company may receive up to&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA" decimals="-5" format="ixt:numdotdecimal" name="chrs:SalesMilestonesEntitled" scale="6" id="Narr_pzqBmM6gWEWtJtIqf2Ff3g">485.0</ix:nonFraction>&#160;million in sales milestone payments. The Company is also eligible to receive royalties on global net sales of any approved products based on the Licensed Antibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the GSK Agreement.&#160;The Company did&#160;not recognize license-related revenue under the GSK Agreement from September 8, 2023 through December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later of&#160;<ix:nonNumeric contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_GKvVg5Ic6ES4-RDKrSHttg" format="ixt-sec:durwordsen" name="chrs:CollaborationAgreementTerm" id="Narr_-9Y6rulVnEq0ZNqLenwq2Q">ten&#160;years</ix:nonNumeric>&#160;from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. The Company may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, the Company would regain worldwide rights to the terminated program.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f4c02f6d_7163_42a4_a029_661f495b56b8"></a><a id="Tc_GNcYz2I2_UGBqcz9nVKFFQ_1_1"></a><a id="Tc_iOBPcOApxUWZyyjAZC-B0Q_2_0"></a><a id="Tc_WxtR82n-5USMO0uOh71DZw_2_1"></a><a id="Tc_1HQwBLeTt0KRDbcb8XVYFw_2_5"></a><a id="Tc_TV5lOjXcIkW3AQZacnb4tg_2_7"></a><a id="Tc_PQxFlmR3wUODmjzXFoSFew_2_10"></a><a id="Tc_luPQM81NE0Wq8ZZBM9lDqg_2_13"></a><a id="Tc__rPlwUH880eAJVcxr3qP9A_3_0"></a><a id="Tc_UR6fuqyazkmk4T6PH6-Kgg_4_0"></a><a id="Tc_JfuZtxrA_kqftAOxHzFkGQ_4_1"></a><a id="Tc_QZlGdnaNYkWgbTu2KCe71Q_4_4"></a><a id="Tc_Mx_25jIhzEKaurt1SH7dqA_4_7"></a><a id="Tc_mG-1BrK1WkmcYRIOiSykGw_4_10"></a><a id="Tc_ABwdUBK85EacvkD6knYPkA_4_13"></a><a id="Tc_wOLXn79tQ0u8LNHJ1aQyHg_5_0"></a><a id="Tc_38n7rnqmGUGwSUl0_wzzFw_5_1"></a><a id="Tc_UgnyeD9ADk-3zm-a83aQqA_5_4"></a><a id="Tc_Kyv0esv2q0614ILql_VHsw_5_7"></a><a id="Tc_fBHjP7qGJUK5C75Uft5ZFA_5_10"></a><a id="Tc_8ngyV9SHN06g5Mm_UgmnsA_5_13"></a><a id="Tc_SqMsirCi7kqlUajcgqINMQ_7_1"></a><a id="Tc_aZPbLpdGxECYIWXjBenhBA_8_0"></a><a id="Tc_Eq2INT98gkSunT8qKvI1sA_8_1"></a><a id="Tc_Ymfs0R5sRk6lpWHeclTi6A_8_4"></a><a id="Tc_CT3mfeR-nkq0DQ2QOdRCRg_8_7"></a><a id="Tc_pPNigeSh6UCOzI7J6f19hg_8_10"></a><a id="Tc_JYh21mXWXkydbaWocClutA_8_13"></a><a id="Tc_iusr5giJ9UKY3yzhcbkmdg_9_0"></a><a id="Tc_63qLx3d5IECH90HI2mYmdA_10_0"></a><a id="Tc__geNGS7jYkaYsaE2X7rHfg_10_1"></a><a id="Tc_EK1xHP7CdkmGNVXCR3hThQ_10_4"></a><a id="Tc_ZCPCgfUwWEiH1ybetZ5ITQ_10_7"></a><a id="Tc__O0jk8YyQEKLhlXgb6aDJQ_10_10"></a><a id="Tc_-wldqiGKTE6WHHoxijPurw_10_13"></a><a id="Tc_3EXI_NGuPUGEZKLAJv9bww_11_0"></a><a id="Tc_LjuPGbr8bEi6Dlqrlyxnng_11_1"></a><a id="Tc_a2YGrF-qqEmN5nT8I2ltWA_11_4"></a><a id="Tc_3YSfvpFa8kWRGeEPzqk2nQ_11_7"></a><a id="Tc_C2LQuxVSVEWmcYZ1Csgzlw_11_10"></a><a id="Tc_TtVunB4TakGTtsMEdXN4nw_11_13"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_I5mOANR7bUmU7ZGEzLdCkA" continuedAt="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span>Debt Obligations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s debt obligations, including level within the fair value hierarchy (see Note 3. Fair Value Measurements), is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="Tb_YwWxmFcdhkWpNoTvVvKAKA" continuedAt="Tb_YwWxmFcdhkWpNoTvVvKAKA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2023</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial Liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 Term Loans</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_eHMqb11O8keiTbfq-owgSQ_4_2">250,000</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_SgLZjfprAk-hpn0KrcmV_Q_4_5">3,519</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_V4AE93jqSUOUGICRaHxSgQ_4_8">246,481</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_JD5BjlwBrUCZGQfkTW5UuA_4_11">246,481</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2*</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 Convertible Notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_5nEgwbb7cE2QDBJlZrcjug_5_2">230,000</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_CG-l5GMnBkiBTW_lYJPJFg_5_5">3,112</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_GMQRlIrfPECTJZBcSvYqFQ_5_8">226,888</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_9SexfL9M8UG1Q3DMfXntOA_5_11">150,155</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2**</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December 31, 2022</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial Liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 Term Loans</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_HPZ7FYE7g0yrS9Zshbbzeg_10_2">250,000</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_ubsol1rpl0aDWlU2zLfHjw_10_5">4,517</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_W4Xohv5LQ0GYIX7nH3B-mw_10_8">245,483</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc_ARMAeoWtBE--ftoWmr_xzg_10_11">245,483</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2*</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 Convertible Notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_-ch-sjvNNkmSxk-vOjOYAg_11_2">230,000</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_u4RmDjsnFkCC_bBecVDx6A_11_5">4,425</ix:nonFraction>)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_TxELvigr30amjG55UxBnsQ_11_8">225,575</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Tc__w2bbRPICEqzfZEvMTsL0w_11_11">157,205</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2**</p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:98.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">*</p></td><td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The principal amounts outstanding are subject to variable interest rates, which are based on three-month SOFR starting April 1, 2023 plus fixed percentages. Through March 31, 2023, the variable component was based on the three-month LIBOR. Therefore, the Company believes the carrying amount of these obligations approximates fair value.</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont1" continuedAt="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont2"><ix:continuation id="Tb_YwWxmFcdhkWpNoTvVvKAKA_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr><td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">**</p></td><td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>The fair value is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs.</p></td></tr></table></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2027 Term Loans </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into the Loan Agreement with BioPharma Credit, PLC, BPCR Limited Partnership, and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC that provides for a senior secured term loan facility of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wOrFEBBx0kqCfY3Jfb9mmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_hEZXPnsghUeVWDpwbJcYZw">300.0</ix:nonFraction> million to be funded in <ix:nonFraction unitRef="Unit_Standard_tranche_ZKmzrBOMS0eN5e6PQhEzOA" contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wOrFEBBx0kqCfY3Jfb9mmA" decimals="INF" format="ixt-sec:numwordsen" name="chrs:DebtInstrumentNumberOfTranches" scale="0" id="Narr_ASjPysY0nkqWfodcNzGEsw">four</ix:nonFraction> committed tranches: (i) the Tranche A Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_UbIxb6J1Y0GS_zqAinL_8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_cLZphGajWkG8nlgaOkUycQ">100.0</ix:nonFraction> million that was funded on January 5, 2022; (ii) the Tranche B Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_M-uRNszAXEi9r-8LL3xQhw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_Y8G3DTEGfkiXiQU7_flc0g">100.0</ix:nonFraction> million that was funded on March 31, 2022; (iii) the Tranche C Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember__qTNMulPqkyLxoNEOq3P_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" scale="6" id="Narr_HV0EaZdJ_0Ogz9TWuJjTFg">50.0</ix:nonFraction> million that was not funded; and (iv) the Tranche D Loan in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_cTMkGi5D4E2X87OVhy9Ppg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_R8YPQpnNT0CiwMJmqtNEmw">50.0</ix:nonFraction> million that was funded on September 14, 2022. The Company has the right to request an uncommitted additional facility amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_aM31ORVDHEOXDbOoQGO-Eg" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtInstrumentUncommittedAdditionalFacility" scale="6" id="Narr_DHWB-qcJzUq6o6AdcFCy6w">100.0</ix:nonFraction> million that is subject to new terms and conditions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company&#8217;s 2026 Convertible Notes is greater than $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bYNDamUcsk2slttHQRFDdQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_jlvJ4D7Cy0KuUE8JjarUwQ">50.0</ix:nonFraction> million on October 1, 2025. The 2027 Term Loans accrued interest from inception through March 31, 2023 at <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_DixWwtQqF0uRVadXYuAfNw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_FVX6NmgL7EiXUD2ePDoJbA">8.25</ix:nonFraction>% plus three-month LIBOR per annum with a LIBOR floor of <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_chrs_ThreeMonthLiborMember_SFCa5VQ500OXf47jZb2Inw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_BqZkSmXxwEWREWdgcO_8og">1.0</ix:nonFraction>%; and starting April 1, 2023, accrue interest at <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4w3mHtTbxUO8oH0eEffh_g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_yBYBf_VPuU-NZ3gJ3rgp2Q">8.25</ix:nonFraction>% plus the Adjusted Term SOFR which is the sum of three-month SOFR and <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr_Od42J0PXj06d9y-0l6s04g">0.26161</ix:nonFraction>% per annum, with a floor on Adjusted Term SOFR of <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_eqjDn0zFdkmGjjeY_jrdCw">1.0</ix:nonFraction>%. The interest rate for the fourth quarter of 2023 was <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr_6qRqd2IlxUKyy2ajzKvx0g">13.91</ix:nonFraction>%. Interest is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The obligations under the Loan Agreement are secured pursuant to customary security documentation, including a guaranty and security agreement among the Credit Parties and the Collateral Agent which provides for a lien on substantially all of the Company&#8217;s tangible and intangible assets and property, including intellectual property.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Loan Agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were used to fund the Company&#8217;s general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to repay in full all amounts outstanding under the 2025 Term Loan, as well as all associated costs and expenses pursuant to which a payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_bli3D_4p8Eu4TDVPspP6-w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_hdZg6Me3oEamhpHzgF0cFg">81.9</ix:nonFraction>&#160;million was outstanding; in March 2022, proceeds of the Tranche B Loan were drawn in connection with the full repayment of all amounts outstanding under the&#160;2022 Convertible Notes, as well as all associated costs and expenses pursuant to which a payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_iNYzqa07B0qe7COlXQZa1w">111.1</ix:nonFraction> million was outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Loan Agreement contains certain customary representations and warranties. In addition, the Loan Agreement includes covenants, such as the requirement to maintain minimum trailing twelve-month net sales in an amount that began at $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodOne" scale="6" id="Narr_35F5vc5d9Ui3lSzXc8qrZQ">200.0</ix:nonFraction>&#160;million for the quarter ending March 31, 2022 and increases to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodTwo" scale="6" id="Narr_I-BA23jajUu0sE2g4JG9bg">210.0</ix:nonFraction>&#160;million for the quarter ended March 31, 2024. As a result of the Consent and Amendment entered into on February 5, 2024, beginning in the second quarter of 2024 and continuing through the quarter ended December 31, 2026, the requirement is to maintain minimum trailing twelve-month net sales of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_2_5_2024_To_2_5_2024_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_otbpUOnq8EKYMPXpah8q6g" decimals="-5" format="ixt:numdotdecimal" name="chrs:LoanAgreementCovenantsNetSalesForPeriodThree" scale="6" id="Narr_ZBrjhRuXh0ejMMWroU1MnQ">125.0</ix:nonFraction> million. In addition, there is a requirement to maintain a minimum trailing twelve-month net sales for LOQTORZI tested quarterly at the end of each quarter commencing with the quarter ended December 31, 2024. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, <span style="background:#ffffff;">make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. The Loan Agreement also contains customary events of default, including among other things, the Company&#8217;s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or its breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#8217;s obligations under the Loan Agreement. A change of control of the Company triggers a mandatory prepayment of the 2027 Term Loans within&#160;</span><span style="-sec-ix-hidden:Hidden_9sZZOOI5Ik6UXQMv7GKoqA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">ten</span></span><span style="background:#ffffff;">&#160;business days. See Note 17. Subsequent Events for further information regarding the Consent and Amendment to the 2027 Term Loans. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company was in full compliance with these covenants and there were no events of default under the 2027 Term Loans.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the closing of Tranche A, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_MV06IYXPdkmqFzBkwhBAXA" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtDiscountsAndIssuanceCosts" scale="6" id="Narr_L1yH75F1ik6gbB4rVqcSKg">7.8</ix:nonFraction> million&#160;in debt discounts and issuance costs<span style="color:#ff0000;"> </span>of which $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtDiscountsAndIssuanceCosts" scale="6" id="Narr_yjkkpW2rwUikjsSz1N2-3g">6.8</ix:nonFraction> million related to all the tranches of the 2027 Term Loans and was thus allocated pro rata between the tranches. The unamortized debt </p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_bhlLckIhVUyaQKomuGlo1Q_1_2"></a><a id="Tc_ODItFLImR0WTKdid7elaKQ_2_0"></a><a id="Tc_QCTu3KoNiEOATcySrIX5iw_2_2"></a><a id="Tc_ibi4IE1lD06QdtLeP7bWCw_2_5"></a><a id="Tc_E-0PZGNpykS76lHlnPFQrQ_3_0"></a><a id="Tc_6cdYcVaWGUOlvaZzs1Uwsg_3_2"></a><a id="Tc_-BPVh7F5s0-rSc1MoLnnIw_3_5"></a><a id="Tc_swdo56Pyw0-6a4oRDcwPqQ_4_0"></a><a id="Tc_dRlJWQvNUEG72F87WLMxuw_5_0"></a><a id="Tc_Lcb2xsUeJU-pCzVYOLkyPA_5_2"></a><a id="Tc_8soZJ838SUSfEtEiQa7w6Q_5_5"></a><a id="Tc_q0Si_FGYw0-WcjbrC5iFWA_1_0"></a><a id="Tc_A7SA4UGlG0yzwqr4fEbRdQ_2_0"></a><a id="Tc_mmWSEfQDHEaSEiT1R026-Q_2_2"></a><a id="Tc_2ouY9ac_c0e6530m98N1hw_3_0"></a><a id="Tc_xXUaNT4I6UKmRcgmgCAmHw_4_0"></a><a id="Tc_oLYmS-sL7kmWWr0jEUuFrA_5_0"></a><a id="Tc_cJD7nN1VoEWmTv8hfzEO0A_6_0"></a><a id="Tc_QpugGhzSz0SwrN7FNSr-fQ_7_0"></a><a id="Tc_OH4Li1RgI0y5ae8SWMzHpg_8_0"></a><a id="Tc_e84dXjDP8E2bN9mLSuHwPw_9_0"></a><a id="Tc_WNg7GwLCuE61VXTLSxpiuw_10_0"></a><a id="Tc_GAhoTi7-q0mR5Dp7OjlD_w_10_2"></a><ix:continuation id="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont2" continuedAt="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont3"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">discount and issuance costs allocated to funded tranches are presented as deductions to the 2027 Term Loan balance and are amortized into interest expense using the effective interest method. The $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_F3uuUNoynEGVqfaLmbmpNQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebtDiscountsAndIssuanceCosts" scale="6" id="Narr_HlZy3MYzxE26CAEEBTcRnA">2.3</ix:nonFraction> million allocated to Tranche B was fully amortized over the commitment period prior to funding and recognized as interest expense in the first quarter of 2022. The associated debt discounts and issuance costs of unfunded tranches were deferred as assets and amortized into interest expense using the straight-line method over the commitment period of the respective tranches. At the closing dates of Tranche B on March 31, 2022 and Tranche D on September 14, 2022, the Company incurred an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_M-uRNszAXEi9r-8LL3xQhw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_XjxxPSlMw06f2wct5VLHGA">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_cTMkGi5D4E2X87OVhy9Ppg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_Qb5IYrPnYkiKySJjUFW7og">0.5</ix:nonFraction> million, respectively,&#160;in debt issuance costs. As of December 31, 2023, the total remaining unamortized debt discount and debt offering costs related to Tranches A, B and D of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_Z0wbfOYnWk6X7ZFZMIo1Gg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_UdzNLybWp068_sS81aaXSQ">3.5</ix:nonFraction> million will be amortized using the effective interest rate over the remaining term of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_OaNk_89S-kO2L5QxklSuhw" format="ixt-sec:duryear" name="chrs:DebtInstrumentRemainingTerm" id="Narr_Rr9Fmn2PEEmZxIRxR6YfVw">3.0</ix:nonNumeric> years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense related to the 2027 Term Loans: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JoIcCfI8pEKowyCw3vvEBg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_F-ABxmq_j0SFhveWHzXJaQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_o3Ya2B-88EOw73_sT7CGSA_3_3">34,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_07e-GI10u0qHW6fBZNicJA_3_6">20,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_7GP2UIBVB0iX1WRRYgy31g_4_3">1,094</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_qP-UgXEj8ky0c76m7Cxeeg_4_6">4,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_bJUiqnAuAkCMdAu_tHEsbw_5_3">35,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_65jHJMCdlk-OisnUFd2l0Q_5_6">24,793</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming the fourth quarter of 2023 interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr__PUrstQfrEqL8OfZefo_8A">13.91</ix:nonFraction>%, future payments on the 2027 Term Loans as of December 31, 2023, are as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JoIcCfI8pEKowyCw3vvEBg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_sP_Ye0zmNEKJTz0ImkzO4g" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_XABaMJ4m-kGuEQBUF7WG1A_2_3">35,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_p5XxgQBWuEi_7c4l-8RfVA_3_3">35,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_nORhZFhY50OCmRnrb1zaag_4_3">224,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="Tc_JkiWdEhj30uwSD8Pmiknig_5_3">50,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_ojwjT3ikSkOGJ55QioHUjA_6_3">345,297</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Tc_g2kIBYuNhkyVmyVgB-DC0Q_7_3">95,297</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 Term Loans, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="chrs:TermLoanGross" scale="3" id="Tc_yq3Yc_n-CEaPqW2N_2OeEQ_8_3">250,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_IhZG4ua2WESIJ-d3X8ux1Q_9_3">3,519</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_0jEEAEK0zUi4qGSwvKCexQ_10_3">246,481</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The table above does not reflect any adjustment for transactions contemplated by the Consent and Amendment entered into on February 5, 2024, including any prepayments to the 2027 Term Loans. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_l9R3IriyEk6Ur5IPqhRstg">1.5</ix:nonFraction>%</b><b style="font-weight:bold;"> Convertible Senior Subordinated Notes due 2026</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In April 2020, the Company issued and sold </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_s3HPntZDe0SMvUDaBmmzIQ">230.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million aggregate principal amount of its&#160;2026 Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="Narr_VLfvzcNlnEijrSPahAIAMg">222.2</ix:nonFraction></span><span style="background:#ffffff;">&#160;million after deducting initial purchasers&#8217; fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company&#8217;s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and&#160;structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables.&#160;</span><ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ" name="us-gaap:DebtInstrumentInterestRateTerms" id="Narr_Yr-hZg_RukmVKt6CtLtgIw"><span style="background:#ffffff;">The 2026 Convertible Notes accrue interest at a rate of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_vVWNjIjyz0eUFEnWm2Ybxg">1.5</ix:nonFraction>%</span><span style="background:#ffffff;"> per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020</span></ix:nonNumeric><span style="background:#ffffff;">, and will mature on&#160;</span><ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr_RCA--MMQaUS_RhrTtbpcWQ"><span style="background:#ffffff;">April 15, 2026</span></ix:nonNumeric><span style="background:#ffffff;">, unless earlier repurchased or converted.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company&#8217;s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. The initial conversion rate is&#160;<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A" decimals="INF" format="ixt:numdotdecimal" name="chrs:DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" scale="0" id="Narr_TwI0rfpaDU-jcMADrf_CbQ">51.9224</ix:nonFraction>&#160;shares of common stock per $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A" decimals="0" format="ixt:numdotdecimal" name="chrs:PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" scale="0" id="Narr_Wp4LTkyXhEaxJwytGpTIhQ">1,000</ix:nonFraction>&#160;principal amount of the 2026 Convertible Notes, which represents an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ" decimals="2" format="ixt:numdotdecimal" name="chrs:EquivalentToConversionPricePerCommonShare" scale="0" id="Narr_nS5CpqS17Uir_xRMuSUOyw">19.26</ix:nonFraction>&#160;per share of common stock. The initial conversion price represents a premium of approximately&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ" decimals="3" format="ixt:numdotdecimal" name="chrs:PercentageOfPremiumOnConvertibleNote" scale="-2" id="Narr_ZaMqW9VvP0O0bu9Uc78WZg">30.0</ix:nonFraction>% over the last reported sale of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_4_14_2020_lOYMm8IewEGa7ecW7rCQ6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4zuNAzNU0EipdLhkYOB8_A">14.82</ix:nonFraction>&#160;per share of the Company&#8217;s common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a &#8220;make-whole fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company&#8217;s election before maturity. If a &#8220;fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, </p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Wptk_4wcckO1m7eUCID5mw_1_2"></a><a id="Tc_zS_VIlRSKkOvNDyXhiK-8Q_2_0"></a><a id="Tc_ES1RwA-8E0Cg2CxLvK6ByQ_2_2"></a><a id="Tc_ocmwBghUZUKOxPedQJICEA_2_5"></a><a id="Tc_mmFoLehTv0GNWSplV0os0w_2_8"></a><a id="Tc_eRKeXUxXgEWFsHUT5GgNHw_3_0"></a><a id="Tc_E61IRZvTfkeSuhuSpA2G7A_3_2"></a><a id="Tc_980AkcSgMkG45tI4s_5Oxg_3_5"></a><a id="Tc_2ZT4Zb7bbEOPvGjhgyUD0A_3_8"></a><a id="Tc_Etc-u7MfNUyEZ25NUouCSQ_4_0"></a><a id="Tc_MNly4PG8r0u0rbIi11dbDg_5_0"></a><a id="Tc_cGQq5H-GEU2HdgCOAmsxng_5_2"></a><a id="Tc_tqSgvXtjVk6AZBIjYGCAYQ_5_5"></a><a id="Tc_Qewsvi8SeEOUsuPn30d3eQ_5_8"></a><ix:continuation id="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont3" continuedAt="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont4"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The 2026 Convertible Notes have customary provisions relating to the occurrence of &#8220;events of default&#8221; (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw" name="us-gaap:DebtInstrumentCovenantCompliance" id="Narr_C-EVjBbBfEi9Ik0xac7JCQ">As of December 31, 2023, the Company was in full compliance with these covenants, and there were <ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_0bsmQzQVxkiRBstBPBwZjw" decimals="INF" format="ixt-sec:numwordsen" name="chrs:NumberOfEventsInDefault" scale="0" id="Narr_CBwXxUMVSUe_bwMUMihq6Q">no</ix:nonFraction> events of default under the 2026 Convertible Notes.</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated the features embedded in the 2026 Convertible Notes under the relevant accounting rules&#160;and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. The proceeds received from the issuance of the convertible debt were recorded as a liability in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Capped Call Transactions</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the pricing of the 2026 Convertible Notes, the Company paid </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA" decimals="-5" format="ixt:numdotdecimal" name="chrs:PaymentForCappedCallTransactions" scale="6" id="Narr_xB0NBVfuxkiNN3DAkyv-8Q">18.2</ix:nonFraction></span><span style="background:#ffffff;">&#160;million to enter into privately negotiated capped call transactions with&#160;one&#160;or a combination of the initial purchasers, their respective affiliates and other financial institutions. The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA" decimals="2" format="ixt:numdotdecimal" name="chrs:CapPriceOfCapCallTransactions" scale="0" id="Narr_V65YhxevjUiRlFwQVY1WDw">25.93</ix:nonFraction></span><span style="background:#ffffff;">&#160;per share, which represents a premium of approximately&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA" decimals="3" format="ixt:numdotdecimal" name="chrs:PercentageOfCapPriceCappedCallTransactions" scale="-2" id="Narr_d_0twZckBEW4Xg6afG8pSQ">75.0</ix:nonFraction>%</span><span style="background:#ffffff;"> over the last reported sale price of the Company&#8217;s common stock of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_4_14_2020_lOYMm8IewEGa7ecW7rCQ6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_3cf-F1k1_Ea_NkfSF7lSLw">14.82</ix:nonFraction></span><span style="background:#ffffff;">&#160;per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and&#160;</span><span style="color:#212529;background:#ffffff;">classified as equity instruments.&#160;Therefore, the total&#160;</span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA" decimals="-5" format="ixt:numdotdecimal" name="chrs:PaymentForCappedCallTransactions" scale="6" id="Narr_d9VP0_LNoE6OuW9QHvJ1Sg">18.2</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million capped call premium paid was recorded as a reduction to additional paid-in capital in the consolidated balance sheets in 2020.</span>&#160;The capped calls will not be subsequently re-measured as long as the conditions for equity classification continue to be met. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="Narr_-Sn50faQD0G_sJIzHF3PJg">0.9</ix:nonFraction> million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the notes in the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg" format="ixt-sec:durwordsen" name="chrs:DebtInstrumentContractualTerm" id="Narr_952OikZP10GPVIK13i64XQ">six-year</ix:nonNumeric> contractual term of the notes using the effective interest rate method.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the 2026 Convertible Notes&#160;were converted on December 31, 2023, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mz08bJgB4EaXuGX2fTgvhQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="Narr_AdV5T-FpCUGmO4vc4lxm-w">39.8</ix:nonFraction> million based on the Company&#8217;s closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_bvMVyrxs-kuOtHMeJa90Lw">3.33</ix:nonFraction> as of December 29, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents the components of interest expense related to 2026 Convertible Notes:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_iuHIGthWmEKmGD7nvhOXGA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_uSSOlBQt6Uufe7Z0nUYnfQ_3_3">3,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_97f1oYNCEk6iN7Cl8NGEHg_3_6">3,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_rQeS6NIwIkq9rSdsm_p2Og_3_9">3,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_aoWrsEcBvUaldVwV9Y4Vrg_4_3">1,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_7amQ-dzu5kqGBUhWoeAT3A_4_6">1,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_RP9jwpcvSU6b9qaXgFNGDQ_4_9">1,259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_akp0aujnAUSMbQf7318J2g_5_3">4,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_jmWsuMgCfkScNCrzHP4RUg_5_6">4,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_sxSdtKvhw0u_0nKiVsz8ng_5_9">4,709</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The remaining unamortized debt discount and debt offering costs related to the Company&#8217;s 2026 Convertible Notes&#160;of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="Narr_GCV0KN4R70CMd2dXz7Xqig">3.1</ix:nonFraction> million as of December 31, 2023, will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_T66JZTM1CU291lvWCqa4CA">2.1</ix:nonFraction>% for the 2026 Convertible Notes.</p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fa3bffb9_def8_46d2_b867_f926087e5d4f"></a><a id="Tc_3vnSBhSqB02gqFfMyOZpqg_1_0"></a><a id="Tc_uwIDd-GnMk-e6SJ7YWN_Sw_2_0"></a><a id="Tc_ITjKk1xET0CyRdcwJs1z1g_2_2"></a><a id="Tc_TaxpwywLHkCkt1I9Lfqpkg_3_0"></a><a id="Tc_yWdmwE6nHkmHUc_yspqmyA_4_0"></a><a id="Tc_BU5yTm_Qyk-udUleZ-9LMg_5_0"></a><a id="Tc_566vJXXJdE-QDsV9kRnVYQ_6_0"></a><a id="Tc_j-JhC-18OECo6zZQ366yoA_7_0"></a><a id="Tc_iTB5B_ZDFkSdyXWqab7KyA_8_0"></a><a id="Tc_oZpdQb2VOEi47ZSX3rRcIg_9_0"></a><a id="Tc_3RiPOyq8VUiAWyfE_DzL8w_9_2"></a><a id="Tc_P85yN46lEUOZWOMjljLrRQ_1_2"></a><a id="Tc_psC3SoaGBEuRFStjD3cxZA_2_0"></a><a id="Tc_MCTsMfpudkyrwBrjenVo4A_2_2"></a><a id="Tc_RpTohzCvSkuKL_2hlYwO8A_2_5"></a><a id="Tc_AX9n0Tz78kW1QmZP2joFyQ_3_0"></a><a id="Tc_fAK7cODKYUOD0P8em30pBg_3_2"></a><a id="Tc_wXYV_Y-2ukqMkiUaKKxMpw_3_5"></a><a id="Tc_CQ12UjZViE2CweaLThCJ5Q_4_0"></a><a id="Tc_QBI-Yl_m8UCqzfbb9yFWDw_5_0"></a><a id="Tc_QKM5wB8E806WalMbIjnJYA_5_2"></a><a id="Tc_XnEyjrCRHkOpxb_YHX6AZA_5_5"></a><a id="Tc_SdZ42LSaUUihnLg5Sue9WQ_1_2"></a><a id="Tc_emXyZLvVz0iVnje20TYVrA_2_0"></a><a id="Tc_0TQuTX210ki6fDmXKhlWiA_2_2"></a><a id="Tc_0DyxdmtkeUOe-xaLRYqe6g_2_5"></a><a id="Tc_bmGKxwmMlE6kqWTjMRYCMg_3_0"></a><a id="Tc_zTLq2zzqnUadTdyY_kJ35Q_3_2"></a><a id="Tc_v94XW7itsUexr3TJlw5Sgg_3_5"></a><a id="Tc_3c5aIXtuoUOEyinn_kCbTw_4_0"></a><a id="Tc_ngJ-lLkppE2IRGqnFf0zXA_5_0"></a><a id="Tc_-br4ZLUFAk-sO-ccwx1Rhg_5_2"></a><a id="Tc_I_OVIUpH10KejU07ZPIMIQ_5_5"></a><ix:continuation id="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont4" continuedAt="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont5"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_-FDhYHxOokSpHHzsD6oPnQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2026 Convertible Notes&#160;as of December 31, 2023 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0070c0;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_SWgU862NqEO2AU-obC3Vrw_2_3">3,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_iva8KUVZpk-XbRVr_1UTPg_3_3">3,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_5W9pDGxTBUa7QvpYEozoFQ_4_3">231,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_rphjv2hw80yyehbexwUFIg_5_3">238,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="Tc_LsSe2DIW7E-WDrCOguazig_6_3">8,625</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 Convertible Notes, principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="chrs:ConvertibleNotesPrincipalAmount" scale="3" id="Tc_M5vCp_rY4kWanXxDhF5nWA_7_3">230,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_lad5XZ1nakGpMisn02YKqA_8_3">3,112</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_ZATBHjxgdUiP0mT8ue-QVQ_9_3">226,888</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_zGnX4dH0nEOqcZhByW2h0w">8.2</ix:nonFraction>% Convertible Notes due 2022</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On February&#160;29, 2016, the Company issued and sold </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_ATzn3ey0pEqH4tZYcWqJBw">100.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million aggregate principal amount of its </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_tH-nSojjqk6xL5y6FjDVMA">8.2</ix:nonFraction>%</span><span style="background:#ffffff;"> Convertible Senior Notes due 2022. </span><ix:nonNumeric contextRef="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_IYOtI7t0s06IRoQfEZsvfg" name="us-gaap:DebtInstrumentInterestRateTerms" id="Narr_Vd9VtT9HKEu_IqNe5d8bQg"><span style="background:#ffffff;">The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company, bore interest at a fixed coupon rate of 8.2% per annum payable quarterly and matured on March 31, 2022</span></ix:nonNumeric><span style="background:#ffffff;">.&#160;In March 2022, the Company fully repaid the 2022 Convertible Notes, and as a result had&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pmdNhIdK2kyIctMI_ST38Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ConvertibleNotesPayable" scale="6" id="Narr_RGOCGdnSjky34cjD2u_duA">no</ix:nonFraction></span><span style="background:#ffffff;">&#160;continuing obligations associated with them thereafter. The payoff amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_gdt1MV0JPkKcC2rjWWOZPg">111.1</ix:nonFraction></span><span style="background:#ffffff;">&#160;million included the repayment of the entire outstanding principal amount, the&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ" decimals="3" format="ixt:numdotdecimal" name="chrs:PercentageOfPremiumOnConvertibleNote" scale="-2" id="Narr_2Xci9XnYiEynWBKxv8M00Q">9.0</ix:nonFraction>%</span><span style="background:#ffffff;"> premium of the outstanding principal amount and accrued and unpaid interest. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2022 Convertible Notes&#160;were issued to Healthcare Royalty Partners III,&#160;L.P., for $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_29_2016_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_2LOhPFc_bEyFVajuBKg_hw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_ybZ_Xv1Wfk6n4E2wr7I_PA">75.0</ix:nonFraction> million in aggregate principal amount, and to three related party investors, KKR Biosimilar&#160;L.P., MX II Associates LLC, and KMG Capital Partners, LLC, for $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_VEix4k9_P0C5vL3mOkva7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_QWDCmJYBBEKTC_55lJSVpQ">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_MXIIAssociatesLLCMember_dlXABsWvD0ytszx5uH9T9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_l9m4QWfxq0-sfvRdVsao4w">4.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KMGCapitalPartnersLLCMember_gM38q0-qfkqM70dI2BG3iA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_uiuw_TiA4Uix3Tq7vhqRQQ">1.0</ix:nonFraction> million, respectively, in aggregate principal amount.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense of the 2022 Convertible Notes:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yPqNV7UizkyOlrp2llCvgA" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_5tbLh_rPdEynYWwA6wl4yA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_HlAAP4HVVEu3v8vXNzUwjQ_3_3">2,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_CZhYQLAfV0GU7aJ2QpPSVQ_3_6">8,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_6pW-QGShakKQifHaPTXZQA_4_3">521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_DzUB7LTyYUiyJKhCfATSSA_4_6">1,966</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_4SwMqGfHW0yfwHNUsXdkzA_5_3">2,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_q5sjlQqpnkGS2d_-kwUpgA_5_6">10,166</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2025 Term Loan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;7, 2019, the Company entered into the 2025 Term Loan with affiliates of Healthcare Royalty Partners (together, the &#8220;Lender&#8221;). The 2025 Term Loan consisted of a <ix:nonNumeric contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-u8VFwKaq0W-VpOwOG1Tug" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_f2xrXVQxfEmPnMLl-O84qQ">six-year</ix:nonNumeric> term loan facility for an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_4dYZePFHI0uh8xLaZDgW8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_zP9gatbNsUmIDWGLIApCkg">75.0</ix:nonFraction> million (the &#8220;Borrowings&#8221;). <ix:nonNumeric contextRef="Duration_1_7_2019_To_1_7_2019_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ESE6x74w_0eBsyYKVq7Vhw" name="us-gaap:DebtInstrumentInterestRateTerms" id="Narr_DU3a-AJ0tkKdl4w3YbSzgA">Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_1_1_2020_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_9RhPVS_PkUqmSIIeRzY6ig" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_gWeqGDakHUCnuHyr1ZK3Cw">6.75</ix:nonFraction>%&#160;per annum plus three&#160;month LIBOR. Interest was payable quarterly in arrears.<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Pursuant to the terms of the 2025 Term Loan, the Company was required to begin paying principal on the Borrowings in equal quarterly installments beginning on January 7, 2022, with the outstanding balance to be repaid on&#160;January&#160;7, 2025, the maturity date. In January 2022, pursuant to the Company entering into the 2027 Term Loans, the Company voluntarily prepaid all amounts outstanding under the 2025 Term Loan. The payoff amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_v8hB-YJyxkSKZgNeyqEp1A">81.9</ix:nonFraction> million included principal repayment in full, accrued interest, a <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_G4zeUvb2AkiJrpZxrWkJfw" decimals="3" format="ixt:numdotdecimal" name="chrs:DebtInstrumentPrepaymentPercentage" scale="-2" id="Narr_txatew0Bj0i9XHDacWR5Ug">5.0</ix:nonFraction>% prepayment premium fee of the Borrowings principal amount, and an exit fee of <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA" decimals="3" format="ixt:numdotdecimal" name="chrs:PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" scale="-2" id="Narr_cfjvKBknUEeReX2UN52SKQ">4.0</ix:nonFraction>% of the Borrowings principal amount. The prepayment premium fee and unamortized exit fee, debt discount and debt issuance costs, net from the 2025 Term Loan totaled $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_MNtpxMClrkKeCf7bsYO5zQ">6.2</ix:nonFraction> million and was recorded in loss on debt extinguishment in the consolidated statements of operations for 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense of the 2025 Term Loan:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_Loyb6ABkV0CqKB-V5_uHvA" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_LIwTxZGfvE6fbGRl2uEbTg" continuedAt="Tb_LIwTxZGfvE6fbGRl2uEbTg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_IE6aQBozm0OLw69CBiSJ1w_3_3">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_Gr7WojjwpkijnOcg2FeTWw_3_6">7,034</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_Sj45RAM0dkimNbQALIx_nQ_4_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_1CGvxOCAsEi4tKAA8BDX7g_4_6">1,032</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_wcz-eLhZ2ESO4RiJIKADIw_5_3">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_Yd63eu6xJki30U8Nrv6nOA_5_6">8,066</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_I5mOANR7bUmU7ZGEzLdCkA_cont5"><ix:continuation id="Tb_LIwTxZGfvE6fbGRl2uEbTg_cont1"></ix:continuation></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4c88c9ca_2160_4536_858b_acb1661c1cce"></a><a id="Tc_NDMyi7WzB0aL5exAXIlE1g_1_0"></a><a id="Tc__4G5t4iSmUeaMyx0H8m9Zw_2_0"></a><a id="Tc_mdnEXB3tAkiri0Yfmdkfkw_2_2"></a><a id="Tc_IEs0Adj9nU6NMB8RNa-L1g_3_0"></a><a id="Tc_iMtAZU4Zz067ZHoiS_VyCw_4_0"></a><a id="Tc_r8BxL3FsPkWezDE9Bj3ptQ_5_0"></a><a id="Tc_rWFQ2h89MU6eW8gudTHFfw_5_2"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_4E8U7ybbPk6_-HVIko_OTg" continuedAt="Tb_4E8U7ybbPk6_-HVIko_OTg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Commitments and Contingencies</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase Commitments</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of December 31, 2023, the Company&#8217;s non-cancelable purchase commitments under the terms of its agreements are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:LongTermPurchaseCommitmentTextBlock" id="Tb_x-Ft_yU8_ECgyBZ9oycRUA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="3" id="Tc_q0VmyIYY8kKVdIQ4fmPucQ_2_3">52,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInSecondYear" scale="3" id="Tc_GJiZoBMTnkmWsYQkT05wmw_3_3">19,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInThirdYear" scale="3" id="Tc_G-jOw7uq3U2tant8a4fDsg_4_3">1,410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="3" id="Tc_tLs7qWSe3UicM423KtTYNw_5_3">73,078</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, total obligations excludes certain purchase commitments that were assumed by Sandoz upon their acquisition of the Company&#8217;s CIMERLI ophthalmology franchise (see Note 17. Subsequent Events). The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Guarantees and Indemnifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings and Other Claims</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved. The outcome of such legal proceedings and claims is inherently uncertain. Accruals are recognized for such legal proceedings and claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it&#8217;s determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. As of December 31, 2023 and 2022, the Company had an accrual of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_2TW5nZJ8wUWRYttn81wTMg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="Narr_tw8YFgdp-0S5wpNkkS_wCQ">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_u0BIpPgozk2LV-saZBzeXQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="Narr_QkVmdgPbeEq3HchL1D3V2Q">4.7</ix:nonFraction> million, respectively, related to such matters that was included in accrued rebates, fees and reserves in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (&#8220;Zinc&#8221;) asserting that Zinc was entitled to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2022_To_4_30_2022_oL0nzgyjPkiv7bL6dvw4Sw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" scale="6" id="Narr_8NV1d1DVeECySp8mF6P37g">14.0</ix:nonFraction> million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. The Company is continuing to evaluate the claims in the letter. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company established an accrual as of December 31, 2023 that represented its estimated liability to resolve the matter. Loss contingencies are inherently unpredictable, the assessment is highly subjective and requires judgments about future events and unfavorable developments or resolutions can occur. The Company regularly reviews litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date<b style="font-weight:bold;">.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_4E8U7ybbPk6_-HVIko_OTg_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other than the matter in connection with the demand letter described in this Note 9, there are no pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries' property is subject.</p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_040bf45a_2ce8_447b_8b93_30cda9f8e0c4"></a><a id="Tc_e1vXT7lB_0SxyVEq1mVubQ_1_0"></a><a id="Tc_ZhjZntWB8EKX3UtHf5Sijw_1_4"></a><a id="Tc_bfQwLDFelEOeo2XmGvh-wg_2_0"></a><a id="Tc_5SE-CL0GjEiH6ujzDiPx9w_2_2"></a><a id="Tc_C-4McLzAoUiWdDBn2YkpcA_2_4"></a><a id="Tc__Dugqtfg-kG7hYb6TR60SQ_2_7"></a><a id="Tc_36Fr4hLUlU6XDLUWcSuWnw_3_0"></a><a id="Tc_j3TzdkbQpEy7YwIgSpaXrw_3_4"></a><a id="Tc_VgFlRbtqL0WgNy4KvKdTJQ_3_7"></a><a id="Tc_Qlr3qkDLo0OIMReY8counw_4_0"></a><a id="Tc_ymrZjmXWV0av8fQVtjMXsQ_5_0"></a><a id="Tc_ChHdpaEM3ECSi-BPMPep3Q_5_4"></a><a id="Tc_idG7e331RkijqJidE70HDw_5_7"></a><a id="_5d40c2c4_9648_4511_924b_19f383e5c873"></a><a id="Tc_7eMRethTgkaX6JtkTnANvg_1_0"></a><a id="Tc_nAVHqxb9xk6sj_INtE3zZA_1_4"></a><a id="Tc_LQ-atT2y306JlNhSGnqbBQ_2_0"></a><a id="Tc_G3slmQVPSEyjScF_b6XLoA_2_2"></a><a id="Tc_DSDI5ZBIi0CdBN1h10fV7g_2_4"></a><a id="Tc_20T9AwCZNEmyp_eGTUKu-w_2_7"></a><a id="Tc_v6Icgh4xtkuJd7v-wfjisw_3_0"></a><a id="Tc_f1Hk-yzexE6DT-TJvrP98g_3_4"></a><a id="Tc__Swjxthffkin3srvryAEnA_3_7"></a><a id="Tc_uCq2ixyc_kuGP3UXZjwhGg_4_0"></a><a id="Tc_FlP-Hyj0JUuCD9pJKI_S-g_5_0"></a><a id="Tc_1WSSKgqL0UuTvHcB8JRwpQ_5_4"></a><a id="Tc_NqPAuYBLqUitoshru8_Eew_5_7"></a><a id="Tc_h2igVpEkO0q1kez29oTw3g_7_0"></a><a id="Tc_83gChXgLgkatF8DskRTdsA_7_4"></a><a id="Tc_jrjYb7v7qki1rDh0EXsxsw_7_7"></a><a id="Tc_D5HvUREVYUaQTmicpNQURQ_8_0"></a><a id="Tc_8FMvoTz6_EuAARCFfY0KGQ_9_0"></a><a id="Tc_IrRsUGdDBUi-w8HK_aEv2A_9_4"></a><a id="Tc_3t5YYMx9yEKT7M_hWITF5g_9_7"></a><a id="Tc_n09_fmAY30y--bBzJ0-NTg_1_4"></a><a id="Tc_21914A2pfECJfQ-U0AA64w_2_4"></a><a id="Tc_4OXcMJkmMUazfP3r1G7ZGg_2_7"></a><a id="Tc_eZ0WcoCmt0evpBLce7U0eQ_2_10"></a><a id="Tc_CKXS8DPjnU-5UMNKIyluJQ_3_0"></a><a id="Tc_-zJIKoQGnUOqyDvgz9gzww_4_0"></a><a id="Tc_7YaLtUB7PkqomRdNnk0t-w_4_5"></a><a id="Tc_qQuSQhIl0EeEX2xcAMDoWA_4_7"></a><a id="Tc_pwXOyuXk2UK0bwE9Kizl5w_4_10"></a><a id="Tc_S8h7YvdhhkGWGRC69TJ7dQ_5_0"></a><a id="Tc_0QOJgvckWEGZGNfkwtViZg_5_5"></a><a id="Tc_bRBpJyuENEa82wqpuEWr3Q_5_7"></a><a id="Tc_stBVj0gZpE-KPeCAMsPUWQ_5_10"></a><a id="Tc_KoZH6wP6YUOqvl7gJ6KCzw_6_0"></a><a id="Tc_kjyBHLqzNUqe5g4SgFFpGw_7_0"></a><a id="Tc_34KYo4qUskGF4lQwDdW-NQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_cFYqaJtE70WJC8hxmj9tGA" continuedAt="Tb_cFYqaJtE70WJC8hxmj9tGA_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span>Leases</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Through December 31, 2023, the Company leased approximately <ix:nonFraction unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_4-NTVWKntkKpLY2m9obR2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_G1YBRIzRqUe5gSkuidu6HQ">47,789</ix:nonFraction> square feet of office space for its corporate headquarters in Redwood City, California (the &#8220;Lease Agreement&#8221;). Prior to an amendment to the Lease Agreement entered into on October 24, 2023 (the &#8220;Sixth Amendment&#8221;), the Lease Agreement was set to expire in <span style="-sec-ix-hidden:Hidden_fHNXk8VMLECyy9jYAF_Fdw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">September 2024</span></span> and contained a <span style="-sec-ix-hidden:Hidden_VkjnRAfIcEy-ZaCcc2AiFA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-time option to extend the lease term for <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_4-NTVWKntkKpLY2m9obR2w" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_srZsoj2VtUiGUpe9TSrneg">five years</ix:nonNumeric>. Under the terms of the Sixth Amendment, the Company extended the lease term through September 30, 2027 and reduced the amount of office space leased to <ix:nonFraction unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A" contextRef="As_Of_10_24_2023_us-gaap_LeaseContractualTermAxis_chrs_OfficeSpaceRemainingPremisesMember_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_1ikJXPlaT0qaIZD07NCcJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_ON5SiDlthEOcJfNyGpeejg">27,532</ix:nonFraction>&#160;square feet. The remaining&#160;<ix:nonFraction unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A" contextRef="As_Of_10_24_2023_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_2VupKf10C0ysFKHcmA-N7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_DQnzpj0fFUOIygE6a4oaSQ">20,257</ix:nonFraction>&#160;square feet of office space expired on December 31, 2023, according to the terms of the Sixth Amendment. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also leases approximately&#160;<ix:nonFraction unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_LaboratoryFacilitiesLeaseAgreementMember_eWCVJY2d0Uy0fzrMJb295g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_hjLOBKmoLECO7o8E7plOag">25,017</ix:nonFraction>&#160;square feet for its laboratory facilities in Camarillo, California which commenced in January 2020. This lease terminates in&#160;<span style="-sec-ix-hidden:Hidden_2eeuHZDPwkuwZhYvkItgaQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">May 2027</span></span> and contains a <span style="-sec-ix-hidden:Hidden_TfxsXMoIkUuAjOrWK1_x9w;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-time option to extend the lease term for&#160;<ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_LaboratoryFacilitiesLeaseAgreementMember_eWCVJY2d0Uy0fzrMJb295g" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_0X07lifBEEOr1GMSVzIYLA">five years</ix:nonNumeric>. Both facility leases provide for certain limited rent abatement and annual scheduled rent increases over their respective lease terms.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the above facility leases were operating leases. The options to extend the lease terms, if any, for these leases were not included as part of the right-of-use asset or lease liability as it was not reasonably certain the Company would exercise those options. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2019, the Company entered into the Vehicle Lease Agreement, pursuant to which the Company leased approximately <ix:nonFraction unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_AndqifxXsEG2Tfoo9es73w" decimals="INF" format="ixt:numdotdecimal" name="chrs:NumberOfVehiclesLeased" scale="0" id="Narr_3K3ynSgiNkCv_seyjR3fhQ">50</ix:nonFraction> vehicles as of December 31, 2023. The term of each leased vehicle is <ix:nonNumeric contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_IkAU-wbfW06hNr0VdkRc-A" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Narr_wP0P4Hg0_kOCe7viS3zpJg">36 months</ix:nonNumeric> and commences upon the delivery of the vehicle. The vehicles leased under this arrangement were classified as finance leases. Beginning in February 2023, the Company no longer enters into these leasing arrangements and began transitioning to a reimbursement program with employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental information related to the Company&#8217;s leases is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" id="Tb_yeQ14a-AbUebYmWxW8wjjg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-mf-ZxnNGEipJwEpza_71w;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other assets, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_E0cu3cG6Zky-H5gmK1bepA_3_5">5,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_2ZvlPFqCcEez_bDqziYtCA_3_8">5,690</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WgpZY07_p0GbKqCO5gEf4g;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Property and equipment, net</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_UHNyhu8cyUWLSw8i4v7oyA_4_5">1,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_urrpOmnrlky8I0jesqQ9pw_4_8">2,584</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:OperatingAndFinanceLeaseRightOfUseAssets" scale="3" id="Tc_Q8JDcicdNEKlajnpOzC9EA_5_5">6,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:OperatingAndFinanceLeaseRightOfUseAssets" scale="3" id="Tc_0vk6u15w7Em81uv4Aajiwg_5_8">8,274</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_liJO04hsZUOJwgNDIHYjyw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_kyq3fw7WUUqGM0IKdwGRlA_3_5">1,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_IU7re1Xe-0m0ehBOtzf-gg_3_8">3,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TFQ5qkqFP0exAVaWIavjVw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_5Xsn1QCkrE2pDk9FlaPW9A_4_5">4,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_4y73UIRG3EadMiYFbCn3MQ_4_8">3,628</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_HgwWdkAtAUOUFJey1bodFw_5_5">6,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_0T_YlMO79UyUU0jCi-Ahrw_5_8">6,755</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ieMrVFi9_UGwUiP2AK3LZQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_hBKOIAyPxEOMyEglFvMFBg_7_5">721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_1CPp94BBS0K2XCyHYnwkdQ_7_8">1,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wCWMjCewb0K1TBEZgR53KQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_jdkw6GhZwEGOQ0Ztfh6J5Q_8_5">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_pNNpx_Bj90uFIJbuXXfjwA_8_8">1,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_0XiC4VVg50iFIg5mQ-EpHg_9_5">1,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_XZXmOF61d0KwEZALEO854A_9_8">2,609</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other information related to lease term and discount rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" id="Tb_TsJztV7Zoke2gwDmUGWKUw" continuedAt="Tb_TsJztV7Zoke2gwDmUGWKUw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:28.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-Average Remaining Lease Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_6qYUNB7nUkmPLsrYnW3fNw">3.6</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_xcp2M-XpRU6GEnTSOT8dwA">2.2</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_cq4koSmbZ0qJj7jcJT0OgQ">3.2</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_0ZvKk9FKLUKosWNNl4coCQ">1.4</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_ZIpav3teqECsnjUylUzYVg">2.2</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_rivt9ypXLkS7SUY03cglJQ">1.7</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-Average Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_QFh4c_BtXEenAz3kPIko1w_7_5">11.8</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_pajx0OojlEmkxAfErRKNjg_7_7">8.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_OqLky0zfuEuxUM-nVUq3Wg_7_10">8.0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_0ponVVnYUEG1RQ4tiskXVA_8_5">8.7</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Sgm5rSHN4E26lX53eYtwJQ_8_7">8.4</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_F-MwJ8dzv0C--YBYXGSLog_8_10">5.8</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_e_d1Cz6Cb0y3w7xIegxVBg_1_4"></a><a id="Tc_gRHPpTbiXEmGDV-XYjqQyQ_2_0"></a><a id="Tc_OaOSpSOIokun_jRHgFBxdw_2_4"></a><a id="Tc_QzQPrsrrAEOCr8aF7LPF8w_2_7"></a><a id="Tc_h3PIG3G2gUKwDfuq5eCz2g_2_10"></a><a id="Tc_9_A11O_2qE6JAX3l9Ah-iw_3_0"></a><a id="Tc_4rC78QMPM0K6910KdBrXOQ_4_0"></a><a id="Tc_GcOSFbIrYUiVnWrXH0rDDw_4_4"></a><a id="Tc_6_ioqgg6KkyIb3DS1J0yaw_4_7"></a><a id="Tc_yz1Vzi0E3EGW4Q5ZEmzwJw_4_10"></a><a id="Tc_f-IDrcBCoEyp2ZpUSdcvBA_5_0"></a><a id="Tc_4ulmxbbWZ02OPR76Y4eGSA_6_0"></a><a id="Tc_cvBqFfN5q06zCzg8u9BJ_Q_7_0"></a><a id="Tc_LKzvyoSG-Ei6AcIv868JwA_8_0"></a><a id="Tc_02kE1qjGR0GfdUWX55oEFQ_8_4"></a><a id="Tc_m02U82jsJkyI8J6KR2OzOQ_8_7"></a><a id="Tc_0WhpZpUQBkavda1oRlq9WQ_8_10"></a><a id="Tc_iz6GSq9e_UCPsbb9zH7w8g_1_4"></a><a id="Tc_MxmIhzr5gk6k1sW10nEnaA_2_0"></a><a id="Tc_2s7ob8FrOUuhA_yvUu5VZQ_2_4"></a><a id="Tc_hxNN9dufx0ut6vWYvDngjg_2_7"></a><a id="Tc_wfufbS5y9UmRnok4saS0oA_2_10"></a><a id="Tc_nrvhgG1yHUu-js5qxoibng_3_0"></a><a id="Tc_sxoxtrs3cU6MMimYnyTPBg_4_0"></a><a id="Tc_feEtDStT3EejdINOU33Kdg_4_4"></a><a id="Tc_ZhPsCOIHV0udsWxzIMv8dQ_4_7"></a><a id="Tc_tiCgrU5zlkKVOPL323mrlA_4_10"></a><a id="Tc_MSaa3j6qVUyNBejpugrXAg_5_0"></a><a id="Tc_fTVlpJH2x02CFfjlcazyIQ_5_4"></a><a id="Tc_R85qSILOIUmsZGQ0cpbUeA_5_7"></a><a id="Tc_Pw4xzKrdo0O73ynfqYuKBQ_5_10"></a><a id="Tc_XfiTKQHMY0KhnUAyedr1lg_6_0"></a><a id="Tc_DonG5l5vJ06Ye9S_zs5l1w_6_4"></a><a id="Tc_9vOe9KnsSkCzjGUAohdLgQ_6_7"></a><a id="Tc_tgcoupT7wUmEQ5HXTEsflg_6_10"></a><a id="Tc_LbTFSTOGeUKoqpyAj4xgbw_7_0"></a><a id="Tc_g6A2RbjjXUamR4aJoHpXlA_8_0"></a><a id="Tc_MiAOiJquCUOvkU-D3OHeFg_8_4"></a><a id="Tc_DMQEfeBHIUaqkSSoHTa_cQ_8_7"></a><a id="Tc_tWJpSdznxkuX6OebZ9OoXQ_8_8"></a><a id="Tc_qcb8SxzHnU-T1ycABIbmAw_8_10"></a><a id="Tc_b5CA0a_oE0qf_1ivByODfQ_9_0"></a><a id="Tc_8p3N880zG0SRmy6IMZl3mQ_9_4"></a><a id="Tc_2CHhwgbtY0-4apiqCSLolw_9_5"></a><a id="Tc__x-itKN_L0iG8IJhLWeOKQ_9_7"></a><a id="Tc_M_zFM1jrIkex7KSNwyN47Q_9_10"></a><a id="Tc_QI0GugUvfkWR7WPOSUv5AA_1_0"></a><a id="Tc_eJG0R8dJlUi1Z4bYebgcww_1_2"></a><a id="Tc_ts1WzWMzukS6tlFFPkP4Wg_1_5"></a><a id="Tc__-xsdhD8mUutyq_HMmWHrw_2_0"></a><a id="Tc_xj-u-3U8zUaGg9ssaCSQCA_2_2"></a><a id="Tc_VrGV5s4IEkKAYLEduNZeJg_2_5"></a><a id="Tc_smtnxqn9lEO2CmFwp1UgZQ_3_0"></a><a id="Tc_zsG_LQSTSUegvdLLm0lREw_4_0"></a><a id="Tc_68o648urTEO47qLPHCO3FA_4_6"></a><a id="Tc_bQao6GscXUClszzuGaMTaQ_5_0"></a><a id="Tc_jxqX6mBloE6iViqoyy_hEA_5_6"></a><a id="Tc_Nfc4qaM7qkifTzJMTHOoqA_6_0"></a><a id="Tc_yMu5PCG5jUe0u4Bi5Sg98g_7_0"></a><a id="Tc_vLVFXPGSUkisjSisT4Ocbw_8_0"></a><a id="Tc_uLCw3x-PnUSq8bJqZGXV0A_8_2"></a><a id="Tc_TLlMCH1hCU-yL0sjNyP68g_8_5"></a><ix:continuation id="Tb_cFYqaJtE70WJC8hxmj9tGA_cont1"><ix:continuation id="Tb_TsJztV7Zoke2gwDmUGWKUw_cont1"></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_unZF7BQUr0-7rEszpGj7ZQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_03NRSJ6yz06MDyAv0w78xw_4_5">1,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_f5pX2CiIckOtzMF4bU8Wbg_4_8">1,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_mFmVu-qqC0-S4MhxhRbaAA_4_11">707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_c1d9zTUg6063HV4QwOG3ZA_5_5">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_AQW9_EVbQUWfNxtyvS1zEw_5_8">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_pdvz5tMdPU6GikkYPKqXJg_5_11">82</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="chrs:FinanceLeaseCost" scale="3" id="Tc_l53uXcFj3kSAWq--xx0WCQ_6_5">1,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:FinanceLeaseCost" scale="3" id="Tc_h6o2Qtf-REWOpvW41qiHKw_6_8">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="chrs:FinanceLeaseCost" scale="3" id="Tc_pmNIOOGfNkewaPEixUZj-g_6_11">789</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_ejYk46wdv0ewg-2MkrIcew_7_5">2,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_L-tZAPfuG0K8NPySjZVV5Q_7_8">3,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_PEP2fcA8lkCBy5bqDaFzuA_7_11">3,066</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_eFbbB-zJgES57_fFs5SbaA_8_5">4,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_kHfey-ry3kCWlIV0u8KVsQ_8_8">4,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_dVQMdSt6VEGC8_GaNLF1fQ_8_11">3,855</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to leases was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" id="Tb_Xrby58qDbU23ncf6Tofo6w" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="8" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in measurement of lease liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows from operating leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_eNN2A2x1B0awpUVXl2ZzYA_4_5">3,560</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_czSQLpNcQUGg3nJ4FIBqyw_4_8">3,401</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_mXXnvoVeEEy8dkvzJe1uBA_4_11">3,435</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows from finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_5cSuZpaWFU2y-xl-kN5bwQ_5_5">145</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_7ibqeuFNVUufCJ_q4zor_Q_5_8">155</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_C_oFnjsruUangTMACEktZw_5_11">81</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financing cash flows from finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_G5hlRZMR40i0weqeFoIauw_6_5">1,034</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_--nXdiUWgEGkrL0DuYHt1A_6_8">1,228</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_Ow0p0enxe0m07qcI_z4rhA_6_11">672</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for lease obligations:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_85tEXrTiRkaCaWAWgBFWOA_8_5">2,653</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_Bhot-Y625U2IbzgFd7hI7A_8_11">434</ix:nonFraction></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_zteukGf2kE62wQmzjAG1tw_9_8">2,694</ix:nonFraction></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_9S_2JxAsJEuTBeP3LTcV_w_9_11">477</ix:nonFraction></p></th></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the maturities of the lease liabilities were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_5L27L9GM-kyRW4GQ9h1qbg" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating&#160;leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance&#160;leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_qiiJu-LIx0e99AWx11r07Q_2_3">2,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_KTsXD_0NkUmpZ111LOEXiA_2_6">781</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_YynIidtvqUO2cKBjJEuLHg_3_3">2,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_0vyhsPQanUiYaqI-Ub3Nvg_3_6">358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_7JFWRogGJ0a5Tyjgt7bZMQ_4_3">2,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_4eFSX-iiW06BOu9_3xas_Q_5_3">1,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_OdOI8spsIk2U6Jr7hael7Q_6_3">7,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_28QP-jKUCEeV7L7OmzTgbg_6_6">1,139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_QGgkGxVdoUyutbS9T55m-g_7_3">1,543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_E3wVNQA8HU-kcTGfGZ1GiQ_7_6">67</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_2DUHNQ_i5UmHIf3zMN8_Xg_8_3">6,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_iFJqcjFRtU2ykfWZRvcIjg_8_6">1,072</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk122694270"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:StockholdersDeficitTextBlock" id="Tb_j3ailpxXRUOEsewSm955tg" continuedAt="Tb_j3ailpxXRUOEsewSm955tg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;background:#ffffff;">Stockholders&#8217; Deficit</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Public Offering  </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On May&#160;16, 2023, the Company entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company issued and sold the Firm Shares to the Underwriters. Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, for&#160;<ix:nonNumeric contextRef="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Y1Km_JnNyku-WuF69J4RdA" format="ixt-sec:durwordsen" name="chrs:SharesOfferingUnderwritersOptionTerm" id="Narr_clnpbFcFK0OuBjvpKdXusw">30 days</ix:nonNumeric>&#160;from the date of the Underwriting Agreement, to purchase the Option Shares, which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_BTKj2cvojU24AiFKRX3zBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_KU8WelX9bU6DnsX8koFtfA">4.25</ix:nonFraction>&#160;per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_1ztFg0EZYE-MyDgGu8F23A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_tKMT5ltRHUWPwDANDeBtJg">3.995</ix:nonFraction>&#160;per share.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The Offering was made pursuant to a prospectus supplement and related prospectus filed with the SEC pursuant to the Company&#8217;s Registration Statement under which the Company may offer and sell up to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_5_16_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_t94RIbg44kqe6E07Ycbe0Q" decimals="-5" format="ixt:numdotdecimal" name="chrs:SharesOfferingAggregateAmount" scale="6" id="Narr_kClT1Odxl0eJVTKX5rS0Ww">150.0</ix:nonFraction>&#160;million in the aggregate of its common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings. On May&#160;18, 2023, the Company completed the sale and issuance of an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_5VUKYAUWS0WOL1uTbEXYnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-a62Dz9gn0-HDaNuyHD54Q">13,529,411</ix:nonFraction>&#160;Shares, including the exercise in full of the Underwriters&#8217; option to purchase the Option Shares. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_5VUKYAUWS0WOL1uTbEXYnw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_3jWZeiytFka4rZWkkwQurQ">53.6</ix:nonFraction>&#160;million, after deducting the Underwriters&#8217; discounts and commissions and offering expenses payable by the Company.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_FFuL_H6KgUGcDzYmignXMw_1_2"></a><a id="Tc_LqIB1dguDk-WLGzP7HrpUQ_2_0"></a><a id="Tc_tZHie5ULqEuwGJsLZjR40w_2_2"></a><a id="Tc_l7fIyuktkkSbhzw_G9oNWw_2_5"></a><a id="Tc_o3pbInVx-EmxUiDBxPpeaw_3_0"></a><a id="Tc_XEWfZeUKxEaiia5Z_1Qudg_4_0"></a><a id="Tc_CISk669ov0Oy4zZ2KkhbBw_4_2"></a><a id="Tc_O8PqwQwx7kOAWr9bUwjLow_4_5"></a><a id="Tc_dSNFOtVw7E6qoJ1dGxAx0g_5_0"></a><a id="Tc_58l4cbSCzUyLG84z00fvTg_5_2"></a><a id="Tc_1-dCP919_0aA_UgCQIZwYw_5_5"></a><a id="Tc_wvx1w8cGUUiCJ9qKozHu2g_6_0"></a><a id="Tc_TKR6T_X3jEiVvUR7ptcq7A_7_0"></a><a id="Tc_iqt_ecE-b0CBIymGLv5zuw_7_2"></a><a id="Tc_te5w0eCPK0O5ziB2ek9v-A_7_5"></a><ix:continuation id="Tb_j3ailpxXRUOEsewSm955tg_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">ATM Offering</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 8, 2022, the Company filed a Registration Statement. Also on November 8, 2022, the Company entered into a Sales Agreement with Cowen, pursuant to which the Company may issue and sell from time to time up to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_11_8_2022_To_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_DuLOSPFfNUakKw9YrfEp6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_FymTBJnuzkmMFTY8LDotsQ">150.0</ix:nonFraction> million of its common stock through or to Cowen as the Company&#8217;s sales agent or principal in the ATM Offering.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, the Company reduced the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_5_15_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_xIobUuv7xkaTn4Q-FI1LMA" decimals="-4" format="ixt:numdotdecimal" name="chrs:SharesOfferingAggregateAmountDecrease" scale="6" id="Narr_4dbbaSxfe0-LmInJ0pu4yw">86.25</ix:nonFraction>&#160;million, lowering the aggregate offering price under the Sales Agreement from $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_N0EdjlOAy0Sqb92Q_d-eKA" decimals="-5" format="ixt:numdotdecimal" name="chrs:SharesOfferingAggregateAmount" scale="6" id="Narr_sr-53FiN8k-N3IpOYghghA">150.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_5_15_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_f9ef-yFAYEWYmhIzUHYLVw" decimals="-4" format="ixt:numdotdecimal" name="chrs:SharesOfferingAggregateAmount" scale="6" id="Narr_R_5ocpmw6ky-WpXLunBbWg">63.75</ix:nonFraction>&#160;million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, the Company increased the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_9_11_2023_To_9_11_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_wNY0LcAqy0m5BY-y3yR8Yg" decimals="-4" format="ixt:numdotdecimal" name="chrs:IncreaseInAmountOfSharesToBeIssuedAndSold" scale="6" id="Narr_YIFY5BTbskqBahaqGTIH8Q">28.75</ix:nonFraction>&#160;million, increasing the aggregate offering price under the Sales Agreement from $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_5_15_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_f9ef-yFAYEWYmhIzUHYLVw" decimals="-4" format="ixt:numdotdecimal" name="chrs:SharesOfferingAggregateAmount" scale="6" id="Narr_y_tj2lvf30KwBZvm5XYLKA">63.75</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_9_11_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_D_dyxc-7bk6FZ7_nraT6IQ" decimals="-5" format="ixt:numdotdecimal" name="chrs:SharesOfferingAggregateAmount" scale="6" id="Narr_ae1IDlHngUy4whTswuRNwg">92.5</ix:nonFraction>&#160;million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The following table summarizes information regarding settlements under the ATM Offering:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" id="Tb_LFw3xVJYAU-Rv9kpwMzs-w" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of common stock shares sold during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_0vl2xA5fhkei3aThpSxvDw_3_3">3,559,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_Dx4wNFpUFkOS38bBcEC0fQ_3_5">916,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_rO5PqjjHM061tAOT8W_pJg" decimals="2" format="ixt:numdotdecimal" name="chrs:WeightedAveragePricePerShare" scale="0" id="Tc_rBIq_QMJVUaPwTIzbZmElQ_4_3">5.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_n-FydJrePEuzzIDzlXSx6Q" decimals="2" format="ixt:numdotdecimal" name="chrs:WeightedAveragePricePerShare" scale="0" id="Tc_sOZYB0HS_US1BGdBSLrHhw_4_6">7.30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProceedsFromIssuanceOfCommonStockGross" scale="3" id="Tc_fFVMiLddPESBzMiHUTGKAw_5_3">19,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:ProceedsFromIssuanceOfCommonStockGross" scale="3" id="Tc_IZz4B8kf40mRnqp60yLXWg_5_6">6,692</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less commissions and fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_gSZsmFuYV0GzPF6051EfIQ_6_3">483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_5347coYZIk2A1YKZi5ACyQ_6_6">168</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net proceeds after commissions and fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Tc_4w9IS3bnsEW1Z7CiPGBh5w_7_3">18,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Tc_6HEpcuq_00KvNvCxIDXsiQ_7_6">6,524</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2023, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_hK4XJ0wrhk2gRd8IsFyEIA" decimals="-5" format="ixt:numdotdecimal" name="chrs:CommonStockRemainingAvailableForSaleUnderAtmOffering" scale="6" id="Narr_Q94QacRlkUimnzSRb-ot4Q">66.5</ix:nonFraction> million of its common stock remaining available for sales under the ATM Offering. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Common Stock </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On October 9, 2023, in accordance with the terms of the Optional Stock Purchase Agreement, the Company issued&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_smPtKbH5gUSVAkSL70VxvQ">2,225,513</ix:nonFraction></span><span style="background:#ffffff;">&#160;shares of its common stock to the CMO for a price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_bovPFj58gkCF6OVAq9cZrg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_9w9tVB4qg02gLpj38DaQXA">3.675</ix:nonFraction></span><span style="background:#ffffff;">&#160;per share, with a total value of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_lWdideQVm06VN9oRIC8nsQ">8.2</ix:nonFraction></span><span style="background:#ffffff;">&#160;million in this non-cash transaction.&#160;The Optional Stock Purchase Agreement gave the Company the option, in its sole discretion, to elect to pay for certain manufacturing services provided by the CMO by either paying cash or a Stock Service Fee Payment. On October 4, 2023, the Company notified the CMO of its election of the Stock Service Fee Payment. The price per share of common stock was equal to the volume-weighted average closing trading price per share of common stock on the Nasdaq Global Market over the&#160;</span><span style="-sec-ix-hidden:Hidden_I67Wh2887EWvSltZhszIEw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">ten</span></span><span style="background:#ffffff;">-trading day period ending on and including October 6, 2023.&#160;</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_COM0rWdBxUeYAqBG44Z5vQ" continuedAt="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span>Stock-Based Compensation and Employee Benefits</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2014, the Company&#8217;s board of directors and its stockholders adopted the 2014 Equity Incentive Plan, which became effective upon the closing of the Company&#8217;s IPO on November&#160;6,&#160;2014. The 2014 Plan is subject to automatic annual increases in the number of shares available for issuance on the first business day of each fiscal&#160;year equal to four&#160;percent (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_7crZcL4mN0ypA7JbGnmqqA" decimals="2" format="ixt:numdotdecimal" name="chrs:RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" scale="-2" id="Narr_HWEi-dUt1UufrkyRMuuV5Q">4</ix:nonFraction>%)&#160;of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors with 2024 being the last calendar year with an automatic annual increase under the 2014 Plan. All remaining shares under the Company&#8217;s 2010 Stock Plan (the &#8220;2010 Plan&#8221;) were transferred to the 2014 Plan upon adoption and any additional shares that would otherwise return to the 2010 Plan as a result of forfeiture, termination or expiration of the awards will return to the 2014 Plan. The 2014 Plan provided for the Company to grant shares and/or options to purchase shares of common stock to employees, directors, consultants and other service providers. While the 2014 Plan allows for non-qualified or incentive stock options, primarily all option grants made since June 2016 have been for non-qualified stock options. Under the 2010 Plan, <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2014_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_9Fk-bFLoyEefRodmTzt7Qw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_TqshrS0P6kK8fBkCNrACsw">no</ix:nonFraction> awards have been issued since 2014, and there were <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_5TOTwxrkukmWntYx2iyH2g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_PWfaudQSnEK1EchGwub9Sw">no</ix:nonFraction> shares of common stock available for future issuance as of December 31, 2023. There were <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_Hh7T20nqkUe4hvfBDJLy5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_s7OJNV_K2keuln-TWTwLHQ">881,231</ix:nonFraction> shares of common stock available for future issuance as of December 31, 2023 under the 2014 Plan.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ckN2HOxBeEWOUdf9ZGq57Q_1_2"></a><a id="Tc_4zefKDWk3EiAq45XlGL6Ag_2_7"></a><a id="Tc_KZgjOoh1ckmN_X6jQJrgbA_3_7"></a><a id="Tc_J2VxV13-Vk2PZ59TC0ONoQ_3_9"></a><a id="Tc_tDIuu5mJDUOgNPDYCmLb3w_4_4"></a><a id="Tc_41bOQsvOwkea2OEBl7FElQ_4_7"></a><a id="Tc_JzIehBeMuU6NAs2yZmw53g_4_9"></a><a id="Tc_J7xwtDaS-U--g79Q7lM7ug_5_2"></a><a id="Tc__M9tio9AukaTn0qLvIoitw_5_4"></a><a id="Tc_WclWa_gBfkePVl4DVzzHQQ_5_7"></a><a id="Tc_HelWl36dv0KGtXShqrAfMA_5_9"></a><a id="Tc_yNMOVldHBUOu4YL4pil-gA_6_2"></a><a id="Tc_tcL9ZL4JbUm6x8pQOJJctA_6_4"></a><a id="Tc_8WyrH7gHsUWw024x-jHa0w_6_7"></a><a id="Tc_rwyovMLeEESpn0OK8akQLw_6_9"></a><a id="Tc_tWn1djoS_0eVyw26Otgj0A_7_0"></a><a id="Tc_jS8C3Lo7_UuGwrnlQll60w_7_4"></a><a id="Tc_64ockZURX0KWKMsFgXHKiA_8_0"></a><a id="Tc_SSSvNKNauECj1pNH52KpRg_8_4"></a><a id="Tc_WVKRgBssJUiYbXWe3v93Pg_9_0"></a><a id="Tc_3mxYaHf5nkCkSAh-kWz3DA_9_4"></a><a id="Tc_NcKj5HRZUUelRa01myjoSw_10_0"></a><a id="Tc_3d7Nsmo5vkupisorgyM2Yg_10_4"></a><a id="Tc_9kVD0sCqFk2GPYZ8pK54yw_11_0"></a><a id="Tc_PbEFU0c9LUCc9RwAxye-KA_11_4"></a><a id="Tc_-AyDCCUfcU2n7JJucWSLjg_11_9"></a><a id="Tc_ROs8JaSdnEWWcuOASsE-UA_12_0"></a><a id="Tc_shLNFc2rQUmc5HdgRQhkpw_12_4"></a><a id="Tc_cmM3obsIyUOSkvXfq6-Exg_12_9"></a><a id="_d48f0b9d_a9af_4b6a_a2e2_5434b24f343e"></a><a id="Tc_I2c-QbPGrk-P2KiAI0me1w_1_6"></a><a id="Tc_hLmdn3hcmE-mRYbcfQO1Qg_1_13"></a><a id="Tc_GnwBqqQ480CnYQSuM4UPmA_2_8"></a><a id="Tc_y7vlbAlVj0yPNO4nh_N_gA_3_8"></a><a id="Tc_IMVFrWhenE2h5euV7SWfYw_3_10"></a><a id="Tc_gDllzabKEE6GQFimKygPMg_3_15"></a><a id="Tc_P3Lb1147qE-sd6Exk8gR9g_4_8"></a><a id="Tc_LlLsjss3OUuswWSByNKqPQ_4_10"></a><a id="Tc_l8cus9rGiEqyIWPKt7JdzA_4_15"></a><a id="Tc_OU9Z8_gZ8EeEoHRXQg20QQ_5_6"></a><a id="Tc_HK_tsxyC7UCeM2ytrDgmuw_5_8"></a><a id="Tc_L2JlTdom4k2KElUHrnOwbw_5_10"></a><a id="Tc_AfiO3TnA_kimfCSzOdwB5w_5_13"></a><a id="Tc_k3nit4MhgUa6TuRUfu_Agw_5_15"></a><a id="Tc_ZOkieYAdD0OA9B94fhVvBQ_6_0"></a><a id="Tc_Z7lyPzyhVkSzB9AtQF8UqA_6_6"></a><a id="Tc_diwYqUTsEUS9R_P1ZRbpnQ_6_8"></a><a id="Tc__mQHgdlal0GR7-Cenu-7Bw_6_10"></a><a id="Tc_xGhwSJurqkmxaQYUQOT-Gw_6_13"></a><a id="Tc_JhIx_wpjp0iMVCjMt48-Ag_6_15"></a><a id="Tc_dU2NRcRTSkCzUawOqutq7A_7_0"></a><a id="Tc_a6LHoCQh8kKA7ToSaT5Bkg_7_2"></a><a id="Tc_UyRxCNYk90m1JeYx35WWXA_7_3"></a><a id="Tc_DNfg9G6SX0Ov19M1_9lQCQ_7_10"></a><a id="Tc_gNK6Ev4wE0S68X1B1Wl8zw_7_15"></a><a id="Tc_dqtCcZsNk0qRzoTHcyyVEQ_8_0"></a><a id="Tc_BwQ3CnFkwUmsfHRP9n1zGw_8_2"></a><a id="Tc_Gz-X1VLNK0-vR406pxsoLw_8_3"></a><a id="Tc_Ni0gkGUKH0SzbLy9qlhtNw_8_10"></a><a id="Tc_Bb0-sdUfykGxE4VNVFaW9A_8_15"></a><a id="Tc_1C4-OafnsEiojQNGQAgHsA_9_0"></a><a id="Tc_nTz-dpe0FUCo1wkw6nruzQ_9_2"></a><a id="Tc_CtZzlfdCeU2pk5MwLJ3NAQ_9_3"></a><a id="Tc_87pm4enaMkaqQJ0NIuEI2Q_9_10"></a><a id="Tc_MuMtVqIGV026oKukVXJzdA_9_15"></a><a id="Tc_5Bh5vYiedk2TXBaUpHz_Ng_10_0"></a><a id="Tc__iproGJ9Ukijc0Q-X6qYBA_10_2"></a><a id="Tc_i8VpxDubZUSqv-LcYt5UWQ_10_3"></a><a id="Tc_IqKdf5ufeUCXB9PUrxPhQg_10_10"></a><a id="Tc_5VfQump-_Ui-tvUb-m34UQ_10_15"></a><a id="Tc_hAVYWB6lcUCOwGe1AbzNtw_11_0"></a><a id="Tc_DZBLb46bwEyAp9aB6-Wjww_11_2"></a><a id="Tc__7WThjqS2EuJaBvXBD3TeQ_11_3"></a><a id="Tc_1OZQYPhnH0Oykp3Xku9aJQ_11_10"></a><a id="Tc_33AFNg23cU-i_roxHAg4AQ_11_15"></a><a id="Tc_op63zHp98ESk7oE4gPKiGw_12_0"></a><a id="Tc_LwbdAF5EtEGFQ0ELg7jbxQ_12_2"></a><a id="Tc_BNOjkb0A5UeOorhX6TDFiw_12_3"></a><a id="Tc_AInKoHlrkE6e0GjQfGNHSw_12_10"></a><a id="Tc_uisk93IzrE-nsgjAYuowrw_12_15"></a><a id="Tc_ahLdjFLGmUGEU1ErEnM71A_13_10"></a><a id="Tc_B-rs82cmr02lVV4JPlde6Q_13_15"></a><ix:continuation id="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont1" continuedAt="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the Company adopted the 2016 Employment Commencement Incentive Plan. The 2016 Plan is designed to comply with the inducement exemption contained in Nasdaq&#8217;s Rule&#160;5635(c)(4), which provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual&#8217;s entering into employment with the Company. As of December&#160;31, 2023, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EmploymentCommencementIncentivePlanMember_PYQsmuC8gEmAkSzwx_wKQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_wFn8DdLfZ0OdXQTL1A3kLg">1,773,921</ix:nonFraction> shares of common stock available for future issuance for new employees. The 2016 Plan does not provide for any annual increases in the number of shares available.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option exercises are settled with common stock from the plans&#8217; previously authorized and available pool of shares. If any shares subject to an award granted under the 2014 Plan or the 2016 Plan expire or become forfeited or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool. The annual grant to eligible employees can vary depending on the type of award, and the award size is determined by the employee&#8217;s grade level.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incentive stock options and non-statutory stock options may be granted with exercise prices of not less than the fair value of the common stock on the date of grant. These stock options generally vest over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ahD7R902V0CUv6tp7i0KZg">four years</ix:nonNumeric>, expire in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_4mJJLSwH3kqEvpmlNWOo_A">ten years</ix:nonNumeric> from the date of grant and are generally exercisable after vesting.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the summary of option activities under the 2016 Plan and the 2014 Plan:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_5oP-UTk6mEOWltiH_rD52Q" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Terms</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_79jf7MP140i3lgc8RT2n0w_7_2">21,691,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_TIFJVJYXo0KCesdcVi3Ghw_7_5">15.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted - at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_0L9lm3isBkKAb28WjCphcQ_8_2">5,947,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_FcpTIQdbCUOsOnh1eZ-AvA_8_5">6.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EOqzHJl4Y0W5sbAeFBx1RQ_9_2">430,504</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_jfOrWYuj_UmN6kQcIZJOkA_9_5">1.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/Canceled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_w-ZUCEAv40myYMoIPXojcw_10_2">3,549,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3N7uqOfNDUmS_7_qoolZxQ_10_5">14.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_kpf4rxkygEiFWXQBDVajDg_11_2">23,659,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_jzVzmeJijUCETlgGpEmUhA_11_5">13.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_FpHbOQc9Kki0fvtyvx0ERg_11_7"> 5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_VEhYPfUnaUWJV_NBdklSRA_11_10">2,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_-JYj3Q-7rUCtYj_XhlI5Vw_12_2">16,279,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_wSjGmJZC8kqjJa1dT7WXpg_12_5">15.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_uBcUhsg2f0Kr8j5T9mnQqw_12_7"> 4.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_Doomx5Mms06O1Q-zje_9Cg_12_10">1,815</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aggregate intrinsic value represents the value of the Company&#8217;s closing stock price on the last trading day of the year in excess of the exercise price multiplied by the number of options outstanding or exercisable.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_GdddJFxLvk-slm4v3Fn14g" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information on options outstanding and exercisable as of December&#160;31, 2023 is summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:42.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Terms</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Exercise Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_mpziosAu40-Nkyimg4HXEg_7_1">1.67</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_NnH9FNYHoU6gWEAnvoB_3A_7_4">5.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_rNbnsIfgpk6Y0c9A419AAA_7_6">4,288,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_CFEjMuDq9kWqMIuhOBx0uA_7_8"> 6.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_tQLrjJZEYkafue92uCK2tw_7_11">3.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_edK74OY260C4qIcsGZbYvw_7_13">1,356,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_dNbcFtMxDU20QsOiWoDXGA_7_16">2.32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc__rmAxzSXckKhASA6_PgP7w_8_1">5.86</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_M-Anfoz1B0iCesfDNk5UqA_8_4">10.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_yTPdNwypvUunmuV_lZQl4w_8_6">4,493,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_JzepPIINFk-JUtXdShGwDg_8_8"> 6.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QKG09-dxfU6uGHiLHzoq7A_8_11">9.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_iEcNQ4iJCUCrGowWKqxDLA_8_13">2,436,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_3mseEavT-0eBbh0VQ6JuJA_8_16">9.45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_7jB-KYQie0Cxp4wst8kXWw_9_1">10.37</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_fs4dBBbMh0-aF_wZ5KjHzQ_9_4">13.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_dSPS-MKZrkmicHkkYsDKiQ_9_6">4,143,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_doDx4x9mYEWHe-w_960P8A_9_8"> 5.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_GhWvbejMEkiry26grUrwoA_9_11">12.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_zv32kBSNDEilU0PJrwOLtQ_9_13">3,317,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc__tnKZxc48ESCpml320039w_9_16">12.53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_djNXWOomfUKGQMfMBwr1Tw_10_1">14.03</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_Yb8aqvyf5keOkjWqZ_HUaQ_10_4">17.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_UXgiLyC-5EGFaQ1_-viU1Q_10_6">4,436,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_R4FsPUTQhE6bb2azJXJBjg_10_8"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Urhe4Oih_UOOhA1Wrt0Vtw_10_11">15.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_twzBWCoSz0uSE4u9nZMf1w_10_13">3,304,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_WetYuo3FXkyrnCCHx8FN0w_10_16">15.86</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_KyJKwlBQDEK23jB_stFA2A_11_1">17.30</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_s5ouM9Zu1EGvaX4q_B2UVg_11_4">19.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_E01b-3pq3kmY6VAo95YuKQ_11_6">3,827,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_-R6eyKOuoECLdAyw6BbLmA_11_8"> 5.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_SysuWi23i0GJMvDTzjRRGg_11_11">17.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_C-T2DRjtRUiwY87scGu1Zw_11_13">3,403,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_A2hLlbw02UiP4BwlA-dtEA_11_16">17.95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_uyO0qchhN0-Tw4dIiS5DvQ_12_1">19.85</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_pIjpJuJLGEqzAUZzGNcCjw_12_4">46.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_9VmTBdKwI0ucKOmCw1m4Ag_12_6">2,469,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Ck1TAXDXtUCgGSif7XrqcA_12_8"> 2.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zkel-U6Yf0SFk9WNkb3LHw_12_11">26.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_JmxqPr9bBU-5mvS3BqWXmg_12_13">2,461,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_G9rmDL947kSzOOc-9V5J9A_12_16">26.91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_-47NzdNRdUmfQXvUPxq4Sg_13_6">23,659,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_FG68CS3yP0eg6xtVho7h2w_13_8"> 5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_51d0Lu08KUaYaGv0sYuDUw_13_11">13.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_UM8LCdLcc02UJQWoeJpSGA_13_13">16,279,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_ffSlroOwakyGCiPEtRGAfA_13_16">15.20</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IWT7YkB4ukaiLkzPM_-uvw_1_2"></a><a id="Tc_Rsy9lXbtbUWtCgFTWCMZUw_2_0"></a><a id="Tc_JMP6ep4nFky_rDxuJ7qLOA_2_2"></a><a id="Tc_EZuOnI27K0m3gvctFEaZtw_2_5"></a><a id="Tc_cywUBvtDMUyNqxupzaX4Cg_2_8"></a><a id="Tc_CeQQl8cGlUS5cBHKHdCF3A_3_0"></a><a id="Tc_kHl7wFFztkSUrj9CVJCnmA_3_2"></a><a id="Tc_QN-RiOUCMEaPy3ykmMJH9Q_3_5"></a><a id="Tc_hvPoNllSf0i35T3Gv5i-Tg_3_8"></a><a id="Tc_-ECj8tqHb0uDQHU3L0jqXw_4_0"></a><a id="Tc_COWtpgc7aEed4h6CwOdMJg_4_2"></a><a id="Tc_si0uRRlSw0G5_Wqoe7Auew_4_5"></a><a id="Tc_fNNojg4Lf06IgXq29JmpUQ_4_8"></a><a id="Tc_YbhLMg3rxkqJjs-mUwYyjg_5_0"></a><a id="Tc_ukyhaUiuokysRcu9_M4IjA_5_2"></a><a id="Tc_w-4aOD6wkE6I04zvNkyRsQ_5_5"></a><a id="Tc_mnZEJvxd40KZb_g-POn07A_5_8"></a><a id="Tc_rs2twKrD-k6QPzHoNGpEGw_1_2"></a><a id="Tc_9Vg55TT32UagliZy7bOLMw_2_4"></a><a id="Tc_1XPUzTvA8UqMfxr8_Nkn4g_3_2"></a><a id="Tc_xZBuCFRGTEKKHtac7d3TsA_3_4"></a><a id="Tc_TrYgWWDKeUeW4ECFhTdLOQ_4_2"></a><a id="Tc_9_R3hVxr20WOp1JlFYSvjw_4_4"></a><a id="Tc_9O0xuR4oDECdaOT-Hwcv5A_5_0"></a><a id="Tc_6a3kgWLyqE6gN1flVHUHPw_5_4"></a><a id="Tc_NdPnMf1HoUeL74pxzDBnhQ_6_0"></a><a id="Tc_TCLGgMvmtEmVV0nCu5cxwQ_6_4"></a><a id="Tc_6-U57Ql91UGSnRV4CVDnsw_7_0"></a><a id="Tc_IbRLA-96FkSTYZppzC8bUw_7_4"></a><a id="Tc_Rsusx3JWMk-9BgYSE4HvgQ_8_0"></a><a id="Tc_xDiXJaN72EauTelAYHJNmA_8_4"></a><a id="Tc_Rkm_r1qqk0K2V4ENkLIX-Q_9_0"></a><a id="Tc_81yo3T---EaO1vK8bNebPg_9_4"></a><a id="Tc_AqlMnIqt_EuVvusvub3dsw_1_2"></a><a id="Tc_342XEbjzSEiPq6TrYkJ42g_2_0"></a><a id="Tc_hhuQ76V5NEu3xtthPzraog_2_2"></a><a id="Tc_BEaQpgVFRkCoc9O6RMI7IQ_2_5"></a><a id="Tc_WvjJrHVisUmOKgdzCqeRpA_2_8"></a><a id="Tc_w52lP8VRxUW9OLri83mvaQ_3_0"></a><a id="Tc_dhN0nueBk0Crm2kul7DFVQ_3_2"></a><a id="Tc_SCHTIZ3EH0yOk5PDo2Q_kQ_3_5"></a><a id="Tc_Qak9RMTij0mt1RTAZccXMg_3_8"></a><a id="Tc_1cMT_8VPaE2zijGrpMHbZw_4_0"></a><a id="Tc_MfuQpQiU5keKwsLCThZi2w_4_2"></a><a id="Tc_VTSaGSm3m025xuc7u_589w_4_5"></a><a id="Tc_rGQxgkwUrEqw-KwmDjaTzQ_4_8"></a><a id="Tc_UoyKpxOn1Uic65lGs5ItQA_5_0"></a><a id="Tc_ydp0TgfTqUCOVsyEiSopDg_5_2"></a><a id="Tc_DjxHRGjXuU-ydcWQ8J3C1Q_5_5"></a><a id="Tc_ziJDN2TRYkKO2MdGqwN1AQ_5_8"></a><a id="_Hlk126097542"></a><ix:continuation id="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont2" continuedAt="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont3"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional information on options is summarized as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="chrs:ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" id="Tb_Ir0s1vt5b02LRJ7gLIxWrQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except weighted-average grant-date fair value per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total intrinsic value of options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_lW2kCcn-kEqRX1akvFTn4A_3_3">425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_kZ5joux6nE2w7sQPzpaPbg_3_6">914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_8cK3vn8_zEukSyfbWjzkOQ_3_9">9,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of options vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="Tc_ZvWk4WI70EOM7egYVupO3g_4_3">30,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="Tc_a1UH0VLcHECLn-g-4e1QKg_4_6">34,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="Tc_-2fZP7daAE6Y6-H_jR5PnQ_4_9">40,365</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average grant date fair value per share of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_NOHvrxgZ9E6TOGwEfEcH0w_5_3">4.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_7kpUPb_KoUqWpsCurKQ-gw_5_6">7.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_ab31qecE7021vJUPVhRoLw_5_9">9.80</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, total unrecognized stock-based compensation expense related to unvested stock options was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_Nms7y8PHtUuzUD__ZMwq1g">37.4</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_yafBzMQkG0GR7CMxvilzlA">2.3</ix:nonNumeric> years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants RSUs primarily to its employees. RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The RSUs cannot be transferred and are subject to forfeiture if the holder&#8217;s employment terminates prior to the release of the vesting restrictions. The Company&#8217;s RSUs generally vest over <span style="-sec-ix-hidden:Hidden_AKrDviHwTEWrO6-oIS4MzA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZaEeUbUKZ0m5v1ED2M0RTA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ULgmyMRl0Eixc5xDBsFOFQ">three years</ix:nonNumeric> from the applicable grant date, provided the employee remains continuously employed with the Company. The estimated fair value of RSUs is based on the closing price of the Company&#8217;s common stock on the grant date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the summary of RSUs activity, under the 2014 Plan:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Group_O05y5bB3A0-cvDDfX2duLw" continuedAt="Group_O05y5bB3A0-cvDDfX2duLw_2" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Balances at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_HRPY2CuBBUil2thPMWQoWA_5_2">2,333,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_1N3ascPjfEK0ZUNYHYU-MA_5_5">14.66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_QcfGVkRX30W_9Y3DKtZrpQ_6_2">1,274,753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_fSYwir6MN0WJdwRbeOqzFQ_6_5">8.93</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_7tosUKSG50iZMQZgb8WuIg_7_2">1,280,901</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Bc_gh4rhh0WBej23j3DI5w_7_5">14.35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs canceled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_Ipk0fkJjIU6xr5QBrOAePA_8_2">600,430</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_NmvV2wGUm0eGDUcLeMZuEA_8_5">11.02</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Balances at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_z55qAjKQ4UCOtKyxIQi_PQ_9_2">1,726,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_tCcCSoo_7kKLxj_zepekow_9_5">11.93</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additional information on RSUs is summarized as follows:</p><ix:continuation id="Group_O05y5bB3A0-cvDDfX2duLw_2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except weighted-average grant-date fair value per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of RSUs vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Tc_cUVB9Snas0K_VpWZL9ty0Q_3_3">18,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Tc_vSbr-1ffMUm6CsFA_ZTtMA_3_6">13,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="Tc_ql5a_RT5EEuhBFK6C0jXZQ_3_9">8,434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" scale="3" id="Tc_WtCVsO1L6UCc4mEK9-advQ_4_3">11,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g" decimals="-3" format="ixt:numdotdecimal" name="chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" scale="3" id="Tc_GtTtZx8VeUaE7FGM0Sudag_4_6">22,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA" decimals="-3" format="ixt:numdotdecimal" name="chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" scale="3" id="Tc_ehe9p-4-7ka-YMbJbxRDAQ_4_9">27,869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average grant-date fair value per share of RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_7n3DPcV3nki0yG8EmS-NDA_5_3">8.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_ZqMpzgYuQ0yr0FhK__GlPQ_5_6">13.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_vSwzjNXAPEirIGrrsUPIGg_5_9">16.86</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, total unrecognized stock-based compensation expense related to unvested RSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_aMwjkOgCDk6T9W3Qk4N54Q">10.8</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Zwm_bONmeUum6vu4tSRuiA">1.5</ix:nonNumeric> years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the ESPP. The ESPP provides for annual increases in the number of shares available for issuance on the first business day of each fiscal&#160;year equal to the lesser of one&#160;percent (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_10_31_2014_To_10_31_2014_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_Y3ICWQYaSEa4JfXz8gYGiQ" decimals="2" format="ixt:numdotdecimal" name="chrs:RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" scale="-2" id="Narr_3SvIxvC4y0io28e2Qkj4ZQ">1</ix:nonFraction>%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. The ESPP had <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_P0nsKUTu1ESDW7kPniTMTw">2,541,769</ix:nonFraction> shares of common stock available for future issuance as of December&#160;31, 2023. Eligible employees may purchase common stock at <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_vNRcjLnu3UGpHYvMyosgoQ">85</ix:nonFraction>% of the lesser of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period. The offering periods of the ESPP are on <span style="-sec-ix-hidden:Hidden_VnDr0p6zgkaCQAXWjop8Wg;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">May&#160;16</span></span> and <span style="-sec-ix-hidden:Hidden_y3PMsjUAX0CNLgPeFQI8aw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">November&#160;16</span></span>. As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_Nk2lU-hUBEeNjbT_R5_2QA">0.4</ix:nonFraction> million of unrecognized compensation expense associated with the ESPP, which is expected to be recognized over an estimated weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg" format="ixt-sec:durmonth" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_4oCf78x9CEKcAlwlXLnMCA">4.5</ix:nonNumeric> months.</p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_492a9556_22a9_4506_bca1_32784ec9c6e9"></a><a id="Tc_JC6-t6uaQ0yRhoLrZtg9Sw_2_2"></a><a id="Tc_q1VnjS2TakCVSBMDArmyqw_3_0"></a><a id="Tc_AEQ6_SfK_0O0yx9dCzHPAA_3_2"></a><a id="Tc_aA5uclx0akColame4MHqPQ_3_5"></a><a id="Tc_4Vfkpd0XXEye4A0RgH9pQw_3_8"></a><a id="Tc_ZEibpeHbq0yBzi2W8qwvAw_4_0"></a><a id="Tc_BHBV8I6M1Uy8tj5mP3BXEg_4_2"></a><a id="Tc_k3wLXE_Yt0y1E69F80sBNQ_4_5"></a><a id="Tc_SVf0LdN28U-NcDI0wo42rA_4_8"></a><a id="Tc_yF5LEvz5N064SDZ8b0ORsw_5_0"></a><a id="Tc_elupIk9ZFUawT_YqAWAalg_6_0"></a><a id="Tc_QfgMfZeDQUK-X07QiWqmOQ_7_0"></a><a id="Tc_PBhdnn6uL0W6OuQk2srtdw_7_2"></a><a id="Tc_6GzHSvca_0agGoT90sN5RA_7_5"></a><a id="Tc_1a-tsKoCM0q5vtVi8IAhIQ_7_8"></a><a id="Tc_fSFH78dw2UWBXU5oON7fEA_9_0"></a><a id="Tc_steqlB21JUCgdnxNuLacGg_9_2"></a><a id="Tc_tIrV45DcgEiFGS1_qO4O_Q_9_5"></a><a id="Tc_3Lm3iN_cg0uB0B0lp1SfTA_9_8"></a><a id="_cff4075e_f3fd_4125_88c3_57182bd3fc59"></a><a id="Tc_8Ev1VqgE0EGeAINgONR2_w_1_2"></a><a id="Tc_EyeSvuxMnEq2dB5aPvIadA_2_2"></a><a id="Tc_gBGeFz1iuEGqzyeAk98SAw_2_4"></a><a id="Tc_KRD9PxBQ3U-d_MlEVPAFmQ_2_6"></a><a id="Tc_9afPhmWXw0usES3AFEfbPQ_3_0"></a><a id="Tc_ljbHArKaakGyEcNl42kHUw_4_0"></a><a id="Tc_tmcJl4kWxkWQa_Hm8d8DVA_5_0"></a><a id="Tc_kWymGjfNIUmxx-le2glFvA_6_0"></a><a id="Tc_ZLYVTdVyJEeB1eAwum3RsQ_7_0"></a><a id="Tc_NWgW8DGtj0q88KqiWshA5A_7_3"></a><a id="Tc_CzXW7G8b_kW002hxA4bsiQ_7_5"></a><a id="Tc_1PFKgB9cpEyBkrUQfab2pg_7_7"></a><a id="Tc_RgDf7uGex0m_b00G2pvouQ_8_0"></a><a id="Tc_-H0upjf-xkOtOHEfF1hpdw_8_3"></a><a id="Tc_3dU2-V9vCEiVqaguPIMlqg_8_5"></a><a id="Tc_PWjxn9QxvEe33ssyGR_P5A_8_7"></a><a id="Tc_e11wi9cPqUe6HHK4hJFl8A_9_0"></a><a id="Tc_n01MtCWgUkW_MM7oFnlgBA_10_0"></a><a id="Tc_CmBbGxrHSUqun-hTIoDi_w_10_3"></a><a id="Tc_lharDO6t0kaBqwVYgFO7pA_10_5"></a><a id="Tc_Fq4Gv43CZ0Cui9obdVwiMQ_10_7"></a><a id="Tc_sEKmCKlCYkCpbyZYBqlEVw_11_0"></a><a id="Tc_3UHX1Yt3bUKTt9_IHZx4Dg_11_3"></a><a id="Tc_ZZh-wlAiFEqAsXc4bsfexg_11_5"></a><a id="Tc_RfdiS0FVVkGi6pAZRh24Vg_11_7"></a><a id="Tc_mmvMSLoAFEu8pWs8Ts5P6A_12_0"></a><a id="Tc_UNosj2NtX0ifNt8KVnlMug_13_0"></a><a id="Tc_-8xcB41foU63xV5dqYQUTQ_13_2"></a><a id="Tc_eCHNOMQ8F0KTENqdLyV7hw_13_3"></a><a id="Tc_zeiWshwf-UCMqTgfKsCXcw_13_4"></a><a id="Tc_bmdDQF8WdUyWzp324RPLfQ_13_5"></a><a id="Tc_ph0Yb_65F0irq3vA6ZjWMw_13_6"></a><a id="Tc_ob-k2PAuvEenVyFc0ALIfw_13_7"></a><a id="Tc_sxPJEcsS-0C6zcqvArIycQ_14_0"></a><a id="Tc_aSzzYskPgUyzqaoqY-hNxg_14_2"></a><a id="Tc_-r2P4uCYXk6_b_lz5Pfx5Q_14_3"></a><a id="Tc_x2ru48SuJkGGjIZTy3XBeQ_14_4"></a><a id="Tc_mYgTQqJYZU2H3tWqVs1K5g_14_5"></a><a id="Tc_WtNtORdNuEG_VtS7ClJwNQ_14_6"></a><a id="Tc_XZs343CdFEKesX2vkmLA1g_14_7"></a><a id="_Hlk94253824"></a><ix:continuation id="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont3" continuedAt="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont4"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the classification of stock-based compensation expense in the Company&#8217;s consolidated statements of operations related to employees and nonemployees:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_9_Lc7Swh-EqOZ7QhB29W4g" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XMbrH6JTt0C2lK2IbdxkqA_4_3">632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_yPWVLupjLUC-LrZ0QvW9YA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_SwFPg1Q9m0ydX_1EnHDMaQ_4_6">736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_i6sG_wGq0kGSogKwmLXRFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_QooXm4GBDEi0pYHGoPUQqw_4_9">1,099</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wrjDrMYWnEG3vQ3_hGdwAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_S6RQ2UJlzkqgQx7b7OjGrQ_5_3">14,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rdMdgsUj7kOwcgAE94-32g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_oFl_QJ1-10uyAKAyNVDmIg_5_6">18,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Lv-W7pNdHEiIdf02okAMpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vlurBlj5wEiJ4y_uphArEw_5_9">18,688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jItQvbGTK0Sy8MYmJwHtDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cvj3VpmHfk-9gNgmTClF-A_6_3">27,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_V7Ntz2koqkOY3qfjC84Z6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TtXv7k0r0kaetVfrhqIT-A_6_6">31,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_X4a12fHdGkKcfkBHCiHSBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Er_h7m-VcE2GLYjXKK_FqQ_6_9">31,577</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_n-5BhGCImk-NJFttNlHmcA_7_3">43,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_d07-i0lz7kqo9Ew-fMnuHA_7_6">50,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_EWbWKmK3M0qp5t-83_IdgA_7_9">51,364</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_BqkaWa80H0aUpeWNTP7vOg_9_3">1,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_srqwsum_GUaB7z3fWZJFrg_9_6">1,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="Tc_-_O8MnufV0q-D5-JQrvkyg_9_9">1,025</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The stock-based compensation for the year ended December 31, 2023 includes restructuring charges described in Note 15 of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_PdGnVstbm0yndk6laylDZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="Narr_TpTCVSn4xEGs7sOX1PQn8w">1.1</ix:nonFraction>&#160;million in research and development expense and a net forfeiture credit of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IQec6wbqNkyXTV-ONWSp-g" decimals="-5" format="ixt:numdotdecimal" name="chrs:ShareBasedPaymentArrangementForfeitureCredit" scale="6" id="Narr_Vr5NLv-DCUmGjchpLJqZ1w">0.1</ix:nonFraction>&#160;million in selling, general and administrative expense.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The stock-based compensation expense recorded in connection with the Surface Acquisition that was not included in the consideration transferred was immaterial.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Valuation Assumptions of Awards Granted to Employees<b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of each stock option and awards granted under the ESPP on the date of grant using the Black-Scholes option-pricing model. The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of the awards during the&#160;years ended December 31, 2023, 2022 and 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_Y45Aq82Jx02ORrlaALyfEQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_A5RPhIW44EyyntZqus5xww_4_2"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_OgnBrSbosE2Aict459OVkA_4_4"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_EEgB6I1dhUmkaNSIlpuuFA_4_6"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_99cId7PsxU-ethwwxR4o5w_5_2"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_EI9Qe0mU50q_3zte7_EYww_5_4"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Rumpuzyz4UGWbvMXhvlXWA_5_6"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_YFLDwK5SAUG1JBVpgwT5dg_7_2">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_vyvDxHweHUaRixAqHzVVxg_7_4">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_U8iDmYo8oUmfZpidgX_P0A_7_6">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ZY94RjWh0U6zPIj_h_b4qA_8_2">105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_1g9lkZRddkWdvUWx7KUzRA_8_4">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_cb6ZSnIjRUyacMp7S9y7Kw_8_6">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_82QpjOJLY0K6ROUZyaBM6w_10_2">3.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_MrL2WezzpkSyafBqgQQMKA_10_4">2.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_mxunIZBUb0yVomCS3E2Org_10_6">0.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_Qny2lADHbkmUQVZ7LxULYg_11_2">5.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_a0sAMFNGmU-YSGaFaoquCw_11_4">3.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_SB0t8YakTkqvjRZPFBt2WA_11_6">0.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term: </i>The expected term represents the period for which the stock-based awards are expected to be outstanding and is based on the options&#8217; vesting term and contractual term. Since January 1, 2021, the Company has used historical data to calculate the expected term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility: </i>The expected volatility is calculated based on the Company&#8217;s daily stock closing prices for a period equal to the expected life of the award. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate: </i>The risk-free interest rate is based on the United States Treasury constant maturity rate at the time of grant using a term equal to the expected life.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends: </i>The Company has not paid and does not anticipate paying any dividends in the near future, and therefore used an expected dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_y-D3rN7e8k25U0mnRZjvqw">zero</ix:nonFraction> in the valuation model.</p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_COM0rWdBxUeYAqBG44Z5vQ_cont4"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">401(k)&#160;Retirement Plan </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">In 2019, the Company&#8217;s Compensation Committee approved the Company&#8217;s matching of the employees&#160;401(k)&#160;Plan whereby eligible employees may elect to contribute up to the lesser of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_s5c_u_nwN0uYnEawr_ZR3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_TOh3kDFLLkq6WI1_4hsAHQ">90</ix:nonFraction>% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. Beginning January 1, 2021, the Company made matching contributions of <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_OyFP1Z_MlUylfCLom3PtlQ">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_fo0yiw1iyUiG0i_wC4e7wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_oBDZjdLSM0mfu5Mdhz-NFQ">4</ix:nonFraction>% of eligible compensation, up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_olJuRbSk30m5yrswpWCbjQ">7,500</ix:nonFraction>. The Company recorded compensation expense related to the match of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_Plan401KMember_GZqVTPVTJESoNA_KLec_Tg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_kIPrv64o402seZG5t4vBBg">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_Plan401KMember_vkpLaKLvgkiXZssii_XeDQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_mttle6d5NkKraTDy6uFIbQ">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_lNjCDd30AUOs6J6vHJl6RQ">1.7</ix:nonFraction>&#160;million in 2023, 2022 and 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_IAR6JyEWJEa6oNSo6FuWFA_1_2"></a><a id="Tc_ukv8kapzZkS1koluAgHjIQ_2_0"></a><a id="Tc_QHCzBZ9cTUOheQ4PtA1Jtw_2_2"></a><a id="Tc_O4Jywgu7r0aU_kaCIs3WnA_2_5"></a><a id="Tc_8Qsh4KXeA02JE4PBqYeaKQ_2_8"></a><a id="Tc_ZKNdp5_0DUmI32RYRlXZpA_3_0"></a><a id="Tc_UNzA-_HGGUenPZ3OMFW0WA_3_2"></a><a id="Tc_EjN6HvIA80SvSWepTcBseg_3_5"></a><a id="Tc_MHWf9Kxj1EWLubMXI2VkZw_3_8"></a><a id="Tc_RqaDG0AVSUyqFYJl-TwerQ_4_0"></a><a id="Tc_Du-wE4gMAkmVyBuxDZO71Q_4_3"></a><a id="Tc_L_PCVxv3oEmAuaLNbk3Rqw_5_0"></a><a id="Tc_Dx4ztvUcJ0-OU7oR3dVABw_5_2"></a><a id="Tc_Ycb7pYe4bkymdW_bbLmLGA_5_5"></a><a id="Tc_Pa6VqIl7L0CKD0WDDWKTIg_5_8"></a><a id="Tc_fEwbbznklU2rj1dmGPJHZQ_1_2"></a><a id="Tc_aJ_sjETjKE6SqvtVZMlNgw_2_0"></a><a id="Tc_VL9svqDo0E6vmX1heD7gkg_2_2"></a><a id="Tc_e9UFkJe8zEy3Dbzj0H_V3g_2_5"></a><a id="Tc_GxnTb0Z_nU6LLEkn7qDgpw_2_8"></a><a id="Tc_J31dFoQdOkmR06w_8f9BwQ_3_0"></a><a id="Tc_1-iucOPcZk2hc9ClPxCLXg_4_0"></a><a id="Tc_E2Yh0orPgEGNiiiX7idG0g_4_2"></a><a id="Tc_Sq9TSms9_UCFjGGTU-W4Og_4_3"></a><a id="Tc_fttGmiQtgE-fhYGUv8fCOA_4_5"></a><a id="Tc_w_Hykg19mkCaxllX5MTXFA_4_6"></a><a id="Tc_BdU2iDUhUE6e1iW3ZCjtUQ_4_8"></a><a id="Tc_fB81jSalcEa0my31yPG85w_4_9"></a><a id="Tc_her8JOjTBkqDhJYOTWu1fg_5_0"></a><a id="Tc_ddSW42jLpk6Bk9VT1ZrOhg_5_3"></a><a id="Tc_HKyQ7frhUUyFsZimd9a5tg_5_6"></a><a id="Tc_TIdWAoHI8kqdgma-jO7V0w_5_9"></a><a id="Tc_W1y3Io4y3ke1DwvZ6pkgxg_6_0"></a><a id="Tc_XKgmPxuIRkSDSdjE5bwPrg_6_3"></a><a id="Tc_4LXPOQ9XOkSxefYbH_eEeQ_6_6"></a><a id="Tc_zigxlXVaaUuPxAXuSk3iqA_6_9"></a><a id="Tc_i94R0W9tmUehh8Hcf0_c0g_7_0"></a><a id="Tc_e0N9177vZ0qodb_B5DTPrA_7_2"></a><a id="Tc_GAdoTeIUgEyVnqROjTyung_7_3"></a><a id="Tc_XpdWB4mGsUmxK1VqsJcFLA_7_5"></a><a id="Tc_XJuEunOJFEeSSuxriapdeQ_7_6"></a><a id="Tc_H6ZXwM8LuEGtgij01N5djw_7_8"></a><a id="Tc_WbFBQ-h3mUylvTT82ebcbA_7_9"></a><a id="Tc_4eGRebc7s0Oh0PId8y3pkg_9_0"></a><a id="Tc_RcEhMwqV50mzFol6O33OTg_10_0"></a><a id="Tc_qtI4FkZR00-SZ0PbhIH3dA_10_2"></a><a id="Tc_qtlO1tqOjkWkrDxsh8wXqg_10_5"></a><a id="Tc_8W34Cgk67EOvU2RxjpX8Ow_10_6"></a><a id="Tc_Mjihwfx_1UWnoLzPZlxpvw_10_8"></a><a id="Tc_t7fvdebmN0SuovkBzoDBKQ_10_9"></a><a id="Tc_NNIupNLQgkyAtRL11eZGaA_11_0"></a><a id="Tc_SpjJ56AeVEez8g2Omyu9Zg_11_3"></a><a id="Tc_RW3wzbHkSEGmVLS3QBEpcg_11_6"></a><a id="Tc_a6GDnW3dOUaOZuJ8LFp0SQ_11_9"></a><a id="Tc_aphZZDhfOEevZcgKedFUYw_12_0"></a><a id="Tc_7uTUBSWx1kqqhGFWDO-6MA_12_3"></a><a id="Tc_vjJutCG2gkCnjMuUR3MJcw_12_6"></a><a id="Tc_GX6UwDrYS0WikH0lroD2cA_12_9"></a><a id="Tc_IZbPtv5DRE6sumtnN_5pew_13_0"></a><a id="Tc_rVKvE86Q2kS0PtUVPGJiWA_13_2"></a><a id="Tc_WOvp2E51fkq-iU23tnDVow_13_5"></a><a id="Tc_RbEL0kzE3UeGGhAnBwumnA_13_6"></a><a id="Tc_QpsutAbqvkWmfc9VkSLzKQ_13_8"></a><a id="Tc__wGDQMfRQ0uxtuXnY0HwXg_13_9"></a><a id="Tc_DdnqZzOQUUCfSFlmbP3zNw_15_0"></a><a id="Tc_wcOqUuw_S0ac-Zu1_pV_Iw_15_2"></a><a id="Tc_LXCaMDmpwUCUj37AiVxl5Q_15_5"></a><a id="Tc_ZIaWuT5LZ0GDVZYXq-bk4w_15_6"></a><a id="Tc_nGXwmLePck-YDvWOTl8seA_15_8"></a><a id="Tc_dDTi12m8GEa9TERdzkdPSg_15_9"></a><a id="Tc_nzTBmFuzXEORZZ5gcWiqWw_1_2"></a><a id="Tc_BLqNFR2ZxkWucO3JvY5goQ_2_2"></a><a id="Tc_Bm09UwzRSEKTWd6eQxNHzA_2_4"></a><a id="Tc_sue4s3S-nUakf3ziOxGqPA_2_6"></a><a id="Tc_Z4a8bIvSSUOMS8EaB0GpZA_3_0"></a><a id="Tc_FoF66FavWkart4-S1QnLdA_4_0"></a><a id="Tc_skJ6DOkP0EeC4oHSWFVTSw_4_3"></a><a id="Tc_Yb9nRRDhq0WEw65QrZ_EuQ_4_5"></a><a id="Tc_NbuyYW9Xn0S9JwuGbN2Znw_4_7"></a><a id="Tc_fAcENZKFy0WPDflvgliKvw_5_0"></a><a id="Tc_DTVAax45q0qylVD8YMVK3Q_6_0"></a><a id="Tc_e2-t8Lsvb0KMIv-TnbKBFg_6_2"></a><a id="Tc_KA4wNHRsZUqewbcf8fksgg_6_4"></a><a id="Tc_Qu3FyjohvUqDTKiP15Am1Q_6_6"></a><a id="Tc_T8rM1ybQi0GqeptgeEiJ8Q_7_0"></a><a id="Tc_SVqenEFJTU6kPL4GxeBBDQ_7_2"></a><a id="Tc_HD5gBw8Eiki3NEjKYLzNwg_8_0"></a><a id="Tc_qr3AnQlsz0i1i_z9smdGcw_9_0"></a><a id="Tc_QR9MAErGW0CLDzBeaGu-jw_10_0"></a><a id="Tc_mRq8M_LUwkCLAmkooISFbQ_10_4"></a><a id="Tc_f2Az0zZznkG9ru2sj1cQTw_10_6"></a><a id="Tc_A-M1rBq76kGvtHARp3c3pQ_11_0"></a><a id="Tc_XotmKA1tH0K_TC_aQG99BA_12_0"></a><a id="Tc_bQA1VwWyZEeRZ8WH2KxjUQ_12_3"></a><a id="Tc_UhYZPa1HhEq72defFS1sMA_12_4"></a><a id="Tc_iw5ZINjfQEqEf3CCFhCTAg_12_5"></a><a id="Tc_XfJrtHC35kGZXgZ8j0Beow_12_6"></a><a id="Tc_ju3MiNhFRUezO-3V5Ri3tQ_12_7"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_DALK5EgAxUyM0MePQZf2tg" continuedAt="Tb_DALK5EgAxUyM0MePQZf2tg_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></span>Income Taxes </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of loss before income taxes are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_H-5GT8O0ukmX1FhqwCp_BA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_LbXp_d2AckKlHs6BSpSJ6Q_3_3">238,272</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_VBSA7-WN0U6ANvKZWDiQvg_3_6">291,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_Ouu63YFjUE28uYmSruUQ7g_3_9">287,058</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_-TZGQBLFokSoJj5ey4Sd-w_4_6">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_Zwg6WWFRbUKQ8Gh9d7xynA_4_9">42</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_nqIaFVb3x0uTV5OCs-r0Rg_5_3">238,272</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_R1fVgrRXEkKuIgroBUdllQ_5_6">291,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_7TNOqmEHvUydbOlJMzsF2A_5_9">287,100</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">For the periods presented, the income tax provision (benefit) is as follows:<b style="font-weight:bold;"> </b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_jPDGFyF-C0yqq2Q-ncW-Ug" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_U2SSzJzHxkGeEq1DyCpCPg_10_3">380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_MR38Z_h7q06HdyE1Tmm6_w_13_3">380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Income tax provision (benefit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_xxOylnn_YUy0H-AlN0gwMQ_15_3">380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_DCg0IU_TC0qgztPI1UIhMw"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_HgiLWUNDk0Ww8MbLLw-Mvg">no</ix:nonFraction></ix:nonFraction> income tax provision in 2022 and 2021 due to the Company&#8217;s history of losses and valuation of allowances against the deferred tax assets. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">A reconciliation of the statutory United States federal rate to the Company&#8217;s effective tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_fM49CenuR0SW7ntiGxtKyQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Percent of pre-tax income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">United States federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_wfYH7FwCgUq8WeD3l9nIPw_4_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_OgbvNa4HqkWeV-DfyTDc_Q_4_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_JnzBWq5INEyuIHms_v86xw_4_6">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_c7F3AUf9U0Gn9xHR1THTbA_5_2">1.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_eKDlPwDHjkS5uUcqD42esg_5_4">1.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_DI9albhwXU2ouKL0gb35pg_5_6">2.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign rate differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="3" format="ixt:numdotdecimal" name="chrs:EffectiveIncomeTaxRateReconciliationPermanentDifferences" sign="-" scale="-2" id="Tc_Aoc_o1q5Eke4cK0hGYpckQ_7_4">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="3" format="ixt:numdotdecimal" name="chrs:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="Tc_1VtEn9Oh2kqQ3147LjpQhA_7_6">0.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" scale="-2" id="Tc_gfV-4ONh3kW7nvmVsbczQw_8_2">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="3" format="ixt:numdotdecimal" name="chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" scale="-2" id="Tc_cb2ZZLCusEK6EM5yfjCaCQ_8_4">1.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="3" format="ixt:numdotdecimal" name="chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" scale="-2" id="Tc_VQ0boQjp9ECpWT4Kl0zxTQ_8_6">2.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_7tEC0e3flEm-TBGM0Uc2Ew_9_2">3.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_xslexinvy0SNpVOSTCaFXg_9_4">2.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_3zrMLvsw_U24A4Z7RaThLw_9_6">1.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_LCF9P32mR06MM26tasHauA_10_2">0.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_5co4Z1wYYUu-c46ZzhtheQ_11_2">17.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_PuWUhZXSVUqdUiQwUtF1jg_11_4">22.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_CbRuODScpkC7wCT4tbMIfQ_11_6">25.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_gk8fTFPWnku_7vzoDjbiVw_12_2">0.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_KaZkl2b3hkSXAWAgl4HWLg_1_2"></a><a id="Tc_r7mcdvXtYkW1ac99YeoRQw_2_0"></a><a id="Tc_e-ZXbTjyuk6fNoDTW-MdWg_2_2"></a><a id="Tc_GbBhOv-4PEa11kEzkTgLDw_2_5"></a><a id="Tc_N1ayxqvF1USPaWnw2_diUg_3_0"></a><a id="Tc_0GLWeDPazEyueJHOtDDSzQ_3_2"></a><a id="Tc_s08j-4JQw0ed5OArSEziXg_3_5"></a><a id="Tc_Nx6M5h_VH0Wh9iSRTlbXjQ_4_0"></a><a id="Tc_9Jao6tE1skyj7W5RrWt5wg_5_0"></a><a id="Tc_NujWDsvQykOG-N3WD407zQ_6_0"></a><a id="Tc_Qawj8h5to0KJWqoggSGznA_7_0"></a><a id="Tc_9ELjsTw1uk6oehzedme8vw_8_0"></a><a id="Tc_fVaYGFwy6UWu3w8BhyPnnw_9_0"></a><a id="Tc_RVilC7H2ukqgpyxHhPVOhw_10_0"></a><a id="Tc_HaCH0tjQHkKb4ux2aMrR3g_11_0"></a><a id="Tc_NHID21ebw0GInfvEn79-8A_12_0"></a><a id="Tc_t3oLKluMY0SyMAr_0UiBpw_13_0"></a><a id="Tc_FtNi5kaixUaAy57fJsVSSg_14_0"></a><a id="Tc_Bg3hOqYVh0m9ZCsUKfdN0A_15_0"></a><a id="Tc_v1wPrSWq5ka4894NZ6xeFw_16_0"></a><a id="Tc_2e7p2i_M-kKI-38graxI6w_16_2"></a><a id="Tc_-YhS5Jks_EWP34iY0zJYqg_16_5"></a><a id="Tc_h7QhC7ZaZkOXIepleWWB6w_16_6"></a><a id="_Hlk95215585"></a><a id="_Hlk95558336"></a><a id="Tc_GKNnKO-TKEyZQwqnv7qKmw_1_2"></a><a id="Tc_Y2KftdnLDk6h5mb3JmeZ1A_2_0"></a><a id="Tc_DoAR68eUgUuD3RJZaI7V2Q_2_2"></a><a id="Tc_BbMaXuGsc0Wb6luXgU7ZRQ_2_5"></a><a id="Tc_3OYaMrhkDUKMdce18xJGUg_2_8"></a><a id="Tc_hvKmoV35fkyskqLT5fXhzg_3_0"></a><a id="Tc_cEjhhtH4z0iwH5I6Wnp_bQ_3_2"></a><a id="Tc_PiO3C-MFlEKER5WLhJlydA_3_5"></a><a id="Tc_rjbw6SfJ6UG7Qcwz2Z-c6w_3_8"></a><a id="Tc_Jmwo_oaNy0OwhhNv3KhPpQ_4_0"></a><a id="Tc_Sh03WKYQt0mIbbYiCWelhA_5_0"></a><a id="Tc_ZKMQ3GVMDUyxVOEtH4b1_Q_6_0"></a><a id="Tc_3tqdXVbL8UyvvL5jj89zwA_6_2"></a><a id="Tc_ru1etA7_FU2TZrHGaN4XDw_6_5"></a><a id="Tc_xt19PgOgxE-B8h38YHpNOA_6_8"></a><ix:continuation id="Tb_DALK5EgAxUyM0MePQZf2tg_cont1" continuedAt="Tb_DALK5EgAxUyM0MePQZf2tg_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2023 and 2022 consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_Ete_Y0a0fEefgpKU1HaviA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_QJrImlLFiEm9eHO6kpS5Dg_3_3">170,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Pxqv5Rb6DUCCkmxvq3ZXcw_3_6">131,423</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_gZo65qfgMk-MiremWfhBfg_4_3">65,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_44N9zfvhv0GScCOQoPw4mQ_4_6">63,164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_MeCnMbwEgkeY3wzNLa167g_5_3">37,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_2ZTPYxNk-k-gP_nKm7Qdng_5_6">51,877</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_ngRdSILoS0Cszapk76KotA_6_3">30,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_LHDymo8GoUSYWL2JHSysPg_6_6">32,561</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" scale="3" id="Tc_-0yFGZkAu0q0Y7yWAINigg_7_3">38,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" scale="3" id="Tc_CuKrgMxQ2kOZAWEkrrAR2Q_7_6">23,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="3" id="Tc_atM7nC-JREqU3R5uBmKoTA_8_3">42,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="3" id="Tc_BS3Hj5KW4UyxJtCDbL83Lg_8_6">19,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_5sQ44RK5Y0i-nCwV3oIKag_9_3">46,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_RrKGFY-5nEa6dhJdTTJG_A_9_6">17,673</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_6BRjSWOkdECd3xhEz4vPKA_10_3">430,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_JkP_vOWfQU6YtuecMIPk9w_10_6">340,279</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_zhZ1YJLMIky9-kUwessKpQ_11_3">1,538</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_-KIJBKgoPUa2FR6gPbBNhQ_11_6">1,903</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_lAv2E2RoYU-k3QYOu4A3Lg_12_3">6,403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_k1Gc0XVMZEGoW_cgL-7CQw_12_6">603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_9S8H8Hoq5Uebf2JkNzBCzQ_13_3">7,941</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_lORRPNXYJ0Gx1uld0TsJrQ_13_6">2,506</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="chrs:DeferredTaxAssetLiabilityNet" scale="3" id="Tc_tiFMRy9G7UKGP4GINcioOA_14_3">422,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="chrs:DeferredTaxAssetLiabilityNet" scale="3" id="Tc_IOay5U-fi0K_m06UHfVtDA_14_6">337,773</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_mM_9gid370CFInQKsFrI9A_15_3">423,385</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_-tQJG2ZBgkusx0VaeOIIvA_15_6">337,773</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net deferred tax assets (liabilities)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_pb4zL022cUSQGVnRP5KfeA_16_3">1,102</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The tax benefit of net operating losses, temporary differences and credit carry forwards is recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its federal net deferred tax assets and certain state net deferred tax assets will not be realized, and therefore, the Company has offset the federal and certain state net deferred tax assets by a valuation allowance as of December 31, 2023 and 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_lsMsSU1eiEyjepGfKzaifQ">85.6</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_wzS1FyoG90OxboJD_qbekA">64.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr__220Vv3mfE2jT7ldxpxW6A">72.4</ix:nonFraction> million during the years ended December 31, 2023, 2022 and 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had net operating loss carryforwards for federal income of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Pnm4g_v2k6bFQvlK9UGDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_J2sesIY_wUeCUzPguh866g">774.9</ix:nonFraction> million, which will start to expire in the year <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Mozz1GcMBEOZ4p50-Yzzeg" name="chrs:OperatingLossCarryforwardsExpirationYear" id="Narr_Yes1_pLSUE6jbYjjzK-iMA">2036</ix:nonNumeric>, and various states net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_S-PFsrc-YEyD32_Z5ut0iQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_-l6fF0ZueEWlB0nhTCQAnA">128.0</ix:nonFraction> million, which have various expiration dates beginning in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_tLJFKpYaNUKKGQtoFUHYZA" name="chrs:OperatingLossCarryforwardsExpirationYear" id="Narr_pL1TizBE0k2Z88P9vzkZJA">2031</ix:nonNumeric>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal research and development credit carryforwards for federal income tax purposes of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5guUqMGHzkGsdOQekHmiiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_mu6mIElbk0iyU3dlYZJvjg">60.6</ix:nonFraction> million, which will start to expire in the year <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_oW7u_hLkakKhdnoyoEmKmQ" name="chrs:TaxCreditCarryforwardExpirationYear" id="Narr_Wh6gA_R2aE6wulg0nMFFvg">2031</ix:nonNumeric>, and state research and development credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_-SnhX9CP50mp8ATn7g01-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_BUHK5oYICUeg8QaqI6V-Ww">26.5</ix:nonFraction> million, which have no expiration date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Utilization of the net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of certain net operating loss and tax credit carryforwards before their utilization. Under the new enacted tax law, the carry forward period of net operating losses generated from 2018 forward is indefinite. However, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. The Company files income tax returns in the United States federal jurisdiction, various United States state jurisdictions, and a foreign jurisdiction with varying statutes of limitations. The tax&#160;years from inception in 2011 forward remain open to examination due to the carryover of unused net operating losses and tax credits. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the Company&#8217;s unrecognized tax benefits during 2023, 2022 and 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_JjP-OTbeLkWwlRMMczvl6g" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_ifWFvOP5ak6vkUp45bMRCg_3_3">16,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_xAFYS0phtUSexu0Gqgx26Q_3_6">15,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_Zo5evQokuUCyW_gYbRlYDw_3_9">13,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additions based on tax positions related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_5EtNxaULm0GsquUOHPnYTQ_4_3">865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_Oj4d1W2TZEq5ut9eeMUnfg_4_6">1,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_DZ6k5IIVlUiQO_9vdXP3ew_4_9">2,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additions (reductions) for tax positions of prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_KHK4Rba-4UGAVSh0P49BMw_5_3">286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_1lzsyOrcokGrbLNDY_oK9w_5_6">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_a159gxf5-EqPPkMckl1qGg_5_9">214</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_-MaQ7TnA706k9lGl4-Fugg_6_3">17,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_SST8j5-gyEaFVkDdr58TdQ_6_6">16,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_8ijqT7n2BkuCjQOtpkSNhQ_6_9">15,495</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_DALK5EgAxUyM0MePQZf2tg_cont2"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December&#160;31, 2023, 2022 and 2021, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_Ng5A4V6fjkeyPDbwly854g">17.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_p2U6JNfIYkqto4CIeUGx2g">16.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_i2Xwb1ZZ702YYk34M_QiVQ">15.5</ix:nonFraction> million, respectively, of unrecognized benefits, none of which would currently affect the Company&#8217;s effective tax rate if recognized due to the Company&#8217;s deferred tax assets being fully offset by a valuation allowance.&#160;During 2023, 2022 and 2021, the Company did <ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_lBfsTh00HU2nZsK3dSAFNQ"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_p6omNC-hQ0SdJLuVaK2LEA"><ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_Lrk7RUEky0WsxApi6d4r9w">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate a material adjustment of unrecognized tax benefits during the next twelve&#160;months from the balance sheet date as reductions for tax positions of prior years.</p></ix:continuation><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6e7133cf_f626_48d4_899a_8b504d4467c6"></a><a id="Tc_FDFbR_1SGUiuIp1Wz0UlZw_1_2"></a><a id="Tc_LzPPxjdjCkyb4lZCjcY3FQ_2_2"></a><a id="Tc_3RcYL-d7kUum0dVkS5VAsA_2_4"></a><a id="Tc_e-jDJKTQTE-NGisd_9QhqA_2_6"></a><a id="Tc_mz9fXJGn9EC4GlOCC4GmWg_3_0"></a><a id="Tc_aICTrv0zQE2enlmvnl46jg_4_0"></a><a id="Tc_hGMRbwkagUK8fK7XTCauSw_5_0"></a><a id="Tc_Et-uUqnfxEigrcrA2z6bOA_5_2"></a><a id="Tc_eblfPWH7dEmudImyvi8tWw_6_0"></a><a id="Tc_QwV_dMiA-k-bosr_UVkwwA_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_FsA6c5y8X0eYE4b_MufqxQ" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span>Net Loss Per Share</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_AvtcDUbIV0KgKGe7Gy7e9A" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, including shares subject to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_CTwRAY9QGkWlaOjDUS3erA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_OXaG-GCGj0WUowgeQ6cpwQ_3_2">24,083,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_w5gYK5ZD10mxWUfBk3mCAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_7gIa2oM8IkeY4XYaEWMDKQ_3_4">22,214,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_yimB1PocVk6HJoJLxYsOcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_1WVu-N1Kn0-oCCP-D-oETg_3_6">19,895,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_AYPPQ8ihj0mbo87bSd2xhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_S6M6Uoti502qHuH5ydIYgA_4_2">2,266,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8C3aK0xQf0Go0f8lJiI49A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GdSN-KhCPE-p0Qj7vXyraQ_4_4">2,399,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pQgsHAcxhEiHaH9C5c3xTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_OLPHWOsoN0a8r_I2RCJ45g_4_6">1,811,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lJUaials20Ozgd2f9R3-Cg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_PO_8879LaEa6rGVVyXJQIA_5_4">1,078,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_7tgQKK_EDUasryLtCO67SA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_N6ID3j71iE-ZsgMMa1hkfw_5_6">4,473,871</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_trJKeZ-blEWFIlIsmGdHcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8H75QqxC50y6E_1I3Z0ymA_6_2">11,942,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6-wHjlrUb0eK7XFKJFi0cA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_dbKFn_mj9UG11Q7vhGjGZg_6_4">11,942,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nDHklqDsSkqnJXBtDs4Nbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_biYQCSWD3ECIt47zE-zJeQ_6_6">11,942,152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TQ8j6HmUPE-HtcweNqT3CQ_7_2">38,291,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_JAj6suswrEW7yytMzetA0w_7_4">37,635,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VAbMw8f270Ssws2EWPr8Bg_7_6">38,122,727</ix:nonFraction></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_o5sZw9LnFUCwqHkU0yYPDA" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;">15. </p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;">Restructuring Charges</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">On March 3, 2023, the Company committed to a plan to reduce its workforce to focus resources on strategic priorities including the commercialization of its diversified product portfolio and development of innovative immuno-oncology product candidates. The reduction in force impacted approximately&#160;<ix:nonFraction unitRef="Unit_Standard_employee_AAmVcdTDXkmNakyN2ltl5g" contextRef="Duration_3_10_2023_To_3_10_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_4wHJPeiz5EGGZlHVcqOJhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_iOK9taw--0acpsqF4af0iw">50</ix:nonFraction>&#160;full-time and part-time employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduction in force consisted of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_Ylq06wNdZ0yAKyy1iHQz6w">3.9</ix:nonFraction>&#160;million in cash expenses related to personnel expenses such as salaries, severance payments and other benefits; and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="Narr_Pl9JNJGqjkaVhMZXc4qKsA">1.5</ix:nonFraction>&#160;million in non-cash stock-based compensation related to acceleration of vesting and extension of the stock option exercise windows for&#160;two&#160;impacted executives; partially offset by $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q" decimals="-5" format="ixt:numdotdecimal" name="chrs:ShareBasedPaymentArrangementForfeitureCredit" scale="6" id="Narr_Iz2BYWIFpkejYvPCtmdWAA">0.5</ix:nonFraction>&#160;million in non-cash stock-based compensation forfeiture credits. The reduction in force was completed during the second quarter of 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, the consolidated statements of operations include $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_PdGnVstbm0yndk6laylDZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_IOwSoNmFVk-wepxLDW20kw">3.6</ix:nonFraction>&#160;million in research and development expense and $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IQec6wbqNkyXTV-ONWSp-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_pQJjQE0xRUWCU1Wj2i4vUw">1.3</ix:nonFraction>&#160;million in selling, general and administrative expense related to the reduction in force.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_bIJrSTjwD0yDlxAZ8k7CYw" continuedAt="Tb_bIJrSTjwD0yDlxAZ8k7CYw_cont1" escape="true"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">16.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">Related Party Transactions</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consulting services</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2020, the Company entered into a consulting agreement with Lanfear Advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board of Directors. Mr. Jonathan Lanfear provided consulting services with respect to the Collaboration Agreement executed with Junshi Biosciences in February 2021 and the Letter Agreement with Junshi Biosciences related to the Collaboration Agreement dated January 9, 2022 (See Note 7. Collaborations and Other Arrangements). In addition to the hourly consulting fee paid to Lanfear Advisors under the consulting agreement, the Company granted fully vested stock options to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_SA1gdaF6PECwIgEbjQI-6w">65,000</ix:nonFraction>&#160;shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_r9LiXWQv1EK3aYnX5Af0uA">17.60</ix:nonFraction>&#160;per share to Mr. Jonathan Lanfear in February 2021 upon the execution of the Collaboration Agreement with Junshi Biosciences and recognized stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_2_1_2021_To_2_28_2021_NvtDoX2JKU-V8xqMiC3p8w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_Y8c3X8RuFE-tQLaOx-ndSA">0.8</ix:nonFraction>&#160;million. The Company recorded cash consulting expense of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_PoW1P6R9s0CVYOhvmiJS7Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="Narr_LrS8h5CYVEGDq22FjiyZXg">0.2</ix:nonFraction>&#160;million in 2021 with respect to these consulting services. There have been no subsequent material related party expenses. Total liabilities recognized in the consolidated balance sheets with respect to these services were immaterial as of December 31, 2023 and 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_bIJrSTjwD0yDlxAZ8k7CYw_cont1"></ix:continuation><a id="_Hlk158820507"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_XjP8QFWt00Ox8Jgx2Z9j8g" continuedAt="Tb_XjP8QFWt00Ox8Jgx2Z9j8g_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">17.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">Subsequent Events <b style="font-weight:bold;background:#ffff00;"> </b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CIMERLI Sale Transaction</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 19, 2024, the Company entered into the Purchase Agreement by and between the Company and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, the Company completed the Sale Transaction for its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="Narr_ZVXH1ir_FEuJiUoOIlZnWA">170.0</ix:nonFraction> million plus an additional $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA" decimals="-5" format="ixt:numdotdecimal" name="chrs:BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" scale="6" id="Narr_VGNqldpk40iN3RLts3Whdw">17.8</ix:nonFraction> million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Partial Release and Third Amendment to 2027 Term Loan</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2024, the Company, entered into the Consent and Amendment with the Collateral Agent and the Lenders, pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the 2027 Term Loans and the other loan documents in connection therewith, and the parties thereto agreed to amend the Loan Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the Purchase Agreement, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the Lenders and the Collateral Agent permitted the Company to make a partial prepayment of the principal of the loans outstanding under the 2027 Term Loans in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_2_5_2024_To_2_5_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_F3gEcw2SlkGZ3F3ZhhXOuw" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebInstrumentPartialRepaymentPrincipal" scale="6" id="Narr_MjyL8pZqcU2Npg3quPlukQ">175.0</ix:nonFraction> million upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions including a prepayment premium and makewhole amount calculated pursuant to the Consent and Amendment and (3) the parties thereto agreed to adjust the minimum net sales covenant level under the 2027 Term Loans. Upon the closing of the Sale Transaction the Company became liable to repay $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebInstrumentPartialRepaymentPrincipal" scale="6" id="Narr_Kfpa4oRigki_z06H9APCag">175.0</ix:nonFraction> million of the existing principal balance of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_H5jjpUn1Hkae89daAw6YHg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_c1w0B9CQGEaxb9VfUKPRkQ">250.0</ix:nonFraction> million of the loans outstanding under the Loan Agreement on April 1, 2024 and the Company plans to repay $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A" decimals="-5" format="ixt:numdotdecimal" name="chrs:DebInstrumentPartialRepaymentPrincipal" scale="6" id="Narr_RMOdIHLRQk-U9QCOyIYrew">175.0</ix:nonFraction> million and the prepayment premium and makewhole amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ" contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_H5jjpUn1Hkae89daAw6YHg" decimals="-5" format="ixt:numdotdecimal" name="chrs:EarlyRedemptionFee" scale="6" id="Narr_KiVGDO6dI0iMcFzhtsdzIg">6.8</ix:nonFraction> million to the Lenders on or before April 1, 2024 pursuant to the Consent and Amendment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other terms of the 2027 Term Loans, as amended by the Consent and Amendment, remain generally identical to those under the 2027 Term Loans. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_XjP8QFWt00Ox8Jgx2Z9j8g_cont1"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_Item_9._"></a><a id="_52614b6b_739c_4585_946b_145680f271a5"></a><a id="Item9"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;9.&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><a id="_Item_9A._"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3e235c67_1961_4e03_a0c7_2be704411f64"></a><a id="Item9AControlsandProcedures_21407"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;<span style="font-style:italic;">Controls and Procedures</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;Evaluation of Effectiveness of Disclosure Controls and Procedures</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We carried out an evaluation, under the supervision of our Chief Executive Officer and our Interim Chief Financial Officer, and evaluated the effectiveness of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as of the end of the period covered by this Annual Report on Form&#160;10-K. Based on that evaluation, our President and Chief Executive Officer and our Interim Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form&#160;10-K, our disclosure controls and procedures were, in design and operation, effective.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms and that such information is accumulated and communicated to our management, including our chief executive officer, principal financial officer and principal accounting officer, as appropriate, to allow for timely decisions regarding required disclosure.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to correct any material deficiencies that we may discover. Our goal is to ensure that our management has timely access to material information that could affect our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to modify our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;&#160;Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules&#160;13a-15(f). Under the supervision and with the participation of our management, including our principal executive officer, principal financial officer and principal accounting officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in&#160;<i style="font-style:italic;">Internal Control&#8212;Integrated Framework</i>&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on our evaluation under the framework in&#160;<i style="font-style:italic;">Internal Control&#8212;Integrated Framework</i>, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2023. Ernst&#160;&amp; Young&#160;LLP, our independent registered public accounting firm, has attested to and issued a report on the effectiveness of our internal control over financial reporting, which is included herein.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Item_9B._"></a><a id="_Hlk161396129"></a><a id="_0a9eb3bf_e058_4c1b_b828_858fb19f41a8"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 0pt 108pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;">To the Stockholders and the Board of Directors of Coherus BioSciences, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Opinion on Internal Control Over Financial Reporting</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have audited Coherus BioSciences, Inc.&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Coherus BioSciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated March 15, 2024 expressed an unqualified opinion thereon.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;text-align:justify;margin:0pt;">San Mateo, California</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">March 15, 2024</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d)&#160;and 15d-15(d)&#160;of the Exchange Act that occurred during the quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_9f3169cc_8a18_4b9f_a6d3_249c5f178fff"></a><a id="Item9BOtherInformation_597802"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;&#160;<span style="font-style:italic;">Other Information</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"/></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1.01 Entry into a Material Definitive Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendment No. 2 to Collaboration Agreement </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 1, 2021, we announced that we had entered into the Collaboration Agreement with Junshi Biosciences for the co-development and commercialization of toripalimab, Junshi Biosciences&#8217; anti-PD-1 antibody in the United States and Canada. We entered into an amendment and waiver under the Collaboration Agreement on October 25, 2023 (Amendment No. 1 to Collaboration Agreement&#8221;). On March 13, 2024, we and Junshi Biosciences entered into Amendment No. 2 to the Collaboration Agreement (&#8220;Amendment No. 2 to Collaboration Agreement&#8221;).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under Amendment No. 2 to Collaboration Agreement, we agreed with Junshi Biosciences to change the $25.0 million milestone payment to Junshi Biosciences that became due in connection with the approval by the FDA of toripalimab for the treatment of patients with NPC in the first quarter of 2024. We agreed to split the $25.0 million milestone payment into two equal installments of $12.5 million each, one due in the second quarter of 2024 and one due in the first quarter of 2025. We also agreed to pay approximately $2.5 million in the first quarter of 2024 to Junshi Biosciences for routine expenses incurred pursuant to the Collaboration Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The foregoing summary of Amendment No. 2 to Collaboration Agreement does not purport to be complete and is qualified in its entirety by the full text of the Amendment No. 2 to Collaboration Agreement, a copy of which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2.05 Costs Associated with Exit or Disposal Activities</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to our 35 former employees who transferred to Sandoz in connection with the closing of the Sale Transaction, on March 11, 2024 we committed to a plan to reduce our workforce (the &#8220;Plan&#8221;) by approximately 26 employees effective March 18, 2024 to focus resources on strategic priorities including the research, development and commercialization of innovative cancer treatments and the commercialization of our portfolio of FDA-approved oncology products. One-time restructuring charges associated with the Plan are expected to be approximately $1.5 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits. Cash payments related to these expenses will be paid out and the Plan is expected to be completed in the first half of 2024.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The estimated costs that we expect to incur in connection with the Plan are subject to a number of assumptions, and actual results may differ significantly from these estimates. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Plan. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">(b) During the three months ended December 31, 2023, neither we nor any of our directors or officers <span style="-sec-ix-hidden:Hidden_DILPxNagiE2rs6ISbTZ4RA;"><span style="-sec-ix-hidden:Hidden_6muBIslFhk2zKGVekJX6QA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adopted</span></span></span> or <span style="-sec-ix-hidden:Hidden_YgjPL260ZU2HOBfFy0NsgA;"><span style="-sec-ix-hidden:Hidden_6Ta87eBqSEq-2bamScPPEQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">terminated</span></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each such term is defined in Item 408(a) of Regulation S-K.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 108pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_Item_9C._"></a><a id="_aeb92585_fc35_442d_b934_e9e93c3af8c1"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C.&#160;&#160;&#160;<span style="font-style:italic;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 108pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 108pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f681105c_c5cd_4f1b_9f39_60eeb10abdd4"></a><a id="PARTIII_837998"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain information required by Part&#160;III is omitted from this Annual Report on From 10-K because we will file a Definitive Proxy Statement (the &#8220;Proxy Statement&#8221;) with the Securities and Exchange Commission within 120&#160;days after the end of our&#160;fiscal year ended December&#160;31, 2023.</p><a id="_Item_10._"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10.&#160;&#160;&#160;<span style="font-style:italic;">Directors, Executive Officers and Corporate Governance</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item is included in the Proxy Statement to be filed with the SEC within 120 days after the end of our&#160;fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_46fc64fc_53dd_48be_8bd1_3195aea42914"></a><a id="Item11ExecutiveCompensation_746019"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;&#160;&#160;<span style="font-style:italic;">Executive Compensation</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item is included in the Proxy Statement to be filed with the SEC within 120 days after the end of our&#160;fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_08da11de_43fc_44b8_bf0c_d5d4a1db883d"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12.&#160;&#160;&#160;<span style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item is included in the Proxy Statement to be filed with the SEC within 120 days after the end of our&#160;fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6603e1ba_47e3_4a42_a70f_9e42fc39bdf2"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13.&#160;&#160;&#160;<span style="font-style:italic;">Certain Relationships and Related Transactions, and Director Independence</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item is included in the Proxy Statement to be filed with the SEC within 120 days after the end of our&#160;fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8ff0616f_51a1_44a7_93ab_16f55cdf21fa"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14.&#160;&#160;&#160;<span style="font-style:italic;">Principal Accounting Fees and Services</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item is included in the Proxy Statement to be filed with the SEC within 120 days after the end of our&#160;fiscal year ended December&#160;31, 2023, and is incorporated herein by reference.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIV_110740"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;IV</p><a id="_6cc81758_4bfa_4b86_8690_b56306f6b5f2"></a><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;&#160;&#160;<span style="font-style:italic;">Exhibits and Financial Statement Schedules</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:91.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">(a)</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">(1)</p></td><td style="vertical-align:top;width:91.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The financial statements required by Item&#160;15(a)&#160;are filed in Item&#160;8 of this Annual Report on Form&#160;10-K. </p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">(2)</p></td><td style="vertical-align:top;width:91.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The financial statement schedules required by Item&#160;15(a)&#160;are omitted because they are not applicable, not required or the required information is included in the financial statements or notes thereto as filed in Item&#160;8 of this Annual Report on Form&#160;10-K.</p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">(3)</p></td><td style="vertical-align:top;width:91.94%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">We have filed, or incorporated into this report by reference, the exhibits listed on the accompanying Index to Exhibits immediately preceding the signature page&#160;of this Annual Report on Form&#160;10-K. </p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_fe153e7c_4867_4618_8cee_7c2a401fb5a8"></a><a id="Item16Form10KSummary_259502"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16.&#160;&#160;&#160;<span style="font-style:italic;">Form&#160;10-K Summary</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7efbb04c_b6aa_4664_8194_a7bfd4d9ea6a"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEX TO EXHIBITS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.049346924%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="5" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Incorporated by Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt 0pt 0pt 6.1pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Filed</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:7.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:56.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:4.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:6.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">3.1</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514409798/d820280dex31.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8-K</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/13/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">3.1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">3.2</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837020013970/chrs-20201112xex3d1.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Bylaws.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">11/18/2020</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">4.1</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Reference is made to Exhibits&#160;3.1 and 3.2.</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">4.2</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514380821/d744283dex42.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Common Stock Certificate.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10/24/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">4.2</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">4.3</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459020007416/chrs-ex43_444.htm"><span style="font-style:normal;font-weight:normal;">Description of Coherus&#8217; Securities Registered Pursuant to Section&#160;12 of the Securities Exchange Act of 1934.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">2/27/2020</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">4.4</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex4-1.htm"><span style="font-style:normal;font-weight:normal;">Indenture, dated April 17, 2020, by and between Coherus BioSciences,&#160;Inc. and U.S. Bank National Association.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8-K</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">4/17/2020</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">4.1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">4.5</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex4-1.htm"><span style="font-style:normal;font-weight:normal;">Form of certificate representing the 1.5% Convertible Senior Subordinated Notes due 2026.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8-K</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">4/17/2020</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">4.1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">4.6</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837022007420/chrs-20220331xex4d5.htm"><span style="font-style:normal;font-weight:normal;">Notice of Successor Trustee to Indenture dated February 7, 2022</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/5/2022</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.1&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514353133/d744283dex103.htm"><span style="font-style:normal;font-weight:normal;">Distribution Agreement, effective December&#160;26, 2012, by and between Orox Pharmaceuticals B.V. and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">9/25/2014</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.2(a)</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514353133/d744283dex109a.htm"><span style="font-style:normal;font-weight:normal;">Standard Industrial/Commercial Multi-tenant Lease-Gross, effective December&#160;5, 2011, by and between Howard California Property Camarillo 5 and BioGenerics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">9/25/2014</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.9(a)</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.2(b)</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514353133/d744283dex109b.htm"><span style="font-style:normal;font-weight:normal;">First Amendment to Lease, effective December&#160;21, 2013, by and between Howard California Property Camarillo 5 and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">9/25/2014</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.9(b)</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.3(a)#</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514353133/d744283dex1010a.htm"><span style="font-style:normal;font-weight:normal;">BioGenerics,&#160;Inc. 2010 Equity Incentive Plan, as amended.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">9/25/2014</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.10(a)</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.3(b)#</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514353133/d744283dex1010b.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the 2010 Equity Incentive Plan, as amended.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">9/25/2014</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.10(b)</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.4(a)#</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514380821/d744283dex1011.htm"><span style="font-style:normal;font-weight:normal;">Coherus BioSciences,&#160;Inc. 2014 Equity Incentive Award Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10/24/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.11</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.4(b)#</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514396092/d744283dex1011b.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/4/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.11(b)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.4(c)#</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514396092/d744283dex1011c.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2014 Equity Incentive Award Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/4/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.11(c)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.4(d)#</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514396092/d744283dex1011d.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2014 Equity Incentive Award Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/4/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.11(d)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.5#</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514380821/d744283dex1012.htm"><span style="font-style:normal;font-weight:normal;">Coherus BioSciences,&#160;Inc. 2014 Employee Stock Purchase Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10/24/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.12</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.6#</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514380821/d744283dex1013.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between Coherus BioSciences,&#160;Inc. and each of its directors, officers and certain employees.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1/A</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10/24/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.13</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.7&#8224;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312514353133/d744283dex1015.htm"><span style="font-style:normal;font-weight:normal;">Master Services Agreement, effective January&#160;23, 2012, by and between Medpace,&#160;Inc. and BioGenerics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">S-1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">9/25/2014</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.15</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.049346924%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="5" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Incorporated by Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt 0pt 0pt 6.1pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Filed</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:7.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:56.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:4.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:6.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.8</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459015006845/chrs-ex103_339.htm"><span style="font-style:normal;font-weight:normal;">New Office Lease, effective July&#160;6, 2015, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/10/2015</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.3</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;margin:0pt;"><span style="font-size:9.5pt;">10.9</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459015006845/chrs-ex104_371.htm"><span style="font-style:normal;font-weight:normal;">First Amendment, effective August&#160;10, 2015, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences,&#160;Inc.</span></a> </p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/10/2015</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.4</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.10(a)#</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.05pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459016023684/chrs-ex101a_504.htm"><span style="font-style:normal;font-weight:normal;">Coherus BioSciences,&#160;Inc. 2016 Employment Commencement Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/9/2016</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1(a)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.10(b)#</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459016023684/chrs-ex101b_501.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the Coherus BioSciences,&#160;Inc. 2016 Employment Commencement Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/9/2016</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1(b)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.10(c)#</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459016023684/chrs-ex101c_503.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Coherus BioSciences,&#160;Inc. 2016 Employment Commencement Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/9/2016</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1(c)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.10(d)#</p></td><td style="vertical-align:top;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459016023684/chrs-ex101d_502.htm"><span style="font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the Coherus BioSciences,&#160;Inc. 2016 Employment Commencement Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/9/2016</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1(d)</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.11</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312516719876/d263150dex101.htm"><span style="font-style:normal;font-weight:normal;">Second Amendment, dated September&#160;21, 2016, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8-K</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">9/26/2016</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.12</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459017021844/chrs-ex102_559.htm"><span style="font-style:normal;font-weight:normal;">Letter Agreement to Master Service Agreement, dated as of September&#160;6, 2017, by and between Medpace,&#160;Inc. and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/06/2017</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.2</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.13&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459019028841/chrs-ex101_146.htm"><span style="font-style:normal;font-weight:normal;">Confidential Litigation Settlement Agreement and Release, dated as of April&#160;30, 2019 between Amgen&#160;Inc. and Amgen USA&#160;Inc. (collectively &#8220;Amgen&#8221;), and Coherus BioSciences&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">8/5/2019</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.14</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459019042255/chrs-ex101_9.htm"><span style="font-style:normal;font-weight:normal;">Third Amendment, effective May&#160;24, 2019, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/8/2019</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.1</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.15</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459019042255/chrs-ex102_233.htm"><span style="font-style:normal;font-weight:normal;">Fourth Amendment, effective September&#160;4, 2019, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10-Q</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">11/8/2019</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">10.2</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.16&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000156459020007416/chrs-ex1029_580.htm"><span style="font-style:normal;font-weight:normal;">License Agreement, dated November&#160;4, 2019, by and between Coherus BioSciences,&#160;Inc. and Bioeq IP AG</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">2/27/2020</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.17&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000110465920048214/tm2015668d4_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Form of Confirmation for Base Capped Call Transactions under the Indenture.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">4/17/2020</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.75pt;"><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.18</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837021006257/chrs-20210331xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Exclusive License and Commercialization Agreement, dated February 1, 2021, by and between Coherus Biosciences, Inc. and Shanghai Junshi Biosciences, Co. Ltd.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/6/2021</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.19</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837021006257/chrs-20210331xex10d2.htm"><span style="font-style:normal;font-weight:normal;">Stock Purchase Agreement, dated February 1, 2021, by and between the Coherus Biosciences, Inc. and Shanghai Junshi Biosciences, Co. Ltd.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/6/2021</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.20&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312522004051/d231535dex101.htm"><span style="font-style:normal;font-weight:normal;">Loan Agreement dated as of January 5, 2022 among Coherus BioSciences, Inc., the Guarantors, the Collateral Agent and the Lenders party thereto.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">1/7/2022</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.21&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837022007420/chrs-20220331xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Letter Agreement, dated February 9, 2022, between Coherus BioSciences, Inc. and Shanghai Junshi Biosciences, Co., Ltd.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/5/2022</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.22&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837022012251/chrs-20220630xex10d1.htm"><span style="font-style:normal;font-weight:normal;">First Amendment to Loan Agreement dated as of April 7, 2022, among Coherus BioSciences, Inc., the Collateral Agent and the Lenders party thereto.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">8/4/2022</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.049346924%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="5" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Incorporated by Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt 0pt 0pt 6.1pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Filed</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:7.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:56.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:4.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:6.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.23&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023002917/chrs-20221231xex10d25.htm"><span style="font-style:normal;font-weight:normal;">License Agreement, dated June 22, 2022, among Coherus BioSciences, Inc., Bioeq AG and Genentech Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">3/6/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.24&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023008529/chrs-20230331xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Second Amendment and Waiver to Loan Agreement dated as of February 6, 2023, among Coherus BioSciences, Inc., the Collateral Agent and the Lenders party thereto.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/8/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.25#</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023008529/chrs-20230331xex10d2.htm"><span style="font-style:normal;font-weight:normal;">Executive Change in Control and Severance Plan, effective January 1, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/8/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.26#&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023008529/chrs-20230331xex10d3.htm"><span style="font-style:normal;font-weight:normal;">Letter Agreement between Coherus BioSciences, Inc. and Vladimir Vexler, dated as of March 27, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">5/8/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.27</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023012915/chrs-20230630xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Amendment No. 1 to Sales Agreement between Coherus BioSciences, Inc. and Cowen and Company, LLC, dated May 15, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">8/2/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.28&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/d523169dex21.htm"><span style="font-style:normal;font-weight:normal;">Agreement and Plan of Merger, by and among Coherus BioSciences, Inc., Crimson Merger Sub I, Inc., Crimson Merger Sub II, LLC and Surface Oncology, Inc., dated June 15, 2023 (Form of CVR Agreement included as Exhibit A thereto)</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">6/16/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.29&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023017779/chrs-20230930xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Settlement and License Agreement among Coherus BioSciences, Inc., AbbVie Inc. and AbbVie Biotechnology Ltd dated January 24, 2019.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">11/6/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.30</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1512762/000155837023017779/chrs-20230930xex10d2.htm"><span style="font-style:normal;font-weight:normal;">Amendment No. 2 to Sales Agreement between Coherus BioSciences, Inc. and Cowen and Company, LLC dated September 11, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">11/6/2023</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.31&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex1.htm"><span style="font-style:normal;font-weight:normal;">First Amended and Restated Development and Option Agreement between Adimab, LLC and Surface Oncology, Inc., dated October 3, 2018.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.32&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex2.htm"><span style="font-style:normal;font-weight:normal;">Collaboration Agreement between Novartis Institutes for BioMedical Research, Inc. and Surface Oncology, Inc., dated January 9, 2016, as amended on May 6, 2016, as further amended on July 14, 2017, and as further amended on September 18, 2017.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.33&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex3.htm"><span style="font-style:normal;font-weight:normal;">Amendment No. 4 to the Collaboration Agreement between Novartis Institutes for BioMedical Research, Inc. and Surface Oncology, Inc., dated October 9, 2018.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.34&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex4.htm"><span style="font-style:normal;font-weight:normal;">License Agreement, dated as of December 16, 2020, by and between Surface Oncology, Inc. and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.35&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex5.htm"><span style="font-style:normal;font-weight:normal;">Amendment No. 1, dated as of August 11, 2021, to License Agreement, dated as of December 16, 2020, by and between Surface Oncology, Inc. and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.36&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex7.htm"><span style="font-style:normal;font-weight:normal;">Sixth Amendment, effective October 24, 2023, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences, Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.37&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex8.htm"><span style="font-style:normal;font-weight:normal;">Amendment to and Waiver, dated October 25, 2023, under the Exclusive License and Commercialization Agreement, dated February 1, 2021, by and between Coherus Biosciences, Inc. and Shanghai Junshi Biosciences, Co. Ltd.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.049346924%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="5" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:25.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Incorporated by Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:56.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt 0pt 0pt 6.1pt;"><b style="font-size:7.5pt;font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:6pt;line-height:11.5pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:11.5pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Filed</b><span style="font-size:7.5pt;"><br/></span><b style="font-size:7.5pt;font-weight:bold;">Herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:7.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:56.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:4.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:10.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;white-space:nowrap;width:6.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:6.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.38</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex9.htm"><span style="font-style:normal;font-weight:normal;">Coherus BioSciences, Inc. Insider Trading Compliance Policy and Procedures, effective February 27, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.39#&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex10.htm"><span style="font-style:normal;font-weight:normal;">Letter Agreement between Coherus BioSciences, Inc. and McDavid Stilwell, dated as of December 11, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">10.40&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex10d40.htm"><span style="font-style:normal;font-weight:normal;">Exclusive Product License Agreement, dated March 23, 2021, by and between Vaccinex, Inc. and Surface Oncology, Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">21.1</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex21d1.htm"><span style="font-style:normal;font-weight:normal;">Subsidiaries of Coherus BioSciences, Inc.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">23.1</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex23.htm"><span style="font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">24.1</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><a href="#PowerofAttorney"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included in the signature page&#160;to this Form&#160;10-K).</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">31.1</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex31.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Required Under Rule&#160;13a-14(a)&#160;and 15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</span></a>.</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">31.2</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex32.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Required Under Rule&#160;13a-14(a)&#160;and 15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">32.1</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex33.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. &#167;1350.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">97.1</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20231231xex97.htm"><span style="font-style:normal;font-weight:normal;">Coherus BioSciences, Inc. Clawback Policy, effective December 1, 2023.</span></a></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">101.INS</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Inline XBRL Instance Document&#160;&#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">101.SCH</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">101.CAL</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">101.DEF</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">101.LAB</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt 0pt 0pt 6.1pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">101.PRE</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;">104</p></td><td colspan="2" style="vertical-align:top;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt 0pt 0pt 5.75pt;"><span style="font-size:11.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.92%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:justify;margin:0pt;">Cover page&#160;Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:11.5pt;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:11.5pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">X</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.049346924%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:57.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;text-align:justify;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:6pt;text-align:justify;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">&#8224;&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment or pursuant to Regulation S-K, Item&#160;601(b)(10). Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Additionally, schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item&#160;601(a)(5).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">#</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Indicates management contract or compensatory plan.</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_12932376_89ea_4f0f_84e7_c80e44d9d0e5"></a><a id="SIGNATURES_311562"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="3" style="vertical-align:top;width:39.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">COHERUS BIOSCIENCES,&#160;INC.</span></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Date: </span><span style="font-size:10pt;">March 15, 2024</span></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">By:</span></p></td><td colspan="2" style="vertical-align:top;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">/s/ Dennis M. Lanfear</span></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Name:</span></p></td><td colspan="2" style="vertical-align:top;width:34.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Dennis M. Lanfear</span></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Title:</span></p></td><td colspan="2" style="vertical-align:top;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">President and Chief Executive Officer</span></p></td></tr><tr><td style="vertical-align:top;width:58.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">(Principal Executive Officer)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PowerofAttorney"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dennis M. Lanfear and Bryan McMichael, his or her attorneys-in-fact, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form&#160;10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute, may do or cause to be done by virtue thereof.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Dennis M. Lanfear</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Dennis M. Lanfear</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Chairman,&#160;President&#160;and&#160;Chief Executive&#160;Officer<br/><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Bryan McMichael</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Bryan McMichael</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Interim Chief Financial Officer, Executive Vice President, Accounting and Corporate Controller</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer and Principal&#160;Accounting&#160;Officer)</i></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Georgia Erbez</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Georgia Erbez</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Lee N. Newcomer</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td rowspan="2" style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:top;width:43.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Lee N. Newcomer</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="display:none;vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Charles Newton</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Charles Newton</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Jill O&#8217;Donnell-Tormey</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Jill O&#8217;Donnell-Tormey</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Michael Ryan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Michael Ryan</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Ali J. Satvat</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Ali J. Satvat</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Mark D. Stolper</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Mark D. Stolper</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Kimberly J. Tzoumakas</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Kimberly J. Tzoumakas</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;">/s/ Mats Wahlstr&#246;m</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Mats Wahlstr&#246;m</p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2024</p></td></tr><tr><td style="vertical-align:middle;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#00ff00;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:36.78%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:19.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#00ff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>2
<FILENAME>chrs-20231231xex1.htm
<DESCRIPTION>EX-10_31
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:01:41 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;"><a name="_cp_textHF_105_287"></a></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.31</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Execution Copy</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">CONFIDENTIAL</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="_cp_text_1_1"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">FIRST AMENDED AND RESTATED</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">DEVELOPMENT AND OPTION</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> AGREEMENT</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_2"></a><a name="_cp_text_1_4"></a><a name="_cp_text_1_7"></a><a name="_cp_text_1_9"></a><a name="_cp_text_1_10"></a><a name="_cp_text_1_11"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">This First Amended and Restated Development and Option Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (this &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">made effective as of October </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">3, 2018 </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Amended Effective Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), is entered into by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), and Surface Oncology, Inc., a Delaware corporation having an address at 25 First Street, Suite 303, Cambridge, MA 02141 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Background</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Whereas,</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> Adimab is a leader in yeast-based, fully human antibody discovery and optimization using its proprietary core technology platform;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Whereas,</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> Surface wishes to discover and optimize certain proprietary antibodies as potential therapeutic product candidates directed against disease-related biological targets to be identified by Surface;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_16"></a><a name="_cp_text_4_17"></a><a name="_cp_text_1_18"></a><a name="_cp_text_1_20"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Whereas,</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> the Parties previously entered into that certain Development and Option Agreement, dated as of June 3, 2014, as amended (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Original Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; and such date, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Effective Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), pursuant to which the Parties collaborated </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to have Adimab discover and optimize antibodies, and Surface obtained </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a research license to determine the activity of such antibodies and to evaluate such antibodies, as well as an option to a license for commercial rights to certain of the antibodies to each such target for development and commercialization as a pharmaceutical product; and</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_21"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Whereas,</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> the Parties now desire to amend and restate the Original Agreement in its entirety and replace the Original Agreement with this Agreement to, among other things, expand the right of Surface to evaluate and use antibodies for diagnostic purposes.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_textHF_1_286"></a><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Now, Therefore,</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and valuable consideration, the receipt of which is hereby acknowledged, Adimab and Surface hereby agree as follows:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 1</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">DEFINITIONS</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The following initially capitalized terms have the following meanings (and derivative forms of them shall be interpreted accordingly):</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.1</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">AAA</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 10.2(c)(i).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.2</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the recitals.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_22"></a><a name="_cp_text_1_23"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.3</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Diagnostic Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any Licensed Antibody that [***]. For clarity, &#8220;Adimab Diagnostic Product&#8221; as defined herein (i) includes Companion Diagnostics and (ii) excludes (A) prophylactic or therapeutic Products containing [***] Licensed Antibodies and (B) any Other Diagnostic Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_25"></a><a name="_cp_blt_2_24"></a><a name="_cp_blt_2_26"></a><a name="_cp_blt_1_27"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.4</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Section 8.2.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.5</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Materials</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any tangible biological or chemical materials (including all [***] and other [***] in the form of tangible biological or chemical materials) provided by Adimab to Surface under the Research Program, [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_29"></a><a name="_cp_blt_2_28"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.6</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Platform Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means all Patents [***] the [***] that [***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_31"></a><a name="_cp_blt_2_30"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.7</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Platform Technology</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means (a) the discovery and optimization of antibodies via methods that include the use of synthetic DNA antibody libraries and engineered strains of yeast, (b) all methods, materials and other Know-How used in the foregoing and (c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b). For clarity, Adimab Platform Technology includes technology used in the discovery, and optimization of any Program Antibody, in each case not based on the specific composition of such Program Antibody (or product containing a Program Antibody), but based instead on the manner in which such Program Antibody was discovered or optimized under a Research Program.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_33"></a><a name="_cp_blt_2_32"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.8</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Platform Technology Improvement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means all Program Inventions that [***] Adimab Platform Technology, including any and all improvements, enhancements, modifications, substitutions, alternatives or alterations to Adimab Platform Technology.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_37"></a><a name="_cp_blt_2_36"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.10</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Affiliate</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means an entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with a Party. For this purpose, &#8220;control&#8221; means the ownership of fifty percent (50%) or more of the voting securities entitled to elect the directors or management of the entity, or the actual power to elect or direct the management of the entity. Moreover, notwithstanding anything in this Agreement to the contrary, any venture capital fund, private equity fund or other investor who is not primarily an operating biopharmaceutical, pharmaceutical, diagnostics, or medical device research and development and/or marketing company (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Non-affiliate Investor</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) shall not be considered an Affiliate of a Party, and any person or entity that directly or indirectly controls or is controlled by a Non-affiliate Investor (except for any entity directly or indirectly controlled by a Party, controlling a Party, or under common control with a Party, in each case other than through Non-affiliate Investor(s)) shall not be considered an Affiliate of a Party solely by reason of being controlled by the same Non-affiliate Investors. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_39"></a><a name="_cp_blt_2_38"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.11</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the recitals. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_41"></a><a name="_cp_blt_2_40"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.12</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Bankruptcy Code</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 9.7.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_45"></a><a name="_cp_blt_2_44"></a><a name="_cp_field_47_43"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.13</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Binding Sequence Information</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 1.60.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_47"></a><a name="_cp_blt_2_46"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.14</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Change of Control</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any transaction or series of transactions in which Surface (a) sells, conveys or otherwise disposes of all or substantially all of its property or business to a single entity or set of Affiliated entities; or (b) (i) merges with, consolidates with, acquires or is acquired by any other entity; or (ii) effects any other transaction or series of related transactions; in the case of each of clause (i) and clause (ii), such that the members, stockholders or shareholders of Surface immediately prior thereto, in the aggregate, no longer own, directly or indirectly, at least fifty percent (50%) of the outstanding voting securities or capital stock (including membership interests) of the surviving entity following the closing of such merger, consolidation, other transaction or series of related transactions, other than a capital-raising transaction with a Non-Affiliate Investor.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_49"></a><a name="_cp_blt_2_48"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.15</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Combination Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">means a product containing a Licensed Antibody as well as one or more other active therapeutic ingredient. Notwithstanding the foregoing, [***]. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_51"></a><a name="_cp_blt_2_50"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.16</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Commercial</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 3.3(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_53"></a><a name="_cp_blt_2_52"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.17</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Commercial</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Option Fee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 4.3.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_55"></a><a name="_cp_blt_2_54"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.18</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Commercially Reasonable Efforts</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">means the level of efforts required to carry out a task in a diligent and sustained manner without undue interruption, pause or delay; which level is at least commensurate with the level of efforts that a similarly situated biopharmaceutical company would devote to a product of similar potential and having similar commercial and scientific advantages and disadvantages resulting from the company&#8217;s own research efforts (i.e., explicitly ignoring the royalty, milestone and other payments due Adimab under this Agreement), taking into account safety and efficacy; the competitiveness of alternative products; the proprietary position of the product; pricing and reimbursement; and all other relevant commercial factors.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_56"></a><a name="_cp_text_1_57"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.19</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Companion Diagnostic</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any Adimab Diagnostic Product used with or in connection with a particular prophylactic or therapeutic Product containing [***] Licensed Antibodies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_59"></a><a name="_cp_blt_2_58"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.20</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Confidential Information</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 6.1(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_61"></a><a name="_cp_blt_2_60"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.21</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Control</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to any Know-How or Patent [***] (other than pursuant to this Agreement), of the [***] as provided for in this Agreement without violating the terms of any written agreement with any Third Party.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_63"></a><a name="_cp_blt_2_62"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.22</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Controlled Contractor</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 2.1(b).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_65"></a><a name="_cp_blt_2_64"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.23</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Cover</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to a particular item and a particular Patent, that such Patent [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_66"></a><a name="_cp_text_1_67"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.24</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Diagnostic Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any Adimab Diagnostic Product or Other Diagnostic Product. For clarity, &#8220;Diagnostic Product&#8221; as defined herein excludes prophylactic or therapeutic Products containing [***] Licensed Antibodies. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_71"></a><a name="_cp_blt_2_70"></a><a name="_cp_text_1_69"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.25</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Discovery Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the term beginning on the Effective Date and ending on [***]. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_73"></a><a name="_cp_blt_2_72"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.26</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Dispute</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 10.2(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_75"></a><a name="_cp_blt_2_74"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.27</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Effective Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the recitals.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_76"></a><a name="_cp_text_1_77"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.28</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">External Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any compound or product other than (a) a Licensed Antibody or (b) Product containing [***] Licensed Antibodies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_79"></a><a name="_cp_blt_2_78"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.29</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Evaluation Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to each Target, the time period beginning at the end of the Research Term for such Target and ending [***] thereafter, unless otherwise extended by mutual agreement of the Parties.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_81"></a><a name="_cp_blt_2_80"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.30</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Field</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means diagnostic, therapeutic or prophylactic uses in human or other animal disease.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_83"></a><a name="_cp_blt_2_82"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.31</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">First Commercial Sale</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to a Licensed Product in any country, the first sale, transfer or disposition for value or for end use or consumption of such Licensed Product in such country after Marketing Approval for such Licensed Product has been received in such country, but excluding any distribution or other sale solely for so-called treatment investigational new drug sales, named patient sales, compassionate or emergency use sales and pre-license sales.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_85"></a><a name="_cp_blt_2_84"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.32</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Force Majeure</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means conditions beyond a Party&#8217;s reasonable control or ability to plan for, including acts of God, war, terrorism, civil commotion, labor strike or lock-out; epidemic; failure or default of public utilities or common carriers; and destruction of facilities or materials by fire, earthquake, storm or like catastrophe; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, the payment of invoices due and owing under this Agreement shall not be excused by reason of a Force Majeure affecting the payor.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_87"></a><a name="_cp_blt_2_86"></a><a name="_DV_M92"></a><a name="_DV_M93"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.33</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">FTE</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the equivalent of a full-time employee&#8217;s working days over a twelve (12) month period (taking account of normal vacations, sick days and holidays not being considered working days), </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">which equates to a total of [***] hours per twelve (12) month period of work performed by a fully qualified Adimab employee or consultant in a Research Program. To provide an FTE over a given time period that is less than a year means to provide the proportionate share (corresponding to the proportion that such time period bears to a full year) during such time period of a full year&#8217;s FTE. In no event shall the work over the course of a year of one individual person account for more than one (1) FTE year.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_89"></a><a name="_cp_blt_2_88"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.34</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">FTE Rate</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means [***] per FTE.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_91"></a><a name="_cp_blt_2_90"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.35</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Indemnify</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 8.1.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_93"></a><a name="_cp_blt_2_92"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.36</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Interest Payment</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 4.5.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_95"></a><a name="_cp_blt_2_94"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.37</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Joint Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">means any and all Program Inventions made jointly by employees of, or others obligated to assign Program Inventions to, each of Adimab (or any of its Affiliates) and Surface (or any of its Affiliates).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_97"></a><a name="_cp_blt_2_96"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.38</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Joint Serendipitous Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means all Joint Inventions other than those Covered by Program Antibody Patents or constituting Adimab Platform Technology Improvements.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_99"></a><a name="_cp_blt_2_98"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.39</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Know-How</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means all technical information and know-how, including (i) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, DNA, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (ii) all data, instructions, processes, formula, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_101"></a><a name="_cp_blt_2_100"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.40</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Licensed Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means those Program Antibodies that are selected by Surface pursuant to Section 3.3(a), and any Program-Benefited Antibody generated from such Program Antibodies.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_103"></a><a name="_cp_blt_2_102"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.41</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Licensed Research Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means those Program Antibodies that are selected by Surface pursuant to Section 3.2(a), and any Program-Benefited Antibody generated from such Program Antibodies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_109"></a><a name="_cp_blt_2_108"></a><a name="_cp_text_1_104"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.42</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Licensed Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means a Product that [***] Licensed Antibodies, and includes Combination Products containing any one or more Licensed Antibodies or any Adimab Diagnostic Product. [***]. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_111"></a><a name="_cp_blt_2_110"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.43</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Licensed Program Antibody Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means those Program Antibody Patents that Cover any Licensed Antibodies or Licensed Research Antibodies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_113"></a><a name="_cp_blt_2_112"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.44</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Losses</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 8.1.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_115"></a><a name="_cp_blt_2_114"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.45</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Major Markets</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means each of the [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_128"></a><a name="_cp_blt_2_127"></a><a name="_cp_text_1_117"></a><a name="_cp_text_1_119"></a><a name="_cp_text_1_121"></a><a name="_cp_text_1_123"></a><a name="_cp_text_1_124"></a><a name="_cp_text_1_126"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.46</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Marketing Approval</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; each means approval to market a Licensed Product legally as a drug or biologic, including approval of a Biologics </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">License Application (as defined in the Federal Food, Drug, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">and Cosmetic Act, the Public Health Service </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Act and the regulations promulgated thereunder) in the United States, or license, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">approval, registration, or authorization </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of a comparable filing in any other jurisdiction, or the clearance, approval, license, registration, or authorization of a comparable filing for medical device, diagnostic or animal use. [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_130"></a><a name="_cp_blt_2_129"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.47</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Milestone Event</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 4.4.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_132"></a><a name="_cp_blt_2_131"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.48</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Milestone Payment</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 4.4.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_134"></a><a name="_cp_blt_2_133"></a><a name="_cp_blt_2_135"></a><a name="_cp_blt_1_136"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.49</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Na&#239;ve Antibody Library</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 2.6(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.50</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Net Sales</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means [***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If any Licensed Antibody is sold as part of a Combination Product, the Net Sales for such Licensed Antibody shall be determined by [***]</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_138"></a><a name="_cp_blt_2_137"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.51</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Non-Affiliate Investor</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 1.9.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_140"></a><a name="_cp_blt_2_139"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.52</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Optimization Antibody Library</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 2.6(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_141"></a><a name="_cp_text_1_142"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.53</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Other Diagnostic Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any assay, medical device, product or compound that (a) does not comprise, incorporate, contain or use a Licensed Antibody and (b) [***]. For clarity, &#8220;Other Diagnostic Product&#8221; as defined herein excludes (A) Adimab Diagnostic Products and (B) prophylactic or therapeutic Products containing Licensed Antibodies.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_144"></a><a name="_cp_blt_2_143"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.54</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Party</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means Adimab or Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_146"></a><a name="_cp_blt_2_145"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.55</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Patent</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any patent application or patent anywhere in the world, including all of the following categories of patents and patent applications, and their foreign equivalents: provisional, utility, divisional, continuation, continuation-in-part, and substitution applications; and utility, re-issue, re-examination, renewal and extended patents, and patents of addition, and any Supplementary Protection Certificates, patent extensions, restoration of patent terms and other similar rights.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_150"></a><a name="_cp_blt_2_149"></a><a name="_cp_field_47_148"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.56</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Permitted Comparison</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 1.60.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_152"></a><a name="_cp_blt_2_151"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.57</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any actual or potential product [***] that [***] Program-Benefited Antibodies [***]. For clarity, it is possible that there will be multiple Products against a single Target.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_154"></a><a name="_cp_blt_2_153"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.58</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Program Antibody</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to each Target, each antibody [***] under</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a Research Program for such Target. It is understood and agreed that [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_156"></a><a name="_cp_blt_2_155"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.59</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Program Antibody Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, for each Target, Patents that, [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_158"></a><a name="_cp_blt_2_157"></a><a name="_Ref517709566"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.60</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Program-Benefited Antibody</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any Program Antibody or any modified or derivative form of any such Program Antibody that comprises or contains either [***] (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Binding Sequence Information</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Notwithstanding the foregoing, an antibody product will not be deemed a Program-Benefited Antibody [***] (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Permitted Comparisons</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_160"></a><a name="_cp_blt_2_159"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.61</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Program Deliverables</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, for each Target, the deliverables for a given part of the Research Plan as defined in the Research Plan for such Target.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_162"></a><a name="_cp_blt_2_161"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.62</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Program Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, for each Target, any invention or Know-How that is [***] in the course of performing or as a result of the activities conducted under a Research Program.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_164"></a><a name="_cp_blt_2_163"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.63</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Program Patent</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, for each Target, any Patent Covering a Program Invention.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_166"></a><a name="_cp_blt_2_165"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.64</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Prosecute</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(d)(i).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_168"></a><a name="_cp_blt_2_167"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.65</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Committee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 2.2(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_170"></a><a name="_cp_blt_2_169"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.66</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research License Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 3.2(b)(i).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_172"></a><a name="_cp_blt_2_171"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.67</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 3.2(a).</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_174"></a><a name="_cp_blt_2_173"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.68</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Plan</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the research plan to be agreed upon by the Parties with respect to a Target in accordance with Section 2.1(a) hereof.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_176"></a><a name="_cp_blt_2_175"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.69</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Program</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the program of research conducted under this Agreement in accordance with a Research Plan, and, as applicable, all programs of research conducted under this Agreement in accordance with all Research Plans.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_178"></a><a name="_cp_blt_2_177"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.70</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the period beginning on the Effective Date and ending, on a Research Program-by-Research Program basis, when Adimab delivers final antibodies under a Research Plan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_180"></a><a name="_cp_blt_2_179"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.71</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Royalty Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the term ending at the later to occur of (a) the expiration of the last Valid Claim Covering the Licensed Product in the country in which such Licensed Product is manufactured or sold, or (b) ten (10) years after the First Commercial Sale of such Licensed Product in such country.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_182"></a><a name="_cp_blt_2_181"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.72</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Senior Executive Discussions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 10.2(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_184"></a><a name="_cp_blt_2_183"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.73</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the recitals.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_186"></a><a name="_cp_blt_2_185"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.74</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 8.1.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_188"></a><a name="_cp_blt_2_187"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.75</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface Materials</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">means (a) any tangible biological or chemical materials (including antigen samples and other Know-How in the form of tangible biological or chemical materials) provided by Surface to Adimab under a Research Program (other than commercial material purchased by Surface and delivered to Adimab), and (b) from and after the time of the Commercial Option exercise for a Target, the quantities of Licensed Antibody to such Target (and DNA encoding that Licensed Antibody) provided to Surface by Adimab under this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_190"></a><a name="_cp_blt_2_189"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.76</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface Program Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means all Program Inventions made solely by employees of, or others obligated to assign Program Inventions to, Surface (or any of its Affiliates). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_192"></a><a name="_cp_blt_2_191"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.77</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Target</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means a target selected by Surface pursuant to Section 2.1(a).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_194"></a><a name="_cp_blt_2_193"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.78</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Target Questionnaire</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the form of target questionnaire attached hereto as Exhibit A.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_196"></a><a name="_cp_blt_2_195"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.79</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Third Party</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means an entity other than a Party or the Affiliate of a Party.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_198"></a><a name="_cp_blt_2_197"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.80</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Third Party Claims</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in Section 8.1.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_200"></a><a name="_cp_blt_2_199"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.81</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Third Party Patent Licenses</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means Patent licenses obtained by Surface after Surface determines in good faith that one or more such Patent licenses from Third Parties are [***], in order to avoid Third Party claims of patent infringement [***] of a Licensed Antibody, [***]. For clarity, Third Party Patent Licenses explicitly excludes licenses to any of the foregoing: </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(1)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(2)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(3)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(4)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(5)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(6)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(7)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_202"></a><a name="_cp_blt_2_201"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.82</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Valid Claim</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means a claim of a Licensed Program Antibody Patent, which claim [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_204"></a><a name="_cp_blt_2_203"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.83</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">References in the body of this Agreement to &#8220;Sections&#8221; and &#8220;Articles&#8221; refer to the sections and articles of this Agreement. The terms &#8220;include,&#8221; &#8220;includes,&#8221; &#8220;including&#8221; and derivative forms of them shall be deemed followed by the phrase &#8220;without limitation&#8221; regardless of whether such phrase appears there (and with no implication being drawn from its inconsistent inclusion or non-inclusion), and the use of the word &#8220;or&#8221; shall not be exclusive.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_206"></a><a name="_cp_blt_2_205"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">1.84</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">To avoid doubt, the term &#8220;antibody&#8221; as used everywhere else in this Agreement includes both full-length antibodies, functional fragments thereof, and chemically modified versions thereof (including pegylated versions and regardless of whether containing amino acid substitutions), all of the foregoing whether naturally occurring, artificially produced, raised in an artificial system, or created through modification of an antibody produced in any of the foregoing ways or otherwise.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 2</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">PROGRAM</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.1Research Programs.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Target Selection</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface shall nominate the first Target by providing notice of such Target to Adimab before the Effective Date. At any time prior to the expiration of the Discovery Term, Surface may initiate Research Programs with respect to additional Targets by notifying Adimab. In each case, such notice shall be in writing on a Target-by-Target basis, and shall be in the form of a completed Target Questionnaire with respect to each such Target and delivery of Surface&#8217;s antigen for such Target. Adimab&#8217;s obligation to perform such additional Research Programs shall be subject to the availability of Adimab researchers. Upon receipt of such notice by Adimab and Adimab&#8217;s confirmation of availability, the Parties shall work together to prepare the content of a Research Plan with respect to such Target, including the relevant Deliverables and success criteria. Such Research Plan shall be based upon the form of Research Plan attached hereto as Exhibit B, and shall include Adimab&#8217;s responsibilities with respect to the discovery and optimization of antibodies with respect to each Target. Each Research Plan shall be agreed upon in writing by the Parties, and each Research Program shall be conducted in accordance therewith. Neither Party is required to perform a Research Program under this Agreement if the Parties do not mutually agree in writing on Research Plan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Conduct of Research</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party shall use its commercially reasonable efforts to perform the Research Program activities assigned to such Party in each Research Plan and to achieve the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">timeline(s) set forth in such Research Plan. Adimab&#8217;s performance obligations under each Research Program shall be contingent upon Surface providing the Surface Materials, if any, set forth in the applicable Research Plan. Such Surface Materials are expected to include Target antigen. Adimab&#8217;s obligations with regard to the performance of a particular Research Program shall expire at the end of the applicable Research Term. Adimab shall have the right to use Third Parties in the performance of its obligations hereunder, subject to Surface&#8217;s prior written consent if such Third Party is not identified and the applicable work not described in the Research Plan (any such permitted Third Party, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Controlled Contractor</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.2Project Management. </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Scientific Research Committee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Promptly after the completion of the first Research Plan, the Parties shall form a steering committee consisting of [***]</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">representatives from each Party with respect to the relevant Research Program (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Committee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) to oversee the Research Programs. The Research Committee&#8217;s role is to facilitate communication regarding progress in relation to the Research Programs and the collaboration generally. Either Party may change its Research Committee members upon written notice to the other Party. The Research Committee may meet in person or by teleconference or videoconference. Each Party shall designate one of its Research Committee members as co-chair. The Research Committee shall meet from time to time promptly after the date of a written request by either Party. Additional members representing either Party may attend any Research Committee meeting. The co-chairs shall be responsible to circulate, finalize and agree on minutes of each meeting within [***] days after the meeting date. Upon expiration of the final Research Term, the Research Committee shall be disbanded. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Decision Making</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Research Committee shall operate by consensus but solely within the limits specified in this Section 2.2, it being understood that if the co-chairs cannot agree with regards to a specific matter within their decision-making authority, no decision of the Research Committee shall be deemed taken by the Research Committee. The Research Committee shall have the limited authority to amend the Research Plans in a manner not substantially affecting resources required to perform, timing for performance, or success criteria. Except for the limited authority set forth in this Section 2.2, the Research Committee shall not have any decision-making authority and in no event shall the Research Committee shall have the power to amend or waive compliance with this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)Alliance Managers</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party shall designate in writing within [***] days after signing an &#8220;Alliance Manager&#8221; to be the primary contact for such Party. The Alliance Manager shall be responsible for managing communications between the Parties with respect to a Research Program, including responsibility for scheduling teleconferences and coordinating Research Committee meetings.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(d)Exclusive Use of Campaign Manager</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the applicable Research Term and for a period of [***] year after, the person whom Adimab has designated as the &#8220;Campaign Manager&#8221; for a given Research Program shall not perform, or supervise the performance of, research relating to the same Target using Adimab Platform Technology for Adimab or its Affiliates (whether for their own account or on behalf of any Third Party). It is understood and agreed that if such a person is no longer in Adimab&#8217;s or its Affiliate&#8217;s employ, then such person&#8217;s activities for another employer </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">are beyond the scope of (and are not Adimab&#8217;s responsibility to prevent under) the foregoing sentence.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.3Reports; Records</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)By Adimab</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the applicable Research Term, at the junctures specified in the applicable Research Plan, Adimab shall provide written reports to Surface regarding the Research Plan. Notwithstanding the foregoing or anything express or implied anywhere in this Agreement, Adimab shall not be required to disclose any Adimab Platform Technology or Adimab Platform Technology Improvements to Surface. Adimab shall maintain records, in sufficient details and in good scientific manner appropriate for patent purposes, which shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance of a Research Program, by or on behalf of Adimab or any of its Affiliates or Controlled Contractors. All such records shall be kept in sufficient detail to identify and report those research activities conducted by Adimab, and shall be made available for inspection or copies provided to Surface upon Surface&#8217;s request. In the event that such records and data include disclosure of Adimab Platform Technology or Adimab Platform Technology Improvements, Adimab may redact those portions as is necessary to protect Adimab Platform Technology or Adimab Platform Technology Improvements prior to any review or inspection by or delivery to Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)By Surface</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the applicable Research Term, at the junctures set forth in the applicable Research Plan, for so long as Surface or any of its Affiliates, licensees or sublicensees continue to generate or test any Program-Benefited Antibodies, Surface shall provide written reports to Adimab which provide any data Surface is required to provide under the applicable Research Plan and shall disclose information regarding the existence and progress of all Program-Benefited Antibodies since the date of the last report. For clarity, the information reported by Surface after the Research Term shall be solely for the purpose of allowing Adimab to monitor Surface&#8217;s obligations under this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.4Use of Adimab Materials</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. With respect to each Target, Surface and its Affiliates shall only use Adimab Materials (a) as is necessary to conduct a Research Program during the Research Term and the Evaluation Term, (b) pursuant to the license granted under Section 3.1(a) and Section 3.2(b) of this Agreement while such licenses are in effect, including for Permitted Comparisons, or (c) to generate and test Program-Benefited Antibodies in accordance with Section 9.4. Surface and its Affiliates shall not use Adimab Materials for any other purposes. Without limiting the foregoing, Adimab acknowledges and agrees that upon receipt of Program Antibodies, Surface may conduct testing on such Program Antibodies to optimize such Program Antibodies (and, to avoid doubt, the optimized versions thus created shall be Program-Benefited Antibodies).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab retains title to the Adimab Materials, including all quantities of Program Antibodies that it provides under a Research Program, including during the Evaluation Term. During the Evaluation Term, such quantities of Program Antibodies are (i) for use solely in assessing whether to exercise the Commercial Option or Research Option for the applicable Target and for Permitted Comparisons, and (ii) shall not be used in humans or for any commercial purpose. Should Surface exercise neither its Research Option pursuant to Section 3.2(a) nor its Commercial Option pursuant to Section 3.3(a), Surface shall return to Adimab or destroy any Program-Benefitted Antibodies in its possession on expiration of the Evaluation Term for such Target. Surface shall destroy any </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Licensed Research Antibodies in its possession on expiration of the relevant Research License Term. Without limiting the generality of the foregoing, during the Evaluation Term and after expiration of the Options, if unexercised, Surface shall not provide Program-Benefitted Antibodies to Third Parties, except as permitted by this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.5Use of Surface Materials</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab shall use the Surface Materials solely to perform the Research Program for the applicable Target. Adimab shall not transfer the Surface Materials outside of Adimab nor, for clarity, provide the Surface Materials to any Third Party. Within [***] days after the Research Term for such Target ends, Adimab will return to Surface or destroy any remaining Surface Materials (at Surface&#8217;s direction).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.6Certain Restrictions on the Use of Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Adimab Restrictions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. For each Target, until the earlier of expiration of the Evaluation Term for such Target or Surface&#8217;s exercise of its Commercial Option for such Target, Adimab shall not provide any of the Program Antibodies (or any of their Binding Sequence Information) to any Third Party in connection with performing a funded or sponsored research program for such Third Party. In addition, even if Surface does not exercise its Commercial Option for a particular Target, Adimab shall not file Program Antibody Patents for such Target or any patent application Covering any Program Antibody, unless independently rediscovered as contemplated below. For purposes of this Section 2.6, the performance of a program by Adimab means use of any of the Adimab Platform Technology to discover or optimize antibodies to the applicable Target based on activity against or with respect to such Target. Further, at all times, unless independently rediscovered without the use of (i) Surface Materials, (ii) Confidential Information of Surface (subject to Section 6.2(e)), (iii) any antibody library that is (A) [***] and (B) [***] (any such antibody library satisfying clauses (A) and (B)(1), a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Naive Antibody Library</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) or (2) created specifically for use in the Research Program and [***] from a Naive Antibody Library in a Research Program (any such antibody library satisfying clauses (A) and (B)(2) an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Optimization Antibody Library</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and or any antibodies identified therefrom (including Program Antibodies), or any of their partial or whole sequences, or (iv) any Program Inventions to the extent solely owned by Surface based on the terms of this Agreement (subject to Section 6.2(e)), Adimab and its Affiliates shall not (I) provide the Program Antibodies or their Binding Sequence Information to any Third Party at any time, or any other antibody or their Binding Sequence Information identified from any Naive Antibody Library or Optimization Antibody Library under a Research Program or (II) use the Program Antibodies, any other antibody identified from any Naive Antibody Library or Optimization Antibody Library under a Research Program, or any of their Binding Sequence Information, to research, develop, manufacture or commercialize any biologic or drug products in for Adimab, its Affiliates or any Third Parties. Further, Adimab shall not perform any research, discovery or development with respect to a Target using any Naive Antibody Library or Optimization Antibody Library for which research, discovery or development was pursued with respect to such Target under a Research Program, and Adimab shall not provide (by any means, such as sale, license or transfer), any Naive Antibody Library or Optimization Antibody Library (or any substantial portion thereof) to any others.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">To avoid doubt and notwithstanding anything to the contrary in this Agreement:</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">nothing herein shall prevent Adimab from licensing or transferring some or all of the Adimab Platform Technology and/or Adimab Platform Technology Improvements to a Third Party (including technical support in connection therewith) nor shall anything herein require Adimab to in any way limit the use of the Adimab Platform Technology and/or Adimab Platform Technology Improvements by a Third Party, subject to the restrictions above regarding any Naive Antibody Library or Optimization Antibody Library and antibodies identified therefrom (including Program Antibodies), or any of their Binding Sequence Information; and</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">nothing herein shall require Adimab to physically remove from its libraries, or to prevent from being included in future libraries, any Program-Benefited Antibodies, but Adimab is limited with respect to the use of any Naive Antibody Library and Optimization Antibody Library as provided above. This Agreement expressly provides for a reserved right for Adimab, its Affiliates, and those deriving rights from them (a) to include Program-Benefited Antibodies in antibody library(ies) (other than Naive Libraries) transferred or licensed by Adimab to Third Parties (including the transfer of physical possession of samples of Program-Benefited Antibodies to a Third Party as part of such transactions) and (b) to conduct any activity with respect to Program-Benefited Antibodies that are not Licensed Antibodies under this Agreement if Adimab (or such other party) arrives at such Program-Benefited Antibodies in a manner fully compliant with Adimab&#8217;s other covenants and obligations in this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab may independently regenerate Binding Sequence Information for any Program Antibodies without use or reference to any Program Inventions or any Naive Antibody Library or Optimization Antibody Library, other than Adimab Platform Technology Improvements (which nothing in this Agreement shall be read to restrict Adimab from using). In the case of independent rediscovery as provided above, Adimab shall be unrestricted in its use of and ability to provide the applicable independently rediscovered or independently regenerated antibodies to others.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Surface Restrictions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface hereby covenants that it and its Affiliates shall not seek to or actually clinically develop or commercialize any Program-Benefited Antibody, or product containing either of the foregoing (other than the activities permitted hereunder during the Research Term and the Evaluation Term for the purpose of determining whether or not to exercise an Option for such Target), without first executing the Commercial Option with Adimab with respect to the applicable Target.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_207"></a><a name="_cp_text_1_208"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">2.7Amendment and Restatement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties hereby agree and acknowledge that this Agreement amends and restates the Original Agreement in its entirety and the Original Agreement is replaced with, and superseded by, this Agreement; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that, for the avoidance of doubt, any activities conducted under the Original Agreement shall be deemed to have been conducted under this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 3</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">LICENSES; OPTION; DEVELOPMENT &amp; COMMERCIALIZATION</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">3.1Mutual Research Program Licenses</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_209"></a><a name="_cp_text_1_211"></a><a name="_cp_text_1_212"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)To Surface</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the Research Term and Evaluation Term for each Target, Adimab hereby grants to Surface a non-exclusive, non-sublicensable license with respect to such Target, under the Adimab Platform Patents, Program Antibody Patents and Know-How Controlled by Adimab (or its Affiliates) during the term of this Agreement, to perform research, and to design, research, preclinically develop, make, import and use Program-Benefited Antibodies and Adimab Materials pertaining thereto in the Field, including for Surface to (i) </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">evaluate Program-Benefited Antibodies, (ii) </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">perform Permitted Comparisons and Surface&#8217;s responsibilities under the Research Plan and this Agreement for each Target, and (iii) design, research, preclinically develop, make, import and use Program-Benefited Antibodies and Adimab Materials as Adimab Diagnostic Products. For clarity, the license to Surface excludes the right to [***] but includes the right to (1) perform Permitted Comparisons and (2) have others perform the licensed activities on behalf of Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)To Adimab</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the Research Term and Evaluation Term for each Target, Surface hereby grants to Adimab a non-exclusive, nontransferable (except in connection with a permitted assignment of this Agreement) license (without the right to grant sublicenses except to Controlled Contractors) with respect to such Target under all Patents and Know-How Controlled by Surface (or its Affiliates) which Cover or relate to the Targets (including any that so relate by claiming antibodies directed to the Targets or a mechanism of action via the Targets) or any Surface Materials, solely to perform Adimab&#8217;s responsibilities as provided for in the applicable Research Plan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">3.2Research Rights.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Research Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. On a Target-by-Target basis, Adimab hereby grants to Surface the exclusive option (for each Target, a &quot;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&quot;) to obtain the licenses set forth in Section 3.2(b) for Licensed Research Antibodies to the Target, exercisable by written notice to Adimab and (i) payment by Surface to Adimab of [***] on or before the date that is [***] months after the date on which Technical Milestone 1 is achieved for the Target, or (ii) payment of Technical Milestone 2 with respect to the Target and on or before the expiry of the Evaluation Term. Surface shall, in its written notice to exercise the Research Option for a Target, specify up to ten (10) Program Antibodies against the Target as the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Licensed Research Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;. Upon such Research Option exercise, Adimab will provide to Surface sufficient materials to allow Surface to express any such Licensed Research Antibodies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Research License</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab hereby, effective on Surface&#39;s exercise of the Research Option for a Target and the applicable Licensed Research Antibodies:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">grants to Surface a worldwide, fully paid-up, sublicenseable through multiple tiers (solely as provided in Section 3.2(b)(ii)) license, under (A) the Adimab Platform Patents and, (B) any Licensed Program Antibody Patents, and (C) Know-How and other Patents Covering the Adimab Platform Technology, Adimab Platform Technology Improvements or Program Inventions, in each case, Controlled by Adimab (or its Affiliates) as of the start of and during the applicable Research License Term, to make, have made, import, have imported, export and have exported, in each case, for research purposes only, the Licensed Research Antibodies for such Target for a period beginning on the date of Surface&#8217;s exercise of the Research Option for such Target and expiring on the date [***] years after such exercise (subject to Section 9.1) (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Research License Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Such license shall be non-exclusive and shall exclude the use of any Licensed Research </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Antibodies in humans. This license grant is granted by Adimab as of the Effective Date as a current license grant, subject only to the Research Option exercise by Surface but not any other action by Adimab. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The license granted under Section 3.2(b)(i) shall be sublicensable solely to (x) Controlled Contractors or (y) in connection with the sublicensing of commercial rights to a therapeutic product against the same Target, in either case, pursuant to sublicenses that are consistent with all relevant terms and conditions of this Agreement, including Sections 2.4 and 9.4 hereof. Surface shall remain responsible for all payments and other performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">3.3Commercial Rights</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_223"></a><a name="_cp_text_1_225"></a><a name="_cp_text_1_226"></a><a name="_cp_field_47_227"></a><a name="_cp_text_1_228"></a><a name="_cp_text_1_229"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Commercial Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. On a Target-by-Target basis, Adimab hereby grants to Surface the exclusive option (for each Target, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Commercial</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) to obtain the licenses of Section 3.3(b) for Licensed Antibodies to the Target, exercisable by payment of the Commercial Option Fee with respect to such Target to Adimab on or before the expiry of the Evaluation Term. Surface shall, in its written notice to exercise the Commercial Option for a Target, specify up to twenty </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(20) Program-Benefited Antibodies against the Target as the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Licensed Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.&#8221; Additionally, Surface shall have the exclusive option to obtain licenses for up to five (5) additional Licensed Antibodies (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Additional Licensed Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), up to a total of twenty-five (25) Licensed Antibodies, with each Additional Licensed Antibody beyond the initial twenty (20) increasing the Commercial Option Fee in accordance with Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.3. For clarity, Additional Licensed Antibodies shall be classified as &#8220;Licensed Antibodies&#8221; under this Agreement. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Upon such Commercial Option exercise, Adimab will provide to Surface sufficient materials to allow Surface to express any such Licensed Antibodies that were generated in the Research Program. Notwithstanding the foregoing, Surface may elect to partially exercise the Commercial Option by paying sixty five percent (65%) of the Commercial </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Option Fee and designating up to ten (10) Program-Benefited Antibodies as Licensed Antibodies; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that prior to the expiration of the Evaluation Term, Surface shall either (i) pay the remaining thirty five percent (35%) of the Commercial Option Fee and, at any time prior to the expiration of the Evaluation Term (even if after payment of the remaining thirty five percent (35%) of the Commercial Option Fee) designate additional Program-Benefited Antibodies as Licensed Antibodies such that the total number of Licensed Antibodies does not exceed twenty (20) or (ii) fail to pay the remaining thirty five percent (35%) of the Commercial Option Fee, in which case the Commercial Option shall be deemed not to have been exercised with respect to such Target and no Program-Benefited Antibodies against such shall be deemed Licensed Antibodies from that point forward. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Development and Commercialization License and Assignment</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab hereby, effective on Surface&#8217;s exercise of the Commercial Option for a Target and the applicable Licensed Antibodies:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">assigns to Surface, subject to the terms and conditions of this Agreement and without any further action required of either Party, all right, title and interest in and to those Licensed Program Antibody Patents that solely Cover those Licensed Antibodies, and at Surface&#8217;s request, Adimab </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">will execute title transfer and recordation assignments for any such Licensed Program Antibody Patents; and</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">grants to Surface a worldwide, royalty-bearing, sublicenseable through multiple tiers (solely as provided in Section 3.3(b)(iii)) license, under (A) the Adimab Platform Patents, (B) those Licensed Program Antibody Patents which are not assigned to Surface pursuant to Section 3.3(b)(i) (for any reason, including bankruptcy and other like proceedings described in Section 9.7), and (C) Know-How Covering the Adimab Platform Technology, Adimab Platform Technology Improvements or Program Inventions, in each case, Controlled by Adimab (or its Affiliates) as of the start of and during the term of this Agreement, in the Field, to research, have researched, develop, have developed, commercialize, have commercialized, make, have made, use, have used, sell, have sold, offer to sell, have offered to sell, import, have imported, export and have exported the Licensed Antibodies and Licensed Products for such Target during the term of this Agreement (subject to Section 9.1). Such license shall be non-exclusive under the Adimab Platform Patents and Know-How, and exclusive (even as to Adimab and its Affiliates) under the Licensed Program Antibody Patents. This license grant is granted by Adimab as of the Effective Date as a current license grant, subject only to the Commercial Option exercise by Surface but not any other action by Adimab.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The license granted under Section 3.3(b)(ii) shall be sublicensable solely pursuant to sublicenses that are consistent with all relevant terms and conditions of this Agreement, including Section 9.4 hereof. Surface shall remain responsible for all payments and other performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">3.4Diligent Development and Commercialization</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface shall, if it exercises the Commercial Option with respect to a Target, devote Commercially Reasonable Efforts to preclinically and clinically develop, seek Marketing Approval for in the Major Markets, and launch and actively commercialize in the Major Markets at least one (1) Licensed Antibody against such Target. Annually, Surface will provide Adimab with a written report of Licensed Product progress in development and commercialization, by Surface&#8217;s and its Affiliates&#8217; activities in that regard. If requested by Adimab, Surface shall meet with Adimab to discuss such report once annually.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">3.5No Implied Licenses</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Other than the licenses, options and assignments explicitly set forth in this Agreement, neither Party grants any intellectual property licenses, options or assignments to the other Party under this Agreement. This Agreement does not create any implied licenses.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 4</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">FINANCIAL TERMS</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.1Research Stage Fees</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Research Funding</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. For each Research Program, Surface shall pay Adimab (i) an amount equal to [***] percent [***] of the estimated FTEs (at the FTE Rate) for the Research Program, such amount to be paid within [***] business days of agreement on a Research Plan, and (ii) within [***] business days of completion of a Research Program, an amount equal to [***] percent [***] of the actual FTEs expended by Adimab on the Research Program (at the FTE Rate) less the amount previous paid with respect to such Research Program pursuant to clause (i); </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, </i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that (1) such actual FTEs do not exceed the FTEs set forth in the applicable Research Plan (as amended from time to time) for such Research Program by more than [***] percent [***] and (2) Adimab has provided Surface with an invoice for each of such payments. Upon Surface&#8217;s reasonable request, Adimab shall provide customary and reasonable documentation to evidence that all such amounts so paid by Surface were used on FTE&#8217;s for the applicable Research Program.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Technical Milestones</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface shall pay Adimab two technical milestone fees with respect to each Research Program on each Target, as follows:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The first technical milestone fee shall be equal to [***] for each Research Program, and such fee will be paid to Adimab by Surface within [***] business days of the later of (1) [***] and (2) provision by Adimab of an invoice for such payment to Surface; and</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The second technical milestone fee shall be equal to [***] for each Research Program, and such fee will be paid to Adimab by Surface within [***] business days of the later of (1) [***] and (2) provision by Adimab of an invoice for such payment to Surface. In the event that the second technical milestone is met in the initial delivery, or in the event that the second technical milestone is met without payment of the first technical milestone, then, in either case, Surface shall pay both technical milestones.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.2Research License Maintenance Fee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. For each Research Option that is exercised by Surface, Surface shall pay an annual maintenance fee of [***] on each of the [***] anniversaries of the date of exercise of the relevant Research Option, subject to early termination as provided in this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Ref517710258"></a><a name="_cp_text_1_235"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.3Commercial Option Fee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. In order to exercise the Commercial Option under Section 3.3(a) for a Target, Surface shall pay to Adimab a non-creditable, nonrefundable</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">option exercise fee of [***] for each such Target (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Commercial</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Option Fee</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). If Surface elects to license Additional Licensed Antibodies, each Additional Licensed Antibody will increase the Commercial Option Fee by [***] up to a maximum Commercial Option Fee of [***] for each such Target.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Ref518305706"></a><a name="_cp_text_1_237"></a><a name="_cp_field_47_238"></a><a name="_cp_text_1_239"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.4Milestone Payments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Subject to Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.7, for each Target, Surface shall report in writing to Adimab the achievement of each event (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Milestone Event</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and pay the corresponding development milestone payment (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Milestone Payment</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) to Adimab, each within [***] days after the achievement of the corresponding milestone event in the following table (whether achieved by or on behalf of Surface or its Affiliates or any other entity acting on behalf of any of them or having received a license, sublicense or other rights from any of the foregoing with respect to a Licensed Product):</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Milestone Event for each Licensed Product for a Target</b></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Milestones Payments are payable one time only per Licensed Product, the first time each is achieved for such Licensed Product. If a subsequent Milestones Event is achieved for any Licensed </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Product without a prior Milestone Event having been achieved for that Licensed Product, then Surface shall pay the Milestone Payment for such previous Milestone Event along with the payment for the most recently achieved Milestone Event. Notwithstanding the foregoing, if a Milestone Payment has been paid by Surface with respect to a Product that is then abandoned prior to the receipt of Marketing Approval by Surface, and Surface subsequently elects to research, develop and commercialize a back-up Product against the same Target, then no Milestone Payment shall be due for such previously paid Milestone Payment with respect to such back-up Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Ref366841136"></a><a name="_DV_M209"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.5Deferred Payment Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Commercial Option Fee and the Milestone Payments with respect to the first two Milestone Events set forth in Section 4.4 (i.e., those related to (a) [***] and (b) [***]) shall be deemed met and accrue when the Commercial Option is exercised or the applicable Milestone Event is achieved for a given Licensed Product, respectively and as the case may be. Surface may pay the Commercial Option Fee or the corresponding Milestone Payment, or Surface may provide written notice prior to the due date for such Commercial Option Fee or Milestone Payment of its election to delay payment of such amount until the earlier of (i) [***] (ii) [***] (iii) [***]. If Surface opts to delay any such payment, Surface shall pay Adimab, on the first business day of every calendar year, interest (each, an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Interest Payment</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) accrued on all such deferred amounts at a rate of [***] per [***] (calculated on a daily basis), from the date any such Commercial Option Fee and/or Milestone Payments are due hereunder until such Commercial Option Fee and/or Milestone Payments, and any interest thereon, are paid in full; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that if Surface ceases all research and development activities with respect to Program-Benefited Antibodies against the same Target for which a payment is delayed, then Surface shall not be obligated to make such Interest Payment and the applicable Commercial Option Fee and Milestone Payments, all of which are hereby forgiven in such circumstances; and </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, further, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that in the event that Surface (or its Affiliate or licensee) subsequently resumes research or development on Program-Benefited Antibodies against such Target, Surface shall immediately pay to Adimab any unpaid Interest Payments (including any interest which has accrued on such Interest Payments during the period since Surface last made an Interest Payment to Adimab with respect to such Program-Benefited Antibody), and Surface shall resume the payment of Interest Payments on the first business day of the next calendar year.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Ref518915184"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.6Royalties</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_Ref518305731"></a><a name="_Ref352329539"></a><a name="_Ref366838435"></a><a name="_cp_text_1_241"></a><a name="_DV_M213"></a><a name="_cp_field_47_242"></a><a name="_cp_text_1_243"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Royalty Payments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Subject to Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.7, as to each Licensed Product sold during the applicable Royalty Term in a country, on a Licensed Product-by-Licensed Product basis, Surface shall pay Adimab the following royalties, based on the royalty rate applicable to the relevant portion of annual worldwide Net Sales for such Licensed Product during the applicable Royalty Term for such Licensed Product in such country (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Royalty Payments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;):</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Portion of Worldwide Calendar Year Net Sales</b></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Royalty Rate</b></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Other Royalty Provisions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Only one royalty will be due with respect to the same unit of Licensed Product, even if such Licensed Product unit is comprised of more than one Licensed Antibody or any modified or derivative forms thereof.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)Adjustment for Third Party IP</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If Surface or any of its Affiliates enters into any Third Party Patent Licenses, then [***] of the net sales royalties actually paid to the Third Party under the Third Party Patent License with respect to Net Sales of any given Licensed Product in any given calendar quarter in any given country may be offset against the royalty that would otherwise have been payable to Adimab with respect to such same Net Sales; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that in no event shall the royalty owed to Adimab be reduced by more than [***] than the payment which would otherwise be due hereunder with any excess carried over to future royalty period(s) until such excess may be used in compliance with this proviso.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">It is understood, agreed and acknowledged that Adimab&#8217;s allowing Surface to claim the credit of this Section 4.6 as to any particular Third Party Patent License: [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_244"></a><a name="_Ref518305746"></a><a name="_cp_text_1_245"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(d)Milestone Payments and Royalty Payments for Certain [***]</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. In the event that a single Licensed Product contains [***] Program Antibodies, [***], then (i) Surface shall owe only one Milestone Payment for the achievement of a given Milestone Event with respect to such Licensed Product, and (ii) Surface shall owe only one Royalty Payment with respect to any specific portion of Net Sales of such Licensed Product.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_251"></a><a name="_cp_text_1_246"></a><a name="_Ref518305689"></a><a name="_cp_field_47_247"></a><a name="_cp_text_1_248"></a><a name="_cp_field_47_249"></a><a name="_cp_field_47_250"></a><a name="_cp_text_1_252"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.7Milestone Payments and Royalty Payments for Adimab Diagnostic Products for use with or in connection with External Products</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface shall make the following payments with respect to Adimab Diagnostic Products for use with or in connection with External Products in lieu of the payments set forth in Sections 4.4</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.6</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(a). </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:top;width:69.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.02pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td><td style="vertical-align:top;width:0.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.4pt 0.02pt;"></td><td style="vertical-align:top;width:29.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.02pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:5pt 0pt 5pt 0pt;"><a name="_cp_text_1_254"></a><a name="_cp_field_47_255"></a><a name="_cp_text_1_256"></a><a name="_cp_field_47_257"></a><a name="_cp_text_1_258"></a><a name="_cp_field_47_259"></a><a name="_cp_text_1_260"></a><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">For clarity, no payment is due under this Agreement (including under Section 4.4 or 4.6) with respect to (a) any Companion Diagnostic or Other Diagnostic Product (although payments shall be due under Sections 4.4 and 4.6(a) with respect to any applicable therapeutic Licensed Product(s)) or (b) any External Product. In addition, except as expressly provided in this Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.7</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, (i) milestone payments due for Adimab Diagnostic Products for use with or in connection with External Products are subject to the remaining terms and conditions of Section 4.4</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">), and (ii) royalty payments due for Adimab Diagnostic Products for use with or in connection with External Products are subject to the remaining terms and conditions of Section 4.6</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_264"></a><a name="_cp_blt_2_263"></a><a name="_Ref518305847"></a><a name="_cp_text_1_262"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.8Quarterly Payment Timings</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. All royalties due under this Agreement shall be paid quarterly within [***] days after the end of the relevant calendar quarter for which royalties are due. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_266"></a><a name="_cp_blt_2_265"></a><a name="_Ref520100861"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.9Royalty Payment Reports</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. With respect to each calendar quarter, within [***] days after the end of the calendar quarter, Surface shall provide to Adimab a written report stating the number and description of all Licensed Products sold during the relevant calendar quarter; the gross sales associated with such sales; and the calculation of Net Sales on such sales. The report shall provide all such information on a country-by-country and Licensed Product-by-Licensed Product basis if reasonably available.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_268"></a><a name="_cp_blt_2_267"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.10Payment Method</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. All payments due under this Agreement to Adimab shall be made by bank wire transfer in immediately available funds to an account designated by Adimab. All payments hereunder shall be made in the legal currency of the United States of America, and all references to &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">dollars</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; shall refer to United States dollars (i.e., the legal currency of the United States).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_270"></a><a name="_cp_blt_2_269"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.11Taxes</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other taxes required by applicable law to be withheld or deducted from any royalties, milestone payments or other payments made by Surface to Adimab under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to ensure that any withholding tax is reduced or eliminated to the extent permitted under applicable law, including income tax treaty provisions and related procedures for claiming treaty relief. To the extent that Surface is required to deduct and withhold taxes on any payment to Adimab, Surface shall deduct and withhold such taxes and pay the amounts of such taxes to the proper government authority in a timely manner and promptly submit to Adimab an official tax certificate or other evidence of such withholding sufficient to enable Adimab to claim such payment of taxes. Surface shall provide Adimab with reasonable assistance in order to allow Adimab to recover, as permitted by applicable law, withholding taxes, value added taxes or similar obligations resulting from payments made hereunder or to obtain the benefit of any present or future treaty against double taxation which may apply to such payments. Adimab shall provide Surface with any tax forms that may be reasonably necessary in order for Surface to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral tax income treaty. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_272"></a><a name="_cp_blt_2_271"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.12Records; Inspection</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface shall keep and ensure that its Affiliates keep complete and accurate records of its sales and other dispositions (including use in clinical trials, or provision on a compassionate use basis or as marketing samples) of Licensed Antibody and Licensed Product including all records that may be necessary for the purposes of calculating all payments due under this Agreement for a period of at least [***] years. Surface shall make such records available for inspection by an accounting firm selected by Adimab (and which is reasonably acceptable to Surface) at Surface&#8217;s premises in the United States on reasonable notice during regular business hours as provided in Section 4.11(b).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">At Adimab&#8217;s expense no more than [***] per calendar year, Adimab has the right to retain an independent certified public accountant from a nationally recognized (in the U.S.) accounting firm to perform on behalf of Adimab an audit, conducted in accordance with U.S. generally accepted accounting principles (GAAP), of such books and records of Surface and its Affiliates as are deemed necessary by the independent public accountant to report on Net Sales, for the period or periods requested by Adimab within the [***] most recent calendar years as of the date of the audit performance, and the correctness of any report or payments made under this Agreement. No period may be audited more than once. Prior to any review, such accounting firm shall have entered into a written agreement with Surface (or its Affiliates, licensees or sublicensees) limiting the use of such records to verification of the accuracy of payments due under this Agreement and prohibiting the disclosure of any information contained in such records to a Third Party and to Adimab for a purpose other than as set forth in this Section 4.11(b). The report of such accounting firm shall be limited to a certificate stating whether any report made or invoice or payment submitted by Surface </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">during such period is accurate or inaccurate and the actual amounts owed by or due under this Agreement to Adimab for such period.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If the audit reveals an underpayment, Surface shall promptly pay to Adimab the amount of such underpayment plus interest in accordance with Section 4.15. Any overpayment made by Surface shall be fully creditable against amounts payable in subsequent payment periods or promptly refunded, at Adimab&#8217;s election. Any audit by an independent certified public accounting firm under this Section 4.11 is to be made at the expense of Adimab, but if the audit reveals that the monies owed by Surface to Adimab has been understated by more than [***] percent [***] for the period audited, Surface shall, in addition, pay the reasonable out-of-pocket costs incurred by Adimab of such audit.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(d)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Parties agree that all information provided in a royalty payment report, all records kept by Surface or its Affiliates, licensees and sublicensees under this Section 4.11 or Section 4.12, and any information provided by the independent certified public accounting firm to Adimab are Confidential Information of Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_274"></a><a name="_cp_blt_2_273"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.13Licensee/Sublicensee Reports, Records and Audits</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If Surface grants any Product licenses or sublicenses, the agreements for such licenses and sublicenses shall include an obligation for the licensee or sublicensee to (i) maintain records adequate to document and verify the proper payments (including milestones and royalties) to be paid to Adimab; (ii) provide reports with sufficient information to allow such verification; and (iii) allow Adimab (or Surface if requested by Adimab) to verify the payments due (such audit right is not required to be any stronger than that of Section 4.11).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_276"></a><a name="_cp_blt_2_275"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.14Foreign Exchange</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the exchange rates (a) used by Surface (or the selling entity) for its own financial reporting purposes in its worldwide accounting system (which shall be consistent with applicable accounting standards), if Surface (or the selling entity) is a public company, or (b) if Surface is not a public company, then shall be determined the same way except that the rates shall be the average of the purchase and sale rates for U.S. Dollars for such day as reported on the fifth (5th) business day prior the payment due date for the purchase and sale of U.S. dollars, as reported by the Wall Street Journal, Eastern Edition (or if it no longer exists, a similarly authoritative source). With any payment in relation to which a currency conversion is performed to calculate the amount of payment due, Surface shall provide to Adimab a true, accurate and complete copy of the exchange rates used in such calculation.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_278"></a><a name="_cp_blt_2_277"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.15Non-refundable, non-creditable payments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each payment that is required under this Agreement is non-refundable and non-creditable.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_blt_1_280"></a><a name="_cp_blt_2_279"></a><a name="_Ref518915275"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">4.16Late Payments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Any amount owed by Surface to Adimab under this Agreement that is not paid within the applicable time period set forth herein will accrue interest at the rate of [***] percent [***] above the then-applicable short-term three-month London Interbank Offered Rate (LIBOR) as quoted in the Wall Street Journal, Eastern Edition (or if it no longer exists, a similarly authoritative source) calculated on a daily basis, or, if lower, the highest rate permitted under applicable law.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 5</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Patent Ownership</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.1Ownership and Inventorship</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Program Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab shall solely own, regardless of inventorship, all Patents Covering Adimab Platform Technology Improvements and, prior to Commercial Option exercise, all Program Antibody Patents. Surface shall own, regardless of inventorship, from and after the date of Commercial Option exercise, all Licensed Program Antibody Patents, subject to the terms and conditions of this Agreement. Ownership of all Program Patents other than those referred to in the foregoing two (2) sentences shall be owned based on inventorship. Program Inventions (to the extent not Patented and addressed above) that constitute Adimab Platform Technology Improvements shall be owned by Adimab and all other Program Inventions shall be owned by the Party that created it.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Other Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. To avoid doubt, nothing in this Agreement shall alter the ownership of the Parties&#8217; pre-existing Patents. Section 5.1(a) speaks only to ownership of Program Patents.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)Inventorship</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Inventorship for purposes of this Agreement, and all intellectual property-related definitions in this Agreement, shall be determined in accordance with United States patent law for all Patents worldwide.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.2Implementation</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Assignments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party hereby assigns to the other Party Program Inventions and associated Patents as necessary to achieve ownership as provided in Section 5.1. Each assigning Party shall execute and deliver all documents and instruments reasonably requested by the other Party to evidence or record such assignment or to file for, perfect or enforce the assigned rights. Each assigning Party hereby appoints the other Party as attorney-in-fact solely to execute and deliver the foregoing documents and instruments if such other Party after making reasonable inquiry does not obtain them from the assigning Party. Each Party (and its Affiliates) shall perform its activities under this Agreement through personnel who have made a similar assignment and appointment to and of such Party or any of its Affiliate. Each assigning Party shall make its relevant personnel (and their assignments and signatures on such documents and instruments) reasonably available to the other Party for assistance in accordance with this Article at no charge.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Joint Ownership Implementation</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. As regards Joint Serendipitous Inventions and the Program Patents to the extent claiming them, either Party is entitled to practice and license them without consent of and without a duty of accounting to the other Party in accordance with the co-ownership rights of co-inventors under U.S. law, subject to the terms of this Agreement. Each Party hereby grants all permissions, consents and waivers with respect to, and all licenses under, the Joint Serendipitous Inventions and the Program Patents claiming them as necessary to achieve throughout the world the nature of joint ownership rights of the foregoing as described in Section 5.1 and the foregoing sentence and otherwise subject to the terms of this Agreement. To avoid doubt, this Section 5.2(b) does not imply any permission, consent or waiver with respect to, or </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">license under, any Patent or item of Know-How other than the Joint Serendipitous Inventions and the Program Patents to the extent claiming them.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.3Disclosure</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">During the term of the Agreement, each Party shall promptly disclose to the other Party [***] any Program Inventions that would be Covered by Program Antibody Patents or in Surface&#8217;s case that are Adimab Platform Technology Improvements (which, to avoid doubt, are assigned to Adimab under this Agreement). Such disclosure shall occur as soon as possible, but in any case within [***] days after the Party determines such Program Inventions have been invented. To avoid doubt, this Section 5.3 shall not be read to require Adimab to disclose Program Inventions constituting Adimab Platform Technology Improvements to Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.4Program Patent Prosecution</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Adimab Platform Technology</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab shall have the sole right (but not the obligation) to Prosecute all Adimab Platform Patents, all at its own expense.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Program Antibody Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface shall have the sole right (but not obligation except as provided below) to Prosecute all Program Antibody Patents, at Surface&#8217;s expense, and prior to Commercial Option exercise, in Adimab&#8217;s name, and after Commercial Option exercise, in Adimab&#8217;s name to the extent that any Licensed Program Antibody Patent is not assigned to Surface pursuant to Section 3.3(b)(i). Such right shall continue for the duration of the longer of the Evaluation Term and, if Surface exercises the Commercial Option, the term of the license under Section 3.3(b)(ii), subject to all of the following:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Prior to Commercial Option exercise, [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Prior to Commercial Option exercise, [***]. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Both prior to and after Commercial Option exercise, Adimab shall have the right to review and comment on prosecution of the Program Antibody Patents, and Surface shall reasonably consider but is not required to accept any such comments. Adimab shall grant Surface the necessary authority to Prosecute the Program Antibody Patents (including that Adimab shall join any suit or action regarding the foregoing at Surface&#8217;s request). Surface shall provide Adimab with copies of all correspondence with patent offices relating thereto (including office actions and the like) promptly after receipt and drafts of all filings and correspondence with such offices no less than [***] in advance of filing.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iv)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If Surface does </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">not</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> exercise the Commercial Option for a Target, then [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(v)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If Surface </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">does</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> exercise the Commercial Option for a Target, then [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(vi)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(vii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface shall use Commercially Reasonable Efforts to Prosecute at least one Licensed Program Antibody Patent in at least each country of the Major Markets. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(viii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface shall be solely responsible for all costs of the activities under this Section 5.4(b), except (A) as expressly provided under this Section 5.4(b) or (B) that to the extent Adimab hires </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">counsel to review and comment on Surface&#8217;s prosecution then Adimab shall be solely responsible for the fees to such counsel.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ix)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Except as provided in this Agreement, Adimab shall not disclose or claim (or have or license any others to disclose or claim) any Program Antibody (or the Binding Sequence Information thereof) or any other antibody or their Binding Sequence Information identified from any Naive Antibody Library or Optimization Antibody Library, unless independently invented in a manner in compliance with the terms of this Agreement (including the restrictions on Naive Antibody Libraries and Optimization Antibody Libraries contained herein). For clarity, (1) Adimab shall not nor allow any others to refile or Prosecute any Patent applications [***] and (2) the foregoing prohibitions shall not prevent Adimab from filing broad Patents (such as, for example, Patents which Cover an antibody library) which Cover a Program Antibody or its Binding Sequence Information so long as Adimab does recite in any claim the such Program Antibody or its Binding Sequence Information in such Patent, and so long as Adimab does not disclose such Program Antibody or its Binding Sequence Information in such Patent.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)Responsibility</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. It is understood and agreed that searching for, identification and evaluation of Third-Party Patents that may apply to any Program Antibodies based on sequence, Target or the like is the responsibility of Surface and Adimab shall have no responsibility for the foregoing nor liability if any such Third-Party Patents exist.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(d)Serendipitous Program Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)Adimab Program Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. As between the Parties, Adimab shall have the sole right, at its sole expense, to prepare, file, prosecute, enforce and maintain (including conducting or participating in interferences and oppositions and the like) (collectively &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Prosecute</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) all Patents directed to Adimab Program Inventions but not falling within the Program Antibody Patents or the Adimab Platform Technology Improvements (which, to avoid doubt, are both addressed above).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)Surface Program Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface shall be responsible, at its sole expense, to Prosecute all Program Patents directed to Surface Program Inventions but not falling within Program Antibody Patents or the Adimab Platform Technology Improvements (which, to avoid doubt, are both addressed above). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iii)Serendipitous Joint Program Inventions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties shall mutually agree which of them shall be responsible for either using its in-house patent attorneys or through mutually agreed upon outside counsel to Prosecute Program Patents directed to Joint Serendipitous Inventions, and how the costs of such activities will be shared. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.5Patent Term Restoration</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties shall cooperate with each other, including by providing necessary information and assistance as the other Party may reasonably request, to obtain patent term restoration or supplemental protection certificates or their equivalents in any country where applicable to Licensed Program Antibody Patents. After Commercial Option exercise, if elections with respect to obtaining such patent term restoration are to be made with respect to Licensed Program Antibody Patents, and the Parties do not agree, Surface shall have the right to make the election and Adimab agrees to abide by such election. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.6Cooperation of the Parties</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. At the reasonable request of the responsible (as provided for in this Article 5) Party, the other Party agrees to cooperate fully in the Prosecution of any Program Patents under this Agreement. Such cooperation includes executing all papers and instruments (or causing its personnel to do so) reasonably useful to enable the other Party to apply for and to prosecute patent applications in any country; and promptly informing the other Party of any matters coming to such Party&#8217;s attention that may affect the Prosecution of any such Patents. Adimab shall not be required pursuant to this Section to disclose Adimab Platform Technology to Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">5.7Patent Challenges</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If Surface or its Affiliates challenges in a court the validity, enforceability or scope of any Adimab Platform Patents or any Program Antibody Patent, then: [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 6</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CONFIDENTIALITY; PUBLICITY</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.1General</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Any and all information disclosed or submitted in writing or in other tangible form -- or if disclosed orally, that is indicated to be confidential at the time of disclosure and confirmed in writing as such within [***] days after initial disclosure -- to one Party by the other Party under this Agreement or that certain Mutual Confidentiality Agreement between the Parties dated March 27, 2014 is the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Confidential Information</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; of the disclosing Party. In addition, information embodied in Adimab Materials is Adimab&#8217;s Confidential Information, and information embodied in the Surface Materials is Surface&#8217;s Confidential Information, and Program Antibodies will be treated as Surface&#8217;s Confidential Information after Commercial Option exercise. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">To avoid doubt, sequence information (whether as to amino acid sequence or nucleic acid sequence) with respect to Program Antibodies shall be deemed the Confidential Information of Adimab, except that from and after the date of Commercial Option exercise, the sequence information as to the Licensed Antibodies shall be Confidential Information of Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Each Party shall receive and maintain the other Party&#8217;s Confidential Information in strict confidence. Neither Party shall disclose any Confidential Information of the other Party to any Third Party. Neither Party shall use the Confidential Information of the other Party for any purpose other than as required to perform its obligations or exercise its rights hereunder. Each Party may disclose the other Party&#8217;s Confidential Information to the receiving Party&#8217;s directors, employees, contractors and advisors requiring access thereto for the purposes of this Agreement, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that prior to making any such disclosures, each such person shall be bound by written agreement to maintain Confidential Information in confidence, and not to use such information for any purpose other than, in accordance with the terms and conditions of this Agreement. Surface may disclose sequence data and other data generated under the Research Program to legal, financial and investment banking advisors, and potential and actual investors, lenders, financing sources, Change of Control counterparties, acquirers, collaborators, sublicensees and licensees and counsel for the foregoing, that are under legally binding obligations of confidence and limited use and to national patent offices in accordance with Section 5.4. Each Party agrees to take all steps necessary to ensure that the other Party&#8217;s Confidential Information shall be maintained in </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">confidence including such steps as it takes to prevent the disclosure of its own proprietary and confidential information of like character. Each Party agrees that this Agreement shall be binding upon its Affiliates, and upon the employees and contractors involved in the Research Program of such Party and its Affiliates. Each Party shall take all steps necessary to ensure that its Affiliates and employees and contractors shall comply with the terms and conditions of this Agreement. The foregoing obligations of confidentiality and non-use shall survive, and remain in effect for a period of [***] years from, the termination or expiration of this Agreement in accordance with Article 9. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.2Exclusions from Nondisclosure Obligation</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The nondisclosure and nonuse obligations in Section 6.1 shall not apply to any Confidential Information to the extent that the receiving Party can establish by competent written proof that it:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">at the time of disclosure is publicly known;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">after disclosure, becomes publicly known by publication or otherwise, except by breach of this Agreement by such Party;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">was in such Party&#8217;s possession in documentary form at the time of the earlier of disclosure hereunder and disclosure under the agreement referred to in Section 6.1; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(d)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is received by such Party from a Third Party who has the lawful right to disclose the Confidential Information and who shall not have obtained the Confidential Information either directly or indirectly from the disclosing Party; or</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(e)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is independently developed by such Party (i.e., without reference to Confidential Information of the disclosing Party).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.3Required Disclosures</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If either Party is required to disclose any Confidential Information of the other Party, pursuant to a governmental law, regulation or order, or an order of a court of competent jurisdiction or to defend or prosecute litigation or as part of an arbitration; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that the receiving Party (i) shall give advance written notice to the disclosing Party, (ii) shall make a reasonable effort to assist the disclosing Party to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation required and (iii) shall use and disclose the Confidential Information solely to the extent so required.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.4Terms of Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The terms of this Agreement are the Confidential Information of both Parties. However, each Party shall be entitled to disclose the terms of this Agreement under legally binding obligations of confidence and limited use to: legal, financial and investment banking advisors; and potential and actual investors, lenders, financing sources, Change of Control counterparties, acquirers, collaborators, sublicensees and licensees and counsel for the foregoing. In addition, if legally required, a copy of this Agreement may be filed by either Party with the SEC (or relevant ex-U.S. counterpart). In that case, the filing Party will if requested by the other Party diligently seek confidential treatment for terms of this Agreement for which confidential treatment is reasonably available, and shall provide the non-filing Party reasonable advance notice of the terms proposed for redactions and a reasonable opportunity to request that the filing Party make additional redactions to the extent confidential treatment is reasonably available under the law. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The filing Party shall seek and diligently pursue such confidential treatment requested by the non-filing Party.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.5Return of Confidential Information</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Promptly after the termination or expiration of this Agreement for any reason, each Party shall return to the other Party all tangible manifestations of such other Party&#8217;s Confidential Information at that time in the possession of the receiving Party; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that the receiving Party shall be entitled to retain one (1) copy of such information solely for the purpose of monitoring such Party&#8217;s surviving obligations under this Agreement. Electronic copies of Confidential Information contained in backups or electronic archives made in the normal course of the receiving Party&#8217;s business shall not be required to be destroyed or returned in accordance with this Section 6.5.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.6Publicity</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each of Adimab and Surface may publish a press release describing the collaboration, but without identifying the targets to be worked on or the economic terms of the collaboration. The Parties will agree on specific press release language promptly following the Effective Date. Other than repeating information in such press release (or any subsequent mutually agreed press release), neither Party will generate or allow any further publicity regarding this Agreement or the transaction or research contemplated hereunder in which the other Party is identified, without giving the other Party the opportunity to review and comment on the press release. The Parties recognize the importance of announcing Commercial Option exercise and the achievement of Milestones, and that Adimab is entitled to disclose these occurrences; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that Adimab may disclose the identity of Surface but will not disclose the identity of any of Surfaces&#8217; licensees, sublicensees or collaborators (if applicable) or the identity of the Target or the possible indication(s) (although the class of protein of the Target (but not the family) may be disclosed). Accordingly, the Parties hereby agree that each such event shall be publicly announced by the Parties if requested by Adimab, and the Parties shall mutually agree upon the text of a press release to announce each such event. Surface shall not unreasonably withhold its consent to the manner in which Adimab proposes to make such disclosure. It is understood and agreed that Adimab sometimes issues press releases that group multiple achievements of the company, and that if Adimab chooses to group the initially approved text or the announcement of Commercial Option exercise and/or a milestone achievement under this Agreement with other accomplishments or events not relating to this Agreement, then the only portion of the press release into which the Surface shall have a consent right (such consent not to be unreasonably withheld), shall be those portions that relate to this Agreement.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">6.7Certain Data</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Notwithstanding this Article 6, without disclosing Surface&#8217;s (or any of its Affiliates&#8217; or licensees&#8217;, sublicensees&#8217; or collaborators&#8217;) identity or the identity of the Target or the possible indication(s), or information making such identities or indications reasonably discernable (although the class of protein of the Target (but not the family) may be disclosed), or the sequence of any Program Antibody, in order to describe the general capabilities and performance of the Adimab platform, Adimab shall be entitled to disclose generally Program Antibody attributes , including the following: (a) Program Antibody binding affinities (K</font><font style="font-family:'Times New Roman','Times','serif';">D</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">), (b) expression range regarding Program Antibodies, and (c) germline distribution of Program Antibodies.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 7</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">7.1Mutual</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each of Adimab and Surface hereby represents and warrants to the other of them that the representing and warranting Party is duly organized in its jurisdiction of incorporation; that the representing and warranting Party has the full power and authority to enter into this Agreement; that this Agreement is binding upon the representing and warranting Party; that this Agreement has been duly authorized by all requisite corporate action within the representing and warranting Party; and that the execution, delivery and performance by the representing and warranting Party of this Agreement and its compliance with the terms and conditions hereof does not and shall not conflict with or result in a breach of any of the terms and conditions of or constitute a default under (a) any agreement or other instrument binding or affecting it or its Affiliate or the property of either of them, (b) the provisions of its bylaws or other governing documents or (c) any order, writ, injunction or decree of any governmental authority entered against it or by which any of its property is bound.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">7.2Adimab</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab hereby represents, warrants and covenants to Surface that:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">7.3DISCLAIMER OF WARRANTIES</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. OTHER THAN THE EXPRESS WARRANTIES OF SECTIONS 7.1 AND 7.2, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-transform:uppercase;">Each party DISCLAIMS ALL </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT ANY PRODUCTS DEVELOPED UNDER THIS AGREEMENT ARE FREE FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE OR THAT ANY PROGRAM PATENTS WILL ISSUE OR BE VALID OR ENFORCEABLE.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 8</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">INDEMNIFICATION</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">8.1By Adimab</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Adimab hereby agrees to indemnify, defend and hold harmless (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Indemnify</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) Surface, its Affiliates and its and their directors, officers, agents and employees (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) from and against any and all liability, loss, damage or expense (including without limitation reasonable attorney&#8217;s fees) (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Losses</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) they may suffer as the result of Third-Party claims, demands and actions (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Third-Party Claims</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) arising out of or relating to (a) any breach of a representation or warranty or covenant made by Adimab under Article 7 or otherwise of this Agreement, or (b) arising out of or in connection with or attributable to Adimab&#8217;s negligence, gross negligence or willful misconduct in performance of any Research Plan, except to the extent of any Losses [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">8.2By Surface</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface hereby agrees that it and its licensees and sublicensees shall Indemnify Adimab, its Affiliates and its and their directors, officers, agents and employees (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Adimab Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) from and against any and all Losses they may suffer as the result of </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Third-Party Claims arising out of or relating to (a) any breach of a representation or warranty or covenant made by Surface under Article 7 or otherwise of this Agreement, (b) Surface&#8217;s research, testing, development, manufacture, use, sale, distribution, licensing and/or commercialization of Program Antibodies and/or Licensed Products (or Program-Benefited Antibodies or products incorporating them), (c) Target-related intellectual property (including Patents directed to antibodies based on their interaction with a Target), (d) Target-related or Surface Materials-related contractual obligations of Surface and its Affiliates, or (e) intellectual property applying to any Program Antibody based on its sequence or other characteristics (it being understood and agreed in accordance with Section 5.4(c) that Adimab does not perform intellectual property searches on Program Antibodies (including sequence-based searches) and this is the responsibility of Surface), except in each case to the extent of any Losses [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">8.3Procedures</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each of the foregoing agreements to Indemnify is conditioned on the relevant Adimab Indemnitees or Surface Indemnitees (i) providing prompt written notice of any Third-Party Claim giving rise to an indemnification obligation hereunder, (ii) permitting the indemnifying Party to assume full responsibility to investigate, prepare for and defend against any such Third-Party Claim, (iii) providing reasonable assistance in the defense of such claim at the indemnifying Party&#8217;s reasonable expense, and (iv) not compromising or settling such Third-Party Claim without the indemnifying Party&#8217;s advance written consent. If the Parties cannot agree as to the application of the foregoing Sections 8.1 and 8.2, each may conduct separate defenses of the Third-Party Claim, and each Party reserves the right to claim indemnity from the other in accordance with this Article 8 upon the resolution of the underlying Third-Party Claim.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">8.4Limitation of Liability</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. EXCEPT TO THE EXTENT SUCH PARTY MAY BE REQUIRED TO INDEMNIFY THE OTHER PARTY UNDER THIS ARTICLE 8 (INDEMNIFICATION) OR AS REGARDS A BREACH OF A PARTY&#8217;S RESPONSIBILITIES PURSUANT TO ARTICLE 6 (CONFIDENTIALITY; PUBLICITY), NEITHER PARTY NOR ITS RESPECTIVE AFFILIATES SHALL BE LIABLE FOR ANY SPECIAL, INDIRECT, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES HEREUNDER, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 9</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">TERM</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.1Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The term of this Agreement shall commence on the Effective Date and shall expire upon the later of (a) the earlier of (i) the expiration of the Commercial Option(s) and Research Option(s) (if they expire without being exercised), and (ii) expiration of 12 months from the Effective Date without Surface providing Surface Materials that successfully pass Adimab&#8217;s QC; or (b) if at least one Research Option has been exercised but no Commercial Option has been exercised, upon the expiration of the last to expire Research License Term; or (c) on a country-by-country and Licensed Product-by-Licensed Product basis on the expiration of the last Royalty Term for a Licensed Product in the particular country, in each case, unless earlier terminated by a Party as set forth below in this Article 9. On expiration under (c) in a particular country, the license of Section 3.3(b)(ii) for the corresponding Licensed Product and its Licensed Antibody shall automatically convert to be perpetual, irrevocable, non-exclusive and fully-paid up in such country.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.2Material Breach</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Either Party may terminate this Agreement for the material breach of this Agreement by the other Party, if such breach remains uncured [***] days following notice from the non-breaching Party to the breaching Party specifying such breach.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">For Targets for which the Commercial Option or Research Option has been exercised, the foregoing Section 9.2(a) applies on a Target-by-Target basis to the extent that a breach relates to specific Targets, and such termination shall be applicable to only those Targets (and its associated Patents, Licensed Antibodies, Licensed Research Antibodies, and Licensed Products) to which the uncured the material breach relates. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If there is a good faith dispute as to the existence or cure of a breach or default pursuant to Section 9.2(a), all applicable cure periods will be tolled during the existence of such good faith dispute and no termination for a breach which is disputed in good faith will become effective until such dispute is resolved pursuant to the process set forth in Section 10.2 and a [***] day cure period offered thereafter.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.3Termination for Convenience</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface may terminate this Agreement in its entirety on [***] prior written notice to Adimab. On a Target-by-Target basis, after Commercial Option or Research Option exercise, Surface may also terminate this Agreement as to all Licensed Antibodies, Licensed Research Antibodies and Licensed Products to a particular Target by [***] prior written notice to Adimab.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.4Commitments Regarding Program-Benefited Antibodies</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties intend that if Surface, its licensees, or its sublicensees, or the Affiliate of any of the foregoing, will pursue any Program-Benefited Antibodies, they shall do so under this Agreement paying fees to Adimab as provided in Article 4. This Agreement gives Surface, its licensee, its sublicensee or the Affiliate of any of the foregoing the right to modify the Program Antibodies, by including modified versions of them and derivatives of them in the definition of &#8220;Licensed Antibodies&#8221; provided above. Surface, its licensee, its sublicensee or the Affiliate of any of the foregoing shall even be entitled to choose to pursue or use information obtained under this Agreement from Adimab to pursue an antibody not covered by the Program Antibody Patents, but only if Surface, its licensee, its sublicensee or the Affiliate of any of the foregoing treats the pursued antibody as milestone- and royalty-bearing under this Agreement to the extent such pursued antibody is a Program-Benefited Antibody. The Parties intend that Surface, its licensee, its sublicensee or the Affiliate of any of the foregoing shall not develop or commercialize a Program-Benefited Antibody, except in accordance with this Agreement (including exercising the Commercial Option and paying Adimab the Commercial Option Fee, Milestone Payments and royalties on the Program-Benefited Antibody product as (or as if) a Licensed Product under this Agreement). Accordingly, even if this Agreement expires or terminates (other than an expiration under Section 9.1 following a Commercial Option exercise after all Royalty Terms have expired for the applicable Program-Benefited Antibody or Licensed Product), Surface hereby covenants that Surface, its licensees and sublicensees and the Affiliates of any of the foregoing (a) shall not research, develop or commercialize any Program-Benefited Antibody or Licensed Product containing such an antibody except as a Licensed Product under this Agreement, and (b) shall not license or otherwise grant rights to any entity to do the foregoing.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_282"></a><a name="_cp_field_47_284"></a><a name="_cp_text_1_285"></a><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.5Survival in All Cases</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Termination of this Agreement shall be without prejudice to or limitation on any other remedies available to nor any accrued obligations of either Party. In addition, Sections 2.3, 2.4, 2.5, 2.6, 3.5, 4.8 </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">through </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.16 (with respect to payment obligations outstanding or having accrued as the effective date of termination or expiration), 5.1, 5.2, 5.4, 5.6, and 7.3, and Articles 1, 6, 8, 9 and 10 shall survive any expiration or termination of this Agreement. Further, upon termination of this Agreement by either Party under Section 9.2 or 9.3, Surface, its licensees and sublicensees, and their Affiliates will no longer develop or commercialize any Licensed Antibody or Licensed Product (subject to Section 9.2(b) for partial terminations).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.6Survival of Sublicenses</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. In the event that the licenses granted to Surface under this Agreement are terminated, any granted sublicenses to Third Parties will remain, at any such Third Party&#8217;s election, in full force and effect; provided, that the sublicense agreement is consistent with the terms of this Agreement, the sublicensee is not then in breach of its sublicense agreement, and such Third Party agrees to be bound to Adimab as a licensor under the terms and conditions of this Agreement (including payment obligations as reflected in this Agreement with respect to Adimab). In such event, Adimab will negotiate and enter into an appropriate license agreement with such Third Party incorporating the terms and conditions of this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.7Bankruptcy</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. All licenses and rights to licenses granted under or pursuant to this Agreement by Adimab to Surface are, and will otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Bankruptcy Code</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that Surface, as a licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that that upon commencement of a bankruptcy proceeding by or against Adimab under the Bankruptcy Code, Surface will be entitled to a complete duplicate of, or complete access to (as Surface deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to Surface (a) upon any such commencement of a bankruptcy proceeding and upon written request by Surface, unless Adimab elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of Adimab and upon written request by the Surface. Adimab (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agrees not to interfere with the exercise by Surface or its Affiliates of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with this Agreement, and agrees to assist Surface and its Affiliates in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for Surface to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice to any rights Surface may have arising under the Bankruptcy Code or other applicable law. Notwithstanding the foregoing in this Section 9.7, nothing in this Section 9.7 shall be read to entitle Surface to obtain disclosure of or access to Adimab Platform Technology (including Adimab Platform Technology Improvements), whether or not as an &#8220;embodiment,&#8221; &#8220;update,&#8221; or otherwise, at any time, and Surface shall not under any circumstances notwithstanding anything express or implied in this Agreement be entitled to disclosure of Adimab Platform Technology or Adimab Platform Technology Improvements.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">9.8Return of Adimab Materials</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Except as otherwise provided in Section 2.4, on a Target-by-Target basis, Surface shall either return to Adimab or destroy all Adimab Materials (other than Adimab Materials relating to Licensed Antibodies) upon expiration or termination of the Evaluation Term without any Commercial Option or Research Option being exercised, and all Adimab Materials on expiration (other than for any Licensed Product and the corresponding Licensed Antibody an expiration under Section 9.1 following a Commercial Option exercise and after all Royalty Terms for such Licensed Product have expired) or termination of this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;">article 10</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:uppercase;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">MISCELLANEOUS</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.1Independent Contractors</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">shall perform their obligations under this Agreement as independent contractors. Nothing contained in this Agreement shall be construed to be inconsistent with such relationship or status. This Agreement and the Parties&#8217; relationship in connection with it shall not constitute, create or in any way be interpreted as a joint venture, fiduciary relationship, partnership or agency of any kind.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.2Dispute Resolution</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(a)Initial Dispute Resolution</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Either Party may refer any dispute in connection with this Agreement (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Dispute</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) not resolved by discussion of the BD/Contract Liaisons to senior executives of the Parties (for Adimab, its CEO or his designee and for Surface, its CEO or his designee) for good-faith discussions over a period of not less than sixty (60) days (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Senior Executives Discussions</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Each Party will make its executives reasonably available for such discussions.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(b)Disputes Not Resolved Between the Parties</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If the Parties are unable to resolve the dispute through the Senior Executives Discussions within such sixty (60) days, then either Party may, as the sole and exclusive means for resolving disputes under this Agreement, proceed to demand confidential arbitration by written notice to the other Party and making a filing with the AAA in accordance with Section 10.2(c). For clarity, each Party hereby acknowledges that both the fact of and nature of a dispute is the Confidential Information of both Parties, and any disclosure of the fact of or the nature of such a dispute would be highly damaging to the non-disclosing Party. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(c)Arbitration</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(i)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Any Dispute referred for arbitration shall be finally resolved by binding arbitration in accordance with the most applicable rules of the American Arbitration Association (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">AAA</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and judgment on the arbitration award may be entered in any court having jurisdiction.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(ii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The arbitration shall be conducted by a panel of three (3) people experienced in the business of biopharmaceuticals. If the issues in dispute involve scientific, technical or commercial matters, then any arbitrator chosen under this Agreement shall have educational training and/or industry experience sufficient to demonstrate a reasonable level of relevant scientific, technical and commercial knowledge as applied to the pharmaceutical industry. If the issues in dispute involve patent matters, then at least one (1) of the arbitrators shall be a licensed patent attorney or otherwise </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">knowledgeable about patent law matters. Within [***] days after a Party demands arbitration, each Party shall select one person to act as arbitrator, and the two Party-selected arbitrators shall select a third arbitrator within [***] days after their own appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, then the third arbitrator shall be appointed by the AAA. The place of arbitration shall be Boston, Massachusetts. All proceedings and communications as part of the arbitration shall be in English. Following selection of the third arbitrator, the arbitrators shall complete the arbitration proceedings and render an award within [***] months after the last arbitrator is appointed.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iii)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Each Party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees or arbitration, unless in each case the arbitrators agree otherwise, which they are hereby empowered, authorized and instructed to do if they determine that to be fair and appropriate.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(iv)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Except to the extent necessary to confirm an award or as may be required by law, regulation, or the requirement of any exchange on which a Party&#8217;s shares are traded, neither Party shall disclose the existence, content or results of an arbitration under this Agreement without the prior written consent of the other Party.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">(v)</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the subject matter of the Dispute would be barred by the applicable statute of limitations under New York law.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.3Governing Law</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts, excluding its conflicts of laws principles; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that matters of Patent law will be determined in accordance with the United States federal law. Any and all judicial resolutions of disputes in connection with this Agreement shall be in federal or state court located in Massachusetts, and each Party hereby consents to the jurisdiction and venue of such courts, and waives all defenses it may have to such jurisdiction and venue, including that the court cannot assert personal jurisdiction over the defendant and </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">forum non conveniens</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.4Entire Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Agreement (including its Exhibits) set forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the Parties with respect to such subject matter (including that certain Mutual Confidentiality Agreement between the Parties dated March 27, 2014). No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.5Assignment</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Neither Party may assign in whole or in part this Agreement without the advance written consent of the other Party, except as set forth in the following sentence. Either Party may assign this Agreement in its entirety to the successor to all or substantially all of its stock or assets to which this Agreement relates in connection with its merger with, or the sale of all or substantially all of its stock or assets to which this Agreement relates to, another entity, regardless of the form of the transaction (including any Change of Control). In addition, Adimab may assign this </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Agreement or any of its rights under this Agreement, in connection with the sale of, monetization of, transfer of, or obtaining financing on the basis of the payments due to Adimab under this Agreement or debt or project financing in connection with this Agreement. Also, Surface may assign its rights and obligations under this Agreement on a Target-by-Target basis, at any time after Commercial Option exercise for the particular Target, to any entity to which Surface assigns all or substantially all of its assets with respect to such Target (and its related Patents, Licensed Antibodies and Licensed Products); </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided, however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, [***]. Subject to the foregoing, this Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns. Notwithstanding the foregoing, Adimab may not assign or otherwise transfer (by operation of law or otherwise) this Agreement if the assignee does not assume all of Adimab&#8217;s obligations under this Agreement or Adimab does not remain bound to perform all obligations that are not assigned to the assignee. Any assignment of this Agreement not made in accordance with this Agreement is prohibited hereunder and shall be null and void.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.6Severability</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If one or more of the provisions in this Agreement are deemed unenforceable by law, then such provision shall be deemed stricken from this Agreement and the remaining provisions shall continue in full force and effect.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.7Force Majeure</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by a Force Majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and the nonperforming Party takes reasonable efforts to remove the condition, but no longer than [***], whereupon the other Party may assert breach by the nonperforming Party.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.8Notices</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if mailed by first class certified or registered mail, postage prepaid, delivered by express delivery service or personally delivered. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If to Adimab:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab, LLC</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">7 Lucent Drive</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Lebanon, NH 03766</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Attention: General Counsel</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">with a required copy to:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Attention: Head, Business Development at the same address.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In the case of Surface: </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface Oncology, Inc.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">25 First Street</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Suite 303</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Cambridge, MA 02141</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Attn: Chief Executive Officer</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.9Construction</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Agreement has been prepared jointly and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.10Headings</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The headings for each article and section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on, nor to be used to interpret, the meaning of the language contained in the particular article or section.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.11No Waiver</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Any delay in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party&#8217;s rights to the subsequent enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time executed by an authorized officer of the waiving Party.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.12Performance by Affiliates</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. A Party may perform some or all of its obligations under this Agreement through Affiliate(s) or may exercise some or all of its rights under this Agreement through Affiliates, or in the case of Adimab, Controlled Contractors, which will be treated as &#8220;Affiliates&#8221; for purposes of this Section 10.12. However, each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. In particular and without limitation, all Affiliates of a Party that receive Confidential Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in Article 6, and shall (to avoid doubt) be subject to the intellectual property assignment and other intellectual property provisions of Article 5 as if they were the original Party to this Agreement (and be deemed included in the actual Party to this Agreement for purposes of all intellectual property-related definitions). A Party and its Affiliates shall be jointly and severally liable for their performance under this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">10.13Counterparts</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Agreement may be executed in one or more identical counterparts, each of which shall be deemed to be an original, and which collectively shall be deemed to be one and the same instrument. In addition, signatures may be exchanged by facsimile or PDF.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">[Remainder of Page Left Intentionally Blank; Signature Page Follows]</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">In Witness Whereof,</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> the Parties have by duly authorized persons executed this Agreement as of the Effective Date.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:top;width:46.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Surface Oncology, Inc.:</b></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:top;width:47.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Adimab, LLC</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:0.33%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:41%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:5.66%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:0.33%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:40.99%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;">/</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">s/ J. Jeffrey Goater</font></p></td><td style="vertical-align:top;width:5.83%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:0.34%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Tillman Gerngross</font></p></td></tr><tr><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:0.33%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:40.99%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:41%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:5.66%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:0.33%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:40.99%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;">CEO</font></p></td><td style="vertical-align:top;width:5.83%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:0.34%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;">CEO</font></p></td></tr><tr><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:0.33%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:40.99%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:41%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:5.66%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Date:</font></p></td><td style="vertical-align:top;width:0.33%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:40.99%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;">10/4/2018</font></p></td><td style="vertical-align:top;width:5.83%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Date:</font></p></td><td style="vertical-align:top;width:0.34%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;">10/3/2018</font></p></td></tr><tr><td style="vertical-align:top;width:5.66%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:0.33%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:40.99%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:0.34%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:41%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">Exhibits List</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">A - Target Questionnaire</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;font-weight:bold;">B - Form Of Research Plan</b></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="1.5" style="height:1.5pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Partner Target Questionnaire </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Selection of Human Antibodies Binding To Target </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Sample Work Plan</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Page 1</font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="1.5" style="height:1.5pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partner Completed Target Questionnaire </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Information you are able to provide about your target will help Adimab design a customized selection strategy and detailed work plan. This will ultimately allow Adimab to deliver antibodies that fit your desired properties. </i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:18pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Overview </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The primary factors that determine the successful outcome of an IgG library screen are </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(i)</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the quality of the antibody library </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(ii)</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the quality and consistency of the antigens used in the selection process </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">While Adimab has taken extensive steps to ensure the quality of its libraries, the antigen used to interrogate our library is provided by the Partner and must be properly characterized to meet screening requirements. Adimab has compiled the following set of criteria to help ensure the quality of the antigen(s) used in the selection process which will ultimately lead to a successful campaign. Any additional information the Partner can provide relating to your antigen is valuable. </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">When multiple forms of the antigen are available, and are used in the selection, it increases the potential success of the campaign. </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">As an example, an RTK-ECD can be supplied as both an Fc-fusion protein and as a tagged monomeric protein, or produced and purified using preferred host expression systems and purification tags. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target (</b><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">sample answers provided below in blue</u><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)</b></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">What is the nature of your target (e.g., extracellular domain of a membrane protein)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Serum enzyme </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Does your target protein have an affinity tag? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If yes, what tag? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">C-terminus His-tag </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Are you aware of any post-translational modification to your target protein (e.g., N-glycosylation, O-glycosylation or phosphorylation)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">None </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Sample Work Plan</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Is your target a chimeric protein (e.g., Fc-fusion protein)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Does your target protein interact with other proteins or form complexes? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Yes </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Does your target exist naturally as a monomer, dimer, trimer, etc.? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Target is naturally monomeric </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Is your target available in multiple formats (e.g., monomeric, dimeric, multiple tags, etc.)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">How stable is your target protein (e.g., stability @ 4&#176;C, freeze thaw cycle data)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Stable at +4&#176;C for months </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Do you have access to 10 nmol quantities (e.g., ~1 mg of 75 kDa protein) of your target protein? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Yes </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Do you have cell-based or other assays to determine the bioactivity of your target? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Yes, there are cell-based assays in place </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Is cross-reactivity of your final antibody essential (e.g., cross-reactivity to murine, cynomolgus or macaque target)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Cross-reactivity to murine and macaca ortholog mandatory </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If yes, what is the homology between antigens? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Specificity versus family members is mandatory. Family members are also available </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Sample Work Plan</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mode of action </b></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Could you describe the profile of your &#8220;ideal antibody&#8221; (e.g., affinity, specificity, mechanism of action, expressability, etc.)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Affinity to human and murine targets: K</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-variant:small-caps;">d</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> &#8804; 10 nM and koff &#8804; 5x10-4s-1</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Specificity: selective versus family members and cross reactive with murine and macaca targets. Competes with control mAb provided </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Do you wish to disrupt a protein-protein interaction (e.g., a receptor-ligand interaction or dimerization)? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">We do not know at this stage </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Do you have an existing antibody (murine or other) that binds to your target? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Yes </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:86.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If yes, does the antibody have the &#8220;biology&#8221; you are looking for? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">We have already mAbs close to what we are looking for, that we&#8217;ll use internally for comparison </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Are you looking to discover an antibody against a known epitope? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Can you describe the desired biological mode of action for the antibodies to be discovered? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">What </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">in vitro</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> and </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">in vivo</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> screening assays are you planning to do in-house with purified IgGs discovered by Adimab? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Is ADCC expected to be important? </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:13.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ADCC not important </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Sample Work Plan</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Human Antibodies Binding To </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Goal:</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">TABLE OF CONTENTS </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Profile of Desired Antibody</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">3</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">SECTION A - RESEARCH PLAN</b></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Research Materials Provided by Partner</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Overview of Project</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">5</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Phase 1: Reagent Generation</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">6</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Phase 2: Na&#239;ve Selection and Characterization of Human Antibodies Binding To Target</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">7</font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Phase 3: Assessment of IgGs</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">8</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Phase 4: Optimization of nominated IgGs</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">9</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Phase 5: Analysis of IgGs</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">10</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:88.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:88.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Phase 6: Scaling of IgGs or Fabs</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">11</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Profile of Desired Antibody </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Section A: RESEARCH PLAN </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research Materials </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview of Project Flow </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 1: Reagent Generation </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 2: Na&#239;ve Selection and Characterization of Human Antibodies Binding To Target</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 3: Assessment of IgGs </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 4: Optimization of nominated IgGs </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 5: Analysis of IgGs </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><img src="chrs-20231231xex1002.jpg" alt="Graphic" style="display:inline-block;height:49.6pt;width:162.35pt;"></font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 6: Scaling of IgGs or Fabs </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Adimab Confidential - Work Plan </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2
<SEQUENCE>3
<FILENAME>chrs-20231231xex2.htm
<DESCRIPTION>EX-10_32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:01:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.32</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">COLLABORATION AGREEMENT </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">by and between </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SURFACE ONCOLOGY, INC. </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">and </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. </b></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TABLE OF CONTENTS </b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:92.13%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:3.31%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEFINITIONS</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">GOVERNANCE</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RESEARCH</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">43</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OPTION PURCHASE, GRANT AND EXERCISE OF OPTIONS</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">46</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEVELOPMENT</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">52</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">COMMERCIALIZATION</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">68</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">REGULATORY</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">76</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MANUFACTURE</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">86</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSES</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">95</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PAYMENTS</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">107</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONFIDENTIALITY AND PUBLICATION</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">123</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">REPRESENTATIONS, WARRANTIES AND COVENANTS</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">126</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">137</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INTELLECTUAL PROPERTY</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">140</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TERM AND TERMINATION</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">157</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:2.77%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:92.85%;margin:0pt;padding:0.25pt;"></td><td colspan="4" style="vertical-align:middle;width:4.36%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:2.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:92.13%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MISCELLANEOUS</b></p></td><td style="vertical-align:bottom;width:0.71%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">165</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0.25pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBITS AND SCHEDULES </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit A-1: Determination of Component Values </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit A-2: Manufacturing Costs for Combinations </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit B: Manufacturing Costs </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit C: Form of Option Exercise Notice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit D: Form of Option Purchase Notice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit E: Initial JSC Representatives </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit F: T1 Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit G: Surface T1 Target Third Party Agreements </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit H-1: CD47 Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit H-2: IL-27 Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit H-3: [***] Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit H-4: [***] Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit I: Surface Option Target Third Party Agreements </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit J: Form of Option Selection Notice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit K: Surface Manufacturing Third Party Agreements </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit L: Form of Invoice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit M: Royalty Calculation Examples </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit N: Disclosure Obligation </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Schedule 1.1.158: Option IND Package Information </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Schedule 1.1.167: Option Tox Package Information </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Schedule 12.2: Exceptions to Representations and Warranties </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">COLLABORATION AGREEMENT </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">THIS COLLABORATION AGREEMENT (this &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Agreement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), entered into as of January 9, 2016 (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Effective Date</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), is entered into by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Surface and Novartis are referred to in this Agreement individually as a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; and collectively as the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Parties</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RECITALS: </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS</b><font style="font-family:'Times New Roman','Times','serif';">, Surface discovers, researches and develops next-generation approaches to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS</b><font style="font-family:'Times New Roman','Times','serif';">, Novartis and its Affiliates possess expertise in discovering, developing,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">manufacturing, marketing, and selling pharmaceutical products worldwide; and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS</b><font style="font-family:'Times New Roman','Times','serif';">, Surface and Novartis desire to collaborate to research, develop and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">commercialize new cancer immunotherapies, and Novartis would obtain certain rights to the technology and products discovered in such collaboration. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOW, THEREFORE</b><font style="font-family:'Times New Roman','Times','serif';">, in consideration of the foregoing premises and the mutual</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">covenants herein contained, the Parties hereby agree as follows: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1. DEFINITIONS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, will have the respective meanings set forth below: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.1.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AAA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 16.3.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounting Standards</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, GAAP, with respect to Surface and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">IFRS, with respect to Novartis, in each case, as generally and consistently applied throughout the Party&#8217;s organization. Each Party shall promptly notify the other in the event that it changes the Accounting Standards pursuant to which its records are maintained; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that each Party may only use internationally recognized accounting principles (e.g. IFRS, GAAP, etc.). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.3. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Acquirer</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, the Third Party referenced in the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">definition of Change of Control and such Third Party&#8217;s Affiliates, other than the applicable Party in the definition of Change of Control and such Party&#8217;s Affiliates, determined as of immediately prior to the closing of such Change of Control. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.4. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Adimab Agreement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means that certain Development and Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, dated as of July 3, 2014, by and between Adimab, LLC (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Adimab</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and Surface, as such agreement may be amended, restated or otherwise replaced from time to time to the extent permitted under Section 12.4.3 of this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.5. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.2.2.4(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.6. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development Data Package</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.2.2.4(d). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.7. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development Opt-In Date</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.2.2.4(d). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.8. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development Opt-In Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.2.2.4(d). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.9.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development Proposal</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.2.2.4(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.10. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Affiliate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Person, any other Person that</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">controls, is controlled by, or is under common control with such Person. For purposes of this Agreement, a Person will be deemed to control another Person if it owns or controls, directly or indirectly, more than fifty percent (50%) of the equity securities of such other Person entitled to vote in the election of directors (or, in the case that such other Person is not a corporation, for the election of the corresponding managing authority), or otherwise has the power to direct the management and policies of such other Person. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage will be substituted in the preceding sentence, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such foreign investor has the power to direct the management and policies of such entity. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.11. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Alliance Manager</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 2.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.12. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; mean Net Sales recorded in a given Calendar Year. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.13. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Antibody</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any [***] provided however, that solely for purposes of Section 12.5, the term &#8220;Antibody&#8221; shall be deemed to include those molecules that meet the criteria of (a) through (c) and for which [***] For clarity, [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.14. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Antibody Candidates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the T1 Antibody Candidates, the Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target Antibody Candidates, the Regional Antibody Candidates and the Global Antibody Candidates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.15. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Antitrust Laws</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any federal, state or foreign law, regulation or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">decree, including the HSR Act, designed to prohibit, restrict or regulate actions for the purpose or effect of monopolization or restraint of trade. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.16. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Audited Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.12.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.17. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Auditing Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.12.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.18. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Auditor</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.12.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.19. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Bankruptcy Code</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 15.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.20. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Bankrupt Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 9.7. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.21. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Biosimilar Application</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an application submitted to the FDA</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">under subsection (k) of Section 351 of the PHSA, or any analogous application submitted to a Regulatory Authority in the United States or in another country in the world. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.22. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Biosimilar Product</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with [***] a product that [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.23. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">BLA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) a Biologics License Application as defined in the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">FD&amp;C Act and the regulations promulgated thereunder, (b) a Marketing Authorization Application (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MAA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) in the EU, or (c) any equivalent or comparable application, registration or certification in any other country or region. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.24. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Brief</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 16.3.4.2(b). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.25. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Business Day</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a day other than a Saturday, Sunday or a bank or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">other public holiday in Massachusetts or New York in the United States or Basel, Switzerland. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.26. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Calendar Quarter</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 of each Calendar Year. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.27. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Calendar Year</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means each successive period of twelve (12) months</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">commencing on January 1 and ending on December 31. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.28. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">cGCP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the ethical, scientific, and quality standards required by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">FDA for designing, conducting, recording, and reporting trials that involve the participation of human subjects, as set forth in FDA regulations in 21 C.F.R. Parts 11, 50, 54, 56, and 312 and related FDA guidance documents, and by the International Conference on Harmonization E6: Good Clinical Practices Consolidated Guideline, or as otherwise required by applicable Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.29. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">cGLP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means current good laboratory practice as required by the FDA</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">under 21 C.F.R. part 58 and all applicable FDA rules, regulations, orders and guidances, and the requirements with respect to current good laboratory practices prescribed by the European Community, the OECD (Organization for Economic Cooperation and Development Council) and the ICH Guidelines, or as otherwise required by applicable Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.30. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">cGMP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means current good manufacturing practices as required by the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">FDA under provisions of 21 C.F.R. parts 210 and 211 and all applicable FDA rules, regulations, orders and guidances, and the requirements with respect to current good manufacturing practices prescribed by the European Community under provisions of &#8220;The Rules Governing Medicinal Products in the European Community, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture of Investigational Medicinal Products, July 2003,&#8221; or as otherwise required by applicable Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.31. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Change of Control</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Party, (a) a merger or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the direct or indirect beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party&#8217;s and its controlled Affiliates&#8217; assets. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.32. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Clinical Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Phase 1 Study, Phase 2 Study, Phase 3 Study,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Post-Marketing Study, Supplemental Study or other study (including a non-interventional study) in humans to obtain information regarding the product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.33. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Clinical Study Phase</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Phase 1 Study, Phase 2 Study or Phase 3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Study, as applicable. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.34. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Collaboration</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the collaboration of the Parties under this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, including the Research, Development, Commercialization and Manufacture of Antibody Candidates and Licensed Products in the Field. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.35. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Collaboration Component</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Combination, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">portion of such Licensed Product comprising an Antibody Candidate. If the applicable Combination includes more than one Antibody Candidate, then &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Collaboration</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Component</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall refer to each such Antibody Candidate. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.36. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Collaboration In-License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 9.5.1.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.37. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Combination</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Combination Product or Combination</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Therapy. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.38. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Combination Product</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a product that includes an Antibody</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Candidate and at least one (1) additional active ingredient that is not an Antibody Candidate that is either co-formulated or administered through a single formulation, including, for clarity, an Antibody Candidate comprising a bi-specific Antibody. [***] For clarity [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.39. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Combination Therapy</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a therapy that includes an Antibody</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Candidate and at least one (1) additional active ingredient that is not an Antibody Candidate [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.40. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Combination Trial</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Clinical Study that is designed to provide</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">safety, dose ranging, dose selection or efficacy data for a Combination. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.41. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercialization</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> or </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercialize</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any and all activities</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">directed to marketing, promoting, distributing, importing, exporting, using, offering to sell or selling a product, and activities directed to obtaining Pricing Approvals, as applicable. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.42. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercialization Plans</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, the T1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Commercialization Plan, the Novartis Commercialization Plan, the Surface Commercialization Plan and the Global Licensed Product Commercialization Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.43. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercially Reasonable Efforts</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Party [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.44. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Committee</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Joint Steering Committee, Joint Research</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Committee, Joint Development Committee or Joint Commercialization Committee, or any other subcommittee established under Section 2.2.3.11, as applicable. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.45. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Competing Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Surface Competing Program or a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis Competing Program, as applicable. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.46. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Competitive Infringement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, [***] where the making, using, selling, offering for sale, or importing, by any Third Party (other than any Sublicensee or authorized purchaser or other transferee of such Licensed Product), of any pharmaceutical product comprising [***] For clarity, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.47. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Competitive (Novartis) Infringement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Competitive</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Infringement with respect to any Licensed Product in the Novartis Territory, but does not include any Competitive (Surface) Infringement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.48. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Competitive (Surface) Infringement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; any means Competitive</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Infringement with respect to any Regional Licensed Product in the Surface Territory, and does not include any Competitive (Novartis) Infringement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.49. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Completion</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Phase 1 Safety Study of a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product, [***] days from the date of the last patient last dose for such Phase 1 Safety Study (and for clarity not any later portions of the applicable Phase 1 Study, other than such Phase 1 Safety Study as so defined). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.50. &#8220;Component&#8221; </b><font style="font-family:'Times New Roman','Times','serif';">means a Collaboration Component or a Party Component. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.51. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Component Value&#8221; </b><font style="font-family:'Times New Roman','Times','serif';">means, with respect to a Component of a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Combination, the value of such Component as determined in accordance with Exhibit A-1.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.52. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Confidential Information</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any and all confidential or proprietary</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">information and data and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is or has been provided by one Party to the other Party in connection with this Agreement. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.53. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Control</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to any Patents or Know-How, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">possession (whether by ownership, license or sublicense, other than by a license, sublicense or other right granted (but not assignment) pursuant to this Agreement) by a Party of the ability to assign or grant to the other Party the licenses, sublicenses or rights to access and use such Patents or Know-How as provided for in this Agreement, without, other than with respect to any In-Licenses, paying any consideration to any Third Party (now or in the future) or violating the terms of any agreement or other arrangement with any Third Party in existence as of the time such Party would be required hereunder to grant such license, sublicense, or rights of access and use. Notwithstanding anything in this Agreement to the contrary, [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.54. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Cover</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Covering</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Covered</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; with respect to each Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Product, means that, but for a license granted to a Person under a claim included in a Patent, the use, sale, offer for sale or importation of such Licensed Product in the Field in the Territory by such Person would infringe such claim. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.55. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CREATE Act</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 14.1.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.56. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CRO</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a contract research organization. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.57. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Develop</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; and &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any and all clinical drug</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">development activities conducted before or after obtaining Regulatory Approval that are reasonably related to or leading to the development, preparation, and submission of data and information to a Regulatory Authority for the purpose of obtaining, supporting or expanding Regulatory Approval or to the appropriate body for obtaining, supporting or expanding Pricing Approval, including all activities related to pharmacokinetic profiling, design and conduct of Clinical Studies, regulatory affairs, statistical analysis, report writing, and regulatory filing creation and submission (including the services of outside advisors and consultants in connection therewith). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.58. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Costs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Licensed Target, those</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">costs and expenses [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.59. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Event</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.7. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.60. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Payment</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.7. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.61. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Plans</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, the T1 Development Plan, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">RLP Development Plan, and the Global Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.62. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Disputes</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 16.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.63. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DOJ</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the U.S. Department of Justice. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.64. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dollars</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the legal tender of the United States of America. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.65. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Early Global Development Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Global Target-by-Global Target basis, the time period commencing on the [***] and ending upon the date of [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.66. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Early RLP Development Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Regional Target-by-Regional Target basis, the time period commencing on [***] and ending upon the [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.67. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Effective Date</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in the preamble. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.68. &#8220;EMA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the European Medicines Agency and any successor</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Governmental Authority having substantially the same function. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.69. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Equity Agreements</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) Series A-1 Stock Purchase Agreement,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">by and among Surface and the Purchaser listed on Schedule 1 thereto, dated as of the Effective Date; (b) Amendment No. 1 to Investors&#8217; Rights Agreement, by and among Surface and the investors party thereto, dated as of the Effective Date; (c) Amendment No. 1 to Voting Agreement, by and among Surface and the stockholders party thereto, dated as of the Effective Date; (d) Amendment No. 1 to Right of First Refusal and Co-Sale Agreement, by and among Surface and the stockholders party thereto, dated as of the Effective Date; and (e) Participation Agreement, by and between Surface and Novartis, dated as of the Effective Date, in each case ((a)-(e)) as may be amended or restated from time to time. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.70. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EU</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the European Union, as its membership may be constituted</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">from time to time, and any successor thereto. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.71. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exclusivity Period</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) for each Option Target, from the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">[***] until the earliest of [***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.72. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Executive Officer</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, for Surface, its Chief Executive Officer, and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for Novartis, its President or another senior executive designee with responsibilities and seniority comparable thereto; provided that any of the foregoing individuals may designate the Chief Financial Officer as his/her designee for financial related matters. In the event that the position of any of the Executive Officers identified in this Section 1.1.72 no longer exists due to a Change of Control, corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable Executive Officer will be replaced with another executive officer with responsibilities and seniority comparable to the eliminated Executive Officer. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.73. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Existing Novartis In-License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any agreements entered into by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis or an Affiliate with a Third Party prior to the Effective Date, including any amendments or restatements thereto during the Term in accordance with Section 12.4.3, pursuant to which Novartis or any of its Affiliates Controls any Novartis Technology, but excluding any Collaboration In-License to which Novartis or its Affiliates is a Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.74. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Existing Surface In-License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any agreements entered into by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface or an Affiliate with a Third Party prior to the Effective Date, including any amendments or restatements thereto during the Term in accordance with Section 12.4.3, pursuant to which Surface or any of its Affiliates Controls any Surface Technology, but excluding any Collaboration In-License to which Surface or its Affiliates is a Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.75. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Expedited Arbitration</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 16.3.4.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.76. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Expedited Dispute</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 16.3.4.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.77. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FDA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States Food and Drug Administration or any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">successor agency thereto. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.78. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FD&amp;C Act</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States Federal Food, Drug and Cosmetic</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Act, as amended. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.79. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Field</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.80. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Finance Officers</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.6.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.81. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">First Commercial Sale</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Licensed Product-by-Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Product, and country-by-country basis, the first commercial sale in an arms&#8217; length transaction of a Licensed Product to a Third Party by a Party or any of its Related Parties in such country following receipt of applicable Regulatory Approval of such Licensed Product in such country. For clarity, the First Commercial Sale shall not include any distribution or other sale solely for patient assistance, named patient use, compassionate use, or test marketing programs or non-registrational studies or similar programs or studies where the Licensed Product is supplied without charge or at the actual manufacturing cost thereof (without allocation of indirect costs or any markup). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.82. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FTC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the U.S. Federal Trade Commission or any successor</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">agency thereto. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.83. &#8220;FTE</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a full-time scientific or technical person, or in the case of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">less than a full-time scientific or technical person, a full-time equivalent scientific or technical person year, carried out by an appropriately qualified employee of a Party or its Related Parties, based on [***] person-hours per year. For clarity, indirect personnel (including support functions such as managerial, financial, legal or business development) shall not constitute FTEs. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.84. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FTE Costs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, for any period, the FTE Rate multiplied by the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">number of FTE&#8217;s in such period. For clarity, FTEs will be pro-rated on a daily basis if necessary. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.85. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FTE Rate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] per</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">one (1) full FTE per full twelve (12) month Calendar Year, [***] Notwithstanding the foregoing, for any Calendar Year during the Term that is less than a full year, the above referenced rate will be proportionately reduced to reflect such portion of FTEs for such full Calendar Year. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.86. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">GAAP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means generally accepted accounting principles as practiced in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the United States, as consistently applied. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.87. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Antibody Candidate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Global Target-by-Global</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, any Antibody that [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.88. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Development Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.89. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Licensed Product</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Global Target-by-Global Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">basis [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.90. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Licensed Product Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">set forth in Section 6.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.91. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.9.2. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.92. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Option</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an Option that is (a) designated as a Global</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Option in accordance with Section 4.2.3, or (b) otherwise designated as or converted into a Global Option in accordance with the terms of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.93. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.9.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.94. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Target</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.95. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">GLP Toxicology Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a toxicology study, in species that</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">satisfies applicable regulatory requirements, using applicable cGLP that meets the standard necessary for submission as part of an IND Filing with the applicable Regulatory Authority. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.96. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Transition Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.3.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.97. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Transition Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.3.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.98. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Governmental Authority</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any applicable government authority,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">court, tribunal, arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any nation, state, province, county, city or other political subdivision thereof or (c) any supranational body. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.99. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">HSR Act</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.100.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">HSR Filing</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 4.2.6.6. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.101. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IFRS</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means International Financial Reporting Standards, as</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">consistently applied. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.102.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IL-27</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.103. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IND</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an Investigational New Drug application, clinical</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">trial application or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirement of such Regulatory Authority, and any amendments thereto. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.104. &#8220;IND Acceptance</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the acceptance by a Regulatory</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Authority in a Major Market Country of an IND. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.105. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IND Filing</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the filing with a Regulatory Authority in a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Major Market Country of an IND. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.106.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indemnified Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 13.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.107.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indemnifying Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 13.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.108. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indication</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a disease or pathological condition for which</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">clinical results for such disease or condition and a separate BLA application or a supplement (or other addition) to an existing BLA application is required for the purpose of obtaining Regulatory Approval in a country. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.109. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Initiation</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Clinical Study of a Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Product, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.110. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">In-Licenses</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, all Existing Surface In-Licenses, all Existing Novartis In-Licenses and all Collaboration In-Licenses.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.111. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">IP Committee</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the intellectual property advisory</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">committee as more fully described in Section 14.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.112.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JCC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 2.5.1. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.113.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JDC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 2.4.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.114. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Joint Collaboration IP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, (a) [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.115.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JRC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 2.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.116.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JSC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 2.2.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.117. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Know-How</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all commercial, technical, scientific and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and know-how, including regulatory </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">data, study designs and protocols), and Materials, in all cases, whether or not confidential, proprietary, patented or patentable, in written, electronic or any other form now known or hereafter developed. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.118. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Late Global Development Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Global Target-by-Global Target basis, the time period commencing [***] and ending upon [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.119. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Late RLP Development Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Regional Target-by-Regional Target basis, the time period commencing [***] and ending [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.120. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Laws</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all applicable laws, statutes, rules, regulations,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">orders, judgments, injunctions, ordinances or other pronouncements having the binding effect of law of any Governmental Authority, including if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.121.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lead Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 14.4.2.3(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.122. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means collectively, the T1 Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Products, the Global Licensed Products, and the Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.123. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Licensed Targets</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the T1 Target, the Regional Targets</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and the Global Targets. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.124.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Losses</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 13.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.125. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Loss of Market Exclusivity</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall mean [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.126.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MAA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall have the meaning in Section 1.1.23. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.127. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Major Market Countries</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.128. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Manufacturing</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Manufacture</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all activities related</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to the manufacture of Antibody Candidates or Licensed Products, including, but not limited to, manufacturing supplies for Research, Development or Commercialization, packaging, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of product, ongoing stability tests, storage, shipment, and regulatory activities related to any of the foregoing. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.129. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Manufacturing Costs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth on Exhibit B,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">subject to Section 8.3.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.130. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Mark-Up</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.131. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Materials</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all tangible compositions of matter, devices,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">articles of manufacture, assays, biological, chemical or physical materials and other similar materials. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.132.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Milestone Payments</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.8. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Sales</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Licensed Product, the net</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">sales on behalf of a Party and any of its Related Parties for any Licensed Product sold to Third Parties (other than Sublicensees) in bona fide, arms-length transactions, as determined in accordance with such Party&#8217;s Accounting Standards as consistently applied, less a deduction of [***] percent [***%] for direct expenses related to the sales of </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Licensed Product(s), distribution and warehousing expenses and uncollectible amounts on previously sold Licensed Products. The deductions booked on an accrual basis by such Party and its Affiliates under its Accounting Standards to calculate the recorded net sales from gross sales include the following: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.1. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.2. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.3. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.4. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.5. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.6. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.7. </b><font style="font-family:'Times New Roman','Times','serif';">[***] and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.133.8. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to a Combination, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.134.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Sales Royalties</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Regional Net Sales Royalty, the T1 Net Sales Royalty and the Global Net Sales Royalty. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.135.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-Bankrupt Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 9.7. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.136. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-Proposing Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.2.2.4(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.137. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Collaboration IP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.138. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Competing Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 12.5.2.2(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.139. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Component</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Party Component Controlled by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis or its Related Parties. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.140.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Deferral Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 4.2.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.141.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Election</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 8.3.1.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.142.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 13.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.143. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis In-Licenses</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Existing Novartis In-License</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">or any Collaboration In-License to which Novartis is a party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.144. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Know-How</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Know-How Controlled by Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">or its Affiliates during the Term that is reasonably necessary for Surface to Research, Develop, Commercialize or Manufacture Antibody Candidates or Licensed Products in the Field in the Surface Territory, other than Novartis&#8217;s interest in Joint Collaboration IP, and Novartis Collaboration IP. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.145. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Option Target Manufacturing Election</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">meaning set forth in Section 8.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.146. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Patents</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.147. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Regional Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in Section 10.9.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.148. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Regional Royalty Rate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.9.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.149.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis RLP Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 14.9.2.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.150. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Technology</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, Novartis Know-How,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis Patents, Novartis Collaboration IP and Novartis&#8217;s interest in Joint Collaboration IP. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.151. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Territory</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) with respect to any T1 Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Product, worldwide, (b) with respect to any Regional Licensed Product, all countries and territories of the world other than the Surface Territory, and (c) with respect to any Global Licensed Product, worldwide. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.152. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Territory Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">set forth in Section 6.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.153.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other Patents</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 14.3.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.154.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 4.1.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.155. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Exercise Date</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on an Option-by-Option basis, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">date on which an Option Exercise Notice delivered by Novartis to Surface for such Option pursuant to Section 4.2.6 takes effect. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.156. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Exercise Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the written notice Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">delivers to Surface to exercise an Option with respect to an Option Target, in the form set forth on Exhibit C, containing the information set forth in such form. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.157. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Exercise Period</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on an Option-by-Option basis,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.158. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option IND Package</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on an Option Target-by-Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, [***] the information set forth on Schedule 1.1.158 for such Option Target. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.159.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Purchase Fee</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.160. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Purchase Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the written notice Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">delivers to Surface to purchase an Option for an Option Target, in the form set forth on Exhibit D, containing the information set forth in such form. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.161. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Purchase Period</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on an Option Target-by-Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, the time period commencing [***] and ending [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.162.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Selection Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 4.2.3.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.163. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Target</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any of the following: (a) CD47 (NCBI</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Entrez Gene ID:961), [***] (d) IL-27.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.164. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Target Antibody Candidate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on an Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target-by-Option Target basis, any Antibody that (a) Specifically Binds to such Option Target, and (b) is Researched by or on behalf of Surface or its Related Parties pursuant to this Agreement under the applicable Option Target Research Program; provided that after a Change of Control of a Party, [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.165. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Target Research Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 3.2.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.166. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Target Research Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 3.2.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.167. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Tox Package</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on an Option Target-by-Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, the information set forth on Schedule 1.1.167 for such Option Target. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.168.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Opt-Out Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.2.9. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.169. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Opt-Out Right</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Surface&#8217;s right to opt-out of the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Development and Commercialization of all Regional Antibody Candidates and Regional Licensed Products for a Regional Target in accordance with Section 5.2.9. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.170. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Out-of-Pocket Costs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to certain activities</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">hereunder [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.171. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Party Component</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Combination, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">portion of such Licensed Product comprising any active ingredient(s) other than an Antibody Candidate. If the applicable Combination includes more than one such active ingredient, then &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Party Component</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall refer to each such active ingredient. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.172. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Patent</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all patents and patent applications and all</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">substitutions, divisions, continuations, continuations-in-part, any patent issued with respect to any such patent applications, any reissue, reexamination, utility models or designs, renewal or extension (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all counterparts thereof in any country. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.173. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Patent(s) Costs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the out-of-pocket costs and expenses</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">paid to outside legal counsel and other Third Parties (including to any licensor pursuant to any in-license), and filing and maintenance expenses, incurred in Prosecuting and Maintaining Patents and enforcing and defending them. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.174. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Person</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any natural person, corporation, unincorporated</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">organization, partnership, association, sole proprietorship, joint stock company, joint venture, limited liability company, trust or government, or Governmental Authority, or any other similar entity. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.175. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Phase 1 Safety Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.176. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Phase 1 Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a clinical study of an investigational</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">product in patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. 312.21(a), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents and [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.177. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Phase 2 Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a clinical study of an investigational</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">product in patients with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information as described in 21 C.F.R. 312.21(b), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States including a human clinical trial that is also designed to satisfy the requirements of 21 C.F.R. 312.21(a) or corresponding foreign regulations and is subsequently optimized or expanded to satisfy the requirements of 21 C.F.R. 312.21(b) (or corresponding foreign regulations) or otherwise to enable a Phase 3 Clinical Study (e.g., a phase 1/2 trial). The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents and [***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.178. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Phase 3 Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a clinical study of an investigational</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">product in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.179. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PHSA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States Public Health Service Act, as</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">amended. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.180.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Potential In-License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 9.5.1.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.181. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Post-Marketing Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a non-human or human clinical</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">study of a Licensed Product initiated after receipt of Regulatory Approval for such Licensed Product in a country or territory, that is required by the Regulatory Authority in such country or territory to maintain the Regulatory Approval for such Licensed Product in such country or territory, but excluding any Supplemental Study. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.182. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Pricing Approval</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means such governmental approval,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">agreement, determination or decision establishing prices for a Licensed Product that can be charged or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price or reimbursement of pharmaceutical products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.183. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Pricing Matters</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all issues and decisions regarding (a) price, price terms and other contract terms with respect to Licensed Product sales, including discounts, rebates, other price concessions and service fees to payors and purchasers and (b) reimbursement programs applicable to a Licensed Product. For clarity, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.184. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Product Global Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Trademarks used, or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">intended for use, in connection with the distribution, marketing, promotion and sale of the T1 Licensed Products and Global Licensed Products by Novartis and its Related Parties in the Novartis Territory. Product Global Trademarks specifically exclude the corporate names and logos of the Parties and their Affiliates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.185.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Promotional Materials</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 6.2.5.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.186.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Proposing Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.2.2.4(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.187.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prosecution and Maintenance</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with regard to a particular Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as re-examinations, reissues and the like with respect to that Patent, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to that Patent. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.188. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prosecution Patents</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) all Patents within the Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Technology that are Controlled by Surface as of the Effective Date and (b) all Patents within the Surface Collaboration IP that, in each case ((a) and (b)), [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.189. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional [***] Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 4.2.6.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.190. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional [***] Candidate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 4.2.6.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.191. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Antibody Candidate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Regional Target-by-Regional Target basis, any Antibody that [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.192. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Licensed Product</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a Regional Target-by-Regional Target basis, a [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.193. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Option</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an Option that is designated as a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Option in accordance with Section 4.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.194. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.9.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.195. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.9.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.196. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Target</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an Option Target that is designated as a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Target in accordance with Section 4.2.6.2 and with respect to which an Option has been exercised pursuant to Section 4.2.6.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.197. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regulatory Approval</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a BLA, together with all other</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">approvals (including, but not limited to, where applicable, Pricing Approval and schedule classifications), product or establishment licenses, registrations or authorizations (including, but not limited to, marketing authorizations) of any Regulatory Authority that may be necessary for the marketing, sale and commercialization of a pharmaceutical product in any country or region in the Territory. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.198. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regulatory Authority</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Governmental Authority</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">involved in granting approvals for the Development, Manufacturing, Commercialization, Pricing Approval of Licensed Products, including the FDA, the EMA, the Japanese Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency in Japan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.199. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regulatory Materials</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any regulatory application,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">submission, notification, communication, correspondence, registration, Regulatory Approvals and other filings made to, received from or otherwise conducted with a Regulatory Authority related to Developing, Manufacturing, obtaining marketing authorization, marketing, selling or otherwise Commercializing a pharmaceutical product in a particular country or jurisdiction. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.200. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Related Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Party&#8217;s Affiliates and permitted</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Sublicensees. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.201. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Research</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Researching</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means activities, other than</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Development, related to the design, discovery, generation, identification, profiling, characterization, production, process development, cell line development, pre-clinical development or non-clinical or pre-clinical studies of drug candidates and products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.202. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Research Plans</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, the T1 Research Plan and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">each of the Option Target Research Plans. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.203. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Research Programs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, collectively, the T1 Research</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Program and each of the Option Target Research Programs. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.204. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Research Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.205.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Research Target</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the T1 Target and the Option Targets. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.206. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Restricted Technology</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Surface Technology, Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Technology, and any Confidential Information of either Party or its Related Parties provided under or developed in connection with the Collaboration. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.207.</b><font style="font-family:'Times New Roman','Times','serif';"> [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.208.</b><font style="font-family:'Times New Roman','Times','serif';"> [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.209.</b><font style="font-family:'Times New Roman','Times','serif';"> [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.210.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Branding Strategy</b><font style="font-family:'Times New Roman','Times','serif';"> has the meaning set forth in Section 6.2.5.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.211. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Commercial Strategy</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 6.2.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.212. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Development Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means collectively, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.213.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Development Budget</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.2.2.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.214.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Development Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.2.2.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.215. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Trademarks used, or intended for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">use, in connection with the distribution, marketing, promotion and sale of the Regional Licensed Products. RLP Trademarks specifically exclude the corporate names and logos of the Parties and their Affiliates and Sublicensees. RLP Trademarks include both the Surface RLP Trademarks and the Novartis RLP Trademarks. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.216. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Patents</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.217. &#8220;Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Regional Royalty Rates, the T1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Royalty Rates and the Global Royalty Rates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.218.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.10.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.219. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Safety Concern</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) any safety concern required to be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">reported under 21 C.F.R. &#167; 312.32(c)(1)(iii) (&#8220;Findings from animal or in vitro testing&#8221;) if an IND with respect to such Antibody Candidate or Licensed Product was open at the time of the observation or (b) a toxicity or drug safety issue or a Serious Adverse Event reasonably related to or observed in connection with Research, Development or Commercialization activities with respect to an Antibody Candidate or Licensed Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.220.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Event</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.8. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.221. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Payment</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.9. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.222.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SDEA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 7.4. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.223. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Serious Adverse Event</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an adverse drug experience or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">circumstance that results in any of the following outcomes (a) death, (b) life-threatening condition, (c) inpatient hospitalization or a significant prolongation of existing hospitalization, (d) persistent or significant disability or incapacity or substantial disruption of the ability to conduct normal life functions, (e) or a congenital anomaly/birth defect or (f) significant intervention required to prevent permanent impairment or damage. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.224. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Specifically Bind</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.225. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sublicensee</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Third Party to which a Party or its Affiliate</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">has granted or grants rights, as permitted under this Agreement, to Research, Develop, Manufacture or Commercialize any Antibody Candidates or Licensed Product(s), or any further sublicensee of such rights (regardless of the number of tiers, layers or levels of sublicenses of such rights). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.226. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Supplemental Study</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; is any Clinical Study (other than any Post-Marketing Study) for an additional indication or other label expansion for a Licensed Product beyond the initial Indication contemplated by the Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.227. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Supply Agreement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any supply agreement entered into by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties pursuant to Section 8. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.228. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Collaboration IP</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.229. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Competing Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 12.5.2.1(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.230. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Component</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Party Component Controlled by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface or its Related Parties. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.231.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Election</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 8.3.1.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.232.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 13.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.233. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface In-Licenses</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Existing Surface In-License or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">any Collaboration In-License to which Surface is a party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.234. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Know-How</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.235. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Regional Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in Section 10.9.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.236. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Regional Royalty Rate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.9.3.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.237. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Patents</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.238.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface RLP Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 14.9.2.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.239. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Technology</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Surface Know-How, Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Patents, Surface Collaboration IP and Surface&#8217;s interest in Joint Collaboration IP. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.240. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Territory</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to any Regional</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product, the United States. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.241. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Territory Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">set forth in Section 6.2.4. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.242. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Antibody Candidate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Antibody that [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.243. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 6.1.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.244. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Development Information</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.1.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.245. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Development Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 5.1.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.246. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Licensed Product</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.247.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.9.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.248.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 3.1.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.249.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 3.1.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.250.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 10.9.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.251.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Target</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means CD73 [***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.252.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Transition Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.1.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.253.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Transition Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 5.1.2. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.254.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Target</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Licensed Target or Option Target, as applicable. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.255. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Tax</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; and &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Taxation</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any form of tax or taxation, levy,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">duty, charge or withholding (including any related fine, penalty, addition to tax, surcharge or interest) imposed by, or payable to, a governmental authority. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.256. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Technical Failure</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.257. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Territory</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) with respect to Surface, the Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Territory and (b) with respect to Novartis, the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.258.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 15.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.259. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Person other than Novartis, Surface or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">their respective Affiliates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.260. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party Acquisition</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 12.5.2.1(a). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.261.</b><font style="font-family:'Times New Roman','Times','serif';"> &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party Payment</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section 9.5.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.262. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Trademark</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any trademark, trade name, service mark,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.263. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">United States</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">U.S.</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States and its</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">territories, possessions and commonwealths. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1.1.264. </b><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Valid Claim</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a claim of a Patent that (a) has not been</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">rejected, revoked or held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal can be further taken, or (b) has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable through reissue or disclaimer. In order to be a Valid Claim, any claim being prosecuted in a pending patent application must be prosecuted in good faith and not have been pending for more than [***] years from the filing date of the first utility patent application (or equivalent concept in any such country) in the patent application family in the country in question, in which case it will cease to be considered a Valid Claim until the patent issues and recites said claim. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2. GOVERNANCE </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alliance Manager</b><font style="font-family:'Times New Roman','Times','serif';">. Promptly following the Effective Date, each Party will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">designate an individual to facilitate communication and coordination of the Parties&#8217; activities under this Agreement relating to Antibody Candidates and Licensed Products and to provide support and guidance to the JSC (each, an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Alliance Manager</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Alliance Manager may also serve as a representative of its respective Party on one or more Committees. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Steering Committee</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Purpose; Formation</i><font style="font-family:'Times New Roman','Times','serif';">. Within [***] days after the Effective Date, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties will establish a joint steering committee (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JSC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) that will monitor and provide strategic oversight of the activities under this Agreement and facilitate communications between the Parties with respect to the Research, Development, Manufacture and Commercialization of Antibody Candidates and Licensed Products, all in accordance with this Section 2.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Composition</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party will initially appoint [***] representatives to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the JSC, all of whom will have sufficient seniority within the applicable Party to make decisions arising within the scope of the JSC&#8217;s responsibilities. The Parties&#8217; initial representatives to the JSC are set forth on Exhibit E. The JSC may change its size from time to time by mutual consent of its members, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the JSC will consist at all times of an equal number of representatives of each of Surface and Novartis. Each Party may replace its JSC representatives at any time upon written notice to the other Party. The JSC may invite non-members to participate in the discussions and meetings of the JSC, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such participants have no voting authority at the JSC and are bound under written obligation of confidentiality no less protective of the Parties&#8217; Confidential Information than those set forth in this Agreement. The JSC will be co-chaired, with one chairperson designated by Surface and [***] designated by Novartis, whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. Responsibility for running each meeting of the JSC will alternate between the chairpersons from meeting-to-meeting, with Surface&#8217;s chairperson running the first meeting. The Alliance Managers </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">will work with the chairpersons to prepare and circulate agendas and to ensure the preparation of minutes. The chairpersons have no additional powers or rights beyond those held by the other JSC representatives. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Specific Responsibilities</i><font style="font-family:'Times New Roman','Times','serif';">. In addition to its overall responsibility for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">monitoring and providing strategic oversight with respect to the Parties&#8217; activities under this Agreement, the JSC will in particular have the following responsibilities: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss the Research by the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties with respect to the T1 Antibody Candidates and Option Target Antibody Candidates, including whether a Technical Failure has occurred with respect to Option Target Antibody Candidates; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss the Development of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Antibody Candidates; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.3. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss the Commercialization</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of Regional Licensed Products and any other ongoing related activities; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.4. </b><font style="font-family:'Times New Roman','Times','serif';">review, discuss and oversee Manufacturing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for the T1 Antibody Candidates and Option Antibody Candidates, including the supply chain for Antibody Candidates; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.5. </b><font style="font-family:'Times New Roman','Times','serif';">facilitate the flow of information between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties with respect to T1 Antibody Candidates, Regional Antibody Candidates, Global Antibody Candidates and Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.6. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss reports from the JRC,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">JDC and JCC, and provide guidance thereto and direct the activities of such Committees, and review and approve all Research Plans and each RLP Development Plan, and, in each case, all amendments thereto; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.7. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss the entry of any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Collaboration In-Licenses with respect to the Research, Development, Manufacture or Commercialization of any Antibody Candidates or Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.8. </b><font style="font-family:'Times New Roman','Times','serif';">review, discuss and coordinate the Parties&#8217; scientific</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">presentation and publication strategy relating to the Regional Licensed Products in the Territory; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.9. </b><font style="font-family:'Times New Roman','Times','serif';">review and facilitate discussion of proposed publications and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">resolve disputes with respect thereto taking into consideration Section 11.2.1; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.10. </b><font style="font-family:'Times New Roman','Times','serif';">attempt to resolve issues presented to it by, and disputes within,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the JRC, JDC or JCC, or any other subcommittee; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.11. </b><font style="font-family:'Times New Roman','Times','serif';">establish such additional joint subcommittees as it deems</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">necessary to achieve the objectives and intent of this Agreement; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.3.12. </b><font style="font-family:'Times New Roman','Times','serif';">perform such other functions as appropriate, and direct each</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">other Committee to perform such other functions as appropriate, to further the purposes of this Agreement, in each case as agreed in writing by the Parties or as expressly provided in this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.2.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Meetings</i><font style="font-family:'Times New Roman','Times','serif';">. The JSC will meet at least once per [***] during</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Term unless the Parties mutually agree in writing to a different frequency. No later than [***] Business Days prior to any meeting of the JSC (or such shorter time period as the Parties may agree), the Alliance Managers will prepare and circulate an agenda for such meeting; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that either Party may propose additional topics to be included on such agenda, either prior to or in the course of such meeting. Either Party may also call a special meeting of the JSC (by videoconference, teleconference or in person) by providing at least [***] Business Days prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the chairperson of the JSC and the Alliance Managers of both Parties to provide the members of the JSC no later than [***] Business Days prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision on the matters to be considered. The JSC may meet in person, by videoconference or by teleconference. Notwithstanding the foregoing, at least one (1) meeting per [***] will be in person unless the Parties mutually agree in writing to waive such requirement. In-person JSC meetings will be held at locations alternately selected by Surface and by Novartis. Each Party will bear the expense of its respective JSC members&#8217; participation in JSC meetings. Meetings of the JSC will be effective only if at least [***] representative of each Party (which representative is not such Party&#8217;s Alliance Manager) is present or participating in such meeting. The Alliance Managers will be responsible for preparing reasonably detailed written minutes of all JSC meetings that reflect material decisions made and action items identified at such meetings. The </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Alliance Managers will send draft meeting minutes to each member of the JSC for review and approval within [***] Business Days after each JSC meeting. Such minutes will be deemed approved unless [***] of the JSC objects to the accuracy of such minutes within [***] Business Days of receipt. Minutes will be officially endorsed by the JSC at the next JSC meeting, and will be signed by the Alliance Managers. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Research Committee</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Formation; Composition; Dissolution</i><font style="font-family:'Times New Roman','Times','serif';">. Within [***] days after the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Effective Date, the Parties will establish a committee to oversee the Research of Antibody Candidates and Licensed Products in accordance with the Research Plan(s) and to coordinate the Research activities of the Parties with respect thereto (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JRC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Party will initially appoint [***] representatives to the JRC, with each representative having knowledge and expertise in the Research of compounds and products similar to the Antibody Candidates and Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JRC&#8217;s responsibilities. The JRC may change its size from time to time, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the JRC will consist at all times of an equal number of representatives of each of Surface and Novartis. Each Party may replace its JRC representatives at any time upon written notice to the other Party. The JRC may invite non-members to participate in the discussions and meetings of the JRC, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such participants have no voting authority at the JRC and are bound under written obligation of confidentiality no less protective of the Parties&#8217; Confidential Information than those set forth in this Agreement. The JRC will be co-chaired, with one chairperson designated by Surface and [***] designated by Novartis, whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. Responsibility for running each meeting of the JRC will alternate between the chairpersons from meeting-to-meeting, with Surface&#8217;s chairperson running the first meeting. Subject to Section 2.8, after Completion of the last Phase 1 Study for the last Antibody Candidate or Licensed Product, the Parties agree that the JRC will be automatically dissolved with no further action required by either Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Specific Responsibilities of the JRC</i><font style="font-family:'Times New Roman','Times','serif';">. The JRC has the following</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsibilities: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.1. </b><font style="font-family:'Times New Roman','Times','serif';">oversee and review Research responsibilities</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for T1 Antibody Candidate and Option Antibody Candidates; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.2. </b><font style="font-family:'Times New Roman','Times','serif';">discuss, prepare and approve for submission</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to the JSC the Research Plans and all amendments thereto; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.3. </b><font style="font-family:'Times New Roman','Times','serif';">oversee the conduct of the T1 Research Plan</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and Option Target Research Plans; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.4. </b><font style="font-family:'Times New Roman','Times','serif';">create, implement, review the overall</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">strategy and approve protocols and the selection and use of Third Parties for Research of T1 Antibody Candidates and Option Antibody Candidates, including the design of all nonclinical studies, preclinical studies and GLP Toxicology Studies, conducted under the Research Plans; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.5. </b><font style="font-family:'Times New Roman','Times','serif';">decide whether and when to initiate or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">discontinue any nonclinical studies, preclinical studies or GLP Toxicology Studies for T1 Antibody Candidates and Option Antibody Candidates under the Research Plans, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that nothing is intended to limit a Party&#8217;s ability to comply with applicable Law or manage subject safety; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.6. </b><font style="font-family:'Times New Roman','Times','serif';">review, discuss and oversee Manufacturing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for the Research of T1 Antibody Candidates and Option Antibody Candidates, including the supply chain for Antibody Candidates; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.7. </b><font style="font-family:'Times New Roman','Times','serif';">allocate budgeted resources and determine</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">priorities for each nonclinical study, preclinical study and GLP Toxicology Study for T1 Antibody Candidates and Option Antibody Candidates included under the Research Plans; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.8. </b><font style="font-family:'Times New Roman','Times','serif';">facilitate the flow of information between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties with respect to the Research of T1 Antibody Candidates and Option Antibody Candidates; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.9. </b><font style="font-family:'Times New Roman','Times','serif';">facilitate the flow of information between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties with respect to the Research activities for the T1 Research Program and Option Target Research Programs; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.2.10. </b><font style="font-family:'Times New Roman','Times','serif';">perform such other functions as may be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">appropriate to further the purposes of this Agreement, as directed by the JSC in accordance with Section 2.2.3.12 or as expressly provided in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Meetings</i><font style="font-family:'Times New Roman','Times','serif';">. The JRC will meet at least once per [***] unless</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties mutually agree in writing to a different frequency. No later than [***] prior to any meeting of the JRC (or such shorter time period as the Parties may agree), the Alliance Managers will prepare and circulate an agenda for such meeting; provided, however, that either Party will be free to propose additional topics to be included on such agenda, either prior to or in the course of such meeting. Either Party may also call a special meeting of the JRC (by videoconference, teleconference or in person) by providing at least [***] prior written notice to the other Party if such Party reasonably believes that a significant </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the Alliance Manager to provide the members of the JRC no later than [***] prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision. The JRC may meet in person, by videoconference, or by teleconference. In-person JRC meetings will be held at locations in the United States alternately selected by Surface and by Novartis or at any other location mutually agreed by the members of the JRC. Each Party will report to the JRC on all material issues relating to the Research of Antibody Candidates promptly after such issues arise. Each Party will bear the expense of its respective JRC members&#8217; participation in JRC meetings. The JRC chairperson will be responsible for preparing reasonably detailed written minutes of JRC meetings that reflect all decisions made and action items identified at such meetings. The JRC chairperson will send meeting minutes to each member of the JRC for review and approval within [***] after each JRC meeting. Minutes will be deemed approved unless [***] members of the JRC objects to the accuracy of such minutes within [***] of receipt. Minutes will be officially endorsed by the JRC at the next JRC meeting, and will be signed by the Alliance Managers. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.3.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Decision-Making</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the remainder of this Section 2.3.4 and Section 2.6, the JRC will act by unanimous agreement. The representatives from each Party have, collectively, [***] vote on behalf of that Party. If the JRC cannot reach unanimous agreement on an issue that comes before the JRC within [***] of the meeting such issue was raised and over which the JRC has oversight, then the Parties will refer such matter to the JSC for resolution in accordance with Section 2.6. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Development Committee</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Formation; Composition; Dissolution</i><font style="font-family:'Times New Roman','Times','serif';">. No later than [***] after</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Initiation of the first GLP Toxicology Study for any Antibody Candidate or Licensed Product, the Parties will establish a committee to (a) oversee the Development of Regional Licensed Antibody Candidates and Regional Licensed Products in accordance with the Development Plan(s) for the same and to coordinate the Development activities of the Parties with respect thereto, and (b) facilitate the flow of information between the Parties with respect to, and provide a forum to discuss, the Development of T1 Antibody Candidates, T1 Licensed Products, Global Antibody Candidates and Global Licensed Products (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JDC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Party will initially appoint [***] representatives to the JDC, with each representative having knowledge and expertise in the Development of compounds and products similar to the Antibody Candidates and Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC&#8217;s responsibilities. The JDC may change its size from time to time, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the JDC will consist at all times of an equal number of representatives of each of Surface and Novartis. Each Party may replace its JDC representatives at any time upon written notice to the other Party. The JDC may invite non-members to participate in the discussions and meetings of the JDC, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such participants have no voting authority at the JDC and are bound under written obligation of confidentiality no less protective of the Parties&#8217; Confidential Information than those set forth in this Agreement. The JDC will be co-chaired, with one chairperson designated by Surface and [***] designated by Novartis, whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. Responsibility for running each meeting of the JDC will alternate between the chairpersons from meeting-to-meeting, with Novartis&#8217;s chairperson running the first meeting. Subject to Section 2.8, upon later of [***] the Parties agree that the JDC will be automatically dissolved with no further action required by either Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Specific Responsibilities of the JDC</i><font style="font-family:'Times New Roman','Times','serif';">. The JDC has the following</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsibilities: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.1. </b><font style="font-family:'Times New Roman','Times','serif';">oversee and review Development</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsibilities for each Regional Antibody Candidate and Regional Licensed Product; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.2. </b><font style="font-family:'Times New Roman','Times','serif';">discuss, prepare and approve for submission</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to the JSC all RLP Development Plans, and all amendments to RLP Development Plans for Regional Antibody Candidates and Regional Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.3.</b><font style="font-family:'Times New Roman','Times','serif';"> oversee the conduct of all RLP Development Plans; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.4. </b><font style="font-family:'Times New Roman','Times','serif';">create, implement and review the overall</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">strategy for Development, including the design of all Clinical Studies for Regional Antibody Candidates and Regional Licensed Products, conducted under the RLP Development Plans, as applicable; </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.5. </b><font style="font-family:'Times New Roman','Times','serif';">decide whether and when to initiate or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">discontinue any Clinical Study for any Regional Antibody Candidate or Regional Licensed Product under each RLP Development Plan, as applicable, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that nothing is intended to limit a Party&#8217;s ability to comply with applicable Law or manage subject safety; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.6. </b><font style="font-family:'Times New Roman','Times','serif';">allocate budgeted resources and determine</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">priorities for each Clinical Study for Regional Antibody Candidates and Regional Licensed Products included under each RLP Development Plan; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.7. </b><font style="font-family:'Times New Roman','Times','serif';">oversee the conduct of all Clinical Studies</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for Regional Antibody Candidates and Regional Licensed Products included under each RLP Development Plan; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.8. </b><font style="font-family:'Times New Roman','Times','serif';">facilitate the flow of information between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties with respect to the Development of T1 Antibody Candidates, T1 Licensed Products, Regional Antibody Candidates, Regional Licensed Products, Global Antibody Candidates or Global Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.9. </b><font style="font-family:'Times New Roman','Times','serif';">allocate primary responsibility as between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties for tasks relating to the Development of Regional Antibody Candidates where not already specified in the RLP Development Plans therefor; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.10. </b><font style="font-family:'Times New Roman','Times','serif';">review, discuss and oversee Manufacturing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for the Development of Regional Antibody Candidates and Regional Licensed Products, including the supply chain for Regional Antibody Candidates and Regional Licensed Products; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.11. </b><font style="font-family:'Times New Roman','Times','serif';">create, implement and review the overall</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">strategy regarding Regulatory Approval of Regional Licensed Products in the Territory; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.12. </b><font style="font-family:'Times New Roman','Times','serif';">without limitation to Section 2.4.2.11, review the regulatory strategy with respect to discussions with and commitments to or agreements with Regulatory Authorities (including post-approval commitments) with respect to Regional Licensed Product labeling, risk management or Clinical Studies; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.13. </b><font style="font-family:'Times New Roman','Times','serif';">without limitation to Section 2.4.2.12, review and approve any material submission to, or any material agreement with or material commitment made to, a Regulatory Authority with respect to a Regional Licensed Product, such as any BLA or MAA, or any submission, agreement or commitment with respect to Licensed Product labeling, any risk management plans or post-approval commitment for such Licensed Product; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.14. </b><font style="font-family:'Times New Roman','Times','serif';">facilitate the flow of information between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties with respect obtaining Regulatory Approval for Regional Licensed Products; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.2.15. </b><font style="font-family:'Times New Roman','Times','serif';">perform such other functions as may be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">appropriate to further the purposes of this Agreement, as directed by the JSC in accordance with Section 2.2.3.12 or as expressly provided in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Meetings</i><font style="font-family:'Times New Roman','Times','serif';">. The JDC will meet at least once per [***] unless</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties mutually agree in writing to a different frequency. No later than [***] prior to any meeting of the JDC (or such shorter time period as the Parties may agree), the Alliance Managers will prepare and circulate an agenda for such meeting; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, however, that either Party will be free to propose additional topics to be included on such agenda, either prior to or in the course of such meeting. Either Party may also call a special meeting of the JDC (by videoconference, teleconference or in person) by providing at least [***] prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the Alliance Manager to provide the members of the JDC no later than [***] prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision. The JDC may meet in person, by videoconference, or by teleconference. In-person JDC meetings will be held at locations in the United States alternately selected by Surface and by Novartis or at any other location mutually agreed by the members of the JDC. Each Party will report to the JDC on all material issues relating to the Development of Antibody Candidates and Licensed Products for and in the Territory promptly after such issues arise. Each Party will bear the expense of its respective JDC members&#8217; participation in JDC meetings. The JDC chairperson will be responsible for preparing reasonably detailed written minutes of JDC meetings that reflect all decisions made and action items identified at such meetings. The JDC chairperson will send meeting minutes to each member of the JDC for review and approval within [***] after each JDC meeting. Minutes will be deemed approved unless [***] members of the JDC objects to the accuracy of such minutes within [***] of receipt. Minutes will be officially endorsed by the JDC at the next JDC meeting, and will be signed by the Alliance Managers. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.4.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Decision-Making</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the remainder of this Section 2.4.4 and Section 2.6, the JDC will act by unanimous agreement. The representatives from each Party have, collectively, [***] on behalf of that Party. If the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">JDC cannot reach unanimous agreement on an issue that comes before the JDC within [***] of the meeting such issue was raised and over which the JDC has oversight, then the Parties will refer such matter to the JSC for resolution in accordance with Section 2.6. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Commercialization Committee</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">General</i><font style="font-family:'Times New Roman','Times','serif';">. The Parties will establish a committee, no later than completion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of the first Phase 2 Clinical Study for the first Regional Licensed Product, to (a) oversee Commercialization of Regional Licensed Products in the Territory, and (b) facilitate the flow of information between the Parties with respect to, and provide a forum to discuss, the Commercialization of T1 Antibody Candidates, T1 Licensed Products, Global Antibody Candidates and Global Licensed Products (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">JCC</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Formation; Composition</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party will initially appoint [***] representatives to the JCC, with each representative having knowledge and expertise in the commercialization of products similar to the Regional Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JCC&#8217;s responsibilities. The JCC may change its size from time to time by mutual consent of its members, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the JCC will consist at all times of an equal number of representatives of each of Surface and Novartis. Each Party may replace its JCC representatives at any time upon written notice to the other Party. The JCC may invite non-members to participate in the discussions and meetings of the JCC, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such participants have no voting authority at the JCC and are bound under written obligation of confidentiality no less protective of the Parties&#8217; Confidential Information than those set forth in this Agreement. The JCC will be co-chaired, with one chairperson designated by Surface and [***] designated by Novartis, whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. Responsibility for running each meeting of the JCC will alternate between the chairpersons from meeting-to-meeting, with Novartis&#8217;s chairperson running the first meeting. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Specific Responsibilities of the JCC</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to any limitations under</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">applicable Law, including Antitrust Laws, the JCC has the following responsibilities: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">discuss, prepare and approve for submission</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to the JSC the Commercialization Plan for each Regional Licensed Product, including, in each case, any amendments thereto; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">oversee implementation of each</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Commercialization Plan for a Regional Licensed Product; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.3. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss Commercialization</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">activities with respect to Regional Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.4. </b><font style="font-family:'Times New Roman','Times','serif';">facilitate the flow of information between</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties with respect to the Commercialization of T1 Antibody Candidates, T1 Licensed Products, Regional Antibody Candidates, Regional Licensed Products, Global Antibody Candidates or Global Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.5. </b><font style="font-family:'Times New Roman','Times','serif';">allocate between the Parties primary</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsibility for tasks relating to Commercialization of Regional Licensed Products in their respective Territory in a manner consistent with Section 6; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.6. </b><font style="font-family:'Times New Roman','Times','serif';">oversee forecasting and market planning</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">with respect to Regional Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.7. </b><font style="font-family:'Times New Roman','Times','serif';">review and discuss strategies with respect to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Pricing Matters for Regional Licensed Products in the Territory, to the extent operationally feasible and not prohibited by applicable Law; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.8. </b><font style="font-family:'Times New Roman','Times','serif';">review, discuss and oversee Manufacturing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for the Commercialization of Regional Licensed Products, including the supply chain for Regional Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.9. </b><font style="font-family:'Times New Roman','Times','serif';">manage Trademarks as contemplated by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 14.9; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.3.10. </b><font style="font-family:'Times New Roman','Times','serif';">perform such other functions as appropriate to further the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">purposes of this Agreement, as directed by the JSC in accordance with Section 2.2.3.12 or as expressly provided in this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Meetings</i><font style="font-family:'Times New Roman','Times','serif';">. The JCC will meet at least once per [***] unless</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties mutually agree in writing to a different frequency. No later than [***] prior to any meeting of the JCC (or such shorter time period as the Parties may agree), the Alliance Managers will prepare and circulate an agenda for such meeting; provided, however, that either Party will be free to propose additional topics to be included on such agenda, either prior to or in the course of such meeting. Either Party may also call a special meeting of the JCC (by videoconference, teleconference or in person) by providing at least [***] prior written notice to the other Party if such Party reasonably believes that a significant </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the chairperson of the JCC to provide the members of the JCC no later than [***] prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision. The JCC may meet in person, by videoconference, or by teleconference. In-person JCC meetings will be held at locations in the United States alternately selected by Surface and by Novartis or at any other location mutually agreed by the members of the JCC. Meetings of the JCC will be effective only if at least one (1) representative of each Party is present or participating in such meeting. Each Party will report to the JCC on all material issues relating to the Commercialization of Regional Licensed Products promptly after such issues arise. Each Party will bear the expense of its respective JCC members&#8217; participation in JCC meetings. The JCC chairperson will be responsible for preparing reasonably detailed written minutes of JCC meetings that reflect all decisions made and action items identified at such meetings. The JCC chairperson will send meeting minutes to each member of the JCC for review and approval within [***] after each JCC meeting. Minutes will be deemed approved unless [***] members of the JCC object to the accuracy of such minutes within [***] of receipt. Minutes will be officially endorsed by the JCC at the next JCC meeting, and will be signed by the Alliance Managers. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.5.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Decision-Making</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the remainder of this Section 2.5.5 and Section 2.6, the JCC will act by unanimous agreement. The representatives from each Party have, collectively, [***] on behalf of that Party. If the JCC cannot reach unanimous agreement on an issue that comes before the JCC within [***] of the meeting such issue was raised and over which the JCC has oversight, then the Parties will refer such matter to the JSC for resolution in accordance with Section 2.6.3 and Section 2.6; provided that any issues arising under Section 2.5.3.7 shall not be subject to such escalation or decision-making authority, and instead shall be determined by each Party in its respective Territory. For clarity, any and all such communications or strategy involving the Commercialization activities shall be limited to those permitted under applicable Law, including Antitrust Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resolution of Committee Disputes</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.6.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Within Operating Committees</i><font style="font-family:'Times New Roman','Times','serif';">. All decisions within the JRC, JDC and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">JCC will be made by unanimous agreement and all decisions within the other Committees, other than the JSC, will be made by unanimous agreement. If a dispute arises which cannot be resolved within the JRC, JDC, JCC or such other Committees, then if such dispute relates to a matter within the jurisdiction of the applicable Committee, the representatives of either Party may cause such matter to be referred to the JSC for resolution as provided in Section 2.6.2. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.6.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Decision Making Within the JSC</i><font style="font-family:'Times New Roman','Times','serif';">. In addition to resolving issues</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">specifically delegated to it, the JSC has the authority to resolve disputes within the jurisdiction of the JRC, JDC, JCC and any other Committees that the Parties may subsequently create to assist in governance of this Agreement, but otherwise has no authority except where expressly specified elsewhere in this Agreement or mutually agreed by the Parties in writing. The representatives from each Party have, collectively, [***] on behalf of that Party, and all decisions within the JSC (whether originating there, or referred to it by an operating Committee) will be made by unanimous agreement. If a matter is referred by an operating Committee to the JSC, the JSC will use good faith efforts, in compliance with this Section 2.6.2, to resolve promptly such matter. If the JSC is unable to reach unanimous agreement, within [***] after a Party affirmatively states that a decision needs to be made, on any issue for which it is responsible, either Party may elect to submit such issue to the Parties&#8217; Executive Officers in accordance with Section 2.6.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.6.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Referral to Executive Officers</i><font style="font-family:'Times New Roman','Times','serif';">. If a Party makes an election under Section 2.6.2 to refer a matter to the Executive Officers, the JSC will submit in writing the respective positions of the Parties to their respective Executive Officers. Such Executive Officers will use good faith efforts, in compliance with this Section 2.6.3, to resolve promptly such matter, which good faith efforts will include at least one meeting between such Executive Officers within [***] after the JSC&#8217;s submission of such matter to them. If the Executive Officers are unable to reach unanimous agreement on any such matter, (i) if the matter relates to [***] provided, however, that [***] (ii) if the matter relates to [***] (iii) if the matter relates to [***] (iv) if the matter relates to [***] and (v) [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding anything herein to the contrary, no exercise of a Party&#8217;s decision-making authority on any such matters may, without the other Party&#8217;s prior written consent (i) result in a material increase in the other Party&#8217;s or its Related Parties&#8217; obligations, costs or expenses under this Agreement or any Research Plan, Development Plan or Commercialization Plan, or (ii) otherwise conflict with this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.6.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Good Faith</i><font style="font-family:'Times New Roman','Times','serif';">. In conducting themselves on committees, and in exercising</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">their rights under this Section 2.6, all representatives of both Parties will consider diligently, reasonably and in good faith all input received from the other Party, and will use reasonable efforts to reach unanimous agreement on all matters before them. In exercising any </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">decision-making authority granted to it under this Section 2.6, each Party will act based on its good faith judgment taking into consideration such Party&#8217;s obligations to use Commercially Reasonable Efforts with respect to Research, Development or Commercialization activities as provided in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.7. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Committee Authority</b><font style="font-family:'Times New Roman','Times','serif';">. Each Committee has solely the powers</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">expressly assigned to it in this Section 2. No Committee will have any power to amend, modify, or waive compliance with this Agreement. It is expressly understood and agreed that the control of decision-making authority by Surface or Novartis, as applicable, pursuant to Section 2.6, so as to resolve a disagreement or deadlock on a Committee for any matter will not authorize either Party to perform any function or exercise any decision-making right not delegated to a Committee or such Party, and that neither Surface nor Novartis has any right to unilaterally modify, amend or waive its own compliance with, the terms of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2.8. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Discontinuation of Participation on a Committee</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. </b><font style="font-family:'Times New Roman','Times','serif';">The activities to be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">performed by each Committee will solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. Subject to Sections 2.3.1 and 2.4.1, each Committee will continue to exist until the Parties mutually agree to disband the Committee. If each Committee is not disbanded pursuant to the preceding sentence, Surface will have the right, but not the obligation, to discontinue Surface&#8217;s participation on each Committee no earlier than [***] after the expiration of the Research Term with respect to any Licensed Target, other than a Regional Targets. If Surface exercises such right to discontinue its participation, Surface will provide prompt written notice to Novartis of such election including the applicable Licensed Target, and Novartis will have the sole right and authority to take any action that had been within each Committee&#8217;s purview previously with respect to the applicable Antibody Candidates or Licensed Products within such Licensed Target identified in Surface&#8217;s written notice. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3. RESEARCH </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T1 Target</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Overview</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will be responsible for performing Research of T1 Antibody Candidates in accordance with this Agreement and the T1 Research Plan during the Research Term (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). An initial draft of the research plan for the T1 Research Program, to be finalized by the JRC, is attached as Exhibit F (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). In the event of any inconsistency between the T1 Research Plan and this Agreement, the terms of this Agreement will prevail. During and after the expiration of the T1 Research Term, each Party will have the right, but not the obligation, to perform Research of T1 Antibody Candidates in accordance with this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Diligence; Standards of Conduct.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">During the Research Term, Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">(itself or through its Affiliates or by permitted subcontracting pursuant to Section 3.1.7) will use Commercially Reasonable Efforts to [***] Surface will conduct its activities under the T1 Research Plan in a good scientific manner and in compliance with applicable Law. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Oversight.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">The T1 Research Program will be conducted under the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">oversight of the JRC, which will have the responsibilities outlined in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research Costs</i><font style="font-family:'Times New Roman','Times','serif';">. During the Research Term, Surface will be responsible</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for [***] of all costs and expenses incurred by or on behalf of Surface in connection with the T1 Research Program. During and after the expiration of the Research Term for the T1 Research Program, each Party will be responsible for [***] of all costs and expenses incurred by or on behalf of such Party or its Related Parties in connection with Research of T1 Antibody Candidates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research Reports</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will keep the JRC informed regarding the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">progress of Research activities for the T1 Research Program during the Research Term, including a review of results and progress against timelines in the T1 Research Plan on a [***] basis. Following any dissolution of the JRC, Surface will continue to provide Novartis with written updates on its and its Related Parties&#8217; ongoing Research activities with respect to any TI Antibody Candidate on a [***] basis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research Records</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will maintain scientific records in sufficient</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">detail and in good scientific manner appropriate for patent and regulatory purposes, and in compliance with cGLP with respect to activities intended to be submitted in regulatory filings (including INDs), which will fully and accurately reflect all work done and results achieved in the performance of the Research activities by or on behalf of Surface with respect to potential T1 Antibody Candidates. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.1.7. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Third Parties</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will be entitled to utilize the services of Third</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties to perform its Research activities under this Section 3.1, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) Surface will require that such Third Party operates in a manner consistent with the terms of this </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Agreement and is reasonably acceptable to Novartis, and (b) Surface will remain at all times fully liable for its responsibilities. Surface will require that any Third Party agreement entered into pursuant to this Section 3.1.7 (x) include confidentiality and non-use provisions that are no less stringent than those set forth in Section 11.1 (but of duration customary in confidentiality agreements entered into for a similar purpose), other than the agreements listed on Schedule 12.2.1, each of which contains reasonable and customary confidentiality and non-use provisions; and (y) except as identified on Exhibit G, obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) under and to, any Know-How and Patents that are developed by such Third Party in the performance of its obligations under such agreement and are reasonably necessary or useful to Research, Develop, Manufacture or Commercialize T1 Antibody Candidates or T1 Licensed Products in the Field. For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) shall not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Third Party or its Affiliates unless such improvements are reasonably necessary to Research, Develop, Manufacture or Commercialize those Antibody Candidates or Licensed Products with respect to which such Third Party or its Affiliate conducted its activities under such Third Party agreement. Surface will be solely responsible for direction of and communications with such Third Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Targets</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Overview</i><font style="font-family:'Times New Roman','Times','serif';">. On an Option Target-by-Option Target basis, Surface will be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for performing Research of Option Target Antibody Candidates in accordance with this Agreement and the Option Target Research Plan for the applicable Option Target during the Research Term (each an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Target Research</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). An initial draft of each of the Option Target research plans for each of the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Option Target Research Programs is attached as Exhibit H-1, H-2, H-3 and H-4, respectively (each an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Target Research Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). In the event of any inconsistency between an Option Target Research Plan and this Agreement, the terms of this Agreement will prevail. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Diligence; Standards of Conduct.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">On an Option Target-by-Option Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">basis, during the Research Term, Surface (itself or through its Affiliates or by permitted subcontracting pursuant to Section 3.2.6) will use Commercially Reasonable Efforts to [***] Surface will conduct its activities under the Option Target Research Plans in a good scientific manner and in compliance with applicable Law. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research Costs</i><font style="font-family:'Times New Roman','Times','serif';">. During the Research Term, Surface will be responsible</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for [***] of all costs and expenses incurred by or on behalf of Surface in connection with the Option Target Research Programs. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research Reports</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will keep the JRC informed regarding the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">progress of Research activities for the Option Target Research Programs during the Research Term, including a review of results and progress against timelines in the applicable Option Target Research Plan on a [***] basis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research Records</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will maintain scientific records in sufficient</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">detail and in good scientific manner appropriate for Patent and regulatory purposes, and in compliance with cGLP with respect to activities intended to be submitted in regulatory filings (including INDs), which will fully and accurately reflect all work done and results achieved in the performance of the Research activities by or on behalf of Surface with respect to potential Option Target Antibody Candidates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.2.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Third Parties</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will be entitled to utilize the services of Third</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties to perform its Research activities under this Section 3.2, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) Surface will require that such Third Party operates in a manner consistent with the terms of this Agreement and is reasonably acceptable to Novartis and (b) Surface will remain at all times fully liable for its responsibilities. Surface will require that any Third Party agreement entered into pursuant to this Section 3.2.6 (x) include confidentiality and non-use provisions that are no less stringent than those set forth in Section 11.1 (but of duration customary in confidentiality agreements entered into for a similar purpose), other than the agreements set forth on Schedule 12.2.1, each of which contains reasonable and customary confidentiality and non-use provisions; and (y) except as identified on Exhibit I obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) under and to, any Know-How and Patents that are developed by such Third Party in the performance of its obligations under such agreement and are reasonably necessary or useful to Research, Develop, Manufacture or Commercialize Option Target Antibody Candidates or Option Target Licensed Products in the Field. For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(or an exclusive option to obtain such license) shall not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Third Party or its Affiliates unless such improvements are reasonably necessary to Research, Develop, Manufacture or Commercialize those Antibody Candidates or Licensed Products with respect to which such Third Party or its Affiliate conducted its activities under such Third Party agreement. Surface will be solely responsible for direction of and communications with such Third Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">3.3. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Failure</b><font style="font-family:'Times New Roman','Times','serif';">. On an Option Target-by-Option Target basis, if the JSC</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">determines that a Technical Failure has occurred with respect to such Option Target within the Research Term, then Surface&#8217;s obligation to use Commercially Reasonable Efforts to [***] shall be suspended for the remainder of the Research Term; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that Surface will resume Commercially Reasonable Efforts to Research Option Target Antibody Candidates for the remainder of the Research Term for any Option Target for which Technical Failure previously occurred, but where changes in circumstance would render continuing activities consistent with the use of Commercially Reasonable Efforts. Notwithstanding any such Technical Failure, during the Exclusivity Period with respect to such Option Target (a) Novartis may, in its sole discretion, purchase the Option for such Option Target by issuing an Option Purchase Notice in accordance with Section 4.1 of this Agreement, or (b) if Novartis has already delivered an Option Purchase Notice with respect to such Option Target, exercise its Option with respect to such Option Target by issuing an Option Exercise Notice. If Novartis opts not to purchase or exercise its Option with respect to such Option Target, then the Option for such Option Target will terminate with the consequences set forth in Section 4.2.7 and elsewhere in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4. OPTION PURCHASE, GRANT AND EXERCISE OF OPTIONS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Purchase Rights</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Option Purchase</i><font style="font-family:'Times New Roman','Times','serif';">. On an Option Target-by-Option Target basis, Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">hereby grants Novartis the right, but not the obligation, to purchase up to a total of four (4) exclusive option rights with respect to the Option Targets (each an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). For each Option Target, promptly [***] Surface will (a) provide to Novartis the Option Tox Package with respect to the applicable Option Target, and (b) afford reasonable access during normal business hours to Surface&#8217;s personnel by Novartis and its representatives as Novartis may reasonably request to assist Novartis in deciding whether to purchase the Option for such Option Target. In addition, during the Option Purchase Period, Novartis may, in its sole discretion, reasonably request that Surface provide to Novartis other information and documentation relating to such Option Target Antibody Candidate, and Surface will provide such information and documentation in the possession or control of Surface to Novartis within [***] weeks after the date of Novartis&#8217; request; provided that, for clarity, any such information delivery that occurs after the expiration of the Option Purchase Period will not extend such Option Purchase Period. For each Option, Novartis will be entitled to purchase the applicable Option by providing a completed Option Purchase Notice with respect to the applicable Option to Surface at any time during the applicable Option Purchase Period for such Option and paying the Option Purchase Fee in accordance with Section 10.3. If Novartis purchases the applicable Option for an Option Target during the Option Purchase Period, then Novartis will be entitled to exercise the Option with respect to such Option Target as set forth in Section 4.2. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Option Purchase Not Exercised.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">For each Option, if Novartis does not</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">deliver to Surface an Option Purchase Notice with respect to an Option Target during the Option Purchase Period, or if Novartis elects and delivers written notice to Surface to terminate an Option prior to expiration of the applicable Option Purchase Period, then (a) Novartis&#8217;s Option with respect to such Option Target will expire, (b) the Research Term with respect to such Option Target will terminate, (c) each Party&#8217;s rights and obligations under this Agreement with respect to such Option Target and any Option Target Antibody Candidates relating thereto (including the right to exercise the Option under Section 4.2 and the exclusivity under Section 12.5) will terminate, and (d) each Party will thereafter be free to research, develop, manufacture or commercialize, alone or with one or more Third Parties, any Antibodies or products relating to such Option Target, in each case without any further obligation to the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Grant</i><font style="font-family:'Times New Roman','Times','serif';">. Surface hereby grants Novartis the right, but not the obligation, to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">exercise up to a total of three (3) Options with respect to any three (3) Option Targets for which (a) Novartis has purchased an Option in accordance with Section 4.1, and (b) Surface has received IND Acceptance with respect to such Option Target. Each Option will </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">be designated as either a Regional Option or a Global Option in accordance with the selection mechanism set forth in Section 4.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Information Sharing for Options</i><font style="font-family:'Times New Roman','Times','serif';">. For each of the Options, promptly after</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the first IND Acceptance with respect to an Option Target, Surface will (a) provide to Novartis the Option IND Package with respect to the applicable Option Target, and (b) afford reasonable access during normal business hours to Surface&#8217;s personnel by Novartis and its representatives as Novartis may reasonably request to assist Novartis in deciding whether to exercise the Option for such Option Target. In addition, during the Option Exercise Period, Novartis may, in its sole discretion, reasonably request that Surface provide to Novartis other information and documentation relating to the Option Target, and Surface will provide such information and documentation in the possession or control of Surface to Novartis within [***] weeks after the date of Novartis&#8217; request; provided that, for clarity, any such information delivery that occurs after the expiration of the Option Exercise Period will not extend such Option Exercise Period. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Selection Mechanism</i><font style="font-family:'Times New Roman','Times','serif';">. For each Option, the Parties will determine if the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Option for such Option Target will be a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Option</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; or a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Option</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; in accordance with the following procedure: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">First Option</i><font style="font-family:'Times New Roman','Times','serif';">. Contemporaneously with the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">delivery of the Option IND Package for the first Option Target, Surface will provide written notice in the form set forth on Exhibit J (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Selection Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) to Novartis indicating whether the Option for the first Option Target will be a Regional Option or a Global Option. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Second Option</i><font style="font-family:'Times New Roman','Times','serif';">. Contemporaneously with</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the delivery of the Option Exercise Notice for the second Option Target, Novartis will provide an Option Selection Notice to Surface indicating whether the Option for the second Option Target will be a Regional Option or a Global Option or whether Novartis will terminate its rights to such Option Target in accordance with Section 4.2.7. Notwithstanding the foregoing, Novartis, in its sole discretion, may indicate that Novartis elects to defer its right to select the Option structure until the third Option Target achieves an IND Acceptance in accordance with Section 4.2.3.3 and instead permit Surface to issue an Option Selection Notice to Novartis for the second Option Target (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Deferral Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). In the event that Novartis issues the Novartis Deferral Notice, Surface will provide an Option Selection Notice to Novartis within [***] after receipt of the Novartis Deferral Notice indicating whether the Option for the second Option Target will be a Regional Option or a Global Option. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Third Option</i><font style="font-family:'Times New Roman','Times','serif';">. Contemporaneously with the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">delivery of the Option IND Package for the third Option Target, Surface will provide an Option Selection Notice to Novartis indicating whether the Option for the third Option Target will be a Regional Option or a Global Option. Notwithstanding the foregoing, if Novartis provided a Novartis Deferral Notice in accordance with Section 4.2.3.2, then contemporaneously with the delivery of the Option Exercise Notice for the third Option Target, Novartis will provide an Option Selection Notice to Surface indicating whether the Option for the third Option Target will be a Regional Option or a Global Option or whether Novartis will terminate its rights to such Option Target in accordance with Section 4.1.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional Option Grants</i><font style="font-family:'Times New Roman','Times','serif';">. For each Option that is designated as a Regional</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Option in accordance with Section 4.2.3, Surface hereby grants to Novartis an exclusive option, but not the obligation, to obtain an exclusive license on the terms set forth in Section 9.2 to such Option Target and all associated Option Target Antibody Candidates. Each Regional Option may be exercised by Novartis at any time during the applicable Option Exercise Period for such Regional Option in accordance with the terms and conditions set forth in Section 4.2.6. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Global Option Grants</i><font style="font-family:'Times New Roman','Times','serif';">. For each Option that is designated as a Global</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Option in accordance with Section 4.2.3, Surface hereby grants Novartis an exclusive option, but not the obligation, to obtain an exclusive license on the terms set forth in Section 9.3 to such Option Target and all associated Option Target Antibody Candidates. Each Global Option may be exercised by Novartis at any time during the applicable Option Exercise Period for such Global Option in accordance with the terms and conditions set forth in Section 4.2.6. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exercise of an Option</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Option Exercise Notice</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">exercise an Option, if at all, by properly delivering a completed Option Exercise Notice in respect of such Option to Surface at any time during the applicable Option Exercise Period for such Option. For clarity, Novartis will be entitled to exercise a maximum of three (3) Options, and thereafter all rights and obligations with respect to any remaining Option Target will terminate in accordance with Section 4.2.7. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exercise of Regional Options</i><font style="font-family:'Times New Roman','Times','serif';">. On the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">applicable Option Exercise Date for the exercise of any Regional Option, all Option Target Antibody Candidates for such Option Target will automatically be deemed &#8220;Regional Antibody Candidates&#8221;, the applicable Option Target will automatically be deemed a &#8220;Regional Target&#8221; for all purposes under this Agreement, the license from Surface to Novartis for such Regional Antibody Candidates and associated Regional Licensed Products set forth in Section 9.2 will automatically, with no further action by any Party, go into full force and effect, and all of the obligations of Surface and Novartis with respect to such Regional Licensed Products, including the payment obligations relating thereto, will become the binding obligations of the applicable Party in respect of such Regional Antibody Candidates and Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exercise of Global Options</i><font style="font-family:'Times New Roman','Times','serif';">. On the applicable Option Exercise Date for the exercise of any Global Option, all Option Target Antibody Candidates for such Option Target will automatically be deemed a &#8220;Global Antibody Candidates&#8221; and the applicable Option Target will automatically be deemed a &#8220;Global Target&#8221; for all purposes under this Agreement, the license from Surface to Novartis to such Global Antibody Candidates and associated Global Licensed Products set forth in Section 9.3 will automatically, with no further action by any Party, go into full force and effect, and all of the obligations of Surface and Novartis with respect to such Global Licensed Products, including the payment obligations relating thereto, will become the binding obligations of the applicable Party in respect of such Global Antibody Candidates and Global Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional [***] Candidate</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding anything herein to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the contrary, in the event Novartis exercises an Option with respect to [***] pursuant to Section 4.2.6 and [***] is a Regional Target under this Agreement, then either Party may, pursuant to Section 5.2.2.4(a), present a proposal to the JDC requesting the right to Develop and Commercialize (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional [***] Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) one (1) or more Antibodies that Specifically Binds to any of the [***] other than that Antibody Candidate [***] exercised in connection with the Option for [***] (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional [***] Candidate</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Subject to Section 2.4.4, if JDC decides that the Parties will conduct the Regional [***] Activities with respect to the Regional [***] Candidate, then such Regional [***] Candidate will be treated as &#8220;Regional Antibody Candidate&#8221; or &#8220;Regional Licensed Product&#8221; on the same basis as all other Antibody Candidates for [***] that were exercised under the Option. However, if the JDC is unable to agree that the Parties will conduct the Regional [***] Activities, then either Party will be entitled, if permitted under Section 5.2.2.4(c), to proceed with the Regional [***] Activities of such Regional [***] Candidate by itself in its respective Territory; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) such Party&#8217;s rights will be limited to those Regional [***] Activities with respect to the Regional [***] Candidate and associated Regional Licensed Product solely in such Party&#8217;s Territory, (b) all associated Regional Licensed Products will be royalty-bearing Regional Licensed Products under this Agreement; and (c) the Non-Proposing Party shall, pursuant to Section 5.2.2.4(d) have the right to opt-in with respect to the Regional [***] Candidate. For the avoidance of doubt, Surface will have no rights to conduct Regional [***] Activities in the event [***] is a Global Target. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research, Development and Commercialization Following</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Option Exercise. </i><font style="font-family:'Times New Roman','Times','serif';">Following the Option Exercise Date for a Regional Option, (a) each Party will have the right, but not the obligation, to perform Research of Regional Antibody Candidates in accordance with this Agreement, (b) each Party will be responsible for [***] of all costs and expenses incurred by or on behalf of such Party or its Related Parties in connection with Research of Regional Antibody Candidates, and (c) the Development and Commercialization of Regional Antibody Candidates and Regional Licensed Products for such Regional Target will thereafter be governed by Sections 5.2 and 6.2, respectively. Following the Option Exercise Date for a Global Option, (x) each Party will have the right, but not the obligation, to perform Research of Global Antibody Candidates in accordance with this Agreement, (y) each Party will be responsible for [***] of all costs and expenses incurred by or on behalf of such Party or its Related Parties in connection with Research of Global Antibody Candidates, and (z) the Development and Commercialization of Global Antibody Candidates and Global Licensed Product for such Global Target will thereafter be governed by Sections 5.3 and 6.3, respectively. Following any dissolution of the JRC or JDC, Surface will continue to provide Novartis with written updates on its and its Related Parties&#8217; ongoing Research activities with respect to any Regional Antibody Candidate and Global Antibody Candidate on a [***] basis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.6.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Further Assurances and Transaction Approvals in Connection</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">with Option. </i><font style="font-family:'Times New Roman','Times','serif';">Novartis shall specify in each Option Exercise Notice provided with</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">respect to an Option Target pursuant to Section 4.2.6, whether, in Novartis&#8217; reasonable opinion, the Parties would be required by applicable Laws to file with the FTC and the Antitrust Division of the DOJ, any notification and report form under the HSR Act (an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">HSR Filing</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) with respect to Novartis&#8217; exercise of the Option for such Option Target. The Parties will reasonably cooperate with one another to the extent necessary in the preparation of any such HSR Filing. Novartis shall be responsible for all filing fees associated with </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">any such HSR Filing. The Parties shall each use Commercially Reasonable Efforts to ensure that applicable waiting period under the HSR Act or any applicable comparable foreign law in the Territory expires or is terminated as soon as practicable. Notwithstanding the foregoing, nothing in this Section 4.2.6 shall require either Party or such Party&#8217;s Affiliates to (a) disclose to the other Party any information that is subject to obligations of confidentiality owed to Third Parties (nor shall either Party be required to conduct joint meetings with any Governmental Authority in which such information might be shared with the other Party), or (b) to commit to any divestiture, license (in whole or in part) or any arrangement to hold separate (or any similar arrangement) with respect to any of its products or assets. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">4.2.7. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Termination of Option</i><font style="font-family:'Times New Roman','Times','serif';">. On an Option-by-Option basis, if (a) Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">does not deliver to Surface an Option Exercise Notice with respect to an Option during the Option Exercise Period, (b) Novartis makes an HSR Filing with respect to the exercise of an Option for an Option Target, but the applicable waiting period under the HSR Act with respect to such HSR Filing does not expire or is not terminated within [***] days after the filing date, or (c) Novartis elects, in its sole discretion, to deliver written notice to Surface to terminate an Option prior to the expiration of the applicable Option Exercise Period, then (i) Novartis&#8217;s Option with respect to such Option Target will expire, (ii) the Research Term with respect to such Option Target will terminate, (iii) each Party&#8217;s rights and obligations under this Agreement with respect to such Option Target and any Option Target Antibody Candidates relating thereto (including exclusivity under Section 12.5), will terminate, and (iv) each Party will thereafter be free to Research, Develop, Manufacture or Commercialize, alone or with one or more Third Parties, any Antibodies or products relating to such Option Target, in each case without any further obligation to the other Party. For clarity, Novartis will be entitled to exercise a maximum of three (3) Options, and thereafter all rights and obligations with respect to any remaining Option Target will terminate in accordance with this Section 4.2.7. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5. DEVELOPMENT </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T1 Antibody Candidates and T1 Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Overview</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will have the sole right to Develop T1 Antibody</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Candidates and T1 Licensed Products in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Transition</i><font style="font-family:'Times New Roman','Times','serif';">. By no later than [***] for a T1 Licensed Product, Surface will prepare and provide to Novartis a draft plan for the transition of the Development of such T1 Licensed Products from Surface to Novartis or its designee (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Transition Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The T1 Transition Plan for each T1 Licensed Product will require Surface to, as soon as reasonably practicable following the Research Term: (a) transfer to Novartis of a copy of all Know-How Controlled by Surface that is reasonably necessary or useful for Development of such T1 Antibody Candidates or T1 Licensed Products, or obtaining or maintaining Regulatory Approval for such T1 Licensed Products in the Novartis Territory, including information and materials reasonably requested by Novartis, in a format reasonably acceptable to Novartis (which will be specified in such T1 Transition Plan, along with the process of transferring such Know-How); (b) assign to Novartis any INDs and other Regulatory Materials submitted to, or filed with, any Regulatory Authority with respect to such T1 Antibody Candidates or T1 Licensed Products, including any drug master files maintained by or on behalf of Surface solely related thereto (provided however that Surface will not be required to transfer any drug master files maintained by or on behalf of any Third Party, including any contract manufacturers); (c) transfer to Novartis a copy of all written correspondence with any Regulatory Authority with respect to such T1 Antibody Candidates or T1 Licensed Products and all written minutes of meetings and memoranda of oral communications with any Regulatory Authority with respect to such T1 Antibody Candidates or T1 Licensed Products; and (d) transfer to Novartis a copy of any other information or materials reasonably requested by Novartis that are reasonably necessary or useful for Development of such T1 Antibody Candidates or T1 Licensed Products in the Novartis Territory, including if so reasonably requested by Novartis, and Third Party agreements relating solely thereto (the items described in clauses (a) through (d) collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Development Information</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The T1 Transition Plan for each T1 Licensed Product will also describe any Development activities with respect to such T1 Licensed Product that Surface is required to perform as requested by Novartis and mutually agreed upon by the Parties (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Transition Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Party will use Commercially Reasonable Efforts to perform the obligations assigned to it under the T1 Transition Plan in accordance with any timelines set forth therein, and [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Development Plan.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Within [***] days prior to the anticipated</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">expiration date of the Research Term with respect to the T1 Target, Novartis will provide the JDC with a work plan and time table for the Development activities, including Clinical Studies, to be undertaken with respect to T1 Antibody Candidates and T1 Licensed </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Products in the Novartis Territory (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Development Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The terms of, and Development activities set forth in, each T1 Development Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the pharmaceutical industry. Novartis will update the T1 Development Plan for such T1 Antibody Candidates and T1 Licensed Products [***] and will provide such updated T1 Development Plan to the JDC. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Diligence.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will use Commercially Reasonable Efforts to (a) [***] and (b) perform all Development activities for the T1 Antibody Candidates and T1 Licensed Products in accordance with the T1 Development Plan. Without limiting the foregoing, at all times during the Term, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Costs</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will be responsible for [***] Development Costs for the Development of T1 Antibody Candidates or T1 Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Records; Reports; Information Sharing.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.6.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Development Activities</i><font style="font-family:'Times New Roman','Times','serif';">. Following the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">transition period with respect to a T1 Licensed Product, once per [***] Novartis will provide to Surface, through the JDC, an update regarding Development activities conducted by or on behalf of Novartis with respect to such T1 Licensed Product, as well as any Clinical Studies with respect to such T1 Licensed Products conducted by Novartis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.6.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Scientific Records</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will maintain</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">scientific records, in sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in compliance with cGLP with respect to activities intended to be submitted in regulatory filings (including INDs and BLAs), which will reflect all material work done and results achieved in the performance of the Development activities and Clinical Studies with respect to T1 Licensed Products. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.6.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Personnel.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">During the period commencing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">after the completion of the T1 Transition Activities and ending upon Regulatory Approval of the first T1 Licensed Product, Novartis may request that Surface reasonably make available for consultation regarding the Development of T1 Antibody Candidates and T1 Licensed Products certain of its employees engaged in Research and Development activities with respect to such T1 Antibody Candidates and T1 Licensed Products. Surface will reasonably cooperate with Novartis to provide (a) up to [***] hours of consultation without charge to Novartis, and (b) any additional hours of consultation as Novartis may reasonably request, for which Novartis will pay Surface a rate of [***] per hour of such consultation services. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.1.7. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Third Parties</i><font style="font-family:'Times New Roman','Times','serif';">. The Parties will be entitled to utilize the services of Third</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties to perform their respective Development activities under this Section 5.1, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) each Party will require that such Third Party operates in a manner consistent with the terms of this Agreement and in the case of Surface, reasonably acceptable to Novartis and (b) each Party will remain at all times fully liable for its respective responsibilities. Each Party will require that any Third Party agreement entered into pursuant to this Section 5.1.7 (x) include confidentiality and non-use provisions that are no less stringent than those set forth in Section 11.1 (but of duration customary in confidentiality agreements entered into for a similar purpose), other than Existing Novartis In-Licenses and the agreements listed on Schedule 12.2.1, each of which contains reasonable and customary confidentiality and non-use provisions; and (y) except as identified on Exhibit G, obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) under and to, any Know-How and Patents that are developed by such Third Party in the performance of its obligations under such agreement and are reasonably necessary or useful to Research, Develop, Manufacture or Commercialize T1 Antibody Candidates or T1 Licensed Products in the Field. For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) shall not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Third Party or its Affiliates unless such improvements are reasonably necessary to Research, Develop, Manufacture or Commercialize those Antibody Candidates or Licensed Products with respect to which such Third Party or its Affiliate conducted its activities under such Third Party agreement. The Party utilizing the services of a Third Party service provider will be solely responsible for direction of and communications with such Third Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regional Antibody Candidates and Regional Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Overview</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the oversight of the JSC and the JDC, on a Regional</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target-by-Regional Target basis: </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be primarily responsible for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Development of all Regional Antibody Candidates and Regional Licensed Products in accordance with this Agreement and the RLP Development Plan for such Regional Target during the Early RLP Development Term. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Unless Surface exercises its Opt-Out Right</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in accordance with Section 5.2.9, the Parties will collaborate on further global Development of Regional Antibody Candidates and Regional Licensed Products in accordance with this Agreement and the RLP Development Plan during the Late RLP Development Term, with each Party&#8217;s responsibility for Development activities specifically related to obtaining Regulatory Approval in its Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Development Plans</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">RLP Development Plans</i><font style="font-family:'Times New Roman','Times','serif';">. On a Regional</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target-by-Regional Target basis, the Development activities that are necessary or useful to be undertaken for the applicable Regional Antibody Candidates and Regional Licensed Products to achieve initial Regulatory Approval will be mutually agreed upon by the Parties and set forth in reasonable detail in a written work plan and time table (each, as updated from time to time, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Development Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) . The initial RLP Development Plan for each Regional Target will be included in the Option IND Package for such Regional Target provided by Surface to Novartis under Section 4.2.2, and within [***] days after the Option Exercise Date for such Regional Target, or as soon as reasonably practicable thereafter, the JDC will review, update and approve such RLP Development Plan. Each RLP Development Plan will allocate responsibility for the performance of each RLP Development Activity to one or both of the Parties in their respective Territories. The terms of, and Development activities set forth in, each RLP Development Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the pharmaceutical industry. The Parties will update the applicable RLP Development Plan for such Regional Antibody Candidates and Regional Licensed Products [***] and will provide such updated RLP Development Plan to the JDC. The JDC will review and approve each RLP Development Plan submitted to it in accordance with Section 2.4.4. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">RLP Development Budgets</i><font style="font-family:'Times New Roman','Times','serif';">. Each RLP</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Development Plan will contain a [***] rolling budget covering the anticipated RLP Development Activities to be performed during the then-current Calendar Year (broken down by Calendar Quarter) and the next Calendar Year (broken down by Calendar Quarter), and a forecast of the budgets for each subsequent Calendar Year thereafter through completion of all RLP Development Activities set forth in any such RLP Development Plan, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that each initial RLP Development Plan will also include such a budget for the partial Calendar Year commencing as of the date of such RLP Development Plan and ending December 31 of such Calendar Year (each such two-year budget plus any such partial Calendar Year is a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Budget</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each RLP Development Budget will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">be updated [***] by the JDC in accordance with Section 5.2.2.3. The initial RLP Development Budget for a Regional Target, and each update thereto, will be prepared by the JDC, based on (a) the Parties&#8217; good faith estimation of the anticipated RLP Development Activities to be conducted during the relevant [***] year period and (b) information prepared by the Parties in good faith for their own internal planning processes relating to anticipated RLP Development Activities for such Regional Target, a summary of which will be provided to the JDC for review and incorporation into the RLP Development Budget. Each RLP Development Budget will include an itemized list of the applicable RLP Development Activities to be performed during the [***] year period covered by such RLP Development Budget, with detailed line item entries for each RLP Development Activity setting forth the costs directly related to such RLP Development Activity (broken out to show Out-of-Pocket Costs and FTE Costs for FTEs directly engaged to perform such RLP Development Activity) and specifying what Party or Third Party is responsible for performing the applicable RLP Development Activity, which itemized list may include: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) Any material preclinical, non-clinical studies or GLP Toxicology Studies, itemized by study; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) Clinical Studies, including (A) the following costs itemized by Clinical Study: [***] and (B) the following information itemized by Clinical Study: [***] and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii) allocation of responsibility for Manufacturing the applicable Regional Antibody Candidates and Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Confidential</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">- 56 - </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Managing and Amending RLP Development</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Plans and RLP Development Budgets</i><font style="font-family:'Times New Roman','Times','serif';">. The JDC will update and</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">amend the applicable RLP Development Plan from time-to-time as it deems necessary and, until such time as no further RLP Development Activities are occurring or expected to occur with respect to such Regional Target. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.2.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Supplemental Studies; Regional [***] Candidates</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Additional Development Proposals</i><font style="font-family:'Times New Roman','Times','serif';">. If a Party desires to conduct (i) a Supplemental Study of a Regional Licensed Product for a Regional Target for the purpose of seeking Regulatory Approval to market such Regional Licensed Product, or (ii) Regional [***] Activities, such Party (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Proposing</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Party,</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; and such other Party, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-Proposing Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) will submit to the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">JDC a proposal to add such Supplemental Study or Regional [***] Activities, as applicable, to the applicable RLP Development Plan (an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Proposal</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Additional Development Proposal will describe</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in reasonable detail the applicable Regional Target or Regional [***] Candidate, the Supplemental Study(ies) or Regional [***] Activities that the Proposing Party desires to conduct, including a synopsis of the trial or activities, the proposed enrollment criteria, number of patients to be included, endpoints to be measured, and statistical design and powering (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), as well as a proposed timeline and budget and an analysis of the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">business opportunity and revenue potential for such Additional Development Activities. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">JDC Decision Regarding Additional Development Activities</i><font style="font-family:'Times New Roman','Times','serif';">. The</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">JDC will approve or reject an Additional Development Proposal within [***] days after receipt thereof from the Proposing Party as set forth in this Section 5.2.2.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) If the JDC approves an Additional Development Proposal, upon such an approval, the applicable RLP Development Plan will be amended to include the Additional Development Activities, including the proposed timeline and budget for such Additional Development Activities, set forth in such Additional Development Proposal (as may be amended by the JDC) upon such approval. Any Additional Development Activities included in a RLP Development Plan pursuant to this Section 5.2.2.4 will be deemed to be RLP Development Activities for all purposes under Section 5.2.3.2. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) If the JDC fails to approve an Additional Development Proposal, upon such a failure, the Supplemental Study or Regional [***] Activities proposed in the Additional Development Proposal will not be deemed an RLP Development Activity for any purpose under this Agreement, and Sections 5.2.2.4(c) and 5.2.2.4(d) will apply. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Independent Performance of Additional Development Activities</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) If, the JDC fails to approve for inclusion in the RLP Development Plan an Additional Development Proposal proposed by Surface for a Supplemental Study(ies) for such Regional Licensed Product or Regional [***] Activities for such Regional [***] Candidate, Surface may, upon notice to Novartis, conduct the proposed Supplemental Study(ies) or Regional [***] Activities at its own expense; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that if Novartis determines reasonably and in good faith that the performance of such proposed Supplemental Study(ies) or Regional [***] Activities would pose Safety Concerns or other ethical concerns, then Surface will not undertake such Supplemental Study(ies) or Regional [***] Activities, unless and until Novartis determines that such Additional Development Activities should be permitted. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) If the JDC fails to approve for inclusion in the RLP Development Plan an Additional Development Proposal proposed by Novartis for a Supplemental Study(ies) for such Regional Licensed Product or Regional [***] Activities for such Regional [***] Candidate, Novartis may, upon notice to Surface, conduct the proposed Supplemental Study(ies) or Regional [***] Activities at its own expense; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that if Surface determines reasonably and in good faith that the performance of such proposed Supplemental Study(ies) or Regional [***] Activities would pose Safety Concern or other ethical concerns, then Novartis will not undertake such Supplemental Study(ies) or Regional [***] Activities, unless and until Surface determines that such Additional Development Activities should be permitted. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii) Notwithstanding anything in Section 7.1.3 to the contrary, if the JDC does not approve an Additional Development Proposal, unless and until the Non-Proposing Party delivers an Additional Development Opt-In Notice </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">with respect to such Additional Development Activity, as described in Section 5.2.2.4(d), the Non-Proposing Party will not have any rights under Section 7.1.3 with respect to any information or data generated from any Supplemental Study or Regional [***] Activity that was the subject of the unapproved Additional Development Proposal or from any future information or data generated from any future Clinical Studies with respect to the same Indication or the applicable Regional [***] Candidate, other than to use such information or data to determine whether to deliver an Additional Development Opt-In Notice in accordance with Section 5.2.2.4(d) or as permitted pursuant to the SDEA. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Opt-In for Additional Development Activities</i><font style="font-family:'Times New Roman','Times','serif';">. In the event that the</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Proposing Party conducts a Supplemental Study or Regional [***] Activity pursuant to Section 5.2.2.4(c), the Proposing Party will provide to the Non-Proposing Party (i) [***] (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Data Package</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Non-Proposing Party shall have the one-time right to elect, in its sole discretion and upon written notice to the Proposing Party no later than [***] days after the date the Additional Development Data Package is made available to the Non-Proposing Party (an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development Opt-In Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), to opt in with respect to any Supplemental Study or Regional [***] Activity that was the subject of such Additional Development Proposal that the Proposing Party elected to conduct in accordance with Section 5.2.2.4(c), and then (A) such Supplemental Study or Regional [***] Activity, as applicable, will be deemed to be an RLP Development Activity under the RLP Development Plan for the applicable Regional Target from and after the date on which such Additional Development Opt-In Notice is received by the Proposing Party (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Additional Development</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Opt-In Date</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;); (B) the then-current plan and budget of the Proposing Party with</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">respect to such Supplemental Study or Regional [***] Activity, as applicable, will be deemed to be included within, and part of, the RLP Development Plan for such Regional Licensed Product as of the Additional Development Opt-In Date, and will control with respect to such Supplemental Study or Regional [***] Activity unless and until an amendment to the RLP Development Plan providing for a different or modified plan and budget is approved by the JDC; and (C) the Non-Proposing Party will have all rights granted to it under Section 7.1.3 with respect to the information and data generated from such Supplemental Study or Regional [***] Activity as if such Supplemental Study or Regional [***] Activity was conducted under the RLP Development Plan for such Regional Licensed Product, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that, (1) the Non-Proposing Party&#8217;s right to so opt-in with respect to such Additional Development Activities, triggering the results described in the foregoing clauses (A) through (C), is conditioned on the payment by the Non-Proposing Party to the Proposing Party of a payment of [***] of those costs and expenses incurred by the Proposing Party prior to the Additional Development Opt-in Date that the Non-Proposing Party should have paid in connection with such Additional Development Activities had such Additional Development Activities been included in the RLP Development Plan pursuant to Section 5.2.2.4(b)(i); and (2) any future Development Costs with respect to such Regional Licensed Product, including any future Clinical Studies, will be allocated in accordance with Section 5.2.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Diligence; Standards of Conduct.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis Diligence</i><font style="font-family:'Times New Roman','Times','serif';">. On a Regional Target-by-Regional Target basis, Novartis will use Commercially Reasonable Efforts to (a) [***] and (b) perform the RLP Development Activities allocated to it under the RLP Development Plan for such Regional Antibody Candidates and Regional Licensed Products for such Regional Target in accordance with the RLP Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface Diligence</i><font style="font-family:'Times New Roman','Times','serif';">. On a Regional Target-by-Regional Target basis, Surface will use Commercially Reasonable Efforts to (a) [***] and (b) perform the RLP Development Activities allocated to it under the RLP Development Plan for such Regional Antibody Candidates and Regional Licensed Products for such Regional Target in accordance with the RLP Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Development Costs.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to each Regional Target,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be responsible for [***] of all Development Costs for the Development of Regional Antibody Candidates or Regional Licensed Products for such Regional Target during the Early RLP Development Term. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to each Regional Target,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be responsible for [***] of all Development Costs and Novartis will be responsible for [***] of all Development Costs, in each case for the Development of all Regional Antibody Candidates or Regional Licensed Products during the Late RLP Development Term. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis Development</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will use Commercially Reasonable</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Efforts to conduct its Development of each Regional Licensed Product in accordance with the applicable RLP Development Plan, as such RLP </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Development Plan may be amended in accordance with this Agreement, in sound scientific manner and in compliance with applicable Law. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface Development</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will use Commercially Reasonable Efforts</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to conduct its Development of each Regional Licensed Product for the Surface Territory in accordance with the applicable terms of the RLP Development Plan, as such RLP Development Plan may be amended in accordance with this Agreement, in sound scientific manner and in compliance with applicable Law. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.7.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Records; Reports; Information Sharing.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.7.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Development Activities Reports</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. </b><font style="font-family:'Times New Roman','Times','serif';">On a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Target-by-Regional Target basis, each Party will periodically provide to the JDC, on a [***] basis, or more frequently as reasonably requested by the JDC, an update regarding Development activities conducted by or on behalf of such Party with respect to Regional Antibody Candidates and Regional Licensed Products for such Regional Target, as well as any Supplemental Studies, Regional [***] Activities and Post-Marketing Studies conducted by or on behalf of such Party with respect to Regional Antibody Candidates and Regional Licensed Products for such Regional Target. The Parties will periodically report to the JDC, but in no event less than on a [***] basis, regarding their respective activities conducted under the RLP Development Plan for Regional Antibody Candidates and Regional Licensed Products for such Regional Target. In addition, each Party will promptly share with the other Party all material developments and information that it comes to possess relating to the Development of any Regional Antibody Candidates and Regional Licensed Products for such Regional Target, including (a) Safety Concerns for Regional Antibody Candidates or Regional Licensed Products, and (b) study reports and data generated from Clinical Studies of such Regional Antibody Candidates and Regional Licensed Products for such Regional Target; provided however, that excluding Safety Concerns or as required under the SDEA, a Party as Proposing Party will not be obligated to share any study reports and data generated from Clinical Studies for any Additional Development Activities (including Regional [***] Activities) conducted by or on behalf of the Proposing Party where the Non-Proposing Party has not exercised an Additional Development Opt-in Notice other than to permit the Non-Proposing Party data to determine whether to deliver an Additional Development Opt-In Notice in accordance with Section 5.2.2.4(d). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.7.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Scientific Records</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will maintain</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">scientific records, in sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in compliance with cGLP with respect to activities intended to be submitted in regulatory filings (including INDs and BLAs), which will fully and accurately reflect all work done and results achieved in the performance of the Development activities, Clinical Studies, Regional [***] Activities and Supplemental Studies with respect to Regional Antibody Candidates and Regional Licensed Products by such Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.7.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Information Exchange and Development</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Assistance</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Until the expiration or termination of the final RLP</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Development Plan, upon the reasonable request of the other Party, each Party will provide to the other Party, without additional compensation and in a commercially reasonable format, Know-How Controlled by such Party or its Related Parties that is licensed to the other Party under this Agreement (i.e., Know-How included in Novartis Technology for Novartis and Know-How included in Surface Technology for Surface) to the extent that it is reasonably necessary or useful for Development of Regional Antibody Candidates or Regional Licensed Products in the requesting Party&#8217;s Territory or for obtaining or maintaining Regulatory Approval for Regional Licensed Products in the requesting Party&#8217;s Territory, including copies of (a) all scientific information and data related to such Regional Antibody Candidates or Regional Licensed Products (including all data made, collected or otherwise generated in the conduct of any pre-clinical studies, Clinical Studies, Supplemental Studies or Regional [***] Activities for which a Party as Non- Proposing Party has exercised its Additional Development Opt-In Notice, or early access/named patient programs for the Regional Licensed Products, as well as CMC information), and (b) protocols and investigator brochures, in each case, that are reasonably necessary for the other Party (or its Related Parties) to perform its obligations or exploit its rights under this Agreement with respect to such Regional Antibody Candidates or Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.7.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Personnel</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party may request, through</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the JDC or the other Party&#8217;s Alliance Manager, that the other Party reasonably make available for consultation regarding the Development of such Regional Antibody Candidates or Regional Licensed Products certain of its employees engaged in Development activities and Supplemental Studies or Regional [***] Activities for which a Party as Non-Proposing Party has exercised its Additional Development Opt-In Notice, with respect to such Regional Antibody Candidates or Regional Licensed Products. The JDC or the Alliance Managers will reasonably coordinate, upon reasonable notice during normal business hours </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">and at their respective places of employment, consultation between the Parties on the progress of the Development for such Regional Antibody Candidates or Regional Licensed Products, including any Supplemental Studies or Regional [***] Activities for which a Party as Non-Proposing Party has exercised its Additional Development Opt-In Notice. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.8. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Third Parties.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">The Parties will be entitled to utilize the services of Third</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties to perform their respective Development under this Section 5.2, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) each Party will require that such Third Party operates in a manner consistent with this Agreement and reasonably acceptable to the other Party, (b) each Party will remain at all times fully liable for its respective responsibilities and (c) the Parties will make reasonable efforts to share, through the JDC, information regarding any prior experience with specific CROs that are anticipated to be engaged to perform work under the RLP Development Plan. Each Party will require that any Third Party agreement entered into pursuant to this Section 5.2.8 (x) include confidentiality and non-use provisions that are no less stringent than those set forth in Section 11.1 (but of duration customary in confidentiality agreements entered into for a similar purpose), other than Existing Novartis In-Licenses and the agreements listed on Schedule 12.2.1, each of which contains reasonable and customary confidentiality and non-use provisions; and (y) except as identified on Exhibit I, obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) under and to, any Know-How and Patents that are developed by such Third Party in the performance of such agreement and are reasonably necessary or useful to Research, Develop, Manufacture or Commercialize Regional Antibody Candidates or Regional Licensed Products in the Field. For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) shall not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Third Party or its Affiliates unless such improvements are reasonably necessary to Research, Develop, Manufacture or Commercialize those Antibody Candidates or Licensed Products with repect to which such Third Party or its Affiliate conducted its activities under such Third Party agreement. The Party utilizing the services of a Third Party service provider will be solely responsible for direction of and communications with such Third Party, but such Party will provide the other Party with reasonably detailed updates regarding any such activities from time to time. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.2.9. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Opt-Out Right</i><font style="font-family:'Times New Roman','Times','serif';">. On a Regional Target-by-Regional Target basis, at any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">time during the Early RLP Development Term or the Late RLP Development Term, Surface has the right, at its sole discretion, to opt-out of further Development and Commercialization of all Regional Antibody Candidates or Regional Licensed Products for such Regional Target upon [***] prior written notice to Novartis (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Opt-Out Notice</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Opt-Out Notice will clearly identify the applicable Regional Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and associated Regional Antibody Candidates and Regional Licensed Products. Upon the delivery of an Opt-Out Notice, Surface&#8217;s then on-going funding commitments and Development Activities, will continue until [***] from the date of the Opt-Out Notice. In the event that Surface delivers an Opt-Out Notice with respect to a Regional Target, the following will automatically occur (without any further action by the Parties) upon such date, (a) the Regional Target will convert to a Global Target, (b) all Regional Antibody Candidates and Regional Licensed Products will convert to Global Antibody Candidates and Global Licensed Products, respectively, (c) the licenses set forth in Section 9.2 will terminate, and (d) the licenses set forth in Section 9.3 will apply to such new Global Target, Global Antibody Candidates and Global Licensed Products. For the sake of clarity, Surface will not be reimbursed, in whole or in part, for any Development Costs incurred prior to the end of such [***] period with respect to the Regional Antibody Candidates or Regional Licensed Products for which an Opt-Out Right was exercised. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Antibody Candidates and Global Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Overview</i><font style="font-family:'Times New Roman','Times','serif';">. On a Global Target-by-Global Target basis: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be responsible for Development</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of all Global Antibody Candidates and Global Licensed Products in accordance with this Agreement and the Global Development Plan for such Global Target during the Early Global Development Term. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will be responsible for further</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Development of Global Antibody Candidates and Global Licensed Products in accordance with this Agreement and the Global Development Plan during the Late Global Development Term. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Global Development Plan</i><font style="font-family:'Times New Roman','Times','serif';">. On a Global Target-by-Global Target basis,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Development activities that are necessary or useful to be undertaken for the applicable Global Antibody Candidates or Global Licensed Products to achieve initial Regulatory Approval for each of the Indications selected by Novartis using Commercially Reasonable Efforts in the Major Market Countries (including the design of the initial Phase 1 Study) will be set forth in </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">reasonable detail in a written work plan and time table (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Development Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The initial Global Development Plan for each Global Target will be included in the Option IND Package for such Global Target provided by Surface to Novartis under Section 4.2.2. The terms of, and Development activities set forth in, each Global Development Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the pharmaceutical industry. Novartis will update the Global Development Plan for such Global Antibody Candidates and Global Licensed Products [***] and will provide such updated Global Development Plan to the JDC. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Transition</i><font style="font-family:'Times New Roman','Times','serif';">. On a Global Target-by-Global Target basis, by no later than</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">[***] Surface will prepare and provide to Novartis a draft plan for the transition of the Development of the Global Antibody Candidates and Global Licensed Products for such Global Target from Surface to Novartis (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Transition Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Global Transition Plan for each Global Target will require Surface to, as soon as reasonably practicable following the Research Term: (a) transfer to Novartis a copy of all Know-How Controlled by Surface that is reasonably necessary or useful for Development of Global Antibody Candidates or Global Licensed Products for such Global Target, or obtaining or maintaining Regulatory Approval for such Global Licensed Products in the Novartis Territory, including information and materials reasonably requested by Novartis, in a format reasonably acceptable to Novartis (which will be specified in such Global Transition Plan, along with the process of transferring such Know-How); (b) assign to Novartis all INDs and other Regulatory Materials submitted to, or filed with, any Regulatory Authority with respect to such Global Antibody Candidates or Global Licensed Products, including any drug master files maintained by or on behalf of Surface solely related thereto (provided however that Surface will not be required to transfer any drug master files maintained by or on behalf of any Third Party, including any contract manufacturer); (c) transfer to Novartis a copy of all written correspondence with any Regulatory Authority with respect to such Global Antibody Candidates or Global Licensed Products and all written minutes of meetings and memoranda of oral communications with any Regulatory Authority with respect to such Global Antibody Candidates or Global Licensed Products; and (d) transfer to Novartis any other a copy of information or materials reasonably requested by Novartis that are reasonably necessary or useful for Development of such Global Antibody Candidates or Global Licensed Products in the Novartis Territory, including if so reasonably requested by Novartis, and Third Party agreements relating solely thereto. The Global Transition Plan for each Global Target will also describe any Development activities with respect to Global Antibody Candidates or Global Licensed Products for such Global Target that Surface is required to perform as requested by Novartis and mutually agreed upon by the Parties (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Transition Activities</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Party will use Commercially Reasonable Efforts to perform the obligations assigned to it under the Global Transition Plan in accordance with any timelines set forth therein and, subject to Section 5.2.3.2, [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Diligence; Standards of Conduct.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">On a Global Target-by-Global Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">basis, Novartis will use Commercially Reasonable Efforts to (a) [***] and (b) perform all Development activities for the Global Antibody Candidates and Global Licensed Products for such Global Target in accordance with the Global Development Plan. On a Global Target-by-Global Target basis, Surface will use Commercially Reasonable Efforts to (x) [***] and (y) perform all Development activities for the Global Antibody Candidates and Global Licensed Products for such Global Target in accordance with the Global Development Plan that Surface agrees to perform at Novartis&#8217; request. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.5.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Development Costs</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.5.1. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to each Global Target, Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">will be responsible for [***] of all Development Costs for the Development of Global Antibody Candidates or Global Licensed Products for such Global Target during the Early Global Development Term. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.5.2. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to each Global Target, Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">will be responsible for [***] of all Development Costs for the Development of Global Antibody Candidates or Global Licensed Products for such Global Target during the Late Global Development Term. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Records; Reports; Information Sharing.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.6.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Development Activities; Reports</i><font style="font-family:'Times New Roman','Times','serif';">. On a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Global Target-by-Global Target basis and until the transition of Development to Novartis, each Party will periodically (a) provide to the JDC, on a [***] basis, an update regarding Development activities conducted by or on behalf of such Party with respect to Global Antibody Candidates or Global Licensed Products for such Global Target, and (b) report to the JDC, but in no event less than on a [***] basis, regarding their respective activities conducted under the Global Transition Plan for Global Antibody Candidates and Global Licensed Products for such Global Target. Following the transition period with respect to a </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Global Target, once per [***] Novartis will provide to Surface, through the JDC, an update regarding Development activities conducted by or on behalf of Novartis with respect to such Global Target Antibody Candidates and Global Licensed Product, as well as any Clinical Studies with respect to such Global Target Antibody Candidates and Global Licensed Product conducted by Novartis. The Parties will share any Safety Concerns with respect to such Global Antibody Candidates and Global Licensed Products in accordance with the SDEA. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.6.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Scientific Records</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party will maintain</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">scientific records, in sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in compliance with cGLP with respect to activities intended to be submitted in regulatory filings (including INDs and BLAs), which will reflect all material work done and results achieved in the performance of the Development activities and Clinical Studies with respect to Global Antibody Candidates and Global Licensed Products by such Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.6.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Information Exchange and Development</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Assistance</i><font style="font-family:'Times New Roman','Times','serif';">. Until the expiration or termination of the final</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Global Development Plan, upon the reasonable request of Novartis, Surface will provide to Novartis, without additional compensation and in a commercially reasonable format, a copy of Know-How Controlled by Surface or its Related Parties that is licensed to Novartis under this Agreement (i.e. Know-How included in Surface Technology for Surface) to the extent that it is reasonably necessary or useful for Development of Global Antibody Candidates or Global Licensed Products or for obtaining or maintaining Regulatory Approval for Global Licensed Products, including copies of (a) all scientific information and data related to such Global Antibody Candidates or Global Licensed Products (including all data made, collected or otherwise generated in the conduct of any pre-clinical studies, Clinical Studies, Supplemental Studies or early access/named patient programs for the Global Licensed Products, as well as CMC information), and (b) protocols and investigator brochures, in each case, that are reasonably necessary for Novartis (or its Related Parties) to perform its obligations or exploit its rights under this Agreement with respect to such Global Antibody Candidates or Global Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.6.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Personnel</i><font style="font-family:'Times New Roman','Times','serif';">. During the period commencing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">after the completion of the Global Transition Activities and ending upon Regulatory Approval of the first Global Licensed Product, Novartis may request that Surface reasonably make available for consultation regarding the Development of Global Antibody Candidates and Global Licensed Products certain of its employees engaged in Research and Development activities with respect to such Global Antibody Candidates and Global Licensed Products. Surface will reasonably cooperate with Novartis to provide (a) up to [***] hours of consultation without charge to Novartis, and (b) any additional hours of consultation as Novartis may reasonably request, for which Novartis will pay Surface a rate of [***] per hour of such consultation services. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">5.3.7. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Third Parties</i><font style="font-family:'Times New Roman','Times','serif';">. The Parties will be entitled to utilize the services of Third</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties to perform their respective Development under this Section 5.3.7, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) each Party will require that such Third Party operates in a manner consistent with the terms of this Agreement and, in the case of Surface, reasonably acceptable to Novartis and (b) each Party will remain at all times fully liable for its respective responsibilities. Each Party will require that any such Third Party agreement entered into pursuant to this Section 5.3.7 (x) include confidentiality and non-use provisions that are no less stringent than those set forth in Section 11.1 (but of duration customary in confidentiality agreements entered into for a similar purpose), other than Existing Novartis In-Licenses and the agreements listed on Schedule 12.2.1, each of which contains reasonable and customary confidentiality and non-use provisions; and (y) except as identified on Exhibit I, obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) under and to, any Know-How and Patents that are developed by such Third Party in the performance of such agreement and are reasonably necessary or useful to Research, Develop, Manufacture or Commercialize Global Antibody Candidates or Global Licensed Products in the Field. For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) shall not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Third Party or its Affiliates unless such improvements are reasonably necessary to Research, Develop, Manufacture or Commercialize those Antibody Candidates or Licensed Products with respect to which such Third Party or its Affiliate conducted its activities under such Third Party agreement. The Party utilizing the services of a Third Party service provider will be solely responsible for direction of and communications with such Third Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6</b><font style="font-family:'Times New Roman','Times','serif';">. </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">COMMERCIALIZATION</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T1 Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Responsibility, Cost and Diligence</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will be solely responsible, at</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">its expense, for all Commercialization activities relating to T1 Licensed Products in the Field in the Novartis Territory. Novartis will </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">use Commercially Reasonable Efforts to (a) Commercialize each T1 Licensed Product for which Novartis has obtained Regulatory Approval within the Novartis Territory, and (b) perform all Commercialization activities for T1 Licensed Products in accordance with the T1 Commercialization Plan. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Commercialization Plan</i><font style="font-family:'Times New Roman','Times','serif';">. No less than [***], and [***] thereafter, Novartis will prepare and deliver to Surface, through the JSC, (a) a high level summary of the Commercialization and Development Activities performed with respect to such T1 Licensed Product in the Novartis Territory during the just-completed Calendar Year and (b) a high level summary of the Commercialization and Development activities to be undertaken with respect to such T1 Licensed Product in the then-current Calendar Year, including any plans to obtain further Regulatory Approvals and launch such T1 Licensed Products in countries in the Novartis Territory in which Novartis is not then Commercializing such T1 Licensed Products, and the dates by which any such activities are targeted to be accomplished (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">First Commercial Sale Reporting Obligations</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to each T1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product, Novartis will provide Surface with written notice of the First Commercial Sale of such T1 Licensed Product in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Advertising and Promotional Materials</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.4.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Branding</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will have the sole</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">right, from time to time during the Term, to develop (and thereafter modify and update) a global branding strategy (including global positioning, messages, logo, colors and other visual branding elements) for each T1 Licensed Product for use in the Field throughout the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.4.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Promotional Materials</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for the creation, preparation, production, reproduction and filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each T1 Licensed Product for use in the Novartis Territory. All such Promotional Materials will be compliant with applicable Law. If permitted under applicable Law, Novartis will include a reference in such TI Promotional Materials to such T1 Licensed Product as being sold under license from Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sales and Distribution</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis and its Related Parties will be solely</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for booking sales and will warehouse and distribute T1 Licensed Products in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.1.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recalls, Market Withdrawals or Corrective Actions</i><font style="font-family:'Times New Roman','Times','serif';">. In the event that any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regulatory Authority issues or requests a recall or takes a similar action in connection with a T1 Licensed Product, Novartis will have the sole right to decide whether to conduct a recall and the manner in which any such recall will be conducted. [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regional Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Responsibility, Cost and Diligence</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">On a Regional Target-by-Regional Target basis, Novartis will be solely responsible, at its expense, for all Commercialization activities relating to Regional Licensed Products in the Field in the Novartis Territory. On a Regional Target-by-Regional Target basis, Novartis will use Commercially Reasonable Efforts to (a) Commercialize each Regional Licensed Product for which Novartis has obtained Regulatory Approval within the Novartis Territory, and (b) perform all Commercialization activities for such Regional Licensed Product in accordance with the RLP Commercialization Strategy. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">On a Regional Target-by-Regional</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, Surface will be solely responsible, at its expense, for all Commercialization activities relating to Regional Licensed Products in the Field in the Surface Territory. On a Regional Target-by-Regional Target basis, Surface will use Commercially Reasonable Efforts to (a) Commercialize each Regional Licensed Product for which Surface has obtained Regulatory Approval within the Surface Territory, and (b) perform all Commercialization activities for each Regional Licensed Product in accordance with the RLP Commercialization Strategy. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">RLP Commercial Strategy.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Within [***] Novartis will provide and within [***] days after such provision the JCC will, subject to applicable Law including Antitrust Laws, review, update and approve a written summary of the global Commercial strategy for such Regional Licensed Product (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercial Strategy</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). For clarity, any and all such communications and strategy</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">involving the Commercialization of Regional Licensed Products shall be limited to those permitted under applicable Law, including Antitrust Laws. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis Territory Commercialization Plan.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">No less than [***] Novartis will prepare and deliver to the JCC for review a reasonable written plan that summarizes the Commercialization activities to be undertaken with respect to such Regional Licensed Product in the Novartis Territory in the next Calendar Year (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Territory Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Novartis Territory Commercialization Plan for a Regional Licensed Product will subsequently be updated and modified by Novartis, from time to time at its discretion and no less frequently than [***] based upon, among other things, Novartis&#8217;s Commercialization activities with respect to such Regional Licensed Product in the Novartis Territory, a copy of which updated plan Novartis will provide to the JCC. Notwithstanding the foregoing, in the event of any disagreement between the Parties regarding the Novartis Territory Commercialization Plan for a Regional Licensed Product pursuant to Section 2.5.5, the Novartis representatives on the JCC will have final decision-making authority over the preparation and updating of such Novartis Territory Commercialization Plan, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such decisions do not materially adversely affect the Commercialization of such Regional Licensed Product in the Surface Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface Territory Commercialization Plan.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">No less than [***] Surface will prepare and deliver to the JCC for review a reasonable written plan that summarizes the Commercialization activities to be undertaken with respect to such Regional Licensed Product in the Surface Territory in the next Calendar Year (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Territory Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Surface Territory Commercialization Plan for a Regional Licensed Product will subsequently be updated and modified by Surface, from time to time at its discretion and no less frequently than [***] based upon, among other things, Surface&#8217;s Commercialization activities with respect to such Regional Licensed Product in the Surface Territory, a copy of which updated plan Surface will provide to the JCC. Notwithstanding the foregoing, in the event of any disagreement between the Parties regarding the Surface Territory Commercialization Plan for a Regional Licensed Product pursuant to Section 2.5.5, the Surface representatives on the JCC will have final decision-making authority over the preparation and updating of such Surface Territory Commercialization Plan, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such decisions do not materially adversely affect the Commercialization of such Regional Licensed Product in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.5.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Advertising and Promotional Materials</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.5.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">RLP Branding.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will use</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Commercially Reasonable Efforts to develop (and thereafter modify and update) a branding strategy (including positioning, colors, other visual branding elements and Novartis RLP Trademarks and Surface RLP Trademarks in accordance with Section 14.9.2) for each Regional Licensed Product for use in the Field for its Territory (each a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Branding Strategy</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), which the JCC will, in accordance with Sections 2.5.3.3 and 2.5.5, review, coordinate and approve, and which the Parties will, following such review and approval, implement. Each Party will submit its RLP Branding Strategy for a Regional Licensed Product to the JCC at least [***] (or more frequently if reasonably requested by the other Party). Each Party will consider in good faith any timely comments by the other Party with respect to its RLP Branding Strategy, but will have final decision-making authority with respect to such its RLP Branding Strategy in its Territory. Notwithstanding the foregoing, each Party will use Commercially Reasonable Efforts to ensure that (a) its RLP Branding Strategy complies with applicable Laws in its Territory, and (b) that any branding elements selected for inclusion in its RLP Branding Strategy do not infringe any Third Party trademarks or other intellectual property rights. If any such RLP Branding Strategy infringes Third Party trademarks or other intellectual property rights or otherwise does not comply with applicable Law in the Territory in which such RLP Branding Strategy is used, the affected Party will take action to end such infringement or other noncompliance (including by modifying its RLP Branding Strategy) in its Territory and the other Party will not be obligated to implement its RLP Branding Strategy in its Territory pursuant to this Section unless and until such infringement or noncompliance is ended. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.5.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface A&amp;P.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be responsible</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for the creation, preparation, production, reproduction and filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each Regional Licensed Product (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Promotional Materials</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) for use in the Surface Territory. All such Promotional Materials will be compliant with applicable Law and, if applicable, consistent in all material respects with the Surface Territory Commercialization Plan and, if applicable, consistent in all material respects with the RLP Branding Strategy for such Regional Licensed Product in the Surface Territory. Surface will submit representative samples of its Promotional Materials developed by it for use in the Surface Territory to the JCC at least [***] (or more frequently if reasonably requested by Novartis). Surface will consider in good faith any timely comments Novartis may have with respect to any such Promotional Materials, but will have final decision-making authority in the Surface Territory with respect to such Promotional Materials. Notwithstanding the foregoing, Surface will incorporate any changes to Promotional Materials requested by Novartis in a timely fashion in cases where Novartis </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">indicates that it believes in good faith that such change is necessary to enable Novartis to comply with any applicable Law. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.5.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis A&amp;P.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will be responsible</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for the creation, preparation, production, reproduction and filing with the applicable Regulatory Authorities, of relevant Promotional Materials relating to each Regional Licensed Product for use in the Novartis Territory. All such Promotional Materials will be compliant with applicable Law, consistent in all material respects with the Novartis Territory Commercialization Plan and, if applicable, consistent in all material respects with the RLP Branding Strategy for such Regional Licensed Product in the Novartis Territory. Novartis will submit representative samples of its Promotional Materials developed by it for use in the Novartis Territory to the JCC at least [***] thereafter (or more frequently if reasonably requested by Surface). Novartis will consider in good faith any timely comments Surface may have with respect to any such Promotional Materials, but will have final decision-making authority in the Novartis Territory with respect to such Promotional Materials. Notwithstanding the foregoing, Novartis will incorporate any changes to Promotional Materials requested by Surface in a timely fashion in cases where Surface indicates that it believes in good faith that such change is necessary to enable Surface to comply with any applicable Law. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.5.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Reporting Obligations.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">report to the JCC in writing, on an [***] basis in the first [***] following the first Regulatory Approval of such Regional Licensed Product in the Field in such Party&#8217;s Territory (for the period ending December 31 of the prior Calendar Year), summarizing in reasonable detail such Party&#8217;s Commercialization activities for such Regional Licensed Product performed to date (or updating such report for activities performed since the last such report was given hereunder, as applicable). In addition, each Party will provide the other Party with written notice of the First Commercial Sale of each Regional Licensed Product in such Party&#8217;s Territory as soon as reasonably practicable after such event; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that such Party will inform the other Party of such event prior to public disclosure of such event by such Party. Each Party will provide such other information to the JCC as the other Party may reasonably request with respect to Commercialization of such Regional Licensed Product and will keep such JCC reasonably informed of such Party&#8217;s Commercialization activities with respect to such Regional Licensed Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Commercialization Reporting Obligations.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party and its Related</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties will be responsible for booking sales of the Regional Licensed Products sold in its Territory. Each Party and its Related Parties may warehouse Regional Licensed Products both inside and outside of such Party&#8217;s Territory, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that any sales with respect to such Regional Licensed Products are booked in such Party&#8217;s Territory. If a Party receives any orders for any Regional Licensed Product in the other Party&#8217;s Territory, it will refer such orders to the other Party, to the extent it is not prohibited from doing so under applicable Law. Moreover, each Party and its Related Parties will, using Commercially Reasonable Efforts, be solely responsible for handling all returns of any Regional Licensed Product sold in its Territory, as well as all aspects of Regional Licensed Product order processing, invoicing and collection, distribution, inventory and receivables of Regional Licensed Products sold in its Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.7. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recalls, Market Withdrawals or Corrective Actions.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">In the event that any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regulatory Authority issues or requests a recall or takes a similar action in connection with a Regional Licensed Product in a Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal of a Regional Licensed Product in its Territory, the Party notified of such recall or similar action, or the Party that desires such recall or similar action, will as promptly as possible, notify the other Party&#8217;s Alliance Manager and JCC representatives thereof by telephone or e-mail. Each Party, in consultation with the other Party, will decide whether to conduct a recall of a Regional Licensed Product in its own Territory and the manner in which any such recall will be conducted (except in the case of a government mandated recall, when such Party may act without such advance notice but will notify the other Party as soon as possible thereafter). Except as may otherwise be agreed to by the Parties, [***] Each Party will make available all of its pertinent records that may be reasonably requested by the other Party in order for a Party to effect a recall of a Regional Licensed Product in its Territory. The Parties&#8217; rights and obligations under this Section 6.2.7 will be subject to the terms of any supply agreement(s), including any SDEA or quality related agreements entered into between the Parties. In the event of a conflict between the provisions of any such supply agreement, SDEA or quality related agreements and this Section 6.2.7, the provisions of such supply agreement, SDEA or quality related agreements will govern. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.8.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Ex-Territory Sales; Export Monitoring.</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.8.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Ex-Territory Sales.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Subject to applicable</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Law, neither Party will engage in any advertising or promotional activities relating to any Regional Licensed Product directed primarily to customers or other buyers or users of such Regional Licensed Product located outside its Territory or accept orders for Regional Licensed Products from or sell Regional Licensed Products into such other Party&#8217;s Territory for its own account, and if a Party receives any order for any Regional Licensed Product in the other Party&#8217;s Territory, it will refer such orders to the other Party. The Parties expressly acknowledge and agree that applicable Law may prevent or limit a Party from taking action to prevent exports from one EU country to another. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.8.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Export Monitoring.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party and its</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Related Parties will use Commercially Reasonable Efforts to monitor and prevent exports of Regional Licensed Products from its own Territory for Commercialization in the other Party&#8217;s Territory using methods permitted under applicable Law that are commonly used in the industry for such purpose (if any), and will promptly inform the other Party of any such exports of Regional Licensed Products from its Territory, and any actions taken to prevent such exports. Each Party agrees to take reasonable actions requested in writing by the other Party that are consistent with applicable Law to prevent exports of Regional Licensed Products from its Territory for Commercialization in the other Party&#8217;s Territory. The Parties expressly acknowledge and agree that applicable Law may prevent or limit a Party from taking action to prevent exports from one EU country to another. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.2.9. Combinations</b><font style="font-family:'Times New Roman','Times','serif';">. Net Sales received by the Parties or their respective</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Related Parties in respect of certain Combinations in the Surface Territory shall be allocated between the Parties in accordance with the provisions of Exhibit A. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Responsibility, Cost and Diligence</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will be solely responsible, at</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">its expense, for all Commercialization activities relating to Global Licensed Products in the Field in the Novartis Territory. Novartis will use Commercially Reasonable Efforts to (a) Commercialize each Global Licensed Product for which Novartis has obtained Regulatory Approval in the Novartis Territory, and (b) perform all Commercialization activities for each Global Licensed Product in accordance with the Global Licensed Product Commercialization Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Commercialization Plan</i><font style="font-family:'Times New Roman','Times','serif';">. No less than [***] and [***] thereafter, Novartis will prepare and deliver to Surface, through the JSC, (a) a high level summary of the Commercialization activities performed with respect to such Global Licensed Product in the Novartis Territory during the just-completed Calendar Year, and (b) a high level summary of the Commercialization activities to be undertaken with respect to such Global Licensed Product in the then-current Calendar Year (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Licensed Product</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercialization Plan</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">First Commercial Sale Reporting Obligations</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to a Global</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product, Novartis will provide Surface with written notice of the First Commercial Sale of such Global Licensed Product in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Advertising and Promotional Materials</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.4.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Global Licensed Product Branding</i><font style="font-family:'Times New Roman','Times','serif';">.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will have the sole right, from time to time during the Term, to develop (and thereafter modify and update) a global branding strategy (including global positioning, messages, logo, colors and other visual branding elements) for each Global Licensed Product for use in the Field throughout the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.4.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Promotional Materials</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for the creation, preparation, production, reproduction and filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each Global Licensed Product for use in the Novartis Territory. All such Promotional Materials will be compliant with applicable Law. If permitted under applicable Law, Novartis will include a reference in such Global Licensed Promotional Materials to such Global Licensed Product as being sold under license from Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sales and Distribution</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis and its Related Parties will be solely</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for booking sales and will warehouse and distribute Global Licensed Products in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">6.3.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Recalls, Market Withdrawals or Corrective Actions</i><font style="font-family:'Times New Roman','Times','serif';">. In the event that any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regulatory Authority issues or requests a recall or takes a similar action in connection with a Global Licensed Product, Novartis will have the sole right to decide whether to conduct a recall and the manner in which any such recall will be conducted. [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7. REGULATORY </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T1 Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regulatory Filings and Interactions</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Ownership of Regulatory Filings</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">will own all INDs, NDAs, Regulatory Materials and related regulatory documentation with respect to any T1 Licensed Product, including any drug master files maintained by or on behalf of Surface solely with respect thereto (provided however that Surface will not be obligated to transfer any drug master files maintained by or on behalf of any Third Party, including any contract manufacturer). At Novartis&#8217;s request following [***] for the T1 Research Program, Surface will promptly assign and transfer to Novartis all INDs, Regulatory Materials and other regulatory documentation in the Novartis Territory with respect to such T1 Licensed Product that is in the possession or control of Surface, including any drug master files maintained by or on behalf of Surface solely with respect thereto, and each Party will submit all filings, letters and other documentation necessary to effect such assignment and transfer to the applicable Regulatory Authority as soon as reasonably practicable, but no later than [***] after such request for such T1 Licensed Product. For clarity, Surface will not be required to transfer any drug master files maintained by or on behalf of any Third Party, including any contract manufacturer; provided that Novartis has access to or rights to cross-reference those drug master files pursuant to Section 7.1.3 to permit Novartis to comply with its regulatory obligation in connection with the Research, Development, Manufacture, and Commercialization of T1 Licensed Products. Surface hereby appoints Novartis as Surface&#8217;s agent for all matters related to each T1 Licensed Product involving Regulatory Authorities in the Novartis Territory during the period beginning on the Effective Date for the T1 Licensed Product and ending on the date that the transfer of all INDs, Regulatory Materials and related regulatory documents in the Novartis Territory that relate to such T1 Licensed Product, including any drug master files maintained by or on behalf of Surface solely with respect thereto, becomes effective, and Novartis hereby accepts such appointment. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Responsibilities for Regulatory Matters</i><font style="font-family:'Times New Roman','Times','serif';">.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will, using Commercially Reasonable Efforts, be solely responsible for all regulatory matters relating to T1 Licensed Products in the Novartis Territory, including (a) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority in the Novartis Territory with respect to T1 Licensed Products; (b) interfacing, corresponding and meeting with each Regulatory Authority in the Novartis Territory with respect to T1 Licensed Products; and (c) seeking and maintaining all Regulatory Materials in the Novartis Territory with respect to T1 Licensed Products. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Communications with Regulatory</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Authorities</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will provide Surface, through the JDC, as</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">part of the [***] updates regarding Development activities described in Section 5.1.6.1, with a brief description in English, of the principal issues raised in any material communication with any Regulatory Authority in the Novartis Territory with respect to any T1 Licensed Product during the preceding Calendar Quarter. For purposes of this Section 7.1.1.3, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">material communication</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; with Regulatory Authorities include meetings with Regulatory Authorities and Regulatory Authority questions or concerns regarding significant issues, including any of the following: key product quality attributes (e.g., purity), safety findings affecting the platform (e.g., Serious Adverse Events, emerging safety signals), clinical or nonclinical findings affecting patient safety, or lack of efficacy. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.1.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regulatory Meetings.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will use</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Commercially Reasonable Efforts, to the extent reasonably practicable, to permit Surface to have, at Surface&#8217;s expense, mutually acceptable representatives of Surface attend, solely as a non-participating observer, material, substantive meetings including pre-IND meetings, with the Governmental Authorities pertaining to Research of such T1 Licensed Product; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that (a) if required by the Governmental Authority, attendance by Surface will be permitted; (b) attendance by Surface representatives will not prevent participation of a Novartis representative due to restrictions imposed by Regulatory Agencies on the number of attendees; and (c) Novartis will not be obligated to change the schedule of such meeting in order to accommodate the schedule of Surface&#8217;s representatives. Novartis will provide Surface, through the JDC, with [***] updates of substantive meetings with the Governmental Authorities in the Novartis Territory pertaining to the Development of each T1 Licensed Product. For clarity, Novartis has the right to attend, at Novartis&#8217; expense, any material, substantive meetings held by or on behalf of Surface, including pre-IND meetings, with the Governmental Authorities pertaining to such T1 Licensed Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.1.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Submissions</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to each T1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product, Novartis will provide Surface with written notice of each of the following events (a) within a reasonable period of time after the occurrence of such event in the Novartis Territory: (i); the submission of any filings or applications for Regulatory Approval (other than INDs) of such T1 </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Licensed Product to any Regulatory Authority; and (ii) receipt or denial of Regulatory Approval for such T1 Licensed Product; and (b) on a [***] basis, a summary of any INDs (including orphan drug applications and designations) that were filed for such T1 Licensed Product during such preceding [***] and those anticipated to be filed within the upcoming [***] provided, however, that Novartis will inform Surface of any such events under (a) or (b) prior to public disclosure of such event by Novartis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Costs of Regulatory Affairs</i><font style="font-family:'Times New Roman','Times','serif';">. [***] costs and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">expenses incurred in connection with applying for Regulatory Approval with respect to T1 Licensed Products in the Novartis Territory, and related regulatory affairs activities. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Right of Reference</i><font style="font-family:'Times New Roman','Times','serif';">. Surface hereby grants to Novartis, and at the request</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of Novartis will grant to Novartis&#8217;s Related Parties, a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or early access/named patient programs for the T1 Licensed Products) included in or used in support of any drug master file maintained by or on behalf of Surface (including its Related Parties) that relates to any T1 Licensed Product to the extent necessary or useful to Research, Develop, Manufacture or Commercialize T1 Licensed Products in the Novartis Territory. Notwithstanding anything to the contrary in this Agreement, Surface will not withdraw or inactivate any regulatory filing that Novartis or its Related Parties reference or otherwise use pursuant to this Section 7.1.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regional Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regulatory Filings and Interactions</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.1.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Responsibilities</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Pursuant to the RLP Development Plan for a Regional Licensed Product and, except as otherwise provided in such RLP Development Plan, or set forth in Section 7.2.1.1(b) below, each Party will be solely responsible for all regulatory matters relating to such Regional Licensed Product in its Territory and will own all INDs, NDAs, Regulatory Materials and related regulatory documents in its Territory with respect to such Regional Licensed Product, including any drug master files maintained by or on behalf of such Party solely with respect thereto in such Territory, which will be and remain such Party&#8217;s sole responsibility. At Novartis&#8217;s request, [***] for a Regional Licensed Product, Surface will promptly assign and transfer to Novartis all INDs, Regulatory Materials and other regulatory documentation in the Novartis Territory with respect to such Regional Licensed Product that is in the possession and control of Surface, and each Party will submit to the applicable Regulatory Authority all filings, letters and other documentation necessary to effect such assignment and transfer as soon as practicable and no later than [***] after such request for such Regional Licensed Product, in each case, including any drug master files maintained by or on behalf of Surface solely with respect thereto. For clarity, Surface will not be required to transfer any drug master files maintained by or on behalf of any Third Party, including any contract manufacturer; provided that Novartis has access to or rights to cross-reference those drug master files pursuant to Section 7.2.3 to permit Novartis to comply with its regulatory obligation in connection with the Research, Development, Manufacture, and Commercialization of Regional Licensed Products. Each Party will have the sole right to (i) oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority in its Territory with respect to such Regional Licensed Product; (ii) interface, correspond and meet with each Regulatory Authority in its Territory with respect to such Regional Licensed Product, and (iii) seek and maintain all regulatory filings in its Territory with respect to such Regional Licensed Product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) Notwithstanding the foregoing, and solely with respect to the first Phase 1 Safety Study conducted under a RLP Development Plan, Surface will have the right, but not the obligation, to draft the protocol, develop the IND strategy, and file INDs globally, including in the Novartis Territory, after input and review by Novartis, and, if Surface exercises such right, Surface will use reasonable efforts to address any concerns raised by Novartis in connection with such activities. If Surface files INDs in the Novartis Territory as set forth above, then, unless otherwise agreed by the Parties, promptly following [***] Surface will assign the INDs in the Novartis Territory to Novartis and from that point forward, Novartis will be primarily responsible for the related regulatory activities with respect thereto in the Novartis Territory. Novartis will reimburse Surface for its portion of Development Costs incurred by Surface in accordance with Section 5.2.3.2 with respect to the performance of activities described in this Section 7.2.1.1, including drafting protocols, developing IND strategies and preparing and submitting INDs. If Surface does not exercise such right to file INDs in the Novartis Territory, then Novartis will draft the protocol, develop the IND strategy, and file the INDs in the Novartis Territory. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Communications with Regulatory Authorities. </i><font style="font-family:'Times New Roman','Times','serif';">Each Party will</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">notify the JDC, including a brief description in English, of the principal issues raised in each material communication with Regulatory Authorities with respect to such Regional Licensed Product within [***] after receipt thereof. Upon request, each Party will provide to the other Party: (a) at the requesting Party&#8217;s expense, a summary translation of such material communications in English, (b) at the requesting Party&#8217;s expense, complete copies of the original correspondence in their native language, or (c) at the requesting Party&#8217;s expense, a full translation of such material communications in English, in each case of (a) through (c) within a reasonable period of time following such request. For the purposes of this Section 7.2, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">material communications</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; with Regulatory Authorities include meetings with Regulatory Authorities and Regulatory Authority questions or concerns with respect to significant issues, including any of the following: key product quality attributes (</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">e.g</i><font style="font-family:'Times New Roman','Times','serif';">., purity), safety findings affecting the platform (</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">e.g.</i><font style="font-family:'Times New Roman','Times','serif';">, Serious Adverse Events, emerging safety signals), clinical or nonclinical findings affecting patient safety, lack of efficacy or receipt or denial of Regulatory Approval. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regulatory Meetings.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">provide the other Party with reasonable advance notice of all substantive meetings with the Governmental Authorities in its Territory pertaining to each Regional Licensed Product, or with as much advance notice as practicable under the circumstances. Each Party will use Commercially Reasonable Efforts, to the extent reasonably practicable, to permit the other Party to have, at the other Party&#8217;s expense, mutually acceptable representatives of the other Party attend, solely as a non-participating observer, material, substantive meetings, including pre-IND and end of Phase 2 Study meetings, with the Governmental Authorities within either its or the other Party&#8217;s Territory pertaining to such Regional Licensed Product; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that (a) if required by the Governmental Authority, attendance by the other Party will be permitted; (b) attendance by the representatives of the other Party will not prevent participation of a representative of the Party in charge of its Territory due to restrictions imposed by Regulatory Agencies on the number of attendees; and (c) neither Party will be obligated to change the schedule of such meeting in order to accommodate the schedule of the other Party&#8217;s representatives. In the event that Surface exercises its rights pursuant to Section 7.2.1.1 to files INDs in the Novartis Territory, then prior to the acceptance or approval of the IND, Surface will provide Novartis with reasonable advance notice of all substantive meetings with Regulatory Authorities in the Novartis Territory pertaining to such Regional Licensed Product, or with as much advance notice as practicable under the circumstances. Surface will use reasonable efforts, to the extent reasonably practicable, to permit Novartis to have, at Novartis&#8217;s expense, mutually acceptable representatives of Novartis to attend, as full and equal participants, material, substantive meetings, including pre-IND meetings, with Regulatory Authorities in the Novartis Territory pertaining to such Regional Licensed Product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Submissions.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will provide the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">other Party with written notice of each of the following events with regard to each Regional Licensed Product (a) within a reasonable period of time following the occurrence thereof, to the extent notice was not provided prior to the Option Exercise Date for such Regional Licensed Product: (i) the submission of any filings or applications for Regulatory Approval (other than INDs) of such Regional Licensed Product in such Party&#8217;s Territory to any Regulatory Authority; and (ii) receipt or denial of Regulatory Approval for such Regional Licensed Product; and (b) on a [***] basis, a summary of any INDs (including orphan drug applications and designations) that were filed for such Regional Licensed Product during such preceding [***] and those anticipated to be filed within the upcoming [***] </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that each Party will inform the other Party of such event under (a) or (b) prior to public disclosure of such event by such Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Costs of Regulatory Affairs</i><font style="font-family:'Times New Roman','Times','serif';">. Except as provided in Section 5.3.5, [***] costs and expenses incurred in connection with applying for, obtaining and maintaining Regulatory Approval with respect to Regional Licensed Products in its Territory, and related regulatory affairs activities. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Right of Reference.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Each Party hereby grants to the other Party, and at the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">request of the other Party will grant to the other Party&#8217;s Related Parties, a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or upon exercise of the Additional Development Opt-In Right, Supplemental Studies or Regional [***] Activities, or early access/named patient programs for the Regional Licensed Products) included in or used in support of any regulatory filing, Regulatory Approval, drug master file or other regulatory documentation (including orphan drug applications and designations) maintained on behalf of such Party (or its Related Parties) that relates to any Regional Licensed Product, to the extent necessary or useful to obtain Regulatory Approval of a Regional Licensed Product in the Novartis Territory or the Surface Territory, as </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">applicable, and such Party will provide a signed statement to this effect, if requested by the other Party, in accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any successor or analogous Law outside of the United States). In addition, upon reasonable request of either Party (on behalf of itself or a Sublicensee), the other Party will obtain and provide to the requesting Party certificates or other formal or official attestations concerning the regulatory status of the Regional Licensed Products in the Novartis Territory or the Surface Territory, as applicable (e.g., Certificates of Free Sale, Certificates for Export, Certificates to Foreign Governments), at the requesting Party&#8217;s request, and provided further that such attestations are reasonably necessary for the requesting Party to exercise its rights under this Agreement. Notwithstanding anything to the contrary in this Agreement other than for Safety Concerns, neither Party will withdraw or inactivate any regulatory filing that the other Party references or otherwise uses pursuant to this Section 7.2.3. For clarity, the benefit of any regulatory vouchers [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regulatory Filings and Interactions</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Ownership of Regulatory Filings</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">will own all INDs, NDAs, Regulatory Materials and related regulatory documentation submitted to any Regulatory Authority with respect to any Global Licensed Product, including any drug master files maintained by or on behalf of Surface solely with respect thereto. At Novartis&#8217;s request following [***] for a Global Licensed Product, Surface will promptly assign and transfer to Novartis all INDs, Regulatory Materials and other regulatory documentation in the Novartis Territory with respect to such Global Licensed Product that is in the possession or control of Surface, including any drug master files maintained by or on behalf of Surface solely with respect thereto, and each Party will submit all filings, letters and other documentation necessary to effect such assignment and transfer to the applicable Regulatory Authority as soon as reasonably practicable, but no later than [***] after such request for such Global Licensed Product. For clarity, Surface will not be required to transfer any drug master files maintained by or on behalf of any Third Party, including any contract manufacturer; provided that Novartis has access to or rights to cross-reference those drug master files pursuant to Section 7.3.3 to permit Novartis to comply with its regulatory obligation in connection with the Research, Development, Manufacture, and Commercialization of Global Licensed Products. Surface hereby appoints Novartis as Surface&#8217;s agent for all matters related to each Global Licensed Product involving Regulatory Authorities in the Novartis Territory during the period beginning on the Option Exercise Date for such Global Licensed Product and ending on the date that the transfer of all INDs, Regulatory Materials and related regulatory documents in the Novartis Territory that relate to such Global Licensed Product, including any drug master files maintained by or on behalf of Surface solely with respect thereto, becomes effective, and Novartis hereby accepts such appointment. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Responsibilities for Regulatory Matters</i><font style="font-family:'Times New Roman','Times','serif';">.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will, using Commercially Reasonable Efforts, be solely responsible for all regulatory matters relating to Global Licensed Products in the Novartis Territory, including (i) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority in the Novartis Territory with respect to Global Licensed Products; (ii) interfacing, corresponding and meeting with each Regulatory Authority in the Novartis Territory with respect to Global Licensed Products; and (iii) seeking and maintaining all Regulatory Materials in the Novartis Territory with respect to Global Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Communications with Regulatory</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Authorities</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will provide Surface, through the JDC, as</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">part of the [***] updates regarding Development activities described in Section 5.3.6.1, with a brief description in English, of the principal issues raised in any material communication with any Regulatory Authority in the Novartis Territory with respect to any Global Licensed Product during the preceding Calendar Quarter. For purposes of this Section 7.3.1.3, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">material communication</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; with Regulatory Authorities include meetings with Regulatory Authorities and Regulatory Authority questions or concerns regarding significant issues, including any of the following: key product quality attributes (e.g., purity), safety findings affecting the platform (e.g., Serious Adverse Events, emerging safety signals), clinical or nonclinical findings affecting patient safety, or lack of efficacy. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.1.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regulatory Meetings.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will use</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Commercially Reasonable Efforts, to the extent reasonably practicable, to permit Surface to have, at Surface&#8217;s expense, mutually acceptable representatives of Surface attend, solely as a non-participating observer, material, substantive meetings, including pre-IND meetings, with the Governmental Authorities pertaining to Research of such Global Licensed Product should such meetings be deemed necessary by Novartis; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that (a) if required by the Governmental Authority, attendance by Surface will be permitted; (b) attendance by Surface representatives will not prevent participation of a Novartis representative due to restrictions imposed by Regulatory Agencies on the number of attendees; and (c) Novartis will </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">not be obligated to change the schedule of such meeting in order to accommodate the schedule of Surface&#8217;s representatives. Novartis will provide Surface, through the JDC, with [***] updates of substantive meetings with the Governmental Authorities in the Novartis Territory pertaining to the Development of each Global Licensed Product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.1.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Submissions</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to each Global</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product, Novartis will provide Surface with prompt written notice of each of the following events (a) within a reasonable period of time after the occurrence of such event in the Novartis Territory: (i) the submission of any filings or applications for Regulatory Approval (other than INDs) of such Global Licensed Product to any Regulatory Authority; and ii) receipt or denial of Regulatory Approval for such Global Licensed Product; and (b) on a [***] basis, a summary of any INDs (including orphan drug applications and designations) that were filed for such Global Licensed Product during such preceding [***] and those anticipated to be filed within the upcoming [***] provided, however, that Novartis will inform Surface of any such events under (a) or (b) prior to public disclosure of such event by Novartis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Costs of Regulatory Affairs</i><font style="font-family:'Times New Roman','Times','serif';">. Except as set forth in Section 5.3.5, [***] incurred in connection with applying for Regulatory Approval with respect to Global Licensed Products in the Novartis Territory, and related regulatory affairs activities. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Right of Reference</i><font style="font-family:'Times New Roman','Times','serif';">. Surface hereby grants to Novartis, and at the request</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of Novartis will grant to Novartis&#8217;s Related Parties, a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or early access/named patient programs for the Global Licensed Products) included in or used in support of any drug master file maintained on behalf of Surface or its Related Parties that relates to any Global Licensed Product to the extent necessary or useful to Research, Develop, Manufacture or Commercialize Global Licensed Products in the Novartis Territory. Notwithstanding anything to the contrary in this Agreement, Surface will not withdraw or inactivate any regulatory filing that Novartis or its Related Parties reference or otherwise use pursuant to this Section 7.3.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">7.4. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmacovigilance</b><font style="font-family:'Times New Roman','Times','serif';">. The Parties will cooperate with regard to the reporting and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">handling of safety information involving the Regional Antibody Candidates or Regional Licensed Products in accordance with the applicable regulatory Laws and regulations on pharmacovigilance and clinical safety. Within such time to ensure that all regulatory requirements are met, the Parties shall negotiate in good faith and enter into a Safety Data Exchange Agreement (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SDEA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), which will define the pharmacovigilance responsibilities of the Parties and include safety data exchange procedures to enable each Party (and their respective related Third Parties, if any) to comply with all of its legal and regulatory obligations related to such Regional Antibody Candidates or Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8. MANUFACTURE </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T1 Antibody Candidates and T1 Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Responsibilities</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to the oversight of the JRC, Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">has the sole responsibility to Manufacture (or have Manufactured) T1 Antibody Candidates for use in the T1 Research Program in accordance with the T1 Research Plan. Surface will Manufacture (or have Manufactured) such T1 Antibody Candidates in accordance with Novartis quality standards. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to the oversight of the JDC, Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">has the sole responsibility to Manufacture (or have Manufactured) T1 Antibody Candidates and T1 Licensed Products for use in the first Phase 1 Safety Study for the T1 Antibody Candidates and T1 Licensed Products in accordance with the T1 Development Plan. Surface will Manufacture (or have Manufactured) such T1 Antibody Candidates in accordance with Novartis quality standards. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.1.3. </b><font style="font-family:'Times New Roman','Times','serif';">Other than the first Phase 1 Safety Study for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the T1 Antibody Candidates and T1 Licensed Products, Novartis has the sole responsibility to Manufacture (or have Manufactured) T1 Antibody Candidates and T1 Licensed Products for use in Development and Commercialization of such T1 Antibody Candidates and T1 Licensed Products in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Costs</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.2.1. </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be responsible for [***] of all Manufacturing Costs relating to T1 Antibody Candidates incurred by or on behalf of Surface to support the T1 Research Program. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.2.2. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will pay to Surface [***] of reasonable Manufacturing Costs relating to the first Phase 1 Safety Study for T1 Antibody Candidates and T1 Licensed Products set forth in the Novartis approved budget for such Phase 1 Safety Study. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.2.3. </b><font style="font-family:'Times New Roman','Times','serif';">Other than the first Phase 1 Safety Study for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the T1 Antibody Candidates and T1 Licensed Products, Novartis will be responsible for [***] of all Manufacturing Costs relating to T1 Antibody Candidates and T1 Licensed Products for use in the Research, Development and Commercialization of such T1 Antibody Candidates and T1 Licensed Products in the Novartis Territory incurred by or on behalf of Novartis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Contracts</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will, at such time as determined by the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">JSC, use Commercially Reasonable Efforts to assign to Novartis or its designee all then-existing Manufacturing contracts with Third Party contract manufacturers that are solely related to the Manufacture of any T1 Antibody Candidates or T1 Licensed Products and that Novartis agrees to assume. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Antibody Candidates</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Responsibilities</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the oversight of the JRC,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface has the sole responsibility to Manufacture (or have Manufactured) Option Target Antibody Candidates, including CD47 Option Target Antibody Candidates, for use in the Option Target Research Programs in accordance with the Option Target Research Plans. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Costs</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will be responsible for [***] of all Manufacturing Costs incurred by or on behalf of Surface relating to Option Target Antibody Candidates, including CD47 Option Target Antibody Candidates, for use in the Option Target Research Programs. For clarity, responsibility for Manufacturing Clinical Study material will be allocated as set forth in under Sections 8.3 or 8.4, as applicable. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis Manufacturing Election</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding Sections 8.2.1 and 8.2.2, with respect to Option Target Antibody Candidates other than CD47 Option Target Antibody Candidates, Novartis shall have the right, on an Option Target-by-Option Target basis, exercisable at or about the time of selection by the JRC of the lead Option Target Antibody Candidate for the applicable Option Target, to Manufacture (or have Manufactured) Option Target Antibody Candidates for use in the applicable Option Target Research Program in accordance with the Option Target Research Plan (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Option Target Manufacturing Election</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">If Novartis makes a Novartis Option Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Manufacturing Election with respect to an Option Target (a) Novartis shall have sole responsibility to Manufacture (or have Manufactured) (i) effective upon such election, Option Target Antibody Candidates for such Option Target for use in the applicable Option Target Research Program; and (ii) effective upon Novartis&#8217; exercise of an Option with respect to such Option Target, Antibody Candidates and Licensed Products associated with such Licensed Target for use in the first Phase 1 Safety Study in accordance with the applicable Development Plan, and (b) Novartis will be responsible for [***] of all Manufacturing Costs incurred by or on behalf of Novartis (i) effective upon such election, Option Target Antibody Candidates for use in the applicable Option Target Research Program and (ii) effective upon Novartis&#8217; exercise of an Option with respect to such Option Target, Antibody Candidates and Licensed Products to support the first Phase 1 Safety Study for the applicable Antibody Candidates and Regional Licensed Products, including reasonable costs (calculated in the same manner as Development Costs) incurred by or on behalf of Surface to effect a technology transfer (to the extent necessary) to Novartis for purposes of Manufacturing pursuant to the Novartis Option Target Manufacturing Election. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">If Novartis makes a Novartis Option Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Manufacturing Election with respect to an Option Target and thereafter does not purchase an Option with respect to such Option Target in accordance with Section 4.1.1 or exercise a purchased Option with respect to such Option Target in accordance with Section 4.2.6, then Novartis shall, (a) within [***] of expiration of the Option Purchase Period or Option Exercise Period, as applicable, provide to Surface or Surface&#8217;s designated contract manufacturer(s), copies of all material data, reports, records and information in Novartis&#8217;s possession and Control to the extent that such data, reports, records and information are used in the Manufacture of the applicable Antibody Candidates; (b) as soon as reasonably practicable, transfer to a Third Party approved by Novartis (such approval not to be unreasonably withheld, conditioned or delayed), those cell lines and master cell banks to the extent used solely in the Manufacture of the applicable Antibody Candidates; (c) within such [***] period if Surface so requests, and to the extent permitted under Novartis&#8217;s obligations to Third Parties, use Commercially Reasonable Efforts to transfer to Surface any Third Party agreements relating solely to the Manufacture of the applicable Antibody Candidates to which Novartis is a party, subject to any required consents of such Third Party, which Novartis will use Commercially Reasonable Efforts to obtain promptly; and (d) </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">use Commercially Reasonable Efforts to continue to supply Surface with Antibody Candidates then being Manufactured (at the time of expiration of the Option Purchase Period or Option Exercise Period, as applicable) until the earlier of (i) Surface having established a source of supply for the applicable Antibody Candidates or (ii) [***] after expiration of the Option Purchase Period or Option Exercise Period, as applicable. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.2.3.3. </b><font style="font-family:'Times New Roman','Times','serif';">In addition, to (a) through (d) set forth in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 8.2.3.2 above, Novartis will grant to Surface a worldwide, royalty-bearing non-exclusive license (with the right to sublicense subject to Section 9.2.2.4, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis</i><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutandis</i><font style="font-family:'Times New Roman','Times','serif';">) under such Know-How and Patents both (a) Controlled by Novartis as of the date of expiration of the Option Purchase Period or Option Exercise Period, as applicable and (b) necessary to Manufacture the applicable Antibody Candidate and corresponding Licensed Product (it being understood and agreed that with respect to any such Patents or Know-How that are in-licensed by Novartis or any of its Related Parties, Surface will be responsible for any payments due to a Third Party with respect thereto and Surface&#8217;s rights will be subject to the terms of the applicable Third Party agreement), solely to the extent necessary to Manufacture such Antibody Candidate and corresponding Licensed Products in the Field (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;);</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">that the Parties agree to negotiate in good</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">faith commercially reasonable financial terms for such Option License, subject to Expedited Arbitration if the Parties are unable to agree on such financial terms within [***] following the date of expiration of the Option Purchase Period or Option Exercise Period, as applicable; provided further that after completion of such Expedited Arbitration, Surface will have the right to reject such Option License upon written notice to Novartis within [***] after the completion of the Expedited Arbitration, in which case, the Option License will not take effect and Surface will have no obligation to pay the amounts specified in such Expedited Arbitration. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regional Antibody Candidates and Regional Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Responsibilities.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.1.1. </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 1 Safety Study</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to Section 8.2.3, and subject to the oversight of the JDC, Surface has the sole responsibility to Manufacture (or have Manufactured) Regional Antibody Candidates and Regional Licensed Products for use in the first Phase 1 Safety Study for the Regional Antibody Candidates and Regional Licensed Products in accordance with the RLP Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.1.2. </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development</u><font style="font-family:'Times New Roman','Times','serif';">. Other than the first Phase 1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Safety Study for the Regional Antibody Candidates and Regional Licensed Products (subject to Section 8.2.3), Novartis has the sole responsibility to Manufacture (or have Manufactured) Regional Antibody Candidates and Regional Licensed Products for use in Development of such Regional Antibody Candidates and Regional Licensed Products in the Novartis Territory and the Surface Territory. Novartis will use Commercially Reasonable Efforts to Manufacture sufficient Regional Licensed Products for use in all Clinical Studies provided for in the then-applicable RLP Development Plan and the Parties shall discuss in good faith engaging a Third Party contract manufacturer as a second source in order to ensure adequate supply. In the event of a shortage of Regional Licensed Products for Development, (a) the available Regional Licensed Products shall be allocated first to those Clinical Studies contemplated in the then-applicable RLP Development Plan and thereafter to Supplemental Studies in the order that such Supplemental Studies were initiated and (b) the Parties will in good faith discuss and agree upon a plan to increase supply volume as necessary, which plan may include utilization of a second source supplier. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.1.3. </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization</u><font style="font-family:'Times New Roman','Times','serif';">. Novartis shall have the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">right to determine whether it is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory and shall communicate such determination by written notice to Surface no later than Initiation of the first Phase 3 Study. If Novartis notifies Surface that it is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization in the Surface Territory in accordance with the foregoing, then, Surface may elect, by written notice to Novartis no later than [***] after its receipt of such notice from Novartis whether to utilize Novartis for such Commercial Manufacturing in the Surface Territory or to retain a Third Party contract manufacturer(s) for such purpose. If either Novartis is not willing to provide such Commercial supply (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Election</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) or Surface elects not to utilize Novartis for such Commercial supply (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Election</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), then Novartis shall effect a technology transfer to a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Third Party contract manufacturer(s) to enable such Third Party to provide Commercial supply of Regional Antibody Candidates and Regional Licensed Products for use in the Surface Territory, provided that such Third Party contract manufacturer(s) is approved by Novartis, such approval not to be unreasonably withheld, conditioned or delayed. The cost of such technology transfer shall be borne by (a) Novartis in the case of a Novartis Election; and (b) Surface in the case of either (i) a Surface Election or (ii) any request for a second </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">technology transfer, whether in the case of a Novartis Election or Surface Election; provided, however that Surface may not require of Novartis more than [***] such transfers for any Regional Licensed Product. Further, in the case of a Novartis Election, Novartis shall remain responsible for Manufacturing Commercial supply for use in the Surface Territory until the earlier of (x) such time as the technology transfer is completed or (y) [***] If Novartis is willing to Manufacture Regional Antibody Candidates and Regional Licensed Products for use in Commercialization in the Surface Territory and Surface elects to utilize Novartis for such Commercial Manufacturing in the Surface Territory, the terms of supply of such Regional Antibody Candidates and Regional Licensed Products for use in Commercialization of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory will be set forth in the RLP Supply Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Costs</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.2.1. </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 1 Safety Study</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to Section 8.2.3, Surface will be responsible for [***] of all Manufacturing Costs relating to Regional Antibody Candidates and Global Licensed Products incurred by or on behalf of Surface to support the first Phase 1 Safety Study for Regional Antibody Candidates and Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.2.2. </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development</u><font style="font-family:'Times New Roman','Times','serif';">. Novartis will be responsible</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for [***] of all Manufacturing Costs relating to Regional Antibody Candidates and Regional Licensed Products incurred by or on behalf of Novartis for use in the Development of such Regional Antibody Candidates and Regional Licensed Products in the Novartis Territory. Other than the first Phase 1 Safety Study for the Regional Antibody Candidates and Regional Licensed Products (subject to Section 8.2.3), Surface shall reimburse Novartis for [***] of all Manufacturing Costs relating to Regional Antibody Candidates and Regional Licensed Products incurred by or on behalf of Novartis for use in the Development of such Regional Antibody Candidates and Regional Licensed Products in the Surface Territory. For clarity, costs incurred by the Parties in connection with the Manufacture of Regional Antibody Candidates and Regional Licensed Products for use in the Development of such Regional Antibody Candidates and Regional Licensed Products in the Novartis Territory or the Surface Territory in accordance with the applicable RLP Development Plan shall constitute Development Costs to be allocated between the Parties in accordance with Section 5.2.4.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.2.3. </b><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party shall be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for [***] of all Manufacturing Costs relating to Regional Licensed Products for use by such Party or its Related Parties in the Commercialization of Regional Licensed Products in such Party&#8217;s Territory. With respect to Regional Licensed Products (including any Component of a Regional Licensed Product that is a Combination) purchased by Surface from Novartis for use in the Surface Territory, Surface shall pay Novartis an amount equal to Commercial Manufacturing Cost for such Regional Licensed Products. For purposes hereof, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Commercial</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Manufacturing Cost</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall be calculated as follows: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) With respect to any Regional Licensed Product which is not a Combination, an amount equal to Manufacturing Cost plus a Mark-Up. The Mark-Up shall be set forth in the RLP Supply Agreement to be entered into between the Parties; in the event the Parties are unable to agree upon such Mark-Up, the dispute shall be submitted to Expedited Arbitration for resolution. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) With respect to any Regional Licensed Product which is a Combination, an amount specified on Exhibit A-2. Any Mark-Up set forth in such Exhibit shall be set forth in the RLP Supply Agreement to be entered into between the Parties; in the event the Parties are unable to agree upon such Mark-Up, the dispute shall be submitted to Expedited Arbitration for resolution. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing and Supply Agreements.</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">The terms under which Novartis will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Manufacture and supply Regional Antibody Candidates and Regional Licensed Products to Novartis pursuant to Section 8.3 will be set forth in a supply agreement to be entered into between the Parties (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Supply Agreement</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) within [***] of either Party&#8217;s written request. The RLP Supply Agreement will contain customary terms and conditions, including quality, and otherwise be consistent with this Agreement and Novartis quality standards. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.3.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to Section 8.2.3, Surface will, at</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">such time as determined by the JSC, use Commercially Reasonable Efforts to assign to Novartis or its designee all then-existing Manufacturing contracts with Third Party contract manufacturers that are solely related to the Manufacture of any Regional Antibody Candidates or Regional Licensed Products and that Novartis agrees to assume. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Antibody Candidates and Global Licensed Products</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Responsibilities</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to Section 8.2.3 and subject to the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">oversight of the JDC, Surface has the sole responsibility to Manufacture (or have Manufactured) Global Antibody Candidates and Global Licensed Products for use in the first Phase 1 Safety Study for the Global Antibody Candidates and Global Licensed Products in accordance with the Global Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Other than the first Phase 1 Safety Study for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Global Antibody Candidates and Global Licensed Products (subject to Section 8.2.3), Novartis has the sole responsibility to Manufacture (or have Manufactured) Global Antibody Candidates and Global Licensed Products for use in Development and Commercialization of such Global Antibody Candidates and Global Licensed Products in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Costs</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.2.1. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to Section 8.2.3, Surface will be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">responsible for [***] of all Manufacturing Costs relating to Global Antibody Candidates and Global Licensed Products incurred by or on behalf of Surface to support the first Phase 1 Safety Study for Global Antibody Candidates and Global Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.2.2. </b><font style="font-family:'Times New Roman','Times','serif';">Other than the first Phase 1 Safety Study for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Global Antibody Candidates and Global Licensed Products (subject to Section 8.2.3), Novartis will be responsible for [***] of all Manufacturing Costs relating to Global Antibody Candidates and Global Licensed Products for use in the Research, Development and Commercialization of such Global Antibody Candidates and Global Licensed Products by or on behalf of Novartis in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.4.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Agreements</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will, at such time as determined by</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the JSC, use Commercially Reasonable Efforts to assign to Novartis or its designee all then-existing Manufacturing contracts with Third Party contract manufacturers that are solely related to the Manufacture of any Global Antibody Candidates or Global Licensed Products and that Novartis agrees to assume . </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8.5. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Parties</b><font style="font-family:'Times New Roman','Times','serif';">. The Parties will be entitled to utilize the services of Third Parties</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to perform their respective Manufacturing activities under this Section 8, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (a) [***] (b) each Party will require that such Third Party operates in a manner consistent with the terms of this Agreement, and (c) each Party will remain at all times fully liable for its respective responsibilities contracted to such Third Party. Each Party will require that any such Third Party agreement entered into pursuant to this Section 8.5 (x) include confidentiality and non-use provisions that are no less stringent than those set forth in Section 11.1 (but of duration customary in confidentiality agreements entered into for a similar purpose), other than Existing Novartis In-Licenses and the agreements listed on Schedule 12.2.1, each of which contains reasonable and customary confidentiality and non-use provisions; and (y) except as identified on Exhibit K, obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) under and to, any Know-How and Patents that are developed by such Third Party in the performance of such agreement and are reasonably necessary or useful to Research, Develop, Manufacture or Commercialize Antibody Candidates or Licensed Products in the Field. For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license (or an exclusive option to obtain such license) shall not apply to any background or foundational Know-How or Patents owned or in-licensed by a Third Party contract manufacturer or its Affiliates (including any improvements thereto) unless such background or foundational Know-How or Patents (or improvements thereto) are reasonably necessary to Research, Develop, Manufacture or Commercialize those Antibody Candidates or Licensed Products in the Field with respect to which such Third Party or its Affiliate conducted its activities under such Third Party agreement. The Party utilizing the services of a Third Party service provider will be solely responsible for direction of and communications with such Third Party. [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9. LICENSES </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T1 Target</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research and Development License</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of this Agreement, effective upon the Effective Date, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.1.4) exclusive (even as to Surface) license under Surface Technology to Research and Develop T1 Antibody Candidates and T1 Licensed Products in the Field anywhere in the world. Notwithstanding the foregoing, Surface retains the right under the Surface Technology, without the right to grant licenses or sublicenses without Novartis&#8217; prior written consent, to Research T1 Antibody Candidates and T1 Licensed Products in the Field </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">anywhere in the world as and to the extent provided in any approved T1 Research Plan or as otherwise permitted under Section 3.1.1 or elsewhere under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Commercialization License</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, effective upon the Effective Date, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.1.4), royalty-bearing, exclusive (even as to Surface) license under Surface Technology to Commercialize T1 Licensed Products in the Field anywhere in the world. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, effective upon the Effective Date, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.1.4), exclusive (even as to Surface) license under Surface Technology to Manufacture T1 Antibody Candidates and T1 Licensed Products anywhere in the world for Research, Development and Commercialization in the Novartis Territory. Notwithstanding the foregoing, Surface retains the right under the Surface Technology, without the right to grant licenses or sublicenses without Novartis&#8217; prior written consent, to Manufacture T1 Antibody Candidates and T1 Licensed Products in the Field anywhere in the world for Research as and to the extent provided in any approved T1 Research Plan or permitted under Section 8.1.1 of this Agreement or as permitted elsewhere under this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sublicensing Terms</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will have the right to sublicense any of its rights under</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Sections 9.1.1, 9.1.2 and 9.1.3 to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple tiers) without the prior consent of Surface, subject to the requirements of this Section 9.1.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">Each sublicense granted by Novartis pursuant to this Section 9.1.4 will be subject and subordinate to this Agreement and will contain provisions consistent with the terms and conditions of this Agreement. Novartis will as soon as reasonably practicable thereafter, provide Surface with a copy of any executed sublicense agreement covering a material sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 9.1.4), and each such sublicense agreement will contain the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 11.1 with respect to Surface&#8217;s Confidential Information, (ii) if such sublicense agreement contains a sublicense of Section 9.1.2, such sublicense agreement will also contain the following provisions: (x) a requirement that the Sublicensee submit applicable sales or other reports to Novartis to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement; and (y) the audit requirement set forth in Section 10.12.3; and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Surface In-License.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.1.4.3. </b><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding any sublicense, Novartis will remain primarily</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">liable to Surface for the performance of all of Novartis&#8217;s obligations under, and Novartis&#8217;s compliance with all provisions of, this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regional Targets</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">License Grants to Novartis</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research and Development License</i><font style="font-family:'Times New Roman','Times','serif';">.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Subject to the terms and conditions of this Agreement, on a Regional Target-by-Regional Target basis, effective upon the Option Exercise Date for each Regional Target, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.2.1.4) exclusive (even as to Surface) license under Surface Technology to Research and Develop such Regional Antibody Candidates and Regional Licensed Products in the Field anywhere in the world; provided, that, such license grant for Research and Development will be limited in each case solely as and to the extent provided in any approved RLP Development Plan or as otherwise permitted under Section 4.2.6.5 or elsewhere under this Agreement, and in each case, solely for Regulatory Approval and Commercialization in the Novartis Territory. Notwithstanding the foregoing, Surface retains the right under the Surface Technology, with the right to grant licenses through multiple tiers in accordance with Section 9.2.2.4, which shall apply </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';">, to (a) conduct the Phase 1 Safety Study for each Regional Antibody Candidate or Regional Licensed Product, and (b) to Research and Develop each Regional Antibody Candidate or Regional Licensed Product in the Field anywhere in the world, in each case solely as and to the extent provided in any approved RLP Development Plan or as otherwise permitted under Section 4.2.6.5 or elsewhere under this Agreement, and in each case, solely for Regulatory Approval and Commercialization in the Surface Territory. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Commercialization License in the Novartis</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Territory</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Agreement, on a Regional Target-by-Regional Target basis, effective upon the Option Exercise Date for each Regional Target, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.2.1.4), royalty-bearing, exclusive (even as to Surface) license under Surface Technology to Commercialize such Regional Licensed Products in the Field in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">terms and conditions of this Agreement and the applicable RLP Supply Agreement (if any), on a Regional Target-by-Regional Target basis, effective upon the Option Exercise Date for each Regional Target, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.2.1.4), exclusive (even as to Surface) license under Surface Technology to Manufacture such Regional Antibody Candidates and Regional Licensed Products anywhere in the world solely for (a) Research, Development and Commercialization in the Field in the Novartis Territory and, to the extent permitted under this Agreement or any RLP Supply Agreement, for Research and Development in the Field in the Surface Territory; and (b) to the extent provided for under Section 8.2.3 or 8.3 or elsewhere under this Agreement or any RLP Supply Agreement, to supply (or have supplied) to Surface or use in the Field. Notwithstanding the foregoing, Surface retains the right under the Surface Technology, with the right to grant licenses through multiple tiers in accordance with Section 9.2.2.4, which shall apply </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';">, to Manufacture Regional Antibody Candidates and Regional Licensed Products anywhere in the world (a) for Research and Development in the Field as and to the extent provided in any approved RLP Development Plan, or permitted under Section 8.3 or elsewhere under this Agreement or under any RLP Supply Agreement and (b) to the extent provided for under Section 8.2.3 or any RLP Supply Agreement for Commercialization in the Field in the Surface Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.1.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sublicensing Terms</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Novartis will have the right to sublicense any of its rights under Sections 9.2.1.1, 9.2.1.2 and 9.2.1.3 to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple tiers) without the prior consent of Surface, subject to the requirements of this Section 9.2.1.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) Each sublicense granted by Novartis pursuant to this Section 9.2.1.4 will be subject and subordinate to this Agreement and will contain provisions consistent with the terms and conditions of this Agreement. Novartis will as soon as reasonably practicable thereafter, provide Surface with a copy of any executed sublicense agreement covering a material sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 9.2.1.4), and each such sublicense agreement will contain the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 11.1 with respect to Surface&#8217;s Confidential Information, (ii) if such sublicense agreement contains a sublicense of Section 9.2.1.2, such sublicense agreement will also contain the following provisions: (x) a requirement that the Sublicensee submit applicable sales or other reports to Novartis to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement; and (y) the audit requirement set forth in Section 10.12.3; and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Surface In-License.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) Notwithstanding any sublicense, Novartis will remain primarily liable to Surface for the performance of all of Novartis&#8217;s obligations under, and Novartis&#8217;s compliance with all provisions of, this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">License Grants to Surface</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research and Development License</i><font style="font-family:'Times New Roman','Times','serif';">.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Subject to the terms and conditions of this Agreement, on a Regional Target-by-Regional Target basis, effective upon the Option Exercise Date for each Regional Target, Novartis hereby grants Surface a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.2.2.4) exclusive (even as to Novartis) license under Novartis Technology to Research and Develop such Regional Antibody Candidates and Regional Licensed Products in the Field anywhere in the world; provided, that such license grant for Research and Development will be limited in each case solely as and to the extent provided in any approved RLP Development Plan or as otherwise permitted under this Agreement, and in each case, solely for Regulatory Approval and Commercialization in the Surface Territory. Notwithstanding the foregoing, Novartis retains the right under the Novartis Technology, with the right to grant licenses through multiple tiers in accordance with Section 9.2.2.4, which shall apply </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';">, to Research and Develop each Regional Antibody Candidate or Regional Licensed Product in the Field anywhere in the world, in each case solely as and to the extent provided in any approved RLP Development Plan or as otherwise permitted under Section 4.2.6.5 or elsewhere </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">under this Agreement, and in each case, solely for Regulatory Approval and Commercialization by Novartis in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Commercialization License in the Surface</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Territory</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Agreement, on a Regional Target-by-Regional Target basis, effective upon the Option Exercise Date for each Regional Target, Novartis hereby grants Surface a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.2.2.4), royalty-bearing, exclusive (even as to Novartis) license under Novartis Technology to Commercialize such Regional Licensed Products in the Field in the Surface Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">terms and conditions of this Agreement and the applicable RLP Supply Agreement (if any), on a Regional Target-by-Regional Target basis, effective upon the Option Exercise Date for each Regional Target, Novartis hereby grants Surface a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.2.2.4), exclusive (even as to Novartis) license under Novartis Technology to Manufacture such Regional Antibody Candidates and Regional Licensed Products anywhere in the world solely for (a) Research and Development as and to the extent provided in any approved RLP Development Plan, or permitted elsewhere under this Agreement or any RLP Supply Agreement and (b) to the extent provided for under Section 8.2.3 or 8.3 or elsewhere under this Agreement or any RLP Supply Agreement, for Commercialization in the Surface Territory. Notwithstanding the foregoing, Novartis retains the right under the Novartis Technology, with the right to grant licenses through multiple tiers in accordance with Section 9.2.2.4, which shall apply </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';">, to Manufacture Regional Antibody</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Candidates and Regional Licensed Products anywhere in the world (a) for Research, Development and Commercialization in the Novartis Territory and, to the extent permitted pursuant to Section 5.2.2 or elsewhere under this Agreement or any RLP Supply Agreement for Research and Development in the Surface Territory, and (b) to the extent permitted pursuant to Section 8.2.3 or Section 8.3.3 or elsewhere under this Agreement or any RLP Supply Agreement, to supply (or have supplied to) Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.2.2.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sublicensing Terms</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Surface will have the right to sublicense any of its rights under Sections 9.2.1.1, 9.2.1.2,9.2.1.3, 9.2.2.1, 9.2.2.2, and 9.2.1.3 to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple tiers) without the prior consent of Novartis, subject to the requirements of this Section 9.2.2.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) Each sublicense granted by Surface pursuant to this Section 9.2.2.4 will be subject and subordinate to this Agreement and will contain provisions consistent with the terms and conditions of this Agreement. Surface will as soon as reasonably practicable thereafter, provide Novartis with a copy of any executed sublicense agreement covering a material sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 9.2.2.4), and each such sublicense agreement will contain the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 11.1 with respect to Novartis&#8217;s Confidential Information, (ii) if such sublicense agreement contains a sublicense of Section 9.2.2.2, such sublicense agreement will also contain the following provisions: (x) a requirement that the Sublicensee submit applicable sales or other reports to Surface to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement; and (y) the audit requirement set forth in Section 10.12.3; and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Novartis In-License.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) Notwithstanding any sublicense, Surface will remain primarily liable to Novartis for the performance of all of Surface&#8217;s obligations under, and Surface&#8217;s compliance with all provisions of, this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) Notwithstanding the other provisions of this Section 9.2.2.4, if Surface proposes to enter into an agreement with a Third Party with respect to the Research, Development, Manufacture or Commercialization of any Regional Antibody Candidate or Regional Licensed Product, which agreement includes the grant of a sublicense under Section 9.2.2.2 or other rights to Commercialize any Regional Licensed Product in the Surface Territory (any such agreement, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Proposed Surface Sublicense</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Surface will so notify Novartis in writing. Novartis will have [***] exercisable by written notice to Surface at any time within [***] following receipt of Surface&#8217;s notice, to obtain (via termination and reversion to Novartis of the applicable licenses granted by Novartis to Surface hereunder, grant of a sublicense back to Novartis or to otherwise) the licenses or other rights proposed to be granted to the Third Party pursuant to such Proposed Surface Sublicense on terms to be negotiated in good faith by the Parties for up to [***] following exercise of such right of first negotiation. If Novartis does not exercise [***] within such initial [***] period, or if the Parties cannot agree on mutually acceptable terms during such subsequent [***] period, then, subject to the other terms of this Section 9.2.2.4, for a period of [***] following expiration of such subsequent [***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">period, Surface may enter into the Proposed Surface Sublicense with a Third Party, provided, however, that Surface may not enter into any such Proposed Surface Sublicense during such [***] In all events, this Section 9.2.2.4(d) will not apply to (a) any permitted assignment of this Agreement under Section 16.1, or (b) any bona fide agreement with a Third Party contract sales organization, contract research organization or contract manufacturer, under which such Third Party performs contract services on behalf of Surface or any of its Affiliates for the Research, Development, or Manufacture of any Regional Antibody Candidate or Regional Licensed Product as permitted under this Agreement on a fee-for-services basis, it being understood that under an agreement for such fee-for-services, fees paid to the Third Party for such services may include milestones or royalties. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Targets</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Research and Development License</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of this Agreement, on a Global Target-by-Global Target basis, effective upon the Option Exercise Date for each Global Target, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.3.4) exclusive (even as to Surface), license under Surface Technology to Develop such Global Antibody Candidates and Global Licensed Products in the Field anywhere in the world. Notwithstanding the foregoing, Surface retains the right under the Surface Technology, with the right to grant licenses through multiple tiers in accordance with Section 9.2.2.4, which shall apply </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis mutandis</i><font style="font-family:'Times New Roman','Times','serif';"> solely to (a) Research Global Antibody Candidates and Global Licensed Products in the Field anywhere in the world as permitted under Section 4.2.6.5 or elsewhere under this Agreement, and (b) conduct the Phase 1 Safety Study for each Global Antibody Candidate and Global Licensed Product in accordance with the Global Development Plan. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Commercialization License</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, on a Global Target-by-Global Target basis, effective upon the Option Exercise Date for each Global Target, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.3.4), royalty-bearing, exclusive (even as to Surface), license under Surface Technology to Commercialize such Global Licensed Products in the Field anywhere in the world. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manufacturing Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, on a Global Target-by-Global Target basis, effective upon the Option Exercise Date for each Global Target, Surface hereby grants Novartis a non-transferable (except as provided in Section 16.1), sublicensable (subject to Section 9.3.4), exclusive (even as to Surface) license under Surface Technology to Manufacture such Global Antibody Candidates or Global Licensed Products anywhere in the world for Research, Development and Commercialization in the Novartis Territory. Notwithstanding the foregoing, Surface retains the right under the Surface Technology, with the right to grant licenses through multiple tiers in accordance with Section 9.2.2.4, which shall apply </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">mutatis mutandis </i><font style="font-family:'Times New Roman','Times','serif';">solely to Manufacture Global Antibody Candidates and Global</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Licensed Products in the Field anywhere in the world for Research as and to the extent permitted under the approved Global Development Plan or permitted under Section 8.4.1 of this Agreement or as permitted elsewhere under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Sublicensing Terms</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will have the right to sublicense any of its rights under</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Sections 9.3.1, 9.3.2 and 9.3.3 to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple tiers) without the prior consent of Surface, subject to the requirements of this Section 9.3.4. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">Each sublicense granted by Novartis pursuant to this Section 9.3.4 will be subject and subordinate to this Agreement and will contain provisions consistent with the terms and conditions of this Agreement. Novartis will as soon as reasonably practicable thereafter, provide Surface with a copy of any executed sublicense agreement covering a material sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 9.3.4), and each such sublicense agreement will contain the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 11.1 with respect to Surface&#8217;s Confidential Information, (ii) if such sublicense agreement contains a sublicense of Section 9.3.2, such sublicense agreement will also contain the following provisions: (x) a requirement that the Sublicensee submit applicable sales or other reports to Novartis to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement; and (y) the audit requirement set forth in Section 10.12.3; and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Surface In-License.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.3.4.3. </b><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding any sublicense, Novartis will remain primarily</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">liable to Surface for the performance of all of Novartis&#8217;s obligations under, and Novartis&#8217;s compliance with all provisions of, this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.4. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Collaboration IP</b><font style="font-family:'Times New Roman','Times','serif';">. Subject to the rights and licenses granted to, and the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">obligations (including royalty obligations) of, each Party under this Agreement, including any exclusivity obligations, either Party is entitled to practice Joint Collaboration IP for all purposes on a worldwide basis without consent of and without a duty of accounting to the other Party. Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, the Joint Collaboration IP, throughout the world, necessary to provide the other Party with such rights of use and exploitation of the Joint Collaboration IP, and will execute documents as necessary to accomplish the foregoing. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.5.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In-Licenses</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.5.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">In-Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. The Parties agree that all [***] payments to any Third Party in respect of any Collaboration In-License, Surface Existing In-Licenses or Novartis Existing In-License will be deemed a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Payment</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; and subject to this Section 9.5. Responsibility for Collaboration In-Licenses, Surface Existing In-Licenses, Novartis Existing In-License and Third Party Payments will be as follows: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.5.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to Section 10.10.6 Surface will be responsible for all Third Party Payments under the Surface Existing In-Licenses.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.5.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will be responsible for all Third</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Party Payments under the Novartis Existing In-Licenses.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.5.1.3. </b><font style="font-family:'Times New Roman','Times','serif';">The Parties acknowledge that during the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Term, the JSC may determine that Research, Development, Manufacture or Commercialization of any Antibody Candidates or Licensed Products may require or benefit from a license acquired or entered into after the Effective Date with respect to additional Patents or Know-How of Third Parties (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Potential</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">In-License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). If a Party acquires or otherwise enters into any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Potential In-License after the Effective Date with respect to the Research, Development, Manufacture, or Commercialization of any Antibody Candidates or Licensed Products, such Party will endeavor to bring such Potential In-License to the attention of the JSC. If a Potential In-License is brought to the attention of the JSC pursuant to this Section 9.5.1.3, the Parties will, through the JSC, discuss in good faith whether such Potential In-License should be made available for use by the Parties pursuant to this Agreement with respect to such Party&#8217;s rights under this Agreement to conduct Research, Development, Manufacture, or Commercialization of any Antibody Candidates or Licensed Products. The Party to the Potential In-License will propose, through the JSC, an equitable allocation of any non-product specific upfront payments, milestone payments or similar payments payable under the Potential In-License [***] Any upfront payments, milestone payments or similar payments that are specific to the Antibody Candidates or Licensed Products will be allocated [***] to the corresponding Antibody Candidates or Licensed Products. The JSC will discuss the rationale of including the Potential In-License and the proposed economics associated with doing so (including related royalty obligations). For any Potential In-License that the JSC approves for use by the Parties pursuant to this Agreement, (i) such Potential In-License will be deemed to be a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Collaboration In-License</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; hereunder, (ii) the Patents and Know-How in-licensed under such Collaboration In-License will be deemed &#8220;Controlled&#8221; under this Agreement as Surface Patents or Surface Know-How (as applicable) or Novartis Patents or Novartis Know-How (as applicable) for purposes of Research, Development, Manufacture, or Commercialization of any Antibody Candidates or Licensed Products, (iii) any allocated payments for Regional Antibody Candidates or Regional Licensed products that are non-territory specific or for the Surface Territory will be allocated as Development Costs under Section 5.2.3.2, and (iv) any allocated payments for a Party&#8217;s Territory will be borne by the applicable Party. If the JSC does not approve such Potential In-License, then the applicable Party may proceed to enter into the Potential In-License, provided that (A) such Potential In-License will not be deemed to be a Collaboration In-License hereunder, (B) the Patents and Know-How in-licensed under such Potential In-License will not be deemed Surface Patents or Surface Know-How (as applicable) or Novartis Patents or Novartis Know-How (as applicable) and will not be deemed &#8220;Controlled&#8221; for purposes of this Agreement, (C) each Party will have the right to enter into such Potential In-License solely with respect to in its own Territory and, subject to Section 10.10.3, bear [***] of any Third Party Payment thereunder, and the other Party will not be entitled to use any Patents or Know-How in-licensed under such Potential In-License in connection with the performance of this Agreement in its Territory; [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.5.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compliance with In-Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. All licenses and other rights granted to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis under this Section 9 are subject to the rights and obligations of Surface under the Surface In-Licenses. All licenses and other rights granted to Surface under this Section 9 are subject to the rights and obligations of Novartis under the Novartis In-Licenses. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Each Party will comply with all applicable provisions of the In-Licenses, and will perform and take such actions as may be required to allow the Party that is party to such In-License to comply with its obligations thereunder, including obligations relating to sublicensing, patent matters, confidentiality, reporting, audit rights, indemnification and diligence. Without limiting the foregoing, each Party will prepare and deliver to the other Party any additional reports required under the applicable In-Licenses and reasonably requested by such other Party, in each case sufficiently in advance to enable the Party that is party to such In-License to comply with its obligations under the applicable In-Licenses. Each Party agrees, upon the other Party&#8217;s reasonable request, to provide the other Party with copies of any In-Licenses to which it is a party. Confidential Information of the providing Party or its counterparty may be redacted from such copies, except to the extent that such information is required in order to enable the other Party to comply with its obligations to the providing Party under this Agreement with respect to such In-License or in order to enable the providing Party to ascertain compliance with the terms and conditions of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.6. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Combinations</b><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding any other provision of this Agreement, for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">purposes of the license grants under Sections 9.1 through Section 9.3 with respect to any Licensed Product that is a Combination, such license will only include a license with respect to any Party Component of such Combination if such Licensed Product (a) is a Combination Product or (b) a Combination Therapy [***] For clarity, except in the case of the foregoing clause (b), in no event is a license granted hereunder to either Party or its Related Parties with respect to a the other Party&#8217;s Component of a Combination Therapy. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.7. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bankruptcy</b><font style="font-family:'Times New Roman','Times','serif';">. All rights and licenses granted under or pursuant to this Agreement</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">by a Party to the other are and will otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of right to &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code. The Parties agree that the Parties and their respective Sublicensees, as Sublicensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Bankruptcy Code and any foreign counterpart thereto. The Parties further agree that upon commencement of a bankruptcy proceeding by or against a Party (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Bankrupt Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) under the Bankruptcy Code, the other Party (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-Bankrupt Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt Party (a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agree not to interfere with the exercise by the Non-Bankrupt Party or its Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with this Agreement, and agrees to assist the Non-Bankrupt Party and its Related Parties in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as are reasonably necessary or desirable for the Non-Bankrupt Party to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9.8. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Rights</b><font style="font-family:'Times New Roman','Times','serif';">. Except as otherwise expressly provided in this Agreement,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">under no circumstances will a Party or any of its Affiliates, as a result of this Agreement, obtain any ownership interest, license or other right in or to any Know-How, Patents or other intellectual property rights of the other Party, including tangible or intangible items owned, controlled or developed by the other Party, or provided by the other Party to the receiving Party at any time, pursuant to this Agreement. Neither Party nor any of its Affiliates will use or practice any Know-How or Patents licensed or provided to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10. PAYMENTS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial License Fee</b><font style="font-family:'Times New Roman','Times','serif';">. Novartis will pay to Surface within [***] after</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">receipt of an invoice from Surface, which invoice shall be substantially in the form of Exhibit L and issued promptly following the Effective Date, a one-time payment of Seventy Million Dollars ($70,000,000). Such payment will be non-refundable, non-creditable and not subject to set-off.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.2. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Investment</b><font style="font-family:'Times New Roman','Times','serif';">. Novartis and Surface will enter into the Equity Agreements</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">as of the Effective Date. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.3. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Purchase Fee</b><font style="font-family:'Times New Roman','Times','serif';">. On a Regional Option Target-by-Regional Option Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">basis, no later than [***] after receipt of an invoice from Surface, which invoice shall be substantially in the form of Exhibit L and issued by Surface promptly following the date of the Option Purchase Notice for each Option Target, Novartis will pay to Surface an option exercise right purchase fee of (a) Five Million Dollars ($5,000,000) for each of the following Option Targets: CD47, [***] and (b) [***] (for [***] (each, an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Option Purchase Fee</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Such payments will be non-refundable and non-creditable and not subject to set-off.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.4. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regional Option Exercise Fee</b><font style="font-family:'Times New Roman','Times','serif';">. On a Regional Option-by-Regional Option basis,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">no later than [***] after receipt of an invoice from Surface, which invoice shall be substantially in the form of Exhibit L and issued by Surface promptly following the date of the Option Exercise Notice for each Regional Option, as applicable, Novartis will pay to Surface an exercise fee of (a) [***] where the Regional Option Target is [***] CD47, [***] and (b) [***] where the Regional Option Target is [***] Such payments will be non-refundable and non-creditable and not subject to set-off.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.5. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Option Exercise Fee</b><font style="font-family:'Times New Roman','Times','serif';">. On a Global Option Target-by-Global Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, no later than [***] after receipt of an invoice from Surface, which invoice shall be substantially in the form of Exhibit L and issued by Surface promptly following date of the Option Exercise Notice for each Global Option, as applicable, Novartis will pay to Surface to an exercise fee of (a) [***] where the Global Option Target is [***] CD47, [***] and (b) [***] where the Global Option Target is [***] Such payments will be non-refundable and non-creditable and not subject to set-off.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Costs for Regional Targets</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.6.1. </b><font style="font-family:'Times New Roman','Times','serif';">For each Regional Target, commencing upon the first Calendar Quarter</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">immediately following the approval of the first RLP Development Plan and continuing thereafter so long as a Party incurs Development Costs under this Agreement for which reconciliation will be provided, Surface and Novartis will, within [***] of such Calendar Quarter submit to a finance officer designated by Surface and a finance officer designated by Novartis (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Finance Officers</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) a report setting forth the Development Costs it incurred in such Calendar Quarter with respect to Regional Antibody Candidates and Regional Licensed Products for each Regional Target as approved by the JDC. Each such report will specify in reasonable detail all such costs, and, if requested by Surface or Novartis, any such invoices or other supporting documentation for any payments to a Third Party or with respect to which documentation is otherwise reasonably requested will be promptly provided. Within [***] after receipt of such reports, the Finance Officers will confer and agree in writing on whether a reconciliation payment is due from Surface to Novartis or Novartis to Surface, and if so, the amount of such reconciliation payment, so that Surface and Novartis share Development Costs in accordance with Section 5.2.4. Surface or Novartis, as applicable, if required to pay such reconciliation payment, will submit such payment to Novartis or Surface, respectively, as applicable, within [***] of receipt of the other Party&#8217;s invoice for such amount; [***] In addition, each Party will consider in good faith other reasonable procedures proposed by the other Party for sharing financial information in order to permit each Party to close its books periodically in a timely manner. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.6.2. </b><font style="font-family:'Times New Roman','Times','serif';">Any expenses incurred by a Party for Development activities related to a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Antibody Candidate or Regional Licensed Product that do not fall within the definitions of Development Costs (as the case may be) will be borne solely by such Party unless the JDC determines otherwise. In addition, any expenditure or cost that exceeds the amount set forth in the RLP Development Plan (as applicable) by more than [***] for a Calendar Year or any unbudgeted cost that is incurred by either Party will be borne by such Party; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the JDC will have the discretion to review such expenditures or costs and propose that they be designated as Development Costs in accordance with Section 5.2.3.2 (as the case may be). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development and Regulatory Milestone Payments</b><font style="font-family:'Times New Roman','Times','serif';">. Subject to Section 10.7.4, on a Licensed Target-by-Licensed Target basis, Novartis will make one-time milestone payments to Surface (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Payment</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) upon the first achievement of the development and regulatory milestone events set forth in this Section 10.7 (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Event</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) with respect to a Licensed Target as set forth in the applicable table below for T1 Licensed Products, Global Licensed Products or Regional Licensed Products, as applicable. For clarity, and without limitation, references to Licensed Product include a Combination. Notwithstanding any other provision of this Agreement, each series of Development Milestone Payments will be payable only once with respect to the specified Licensed Target, notwithstanding the number of Licensed Products (or the number of times a Licensed Product) may achieve the applicable Development Milestone Event. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Licensed Products.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will make the following Developmental</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Milestone Payments to Surface upon the first achievement of the corresponding Developmental Milestone Event for the T1 Target: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Event</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Payment</b></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Initiation of the first GLP Toxicology Study for a T1 Licensed Product</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$30,000,000</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(Thirty Million Dollars)</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Global Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will, on a Global Target-by-Global</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target basis, make the following Developmental Milestone Payments to Surface upon the first achievement of the corresponding Developmental Milestone Event for a Global Target: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Event</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Payment</b></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will, on a Regional Target-by-Regional Target basis, make the following Developmental Milestone Payments to Surface upon the first achievement of the corresponding Developmental Milestone Event for a Regional Target: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Event</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Payment</b></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Additional Development Milestone Terms</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">foregoing, for the purpose of construing the Development Milestone Payments specified in the above tables: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">For clarity, each Development Milestone Payment shall be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">payable only on the first occurrence of the applicable Development Milestone Event for the Licensed Target, and none of the Development Milestone Payments shall be payable more than once with respect to a Licensed Target; [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">If Development of a Licensed Product is terminated after it</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">achieves a Development Milestone Event, then the corresponding Development Milestone Payment will not be due on any subsequent achievement of the same Development Milestone Event by a subsequent Licensed Product for such Licensed Target. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.3.3. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.3.4. </b><font style="font-family:'Times New Roman','Times','serif';">Milestone Payments for Regulatory Approval in the EU [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.7.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Payment Terms for Development Milestone Payments</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis shall</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">provide Surface with written notice of its achievement of each Development Milestone Event within [***] after such Development Milestone Event is achieved by Novartis. After receipt of such notice, Surface shall submit an invoice to Novartis substantially in the form of Exhibit L for the corresponding Development Milestone Payment. Novartis shall make the corresponding Development Milestone Payment within [***] after receipt of such invoice. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales Milestone Payments</b><font style="font-family:'Times New Roman','Times','serif';">. Subject to Section 10.8.4, on a Licensed Target-by-Licensed Target basis, Novartis will make one-time payments of each of the sales milestone payments indicated below (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Payment</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; and together with the Developmental Milestone Payments, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Milestone Payments</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) to Surface when aggregate Annual Net Sales of all Licensed Products for such Licensed Target in the Territory in a given Calendar Year first reach the dollar values indicated on each table below for the applicable T1 Licensed Products, Global Licensed Products or Regional Licensed Products (each, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Milestone Event</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Notwithstanding any other provision of this Agreement, each series of Sales</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Milestone Payments will be payable only once with respect to the specified Licensed Target, notwithstanding the number of Licensed Products (or the number of times a Licensed Product) may achieve the applicable Sales Milestone Event. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will make the following Sales Milestone</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Payments to Surface upon achievement of the corresponding Sales Milestone Event for the T1 Licensed Products: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales in a Given Calendar</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year for all T1 Licensed Products</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Global Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. On a Global Target-by-Global Target basis,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will make the following Sales Milestone Payments to Surface upon achievement of the corresponding Sales Milestone Event for all Global Licensed Products for such Global Target: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales in a Given Calendar</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year for all Global Licensed Products</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. On a Regional Target-by-Regional Target</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">basis, Novartis will make the following Sales Milestone Payments to Surface upon achievement of the corresponding Sales Milestone Event for all Regional Licensed Products for such Regional Target: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales in the Novartis</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Territory in a Given Calendar Year for</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">all Regional Licensed Products</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Additional Sales Milestone Payment Terms</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">Each Sales Milestone shall be payable only</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">once per Licensed Target, the first time worldwide Annual Net Sales for all Licensed Products in a Calendar Year for such Licensed Target exceeds the relevant threshold set forth above. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">The Sales Milestone Payments in this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.8 are [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.8.5. </b><font style="font-family:'Times New Roman','Times','serif';">Each Sales Milestone Payment shall be deemed earned upon achievement</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">of the corresponding Sales Milestone, and shall be notified by Novartis to Surface within [***] after [***] After receipt of such notice, Surface shall submit an invoice to Novartis substantially in the form of Exhibit L for the corresponding Sales Milestone Payment. Novartis shall make the corresponding Sales Milestone Payment within [***] after receipt of such invoice. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalties</b><font style="font-family:'Times New Roman','Times','serif';">. During the applicable Royalty Term and subject to Section 10.10,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will make royalty payments to Surface, on a Licensed Product-by-Licensed Product basis, based on Annual Net Sales of the applicable Licensed Product within the Field in the Novartis Territory by Novartis and its Related Parties at the applicable rates set forth below. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will pay to Surface royalties on a T1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Licensed Product-by-T1 Licensed Product basis on Annual Net Sales for each T1 Licensed Product at the royalty rates (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) set forth below (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Net</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:76%;" align="center"><tr><td style="vertical-align:middle;width:65.87%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:7.64%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:7.64%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.87%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales</b></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:7.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Paid on the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Portion of</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales in the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">United States</b></p></td><td style="vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:7.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Paid on the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Portion of</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales outside the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">United States</b></p></td></tr><tr><td style="vertical-align:top;width:65.87%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:7.64%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:7.64%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The applicable T1 Net Sales Royalty will be calculated by reference to the worldwide Annual Net Sales of each T1 Licensed Product. See Exhibit M for an example of such calculation. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Global Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. Novartis will pay to Surface royalties on a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Global Licensed Product-by-Global Licensed Product basis on Annual Net Sales for each Global Licensed Product at the royalty rates (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) set forth below (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Global Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:76%;" align="center"><tr><td style="vertical-align:middle;width:65.87%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:7.64%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:7.64%;margin:0pt;padding:0.25pt;"></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:76%;" align="center"><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.87%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales</b></p></td><td style="vertical-align:bottom;width:9.41%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:7.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Paid on the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Portion of</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales in the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">United States</b></p></td><td style="vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:7.64%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Paid on the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Portion of</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales outside the</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">United States</b></p></td></tr><tr><td style="vertical-align:top;width:65.87%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:7.64%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:9.41%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:7.64%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The applicable Global Net Sales Royalty will be calculated by reference to the worldwide Annual Net Sales of each Global Licensed Product. See Exhibit M for an example of such calculation. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will pay to Surface royalties on a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Licensed Product-by-Regional Licensed Product basis on Annual Net Sales for each Regional Licensed Product in the Novartis Territory at the royalty rates (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Regional</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) set forth below (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Regional Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:68%;" align="center"><tr><td style="vertical-align:middle;width:81.83%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:8.54%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.83%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales</b></p></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:8.54%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b></p></td></tr><tr><td style="vertical-align:top;width:81.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The applicable Novartis Regional Net Sales Royalty will be calculated by reference to the Annual Net Sales of each Regional Licensed Product in the Novartis Territory. See Exhibit M for an example of such calculation. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">Surface will pay to Novartis royalties on a</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Regional Licensed Product-by-Regional Licensed Product basis on Annual Net Sales for each Regional Licensed Product in the Surface Territory at the royalty rates (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Regional</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">,&#8221; and together with the Novartis Regional</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Royalty Rates, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Royalty Rates</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) set forth below (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Regional Net Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">,&#8221; and together with the Novartis Regional Net Sales Royalty, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regional Net</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Royalty</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:68%;" align="center"><tr><td style="vertical-align:middle;width:81.83%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:8.54%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.83%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Net Sales</b></p></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:8.54%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b></p></td></tr><tr><td style="vertical-align:top;width:81.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:9.61%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:8.54%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The applicable Surface Regional Net Sales Royalty will be calculated by reference to the Annual Net Sales of each Regional Licensed Product in the Surface Territory. See Exhibit M for an example of such calculation. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.9.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Combinations</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the foregoing, royalties on any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Combinations will be calculated in accordance with Exhibit A-1.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Royalty Terms</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Royalty Term</i><font style="font-family:'Times New Roman','Times','serif';">. Subject to this Section 10.10, on a Licensed Product-by-Licensed Product and country-by-country basis, the royalties due under Section 10.9 will be payable on Annual Net Sales from the First Commercial Sale of a particular Licensed Product in a country until the later of (a) expiration of the last Valid Claim of Royalty Patents Covering such Licensed Product in such country, or (b) fifteen (15) years after First Commercial Sale of such Licensed Product in such country (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Royalty Reduction upon Patent Expiration</i><font style="font-family:'Times New Roman','Times','serif';">. If royalties are payable</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in a particular country under Section 10.9 on Annual Net Sales of a particular Licensed Product during the Royalty Term but after the expiration of the last Valid Claim of Royalty Patents Covering such Licensed Product in such country, then the royalties payable on Annual Net Sales of such Licensed Product in such country will be calculated as set forth in Section 10.9, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the royalties payable on Annual Net Sales of such Licensed Product in such country will be reduced by [***] as of the date that such Licensed Product is no longer Covered by a Valid Claim of Royalty Patents in such country. The royalty rate tier applicable to the Annual Net Sales of such Licensed Product in such country will be applied </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">pro rata</i><font style="font-family:'Times New Roman','Times','serif';"> on a Calendar Quarter-by-Calendar Quarter basis, with reference to the aggregate worldwide Annual Net Sales </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">of all Licensed Products with respect to the applicable Licensed Target. See Exhibit M for an example of such calculation. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Reduction for Third Party Obligations</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">In the event that Novartis determines that</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">intellectual property owned or controlled by a Third Party would be infringed or misappropriated by the [***] of any Licensed Product in the Field in the Novartis Territory under this Agreement, Novartis shall have the right to negotiate and acquire rights to such intellectual property through a license or otherwise (including pursuant to any settlement agreement) and to deduct from [***] on such Licensed Product due to Surface with respect to a given Calendar Quarter [***] by Novartis to such Third Party with respect to such Licensed Product, subject to the limitation set forth in Section 10.10.6. [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">In the event that Surface determines that</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">intellectual property owned or controlled by a Third Party would be infringed or misappropriated by the [***] any Regional Licensed Product in the Field in the Surface Territory under this Agreement, Surface shall have the right to negotiate and acquire rights to such intellectual property through a license or otherwise (including pursuant to any settlement agreement) and to deduct from [***] on such Regional Licensed Product due to Novartis with respect to a given Calendar Quarter [***] by Surface to such Third Party with respect to such Regional Licensed Product, subject to the limitation set forth in Section 10.10.6. [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Only One Royalty</i><font style="font-family:'Times New Roman','Times','serif';">. Only one royalty will be due with respect to the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">sale of the same unit of Licensed Product. Only one royalty will be due hereunder on the sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of such Licensed Product infringes more than one claim of the Royalty Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Reduction for Biosimilar Competition</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">foregoing, on a country-by-country basis, in the event of Loss of Market Exclusivity with respect to a Licensed Product in a country, the applicable Royalty Rates for Annual Net Sales of such Licensed Product set forth in Section 10.9 will be reduced by [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.10.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Royalty Minimum</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the foregoing in this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 10.10, in no event will the [***] otherwise due to a Party in a Calendar Quarter be reduced by more than [***] of the amount that would otherwise be due hereunder; and provided further that any such reduction not fully taken as a result of the application of this Section 10.10.6, may be carried forward and applied against future [***] otherwise owed. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.11. Other Amounts Payable</b><font style="font-family:'Times New Roman','Times','serif';">. With respect to any amounts owed under this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement by one Party to the other for which no other invoicing and payment procedure is specified in this Section 10 (which amounts may include, for example, Manufacturing Costs pursuant to Section 8 and Third Party Payments that are the responsibility of one Party or the other pursuant to Section 9.5), within [***] after the end of each Calendar Quarter, each Party will provide an invoice, together with reasonable supporting documentation, to the other Party for such amounts owed in respect of such Calendar Quarter. The owing Party will pay any undisputed amounts within [***] of receipt of the invoice, and any disputed amounts owed by a Party will be paid within [***] of resolution of the dispute. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Terms</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Manner of Payment</i><font style="font-family:'Times New Roman','Times','serif';">. All payments to be made by a Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">hereunder will be made in Dollars by wire transfer to such bank account as the other Party may designate. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Reports and Royalty Payments</i><font style="font-family:'Times New Roman','Times','serif';">. For as long as royalties are due</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">under Section 10.9, to the extent a Party owes royalties to the other Party hereunder, such paying Party will furnish to the other Party a written report, within [***] after the end of each Calendar Quarter, showing in Dollars, the amount of Annual Net Sales of Licensed Products and royalty due for such Calendar Quarter. Upon receipt of such written report, the receiving Party shall issue an invoice to the paying Party. Royalty payments for each Calendar Quarter will be due within [***] of receipt of such written invoice for the Calendar Quarter. The report will include, at a minimum, the following information for the applicable Calendar Quarter, each listed by product and by country of sale: [***] such reports will be treated as Confidential Information of Novartis or Surface, as applicable. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Records and Audits</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party shall keep complete, true and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including in relation to Development Costs and Net Sales and royalties. Each Party will keep such books and records for at least [***] following the Calendar Year to which they pertain. Each Party (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Auditing Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) may, upon written request, cause an internationally-recognized independent accounting firm (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Auditor</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), which is reasonably acceptable to the other Party (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Audited Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), to inspect the relevant records of such Audited Party and its Affiliates to verify the payments </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">made by the Audited Party and the related reports, statements and books of accounts, as applicable. Before beginning its audit, the Auditor shall execute an undertaking acceptable to the Audited Party by which the Auditor agrees to keep confidential all information reviewed during the audit. The Auditor shall have the right to disclose to Auditing Party only its conclusions regarding any payments owed under this Agreement. Each Party and its Affiliates shall make their records available for inspection by the Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from the Auditing Partner. The records shall be reviewed solely to verify the accuracy of the Audited Party&#8217; royalties and other payment obligations and compliance with the financial terms of this Agreement. Such inspection right shall not be exercised more than [***] in any [***] and not more frequently than [***] with respect to records covering any specific period of time. In addition, Auditing Party shall only be entitled to audit the books and records of Audited Party from the [***] prior to the Calendar Year in which the audit request is made. The Auditing Party agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any law, regulation or judicial order. The Auditor shall provide its audit report and basis for any determination to Audited Party at the time such report is provided to the Auditing Party before it is considered final. In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by either Party, the underpaid or overpaid amount shall be settled promptly. The Auditing Party shall pay for such inspections, as well as its expenses associated with enforcing its rights with respect to any payments hereunder. In addition, if an underpayment of more than [***] of the total payments due hereunder for the applicable year is discovered, the fees and expenses charged by the Auditor shall be paid by Audited Party. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Currency Exchange</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to Annual Net Sales invoiced in</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Dollars, the Annual Net Sales and the amounts due to Surface hereunder will be expressed in Dollars. When conversion of payments from any foreign currency is required to be undertaken by Novartis, the Dollar equivalent shall be calculated using Novartis&#8217; then-current standard exchange rate methodology as applied in its external reporting for the conversion of foreign currency sales into Dollars. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.5.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Taxes</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.5.1. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis may withhold from payments due to Surface amounts</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for payment of any withholding tax that is required by Law to be paid to any taxing authority with respect to such payments. Novartis will provide Surface all relevant documents and correspondence, and will also provide to Surface any other cooperation or assistance on a reasonable basis as may be necessary to enable Surface to claim exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Novartis will give proper evidence from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Novartis making payments from a single source in the U.S., where possible. Notwithstanding the foregoing, if Novartis assigns its rights and obligations hereunder to, or otherwise causes payments to be made to Surface by, an Affiliate or Third Party outside the United States pursuant to Section 16.1 or uses intellectual property described herein outside of the United States, and if Novartis or such Affiliate or Third Party is required by applicable Law to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings (including withholdings on the withheld amounts), Surface receives an amount equal to the sum it would have received had no such withholding been made, provided, however, that that Novartis will have no obligation to pay any additional amount to the extent that the withholding tax would not have been imposed but for (a) the failure by Surface to take advantage of an otherwise available exemption from or reduction in the rate of withholding tax under any applicable income tax convention between the United States and the jurisdiction in which such Affiliate or Third Party is domiciled, or (b) the assignment by Surface of its rights under this Agreement or any redomiciliation of Surface outside of the United States. Notwithstanding the foregoing, if Novartis has an obligation to pay additional amounts to account for withholding taxes, it will be entitled to a full amount of any foreign tax credit attributable to Surface if and when realized in cash by Surface as a result of such payment. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.5.2. </b><font style="font-family:'Times New Roman','Times','serif';">Surface may withhold from payments due to Novartis amounts</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">for payment of any withholding tax that is required by Law to be paid to any taxing authority with respect to such payments. Surface will provide Novartis all relevant documents and correspondence, and will also provide to Novartis any other cooperation or assistance on a reasonable basis as may be necessary to enable Novartis to claim exemption from such withholding taxes and to </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">receive a refund of such withholding tax or claim a foreign tax credit. Surface will give proper evidence from time to time as to the payment of any such tax. The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Surface making payments from a single source in the U.S., where possible. Notwithstanding the foregoing, if Surface assigns its rights and obligations hereunder to, or otherwise causes payments to be made to Novartis by, an Affiliate or Third Party outside the United States pursuant to Section 16.1 or uses intellectual property described herein outside of the United States, and if Surface or such Affiliate or Third Party is required by applicable Law to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings (including withholdings on the withheld amounts), Novartis receives an amount equal to the sum it would have received had no such withholding been made, provided, however, that that Surface will have no obligation to pay any additional amount to the extent that the withholding tax would not have been imposed but for (a) the failure by Novartis to take advantage of an otherwise available exemption from or reduction in the rate of withholding tax under any applicable income tax convention between the United States and the jurisdiction in which such Affiliate or Third Party is domiciled, or (b) the assignment by Novartis of its rights under this Agreement or any redomiciliation of Novartis outside of the United States. Notwithstanding the foregoing, if Surface has an obligation to pay additional amounts to account for withholding taxes, it will be entitled to a full amount of any foreign tax credit attributable to Novartis if and when realized in cash by Novartis as a result of such payment. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.5.3. </b><font style="font-family:'Times New Roman','Times','serif';">Apart from any such permitted withholding and those</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">deductions expressly included in the definition of Net Sales, the amounts payable hereunder will not be reduced on account of any taxes, charges, duties or other levies. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Blocked Payments</i><font style="font-family:'Times New Roman','Times','serif';">. In the event that, by reason of applicable Law</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in any country, it becomes impossible or illegal for a Party to transfer, or have transferred on its behalf, payments owed the other Party hereunder, such Party will promptly notify the other Party of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the other Party within a period of [***], in a recognized banking institution selected by the transferring Party, as the case may be, and identified in a written notice given to the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.12.7. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Interest Due</i><font style="font-family:'Times New Roman','Times','serif';">. Each paying Party will pay the other Party interest</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">on any undisputed payments that are not paid on or before the date such payments are due under this Agreement at a rate of [***] or the maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">10.13. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Convenience</b><font style="font-family:'Times New Roman','Times','serif';">. The royalty and other payment obligations set forth</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">hereunder have been agreed to by the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts to each Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11. CONFIDENTIALITY AND PUBLICATION </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nondisclosure Obligation</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">All Confidential Information disclosed by one Party to the other Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">under this Agreement will be maintained in confidence by the receiving Party and will not be disclosed to a Third Party or used for any purpose except to exercise its licenses and other rights, to perform its obligations, or as otherwise set forth herein, without the prior written consent of the disclosing Party, except to the extent that such Confidential Information: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#8217;s business records; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) is known to the public before its receipt from the disclosing Party, or thereafter becomes generally known to the public through no breach of this Agreement by the receiving Party; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) is subsequently disclosed to the receiving Party by a Third Party who is not known by the receiving Party to be under an obligation of confidentiality to the disclosing Party; or </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) is developed by the receiving Party independently of Confidential Information received from the disclosing Party, as documented by the receiving Party&#8217;s business records. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Specific aspects or details of Confidential Information will not be deemed to be within the public domain or in the possession of the recipient Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the recipient Party. Further, any combination of Confidential Information will not be considered in the public domain or in the possession of the recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the recipient Party unless the combination and its principles are in the public domain or in the possession of the recipient Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding the obligations of confidentiality and non-use set forth</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">above and in Section 11.1.3. below, a receiving Party may provide Confidential Information disclosed to it, and disclose the existence and terms of this Agreement or the as may be reasonably required in order to perform its obligations and to exploit its licenses and other rights under this Agreement, and specifically to (a) Related Parties, and their employees, directors, agents, consultants, or advisors to the extent necessary for the potential or actual performance of its obligations or exercise of its licenses and other rights under this Agreement in each case who are under an obligation of confidentiality with respect to such information that is no less stringent than the terms of this Section 11.1; (b) governmental or other Regulatory Authorities in order to obtain patents or perform its obligations or exploit its rights under this Agreement, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such Confidential Information will be disclosed only to the extent reasonably necessary to do so, and where permitted, subject to confidential treatment; (d) the extent required by Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity (including as a result of an initial public offering by Surface); [***] and (e) to Third Parties to the extent a Party is required to do so pursuant to the terms of an In-License. If a Party is required by Law to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section 11.1, such Party will promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure. Notwithstanding Section 11.1.1, Confidential Information that is permitted or required to be disclosed will remain otherwise subject to the confidentiality and non-use provisions of this Section 11.1.[***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.2. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publication and Publicity</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Publication</i><font style="font-family:'Times New Roman','Times','serif';">. Except for disclosures permitted pursuant to Section 11.1 and 11.2.2, either Party wishing to make a publication or public presentation that contains the Confidential Information of the other Party or any results of Research and Development activities under the Collaboration will deliver to the other Party a copy of the proposed written publication or presentation at least [***] prior to submission for publication or presentation. The reviewing Party will have the right (a) to propose modifications to the publication or presentation for patent reasons or trade secret reasons or to remove Confidential Information of the reviewing Party or its Related Parties, and the publishing Party will remove all Confidential Information of the other Party if requested by the reviewing Party and otherwise reflect such Party&#8217;s reasonable comments into consideration, or (b) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party will delay submission or presentation for a period of [***] (or such shorter period as may be mutually agreed by the Parties) to enable the non-publishing Party to file patent applications protecting such Party&#8217;s rights in such information. [***] Notwithstanding the foregoing, in no event will Surface, its Affiliates or Sublicensees make a publication or public presentation with respect to any T1 Target, T1 Antibody Candidate, T1 Licensed Product, Global Target, Global Antibody Candidate or Global Licensed Product without the prior written consent of Novartis. Further, neither Party will submit or publish any article or other publication to or with any scientific journal or other publisher that requires, as a condition of publication, that the submitting Party agree to make available to the publisher or Third Parties any Antibodies or other Materials which are the subject of the publication. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Publicity</i><font style="font-family:'Times New Roman','Times','serif';">. Except as set forth in Section 11.1, 11.2.1 and 11.3, the terms of this Agreement may not be disclosed by either Party, and neither Party will use the name, Trademark, trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to this Agreement, its subject matter, or the activities of the Parties hereunder without the prior express written permission of the other Party except (a) as may be required by applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in any country other than the United States or of any stock exchange or listing entity, provided that the Party issuing such press release gives reasonable notice prior to use of such name, Trademark, trade name or logo of the other Party, and otherwise complies with Section 11.1.2, or (b) as expressly permitted by the terms hereof. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Press Release</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.3.1. </b><font style="font-family:'Times New Roman','Times','serif';">Except as provided in Section 11.3.2, neither Party will issue a press release or public announcement relating to this Agreement without the prior written approval of the other Party (such approval not to be unreasonably withheld, conditioned or delayed), except that a Party may (a) once a press release or other public statement is approved in writing by both Parties, make subsequent public disclosure of the information contained in such press release or other written statement without the further approval of the other Party, and (b) issue a press release or public announcement as required by applicable Law (including a press release corresponding to any securities disclosure, such as pursuant to a Form 8-K), including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or listing entity, provided that the Party issuing such press release gives reasonable prior notice to the other Party of and the opportunity to comment on the press release or public announcement, and otherwise complies with this Section 11. In addition, Surface may with Novartis&#8217; prior written approval, such approval not to be unreasonably withheld, conditioned or delayed, issue a press release regarding (x) the exercise of any Option, or (y) the payment or receipt of any milestone payments under this Agreement with respect to any Licensed Products, provided, that (i) such press release does not identify the Antibody Candidate or Licensed Target; and (ii) otherwise complies with this Section 11. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">11.3.2. </b><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding anything in this Section 11.3 to the contrary, (a) either Party may issue a press release or make a public disclosure relating to such Party&#8217;s Development, Manufacturing or Commercialization activities under this Agreement with respect to Regional Licensed Products in such Party&#8217;s Territory; and (b) Novartis may issue a press release or make a public disclosure relating to the Research, Development, Manufacturing or Commercialization activities under this Agreement with respect to the T1 Target, T1 Antibody Candidates, T1 Licensed Products, Global Targets, Global Antibody Candidates and Global Licensed Products, provided that such press release or public disclosure does not disclose Confidential Information of the other Party. Prior to making any such disclosure under clause (a) of this Section 11.3.2, however, the Party making the disclosure will provide the other Party with a draft of such proposed disclosure within a reasonable time (but at least [***] prior to disclosure for the other Party&#8217;s review and comment, and the disclosing Party will consider in good faith any timely comments provided by the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12. REPRESENTATIONS, WARRANTIES AND COVENANTS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Representations and Warranties as of the Effective Date</b><font style="font-family:'Times New Roman','Times','serif';">. Each Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">represents and warrants to the other Party that, as of the Effective Date: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">such Party is a corporation duly organized, validly existing and in good</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">standing under the laws of its jurisdiction of incorporation or formation; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">such Party has all requisite corporate power and corporate authority to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">enter into this Agreement and to carry out its obligations under this Agreement; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.1.3. </b><font style="font-family:'Times New Roman','Times','serif';">all requisite corporate action on the part of such Party, its directors and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">stockholders required by applicable Law for the authorization, execution and delivery by such Party of this Agreement, and the performance of all obligations of such Party under this Agreement, has been taken; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.1.4. </b><font style="font-family:'Times New Roman','Times','serif';">the execution, delivery and performance of this Agreement, and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">compliance with the provisions of this Agreement, by such Party do not and will not: (a) violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b) constitute a breach of, or default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or instrument, whether written or oral, by which such Party or any of its assets are bound, or (c) violate or conflict with any of the provisions of such Party&#8217;s organizational documents (including any articles or memoranda of organization or association, charter, bylaws or similar documents; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.1.5. </b><font style="font-family:'Times New Roman','Times','serif';">no consent, approval, authorization or other order of, or filing with, or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">notice to, any Governmental Authority or other Third Party is required to be obtained or made by such Party in connection with the authorization, execution and delivery by the Company of this Agreement, except as required pursuant to the HSR Act. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties by Surface</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface represents and warrants to Novartis as of the Effective Date that: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.1. </b><font style="font-family:'Times New Roman','Times','serif';">Schedule 12.2.1 sets forth a complete and accurate list of (a) all Surface Patents in existence as of the Effective Date, indicating the owner; and (b) all license, assignment, distribution or other agreements in existence as of the Effective Date relating to the Surface Technology, including all Existing Surface In-Licenses;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.2. </b><font style="font-family:'Times New Roman','Times','serif';">Except as set forth on Schedule 12.2.2, to Surface&#8217;s knowledge, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface Technology in existence as of the Effective Date comprises all of the intellectual property rights used by or on behalf of Surface and its Affiliates in the Research, Development and Manufacturing of the Antibody Candidates and Licensed Products as of the Effective Date; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.3. </b><font style="font-family:'Times New Roman','Times','serif';">Except as set forth on Schedule 12.2.3, Surface (a) owns or has a valid</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">license to, or has a valid option to license, all Surface Technology in existence as of the Effective Date, including those Antibody Candidates and Licensed Products in existence as of the Effective Date; and (b) has the right, or an option to obtain the right, and authority to (i) grant to Novartis and its Related Parties, the licenses under the Surface Technology in existence as of the Effective Date hereunder; and (ii) use, disclose, and commercially exploit, and to enable Novartis and its Related Parties to use, disclose, and commercially exploit (in each case under appropriate conditions of confidentiality) the Surface Technology in existence as of the Effective Date in the Field; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.4. </b><font style="font-family:'Times New Roman','Times','serif';">Surface has not granted its Affiliates or any Third Party, including any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">academic organization or agency, rights that would otherwise interfere or be inconsistent with Novartis&#8217; rights hereunder, and there are no agreements or arrangements other than as set forth on Schedule 12.2.4 to which Surface or any of its Affiliates is a party relating to Surface Technology, Antibody Candidates, or Licensed Product(s), that would (a) limit the rights granted to Novartis under this Agreement or (b) that restrict or result in a restriction on Novartis&#8217; ability to Research, Develop, Manufacture, use or Commercialize the Antibody Candidates and Licensed Product(s) in the Novartis Territory, in accordance with this Agreement; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.5. </b><font style="font-family:'Times New Roman','Times','serif';">with respect to any Surface Technology owned by Surface, (a) Surface and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">its Affiliates have obtained from all individuals who participated in any respect in the invention or authorship thereof, effective assignments of all ownership rights of such individuals in such Surface Technology, either pursuant to written agreement or by operation of law; and (b) all of its employees, officers, and consultants have executed agreements or have existing obligations under applicable Law requiring assignment to Surface or its Affiliate, as applicable, of all inventions made during the course of and as the result of the Collaboration; and, no officer or employee of Surface or its Affiliate is subject to any agreement with any other Third Party that requires such officer or employee to assign any interest in any Surface Technology to any Third Party; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.6. </b><font style="font-family:'Times New Roman','Times','serif';">all employees, officers, and consultants of Surface and its Affiliates have</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">executed agreements or have existing obligations under applicable Law and obligating the individual to maintain as confidential Surface&#8217;s Confidential Information as well as confidential information of other parties (including of Novartis and its Affiliates) that such individual may receive in the conduct of the Collaboration, to the extent required to support Surface&#8217;s obligations under this Agreement; and Surface and its Affiliates have taken all reasonable precautions to preserve the confidentiality of the Surface Know-How;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.7. </b><font style="font-family:'Times New Roman','Times','serif';">Except as set forth on Schedule 12.2.7, to Surface&#8217;s knowledge, no</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">sequence or any portion thereof of any Antibody Candidate including has been publicly disclosed or provided or otherwise made available to any Third Parties, including to any academic institutions or journals; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.8. </b><font style="font-family:'Times New Roman','Times','serif';">to Surface&#8217;s knowledge, Research, Development, Manufacture, use or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Commercialization of the Antibody Candidates and Licensed Products in the Field as proposed with this Agreement do not infringe or misappropriate the intellectual property rights of any Third Party, nor has Surface or any Affiliate received, any written notice alleging such infringement or misappropriation; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.9. </b><font style="font-family:'Times New Roman','Times','serif';">Neither Surface nor any Affiliate has initiated or been involved in any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">proceedings or other claims in which such Person alleges that any Third Party is or was infringing or misappropriating any Surface Technology, nor have any such proceedings been threatened by Surface or its Affiliates, nor does Surface or its Affiliates know of any valid basis for any such proceedings; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.10. </b><font style="font-family:'Times New Roman','Times','serif';">Neither Surface nor its Affiliates have entered into a government</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">funding relationship that would result in rights to any Antibody Candidate or Licensed Product residing in the US Government, National Institutes of Health, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the US Government as set forth in Public Law 96 517 (35 U.S.C. 200 204), as amended, or any similar obligations under the laws of any other country; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.11. </b><font style="font-family:'Times New Roman','Times','serif';">to the knowledge of Surface, (a) the issued patents in the Surface</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Patents as of the Effective Date are valid and enforceable without any claims, challenges, oppositions, nullity actions, interferences, inter-partes reexaminations, inter-partes reviews, post-grant reviews, derivation proceedings, or other proceedings pending or threatened and Surface has filed and prosecuted patent applications within the Surface Patents owned by Surface in good faith and complied with all duties of disclosure with respect thereto; (b) Surface has not committed any act, or omitted to commit any act, that may cause the Surface Patents to expire prematurely or be declared invalid or unenforceable; and (c) all application, registration, maintenance and renewal fees in respect of the Surface Patents as of the Effective Date have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of maintaining the Surface Patents; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.12. </b><font style="font-family:'Times New Roman','Times','serif';">Surface is its own &#8220;ultimate parent entity,&#8221; as that term is defined</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in 16 C.F.R.&#167; 801.1(a)(3) and as determined in compliance with 16 C.F.R. &#167;&#167; 801.1 and 801.12, and is not engaged in &#8220;manufacturing&#8221; as that term is defined in 16 C.F.R. &#167; 801.1(j). Surface does not have &#8220;total assets&#8221; equal to or greater than Fifteen Million, Three Hundred Thousand Dollars ($15,300,000), and Surface does not have &#8220;annual net sales&#8221; equal to or greater than One Hundred and Fifty-Two Million, Five Hundred Thousand Dollars ($152,500,000), in both cases, as determined in compliance with 16 C.F.R.&#167; 801.11 and used in Section 7A(a)(2)(B) of the Clayton Act, 15 U.S.C.&#167; 18A. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.3. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warranty Disclaimer</b><font style="font-family:'Times New Roman','Times','serif';">. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY PATENTS, KNOW-HOW, MATERIALS, ANTIBODY CANDIDATE, LICENSED PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE RESEARCH, DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY ANTIBODY CANDIDATE OR LICENSED PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Covenants</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Compliance</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party and its Related Parties will conduct the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Collaboration and the Development, Manufacture and Commercialization of the Licensed Products in accordance with all applicable Laws, including governmental regulations concerning cGLP, cGCP and cGMP. In addition, if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority), then the other Party will perform such activities as may be reasonably requested by the obligated Party to enable the obligated Party to comply with its legal obligation to such Regulatory Authority with respect to the Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Conflicting Transactions</i><font style="font-family:'Times New Roman','Times','serif';">. During the Term, Surface will not, and will</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">cause its Affiliates not to, enter into any agreement granting a license or other right under the Surface Technology that is inconsistent with this Agreement. During the Term, Novartis will not, and will cause its Affiliates not to, enter into any agreement granting a license or other right under the Novartis Technology that is inconsistent with this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">In-Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party will use Commercially Reasonable Efforts to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">maintain Control of all Patents, and Know-How licensed to such Party under the In-Licenses to which such Party is the contracting party. Each Party will use Commercially Reasonable Efforts not to materially breach or be in material default under any of its obligations under any In-License to which such Party is the contracting party that would be necessary or useful for the other Party to Research, Develop, Manufacture and Commercialize any Antibody Candidates or Licensed Products in the Field in such Party&#8217;s Territory pursuant to this Agreement. Each Party will not terminate any In-License to which such Party is the contracting party in a manner that would terminate rights that are sublicensed to the other Party. In the event that a Party receives notice of an alleged breach by such Party under an In-License to which it is a party and for which termination of such In-License is being sought by the counterparty, then such Party will promptly, but in no event less than [***] thereafter, provide written notice thereof to the other Party and grant the other Party the right (but not the obligation) to cure such alleged breach. In the event that a Party intends to materially amend an In-License to which it is a party, then such Party will promptly, but in no event less than [***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">before, provide written notice thereof to the other Party and grant the other Party the right (but not the obligation), acting reasonably, to reject any amendment that would either increase the receiving Party&#8217;s obligations under this Agreement, including any financial obligations or decrease the receiving Party&#8217;s rights under this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface In-Licenses</i><font style="font-family:'Times New Roman','Times','serif';">. Surface will [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">No Debarment</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party will use Commercially Reasonable Efforts to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">not use, in any capacity in connection with the Collaboration or the performance of its obligations under the Collaboration Agreement, any Person that has been debarred pursuant to Section 306 of the FD&amp;C Act, as amended, or that is the subject of a conviction described in such section. Each Party agrees to inform the other Party in writing immediately if it or any Person that is performing activities in the Collaboration or under the Collaboration Agreement, is debarred or is subject to debarment or is the subject of a conviction described in Section 306 of the FD&amp;C Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of the notifying Party&#8217;s knowledge, is threatened, relating to the debarment or conviction of the notifying Party or any Person or entity used in any capacity by such Party or any of its Affiliates in connection with the Collaboration or the performance of its other obligations under the Collaboration Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.4.6. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis represents and warrants as of the Effective Date that it has</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">determined in accordance with 16 C.F.R. Parts &#167;801.10 and &#167;801.13 that the value of the assets and voting securities of Surface as identified in accordance with the HSR Act rules including 16 C.F.R. &#167;801.13, &#167;801.14 and &#167;801.15, that Novartis will acquire and hold as of the Effective Date is less than [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Exclusivity</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">During the Exclusivity Period for an Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target, Surface will not, alone or with any Affiliates or Third Parties, [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">During the Exclusivity Period for an Option</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target, Novartis will not, alone or with any Affiliates or Third Parties, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1.3. </b><font style="font-family:'Times New Roman','Times','serif';">During the Exclusivity Period for a Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target, Surface will not, alone or with any Affiliates or Third Parties, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1.4. </b><font style="font-family:'Times New Roman','Times','serif';">During the Exclusivity Period for a Licensed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Target, Novartis will not, alone or with any Affiliates or Third Parties, [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1.5. </b><font style="font-family:'Times New Roman','Times','serif';">The Parties hereby acknowledge and agree</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">that (I) each Party&#8217;s obligations under this Section 12.5.1 will not apply to (A) any Research, Development, Manufacture or Commercialization of any molecule (including any Antibodies) that [***] and (B) any activities intended by either Party to ensure their compliance with this Section 12.5.1 (e.g., counter-screening), (II) this Section 12.5.1 will apply to any Antibody that is intended to [***]; and (III) each Party retains (A) the right to Research (but not Develop or Commercialize), and, subject to the terms and conditions of this Agreement, have others Research on its behalf, T1 Antibody Candidates, Option Target Antibody Candidates, Regional Antibody Candidates, Global Antibody Candidates or Licensed Products outside of the applicable Research Plan, (B) the right, solely to the extent reasonably necessary for any such Research, to Manufacture, or subject to the terms and conditions of this Agreement, have others Manufacture on its behalf, T1 Antibody Candidates, Option Target Antibody Candidates, Regional Antibody Candidates, Global Antibody Candidates or Licensed Products outside of the applicable Research Plan; and (C) the rights under the license grants in Section 9; provided further [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.1.6. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Other Programs</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.2.1.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Notwithstanding Section 12.5.1, in the event that Surface or its Affiliates acquire a Third Party or a portion of the business of a Third Party (whether by merger, stock purchase, purchase of assets, in-license or other means) (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party Acquisition</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) that is, prior to such acquisition, conducting a research, development or commercialization program that, if conducted by Surface at such time, would be a breach of Surface&#8217;s exclusivity obligation in Section 12.5.1 (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Competing Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Surface will use commercially reasonable efforts </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">to divest such Surface Competing Program promptly following the closing of such acquisition, and in any event will complete such divestment within [***] after the closing of such acquisition, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (i) such [***] period will be extended if, at the expiration of such time period, Surface provides competent evidence of reasonable on-going efforts to divest such Surface Competing Program, (ii) Surface may conduct the Surface Competing Program independently of Surface&#8217;s activities under this Agreement during such time period and without any use of any Restricted Technology, and (iii) Surface will cease all research, development and commercialization activities with respect to such Surface Competing Program if Surface has not completed such divestment within [***] after the closing of such acquisition (it being understood that Surface may thereafter continue its efforts to divest such asset). Surface will not be deemed in breach of Section 12.5.1 with respect to such Surface Competing Program so long as Surface complies with the terms of this Section 12.5.2.1. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) In the event of a Change of Control of Surface, the exclusivity obligations of Surface set forth in Section 12.5.1 will apply to and bind the Third Party referred to in the definition of Change of Control and its Affiliates subject to the following provisions: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii)[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) With respect to Sections 12.5.2.1(a), 12.5.2.1(b) and 12.5.2.1(c), Surface and its Affiliates (including such Third Party and its Affiliates under Sections 12.5.2.1(b) and 12.5.2.1(c)) will adopt reasonable procedures (which include appropriate administrative, physical and technical safeguards, including underlying operating system and network security controls and other firewalls) to prevent the use of any Restricted Technology in a manner that is in violation of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.5.2.2.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Notwithstanding Section 12.5.1, in the event that Novartis or its Affiliates make a Third Party Acquisition where the applicable Third Party or portion of such Third Party&#8217;s business, prior to such acquisition, conducting a research, development or commercialization program that, if conducted by Novartis at such time, would be a breach of Novartis&#8217;s exclusivity obligation in Section 12.5.1 (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Competing Program</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Novartis will use Commercially Reasonable Efforts to divest such Novartis Competing Program promptly following the closing of such acquisition, unless Novartis has exercised its right to terminate this Agreement pursuant to Section 15.2 with respect to the target of the Novartis Competing Program, and in any event will complete such divestment within [***] after the closing of such acquisition, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that (i) such [***] time period will be extended if, at the expiration of such time period (and any extensions thereto), Novartis provides competent evidence of reasonable on-going efforts to divest such Novartis Competing Program, (ii) Novartis may conduct the Novartis Competing Program independently of Novartis&#8217;s activities under this Agreement during such time period and without any use of any Restricted Technology, and (iii) Novartis will cease all research, development and commercialization activities with respect to such Novartis Competing Program if Novartis has not completed such divestment within one (1) year after the closing of such acquisition (it being understood that Novartis may thereafter continue its efforts to divest such asset). Novartis will not be deemed in breach of Section 12.5.1 with respect to such Novartis Competing Program so long as Novartis complies with the terms of this Section 12.5.2.2. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) In the event of a Change of Control of Novartis, the exclusivity obligations of Novartis set forth in Section 12.5.1 will apply to and bind the Third Party referred to in the definition of Change of Control and its Affiliates subject to the following provisions: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) With respect to Sections 12.5.2.2(a), 12.5.2.2(b) and 12.5.2.1(c), Novartis and its Affiliates (including such Third Party and its Affiliates under Sections 12.5.2.2(b) and 12.5.2.1(c)) will adopt reasonable procedures (which include appropriate administrative, physical and technical safeguards, including underlying operating system and network security controls and other firewalls) to prevent the use of any Restricted Technology in a manner that is in violation of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13. INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Indemnification by Novartis</b><font style="font-family:'Times New Roman','Times','serif';">. Novartis will indemnify, hold harmless</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and defend Surface, its Related Parties, and their respective directors, officers, employees and agents (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) from and against any and all Third Party claims, suits, losses, liabilities, damages, costs, fees and expenses (including reasonable attorneys&#8217; fees and litigation expenses) (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Losses</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) arising out of or resulting from, directly or indirectly, (a) any breach of, or inaccuracy in, any representation or warranty made by Novartis in this Agreement, or any breach or violation of any covenant or agreement of Novartis in or in the performance of this Agreement, (b) the negligence or willful misconduct by or of Novartis and its Related Parties, and their respective directors, officers, employees and agents in the performance of Novartis&#8217;s obligations under this Agreement, or (c) to the extent such Losses arise out of the Research, Development, Manufacturing or Commercialization of Antibody Candidates or Licensed Products by or on behalf of Novartis or its Related Parties pursuant to this Agreement. Novartis will have no obligation to indemnify the Surface Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by Surface in this Agreement, or any breach or violation of any covenant or agreement of Surface in, or in the performance of, this Agreement, or the negligence or willful misconduct by or of any of the Surface Indemnitees, or matters for which Surface is obligated to indemnify Novartis under Sections 13.2 or 13.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.2. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Indemnification by Surface</b><font style="font-family:'Times New Roman','Times','serif';">. Surface will indemnify, hold harmless,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and defend Novartis, its Related Parties and their respective directors, officers, employees and agents (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) from and against any and all Losses arising out of or resulting from, directly or indirectly, (a) any breach of, or inaccuracy in, any representation or warranty made by Surface in this Agreement, or any breach or violation of any covenant or agreement of Surface in, or in the performance of, this Agreement, (b) the negligence or willful misconduct by or of Surface and its Related Parties, and their respective directors, officers, employees and agents in the performance of Surface&#8217;s obligations under this Agreement, or (c) to the extent such Losses arise out of the Research, Development, Manufacturing or Commercialization of Antibody Candidates or Licensed Products by or on behalf of Surface and its Related Parties pursuant to this Agreement. Surface will have no obligation to indemnify the Novartis Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by Novartis in this Agreement, or any breach or violation of any covenant or agreement of Novartis in or in the performance of this Agreement, or the negligence or willful misconduct by or of any of the Novartis Indemnitees, or matters for which Novartis is obligated to indemnify Surface under Sections 13.1 or 13.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.3. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Liability</b><font style="font-family:'Times New Roman','Times','serif';">. Subject to any Supply Agreement, any Losses arising out of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Third Party product liability claims arising from the Development, Manufacture or Commercialization of Licensed Products will be (a) borne by Novartis, to the extent such Losses arise out of (i) the Research, Manufacture or Commercialization in or for the Novartis Territory by or on behalf of Novartis or its Related Parties of a Regional Licensed Product, or (ii) a T1 Licensed Product or Global Licensed Product anywhere in or for the world by or on behalf of Novartis and its Related Parties, and (b) borne by Surface, to the extent such Losses arise out of the Research, Manufacture or Commercialization in or for the Surface Territory by or on behalf of Surface and its Related Parties of a Regional Licensed Product. Subject to any Supply Agreement, any Losses arising out of Third Party product liability claims arising from the Development of Regional Licensed Products will be treated as Development Costs in accordance with Section 5.2.4; provided that (x) with respect to any Additional Development Activities, the Proposing Party will be solely responsible for any such liability claims unless and until the Non-Proposing Party delivers an Additional Development Opt-In Notice with respect to such Additional Development Activity; (y) after Surface exercises its Opt-Out Right, Surface will remain responsible for its portion of any such liability claims with respect to Development activities occurring up to and through the [***] period following Novartis&#8217; receipt of Surface&#8217;s Opt-Out Notice; and (z) after termination of this Agreement with respect to any Licensed Target by Novartis pursuant to Section 15.2 or by Surface pursuant to Section 15.3.1.1 or 15.4, (i) Novartis will remain responsible for its portion of any such liability claims with respect to any ongoing Clinical Studies that Surface elects to wind down under Section 15.5.1(b) until such wind-down process is complete, and (ii) Surface will be responsible for any liability claims with respect to any ongoing Clinical Studies that Surface elects to continue. The Party bearing such Losses in accordance with the immediately preceding two sentences will indemnify, hold harmless and defend the other Party and its Related Parties and their respective directors, officers, employees and agents from and against such Losses. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.4. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Procedure</b><font style="font-family:'Times New Roman','Times','serif';">. The Party entitled to indemnification under Section 13 (an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indemnified Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) shall notify the Party potentially responsible for such indemnification (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indemnifying Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) in writing promptly upon being notified of or actual knowledge of any claim or claims asserted or threatened against the Indemnified Party which could give rise to a right of indemnification under this Agreement; provided, that the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">failure to give such notice shall not relieve the Indemnifying Party of its indemnity obligation hereunder except to the extent that such failure materially prejudices the Indemnifying Party. If the Indemnifying Party has acknowledged in writing to the Indemnified Party the Indemnifying Party&#8217;s responsibility for defending a claim, the Indemnifying Party shall have the right to defend, at its sole cost and expense, such claim by all appropriate proceedings; provided, that the Indemnifying Party may not enter into any compromise or settlement unless (i) such compromise or settlement imposes only a monetary obligation on the Indemnifying Party and which includes as an unconditional term thereof, the giving by each claimant or plaintiff to the Indemnified Party of a release from all liability in respect of such claim; or (ii) the Indemnified Party consents to such compromise or settlement, which consent shall not be unreasonably withheld, conditioned or delayed unless such compromise or settlement involves (A) any admission of legal wrongdoing by the Indemnified Party, (B) any payment by the Indemnified Party that is not indemnified hereunder or (C) the imposition of any equitable relief against the Indemnified Party. If the Indemnifying Party does not elect to assume control of the defense of a claim or if a good faith and diligent defense, in the Indemnified Party&#8217;s reasonable opinion, is not being or ceases to be materially conducted by the Indemnifying Party, the Indemnified Party shall have the right, at the expense of the Indemnifying Party, upon at least [***] prior written notice to the Indemnifying Party of its intent to do so, to undertake the defense of such claim for the account of the Indemnifying Party (with counsel reasonably selected by the Indemnified Party and approved by the Indemnifying Party, such approval not to be unreasonably withheld, conditioned or delayed); </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the Indemnified Party shall keep the Indemnifying Party apprised of all material developments with respect to such claim. The Indemnified Party may not enter into any compromise or settlement without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed. The Indemnified Party will cooperate with the Indemnifying Party and may participate in, but not control, any defense or settlement of any claim controlled by the Indemnifying Party pursuant to this Section 13.4 and shall bear its own costs and expenses with respect to such participation; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that the Indemnifying Party shall bear such costs and expenses if counsel for the Indemnifying Party shall have reasonably determined that such counsel may not properly represent both the Indemnifying Party and the Indemnified Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.5. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</b><font style="font-family:'Times New Roman','Times','serif';">. NEITHER PARTY HERETO WILL BE LIABLE FOR</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT, OR THE EXERCISE OF ITS RIGHTS OR THE PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF [***] NOTHING IN THIS SECTION 13.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</b><font style="font-family:'Times New Roman','Times','serif';">. Commencing not later than the Initiation of the first Phase 1 Study under this Agreement, each Party will obtain and maintain insurance during the Term and for a period of at least [***] after the last commercial sale of any Licensed Product generated under the Collaboration for which it is responsible, with a reputable, solvent insurer in an amount appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under this Agreement. Specifically, each Party will maintain product liability insurance and clinical trial liability insurance with limits of at least [***] per occurrence and in annual aggregate. Upon request, each Party will provide the other Party with evidence of the existence and maintenance of such insurance coverage. Notwithstanding the foregoing, in the case of Novartis, and, in the case of Surface (whether or not after a Change of Control of Surface), after such time that Surface and its Affiliates have sales within one of the top [***] pharmaceutical companies by global sales, such obligation may be satisfied by a program of self-insurance. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">13.7. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer</b><font style="font-family:'Times New Roman','Times','serif';">. The Parties each acknowledge and agree, that (a) Research,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Development, and Commercialization is inherently uncertain, (b) no outcome or success of any Antibody Candidates or Licensed Products is or can be assured and (c) failure to achieve Development and Commercialization of Licensed Products will not in and of itself constitute a breach or default of any obligation in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14. INTELLECTUAL PROPERTY </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inventorship</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Inventorship for inventions and discoveries (including Know-How) first</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">made during the course of the performance of activities pursuant to the Collaboration will be determined in accordance with United States patent Laws for determining inventorship. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding anything to the contrary in this Agreement, each Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">will have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#167; 103(c)(2)-(c)(3) (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CREATE Act</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) when exercising its rights under this Agreement, but with respect to any Other Patents, only with the prior written consent of Surface in its sole discretion, and with respect to any Patents within Novartis Technology, only with the prior written consent of Novartis in its sole discretion. In the event that a Party intends to invoke the CREATE Act, once agreed to by the other Party if required by the preceding sentence, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#8220;joint research agreement&#8221; as defined in the CREATE Act. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.2. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership</b><font style="font-family:'Times New Roman','Times','serif';">. Surface will own the entire right, title and interest in and to all</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Know-How (and Patents claiming inventions therein) first developed or conceived solely by employee(s), agent(s) or consultant(s) of Surface or its Affiliates in the conduct of the Collaboration. Novartis will own the entire right, title and interest in and to all Know-How (and Patents claiming inventions therein) first developed or conceived solely by employee(s), agent(s) or consultant(s) of Novartis or its Affiliates in the conduct of the Collaboration. The Parties will jointly own the entire right, title and interest in and to all Know-How (and Patents claiming inventions therein) first developed or conceived jointly by employee(s), agent(s) or consultant(s) acting on behalf of Surface or its Affiliates, on the one hand, and employee(s), agent(s) or consultant(s) acting on behalf of Novartis or its Affiliates, on the other hand, in the conduct of the Collaboration. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution and Maintenance of Patents</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">IP Committee</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.1.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Composition</i><font style="font-family:'Times New Roman','Times','serif';">. The IP Committee will be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">comprised of at least [***] representative who is an employee of each Party. Each Party will appoint its respective representatives to the IP Committee within [***] of the Effective Date, and from time to time, may substitute one or more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. All IP Committee representatives will have appropriate expertise, seniority, decision-making authority and ongoing familiarity with the Collaboration and each Party&#8217;s representatives collectively will have relevant expertise in intellectual property portfolio management and licensing matters. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend IP Committee meetings, subject to such representatives and consultants (or the representative&#8217;s or consultant&#8217;s employer) undertaking confidentiality obligations, whether in a written agreement or by operation of law, no less stringent than the requirements of Section 11.1. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.1.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Meetings</i><font style="font-family:'Times New Roman','Times','serif';">. The IP Committee will meet as</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">necessary to carry out its duties under Section 14.3.1.3, but no more often than once per Calendar Quarter, unless otherwise agreed by its members. The IP Committee will meet in-person at Surface or Novartis or, alternatively, by means of teleconference, videoconference or other similar communications equipment. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.1.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">IP Committee Responsibilities</i><font style="font-family:'Times New Roman','Times','serif';">. The IP</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Committee will provide input regarding the following with respect to Licensed Products: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) strategies for Prosecuting and Maintaining Patents within the Novartis Technology and the Surface Technology; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) such other matters as the Parties agree in writing will be the responsibility of the IP Committee. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.1.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Decision-Making</i><font style="font-family:'Times New Roman','Times','serif';">. [***] </font></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">14.3.1.5. </b><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;">Term</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">. Either Party will have the right to</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">terminate the IP Committee upon [***] advance written notice to the other Party. Notwithstanding the foregoing, on a Regional Licensed Product-by-Regional Licensed Product basis during the Term for such Regional Licensed Product, Surface will have the right (but not the obligation) to continue to participate in the IP Committee in relation to any such Licensed Product until the fifteenth (15</font><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">th</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">) anniversary of the First Commercial Sale of such Regional Licensed Product in the Novartis Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Novartis Technology</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">General.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Subject to remainder of this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 14.3.2, as between the Parties, Novartis will have the sole responsibility to, at Novartis&#8217;s sole discretion, and sole responsibility for all applicable Patents Costs, to Prosecute and Maintain all Patents within Novartis Technology (other than within Joint Collaboration IP), in Novartis&#8217;s name. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Novartis will consult with Surface, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Patents. Novartis will furnish Surface, via electronic mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Patents, or copies of substantive documents filed with the relevant patent offices with respect to such Patents, and such other documents related to the Prosecution and Maintenance of such Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Surface and will consider in good faith timely comments from Surface thereon. Novartis will furnish Surface, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional Licensed Products in the Surface</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Territory and Novartis Technology</i><font style="font-family:'Times New Roman','Times','serif';">. In the event that Novartis</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">elects not to Prosecute and Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any Patent within the Novartis Technology (other than within Joint Collaboration IP) in the Surface Territory that Covers the sale, offer for sale, manufacture, use or import of any Regional Licensed Product, Novartis will notify Surface at least [***] before any such Patent would become abandoned, no longer available or otherwise forfeited, and subject to the provisions of any applicable Novartis In-License, Surface will have the right (but not the obligation), at Surface&#8217;s sole discretion, and sole responsibility for all applicable Patent Costs, to Prosecute and Maintain in the Surface Territory such Patent in the name of Novartis (which right will include the right to file additional Patents claiming priority to such Patent). Surface will consult with Novartis, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Patents. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Patents, or copies of documents filed with the relevant patent offices with respect to such Patents, and such other substantive documents related to the Prosecution and Maintenance of such Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Novartis and will consider in good faith timely comments from Novartis thereon. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Patents. Novartis will use Commercially Reasonable Efforts to make available to Surface its authorized attorneys, agents or representatives, or such of its employees as are reasonably necessary to assist Surface in exercising its rights described under this Section 14.3.2.2. Novartis will sign, or will use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to Prosecute and Maintain such Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Licensed Products and Global Licensed</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Products Worldwide, and Regional Licensed Products in the Novartis Territory, and Novartis Technology</i><font style="font-family:'Times New Roman','Times','serif';">. In the event that</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Novartis elects not to Prosecute and Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any Patent within the Novartis Technology (other than within Joint Collaboration IP) in the Novartis Territory that Covers the sale, offer for sale, manufacture, use or import of any T1 Licensed Product, Global Licensed Product or Regional Licensed Product (where, for clarity, the applicable territory is worldwide for any T1 Licensed Product or Global Licensed Product, and worldwide minus the Surface Territory for any Regional Licensed Product), Novartis will notify Surface at least [***] before any such Patent would become abandoned, no longer available or otherwise forfeited, whereupon at the written request of Surface </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Confidential</i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">- 144 - </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the Parties will meet to discuss any such decision by Novartis. Subject to Novartis&#8217;s consent, and subject to the provisions of any applicable Novartis In-License, Surface will have the right (but not the obligation), at Surface&#8217;s sole discretion, and sole responsibility for all applicable Patent Costs, to Prosecute and Maintain such Patent in the applicable territory described above in the name of Novartis (which right will include the right to file additional Patents claiming priority to such Patent). Surface will consult with Novartis, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Patents. Surface will furnish Novartis, via electronic </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Patents, or copies of documents filed with the relevant patent offices or other Governmental Authorities with respect to such Patents, and such other substantive documents related to the Prosecution and Maintenance of such Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Novartis and will consider in good faith timely comments from Novartis thereon. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Patents. Novartis will use Commercially Reasonable Efforts to make available to Surface its authorized attorneys, agents or representatives, or such of its employees as are reasonably necessary to assist Surface in exercising its rights described under this Section 14.3.2.3. Novartis will sign, or will use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to Prosecute and Maintain such Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Surface Technology</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">General.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Subject to remainder of this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Section 14.3.3, as between the Parties, Surface will have the sole responsibility to, at Surface&#8217;s sole discretion, and sole responsibility for all applicable Patents Costs, to Prosecute and Maintain all Patents within Surface Technology (other than within Joint Collaboration IP or Prosecution Patents) (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Patents</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), in Surface&#8217;s name. Surface will consult with</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Other Patents. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Other Patents, or copies of documents filed with the relevant patent offices or other Governmental Authorities with respect to such Other Patents, and such other substantive documents related to the Prosecution and Maintenance of such Other Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Novartis and will consider in good faith timely comments from Novartis thereon. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Other Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Licensed Products in the Surface Territory</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">and Novartis Territory and Surface Technology</i><font style="font-family:'Times New Roman','Times','serif';">. In the event</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">that Surface elects not to Prosecute and Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any Other Patent that Covers the sale, offer for sale, manufacture, use or import of any Licensed Product, Surface will notify Novartis at least [***] before any such Other Patent would become abandoned, no longer available or otherwise forfeited, whereupon at the written request of Novartis the Parties will meet to discuss any such decision by Surface. Subject to Surface&#8217;s consent, and subject to the provisions of any applicable Surface In-License, Novartis will have the right (but not the obligation), at Novartis&#8217;s sole discretion, and sole responsibility for all applicable Patents Costs, to Prosecute and Maintain in the Surface Territory such Other Patent in the name of Surface (which right will include the right to file additional Patents claiming priority to such Other Patent). Novartis will consult with Surface, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Other Patents. Novartis will furnish Surface, via electronic mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Other Patents, or copies of documents filed with the relevant patent offices or Governmental Authorities with respect to such Other Patents, and such other substantive documents related to the Prosecution and Maintenance of such Other Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Surface and will consider in good faith timely comments from Surface thereon. Novartis will furnish Surface, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Other Patents. Surface will use Commercially Reasonable Efforts to make available to Novartis its authorized attorneys, agents or representatives, or such of its employees as are reasonably necessary to assist Novartis in exercising its rights described under this Section 14.3.3.2. Surface will sign, or will use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to Prosecute and Maintain such Other Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Joint Collaboration IP and Prosecution Patents</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to remainder of this Section 14.3.4, as between the Parties, Novartis will have the right (but not the obligation), at Novartis&#8217;s sole discretion, and sole responsibility for all applicable Patents Costs, to Prosecute and Maintain all Patents (a) within Joint Collaboration IP, in the names of both Novartis and Surface; and (b) all Prosecution Patents in the name of Surface. Novartis will consult with Surface, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Patents within Joint Collaboration IP and Prosecution Patents. Novartis will furnish Surface, via electronic mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Patents within Joint Collaboration IP and Prosecution Patents, or copies of documents filed with the relevant patent offices or other Governmental Authorities with respect to such Patents within Joint Collaboration IP and Prosecution Patents, and such other substantive documents related to the Prosecution and Maintenance of such Patents within Joint Collaboration IP and Prosecution Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Surface and will consider in good faith timely comments from Surface thereon. Novartis will furnish Surface, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Patents within Joint Collaboration IP and Prosecution Patents. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">In the event that Novartis elects not to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Prosecute and Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any Patent within Joint Collaboration IP or any Prosecution Patent anywhere in the world, Novartis will notify Surface at least [***] before any such Patent within Joint Collaboration IP and Prosecution Patent would become abandoned, no longer available or otherwise forfeited, Surface will have the right (but not the obligation), at Surface&#8217;s sole discretion, and sole responsibility for all applicable Patents Costs, to Prosecute and Maintain such Patent worldwide (a) within Joint Collaboration IP in the names of both Novartis and Surface and (b) within Prosecution Patent in the name of Surface only. Surface will consult with Novartis, including through the IP Committee, on its strategy for the Prosecution and Maintenance of all such Patents within Joint Collaboration IP and Prosecution Patents. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of substantive proposed filings and documents received from outside counsel in the course of Prosecuting and Maintaining such Patents within Joint Collaboration IP and Prosecution Patents, or copies of documents filed with the relevant patent offices or other Governmental Authorities with respect to such Patents within Joint Collaboration IP and Prosecution Patents, and such other substantive documents related to the Prosecution and Maintenance of such Patents, and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Novartis and will consider in good faith timely comments from Novartis thereon. Surface will furnish Novartis, via electronic mail or such other method as mutually agreed by the Parties, copies of documents filed with the relevant national patent offices or other Governmental Authorities with respect to such Patents within Joint Collaboration IP and Prosecution Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.4.3. </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will use Commercially</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Reasonable Efforts to make available to the other its authorized attorneys, agents or representatives, or such of its employees as are reasonably necessary to assist the other Party in exercising its rights described under this Section 14.3.4. Each Party will sign, or will use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to Prosecute and Maintain Patents within Joint Collaboration IP and Prosecution Patents. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.3.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Patent Miscellaneous</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party hereby agrees: (a) to use Commercially</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Reasonable Efforts to make its employees, agents and consultants reasonably available to the other Party (or to the other Party&#8217;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such Party to undertake any Prosecution and Maintenance described herein; and (b) to reasonably cooperate in any such Prosecution and Maintenance by the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Infringement and Defense</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Notices</i><font style="font-family:'Times New Roman','Times','serif';">. Each Party will promptly report in writing to the other Party of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">any Competitive Infringement of which such Party (or any of its Affiliates or Sublicensees) becomes aware, and will provide the other Party with all available evidence of such Competitive Infringement in such Party&#8217;s Control. Subject to the terms of this Section 14.4, the JSC will discuss in good faith strategies for abating such Competitive Infringement of any Regional Licensed Product within each of the Party&#8217;s respective Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Rights to Enforce</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.2.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Competitive (Novartis) Infringement</i><font style="font-family:'Times New Roman','Times','serif';">. As</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">between the Parties, Novartis will have the exclusive right (but not the obligation), at Novartis&#8217;s sole discretion, through counsel of its choosing which is reasonably acceptable to Surface, to seek to abate any Competitive (Novartis) Infringement by enforcing any Patents within Surface Technology exclusively (even as to Surface) licensed to Novartis hereunder or any Novartis Technology. If Novartis does not take steps to abate such Competitive (Novartis) Infringement, within [***] after receipt of written notice of such Competitive (Novartis) Infringement (or such shorter period of time as is required to comply with the provisions of Section 14.4.2.3 or any other applicable Law in the United States or any other country in the Territory to not waive any statutory rights). Novartis will provide Surface with notice of such decision. Novartis will pay all Patent Costs incurred by Novartis for such enforcement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.2.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Competitive (Surface) Infringement</i><font style="font-family:'Times New Roman','Times','serif';">. As</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">between the Parties, Surface will have the exclusive right (but not the obligation), at Surface&#8217;s sole discretion, through counsel of its choosing which is reasonably acceptable to Novartis, to seek to abate any Competitive (Surface) Infringement by enforcing any Patents within Novartis Technology exclusively (even as to Novartis) licensed to Surface hereunder or any Surface Technology. If Surface does not take steps to abate such Competitive (Surface) Infringement, within [***] after receipt of written notice of such Competitive (Surface) Infringement (or such shorter period of time as is required to comply with the provisions of Section 14.4.2.3 or any other applicable Law in the United States or any other country in the Territory to not waive any statutory rights), Surface will provide Novartis will notice of such decision. Surface will pay all Patent Costs incurred by such Surface for such enforcement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.2.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Biosimilar Application</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Sections 14.4.2.1 or 14.4.2.2, if either Party (or any of their Related Parties) receives a copy of a Biosimilar Application naming a Licensed Product as a reference product or otherwise becomes aware that such a Biosimilar Application has been filed (such as in an instance described in Section 351(1)(9)(C) of the PHSA), such Party will promptly notify the other Party. If either Party receives any equivalent or similar certification or notice in the United States or any other jurisdiction, either Party will, promptly, notify and provide the other Party copies of such communication. Regardless of the Party that is the &#8220;reference product sponsor&#8221; for purposes of such Biosimilar Application: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) The Party with the enforcement rights under Sections 14.4.2.1 or 14.4.2.2 (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Lead Party</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; for the remainder of this Section 14.4.2.3) will designate pursuant to Section 351(l)(1)(B)(ii) of the PHSA the outside counsel and in-house counsel who will receive confidential access to the Biosimilar Application. The Lead Party will pay all Patent Costs incurred by such Party for such enforcement under this Section 14.4.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) The Lead Party will have the right, after consulting with the other Party, to list any Patents for which the enforcement rights in Sections 14.4.2.1 and 14.4.2.2 are applicable, insofar as they meet the statutory requirements pursuant to Section 351(l)(1)(3)(A), Section 351(l)(5)(b)(i)(II), or Section 351(l)(7) of the PHSA, to respond to any communications with respect to such lists from the filer of the Biosimilar Application, and to negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange other than that specified in Section 351(l) of the PHSA. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) The Lead Party will have the right, after consulting with the other Party, to identify Patents for which the enforcement rights in Sections 14.4.2.1 and 14.4.2.2 are applicable, or respond to relevant communications under any equivalent or similar listing to those described in the preceding Section 14.4.2.3(b) in any other jurisdiction outside of the United States. If required pursuant to applicable Law, upon the Lead Party&#8217;s request, the other Party will assist in the preparation of such list and make such response after consulting with the Lead Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) The other Party will (1) within [***] after the Lead Party&#8217;s written request, provide to the Lead Party all information, including a list of Patents Controlled by such other Party and for which the enforcement rights in Sections 14.4.2.1 and 14.4.2.2 are applicable, that is necessary or reasonably useful to enable the Lead Party to make any lists or communications with respect to such Patents that are described in the foregoing Sections 14.4.2.3(b) or 14.4.2.3(c), and (2) cooperate with the Lead Party&#8217;s reasonable requests in connection therewith to the extent required or not prohibited by applicable Law. The Lead Party will consult with the other Party prior to identifying any Patents controlled by such other Party as contemplated by this Section 14.4.2.3. The Lead Party will consider in good faith advice and suggestions with respect thereto received from the other Party, and will notify the other Party of any such lists or communications promptly after they are made. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) The Parties recognize that procedures other than those set forth above in this Section 14.4.2.3 may be applicable to Biosimilar Applications that are not governed by the PHSA. As a result, in the event that the Parties acting in </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">good faith mutually determine that certain provisions of Law in the United States or in any other country in the Territory are applicable to actions taken by the Parties with respect to Biosimilar Applications under this Section 14.4.2.3 in such country, the Parties will comply with any such applicable Law in such country (and any relevant and reasonable procedures established by the) in exercising their rights and obligations with respect to Biosimilar Applications under this Section 14.4.2.3. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Defense</i><font style="font-family:'Times New Roman','Times','serif';">. As between the Parties, the Party controlling the Prosecution and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Maintenance of any Patent under Section 14.3 (i.e., initially, Novartis for Patents contained in Novartis Technology and Joint Collaboration IP and Prosecution Patents and Surface for Other Patents ), will have the right (but not the obligation), at its sole discretion, to defend against a declaratory judgment action or other action challenging any such Patent, other than with respect to (a) any counter-claims in any enforcement action brought by the other Party pursuant to Section 14.4.2 or (b) any action by a Third Party in response to an enforcement action brought by the other Party, which in both cases ((a) and (b)) will be controlled by such other Party. If the Party controlling such Prosecution and Maintenance of Patents under Section 14.3 does not defend such Patent under this Section 14.4.3 within [***] (or such shorter period of time as is required to comply with the provisions of Section 14.4.2.3 or any other applicable Law in the United States or any other country in the Territory to not waive any statutory rights), or elects not to continue any such defense (in which case it will promptly provide notice thereof to the other Party), then the other Party will have the right (but not the obligation), at its sole discretion, to defend any such Patent. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Withdrawal, Cooperation and Participation</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">infringement or defensive action identified above in this Section 14.4 and subject to the terms of this Section: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">If the controlling Party ceases to pursue or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">withdraws from such action, it will promptly notify the other Party (in sufficient time to enable the other Party to meet any deadlines by which any action must be taken to preserve any rights in such infringement or defensive action (including any such period of time as is required to comply with the provisions of Section 14.4.2.3)) and, if permitted under Sections 14.4.3, such other Party may substitute itself for the withdrawing Party and proceed under the terms and conditions of this Section 14.4. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">The non-controlling Party will cooperate</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">with the Party controlling any such action (as may be reasonably requested by the controlling Party), including, at the controlling Party&#8217;s sole cost and expense, (1) providing access to relevant documents and other evidence, (2) using reasonable efforts to make its and its Affiliates and licensees and Sublicensees and all of their respective employees, subcontractors, consultants and agents available at reasonable business hours and for reasonable periods of time, but only to the extent relevant to such action, and (3) if reasonably necessary, by being joined as a party, subject for this clause (3) to the controlling Party agreeing to indemnify such non-controlling Party for its involvement as a named party in such action and paying those Patent Costs incurred by such non-controlling Party in connection with such joinder. The Party controlling any such action will keep the other Party reasonably updated with respect to any such action, including providing copies of all materials documents received or filed in connection with any such action. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.4.3. </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will have the right to consult</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">with the other Party regarding any such action controlled by such other Party, in each case at such first Party&#8217;s sole cost and expense. If a Party elects to so be involved, the controlling Party will provide the other Party and its counsel with an opportunity to consult with the controlling Party and its counsel regarding the prosecution of such action (including reviewing the contents of any correspondence, legal papers or other documents related thereto), and the controlling Party will take into account reasonable and timely requests of the other Party regarding such enforcement or defense. Nothing in this Section 14.4.4.3 will limit the controlling Party&#8217;s ability to prosecute any such action. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Settlement</i><font style="font-family:'Times New Roman','Times','serif';">. With respect to any infringement or defensive action</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">identified above in this Section 14.4, the Party controlling such action will have the right to settle or otherwise dispose of such action on such terms as such Party will determine in its sole discretion, including by granting a license or sublicense to a Third Party under the rights granted to such Party in Section 9; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that, notwithstanding the foregoing, no such settlement or other disposition will (a) impose any monetary restriction or obligation on or admit fault of the other Party and (b) adversely affect the other Party&#8217;s rights under this Agreement to any such Patent then being enforced or defended, in each case ((a) and (b) without the prior written consent of the other Party, not to be unreasonably withheld, delayed, or conditioned.) </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.4.6. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Damages</i><font style="font-family:'Times New Roman','Times','serif';">. [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.5. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Extensions</b><font style="font-family:'Times New Roman','Times','serif';">. For clarity, the Party controlling the Prosecution and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Maintenance of any Patent under Section 14.3 (i.e., initially, Novartis for Patents contained in Novartis Technology and Joint Collaboration IP and Prosecution Patents and Surface for Other Patents), will have the right to elect and file for patent term restoration or extension, supplemental protection certificate or any of their equivalents with respect to such Patents with respect to any Licensed Product in their respective Territories; provided that with respect to any Other Patents (whether so controlled by Novartis or Surface) in the Novartis Territory for any Licensed Product, Novartis will have the right to make any such election or filing in any country or region, other than the United States or any other country or region where such election or filing would impair the ability to obtain any other restoration, extension, certificate or equivalent for the same Other Patent in such country or region. The Parties will cooperate and shall take the other Party&#8217;s reasonable input into account in determining whether to obtain such patent term restoration, extension, supplemental protection certificate or equivalent thereof. Upon the request by a Party, such other Party will reasonably cooperate in the implementation of such requesting Party&#8217;s decisions made in a manner with this Section 14.5. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.6. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Listings</b><font style="font-family:'Times New Roman','Times','serif';">. With respect to any filings made to Regulatory Authorities with</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">respect to any Patents within the Novartis Technology or the Surface Technology for any Licensed Product within such Party&#8217;s Territory, including as required or allowed in connection with in the United States, the FDA&#8217;s Orange or Purple Book, if applicable, or outside the United States, other international equivalents, but subject to Section 14.4.2.3, (a) the Parties will list any such Patents as may be required by applicable Laws, and (b) otherwise (i) Novartis will have the sole right to make any such decision whether to list for Patents within the Collaboration IP or Joint Collaboration IP for the Novartis Territory and for any Licensed Product (other than any Regional Licensed Product in the Surface Territory); (ii) Surface will have the sole right to make any such decision whether to list for Patents within the Collaboration IP or Joint Collaboration IP for the Surface Territory for any Regional Licensed Product; and (iii) each Party will have the sole right to make any such decision whether to list for Patents otherwise within the Novartis Technology for Novartis or the Surface Technology for Surface with respect to any Licensed Product. Upon the request by a Party, such other Party will reasonably cooperate in the implementation of such requesting Party&#8217;s decisions made in a manner with this Section 14.6. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.7.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Rights</b><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the foregoing provisions of this Section 14, each Party&#8217;s rights and obligations with respect to any Patent under this Section 14 will be subject to the Third Party rights and obligations (including under any applicable In- License). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.8. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Interest</b><font style="font-family:'Times New Roman','Times','serif';">. All information exchanged between the Parties regarding the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Prosecution and Maintenance, and enforcement and defense, of the Patents under this Section 14 will be deemed Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such Prosecution and Maintenance, and enforcement and defense, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patents under this Section 14, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary contained herein, to the extent a Party has a good faith believe that any information required to be disclosed by such Party to the other Party under this Section 14 is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information and the Parties shall in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement, disclosing such information on a &#8220;for counsel eyes only&#8221; basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">T1 Licensed Products and Global Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">As between the Parties, Novartis has the sole</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and exclusive right to select and develop one or more Product Global Trademark(s) for use throughout the Novartis Territory for all T1 Licensed Products and Global Licensed Products. Such Product Global Trademark(s) may not include Trademarks owned or controlled by Surface. Novartis will own all rights to Product Global Trademarks and all goodwill associated therewith, throughout the Novartis Territory. Novartis will also own rights to any Internet domain names incorporating the applicable Product Global </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Trademarks or any variation or part of such Product Global Trademarks used as its URL address or any part of such address. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">In the event that Surface becomes aware of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">any infringement of any Product Global Trademark by a Third Party, Surface will promptly notify Novartis and the Parties will reasonably consult with each other and jointly determine the best way to prevent such infringement, including by the institution of legal proceedings against such Third Party; provided further that Novartis retains the sole right (but not obligation) to seek to abate any such infringement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Regional Licensed Products</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.2.1. </b><font style="font-family:'Times New Roman','Times','serif';">Each Party has the right to use any</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Trademark it owns or controls for Regional Licensed Products in its Territory at its sole discretion, and each Party and its Affiliates will retain all right, title and interest in and to its and their respective corporate names and logos. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.2.2. </b><font style="font-family:'Times New Roman','Times','serif';">Pursuant to Section 6.2.5, each Party will develop and propose, and the JSC will review and comment on, one or more RLP Trademark(s) for use throughout the Novartis Territory and Surface Territory, as applicable. Such RLP Trademark(s) considered by the JSC may include, in each Party&#8217;s sole discretion, the RLP Trademark(s) developed by the other Party with respect to the Commercialization of Regional Licensed Products in such Party&#8217;s Territory, but may not include other Trademarks owned or controlled by the other Party. Any RLP Trademark(s) that are developed and used by Novartis to promote and sell Regional Licensed Products in the Novartis Territory are hereinafter referred to as the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Novartis</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">RLP Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;. Any RLP Trademark(s) that are developed</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and used by Surface to promote and sell Regional Licensed Products in the Surface Territory are hereinafter referred to as the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Surface RLP Trademarks</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;. As between the Parties, Surface will own all rights to Surface RLP Trademarks and all goodwill associated therewith, throughout the Surface Territory and, if Novartis chooses to use such Surface RLP Trademarks for the Regional Licensed Products in the Novartis Territory, the Novartis Territory. As between the Parties, Novartis will own all rights to Novartis RLP Trademarks and all goodwill associated therewith, throughout the Novartis Territory and, if Surface chooses to use such Novartis RLP Trademarks for the Regional Licensed Products in the Surface Territory, the Surface Territory. Surface will also own rights to any Internet domain names incorporating the applicable Surface RLP Trademarks or any variation or part of such Surface RLP Trademarks used as its URL address or any part of such address; and Novartis will also own rights to any Internet domain names incorporating the applicable Novartis RLP Trademarks or any variation or part of such Novartis RLP Trademarks used as its URL address or any part of such address. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.2.3. </b><font style="font-family:'Times New Roman','Times','serif';">If a Party determines to use the other Party&#8217;s</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">RLP Trademarks to promote and sell any Regional Licensed Product in its Territory, then Surface and Novartis will enter into a separate trademark license agreement containing commercially reasonable and customary terms pursuant to which the Party owning such RLP Trademark will grant the other Party an exclusive, royalty-free license to use the applicable RLP Trademark(s) to Commercialize Regional Licensed Products in the other Party&#8217;s Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.2.4. </b><font style="font-family:'Times New Roman','Times','serif';">In the event either Party becomes aware of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">any infringement of any RLP Trademark by a Third Party, such Party will promptly notify the other Party and the Parties will consult with each other and jointly determine the best way to prevent such infringement, including by the institution of legal proceedings against such Third Party; provided further that the Party owning such RLP Trademark retains the sole right (but not obligation) to seek to abate any such infringement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">14.9.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">No Other Trademark Rights</i><font style="font-family:'Times New Roman','Times','serif';">. For the avoidance of doubt, neither Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">will have any right to use the other Party&#8217;s or the other Party&#8217;s Affiliates&#8217; corporate names or logos in connection with Research, Development, Manufacturing and Commercialization of Regional Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15. TERM AND TERMINATION </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</b><font style="font-family:'Times New Roman','Times','serif';">. This Agreement will be effective as of the Effective Date and, unless</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">terminated earlier, this Agreement will continue until the date on which neither Party is Researching, Developing, Manufacturing or Commercializing any Antibody Candidates or Licensed Products under this Agreement (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Term</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.2. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Novartis at Will</b><font style="font-family:'Times New Roman','Times','serif';">. Novartis may terminate this Agreement for</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">any reason or no reason on an Option Target-by Option Target or Licensed Target-by-Licensed Target basis at any time upon [***] prior written notice. Notwithstanding the foregoing, Novartis may not terminate this Agreement with respect to the T1 Licensed </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Target with effect prior to the earlier of (a) [***] following the Effective Date or (b) [***] following the first IND Filing with respect to a T1 Licensed Product; provided that this sentence shall not apply in the event of a Change of Control of Novartis or a Third Party Acquisition by Novartis or its Affiliates where the applicable Third Party or its Affiliates have a Competing Program (and in the case of a Third Party Acquisition, in Novartis&#8217; reasonable judgment, the Competing Program constitutes [***] or less of the value of the Third Party or business acquired in such Third Party Acquisition). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Material Breach</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Material Breach</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.3.1.1. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to Section 15.3.2, Surface will have</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the right to terminate this Agreement, on an Option Target-by-Option Target basis or Licensed Target-by-Licensed Target basis, upon delivery of written notice to Novartis in the event of any material breach by Novartis of any terms and conditions of this Agreement in a manner that fundamentally frustrates the transactions contemplated by this Agreement with respect to such Target, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such termination will not be effective if such breach has been cured within [***] after written notice thereof is given by Surface to Novartis specifying the nature of the alleged breach (or, if such default cannot be cured within such [***] period, within [***] after such notice if Novartis commences actions to cure such default within such [***] period and thereafter diligently continues such actions, but fails to cure the default by the end of such [***]; provided, however, that to the extent such material breach involves the failure to make a payment when due, such breach must be cured within [***] after written notice thereof is given by Surface to Novartis. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.3.1.2. </b><font style="font-family:'Times New Roman','Times','serif';">Subject to Section 15.3.2, Novartis will have</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the right to terminate this Agreement, on an Option Target-by-Option Target basis or Licensed Target-by-Licensed Target basis, upon delivery of written notice to Surface in the event of any material breach by Surface of any terms and conditions of this Agreement in a manner that fundamentally frustrates the transactions contemplated by this Agreement with respect to such Target, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';"> that such termination will not be effective if such breach has been cured within [***] after written notice thereof is given by Novartis to Surface specifying the nature of the alleged breach (or, if such default cannot be cured within such [***] period, within [***] after such notice if Surface commences actions to cure such default within such [***] period and thereafter diligently continues such actions, but fails to cure the default by the end of such [***]; provided, however, that to the extent such material breach involves the failure to make a payment when due, such breach must be cured within [***] after written notice thereof is given by Novartis to Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Disputed Breach</i><font style="font-family:'Times New Roman','Times','serif';">. If the alleged breaching Party disputes in good faith the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">existence or materiality of a breach specified in a notice provided by the other Party in accordance with Section 15.3.1 and such alleged breaching Party provides the other Party notice of such dispute within such [***] or [***] period, as applicable, then the non-breaching Party will not have the right to terminate this Agreement under Section 15.3.1 unless and until the dispute resolution process set forth in Section 16.3 has be completed (including the tolling and cure periods set forth therein). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.4. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Insolvency</b><font style="font-family:'Times New Roman','Times','serif';">. If, at any time during the Term (a) a case is</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">commenced by or against either Party under Title 11, United States Code, as amended, or analogous provisions of applicable Law outside the United States (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Bankruptcy Code</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and, in the event of an involuntary case under the Bankruptcy Code, such case is not dismissed within [***] after the commencement thereof, (b) either Party files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings (other than a case under the Bankruptcy Code), (c) either Party assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for either Party&#8217;s business, or (e) a substantial portion of either Party&#8217;s business is subject to attachment or similar process; then, in any such case ((a), (b), (c), (d) or (e)), the other Party may terminate this Agreement upon written notice to the extent permitted under applicable Law. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination by Surface for Cause or by Novartis for Convenience</b><font style="font-family:'Times New Roman','Times','serif';">.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Upon termination of this Agreement with respect to any Licensed Target or any Option Target by Novartis pursuant to Section 15.2 or by Surface pursuant to Section 15.3.1.1 or 15.4: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.1. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to such terminated Licensed Target, Novartis will pay for (a) for a period of [***] after the effective date of termination for the applicable Licensed Target, its portion of Development Costs for those Antibody Candidates or Licensed Products against such Licensed Target in the budget for the applicable Development Plan, and (b) its portion of reasonable costs and expenses (calculated in the same manner as </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Development Costs) to wind down those then on-going associated Clinical Studies that Surface identifies, by written notice to Novartis provided no later than [***] after the effective date of termination, will not be continued. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.2. </b><font style="font-family:'Times New Roman','Times','serif';">All licenses granted under Section 9 and other rights and obligations under</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">this Agreement with respect to such Licensed Target will terminate. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.3. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.4. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will as promptly as practicable (a) assign to Surface or Surface&#8217;s</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">designee possession and ownership of all material governmental or regulatory filings and approvals (including all material Regulatory Approvals, Regulatory Materials, Pricing Approvals) and copies of material correspondence and conversation logs [***] (to the extent assignable under applicable Laws), and (b) provide to Surface or Surface&#8217;s designee copies of all material data, reports, records and materials, and other material sales and marketing related information in Novartis&#8217;s possession and Control [***] In addition, Novartis will appoint Surface as Novartis&#8217;s or Novartis&#8217;s Affiliates&#8217; (and to the extent permitted by the applicable sublicense, its Sublicensees&#8217;) agent for [***] involving Regulatory Authorities in the Novartis Territory until all Regulatory Approvals, Regulatory Materials, Pricing Approvals and other governmental or regulatory filings required to be assigned to Surface hereunder have, in fact, been assigned to Surface or its designee but in no event longer than the [***] anniversary of the effective date of termination. In the event of failure to obtain assignment of any of the items required to be assigned under this Section 15.5.4, Novartis hereby consents and grants to Surface the right to access and reference (without any further action required on the part of Novartis, whose authorization to file this consent with any Regulatory Authority is hereby granted) [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.5. </b><font style="font-family:'Times New Roman','Times','serif';">If the effective date of termination is after [***] then, to the extent permitted by applicable Laws, Novartis or its Affiliates&#8217; (or to the extent permitted by the applicable sublicense, its Sublicensees&#8217;) will appoint Surface as its exclusive distributor [***] and grant Surface the right to appoint sub-distributors, until such time as all Regulatory Approvals in the Novartis Territory have been transferred to Surface or its designee but in no event longer than the [***] anniversary of the effective date of termination. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.6. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to [***] if</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees) are Manufacturing [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.7. Manufacturing of Combinations. </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.7.1. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to the Novartis Component of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">[***] that is a Combination: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) if Novartis or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees&#8217;) are selling such Novartis Component [***] following the effective date of termination). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) if Novartis or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees&#8217;) are not selling such Novartis Component [***] following the effective date of termination). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) if Novartis or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees&#8217;) are Manufacturing and supplying such Novartis Component [***] to Surface [***] following the effective date of termination. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.7.2. </b><font style="font-family:'Times New Roman','Times','serif';">With respect to the Surface Component of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">[***] that is a Combination, if Novartis or its Affiliates&#8217; (or to the extent permitted by the applicable sublicense, its Sublicensees&#8217;) are Manufacturing and supplying the Surface Component [***] following the effective date of termination. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.7.3. </b><font style="font-family:'Times New Roman','Times','serif';">For clarity, in no event will Novartis or its</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Related Parties be obligated to (or obligated to use Commercially Reasonable Efforts to) Develop or Commercialize any Novartis Component [***] that is a Combination Product after the effective date of termination anywhere in the world other than the U.S. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.8. </b><font style="font-family:'Times New Roman','Times','serif';">If Surface so requests, and to the extent permitted under Novartis&#8217;s</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">obligations to Third Parties on the effective date of termination, Novartis will [***] any Third Party [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.9. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will promptly transfer and assign to Surface all of Novartis&#8217;s and</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">its Affiliates&#8217; rights, title and interests in and to the Novartis Trademark(s) solely used to identify the Reversion Products (but not any house marks, or logos or any trademark of Novartis or its Affiliates, containing the word &#8220;Novartis&#8221; or any such Affiliate) owned by Novartis and used for the Reversion Products in the Field. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.10. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will transfer to Surface any finished goods inventory of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Reversion Products Controlled by Novartis or its Affiliates as of the termination date at [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.5.11. </b><font style="font-family:'Times New Roman','Times','serif';">Novartis will execute all documents and take all such further</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">actions as may be reasonably requested by Surface in order to give effect to the foregoing clauses. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination by Novartis for Cause. </b><font style="font-family:'Times New Roman','Times','serif';">Upon termination of this Agreement with respect to a Licensed Target or Option Target by Novartis pursuant to Sections 15.3.1.2 or 15.4: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.1. </b><font style="font-family:'Times New Roman','Times','serif';">All licenses granted under Section 9 by Novartis to Surface with respect to such Licensed Target will terminate; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.2. </b><font style="font-family:'Times New Roman','Times','serif';">The licenses and other rights granted by Surface to Novartis under the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Surface Technology with respect to such Licensed Target will remain in effect in accordance with their respective terms; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that [***] and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.3. </b><font style="font-family:'Times New Roman','Times','serif';">Surface will be deemed to have exercised its right pursuant to Section 2.8 to discontinue its participation in all Committees with respect to such Target, and Novartis&#8217; obligations to provide updates to Surface on the Research, Development, Manufacture or Commercialization of any affected Licensed Antibody Candidates or Licensed Product with respect to such Target shall be limited to that information set forth on Exhibit N. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.4. </b><font style="font-family:'Times New Roman','Times','serif';">Except as set forth in this Section 15.6. the rights and obligations of the Parties hereunder shall terminate with respect to such Licensed Target as of the effective date of such termination. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.5. </b><font style="font-family:'Times New Roman','Times','serif';">Surface will execute all documents and take all such further actions as</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">may be reasonably requested by Novartis in order to give effect to the foregoing clauses. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">15.6.5.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Expiration or Termination; Survival</b><font style="font-family:'Times New Roman','Times','serif';">. In addition to the termination consequences set forth</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">in Sections 15.5 and 15.6, the following provisions will survive expiration or termination of this Agreement for any reason: all of Sections 1, 10 (but only with respect to any payments accrued thereunder prior to any such termination or expiration), 11, 13, 15 and 16, and Sections 4.2.7, 9.4, 9.6, 9.7, 9.8, 10.12.3, 10.12.5, 10.13, 12.3, 14.1, 14.2 and 14.8. Expiration or termination of this Agreement for any reason will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity, with respect to any breach of this Agreement. For the avoidance of doubt, termination of this Agreement will not affect any SDEA, which will continue to survive so long as any Licensed Products thereunder are being Commercialized. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16. MISCELLANEOUS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.1. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</b><font style="font-family:'Times New Roman','Times','serif';">. Except as provided in this Section 16.1, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party&#8217;s written consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate or to a party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the subject matter of this Agreement relates. The assigning Party will remain responsible for the performance by its assignee of any obligation hereunder so assigned. An assignment to an Affiliate will terminate, and all rights so assigned will revert to the assigning Party, if and when such Affiliate ceases to be an Affiliate of the assigning Party. Any purported assignment in violation of this Section 16.1 will be void. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.2. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</b><font style="font-family:'Times New Roman','Times','serif';">. The Agreement will be construed and the respective rights of</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">the Parties determined in accordance with the substantive Laws of the State of New York, notwithstanding any provisions of New York Law or any other Law governing conflicts of laws to the contrary. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</b><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.1. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Disputes</i><font style="font-family:'Times New Roman','Times','serif';">. Except as otherwise expressly set forth in this Agreement,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">including Section 2.6.3, disputes of any nature arising under, relating to, or in connection with this Agreement (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Disputes</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) will be resolved pursuant to this Section 16.3. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.2. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Dispute Escalation</i><font style="font-family:'Times New Roman','Times','serif';">. In the event of a Dispute between the Parties, the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Parties will first attempt to resolve such Dispute by negotiation and consultation between themselves or at the JSC. In the event that such Dispute is not resolved on an informal basis within [***] from receipt of the written notice of a Dispute, any Party may, by written notice to the other, have such Dispute referred to the Executive Officers (or their designees, which designee is required to have decision-making authority on behalf of such Party), who will attempt to resolve such Dispute by negotiation and consultation for a [***] period following receipt of such written notice. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.3. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Full Arbitration</i><font style="font-family:'Times New Roman','Times','serif';">. Except as otherwise expressly set forth in this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement, in the event the Parties have not resolved such Dispute within [***] of receipt of the written notice referring such Dispute to the Executive Officers, either Party may at any time after such [***] period submit such Dispute to be finally settled by arbitration administered in accordance with the procedural rules of the American Arbitration Association (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AAA</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) in effect at the time of submission, as modified by this Section 16.3. The arbitration will be governed by the Laws of the State of New York. The arbitration will be heard and determined by [***] arbitrators who are retired judges or attorneys with at least [***] of relevant experience in the pharmaceutical and biotechnology industry, each of whom will be impartial and independent. Each Party will appoint [***] and the [***] arbitrator will be selected by the [***] Party-appointed arbitrators, or, failing agreement within [***] following appointment of the second arbitrator, by the AAA. Such arbitration will take place in New York, New York. The arbitration award so given will, absent manifest error, be a final and binding determination of the Dispute, will be fully enforceable in any court of competent jurisdiction, and will not include any damages expressly prohibited by Section 13.5. Fees, costs and expenses of arbitration are to be divided by the Parties in the following manner: Novartis [***] it chooses, Surface [***] it chooses, and the Parties [***] arbitrator. Except in a proceeding to enforce the results of the arbitration or as otherwise required by Law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.4. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Expedited Arbitration</i><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.4.1. </b><font style="font-family:'Times New Roman','Times','serif';">If a Party exercises its rights under this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement to refer a dispute to expedited arbitration (an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Expedited Dispute</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), then the Parties will follow the expedited dispute resolution process in this Section 16.3.4 (and not the dispute resolution process in Section 16.3.3 of this Agreement) (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Expedited Arbitration</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Parties agree and acknowledge that any good faith dispute under Expedited Arbitration will not be deemed to be a material breach of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.4.2. </b><font style="font-family:'Times New Roman','Times','serif';">The Expedited Dispute will be submitted to</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">fast-track, binding arbitration in accordance with the following: </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Arbitration will be conducted in New York, New York under the rules of the AAA for the resolution of commercial disputes in the most expedited manner permitted by such rules. The Parties will appoint a single arbitrator to be - 166 - selected by mutual agreement. If the Parties are unable to agree on an arbitrator, the Parties will request that the AAA select the arbitrator. The arbitrator will be a professional in business or licensing experienced [***] The cost of the arbitration will be borne equally by the Parties. Except in a proceeding to enforce the results of the arbitration or as otherwise required by applicable Laws, neither Novartis nor Surface nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written agreement of Novartis and Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) Within [***] after such matter is referred to arbitration, each Party will provide the arbitrator with a proposal and written memorandum in support of its position regarding the Expedited Dispute, as well as any documentary evidence it wishes to provide in support thereof (each a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Brief</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and the arbitrator will provide each Party&#8217;s Brief to the other Party after it receives it from both Parties. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) Within [***] after a Party submits its Brief, the other Party will have the right to respond thereto. The response and any material in support thereof will be provided to the arbitrator and the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) The arbitrator will have the right to meet with the Parties as necessary to inform the arbitrator&#8217;s determination and to perform independent research and analysis. Within [***] of the receipt by the arbitrator of both Parties&#8217; responses (or expiration of the [***] period if any Party fails to submit a response), the arbitrator will deliver his/her decision regarding the Expedited Dispute in writing; provided that the arbitrator will select one of the resolutions proposed by the Parties. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.5. </b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Injunctive Relief</i><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the dispute resolution procedures set</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">forth in this Section 16.3, in the event of an actual or threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief), without first submitting to any dispute resolution procedures hereunder. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.3.6. </b><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.4. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Amendments</b><font style="font-family:'Times New Roman','Times','serif';">. This Agreement, together with the Equity</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreements, Supply Agreements and SDEA, contains the entire understanding of the Parties with respect to the subject matter hereof, and supersedes all previous arrangements with respect to the subject matter hereof, whether written or oral, including, effective as of the Effective Date, that Confidentiality Agreement between Surface and Novartis Institutes for BioMedical Research, Inc., dated as of [***] (provided that all information disclosed or exchanged under such agreement will be treated as Confidential Information hereunder). This Agreement may be amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto. The Exhibits and Schedules attached hereto may be amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.5. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</b><font style="font-family:'Times New Roman','Times','serif';">. If any provision hereof should be held invalid, illegal or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">unenforceable in any respect in any jurisdiction, the Parties hereto will substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable of one or several provisions of this Agreement will not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.6. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</b><font style="font-family:'Times New Roman','Times','serif';">. The captions to the Sections hereof are not a part of this Agreement,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">but are merely for convenience to assist in locating and reading the several Sections hereof. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.7. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Rule of Construction</b><font style="font-family:'Times New Roman','Times','serif';">. Each Party has had the opportunity to consult</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.8. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</b><font style="font-family:'Times New Roman','Times','serif';">. Except where the context expressly requires otherwise, (a) the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (b) the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation&#8221; and will not be interpreted to limit the provision to which it relates; (c) the word &#8220;shall&#8221; will be construed to have the same meaning and effect as the word &#8220;will&#8221;; (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (e) any reference herein to any Person will be construed to include the Person&#8217;s successors and assigns; (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in each of their entirety, as the context requires, and not to any particular provision hereof; (g) all references herein to Sections, Exhibits or Schedules will be construed to refer to Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto; (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement; (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging); (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof; and (k) the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and/or&#8221;. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.9. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Implied Waivers; Rights Cumulative</b><font style="font-family:'Times New Roman','Times','serif';">. No failure on the part of Surface or</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Novartis to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at Law or in equity or otherwise, will impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor will any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.10. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</b><font style="font-family:'Times New Roman','Times','serif';">. All notices which are required or permitted hereunder will be in writing</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Surface, to:</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface Oncology, Inc.</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">215 First Street, Suite 400-S</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cambridge, Massachusetts 02142</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile No.: (617) 945-9574</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With a copy to:</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Goodwin Procter LLP</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exchange Place</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">53 State Street</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts 02109</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: Kingsley L. Taft, Esq.</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile No.: (617) 523-1231</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Novartis, to:</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Novartis Institutes for BioMedical Research, Inc.</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">250 Massachusetts Avenue</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cambridge, MA 02139</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: General Counsel</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile No.: (617) 871-5786</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:48.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With a copy to:</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Hogan Lovells US LLP</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">875 Third Avenue</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">New York, NY 10022</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: Adam H. Golden, Esq.</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile No.: (212) 918-3100</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice will be deemed to have been given: (a) when delivered if personally delivered on a Business Day (or if delivered or sent on a non-Business Day, then on the next Business Day); (b) on the Business Day of receipt if sent by overnight courier or facsimile; or (c) on the Business Day of receipt if sent by mail. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.11. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Export Regulations</b><font style="font-family:'Times New Roman','Times','serif';">. Neither Party will export any technology</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">licensed to it by the other Party under this Agreement except in compliance with U.S. export Laws and regulations. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.12. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</b><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">.</i><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Neither Party will be held liable to the other Party nor be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, earthquakes, floods, or other acts of God. The affected Party will notify the other Party of such force majeure circumstances as soon as reasonably practical, and will promptly undertake all reasonable efforts necessary to cure such force majeure circumstances and resume performance of its obligations hereunder. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.13. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Parties</b><font style="font-family:'Times New Roman','Times','serif';">. It is expressly agreed that Surface and Novartis will be</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">independent contractors and that the relationship between Surface and Novartis will not constitute a partnership, joint venture or agency. Surface will not have the authority to make any statements, representations or commitments of any kind, or to take any action, which will be binding on Novartis, without the prior written consent of Novartis, and Novartis will not have the authority to make any statements, representations or commitments of any kind, or to take any action, which will be binding on Surface, without the prior written consent of Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.14. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b><font style="font-family:'Times New Roman','Times','serif';">. The Agreement may be executed in two or more counterparts,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">including by facsimile or PDF signature pages, each of which will be deemed an original, but all of which together will constitute one and the same instrument. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.15. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance by Affiliates</b><font style="font-family:'Times New Roman','Times','serif';">. Each Party acknowledges and accepts that the other</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Party may exercise its rights and perform its obligations (including granting or continuing licenses and other rights) under this Agreement either directly or through one or more of its Affiliates. A Party&#8217;s Affiliates will have the benefit of all rights (including all licenses and other rights) of such Party under this Agreement, but not be subject to such Party&#8217;s obligation, unless expressly provided herein, or in the case of a permitted assignment, in accordance with Section 16.1. Accordingly, in this Agreement &#8220;Novartis&#8221; will be interpreted to mean &#8220;Novartis or its Affiliates&#8221; and &#8220;Surface&#8221; will be interpreted to mean &#8220;Surface or its Affiliates&#8221; where necessary to give each Party&#8217;s Affiliates the benefit of the rights provided to such Party in this Agreement and the ability to perform its obligations (including granting or continuing licenses and other rights) under this Agreement; provided, however, that in any event each Party will remain responsible for the acts and omissions, including financial liabilities, of its Affiliates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">16.16. </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect; No Third Party Beneficiaries</b><font style="font-family:'Times New Roman','Times','serif';">. As of the Effective Date, this</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">Agreement will be binding upon and inure to the benefit of the Parties and their respective permitted successors and permitted assigns. Except as expressly set forth in this Agreement, no Person other than the Parties and their respective Affiliates and permitted assignees hereunder will be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK] </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:40.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:6.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:40.43%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:47.85%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOVARTIS INSTITUTES FOR</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">BIOMEDICAL RESEARCH, INC.</b></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:top;width:47.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SURFACE ONCOLOGY, INC.</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:6.99%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:40.85%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:3.84%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:7.42%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:40.87%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BY:</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.42%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ H. MARTIN SEIDEL</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BY:</font></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Detlev Biniszkiewicz</font></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NAME:</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.42%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">H. MARTIN SEIDEL</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NAME:</font></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Detlev Biniszkiewicz</font></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TITLE:</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.42%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">GLOBAL HEAD, STRATEGIC ALLIANCES</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TITLE:</font></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">President and CEO</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit A-1</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determination of Component Value </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT A-2</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Costs for Combinations for Regional Licensed Products in the Surface Territory </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT B </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Manufacturing Costs </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Manufacturing Costs</b><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT C </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Form of Option Exercise Notice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:18pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[Novartis Institutes for Biomedical Research, Inc.] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[250 Massachusetts Ave.] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[Cambridge, MA 02139] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';">, 20 ] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface Oncology, Inc. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">215 First Street, Suite 400-S</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cambridge, MA 02142 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Chief Executive Officer </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dear Sir or Madam: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In accordance with Section 4.2.6 of that certain Collaboration Agreement by and between Surface Oncology, Inc. (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and Novartis Institutes for Biomedical Research, Inc. (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Novartis</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) executed as of January 9, 2016 (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration Agreement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Novartis hereby provides written notice exercising the Option set forth in Exhibit A attached hereto, for which Novartis previously provided an Option Purchase Notice, pursuant to the terms of the Collaboration Agreement. Capitalized terms used but not defined herein will have the meanings assigned to them in the Collaboration Agreement. </font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr><td style="vertical-align:middle;width:8.01%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:90.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Very truly yours,</font></p></td></tr><tr style="height:12pt;"><td colspan="3" style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[NOVARTIS INSTITUTES FOR</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BIOMEDICAL RESEARCH, INC.]</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:8.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:91.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">cc:</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Goodwin Proctor LLP </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exchange Place </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">55 State Street </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, MA 02109 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Kingsley L. Taft, Esq. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Confidential</i></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A </u></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Option: . </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Novartis has determined that: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">a filing or notification under applicable Antitrust Laws is not necessary. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">a filing or notification must be made under applicable Antitrust Laws. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Summary of any such filing(s) or notification(s): </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT D </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Form of Option Purchase Notice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[Novartis Institutes for Biomedical Research, Inc.] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[250 Massachusetts Ave.] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[Cambridge, MA 02139] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';">, 20 ] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface Oncology, Inc. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">215 First Street, Suite 400-S</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cambridge, MA 02142 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Chief Executive Officer </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dear Sir or Madam: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In accordance with Section 4.1.1 of that certain Collaboration Agreement by and between Surface Oncology, Inc. (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and Novartis Institutes for Biomedical Research, Inc. (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Novartis</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) executed as of January 9, 2016 (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration Agreement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Novartis hereby provides written notice to purchase the Option set forth in Exhibit A attached hereto, pursuant to the terms of the Collaboration Agreement. Capitalized terms used but not defined herein will have the meanings assigned to them in the Collaboration Agreement. </font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr><td style="vertical-align:middle;width:8.01%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:90.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Very truly yours,</font></p></td></tr><tr style="height:12pt;"><td colspan="3" style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[NOVARTIS INSTITUTES FOR</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BIOMEDICAL RESEARCH, INC.]</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:8.01%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:91.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td></tr><tr><td style="vertical-align:top;width:8.01%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">cc:</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Goodwin Proctor LLP </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exchange Place </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">55 State Street </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, MA 02109 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Kingsley L. Taft, Esq. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A </u></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Option: . </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In accordance with Section 10.3, Novartis will pay to Surface an option exercise right purchase fee of: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Five Million Dollars ($5,000,000) </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Segoe UI Symbol';">&#9744;</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT E </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Initial JSC Representatives </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For Novartis: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For Surface: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT F </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">T1 Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT G </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface T1 Target Third Party Agreements (&#167;3.1.7, 5.1.7) </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT H-1</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:10pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">CD47 Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:10pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT H-2</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">IL-27 Research Plan </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:18pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT H-3</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT H-4</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT I </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface Option Target Third Party Agreements (&#167;3.2.6, 5.2.8, 5.3.7) </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT J </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Form of Option Selection Notice </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[Novartis Institutes of Biomedical Research, Inc.]/[Surface Oncology, Inc.] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[250 Massachusetts Ave.]/[215 First Street, Suite 400-S] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Cambridge, MA [02139]/[02142] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';">, 20 ] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Surface Oncology, Inc. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">215 First Street, Suite 400-S</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cambridge, MA 02142 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Chief Executive Officer] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Novartis Institutes for Biomedical Research, Inc.] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[250 Massachusetts Ave.] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Cambridge, MA 02139] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: [</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="font-family:'Times New Roman','Times','serif';">] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dear Sir or Madam: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In accordance with Section 4.2.3 of that certain Collaboration Agreement by and between Surface Oncology, Inc. (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and Novartis Institutes of Biomedical Research, Inc. (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Novartis</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) executed as of January 9, 2016 (the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration Agreement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), [Novartis]/[Surface] hereby provides written notice indicating the selection of the Option set forth in Exhibit A attached hereto, pursuant to the terms of the Collaboration Agreement. Capitalized terms used but not defined herein will have the meanings assigned to them in the Collaboration Agreement. </font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr><td style="vertical-align:middle;width:8.03%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:90.97%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Very truly yours,</font></p></td></tr><tr style="height:12pt;"><td colspan="3" style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[NOVARTIS INSTITUTES FOR</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BIOMEDICAL RESEARCH,</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">INC.]/[SURFACE ONCOLOGY, INC.]</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:8.03%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:91.96%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:8.03%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.97%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:8.03%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td></tr><tr><td style="vertical-align:top;width:8.03%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:90.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">cc:</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Goodwin Proctor LLP </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exchange Place </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">55 State Street </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, MA 02109 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Kingsley L. Taft, Esq.] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">cc:</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Hogan Lovells US LLP </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">875 Third Avenue </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">New York, NY 10022 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: Adam H. Golden, Esq. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile No.: (212) 918-3100]</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A </u></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Option: . </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Novartis]/[Surface] is designating the Option listed above as a: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.62%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:4.74%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:top;width:91.63%;margin:0pt;padding:0.25pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT K </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface Manufacturing Third Party Agreements (&#167;8.5) </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT L </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Form of Invoice </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Company Name</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">INVOICE</font></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Street Address</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">DATE: Month Day, Year</font></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">City, State ZIP Code</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">INVOICE #: XX</font></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Phone 1xxxxxx</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOVARTIS PO#: XXXXXXXX</font></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Fax 1xxxxxx</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Bill To: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Novartis Institutes for Biomedical Research, Inc. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Novartis Contact Name </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">P.O. Box 5990 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Portland OR, 97228-5990 </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Re: Collaborative Agreement between Surface Oncology, Inc. and Novartis Institutes for BioMedical Research, Inc. effective as of January 9, 2016. </b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:76%;" align="center"><tr><td style="vertical-align:middle;width:8.65%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:73.23%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:10.37%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">PO Line</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">Number</font></p></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:73.23%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">DESCRIPTION</font></p></td><td style="vertical-align:bottom;width:3.86%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:10.37%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">AMOUNT</font></p></td></tr><tr><td style="vertical-align:middle;width:8.65%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">X</font></p></td><td style="vertical-align:bottom;width:3.86%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:73.23%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[Upfront/Development Milestone/Sales Milestone] payment with reference made to the relevant section of the contract</font></p></td><td style="vertical-align:bottom;width:3.86%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10.37%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$XX.XX</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0.25pt;"></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:76%;" align="center"><tr><td style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:73.23%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TOTAL</font></p></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:10.37%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$XX.XX</font></p></td></tr><tr><td style="vertical-align:bottom;width:8.65%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0.25pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:24.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:74.48%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Remit to:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:74.48%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Bank Wire Information:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:74.48%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Bank Name:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:74.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XX</font></p></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Account No.:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:74.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XX</font></p></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">ABA#:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:74.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XX (only applicable in the US)</font></p></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">IBAN:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:74.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XX (only applicable in Europe)</font></p></td></tr><tr><td style="vertical-align:top;width:24.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">SWIFT CODE:</font></p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:74.48%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XX (applicable US and Europe)</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Note for e-mail submission of invoices: </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The address is: [***] </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8226;</font></p></td><td style="vertical-align:top;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attached invoice files must contain a Novartis issued purchase order number (PO) on them and cannot be zipped</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">. Invoices without a PO number on them or zipped attachments will not</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">be accepted for processing.</b></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT M </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Royalty Calculation Examples </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9.1</u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9.2</u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9.3.1</u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.9.3.2</u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reduction Sample Calculation</u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:18pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ex-U.S.</u><font style="font-family:'Times New Roman','Times','serif';">: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:18pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S.: </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT N </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Obligations </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1.158 </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option IND Package Information </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1.167 </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Tox Package Information</u></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 12.2 </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exceptions to Representations and Warranties </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">12.2.1</b><font style="font-family:'Times New Roman','Times','serif';">: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">FIRST AMENDMENT TO COLLABORATION AGREEMENT </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This first amendment (the &#8220;First Amendment&#8221;) to the Agreement (as defined below), is entered into as of May 6, 2016 (the &#8220;Amendment Effective Date&#8221;), by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Surface&#8221;), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Novartis&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis are parties to that certain Collaboration Agreement dated January 9, 2016 (the &#8220;Agreement&#8221;); </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to have Novartis assume Manufacturing responsibilities with respect to Tl Antibody Candidates and Tl Licensed Products; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to amend the Agreement as provided herein. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, in consideration of the mutual provisions and covenants herein, the receipt and sufficiency of which are hereby acknowledged, Surface and Novartis hereby agree as follows: </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1.1.1 is hereby amended by deleting Section 8.1.1.1 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;8.1.1.1. Subject to the oversight of the JRC, the responsibility to Manufacture (or have Manufactured) Tl Antibody Candidates for use in the Tl Research Program shall be allocated between Surface and Novartis (or such Party&#8217;s designated Third Party contract manufacturers) in accordance with the Tl Research Plan.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1.1.2 is hereby amended by deleting Section 8.1.1.2 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;8.1.1.2. Subject to the oversight of the JDC, Novartis has the sole responsibility to Manufacture (or have Manufactured) Tl Antibody Candidates and Tl Licensed Products for use in the first Phase 1 Safety Study for the Tl Antibody Candidates and Tl Licensed Products in accordance with the Tl Development Plan.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">3.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1.1.3 is hereby amended by deleting Section 8.1.1.3 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;8.1.1.3. Novartis has the sole responsibility to Manufacture (or have Manufactured) Tl Antibody Candidates and Tl Licensed Products for use in Development and Commercialization of such Tl Antibody Candidates and Tl Licensed Products in the Novartis Territory.&#8221; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1.2.1 is hereby amended by deleting Section 8.1.2.1 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;8.1.2.1. Surface will be responsible for [***] of all Manufacturing Costs relating to Tl Antibody Candidates incurred to support the Tl Research Program, including reimbursement to Novartis of all Manufacturing Costs </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">reasonably incurred by or on behalf of Novartis for the Manufacture of Tl Antibody Candidates for use in the Tl Research Program.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1.2.2 is hereby amended by deleting Section 8.1.2.2 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;8.1.2.2. Novartis will be responsible for [***] of all Manufacturing Costs relating to the first Phase 1 Safety Study for Tl Antibody Candidates and Tl Licensed Products set forth in the Novartis approved budget for such Phase 1 Safety Study.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">6.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1.2.3 is hereby amended by deleting Section 8.1.2.3 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;8.1.2.3. Except as provided in Section 8.1.2.1, Novartis will be responsible for [***] of all Manufacturing Costs relating to Tl Antibody Candidates and Tl Licensed Products for use in the Research, Development and Commercialization of such Tl Antibody Candidates and Tl Licensed Products in the Novartis Territory incurred by or on behalf of Novartis.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.5.3 is hereby amended by deleting Section 15.5.3 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;15.5.3. [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">8.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.5.8 is hereby amended by deleting Section 15.5.8 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;15.5.8. If Surface so requests, and to the extent permitted under Novartis&#8217;s obligations to Third Parties on the effective date of termination, Novartis will [***] any Third Party [***]&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">9.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit F (Tl Research Plan) is hereby deleted in its entirety and replaced by the Exhibit F as appended to this First Amendment. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">10.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as expressly set forth in this First Amendment, all provisions of the Agreement shall remain in full force and effect. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[Signature Page Follows] </i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, Surface and Novartis have caused this First Amendment to be executed by their respective authorized representatives as of the Amendment Effective Date. </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:39.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:40.49%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:45.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">S</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">URFACE</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> O</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NCOLOGY</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, I</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NC</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">.</b></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:top;width:46.79%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">N</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">OVARTIS</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> I</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NSTITUTES</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">FOR</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> B</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">IO</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">M</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">EDICAL</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> R</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">ESEARCH</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, I</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NC</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">.</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:39.95%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:6.95%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:6.29%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:40.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Nick Buffinger</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ H. Martin Seidel</font></p></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Nick Buffinger</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">H. Martin Seidel</font></p></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">VP, Corporate Development &amp; IP Strategy</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Global Head of Strategic Alliances</font></p></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date:</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">9 May 2016</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date:</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">May 11, 2016</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT F </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Plan </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:18pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">SECOND AMENDMENT TO COLLABORATION AGREEMENT </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This second amendment (the &#8220;Second Amendment&#8221;) to the Agreement (as defined below), is entered into as of July 14, 2017 (the &#8220;Amendment Effective Date&#8221;), by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Surface&#8221;), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Novartis&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis are parties to that certain Collaboration Agreement dated January 9, 2016 (the &#8220;Agreement&#8221;), as amended by the May 6, 2016 First Amendment to Collaboration Agreement; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to [***] and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to amend the Agreement as provided herein. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, in consideration of the mutual provisions and covenants herein, the receipt and sufficiency of which are hereby acknowledged, Surface and Novartis hereby agree as follows: </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit F (Tl Research Plan) is hereby deleted in its entirety and replaced by the Exhibit F as appended to this Second Amendment. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as expressly set forth in this First Amendment, all provisions of the Agreement shall remain in full force and effect. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, Surface and Novartis have caused this Second Amendment to be executed by their respective authorized representatives as of the Amendment Effective Date. </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:39.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:40.49%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:45.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">S</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">URFACE</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> O</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NCOLOGY</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, I</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NC</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">.</b></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:top;width:46.79%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">N</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">OVARTIS</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> I</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NSTITUTES</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">FOR</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"> B</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">IOMEDICAL</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">R</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">ESEARCH</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, I</b><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">NC</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">.</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:5.81%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:39.95%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:6.95%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:6.29%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:40.98%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Detlev Biniszkiewicz</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Scott A Brown</font></p></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Detlev Biniszkiewicz</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name:</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scott A Brown</font></p></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">President &amp; CEO</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title:</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">VP, General Counsel</font></p></td></tr><tr><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date:</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:39.47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">July 14, 2017</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.47%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.81%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date:</font></p></td><td style="vertical-align:bottom;width:0.49%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">7/17/17</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT F </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Plan </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">THIRD AMENDMENT TO COLLABORATION AGREEMENT </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Third Amendment (the &#8220;Third Amendment&#8221;) to the Agreement (as defined below), is entered into as of September 18th, 2017 (the &#8220;Amendment Effective Date&#8221;), by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Surface&#8221;), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Novartis&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis are parties to that certain Collaboration Agreement dated January 9, 2016, as amended by that certain First Amendment to Collaboration Agreement dated May 6, 2016, and that certain Second Amendment to Collaboration Agreement dated July 14, 2017 (the &#8220;Agreement&#8221;); </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to clarify the Parties&#8217; respective responsibilities relating to certain Research, Development and regulatory activities with respect to T1 Antibody Candidates and T1 Licensed Products; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to [***] and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to amend the Agreement as provided herein. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, in consideration of the mutual provisions and covenants herein, the receipt and sufficiency of which are hereby acknowledged, Surface and Novartis hereby agree as follows: </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Clause (a) of Section 1.1.204 is hereby amended by deleting Section 1.1.204 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;1.1.204. </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;Research Term&#8221;</b><font style="font-family:'Times New Roman','Times','serif';"> means, [***] </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">A new Section 1.1.265 is hereby added as follows: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;1.1.265</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> &#8220;Final Audited GLP Toxicology Study Report&#8221; </b><font style="font-family:'Times New Roman','Times','serif';">means [***] </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">3.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">A new Section 1.1.266 is hereby added as follows: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;l.1.266 </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;Receipt&#8221; </b><font style="font-family:'Times New Roman','Times','serif';">means [***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.1.2 is hereby amended by deleting Section 3.1.2 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;3.1.2</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> Diligence; Standards of Conduct. </i><font style="font-family:'Times New Roman','Times','serif';">During the Research Term, Surface (itself or</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">through its Affiliates or by permitted subcontracting pursuant to Section 3.1.7) will use Commercially Reasonable Efforts to [***] Surface will conduct its activities under the T1 Research Plan in a good scientific manner and in compliance with applicable Law.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 5.1.2 is hereby amended by deleting Section 5.1.2 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;5.1.2.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> Transition</i><font style="font-family:'Times New Roman','Times','serif';">. By no later than [***] for a T1 Licensed Product, Surface will prepare and provide to Novartis a draft plan for the transition of the Development of such T1 Licensed Products from Surface to Novartis or its designee (a </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;T1</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transition Plan&#8221;). </b><font style="font-family:'Times New Roman','Times','serif';">The T1 Transition Plan for each T1 Licensed Product will require Surface to,</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">as soon as reasonably practicable following the Research Term: (a) transfer to Novartis of a copy of all Know-How Controlled by Surface that is reasonably necessary or useful for Development of such T1 Antibody Candidates or T1 Licensed Products, or obtaining or maintaining Regulatory Approval for such T1 Licensed Products in the Novartis Territory, including information and materials reasonably requested by Novartis, in a format reasonably acceptable to Novartis (which will be specified in such T1 Transition Plan, along with the process of transferring such Know-How); (b) assign to Novartis any Regulatory Materials submitted to, or filed with, any Regulatory Authority with respect to such T1 Antibody Candidates or T1 Licensed Products; (c) transfer to Novartis a copy of all written correspondence with any Regulatory Authority with respect to such T1 Antibody Candidates or T1 Licensed Products and all written minutes of meetings and memoranda of oral communications with any Regulatory Authority with respect to such T1 Antibody Candidates or T1 Licensed Products; and (d) transfer to Novartis a copy of any other information or materials reasonably requested by Novartis that are reasonably necessary or useful for Development of such T1 Antibody Candidates or T1 Licensed Products in the Novartis Territory, including if so reasonably requested by Novartis, and Third Party agreements relating solely thereto (the items described in clauses (a) through (d) collectively, </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;T1 Development</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Information&#8221;). </b><font style="font-family:'Times New Roman','Times','serif';">The T1 Transition Plan for each T1 Licensed Product will also describe any Development activities with respect to such T1 Licensed Product that Surface is required to perform as requested by Novartis and mutually agreed upon by the Parties (collectively, </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;T1</b><font style="font-family:'Times New Roman','Times','serif';"> </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transition Activities&#8221;). </b><font style="font-family:'Times New Roman','Times','serif';">Each Party will use Commercially Reasonable Efforts to perform the</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">obligations assigned to it under the T1 Transition Plan in accordance with any timelines set forth therein, [***]&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">6.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.1.1.1 is hereby amended by deleting Section 7.1.1.1 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;7.1.1.1. </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Ownership of Regulatory Filings.</i><font style="font-family:'Times New Roman','Times','serif';"> Novartis will be responsible for filing, and Novartis will own, all INDs, NDAs, Regulatory Materials and related regulatory documentation with respect to any T1 Licensed Product. At Novartis&#8217;s request following [***] for the T1 Research Program, Surface will promptly assign and transfer to Novartis all Regulatory Materials and other regulatory documentation in the Novartis Territory </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">with respect to such T1 Licensed Product that is in the possession or control of Surface, and each Party will submit all filings, letters and other documentation necessary to effect such assignment and transfer to the applicable Regulatory Authority as soon as reasonably practicable, but no later than [***] days after such request for such T1 Licensed Product. Surface hereby appoints Novartis as Surface&#8217;s agent for all matters related to each T1 Licensed Product involving Regulatory Authorities in the Novartis Territory during the period beginning on the Effective </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date for the T1 Licensed Product and ending on the date that the transfer of all Regulatory Materials and related regulatory documents in the Novartis Territory that relate to such T1 Licensed Product, and Novartis hereby accepts such appointment.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">7.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.7.1 is hereby amended by deleting the second row in the table set forth in Section 10.7.1 and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:51%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:46.99%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Event</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:46.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Developmental Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:46.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">8.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.7.4 is hereby amended by deleting Section 10.7.4 in its entirety and replacing it with the following: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;10.7.4</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> Payment Terms for Development Milestone Payments. </i><font style="font-family:'Times New Roman','Times','serif';">The Party who achieves a</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Development Milestone Event shall provide the other Party with written notice of its achievement of such Development Milestone Event within [***] days after such Development Milestone Event is achieved. After Surface&#8217;s delivery or receipt of such notice (as applicable), Surface shall submit an invoice to Novartis substantially in the form of Exhibit L for the corresponding Development Milestone Payment. Novartis shall make the corresponding Development Milestone Payment within [***] days after receipt of such invoice. Notwithstanding the foregoing, in the event that Surface achieves a given Development Milestone Event, Novartis shall make the corresponding Development Milestone Payment within [***] days after receipt of the relevant invoice from Surface.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">9.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit F (T1 Research Plan) is hereby deleted in its entirety and replaced by Exhibit F as appended to this Third Amendment. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:4%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">10.</font></p></td><td style="vertical-align:top;width:91.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as expressly set forth in this Third Amendment, all provisions of the Agreement shall remain in full force and effect. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[SIGNATURE PAGE FOLLOWS] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, Surface and Novartis have caused this Third Amendment to be executed by their respective authorized representatives as of the Amendment Effective Date. </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:40.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:6.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:40.43%;margin:0pt;padding:0.25pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:47.85%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NOVARTIS INSTITUTES FOR</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">BIOMEDICAL RESEARCH, INC.</b></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:top;width:47.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SURFACE ONCOLOGY, INC.</b></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:6.99%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:40.85%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:3.84%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:7.42%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:40.87%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BY:</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.42%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Scott Brown</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BY:</font></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Scott Chappel</font></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NAME:</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.42%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scott Brown</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NAME:</font></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scott Chappel</font></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TITLE:</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.42%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">VP General Counsel</font></p></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:3.41%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:0.42%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TITLE:</font></p></td><td style="vertical-align:bottom;width:0.43%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:40.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CTO</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4 </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">EXHIBIT F </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">T1 Research Plan </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3
<SEQUENCE>4
<FILENAME>chrs-20231231xex3.htm
<DESCRIPTION>EX-10_33
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:01:40 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.33</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH &#8220;[***]&#8221;. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CONFIDENTIAL</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">FOURTH AMENDMENT TO COLLABORATION AGREEMENT</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Fourth Amendment (the &#8220;Fourth Amendment&#8221;) to the Agreement (as defined below), is entered into as of October 9, 2018 (the &#8220;Amendment Effective Date&#8221;), by and between Surface Oncology, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Surface&#8221;), and Novartis Institutes for BioMedical Research, Inc., a corporation organized and existing under the Laws of the State of Delaware (&#8220;Novartis&#8221;).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis are parties to that certain Collaboration Agreement dated January 9, 2016, as amended by that certain First Amendment to Collaboration Agreement dated May 6, 2016, that certain Second Amendment to Collaboration Agreement dated July 14, 2017 and that certain Third Amendment to Collaboration Agreement dated September 18, 2017 (the &#8220;Agreement&#8221;);</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface has entered into that certain Amended and Restated Development and Option Agreement with Adimab, LLC, dated as of October 4, 2018 (the &#8220;A&amp;R Adimab Agreement&#8221;);</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to clarify the Parties&#8217; respective rights and responsibilities relating to the A&amp;R Adimab Agreement and diagnostic products; and</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface and Novartis desire to amend the Agreement as provided herein.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, in consideration of the mutual provisions and covenants herein, the receipt and sufficiency of which are hereby acknowledged, Surface and Novartis hereby agree as follows: </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:3.84%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.</font></p></td><td style="vertical-align:top;width:92.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Novartis hereby acknowledges and agrees that Surface was entitled to enter into the A&amp;R Adimab Agreement in accordance with Section 12.4.3, and all references to the &#8220;Adimab Agreement&#8221; in the Agreement will refer to the A&amp;R Adimab Agreement, as such agreement may be amended, restated or otherwise replaced from time to time to the extent permitted under Section 12.4.3 of the Agreement.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:3.84%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.</font></p></td><td style="vertical-align:top;width:92.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 9.5.1.1 of the Agreement is hereby amended by appending the following to the end thereof:</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;For each Licensed Target, Surface acknowledges and agrees that Novartis shall not owe any (a) payments to Surface under this Agreement or (b) Third Party Payments to Surface or Adimab under the Adimab Agreement, in each case ((a)-(b)) with respect to the Research, Development, Manufacture or Commercialization of any Adimab Diagnostic Product (as defined in the Adimab Agreement) for such Licensed Target solely for the purposes of Research, Development or Commercialization of therapeutic or prophylactic Licensed Products that Specifically Binds to such Licensed Target in accordance with the terms and conditions of this Agreement.&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:3.84%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3.</font></p></td><td style="vertical-align:top;width:92.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:'Times New Roman','Times','serif';">Section 9.5.2 of the Agreement is hereby amended by appending the following to the end thereof: &#8220;Novartis hereby acknowledges and agrees that Surface has not granted to Novartis any licenses or rights under the Surface Technology to Research, Develop, Manufacture or Commercialize any Adimab Diagnostic Product (as defined in the Adimab Agreement) for a Licensed Target other than solely for the purposes of Research, Development or Commercialization of therapeutic or prophylactic Licensed Products that Specifically Binds to such Licensed Target in accordance with the terms and conditions of this Agreement.&#8221;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:3.84%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.</font></p></td><td style="vertical-align:top;width:92.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 12.5.1.4 of the Agreement is hereby amended by appending the following to the end thereof:</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';">[***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">.&#8221; </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:3.84%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.</font></p></td><td style="vertical-align:top;width:92.31%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as expressly set forth in this Fourth Amendment, all provisions of the Agreement shall remain in full force and effect.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[SIGNATURE PAGE FOLLOWS]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, Surface and Novartis have caused this Fourth Amendment to be executed by their respective authorized representatives as of the Amendment Effective Date.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:top;width:49.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;background:#ffffff;">NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.</b></p></td><td style="vertical-align:top;width:2.38%;margin:0pt;padding:0.25pt;"></td><td colspan="3" style="vertical-align:top;width:47.75%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SURFACE ONCOLOGY, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:37.08%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:35.29%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:9.88%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BY:</font></p></td><td style="vertical-align:top;width:2.89%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:37.08%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Scott Brown</font></p></td><td style="vertical-align:top;width:2.38%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:9.88%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">BY:</font></p></td><td style="vertical-align:top;width:2.57%;border-bottom:1px solid #ffffff;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"></td><td style="vertical-align:top;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ J. Jeffrey Goater</font></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NAME:</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:37.08%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scott Brown</font></p></td><td style="vertical-align:top;width:2.38%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NAME:</font></p></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:35.29%;border-top:1px solid #000000;margin:0pt;padding:0.4pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Jeff Goater</font></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TITLE:</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:37.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">General Counsel and Chief Administrative Officer, NIBR</font></p></td><td style="vertical-align:top;width:2.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TITLE:</font></p></td><td style="vertical-align:top;width:2.57%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:35.29%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CEO</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>5
<FILENAME>chrs-20231231xex4.htm
<DESCRIPTION>EX-10_34
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:01:42 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.34</b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY &#8220;[***]&#8221;, HAS BEEN EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LICENSE AGREEMENT </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">THIS LICENSE AGREEMENT (this &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), is entered into as of December 16, 2020 (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), by and between Surface Oncology, Inc., a Delaware corporation having business offices at 50 Hampshire Street, Cambridge MA 02139 (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED, a company registered in England and Wales (registered number 11721880) and having business offices at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INTRODUCTION </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface Controls certain Patent Rights, Know-How and other intellectual property rights related to the Licensed Target and the Licensed Antibody known as SRF813; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, Surface obtained certain intellectual property rights related to Licensed Antibodies targeting the Licensed Target from [***] pursuant to the [***]; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, GSK wishes to obtain from Surface and Surface wishes to grant to GSK certain rights and licenses under certain Patent Rights, Know-How, and other intellectual property rights Controlled by Surface to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products in the Territory, subject to the terms and conditions set forth herein; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">WHEREAS, in connection with this Agreement, [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE I </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEFINITIONS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following terms used in this Agreement will have the meanings set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE I</u><font style="font-family:'Times New Roman','Times','serif';">: </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.1.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Standards</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to GSK, IFRS (International Financial Reporting Standards) as adopted by the United Kingdom, or such other generally accepted accounting standard as it may from time to time adopt, in each case, consistently applied, and with respect to Surface, GAAP (accounting principles generally accepted in the United States of America), or such other generally accepted accounting standard as it may from time to time adopt, in each case, consistently applied. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.2.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.3.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Third Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.8(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.4.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Transaction</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.8(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.5.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.6.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, (a) with respect to GSK, any Person controlling, controlled by or under common control with such first Person, at the time that the determination of affiliation is made and for as long as such control exists, (b) with respect to Surface, any entity that is controlled by Surface at the time that the determination of affiliation is made and for as long as such control exists, and (c) with respect to any other Person, any entity controlling, controlled by or under common control with such first Person, at the time that the determination of affiliation is made and for as long as such control exists. For purposes of this definition, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">control</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (i) direct or indirect ownership of fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such Laws; provided, however, that such ownership interest provides actual control over such Person), (ii) status as a general partner in any partnership, or (iii) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise. Affiliates of a Party will exclude Persons who are financial investors of such Party or under common control of such financial investors other than such Party and its subsidiary entities. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.7.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alternative Product</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.8(c)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.8.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Antibody</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to the Licensed Target, any monoclonal antibody or antigen-binding fragment, modification, or derivative thereof that binds to such Licensed Target, and includes an immunoglobulin, such as IgA, IgD, IgE, IgG and IgM, in each case, whether multiple or single chain, recombinant or naturally occurring or a combination of the foregoing in any species, whole or antigen-binding fragment, including any monospecific or any bispecific/multi-specific/multivalent antibody, and any analogs, constructs, conjugates, fusions or chemical or other modifications or attachments thereof or thereto. An antigen binding portion of an Antibody includes an antigen binding heavy chain, light chain, heavy chain dimer, diabody, Fab fragment, F(ab&#8217;)2 fragment, single domain, or any FV fragment, including a single chain FV (SCFV), a disulfide stabilized FV fragment (DSFV), or a bispecific DSFV, or a conjugate containing the immunoglobulin or an antigen-binding fragment thereof. For clarity, an antibody that differs in amino acid sequence with respect to the antigen-binding portion thereof will be treated as a separate antibody. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.9.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audited Site</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3(d)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.10.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Auditor</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.11.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biosimilar Application</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(f)(iii)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.12.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biosimilar Product</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a given Licensed Product in a particular country in the Territory, any product sold by a Third Party not authorized by GSK or its Affiliates or its or their Sublicensees that is approved by the applicable Regulatory Authority for such country through any application or submission filed with a Regulatory Authority for Regulatory Approval of a biological product claimed to be biosimilar or interchangeable to such Licensed Product or otherwise relying on the approval of such Licensed Product in such country, including, an application filed under 42 U.S.C. &#167; 262(k) or any similar provisions in a country outside the United States, based in reliance, at least in part, on data generated for a Regulatory Approval of such Licensed Product. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.13.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breaching Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.14.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any day, other than a Saturday or a Sunday, on which banking institutions in Massachusetts, United States and London, England are open for business, but excluding the nine (9) consecutive calendar days beginning on December 24th and continuing through January 1st of each Calendar Year during the Term. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.15.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calendar Quarter</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means each of the three month periods ending on March 31, June 30, September 30, and December 31 of any Calendar Year; provided, however: (a) the first Calendar Quarter of the Term will extend from the Effective Date to the end of the Calendar Quarter in which the Effective Date occurs; and (b) the last Calendar Quarter will extend from the beginning of the Calendar Quarter in which this Agreement expires or terminates until the effective date of such expiration or termination. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.16.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calendar Year</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, for the first Calendar Year, the period beginning on the Effective Date and ending on December 31, 2020, and for each Calendar Year thereafter each twelve (12)-month period commencing on January 1, and ending on December 31, except that the last Calendar Year will commence on January 1 of the year in which this Agreement expires or terminates and end on the effective date of such expiration or termination. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.17.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAPA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3(d)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.18.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cessation of Development</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(e)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.19.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Party, (a) a merger, consolidation, reorganization, amalgamation, arrangement, share exchange, tender or exchange offer, private purchase, business combination or other transaction of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the direct or indirect beneficial owner of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party&#8217;s and its controlled Affiliates&#8217; assets. Notwithstanding the foregoing, any transaction or series of transactions effected for the primary purpose of financing the operations of the applicable Party or changing the form or jurisdiction of organization of such Party will not be deemed a &#8220;Change of Control&#8221; for purposes of this Agreement. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.20.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Data</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the original human subject data and case report forms (CRFs) collected or generated with respect to Clinical Studies of any Licensed Antibody or Licensed Product, together with all analysis, reports, and results with respect thereto. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.21.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Study</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a study in which human subjects or patients are dosed with a drug, whether approved or investigational, pursuant to a prospectively defined clinical protocol. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.22.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Combination Product</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any pharmaceutical preparation containing as its active ingredients both a Licensed Antibody and one or more other therapeutically or prophylactically active ingredients (each an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Component</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), so long as the applicable Licensed Product and other pharmaceutical preparation are fixed dose combinations and </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">co-packaged combinations of the Licensed Antibody and the Other Components. Drug delivery vehicles, adjuvants, and excipients will not be deemed to be &#8220;active ingredients&#8221;, except in the case where such delivery vehicle, adjuvant, or excipient is recognized as an active ingredient in accordance with 21 C.F.R. &#167; 210.3(b)(7) (as amended), or any foreign counterpart.</font><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;"> </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.23.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercializing</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialize</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any and all activities related to the pre-marketing, launching, marketing, promotion (including advertising and detailing), labeling, bidding and listing, pricing and reimbursement, distribution, having distributed, storage, handling, offering for sale, selling, having sold, importing and exporting for sale, having imported and exported for sale, customer service and support, and post-marketing safety surveillance and reporting of a product (including the Licensed Product). </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.24.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercially Reasonable Efforts</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to any Licensed Antibody or Licensed Product, such efforts that are consistent with the efforts and resources [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.25.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) all trade secrets or confidential or proprietary information (including any tangible materials embodying any of the foregoing) of the disclosing Party or its Affiliates provided or disclosed to the other Party or any of its Affiliates in connection with this Agreement, (b) &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; (as defined in the Prior CDA) that was disclosed by a Party or any of its Affiliates to the other Party or any of its Affiliates under the Prior CDA, and (c) the terms and conditions of this Agreement; provided, however, that Confidential Information will not include information that: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) has been published by a Third Party or otherwise is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of this Agreement on the part of the receiving Party; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) has been in the receiving Party&#8217;s possession prior to disclosure by the disclosing Party hereunder, and not through a prior disclosure by the disclosing Party, without any obligation of confidentiality with respect to such information (as evidenced by the receiving Party&#8217;s or such Affiliate&#8217;s written records or other competent evidence); </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii) is subsequently received by the receiving Party from a Third Party who is not known by the receiving Party to be under an obligation of confidentiality to the disclosing Party under any agreement between such Third Party and the disclosing Party; or </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iv) has been independently developed by or for the receiving Party without reference to, or use or disclosure of, the disclosing Party&#8217;s Confidential Information (as evidenced by the receiving Party&#8217;s or such Affiliate&#8217;s written records or other competent evidence); </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">provided, further, that clauses (ii) through (iv) above will not apply to the terms and conditions of this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.26.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Control</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controlled</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to any Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right, the legal authority or right (whether by ownership, license (other than a license granted pursuant to this Agreement) or otherwise) of a Person or its Affiliate, to grant access, a license or a sublicense of or under such Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right, without (a) breaching the terms of any agreement with a Third Party and (b) with respect to any Patent Rights which are reasonably useful [***] for the Development, Manufacture, or Commercialization of the Licensed Antibodies or Licensed Products in the Field in the Territory, [***] to any Third Party, except for that which a Party in-licenses and under which the other Party [***] as contemplated in [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.27.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cover</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covering</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, when referring to the Licensed Product or Licensed Antibody: (a) with respect to a Patent Right, that, in the absence of a license granted to a Person under an issued claim included in such Patent Right, the practice by such Person of a specified activity with respect to such Licensed Product or Licensed Antibody would infringe such claim, or (b) with respect to an application for Patent Rights, that, in the absence of a license granted to a Person under a claim included in such application, the practice by such Person of a specified activity with respect to such Licensed Product or Licensed Antibody would infringe such claim if such patent application were to issue as a patent. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.28.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Security Breach</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(d)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.29.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Sharing Initiative</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means GSK&#8217;s policy initiative (as may be amended from time to time), known at the Effective Date as the &#8220;SHARE Initiative,&#8221; to provide researchers with access to Clinical Data, including anonymized patient level data. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.30.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Developing</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Develop</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means non-clinical, pre-clinical, and clinical drug research and development activities, whether before or after Regulatory Approval, including drug metabolism and pharmacokinetics, translational research, toxicology, pharmacology, test method development and stability testing, process and packaging development and improvement, process validation, process scale-up, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, conduct of Clinical Studies, regulatory affairs, the preparation and submission of Regulatory Materials, Clinical Study regulatory activities, and any other activities directed towards obtaining or maintaining Regulatory Approval of any Licensed Product. Development includes use and importation of the relevant Licensed Antibody or Licensed Product to conduct such Development activities. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.31.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Milestone Event</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.32.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Milestone Payment</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.33.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distributor</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Third Party appointed by GSK or any of its Affiliates or its or their Sublicensees to distribute, market and sell Licensed Product, with or without packaging rights, in one or more countries in the Territory, in circumstances where such Third Party purchases its requirements of Licensed Product from GSK or its Affiliates or its or their Sublicensees. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.34.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dollars</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">US$</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means United States dollars. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.35.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in the preamble. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.36.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EU</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the European Union, as its membership may be constituted from time to time, and any successor thereto. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.37.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">European Opposition Proceeding</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.38.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing CMO</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.39.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing CMO Agreements</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.40.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">External Costs</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.41.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States Food and Drug Administration or any successor agency thereto. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.42.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FFDCA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Federal Food, Drug and Cosmetic Act under United States Code, Title 21, as amended from time to time, together with any rules, regulations, and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.43.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Field</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any use or purpose, including the treatment, palliation, diagnosis, cure or prevention of any human or animal disease, disorder or condition. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.44.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Commercial Sale</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means with respect to the Licensed Product in any country in the Territory, the first sale for monetary value for use or consumption by the end user of such Licensed Product in such country after the Regulatory Approval (and Pricing and Reimbursement Approval where relevant) for such Licensed Product has been obtained in such country. First Commercial Sale shall not include any transfer of a Licensed Product (a) between or among GSK and its Affiliates or its or their Sublicensees or (b) for purposes of patient assistance programs, treatment IND sales, named patient sales, compassionate use sales or the like. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.45.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Indication</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, on a country-by-country basis, the first Indication for which Regulatory Approval for a Licensed Product in (a) [***], (b) [***] or (c) [***], as applicable, has been filed with, or approved by, the applicable Regulatory Authority. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.46.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FTE</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the equivalent of a full-time individual&#8217;s work, performed by one or more individuals, at [***] per year for a twelve-month period, carried out by an appropriately qualified employee of Surface or its Affiliates performing activities pursuant to this Agreement. [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.47.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FTE Rate</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the rate of [***] per one full FTE per Calendar Year, which rate shall be prorated on a daily basis as necessary. [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.48.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GCP</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Clinical Practice</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all applicable then-current standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Studies, including, as applicable, (a) as set forth in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products, (b) the Declaration of Helsinki (2013) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), and (d) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the Clinical Data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.49.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GLP</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Laboratory Practice</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all applicable then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (OECD), and such standards of good laboratory practice as are required by the equivalent applicable Laws in the relevant country and other organizations and Governmental Authorities in countries in which the Licensed Product is intended to be sold by the Party that is subject to such standards. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.50.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GMP</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Manufacturing Practice</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all applicable then-current standards for Manufacturing, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. &#167;&#167; 201, 211, 600 and 610 and all applicable FDA guidelines and requirements, (b) European Directive 2003/94/EC for medicines and investigational medicines for human use and the applicable guidelines stated in the EudraLex guidelines, (c) the principles detailed in the applicable ICH guidelines, (d) the conduct of an inspection by a Qualified Person (as defined therein) and the execution by such Qualified Person of an appropriate certification of inspection; and (e) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.51.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Government Official</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; (where &#8220;government&#8221; means all levels and subdivisions of governments, i.e. local, regional, national, administrative, legislative, executive, or judicial, and royal or ruling families) means: (a) any officer or employee of a government or any department, agency or instrumentality of a government (which includes public enterprises, and entities owned or controlled by the state); (b) any officer or employee of a public international organization such as the World Bank or United Nations; (c) any officer or employee of a political party, or any candidate for public office; (d) any person defined as a government or public official under applicable local Laws and not already covered by any of the above; and (e) any person acting in an official capacity for or on behalf of any of the above. &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Government Official</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall include any person with close family members who are Government Officials (as defined above) with the capacity, actual or perceived, to influence or take official decisions affecting a Party&#8217;s business. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.52.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any multinational, federal, national, state, provincial, local or other entity, office, commission, bureau, agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or officer, exercising executive, judicial, legislative, police, regulatory, administrative or taxing authority or functions of any nature pertaining to government. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.53.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in the preamble. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.54.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.55.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Patents</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.56.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Sole Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.57.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Human Biological Samples</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any human biological material (including any derivative or progeny thereof), including any portion of an organ, any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, cells, gametes, or sub-cellular structures such as DNA, or any derivative of such biological material such as stem cells or cell lines; and any human biological product, including, but not limited to, hair, nail clippings, teeth, urine, feces, breast milk, and sweat. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.58.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ICH</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.59.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incremental Withholding</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.60.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IND</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means an Investigational New Drug application, clinical trial application or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirement of such Regulatory Authority, and any amendments thereto. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.61.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IND Acceptance</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to an IND, the earlier of: (a) receipt by GSK, its Affiliate or a Sublicensee of written confirmation from a Regulatory Authority or other applicable Person that Clinical Studies may proceed under such IND; and (b) expiration of the applicable waiting period after which Clinical Studies may proceed under such IND. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.62.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Person entitled to indemnification under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XI</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.63.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Party from whom indemnification is sought under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XI</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.64.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indication</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a disease, disorder or pathological condition for which clinical results for such disease, disorder or pathological condition and a separate Regulatory Approval application or a supplement (or other addition) to a Regulatory Approval application are required for the purpose of obtaining Regulatory Approval in a country or territory. For clarity, (a) moving from one line of therapy to another within an Indication will not be considered to be a new Indication, a non-limiting example of which is moving from second line therapy to first line therapy, (b) a single Indication would include the primary disease, disorder or condition and all variants or sub-divisions or sub-classifications within such primary disease, disorder or condition, and regardless of prophylactic or therapeutic use, pediatric or adult use and irrespective of different formulation(s), dosage forms, dosage strengths, or delivery system(s) used, (c) in cancer, (i) a single Indication means a tumor of a specific organ or a specific hematological malignancy or any discrete form of precursor condition of such tumor or malignancy, and the treatment of any of them, and (ii) a new Indication will require a different tissue of origin (e.g., pancreatic cancer vs endometrial cancer) and will not mean a different line of therapy or combination within the same tumor type; (d) obtaining a label expansion for use of a Licensed Product as a Combination Product or as part of a combination therapy will not be considered to be a new Indication; and (e) the use of a Licensed Product in a biomarker-directed study across a range of tumor types shall be a single Indication based on the applicable biomarker-specified product use for such Licensed Product being studied (e.g. unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors). </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.65.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.66.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement Action</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.67.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement Claim</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.4</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.68.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initiation</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, as to a Clinical Study, the date upon which the first patient is dosed in such Clinical Study. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.69.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Internal Costs</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.70.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JDC</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.71.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(c)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.72.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Patents</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Patent Rights Covering the Joint Inventions. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.73.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Know-How</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all chemical and biological materials and other tangible materials, inventions, practices, methods, protocols, formulae, knowledge, improvements, know-how, trade secrets, quality assurance, quality control, analytical test methods, processes, procedures, assays, skills, experience, techniques, technology, information, data and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical test data and analytical and quality control data, patentable or otherwise. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.74.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Laws</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any applicable federal, state, local, municipal, foreign, or other law, statute, legislation, constitution, principle of common law, code, treaty, ordinance, regulation, rule, or order of any kind whatsoever put into place under the authority of any Governmental Authority, including the FFDCA, PHSA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335a et seq.), U.S. Patent Act (35 U.S.C. &#167;1 et seq.), Federal Civil False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder. &#8220;Law&#8221; will include the applicable regulations and guidance of the FDA and European Union (and national implementations thereof) that constitute GLP, GMP, and GCP (and, if and as appropriate under the circumstances, ICH guidance or other comparable regulation and guidance of any applicable Governmental Authority). </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.75.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Antibody</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) the antibody SRF813, further described on </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-family:'Times New Roman','Times','serif';">, and (b) any other Antibody listed on </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.76.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Antibody Materials</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.8</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.77.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Know-How</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any and all Know-How relating to the Licensed Antibody or Licensed Products that is Controlled by Surface as of the Effective Date or at any time during the Term, in each case, that is necessary or useful to research, Develop, Manufacture, import, export, use, sell or Commercialize the Licensed Antibody or Licensed Products in the Field and in the Territory. For clarity, Licensed Know-How includes Surface Sole Inventions. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.78.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Patents</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) the issued patents and patent applications listed in Exhibit B attached hereto, plus (i) all divisionals, continuations, continuations-in-part thereof or any other patent rights claiming priority directly or indirectly to any of the issued patents or patent applications identified on Exhibit B, and (ii) all patents issuing on any of the foregoing, together with all registrations, reissues, re-examinations, renewals, supplemental protection certificates and extensions of any of the foregoing, and all foreign counterparts thereof, and (b) any other Patent Rights, existing as of the Effective Date or arising during the Term, Controlled by Surface, that (i) claim the composition, Manufacture or use of the Licensed Antibody(s) (including use as a monotherapy or in combination with other compositions of matter), or (ii) are necessary or useful for the research, Development, Manufacture, import, export, use, sale or Commercialization of any Licensed Antibodies or Licensed Products in the Field in the Territory. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.79.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Product</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any pharmaceutical product in final form containing the Licensed Antibody (whether alone as the sole active pharmaceutical ingredient or as a combination with other active pharmaceutical ingredient(s)) in any presentation, formulation or dosage form. For clarification, Licensed Product will include any Combination Product. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.80.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Target</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the inhibitory receptor CD112R (also known as Poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), Nectin-2 Receptor, C7orf15 and MGC2463). </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.81.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Technology</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means collectively, Licensed Patents, Licensed Know-How and Surface&#8217;s interest in Joint Inventions and Joint Patents. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.82.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means damages, losses, liabilities, costs (including costs of investigation and defense), fines, penalties, taxes, expenses, or amounts paid in settlement (in each case, including reasonable attorneys&#8217; and experts&#8217; fees and expenses), in each case resulting from an Action. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.83.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Major European Country</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.84.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacture</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all activities related to the production of the Licensed Product, including the production of any of the following to the extent used in the Licensed Product: any drug substance produced in bulk form for use as an active pharmaceutical ingredient, drug product, compounded or finished final packaged and labeled form, and in intermediate states, including the following activities: planning, purchasing, reference standard preparation, cell bank preparation, mammalian cell production, purification, formulation, scale-up, packaging, quality assurance oversight, quality control testing (including in-process release and stability testing), testing, release, sample retention, stability testing, storage, shipping, validation activities directly related to all of the foregoing, and data management and recordkeeping related to all of the foregoing. References to a Person engaging in Manufacturing activities will include having any or all of the foregoing activities performed by a Third Party. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">means gross invoiced sales of Licensed Products to Third Parties by GSK, its Affiliates and its and their Sublicensees, less the following deductions from such gross amounts which are actually incurred, allowed, paid, accrued or specifically allocated to the extent that such amounts are deducted from gross invoiced sales amounts as reported by GSK in its financial statements in accordance with the applicable Accounting Standards: </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.1.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]; </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.2.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]; </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.3.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]; </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.4.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]; </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.5.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]; </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.6.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]; and </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:8.5%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.85.7.</font></p></td><td style="vertical-align:top;width:85.51%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]. </font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.86.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Breaching Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.87.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means either Surface or GSK; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Surface and GSK, collectively. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.88.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Challenge</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)(i)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.89.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Rights</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the rights and interests in and to (a) all patents and patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of any of the foregoing, (b) any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and the like of any of the foregoing, (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents and certificates of invention. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.90.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization or a Governmental Authority. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.91.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 1 Study</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Clinical Study of an investigational product in subjects with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. 312.21(a), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.92.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 2 Study</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Clinical Study of an investigational product in subjects with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, pharmacokinetics, pharmacodynamics, and dose finding information as described in 21 C.F.R. 312.21(b), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States including a human clinical trial that is also designed to satisfy the requirements of 21 C.F.R. 312.21(a) or corresponding foreign regulations and is subsequently optimized or expanded to satisfy the requirements of 21 C.F.R. 312.21(b) (or corresponding foreign regulations) or otherwise to enable a Phase 3 Study (</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">e.g.</i><font style="font-family:'Times New Roman','Times','serif';">, a Phase 1 Study/ Phase 2 Study). </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.93.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 3 Study</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Clinical Study of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.94.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pricing and Reimbursement Approval</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to the Licensed Product, the governmental approval, agreement, determination or decision establishing the price or level of reimbursement for such Licensed Product, in a given country in the Territory prior to the sale of such Licensed Product in such jurisdiction in the Territory. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.95.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prior CDA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Confidentiality Agreement executed by the Parties as of July 10, 2020. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.96.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Products Warranties</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.2(k)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.97.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecute</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means in relation to any Patent Rights, (a) to prepare and file patent applications, including re-examinations or re-issues thereof, and represent applicants or assignees before relevant patent offices or other relevant Governmental Authorities during examination, re-examination and re-issue thereof, in appeal processes, interferences, oppositions or any equivalent proceedings, (b) to defend all such applications against Third Party oppositions or other challenges, (c) to secure the grant of any patents arising from such patent application, (d) to maintain in force any issued patent (including through payment of any relevant maintenance fees), and (e) to make all decisions with regard to any of the foregoing activities. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.98.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Health Service Act</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PHSA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States Public Health Service Act, as amended. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.99.</font></p></td><td style="vertical-align:top;width:91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Randomized Controlled Study</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Licensed Product, (a) a Phase 2 Study that has been approved or accepted by the applicable Regulatory Authority to be a registrational study sufficient for enabling the filing for Regulatory Approval in the applicable jurisdiction (whether such approval or acceptance occurs prior to Initiation thereof or at a later date on which such Phase 2 Study is amended or supplemented), or (b) a Phase 3 Study of such Licensed Product. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.100.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approval</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the final or conditional approval of the applicable Regulatory Authority necessary for the marketing and sale of the Licensed Product in the Field in a country(ies), excluding separate Pricing and Reimbursement Approval that may be required. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.101.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other Governmental Authority with authority over the Development, Manufacture, or Commercialization of the Licensed Product in a country. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.102.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Exclusivity Period</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to each Licensed Product in any country in the Territory, a period of exclusivity (other than Patent Rights exclusivity) granted or afforded by applicable Law or by a Regulatory Authority in such country that prevents the approval or marketing of any Biosimilar Product of such Licensed Product in such country, including reference product exclusivity under Section 351(k)(7)(C) of the PHSA and pediatric exclusivity under Section 351(m) of the same and any foreign equivalents. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.103.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Materials</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a) any regulatory application, submission, notification, communication, correspondence, registration, Regulatory Approvals and other filings made to, received from or otherwise conducted with a Regulatory Authority related to Developing, Manufacturing, obtaining marketing authorization, marketing, selling or otherwise Commercializing a pharmaceutical product in a particular country or jurisdiction, (b) all supplements and amendments to any of the foregoing, and (c) all data, including Clinical Data, and other information contained in any of the foregoing. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.104.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.105.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rules</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.106.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales Milestone Event</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(c)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.107.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales Milestone Payment</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(c)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.108.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Indication</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means on a country-by-country basis, an Indication that is separate and distinct from the First Indication for the same or a different Licensed Product for which an application for Regulatory Approval has been filed with, or approved by, the applicable Regulatory Authority in (a) [***], (b) [***] or (c) [***], as applicable. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.109.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Senior Officers</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the [***] of Surface and the [***] of GSK, or in each case, his or her designee. If the position of any of the Senior Officers identified in this definition no longer exists due to a corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable title of the Senior Officer set forth herein will be replaced with the title of another executive officer with responsibilities and seniority comparable to the eliminated Senior Officer, and the relevant Party will promptly provide notice of such replacement title to the other Party. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.110.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sole Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.111.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicense</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a grant of rights from GSK to a Sublicensee under any of the rights licensed to GSK by Surface under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.112.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensee</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Person, other than an Affiliate or a Distributor of GSK, that is granted a sublicense by GSK or its Affiliates to the rights granted to GSK in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';">, as provided in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.113.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in the preamble. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.114.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.115.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Sole Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.116.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Transition Services</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.117.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.118.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means worldwide. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.119.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any Person other than a Party or any of its Affiliates. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.120.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.121.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party IP</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.7</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.122.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Losses</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means Losses resulting from an Action by a Third Party. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.123.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademark</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all registered and unregistered trademarks, service marks, trade dress, trade names, logos, insignias, domain names, symbols, designs, and combinations thereof. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.124.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Costs</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means with respect to a Calendar Quarter, the Internal Costs plus the External Costs incurred in connection with the Technical Transition Services for such Calendar Quarter as set forth in the Transition Plan. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.125.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Period</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the period commencing on the Effective Date and ending upon the date of first IND Acceptance for SRF813 in the Territory. Any extensions of the Transition Period will require the mutual written agreement of both Parties. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.126.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.127.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">United States</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S.</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">US</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States and its territories, possessions and commonwealths. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.128.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valid Claim</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a claim of any issued, unexpired patent within the Licensed Patents that has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction and has not been admitted to be invalid or unenforceable through reissue, disclaimer, or otherwise. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.129.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VAT &amp; Indirect Taxes</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any value added, sales, purchase, turnover or consumption tax as may be applicable in any relevant jurisdiction, including value added tax chargeable under legislation implementing Council Directive 2006/112/EC. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><div style="padding-left:0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:3.77%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.130.</font></p></td><td style="vertical-align:top;width:90.77%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Action</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.6</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE II </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSE GRANTS; EXCLUSIVITY </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Grant</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusive License Grant</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this Agreement, Surface hereby grants to GSK a non-transferable (except in accordance with </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.1</u><font style="font-family:'Times New Roman','Times','serif';">), exclusive (even with respect to Surface and its Affiliates, subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';">), sublicensable (subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">), royalty-bearing right and license under the Licensed Technology, to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products in the Field and in the Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) Notwithstanding any other provision of this Agreement, for the purposes of the license grant under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';"> with respect to any Licensed Product that is a Combination Product, (i) such license will only include a license with respect to the Licensed Antibody contained in such Licensed Product, and (ii) in no event is a license granted hereunder with respect to any Other Component of a Combination Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Retained Surface Rights</u><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the license granted to GSK pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(a)</u><font style="font-family:'Times New Roman','Times','serif';">, Surface will retain for itself, and its Affiliates for so long as they remain as Affiliates, the right to practice the Licensed Technology solely to the extent necessary to perform any Technical Transition Services under the Transition Plan and perform other obligations expressly set forth in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensing and Subcontracting</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Right to Sublicense</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will have the right to grant Sublicenses (through multiple tiers) of the rights granted to GSK pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';"> as follows: (i) to its Affiliates, provided such Sublicense only remains in effect for as long as such Sublicensee remains an Affiliate of GSK, and (ii) to Third Parties, in each case, subject to the requirements of </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicense Requirements</u><font style="font-family:'Times New Roman','Times','serif';">. Each Sublicense granted by GSK to a Third Party pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(a)</u><font style="font-family:'Times New Roman','Times','serif';"> will be in writing and will be subject and subordinate to, and consistent with, the terms and conditions of this Agreement. No Sublicense will diminish, reduce or eliminate any obligation of either Party under this Agreement. GSK will be liable for any act or omission of any Sublicensee that is in breach of any of GSK&#8217;s obligations under this Agreement as though the same were a breach by GSK, and Surface will have the right to proceed directly against GSK without any obligation to first proceed against such Sublicensee. Each Sublicense will contain the following provisions: (i) a requirement that the Sublicensee comply with all applicable terms of this Agreement, (ii) if such Sublicense contains a right to Commercialize Licensed Products, such Sublicense will also contain the following provisions: (A) a requirement that the Sublicensee submit applicable sales or other reports to GSK to the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement, and (B) the audit requirement set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u><font style="font-family:'Times New Roman','Times','serif';">, and (iii) provisions whereby GSK obtains, upon termination of such Sublicense, (A) assignment and transfer of ownership and possession of, or a right to reference all Regulatory Materials and Regulatory Approvals Controlled by such Sublicensee that relate to any Licensed Product (which assignment or right of reference may also be provided directly to GSK), and (B) GSK&#8217;s ownership of, or a fully sublicensable exclusive license under and to, any Know-How and Patent Rights that are developed by the Sublicensee in the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">performance of such agreement and are necessary or actually used for the Development, Manufacture or Commercialization of Licensed Products. Any Sublicense granted hereunder that is inconsistent with this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3(b)</u><font style="font-family:'Times New Roman','Times','serif';"> will be null and void. GSK will promptly provide Surface with a true and complete copy of any material Sublicense agreement and each material amendment thereto that it enters into with a Third Party after the execution thereof; provided</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">that the financial and any other terms of any such agreement not pertinent to an understanding of a Party&#8217;s obligations or benefits under this Agreement may be redacted. Each Sublicense granted by GSK to any rights licensed to it hereunder will terminate immediately upon the termination of the license from Surface to GSK with respect to such rights. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance by Independent Contractors</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party may contract or delegate any portion of its obligations or activities hereunder to a Third Party contractor subject to the terms and condition of </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.8</u><font style="font-family:'Times New Roman','Times','serif';"> and provided that, (a) the contractor shall be appropriately qualified to conduct the activities it is engaged to conduct under this Agreement; (b) the contractor undertakes in writing commercially reasonable obligations of confidentiality and non-use regarding Confidential Information, that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';"> hereof; and (c) the contractor undertakes in writing to assign or exclusively license back (with the right to sublicense) all intellectual property that GSK deems to be material to the Development, Manufacture or Commercialization of a Licensed Antibody or Licensed Product developed in the course of performing any such work to the corresponding Party. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Rights</u><font style="font-family:'Times New Roman','Times','serif';">. No rights, other than those expressly set forth in this Agreement, are granted to either Party under this Agreement, and no additional rights will be deemed granted to either Party by implication, estoppel or otherwise, with respect to any intellectual property rights. All rights not expressly granted by either Party or its Affiliates to the other Party under this Agreement are reserved. Neither Party nor any of its Affiliates will use or practice any Know-How or Patent Rights licensed or provided to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.6. [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.7. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party IP</u><font style="font-family:'Times New Roman','Times','serif';">. If Surface or any of its Affiliates enters into any agreement or other arrangement with a Third Party with respect to a grant of rights under any Patent Rights or Know-How of such Third Party (whether by acquisition or by license) that are reasonably useful (but not necessary) for the Development, Manufacture, or Commercialization of the Licensed Antibodies or Licensed Products in the Field in the Territory (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party IP</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Surface shall notify GSK of such Third Party IP. Promptly following the execution of any such agreement, Surface will provide GSK with a copy of the applicable agreement with such Third Party. Within [***] following receipt of such contract, GSK will decide, in its sole discretion, whether or not to [***] and provide Surface written notice of such decision. If GSK desires to [***], (a) GSK shall notify Surface in writing of such election, (b) such [***] under this Agreement and included in [***], (c) [***], and (d) GSK will be [***]. The obligations of Surface set forth above under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.7</u><font style="font-family:'Times New Roman','Times','serif';"> will terminate upon a Change of Control of Surface. For the avoidance of doubt, as between the Parties, it shall be GSK&#8217;s determination and responsibility to obtain rights to any Patent Rights or Know-How that is necessary for the Development, Manufacture or Commercialization of the Licensed Antibodies in the Field in the Territory. For purposes of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.7</u><font style="font-family:'Times New Roman','Times','serif';">, a Patent Right claiming [***] for a Licensed Antibody or a Licensed Product shall be deemed to be necessary for the Development, Manufacture, or Commercialization of such Licensed Antibody or Licensed Product in the Field in the Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 2.8. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusivity and Alternative Products</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Exclusivity</u><font style="font-family:'Times New Roman','Times','serif';">. During the Term, neither Surface nor any of its Affiliates will directly or indirectly research, develop, manufacture or commercialize, nor collaborate with, enable or otherwise authorize, license or grant any right to any Third Party to research, develop, manufacture or commercialize, any Alternative Product anywhere in the Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition of Alternative Product Rights</u><font style="font-family:'Times New Roman','Times','serif';">. In addition, notwithstanding anything to the contrary in this Agreement, in the event Surface or any of its Affiliates acquires or otherwise obtains rights to research, develop, manufacture or commercialize any Alternative Product as the result of any license, merger, acquisition, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">reorganization, consolidation or combination with or of a Third Party other than a Change of Control of Surface or its Affiliates (each, an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Transaction</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; and the Third Party involved in such transaction, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquisition Third Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and, on the date of the completion of such Acquisition Transaction, such Alternative Product is being researched, developed, manufactured or commercialized by such Third Party in a matter that, if done by Surface, would violate Surface&#8217;s exclusivity obligations in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.8(a)</u><font style="font-family:'Times New Roman','Times','serif';">, then Surface or such Affiliate will: [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) For purposes hereof, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alternative Product</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE III </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRANSITION MATTERS; TECHNOLOGY TRANSFER </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Transition Services</u><font style="font-family:'Times New Roman','Times','serif';">. During the Transition Period, Surface will perform certain transition and research services in connection with the Development and Manufacture of Licensed Antibodies and Licensed Products (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Transition Services</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), as more fully detailed in the Transition Plan. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u><font style="font-family:'Times New Roman','Times','serif';">. The Technical Transition Services will be performed in accordance with the terms of a written plan, which sets forth (a) a description of the Technical Transition Services, (b) the proposed timetable for conducting such Technical Transition Services, (c) the estimated Transition Costs for completion of such Technical Transition Services, and (d) the deliverables (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; the initial version of which is attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u><font style="font-family:'Times New Roman','Times','serif';">). Surface will use reasonable efforts to complete the Technical Transition Services set forth in the Transition Plan within the timeframes set forth in the Transition Plan and within the estimated Transition Costs. In the event of any inconsistency between the Transition Plan and this Agreement, the terms of this Agreement will prevail. During the Transition Period, each Party will have the right to propose modifications or amendments to the Transition Plan; provided, however that any modifications or amendments to such Transition Plan that are proposed by either Party will be subject to review by the JDC pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(b)</u><font style="font-family:'Times New Roman','Times','serif';"> and approved by GSK. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Transition Services Reporting</u><font style="font-family:'Times New Roman','Times','serif';">. At each meeting of the JDC, Surface will provide an update regarding the Technical Transition Services it has performed, or caused to be performed, since the previous meeting of the JDC, its Technical Transition Services in process, and the future Technical Transition Services it expects to initiate prior to the next meeting of the JDC. Surface will respond to the reasonable questions or requests of the JDC or GSK, as applicable, for additional information relating to such Technical Transition Services in a timely manner. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Transition Services Costs</u><font style="font-family:'Times New Roman','Times','serif';">. Within [***] after the end of [***] during the Transition Period, Surface shall submit to GSK an invoice and reasonably detailed report (including FTE hours) and any additional documentation reasonably requested by GSK, setting forth all Transition Costs incurred by Surface during such [***]. Surface shall promptly inform GSK upon Surface determining that it is likely to overspend by more than [***] of the Transition Costs for an activity set forth in the Transition Plan. Any and all portion of such overspend shall be borne by Surface unless otherwise approved by GSK prior to the incurrence thereof. GSK shall reimburse Transition Costs within [***] after receipt of an invoice from Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Integrity Practices</u><font style="font-family:'Times New Roman','Times','serif';">. All activities conducted under the Transition Plan will be conducted in accordance with the following practices: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) data will be generated using sound scientific techniques and processes; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) data will be accurately recorded by the persons performing the applicable Technical Transition Services in accordance with data integrity practices; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) data will be analyzed appropriately without bias in accordance with data integrity practices; </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) data and results from experiments will be stored securely such that it can be retrieved without undue burden; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) data trails will exist to demonstrate or reconstruct without undue burden key decisions made during the performance of, presentations made about, and conclusions reached with respect to the activities undertaken in the performance of the Transition Plan. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">GSK may request changes to the requirements set forth above in this Section 3.5 where GSK reasonably believes such changes are required to ensure that such activities are undertaken in compliance with data integrity practices, and Surface shall use reasonable efforts to accommodate such changes. GSK shall be permitted, in its sole discretion and sole cost and expense, no more than once per Calendar Year, to undertake on-site compliance audits of Surface&#8217;s data integrity practices in respect of the activities performed by Surface under the Transition Plan by providing Surface with [***] written notice of GSK&#8217;s intent to do so, such audits to be conducted at a time mutually convenient to both Parties. All information revealed to GSK in such audit shall be considered Confidential Information of Surface. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.6. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Animal Welfare</u><font style="font-family:'Times New Roman','Times','serif';">. Surface agrees to comply with all applicable Laws for the care, welfare and ethical treatment of animals in the country where the animal studies are being performed. Surface further agrees to comply with the &#8220;3Rs&#8221; Principles &#8211; reducing the number of animals used, replacing animals with non-animal methods whenever possible, and refining the research techniques used. All work must be conducted in adherence to the core principles for animals identified below. Applicable Laws may be additive to the core principles, but Surface agrees to comply, and shall procure and ensure that those acting for or on behalf of Surface (including its subcontractors) comply, at a minimum, with these core principles: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) access to species appropriate food and water, </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) access to species specific housing, including species appropriate temperature and humidity levels, </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) provision of humane care and a program of veterinary care through guidance of a veterinarian, </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) animal housing that minimizes the development of abnormal behaviors, </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) adherence to principles of replacement, refinement and reduction in the design of in vivo or ex vivo studies with processes to optimize animal use and to ensure effective population management, </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) work using animals is supported by a relevant scientific justification/rationale, approved by an institutional ethical review process and subjected to independent scientific review, </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(g) commitment to minimizing pain and distress during in vivo and ex vivo studies, and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(h) work is performed by staff documented as trained and competent to conduct the procedures for which they are responsible. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Upon reasonable advanced written notice, GSK (or its delegate) shall have the right to inspect Surface&#8217;s or its subcontractor&#8217;s records and facilities; provided, that if Surface&#8217;s contracts with its subcontractors do not permit GSK (or its delegate) to so inspect, then GSK may request that Surface conduct such inspection on GSK&#8217;s behalf. The scope of the inspection may include a tour of the facility, the opportunity to view relevant SOPs, training records, building management records, animal health records, ethical review documents, and any other documents reasonably necessary to assess compliance by Surface or its subcontractor with the terms of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.6</u><font style="font-family:'Times New Roman','Times','serif';">; provided that such inspection shall not extend to those parts of records and facilities which Surface or its subcontractor can demonstrate to be subject to confidentiality arrangements with other programs or customers. To the extent that any significant deficiencies are identified as the result of such inspection, Surface shall endeavor in good faith to take reasonable and practical corrective measures to remedy any such material deficiencies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.7. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Licensed Know-How</u><font style="font-family:'Times New Roman','Times','serif';">. Surface will use reasonable efforts to disclose and make available to GSK the Licensed Know-How that exists as of the Effective Date pursuant to and within the timeframes set forth in the Transition Plan. Following the Transition Period, Surface will use reasonable efforts to disclose and make available to GSK any additional Licensed Know-How of which Surface or GSK become aware, and respond to any requests by GSK for additional Licensed Know-How Controlled by Surface relating to the Development and Manufacture of the Licensed Antibodies and Licensed Products. Surface will be permitted to make such Licensed Know-How available in such form as Surface will determine, including, if Surface so elects, in the form such Licensed Know-How is maintained by Surface. GSK will bear all Third Party expenses in connection with the transfer of Licensed Know-How after the Transition Period. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 3.8. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Licensed Antibodies</u><font style="font-family:'Times New Roman','Times','serif';">. Surface will deliver, at Surface&#8217;s cost and expense, research grade Licensed Antibodies as described in the Transition Plan (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Antibody Materials</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) EXW (Incoterms 2020) to GSK pursuant to and within the timeframes set forth in the Transition Plan. Title and risk of loss of such Licensed Antibody Materials will transfer upon delivery as defined in the Transition Plan. GSK will only use the Licensed Antibody Materials for the Development performed by or on behalf of GSK for the Licensed Antibodies and Licensed Products; provided that, GSK will not use such Licensed Antibody Materials in research testing involving human subjects. The Licensed Antibody Materials are experimental in nature and are provided &#8220;AS IS,&#8221; without any warranties as to merchantability or fitness for a particular purpose. GSK further acknowledges that the Licensed Antibody Materials&#8217; properties or characteristics are not known, and GSK agrees that GSK will use such Licensed Antibody Materials with reasonable care and will assume responsibility for any losses or injuries incurred by it or its Affiliates or its or their Sublicensees through use of such Licensed Antibody Materials. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE IV </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEVELOPMENT </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 4.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Diligence; Development Responsibilities</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Diligence</u><font style="font-family:'Times New Roman','Times','serif';">. GSK (directly, or through its Affiliates, its or their Sublicensees and subcontractors) will use Commercially Reasonable Efforts to Develop, including obtain and maintain Regulatory Approval of Licensed Products in the Field in the Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Responsibilities and Compliance</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this Agreement, GSK will be solely responsible, at its own expense, for managing and conducting all activities relating to the Development of the Licensed Antibody and Licensed Product for the purpose of obtaining Regulatory Approval in the Field and in the Territory. GSK will conduct its Development activities in good scientific manner and in compliance with applicable Law, including Laws regarding environmental, safety and industrial hygiene, and GLP, GCP, current standards for pharmacovigilance practice, and all applicable requirements relating to the protection of human subjects, as well as GSK&#8217;s applicable internal policies and codes of practice. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 4.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Reporting</u><font style="font-family:'Times New Roman','Times','serif';">. No later than [***] during the Term for so long as GSK is conducting the Development, GSK will provide Surface, via the Alliance Managers pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(f)</u><font style="font-family:'Times New Roman','Times','serif';">, with reasonably detailed written reports summarizing the material Development activities it has performed, or caused to be performed, since the preceding report, its material Development activities in process, and the future material Development activities it expects to initiate prior to the next report. GSK will respond to the reasonable questions or requests of the JDC or Surface, as applicable, for additional information relating to such activities in a timely manner. In addition, upon Surface&#8217;s request, no more than [***] per [***], GSK&#8217;s senior executives responsible for the Development and related Manufacturing activities with respect to the Licensed Products will meet with Surface&#8217;s senior executives to discuss GSK&#8217;s or its Affiliates&#8217; or its or their Sublicensees&#8217; Development and related Manufacturing activities for such Licensed Product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 4.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Submissions and Approvals</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Responsibilities</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) GSK will be responsible, at its sole cost and expense, for exercising Commercially Reasonable Efforts to seek and attempt to obtain Regulatory Approvals for the Licensed Products in the Field in the Territory. GSK will be responsible for and have the exclusive right to seek and attempt to obtain Pricing and Reimbursement Approvals for the Licensed Products in the Field in the Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) During the Transition Period, to the extent set forth in the Transition Plan, Surface shall be responsible for the preparation of the Chemistry, Manufacturing and Control (CMC) section of the IND application for the Licensed Product, which section shall be in form and substance reasonably satisfactory to GSK. Surface shall deliver such CMC section to GSK in accordance with the Transition Plan. Following the end of the Transition Period, Surface shall cooperate and support GSK, [***] as may be reasonably requested by GSK during the Term, in preparing and submitting Regulatory Materials and otherwise with respect to the CMC section of the IND applications. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of Regulatory Approvals</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will own all Regulatory Materials, including all submissions and applications for Regulatory Approvals, and Regulatory Approvals, for the Licensed Products in the Field in the Territory. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Cooperation</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will keep Surface reasonably informed with regard to any material Regulatory Approval or Pricing and Reimbursement Approval proceedings for the Licensed Products in the Field in the Territory in accordance with its reporting obligation set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u><font style="font-family:'Times New Roman','Times','serif';">. At Surface&#8217;s reasonable request, [***]. Surface shall cooperate and support GSK [***], as may be reasonably necessary in preparing and submitting Regulatory Materials and otherwise with respect to obtaining Regulatory Approvals for the Licensed Product and in the activities in support thereof, to the extent Surface has control over or the right to obtain documents or other materials that are necessary or useful for GSK or any of its Affiliates or its or their Sublicensees to obtain Regulatory Approvals for the Licensed Product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Audits</u><font style="font-family:'Times New Roman','Times','serif';">. The Parties will cooperate in good faith with respect to Regulatory Authority inspections of any site or facility of the Existing CMO where Manufacturing of Licensed Products in the Field are conducted pursuant to this Agreement (each an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audited Site</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Subject to applicable Law, GSK will be given a reasonable opportunity to attend any inspection by any Regulatory Authority of the Audited Sites, and the summary, or wrap-up, meeting with a Regulatory Authority at the conclusion of such inspection. If such attendance would result in the disclosure to GSK of Confidential Information unrelated to the subject matter of this Agreement, the Parties will enter into a confidentiality agreement covering such unrelated subject matter. In the event that any Audited Site is found to be non-</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">compliant with one or more GMP standards, Surface will submit to GSK a proposed recovery plan or Corrective and Preventative Actions (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAPA</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) as soon as reasonably practicable after Surface, its Affiliate or its permitted subcontractor receives notification of such non-compliance from the relevant Regulatory Authority and Surface will use reasonable efforts, at Surface&#8217;s cost, to implement such recovery plan or CAPA promptly after submission. Surface agrees, to the maximum extent reasonably possible, to include in any contract or other written arrangement with its permitted subcontractors, a clause permitting GSK to exercise its rights under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3(d)</u><font style="font-family:'Times New Roman','Times','serif';">. Surface&#8217;s obligations under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> will end at the time Surface is no longer performing the activities set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE V </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MANUFACTURE, SUPPLY AND COMMERCIALIZATION </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 5.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing and Supply</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Obligations</u><font style="font-family:'Times New Roman','Times','serif';">. Surface, its Affiliates, or its or their Sublicensees or subcontractors (including the Existing CMO) will be solely responsible, at GSK&#8217;s cost and expense, for Manufacturing and supplying the worldwide requirements for Licensed Antibodies and Licensed Products in the Territory (i) as part of the Technical Transition Services, and (ii) through to the date of IND Acceptance. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Obligations</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to the preceding sentence, GSK, its Affiliates, its or their Sublicensees or subcontractors will be solely responsible, at its sole cost and expense, for Manufacturing and supplying the worldwide requirements for the Development and Commercialization of the Licensed Antibodies and the Licensed Products in the Territory, except for such Manufacturing activities performed by Surface as part of the Technical Transition Services. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Warranties</u><font style="font-family:'Times New Roman','Times','serif';">. Surface shall Manufacture and supply Licensed Antibodies and Licensed Products in accordance with the Product Warranties set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.2(k)</u><font style="font-family:'Times New Roman','Times','serif';">, to the extent such warranties exist in Surface&#8217;s agreement with the Existing CMO. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery</u><font style="font-family:'Times New Roman','Times','serif';">. The Parties will cooperate to ensure that the production schedule for Licensed Antibody or Licensed Product will meet the delivery dates or timelines in the Transition Plan. Surface shall further ensure that for any supply to be delivered to GSK, its Manufacturing subcontractors deliver each shipment of the Licensed Antibody and the Licensed Product, as the case may be, on time and to the location designated by GSK, subject to the terms and conditions of Surface&#8217;s agreement with the Existing CMO. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality</u><font style="font-family:'Times New Roman','Times','serif';">. As between GSK and Surface, Surface shall be responsible to manage all quality aspects of Manufacturing and supply performed by its subcontractors, provided that GSK shall be permitted to have a consultancy role as set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(e)</u><font style="font-family:'Times New Roman','Times','serif';">, subject to the terms and conditions of Surface&#8217;s agreement with the Existing CMO. GSK&#8217;s consultancy role shall include, but not be limited to: [***]. In any event, Surface will notify GSK as soon as it becomes aware of any issue (foreseen or unforeseen) which may result in Surface being unable to provide the required quantities of Licensed Antibody or Licensed Product, and the Parties shall promptly meet to discuss in good faith what actions are required (if any) to resolve such issue. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 5.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization Diligence</u><font style="font-family:'Times New Roman','Times','serif';">. Upon receipt of the Regulatory Approval for a Licensed Product in the Field in a given country in the Territory, GSK (directly, or through its Affiliates, its or their Sublicensees or subcontractors) will use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such country in the Territory. GSK will be solely responsible for, at its expense, and will have sole discretion with respect to, Commercializing the Licensed Product in the Field in the Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting Obligations</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will provide Surface with written notice of the First Commercial Sale of each Licensed Product in the Field in [***] as soon as reasonably practicable after such event. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademarks</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will have the right to brand the Licensed Products in the Field in the Territory using GSK related Trademarks and any other Trademarks and trade names it determines appropriate for the Licensed Products, which branding may vary by country. GSK will own all rights in such Trademarks and register and maintain such Trademarks in the countries within the Territory, where and how it determines appropriate. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE VI </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">GOVERNANCE; JOINT DEVELOPMENT COMMITTEE; JOINT PATENT COMMITTEE </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 6.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Development Committee</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Formation; Purposes and Principles</u><font style="font-family:'Times New Roman','Times','serif';">. Within [***] after the Effective Date, Surface and GSK will form a joint development committee (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JDC</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) to facilitate information sharing between the Parties with respect to the Development of the Licensed Products as more fully described in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u><font style="font-family:'Times New Roman','Times','serif';"> and </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Responsibilities</u><font style="font-family:'Times New Roman','Times','serif';">. In addition to its overall responsibility to facilitate information sharing between the Parties with respect to the Development activities under this Agreement, the JDC will: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) review and discuss proposed amendments or revisions to the Transition Plan (for clarity, GSK shall have the final decision making authority to approve the Transition Plan as described in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2</u><font style="font-family:'Times New Roman','Times','serif';">; provided that any amendment or revision to add additional material obligations that are not set forth in the Transition Plan will require Surface&#8217;s consent); </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) exchange information with respect to the Technical Transition Services, and review and discuss Surface&#8217;s activities and progress under the Transition Plan; and </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii) perform such other functions as are assigned to it in this Agreement or as appropriate to further the purposes of this Agreement to the extent agreed to in writing by the Parties. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Membership</u><font style="font-family:'Times New Roman','Times','serif';">. The JDC will be composed of a total of [***] representatives of each Party, which will be appointed by each of Surface and GSK, respectively. Each individual appointed by a Party as a representative to the JDC will be an employee of such Party with sufficient seniority within the applicable Party to provide meaningful input and make decisions arising within the scope of the JDC&#8217;s responsibilities, and have knowledge and expertise in the Development of compounds and products similar to the Licensed Antibody and Licensed Products under this Agreement. The JDC may change its size from time to time by consent of its members, provided that the JDC will consist at all times of an equal number of representatives of each Party, unless otherwise agreed by the Parties in writing. Each Party may replace any of its JDC representatives at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party. The JDC will be chaired by one designated representative of GSK. The chairperson will be responsible, with support from the Alliance Manager, for calling and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">conducting meetings and preparing and circulating an agenda in advance of each meeting; provided, however, that the chairperson will include any agenda items proposed by either Party on such agenda. The minutes of each JDC meeting that reflect the material decisions made and action items identified at such meetings will be prepared and reviewed in accordance with the procedures established by the JDC. If a representative, within such time period, does not notify the responsible Alliance Manager that he/she does not approve of the minutes, the minutes will be deemed to have been approved by such representative. Each JDC representative and the Alliance Manager will be subject to confidentiality obligations no less stringent than those in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Meetings</u><font style="font-family:'Times New Roman','Times','serif';">. The JDC will hold [***] meetings for so long as the JDC exists, unless the Parties mutually agree in writing to a different frequency. No later than [***] prior to any meeting of the JDC (or such shorter time period as the Parties may agree), the chairperson (or an Alliance Manager) will prepare and circulate an agenda for such meeting. Either Party may also call a special meeting of the JDC by providing at least [***] prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event the Alliance Managers will work with the chairperson of the JDC to provide the members of the JDC no later than [***] prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision on the matters to be considered. The JDC may meet in person or by audio or video conference as its representatives may mutually agree. Other representatives of the Parties, their Affiliates and Third Parties involved in the Development of Licensed Products may be invited by the members of the JDC to attend meetings as observers or to facilitate discussions outside of meetings; provided, however, that such representatives are subject to confidentiality obligations no less stringent than those set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will be responsible for its costs to attend each meeting of the JDC. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JDC Decisions</u><font style="font-family:'Times New Roman','Times','serif';">. Other than as set forth herein, in order to make any decision required of it hereunder with respect to any approval, the JDC must have present (in person, by videoconference or telephonically) at least one member of each Party. The Parties will endeavor to make decisions of the JDC by consensus; provided that GSK will have the tie-breaking vote in the event of any dispute; provided, further, that no decision by GSK may be in conflict with any of the terms of this Agreement (including by amending or increasing any obligations on Surface or any of its Affiliates (other than those set forth in the Transition Plan, which is subject to Surface&#8217;s right to consent under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1(b)(i)</u><font style="font-family:'Times New Roman','Times','serif';">) or by granting any licenses or other rights to GSK or any of its Affiliates that, in each case, are not expressly set forth in this Agreement). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disbanding of JDC</u><font style="font-family:'Times New Roman','Times','serif';">. Unless otherwise agreed by the Parties, the JDC will have no further responsibilities and will disband at the end of the Transition Period. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(g) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Authority of the JDC</u><font style="font-family:'Times New Roman','Times','serif';">. Except as otherwise provided in this Agreement, the JDC will have solely the roles and responsibilities assigned to it in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VI</u><font style="font-family:'Times New Roman','Times','serif';">. The JDC will have no authority to amend, modify or waive compliance with this Agreement or make any decision other that those specifically assigned under this Agreement to be made by the JDC. The JDC shall not have the authority to alter, or waive compliance by a Party with, a Party&#8217;s obligations under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 6.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Patent Committee</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Formation; Purposes and Principles</u><font style="font-family:'Times New Roman','Times','serif';">. Within [***] after the Effective Date, Surface and GSK will form a joint patent committee (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JPC</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) to (i) facilitate information sharing between the Parties with respect to the Prosecution of the Licensed Patents, and the Joint Patents, (ii) review and comment on filings or responses with respect to the Licensed Patents and Joint Patents as and if required under this Agreement, and (iii) any other matters for which the Parties are obligated to cooperate, keep each other informed or otherwise communicate under Article VIII; provided that GSK shall have the final decision making authority. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JPC Decisions</u><font style="font-family:'Times New Roman','Times','serif';">. Other than as set forth herein, in order to make any decision required of it hereunder, the JPC must have present (in person, by videoconference or telephonically) at least one member of each Party. The Parties will endeavor to make decisions of the JPC by consensus; provided that GSK will have the tie-breaking vote in the event of any dispute; provided, further, that no decision by GSK may be in conflict with any of the terms of this Agreement (including by amending or increasing any obligations on Surface or any of its Affiliates or by granting any licenses or other rights to GSK or any of its Affiliates that, in each case, are not expressly set forth in this Agreement). </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disbanding of JPC</u><font style="font-family:'Times New Roman','Times','serif';">. Unless otherwise agreed by the Parties, the JPC will have no further responsibilities and will disband at the end of the Term. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Authority of the JPC</u><font style="font-family:'Times New Roman','Times','serif';">. Except as otherwise provided in this Agreement, the JPC will have solely the roles and responsibilities assigned to it in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VI</u><font style="font-family:'Times New Roman','Times','serif';">. The JPC will have no authority to amend, modify or waive compliance with this Agreement or make any decision other that those specifically assigned under this Agreement to be made by the JPC. The JPC shall not have the authority to alter, or waive compliance by a Party with, a Party&#8217;s obligations under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 6.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alliance Managers</u><font style="font-family:'Times New Roman','Times','serif';">. Promptly after the Effective Date, each Party shall appoint an individual to act as alliance manager for such Party (each, an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alliance Manager</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Each Alliance Manager shall attend meetings of the JDC as a non-voting observer. The Alliance Managers shall be the primary point of contact for the Parties regarding communications contemplated by this Agreement, whether formal reporting obligations or otherwise, including after disbanding of the JDC. The Alliance Managers shall also be responsible for assisting the JDC in performing its responsibilities such as scheduling meetings, circulating agendas as necessary and preparing and finalizing the minutes from meetings of the JDC. Each Party may replace its Alliance Manager, in its sole discretion, from time to time, upon notification to the other Party, which notice may be given by e-mail, sent to the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE VII </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FINANCIAL PROVISIONS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Upfront Payment; Milestone Payments</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Upfront Payment</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this Agreement, and in partial consideration for the rights granted to GSK under this Agreement, GSK will pay Surface a non-refundable, non-creditable payment in the amount of Eighty-Five Million U.S. Dollars (US$ 85,000,000), which upfront payment will be due and payable to Surface within [***] Business Days following receipt of an invoice from Surface for such payment on or after the Effective Date. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Milestone Payment</u><font style="font-family:'Times New Roman','Times','serif';">. During the Term, GSK will notify Surface in writing of the achievement by or on behalf of GSK, its Affiliates or its or their Sublicensees of any milestone event set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(b)</u><font style="font-family:'Times New Roman','Times','serif';"> (each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Milestone Event</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) within [***] after the occurrence thereof. After receipt of such notice, Surface will submit an invoice to GSK for the corresponding non-refundable, non-creditable milestone payment set forth in the tables below (each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Milestone Payment</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). GSK will make the corresponding Development Milestone Payment by [***] from GSK&#8217;s receipt of an invoice, in accordance with GSK&#8217;s standard payment terms. Each of the Development Milestone Payments set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(b)</u><font style="font-family:'Times New Roman','Times','serif';"> is payable only one time upon the first achievement of the corresponding Development Milestone Event by the first Licensed Product to achieve such Development Milestone Event and no amounts shall be due for subsequent or repeated achievements of such Development Milestone Event, whether for the same or a different Licensed Product. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:68%;" align="center"><tr><td style="vertical-align:middle;width:71.76%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:15.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.76%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Milestone Event</b></p></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td colspan="2" style="vertical-align:bottom;width:17.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development Milestone</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Payment</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in Dollars)</b></p></td><td style="vertical-align:bottom;width:0.25%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">6. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">7. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">8. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">9. [***]</font></p></td><td style="vertical-align:bottom;width:10.38%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:71.76%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:10.38%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">245,000,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding anything to the contrary set forth herein, [***]. The maximum aggregate amount of Development Milestone Payments payable by GSK pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(b)</u><font style="font-family:'Times New Roman','Times','serif';"> is Two Hundred Forty-Five Million U.S. Dollars ($245,000,000). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales Milestone Payments</u><font style="font-family:'Times New Roman','Times','serif';">. During the Term, GSK will notify Surface in writing of the achievement by or on behalf of GSK, its Affiliates or its or their Sublicensees of any milestone event set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(c)</u><font style="font-family:'Times New Roman','Times','serif';"> (each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales Milestone Event</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; and the corresponding payment, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales Milestone Payment</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) within [***] after becoming aware of the occurrence thereof. Each of the Sales Milestone Payments set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(c)</u><font style="font-family:'Times New Roman','Times','serif';"> is payable only upon the first achievement of such Sales Milestone Event and none of the Sales Milestone Payments will be payable more than once and no amounts shall be due for subsequent or repeated achievements of such Sales Milestone Event, whether for the same or a different Licensed Product. For clarity, but subject to the following sentence, the Sales Milestone Payments will be additive such that if all [***] Sales Milestone Events set forth below are achieved in the same Calendar Year, GSK will pay to Surface a payment of Four Hundred Eighty-Five Million Dollars ($485,000,000), and the maximum aggregate amount of Sales Milestone Payments payable by GSK pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(c)</u><font style="font-family:'Times New Roman','Times','serif';"> is Four Hundred Eighty-Five Million Dollars ($485,000,000). [***]. After receipt of any notice under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1(c)</u><font style="font-family:'Times New Roman','Times','serif';"> regarding achievement of a Sales Milestone Event [***], Surface will submit an invoice to GSK for the corresponding non-refundable, non-creditable Sales Milestone Payment [***]. GSK will make the corresponding Sales Milestone Payment [***] by [***] from GSK&#8217;s receipt of an invoice, in accordance with GSK&#8217;s standard payment terms. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:68%;" align="center"><tr><td style="vertical-align:middle;width:69.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:12.28%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:15.86%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Event</b></p></td><td style="vertical-align:bottom;width:12.28%;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td colspan="2" style="vertical-align:bottom;width:17.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Sales Milestone Payment</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(in Dollars)</b></p></td><td style="vertical-align:bottom;width:0.25%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. Aggregate annual Net Sales of all Licensed Products in the Territory in a Calendar Year greater than [***]</font></p></td><td style="vertical-align:bottom;width:12.28%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. Aggregate annual Net Sales of all Licensed Products in the Territory in a Calendar Year greater than [***]</font></p></td><td style="vertical-align:bottom;width:12.28%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Aggregate annual Net Sales of all Licensed Products in the Territory in a Calendar Year greater than [***]</font></p></td><td style="vertical-align:bottom;width:12.28%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. Aggregate annual Net Sales of all Licensed Products in the Territory in a Calendar Year greater than [***]</font></p></td><td style="vertical-align:bottom;width:12.28%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:15.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***]</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:69.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:12.28%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;width:15.86%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">485,000,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;background:#cceeff;margin:0pt;padding:0.25pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalties</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Rate</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this Agreement, and in partial consideration for the rights granted to GSK under this Agreement, during the Royalty Term, GSK will pay to Surface non-refundable, non-creditable royalties (except in the case of an overpayment as set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5(b)</u><font style="font-family:'Times New Roman','Times','serif';">) at the graduated royalty rates specified in the following table with respect to the aggregate annual worldwide Net Sales of all Licensed Products across all indications in the Territory in a given Calendar Year: </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:68%;" align="center"><tr><td style="vertical-align:middle;width:66.45%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:21.85%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:11.68%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Aggregate Annual Worldwide Net Sales of All Licensed</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Products in a Calendar Year</b></p></td><td style="vertical-align:bottom;width:21.85%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"></td><td style="vertical-align:bottom;width:11.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.5pt 0.25pt;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Portion of aggregate annual worldwide Net Sales up to and including [***]</font></p></td><td style="vertical-align:bottom;width:21.85%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:11.68%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] percent ([***]%)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Portion of aggregate annual worldwide Net Sales greater than [***] up to and including [***]</font></p></td><td style="vertical-align:bottom;width:21.85%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:11.68%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] percent ([***]%)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Portion of aggregate annual worldwide Net Sales greater than [***] up to and including [***]</font></p></td><td style="vertical-align:bottom;width:21.85%;background:#cceeff;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:11.68%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] percent ([***]%)</font></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Portion of aggregate annual worldwide Net Sales greater than [***]</font></p></td><td style="vertical-align:bottom;width:21.85%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:11.68%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] percent ([***]%)</font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u><font style="font-family:'Times New Roman','Times','serif';">. Royalties will be due under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u><font style="font-family:'Times New Roman','Times','serif';"> with respect to a given Licensed Product in a given country in the Territory during the period commencing upon the First Commercial Sale of such Licensed Product in such country and ending upon the later of (i) the expiration of the last-to-expire Valid Claim that Covers the composition of matter or approved method of use of such Licensed Product or the Licensed Antibody contained in such Licensed Product in such country, (ii) the expiration of the Regulatory Exclusivity Period with respect to such Licensed Product in such country, or (iii) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country (such period, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). For clarity, once the Royalty Term has expired in a given country in the Territory, Net Sales in such country will not be included in the calculation of the aggregate annual worldwide Net Sales used to determine the royalty rate. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Payments and Reports</u><font style="font-family:'Times New Roman','Times','serif';">. Within [***] after the end of each Calendar Quarter, commencing with the Calendar Quarter during which the First Commercial Sale of a Licensed Product is made anywhere in the Territory, GSK will provide to Surface a report setting forth on a Licensed Product&#8211;by&#8211;Licensed Product and country-by-country basis (a) the Net Sales; and (b) the calculation of the royalties payable under this Agreement on account of those Net Sales. Each royalty report along with the royalties shown to have accrued on that report are due and payable to Surface within [***] following the end of such Calendar Quarter. All payments due under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u><font style="font-family:'Times New Roman','Times','serif';"> shall be made by bank wire transfer in immediately available funds to an account designated by Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Payment Reductions</u><font style="font-family:'Times New Roman','Times','serif';">. The royalties payable under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u><font style="font-family:'Times New Roman','Times','serif';"> will be subject to the following: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Licenses</u><font style="font-family:'Times New Roman','Times','serif';">. If GSK enters into a license agreement after the Effective Date with a Third Party for the right to use or Commercialize a Licensed Product under intellectual property controlled by such Third Party, pursuant to which GSK pays a royalty to such Third Party for the right to use or Commercialize such Licensed Product under such Patent Rights, then, subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(e)</u><font style="font-family:'Times New Roman','Times','serif';">, GSK may deduct [***] of all upfront payment, milestone payments, and royalty payments paid to such Third Party to the extent attributable to the use or Commercialization of such Licensed Product against the royalties due under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u><font style="font-family:'Times New Roman','Times','serif';">; provided that GSK shall have the right to carry forward for application against royalties payable to Surface with respect to Net Sales of such Licensed Product in future periods any amount that is not so credited due to the limitation in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(e)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[***]</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lack of Patent Protection</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(e)</u><font style="font-family:'Times New Roman','Times','serif';"> the royalties payable to Surface with respect to Net Sales of Licensed Products shall be reduced, on a Licensed Product&#8211;by&#8211;Licensed Product and country-by-country basis, to [***] of the amounts otherwise payable pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u><font style="font-family:'Times New Roman','Times','serif';"> during any portion of the Royalty Term upon expiration of the last-to-expire Valid Patent Claim Covering the composition of matter or method of use of the applicable Licensed Product in that country. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biosimilar Competition</u><font style="font-family:'Times New Roman','Times','serif';">. If, on a Licensed Product-by-Licensed Product and country-by-country basis, at least one Biosimilar Product is commercially available with respect to such Licensed Product in such country and the combined market share for all such Biosimilar Products [***]. Unit volume sales will be identified and calculated based on relevant information published by IQVIA, any successor to IQVIA, or any other similar industry-standard Third Party source used by GSK. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cumulative Deductions</u><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the foregoing, in no event will the deductions set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u><font style="font-family:'Times New Roman','Times','serif';"> through </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(d)</u><font style="font-family:'Times New Roman','Times','serif';"> reduce the royalties otherwise payable to Surface as specified in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2(a)</u><font style="font-family:'Times New Roman','Times','serif';"> by more than [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Audits</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Keeping</u><font style="font-family:'Times New Roman','Times','serif';">. GSK and its Affiliates will, and will cause their respective Sublicensees to, keep complete, true and accurate books and records in accordance with its Accounting Standards of the items underlying (i) Net Sales, (ii) royalty payments under this Agreement and (iii) [***]. GSK and its Affiliates will, and will cause their respective Sublicensees to keep, such books and records for at least [***] following the Calendar Quarter to which they pertain. Surface [***] will have the right annually, at its own expense, to have an internationally-recognized independent, certified public accountant, selected by Surface [***] and reasonably acceptable to GSK (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Auditor</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), review any such records of GSK in the location(s) where such records are customarily maintained by GSK upon at least [***] prior written notice, during regular business hours and under obligations of confidentiality, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">except to the extent necessary to enforce Surface&#8217;s rights under this Agreement [***] or if disclosure is required by applicable Law, for the sole purpose of verifying the basis and accuracy of payments made under this Agreement and </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">the content of the reports described in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u><font style="font-family:'Times New Roman','Times','serif';">, within the prior [***] period after receipt of such report. The Auditor will have the right to disclose to Surface ([***] its conclusions regarding any payment owed under this Agreement. The records for any Calendar Year may be audited no more than once with respect to records covering any specific period of time. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Report</u><font style="font-family:'Times New Roman','Times','serif';">. The report prepared by the Auditor, a copy of which will be sent or otherwise provided to each Party by such Auditor at the same time before such report is considered final, will contain the conclusions of such Auditor regarding the audit and will specify that the amounts paid pursuant thereto were correct or, if incorrect, the amount of any underpayment or overpayment, and the specific details regarding any discrepancies. No other information will be provided to Surface without the prior consent of GSK unless disclosure is required by applicable Laws, and if so determined by Surface in consultation with GSK, it will, if permitted, give GSK prior notice thereof to the extent possible for GSK to seek a protective order against or limiting such disclosure. If such report shows any underpayment, then GSK will remit to Surface, within [***] after receipt of such report, (i) the amount of such underpayment and (ii) if such underpayment exceeds [***] of the total amount owed for the period then being audited, the actual costs incurred by Surface in conducting such review. For the avoidance of doubt, payment of the underpayment will be considered a late payment, subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.9</u><font style="font-family:'Times New Roman','Times','serif';">. If such report shows any overpayment, then at Surface&#8217;s election, either GSK will deduct the overpaid amount for application against future payments owed to Surface or Surface will reimburse GSK the amount of such overpayment. The Parties mutually agree that all information subject to review under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u><font style="font-family:'Times New Roman','Times','serif';"> is Confidential Information of both Parties and that the receiving Party will retain and cause the Auditor to retain all such information in confidence in accordance with confidentiality and non-use obligations no less stringent than those contained in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.6. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Withholding</u><font style="font-family:'Times New Roman','Times','serif';">. Any tax paid or required to be withheld by GSK under applicable Laws in effect at the time of payment for the benefit of Surface on account of any royalties or other payments payable to Surface under this Agreement shall be deducted from the amount of royalties or other payments otherwise due. The Parties shall reasonably cooperate with one another to reduce or minimize any such deduction or withholding required by applicable Laws, including by providing any forms or other certifications necessary to reduce the amount of such withholding (i.e. including duly completed IRS Form W-9 or applicable IRS Form W-8). If, in accordance with the foregoing, GSK withholds any amount, then it will pay to Surface the balance when due, timely remit to the proper taxing authority the withheld amount, and send Surface proof of such remittance within [***] following Surface&#8217;s request for such proof of remittance. Notwithstanding the foregoing, GSK shall assume the responsibility for, and increase the amount payable hereunder such that Surface receives the amount it would have received but for, any Incremental Withholding (as defined below) in the event that such Incremental Withholding arises as a result of any Withholding Action by or on behalf of GSK. For purposes of this Section, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Action</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; by or on behalf of GSK means any action taken by GSK that would directly result in any additional withholding or reduction from payments made hereunder (any such amount withheld or deducted, an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incremental Withholding</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;, which would not have resulted absent GSK taking, or causing to be taken, such action). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.7. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VAT and Indirect Taxes</u><font style="font-family:'Times New Roman','Times','serif';">. All amounts payable under or in connection with this Agreement are exclusive of VAT &amp; Indirect Taxes. Any VAT &amp; Indirect Taxes payable on the consideration shall be paid at the same time as the payment or provision of the consideration to which it relates, subject to the production of a VAT invoice. GSK will provide to Surface within [***] after the earlier of the Effective Date and receipt of any consideration or a valid VAT invoice, if appropriate. If such amounts of VAT &amp; Indirect Taxes are refunded subsequently by the fiscal authorities to GSK, GSK will refund these monies to Surface within [***] of receipt. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.8. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Currency of Payments</u><font style="font-family:'Times New Roman','Times','serif';">. All amounts payable and calculations under this Agreement will be in Dollars. As applicable, Net Sales and any royalty reductions will be calculated using GSK&#8217;s standard conversion method consistent with its applicable Accounting Standards in a manner consistent with GSK&#8217;s customary and usual conversion procedures used in preparing its financial statements applied on a consistent basis, provided that such procedures use a widely accepted source of published exchange rates, which as of the Effective Date is </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Reuters/Bloomberg. All payments under this Agreement will be paid in Dollars by wire transfer to an account designated by the receiving Party (which account the receiving Party may update from time to time in writing). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.9. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Late Payments</u><font style="font-family:'Times New Roman','Times','serif';">. Without limiting any other rights or remedies available to Surface hereunder, any undisputed late payment or portion thereof by GSK will bear interest, to the extent permitted by Laws, at an annual rate of [***] above the applicable daily rate published in the Wall Street Journal (or any other qualified source that is acceptable to both Parties) on the date payment was due or the highest rate permitted by law (whichever is lower), computed from the date such payment was due until the date GSK makes the payment. Where the late payment is caused by Surface, including for reasons such as failure to communicate in a timely manner changes to bank details, or failure to respond to communications from GSK regarding the interpretation or dispute of the terms of such payment, then no interest will be payable by GSK. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.10. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoices</u><font style="font-family:'Times New Roman','Times','serif';">. To the extent an invoice is required to be submitted to GSK under this Agreement, such invoice shall include the information set forth on </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 7.10</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 7.11. [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE VIII </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INTELLECTUAL PROPERTY OWNERSHIP, </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PROTECTION AND RELATED MATTERS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) Subject only to the rights expressly granted to GSK under this Agreement, Surface will retain all rights, title and interests in and to the Licensed Patents and Licensed Know-How.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) As between the Parties, each Party will own all inventions and Know-How conceived, discovered, developed or otherwise made, as necessary to establish authorship (in case of publication and other copyrightable work), inventorship (in case of inventions, whether patentable or not) or ownership under applicable Law, solely by or on behalf of such Party (or its Affiliates, its or their subcontractors or sublicensees (including Sublicensees) or its or their respective directors, officers, employees or agents) in the course of conducting such Party&#8217;s activities or exercising such Party&#8217;s rights under this Agreement, and any and all Patent Rights and other intellectual property rights thereto (collectively, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sole Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; and with respect to GSK, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Sole Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; and with respect to Surface, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Sole Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). All Patent Rights claiming patentable GSK Sole Inventions will be referred to herein as &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Patents</u><font style="font-family:'Times New Roman','Times','serif';">.&#8221; All Patent Rights claiming patentable Surface Sole Inventions will be considered Licensed Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) As between the Parties, each Party will own an equal, undivided interest in all inventions and Know-How that are conceived, discovered, developed or otherwise made, as necessary to establish authorship (in case of publication and other copyrightable work), inventorship (in case of inventions, whether patentable or not) or ownership under applicable Law, jointly by or on behalf of each Party (or their respective Affiliates, subcontractors or sublicensees (including Sublicensees) or its or their respective directors, officers, employees or agents) in the course of performing activities or exercising rights </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">under this Agreement, whether or not patentable (collectively, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Inventions</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and any and all Joint Patents and other intellectual property rights thereto. Each Party will have full rights to license, assign and exploit such Party&#8217;s interest in such Joint Inventions (and any Joint Patents arising therefrom) anywhere in the world, without any requirement of gaining the consent of, or accounting to, the other Party, subject to the licenses granted herein and subject to any other intellectual property held by such other Party. Each Party will promptly disclose to the other via the JPC all Joint Inventions, in each case, including all invention disclosures or other similar documents submitted to such Party by its, or its Affiliates&#8217; subcontractors or sublicensees (including Sublicensees&#8217;) or its or their directors, officers, employees or agents, describing such Joint Inventions. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment Obligation</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will assign its rights, and cause all employees of such Party who perform activities for such Party under this Agreement to be under an obligation to assign their rights, in any Patent Rights </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">and Know-How, whether or not patentable, resulting therefrom to such Party to effectuate the terms and conditions set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u><font style="font-family:'Times New Roman','Times','serif';">. With respect to any activities of a Party under this Agreement that are subcontracted to a Person that is not an employee, the Party retaining such subcontractor will include in the applicable subcontract an assignment to such Party of all rights in Patent Rights and Know-How made by such subcontractor resulting from such activities, and in any event will include in the applicable subcontract a license to such Party that is sublicensable to the other Party under this Agreement, of any Patent Rights and Know-How made by such subcontractor resulting from such activities. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inventorship</u><font style="font-family:'Times New Roman','Times','serif';">. Inventorship for inventions made during the course of the performance of this Agreement will be determined in accordance with United States patent laws for determining inventorship. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution and Maintenance of the Licensed Patents</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution by GSK</u><font style="font-family:'Times New Roman','Times','serif';">. As between the Parties, GSK will have the first right, and will use diligent, good faith efforts to Prosecute the Licensed Patents and Joint Patents in the Field in the Territory to the extent relating to the Licensed Antibodies or Licensed Products, at GSK&#8217;s sole cost and expense through patent counsel or agents of its choice. In addition, GSK shall have the first right to pursue the European Opposition Proceeding, including to submit arguments relating to the European Opposition Proceeding on behalf of Surface to the European Patent Office, at GSK&#8217;s sole cost and expense through patent counsel or agents of its choice. GSK will keep Surface reasonably informed via the JPC of all steps with regard to and the status of such Prosecution of such Licensed Patents and Joint Patents and the activities in the European Opposition Proceeding, including by providing Surface with (i) copies of all correspondence and material communications it sends to or receives from any patent office or agency in the Territory relating to such Licensed Patents, Joint Patents and European Opposition Proceeding, (ii) a draft copy of all applications and other documents relating to such Licensed Patents, Joint Patents and European Opposition Proceeding sufficiently in advance of filing to permit reasonable review and comment by Surface and giving due consideration to such comments, and (iii) a copy of applications and other documents as filed, together with notice of its filing date and serial number, relating to such Licensed Patents, Joint Patents and European Opposition Proceeding. Before GSK submits any material filing relating to such Licensed Patents or Joint Patents (including a new patent application) or the European Opposition Proceeding, or a response to such patent authorities with respect to such Licensed Patents, Joint Patents or the European Opposition Proceeding, GSK will provide Surface with a reasonable opportunity to review and comment on such filing or response and will take into account and consider in good faith Surface&#8217;s reasonable and timely requests and suggestions regarding the Prosecution of such Licensed Patents and Joint Patents and the activities in the European Opposition Proceeding under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(a)</u><font style="font-family:'Times New Roman','Times','serif';">. In addition, GSK will provide Surface with copies of all final material filings and responses made to any patent office with respect to the Licensed Patents, the Joint Patents and the European Opposition Proceeding in a timely manner following submission thereof. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Step-In Right</u><font style="font-family:'Times New Roman','Times','serif';">. If GSK elects not to continue to (i) Prosecute a given Patent Right within the Licensed Patents or Joint Patents in the Field in the Territory pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(a)</u><font style="font-family:'Times New Roman','Times','serif';"> or (ii) pursue the European Opposition Proceeding, then in each case GSK will give Surface notice thereof within a reasonable period (but not less than [***]) prior to allowing such Patent Rights to lapse or become abandoned or unenforceable or prior to any material deadline in the European Opposition Proceeding, and Surface will have the right to Prosecute such Patent Right within the Licensed Patents or Joint Patents, as applicable or pursue the European Opposition Proceeding. Surface will have the right, but not the obligation, to assume responsibility for continuing the Prosecution of such Patent Right in the Field in such country or pursuing the European Opposition Proceeding and paying any required fees, all at Surface&#8217;s sole expense, through patent counsel or agents of its choice. Upon transfer of GSK&#8217;s responsibility for Prosecuting any of the Patent Rights within the Licensed Patents or Joint Patents to Surface under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(b)</u><font style="font-family:'Times New Roman','Times','serif';">, (i) solely with respect to any Patent Right within the Joint Patents, GSK will assign to Surface all of GSK&#8217;s rights, title, and interests in and to such Patent Right; (ii) such Patent Right will cease to be Licensed Patents or Joint Patents licensed to GSK under this Agreement; (iii) Surface may, in its sole discretion, Prosecute or abandon such Patent Right; and (iv) GSK will promptly deliver to Surface copies of all necessary files related to the Patent Rights with respect to which responsibility has been transferred and will take all actions and execute all documents reasonably necessary for Surface to assume such Prosecution and defense. Upon transfer of GSK&#8217;s responsibility for pursuing the European Opposition Proceeding under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(b)</u><font style="font-family:'Times New Roman','Times','serif';">, (i) Surface may, in its sole discretion, pursue or abandon efforts related to the European Opposition Proceeding; and (ii) GSK will promptly deliver to Surface copies of all necessary files related to the European Opposition Proceeding with respect to which </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">responsibility has been transferred and will take all actions and execute all documents reasonably necessary for Surface to assume activities relating to the European Opposition Proceeding. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation in Support of Assignment</u><font style="font-family:'Times New Roman','Times','serif';">. In the event that Surface exercises its right to be assigned GSK&#8217;s interest in a Joint Patent pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(b)</u><font style="font-family:'Times New Roman','Times','serif';">, then upon Surface&#8217;s request, GSK will provide all further cooperation that Surface reasonably determines is necessary to give effect to such assignment and to ensure Surface the full and quiet enjoyment of such assigned Patent Rights, including executing and delivering further assignments, consents, releases, and other commercially reasonable documentation, and providing good faith testimony by affidavit, declaration, deposition, in person or other proper means, and otherwise assisting Surface in support of any effort by Surface to establish, perfect, defend, or enforce its rights in such assigned Patent Rights. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation in Prosecution and the European Opposition Proceeding</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will, and will cause its Affiliates to, reasonably cooperate, with the other Party with respect to the Prosecution of Licensed Patents and Joint Patents and activities relating to the European Opposition Proceeding pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2</u><font style="font-family:'Times New Roman','Times','serif';">, including providing any necessary powers of attorney, complying with any applicable duty of candor or disclosure with a patent office and executing any other required documents or instruments for such Prosecution. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution of GSK Patents</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will control and be responsible, at its own expense, for the Prosecution of all GSK Patents. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Extensions; Data Exclusivity and Purple Book and Patent Register Listings; Biosimilar Applications</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Term Extension</u><font style="font-family:'Times New Roman','Times','serif';">. If elections with respect to obtaining patent term extension or supplemental protection certificates or their equivalents in any country with respect to any Licensed Product becomes available, upon Regulatory Approval or otherwise, the Parties will mutually agree on which issued patent to extend, and in any event, the Parties understand and agree that a Licensed Patent or Joint Patent will be extended (including in the U.S. upon Regulatory Approval thereof), if possible, in lieu of any other Patent Right only if such Licensed Patent or Joint Patent would extend longer than such other Patent Right. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Exclusivity, Purple Book and Patent Register Listings</u><font style="font-family:'Times New Roman','Times','serif';">. With respect to data exclusivity periods (such as those periods listed in the Purple Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83, and all equivalents in any country), GSK, in consultation with Surface, will seek and maintain all such data exclusivity periods that may be available for any of the Licensed Products. GSK will determine which Licensed Patents and Joint Patents, if any, will be listed with the applicable Regulatory Authorities for any Licensed Product, including all so-called &#8220;Patent Register&#8221; listings required by certain Governmental Authorities, and all similar listings in any other relevant countries. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biosimilar Applications</u><font style="font-family:'Times New Roman','Times','serif';">. If either Party receives a copy of an application submitted to the FDA under subsection (k) of Section 351 of the PHSA (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biosimilar Application</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) naming a Licensed Product as a reference product or otherwise becomes aware that such a Biosimilar Application has been filed (including by the receipt of information disclosed pursuant to Section 351(l)(2) of the PHSA, or in an instance described in Section 351(l)(9)(C) of the PHSA), either Party will, within [***], notify the other Party so that the other Party may seek permission to view the application and related confidential information from the filer of the Biosimilar Application under Section 351(l)(1)(B)(iii) of the PHSA. If either Party receives any equivalent or similar certification, information or notice in any other jurisdiction in the Territory naming a Licensed Product, either Party will, within [***], notify and provide the other Party with copies of such communication. Regardless of the Party that is the &#8220;reference product sponsor&#8221; for purposes of such Biosimilar Application, (A) GSK will have the first right, after consulting with Surface, to designate pursuant to Section 351(l)(1)(B)(ii) of the PHSA the outside counsel and in-house counsel who will receive confidential access to the Biosimilar Application, (B) GSK will have the first right, after consulting with Surface, to (1) list any Licensed Patents, and any other Patent Rights, as required pursuant to Section 351(l)(3)(A), Section 351(l)(5)(b)(i)(II), or Section 351(l)(7) of the PHSA, (2) respond to any communications with respect to such lists from the filer of the Biosimilar Application, and (3) negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange than that specified in Section 351(l) of the PHSA; and (C) GSK will have the first right, after consulting with Surface, to identify Licensed Patents and any other Patent Rights, and to respond to communications under any equivalent or similar listing in any other jurisdiction in the Territory. If GSK does not defend a given Patent Right within the Licensed Patents or Joint Patents under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2(f)(iii)</u><font style="font-family:'Times New Roman','Times','serif';"> within [***] (or such shorter period of time before the time limit, if any, set forth in the appropriate Laws in the United States or any other country in the Territory to not waive any statutory </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">rights), or elects not to continue any such defense (in which case it will promptly provide notice thereof to Surface), then Surface will have the right (but not the obligation), at its sole discretion, to defend any such Patent Right. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Infringement</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will promptly notify the other in writing of any (i) apparent, threatened or actual infringement by a Third Party of any Licensed Patent or Joint Patent, or (ii) unauthorized use or misappropriation of any Licensed Know-How by a Third Party of which it becomes aware, and, in each case, will provide the other Party with all evidence in such Party&#8217;s possession or control supporting such infringement or unauthorized use or misappropriation (each, an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Sole Right</u><font style="font-family:'Times New Roman','Times','serif';">. As between the Parties, GSK will have the sole right, but not the obligation, using counsel of its choosing and at its sole expense, to institute any Action alleging Infringement of the Licensed Patents or Joint Patents by a Third Party conducting the manufacture, use, marketing or sale of a product falling within the scope of the exclusive license granted to GSK in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';"> (any such Action, an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement Action</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). GSK will notify and keep Surface apprised in writing of any such Infringement Action and will consider Surface&#8217;s reasonable interests and requests regarding such Infringement Action. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u><font style="font-family:'Times New Roman','Times','serif';">. In any Infringement Action brought under the Licensed Patents or Joint Patents pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(b)</u><font style="font-family:'Times New Roman','Times','serif';">, Surface will, and will cause its Affiliates to, reasonably cooperate with GSK, in good faith, relative to GSK&#8217;s efforts to protect the Licensed Patents and Joint Patents and will join such suit as a party, if requested by GSK. Furthermore, GSK will consider in good faith all reasonable and timely comments from Surface on any proposed arguments asserted or to be asserted in litigation related to the enforcement or defense of any such Patent Rights. GSK will have the right to settle any patent infringement litigation with respect to any Licensed Patent under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3</u><font style="font-family:'Times New Roman','Times','serif';"> in a manner that diminishes the rights or interests of Surface without the consent of Surface (which will not be unreasonably withheld). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u><font style="font-family:'Times New Roman','Times','serif';">. Subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3(e)</u><font style="font-family:'Times New Roman','Times','serif';">, GSK will be solely responsible for all expenses arising from a suit or Action against an Infringement Action. For the avoidance of doubt, GSK will not be responsible for Surface&#8217;s internal expenses (e.g., FTEs) incurred as a result of Surface&#8217;s cooperation with the enforcement Action as provided in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3</u><font style="font-family:'Times New Roman','Times','serif';">. Surface will be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but Surface will at all times cooperate fully with GSK. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Recoveries</u><font style="font-family:'Times New Roman','Times','serif';">. Any settlements, damages or monetary awards recovered by either Party pursuant to any Infringement Action with respect to the Licensed Patents or Joint Patents will, after reimbursing the Parties for their reasonable expenses in making such recovery (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses), be retained by the Party that has exercised its right to bring the enforcement action; provided, however, that to the extent that any award or settlement (whether by judgment or otherwise) with respect to a Licensed Patent or Joint Patent is attributable to loss of sales or profits with respect to a Licensed Product, such amount shall be paid to or retained by GSK and treated as &#8220;Net Sales&#8221; in the Calendar Year in which the money is actually received and any royalties pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u><font style="font-family:'Times New Roman','Times','serif';"> shall be payable by GSK to Surface with respect thereto. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claimed Infringement</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will promptly notify the other Party if a Third Party brings any Action alleging patent infringement by GSK or Surface or any of their respective Affiliates or sublicensees with respect to the Development, Manufacture or Commercialization of any Licensed Product (any such Action, an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement Claim</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) in the Territory. GSK will have the right, but not the obligation, to control the defense and response to any such Infringement Claim in the Territory, at GSK&#8217;s sole cost and expense, and Surface will have the right, at its own expense, to be represented in any such Infringement Claim in the Territory by counsel of its own choice. Upon the request of GSK, Surface will reasonably cooperate with GSK in the reasonable defense of such Infringement Claim. Surface will have the right to consult with GSK concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation. GSK will (a) consult with Surface as to the strategy for the prosecution of such defense, (b) consider in good faith any comments from Surface with respect thereto and (c) keep Surface reasonably informed of any material steps taken and provide copies of all material documents filed, in connection with such defense. GSK will have the right to settle such Infringement Claim on terms deemed reasonably appropriate by it, provided, that, unless any such settlement includes a full and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">unconditional release from all liability of Surface and does not adversely affect the rights of Surface, any such settlement will be subject to Surface&#8217;s prior written consent. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 8.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Interest</u><font style="font-family:'Times New Roman','Times','serif';">. All information exchanged between the Parties regarding the Prosecution of Licensed Patents and Joint Patents under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VIII</u><font style="font-family:'Times New Roman','Times','serif';"> will be deemed Confidential Information of the disclosing Party. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Licensed Patents, the Joint Patents and the European Opposition Proceeding under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VIII</u><font style="font-family:'Times New Roman','Times','serif';">, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary contained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VIII</u><font style="font-family:'Times New Roman','Times','serif';"> is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party will not be required to disclose such information, and the Parties will in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement, disclosing such information on a &#8220;for counsel eyes only&#8221; basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE IX </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONFIDENTIALITY AND PUBLICITY </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 9.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Obligation</u><font style="font-family:'Times New Roman','Times','serif';">. During the Term and for a period of [***] after any termination or expiration of this Agreement, each Party agrees to, and will cause its Affiliates, its and their sublicensees and subcontractors to, keep in confidence and not to disclose to any Third Party, or use for any purpose, except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of the other Party, without the prior written consent of such disclosing Party. The existence and terms of this Agreement are the Confidential Information of each Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Disclosures</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party agrees that it and its Affiliates will provide or permit access to the other Party&#8217;s Confidential Information only to the receiving Party&#8217;s employees, consultants, subcontractors, advisors and sublicensees, and to the employees, consultants, subcontractors, advisors and sublicensees of the receiving Party&#8217;s Affiliates, in each case on a need to know basis who are subject to obligations of confidentiality and non-use with respect to such Confidential Information no less stringent than the obligations of confidentiality and non-use of the receiving Party pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';">; provided, however, that each Party will remain responsible for any failure by its Affiliates and its and their sublicensees, and its and its Affiliates&#8217; respective employees, consultants, subcontractors and advisors, to treat such Confidential Information as required under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';"> as if such Affiliates, employees, consultants, subcontractors, advisors and sublicensees were parties directly bound to the requirements of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Limitation</u><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding anything to the contrary herein, each Party may use and disclose the other Party&#8217;s Confidential Information as follows: (i) to its Affiliates, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">bona fide</i><font style="font-family:'Times New Roman','Times','serif';"> potential or actual collaborators, licensors, Sublicensees, sublicensees, or strategic partners and to employees, directors, agents, consultants, and advisers of such Third Parties, financial advisors, attorneys and accountants, </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">bona fide</i><font style="font-family:'Times New Roman','Times','serif';"> actual or potential acquisition partners, financing sources or investors and underwriters in all cases on a need to know basis, and under appropriate confidentiality and non-use obligations (which may include professional ethical obligations) no less stringent than those in this Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose); provided, however, that each Party will remain responsible for any failure by any of the foregoing recipients to treat such Confidential Information as required under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';"> as if such recipients were parties directly bound to the requirements of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';">, (ii) as required by any court governmental body or other Governmental Authority as otherwise required by applicable Laws (including any such disclosures as are required by a Regulatory Authority in connection with seeking Regulatory Approval, Pricing and Reimbursement Approval, import authorization for any Licensed Product in the Territory, or the rules or regulations of the United States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States or of any stock exchange or listing entity); provided, that, notice is promptly given to the other Party and the disclosing Party cooperates with reasonable requests from the other Party to seek a protective order or other appropriate remedy to protect the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Confidential Information, or (iii) to a patent authority as may be reasonably necessary or useful for purposes of obtaining Patent Rights as permitted by this Agreement; provided that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available. Notwithstanding anything to the contrary contained in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">, Confidential Information that is permitted or required to be disclosed will remain otherwise subject to the confidentiality and non-use provisions of </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(b)</u><font style="font-family:'Times New Roman','Times','serif';"> and this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(c)</u><font style="font-family:'Times New Roman','Times','serif';">. If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States, then such Party will, within a reasonable time (and in no event less than [***]) prior to any such filing, provide the other Party with a copy of this Agreement showing any provisions hereof as to which the Party proposes to request confidential treatment and will provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions. The Party filing the Agreement will take the other Party&#8217;s reasonable comments into consideration before filing such agreement and use reasonable efforts to have terms identified by such other Party afforded confidential treatment by the applicable Regulatory Authority. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) When transferring Confidential Information, all communications between GSK and Surface will use encryption methods agreed to by the Parties. Upon discovering any suspected or actual unauthorized disclosure, loss or theft of Confidential Information (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Security Breach</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) Surface will send an e-mail to [***] notifying GSK, and upon discovering any suspected or actual Data Security Breach, GSK will send an e-mail to [***], notifying Surface. The Parties shall work with each other in good faith to identify a root cause and remediate the Data Security Breach. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 9.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publicity and Press Release</u><font style="font-family:'Times New Roman','Times','serif';">. The Parties acknowledge the importance of supporting each other&#8217;s efforts to publicly disclose results and significant Developments regarding Licensed Products in the Field in the Territory, and each Party may make such disclosures from time to time, subject to the terms and conditions of this Agreement, including this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';">. Such disclosures may include achievement of milestones, significant events in the Development process with respect to Licensed Products, or Commercialization activities with respect to Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) The Parties have agreed upon the content of a press release which shall be issued by Surface substantially in the form attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 9.2</u><font style="font-family:'Times New Roman','Times','serif';">, promptly after the Effective Date. Except for disclosures permitted in accordance with </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1(b)</u><font style="font-family:'Times New Roman','Times','serif';">, Surface shall not issue any other public announcement, press release or other public disclosure regarding this Agreement, its subject matter or any amendment hereto without GSK&#8217;s prior written consent, except for any such disclosure that (i) repeats any information regarding this Agreement, its subject matter or any amendment hereto that has already been publicly disclosed by either Party in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';">, provided</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">that such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable, or (ii) is, in the opinion of Surface&#8217;s counsel, required by applicable Laws or the rules of a stock exchange on which the securities of Surface are listed (or to which an application for listing has been submitted), provided, that disclosure under this clause (ii) shall include the minimum amount of Confidential Information required by such applicable Laws, and Surface will use reasonable efforts to seek confidential treatment of Confidential Information to be included in such disclosures. In the event Surface is, in the opinion of its counsel, required by applicable Laws or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, Surface shall submit the proposed disclosure in writing to GSK as far in advance as reasonably practicable (and in no event less than [***] prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to comment thereon. For clarity, GSK and its Affiliates and its and their Sublicensees shall have the right to publicly disclose research, development and commercial information (including with respect to regulatory matters) regarding the Licensed Antibody and Licensed Product; provided</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">such disclosure is subject to the provisions of </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';"> with respect to Surface&#8217;s Confidential Information. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) The principles to be observed in such disclosures will include accuracy, compliance with applicable Laws and regulatory guidance documents and the need to keep investors informed regarding the business of the Party making such public disclosure. Nothing in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';"> will restrict a Party from making a disclosure required by Laws as reasonably determined by such Party&#8217;s counsel, including disclosures required by any Laws relating to the public sale of securities; provided, however, that such disclosure will include the minimum amount of Confidential Information required by such applicable Laws, and the Parties will use reasonable efforts to seek confidential treatment of Confidential Information to be included in such disclosures. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 9.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Scientific Publications</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) As between the Parties, GSK shall control all scientific publications relating to all activities undertaken under this Agreement for the relevant Licensed Antibodies and Licensed Products, which publications shall not require the prior written approval of Surface. If GSK or its employees or consultants (such as clinical investigators) wish to publish or publicly present any information about a Licensed Product or the results of any activities relating to the research or development of Licensed Antibodies, which publication contains any of Surface&#8217;s Confidential Information, it shall deliver to Surface a copy of the proposed written publication or an outline of an oral disclosure at least [***] ([***] in the case of abstracts) prior to submission for publication or presentation. Surface will respond in writing promptly and in no event later than [***] ([***] in the case of abstracts) after receipt of the proposed material and shall have the right to propose modifications to the publication or presentation for confidentiality reasons, or request a reasonable delay in publication or presentation in order to protect patentable information. In the event that Surface identifies patentable subject matter in the proposed material, GSK agrees not to submit such publication or to make such presentation that contains such information for a period of up to [***] in order to seek patent protection for any material in such publication or presentation. If Surface reasonably requests modifications to the publication or presentation to prevent disclosure of Surface&#8217;s Confidential Information, GSK shall edit such publication to prevent the disclosure of such Confidential Information prior to submission of the publication or presentation. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) All publications made by GSK relating to any Licensed Antibody or Licensed Product will be prepared, presented, and published in accordance with pharmaceutical industry accepted guidelines. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) In addition to the foregoing, subject to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u><font style="font-family:'Times New Roman','Times','serif';">, GSK shall have the right at any time during and after the Term to (a) publish the results or summaries of results of all Clinical Studies, observational studies and other studies such a meta analyses, conducted with respect to any and all Licensed Antibodies and Licensed Products in any clinical trial register maintained by GSK or its Affiliates and the protocols of such Clinical Studies on www.clinicaltrials.gov or in each case publish the results, summaries or protocols of such Clinical Studies or other studies on such other websites or repositories or at scientific congresses and in peer-reviewed journals within such timescales as required by applicable Laws or GSK&#8217;s or its Affiliate&#8217;s internal policies and procedures, irrespective of the outcome of such Clinical Studies; (b) make information from Clinical Studies or other studies conducted by or on behalf of GSK with respect to Licensed Antibodies or Licensed Products available under its Data Sharing Initiative; and (c) make any other public disclosures of Clinical Data that become required of GSK due to its internal policies and procedures or applicable Laws. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) Each publication made in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u><font style="font-family:'Times New Roman','Times','serif';"> shall not be a breach of the confidentiality provisions set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 9.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equitable Relief</u><font style="font-family:'Times New Roman','Times','serif';">. Given the nature of the Confidential Information and the competitive damage that could result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages will not be a sufficient remedy for any breach of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">. In addition to all other remedies, and notwithstanding the provisions of </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIV</u><font style="font-family:'Times New Roman','Times','serif';">, a Party will be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE X </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Representations and Warranties</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party represents and warrants to the other Party that, as of the Effective Date: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</u><font style="font-family:'Times New Roman','Times','serif';">. It is a corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</u><font style="font-family:'Times New Roman','Times','serif';">. It has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement, and this Agreement and the performance by such Party of this Agreement do not violate such Party&#8217;s charter documents, bylaws or other organizational documents. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</u><font style="font-family:'Times New Roman','Times','serif';">. Except for any Regulatory Approvals, manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of Licensed Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflict</u><font style="font-family:'Times New Roman','Times','serif';">. It is not under any obligation, contractual or otherwise, to any Person that would materially affect the performance of obligations under this Agreement and the execution and delivery of this Agreement by such Party, and the performance of such Party&#8217;s obligations under this Agreement (as contemplated as of the Effective Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (i) do not conflict with or violate any requirement of Laws applicable to such Party, (ii) do not conflict with or violate any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently in effect applicable to such Party, and (iii) do not conflict with, violate, breach or constitute a default under, or give rise to any right of termination, cancellation or acceleration of, any contractual obligations of such Party or any of its Affiliates. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u><font style="font-family:'Times New Roman','Times','serif';">. It has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder and this Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance with its terms, subject to the general principles of equity and subject to bankruptcy, insolvency, moratorium, judicial principles affecting the availability of specific performance and other similar Laws affecting the enforcement of creditors&#8217; rights generally. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Law</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party shall comply, and ensure that its Affiliates, its and their sublicensees and subcontractors comply, in all material respects with all applicable Laws in the performance of its obligations and exercise of its rights under this Agreement to the extent in each case that such applicable Laws cover the performance of the relevant obligations or exercise of rights. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Representations, Warranties and Covenants of Surface</u><font style="font-family:'Times New Roman','Times','serif';">. Surface represents and warrants as of the Effective Date, and covenants to GSK (as applicable) that: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Patents</u><font style="font-family:'Times New Roman','Times','serif';">. All Licensed Patents as of the Effective Date are listed in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Times New Roman','Times','serif';">. Surface is the sole and exclusive owner of the Licensed Patents, all of which are free and clear of any claims, liens, charges or encumbrances. All Licensed Patents have been Prosecuted in good faith in the patent offices in accordance with applicable Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Challenges</u><font style="font-family:'Times New Roman','Times','serif';">. There are no claims, judgments, or settlements against, or amounts with respect thereto, made against Surface or any of its Affiliates relating to the Licensed Patents or the Licensed Know-How. No claim or litigation has been received by Surface or its Affiliates or, to Surface&#8217;s knowledge, threatened by any Person (i) alleging that the Licensed Patents are invalid or unenforceable, (ii) challenging Surface&#8217;s Control of the Licensed Technology (i.e., alleging that a Third Party has a right or interest in or to the Licensed Technology) or (iii) alleging misappropriation of the Know-How of any Third Party used in the Development, Manufacture or Commercialization of Licensed Antibodies or Licensed Products by or on behalf of Surface prior to the Effective Date. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Infringement of Third Party IP</u><font style="font-family:'Times New Roman','Times','serif';">. Except as set forth on </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 10.2(c)</u><font style="font-family:'Times New Roman','Times','serif';">, to Surface&#8217;s knowledge, the Development or Manufacture of the Licensed Product, as conducted by Surface, its Affiliates or its sublicensees, or its subcontractors prior to the Effective Date, and the Commercialization thereof if Surface were Commercializing the Licensed Product as of the Effective Date, did not or would not infringe any issued Patent Right or misappropriate or otherwise violate or misappropriate any Know-How of any Person. No claim of Infringement of the Licensed Patents or misappropriation of the Licensed Know-How of any Third Party has been brought or asserted, or to Surface&#8217;s knowledge, threatened, against Surface or any of its Affiliates with respect to the Development, Manufacture or Commercialization of Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Infringement</u><font style="font-family:'Times New Roman','Times','serif';">. To Surface&#8217;s knowledge, (i) no Person is infringing or threatening to infringe or misappropriating or threatening to misappropriate any Licensed Patents or Licensed Know-How and (ii) there are no activities by Third Parties that would constitute infringement or misappropriation of the Licensed Patents or Licensed Know-How.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Litigation</u><font style="font-family:'Times New Roman','Times','serif';">. There are no judgments or settlements against or owed by Surface, its Affiliates or its or their sublicensees, or, to Surface&#8217;s knowledge, pending litigation against Surface, its Affiliates, or its or their sublicensees, or litigation threatened against Surface, its Affiliates, or its or their sublicensees, in each case related to </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Licensed Products, including any such litigation relating to any Regulatory Materials Controlled by Surface, its Affiliates or its sublicensees as of the Effective Date. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inventors</u><font style="font-family:'Times New Roman','Times','serif';">. Each Person who has or has had any ownership rights in or to any Licensed Patents purported to be owned solely by Surface, has assigned and has executed an agreement assigning its entire right, title, and interest in and to such Licensed Patents to Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(g) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Data</u><font style="font-family:'Times New Roman','Times','serif';">. All information and data provided by or on behalf of Surface to GSK on or before the Effective Date in contemplation of this Agreement was and is true and accurate in all materials respects. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(h) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment Practices</u><font style="font-family:'Times New Roman','Times','serif';">. As relevant to this Agreement: (a) Surface did not and will not employ child labor, forced labor, or cruel or abusive disciplinary practices in the workplace; (b) Surface did not and will not discriminate against any workers on any ground in violation of applicable Law (including race, religion, disability, gender, sexual orientation or gender identity); and (c) Surface paid and will pay each employee at least the minimum wage, provided and will provide each employee with all legally mandated benefits, and has complied and will comply with all applicable Laws on working hours and employment rights in the countries in which it operates. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(j) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment Obligations</u><font style="font-family:'Times New Roman','Times','serif';">. All employees, subcontractors or consultants of Surface that will be involved in the performance of the Technical Transition Services shall be subject to a written obligation to assign to Surface all rights in the Patent Rights and Know-How invented or created by them in the course of providing the Technical Transition Services during the Transition Period. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(k) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Products Warranties</u><font style="font-family:'Times New Roman','Times','serif';">. All Licensed Antibodies and License Product Manufactured and supplied by Surface, with respect to each batch of such Licensed Antibodies and Licensed Products, shall have been Manufactured: (i) in accordance with and shall conform to the specifications existing as of the time of out of freeze for Licensed Antibodies and start of Manufacturing for Licensed Product; (ii) in accordance with the Manufacturing process; (iii) in compliance with applicable GMP requirements; (iv) in compliance with all Laws; and (v) in accordance with the quality or technical agreement(s) between Surface and any of its Manufacturing subcontractors (clauses (i) through (v) collectively, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Products Warranties</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(l) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing CMO Agreements</u><font style="font-family:'Times New Roman','Times','serif';">. Surface has not and shall not amend or modify the Products Warranties, delivery terms or quality-related terms under the Existing CMO Agreements that would in any way have an adverse effect on or otherwise limit or reduce the remedies available to Surface for breach of Product Warranties by the Existing CMO under such Existing CMO Agreements, or otherwise adversely affect the delivery or quality of the Licensed Antibodies or Licensed Products manufactured thereunder. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(m) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Human Biological Samples</u><font style="font-family:'Times New Roman','Times','serif';">. The Human Biological Samples transferred to GSK by Surface in the course of the Technical Transition Services have been obtained and will be stored, transferred, used and disposed of in accordance with all applicable Laws and any generally accepted ethical guidelines regarding the collection, use, transport and disposal of human tissue. All the relevant ethics committee approvals and informed consents have been obtained to enable the use of the Human Biological Samples obtained from patients or human subject volunteers or other donors in the Development or Manufacture of Licensed Antibodies. No human embryonic or fetal derived material (including cell lines) have been or will be used in connection with the Technical Transition Services or other Development or Manufacture of Licensed Antibodies, without the express prior written approval of GSK. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Representations, Warranties and Covenants of GSK</u><font style="font-family:'Times New Roman','Times','serif';">. GSK represents and warrants as of the Effective Date and covenants to Surface (as applicable) that: </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Law</u><font style="font-family:'Times New Roman','Times','serif';">. Without limiting the generality of </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1(f)</u><font style="font-family:'Times New Roman','Times','serif';">, GSK will conduct its Development and Commercialization activities relating to the Licensed Antibody or Licensed Product(s) in accordance with applicable Laws (including data privacy Laws, current international regulatory standards, including, as applicable, GMP, GLP, GCP, and other rules, regulations and requirements), and will cause all permitted subcontractors and Sublicensees hereunder to comply with such applicable Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Solvency</u><font style="font-family:'Times New Roman','Times','serif';">. GSK is solvent and has the ability to pay and perform, or cause its Affiliates to pay and perform, all of its obligations as and when such obligations become due, including payment and other obligations under this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Corruption</u><font style="font-family:'Times New Roman','Times','serif';">. The Parties will comply with all applicable Laws concerning bribery, money laundering, or corrupt practices or which in any manner prohibit the giving of anything of value to any official, agent, or employee of any government, political party, or public international organization, candidate for public office, health care professional, or to any officer, director, employee, or representative of any other organization, for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an improper advantage, or improperly assisting either Party in obtaining or retaining business, specifically including the U.S. Foreign Corrupt Practices Act, and the UK Bribery Act, in each case, in connection with the activities conducted pursuant to this Agreement. Each Party will require any contractors, subcontractors, sublicensees, or other Persons that provide services to it in connection with this Agreement to comply with such Party&#8217;s obligations under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.4</u><font style="font-family:'Times New Roman','Times','serif';">. For the avoidance of doubt the foregoing prohibited payments include facilitating payments, which are unofficial, improper, small payments or gifts offered or made to a Government Official to secure or expedite a routine or necessary action to which a Party is legally entitled. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Debarment</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party represents and warrants that neither it nor any of its or its Affiliates&#8217; employees or agents performing under this Agreement has ever been, or is currently: (a) debarred under 21 U.S.C. &#167; 335a or by any Regulatory Authority; (b) excluded, debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement programs; (c) listed on the FDA&#8217;s Disqualified and Restricted Lists for clinical investigators; or (d) convicted of a criminal offense that falls within the scope of 42 U.S.C. &#167; 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. Each Party further covenants that if, during the Term of this Agreement, it becomes aware that it or any of its or its Affiliates&#8217; employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, such Party will promptly notify the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 10.6. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Warranties. </u><font style="font-family:'Times New Roman','Times','serif';">EACH OF SURFACE AND GSK SPECIFICALLY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE RESEARCH, DEVELOPMENT OR COMMERCIALIZATION OF LICENSED ANTIBODIES OR LICENSED PRODUCTS WILL BE SUCCESSFUL IN WHOLE OR IN PART. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE X, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF TITLE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY WITH RESPECT TO THE LICENSED PRODUCT, VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE XI </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INDEMNIFICATION; DAMAGES </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 11.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by Surface</u><font style="font-family:'Times New Roman','Times','serif';">. Surface will defend, indemnify and hold harmless GSK, its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GSK Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), from, against and in respect of any and all Third Party Losses incurred or suffered by any GSK Indemnified Party to the extent resulting from: (a) any breach of any representation or warranty made by Surface in this Agreement, or any breach by Surface of any obligation, covenant or agreement in this Agreement; (b) the gross negligence or willful misconduct of, or violation of Laws by, Surface or any of its Affiliates, sublicensees, or subcontractors, or any of their respective directors, officers, employees and agents, in performing Surface&#8217;s obligations or exercising Surface&#8217;s rights under this Agreement; (c) the Development, Manufacture, labeling, handling or storage, or use of, or exposure to, the Licensed Antibody or any Licensed Products by or for Surface or any of its Affiliates, its or their sublicensees, subcontractors, agents and consultants or contractors, to the extent relating to the Technical Transition Services; or (d) Surface&#8217;s (or its Affiliates&#8217; and sublicensees&#8217;) use or practice of the Licensed Technology, to the extent relating to the Technical Transition Services; provided, however, that Surface&#8217;s obligations pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1</u><font style="font-family:'Times New Roman','Times','serif';"> will not apply to the extent such Third Party Losses result from Third Party Losses for which GSK has an obligation to indemnify Surface pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.2</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 11.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by GSK</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will defend, indemnify and hold harmless Surface, its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface Indemnified Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) from, against and in respect of any and all Third Party Losses incurred or suffered by any Surface Indemnified Party to the extent resulting from: (a) any breach of any representation or warranty made by GSK in this Agreement, or any breach by GSK of any obligation, covenant or agreement in this Agreement, (b) the gross negligence or willful misconduct of, or violation of Laws by, GSK, any of its Affiliates, its or their Sublicensees or subcontractors, or any of their respective directors, officers, employees and agents, in performing GSK&#8217;s obligations or exercising GSK&#8217;s rights under this Agreement, (c) the Development, Commercialization (including promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, Manufacture, labeling, handling or storage, or use of, or exposure to, the Licensed Antibody or any Licensed Products by or for GSK or any of its Affiliates, its or their Sublicensees, subcontractors, agents and consultants or contractors; or (d) GSK&#8217;s (or its Affiliates&#8217; and Sublicensees&#8217;) use or practice of the Licensed Technology; provided, however, that GSK&#8217;s obligations pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.2</u><font style="font-family:'Times New Roman','Times','serif';"> will not apply to the extent such Third Party Losses result from Third Party Losses for which Surface has an obligation to indemnify GSK pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 11.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claims for Indemnification</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u><font style="font-family:'Times New Roman','Times','serif';">. An Indemnified Party entitled to indemnification under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1</u><font style="font-family:'Times New Roman','Times','serif';"> or </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.2</u><font style="font-family:'Times New Roman','Times','serif';"> will give prompt written notification to the Indemnifying Party of the commencement of any Action by a Third Party for which indemnification may be sought (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) or, if earlier, upon the assertion of such Third Party Claim by a Third Party; provided, however, that failure by an Indemnified Party to give notice of a Third Party Claim as provided in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.3(a)</u><font style="font-family:'Times New Roman','Times','serif';"> will not relieve the Indemnifying Party of its indemnification obligation under this Agreement, except and only to the extent that such Indemnifying Party is materially prejudiced as a result of such failure to give notice. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense</u><font style="font-family:'Times New Roman','Times','serif';">. Within [***] after delivery of a notice of any Third Party Claim in accordance with </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Claim with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party may control such defense (with counsel reasonably selected by the Indemnified Party and approved by the Indemnifying Party, such approval not to be unreasonably withheld). The Party not controlling such defense may participate therein at its own expense. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u><font style="font-family:'Times New Roman','Times','serif';">. The Party controlling the defense of any Third Party Claim will keep the other Party advised of the status and material developments of such Third Party Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto. The other Party will reasonably cooperate, at its expense, with the Party controlling such defense and its Affiliates and agents in defense of the Third Party Claim. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement</u><font style="font-family:'Times New Roman','Times','serif';">. The Indemnified Party will not agree to any settlement of such Third Party Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld. The Indemnifying Party will not agree, without the prior written consent of the Indemnified Party, which will not be unreasonably withheld, to any settlement of such Third Party Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the Indemnified Party (other than a monetary obligation on the Indemnifying Party). In no event will the Indemnifying Party agree to any settlement or compromise that involves (i) any admission of legal wrongdoing by the Indemnified Party, (ii) any payment by the Indemnified Party that is not indemnified under this Agreement, or (iii) the imposition of any equitable relief against the Indemnified Party without the prior written consent of the Indemnified Party, which may be withheld in its sole discretion. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mitigation of Loss</u><font style="font-family:'Times New Roman','Times','serif';">. Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and actions as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Third Party Claims (or potential losses or damages) under this ARTICLE XI</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u><font style="font-family:'Times New Roman','Times','serif';"> Nothing in this Agreement will or will be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 11.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u><font style="font-family:'Times New Roman','Times','serif';">. GSK shall maintain, at its cost, insurance or self-insurance with respect to liabilities and other risks associated with its activities and obligations under this Agreement, including its indemnification obligations herein, in such amounts and on such terms as are customary for prudent practices for large companies in the pharmaceutical industry for the activities to be conducted by GSK under this Agreement. GSK shall furnish to Surface evidence of such insurance or self-insurance, upon reasonable request. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE XII </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LIMITATION OF LIABILITY </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 12.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Consequential or Punitive Damages.</u><font style="font-family:'Times New Roman','Times','serif';"> EXCEPT AS SET FORTH IN </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 12.2</u><font style="font-family:'Times New Roman','Times','serif';">, NEITHER PARTY NOR ANY OF ITS AFFILIATES WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS OR THE PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, INCLUDING ANY LOST PROFITS ARISING OUT OF THIS AGREEMENT, IN EACH CASE HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 12.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXCLUSION FROM LIABILITY LIMITATION</u><font style="font-family:'Times New Roman','Times','serif';">. THE LIMITATIONS AND DISCLAIMER SET FORTH IN </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 12.1</u><font style="font-family:'Times New Roman','Times','serif';"> WILL NOT APPLY TO A CLAIM: (A) FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT; (B) FOR A BREACH OF </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE IX</u><font style="font-family:'Times New Roman','Times','serif';">; OR (C) FOR INDEMNIFIABLE LOSSES PURSUANT TO </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 11.1</u><font style="font-family:'Times New Roman','Times','serif';"> OR </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.2</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE XIII </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TERM AND TERMINATION </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 13.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';">. Unless terminated earlier in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIII</u><font style="font-family:'Times New Roman','Times','serif';">, this Agreement will become effective as of the Effective Date and will continue in full force and effect until the last to expire Royalty Term in all countries in the Territory for all Licensed Products (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;).</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 13.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Paid-Up License Upon End of Royalty Term</u><font style="font-family:'Times New Roman','Times','serif';">. Upon the expiration of the Royalty Term for a given Licensed Product in a given country in the Territory, the license granted to GSK pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';"> under the Licensed Know-How will become perpetual, irrevocable, fully paid-up, and royalty free with respect to such Licensed Product in such country, and upon expiration of all Royalty Terms in all countries in the Territory, the license granted to GSK pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u><font style="font-family:'Times New Roman','Times','serif';"> under the Licensed Know-How will become perpetual, irrevocable, fully paid-up, and royalty free with respect to all Licensed Products in all countries in the Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 13.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Termination</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Material Breach</u><font style="font-family:'Times New Roman','Times','serif';">. Upon (i) any material breach of this Agreement by Surface or (ii) any material breach of this Agreement by GSK (the Party so allegedly breaching being the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breaching Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), the other Party (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Breaching Party</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) will have the right, but not the obligation, to terminate this Agreement in its entirety by providing [***] written notice to the Breaching Party with respect to any breach of any payment obligation under this Agreement and [***] written notice to the Breaching Party with respect to any other breach, which notice will, in each case (A) expressly reference this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(a)</u><font style="font-family:'Times New Roman','Times','serif';">, (B) reasonably describe the alleged breach which is the basis of such termination, and (C) clearly state the Non-Breaching Party&#8217;s intent to terminate this Agreement if the alleged breach is not cured within the applicable cure period. The termination will become effective at the end of the notice period unless the Breaching Party cures such breach during such notice period; provided, that if there is a good faith dispute with respect to the existence of a material breach or whether such material breach has been cured, and if such alleged breach or failure to cure is contested in good faith by the Breaching Party in writing within [***] of the delivery of the breach notice, then the dispute resolution procedure pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIV</u><font style="font-family:'Times New Roman','Times','serif';">, may be initiated by either Party to determine whether a material breach or a failure to cure has actually occurred. If either Party so initiates the dispute resolution procedure, then the applicable cure period (and the corresponding termination of this Agreement, in whole or in part), shall be tolled until such time as the dispute is resolved pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIV</u><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the foregoing, if the breach and failure to cure contemplated by this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(a)</u><font style="font-family:'Times New Roman','Times','serif';"> is with respect to GSK&#8217;s breach of its diligence obligations set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4.1</u><font style="font-family:'Times New Roman','Times','serif';"> and </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2</u><font style="font-family:'Times New Roman','Times','serif';"> with respect to one or more (but not all) of the countries in the Territory, Surface shall not have the right to terminate this Agreement in its entirely, but shall have the right to terminate this Agreement solely with respect to the country(ies) to which such breach and failure to cure applies. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by GSK for Convenience</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will have the right to terminate this Agreement in its entirety for convenience, without cause, and for any or no reason (a) on not less than [***] prior written notice to Surface if such notice is provided prior to GSK&#8217;s receipt of the first Regulatory Approval for a Licensed Product, and (b) on not less than [***] prior written notice to Surface if such notice is provided following GSK&#8217;s receipt of the first Regulatory Approval for a Licensed Product. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Bankruptcy</u><font style="font-family:'Times New Roman','Times','serif';">. This Agreement may be terminated immediately, to the extent permitted by applicable Laws, by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy, reorganization, liquidation or receivership proceeding such right to terminate will only become effective if the Party subject to such proceeding consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Challenge</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) Except to the extent that this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> is unenforceable under the Law of the applicable jurisdiction where the applicable Licensed Patents are pending or issued, Surface has the right to terminate this Agreement upon written notice to GSK in the event that GSK or any of its Affiliates or its or their Sublicensees directly or indirectly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any Licensed Patents (a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Challenge</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;); provided that (A) this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> will not apply to any such Patent Challenge that is first made by GSK or any of its Affiliates or its or their Sublicensees in defense of a claim of patent infringement brought by Surface under the applicable Licensed Patents, (B) with respect to any Affiliate or Sublicensee, Surface will not have the right to terminate this Agreement under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> if GSK (1) causes such Patent Challenge to be terminated or dismissed (or in the case of ex-parte proceedings, multi-party proceedings, or other Patent Challenges in which the challenging party does not have the power to unilaterally cause the Patent Challenge to be withdrawn, causes such Affiliate or Sublicensee to withdraw as a party from such Patent Challenge and to cease actively assisting any other party to such Patent Challenge), or (2) terminates such Sublicensee&#8217;s sublicense to the Licensed Patents being challenged by the Affiliate or Sublicensee, in each case, within [***] of Surface&#8217;s notice to GSK under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(ii) In lieu of exercising its rights to terminate under this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';">, Surface may elect upon written notice [***], which election will be effective retroactively to the date of the commencement of the Patent Challenge. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(iii) GSK acknowledges and agrees that this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> is reasonable, valid and necessary for the adequate protection of Surface&#8217;s interest in and to the Licensed Patents, and that Surface would not have granted to GSK the licenses under those Licensed Patents, without this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';">. Surface will have the right, at any time in its sole discretion, to strike this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> (or any portion thereof) from this Agreement, and Surface will have no liability whatsoever as a result of the presence or absence of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(d)</u><font style="font-family:'Times New Roman','Times','serif';"> (or any struck portion thereof). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Cessation of Development</u><font style="font-family:'Times New Roman','Times','serif';">. Without prejudice to any other remedies available to it at law or in equity (including for any breach of the terms hereof), if (i) GSK does not conduct, or cause to be conducted, or otherwise ceases or abandons, material Development activities with respect to Licensed Antibodies and Licensed Products for a period of [***] at any time during the Term or (ii) GSK has not commenced any material Development activities with respect to any Licensed Antibody or Licensed Product on or after the date that is the [***] anniversary of the Effective Date (each, a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cessation of Development</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), then, in each case ((i) and (ii)), Surface will have the right to terminate this Agreement in its entirety with [***] written notice to GSK, unless GSK cures such Cessation of Development during such notice period; provided, that if there is a good faith dispute with respect to the existence of a Cessation of Development or whether such Cessation of Development has been cured, and if such alleged Cessation of Development or failure to cure is contested in good faith by GSK in writing within [***] of the delivery of the notice thereof, then the dispute resolution procedure pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIV</u><font style="font-family:'Times New Roman','Times','serif';">, may be initiated by either Party to determine whether a Cessation of Development or a failure to cure has actually occurred. If either Party so initiates the dispute resolution procedure, then the applicable cure period (and the corresponding termination of this Agreement, in whole or in part), shall be tolled until such time as the dispute is resolved pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIV</u><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding the foregoing, the abandonment or cessation of material Development activities by GSK with respect to Licensed Antibodies and Licensed Product as described in clauses (i) and (ii) shall not be deemed a Cessation of Development to the extent any such abandonment or cessation is the result of [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights in Bankruptcy</u><font style="font-family:'Times New Roman','Times','serif';">. All rights and licenses granted under or pursuant to this Agreement by GSK or Surface are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">provisions in any other country or jurisdiction, licenses of right to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party&#8217;s possession, shall be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon the non-subject Party&#8217;s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under clause (i) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. The Parties acknowledge and agree that payments made under </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</u><font style="font-family:'Times New Roman','Times','serif';"> shall not (x) constitute royalties within the meaning of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction or (y) relate to licenses of intellectual property hereunder. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 13.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of Termination</u><font style="font-family:'Times New Roman','Times','serif';">. All of the following effects of termination (but not expiration) are in addition to the other rights and remedies that may be available to either of the Parties under this Agreement and will not be construed to limit any such rights or remedies. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of Termination Generally</u><font style="font-family:'Times New Roman','Times','serif';">. Upon termination of this Agreement in its entirety pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3</u><font style="font-family:'Times New Roman','Times','serif';">, the Parties&#8217; rights, licenses, including any Sublicenses, and obligations under this Agreement will terminate and neither Party will have any further rights or obligations under this Agreement from and after the effective date of termination, except as set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reversion of Rights</u><font style="font-family:'Times New Roman','Times','serif';">. All Licensed Antibodies and Licensed Products and all rights related thereto will revert to Surface, including all rights under the Licensed Technology and Surface will have the right, in its sole discretion, to Develop, Manufacture and Commercialize the Licensed Antibodies and Licensed Products. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transitioning Activities</u><font style="font-family:'Times New Roman','Times','serif';">. If there are any on-going Clinical Studies at termination or expiration of this Agreement, the Parties will negotiate in good faith to establish an appropriate course of action, which may include transitioning activities from GSK to Surface or its designee, with due regard for patient safety and the rights of any subjects that are participants in any Clinical Studies of the Licensed Products, and take any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all applicable Laws. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(d) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of Reference to Regulatory Materials</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will and hereby does, and will cause its Affiliates and its and their Sublicensees to, (i) effective as of the effective date of termination, assign to Surface all of its rights, title, and interests in and to all Regulatory Materials, filings for Pricing and Reimbursement Approval, Regulatory Approvals, Clinical Data and other material documentation, to the extent allowed under applicable Law and solely related to the Licensed Antibodies or Licensed Products that are then held by or owned or controlled by GSK or any of its Affiliates or Sublicensees and (ii) to the extent assignment pursuant to clause (i) is not permitted by applicable Law or not solely related to the Licensed Antibodies or Licensed Products that are then held by or owned or controlled by GSK or any of its Affiliates or Sublicensees, GSK will and hereby does grant to Surface an exclusive right of reference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">to such Regulatory Materials, filings for Pricing and Reimbursement Approval, Regulatory Approvals, Clinical Data and other material documentation, to the extent allowed under applicable Laws, for the Licensed Antibodies or the Licensed Products that are then held by or owned or controlled by GSK or any of its Affiliates or its or their Sublicensees for the continued Development and Commercialization thereof by Surface. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(e) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License of Patent Rights related to Licensed Antibodies</u><font style="font-family:'Times New Roman','Times','serif';">. GSK will and hereby does grant, effective as of the effective date of termination (without any further action required on the part of GSK), an exclusive, [***] license grant from GSK to Surface, with the right to sublicense (through multiple tiers) under the Patent Rights and Know-How Controlled by GSK or its Affiliates claiming or relating to the Development, Manufacture and Commercialization of the Licensed Antibody, that are necessary or were actually used by GSK or its Affiliates in the Development, Manufacture or Commercialization of the Licensed Product on or before the effective date of the termination, for Surface to Develop, Manufacture, or Commercialize the Licensed Antibody or the Licensed Product in the Field in the Territory. [***]. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(f) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inventory</u><font style="font-family:'Times New Roman','Times','serif';">. Upon termination of this Agreement, Surface will have the right to purchase all of GSK and its Affiliates&#8217; then-current remaining inventory of non-GMP drug substance, non-GMP drug substance, and Master or Working cell banks. If Surface makes such purchase, GSK will provide primary drug substance reference standard, record of analysis, and a summary report describing it characterization. No raw materials (including chromatography resins, filters, or consumables) will be transferred to Surface. Surface will have the right to purchase such remaining non-GMP inventory at a price equal to [***]. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(g) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trademarks</u><font style="font-family:'Times New Roman','Times','serif';">. Effective as of the date of termination, GSK will assign (or, if applicable, will cause its Affiliates or its or their Sublicensees to assign) to Surface all of GSK&#8217;s (and such Affiliates&#8217; or its or their Sublicensees&#8217;) worldwide right, title and interest in and to any Trademarks that is specific to and solely used for any Licensed Products (it being understood that the foregoing will not include any Trademarks that contain the corporate or business name(s) of GSK or any of its Affiliates or its or their Sublicensees). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(h) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u><font style="font-family:'Times New Roman','Times','serif';">. The parties shall negotiate in good faith to agree a plan acceptable to both Parties for the transition of Development and Manufacture to Surface. GSK will provide any other assistance or take any other actions, in each case reasonably requested by Surface, as necessary to transfer to Surface the Development or Manufacture of the Licensed Antibodies and Licensed Products, and will execute all documents as may be reasonably requested by Surface in order to give effect to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(i) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Information</u><font style="font-family:'Times New Roman','Times','serif';">. GSK, if requested in writing by Surface, will provide any (i) material correspondence with the relevant patent offices pertaining to GSK&#8217;s Prosecution of the Licensed Patents, the Joint Patents and the European Opposition Proceeding to the extent not previously provided to Surface during the course of the Agreement and (ii) a report detailing the status of all Licensed Patents, Joint Patents and the European Opposition Proceeding at the time of termination. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(j) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';">. Within [***] after the effective date of termination (but not expiration) of this Agreement in its entirety, each Party will, and cause its Affiliates to (i) destroy all tangible items solely comprising, bearing or containing any Confidential Information of the other Party that are in such first Party&#8217;s or its Affiliates&#8217; possession or control, and provide written certification of such destruction, or (ii) prepare such tangible items of the other Party&#8217;s Confidential Information for shipment to such other Party, as such other Party may direct, at the first Party&#8217;s expense; provided, however, that, in any event, (A) each Party may retain copies of the Confidential Information of the other Party to the extent necessary to perform its obligations or exercise its rights that survive termination of this Agreement; and (B) each Party may retain one copy of the Confidential Information of the other Party for its legal archives. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(k) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will use reasonable efforts to cause its Affiliates, its and their sublicensees and subcontractors to comply with the obligations in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(l) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u><font style="font-family:'Times New Roman','Times','serif';">. Termination of this Agreement for any reason will not release either Party from any obligation or liability which, on the effective date of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(m) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-family:'Times New Roman','Times','serif';">. The provisions set forth in the following Sections, as well as, to the extent applicable, any other Sections or defined terms referred to in such Sections or Articles or necessary to give them effect, will survive the expiration or termination of this Agreement in its entirety: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VII</u><font style="font-family:'Times New Roman','Times','serif';"> (but only with respect to payments accrued thereunder prior to termination), </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE VIII</u><font style="font-family:'Times New Roman','Times','serif';"> (with respect to the provisions regarding Joint Patents), </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XI</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XII</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XIV</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XV</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.5</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.5</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.6</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u><font style="font-family:'Times New Roman','Times','serif';">, and this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4</u><font style="font-family:'Times New Roman','Times','serif';">. Furthermore, any other provisions required to interpret the Parties&#8217; rights and obligations under this Agreement, including applicable definitions in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE I</u><font style="font-family:'Times New Roman','Times','serif';">, will survive to the extent required. Except as otherwise expressly provided in this Agreement, including this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4</u><font style="font-family:'Times New Roman','Times','serif';">, all rights and obligations of the Parties under this Agreement and any licenses granted under this Agreement, will terminate upon the expiration or termination of this Agreement in its entirety for any reason. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE XIV </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DISPUTE RESOLUTION </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 14.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dispute Resolution; Escalation</u><font style="font-family:'Times New Roman','Times','serif';">. The Parties recognize that disputes as to certain matters arising out of or in connection with this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising out of or in connection with this Agreement in an expedited manner by mutual cooperation. To accomplish this objective, any and all disputes between the Parties arising out of or in connection with this Agreement will first be referred to the Senior Officers for resolution and the Senior Officers will attempt to resolve the matter in good faith. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 14.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mediation</u><font style="font-family:'Times New Roman','Times','serif';">. If the Parties&#8217; Senior Officers are unable for any reason to resolve a dispute within [***] of referral of the dispute to them, then the Parties agree that they shall try in good faith to resolve the dispute by referring it for confidential mediation under the CPR Mediation Procedure in effect at the start of mediation, before resorting to arbitration as set forth in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';">. If the Parties cannot agree on a mediator within [***] after the dispute was referred to mediation, the mediator shall, upon request by either Party, be appointed by CPR pursuant to CPR Mediation Procedure. The cost of mediator shall be borne equally by the Parties. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 14.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u><font style="font-family:'Times New Roman','Times','serif';">. Except as set forth in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';">, each dispute, difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof that cannot be resolved pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.1</u><font style="font-family:'Times New Roman','Times','serif';"> and </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.2</u><font style="font-family:'Times New Roman','Times','serif';"> will be referred to and finally resolved by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rules</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Arbitration proceedings may be commenced by either Party by notice to the other Party. Within [***] after the institution of the arbitration proceedings, each Party will appoint one (1) arbitrator with the third arbitrator to be selected by mutual agreement of the two (2) arbitrators appointed by the Parties, and each arbitrator will have significant experience in the biopharmaceutical industry. If the two initial arbitrators are unable to select a third arbitrator within [***], the third arbitrator will be appointed in accordance with the Rules. Unless otherwise agreed by the Parties, all such arbitration proceedings will be held in New York, New York; provided, however, that proceedings may be conducted by videoconference or telephone conference call with the consent of the Parties and the arbitrator(s). All arbitration proceedings will be conducted in the English language. The arbitrators will consider grants of equitable relief and orders for specific performance as co-equal remedies along with awards of monetary damages. The arbitrators will have no authority to award punitive damages. The allocation of expenses of the arbitration, including reasonable attorney&#8217;s fees, will be determined by the arbitrators, or, in the absence of such determination, each Party will pay its own expenses. The Parties hereby agree that the arbitrators have authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrators deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and judgment. All rulings by the arbitrators will be final. Notwithstanding any contrary provision of this Agreement, any Party may seek equitable measures of protection in the form of attachment of assets or injunctive relief (including specific performance and injunctive relief) in any matter relating to the proprietary rights and interests of either Party from any court of competent jurisdiction, pending a decision by the arbitral tribunal in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';">). The Parties hereby exclude any right of appeal to any court on the merits of such matter. The provisions of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';"> may be enforced and judgment on the award (including equitable remedies) granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets. Except to the extent necessary to confirm an award or as may be required by Laws, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties as if any of the foregoing was the Confidential Information of each Party. The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. Nothing in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';"> will preclude either Party from seeking interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 14.4. Notwithstanding the Parties&#8217; agreement to arbitrate, unless the Parties agree in writing in any particular case, claims and disputes between the Parties relating to or arising out of, or for which resolution depends in whole or in part on a determination of the interpretation, scope, validity, enforceability or infringement of, Patent Rights or of any Trademark rights relating to any Licensed Products will not be subject to arbitration under this Agreement, and the Parties may pursue whatever rights and remedies may be available to them under law or equity, including litigation in a court of competent jurisdiction, with respect to such claims and disputes. All questions concerning (a) inventorship of Patent Rights under this Agreement will be determined in accordance with </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u><font style="font-family:'Times New Roman','Times','serif';"> and (b) the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">construction or effect of Patent Rights or with respect to Trademarks, will be determined in accordance with the Laws of the country or other jurisdiction in which the particular patent within such Patent Rights or the Trademark has been filed or granted, as the case may be. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 14.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jury Waiver</u><font style="font-family:'Times New Roman','Times','serif';">. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u><font style="font-family:'Times New Roman','Times','serif';">. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARTICLE XV </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MISCELLANEOUS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.1. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; Successors</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(a) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u><font style="font-family:'Times New Roman','Times','serif';">. This Agreement and the rights and obligations of each Party under this Agreement will not be assignable, delegable, transferable, pledged or otherwise disposed of by either Party without the prior written consent of the other Party; provided, however, that either Party may assign or transfer this Agreement together with all of its rights and obligations hereunder, without such consent (but with written notice to the other Party), (A) to an Affiliate or (B) to a successor in interest in connection with the transfer or sale of all or substantially all of its business or assets to which this Agreement relates, or in the event of its merger or consolidation, reorganization or similar transaction, subject to the assignee agreeing in writing to be bound by the terms and conditions of this Agreement. Any assignment in violation of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.1(a)</u><font style="font-family:'Times New Roman','Times','serif';"> will be null and void. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(b) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</u><font style="font-family:'Times New Roman','Times','serif';">. Any permitted assignment of the rights and obligations of a Party under this Agreement will be binding on, and inure to the benefit of and be enforceable by and against, the successors and permitted assigns of the assigning Party. The permitted assignee or transferee will assume all obligations of its assignor or transferor under this Agreement. Any assignment or attempted assignment by either Party in violation of the terms of this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.1(b)</u><font style="font-family:'Times New Roman','Times','serif';"> will be null, void and of no legal effect. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(c) </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control of Surface</u><font style="font-family:'Times New Roman','Times','serif';">. Notwithstanding anything in this Agreement to the contrary, a Party or its Affiliates will be deemed to not Control any Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right that is owned or controlled by a Third Party described in the definition of &#8220;Change of Control,&#8221; or such Third Party&#8217;s Affiliates (other than an Affiliate of such Party prior to the Change of Control), (a) [***], except to the extent that any such Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right [***] Affiliate&#8217;s Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right, or (b) [***] to the extent that such Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right [***] Affiliate&#8217;s Know-How, Patent Right, Regulatory Material, Regulatory Approval or other property right. No assets of Surface or any of its Affiliates not owned or in-licensed by Surface or any of its Affiliates before a Change of Control will be subject to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.8(a)</u><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.2. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Choice of Laws</u><font style="font-family:'Times New Roman','Times','serif';">. This Agreement will be governed by and interpreted under the Laws of The State of New York, without regard to the conflicts of law principles thereof. The Parties agree to exclude the application to this Agreement of the United Nations Conventions on Contracts for the International Sale of Goods (1980). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.3. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-family:'Times New Roman','Times','serif';">. Any notice or report required or permitted to be given or made under this Agreement by one Party to the other will be in writing and will be deemed to have been delivered (a) upon personal delivery (upon written confirmation of receipt), (b) when received by the addressee, if sent by a reputable internationally recognized overnight courier that maintains records of delivery, or registered or certified mail, postage prepaid, return receipt requested and (c) in the case of notices provided by telecopy (which notice will be followed immediately by an additional notice pursuant to clause (a) or (b) above if the notice is of a default under this Agreement), upon completion of transmission, with transmission confirmed, to the addressee&#8217;s facsimile machine, as follows (or at such other addresses or facsimile numbers as may have been furnished in writing by a Party to the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">other as provided in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.3</u><font style="font-family:'Times New Roman','Times','serif';">). This </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.3</u><font style="font-family:'Times New Roman','Times','serif';"> is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:18.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:18.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Surface:</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Surface Oncology, Inc.</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">50 Hampshire Street</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cambridge, MA 02139</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: Chief Legal Officer</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:18.99%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:81%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:18.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With copies to:</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Goodwin Procter LLP</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">100 Northern Avenue</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, MA 02210</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attention: [***]</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:18.99%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:81%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:18.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If to GSK:</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">GlaxoSmithKline</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">259 E Grand Ave Fifth Floor, Suite 1</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">S. San Francisco, CA 94080</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: SVP &amp; Head R&amp;D Business Development</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:middle;width:27.99%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:middle;width:71%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:27.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With copies to (which shall not constitute notice to):</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">GlaxoSmithKline</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">980 Great West Road</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Brentford, Middlesex TW8 9GS</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">United Kingdom</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: VP &amp; Head of Legal Business Development &amp; Corporate</font></p></td></tr><tr style="height:6pt;"><td style="vertical-align:middle;width:27.99%;margin:0pt;padding:0.25pt;"></td><td colspan="2" style="vertical-align:middle;width:72%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:27.99%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">With copies to (which shall not constitute notice to):</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0.25pt;"></td><td style="vertical-align:top;width:71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Covington &amp; Burling LLP</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">One CityCenter</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">850 Tenth Street, NW</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Washington, DC 20001</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: [***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.4. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-family:'Times New Roman','Times','serif';">. In the event that one or more provisions of this Agreement is held invalid, illegal or unenforceable in any respect, then such provision will not render any other provision of this Agreement invalid or unenforceable, and all other provisions will remain in full force and effect and will be enforceable, unless the provisions that have been found to be invalid or unenforceable will substantially affect the remaining rights or obligations granted or undertaken by either Party. The Parties agree to attempt to substitute for any invalid or unenforceable provision a provision which achieves to the greatest extent possible the objectives of the invalid or unenforceable provision. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.5. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration</u><font style="font-family:'Times New Roman','Times','serif';">. This Agreement, together with all schedules and exhibits attached hereto, constitutes the entire agreement between the Parties with respect to the subject matter of this Agreement and supersedes all previous arrangements between the Parties with respect to the subject matter hereof, whether written or oral, including, effective as of the Effective Date, the Prior CDA (provided that all information disclosed or exchanged under such agreement will be treated as Confidential Information hereunder). In the event of a conflict between any schedules or attachments to this Agreement, on the one hand, and this Agreement, on the other hand, the terms of this Agreement will govern. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.6. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers and Amendments</u><font style="font-family:'Times New Roman','Times','serif';">. The failure of any Party to assert a right under this Agreement or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. The exercise by any Party of any right or election under the terms or covenants herein will not preclude or prejudice any Party from exercising the same or any other right it may have under this Agreement, irrespective of any previous action or proceeding taken by the Parties hereunder. Notwithstanding the authority granted to the JDC under this Agreement, (a) no waiver will be effective unless it has been given in writing and signed by the Party giving such waiver, and (b) no provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.7. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractors; No Agency</u><font style="font-family:'Times New Roman','Times','serif';">. Neither Party will have any responsibility for the hiring, firing or compensation of the other Party&#8217;s or such other Party&#8217;s Affiliates&#8217; employees or for any employee benefits with respect thereto. No employee or representative of a Party or its Affiliates will have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on such other Party, without such other Party&#8217;s written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, each Party&#8217;s legal relationship under this Agreement to the other Party will be that of independent contractor, and the relationship between the two Parties will not constitute a partnership, joint venture, or agency, including for all tax purposes, except as otherwise required by applicable Law. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.8. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliates, Sublicensees, and subcontractors</u><font style="font-family:'Times New Roman','Times','serif';">. To the extent that this Agreement imposes obligations on Affiliates, Sublicensees or subcontractors of a Party, such Party will cause its Affiliates and its and their sublicensees and subcontractors to perform such obligations, as applicable. Either Party may use one or more of its Affiliates, its or their sublicensees or subcontractors to perform its obligations and duties or exercise its rights under this Agreement, solely to the extent permitted and as specified in this Agreement; provided, however, that (a) each such Affiliate, Sublicensee or subcontractor will perform any such obligations delegated to it in compliance with the applicable terms and conditions of this Agreement as if such Affiliate, Sublicensee or subcontractor were a party hereto, (b) the performance of any obligations of a Party&#8217;s by its Affiliates, its or their sublicensees or subcontractors will not diminish, reduce or eliminate any obligation of such Party under this Agreement, (c) the Party using such contractor will terminate promptly any subcontractor, and will give the other Party notice of such termination, in the case of any material breach of this Agreement by such subcontractor and (d) subject to such Party&#8217;s assignment to an Affiliate pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.1</u><font style="font-family:'Times New Roman','Times','serif';">, such Party will remain liable under this Agreement for the prompt payment and performance of all of its obligations under this Agreement. Subject to this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.8</u><font style="font-family:'Times New Roman','Times','serif';">, if a Party exercises its rights and performs its obligations under this Agreement through one or more of its Affiliates, &#8220;Surface&#8221; will be interpreted to mean &#8220;Surface or its Affiliates&#8221; and &#8220;GSK&#8221; will be interpreted to mean &#8220;GSK or its Affiliates&#8221; where necessary to give each Party&#8217;s Affiliates the benefit of the rights provided to such Party in this Agreement and the ability to perform its obligations under this Agreement. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.9. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiary Rights</u><font style="font-family:'Times New Roman','Times','serif';">. The representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they will not be construed as conferring any rights on any other Third Party. This Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, other than, to the extent provided in </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE XI</u><font style="font-family:'Times New Roman','Times','serif';">, the Indemnified Parties. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.10. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-exclusive Remedy</u><font style="font-family:'Times New Roman','Times','serif';">. Except as expressly provided herein, the rights and remedies provided herein are cumulative and each Party retains all remedies at law or in equity, including the Parties&#8217; ability to receive legal damages or equitable relief, with respect to any breach of this Agreement. Neither Party will be required (but, for clarity, will have the right as specified in this Agreement) to terminate this Agreement due to a breach of this Agreement by the other Party. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.11. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u><font style="font-family:'Times New Roman','Times','serif';">. The Article and Section headings used herein are for reference and convenience only, and will not enter into the interpretation of this Agreement. Except as otherwise explicitly specified to the contrary, (a) references to an Article, Section or Exhibit means an Article or Section of, or a Schedule or Exhibit to this Agreement and all subsections thereof, unless another agreement is specified; (b) references in any Section to any clause are references to such clause of such Section; (c) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto; (d) references to a particular &#8220;Laws&#8221; mean such Laws as in effect as of the relevant time, including all rules and regulations thereunder and any successor Laws in effect as of the relevant time, and including the then-current amendments thereto; (e) words in the singular or plural form include the plural and singular form, respectively; (f) unless the context requires a different interpretation, the word &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">or</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">and/or</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;; (g) the terms &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">including</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">include(s),</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">such as,</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">e.g.</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">for example</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; mean including the generality of any description preceding such term and will be deemed to be followed by &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">without limitation</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;; (h) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Business Day; (i) &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">monthly</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means on a calendar month basis, (j) &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">quarter</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">quarterly</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means on a Calendar Quarter basis; (k) &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">annual</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">annually</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means on a Calendar Year basis; (l) &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">year</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a 365 day period unless Calendar Year is specified; (m) references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement; (n) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (o) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner; (p) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (q) the words &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">hereof</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">herein</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">hereby</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; and derivative or similar words refer to this Agreement (including any Exhibits or Schedules); (r) neither Party or its Affiliates will be deemed to be acting &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">on behalf of</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; the other Party under this Agreement, except to the extent expressly otherwise provided; (s) provisions that require that a Party, or the JDC hereunder &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">agree</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">consent</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">approve</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; or the like will be deemed to require that such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as expressly provided herein, excluding e-mail and instant messaging; and (t) the word &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">shall</u><font style="font-family:'Times New Roman','Times','serif';">&#8221; will be construed to have the same meaning and effect as the word &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">will</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.12. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u><font style="font-family:'Times New Roman','Times','serif';">. Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement (including working collaboratively to correct and clerical, typographical, or other similar errors in this Agreement). </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.13. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ambiguities; No Presumption</u><font style="font-family:'Times New Roman','Times','serif';">. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement will not be construed against any Party under the rule of construction, irrespective of which Party may be deemed to have authored the ambiguous provision. </font></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Section 15.14. </font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Execution in Counterparts; PDF Signatures</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">. This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart. Signatures provided in Adobe</font><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">&#8482;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 15.15. </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Export Control</u><font style="font-family:'Times New Roman','Times','serif';">. This Agreement is made subject to any restrictions required by applicable Laws concerning the export of products or technical information from the U.S. or other countries which may be imposed upon or related to the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technology licensed to it or other technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, except in compliance with U.S. export Laws and regulations. </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[Remainder of this page intentionally blank.] </i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">53 </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized representative on the Effective Date. </font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr><td style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">SURFACE ONCOLOGY, INC.</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ J. Jeffrey Goater</font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: J. Jeffrey Goater</font></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: Chief Executive Officer</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO. 4 LIMITED</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:100%;margin:0pt;padding:0.25pt;"></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ [***]</font></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: [***]</font></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0.25pt;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: [***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[Signature Page to License Agreement]</i></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSED ANTIBODIES </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[***] </font></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit A </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSED PATENTS </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit B </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TRANSITION PLAN </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit C </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D </u></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[See attached.] </i></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit D </font></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Schedule 9.2 </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Form of Press Release </b></p><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[See Attached] </i></p><div style="font-family:'Aptos';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr color="#a0a0a0" size="2.25" style="height:2.25pt;position:relative;top:0.6em;width:100%;margin:0 auto;" align="center"></div><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] </b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5
<SEQUENCE>6
<FILENAME>chrs-20231231xex5.htm
<DESCRIPTION>EX-10_35
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';background:#ffffff;">CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY &#8220;[***]&#8221;, HAS BEEN EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT SURFACE ONCOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:3.95pt 19pt 0pt 136.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 10.35</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:3.95pt 148.6pt 0pt 136.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:3.95pt 142.55pt 0pt 142.55pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">AMENDMENT NO. 1 TO LICENSE AGREEMENT</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 17.75pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Amendment No. 1 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Amendment No. 1</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) to the License Agreement dated December 20, 2020 between GlaxoSmithKline Intellectual Property (No. 4) Limited, having a principal place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">GSK</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and Surface Oncology, Inc., having a place of business at 50 Hampshire Street, Cambridge MA 02139 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Surface</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) is effective as of August 11, 2021 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Amendment Effective Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Each of GSK and Surface may be referred to herein as a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Party</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; and together, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Parties</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.25pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 124.6pt 0pt 124.6pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.25pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 17.95pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">WHEREAS, GSK and Surface desire to amend the Transition Plan as set forth on Exhibit C hereto, in accordance with Section 15.6.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.4pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 18.25pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">NOW THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36.05pt;text-align:justify;text-indent:-36.05pt;margin:8.25pt 18.25pt 0pt 23.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">1.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Capitalized terms used but not defined herein shall have the meaning set forth in the Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36.05pt;text-align:justify;text-indent:-36.05pt;margin:0pt 17pt 0pt 23.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">2.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The Parties agree to amend the Transition Plan as attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> in order to permit Surface to order [***] of Licensed Product from the Existing CMO for transfer to GSK, as described in more detail in the Transition Plan. The Transition Plan sets forth the additional Transition Costs to be reimbursed to Surface by GSK in connection with the Manufacture of [***] of Licensed Product in accordance with Section 3.4 of the Agreement. Further, the Parties acknowledge and agree that [***] in accordance with the Transition Plan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 17.95pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">IN WITNESS WHEREOF, each Party has caused this Amendment No. 1 to be duly executed by its authorized representative on the Amendment Effective Date.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:48.49%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.49%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.81%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:48.91%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.49%;margin:0pt;padding:1pt;"></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="3" style="vertical-align:top;width:49.78%;margin:0pt;padding:1.75pt 1.25pt 1.75pt 1.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:8.14pt 2.75pt 0pt 14.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">SURFACE ONCOLOGY, INC.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Robert Ross</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: Robert Ross, MD</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: President and CEO</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jessica Fees</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: Jessica Fees</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: Chief Financial Officer</font></p></td><td colspan="3" style="vertical-align:top;width:50.21%;margin:0pt;padding:1.75pt 1.25pt 1.75pt 1.25pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Times New Roman','Times','serif';">GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO. 4 LIMITED</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 2.75pt 0pt 2.75pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ John Sadler</u></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:4pt 2.75pt 0pt 2.75pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">N</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">AME</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">: J</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">OHN </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">S</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">ADLER</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0.75pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">A</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">UTHORISED </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">S</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">IGNATORY</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0.75pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">F</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">OR AND ON </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">B</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">EHALF OF</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0.05pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">T</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">HE </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">W</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">ELLCOME </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">F</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">OUNDATION </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">L</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">IMITED</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0.05pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">C</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">ORPORATE </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">D</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">IRECTOR</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 93.85pt 0pt 14.1pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Claire MacLeod</u></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;margin:0pt 93.85pt 0pt 14.1pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NAME: CLAIRE MACLEOD</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">A</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">UTHORISED </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">S</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">IGNATORY</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">F</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">OR AND ON </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">B</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">EHALF OF</font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">E</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">DINBURGH </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">P</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">HARMACEUTICAL </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">I</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">NDUSTRIES </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">L</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">IMITED </font></p><p style="font-family:'Aptos';font-size:6pt;line-height:1.19;margin:0pt 2.75pt 0pt 50.25pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">C</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">ORPORATE </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;">D</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:6.5pt;">IRECTOR</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:4pt;line-height:1.19;margin:0.5pt 0pt 0pt 11.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;">D</font><font style="font-family:'Times New Roman','Times','serif';font-size:6.5pt;">ATE</font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;">: 18</font><font style="font-family:'Times New Roman','Times','serif';">TH </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;">A</font><font style="font-family:'Times New Roman','Times','serif';font-size:6.5pt;">UGUST </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;">2021</font></p><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:17.08%;"><tr><td style="vertical-align:middle;width:2.93%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:94.18%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:2.87%;margin:0pt;padding:1pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;text-indent:0.2pt;margin:3.79pt 223.6pt 0pt 223.6pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">EXHIBIT C TRANSITION PLAN</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;">[***]</b></p><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:17.08%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:2.93%;margin:0pt;padding:1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:94.18%;margin:0pt;padding:1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.87%;margin:0pt;padding:1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:2.93%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:94.18%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:2.87%;margin:0pt;padding:1pt;"></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-7
<SEQUENCE>7
<FILENAME>chrs-20231231xex7.htm
<DESCRIPTION>EX-10_36
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT 10.36</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">SIXTH AMENDMENT</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">THIS SIXTH AMENDMENT</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> (this &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Amendment</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;) is made and entered into as of October 24, 2023, </font><font style="font-family:'Times New Roman','Times','serif';">by and between </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">HUDSON 333 TWIN DOLPHIN PLAZA, LLC, a Delaware limited liability company </b><font style="font-family:'Times New Roman','Times','serif';">(&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Landlord</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">COHERUS BIOSCIENCES, INC., a Delaware corporation</b><font style="font-family:'Times New Roman','Times','serif';"> (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Tenant</b><font style="font-family:'Times New Roman','Times','serif';">&#8221;)</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">RECITALS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">A.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Landlord and Tenant are parties to that certain lease dated July 6, 2015, as previously amended by that certain First Amendment dated August 10, 2015, as confirmed by that certain Confirmation Letter dated December 22, 2015, as further amended by that certain Second Amendment dated September 21, 2016 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Second Amendment</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;), that certain Third Amendment dated May 24, 2019, that certain Fourth Amendment dated September 4, 2019 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Fourth Amendment</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;), that certain Notice of Lease Term Dates dated October 16, 2019, and that certain Fifth Amendment dated December 6, 2019 (as amended, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Lease</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;). &#160;Pursuant to the Lease, Landlord has leased to Tenant space currently containing approximately </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">47,789</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> rentable square feet (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Currently Existing Premises</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;) at the building commonly known as 333 Twin Dolphin located at 333 Twin Dolphin Drive, Redwood City (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Building</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;) and described as (i) Suite 425 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Suite 425</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;) consisting of approximately </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">7,448</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> rentable square feet on the fourth floor of the Building, (ii) Suite 450 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Suite 450</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;) consisting of approximately </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">12,809</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> rentable square feet on the fourth floor of the Building; and (iii) Suite 600 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Suite 600</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Remaining Premises</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;) consisting of approximately </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">27,532</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> rentable square feet on the sixth floor of the Building.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">B.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">The Lease will expire by its terms on September 30, 2024 (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Extended Expiration Date</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;). &#160;Except as provided in </font><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recital&#160;C</u><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> below, the parties wish to extend the term of the Lease on the following terms and conditions.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">C.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">With respect to each of Suite 425 and Suite 450 (both as more particularly shown on </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> attached hereto, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Reduction Space</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221;), the parties wish to accelerate the Extended Expiration Date, on the following terms and conditions.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">NOW, THEREFORE</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">, </font><font style="font-family:'Times New Roman','Times','serif';">in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extension</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">.</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> &#160;Except as provided in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> below, the term of the Lease is hereby extended through September 30, 2027</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;letter-spacing:-0.15pt;"> </i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">(the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Second Extended Expiration Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#8221;). &#160;The portion of the term of the Lease beginning on the date immediately following the Extended Expiration Date (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Second Extension Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#8221;) and ending on the Second Extended Expiration Date shall be referred to herein as the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Second Extended Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#8221;.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction.</b></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Reduction Space Expiration Date.</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> &#160;Subject to the terms hereof, the term of the Lease shall expire, with respect to the Reduction Space only, on December 31, 2023 (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Reduction Space Expiration Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#8221;) with the same force and effect as if such term were, by the provisions of the Lease, fixed to expire with respect to the Reduction Space on the Reduction Space Expiration Date (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Reduction</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#8221;). &#160;Without limiting the foregoing: (a) from and after the date immediately following the Reduction Space Expiration Date (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Reduction Effective Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#8221;), the Premises shall consist solely of the Remaining Premises and shall be deemed to contain </font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">27,532</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">&#160;rentable square feet, (b) Tenant shall surrender the Reduction Space to Landlord in accordance with the terms of the Lease (as amended by </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> below) on or before the Reduction Space Expiration Date, (c) Tenant shall remain liable for all Rent and other amounts payable under the Lease with respect to the Reduction Space for the period up to and including the Reduction Space Expiration Date, even though billings for such amounts may occur after the Reduction Space Expiration Date, (d) Tenant&#8217;s restoration obligations with respect to the Reduction Space shall be as set forth in the Lease (as amended by </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> below), and (e) if Tenant fails to surrender any portion of the Reduction Space on or before the Reduction Space Expiration Date, Tenant&#8217;s tenancy with respect to the Reduction Space shall be subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;16</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> of the Lease.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;">Landlord Waiver</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">. &#160;Notwithstanding </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> of the Lease (entitled, Landlord&#8217;s Property), </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> of the Lease (entitled, Surrender) and/or any other similar provision of the Lease, Tenant shall not be required to remove (nor pay for the removal of) any Tenant-Insured Improvement &#160;(as defined in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> of the Lease) existing in the Reduction Space on the date of mutual execution and delivery of this Amendment.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">.</b></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">3.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Remaining Premises During Second Extended Term.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;With respect to the Remaining Premises during the Second Extended Term, the schedule of Base Rent shall be as follows:</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:77.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:84.61%;"><tr><td style="vertical-align:top;width:31.81%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Period of Second Extended Term</b></p></td><td style="vertical-align:top;width:34.09%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Aptos';font-size:11pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Rate Per Square Foot (rounded to the nearest 100</b><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;font-weight:bold;vertical-align:top;">th</sup><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> of a dollar)</b></p></td><td style="vertical-align:top;width:34.09%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Monthly Base Rent</b></p></td></tr><tr><td style="vertical-align:top;width:31.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">October 1, 2024 &#8211; September 30, 2025</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$64.20</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$147,296.20</font></p></td></tr><tr><td style="vertical-align:top;width:31.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">October 1, 2025 &#8211; September 30, 2026</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$66.13</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$151,715.09</font></p></td></tr><tr><td style="vertical-align:top;width:31.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">October 1, 2026 &#8211; September 30, 2027</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$68.11</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$156,266.54</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">All such Base Rent shall be payable by Tenant in accordance with the terms of the Lease.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">3.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Remaining Premises During Period Beginning on Reduction Effective Date and Ending on Extended Expiration Date.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;With respect to the Remaining Premises during the period beginning on the Reduction Effective Date and ending on the Extended Expiration Date, the schedule of Base Rent shall be as follows:</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:77.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:84.61%;"><tr><td style="vertical-align:top;width:31.81%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Period</b></p></td><td style="vertical-align:top;width:34.09%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Aptos';font-size:11pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Annual Rate Per Square Foot (rounded to the nearest 100</b><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;font-weight:bold;vertical-align:top;">th</sup><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> of a dollar)</b></p></td><td style="vertical-align:top;width:34.09%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Monthly Base Rent</b></p></td></tr><tr><td style="vertical-align:top;width:31.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Reduction Effective Date through Extended Expiration Date</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$72.92</font></p></td><td style="vertical-align:top;width:34.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$167,311.97</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">All such Base Rent shall be payable by Tenant in accordance with the terms of the Lease.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding the foregoing, Base Rent for the Remaining Premises shall be abated, (i) in the amount of $167,311.97 with respect to the month of July, 2024 and (ii) in the amount of $85,766.03 with respect to the month of August, 2024.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Security Deposit.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;The parties acknowledge and agree that Landlord is holding $342,773.00 as the Security Deposit under the Lease. &#160;Effective as of the date hereof the amount of the Security Deposit shall be reduced to $156,266.54; and, within 30 days hereof, Landlord shall return to Tenant any then unapplied portion of the Security Deposit exceeding such reduced amount.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Share For Remaining Premises</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;With respect to the Remaining Premises during the Second Extended Term (and any period beginning on the Reduction Effective Date and ending on the Extended Expiration Date), Tenant&#8217;s Share shall be 15.0622%.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses and Taxes For Remaining Premises</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;With respect to the Remaining Premises during the Second Extended Term (and any period beginning on the Reduction Effective Date and ending on the Extended Expiration Date), Tenant shall pay for Tenant&#8217;s Share of Expenses and Taxes in accordance with the terms of the Lease; provided, however, that, with respect to the Remaining Premises during the Second Extended Term, the Base Year for Expenses and Taxes shall be calendar year 2024.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvements to Remaining Premises</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">.</b></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">7.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Configuration and Condition of Remaining Premises.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Tenant acknowledges that it is in possession of the Remaining Premises and agrees to accept them &#8220;as is&#8221; without any representation by Landlord regarding their configuration or condition and without any obligation on the part of Landlord to perform or pay for any alteration or improvement, except as may be otherwise expressly provided in this Amendment.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">7.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Responsibility for Improvements to Remaining Premises.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Any improvements to the Remaining Premises performed by Tenant shall be paid for by Tenant and performed in accordance with the terms of the Lease.</font></p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman Bold';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Tenant represents and warrants that, as of the date hereof and the Reduction Space Expiration Date: &#160;(a)&#160;Tenant is the rightful owner of all of the Tenant&#8217;s interest in the Lease; (b)&#160;Tenant has not subleased the Reduction Space or made any disposition, assignment or conveyance of the Lease or Tenant&#8217;s interest therein; (c)&#160;Tenant has no knowledge of any fact or circumstance which would give rise to any claim, demand, obligation, liability, action or cause of action arising out of or in connection with Tenant&#8217;s occupancy of the Reduction Space; (d)&#160;no other person or entity has an interest in the Lease, collateral or otherwise; and (e)&#160;there are no outstanding contracts for the supply of labor or material and no work has been done or is being done in, to or about the Reduction Space which has not been fully paid for and for which appropriate waivers of mechanic&#8217;s liens have not been obtained.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Pertinent Provisions</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Landlord and Tenant agree that, effective as of the date of this Amendment (unless different effective date(s) is/are specifically referenced in this Section), the Lease shall be amended in the following additional respects:</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">9.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Energy Usage. &#160;</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">If Tenant (or any party claiming by, through or under Tenant) pays directly to the provider for any energy consumed at the Project, Tenant, promptly upon request, shall deliver to Landlord (or, at Landlord&#8217;s option, execute and deliver to Landlord an instrument enabling Landlord to obtain from such provider) any data about such consumption that Landlord, in its reasonable judgment, is required for benchmarking purposes or to disclose to a prospective buyer, tenant or mortgage lender under any applicable law.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">9.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">California Civil Code Section&#160;1938.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Pursuant to California Civil Code &#167;&#160;1938, Landlord hereby states that the Currently Existing Premises </font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">have not undergone inspection by a Certified Access Specialist (CASp) (defined in California Civil Code &#167; 55.52). </font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">Accordingly, pursuant to California Civil Code &#167; 1938(e), Landlord hereby further states as follows: &#160;&#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. &#160;Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. &#160;The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises&#8221;. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">In accordance with the foregoing, Landlord and Tenant agree that if Tenant requests a CASp inspection of the Currently Existing Premises, then Tenant shall pay (i) the fee for such inspection, and (ii) except as may be otherwise expressly provided in this Amendment, the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the Currently Existing Premises.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">9.3</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Parking</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;white-space:pre-wrap;">.  Effective as of the Reduction Effective Date, </font><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.9</u><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> of the Lease (as amended prior to the date hereof) is hereby amended and restated as the following:</font></p></td></tr></table><div style="padding-left:25.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:94.57%;"><tr><td style="vertical-align:top;width:35.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:10.6pt;margin:12pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:25.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;1.9</font></font><font style="font-family:'Times New Roman','Times','serif';">Parking:</font></p></td><td style="vertical-align:top;width:64.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">86 unreserved parking spaces, at the rate of $0.00 per space per month, as such rate may be adjusted from time to time to reflect Landlord&#8217;s then current rates.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Five (5) reserved parking space, as shown on </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit G</b><font style="font-family:'Times New Roman','Times','serif';"> to the Fourth Amendment, at the rate of $0.00 per space per month, as such rate may be adjusted from time to time to reflect Landlord&#8217;s then current rates.&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">9.4</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Deletions</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;</font><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> of the Second Amendment (entitled, Right of First Offer), as amended prior to the date hereof, is hereby deleted from the Lease and is of no further force or effect. &#160;</font><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> of the Fourth Amendment (entitled, Second Extension Option), as amended prior to the date hereof, is hereby deleted from the Lease and is of no further force or effect.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">9.5 </font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Address of Landlord</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;The address of Landlord set forth in Section 1.11 of the Lease (as amended prior to the date hereof) is hereby amended and restated as follows:</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';">Hudson 333 Twin Dolphin Plaza, LLC </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">c/o Hudson Pacific Properties</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">555 Twin Dolphin Drive, Suite 180</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Redwood City, California &#160;94065</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: &#160;Building manager</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">with copies to</u><font style="font-family:'Times New Roman','Times','serif';">:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Hudson 333 Twin Dolphin Plaza, LLC </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">c/o Hudson Pacific Properties</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">333 Twin Dolphin Drive, Suite 100</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Redwood City, California &#160;94065</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: &#160;Managing Counsel</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">and</u><font style="font-family:'Times New Roman','Times','serif';">:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Hudson 333 Twin Dolphin Plaza, LLC </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">c/o Hudson Pacific Properties</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">11601 Wilshire Boulevard, Suite 900</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Los Angeles, California 90025</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: &#160;Lease Administration&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous.</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">This Amendment </font><font style="font-family:'Times New Roman','Times','serif';">and the attached exhibits, which are hereby incorporated into and made a part of this Amendment, </font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">set forth the entire agreement between the parties with respect to the matters set forth herein. &#160;There have been no additional oral or written representations or agreements. &#160;Tenant shall not be entitled, in connection with entering into this Amendment, to any free rent, allowance, alteration, improvement or similar economic incentive to which Tenant may have been entitled in connection with entering into the Lease, except as may be otherwise expressly provided in this Amendment.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. &#160;Landlord shall not be bound by this Amendment until Landlord has executed and delivered it to Tenant.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Each party hereto, and their respective successors and assigns shall be authorized to rely upon the signatures of all of the parties hereto which are delivered by facsimile, PDF or DocuSign (or the like) as constituting a duly authorized, irrevocable, actual, current delivery hereof with original ink signatures of each person and entity. &#160;This Amendment may be executed in counterparts, each of which shall be deemed an original part and all of which together shall constitute a single agreement.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Capitalized terms used but not defined in this Amendment shall have the meanings given in the Lease.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">10.7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Tenant shall indemnify and hold Landlord, its trustees, members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents harmless from all claims of any brokers (other than Newmark) claiming to have represented Tenant in connection with this Amendment. &#160;Landlord shall indemnify and hold Tenant, its trustees, members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents harmless from all claims of any brokers claiming to have represented Landlord in connection with this Amendment. &#160;Tenant acknowledges that any assistance rendered by any agent or employee of any affiliate of Landlord in connection with this Amendment has been made as an accommodation to Tenant solely in furtherance of consummating the transaction on behalf of Landlord, and not as agent for Tenant.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">[SIGNATURES ARE ON FOLLOWING PAGE]</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">IN WITNESS WHEREOF</b><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">, Landlord and Tenant have duly executed this Amendment as of the day and year first above written.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:101.15%;"><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">LANDLORD:</b></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">HUDSON 333 TWIN DOLPHIN PLAZA, LLC, a Delaware limited liability company</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By:</font></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Hudson Pacific Properties, L.P.,</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">a Maryland limited partnership,</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">its sole member</font></p></div></div></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:36pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Hudson Pacific Properties, Inc.,</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">a Maryland corporation,</font><font style="font-family:'Times New Roman','Times','serif';"><br></font><font style="font-family:'Times New Roman','Times','serif';">its general partner</font></p></div></div></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 35.1pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:72pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:35.1pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">By:</font></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">__</font><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Arther X. Suaso</u><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">__________</font></p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:72pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:35.1pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Name:</font></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arthur X. Suaso</u></p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:72pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:35.1pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">Title:</font></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><u style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Executive Vice President, Leasing</u></p></div></div></div></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TENANT:</b></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">COHERUS BIOSCIENCES, INC., a Delaware corporation</b><font style="font-family:'Times New Roman','Times','serif';"> </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">By:</font></font><font style="font-family:'Times New Roman','Times','serif';">_____</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Dennis M. Lanfear</u><font style="font-family:'Times New Roman','Times','serif';">__________</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Name:</font></font><font style="font-family:'Times New Roman','Times','serif';"> </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dennis M. Lanfear</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Title:</font></font><font style="font-family:'Times New Roman','Times','serif';"> </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chief Executive Officer</u></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:38.21%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:61.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OUTLINE AND LOCATION OF REDUCTION SPACE</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">[***]</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8
<SEQUENCE>8
<FILENAME>chrs-20231231xex8.htm
<DESCRIPTION>EX-10_37
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;font-weight:bold;">EXHIBIT 10.37</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;font-weight:bold;">[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;">Amendment to and Waiver under Exclusive License and Commercialization Agreement</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">This Amendment to and Waiver under the Exclusive License and Commercialization Agreement (this &#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;) is made and entered into as of October 25, 2023, by and between Shanghai Junshi Biosciences Co., Ltd. (&#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Junshi</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;) and Coherus BioSciences, Inc. (&#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Coherus</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;). &#160;Each of Junshi and Coherus is sometimes referred to herein, individually, as a &#8220;Party&#8221; and, collectively as the &#8220;Parties.&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;">Whereas, </font><font style="font-family:'Calibri','Helvetica','sans-serif';">[***];</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;">Whereas, </font><font style="font-family:'Calibri','Helvetica','sans-serif';">[***]; and,</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;">Whereas, </font><font style="font-family:'Calibri','Helvetica','sans-serif';">Coherus desires to amend the due date for a milestone payment and [***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;">Now, therefore</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, in consideration of the foregoing and such other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incorporation of the Agreement</u><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: &#160;To the extent any terms and provisions of the Agreement are inconsistent with the amendments set forth in paragraphs 2 and 3 below, such terms and provisions shall be deemed superseded hereby. Except as specifically set forth herein, the Agreement shall remain in full force and effect and its provisions shall be binding on the Parties.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><u style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of the Agreement</u><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">: &#160;The timing for the due date of Milestone Event No. 2 set forth in Table 8.3(a) of the Agreement &#8211; Regulatory and Sales Milestones for the PD1 Program is hereby amended by adding the following new material to the end of the text of clause (a) of Section 8.3 of the Agreement immediately preceding such table (with new material added underlined): </font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 36pt 0pt 72pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">For the PD1 Program</b><font style="font-family:'Calibri','Helvetica','sans-serif';">. Coherus will make the one-time milestone payments set forth in </font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Table 8.3(a)</u><font style="font-family:'Calibri','Helvetica','sans-serif';"> of the Agreement </font><font style="font-family:'Calibri','Helvetica','sans-serif';">upon the first achievement by Coherus or its Affiliates or Sublicensees of the corresponding milestone event by the first</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> Licensed Product that contains a Licensed Antibody described in clause (a) of the definition of Licensed Antibody</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, provided that such payment for Milestone Event No. 2 will be payable upon the later of (i</font><font style="font-family:'Calibri','Helvetica','sans-serif';">) </font><font style="font-family:'Calibri','Helvetica','sans-serif';">actual receipt of such first Regulatory Approval from FDA and </font><font style="font-family:'Calibri','Helvetica','sans-serif';">(ii) </font><font style="font-family:'Calibri','Helvetica','sans-serif';">[***], and in case of (i) or (ii), such payment would become due on [***], assuming such first Regulatory Approval from the FDA is obtained by [***].&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">[***]</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Calibri','Helvetica','sans-serif';">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effectuation</u><font style="font-family:'Calibri','Helvetica','sans-serif';">: &#160;The amendment to and waiver under the Agreement contemplated by this Amendment shall be deemed effective as of the date first written above upon the full execution and delivery of this Amendment and without any further action required by the Parties. </font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Calibri','Helvetica','sans-serif';">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-family:'Calibri','Helvetica','sans-serif';">: &#160;This Amendment may be executed in two counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument. One or more counterparts of this Amendment may be delivered by facsimile or electronic mail, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof.</font></p></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">[</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;font-weight:bold;">signature page follows</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">]</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;line-height:1.28;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-variant:small-caps;">In Witness Whereof,</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> the Parties have executed this Amendment by their duly authorized representatives.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-variant:small-caps;">Shanghai Junshi Biosciences Co., Ltd.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-variant:small-caps;">Coherus Biosciences, Inc.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">By:  ____</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Dr. Ning Li</u>_________________</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">By:  _</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ McDavid Stilwell</u>_________________</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Name: Dr. Ning Li</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Name: McDavid Stilwell</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Title: CEO</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Title: Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-9
<SEQUENCE>9
<FILENAME>chrs-20231231xex9.htm
<DESCRIPTION>EX-10_38
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:3pt 58.8pt 0pt 58.75pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">EXHIBIT 10.38</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 58.8pt 0pt 58.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 58.8pt 0pt 58.75pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">COHERUS BIOSCIENCES, INC.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 58.8pt 0pt 58.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">INSIDER TRADING COMPLIANCE POLICY AND PROCEDURES</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:6pt 58.8pt 0pt 58.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Effective February 27, 2023</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:6.5pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:35pt;padding:0pt;">I.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUMMARY</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.75pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Federal and state laws prohibit trading in the securities of a company while in possession of material non-public information and in breach of a duty of trust or confidence. These laws &#160;also prohibit anyone who is aware of material non-public information from providing this information to others who may trade. &#160;Violating such laws can undermine investor trust, harm &#160;the reputation and integrity of Coherus BioSciences, Inc. (together with its subsidiaries, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), and result in dismissal from the Company or even serious criminal and civil charges against the individual and the Company. The Company reserves the right to take whatever disciplinary or other measure(s) it determines in its sole discretion to be appropriate in any particular situation, including disclosure of wrongdoing to governmental</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">authorities.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.75pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Insider Trading Compliance Policy and Procedures (this &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) applies to all officers, directors and employees of the Company. &#160;For purposes of this Policy, &#8220;officers&#8221; refer &#160;to those individuals who meet the definition of &#8220;officer&#8221; under Section 16 of the Securities Exchange Act of 1934 (as amended, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Individuals subject to this Policy are responsible for ensuring that members of their household comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, limited liability companies, partnerships or trusts, and transactions by these entities should be treated for the purposes of this Policy as if they were for the individual&#8217;s own account. The Company may determine that this Policy applies to additional persons with access &#160;to material non-public information, such as contractors or consultants. Officers, directors and employees, together with any other person designated as being subject to this Policy by the Chief Legal Officer or his or her designee (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance Officer</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), are referred to collectively as &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Persons</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.9pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Questions regarding the Policy should be directed to the Compliance Officer, who is responsible for the administration of this Policy.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">II.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">STATEMENT OF POLICIES PROHIBITING INSIDER</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRADING</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.85pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No Covered Person shall purchase or sell any type of security while in possession of material non-public information relating to the security or the issuer of such security in breach of a duty of trust or confidence, whether the issuer of such security is the Company or any other company. In addition, if a Covered Person is in possession of material non-public information about other publicly-traded companies, such as suppliers, customers, competitors or potential acquisition targets, the Covered Person may not trade in such other companies&#8217; securities until the information becomes public or is no longer material. Further, no Covered Person shall purchase or sell any security of any other company, including another company in the Company&#8217;s industry, while in possession of material non-public information if such information is obtained in the course of the Covered Person&#8217;s employment or service with the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Company.</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.43%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:3pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In addition, Covered Persons shall not directly or indirectly communicate material non- public information to anyone outside the Company (except in accordance with the Company&#8217;s policies regarding confidential information) or to anyone within the Company other than on a &#8220;need-to-know&#8221; basis.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:35.9pt;padding:0pt;">III.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXPLANATION OF INSIDER</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRADING</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; includes stocks, bonds, notes, debentures, options, warrants, equity and other convertible securities, as well as derivative</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">instruments.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.8pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;Purchase&#8221; and &#8220;sale&#8221; are defined broadly under the federal securities law. &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale</b><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">&#8221; </i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">includes not only the actual sale of a security, but any contract to sell &#160;or otherwise dispose of a security. These definitions extend to a broad range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, transfers, gifts and acquisitions and exercises of warrants or puts, calls, pledging and margin loans or other derivative</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">securities.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Information is considered &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">material</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security, or if the information is likely to have a significant effect on the market price of the security. Material information can be positive or negative, and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt, or equity. Also, information that something is likely to happen in the future&#8212;or even just that it may happen&#8212;could be deemed material.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Examples of material information may include (but are not limited to) information about: corporate earnings or earnings forecasts; dividends; possible mergers, acquisitions, tender offers or dispositions; major new products or product developments; important business developments, such as major contract awards or cancellations and developments regarding strategic collaborations; management or control changes; significant borrowing or financing developments, including pending public sales or offerings of debt or equity securities; defaults &#160;on borrowings; bankruptcies; the results of clinical trials; U.S. Food and Drug Administration and foreign regulatory approvals; cybersecurity or data security incidents; and significant litigation or regulatory actions.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:35.95pt;padding:0pt;">IV.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">STATEMENT OF PROCEDURES PREVENTING INSIDER</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRADING</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading. Every officer, director and employee is required to follow these procedures.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blackout</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Periods</u></td></tr></table><p style="font-family:'Aptos';font-size:8pt;line-height:13.8pt;text-align:justify;text-indent:36pt;margin:6.15pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">director, officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">employee </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">listed </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">I</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, as </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">amended from time </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">time, (as well </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">any </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">individual </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">entity covered </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this Policy </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">virtue </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">their </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">relationship </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">such </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">director, officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">employee) </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">shall </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">purchase </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">sell any </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">security </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">during the period </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">beginning </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">at </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">11:59 </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">pm PT on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">22</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;vertical-align:super;">nd </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">calendar </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">day </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">last </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">month </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">any fiscal quarter </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">ending </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">after completion </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">second </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">full trading day after </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">public </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">release </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">earnings data </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">for</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.43%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:3pt 5.65pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">such fiscal </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">quarter </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">during any other </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">trading suspension period declared </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">such period, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">blackout </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">period</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">.&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">A </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">&#8220;trading </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">day&#8221; </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">day </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">which U.S. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">national </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">stock exchanges </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">open for </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">trading. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">If, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">for </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">example, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">were </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">make </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">announcement </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Monday </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">prior </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">9:30 a.m. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Eastern </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Time, then </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">blackout period </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">would </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">terminate </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">after </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">close </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">trading on</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Tuesday. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">announcement were made </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Monday after </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">9:30 a.m. Eastern Time, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">then the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">blackout </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">period would </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">terminate after </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the close </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">trading </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Wednesday. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">you have any </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">question </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">whether information </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">publicly available, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">please direct </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">inquiry </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Compliance Officer.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:5.94pt 0pt 0pt 42pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">These prohibitions do not apply to:</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">purchases of the Company&#8217;s securities from the Company, or sales of the Company&#8217;s securities to the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Company;</font></td><td style="width:5.95pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:5.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or vesting of equity-based awards, in each case, that do not involve a market sale of the Company&#8217;s securities (the &#8220;cashless exercise&#8221; of a Company stock option or other equity award through a broker does involve a market sale of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Company&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">securities,</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">therefore</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">would</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">qualify</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">under</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">exception);</font></td><td style="width:5.8pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:5.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">purchases of the Company&#8217;s common stock in accordance with the Company&#8217;s 2014 Employee Stock Purchase Plan and the applicable equity award</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.95pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">agreement;</font></td><td style="width:5.9pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:5.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">bona fide </i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">gifts of the Company&#8217;s securities, unless the individual making the gift knows, or is reckless in not knowing, the recipient intends to sell the securities while the donor is in possession of material non-public information about the Company; and</font></td><td style="width:5.85pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:5.94pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:60pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">purchases or sales of the Company&#8217;s securities made pursuant to a plan adopted to comply with the Exchange Act Rule 10b5-1 (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10b5-1</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8221;).</font></td><td style="width:5.95pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Exceptions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">blackout </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">period policy may </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">be </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">approved only by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Compliance Officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or Chief Financial Officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">or, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">case </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">exceptions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">for </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">directors, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Board </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Directors.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.75pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">The </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Compliance Officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">may </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">recommend </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">that </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">directors, officers, employees </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">others </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">suspend trading </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company securities because </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">developments </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">that have not yet been </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">disclosed </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">public. Subject </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">exceptions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">noted </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">above, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">all </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">those </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">individuals affected should </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">not </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">trade</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company&#8217;s securities </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">while </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">suspension </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">effect </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">should </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">not </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">disclose </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">others that </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Company </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">has </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">suspended</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">trading.</font></p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preclearance of Trades by Directors, Officers and</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employees</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.7pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">All </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">transactions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company&#8217;s securities </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">directors, officers, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">employees </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">listed </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">II </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">(each, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preclearance </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">&#8221;) </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">must </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">be </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">precleared </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Compliance Officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Chief </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Financial Officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">for </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">transactions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Compliance Officer.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Preclearance should not be understood to represent legal advice by the company that a proposed transaction complies with the law.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">A request for preclearance must be in writing, should be made at least two business days in advance of the proposed transaction, and should include the identity of the Preclearance Person, a description of the proposed transaction, the proposed date of the transaction and the</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.43%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:3pt 5.8pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">number of shares or other securities involved. In addition, the Preclearance Person must execute a certification that he or she is not aware of material non-public information about the Company. The Compliance Officer, or the Chief Financial Officer for transactions by the Compliance Officer, shall have sole discretion to decide whether to clear any contemplated transaction. All trades that are precleared must be effected within five business days of receipt of the preclearance. A precleared trade (or any portion of a precleared trade) that has not been effected during the five business day period must be submitted for preclearance determination again prior to execution. Notwithstanding receipt of preclearance, if the Preclearance Person becomes aware of material non-public information, or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed. Transactions under a previously established Rule 10b5-1 Trading Plan that has been preapproved in accordance with this Policy are not subject to further</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">preclearance.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.85pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">None of the Company, the Compliance Officer or the Company&#8217;s other employees will have any liability for any delay in reviewing, or refusal of, a request for preclearance.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Termination</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If an individual is in possession of material non-public information when the individual&#8217;s service terminates, the individual may not trade in the Company&#8217;s securities until that information</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">become</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">public</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">no</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">longer</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">material.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Information Relating to the</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Access to material non-public information about the Company, including the Company&#8217;s business, earnings or prospects, should be limited to officers, directors and employees of the Company on a need-to-know basis. &#160;In addition, such information should not be communicated &#160;to anyone outside the Company under any circumstances (except in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of Company information)</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">anyone</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">within</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Company</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">an</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">other</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">than</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">need-to-know</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">basis.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.9pt 5.8pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In communicating material non-public information to employees of the Company, all officers, directors and employees must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#8217;s policies with regard to confidential information.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.85pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">V.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PROHIBITED</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRANSACTIONS</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Company has determined that there is a heightened legal risk and the appearance of improper or inappropriate conduct if persons subject to this Policy engage in certain types of transactions. Therefore, Covered Persons shall comply with the following policies with respect &#160;to certain transactions in the Company&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">securities:</font></p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Short</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sales</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.75pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Short sales of the Company&#8217;s securities are prohibited by this Policy. Short sales of the Company&#8217;s securities, or sales of shares that the insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale, evidence an expectation on the part of the seller that the securities will decline in value, and, therefore, signal to the market that the seller has no confidence in the Company or its &#160;short-term</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.43%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:3pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">prospects. In addition, Section 16(c) of the Exchange Act prohibits Section 16 reporting persons (i.e., directors, officers and the Company&#8217;s 10% stockholders) from making short sales of the Company&#8217;s equity securities.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.65pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Transactions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">puts, calls </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">other derivative securities involving </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Company&#8217;s equity </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">securities, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">exchange, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">over-the-counter market </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">any other organized </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">market, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">are </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">prohibited </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Policy. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">A </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">transaction </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">options </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">is, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">effect, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">bet </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">short-term </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">movement </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company&#8217;s </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">stock and, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">therefore, creates </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">appearance </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">that </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Covered Person </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">is </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">trading </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">based </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">material non-public information. Transactions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">options, whether </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">traded </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">exchange, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on an </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">over-the-counter </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">market </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">any other </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">organized </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">market, also may focus </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Covered </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Person&#8217;s &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">attention </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">on </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">short-term performance </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">at </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the expense </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the Company&#8217;s long-term</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">objectives.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hedging</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transactions</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.75pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Hedging transactions involving </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company&#8217;s securities, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">such </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">prepaid </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">variable </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">forward </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">contracts, equity </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">swaps, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">collars </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">exchange </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">funds, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">other transactions that hedge </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">offset, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">are </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">designed </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">hedge </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">offset, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">any </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">decrease </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">market value </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Company&#8217;s equity </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">securities, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">are </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">prohibited </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Policy.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Such </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">transactions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">allow the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Covered </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Person </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">continue </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">own </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">covered securities </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">but </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">without </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the full </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">risks </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">rewards </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">ownership.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">When that </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">occurs, &#160;the Covered </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Person may </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">no </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">longer have </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">same </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">objectives </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Company&#8217;s </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">other stockholders.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Margin Accounts and</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pledging</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Individuals are prohibited from pledging Company securities as collateral for a loan, purchasing Company securities on margin (i.e., borrowing money to purchase the securities) or placing Company securities in a margin account. This prohibition does not apply to cashless exercises of stock options under the Company&#8217;s equity plans, nor to situations approved in advance by the Compliance Officer.</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partnership</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Distributions</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.9pt 5.8pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Nothing in this Policy is intended to limit the ability of an investment fund, venture capital partnership or other similar entity with which a director is affiliated to distribute Company securities to its partners, members or other similar persons. It is the responsibility of each affected director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances, and applicable securities laws.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.85pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">VI.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RULE 10b5-1 TRADING</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PLANS</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.75pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The trading restrictions set forth in this Policy, other than those transactions described under &#8220;V. Prohibited Transactions,&#8221; do not apply to transactions under a previously established contract, plan or instruction to trade in the Company&#8217;s securities entered into in accordance with Rule 10b5-1 (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Plan</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) that:</font></p><div style="margin-top:5.94pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:35pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">has been submitted to and preapproved by the Compliance</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Officer;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:5.94pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">includes a &#8220;Cooling Off Period&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">for:</font></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.43%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3.15pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:13.8pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:77pt;"></td><td style="font-family:'Courier New';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Section 16 reporting persons that extends to the later of 90 days after adoption or modification of a Trading Plan or two business days after &#160;filing the Form 10-K or Form 10-Q covering the fiscal quarter in which &#160;the Trading Plan was adopted, up to a maximum of 120 days;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font></td><td style="width:5.9pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.44pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:13.8pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:77pt;"></td><td style="font-family:'Courier New';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">employees and any other persons, other than the Company, that extends 30 days after adoption or modification of a Trading</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Plan;</font></td><td style="width:5.85pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.25pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:41pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">for Section 16 reporting persons, includes a representation in the Trading Plan &#160;that the Section 16 reporting person is (1) not aware of any material non-public information about the Company or its securities; and (2) adopting the Trading &#160;Plan</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">good</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">faith</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">not</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">as</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">part</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">plan</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">scheme</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">evade</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Rule</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10b-5;</font></td><td style="width:5.8pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.44pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:41pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">has been entered into in good faith at a time when the individual was not in possession of material non-public information about the Company and not otherwise in a blackout period, and the person who entered into the Trading Plan has acted in good faith with respect to the Trading</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Plan;</font></td><td style="width:5.8pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.4pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:41pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">either (1) specifies the amounts, prices and dates of all transactions under the Trading Plan; or (2) provides a written formula, algorithm or computer program for determining the amount, price and date of the transactions, and (3) prohibits the individual from exercising any subsequent influence over the transactions;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font></td><td style="width:5.85pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.44pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:41pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">complies with all other applicable requirements of Rule</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10b5-1.</font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:11.89pt 5.8pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Compliance Officer may impose such other conditions on the implementation and operation of the Trading Plan as the Compliance Officer deems necessary or advisable. Individuals may not adopt more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 and subject to preapproval by the Compliance Officer.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.85pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">An individual may only modify a Trading Plan outside of a blackout period and, in any event, when the individual does not possess material non-public information. Modifications to and terminations of a Trading Plan are subject to preapproval by the Compliance Officer, and modifications of a Trading Plan that change the amount, price or timing of the purchase or sale &#160;of the securities underlying a Trading Plan will trigger a new Cooling-Off</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Period.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.75pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Company reserves the right to publicly disclose, announce, or respond to inquiries from the media regarding the adoption, modification, or termination of a Trading Plan and non- Rule 10b5-1 trading arrangements, or the execution of transactions made under a Trading Plan. The Company also reserves the right from time to time to suspend, discontinue or otherwise prohibit transactions under a Trading Plan if the Compliance Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.8pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Compliance of a Trading Plan with the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, and none of the Company, the Compliance Officer or the Company&#8217;s other employees assumes any liability for any delay in reviewing and/or refusing to approve a &#160;Trading</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:3pt 5.75pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Plan submitted for approval, nor the legality or consequences relating to a person entering into, informing the Company of or trading under, a Trading Plan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.5pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:17pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;margin-bottom:0pt;margin-top:0pt;min-height:19.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">VII.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INTERPRETATION, AMENDMENT </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AND </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IMPLEMENTATION </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OF </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">THIS POLICY </u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">The</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">Compliance</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">Officer</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">have</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">authority</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">interpret</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">update</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">this</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">Policy</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">all</font></td><td style="width:6.05pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 5.75pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">related policies </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">procedures.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">particular, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">such </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">interpretations </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">and updates </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Policy, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">authorized </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Compliance Officer, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">may </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">include amendments </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">departures </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">from the terms </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Policy, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the extent </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">consistent </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">with the general </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">purpose </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this Policy </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">applicable </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">securities </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">laws.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:6pt 5.85pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Actions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">taken </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">by </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Company, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Compliance Officer </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">any </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">other </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Company </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">personnel </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">do </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">not </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">constitute </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">legal </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">advice, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">nor </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">do </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">they </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">insulate </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">you from </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">consequences </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">noncompliance with</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">Policy </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">with </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">securities laws.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:10.8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">VIII.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OF</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.3pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPLIANCE</u></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:5.94pt 5.75pt 0pt 5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">All </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">directors, officers, employees </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">and others </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">subject </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this Policy may </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">be </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">asked </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">periodically </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">to </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.2pt;">certify their compliance with </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">terms </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">provisions </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">of </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">this Policy </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">in </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">form attached hereto </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.45pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:14.05%;padding-right:14.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 179.8pt 0pt 179.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCHEDULE I</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.05pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:4.5pt 0pt 0pt 40.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">INDIVIDUALS SUBJECT TO QUARTERLY TRADING BLACKOUTS</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.5pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">All directors;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:11.89pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">All Section 16</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">officers;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">All employees;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:11.89pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Consultants specified by the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Company.</font></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:14.05%;margin-right:14.05%;margin-top:30pt;page-break-after:always;width:71.9%;border-width:0;"><div style="max-width:100%;padding-left:14.05%;padding-right:14.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 179.8pt 0pt 179.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCHEDULE II</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.05pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:4.5pt 0pt 0pt 51.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">INDIVIDUALS SUBJECT TO PRECLEARANCE REQUIREMENT</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.5pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">All directors;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:11.89pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">All Section 16</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">officers;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:11.94pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Employees specified by the Company;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:11.89pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Consultants specified by the</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-1.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Company.</font></td></tr></table><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:14.05%;margin-right:14.05%;margin-top:30pt;page-break-after:always;width:71.9%;border-width:0;"><div style="max-width:100%;padding-left:10.78%;padding-right:10.78%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 58.8pt 0pt 58.8pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTACHMENT A</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.3pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="position:relative;white-space:nowrap;"><div style="display:inline-block;padding-right:4.86%;vertical-align:top;white-space:normal;width:5.28%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.4pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">TO:</font></p></div><div style="display:inline-block;padding-left:4.86%;vertical-align:top;white-space:normal;width:85%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:4.5pt 72pt 0pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION OF COMPLIANCE</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:5.94pt 71.95pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">RETURN BY [</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:50.98pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">] </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">[insert return</i><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;"> </i><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">deadline]</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:5.94pt 0pt 0pt 6pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:104.95pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, Chief Legal Officer</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.78%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.43%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:5.94pt 0pt 0pt 6pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">FROM:</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:153pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:90pt;text-indent:-90pt;margin:5.94pt 5.95pt 0pt 5.94pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">RE:</font></font><font style="display:inline-block;width:0.05pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;white-space:pre-wrap;">INSIDER  TRADING  COMPLIANCE  POLICY  AND</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">PROCEDURES</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:2.8pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">OF</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">COHERUS BIOSCIENCES,</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">INC.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:13pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:10.8pt 5.85pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">I have received, reviewed and understand the above-referenced Insider Trading Compliance Policy and Procedures and undertake, as a condition to my present and continued employment (or, if I am not an employee, affiliation) with Coherus BioSciences, Inc., to comply fully with the policies and procedures contained therein.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:5.94pt 5.85pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">I hereby certify, to the best of my knowledge, that during the calendar year ending December 31, 20[ ], I have complied fully with all policies and procedures set forth in the above-referenced Insider Trading Compliance Policy and Procedures.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="height:1.5pt;left:0%;position:relative;top:0pt;width:163.5pt;z-index:251658240;"><div style="height:100%;left:0.75pt;padding-bottom:0.95pt;position:relative;width:162pt;"><img src="chrs-20231231xex9001.jpg" alt="Graphic" style="width:162pt;"></div></div><div style="height:1.5pt;left:46.15%;max-width:53.85%;position:relative;top:0pt;width:91.5pt;z-index:251660288;"><div style="height:100%;left:0.75pt;padding-bottom:0.95pt;position:relative;width:90pt;"><img src="chrs-20231231xex9002.jpg" alt="Graphic" style="width:90pt;"></div></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.3pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:12.35pt;margin:0pt 0pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">SIGNATURE</font><font style="display:inline-block;width:148pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">DATE</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="height:1.5pt;left:0%;position:relative;top:0pt;width:163.5pt;z-index:251662336;"><div style="height:100%;left:0.75pt;padding-bottom:0.95pt;position:relative;width:162pt;"><img src="chrs-20231231xex9001.jpg" alt="Graphic" style="width:162pt;"></div></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:12.35pt;margin:0pt 0pt 0pt 5.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">TITLE</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>10
<FILENAME>chrs-20231231xex10.htm
<DESCRIPTION>EX-10_39
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:40 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">EXHIBIT 10.39</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">December 7, 2023</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">McDavid Stilwell</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font>[***]<font style="font-family:'Arial','Helvetica','sans-serif';"><br></font>[***]</p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';letter-spacing:-0.1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:3.15pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Dear McDavid,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Your resignation from the position as Chief Financial Officer will be effective December 31, 2023 (the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Date</u><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;). &#160;This letter (the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;) provides information regarding the mutual separation package agreement offered to you by Coherus Biosciences, Inc. (the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;) should you agree to sign this Agreement. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">On the eighth day following your signing of this Agreement (after December 31, 2023), and provided it is not revoked as provided herein, (the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), you will be entitled to the severance detailed below, provided that you comply with the terms of the Agreement.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Wages, Accrued Unused PTO, and Business Expenses.</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"> &#160;Effective December 31, 2023, you will receive payment of wages through December 31, 2023, plus paid time off (&#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PTO</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">&#8221;) accrued but unused through the Separation Date. You may submit any business expenses incurred by you in accordance with the Company&#8217;s normal travel and expense policies no later than January 31, 2024, and the Company will promptly reimburse you for all documented and approved expenses. &#160;All items in this Section 1 will be paid to you regardless of whether you elect to sign this Agreement. &#160; </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Payments and Benefits.</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"> &#160;Provided you sign and do not revoke this Agreement, within 8 days after you return the signed Agreement to the Company (after December 31, 2023), you will be paid one year of additional pay, </font>[***]<font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"> in a lump sum (gross) but less applicable taxes and authorized withholdings (&#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Payment</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">&#8221;). Furthermore, if you timely elect to receive continuation of your healthcare benefits pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">&#8221;), the Company will pay for your COBRA premiums through December 31, 2024. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Options:</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;white-space:pre-wrap;">  The amount of stock options and restricted stock units that you would have vested through December 31, 2024, will vest immediately on December 31, 2023, and your exercise window will begin on January 1, 2024.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="padding-top:1.0px;border-top:3.0pt solid #7f350e;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;border-top:1.0pt solid #7f350e;margin:0pt;"><font style="color:#78206e;font-family:'Aptos Display';white-space:pre-wrap;">333 Twin Dolphin Drive, Suite 600, Redwood City, CA  94065  Main: 650.649.3530</font><font style="display:inline-block;width:0pt;"></font> <font style="color:#78206e;font-family:'Aptos Display';">Page </font><font style="color:#78206e;">1</font></p></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:130.8pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Release of Claims.</b></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;min-width:18pt;text-indent:0pt;white-space:nowrap;">A.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">Your Release of Claims.</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"> &#160;</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">You agree not to sue, or otherwise file any claim against, the Company or any of its directors, officers, managers, employees or agents for any reason whatsoever based on anything that has occurred as of the date you sign this Agreement.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">On behalf of yourself and your executors, administrators, heirs and assigns, you hereby release and forever discharge the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Releasees</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; hereunder, consisting of the Company, and each of its owners, directors, officers, managers, employees, representatives, agents, attorneys and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Claims</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), which you now have or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time through the Separation Date. Without limiting the generality of the foregoing, you hereby release and forever discharge the Releasees of and from any Claims arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever your employment by the Company, including, but not limited to, wage claims (base, bonus or commission), your termination of your position and your employment separation, including without limitation any and all claims arising under federal, state, or local laws relating to employment, claims of any kind that may be brought in any court or administrative agency, any claims arising under that Age Discrimination in Employment Act (&#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADEA</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;); Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1866; the Equal Pay Act; the Fair Labor Standards Act; the Employee Retirement Income Security Act; the Family Medical Leave Act; the California Fair Employment and Housing Act; the California Family Rights Act; the California Labor Code; the California Occupational Safety and Health Act; Section 17200 of the California Business and Professions Code; Claims arising under any other local, state or federal laws governing employment, including, but not limited to, the laws of California;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> Claims for breach of contract; Claims arising in tort, including, without limitation, Claims</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> of wrongful dismissal or discharge, failure to pay wages (base, bonus and commission), discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of good faith and fair dealing;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney&#8217;s fees</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">. Notwithstanding the generality of the foregoing, you do not release any claims that cannot be released as a matter of law, including, without limitation, claims for indemnity under California Labor Code Section 2802 and any policy of insurance carried by the Company, and your right to bring to the attention </font></td><td style="width:36pt;"></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="padding-top:1.0px;border-top:3.0pt solid #7f350e;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;border-top:1.0pt solid #7f350e;margin:0pt;"><font style="color:#78206e;font-family:'Aptos Display';white-space:pre-wrap;">333 Twin Dolphin Drive, Suite 600, Redwood City, CA  94065  Main: 650.649.3530</font><font style="display:inline-block;width:0pt;"></font> <font style="color:#78206e;font-family:'Aptos Display';">Page </font><font style="color:#78206e;">2</font></p></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:130.8pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">of the Equal Employment Opportunity Commission or the California Department of Fair Employment and Housing (or similar state agencies) administrative Claims of harassment, discrimination or retaliation; provided, however, that you release your right to secure damages as a remedy for any such administrative Claims.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td><td style="width:36pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Notwithstanding the generality of the foregoing in subsection a) above, you do not release any claims that cannot be released as a matter of law, including, without limitation, claims for indemnity under California Labor Code Section 2802 and any policy of insurance carried by the Company, and your right to bring to the attention of the Equal Employment Opportunity Commission or the California Department of Fair Employment and Housing (or similar state agency) administrative Claims of harassment, discrimination or retaliation; provided, however, that you release your right to secure damages as a remedy for any such administrative Claims.</font></td><td style="width:36pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;width:173.4pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">You have been advised of the following:</font></td><td style="width:36pt;"></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 36pt 0pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">i)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">You have the right to consult with an attorney before signing this Agreement.</font></td><td style="width:36pt;"></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">ii)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">You have seven (7) days after signing this Agreement to revoke your agreement to it, and the Agreement will not be effective, and you will not receive any of the Severance Payments or benefits outlined in Section 2 until that revocation period has expired. &#160;If you wish to revoke your acceptance of this Release, you must deliver such notice by email, to be received no later than 5:00 p.m. Pacific Time on the 7</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">th</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> day following your signature to Rebecca Sunshine, Chief Human Resources Officer, at </font><font style="font-family:'Aptos';font-size:11pt;font-style:normal;font-weight:normal;">[***]</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td><td style="width:36pt;"></td></tr></table><div style="margin-top:6pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><font style="display:inline-block;font-family:'Aptos';font-weight:bold;min-width:18pt;text-indent:0pt;white-space:nowrap;">B.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">The Company&#8217;s Release of Claims.</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;"> &#160;</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Except as provided in this Section 4(B), the Company agrees to release and not to sue, or otherwise file, any claim against You based on anything that has occurred as of the date You sign this Agreement. &#160;Notwithstanding the foregoing, the Parties agree that the Company specifically reserves any claims for misappropriation of trade secrets, embezzlement, </font><font style="color:#212121;font-family:'Arial','Helvetica','sans-serif';">clawbacks of compensation as required by law, the Company&#39;s Clawback Policy or applicable stock exchange rules, </font><font style="font-family:'Arial','Helvetica','sans-serif';">or willful misappropriation of Company funds.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><font style="display:inline-block;font-family:'Aptos';font-size:11pt;font-weight:bold;min-width:18pt;text-indent:0pt;white-space:nowrap;">C.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">YOU AND COMPANY ACKNOWLEDGE THAT YOU BOTH HAVE BEEN ADVISED OF AND ARE FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;width:36pt;"></font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">&quot;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&quot;</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="padding-top:1.0px;border-top:3.0pt solid #7f350e;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;border-top:1.0pt solid #7f350e;margin:0pt;"><font style="color:#78206e;font-family:'Aptos Display';white-space:pre-wrap;">333 Twin Dolphin Drive, Suite 600, Redwood City, CA  94065  Main: 650.649.3530</font><font style="display:inline-block;width:0pt;"></font> <font style="color:#78206e;font-family:'Aptos Display';">Page </font><font style="color:#78206e;">3</font></p></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:130.8pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BEING AWARE OF SAID CODE SECTION, YOU HEREBY EXPRESSLY WAIVE ANY RIGHTS YOU MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">5. </font><font style="display:inline-block;width:23.77pt;"></font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee&#8217;s Representations</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">.</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;white-space:pre-wrap;">  You represent and warrant that:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a)</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">You have returned to the Company all Company property in your possession, including all confidential information that you received while at the Company and/or created for the purposes of your employment while at the Company.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b)</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">You are not owed wages, commissions, bonuses or other compensation, other than as set forth in Section 1-3, above.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c)</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">During the course of your employment, you did not sustain any injuries for which you might be entitled to compensation pursuant to worker&#8217;s compensation laws.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:36pt;text-align:justify;text-indent:-36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d)</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;">You have not initiated any adversarial proceedings of any kind against the Company or against any other person or entity released herein, nor will you do so in the future, except as specifically allowed by this Agreement.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">6.</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-disparagement; Neutral Reference</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">.</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#160;</font>[***]</p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">7.</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintaining Confidential Information</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">. &#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">You will abide by all of your confidentiality obligations to the Company, including those outlined in your Proprietary Information and Inventions Agreement (PIIA) that you entered at the start of your employment with the Company, </font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">see, e.g., </i><font style="font-family:'Arial','Helvetica','sans-serif';">Sections 1, 2 (Proprietary Information, Recognition of Company&#8217;s Rights; Nondisclosure), and Section 10 (Additional Activities).</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;</u><font style="font-family:'Arial','Helvetica','sans-serif';">You will not disclose any confidential information you acquired while an employee of the Company to any other person or use such information in any manner. This includes any confidential information that you created for purposes of your employment at the Company. &#160;For the purposes of this Agreement, confidential information and proprietary information, as defined in the PIIA, are interchangeable. &#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">8. &#160;</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Separation Information</b><font style="font-family:'Arial','Helvetica','sans-serif';">. &#160;Employee and Company agree that the existence of the Agreement, the terms and conditions of this Agreement and any discussions between employee and the Company that led to the terms and conditions of this Agreement are confidential and will not be disclosed to any other person. &#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">9. </font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation with the Company</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">.</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#160;You will cooperate fully with the Company in its defense of or other participation in any administrative, judicial or other proceeding arising from any charge, complaint or other action that has been or may be filed. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">10. &#160;</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Violation of Agreement.</b><font style="font-family:'Arial','Helvetica','sans-serif';"> You understand that any violation of any of Your obligations under this Agreement, will result in this Agreement being deemed null and void, and may require you to repay to the Company any Severance Payments or other benefits you received hereunder.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="padding-top:1.0px;border-top:3.0pt solid #7f350e;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;border-top:1.0pt solid #7f350e;margin:0pt;"><font style="color:#78206e;font-family:'Aptos Display';white-space:pre-wrap;">333 Twin Dolphin Drive, Suite 600, Redwood City, CA  94065  Main: 650.649.3530</font><font style="display:inline-block;width:0pt;"></font> <font style="color:#78206e;font-family:'Aptos Display';">Page </font><font style="color:#78206e;">4</font></p></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:130.8pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">11.</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voluntary and Knowing Agreement</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">. &#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">You represent that you have thoroughly read and considered all aspects of this Agreement, that you understand all its provisions and that you are voluntarily accepting its terms. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">12.</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</b><font style="font-family:'Arial','Helvetica','sans-serif';">. &#160;To the extent that any reimbursements under this Agreement are subject to the provisions of Section 409A of the Code, any such reimbursements payable to you shall be paid to you no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and your right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. &#160; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">13.</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Amendment</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">. &#160;</b><font style="font-family:'Arial','Helvetica','sans-serif';">This Agreement sets forth the entire agreement between you and the Company and supersedes any and all prior oral or written agreements or understanding between you and the Company concerning the terms of your separation. &#160;This Agreement may not be altered, amended or modified, except by a further written document signed by you and the Company. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">14.</font></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law/Venue</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">.</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#160;To the greatest extent allowed by law, this Agreement will be governed in all respects by the laws of the State of California without giving effect to any choice of law rules that would dictate application of the laws of a different jurisdiction. &#160; The parties agree that, to the greatest extent allowed by law, any dispute between them related in any way to this Agreement will be brought in the state or federal courts in San Mateo County. &#160;The parties specifically consent to the sole jurisdiction of such courts. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Kindly sign where indicated below, and return this letter to Rebecca Sunshine, Chief Human Resources Officer, by </font>[***]<font style="font-family:'Arial','Helvetica','sans-serif';">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 8pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 8pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Sincerely,</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 8pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Rebecca Sunshine</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:normal;">Rebecca Sunshine</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:normal;">Chief Human Resources Officer</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 8pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Accepted and agreed to on this __</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11th</u><font style="font-family:'Arial','Helvetica','sans-serif';">_ day of ____</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">December</u><font style="font-family:'Arial','Helvetica','sans-serif';">_____ 2023.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';line-height:1.28;margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ McDavid Stilwell</u><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="bottom:2.8310547pt;display:inline-block;height:1em;width:85.26pt;border-bottom:1.0px solid #000000;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">McDavid Stilwell</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="padding-top:1.0px;border-top:3.0pt solid #7f350e;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;border-top:1.0pt solid #7f350e;margin:0pt;"><font style="color:#78206e;font-family:'Aptos Display';white-space:pre-wrap;">333 Twin Dolphin Drive, Suite 600, Redwood City, CA  94065  Main: 650.649.3530</font><font style="display:inline-block;width:0pt;"></font> <font style="color:#78206e;font-family:'Aptos Display';">Page </font><font style="color:#78206e;">5</font></p></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:130.8pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>11
<FILENAME>chrs-20231231xex10d40.htm
<DESCRIPTION>EX-10_40
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:43 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 10.40</b></p><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:middle;width:0.8%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:98.7%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.49%;margin:0pt;padding:1pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 2pt 1pt;"><p style="font-family:'Aptos';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY &#8220;[***]&#8221;, HAS BEEN EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT SURFACE ONCOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:6pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exclusive Product License Agreement</b></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Exclusive Product License Agreement (this &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) is made and entered into as of this 23</font><font style="font-family:'Times New Roman','Times','serif';">rd</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> day of March, 2021 (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) by and between Vaccinex, Inc.,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">having offices at 1895 Mt. Hope Avenue, Rochester NY 14620 USA (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vaccinex</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), and Surface Oncology, Inc. having offices at 50 Hampshire St, 8</font><font style="font-family:'Times New Roman','Times','serif';">th</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> Floor, Cambridge, MA 02139 (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). Vaccinex and Surface are sometimes referred to herein each individually as a &#8220;Party&#8221; and collectively as the &#8220;Parties.&#8221; </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">WHEREAS, the Parties have entered into a Collaboration Agreement (defined below), pursuant to which Vaccinex granted Surface the right to obtain a license to research, develop and commercialize Licensed Products (defined below);</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">WHEREAS, pursuant to the Collaboration Agreement, Surface has exercised a Product Option (as defined in the Collaboration Agreement) pursuant to which the Parties have agreed to enter into this Agreement setting forth the terms and conditions of the licenses;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">NOW, THEREFORE, the Parties hereby agree as follows: </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 1.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">DEFINITIONS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">For purposes of this Agreement, the following words and phrases will have the following meanings. All words and phrases not defined in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Definitions) will have the meanings ascribed to them in this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounting Standards</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, GAAP, as generally and consistently applied throughout the Party&#8217;s organization. Each Party shall promptly notify the other in the event that it changes the Accounting Standards pursuant to which its records are maintained, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that each Party may only use internationally recognized accounting principles (e.g., IFRS, GAAP, etc.).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to a Party, any corporate or other entity that, directly or indirectly, controls, is controlled by, or is under common control with such Party, where &#8220;control&#8221; means the ownership of not less than fifty percent (50%) of the voting shares of </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a corporation, or fifty percent (50%) of the decision-making authority as to such other unincorporated entity. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Challenge Action</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Surface&#8217;s Right to Enforce and Defend Patent Rights).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means that certain Antibody Selection Research Collaboration and License Option Agreement effective as of November 30, 2017 by and between Vaccinex and Surface, as the same may be amended from time to time a copy of which is attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Combination Product</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means a product or combination therapy that includes a Licensed Product and at least one (1) additional non-Licensed Product comprised of active ingredient(s), that is (are) either (i) co-formulated or administered through a single formulation, or (ii) administered separately but approved (or being developed for approval) for use in combination with the Licensed Product. Drug delivery vehicles, adjuvants and excipients will not be deemed &#8220;active ingredients,&#8221; except in the case where (a) in the case of a drug delivery vehicle or excipient, such delivery vehicle or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7), and if administered independently of the Licensed Product, would have a material clinical benefit (as shown by reasonable scientific evidence), or (b) in the case of an adjuvant, such adjuvant is (1) directly involved in the specific activation of any target affecting any innate immune pathway (as shown by reasonable scientific evidence), and (2) which activation itself produces a material clinical benefit (as shown by reasonable scientific evidence). For clarity, adjuvants that qualify under clause (b) above could include but are not limited to STING (stimulator of interferon genes) agonists and TLR (toll-like receptor) agonists administered alone or in combination with a cancer antigen, and adjuvants that act generally on innate immunity.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">f..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercially Reasonable Efforts</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means [***]. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">g..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Non-Disclosure)</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">h..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Control</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controls</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controlled</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to any intellectual property right (including any know-how, patent right or invention), the possession of (whether by ownership or license, other than pursuant to this Agreement) the ability of a party or its Affiliates to grant access to, or to grant a license or sublicense of, such right as provided for herein without violating the terms of any agreement or other arrangement with any third party existing at the time such party would be required hereunder to grant another person such access or license or sublicense.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">i..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cover</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means with respect to a particular item or method, any patent and/or know-how, that but for a license under or ownership right in such patent and/or know-how, the manufacture, use, offer for sale, sale, importation, duplication, distribution or other exploitation of such item (or any other item used in the manufacture, use, offer for sale, sale, importation, duplication, distribution or other exploitation thereof) or the practice of such </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">method (or the use of any item in the practice of such method), would infringe any patent and/or misappropriate any know-how (assuming, in the case of pending patent applications, that such pending patent applications were issued patents) in any of the countries of manufacture, use, offer for sale, sale, importation, duplication, distribution and/or other exploitation.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">j..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosing Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Non-Disclosure).</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">k..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the preamble.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">l..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Executive Officers</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, for Surface, its Chief Executive Officer, and for Vaccinex, its Chief Executive Officer, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that the foregoing individuals may designate the Chief Financial Officer or the Chief Operating Officer as his/her designee. In the event that the position of the Executive Officers identified in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.12</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> no longer exists due to a change of control, corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable Executive Officer will be replaced with another executive officer with responsibilities and seniority comparable to the eliminated Executive Officer.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">m..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the United States Food and Drug Administration, or any successor agency thereof.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">n..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Field</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means all human and animal prophylactic and therapeutic uses.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">o..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Commercial Sale</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to a Licensed Product in a country, the first sale for end use or consumption of such Licensed Product in such country after all Regulatory Approvals legally required for such sale have been granted by the regulatory authority of such country.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">p..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitee</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification Procedures).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">q..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitor</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification Procedures).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">r..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement Action</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Surface&#8217;s Right to Enforce and Defend Patent Rights).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">s..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringing Product</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Surface&#8217;s Right to Enforce and Defend Patent Rights).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">t..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Product</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any product (including a bi-specific or multi-specific antibody) that consists of or otherwise incorporates any Selected Antibody and/or any modification, variant, fragment, or derivative thereof, in each case, that includes one or more complementarity-determining regions of at least one variable region of such Selected Antibody including (i) any functional fragment of, pegylated version of (whether or not including amino acid changes) of a Selected Antibody and otherwise modified versions (including associated amino acid substitutions) of, a Selected Antibody, or (ii) an antibody designed using, or derived </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">from, some or all of the binding portion of any Selected Antibody (or the sequence coding for it). For the avoidance of doubt, a product that consists of a modified Selected Antibody that contains the same sequences for all six complementarity-determining regions as such Selected Antibody shall be considered the same Licensed Product for the purposes of this Agreement, except that a bi-specific or multi-specific antibody or drug conjugate with such same sequences shall be considered different Licensed Products. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">u..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means [***].</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">v..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New License Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Effect of Termination of Sublicensees).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">w..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Vaccinex Intellectual Property Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means rights in or to all intellectual property owned or Controlled by Vaccinex during the term of this Agreement, other than Vaccinex Program IP, that is required or reasonably necessary for the registration, clinical development, manufacture, use or sale of, or to otherwise exploit, the Selected Antibody, or any modification, variant or fragment thereof contained in a Licensed Product.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">x..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; have the meaning set forth in the preamble.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">y..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.7</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Withholding Taxes).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">z..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 1 Clinical Trial</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means either (i) a clinical study of a Licensed Product in human volunteers or patients with the primary objective of determining initial tolerance, safety and pharmacokinetic information in a single doses, single ascending dose, multiple dose or multiple ascending dose regimens as described in 21 C.F.R. &#167; 312.21(a), or (ii) a comparable human clinical trial of a Licensed Product prescribed by the relevant regulatory authority in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(a), or its foreign equivalent.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">aa..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 2 Clinical Trial</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means either (i) a clinical study of a Licensed Product in patients with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed tolerance, safety and pharmacokinetic information as described in 21 C.F.R. &#167; 312.21(b), or (ii) a comparable human clinical trial of a Licensed Product prescribed by the relevant regulatory authority in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(b), or its foreign equivalent.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ab.. &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 3 Clinical Trial</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means either (i) a clinical study of a Licensed Product in patients, conducted in accordance with a protocol designed to confirm statistical significance of efficacy and safety of a Licensed Product for the purpose of obtaining Regulatory Approval in any country as described in 21 C.F.R. &#167; 312.21(c), or (ii) a comparable human clinical trial of a Licensed Product prescribed by the relevant regulatory authority in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(c), or its foreign equivalent.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ac..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecute</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; or &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the preparation, filing, prosecution, issuance and maintenance of the Selected Antibody Patent Rights before the United States Patent and </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Trademark Office and foreign patent offices in connection with the Selected Antibody Patent Rights. Cognates of the word &#8220;Prosecution&#8221; have their correlative meanings.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ad..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receiving Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Non-Disclosure).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ae..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approval</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, with respect to a particular Licensed Product, receipt of all regulatory clearances, registrations, licenses, authorizations or approvals (which in the case of the European Union may be through the centralized procedure) required in the jurisdiction in question for the sale of the applicable Licensed Product or service in such jurisdiction, including receipt of pricing approval, if any, legally required for such sale.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">af..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the period beginning on the First Commercial Sale of such Licensed Product in such country and ending upon the later of (a) the expiration of the last Valid Claim included within the Vaccinex Program IP that Covers the composition of matter of such Licensed Product in the Territory (if any) and (b) the 10</font><font style="font-family:'Times New Roman','Times','serif';">th</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> anniversary of the First Commercial Sale of such Licensed Product in such country.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ag..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Selected Antibodies</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means antibodies delivered by Vaccinex to Surface pursuant to the Collaboration Agreement and described in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> hereof.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ah..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Selected Antibody Patent Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means (a) rights in or to all patents and patent applications included within the Vaccinex Program IP, owned or Controlled by Vaccinex during the Term that Cover the Selected Antibody, including those patents and patent applications listed in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">; (b) all patents or patent applications filed in any country in the Territory that claim priority to or the benefit of, or share common disclosure or common priority with, the patents and patent applications described in the foregoing clause (a), including all provisional or priority patent applications, divisionals, continuations, continuations-in-part (to the extent directed to the Selected Antibodies), reissues, renewals, reexaminations, supplementary protection certificates, international applications and utility models, and foreign counterparts thereof; (c) all patents granting from (a) and (b); (d) all extensions based on any of the foregoing; and (e) all rights corresponding to any of the foregoing throughout the world (including the right to claim the priority date of any of such patents and patent applications). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ai..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicense</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any agreement pursuant to which Surface or a Sublicensee grants a Third Party a sublicense under the Vaccinex Program IP or Other Vaccinex Intellectual Property Rights to make, have made, use, sell, offer to sell, import or otherwise exploit Licensed Products in the Field. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">aj..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensee</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any person or entity to whom Surface has granted a Sublicense under this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ak..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the preamble.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">al..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.7</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Withholding Taxes).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">am..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Term).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">an..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means worldwide.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ao..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means any person or entity other than Surface, Vaccinex, or the Affiliates of Surface or Vaccinex.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ap..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vaccinex</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the preamble.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">aq..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vaccinex Patent Expenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Reimbursement).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">ar..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vaccinex Program IP</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; has the meaning set forth in the Collaboration Agreement.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">as..&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valid Claim</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means (a) a claim of an issued patent, which claim has not (i) expired, lapsed, been canceled, dedicated to the public, disclaimed or become abandoned, (ii) been declared unpatentable, invalid, unenforceable, revoked, or canceled by a decision or judgment of a court or other appropriate body or authority of competent jurisdiction, or (iii) been admitted to be invalid or unenforceable, or (b) any claim in a pending patent application that has been filed and is being prosecuted in good faith and has not been cancelled, withdrawn from consideration, abandoned or finally disallowed without the possibility of appeal or refiling of the application and that has not been pending for more than seven (7) years from the earliest date from which the patent application claims priority. If such patent application has been re-filed or is a divisional application, the seven (7) year period mentioned above shall be calculated from the first application filed in the series of applications.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 2.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">GRANT</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Subject to the terms and conditions of this Agreement, Vaccinex hereby grants (and will cause its Affiliates to grant), and Surface hereby accepts (i) an exclusive, irrevocable (subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">), license, with the right to grant Sublicenses (as provided in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Right to Sublicense) hereof), under the Vaccinex Program IP, to make, have made, use, sell, offer to sell, have sold, import, export and otherwise exploit Licensed Products in the Field in the Territory, and (ii) a fully-paid up, irrevocable (subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">), license, with the right to grant Sublicenses (as provided in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Right to Sublicense) hereof), under the Other Vaccinex Intellectual Property Rights, to make, have made, use, sell, offer to sell, have sold, import, export and otherwise exploit Licensed Products in the Field in the Territory. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:47.3pt;text-align:justify;text-indent:-47.3pt;margin:0pt 0pt 12pt 60.7pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(i)</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Right to Sublicense</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Subject to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Sublicenses), Surface will have the right to grant Sublicenses of any and all of the rights licensed to Surface under this Agreement through multiple tiers to any Third Party. Surface will be responsible for enforcing each Sublicensee&#8217;s obligations that relate to this Agreement under each Sublicense that Surface executes and Surface shall remain responsible for any such Sublicensee&#8217;s performance hereunder and for all payments due to Vaccinex, including royalties or other payments due on Net Sales of Licensed Products or milestones achieved by Sublicensee. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:50.65pt;text-align:justify;text-indent:-50.65pt;margin:0pt 0pt 12pt 57.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(ii)</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Sublicense Provisions</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Sublicense will be subject to and consistent with the relevant terms and conditions of this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:53.95pt;text-align:justify;text-indent:-53.95pt;margin:0pt 0pt 0pt 54.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(iii)</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Copy of Sublicense</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface will promptly notify Vaccinex of any Sublicense and provide Vaccinex a true, correct and complete copy of the terms of each Sublicense that Surface enters into with a Third Party and any amendment thereto within [***] days following the execution of such Sublicense or amendment; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that Surface may redact from such copy any confidential terms of such Sublicense that relate to financial information or scientific or technical information specific to the Sublicensee&#8217;s compounds </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">or development plans, to the extent not reasonably necessary for Vaccinex to monitor compliance by Surface or such Sublicensee with the terms and conditions of this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights of Affiliates</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface may exercise its rights and perform its obligations under this Agreement either directly or through one or more of its Affiliates. Surface&#8217;s Affiliates will have the benefit of all rights (including all licenses) of Surface under this Agreement, subject to such Affiliates&#8217; compliance with the applicable obligations of Surface hereunder. Accordingly, in this Agreement &#8220;Surface&#8221; will be interpreted to mean &#8220;Surface or its Affiliates&#8221; where necessary to give Surface&#8217;s Affiliates the benefit of the rights provided to Surface in this Agreement</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">; provided, however,</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that in any event Surface will remain responsible for the acts and omissions, including financial liabilities, of its Affiliates and for such Affiliates&#8217; compliance with the applicable obligations of Surface hereunder. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicting Agreements</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Vaccinex will not grant licenses or other rights or interests in or under the Vaccinex Program IP to any Third Party and will not enter into any agreement with any Third Party that would conflict with or otherwise compromise the rights granted to Surface hereunder.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e.. </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Implied Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party acknowledges that the rights and licenses granted under this Agreement are limited to the scope expressly granted herein. Except for the rights expressly granted under this Agreement, no rights, title, licenses, or other interests of any nature whatsoever are granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party. Without limitation, none of the above licenses include the right to select antibodies other than Selected Antibodies. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 3.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">DUE DILIGENCE</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Obligation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface will use Commercially Reasonable Efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">least one Licensed Product in the Field in the Territory during the Term of this Agreement. Such diligence activities shall include, without way of limitation, Surface using Commercially Reasonable Efforts to file an IND in the U.S., Canada, the U.K., a country in the E.U., Australia or Japan (or requiring its Affiliates or Sublicensees to do so) within five (5) years of the Effective Date. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Reports</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface shall provide Vaccinex with (i) regular, and in any event not less than every six months, written high-level summary reports describing Surface&#8217;s progress on development of Licensed Products during the previous six months, and future development plans for the next six months, and (ii) an annual detailed report on Surface&#8217;s progress in meeting its obligations in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, including but not limited to a summary of the evaluations of Licensed Products performed, provided that such summary need not include results of such evaluations</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> and a development plan of Licensed Products indicating development progress to date as well as the projected timeline of expected achievement of milestones by Licensed Products. Vaccinex may </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">reasonably request additional related information in connection with the annual reports in order to establish satisfaction by Surface of its obligations under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;"> </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reversion</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If Surface materially breaches its obligations set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (General Obligations) and fails to cure such breach within [***] days after receiving written notice thereof from Vaccinex, then Vaccinex shall have the right to terminate this Agreement pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2(d)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Diligence Failure). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 4.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">LICENSE CONSIDERATION</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product License Fee</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Within ten (10) days following the Effective Date, Surface will pay to Vaccinex a fee of $850,000.</font></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Maintenance Fee</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Commencing on the third (3</font><font style="font-family:'Times New Roman','Times','serif';">rd</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">) anniversary of the Effective Date and each anniversary thereof occurring prior to the first dosing of the first human patient pursuant to the protocol in the first Phase 1 Clinical Trial for a Licensed Product, Surface will pay Vaccinex an annual maintenance fee according to the following schedule:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;Beginning with the third anniversary of the Effective Date, $[***];</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;Beginning with the fourth anniversary of the Effective Date, $[***];</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;Beginning with the fifth anniversary of the Effective Date, $[***];</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8226;Beginning on the sixth anniversary of the Effective Date, and for each anniversary thereafter, $[***].</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Such fees will accrue on the applicable anniversary date, and Surface will pay the applicable annual maintenance fee to Vaccinex within thirty (30) days following Surface&#8217;s receipt of Vaccinex&#8217;s invoice therefor. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Milestone Payments</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface will pay to Vaccinex the milestone payments set forth in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Milestone Payments) with respect to the first achievement of the relevant milestone event for each Licensed Product. Each milestone payment set forth in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Milestone Payments) is payable only once per Licensed Product, and the total payments payable under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Development Milestone Payments) will in no event exceed $15,000,000 per Licensed Product. The milestone payments will accrue upon the achievement of the applicable milestone event, and Surface will promptly notify Vaccinex of such achievement, and pay the associated milestone payment within thirty (30) days following achievement of each milestone event described in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Milestone Payments).</font></p><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:75.8%;"><tr><td style="vertical-align:middle;width:0.71%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:61.19%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.64%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.73%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:36.05%;margin:0pt;padding:1pt;"></td><td style="vertical-align:middle;width:0.64%;margin:0pt;padding:1pt;"></td></tr><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Milestone Event</i></p></td><td colspan="3" style="vertical-align:top;width:37.43%;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Milestone Payment</i></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(i) Upon first patient dosed in the first Phase 1 Clinical Trial.</font></p></td><td colspan="3" style="vertical-align:middle;width:37.43%;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$[***]</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(ii) Upon first patient dosed in the first Phase 2 Clinical Trial.</font></p></td><td colspan="3" style="vertical-align:middle;width:37.43%;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$[***]</font></p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:75.8%;"><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(iii) Upon first patient dosed in the first Phase 3 Clinical Trial.</font></p></td><td colspan="3" style="vertical-align:middle;width:37.43%;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$[***]</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(iv) Upon filing of a BLA with US FDA.</font></p></td><td colspan="3" style="vertical-align:middle;width:37.43%;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$[***]</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(v) Upon approval of the BLA by the US FDA.</font></p></td><td colspan="3" style="vertical-align:middle;width:37.43%;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 1.75pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$[***]</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:62.56%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 0.75pt 2pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(vi) Upon approval by the EMA.</font></p></td><td colspan="3" style="vertical-align:middle;width:37.43%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:2pt 1pt 2pt 1pt;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">$[***]</font></p></td></tr></table></div><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">For avoidance of doubt, a clinical trial that meets more than one definition of the type of clinical trial (such as a clinical trial with an adaptive design, which morphs from a Phase 1 Clinical Trial to a Phase 2 Clinical Trial), will be considered to be both of such clinical trials, and payment of all milestones achieved as a result of such consideration, will be due and owing.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalties</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:45pt;text-align:justify;text-indent:-45pt;margin:0pt 0pt 12pt 63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">1.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Royalty Payments</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Subject to the provisions of this Agreement, Surface will pay to Vaccinex, on a Licensed Product-by-Licensed Product basis during the Royalty Term for such Licensed Product, a royalty of [***] of Net Sales on Licensed Products sold in the Territory. Royalties will be due within [***] days after the end of each calendar quarter during which the royalties accrued.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">2.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Royalty Adjustments</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font><font style="font-family:'Times New Roman','Times','serif';">If Surface or any of its Affiliates reasonably determines, in consultation with Vaccinex, that a license under Third Party patent rights or know-how is necessary to exploit the Vaccinex Program IP to make, have made, use, sell, offer to sell, have sold, import, export and otherwise exploit Licensed Products in the Field in the Territory, and Surface pays royalties to one or more Third Parties for such license (collectively, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Royalties</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), then Surface will have the right to reduce the royalties otherwise due to Vaccinex </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';">pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(a)</u><font style="font-family:'Times New Roman','Times','serif';"> (Royalty Payments) hereof with respect to Net Sales of such Licensed Product, which requires use of such Third Party license, by applying a credit in an amount equal to [***] of the amount of such Third Party Royalties applicable to such Licensed Product; </font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';"> that the reductions to royalties provided in this </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(b)</u><font style="font-family:'Times New Roman','Times','serif';"> (Royalty Adjustments) will not reduce the royalties payable with respect to Net Sales of such Licensed Product during any calendar quarter of the applicable Royalty Term by more than [***] of the royalties otherwise owed to Vaccinex pursuant to </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(a)</u><font style="font-family:'Times New Roman','Times','serif';"> (Royalty Payments) hereof. Surface shall provide Vaccinex with documentation of its payment of Third Party Royalties with the affected royalty report that shows such reduction being applied. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. All payments pursuant to this Agreement will be paid in U.S. Dollars, without deduction or exchange, collection or other charges and made by wire transfer to such account as may be specified by Vaccinex to Surface in writing, and are non-refundable. When conversion of payments from any foreign currency is required to be undertaken by Surface, payments shall be converted into U.S. Dollars using the average of the daily exchange rates for such currency quoted by Citibank, N.A. for each of the last [***] banking days of each calendar quarter which is the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">reporting period. Any undisputed payments under this Agreement that are not made on or before the applicable due date shall bear interest at the lower of (a) the maximum rate permitted by applicable law and (b) the rate of [***] per annum above &#8220;Prime&#8221; as defined in </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">The Wall Street Journal</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> on the payment due date or, if unavailable, on the latest date prior to the payment due date on which such rate is available, calculated on a daily basis on the actual number of days elapsed from the payment due date to the date of actual payment. Surface shall be solely responsible for the payment of all royalties or other amounts, if any, which are payable to third parties arising out of the manufacture, importation, use, offer to sell or sale of Licensed Products. Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, such amounts paid shall not be deducted from any payments due hereunder. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">f..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoices</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. All invoices to Surface under this Agreement will be sent by Vaccinex electronically, via e-mail to [***], in PDF format, unless otherwise agreed by both Parties. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">g..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Taxes</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Vaccinex will be liable for all income and other taxes (including interest) (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) imposed upon any payments made by Surface to Vaccinex under this Agreement (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). If applicable laws, rules or regulations require the withholding of Taxes, Surface will make such withholding payments and will subtract the amount thereof from the Payments. Surface will submit to Vaccinex appropriate proof of payment of the withheld Taxes, as well as the official receipts, within [***] days. Surface will provide Vaccinex reasonable assistance in order to allow Vaccinex to obtain the benefit of any present or future treaty against double taxation which may apply to the Payments.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">h..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports, Information, and Inspection</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">1.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Reports</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each payment shall be accompanied by a report showing the associated facts that relate to the payment being made. Regarding Net Sales, the information shall be presented for the calendar quarter with </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">respect to which the report is delivered, broken down by the identity of the selling party or parties (Surface, its Affiliates, or any Sublicensee), on a country-by-country/region-by-region (to the extent available to Surface) and Licensed Product-by-Licensed Product basis, together with details of the quantities of Licensed Products sold and, the country of manufacture, if different (to the extent available to Surface), applicable offsets, withholding taxes, whether in Combination Products, the royalty due to Vaccinex, and other information as reasonably requested by Vaccinex and available to Surface. All such reports will be treated as the Confidential Information of Surface. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">2.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Notification of Marketing Approval</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface agrees to notify Vaccinex in writing within thirty (30) days after the date on which Surface, its Affiliates or Sublicensees obtains marketing approval of each Licensed Product in each country in the Territory and to promptly provide Vaccinex with a copy of such notice.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">3.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Records and Audit</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface agrees, and shall cause its Affiliates and Sublicensees, to keep accurate and complete records for a period of at least [***] years </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(or such longer period as may correspond to Surface&#39;s internal records retention policy) showing the status of development efforts, status of patient dosing, and the manufacturing, sales, use and other disposition of Licensed Products in sufficient detail to evaluate the compliance of Surface and that of its Affiliates and Sublicensees, with the obligations hereunder. Surface will, and shall cause its Affiliates and Sublicensees, to permit all relevant books and records to be audited by an independent accounting firm selected by Vaccinex and reasonably satisfactory to Surface, or Surface&#8217;s Affiliate or Sublicensee, as applicable, from time-to-time during regular business hours at such place or places where such records are customarily kept to the extent requested by Vaccinex, but not more than once a year, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that before beginning such audit, such independent accounting firm shall execute an agreement acceptable to Surface by which such independent accounting firm agrees to keep confidential all information reviewed during the audit. Vaccinex agrees to hold in strict confidence all information received and all information learned in the course of any audit, except to the extent necessary to comply with any law, regulation or judicial order. Such examination and audit is to be made at the expense of Vaccinex, except that it shall be at Surface&#8217;s expense if the results of the examination and audit reveal that Surface, its Affiliate or its Sublicensee underpaid Vaccinex by more than [***] for the year at issue.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 5.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">PATENT PROSECUTION</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution of Patent Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Reimbursement</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Within [***] days following the Effective Date, Vaccinex will submit to Surface (i) an invoice for any of its unreimbursed expenses (if any) incurred prior to the Effective Date and associated with Prosecution of Selected Antibody Patent Rights (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vaccinex Patent Expenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), and (ii) summary documentation of such Vaccinex Patent Expenses. Surface will pay the undisputed Vaccinex Patent Expenses to Vaccinex within thirty (30) days following Surface&#8217;s receipt of Vaccinex&#8217;s invoice and documentation therefore.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">5.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Direction of Prosecution</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. As of and after the Effective Date, Surface, at its sole expense and in the name of and with the cooperation of Vaccinex, hereby assumes the responsibility for and shall maintain all control, including the selection of counsel, over the Prosecution of the Selected Antibody Patent Rights. At a reasonable time prior to the contemplated filing date, but in any event not less than [***] days prior, Surface shall submit to Vaccinex for review and comment a substantially completed draft of any patent application hereunder before Surface&#8217;s first filing of such patent application in any jurisdiction, and Vaccinex agrees to review and provide such comments, if any, to Surface on an expedited basis if necessary to avoid loss of patent rights. All expenses of Prosecuting such patents and patent </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">applications shall be borne by Surface. Surface shall provide Vaccinex reports no less frequently than once per calendar year listing all patents and patent applications Prosecuted pursuant to the provisions hereof, including identification of the patents and patent applications by number and country, together with a brief description of the status of the prosecution or patent. Surface shall permit Vaccinex to review and comment on all patent applications, and related decisions and actions under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that Surface will have all final decision-making rights over Prosecution decisions made with respect to the Selected Antibody Patent Rights. If Surface determines not to file or not to continue to Prosecute any patents or patent applications within the Selected Antibody Patent Rights for any country or region such that patent rights to a Selected Antibody would terminate for that country or region, then Surface shall promptly, and in any event not less than [***] days prior to the date in which a failure to file or respond would prejudice the rights of Vaccinex hereunder, notify Vaccinex in writing of such determination. Vaccinex may then Prosecute such patent or patent application at its own expense in that country or region. If Vaccinex exercises its rights under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> with respect to any such patent or patent application in any country or region that Surface has decided not to continue Prosecuting, the licenses set forth in this Agreement shall become non-exclusive but with the same license consideration terms (i.e., fees, payments, royalties) as set forth in Article </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4, with respect to such patent or patent application, and patents issued therefrom in that country or region.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">6.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Cooperation</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Vaccinex agrees to cooperate with Surface in the preparation, filing, prosecution and maintenance of any Selected Antibody Patent Rights pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Prosecution of Patent Rights). Such cooperation includes executing all papers and instruments, or requiring employees or others to execute such papers or instruments, so as to effectuate the ownership of such Selected Antibody Patent Rights and to enable the filing, prosecution, maintenance, and extension thereof in any country or region. In addition, Vaccinex agrees to cooperate with Surface in obtaining patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory where applicable to the Selected Antibody Patent Rights.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">7.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Disclosure</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party agrees that it will not make any public disclosure that would adversely impact the patentability of any Selected Antibody prior to filing of a protective patent in the United States, Europe, Canada and Japan.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">8.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Common Interest</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. All information exchanged between the Parties, or with or between the Parties&#8217; outside patent counsel, including Prosecution counsel, regarding Prosecution of the Selected Antibody Patent Rights will be the Confidential Information of both Parties and potentially be privileged. In </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">addition, the Parties acknowledge and agree that, with regard to such Prosecution of the Selected Antibody Patent Rights, the interests of the Parties are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Selected Antibody Patent Rights, including privilege under the common interest doctrine and similar or related doctrines.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 6.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">INFRINGEMENT ACTIONS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Infringement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the Term, each Party will inform the other Party promptly in writing of any alleged infringement of the Selected Antibody Patent Rights by a Third Party of which it becomes aware, and of any available evidence thereof.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface&#8217;s Right to Enforce and Defend Patent Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. During the Term of this Agreement, Surface will have the first right, and control over in its sole discretion, but will not be obligated, to take any measures with respect to any Third Party&#8217;s activities concerning any product, method or service that infringes or misappropriates, or which Surface reasonably suspects infringes or misappropriates, the Selected Antibody Patent Rights (an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringing Product</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), including (i) by initiating or prosecuting an infringement, misappropriation or other </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">appropriate suit or action against such Third Party in a court of law (each an &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement Action</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) at its sole expense, or (ii) subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Sublicenses), by granting adequate rights and licenses necessary for continued activities, including development, manufacture or commercialization, concerning any Infringing Product in the Territory to any Third Party who at any time has infringed or misappropriated, or is suspected of infringing or misappropriating, any Selected Antibody Patent Rights. Surface will also have the first right, and control over in its sole discretion, but will not be obligated, to defend any action or proceeding (including a declaratory judgment action or nullification action, re-examination, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">inter partes</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> review, opposition, interference, post-grant review or other proceeding) brought by a Third Party in a court of law or before any patent office that challenges the patentability, validity or enforceability of any Selected Antibody Patent Rights or that seeks a determination that any Infringing Product does not infringe or misappropriate any Selected Antibody Patent Rights, and any appeals of the foregoing (any such action or proceeding a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Challenge Action</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) in the Territory, at Surface&#8217;s expense. In furtherance of such right, Vaccinex hereby agrees that Surface may include Vaccinex as a party in any such Infringement Action or Challenge Action and that Vaccinex will provide reasonable assistance to Surface in connection with an Infringement Action or Challenge Action, in each case without expense to Vaccinex. If Surface elects not to exercise its first right with respect to such Infringing Product or Challenge Action, it shall promptly notify Vaccinex of the same. Upon receipt of such notice, Vaccinex shall have the right, but not the obligation, to take any of the measures stated in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> with respect to such Infringing Product or Challenge Action. Both Parties shall cooperate with each other in good faith in the prosecution of any such action or proceeding. The total cost of any such action commenced or defended solely by a Party will be borne by such Party and the other Party will receive a percentage of any recovery or damages for past infringement derived therefrom as follows: the recovered amounts will be used to reimburse </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the Parties for their reasonable and previously unreimbursed documented costs and expenses, including attorneys&#8217; fees incurred in making such recovery (which amounts will be allocated pro rata if insufficient to cover the totality of such expenses) with any remainder to be equally shared by the Parties.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. With respect to any Infringement Action or Challenge Action, or any proceeding that a Party may institute to enforce the Selected Antibody Patent Rights pursuant to this Agreement, the other Party will, at the request and expense of the first Party, reasonably cooperate in all respects and, to the extent reasonably practicable, have its employees testify when requested and make available relevant records, information, samples, specimens, and other evidence upon request. If either Party reasonably determines that the other Party is an indispensable party to the action, the other Party hereby consents to be joined. In such event, both Parties shall have the right to be represented in that action by counsel of their own choice and at their own expense.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EU Unitary Patent System</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Without limitation of Surface&#8217;s rights under </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 6</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Infringement Actions), Surface will have the exclusive right to opt-in and opt-out the Selected Antibody Patent Rights from the jurisdiction of the European Union Unified Patent Court when it becomes operational, in accordance with the Unified Patent Court (Regulation (E.U.) No 1257/2012) and its applicable Annexes and Rules of Procedure, as amended and from time to time in effect, and Vaccinex will not do so.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Term Extensions</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface will have the exclusive right to seek and obtain all available extensions of the Selected Antibody Patent Rights with respect to a Licensed Product, including any supplementary protection certificates, in any country in the Territory. Vaccinex will execute such authorizations and other documents and, at Surface&#8217;s expense, take such other actions as may be reasonably requested by Surface to obtain any such extensions, restorations and supplementary protection certificates of the Selected Antibody Patent Rights in the Territory.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 7.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vaccinex</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Vaccinex represents and warrants to Surface as follows:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">9.Vaccinex (i) is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, (ii) has the corporate power and authority to enter into this Agreement and to perform its obligations hereunder, and (iii) has taken sufficient steps such that the execution and delivery of this Agreement by Vaccinex and the performance by Vaccinex of its obligations hereunder have been duly authorized by all necessary corporate action.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">10.Vaccinex exclusively own all rights, title and interests in and to the Vaccinex Program IP including the patent rights identified on </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, and Vaccinex exclusively Controls all rights, title and interests in and to the Vaccinex Program IP.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">11.As of the Effective Date, there have been no claims, judgments, security interests or settlements with respect to the Vaccinex Program IP, or pending claims or litigation relating to the Vaccinex Program IP.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">12.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> sets forth a complete and accurate list of each of the Selected Antibody Patent Rights as of the Effective Date.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">13.Any Selected Antibody Patent Rights existing as of the Effective Date have been duly prepared, filed, prosecuted, obtained, and maintained by Vaccinex in accordance with all applicable laws, rules, and regulations, it being recognized that Vaccinex has conducted such activities based on advice received from external patent agents.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">14.The execution and delivery of this Agreement and the performance of Vaccinex&#8217;s obligations hereunder are not inconsistent with or in breach of any contractual obligations which Vaccinex owes to any Third Party, and will not constitute a violation of any judgment, order or decree of any court, arbitrator, governmental agency or authority binding upon Vaccinex.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surface</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface represents and warrants to Vaccinex as follows:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">15.Surface is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the corporate power and authority to enter into this Agreement and to perform its obligations hereunder.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">16.The execution and delivery of this Agreement by Surface and the performance by Surface of its obligations hereunder have been duly authorized by all necessary corporate action.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">17.The execution and delivery of this Agreement and the performance of Surface&#8217;s obligations hereunder are not inconsistent with or in breach of any contractual obligations that Surface owes to any Third Party and will not constitute a violation of any judgment, order or decree of any court, arbitrator, governmental agency or authority binding upon Surface. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..No Other Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE 7</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, NEITHER PARTY MAKES ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, TITLE, VALIDITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 8.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">INDEMNIFICATION; LIMITATION OF LIABILITY</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by Surface</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface will at all times, during the term of this Agreement and thereafter, indemnify, defend and hold harmless Vaccinex and its Affiliates, sublicensees, directors, officers, agents and employees from any and all liabilities, damages, losses, costs or expenses (including attorneys&#8217; and professional fees and other expenses of litigation and/or </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">arbitration) resulting from third party claims arising out of or resulting from: (i) the gross negligence or willful misconduct of Surface (or its directors, officers, employees or agents) hereunder; (ii) the breach by Surface of any representation, warranty or covenant in this Agreement; or (iii) the exercise or practice of the rights granted hereunder to Surface, including the development, manufacture, holding, use, testing, marketing, advertisement, sale or other disposition by Surface, its Affiliates or Sublicensees, of the Licensed Product (or any other product or service offered by Surface, and/or its Affiliates or collaborators), the Selected Antibody, or its related cell lines (or their progeny or derivatives, other biological materials, method, process, device or apparatus), except in each case (i)-(iii), to the extent caused by the gross negligence, willful misconduct or breach of this Agreement of or by Vaccinex.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification by Vaccinex</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Vaccinex will at all times, during the term of this Agreement and thereafter, indemnify, defend and hold harmless Surface and its Affiliates, sublicensees, directors, officers, agents and employees from any and all liabilities, damages, losses, costs or expenses (including attorneys&#8217; and professional fees and other expenses of litigation and/or arbitration) resulting from third party claims arising out of or resulting from: (i) the gross negligence or willful misconduct of Vaccinex (or its directors, officers, employees or </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">agents) hereunder; or (ii) the breach by Vaccinex of any representation, warranty or covenant in this Agreement; except in each case (i)-(ii), to the extent caused by the gross negligence, willful misconduct or material breach of Surface.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Procedures</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. If a Party (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitee</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) intends to claim indemnification under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification; Limitation of Liability) it will promptly notify the indemnifying Party (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitor</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) in writing of any claim, demand, action or other proceeding for which the Indemnitee intends to claim such indemnification, and the Indemnitor will assume control of the defense thereof, with counsel of its choice; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that Indemnitor will not settle any such proceeding in a manner that requires the Indemnitee to admit to any legal violation or assume any liability that is not paid for in its entirety by Indemnitor without Indemnitee&#8217;s prior written consent, not to be unreasonably withheld. The Indemnitee will have the right to retain its own counsel and participate in the defense thereof, with the fees and expenses to be paid at its own expense. The indemnity agreement in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification; Limitation of Liability) will not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent will not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, will relieve such Indemnitor of any liability or obligation to the Indemnitee under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification; Limitation of Liability). The Party claiming indemnification under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification; Limitation of Liability), its employees and agents, will reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this indemnification.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 9.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">TERM AND TERMINATION</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The term of this Agreement (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) will commence on the Effective Date and will continue in full force and effect until terminated in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Termination). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">18.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Termination for Convenience</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface may terminate this Agreement at any time upon [***] days&#8217; prior written notice to Vaccinex.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">19.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Termination for Cause</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Either Party may terminate this Agreement in its entirety, effective upon written notice to the other Party, if the other Party materially breaches this Agreement and fails to cure such breach within [***] days after receiving written notice thereof, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that if the alleged breaching Party disputes in good faith the existence or materiality of any such breach specified in the notice provided by the other Party, and the alleged breaching Party provides notice of such dispute within such [***] day period then such [***] day cure period will be tolled during the pendency of such dispute and the Party alleging such breach shall not have </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the right to terminate this Agreement unless and until such dispute is resolved. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">20.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Payment Default</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Notwithstanding </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Termination for Cause), if Surface shall at any time default in the payment of any royalty or other payment required by this Agreement, Vaccinex may, at its option, terminate this Agreement upon [***] days&#8217; written notice, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided </i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">that if Surface disputes in good faith the existence of any such payment default specified in the notice provided by Vaccinex, and Surface provides notice of such dispute within such [***] day period, then such [***] day period will be tolled during the pendency of such dispute, provided such dispute is handled as an Expedited Dispute (as defined in Exhibit D). Vaccinex will not have the right to terminate this Agreement unless and until such Expedited Dispute is resolved, and </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">further</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that (a) if Surface has fully cured its default within such period, then the rights and licenses herein granted shall remain in force as if no breach or default had occurred and (b) if any payments are determined to be payable to Vaccinex following the resolution of the dispute, such payment shall be immediately payable with interest as of the original payment due date at the lower of (a) the maximum rate permitted by applicable law and (b) the rate of [***] per annum above &#8220;Prime&#8221; as defined in </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">The Wall Street Journal</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> on the original payment due date or, if unavailable, on the latest date prior to the payment due date on which such rate is available, calculated on a daily basis on the actual number of days elapsed from the payment due date to the date of actual payment.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">21.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Diligence Failure</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Notwithstanding </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Termination for Cause), Vaccinex may terminate this Agreement in the event that Surface is in material breach of its diligence obligations under </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (General </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Obligation) and fails to cure such material breach within [***] days after receiving written notice thereof from Vaccinex, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that if Surface disputes in good faith the existence or materiality of any such breach specified in the notice provided Vaccinex, and Surface provides notice of such dispute within such [***] day period then such [***] day cure period will be tolled during the pendency of such dispute, and Vaccinex shall not have the right to terminate this Agreement unless and until such dispute is resolved.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">22.Subject to applicable laws, Vaccinex may terminate this Agreement immediately upon written notice to Surface in the event that Surface, its Affiliate or Sublicensee Challenges (as defined below) any patent or patent application contained in the Vaccinex Program IP or Other Intellectual Property Rights (each a &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Patent</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;)</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;"> provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">,</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;"> however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that no such termination right shall apply to (i) any Challenge that is commenced by a Sublicensee where</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface demands that such </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Sublicensee withdraw such Challenge promptly after Surface becomes aware of such Challenge and terminates the sublicense agreement with the applicable Sublicensee if such Sublicensee does not withdraw such Challenge within [***] days after receipt of notice from Surface, or (ii) providing documents or testimony in response to any discovery requests or court order in a valid legal process. As used in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2(e)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Challenge</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means to Contest the validity or enforceability of any Licensed Patent in whole or in part, in any court, arbitration proceeding, or other tribunal, including the USPTO, the United States International Trade Commission, or any foreign equivalent thereof. For the avoidance of doubt, the term &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contest</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means: (a) commencing, filing, joining in, or assisting a Third Party in filing an action under 28 U.S.C. &#167;&#167; 2201-2202, seeking a declaration of invalidity or unenforceability of any Licensed Patent or any portion thereof; (b) commencing, filing, joining in, or assisting a Third Party in filing a petition under 35 U.S.C. &#167; 311 to institute </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">inter-partes</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> review of any Licensed Patent or any portion thereof; (c) commencing, filing, joining in, or assisting a Third Party in filing a petition under 35 U.S.C. &#167; 321 to institute post-grant review of any Licensed Patent or any portion thereof; or (d) any foreign equivalents of subsection (a) through (c) applicable in any country. As used herein, the term &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contest</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; does not include any action taken by Surface, its Affiliate or Sublicensee for the sole purpose of complying with the duty to disclose information material to patentability as set forth in 37 CFR 1.56 or any foreign equivalent thereof, or to exercise its rights to Prosecute the Selected Antibody Patent Rights pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 5</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of Termination</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Upon termination of this Agreement pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Termination), all of Surface&#8217;s unpaid payment obligations to Vaccinex pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (License Consideration) will terminate, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that neither Party will be released from any obligation that accrued prior to the effective date of such termination. Upon termination of this </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Agreement pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Termination), all rights granted by Vaccinex to Surface under </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Grant), including Vaccinex Program IP (including Vaccinex&#8217;s interest in rights jointly controlled with Surface), will revert to Vaccinex. Surface and any Sublicensee may, after the effective date of such termination, sell all Licensed Products that were produced prior to the effective date of such termination but in any event for no longer than [***] months after the effective date of such termination.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination on Sublicenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. In the event of any termination of this Agreement pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Termination), where such termination has not been caused by any action or inaction on the part of any Sublicensee or by any material breach by such Sublicensee of its obligations under its Sublicense from Surface, and termination of this Agreement will be without prejudice to the rights of each non-breaching Sublicensee, and Vaccinex will enter into a license agreement directly with each such Sublicensee (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New License Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) on substantially the same terms and conditions as those set forth in this Agreement; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that (a) the New License Agreement will provide that in no event </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">will such Sublicensee be liable to Vaccinex for any actual or alleged default by Surface of this Agreement, (b) the scope and territory of the license grant under the New License Agreement will be the same as that granted by Surface to such Sublicensee pursuant to the Sublicense between Surface and such Sublicensee, (c) the financial terms of any New License Agreement will be such that Vaccinex will receive no less than the same consideration that it would have received under this Agreement had it not been terminated, and (d) Vaccinex will not have any obligations under the New License Agreement that are greater than or inconsistent with the obligations of Vaccinex under this Agreement. Each such Sublicensee will be deemed a third party beneficiary of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Effect of Termination on Sublicenses) with the right to enforce it directly against Vaccinex. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination on IP</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Effective upon termination of this Agreement, Vaccinex shall have the option for a period of [***] days to enter into good faith negotiations with Surface for an exclusive, worldwide license (with rights to sublicense) under all intellectual property, including without limitation, pre-clinical or clinical data, regulatory approvals and/or submissions, then owned or Controlled by Surface as of the effective date of termination as reasonably necessary to enable Vaccinex to engage in exclusive development and commercialization of the Selected Antibody and/or the applicable Licensed Product(s). </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">f..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The following sections of this Agreement along with applicable definitions in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Definitions) applicable thereto will survive termination or expiration of this Agreement: </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.8(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Records and Audit), </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Effects of Termination), </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Effect of Termination on Sublicensees), </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Effect of Termination on IP), </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Survival), </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Indemnification; Limitation of Liability), </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Confidentiality) and </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 11</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Miscellaneous). Except as otherwise provided in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Survival), all other provisions of this Agreement will terminate upon the termination of this Agreement. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 10.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CONFIDENTIALITY</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Disclosure</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. As used herein, the term &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; includes any information that may be disclosed by one Party (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosing Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) to the other Party (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receiving Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) in connection with this Agreement, regardless of whether such information is specifically designated as confidential and regardless of whether such information is in oral, written, electronic or other form, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided </i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">that where such information is disclosed in oral form if the Confidential Information is not of a nature that should reasonably be understood by the Receiving Party as being confidential, then to be considered Confidential Information for the purposes of this Agreement, the Disclosing Party must confirm in writing that such information is to be treated as Confidential Information within [***] days of such disclosure. The Receiving Party will hold Confidential Information in confidence using the same degree of care that it employs for its own highly-sensitive confidential or proprietary information, which will in no event be less than a reasonable standard of care and will use and disclose the Disclosing Party&#8217;s Confidential Information only for the purpose of performing its obligations and exercising its rights under this Agreement. The Receiving Party may permit those directors, officers, </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">employees, consultants and advisers who have a need to know the Disclosing Party&#8217;s Confidential Information to access such Confidential Information, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that such employees are subject to confidentiality obligations that are no less stringent than those under </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Confidentiality). Notwithstanding the foregoing, Surface may disclose the Confidential Information received from Vaccinex to its advisors or actual or potential acquirers or Sublicensees if such advisors and actual or potential acquirers or Sublicensees agree prior to disclosure to be bound by confidentiality obligations no less stringent than those under </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Confidentiality). The Receiving Party&#8217;s obligations under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Non-Disclosure) will continue throughout the Term and for five (5) years following the termination or expiration of this Agreement. The existence and terms of this Agreement shall be the Confidential Information of both Parties.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exceptions</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The confidentiality and non-use obligations set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Non-Disclosure) will not apply to Confidential Information that the Receiving Party can demonstrate by competent written proof: (a) was known by the Receiving Party without restriction prior to disclosure under this Agreement; (b) was lawfully disclosed to the Receiving Party by a Third Party without an obligation of confidentiality; (c) entered the public domain through means other than an unauthorized disclosure or other breach of this Agreement by the Receiving Party; (d) was independently developed by the Receiving Party without knowledge or use of or access to Confidential Information disclosed by the Disclosing Party under this Agreement; (e) was published or publicly disclosed in accordance with the terms of this Agreement; or (f) to the extent such information can be shown to be necessary to file a patent application subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party may use or disclose Confidential Information disclosed to it by the other Party to the extent such use or disclosure is reasonably necessary in (i) filing or prosecuting patent applications, (ii) conducting clinical trials, (iii) making a permitted sublicense or otherwise exercising its rights hereunder. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Required by Law</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Notwithstanding </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (Non-Disclosure), limited disclosure of Confidential Information will not be prohibited to the extent such Confidential Information is required to be produced under applicable law. If a Receiving Party is required by law, regulation, court order, or request by an agency of a government to disclose any of the Confidential Information, it will: promptly notify the Disclosing Party, reasonably assist the Disclosing Party to obtain a protective order or other remedy of Disclosing Party&#39;s election, and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">provide prior review of any disclosure to Disclosing Party. Only that portion of the Confidential Information that is legally required will be furnished and reasonable efforts will be made to obtain assurance that the Confidential Information will be maintained in confidence.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publication</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Surface may publish or present the results of research or development carried out on any Selected Antibody or Licensed Product in its sole discretion, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that any publication or presentation that includes Vaccinex&#8217;s Confidential Information, or relates to Other Vaccinex Intellectual Property Rights, shall be subject to (i) </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 10.1-10.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> hereto, and (ii) the prior review by Vaccinex, such review period not to exceed [***] days, and Surface shall consider Vaccinex&#8217;s comments in good faith. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publicity</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Vaccinex may, subject to Surface&#8217;s review and approval, issue a press release announcing the Parties&#39; entry into this Agreement, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> that such press release shall not identify the specific indications of the Selected Antibody and Licensed Product hereunder.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Article 11.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Neither Party shall be responsible to the other for failure or delay in performing any of its obligations under this Agreement or for other non-performance hereof (other than failure to pay) provided that such delay or non-performance is occasioned by a cause beyond the reasonable control and without fault or negligence of such Party, including, but not limited to earthquake, fire, flood, explosion, discontinuity in the supply of power, court order or governmental interference, or act of God, and provided that such Party will inform the other Party of such event as soon as is reasonably practicable and that it will use commercially reasonable efforts to perform its obligations immediately after the relevant cause has ceased its effect. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">b..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Validity</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Should one or several provisions of this Agreement be or become invalid, then the Parties shall substitute for such invalid provisions valid ones, which in their economic effect come so close to the invalid provisions that it can be reasonably assumed that the Parties would have contracted this Agreement with those new provisions. In the event that such provisions cannot be determined, the invalidity of one or several provisions of the Agreement shall not affect the validity of the Agreement as a whole, unless the invalid provisions are of such essential importance for this Agreement that it is to be reasonably assumed that the Parties would not have contracted this Agreement without the invalid provisions.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">c..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Any claim, dispute or controversy arising out of or in connection with or relating to this Agreement shall be submitted for adjudication in Federal District Court in the Southern District of New York, USA. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">d..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Any legal notice required or permitted to be given under this Agreement shall be in writing and shall be sent by expedited delivery or emailed with receipt confirmed in writing, as follows and shall be effective upon receipt:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If to Vaccinex:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">President</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vaccinex, Inc.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">1895 Mt. Hope Avenue</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Rochester, NY 14620</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">USA</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">EMAIL: [***]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If to Surface:</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Chief Legal Officer</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Surface Oncology, Inc.</font></p><p style="font-family:'Aptos';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">50 Hampshire Street, 8</font><font style="font-family:'Times New Roman','Times','serif';">th</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> Floor</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Cambridge, Massachusetts 02139</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">USA</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">EMAIL: [***] </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Either Party may update the contact information in this Section 11.4 upon written notice to the other Party by email with receipt confirmed in writing. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">e..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Except as otherwise set forth in this Agreement the validity, performance, construction, and effect of this Agreement shall be governed by the laws of the state of New York, without regard to its conflict of law rules.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">f..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Agreement, if executed, constitutes the entire agreement between the Parties with respect to the subject matter within and supersede all previous agreements, whether written or oral. This Agreement shall not be changed or modified orally, but only by an instrument in writing signed by both Parties.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">g..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. No waiver or release of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by the waiving Party. The failure of either Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any provision hereunder or of any breach of any provision hereof shall not be deemed to be a continuing waiver or a waiver of any other breach of such provision (or any other provision) on such occasion or any succeeding occasion.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">h..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The rights of either Party under this Agreement may not be assigned, and the duties of either Party under this Agreement may not be delegated, without the prior written consent of the other Party, which consent shall not be unreasonably withheld; </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">however</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, that either Party may assign this Agreement without prior written consent to an Affiliate of such Party or to a party which acquires all or substantially all of that Party&#8217;s business to which this Agreement relates, whether by merger, sale of assets or otherwise.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">i..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Export</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Each Party acknowledges that the laws and regulations of the U.S. restrict the export and re-export of commodities and technical data of U.S. origin. Each Party agrees that it will not export or re-export restricted commodities or the technical data of the other Party in any form without the appropriate U.S. and foreign government licenses.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">j..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Any headings and captions used in this Agreement are for convenience and reference only and are not a part of this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">k..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractors</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. The relationship between Vaccinex and Surface hereunder will be that of independent contractors and neither Party shall have the authority to bind or commit the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">other to any third party. Nothing in this Agreement will be construed to create a joint venture, partnership, agency or employer-employee relationship between the Parties and Vaccinex shall be solely responsible for all employment and withholding taxes applicable to the services provided by its employees and contractors under this Agreement.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">l..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NO INDIRECT DAMAGES</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. EXCEPT FOR DAMAGES RESULTING FROM A PARTY&#8217;S BREACH OF CONFIDENTIALITY OR OF </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTIONS 7.1(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.1(f)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> OR </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.2(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, OR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OR IN CONNECTION WITH A PARTY&#8217;S INDEMNIFICATION OBLIGATIONS HEREUNDER, NEITHER PARTY WILL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, MULTIPLE, PUNITIVE, EXEMPLARY OR OTHER INDIRECT DAMAGES, AND NEITHER PARTY WILL BE RESPONSIBLE FOR LOST PROFITS OR LOST REVENUES, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">m..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. This Agreement may be executed in any number of counterparts (which may be transmitted in the form of a facsimile or pdf), each of which shall be an original, and all of which shall constitute together but one and the same document.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">n..</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Whenever the singular number is used in this Agreement and when required by the context, the same shall include the plural and vice versa, and the masculine gender shall include the feminine and neuter genders and vice versa. The words &#8220;include&#8221; and &#8220;including&#8221; shall mean respectively includes and including without limitation. The word &#8220;or&#8221; shall not be deemed to be used in the exclusive sense and shall instead be used in the inclusive sense to mean &#8220;and/or.&#8221; Each Party signing this Agreement acknowledges that such Party has had the opportunity to review this Agreement with legal counsel of such Party&#8217;s choice, and there shall be no presumption that ambiguities shall be construed or interpreted against the drafter.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Signature Page to Exclusive License Agreement Follows</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the Effective Date.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">vaccinex, INC. </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Maurice Zauderer</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name: Maurice Zauderer, Ph.D.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title: President &amp; Chief Executive Officer</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">SURFACE ONCOLOGY, INC.</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jeff Goater</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name: Jeff Goater</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title: Chief Executive Officer</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jessica Fees</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name: Jessica Fees</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title: Senior Vice President, Finance</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Signature Page to Exclusive Product License Agreement</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">]</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">SELECTED ANTIBODY PATENT RIGHTS</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">[***]</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT C</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">SELECTED ANTIBODIES</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">[***]</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:6pt 72pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT D</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determination of Combination Product Value</u></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>12
<FILENAME>chrs-20231231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNIFICANT SUBSIDIARIES OF COHERUS BIOSCIENCES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:57pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:3.78pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>Name of Subsidiary</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction of Organization</b></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;">Surface Oncology, LLC</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;">Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>13
<FILENAME>chrs-20231231xex23.htm
<DESCRIPTION>EX-23_1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:02:48 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 23.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:14pt 0pt 0pt 0pt;"><font style="font-size:12pt;"><a name="_Hlk128815329"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';">We consent to the incorporation by reference in the following Registration Statements: </font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;min-height:13.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-3 Nos. </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">333-208625, 333-220590, 333-222698, and 333-268252</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">) of Coherus BioSciences, Inc., </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:12pt;margin-top:12pt;min-height:13.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-200593, 333-203356, 333-209936, 333-216679, 333-222700, 333-229480, 333-236068, 333-251876, 333-262134, and 333-269291) pertaining to the BioGenerics, Inc. 2010 Equity Incentive Plan, as amended, the Coherus BioSciences, Inc. 2014 Equity Incentive Award Plan, and the Coherus BioSciences, Inc. 2014 Employee Stock Purchase Plan, and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;margin-top:12pt;min-height:13.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-213077, 333-225616, 333-228274, 333-229479, 333-231329, 333-234601, 333-236065, 333-251877 and 333-262941)</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pertaining to the 2016 Employment Commencement Incentive Plan of Coherus BioSciences, Inc.; </font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">of our reports dated March 15, 2024, with respect to the consolidated financial statements of Coherus BioSciences, Inc. and the effectiveness of internal control over financial reporting of Coherus BioSciences, Inc. included in this Annual Report (Form 10-K) of Coherus BioSciences, Inc. for the year ended December 31, 2023.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:13.0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:13.0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">San Mateo, California</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">March 15, 2024</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>14
<FILENAME>chrs-20231231xex31.htm
<DESCRIPTION>EX-31_1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:03:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">PURSUANT TO </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AS ADOPTED PURSUANT TO </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">I, Dennis M. Lanfear, certify that: </font></p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Coherus BioSciences, Inc. (the &quot;registrant&quot;); </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period co</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_GoBack_1"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">vered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: March 15, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">President and Chief Executive Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(Principal Executive Officer)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>15
<FILENAME>chrs-20231231xex32.htm
<DESCRIPTION>EX-31_2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:03:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 31.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">PURSUANT TO </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AS ADOPTED PURSUANT TO </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">I, Bryan McMichael, certify that: </font></p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Coherus BioSciences, Inc. (the &quot;registrant&quot;); </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: March 15, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;padding-left:0pt;padding-right:0pt;width:40%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ Bryan McMichael</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Bryan McMichael</font></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Interim Chief Financial Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">(Principal Financial Officer)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-33
<SEQUENCE>16
<FILENAME>chrs-20231231xex33.htm
<DESCRIPTION>EX-32_1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:03:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Exhibit 32.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Coherus BioSciences, Inc. (the &#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registrant</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;) certify that the Registrant&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;</font><u style="font-family:'Calibri','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Report</u><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:35.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: March 15, 2024</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">By:</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Name:</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Dennis M. Lanfear</font></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Title:</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">President and Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Date: March 15, 2024</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">By:</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">/s/ Bryan McMichael</font></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Name:</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Bryan McMichael</font></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Title:</font></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Interim Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be</i><font style="font-size:12pt;"><a name="_GoBack_3"></a></font><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;"> incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. </i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>17
<FILENAME>chrs-20231231xex97.htm
<DESCRIPTION>EX-97_1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/15/2024 09:03:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:6pt 0pt 0pt 0pt;"><a name="a351848"></a><b style="font-weight:bold;">EXHIBIT 97.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">COHERUS BIOSCIENCES, INC. (the &#8220;Company</b><b style="font-weight:bold;">&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CLAWBACK POLICY </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 0pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:6pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Approved and adopted by the Board on December 1, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a229078"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Introduction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Board of Directors of the Company (the &#8220;<b style="font-weight:bold;">Board</b>&#8221;) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company&#39;s pay-for-performance compensation philosophy. The Board has therefore adopted this policy which provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws (the &#8220;<b style="font-weight:bold;">Policy</b>&#8221;). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934 (the &#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a229070"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee, in which case references herein to the Board shall be deemed references to the Compensation Committee. Any determinations made by the Board shall be final and binding on all affected individuals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a154254"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Executives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">This Policy applies to the Company&#39;s current and former executive officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the listing standards of the national securities exchange on which the Company&#39;s securities are listed (&#8220;<b style="font-weight:bold;">Covered Executives</b>&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a353154"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recoupment; Accounting Restatement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">In the event the Company is required to prepare an accounting restatement of its financial statements due to the Company&#39;s material noncompliance with any financial reporting requirement under the securities laws, the Board will require reimbursement or forfeiture of any excess Incentive Compensation (as defined below) received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an accounting restatement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a229075"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">For purposes of this Policy, &#8220;Incentive Compensation&#8221; means any of the following; provided that, such compensation is granted, earned, or vested based wholly or in part on the attainment of a financial reporting measure:</p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Annual bonuses and other short- and long-term cash incentives.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock options.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock appreciation rights.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restricted stock.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restricted stock units.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance shares.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance units.</font></td></tr></table><div style="margin-top:9pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financial reporting measures include:</p><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Company stock price.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total shareholder return.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Revenues, including Revenues for any particular product.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Net income.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Earnings before interest, taxes, depreciation, and amortization (EBITDA).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expenses, including SG&amp;A and R&amp;D operating expenses.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Funds from operations.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liquidity measures such as working capital or operating cash flow.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:9pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Return measures such as return on invested capital or return on assets.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Earnings measures such as earnings per share.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excess Incentive Compensation: Amount Subject to Recovery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The amount to be recovered will be the excess of the Incentive Compensation paid to the Covered Executive based on the erroneous data over the Incentive Compensation that would have been paid to the Covered Executive had it been based on the restated results, as determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">If the Board cannot determine the amount of excess Incentive Compensation received by the Covered Executive directly from the information in the accounting restatement, then it will make its determination based on a reasonable estimate of the effect of the accounting restatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a79987"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method of Recoupment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Board will determine, in its sole discretion, the method for recouping Incentive Compensation hereunder which may include, without limitation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">(a) requiring reimbursement of cash Incentive Compensation previously paid;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">(b) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">(c) offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">(d) cancelling outstanding vested or unvested equity awards; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">(e) taking any other remedial and recovery action permitted by law, as determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Indemnification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a79985"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the Securities and Exchange Commission or any national securities exchange on which the Company&#39;s securities are listed. </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a name="a799879"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">This Policy shall be effective as of the date it is adopted by the Board (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;) and shall apply to Incentive Compensation that is approved, awarded or granted to Covered Executives on or after that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="aA808908"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment; Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect final regulations adopted by the Securities and Exchange Commission under Section 10D of the Exchange Act and to comply with any rules or standards adopted by a national securities exchange on which the Company&#39;s securities are listed. The Board may terminate this Policy at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a79984"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Recoupment Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impracticability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">The Board shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Board in accordance with Rule 10D-1 of the Exchange Act and the listing standards of the national securities exchange on which the Company&#39;s securities are listed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><a name="a799871"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;">This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chrs-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )7 ^8# 2(  A$! Q$!_\0
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M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\
MHD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?
MM_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H
M_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]
MGC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H
M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\
MHD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?
MM_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H
M_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]
MGC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H
M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\
MHD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?
MM_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H
M_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]
MGC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H
M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\
MHD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?
MM_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H
M_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]
MGC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H
M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\
MHD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?
MM_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H
M_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]
MGC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H
M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\
MHD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?
MM_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H
M_P"& OV>/^B3Z!_W[?\ ^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]
MGC_HD^@?]^W_ /BJ^@:* /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H
M'_?M_P#XJOH&B@#Y^_X8"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\
M^*KZ!HH ^?O^& OV>/\ HD^@?]^W_P#BJ/\ A@+]GC_HD^@?]^W_ /BJ^@:*
M /G[_A@+]GC_ *)/H'_?M_\ XJC_ (8"_9X_Z)/H'_?M_P#XJOH&B@#Y^_X8
M"_9X_P"B3Z!_W[?_ .*H_P"& OV>/^B3Z!_W[?\ ^*KZ!HH _)7_ (*M_ +X
M??L^^ O >I_#CPO:>#M0O]3GMKJYTIGC>:,1!@C'=TR :*] _P""WO\ R2WX
M:?\ 89N?_1 HH ^J?V O^3-?A/\ ]@9/_0WKZ!KY^_8"_P"3-?A/_P!@9/\
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M_"5R[VFL>8L?DM'YA+Q@NT@(?D")FQTSY7XR_:9_:N^$7PU@^*_C7X>^ 9/
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MIECT[3_$UW=C4]32-BK&-XR(D)*E<OM (/) S7)?L[W'[/WQ.\->-/AS\)_
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M?#KP]XS@\(ZGXXT"P\43NL<6D7&HQ)<LS?=41ELY.1@>]=U0 45X)\<OVS/
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MJ05/RG]&?@C\=O"G[0?A6[\0^#Y[FXTVUOI=.D>ZMS"WFQXW8!ZCD8-;MSX
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M*?<U\S^ 8M-USP#X.\*C5_AUX2\=V>N0S+<G1-47Q8MX+G&);A861N3]TMM
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MNF+DXQF08^<XXYS4.F>#M T2XAGT[0]-L)X8S%'+:VD<;(A.2JE0" 3S@<4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\
M AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_
M  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5
M?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://
MU7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@
M#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "
M&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\
M AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_
MY]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5
M?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -
M*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;
M_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "
M&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_G
MTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_
MY]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ
M*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_
M (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;
M_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2
MU_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_G
MTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK
M-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\
MB://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_
M (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7
M_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2
MU_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLW
MS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")
MH\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\
MB: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_
M  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7
M_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")H TJ*S?/
MU7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\  AO_ (FC
MS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_  (;_P")
MH TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5?^?2U_\
M AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://U7_GTM?_
M  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@#2HK-\_5
M?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "&_\ B://
MU7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\  AO_ (F@
M#2HK-\_5?^?2U_\  AO_ (FCS]5_Y]+7_P "&_\ B: -*BLWS]5_Y]+7_P "
M&_\ B://U7_GTM?_  (;_P")H TJ*S?/U7_GTM?_  (;_P")H\_5?^?2U_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MILXEC/#H>'C;^ZP[&JPF.]NW1JKEJ+=?JNZ",KZ/<V:***]0T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *.E5M1U&UTFREN[R=+:VB7<\LAP *\1\1_$;7?BCJ;Z#X.AE@L2-L]X?
ME9E[DG^!?;J?TKS\7C:>$23UD]HK=D2DHFI\8OC!96&G7FA:1-]HOYD,4UQ$
MWR0@\$ ]VQD<=,U4_9Q\9&XM+KP[<RY>',]J&/\  3\RCZ$Y_$UL:-^SKX=M
MM.B34GN+V]QF25)#&I/H .U;N@_!KPUX:U>VU*QBN8[JW8LC-.Q'((.1WX)K
MQ*>'S.>,ABZEDMK7V3W6V_ZF2C-RYF=S1117U9T!1110 4444 %%%% !1110
M!^:O_!;W_DEOPT_[#-S_ .B!11_P6]_Y);\-/^PS<_\ H@44 ?5/[ 7_ "9K
M\)_^P,G_ *&]?0-?/W[ 7_)FOPG_ .P,G_H;U] T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN,8>%C@2XZE,]_5>HKDPV-G"HL+C%:?1])>GGY$QDT^66YZ)1117MFH4444
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M_P!#>OH&OG[]@+_DS7X3_P#8&3_T-Z]B\>ZYJ'AKP;J^J:5IYU74+2W:6&T
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M_P _4/\ W\%']HVG_/U#_P!_!0!9HJM_:-I_S]0_]_!1_:-I_P _4/\ W\%
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M5_PJ[10!2_L73O\ GPM?^_*_X4?V+IW_ #X6O_?E?\*NT4 4O[%T[_GPM?\
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M?V+IW_/A:_\ ?E?\*NT4 4O[%T[_ )\+7_ORO^%']BZ=_P ^%K_WY7_"KM%
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MK^+6O&]W*L9^9+$'#[?3 X0>PY^E;GQ7_9W\/_$KP[96%N!HEU89^R7%O&"
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M"BBBNDH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]WU?JS2,5'8****[2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBF2RI!$\DC!(T!9F8X  ZDF@".^OK?3+.>[NYX[:U@0R2S2L%5%
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M  8 IU%%>X:A1110 4444 %%%>;^-OVA_ /@+S8]0U^">[CR#:6/[^7/IA>
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M-*1UV:A"<?\ CU2_\)YX9_Z&+2?_  .B_P#BJ\+E_85\$L!Y>JZRGKF2,_\
MLE1_\,)>#?\ H,ZQ_P!]1_\ Q-=W/B/Y%]Y\O]6RC_H(E_X!_P $]Y7QUX:=
M@J^(=*9CP +V+)_\>JQ_PE.B_P#07L/_  )3_&OGUOV$O!Q4XUK5P>QW1_\
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MJGG#=_KQ7=UY=2G.E-PFK-&L)QJ14X.Z84445F6%%%% !1110 4444 %%%%
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M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6?\ GK8?]^W_ /BJU**9)E[-9_YZV'_?M_\ XJC9K/\ SUL/^_;_ /Q5:E%
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MXZ_#NT)#^-=#;G'[J^CD_P#02:AS@MV=$<+7G\--OY,Z;9K/_/6P_P"_;_\
MQ5&S6?\ GK8?]^W_ /BJX*Y_:=^&%J/F\6VKG&<11RO_ "6LNY_:Z^&%N<#7
M)9N<?N[20_TJ'7I+[2^\Z8Y9CI;49?\ @+_R/4=FL_\ /6P_[]O_ /%4;-9_
MYZV'_?M__BJ\9N?VU?AO"#Y<VIS\?P69'\R*R[G]NKP)#D1:7KMP>VV"(#]9
M!4/$T5]I'1')<QEM0E]Q[ULUG_GK8?\ ?M__ (JC9K/_ #UL/^_;_P#Q5?GG
M\>/CA)\4/&D>K:,^IZ19):I!]GDG*G<"23A6QSFN:^'/B?67^('AI6U:^*MJ
M5N"#<O@@R+D=:XGF$>?E4;H^CI\)UG056I4Y7:[5MO*]S],=FL_\];#_ +]O
M_P#%4;-9_P">MA_W[?\ ^*K4HKUCX(R]FL_\];#_ +]O_P#%4;-9_P">MA_W
M[?\ ^*K4HH R]FL_\];#_OV__P 51LUG_GK8?]^W_P#BJU** ,O9K/\ SUL/
M^_;_ /Q5&S6?^>MA_P!^W_\ BJU** *MD+T;_M;0-TV^0K#ZYR3[5:HHH _-
M7_@M[_R2WX:?]AFY_P#1 HH_X+>_\DM^&G_89N?_ $0** /JG]@+_DS7X3_]
M@9/_ $-Z^@:^?OV O^3-?A/_ -@9/_0WKZ!H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYY_:,^.]SH\X\#>#O,N_%%]
MB&66U^9K;=P$7'_+0_\ CH]^FI^T7\?5^'EH/#WA]A=>+;U0J*@W_958X#$#
MJY_A7Z$C& 8_V=/@$? L!\3>)$%UXMO<R9D;>;4-R1GNYR=Q_ =\^UAJ,,/3
M6+Q*O_+'N^_HOZ\_+KU9UY_5Z#_Q/MY>IJ_L^? BW^%6D'4-1VW?BB^0&YG/
MS>0#SY:'^9[GVKV&BBO,KUIXBHZE1W;.^E2A1@H06B"BBBL#4**** "BBB@
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MV=/1GK1S_'/2JU-=I13_ $N?)$/Q=_:#\$KLU[P:NM1K]Z86F6/_  *!MO\
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M,?I6M:_LW_#.TQL\'Z>V,?ZT/)T_WF->E45HJ-);17W'++,<;/XJTG_V\_\
M,XNW^"W@*TQY/A#1DQZ6:?X5J6WP]\+6?^I\.:5'TY6RC[=.U=!15J$5LCFE
MB:\OBFW\V?+W[0'[*NO_ !-\;1:MX<N-#TVP6T2$P7#21-O!8D@)$PQR.]<5
MX0_8G\;Z#XJT?4KG5?#[6]G>17$BQ7$Y<JKAB #"!GCU%?:U%<LL'2E+G:U/
M=I<0XZC06'BURI6V"BBBNT^:"BBB@ HHHH **** "BBB@#\U?^"WO_)+?AI_
MV&;G_P!$"BC_ (+>_P#)+?AI_P!AFY_]$"B@#ZI_8"_Y,U^$_P#V!D_]#>OH
M&OG[]@+_ ),U^$__ &!D_P#0WKZ!H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O(_V@/CM:?"31/LMF5N?$MXG^BVW41 \>:X]
M!S@=S[9K4^-WQHT[X/\ ALW#[+K6;D%;*QW<NW]]NX0=SWZ5Y1\ /@OJ/BW7
M#\2?'P>[U"Z?S[&UN.W]V5E[ #[J]ASZ5Z^%P\(P^M8GX%LOYGV].YYN(KSE
M+ZO0^)[OLO\ /L:O[.WP)N[*[/CSQKYEYXFO6,T$%V,M!NY\QL_\M#Z?PCWZ
M?15%%<6)Q$\54=2?_#+LCJH4(8>')#_APHHHKE.@**** "BL#Q'X\T'PI&QU
M+4H8)!_RQ4[Y#]%&37F.I?'S4M=F:S\):%-<RG@33(7(]]B\#\37G8C,,-AG
MRSE[W9:O[D0YQCN>U331V\3R2NL<:#+.YP /4FO/?$_QV\,^'U=+>=M6N1TC
MM.4S[N>,?3-<=!\)O&?CLI/XLUMK6%CN^S!@[#_@*X05Z%X8^$/ACPNJ-#8+
M>7*_\O%Y^\8GUQT'X"N+V^/Q7\&G[./>6_\ X"OU(O.6RL>=GQE\1_B1&5T3
M3SHVGR\"X VY'M(W/XJ*U-"_9WMY)%NO$NJSZG=-R\<3$+GT+GYC^E>Q@8&!
MP*IZIK6GZ';F?4;ZWL81_P M+F58U_,FKCE=.3Y\5)U'Y[?);%1I<SL]6<EK
M7P7\+ZS:VEM]D>Q@ML[5LV";B<<L2"6/'4U1TWX">&=*U"VO;>34%GMY%E0^
M>.H.1_#7SE^UG\<(]0UW1(?!7BZ5HX(9!=_V7<NJ;RPQEEP&X!Z$UX,GQ:\;
M!UV^*]9W9X_TV3_&N>LL#&JVZ*;770^WPG"=;%T(UW)1OT:=T?J3<W4-E;R3
MW$J001C<\LK!54>I)X KQ_QM^UG\//!RRQQ:FVNW:<"#2U\P$_\ 70D+C\37
ME6G_ +,7Q&^*4=O>?$'QI)#;2 2"RCD,[*/]T8C4_3->Q^!_V8/A[X&2)HM%
M75;Q.3=ZH?/<GUVD;!^"UZO/7J?!'E7G_D</U;+,'_'JNK+M#1?^!/\ 0\<'
M[0?Q?^+F]/ 7A+^RK!R56_:/S<?]M9 (\_0&K.B_L?>)O&=P-1^)'C.YNYW.
MXVMM*T[#V,C\+]%4CT-?5\<:0QJD:JB*,*JC  ] *=3^JJ6M63E^7W">=2HI
MQP-*-)=TKR_\"9YYX$^ /@3X=HK:5H-O)=CK>WH\^8GU#-G;]% %>A    #
M':EHKKC&,%:*L>%6KU<1+GK2<GYNX44451@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI]RT"BBBMSS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!Z"@#/\ ^$ATS_G^@_[[H_X2'3/^?Z#_ +[K0P/048'H* ,__A(=,_Y_H/\
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MS_G^@_[[H_X2'3/^?Z#_ +[K0P/048'H* ,__A(=,_Y_H/\ ONC_ (2'3/\
MG^@_[[K0P/048'H* ,__ (2'3/\ G^@_[[H_X2'3/^?Z#_ONM# ]!1@>@H S
M_P#A(=,_Y_H/^^Z/^$ATS_G^@_[[K0P/048'H* ,_P#X2'3/^?Z#_ONC_A(=
M,_Y_H/\ ONM# ]!1@>@H S_^$ATS_G^@_P"^Z/\ A(=,_P"?Z#_ONM# ]!1@
M>@H S_\ A(=,_P"?Z#_ONC_A(=,_Y_H/^^ZT,#T%&!Z"@#/_ .$ATS_G^@_[
M[H_X2'3/^?Z#_ONM# ]!1@>@H S_ /A(=,_Y_H/^^Z/^$ATS_G^@_P"^ZT,#
MT%&!Z"@#/_X2'3/^?Z#_ +[H_P"$ATS_ )_H/^^ZT,#T%&!Z"@#/_P"$ATS_
M )_H/^^Z/^$ATS_G^@_[[K0P/048'H* ,_\ X2'3/^?Z#_ONC_A(=,_Y_H/^
M^ZT,#T%&!Z"@#/\ ^$ATS_G^@_[[H_X2'3/^?Z#_ +[K0P/048'H* ,__A(=
M,_Y_H/\ ONC_ (2'3/\ G^@_[[K0P/048'H* ,__ (2'3/\ G^@_[[H_X2'3
M/^?Z#_ONM# ]!1@>@H S_P#A(=,_Y_H/^^Z/^$ATS_G^@_[[K0P/048'H* ,
M_P#X2'3/^?Z#_ONC_A(=,_Y_H/\ ONM# ]!1@>@H S_^$ATS_G^@_P"^Z/\
MA(=,_P"?Z#_ONM# ]!1@>@H S_\ A(=,_P"?Z#_ONC_A(=,_Y_H/^^ZT,#T%
M&!Z"@#/_ .$ATS_G^@_[[H_X2'3/^?Z#_ONM# ]!1@>@H S_ /A(=,_Y_H/^
M^Z/^$ATS_G^@_P"^ZT,#T%&!Z"@#/_X2'3/^?Z#_ +[H_P"$ATS_ )_H/^^Z
MT,#T%&!Z"@#/_P"$ATS_ )_H/^^Z/^$ATS_G^@_[[K0P/048'H* ,_\ X2'3
M/^?Z#_ONC_A(=,_Y_H/^^ZT,#T%&!Z"@#/\ ^$ATS_G^@_[[H_X2'3/^?Z#_
M +[K0P/048'H* ,__A(=,_Y_H/\ ONC_ (2'3/\ G^@_[[K0P/048'H* ,__
M (2'3/\ G^@_[[H_X2'3/^?Z#_ONM# ]!1@>@H S_P#A(=,_Y_H/^^Z/^$AT
MS_G^@_[[K0P/048'H* ,_P#X2'3/^?Z#_ONC_A(=,_Y_H/\ ONM# ]!1@>@H
M ^>OV@/@YI?C<_\ "3^%[^#3O%MI^]!BDV?:RO(Y'208X;OT/8B?X!?M(0^+
M(AX;\6R+IWB>T'EB68;%N]O!^D@[COU'<#W[ ]!7B'[0'[/<?Q#C/B'P\?L'
MB^V"LDD;^6+G;T!/9Q@;6SVP>Q'LT,13KTUAL4]/LR_E_P"!_7IY=:C.C-U\
M.M>J[_\ !/7_ /A(=,_Y_H/^^Z/^$ATS_G^@_P"^Z\0^ /[0;^)+G_A#_&2_
MV=XLM285DN!L^U%?X2#TD'IWQD>E>_X'H*\_$8>IAJCIU%_P?-';1K0KPYX,
MS_\ A(=,_P"?Z#_ONC_A(=,_Y_H/^^ZT,#T%&!Z"N8W,_P#X2'3/^?Z#_ONC
M_A(=,_Y_H/\ ONM# ]!1@>@H S_^$ATS_G^@_P"^Z/\ A(=,_P"?Z#_ONM#
M]!1@>@H S_\ A(=,_P"?Z#_ONC_A(=,_Y_H/^^ZT,#T%&!Z"@#/_ .$ATS_G
M^@_[[H_X2'3/^?Z#_ONM# ]!1@>@H S_ /A(=,_Y_H/^^Z/^$ATS_G^@_P"^
MZT,#T%&!Z"@#/_X2'3/^?Z#_ +[H_P"$ATS_ )_H/^^ZT,#T%&!Z"@#/_P"$
MATS_ )_H/^^Z/^$ATS_G^@_[[K0P/048'H* ,_\ X2'3/^?Z#_ONC_A(=,_Y
M_H/^^ZT,#T%&!Z"@#/\ ^$ATS_G^@_[[H_X2'3/^?Z#_ +[K0P/048'H* ,_
M_A(=,_Y_H/\ ONC_ (2'3/\ G^@_[[K0P/048'H* ,__ (2'3/\ G^@_[[H_
MX2'3/^?Z#_ONM# ]!1@>@H S_P#A(=,_Y_H/^^Z/^$ATS_G^@_[[K0P/048'
MH* ,_P#X2'3/^?Z#_ONC_A(=,_Y_H/\ ONM# ]!1@>@H KVFHVU_O^S3I-LQ
MNV'.,]/Y59I,8I: /S5_X+>_\DM^&G_89N?_ $0**/\ @M[_ ,DM^&G_ &&;
MG_T0** /JG]@+_DS7X3_ /8&3_T-Z^@:^?OV O\ DS7X3_\ 8&3_ -#>OH&@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#Q3X_P#[/MO\2;8ZWHFW3_%EHNZ*5/D%SCD*Y'1O1NW3ITYCX/\ [3D=A;W7
MAOXDRMH^N:6/+-Y<H1YX7@AP!D/TY_BZ_7Z2KX:_;6L);?XJV=RUL(H)].CV
M3*F!*0SALGN1P/IBOHLN:QW^QU]4M4^J\EY'B8U/"?[51WZKHSZY\%_%7PI\
M0I)8] UJWOYXEW/ ,K(%Z9VL <>]=97YB?"KQ6/!/Q#T'67N'M;>VND-Q(@)
M(B)P_ Y/RD\5^E'A[Q-I7BS38]0T?4(-1LY!D2P.&'T/<'V/-89GEWU&:Y+N
M+-L!C?K<7S64D:=%%%>(>J%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'YJ_\%O?^26_#3_L,W/\ Z(%%'_!;
MW_DEOPT_[#-S_P"B!10!]4_L!?\ )FOPG_[ R?\ H;U] U\_?L!?\F:_"?\
M[ R?^AO7T#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-'IQE&:YHNZ"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /S5_P""WO\ R2WX:?\ 89N?_1 HH_X+>_\ )+?AI_V&;G_T0** /JG]
M@+_DS7X3_P#8&3_T-Z^@:^?OV O^3-?A/_V!D_\ 0WKZ!H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%'_  6]_P"26_#3_L,W/_H@44 ?5/[ 7_)FOPG_ .P,G_H;U] U\_?L!?\
M)FOPG_[ R?\ H;U] T 9^NZ[9>&M*GU'4)O(M8=H9@I8DLP55  )))(  ZDB
MN=3XFV-GX7?6M9LK[1D2]2Q-M-:RM*9))5CAVKL!;?OCZ# +8SP:N_$9=*;P
M;J']N6EY=Z4 C7"V$<CS1J'!$BB/Y_D(#97D;<CI7G.E Z]X.U?_ (2(>(=?
M\'G4K6YT:[:SF&IE%*2B0QQ(LI1)0NT[-Q )(*X:@#TBY\>Z99VMK+/'?0RW
M4K0V]H]E*+B5E7<VV+;N( Y)QBK=AXMTG4?#K:[%=JNEHCO)/*I3RPA(<,"
M5*E2"",@BO'--&O:?X\TOQ=>VNO:AX2LY+ZQLQ=64LNH113);D2O J><4\V&
M51N7>%921CFM :+JTWPQUW14TF_&H^(I=1U*VC,6U(5:7S$BF8\1NZD?*>Y(
M.,&@#TO0/'6D^(]0EL+9[B&^C@6Y^S7EK);R-$QP)%#J,KD8R.AZUT%>8Z!+
M<>-/B?IWB.VTS4=.TO3=&FLI'U2REM)))YI(GV*DBJS!!$<L!MRP )P<>G4
M%%5[V&>>';;W'V:3.=^P/QZ8-4?[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
M5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/
M_ 5?\:/[.U3_ *"X_P# 5?\ &@#6HK)_L[5/^@N/_ 5?\:/[.U3_ *"X_P#
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M90RE6 ((P0>]"J%4*H  & !VI:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU^$__8&3_P!#>OH&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^4OVQOA+KNO:K8^*M(LY=2MHK<6UU#;J7DBPQ*OM')4[L<=,<
MUY/\ /@YXD\5^/\ 2;TZ;<V6E:?<I<W%Y<1F-0%.0JYQN8D8P.G>OT%HKWZ6
M<5:6&^KJ*VLGY'CU,LIU*_MF_.P4445X![ 4444 %%%% !1110 4444 ?FK_
M ,%O?^26_#3_ +#-S_Z(%%'_  6]_P"26_#3_L,W/_H@44 ?5/[ 7_)FOPG_
M .P,G_H;U] U\_?L!?\ )FOPG_[ R?\ H;U] T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!^1_C1_;Y_Z!FH?]^1_C0!K45D_P!OG_H&:A_WY'^-']OG_H&:A_WY'^-
M&M163_;Y_P"@9J'_ 'Y'^-']OG_H&:A_WY'^- &M163_ &^?^@9J'_?D?XT?
MV^?^@9J'_?D?XT :U%9/]OG_ *!FH?\ ?D?XT?V^?^@9J'_?D?XT :U%9/\
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MH_M\_P#0,U#_ +\C_&@#6HJA8ZQ'?7#P&">VF5 ^R=-I*YQD<GO5^@#\U?\
M@M[_ ,DM^&G_ &&;G_T0**/^"WO_ "2WX:?]AFY_]$"B@#ZI_8"_Y,U^$_\
MV!D_]#>OH&OG[]@+_DS7X3_]@9/_ $-Z^@: "BBB@"O?V:ZC8W%J\DL23QM&
M9+>5HY%!&,JZD%3Z$'(KG_"W@9- O&U"]U&ZUO5S&UNM[>-S' 7+"-5' _AR
M>K%03V ZBB@ HHHH AEM8YIH)6!WPDLG/<@@_H:FHHH **** "BBB@ HHHH
M**PO%=UK5E8O<:0=.188I)9GU N1\HR% 7& ><L3QCH<\<II_P 2-6\6OH=I
MH5C:VE_>Z)'K=RVHEF2W63 CAVK@DLV_YN,!.AR, 'I%%>3Q_&/5;R_^'K0:
M%#%I7B2=K2YN9KG+P3B*=VCC0#Y@I@(+-@?,, \X7Q3\8+[1?%M_I%M!8RW=
MK<VL,.C2^9]NU"*4KOGAQQL7+\X8#RFW%10!ZO1110 4444 %%%% !44ULD\
ML,C@[H6++@]\$?R)J6B@ HHHH **** "BBB@ HHK&\2S:U!:B32#I\>Q7>63
M4-Y  &0 %QU/4D\8Z'L ;-%>;Z7\1]6\71^'[;1;*SM-0U#2!K%PU^SO' IP
MJ1@+@L68GYLC 4G!) K/MOC%J]_<>!7B\/Q0:?KMVUC>W$UT"8+A5FW1QJ!E
ML-"V6;:,%< G. #UBBO*_%WQ=O?#G_"4ZDEM9'1/#-S!;WT4SL+F976-G=#G
M:N!*-H(.XJ>1Q7J8(8 CH>: %HHHH **** "BBB@""2TCENH;A@?,A#!#G^]
MC/\ *IZ** "BBB@ HHHH **** "BN4^(&LZ]X>T:^U32UTH6EA937<QU*21=
M[(-P0%>$4@-ER3CCY3UK&D^(6KZVZQ:!8VL=S%HL.L7$.HEL@R[O+@&W&UOW
M;Y8YQQ\ISP >B45Y>/BKJ4^A^%/$]M:6<OA_7[FQ@AM,O]L5;G:-^?NY1F)*
M 'Y5)W=@ZZ^*FH"&_P!;M[2T;PS8:P-(EWEOM$F)1#),I'R@+(2-I!)"DY&0
M* /3J*** "BBB@ HHHH *@EM(YKF"=@?,AW;#GU&#4]% !1110 4444 %%%%
M !117,^.=4US1-)NM0TK^RUM[.UEN9FU%W&XH,A!MP%! ;+DG''RF@#IJ*\V
M@^)>J>)GM+?0+"WM[TZ'!KES%J>X^6)MWE0?+C#$H^6/3 X.>&#XFZI<:%X:
M\36UK8OH6LW%C MJ6<W8^T%4+9^[E&8_+@Y52=PZ  ],HKB+KQOJ]M\5M.\-
M2:/%#H]Y:3S1Z@]P#+*\8C)VQC[J?O,98Y)!X P3V] !1110 4444 %%%% $
M1MD-TMP0?,5#&#GL2"?Y"I:** "BBB@ HHHH **** "BN/\ B-XCUOPCHE_K
M5A%ITUAI]JUS-%<LXEG(.2B$<+QT)W9)Q@=3F:[X^UIK[Q#'H-C9RP^'[2.Y
MNA>NP>XD9#)Y*;?N$(!\S9&7 QP30!Z'17GDWC_5X+GPQ?FWT^70M?O(K:WA
MC=_M2))"TBR$D;21M.Y .!SN.*O7WBO6]$\:Z#IE];V$UAK5Q<00BU9_.MQ'
M$TBNY/# A,' &TLO+4 =K1110 4444 %%%% !436R/<QSD'S$5D4Y['&?Y"I
M:* "BBB@ HHHH **** "BBN2^(6O:YX8T6_U?3H]->RT^TDNIDO'<23%1DHN
MWA.!]X[N2/E[T =;17GNK^/-<NKC5D\/6%G(=(T^*]N(K]V#SR2*SK A7[AV
MJ<N<\LOR\&JTWQ*U>-?"NKK:Z=+H'B&]M[6VMUD?[8J31%UDR1M)!!W(!PH)
MW'&* /2Z*\_N?B#=VOQ"L- 2XT?4OM-Q)%/8V,S/>6,0C9UFE&< $A0057&\
M8+=_0* "BBB@ HHHH **** (/L<?VTW6#YQC\K.>-N<_SJ>BB@#\U?\ @M[_
M ,DM^&G_ &&;G_T0**/^"WO_ "2WX:?]AFY_]$"B@#ZI_8"_Y,U^$_\ V!D_
M]#>OH&OG[]@+_DS7X3_]@9/_ $-Z^@: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#B_B7X6UGQ?:V-A8SVPTDR%M2M)Y7B-V@'RQ;U5B$)^\,?,.,@$
MU5N_".OV_B.U\1Z4VEP:@VFG3;NPF9S;E5<O$Z.%#?*2P*E1D-U&.>^HH \G
MO?A5K5G!X"M-+N+">W\,79OWEO)'1[J5HIHW&U48*"9BP.3TQCO4/BSX*W7B
M75-9E;^RI)=0O(;JWUNXC<ZAIBIL^2 @=BK%2&4 N<@\Y]>HH 11M4#).!C)
MZFEHHH **** "BBB@ HHHH **** "BBB@ HHHH *XWXE^&-9\7:?9Z=I\]LF
MFO*3J5M-,\+740'$0=58A6/WN,D<9&37944 <'=>$M>MM=T[7])&E6U_'ISZ
M;<Z?*S_9O+WAHF1PH8%2",%<$,>F :Q)_A9K>GV/@NRTVXL+J/0+TZE-<7;O
M&]U.RS"0!51@JDS%AR<8Q[UZO10!YQ\0?A7%\1;Y8K_2M#CM7,:W&IF'S+]H
M5.7A1B@V!N5W;CA2>,GCT8   #@"EHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .%^(_A+6_%]UIEM;G3[CP]$QEOM-O'=/MC@@QJS!6!C')*8^8XR
M< @LU?PAX@;7+O6=*FTZVO-2TM-/NXYR[)$Z,Y26,A<MCS7&TA<X7D<UWM%
M'E/A[X6ZSX5U?14MY+'4]#T&SBLM(M[N=XVMP$V23,%C(>5AD9R  2 !DDS/
M\*=1$.HZ''>6A\,7VL_VN^X,+F/=*)Y(0 -I#2@G=D$*Q&"0#7J%% !1110
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MM3.G:B)6,%J_GR*UE:9!V1Q^7C<Q +,6^8@#@ "N^HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N%^(/A+6O%>JZ4L7V"ZT"U/GSZ;=S21"YG# QE
MRJ-N1<;MO=L$\#![JB@#SW6?!?B-M4UN\T>\TZU;7K"*VO/M"NYM9D5E\V+
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M-^.?B-X;^&NG17WB358]+MIG\N,NC.SMC.%5 6/X#BN%_P"&M/A1_P!#6/\
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MY,U^$_\ V!D_]#>OH&OG[]@+_DS7X3_]@9/_ $-Z^@: "BBB@ HHHH ****
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MYA\]^[;%EPN?05[?16,<+1B[J/Z_F>A6SW,J\5&59JW;W?Q5CSCPK^SO\/\
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M(-K ,#R6'S<@U<A^"LFC:?JNEZ'K"6.D:M9P65W#<VIFE BA$&Z-Q(H5FC4
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MG_H(^(/_  3O_P#%4?\ #WG]GG_H(^(/_!.__P 5110 ?\/>?V>?^@CX@_\
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M@_\ !.__ ,51_P />?V>?^@CX@_\$[__ !5%% !_P]Y_9Y_Z"/B#_P $[_\
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M[_\ Q5'_  ]Y_9Y_Z"/B#_P3O_\ %444 '_#WG]GG_H(^(/_  3O_P#%4?\
M#WG]GG_H(^(/_!.__P 5110 ?\/>?V>?^@CX@_\ !.__ ,51_P />?V>?^@C
MX@_\$[__ !5%% !_P]Y_9Y_Z"/B#_P $[_\ Q5'_  ]Y_9Y_Z"/B#_P3O_\
M%444 '_#WG]GG_H(^(/_  3O_P#%4?\ #WG]GG_H(^(/_!.__P 5110 ?\/>
M?V>?^@CX@_\ !.__ ,51_P />?V>?^@CX@_\$[__ !5%% !_P]Y_9Y_Z"/B#
M_P $[_\ Q5'_  ]Y_9Y_Z"/B#_P3O_\ %444 '_#WG]GG_H(^(/_  3O_P#%
M4?\ #WG]GG_H(^(/_!.__P 5110 ?\/>?V>?^@CX@_\ !.__ ,51_P />?V>
M?^@CX@_\$[__ !5%% !_P]Y_9Y_Z"/B#_P $[_\ Q5'_  ]Y_9Y_Z"/B#_P3
MO_\ %444 '_#WG]GG_H(^(/_  3O_P#%4?\ #WG]GG_H(^(/_!.__P 5110
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)GDY[4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>chrs-20231231xex1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20231231xex1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !" -@# 2(  A$! Q$!_\0
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MX8T/28=)@EV;]2F?>_\ WQ71VWQEO- U.#3?&_AZ7P^URVR+48I?.M';_?\
MX?QKS7X*^,=/^$_BGQAX<UR]BL=/MYFFA>?_ - _[XJ/XL?&*V^+NG-X5\)Z
M+>ZM+)*K_:3#]W;_ '4_^+K\OH9K.C@UB)8INO=IP:3NT[644KI>=T?H%?+(
MUL8Z,,,E0TM/5632=W)NS?D?4\4BRQ*R-N4C[PJ:N6^'&FZAH_@?1K'5'#W\
M%NJ2GWKJ:_3*,W4IQFU:Z6G8^!J14)RBG=)VOW"BBLS6]9M?#^EW6H7TJPVM
MK$TTLC?PJ*V;2U9"U-.BL3PIXGL?&?AVQUG3I/,LKR+S8W]JJ>+_ !M:^#O[
M*-S&\G]HWT5BFS^%WZ4N96N.QTU%8>E>(HM2UG4M/6"YBDL=@=YHML;;O[C?
MQ5N4T[B]0HHJ"YF%O;M)_=H;MN!/17/^%/$]KXLT:WU*S5E@GWA0_P![Y6VU
MT%13J1JP52#NGL5*,H2<)*S04445H2%%%% !1110 4444 ?-'[27Q8U&SU:+
MP;HD@M[FXV?:)D^_\_W$JQX5_9*TC[';S^(+ZZO+W;OEAA?8F^N=_:@^'^J6
MGBJW\7:9"T\&Q/-=%_U+I_'75>"/VK_#]QHB)XA6XL+^!41]D6]9?I7Y,Y8.
MIG&(CG=KJWL^;X>7R_ _2>7%T\IH/)KV:?M.7XN:_7KY:>14US]E1M,G%]X.
MURXTVY7YUCF;'_CRU4@^,?CGX5R+9^.-%>^LE^1=0AX/_P 2U+XR_:S^V+]C
M\(Z5+<W#_=FN4_\ 9*YBV^&7Q/\ C%*EUXAOI;#3W^?9<_(G_ (JQQ%7"TZK
M7#W/[3^YK#YWT-*-'$U*2>?.*I_WM)_*VK]'?T/5M0_:L\%6FDI<PRW5Y<-_
MRYI%\]<1)\5/B=\50\/A'0_[(T]OE^V.,_\ CS?)6UJ7[(FAR: L%CJ,\.JI
M_P O<WW6_P" 5S%OJGQ3^!;+%?VK:]X>B_C_ -<B)_O_ 'T_X'73BJ^<J<5F
MCE"BUJZ2O][U:^1AAJ.4RC+^S;3JWT55V^Y:)OU9P6M_#2?PA\2M"M/&MS_:
M4.HNCW$R2O\ -_P.OM'P_P"&-*\,6$=KI5C!8VZK\D<*;:^2/C9\6]#^)FC:
M+>Z?'/8ZW8S?/;S)_!_L/_OU]4?#?7E\2^"]&U)7W^=;(6_WL#_"NKAE8&EC
ML30PK4E[LHRW=FM5=]4SFXA^N5,'AZ^)3C+6,H[*Z>CLNC1U*4^D7I2U^F'P
M05XA^T5K]A+;:'X1O;LV<&KW:M=3$,VRW3YGZ>OW?QKV^N6?P)I+^+9?$<D3
MRZ@UO]E7SCN1$_V5J)IM61479W/!_"7Q(@\$_#[X@:5H<Z3?V-<.^FOM^Y%+
M]S_OAZ3Q%\*H/"EQ\/=5_MS5=1U"YUNT:Z>ZN=T,KM\WW/X:]JU?X4>'M;UB
MZU"YMOWEW9?8;B%/E26+TVUB67P%TRTN-*:76M9OK?2[A+BRMKJZWI"5KG]E
M+8TYU>Z/-+^YOO#VF_&*"VU6]?['=Q/;O-+O>+>F]]E:4WA34+?7O","^)]7
M_P")];[KW_2.OR;_ )/[E>EZE\)=(OXO$JR23H->E26ZVOW1?X*UIO!5E-?Z
M%=[Y?-TE/+M\-U&S;\U?/XO+:N)KNH]K1MJUM*\MNK1[&&Q\,/04(K6\KZ)[
MQ2C]SU^1Y'H6J2:"GC_0=3\07Z6&ERQ);WF[?<)O3[B5;^'%]J.E^,M2TB27
M67TR?36NXDUM]\R/_L5V]_\ "'2-0E\02R23H^LRI-*ZO_JG3[K)2Z?\+H]-
MUI=5FUK4;^\%N]J[W+I\R-_P"N&GE^+I5*;MI!OK]F[TW[-:'3/'86=.I?>2
M73[5DKZ+NF>3:+HVJ^&?AG8^,-/\1ZBC6LCS/IKR_P"B/%YS[TV5]&Z?=_;;
M&VGQL\U%?9_=KSFP^"MK!9V]A-KFIW6BP-YO]ER.AA9]^_'W-VW/;->H10B)
M555VA:]3*,)6PJ:FN5<L5:][M;O?2^BMY=#BS+%4L5+F@[OFD[VMHW=+97MK
MKY[LFHHHKZ4\4**** "BBB@ HHHH @FB2:)ED570_P +5P^I_!;P7K$OGW/A
M^T\W^^B;*[^BN6OA:&)5JT%+U29M2KU:#O1FXOR;1RGA[X>^'?"H!TK2+6R?
M^^B?/_WU75T45K2I0HQY::279)+\B9U)U9<U23;\]0IC(K]:?16AF>*?&SX+
M^']=\+ZMJUOID4&LP0O*D]L-F\_[?]ZOG'X6>*OB!H\5PWA.>>\M;/YI;'_6
MIL_ZY?\ Q%?=E];1WMK+!(NZ.5&5J^-O@M?R> ?CY/H\OR0RRS6CI_Z!7Y7Q
M#@*>'S'"UZ3=-5&XMQTUZ/3?S[GZ+D&,G5R_$T*J53V:4DI:JW5>1ZIX"_:F
MTK5&-GXIA.A:@GR,^Q_);_XFO;M*U:SUFT6YL;F.ZMW^[)"P9:YGQG\(_"_C
MM2=6TV-Y_P#GY3Y9O^^Z^?\ Q!HNN_LR>)+34=*O)=0\,W3[&AF_]!:O=EC,
MQR6*ECK5:*WFM)+S:Z_(\:.$P&;2:P=Z55[0>L7Y1?3T/KJO/_%FK^)-.\3Z
M5I^FR:<+34=ZK]IC?>FU*Z?PUKUKXGT2SU.T;?;W*;T-&HZ!#J&M:;J+.RR6
M._:HZ-NK[-252*E!Z/J?+.+A)QDK-'(:%\5;6)M1M];_ -"FM;BXB\[;B%TB
M_NM70>'/'VC>*ENA8SL9;7YI877:Z5E:K\*=,UB&6&>64A[BXN<9_BEQG_T&
MM+P]X1_X1_3KR+S8KB>5-F]+=(?X?]FA<Z>H:%%?BUX=>)Y&GEBV_,B/$RM+
M\VSY/[U6(OB?X>>*5GO!;>4OSI,NQE^;9_.N6TSX/3SZ=8RZGJLJ:I9JGV5X
M8DVV^U]__ ZT9/@[IE^(9-2GEOYUN);B5RNSS7=?[M*\^PWRK<UKGXI^&[.6
M6-K[>\#.KB*)FV[/O5I:1XOTO7[Z>WL9WN&@X=DB;8O_  /[M<E_PI73+6#3
M5M&BS91/"QO+5+CS49]YSG^*NM\,>&(O#,-['"^]+BX:X"A=NW/\--.3W0M+
M71C:[\4=$TFUU%H[AKB[LD=O)2)_G9?OHC;?F_X#5P^*9;7P?;ZO>""&25$?
M'[U47=_P#?\ ^.UA2_"0SNT3ZHPL(O.>U@\CYXFE^_N??\]=3KGA==9\,R:2
M)_*!1$\W;_<*_P#Q-)<U["]TSIOB;H44%\T=TUQ+9Q/*T4<;Y<)]_9_>J2U^
M(NA365C/+>-;_;84F1)8GRBM_?\ E^3_ ('BLW_A5Z^1%%]M?Y4NTW[?^>M9
MX^$!FO[6[NY;"^=((;>9+FRW;TB^YL^?Y*7O]BO=9T(^)WAF.2X1]3C7[.C.
MTFU]NU>OS?Q5<7QUHHNK>V-]MFN%W1*\3)N'_ A7DFB?##6+G5KVQN89(=,?
M>D4US_RQ3S=^R)-]=;XG^$]QXA\6VFK_ &^+9:W<5W$CQ?.NS^#_ ':(RG+H
M*44F;>D?$S2]9M[">"3R8KAY5?[3\FW9]ZM)/B)X=>W:==5@\I6V$YKE)?A/
M<7FE6NFSW\8@LWN!$\2_/LE_O4^U^&%[-K=KJ>H7EJ\L'E)Y-M%L38G_ +-0
MG/L+W3T*POX-1M8KJVD6:WE7<CK_ !45S_A#P]?>&K.VLGN8IK.&)_NKA][/
MN_K16T'=:BL=71113$%%%% !1110 FT>E?(G[2_@VX\$^.+3QGIO[N*ZN$=Q
MM^Y,G_Q=?7E8GB?PUI_BW1[C3-2@2YM)QM='KP,[RQ9IA'23M-:Q?9H]G*<P
M>6XI56KQ>DEW3W.<^&'Q,TSXB^'K>[M9?+NE79/;/]^)_>N=_:7O+&'X4:DM
MV4,LK(D"_P"WNKQ[Q9^S1XL\&Z@UYX/O);RU_A1)O*F2N2G^%/Q1\87\4&IV
M6HW+K\GG7\OR)7P^+SG,UA)X#$X.3JR7+=:IZ;]3Z["93E_UJ&.P^+BJ47S6
M>DEKL>Q?L@^([N_\+ZGID\C26]C*GV?/\*/7T2GW*\[^"_PL@^%_AA;/S?M%
M]<-YMU-_?>O1E&!7W&18:OA,NHT,0_?2U\O+Y'R&;UZ.*Q]6MA_A;T\_/YBT
M445[YXX4444 %%%% !1110 4444 ,V*E/HHH **** "BBB@ HHHH **** "B
MBB@ IE%%3+8")Z9;?Q444X;R,I_$B>+[M2444EL;/<****H04444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>chrs-20231231xex9001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20231231xex9001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ! 40# 2(  A$! Q$!_\0
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D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>chrs-20231231xex9002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20231231xex9002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ! +0# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>chrs-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2024 9:02:16 PM-->
<!--Modified on: 3/15/2024 9:02:16 PM-->
<xsd:schema targetNamespace="http://www.coherus.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:chrs="http://www.coherus.com/20231231" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.coherus.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" id="DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails">
        <link:definition>40302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryComponentsDetails" id="DisclosureInventoryComponentsDetails">
        <link:definition>40401 - Disclosure - Inventory - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" id="DisclosureInventoryBalanceSheetClassificationsDetails">
        <link:definition>40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" id="DisclosureInventoryAdditionalInformationDetails">
        <link:definition>40403 - Disclosure - Inventory - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" id="DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails">
        <link:definition>40503 - Disclosure - Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" id="DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>40504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" id="DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails">
        <link:definition>40505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss" id="DisclosureSurfaceAcquisitionConsiderationPaidDetailss">
        <link:definition>40602 - Disclosure - Surface Acquisition - Consideration paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss" id="DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss">
        <link:definition>40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" id="DisclosureDebtObligationsSummaryOfDebtObligationsDetails">
        <link:definition>40801 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" id="DisclosureDebtObligations2027TermLoanFuturePaymentsDetails">
        <link:definition>40804 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" id="DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails">
        <link:definition>40807 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" id="DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails">
        <link:definition>40808 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails">
        <link:definition>40901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2" id="DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2">
        <link:definition>40906 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" id="DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails">
        <link:definition>41002 - Disclosure - Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" id="DisclosureLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>41004 - Disclosure - Leases - Components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" id="DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails">
        <link:definition>41006 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" id="DisclosureStockholdersDeficitDetails">
        <link:definition>41101 - Disclosure - Stockholders' Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails">
        <link:definition>41301 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails">
        <link:definition>41302 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails">
        <link:definition>41303 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>41304 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>00400 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsTables" id="DisclosureDebtObligationsTables">
        <link:definition>30803 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables" id="DisclosureStockBasedCompensationAndEmployeeBenefitsTables">
        <link:definition>31203 - Disclosure - Stock-Based Compensation and Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails">
        <link:definition>40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails">
        <link:definition>40110 - Disclosure - Organization and Significant Accounting Policies - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40112 - Disclosure - Organization and Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails">
        <link:definition>40114 - Disclosure - Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails">
        <link:definition>40116 - Disclosure - Organization and Significant Accounting Policies - Net Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails">
        <link:definition>40118 - Disclosure - Organization and Significant Accounting Policies - Cost of Goods Sold (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails" id="DisclosureRevenueNetRevenueDetails">
        <link:definition>40201 - Disclosure - Revenue - Net Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" id="DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails">
        <link:definition>40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" id="DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails">
        <link:definition>40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>40303 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>40502 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails" id="DisclosureSurfaceAcquisitionDetails">
        <link:definition>40601 - Disclosure - Surface Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails" id="DisclosureSurfaceAcquisitionConsiderationPaidDetails">
        <link:definition>40602 - Disclosure - Surface Acquisition - Consideration paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" id="DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails">
        <link:definition>40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" id="DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails">
        <link:definition>40604 - Disclosure - Surface Acquisition - The amount allocated to identifiable intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" id="DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails">
        <link:definition>40605 - Disclosure - Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" id="DisclosureCollaborationsAndOtherArrangementsDetails">
        <link:definition>40701 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" id="DisclosureDebtObligations2027TermLoanNarrativeDetails">
        <link:definition>40802 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" id="DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails">
        <link:definition>40803 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" id="DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails">
        <link:definition>40805 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" id="DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails">
        <link:definition>40806 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" id="DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails">
        <link:definition>40809 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" id="DisclosureDebtObligations2025TermLoanNarrativeDetails">
        <link:definition>40810 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" id="DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails">
        <link:definition>40811 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>41001 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails">
        <link:definition>41201 - Disclosure - Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails">
        <link:definition>41202 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails">
        <link:definition>41203 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails">
        <link:definition>41204 - Disclosure - Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails">
        <link:definition>41205 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails">
        <link:definition>41206 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails">
        <link:definition>41207 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails">
        <link:definition>41208 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails">
        <link:definition>41209 - Disclosure - Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails">
        <link:definition>41210 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>41211 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails">
        <link:definition>41212 - Disclosure - Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" id="DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails">
        <link:definition>41213 - Disclosure - Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41305 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>41401 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRestructuringChargesDetails" id="DisclosureRestructuringChargesDetails">
        <link:definition>41501 - Disclosure - Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41601 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41701 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals" id="StatementConsolidatedBalanceSheetsParentheticals">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10201 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>10401 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>10501 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisition" id="DisclosureSurfaceAcquisition">
        <link:definition>10601 - Disclosure - Surface Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements" id="DisclosureCollaborationsAndOtherArrangements">
        <link:definition>10701 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureDebtObligations" id="DisclosureDebtObligations">
        <link:definition>10801 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11001 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficit" id="DisclosureStockholdersDeficit">
        <link:definition>11101 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits" id="DisclosureStockBasedCompensationAndEmployeeBenefits">
        <link:definition>11201 - Disclosure - Stock-Based Compensation and Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11401 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRestructuringCharges" id="DisclosureRestructuringCharges">
        <link:definition>11501 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11601 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11701 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30203 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>30403 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>30503 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables" id="DisclosureSurfaceAcquisitionTables">
        <link:definition>30603 - Disclosure - Surface Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30903 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>31003 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficitTables" id="DisclosureStockholdersDeficitTables">
        <link:definition>31101 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31403 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails">
        <link:definition>40103 - Disclosure - Organization and Significant Accounting Policies - Investments in Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails">
        <link:definition>40106 - Disclosure - Organization and Significant Accounting Policies - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails">
        <link:definition>40119 - Disclosure - Organization and Significant Accounting Policies - Operating and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails">
        <link:definition>40120 - Disclosure - Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails" id="DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails">
        <link:definition>40122 - Disclosure - Organization and Significant Accounting Policies - Reclassifications (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails" id="DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails">
        <link:definition>41003 - Disclosure - Leases - Other information related to lease term and discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails" id="DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails">
        <link:definition>41005 - Disclosure - Leases - Supplemental cash flow information related to leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>41306 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20231231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="ConvertibleNotesPrincipalAmount" id="chrs_ConvertibleNotesPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="TermLoanGross" id="chrs_TermLoanGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PrepaidManufacturingExpenseCurrent" id="chrs_PrepaidManufacturingExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AccruedRebatesFeesAndReserveCurrent" id="chrs_AccruedRebatesFeesAndReserveCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInAccruedRebatesFeesAndReserve" id="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInAccruedCompensation" id="chrs_IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAndLicenseAgreementsAbstract" id="chrs_CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" id="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" id="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsPolicyTextBlock" id="chrs_LicenseAgreementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" id="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" id="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPaymentTerm" id="chrs_RoyaltyPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentConsiderationMember" id="chrs_ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InventoryCurrentAndNoncurrent" id="chrs_InventoryCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="McKessonMember" id="chrs_McKessonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmeriSourceBergenCorpMember" id="chrs_AmeriSourceBergenCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CardinalMember" id="chrs_CardinalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" id="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" id="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReserveForDiscountsAndAllowancesConstituteVariableConsideration" id="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontAndMilestonePayment" id="chrs_UpfrontAndMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" id="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfGrossProfitsOnSales" id="chrs_PercentageOfGrossProfitsOnSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BioeqIPAGMember" id="chrs_BioeqIPAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialTermOfAgreement" id="chrs_InitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfPremiumOnConvertibleNote" id="chrs_PercentageOfPremiumOnConvertibleNote" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HealthcareRoyaltyPartnersIIILPMember" id="chrs_HealthcareRoyaltyPartnersIIILPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="KKRBiosimilarLPMember" id="chrs_KKRBiosimilarLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MXIIAssociatesLLCMember" id="chrs_MXIIAssociatesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="KMGCapitalPartnersLLCMember" id="chrs_KMGCapitalPartnersLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" id="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EquivalentToConversionPricePerCommonShare" id="chrs_EquivalentToConversionPricePerCommonShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" id="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentPrepaymentPercentage" id="chrs_DebtInstrumentPrepaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" id="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateHeadquartersLeaseAgreementMember" id="chrs_CorporateHeadquartersLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LaboratoryFacilitiesLeaseAgreementMember" id="chrs_LaboratoryFacilitiesLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NewCamarilloLeaseMember" id="chrs_NewCamarilloLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeaseLiabilitiesAbstract" id="chrs_OperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandAndFourteenEquityIncentiveAwardPlanMember" id="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" id="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" id="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" id="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeServiceShareBasedCompensationOfferingPeriodOne" id="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" type="xbrli:gMonthDayItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeServiceShareBasedCompensationOfferingPeriodTwo" id="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" type="xbrli:gMonthDayItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" id="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="chrs_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetLiabilityNet" id="chrs_DeferredTaxAssetLiabilityNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsExpirationYear" id="chrs_OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TaxCreditCarryforwardExpirationYear" id="chrs_TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeesAndNonemployeesStockOptionMember" id="chrs_EmployeesAndNonemployeesStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesMember" id="chrs_ConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionRelatedToSalesMadeAbstract" id="chrs_ProvisionRelatedToSalesMadeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionRelatedToSalesMadeInPriorPeriod" id="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationCosts" id="chrs_CollaborationCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfVehiclesLeased" id="chrs_NumberOfVehiclesLeased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VehiclesLeaseMember" id="chrs_VehiclesLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingAndFinanceLeaseRightOfUseAssets" id="chrs_OperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingAndFinanceLeaseLiabilityNoncurrent" id="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ChargebacksAndDiscountsForPromptPaymentMember" id="chrs_ChargebacksAndDiscountsForPromptPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RebatesMember" id="chrs_RebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherFeesCoPayAssistanceAndReturnsMember" id="chrs_OtherFeesCoPayAssistanceAndReturnsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfInventoryTableTextBlock" id="chrs_ScheduleOfInventoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" id="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorSubordinatedNotesDue20261.5Member" id="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfEventsInDefault" id="chrs_NumberOfEventsInDefault" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PaymentForCappedCallTransactions" id="chrs_PaymentForCappedCallTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" id="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentContractualTerm" id="chrs_DebtInstrumentContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapPriceOfCapCallTransactions" id="chrs_CapPriceOfCapCallTransactions" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorNotes8.2PercentDue2022Member" id="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Plan401KMember" id="chrs_Plan401KMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaymentsMadeToCmoForManufacturingServices" id="chrs_PrepaymentsMadeToCmoForManufacturingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmploymentCommencementIncentivePlanMember" id="chrs_EmploymentCommencementIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" id="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="JunshiBiosciencesMember" id="chrs_JunshiBiosciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementPercentageOfRoyaltyOnNetSales" id="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" id="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborationAgreementOptionExerciseFeePerProgram" id="chrs_CollaborationAgreementOptionExerciseFeePerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" id="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" id="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" id="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockPurchaseAgreementSharesAgreedToBeIssued" id="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockPurchaseAgreementSharesAgreedToBeIssuedValue" id="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumAmountPaidCoDevelopmentActivities" id="chrs_MaximumAmountPaidCoDevelopmentActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ConsultingAgreementWithLanfearAdvisorsMember" id="chrs_ConsultingAgreementWithLanfearAdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueForDiscountForLackOfMarketability" id="chrs_FairValueForDiscountForLackOfMarketability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" id="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseLiabilitiesOperatingAndFinancing" id="chrs_LeaseLiabilitiesOperatingAndFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AccruedAndOtherCurrentLiabilitiesMember" id="chrs_AccruedAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" id="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CoDevelopmentRegulatoryAndTechnologyTransferCosts" id="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ReclassificationsPolicyPolicyTextBlock" id="chrs_ReclassificationsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandTenPlanMember" id="chrs_TwoThousandTenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityPlan2016PlanAnd2014PlanMember" id="chrs_EquityPlan2016PlanAnd2014PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProductPipelineNumberOfDrugCandidates" id="chrs_ProductPipelineNumberOfDrugCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfOperatingAndReportableSegments" id="chrs_NumberOfOperatingAndReportableSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PaymentTermsPeriodFromDateOfShipment" id="chrs_PaymentTermsPeriodFromDateOfShipment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ToripalimabMember" id="chrs_ToripalimabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AntiTigitAntibodyAndIl2CytokineMember" id="chrs_AntiTigitAntibodyAndIl2CytokineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Chs2020Member" id="chrs_Chs2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TermLoansMember" id="chrs_TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheLoanMember" id="chrs_TrancheLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheBLoanMember" id="chrs_TrancheBLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheCLoanMember" id="chrs_TrancheCLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheDLoanMember" id="chrs_TrancheDLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodOne" id="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodTwo" id="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAgreementCovenantsNetSalesForPeriodThree" id="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MandatoryPrepaymentTerm" id="chrs_MandatoryPrepaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TermLoansPayableNoncurrent" id="chrs_TermLoansPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentNumberOfTranches" id="chrs_DebtInstrumentNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DebtDiscountsAndIssuanceCosts" id="chrs_DebtDiscountsAndIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BiopharmaCreditInvestmentsVGpLlcMember" id="chrs_BiopharmaCreditInvestmentsVGpLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfCapPriceCappedCallTransactions" id="chrs_PercentageOfCapPriceCappedCallTransactions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="YusimryProductMember" id="chrs_YusimryProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentRemainingTerm" id="chrs_DebtInstrumentRemainingTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheaBAndDLoansMember" id="chrs_TrancheaBAndDLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" id="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" id="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingMember" id="chrs_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UdenycaMember" id="chrs_UdenycaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CimerliMember" id="chrs_CimerliMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" id="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" id="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FinanceLeaseCost" id="chrs_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketOfferingTable" id="chrs_AtMarketOfferingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOfferingLineItems" id="chrs_AtMarketOfferingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" id="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentUncommittedAdditionalFacility" id="chrs_DebtInstrumentUncommittedAdditionalFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" id="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" id="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedPaymentArrangementForfeitureCredit" id="chrs_ShareBasedPaymentArrangementForfeitureCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedRebatesFeesAndReservesMember" id="chrs_AccruedRebatesFeesAndReservesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockRemainingAvailableForSaleUnderAtmOffering" id="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ThreeMonthLiborMember" id="chrs_ThreeMonthLiborMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PublicOfferingMember" id="chrs_PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SurfaceOncologyInc.Member" id="chrs_SurfaceOncologyInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SurfaceGlaxosmithklineAgreementMember" id="chrs_SurfaceGlaxosmithklineAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SurfaceNovartisAgreementMember" id="chrs_SurfaceNovartisAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SurfaceSrf114ProprietaryDrugProductAgreementMember" id="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SurfaceSrf388ProprietaryDrugProductAgreementMember" id="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BusinessCombinationConsiderationContingentValueRightPerShare" id="chrs_BusinessCombinationConsiderationContingentValueRightPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationConsiderationContingentValueRightPaymentPeriod" id="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" id="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" id="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharesOfferingAggregateAmount" id="chrs_SharesOfferingAggregateAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SharesOfferingAggregateAmountDecrease" id="chrs_SharesOfferingAggregateAmountDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" id="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockholdersDeficitTextBlock" id="chrs_StockholdersDeficitTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockGross" id="chrs_ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharesOfferingUnderwritersOptionTerm" id="chrs_SharesOfferingUnderwritersOptionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NoncashOperatingLeaseExpense" id="chrs_NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="YusimryMember" id="chrs_YusimryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodAcquisitions" id="chrs_StockIssuedDuringPeriodAcquisitions" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" id="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" id="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" id="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" id="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContingentConsiderationPolicyTextBlock" id="chrs_ContingentConsiderationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" id="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OptionalStockPurchaseAgreementMember" id="chrs_OptionalStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SixthAmendmentToLeaseMember" id="chrs_SixthAmendmentToLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChiefMarketingOfficerMember" id="chrs_ChiefMarketingOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeSpaceRemainingPremisesMember" id="chrs_OfficeSpaceRemainingPremisesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" id="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdimabDevelopmentAndOptionAgreementMember" id="chrs_AdimabDevelopmentAndOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NovartisAgreementMember" id="chrs_NovartisAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GskAgreementMember" id="chrs_GskAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SurfaceMember" id="chrs_SurfaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MinimumAntibodiesToBeCommercializedUnderCommercializationOption" id="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" id="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" id="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" id="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" id="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" id="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationAgreementAdditionalPaymentToBeMade" id="chrs_CollaborationAgreementAdditionalPaymentToBeMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" id="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationAgreementTerm" id="chrs_CollaborationAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PotentialDevelopmentMilestonesEntitled" id="chrs_PotentialDevelopmentMilestonesEntitled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SalesMilestonesEntitled" id="chrs_SalesMilestonesEntitled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAgreementMilestonePaymentsEarned" id="chrs_CollaborationAgreementMilestonePaymentsEarned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" id="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAgreementRegulatoryMilestonesEligibleToReceive" id="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseInAmountOfSharesToBeIssuedAndSold" id="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" id="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" id="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="BusinessCombinationNumberOfOutLicensedPartnershipProgram" id="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" id="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" id="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" id="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="InProcessResearchAndDevelopmentSrf388Member" id="chrs_InProcessResearchAndDevelopmentSrf388Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutLicensesWithGrkMember" id="chrs_OutLicensesWithGrkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutLicensesWithNovartisInstitutesMember" id="chrs_OutLicensesWithNovartisInstitutesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InProcessResearchAndDevelopmentSrf114Member" id="chrs_InProcessResearchAndDevelopmentSrf114Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LoqtorziMember" id="chrs_LoqtorziMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WeightedAveragePricePerShare" id="chrs_WeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" id="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedCoDevelopmentCostsAndMilestonePayments" id="chrs_AccruedCoDevelopmentCostsAndMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExercisePriceRange1.67To5.44Member" id="chrs_ExercisePriceRange1.67To5.44Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceRange5.86To10.05Member" id="chrs_ExercisePriceRange5.86To10.05Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceRange10.37To13.63Member" id="chrs_ExercisePriceRange10.37To13.63Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceRange14.03To17.17Member" id="chrs_ExercisePriceRange14.03To17.17Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceRange17.30To19.40Member" id="chrs_ExercisePriceRange17.30To19.40Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceRange19.85To46.38Member" id="chrs_ExercisePriceRange19.85To46.38Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" id="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfRoyaltiesOnNetSales" id="chrs_PercentageOfRoyaltiesOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PrepaidExpensesMember" id="chrs_PrepaidExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebInstrumentPartialRepaymentPrincipal" id="chrs_DebInstrumentPartialRepaymentPrincipal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedMilestonePayment" id="chrs_AccruedMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" id="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VaccinexLicenseAgreementMember" id="chrs_VaccinexLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RegulatoryMilestonesEligibleToPay" id="chrs_RegulatoryMilestonesEligibleToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CoherusOphthalmologyLlcMember" id="chrs_CoherusOphthalmologyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CimerliDivestitureTransactionMember" id="chrs_CimerliDivestitureTransactionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" id="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EarlyRedemptionFee" id="chrs_EarlyRedemptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Chs006AntiTigitAntibodyMember" id="chrs_Chs006AntiTigitAntibodyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermAndShortTermPurchaseCommitmentsAmount" id="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShortTermPurchaseCommitmentAmount" id="chrs_ShortTermPurchaseCommitmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>chrs-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2024 9:02:16 PM-->
<!--Modified on: 3/15/2024 9:02:16 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.coherus.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryBalanceSheetClassificationsDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionConsiderationPaidDetailss" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsSummaryOfDebtObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2" roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockholdersDeficitDetails" roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638461333298467641" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638461333298467641" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333298467641" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638461333298467641" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333298467641" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638461333298467641" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638461333298467641" xlink:to="us-gaap_MarketableSecuritiesCurrent_638461333298467641" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638461333298467641" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638461333298467641" xlink:to="us-gaap_ReceivablesNetCurrent_638461333298467641" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638461333298467641" xlink:to="us-gaap_InventoryNet_638461333298477639" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638461333298467641" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_638461333298477639" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638461333298467641" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638461333298477639" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638461333298477639" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_InventoryNoncurrent_638461333298477639" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638461333298477639" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638461333298477639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638461333298477639" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638461333298487615" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638461333298487615" xlink:to="us-gaap_LiabilitiesCurrent_638461333298487615" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638461333298487615" xlink:to="us-gaap_AccountsPayableCurrent_638461333298487615" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedRebatesFeesAndReserveCurrent" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638461333298487615" xlink:to="chrs_AccruedRebatesFeesAndReserveCurrent_638461333298487615" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638461333298487615" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638461333298487615" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638461333298487615" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638461333298487615" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638461333298487615" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638461333298487615" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansPayableNoncurrent" xlink:label="chrs_TermLoansPayableNoncurrent_638461333298487615" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638461333298487615" xlink:to="chrs_TermLoansPayableNoncurrent_638461333298487615" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638461333298497614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638461333298487615" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638461333298497614" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638461333298497614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638461333298487615" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638461333298497614" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638461333298497614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638461333298497614" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638461333298497614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638461333298497614" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638461333298497614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638461333298497614" xlink:to="us-gaap_CommonStockValue_638461333298497614" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638461333298497614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638461333298497614" xlink:to="us-gaap_AdditionalPaidInCapital_638461333298497614" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638461333298507613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638461333298497614" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638461333298507613" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638461333298507613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638461333298497614" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638461333298507613" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333298507613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333298507613" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638461333298507613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333298507613" xlink:to="us-gaap_OperatingIncomeLoss_638461333298507613" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638461333298507613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638461333298507613" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638461333298507613" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638461333298507613" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638461333298507613" xlink:to="us-gaap_CostsAndExpenses_638461333298507613" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638461333298507613" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638461333298517617" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638461333298507613" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638461333298517617" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638461333298507613" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638461333298517617" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333298507613" xlink:to="us-gaap_InterestExpense_638461333298517617" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333298507613" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333298517617" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333298507613" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638461333298517617" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638461333298517617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638461333298517617" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss_638461333298527617" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638461333298527617" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638461333298527617" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_ProfitLoss_638461333298527617" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_DepreciationAndAmortization_638461333298527617" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_ShareBasedCompensation_638461333298527617" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_638461333298527617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_GainLossOnContractTermination_638461333298527617" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_InventoryWriteDown_638461333298537617" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638461333298537617" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333298537617" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638461333298537617" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_638461333298537617" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638461333298537617" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_IncreaseDecreaseInInventories_638461333298537617" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638461333298537617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638461333298537617" order="12" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333298547614" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638461333298547614" order="14" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638461333298547614" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638461333298547614" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation_638461333298547614" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638461333298547614" order="18" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NoncashOperatingLeaseExpense" xlink:label="chrs_NoncashOperatingLeaseExpense_638461333298547614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333298527617" xlink:to="chrs_NoncashOperatingLeaseExpense_638461333298547614" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638461333298557612" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_638461333298557612" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638461333298557612" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638461333298557612" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638461333298557612" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_638461333298557612" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_638461333298557612" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition_638461333298567617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="us-gaap_CashAcquiredFromAcquisition_638461333298567617" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638461333298567617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333298557612" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638461333298567617" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638461333298567617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638461333298567617" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638461333298567617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638461333298567617" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638461333298567617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638461333298567617" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638461333298577614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_RepaymentsOfDebt_638461333298577614" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638461333298577614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638461333298577614" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638461333298577614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638461333298577614" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638461333298577614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638461333298577614" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638461333298577614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333298567617" xlink:to="us-gaap_ProceedsFromStockPlans_638461333298577614" order="8" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333298587617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333298587617" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638461333298587617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash_638461333298587617" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638461333298587617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638461333298587617" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638461333298587617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638461333298587617" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638461333298587617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638461333298587617" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryComponentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventory - Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="InventoryGross" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638461333298597622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryGross" xlink:to="us-gaap_InventoryRawMaterials_638461333298597622" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638461333298597622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryGross" xlink:to="us-gaap_InventoryWorkInProcess_638461333298597622" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638461333298597622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryGross" xlink:to="us-gaap_InventoryFinishedGoods_638461333298597622" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InventoryCurrentAndNoncurrent" xlink:label="InventoryCurrentAndNoncurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638461333298597622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNet_638461333298597622" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638461333298597622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_638461333298597622" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Inventory - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638461333298597622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638461333298597622" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShortTermPurchaseCommitmentAmount" xlink:label="chrs_ShortTermPurchaseCommitmentAmount_638461333298607618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:to="chrs_ShortTermPurchaseCommitmentAmount_638461333298607618" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638461333298607618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638461333298607618" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638461333298607618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638461333298607618" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638461333298607618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638461333298607618" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638461333298607618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill_1" xlink:to="us-gaap_Goodwill_638461333298607618" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638461333298607618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638461333298607618" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedCoDevelopmentCostsAndMilestonePayments" xlink:label="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_638461333298617619" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="chrs_LeaseLiabilitiesOperatingAndFinancing_638461333298617619" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638461333298617619" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638461333298617619" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638461333298617619" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638461333298617619" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_638461333298617619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_638461333298617619" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638461333298627617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638461333298627617" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_638461333298627617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_638461333298627617" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss" xlink:type="extended" xlink:title="40602 - Disclosure - Surface Acquisition - Consideration paid (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_638461333298627617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_638461333298627617" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_638461333298627617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_638461333298627617" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_638461333298627617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_638461333298627617" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss" xlink:type="extended" xlink:title="40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_638461333298627617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_638461333298627617" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_638461333298627617" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_638461333298637617" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_638461333298627617" xlink:to="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_638461333298637617" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333298637617" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333298637617" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638461333298637617" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333298637617" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638461333298637617" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333298637617" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638461333298637617" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638461333298637617" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333298637617" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638461333298637617" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333298647618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_3" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333298647618" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333298647618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_3" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333298647618" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross_638461333298647618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_2" xlink:to="chrs_TermLoanGross_638461333298647618" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333298647618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_2" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333298647618" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40807 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333298647618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333298647618" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638461333298647618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638461333298647618" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xlink:type="extended" xlink:title="40808 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638461333298657619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638461333298657619" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638461333298657619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638461333298657619" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638461333298657619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638461333298657619" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638461333298657619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638461333298657619" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount_638461333298657619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_1" xlink:to="chrs_ConvertibleNotesPrincipalAmount_638461333298657619" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333298657619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_1" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333298657619" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_638461333298667620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_638461333298667620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_638461333298667620" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="40906 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) Calc2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability_638461333298667620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638461333298667620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638461333298667620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638461333298667620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638461333298667620" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638461333298677620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638461333298677620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638461333298677620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638461333298677620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="OperatingAndFinanceLeaseRightOfUseAssets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638461333298677620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638461333298677620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638461333298677620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638461333298677620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638461333298677620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638461333298677620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638461333298677620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638461333298677620" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638461333298687618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638461333298687618" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FinanceLeaseCost" xlink:label="chrs_FinanceLeaseCost_638461333298687618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="chrs_FinanceLeaseCost_638461333298687618" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638461333298687618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chrs_FinanceLeaseCost_638461333298687618" xlink:to="us-gaap_FinanceLeaseInterestExpense_638461333298687618" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638461333298687618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chrs_FinanceLeaseCost_638461333298687618" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638461333298687618" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638461333298687618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638461333298687618" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638461333298697620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638461333298697620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638461333298697620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638461333298697620" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638461333298697620" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stockholders' Deficit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638461333298697620" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProceedsFromIssuanceOfCommonStockGross" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross_638461333298697620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="chrs_ProceedsFromIssuanceOfCommonStockGross_638461333298697620" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638461333298707618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638461333298707618" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638461333298707618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638461333298707618" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638461333298707618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638461333298707618" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638461333298707618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638461333298707618" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638461333298707618" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638461333298717620" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638461333298717620" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638461333298717620" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_638461333298717620" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638461333298717620" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638461333298717620" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638461333298717620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638461333298717620" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxAssetLiabilityNet" xlink:label="chrs_DeferredTaxAssetLiabilityNet_638461333298727622" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="chrs_DeferredTaxAssetLiabilityNet_638461333298727622" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638461333298737619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638461333298737619" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638461333298737619" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxAssetLiabilityNet" xlink:label="chrs_DeferredTaxAssetLiabilityNet_638461333298737619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="chrs_DeferredTaxAssetLiabilityNet_638461333298737619" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638461333298737619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chrs_DeferredTaxAssetLiabilityNet_638461333298737619" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638461333298737619" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="chrs_DeferredTaxLiabilitiesRightOfUseAsset_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638461333298737619" xlink:to="chrs_DeferredTaxLiabilitiesRightOfUseAsset_638461333298747620" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638461333298737619" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638461333298747620" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="chrs_DeferredTaxAssetLiabilityNet_638461333298737619" xlink:to="us-gaap_DeferredTaxAssetsGross_638461333298747620" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638461333298747620" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_638461333298747620" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_638461333298747620" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638461333298747620" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638461333298747620" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638461333298757619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638461333298757619" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638461333298757619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638461333298757619" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638461333298757619" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638461333298747620" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638461333298757619" order="7" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>chrs-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2024 9:02:16 PM-->
<!--Modified on: 3/15/2024 9:02:16 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsTables" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueNetRevenueDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionConsiderationPaidDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCollaborationsAndOtherArrangementsDetails" roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsSummaryOfDebtObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2025TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockholdersDeficitDetails" roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRestructuringChargesDetails" roleURI="http://www.coherus.com/role/DisclosureRestructuringChargesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.coherus.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: AssetsAbstract to OperatingLeaseRightOfUseAsset" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: AssetsAbstract to PropertyPlantAndEquipmentNet" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:AssetsAbstract To us-gaap_OtherAssetsNoncurrent" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:title="us-gaap_AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent To us-gaap_AccruedLiabilitiesCurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:title="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="PublicUtilitiesInventoryAxis" xlink:title="PublicUtilitiesInventoryAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="PublicUtilitiesInventoryTypeDomain" xlink:title="PublicUtilitiesInventoryTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PublicUtilitiesInventoryAxis" xlink:to="PublicUtilitiesInventoryTypeDomain" xlink:title="definition: PublicUtilitiesInventoryAxis to PublicUtilitiesInventoryTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:title="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="ReceivableTypeDomain" xlink:title="ReceivableTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="ReceivableTypeDomain" xlink:title="definition: AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis to ReceivableTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="OptionIndexedToIssuersEquityEquityAxis" xlink:title="OptionIndexedToIssuersEquityEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="OptionIndexedToIssuersEquityTypeDomain" xlink:title="OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OptionIndexedToIssuersEquityEquityAxis" xlink:to="OptionIndexedToIssuersEquityTypeDomain" xlink:title="definition: OptionIndexedToIssuersEquityEquityAxis to OptionIndexedToIssuersEquityTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="AdjustmentsForChangeInAccountingPrincipleAxis" xlink:title="AdjustmentsForChangeInAccountingPrincipleAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="ChangeInAccountingPrincipleMember" xlink:title="ChangeInAccountingPrincipleMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForChangeInAccountingPrincipleAxis" xlink:to="ChangeInAccountingPrincipleMember" xlink:title="definition: AdjustmentsForChangeInAccountingPrincipleAxis to ChangeInAccountingPrincipleMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:title="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="AdjustmentsForErrorCorrectionDomain" xlink:title="AdjustmentsForErrorCorrectionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="AdjustmentsForErrorCorrectionDomain" xlink:title="definition: ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis to AdjustmentsForErrorCorrectionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis_1" xlink:title="us-gaap_HedgingDesignationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain_1" xlink:title="us-gaap_HedgingDesignationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_HedgingDesignationAxis_1" xlink:to="us-gaap_HedgingDesignationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_HedgingDesignationAxis_1 To us-gaap_HedgingDesignationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OptionalStockPurchaseAgreementMember" xlink:label="chrs_OptionalStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_OptionalStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodAcquisitions" xlink:label="chrs_StockIssuedDuringPeriodAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="chrs_StockIssuedDuringPeriodAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_JunshiBiosciencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnContractTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NoncashOperatingLeaseExpense" xlink:label="chrs_NoncashOperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="chrs_NoncashOperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Debt Obligations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoherusOphthalmologyLlcMember" xlink:label="chrs_CoherusOphthalmologyLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_CoherusOphthalmologyLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliDivestitureTransactionMember" xlink:label="chrs_CimerliDivestitureTransactionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="chrs_CimerliDivestitureTransactionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProductPipelineNumberOfDrugCandidates" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_ProductPipelineNumberOfDrugCandidates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfOperatingAndReportableSegments" xlink:label="chrs_NumberOfOperatingAndReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_NumberOfOperatingAndReportableSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" xlink:title="40110 - Disclosure - Organization and Significant Accounting Policies - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="chrs_YusimryProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="chrs_UdenycaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40112 - Disclosure - Organization and Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" xlink:type="extended" xlink:title="40114 - Disclosure - Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" xlink:type="extended" xlink:title="40116 - Disclosure - Organization and Significant Accounting Policies - Net Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentTermsPeriodFromDateOfShipment" xlink:label="chrs_PaymentTermsPeriodFromDateOfShipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="chrs_PaymentTermsPeriodFromDateOfShipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" xlink:type="extended" xlink:title="40118 - Disclosure - Organization and Significant Accounting Policies - Cost of Goods Sold (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_BioeqIPAGMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoqtorziMember" xlink:label="chrs_LoqtorziMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_LoqtorziMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RoyaltyPaymentTerm" xlink:label="chrs_RoyaltyPaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_RoyaltyPaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfRoyaltiesOnNetSales" xlink:label="chrs_PercentageOfRoyaltiesOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PercentageOfRoyaltiesOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PercentageOfGrossProfitsOnSales" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue - Net Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="chrs_UdenycaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliMember" xlink:label="chrs_CimerliMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductMember" xlink:to="chrs_CimerliMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryMember" xlink:label="chrs_YusimryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProductMember" xlink:to="chrs_YusimryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ProductMember" xlink:to="chrs_ToripalimabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_McKessonMember" xlink:label="chrs_McKessonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="chrs_McKessonMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AmeriSourceBergenCorpMember" xlink:label="chrs_AmeriSourceBergenCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="chrs_AmeriSourceBergenCorpMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CardinalMember" xlink:label="chrs_CardinalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="chrs_CardinalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="chrs_ChargebacksAndDiscountsForPromptPaymentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RebatesMember" xlink:label="chrs_RebatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="chrs_RebatesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="chrs_OtherFeesCoPayAssistanceAndReturnsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProvisionRelatedToSalesMadeAbstract" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="chrs_ProvisionRelatedToSalesMadeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidExpensesMember" xlink:label="chrs_PrepaidExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="chrs_PrepaidExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateNoteSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContingentConsiderationMember" xlink:label="chrs_ContingentConsiderationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="chrs_ContingentConsiderationMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateNoteSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Inventory - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_PublicUtilitiesInventoryAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="chrs_YusimryProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="chrs_UdenycaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Chs2020Member" xlink:label="chrs_Chs2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="chrs_Chs2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWriteDown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShortTermPurchaseCommitmentAmount" xlink:label="chrs_ShortTermPurchaseCommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_ShortTermPurchaseCommitmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_PrepaidManufacturingExpenseCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_PrepaymentsMadeToCmoForManufacturingServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_InventoryLineItems" xlink:to="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_GainLossOnContractTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_JunshiBiosciencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" xlink:label="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_UpfrontAndMilestonePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Surface Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_SurfaceOncologyInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceGlaxosmithklineAgreementMember" xlink:label="chrs_SurfaceGlaxosmithklineAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_SurfaceGlaxosmithklineAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceNovartisAgreementMember" xlink:label="chrs_SurfaceNovartisAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_SurfaceNovartisAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" xlink:label="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" xlink:label="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPerShare" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" xlink:label="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Surface Acquisition - Consideration paid (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_SurfaceOncologyInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_SurfaceOncologyInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Surface Acquisition - The amount allocated to identifiable intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_SurfaceOncologyInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InProcessResearchAndDevelopmentSrf388Member" xlink:label="chrs_InProcessResearchAndDevelopmentSrf388Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="chrs_InProcessResearchAndDevelopmentSrf388Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InProcessResearchAndDevelopmentSrf114Member" xlink:label="chrs_InProcessResearchAndDevelopmentSrf114Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="chrs_InProcessResearchAndDevelopmentSrf114Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OutLicensesWithGrkMember" xlink:label="chrs_OutLicensesWithGrkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="chrs_OutLicensesWithGrkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OutLicensesWithNovartisInstitutesMember" xlink:label="chrs_OutLicensesWithNovartisInstitutesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="chrs_OutLicensesWithNovartisInstitutesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_SurfaceOncologyInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Collaborations and Other Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_VaccinexLicenseAgreementMember" xlink:label="chrs_VaccinexLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_VaccinexLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_BioeqIPAGMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdimabDevelopmentAndOptionAgreementMember" xlink:label="chrs_AdimabDevelopmentAndOptionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_AdimabDevelopmentAndOptionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NovartisAgreementMember" xlink:label="chrs_NovartisAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_NovartisAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_GskAgreementMember" xlink:label="chrs_GskAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_GskAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_JunshiBiosciencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Chs006AntiTigitAntibodyMember" xlink:label="chrs_Chs006AntiTigitAntibodyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="chrs_JunshiBiosciencesMember" xlink:to="chrs_Chs006AntiTigitAntibodyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceMember" xlink:label="chrs_SurfaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="chrs_SurfaceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="chrs_ToripalimabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="chrs_AntiTigitAntibodyAndIl2CytokineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationCosts" xlink:label="chrs_CollaborationCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementOptionExerciseFeePerProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_MaximumAmountPaidCoDevelopmentActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FairValueForDiscountForLackOfMarketability" xlink:label="chrs_FairValueForDiscountForLackOfMarketability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_FairValueForDiscountForLackOfMarketability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InitialTermOfAgreement" xlink:label="chrs_InitialTermOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_InitialTermOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_UpfrontAndMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PercentageOfGrossProfitsOnSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedMilestonePayment" xlink:label="chrs_AccruedMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_AccruedMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" xlink:label="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" xlink:label="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" xlink:label="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" xlink:label="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" xlink:label="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" xlink:label="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementAdditionalPaymentToBeMade" xlink:label="chrs_CollaborationAgreementAdditionalPaymentToBeMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementAdditionalPaymentToBeMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" xlink:label="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementTerm" xlink:label="chrs_CollaborationAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PotentialDevelopmentMilestonesEntitled" xlink:label="chrs_PotentialDevelopmentMilestonesEntitled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_PotentialDevelopmentMilestonesEntitled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SalesMilestonesEntitled" xlink:label="chrs_SalesMilestonesEntitled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_SalesMilestonesEntitled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMilestonePaymentsEarned" xlink:label="chrs_CollaborationAgreementMilestonePaymentsEarned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementMilestonePaymentsEarned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" xlink:label="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" xlink:label="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RegulatoryMilestonesEligibleToPay" xlink:label="chrs_RegulatoryMilestonesEligibleToPay" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="chrs_RegulatoryMilestonesEligibleToPay" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ThreeMonthLiborMember" xlink:label="chrs_ThreeMonthLiborMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="chrs_ThreeMonthLiborMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheLoanMember" xlink:label="chrs_TrancheLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheBLoanMember" xlink:label="chrs_TrancheBLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheBLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheCLoanMember" xlink:label="chrs_TrancheCLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheCLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheDLoanMember" xlink:label="chrs_TrancheDLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TrancheDLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheaBAndDLoansMember" xlink:label="chrs_TrancheaBAndDLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TrancheaBAndDLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentUncommittedAdditionalFacility" xlink:label="chrs_DebtInstrumentUncommittedAdditionalFacility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentUncommittedAdditionalFacility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentNumberOfTranches" xlink:label="chrs_DebtInstrumentNumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentNumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MandatoryPrepaymentTerm" xlink:label="chrs_MandatoryPrepaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_MandatoryPrepaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtDiscountsAndIssuanceCosts" xlink:label="chrs_DebtDiscountsAndIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtDiscountsAndIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentRemainingTerm" xlink:label="chrs_DebtInstrumentRemainingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentRemainingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_TermLoanGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_EquivalentToConversionPricePerCommonShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_NumberOfEventsInDefault" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentContractualTerm" xlink:label="chrs_DebtInstrumentContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_CallOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentForCappedCallTransactions" xlink:label="chrs_PaymentForCappedCallTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="chrs_PaymentForCappedCallTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CapPriceOfCapCallTransactions" xlink:label="chrs_CapPriceOfCapCallTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="chrs_CapPriceOfCapCallTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfCapPriceCappedCallTransactions" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="chrs_PercentageOfCapPriceCappedCallTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40807 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xlink:type="extended" xlink:title="40808 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_ConvertibleNotesPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xlink:type="extended" xlink:title="40809 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_KKRBiosimilarLPMember" xlink:label="chrs_KKRBiosimilarLPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chrs_KKRBiosimilarLPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MXIIAssociatesLLCMember" xlink:label="chrs_MXIIAssociatesLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chrs_MXIIAssociatesLLCMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_KMGCapitalPartnersLLCMember" xlink:label="chrs_KMGCapitalPartnersLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="chrs_KMGCapitalPartnersLLCMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_EquivalentToConversionPricePerCommonShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_NumberOfEventsInDefault" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40810 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentPrepaymentPercentage" xlink:label="chrs_DebtInstrumentPrepaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_DebtInstrumentPrepaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40811 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedRebatesFeesAndReservesMember" xlink:label="chrs_AccruedRebatesFeesAndReservesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="chrs_AccruedRebatesFeesAndReservesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CorporateHeadquartersLeaseAgreementMember" xlink:label="chrs_CorporateHeadquartersLeaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="chrs_CorporateHeadquartersLeaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LaboratoryFacilitiesLeaseAgreementMember" xlink:label="chrs_LaboratoryFacilitiesLeaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="chrs_LaboratoryFacilitiesLeaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NewCamarilloLeaseMember" xlink:label="chrs_NewCamarilloLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="chrs_NewCamarilloLeaseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_VehiclesLeaseMember" xlink:label="chrs_VehiclesLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="chrs_VehiclesLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OfficeSpaceRemainingPremisesMember" xlink:label="chrs_OfficeSpaceRemainingPremisesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="chrs_OfficeSpaceRemainingPremisesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SixthAmendmentToLeaseMember" xlink:label="chrs_SixthAmendmentToLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_SixthAmendmentToLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfVehiclesLeased" xlink:label="chrs_NumberOfVehiclesLeased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="chrs_NumberOfVehiclesLeased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stockholders' Deficit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingTable" xlink:label="chrs_AtMarketOfferingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="chrs_AtMarketOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="chrs_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="chrs_AtMarketOfferingTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="chrs_AtMarketOfferingTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ChiefMarketingOfficerMember" xlink:label="chrs_ChiefMarketingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="chrs_ChiefMarketingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="chrs_AtMarketOfferingTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OptionalStockPurchaseAgreementMember" xlink:label="chrs_OptionalStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="chrs_OptionalStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingLineItems" xlink:label="chrs_AtMarketOfferingLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_AtMarketOfferingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" xlink:label="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingUnderwritersOptionTerm" xlink:label="chrs_SharesOfferingUnderwritersOptionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_SharesOfferingUnderwritersOptionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingAggregateAmount" xlink:label="chrs_SharesOfferingAggregateAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_SharesOfferingAggregateAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingAggregateAmountDecrease" xlink:label="chrs_SharesOfferingAggregateAmountDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_SharesOfferingAggregateAmountDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" xlink:label="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_WeightedAveragePricePerShare" xlink:label="chrs_WeightedAveragePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_WeightedAveragePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProceedsFromIssuanceOfCommonStockGross" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_ProceedsFromIssuanceOfCommonStockGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" xlink:label="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" xlink:label="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandTenPlanMember" xlink:label="chrs_TwoThousandTenPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_TwoThousandTenPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmploymentCommencementIncentivePlanMember" xlink:label="chrs_EmploymentCommencementIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_EmploymentCommencementIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange1.67To5.44Member" xlink:label="chrs_ExercisePriceRange1.67To5.44Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="chrs_ExercisePriceRange1.67To5.44Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange5.86To10.05Member" xlink:label="chrs_ExercisePriceRange5.86To10.05Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="chrs_ExercisePriceRange5.86To10.05Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange10.37To13.63Member" xlink:label="chrs_ExercisePriceRange10.37To13.63Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="chrs_ExercisePriceRange10.37To13.63Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange14.03To17.17Member" xlink:label="chrs_ExercisePriceRange14.03To17.17Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="chrs_ExercisePriceRange14.03To17.17Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange17.30To19.40Member" xlink:label="chrs_ExercisePriceRange17.30To19.40Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="chrs_ExercisePriceRange17.30To19.40Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange19.85To46.38Member" xlink:label="chrs_ExercisePriceRange19.85To46.38Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="chrs_ExercisePriceRange19.85To46.38Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" xlink:type="extended" xlink:title="41208 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" xlink:label="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41209 - Disclosure - Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" xlink:type="extended" xlink:title="41210 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" xlink:type="extended" xlink:title="41211 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedPaymentArrangementForfeitureCredit" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="chrs_ShareBasedPaymentArrangementForfeitureCredit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41212 - Disclosure - Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" xlink:type="extended" xlink:title="41213 - Disclosure - Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Plan401KMember" xlink:label="chrs_Plan401KMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="chrs_Plan401KMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingLossCarryforwardsExpirationYear" xlink:label="chrs_OperatingLossCarryforwardsExpirationYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="chrs_OperatingLossCarryforwardsExpirationYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TaxCreditCarryforwardExpirationYear" xlink:label="chrs_TaxCreditCarryforwardExpirationYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="chrs_TaxCreditCarryforwardExpirationYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeesAndNonemployeesStockOptionMember" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="chrs_EmployeesAndNonemployeesStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesMember" xlink:label="chrs_ConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="chrs_ConvertibleNotesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRestructuringChargesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Restructuring Charges (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedPaymentArrangementForfeitureCredit" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="chrs_ShareBasedPaymentArrangementForfeitureCredit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="chrs_ConsultingAgreementWithLanfearAdvisorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.coherus.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoherusOphthalmologyLlcMember" xlink:label="chrs_CoherusOphthalmologyLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="chrs_CoherusOphthalmologyLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliDivestitureTransactionMember" xlink:label="chrs_CimerliDivestitureTransactionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="chrs_CimerliDivestitureTransactionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="chrs_TermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebInstrumentPartialRepaymentPrincipal" xlink:label="chrs_DebInstrumentPartialRepaymentPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="chrs_DebInstrumentPartialRepaymentPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EarlyRedemptionFee" xlink:label="chrs_EarlyRedemptionFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="chrs_EarlyRedemptionFee" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>chrs-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2024 9:02:16 PM-->
<!--Modified on: 3/15/2024 9:02:16 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address City Or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security12b Title</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated By Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaidManufacturingExpenseCurrent" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Manufacturing current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Manufacturing Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid manufacturing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment made for manufacturing services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaids and current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets Net Excluding Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedRebatesFeesAndReserveCurrent" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedRebatesFeesAndReserveCurrent" xlink:to="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Rebates Fees And Reserve Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansPayableNoncurrent" xlink:label="chrs_TermLoansPayableNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TermLoansPayableNoncurrent" xlink:to="chrs_TermLoansPayableNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TermLoansPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TermLoansPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_TermLoansPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Subordinated Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Other liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' deficit:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 112,215,260 and 78,851,516 at December 31, 2023 and 2022, respectively)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Of Sold Goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (In dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (In dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average number of shares used in computing basic and diluted net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (In shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding - Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (In shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on available-for-sale securities, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustments, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AtMarketOfferingMember" xlink:to="chrs_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to at the market offering issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering.</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PublicOfferingMember" xlink:to="chrs_PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OptionalStockPurchaseAgreementMember" xlink:label="chrs_OptionalStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OptionalStockPurchaseAgreementMember" xlink:to="chrs_OptionalStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OptionalStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Optional Stock Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OptionalStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Optional Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OptionalStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Optional Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units ("RSUs")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodAcquisitions" xlink:label="chrs_StockIssuedDuringPeriodAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions" xlink:to="chrs_StockIssuedDuringPeriodAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockIssuedDuringPeriodAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period on acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockIssuedDuringPeriodAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockIssuedDuringPeriodAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in connection with Surface Acquisition:(1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance to Surface shareholders for acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance to Surface shareholders for acquisition (in shares)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" xlink:to="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of accelerated vesting of equity awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Accelerated Vesting of Equity Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accelerated vesting of equity awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" xlink:to="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock related to accelerated vesting of equity awards issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Accelerated Vesting of Equity Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accelerated vesting of equity awards</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:to="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares settled related to taxes paid related to net share settlement of equity awards during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Taxes Paid Related to Net Share Settlement of Equity Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of equity awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:to="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock settled related to taxes paid related to net share settlement of equity awards during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Taxes Paid Related to Net Share Settlement of Equity Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under ATM Offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under Offering, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under Offering, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued and sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under the employee stock purchase plan ("ESPP")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Paid For Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of RSUs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive gain (loss), net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_JunshiBiosciencesMember" xlink:to="chrs_JunshiBiosciencesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_JunshiBiosciencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Junshi Biosciences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_JunshiBiosciencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Junshi Biosciences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_JunshiBiosciencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Contract Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of prepaid manufacturing services related to the termination of CHS-2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charge within research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write Down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion Amortization Of Discounts And Premiums Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash amortization of premium (accretion of discount) on marketable securities, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest expense from amortization of debt discount and issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NoncashOperatingLeaseExpense" xlink:label="chrs_NoncashOperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NoncashOperatingLeaseExpense" xlink:to="chrs_NoncashOperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash operating lease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash operating lease expense</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront license fee payment related to license and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront License Fee Payments Related To License And Collaboration Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and option payments to Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Activities, Cash Flow Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash adjustments, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid manufacturing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaid, current and non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accounts Payable Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase decrease in accrued rebates, fees and reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Rebates Fees And Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserves</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_IncreaseDecreaseInAccruedCompensation" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase decrease in accrued compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current and non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from maturities of investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Acquired from Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents acquired from Surface Acquisition</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents upfront and milestone based license fee payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront And Milestone Based License Fee Payments, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and option payments to Junshi Biosciences</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:to="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestone payments related to license and collaboration arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront And Milestone Payments Related To License And Collaboration Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone based license fee payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from purchase under the employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of 2022 Convertible Notes and premiums</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding amount payoff</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of 2025 Term Loan, premiums and exit fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding amount paid off</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Payments for) Other Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid (refunded), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Acquisition</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAndLicenseAgreementsAbstract" xlink:label="chrs_CollaborationAndLicenseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAndLicenseAgreementsAbstract" xlink:to="chrs_CollaborationAndLicenseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborations and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborations and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockholdersDeficitTextBlock" xlink:label="chrs_StockholdersDeficitTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockholdersDeficitTextBlock" xlink:to="chrs_StockholdersDeficitTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockholdersDeficitTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure containing information regarding Stockholders' Deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockholdersDeficitTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockholdersDeficitTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation and Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation and Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring And Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" xlink:label="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" xlink:to="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment reporting and revenue by geographic region.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting And Revenue By Geographic Region Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting and Revenue by Geographic Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:label="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:to="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Accounting &amp; Valuation of Acquired Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions And Translations Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill And Intangible Assets Goodwill Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy related to accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContingentConsiderationPolicyTextBlock" xlink:label="chrs_ContingentConsiderationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ContingentConsiderationPolicyTextBlock" xlink:to="chrs_ContingentConsiderationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Information pertaining to Consideration which is contingent upon some future changes in assumptions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Of Sales Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LicenseAgreementsPolicyTextBlock" xlink:label="chrs_LicenseAgreementsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LicenseAgreementsPolicyTextBlock" xlink:to="chrs_LicenseAgreementsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LicenseAgreementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreements policy text block.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LicenseAgreementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LicenseAgreementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expenses Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Option And Incentive Plans Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReclassificationsPolicyPolicyTextBlock" xlink:label="chrs_ReclassificationsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ReclassificationsPolicyPolicyTextBlock" xlink:to="chrs_ReclassificationsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ReclassificationsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for reclassifications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ReclassificationsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ReclassificationsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives of property plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Estimated Useful Lives of Property Plant and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Net product revenue in United States, and Company's net revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xlink:to="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product sales discounts and allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Product Sales Discounts And Allowances Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and cash equivalents, marketable securities and restricted cash</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfInventoryTableTextBlock" xlink:label="chrs_ScheduleOfInventoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfInventoryTableTextBlock" xlink:to="chrs_ScheduleOfInventoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:label="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory current and noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Inventory Current And Noncurrent Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Balance Sheet Classification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Goodwill and Intangible Assets, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Liabilities, Non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total consideration paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of purchase price allocation to the estimated fair value of the net assets acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of amount allocated to identifiable intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of pro forma information does not purport to represent what the Company's actual results would have been if the acquisition had occurred as of January 1, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TermLoansMember" xlink:to="chrs_TermLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents term loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027 Term Loans</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due 2026.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1.5% Convertible Senior Subordinated Notes due 2026</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 8.2% Convertible Senior Notes due 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.2% Convertible Notes due 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Company's Debt Obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income And Interest Expense Disclosure Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Interest Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Maturities Of Long Term Debt Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Payments on Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Purchase Commitment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Non-cancelable Contractual Obligations</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" xlink:label="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" xlink:to="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for lessee's operating and finance leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating and Finance Lease, Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Balance Sheet Classification of Lease Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" xlink:label="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" xlink:to="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of other information relating to lease term and discount rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Information Relating To lease Term And Discount Rate [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other information related to lease term and discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of lease expense</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" xlink:label="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" xlink:to="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of supplemental cash flow information relating to lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Supplemental Cash Flow Information Related To Lease [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow information related to leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of operating and finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" xlink:label="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" xlink:to="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of shares offering settlements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Settlements Under Shares Offering [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Settlements Under the ATM Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Option Activities under 2016 and 2014 Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of options outstanding and exercisable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" xlink:label="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" xlink:to="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the weighted average grant date fair value per share of the options granted, the total intrinsic value of options exercised, the total fair value of options that have vested, and the total cash received from the exercise of stock options during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Payment Award Stock Options Weighted Average Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of additional information on options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of RSU Activity, under 2014 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Weighted Average Assumptions for Black-Scholes Option-Pricing Model Used in Determining Fair Value of Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the statutory United States federal rate to the Company's effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of the Company's net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the Company's unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoherusOphthalmologyLlcMember" xlink:label="chrs_CoherusOphthalmologyLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CoherusOphthalmologyLlcMember" xlink:to="chrs_CoherusOphthalmologyLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CoherusOphthalmologyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Coherus Ophthalmology LLC Divesture Transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CoherusOphthalmologyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coherus Ophthalmology LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CoherusOphthalmologyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coherus Ophthalmology LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliDivestitureTransactionMember" xlink:label="chrs_CimerliDivestitureTransactionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CimerliDivestitureTransactionMember" xlink:to="chrs_CimerliDivestitureTransactionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CimerliDivestitureTransactionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to CIMERLI Divestiture transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CimerliDivestitureTransactionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CIMERLI Divestiture Transaction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CimerliDivestitureTransactionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CIMERLI Disposition Transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Consideration Transferred1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination consideration transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred, Total</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xlink:to="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consideration transferred for inventory and prepaid manufacturing assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Consideration Transferred, Inventory And Prepaid Manufacturing Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration transferred for CIMERLI product inventory and prepaid manufacturing assets</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProductPipelineNumberOfDrugCandidates" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProductPipelineNumberOfDrugCandidates" xlink:to="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of drug candidates in the product pipeline.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product pipeline, Number of Drug Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product pipeline, number of product candidates</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfOperatingAndReportableSegments" xlink:label="chrs_NumberOfOperatingAndReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NumberOfOperatingAndReportableSegments" xlink:to="chrs_NumberOfOperatingAndReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NumberOfOperatingAndReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating and reportable segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NumberOfOperatingAndReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating and Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NumberOfOperatingAndReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable and operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income from marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments related to credit losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssets" xlink:to="us-gaap_DerivativeAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_YusimryProductMember" xlink:to="chrs_YusimryProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_YusimryProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Yusimry product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_YusimryProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Yusimry Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_YusimryProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">YUSIMRY</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UdenycaMember" xlink:to="chrs_UdenycaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UdenycaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the product UDENYCA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UdenycaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Udenyca [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_UdenycaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UDENYCA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives, description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Out-licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets and Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Finite-lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long lived assets, material impairments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Performance Obligation, Description of Payment Terms</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentTermsPeriodFromDateOfShipment" xlink:label="chrs_PaymentTermsPeriodFromDateOfShipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PaymentTermsPeriodFromDateOfShipment" xlink:to="chrs_PaymentTermsPeriodFromDateOfShipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PaymentTermsPeriodFromDateOfShipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the payment terms from date of shipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PaymentTermsPeriodFromDateOfShipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Terms, Period from Date of Shipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PaymentTermsPeriodFromDateOfShipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment terms from date of shipment, period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BioeqIPAGMember" xlink:to="chrs_BioeqIPAGMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BioeqIPAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioeq IP AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BioeqIPAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioeq IP AG</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BioeqIPAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioeq IP AG</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoqtorziMember" xlink:label="chrs_LoqtorziMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoqtorziMember" xlink:to="chrs_LoqtorziMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoqtorziMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents LOQTORZI.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoqtorziMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOQTORZI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoqtorziMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOQTORZI</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements And Noncollaborative Arrangement Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RoyaltyPaymentTerm" xlink:label="chrs_RoyaltyPaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RoyaltyPaymentTerm" xlink:to="chrs_RoyaltyPaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RoyaltyPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RoyaltyPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Payment Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_RoyaltyPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment term</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfRoyaltiesOnNetSales" xlink:label="chrs_PercentageOfRoyaltiesOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfRoyaltiesOnNetSales" xlink:to="chrs_PercentageOfRoyaltiesOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfRoyaltiesOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalties incurred on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfRoyaltiesOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Royalties On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfRoyaltiesOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of royalties on net sales</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfGrossProfitsOnSales" xlink:to="chrs_PercentageOfGrossProfitsOnSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfGrossProfitsOnSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">percentage of profit shared.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfGrossProfitsOnSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Profits On Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfGrossProfitsOnSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of gross profits shared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing And Advertising Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior Period Reclassification Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes to net cash used in operating activities in the consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Or Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net product revenue</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliMember" xlink:label="chrs_CimerliMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CimerliMember" xlink:to="chrs_CimerliMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CimerliMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the product CIMERLI.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CimerliMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CIMERLI</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryMember" xlink:label="chrs_YusimryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_YusimryMember" xlink:to="chrs_YusimryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_YusimryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the product YUSIMRY.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_YusimryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">YUSIMRY</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ToripalimabMember" xlink:to="chrs_ToripalimabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ToripalimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents toripalimab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ToripalimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Toripalimab</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ToripalimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Toripalimab (LOQTORZI)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_ToripalimabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOQTORZI</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Product Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customers [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_McKessonMember" xlink:label="chrs_McKessonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_McKessonMember" xlink:to="chrs_McKessonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_McKessonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">McKesson.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_McKessonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">McKesson</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AmeriSourceBergenCorpMember" xlink:label="chrs_AmeriSourceBergenCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AmeriSourceBergenCorpMember" xlink:to="chrs_AmeriSourceBergenCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AmeriSourceBergenCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AmeriSource-Bergen Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AmeriSourceBergenCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AmeriSource-Bergen Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AmeriSourceBergenCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cencora (previously known as AmeriSource-Bergen Corporation)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CardinalMember" xlink:label="chrs_CardinalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CardinalMember" xlink:to="chrs_CardinalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CardinalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cardinal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CardinalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cardinal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of total gross revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accounts Notes Loans And Financing Receivable [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accounts Notes Loans And Financing Receivable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="chrs_ChargebacksAndDiscountsForPromptPaymentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charge backs and discounts for prompt payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chargebacks and Discounts for Prompt Payment</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RebatesMember" xlink:label="chrs_RebatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RebatesMember" xlink:to="chrs_RebatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rebates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RebatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rebates</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:to="chrs_OtherFeesCoPayAssistanceAndReturnsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other fees, co-pay assistance and returns.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Fees, Co-pay Assistance and Returns</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Notes And Loans Receivable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Notes And Loans Receivable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve for discounts and allowances constitute variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve For Discounts And Allowances Constitute Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Activities and reserve balance, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Activities and reserve balance, beginning balance</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProvisionRelatedToSalesMadeAbstract" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract" xlink:to="chrs_ProvisionRelatedToSalesMadeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision related to sales made in:</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:to="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve for sales discounts and allowances constitute variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve For Sales Discounts And Allowances Constitute Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current period</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:to="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents provision related to sales made in prior period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision Related to Sales Made in Prior Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior period - increase (decrease)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:to="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments and customer credits issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Class</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidExpensesMember" xlink:label="chrs_PrepaidExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaidExpensesMember" xlink:to="chrs_PrepaidExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaidExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaidExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrepaidExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid financial instrument in Prepaid manufacturing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Agencies Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. government agency securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. treasury securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Note Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper and corporate notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContingentConsiderationMember" xlink:label="chrs_ContingentConsiderationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ContingentConsiderationMember" xlink:to="chrs_ContingentConsiderationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ContingentConsiderationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ContingentConsiderationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets measured at fair value on a recurring basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost, Unrealized Gains or Losses, and Fair Value by Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Classified as Equity, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized Gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment in the CVR liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Positions that were in unrealized loss positions</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" xlink:label="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" xlink:to="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum remaining period until maturity of the investment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Maturities of Available-for-sale Debt Securities, Remaining Maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining contractual maturities of available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" xlink:label="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" xlink:to="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average remaining period until maturity of the acquired debt security contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Contractual Maturities of Available-for-sale Debt Securities, Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average maturity of investments upon acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Raw Materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Work In Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Finished Goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InventoryCurrentAndNoncurrent" xlink:label="chrs_InventoryCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InventoryCurrentAndNoncurrent" xlink:to="chrs_InventoryCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory current and noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current And Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chrs_InventoryCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current [Table]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Chs2020Member" xlink:label="chrs_Chs2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_Chs2020Member" xlink:to="chrs_Chs2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_Chs2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents CHS-2020, a biosimilar of Eylea.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_Chs2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHS-2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents accrued and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">other liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:to="chrs_LongTermAndShortTermPurchaseCommitmentsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount the entity agreed to spend under the long-term and short-term purchase commitment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term And Short-Term Purchase Commitments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain firm purchase commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain firm purchase commitments, Long-term</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShortTermPurchaseCommitmentAmount" xlink:label="chrs_ShortTermPurchaseCommitmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ShortTermPurchaseCommitmentAmount" xlink:to="chrs_ShortTermPurchaseCommitmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ShortTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount the entity agreed to spend under the short-term purchase commitment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ShortTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ShortTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain firm purchase commitments, Short-term</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:to="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents prepayments made to a CMO for manufacturing services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments Made to CMO For Manufacturing Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments made to a CMO for manufacturing services for UDENYCA</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:to="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents prepayments made to a CMO for other research and development program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments made to a CMO For Other Research And Development Pipeline Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments made to a CMO For Other Research And Development Pipeline Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Production Related Impairments or Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charge for the write-off of prepaid manufacturing services no longer deemed to have future benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group, Including Discontinued Operation, Operating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to the discontinuation of CHS-2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense related to property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tangible Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material impairments of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software implementation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived assets, net of accumulated amortization of $639 and $61, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived assets - IPR&amp;D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Including Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Goodwill and intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" xlink:label="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" xlink:to="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in each of five succeeding fiscal years. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining life of the finite-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of goodwill</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_UpfrontAndMilestonePayment" xlink:to="chrs_UpfrontAndMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_UpfrontAndMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents upfront and milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_UpfrontAndMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront And Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_UpfrontAndMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestone payment</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:to="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued commercial and research and development manufacturing liabilities current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Commercial and Research and Development Manufacturing Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued commercial and research and development manufacturing</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedCoDevelopmentCostsAndMilestonePayments" xlink:label="chrs_AccruedCoDevelopmentCostsAndMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedCoDevelopmentCostsAndMilestonePayments" xlink:to="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued co-development costs and milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount represents Accrued co-development costs and milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued co-development costs and milestone payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Royalties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued royalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:to="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents lease liabilities for both operating and financing leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities, Operating and Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Contingent Consideration Liability Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Sundry Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SurfaceOncologyInc.Member" xlink:to="chrs_SurfaceOncologyInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SurfaceOncologyInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Surface Oncology, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SurfaceOncologyInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Oncology, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SurfaceOncologyInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Oncology, Inc.</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceGlaxosmithklineAgreementMember" xlink:label="chrs_SurfaceGlaxosmithklineAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SurfaceGlaxosmithklineAgreementMember" xlink:to="chrs_SurfaceGlaxosmithklineAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SurfaceGlaxosmithklineAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Surface GSK agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SurfaceGlaxosmithklineAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface GlaxoSmithKline Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SurfaceGlaxosmithklineAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface GSK Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceNovartisAgreementMember" xlink:label="chrs_SurfaceNovartisAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SurfaceNovartisAgreementMember" xlink:to="chrs_SurfaceNovartisAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SurfaceNovartisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Surface Novartis agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SurfaceNovartisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Novartis Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SurfaceNovartisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface Novartis Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" xlink:label="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" xlink:to="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Surface's SRF114 proprietary drug product candidate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface SRF114 Proprietary Drug Product Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface's SRF114 proprietary drug product candidate</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" xlink:label="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" xlink:to="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Surface's SRF388 proprietary drug product candidate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface SRF388 Proprietary Drug Product Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface's SRF388 proprietary drug product candidate</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" xlink:to="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued in exchange of each share of acquiree in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPerShare" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationContingentValueRightPerShare" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of contingent value rights issuable in consideration for each share under business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration, Contingent Value Right Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value right per share</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The payment period of contingent value rights under business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration, Contingent Value Right, Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value rights payment period</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of milestone and royalty based payments payable as part of contingent value rights under business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration, Contingent Value Right Payments, Percent of Milestone and Royalty Based Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone and royalty based CVR payments (as percent)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of upfront payments payable as part of contingent value rights under business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration, Contingent Value Right Payments, Percent of Upfront Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment based CVR payments (as percent)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" xlink:to="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued to former employees of acquiree.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Shares Issued to Former Employees of Acquiree shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Shares Issued to Former Employees of Acquiree shares</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" xlink:label="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" xlink:to="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of outlicensed partnership program in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Out Licensed Partnership Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Number of Out Licensed Partnership Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue of Acquiree since Acquisition Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings or Loss of Acquiree since Acquisition Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Acquisition Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition related costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coherus common stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consideration transferred, equity of combined company owned by acquiree equity holders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Consideration Transferred, Equity of Combined Company Owned by Acquiree Equity Holders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity of combined company owned by Surface equity holders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Consideration Transferred, Liabilities Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent CVR liability</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consideration transferred, equity of combined company owned by acquiree former employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Consideration Transferred, Equity of Combined Company Owned by Acquiree Former Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity of combined company owned by Surface former employees (1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaids and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identifiable intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Assumed</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" xlink:to="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net assets acquired</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InProcessResearchAndDevelopmentSrf388Member" xlink:label="chrs_InProcessResearchAndDevelopmentSrf388Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InProcessResearchAndDevelopmentSrf388Member" xlink:to="chrs_InProcessResearchAndDevelopmentSrf388Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InProcessResearchAndDevelopmentSrf388Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to In-process research and development - SRF388.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InProcessResearchAndDevelopmentSrf388Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development SRF 388 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_InProcessResearchAndDevelopmentSrf388Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development - casdozokitug</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InProcessResearchAndDevelopmentSrf114Member" xlink:label="chrs_InProcessResearchAndDevelopmentSrf114Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InProcessResearchAndDevelopmentSrf114Member" xlink:to="chrs_InProcessResearchAndDevelopmentSrf114Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InProcessResearchAndDevelopmentSrf114Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to In-process research and development - SRF114.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InProcessResearchAndDevelopmentSrf114Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development SRF 114 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_InProcessResearchAndDevelopmentSrf114Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development - SRF 114</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OutLicensesWithGrkMember" xlink:label="chrs_OutLicensesWithGrkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OutLicensesWithGrkMember" xlink:to="chrs_OutLicensesWithGrkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OutLicensesWithGrkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Out-license - GSK.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OutLicensesWithGrkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Out Licenses with GRK [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OutLicensesWithGrkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Out-license - GSK</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OutLicensesWithNovartisInstitutesMember" xlink:label="chrs_OutLicensesWithNovartisInstitutesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OutLicensesWithNovartisInstitutesMember" xlink:to="chrs_OutLicensesWithNovartisInstitutesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OutLicensesWithNovartisInstitutesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Out-license - Novartis Institutes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OutLicensesWithNovartisInstitutesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Out Licenses with Novartis Institutes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OutLicensesWithNovartisInstitutesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Out-license - Novartis Institutes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Plan</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_VaccinexLicenseAgreementMember" xlink:label="chrs_VaccinexLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_VaccinexLicenseAgreementMember" xlink:to="chrs_VaccinexLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_VaccinexLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Vaccinex License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_VaccinexLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vaccinex License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_VaccinexLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vaccinex License Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdimabDevelopmentAndOptionAgreementMember" xlink:label="chrs_AdimabDevelopmentAndOptionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AdimabDevelopmentAndOptionAgreementMember" xlink:to="chrs_AdimabDevelopmentAndOptionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AdimabDevelopmentAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Adimab Development and Option Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AdimabDevelopmentAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adimab Development and Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AdimabDevelopmentAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adimab Development and Option Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NovartisAgreementMember" xlink:label="chrs_NovartisAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NovartisAgreementMember" xlink:to="chrs_NovartisAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NovartisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Novartis Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NovartisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NovartisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_GskAgreementMember" xlink:label="chrs_GskAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_GskAgreementMember" xlink:to="chrs_GskAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_GskAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to GSK Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_GskAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_GskAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK Agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Chs006AntiTigitAntibodyMember" xlink:label="chrs_Chs006AntiTigitAntibodyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_Chs006AntiTigitAntibodyMember" xlink:to="chrs_Chs006AntiTigitAntibodyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_Chs006AntiTigitAntibodyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents CHS-006 anti-TIGIT antibody.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_Chs006AntiTigitAntibodyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHS-006 Anti-TIGIT Antibody [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_Chs006AntiTigitAntibodyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHS-006 anti-TIGIT antibody</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceMember" xlink:label="chrs_SurfaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SurfaceMember" xlink:to="chrs_SurfaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SurfaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Surface.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SurfaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SurfaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surface</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensed Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensed Products</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:to="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents anti-TIGIT antibody and the IL-2 cytokine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-TIGIT Antibody and IL-2 cytokine</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-TIGIT Antibody and IL-2 cytokine</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" xlink:to="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents intangible assets, net and accrued and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net And Accrued And Other Current Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net and accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationCosts" xlink:label="chrs_CollaborationCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationCosts" xlink:to="chrs_CollaborationCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents costs associated to a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, upfront amount paid</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of royalty on net sales under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Percentage Of Royalty On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, royalty on net sales, percentage</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:to="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of option exercise fee per program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Option Exercise Fee Per Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Fee</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of royalty on net sales for each option program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Percentage Of Royalty On Net Sales For Each Option Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, royalty on net sales for each exercised option, percentage</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:to="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Threshold Payments On Achievement Of Various Milestone For Each Option Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:to="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum paid amount for co-development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Amount Paid, Co-development Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum paid amount for co-development activities (per licensed compound)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:to="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents co-development, regulatory and technology transfer costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Co-development, Regulatory And Technology Transfer Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Co-development, regulatory and technology transfer costs</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement, Shares Agreed To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unregistered shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing stock, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement, Shares Agreed To Be Issued, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate value</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:to="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period before the company can sell, transfer or make any short sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement, Restrictive Requirement on Selling, Transfer and Short Sale of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period before the company can sell, transfer or make any short sale of common stock (in years)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FairValueForDiscountForLackOfMarketability" xlink:label="chrs_FairValueForDiscountForLackOfMarketability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_FairValueForDiscountForLackOfMarketability" xlink:to="chrs_FairValueForDiscountForLackOfMarketability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the fair value for the discount for lack of marketability (DLOM).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value for the Discount for Lack of Marketability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value for the discount for lack of marketability (DLOM)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InitialTermOfAgreement" xlink:label="chrs_InitialTermOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_InitialTermOfAgreement" xlink:to="chrs_InitialTermOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_InitialTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_InitialTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_InitialTermOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments upon achievement of certain development and regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments Upon Achievement Of Certain Development And Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate milestone payments</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments upon achievement of with subject to FDA approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Milestone Payments Upon Achievement With Subject To FDA Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments related to FDA approval</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedMilestonePayment" xlink:label="chrs_AccruedMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedMilestonePayment" xlink:to="chrs_AccruedMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued milestone payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties due</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" xlink:label="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" xlink:to="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum antibodies to be commercialized under commercialization option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Antibodies to be Commercialized under Commercialization Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum antibodies to be commercialized under commercialization option</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" xlink:label="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" xlink:to="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical milestone payments obligated to pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Technical Milestone Payments Obligated to Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical milestone payments obligated to pay</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" xlink:label="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" xlink:to="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for payment of nominal research maintenance fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Period for Payment of Nominal Research Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for payment of nominal research maintenance fee</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" xlink:label="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" xlink:to="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate milestone payments to be made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Maximum Aggregate Milestone Payments to be Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate milestone payments to be made</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" xlink:label="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" xlink:to="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum antibodies partially exercised under commercialization option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Antibodies Partially Exercised under Commercialization Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum antibodies partially exercised under commercialization option</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" xlink:label="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" xlink:to="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of option fee to be paid on partial exercise of commercialization option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Option Fee to be Paid on Partial Exercise of Commercialization Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of option fee to be paid on partial exercise of commercialization option</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementAdditionalPaymentToBeMade" xlink:label="chrs_CollaborationAgreementAdditionalPaymentToBeMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementAdditionalPaymentToBeMade" xlink:to="chrs_CollaborationAgreementAdditionalPaymentToBeMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementAdditionalPaymentToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional payment to be made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementAdditionalPaymentToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Additional Payment to be Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementAdditionalPaymentToBeMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional payment to be made</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" xlink:label="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" xlink:to="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration term from the effective date without providing materials that pass quality control</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Expiration Term From the Effective Date Without Providing Materials that Pass Quality Control</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration term from the effective date without providing materials that pass quality control</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementTerm" xlink:label="chrs_CollaborationAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementTerm" xlink:to="chrs_CollaborationAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PotentialDevelopmentMilestonesEntitled" xlink:label="chrs_PotentialDevelopmentMilestonesEntitled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PotentialDevelopmentMilestonesEntitled" xlink:to="chrs_PotentialDevelopmentMilestonesEntitled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PotentialDevelopmentMilestonesEntitled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of potential development milestones entitled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PotentialDevelopmentMilestonesEntitled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential Development Milestones Entitled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PotentialDevelopmentMilestonesEntitled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential development milestones</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SalesMilestonesEntitled" xlink:label="chrs_SalesMilestonesEntitled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SalesMilestonesEntitled" xlink:to="chrs_SalesMilestonesEntitled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SalesMilestonesEntitled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of sales milestones entitled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SalesMilestonesEntitled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Milestones Entitled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SalesMilestonesEntitled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMilestonePaymentsEarned" xlink:label="chrs_CollaborationAgreementMilestonePaymentsEarned" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementMilestonePaymentsEarned" xlink:to="chrs_CollaborationAgreementMilestonePaymentsEarned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementMilestonePaymentsEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payments earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementMilestonePaymentsEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Milestone Payments Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementMilestonePaymentsEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments earned</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" xlink:label="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" xlink:to="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of additional clinical milestones eligible to receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Additional Clinical Milestones Eligible to Receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional clinical milestones eligible to receive</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" xlink:label="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" xlink:to="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of regulatory milestones eligible to receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Regulatory Milestones Eligible to Receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestones eligible to receive</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RegulatoryMilestonesEligibleToPay" xlink:label="chrs_RegulatoryMilestonesEligibleToPay" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RegulatoryMilestonesEligibleToPay" xlink:to="chrs_RegulatoryMilestonesEligibleToPay_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RegulatoryMilestonesEligibleToPay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of regulatory milestones eligible to pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RegulatoryMilestonesEligibleToPay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory Milestones Eligible to Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_RegulatoryMilestonesEligibleToPay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less unamortized debt discount and debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining unamortized debt discount and debt offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net carrying value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheLoanMember" xlink:label="chrs_TrancheLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheLoanMember" xlink:to="chrs_TrancheLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche A Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Loan, funded January 5, 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheBLoanMember" xlink:label="chrs_TrancheBLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheBLoanMember" xlink:to="chrs_TrancheBLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche B Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B Loan, funded on March 31, 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheCLoanMember" xlink:label="chrs_TrancheCLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheCLoanMember" xlink:to="chrs_TrancheCLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheCLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche C Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheCLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche C Loan, not funded between April 1, 2022 and March 17, 2023</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheDLoanMember" xlink:label="chrs_TrancheDLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheDLoanMember" xlink:to="chrs_TrancheDLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheDLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Tranche D Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheDLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D Loan, funded on September 14, 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheaBAndDLoansMember" xlink:label="chrs_TrancheaBAndDLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TrancheaBAndDLoansMember" xlink:to="chrs_TrancheaBAndDLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TrancheaBAndDLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to  tranche A&amp;B &amp; D loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TrancheaBAndDLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche a B And D Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_TrancheaBAndDLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranches A, B and D</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Through March 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Starting April 1, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional facility amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to BioPharma Credit Investments V GP LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioPharma Credit Investments V GP LLC</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Healthcare Royalty Partners III, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ThreeMonthLiborMember" xlink:label="chrs_ThreeMonthLiborMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ThreeMonthLiborMember" xlink:to="chrs_ThreeMonthLiborMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ThreeMonthLiborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the London Interbank Offered rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ThreeMonthLiborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three-month LIBOR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ThreeMonthLiborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIBOR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unused Borrowing Capacity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount not funded</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentUncommittedAdditionalFacility" xlink:label="chrs_DebtInstrumentUncommittedAdditionalFacility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentUncommittedAdditionalFacility" xlink:to="chrs_DebtInstrumentUncommittedAdditionalFacility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentUncommittedAdditionalFacility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of uncommitted additional facility that is available to the entity as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentUncommittedAdditionalFacility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Uncommitted Additional Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentUncommittedAdditionalFacility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncommitted additional facility</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentNumberOfTranches" xlink:label="chrs_DebtInstrumentNumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentNumberOfTranches" xlink:to="chrs_DebtInstrumentNumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of committed tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spread on variable rate</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants, Net Sales For Period One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve month net sales for current quarter</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants, Net Sales For Period Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales required under loan agreement for period three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement Covenants, Net Sales For Period Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement covenants, minimum trailing twelve-month net sales continuing through the quarter ended December 31, 2026</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MandatoryPrepaymentTerm" xlink:label="chrs_MandatoryPrepaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MandatoryPrepaymentTerm" xlink:to="chrs_MandatoryPrepaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MandatoryPrepaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mandatory prepayment, term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MandatoryPrepaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mandatory Prepayment, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_MandatoryPrepaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mandatory prepayment term</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtDiscountsAndIssuanceCosts" xlink:label="chrs_DebtDiscountsAndIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtDiscountsAndIssuanceCosts" xlink:to="chrs_DebtDiscountsAndIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of debt discounts and issuance costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Discounts and Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt discounts and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Finance Costs Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, Issuance Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total term of the loan</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentRemainingTerm" xlink:label="chrs_DebtInstrumentRemainingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentRemainingTerm" xlink:to="chrs_DebtInstrumentRemainingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to debt instrument remaining term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Remaining Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentRemainingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense Debt Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated coupon interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 - interest only</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal In Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 - interest only</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt Maturities Repayments Of Principal In Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 - principal and interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 - principal and interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027 - principal and interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable Current And Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less amount representing interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual future interest payments due in 2022</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TermLoanGross" xlink:to="chrs_TermLoanGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TermLoanGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan, gross.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TermLoanGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_TermLoanGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027 Term Loans, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of 2026 Convertible Notes, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from offering</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument convertible number of shares per thousand of principal amount of notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Convertible Number Of Shares Per Thousand Of Principal Amount Of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial conversion rate, shares of common stock</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount of notes converted into shares of common stock at conversion rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Amount Of Notes Converted Into Shares Of Common Stock At Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount of notes converted into shares</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EquivalentToConversionPricePerCommonShare" xlink:to="chrs_EquivalentToConversionPricePerCommonShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equivalent to conversion price per common share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equivalent To Conversion Price Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial conversion price per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument maturity date</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfPremiumOnConvertibleNote" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of premium on convertible note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Premium On Convertible Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, premium percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantCompliance" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Covenant Compliance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, covenant compliance</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NumberOfEventsInDefault" xlink:to="chrs_NumberOfEventsInDefault_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NumberOfEventsInDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of events in default.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NumberOfEventsInDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Events in Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NumberOfEventsInDefault_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of events in default</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Noncurrent, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentContractualTerm" xlink:label="chrs_DebtInstrumentContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentContractualTerm" xlink:to="chrs_DebtInstrumentContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to debt instrument contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion Converted Instrument Amount1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, converted amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CallOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capped Call Transactions in connection with the 2026 Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentForCappedCallTransactions" xlink:label="chrs_PaymentForCappedCallTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PaymentForCappedCallTransactions" xlink:to="chrs_PaymentForCappedCallTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PaymentForCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payment made for entering into capped call transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PaymentForCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Capped Call Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PaymentForCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for capped call transactions</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CapPriceOfCapCallTransactions" xlink:label="chrs_CapPriceOfCapCallTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CapPriceOfCapCallTransactions" xlink:to="chrs_CapPriceOfCapCallTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CapPriceOfCapCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the cap price of the cap call transactions (per share).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CapPriceOfCapCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cap Price of Cap Call Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CapPriceOfCapCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial cap price of capped call transactions.</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfCapPriceCappedCallTransactions" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageOfCapPriceCappedCallTransactions" xlink:to="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of premium on cap price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Cap Price, Capped Call Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of cap price</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleNotesPrincipalAmount" xlink:to="chrs_ConvertibleNotesPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleNotesPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes, principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleNotesPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ConvertibleNotesPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 Convertible Notes, principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions By Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_KKRBiosimilarLPMember" xlink:label="chrs_KKRBiosimilarLPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_KKRBiosimilarLPMember" xlink:to="chrs_KKRBiosimilarLPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_KKRBiosimilarLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">KKR Biosimilar L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_KKRBiosimilarLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">KKR Member</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MXIIAssociatesLLCMember" xlink:label="chrs_MXIIAssociatesLLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_MXIIAssociatesLLCMember" xlink:to="chrs_MXIIAssociatesLLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_MXIIAssociatesLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MX II Associates LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_MXIIAssociatesLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MX II Member</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_KMGCapitalPartnersLLCMember" xlink:label="chrs_KMGCapitalPartnersLLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_KMGCapitalPartnersLLCMember" xlink:to="chrs_KMGCapitalPartnersLLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_KMGCapitalPartnersLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">KMG Capital Partners, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_KMGCapitalPartnersLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">KMGCP Member</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentPrepaymentPercentage" xlink:label="chrs_DebtInstrumentPrepaymentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebtInstrumentPrepaymentPercentage" xlink:to="chrs_DebtInstrumentPrepaymentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument prepayment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Prepayment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment premium percentage</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:to="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage required to pay an additional exit fee on principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Required To Pay Additional Exit Fee On Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage required to pay an additional exit fee on principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Second Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInThirdYear" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation Due In Third Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedRebatesFeesAndReservesMember" xlink:label="chrs_AccruedRebatesFeesAndReservesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AccruedRebatesFeesAndReservesMember" xlink:to="chrs_AccruedRebatesFeesAndReservesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AccruedRebatesFeesAndReservesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents accrued rebates, fees and reserves.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AccruedRebatesFeesAndReservesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Rebates, Fees And Reserves [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AccruedRebatesFeesAndReservesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued rebates, fees and reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual related to legal Proceedings and Other Claims</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:to="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Claims related to certain sales of UDENYCA from October 2020 through December 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Lease Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Lease Description [Table]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CorporateHeadquartersLeaseAgreementMember" xlink:label="chrs_CorporateHeadquartersLeaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CorporateHeadquartersLeaseAgreementMember" xlink:to="chrs_CorporateHeadquartersLeaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CorporateHeadquartersLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate headquarters lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CorporateHeadquartersLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Headquarters Lease</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LaboratoryFacilitiesLeaseAgreementMember" xlink:label="chrs_LaboratoryFacilitiesLeaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_LaboratoryFacilitiesLeaseAgreementMember" xlink:to="chrs_LaboratoryFacilitiesLeaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_LaboratoryFacilitiesLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory facilities lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_LaboratoryFacilitiesLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Facilities Lease</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NewCamarilloLeaseMember" xlink:label="chrs_NewCamarilloLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NewCamarilloLeaseMember" xlink:to="chrs_NewCamarilloLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NewCamarilloLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Camarillo Lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NewCamarilloLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Camarillo Lease</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_VehiclesLeaseMember" xlink:label="chrs_VehiclesLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_VehiclesLeaseMember" xlink:to="chrs_VehiclesLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_VehiclesLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents vehicles leased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_VehiclesLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicle Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OfficeSpaceRemainingPremisesMember" xlink:label="chrs_OfficeSpaceRemainingPremisesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OfficeSpaceRemainingPremisesMember" xlink:to="chrs_OfficeSpaceRemainingPremisesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OfficeSpaceRemainingPremisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to remaining premises of office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OfficeSpaceRemainingPremisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space, Remaining Premises [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OfficeSpaceRemainingPremisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Premises</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SixthAmendmentToLeaseMember" xlink:label="chrs_SixthAmendmentToLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SixthAmendmentToLeaseMember" xlink:to="chrs_SixthAmendmentToLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SixthAmendmentToLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to sixth amendment to lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SixthAmendmentToLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sixth Amendment to Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SixthAmendmentToLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sixth amendment to lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Lease Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Lease Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area Of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of office space leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Expiration Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to extend lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of optional lease renewal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfVehiclesLeased" xlink:label="chrs_NumberOfVehiclesLeased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NumberOfVehiclesLeased" xlink:to="chrs_NumberOfVehiclesLeased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NumberOfVehiclesLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of vehicles leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NumberOfVehiclesLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Vehicles Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NumberOfVehiclesLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vehicles leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Discount Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease weighted average remaining term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="chrs_OperatingAndFinanceLeaseRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="chrs_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's right to use underlying asset under operating and finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating And Finance Lease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chrs_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total leased assets</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingLeaseLiabilitiesAbstract" xlink:label="chrs_OperatingLeaseLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract" xlink:to="chrs_OperatingLeaseLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Remaining Lease Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease weighted average remaining term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FinanceLeaseCost" xlink:label="chrs_FinanceLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_FinanceLeaseCost" xlink:to="chrs_FinanceLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of finance lease cost incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chrs_FinanceLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total finance lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows from operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows from finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Payment on Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing cash flows from finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less imputed interest</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingTable" xlink:label="chrs_AtMarketOfferingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AtMarketOfferingTable" xlink:to="chrs_AtMarketOfferingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AtMarketOfferingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AtMarketOfferingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Deficit [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' Option to Purchase Additional Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ChiefMarketingOfficerMember" xlink:label="chrs_ChiefMarketingOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ChiefMarketingOfficerMember" xlink:to="chrs_ChiefMarketingOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ChiefMarketingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to chief marketing officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ChiefMarketingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Marketing Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ChiefMarketingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CMO</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingLineItems" xlink:label="chrs_AtMarketOfferingLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_AtMarketOfferingLineItems" xlink:to="chrs_AtMarketOfferingLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_AtMarketOfferingLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_AtMarketOfferingLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_AtMarketOfferingLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" xlink:label="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" xlink:to="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days considered for price per share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Trading Days Considered for Price per Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days considered for price per share of common stock</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingUnderwritersOptionTerm" xlink:label="chrs_SharesOfferingUnderwritersOptionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SharesOfferingUnderwritersOptionTerm" xlink:to="chrs_SharesOfferingUnderwritersOptionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SharesOfferingUnderwritersOptionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for exercise of option to purchase additional shares by underwriters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SharesOfferingUnderwritersOptionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering, Underwriters Option, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SharesOfferingUnderwritersOptionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of share offering</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingAggregateAmount" xlink:label="chrs_SharesOfferingAggregateAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SharesOfferingAggregateAmount" xlink:to="chrs_SharesOfferingAggregateAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SharesOfferingAggregateAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of shares to be offered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SharesOfferingAggregateAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering, Aggregate Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SharesOfferingAggregateAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering, Aggregate Amount</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingAggregateAmountDecrease" xlink:label="chrs_SharesOfferingAggregateAmountDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_SharesOfferingAggregateAmountDecrease" xlink:to="chrs_SharesOfferingAggregateAmountDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_SharesOfferingAggregateAmountDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The decrease in aggregate amount of shares to be offered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_SharesOfferingAggregateAmountDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering, Aggregate Amount, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_SharesOfferingAggregateAmountDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Offering, Aggregate Amount, Decrease</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" xlink:label="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" xlink:to="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in shares to be issued and sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Amount of Shares To be Issued and Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Amount of Shares To be Issued and Sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Consideration Received On Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds after commissions and fees</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_WeightedAveragePricePerShare" xlink:label="chrs_WeightedAveragePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_WeightedAveragePricePerShare" xlink:to="chrs_WeightedAveragePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_WeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_WeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_WeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average price per share</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProceedsFromIssuanceOfCommonStockGross" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ProceedsFromIssuanceOfCommonStockGross" xlink:to="chrs_ProceedsFromIssuanceOfCommonStockGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the additional capital contribution to the entity, before stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less commissions and fees</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" xlink:label="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" xlink:to="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the common stock remaining available for sale under the atm offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Remaining Available For Sale Under The ATM Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock remaining available for sales under the ATM Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" xlink:label="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" xlink:to="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two thousand and fourteen equity incentive award plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Plan</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandTenPlanMember" xlink:label="chrs_TwoThousandTenPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TwoThousandTenPlanMember" xlink:to="chrs_TwoThousandTenPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TwoThousandTenPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the company's 2010 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TwoThousandTenPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Plan</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmploymentCommencementIncentivePlanMember" xlink:label="chrs_EmploymentCommencementIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmploymentCommencementIncentivePlanMember" xlink:to="chrs_EmploymentCommencementIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmploymentCommencementIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Employment Commencement Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmploymentCommencementIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" xlink:to="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate of increase in number of common stock available for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate Of Increase In Number Of Common Stock Available For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted, weighted-average grant-date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised, aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expenses related to stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the 2016 and 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 plan and 2014 plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding, Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options, granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options, Granted - at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options, Forfeited/Canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding, Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price, Granted - at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Forfeited/Canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding, Weighted-Average Remaining Contractual Terms</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding, Weighted-Average Remaining Contractual Terms, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding, Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange1.67To5.44Member" xlink:label="chrs_ExercisePriceRange1.67To5.44Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExercisePriceRange1.67To5.44Member" xlink:to="chrs_ExercisePriceRange1.67To5.44Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExercisePriceRange1.67To5.44Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">it represents the exercise price range 1.67 to 5.44.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExercisePriceRange1.67To5.44Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 1.67 To 5.44 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ExercisePriceRange1.67To5.44Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1.67 - 5.44</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange5.86To10.05Member" xlink:label="chrs_ExercisePriceRange5.86To10.05Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExercisePriceRange5.86To10.05Member" xlink:to="chrs_ExercisePriceRange5.86To10.05Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExercisePriceRange5.86To10.05Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">it represents the exercise price range 5.86 to 10.05.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExercisePriceRange5.86To10.05Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 5.86 To 10.05 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ExercisePriceRange5.86To10.05Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">5.86 - 10.05</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange10.37To13.63Member" xlink:label="chrs_ExercisePriceRange10.37To13.63Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExercisePriceRange10.37To13.63Member" xlink:to="chrs_ExercisePriceRange10.37To13.63Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExercisePriceRange10.37To13.63Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">it represents the exercise price range 10.37 to 13.63.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExercisePriceRange10.37To13.63Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 10.37 To 13.63 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ExercisePriceRange10.37To13.63Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">10.37 - 13.63</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange14.03To17.17Member" xlink:label="chrs_ExercisePriceRange14.03To17.17Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExercisePriceRange14.03To17.17Member" xlink:to="chrs_ExercisePriceRange14.03To17.17Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExercisePriceRange14.03To17.17Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">it represents the exercise price range 14.03 to 17.17.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExercisePriceRange14.03To17.17Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 14.03 To 17.17 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ExercisePriceRange14.03To17.17Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">14.03 - 17.17</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange17.30To19.40Member" xlink:label="chrs_ExercisePriceRange17.30To19.40Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExercisePriceRange17.30To19.40Member" xlink:to="chrs_ExercisePriceRange17.30To19.40Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExercisePriceRange17.30To19.40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">it represents the exercise price range 17.30 to 19.40.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExercisePriceRange17.30To19.40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 17.30 To 19.40 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ExercisePriceRange17.30To19.40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">17.30 - 19.40</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange19.85To46.38Member" xlink:label="chrs_ExercisePriceRange19.85To46.38Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ExercisePriceRange19.85To46.38Member" xlink:to="chrs_ExercisePriceRange19.85To46.38Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ExercisePriceRange19.85To46.38Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">it represents the exercise price range 19.85 to 46.38.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ExercisePriceRange19.85To46.38Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 19.85 To 46.38 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ExercisePriceRange19.85To46.38Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">19.85 - 46.38</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range, Lower</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range, Upper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total grant date fair value of options vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expenses related to unvested RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs, beginning balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value, ending balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value, beginning balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value, RSUs granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value, RSUs Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Grant Date Fair Value, RSUs canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total grant date fair value of RSUs vested</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" xlink:label="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" xlink:to="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement by share based payment award equity instruments other than options grants in period estimated grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Estimated Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total grant date fair value of RSUs granted</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two thousand and fourteen employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Employee Stock Purchase Plan (ESPP)</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" xlink:to="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate of increase in number of common stock outstanding reserve for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rate Of Increase In Number Of Common Stock Outstanding Reserve For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares reserve for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of purchase common stock of lesser of fair market value of common stock on first or last day of offering period by eligible employees</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" xlink:to="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee service share based compensation offering period one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Offering Period One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan offering period one</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" xlink:to="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee service share based compensation offering period two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Offering Period Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan offering period two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense capitalized into inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost And Reserve [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation includes restructuring charges</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedPaymentArrangementForfeitureCredit" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ShareBasedPaymentArrangementForfeitureCredit" xlink:to="chrs_ShareBasedPaymentArrangementForfeitureCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of share based compensation forfeiture credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Forfeiture Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeiture credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Plan401KMember" xlink:label="chrs_Plan401KMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_Plan401KMember" xlink:to="chrs_Plan401KMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_Plan401KMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_Plan401KMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of maximum contribution of annual compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Employer Matching Contribution Percent Of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employer matching contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First amount of each participant's contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense related to match plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss From Continuing Operations Before Income Taxes Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss From Continuing Operations Before Income Taxes Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subtotal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of pre-tax income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation State And Local Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate reconciliation permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent items</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" xlink:to="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate reconciliation tax (expense) and credits research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Tax Expense And Credits Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales related accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="chrs_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="chrs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chrs_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxAssetLiabilityNet" xlink:label="chrs_DeferredTaxAssetLiabilityNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DeferredTaxAssetLiabilityNet" xlink:to="chrs_DeferredTaxAssetLiabilityNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DeferredTaxAssetLiabilityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets before valuation allowance net of deferred tax liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DeferredTaxAssetLiabilityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Asset Liability Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chrs_DeferredTaxAssetLiabilityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Liabilities Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets (liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Various states</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingLossCarryforwardsExpirationYear" xlink:label="chrs_OperatingLossCarryforwardsExpirationYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_OperatingLossCarryforwardsExpirationYear" xlink:to="chrs_OperatingLossCarryforwardsExpirationYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards expiration year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TaxCreditCarryforwardExpirationYear" xlink:label="chrs_TaxCreditCarryforwardExpirationYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_TaxCreditCarryforwardExpirationYear" xlink:to="chrs_TaxCreditCarryforwardExpirationYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards expiration year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, accrued interest and penalties accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions based on tax positions related to current year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions for tax positions of prior years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reductions for tax positions of prior years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeesAndNonemployeesStockOptionMember" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EmployeesAndNonemployeesStockOptionMember" xlink:to="chrs_EmployeesAndNonemployeesStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and non-employees stock option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, including shares subject to ESPP</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesMember" xlink:label="chrs_ConvertibleNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConvertibleNotesMember" xlink:to="chrs_ConvertibleNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon conversion of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of EPS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Restructuring And Related Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost And Reserve [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees impacted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:to="chrs_ConsultingAgreementWithLanfearAdvisorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the consulting agreement with Lanfear advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, our President, Chief Executive Officer and Chairman of our Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreement With Lanfear Advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebInstrumentPartialRepaymentPrincipal" xlink:label="chrs_DebInstrumentPartialRepaymentPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_DebInstrumentPartialRepaymentPrincipal" xlink:to="chrs_DebInstrumentPartialRepaymentPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_DebInstrumentPartialRepaymentPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of partial repayment of principal of the loans subject to terms and conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_DebInstrumentPartialRepaymentPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deb Instrument, Partial Repayment, Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_DebInstrumentPartialRepaymentPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partial prepayment of principal</label>
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EarlyRedemptionFee" xlink:label="chrs_EarlyRedemptionFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chrs_EarlyRedemptionFee" xlink:to="chrs_EarlyRedemptionFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chrs_EarlyRedemptionFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of prepayment fees for paying off debt early.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chrs_EarlyRedemptionFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Early Redemption Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chrs_EarlyRedemptionFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment fees for partial debt repayment</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>chrs-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2024 9:02:16 PM-->
<!--Modified on: 3/15/2024 9:02:16 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.coherus.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedBalanceSheetsParentheticals" roleURI="http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenue" roleURI="http://www.coherus.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventory" roleURI="http://www.coherus.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponents" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisition" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCollaborationsAndOtherArrangements" roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations" roleURI="http://www.coherus.com/role/DisclosureDebtObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeases" roleURI="http://www.coherus.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockholdersDeficit" roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefits" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureNetLossPerShare" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRestructuringCharges" roleURI="http://www.coherus.com/role/DisclosureRestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.coherus.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueTables" roleURI="http://www.coherus.com/role/DisclosureRevenueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryTables" roleURI="http://www.coherus.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionTables" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsTables" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesTables" roleURI="http://www.coherus.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockholdersDeficitTables" roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficitTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsTables" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails" roleURI="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueNetRevenueDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" roleURI="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryBalanceSheetClassificationsDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureInventoryAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" roleURI="http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionConsiderationPaidDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" roleURI="http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCollaborationsAndOtherArrangementsDetails" roleURI="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsSummaryOfDebtObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2025TermLoanNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" roleURI="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesComponentsOfLeaseExpenseDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" roleURI="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockholdersDeficitDetails" roleURI="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" roleURI="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRestructuringChargesDetails" roleURI="http://www.coherus.com/role/DisclosureRestructuringChargesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="chrs-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.coherus.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638461333300767662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638461333300767662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638461333300777664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638461333300777664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638461333300777664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638461333300777664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638461333300777664" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638461333300777664" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638461333300777664" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638461333300777664" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638461333300777664" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638461333300777664" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638461333300777664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638461333300777664" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638461333300787667" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638461333300787667" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638461333300787667" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638461333300787667" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638461333300787667" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638461333300787667" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638461333300787667" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638461333300787667" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638461333300787667" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638461333300787667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638461333300787667" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638461333300797662" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638461333300797662" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638461333300797662" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638461333300797662" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638461333300797662" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638461333300797662" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638461333300797662" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638461333300797662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638461333300797662" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638461333300807678" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638461333300807678" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638461333300807678" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638461333300807678" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638461333300807678" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638461333300807678" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638461333300807678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638461333300807678" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638461333300817664" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638461333300817664" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638461333300817664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638461333300817664" xlink:to="us-gaap_AssetsCurrentAbstract_638461333300817664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333300817664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="us-gaap_MarketableSecuritiesCurrent_638461333300817664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="us-gaap_ReceivablesNetCurrent_638461333300817664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638461333300817664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="us-gaap_InventoryNet_638461333300817664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_638461333300827662" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638461333300827662" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638461333300817664" xlink:to="us-gaap_AssetsCurrent_638461333300827662" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638461333300817664" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638461333300827662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638461333300817664" xlink:to="us-gaap_InventoryNoncurrent_638461333300827662" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638461333300817664" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638461333300827662" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638461333300817664" xlink:to="us-gaap_OtherAssetsNoncurrent_638461333300827662" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638461333300817664" xlink:to="us-gaap_Assets_638461333300827662" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638461333300827662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" xlink:to="us-gaap_AccountsPayableCurrent_638461333300827662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedRebatesFeesAndReserveCurrent" xlink:label="chrs_AccruedRebatesFeesAndReserveCurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" xlink:to="chrs_AccruedRebatesFeesAndReserveCurrent_638461333300837664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638461333300837664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638461333300837664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638461333300827662" xlink:to="us-gaap_LiabilitiesCurrent_638461333300837664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansPayableNoncurrent" xlink:label="chrs_TermLoansPayableNoncurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="chrs_TermLoansPayableNoncurrent_638461333300837664" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtNoncurrent" xlink:label="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_ConvertibleSubordinatedDebtNoncurrent_638461333300837664" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="chrs_OperatingAndFinanceLeaseLiabilityNoncurrent_638461333300837664" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638461333300837664" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638461333300837664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_Liabilities_638461333300837664" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_CommitmentsAndContingencies_638461333300847668" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" xlink:to="us-gaap_CommonStockValue_638461333300847668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" xlink:to="us-gaap_AdditionalPaidInCapital_638461333300847668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638461333300847668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638461333300847668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638461333300847668" xlink:to="us-gaap_StockholdersEquity_638461333300847668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638461333300847668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638461333300827662" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638461333300847668" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638461333300857670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638461333300857670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638461333300857670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638461333300857670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638461333300857670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638461333300857670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638461333300857670" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638461333300857670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638461333300857670" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_638461333300867668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638461333300867668" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638461333300867668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638461333300867668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638461333300867668" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638461333300867668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638461333300867668" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638461333300867668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638461333300867668" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638461333300867668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638461333300867668" xlink:to="us-gaap_CostsAndExpenses_638461333300867668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638461333300867668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense_638461333300867668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333300867668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638461333300867668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638461333300867668" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333300877673" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638461333300877673" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638461333300877673" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638461333300877673" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638461333300877673" xlink:to="us-gaap_EarningsPerShareBasic_638461333300877673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638461333300877673" xlink:to="us-gaap_EarningsPerShareDiluted_638461333300877673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638461333300877673" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638461333300877673" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638461333300877673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638461333300877673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638461333300877673" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638461333300877673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss_638461333300887667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638461333300887667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638461333300887667" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638461333300887667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638461333300887667" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638461333300887667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638461333300887667" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638461333300887667" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638461333300887667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333300887667" xlink:to="us-gaap_StatementEquityComponentsAxis_638461333300887667" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638461333300887667" xlink:to="us-gaap_CommonStockMember_638461333300887667" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638461333300887667" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638461333300887667" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638461333300887667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638461333300887667" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638461333300887667" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638461333300887667" xlink:to="us-gaap_RetainedEarningsMember_638461333300897667" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638461333300887667" xlink:to="us-gaap_EquityComponentDomain_638461333300897667" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333300887667" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638461333300897667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638461333300897667" xlink:to="chrs_AtMarketOfferingMember_638461333300897667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638461333300897667" xlink:to="chrs_PublicOfferingMember_638461333300897667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OptionalStockPurchaseAgreementMember" xlink:label="chrs_OptionalStockPurchaseAgreementMember_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638461333300897667" xlink:to="chrs_OptionalStockPurchaseAgreementMember_638461333300897667" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638461333300897667" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300897667" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333300887667" xlink:to="us-gaap_StatementLineItems_638461333300897667" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockholdersEquity_638461333300897667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_CommonStockSharesOutstanding_638461333300897667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638461333300897667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_NetIncomeLoss_638461333300897667" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638461333300907670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638461333300907670" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638461333300907670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638461333300907670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638461333300907670" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638461333300907670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodAcquisitions" xlink:label="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_638461333300907670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638461333300907670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" xlink:to="chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards_638461333300907670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" xlink:to="chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards_638461333300907670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards_638461333300907670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" xlink:to="chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards_638461333300907670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards" xlink:label="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_StockIssuedDuringPeriodAcquisitions_638461333300907670" xlink:to="chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards_638461333300917665" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638461333300917665" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_638461333300917665" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638461333300917665" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638461333300917665" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638461333300917665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638461333300917665" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638461333300917665" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638461333300917665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638461333300917665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638461333300917665" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638461333300927665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638461333300917665" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_638461333300927665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638461333300927665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_638461333300927665" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638461333300927665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_StockholdersEquity_638461333300927665" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638461333300927665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300897667" xlink:to="us-gaap_CommonStockSharesOutstanding_638461333300927665" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_638461333300937667" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333300937667" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638461333300937667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638461333300937667" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300937667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300937667" xlink:to="chrs_AtMarketOfferingMember_638461333300937667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300937667" xlink:to="chrs_PublicOfferingMember_638461333300937667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638461333300937667" xlink:to="chrs_JunshiBiosciencesMember_638461333300937667" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333300937667" xlink:to="us-gaap_StatementLineItems_638461333300937667" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638461333300937667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638461333300937667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638461333300937667" xlink:to="us-gaap_ProfitLoss_638461333300937667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638461333300937667" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_DepreciationAndAmortization_638461333300977665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_ShareBasedCompensation_638461333300977665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_GainLossOnContractTermination_638461333300977665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_InventoryWriteDown_638461333300977665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638461333300977665" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333300977665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333300977665" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NoncashOperatingLeaseExpense" xlink:label="chrs_NoncashOperatingLeaseExpense_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="chrs_NoncashOperatingLeaseExpense_638461333300987665" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements_638461333300987665" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333300987665" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638461333300977665" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_638461333300987665" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638461333300937667" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638461333300987665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="us-gaap_IncreaseDecreaseInInventories_638461333300987665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638461333300987665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638461333300987665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638461333300987665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638461333300997667" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve" xlink:label="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve_638461333300997667" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseDecreaseInAccruedCompensation" xlink:label="chrs_IncreaseDecreaseInAccruedCompensation_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="chrs_IncreaseDecreaseInAccruedCompensation_638461333300997667" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638461333300987665" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638461333300997667" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638461333300937667" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638461333300997667" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638461333300997667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_638461333300997667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_638461333300997667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638461333301007665" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638461333301007665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638461333301007665" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_CashAcquiredFromAcquisition_638461333301007665" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities" xlink:label="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities_638461333301007665" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements" xlink:label="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements_638461333301007665" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333301007665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638461333300997667" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638461333301007665" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638461333301017666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638461333301017666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638461333301017666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638461333301017666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638461333301017666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638461333301017666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638461333301017666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_ProceedsFromStockPlans_638461333301017666" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638461333301017666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638461333301017666" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638461333301027668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638461333301027668" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638461333301027668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_RepaymentsOfDebt_638461333301027668" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638461333301027668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638461333301027668" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333301027668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638461333301017666" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638461333301027668" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638461333301027668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638461333301027668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638461333301027668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638461333301027668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638461333301037670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638461333301037670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638461333301037670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333300937667" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638461333301037670" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638461333301037670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638461333301037670" xlink:to="us-gaap_InterestPaidNet_638461333301037670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638461333301037670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638461333301037670" xlink:to="us-gaap_IncomeTaxesPaidNet_638461333301037670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638461333301047668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638461333301047668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10201 - Disclosure - Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638461333301047668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638461333301047668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638461333301047668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638461333301047668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventory" xlink:type="extended" xlink:title="10401 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638461333301057666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638461333301057666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10501 - Disclosure - Balance Sheet Components" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638461333301057666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638461333301057666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisition" xlink:type="extended" xlink:title="10601 - Disclosure - Surface Acquisition" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_638461333301057666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_638461333301057666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements" xlink:type="extended" xlink:title="10701 - Disclosure - Collaborations and Other Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAndLicenseAgreementsAbstract" xlink:label="CollaborationAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638461333301067673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638461333301067673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations" xlink:type="extended" xlink:title="10801 - Disclosure - Debt Obligations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638461333301067673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638461333301067673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638461333301067673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638461333301067673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11001 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638461333301077671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638461333301077671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockholdersDeficit" xlink:type="extended" xlink:title="11101 - Disclosure - Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockholdersDeficitTextBlock" xlink:label="chrs_StockholdersDeficitTextBlock_638461333301077671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="chrs_StockholdersDeficitTextBlock_638461333301077671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits" xlink:type="extended" xlink:title="11201 - Disclosure - Stock-Based Compensation and Employee Benefits" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638461333301077671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638461333301077671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11301 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638461333301087671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638461333301087671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11401 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638461333301087671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638461333301087671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRestructuringCharges" xlink:type="extended" xlink:title="11501 - Disclosure - Restructuring Charges" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638461333301097667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638461333301097667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11601 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638461333301097667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638461333301097667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11701 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638461333301097667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638461333301097667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638461333301107671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638461333301107671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock" xlink:label="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock_638461333301107671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638461333301107671" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638461333301107671" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_638461333301107671" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638461333301107671" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock_638461333301107671" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:label="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_638461333301107671" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638461333301107671" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638461333301107671" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638461333301107671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638461333301107671" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638461333301117668" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_638461333301117668" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_638461333301117668" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContingentConsiderationPolicyTextBlock" xlink:label="chrs_ContingentConsiderationPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_ContingentConsiderationPolicyTextBlock_638461333301117668" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638461333301117668" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_638461333301117668" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638461333301117668" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LicenseAgreementsPolicyTextBlock" xlink:label="chrs_LicenseAgreementsPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_LicenseAgreementsPolicyTextBlock_638461333301117668" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_638461333301117668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_638461333301117668" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638461333301127666" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638461333301127666" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638461333301127666" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638461333301127666" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638461333301127666" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReclassificationsPolicyPolicyTextBlock" xlink:label="chrs_ReclassificationsPolicyPolicyTextBlock_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_ReclassificationsPolicyPolicyTextBlock_638461333301127666" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638461333301127666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638461333301127666" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638461333301137668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_638461333301137668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_638461333301137668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_638461333301137668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30203 - Disclosure - Revenue (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638461333301137668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638461333301137668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_638461333301137668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_638461333301137668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock" xlink:label="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_638461333301137668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock_638461333301137668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638461333301147667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638461333301147667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638461333301147667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638461333301147667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="30403 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfInventoryTableTextBlock" xlink:label="chrs_ScheduleOfInventoryTableTextBlock_638461333301147667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="chrs_ScheduleOfInventoryTableTextBlock_638461333301147667" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:label="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_638461333301147667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_638461333301147667" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Balance Sheet Components (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638461333301157666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_638461333301157666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638461333301157666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_638461333301157666" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables" xlink:type="extended" xlink:title="30603 - Disclosure - Surface Acquisition (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_3" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_638461333301157666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_3" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_638461333301157666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_3" xlink:to="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_638461333301157666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_638461333301157666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_3" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_638461333301157666" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Debt Obligations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301167671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301167671" xlink:to="us-gaap_DebtInstrumentAxis_638461333301167671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301167671" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301167671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301167671" xlink:to="chrs_TermLoansMember_638461333301167671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301167671" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301167671" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301167671" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333301167671" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301167671" xlink:to="us-gaap_LoansPayableMember_638461333301167671" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301167671" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301167671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301167671" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_638461333301167671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301167671" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638461333301167671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638461333301167671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301167671" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638461333301167671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTextBlock" xlink:label="us-gaap_LongTermPurchaseCommitmentTextBlock_638461333301177671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTextBlock_638461333301177671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock" xlink:label="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock_638461333301177671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock_638461333301177671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock" xlink:label="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock_638461333301177671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock_638461333301177671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638461333301177671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638461333301177671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock" xlink:label="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock_638461333301187671" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638461333301187671" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockholdersDeficitTables" xlink:type="extended" xlink:title="31101 - Disclosure - Stockholders' Deficit (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock" xlink:label="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock_638461333301187671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Stock-Based Compensation and Employee Benefits (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638461333301187671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638461333301187671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock" xlink:label="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock_638461333301187671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638461333301187671" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638461333301187671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638461333301187671" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638461333301197671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638461333301197671" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638461333301197671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638461333301197671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638461333301197671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638461333301197671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638461333301197671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638461333301197671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638461333301197671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638461333301197671" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638461333301197671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638461333301197671" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31403 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638461333301207677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301207677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301207677" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333301207677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333301207677" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301207677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoherusOphthalmologyLlcMember" xlink:label="chrs_CoherusOphthalmologyLlcMember_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301207677" xlink:to="chrs_CoherusOphthalmologyLlcMember_638461333301207677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301207677" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638461333301207677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638461333301207677" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638461333301207677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliDivestitureTransactionMember" xlink:label="chrs_CimerliDivestitureTransactionMember_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638461333301207677" xlink:to="chrs_CimerliDivestitureTransactionMember_638461333301207677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638461333301207677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301207677" xlink:to="us-gaap_SubsequentEventTypeAxis_638461333301207677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638461333301207677" xlink:to="us-gaap_SubsequentEventTypeDomain_638461333301217670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638461333301217670" xlink:to="us-gaap_SubsequentEventMember_638461333301217670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301207677" xlink:to="us-gaap_BusinessAcquisitionLineItems_638461333301217670" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301217670" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638461333301217670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301217670" xlink:to="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_638461333301217670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProductPipelineNumberOfDrugCandidates" xlink:label="chrs_ProductPipelineNumberOfDrugCandidates_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301217670" xlink:to="chrs_ProductPipelineNumberOfDrugCandidates_638461333301217670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfOperatingAndReportableSegments" xlink:label="chrs_NumberOfOperatingAndReportableSegments_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301217670" xlink:to="chrs_NumberOfOperatingAndReportableSegments_638461333301217670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638461333301217670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash_638461333301217670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638461333301217670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638461333301217670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40103 - Disclosure - Organization and Significant Accounting Policies - Investments in Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638461333301227670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract_1" xlink:to="us-gaap_InvestmentIncomeInterest_638461333301227670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_638461333301227670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract_1" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_638461333301227670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails" xlink:type="extended" xlink:title="40106 - Disclosure - Organization and Significant Accounting Policies - Derivative Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets_638461333301227670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_DerivativeAssets_638461333301227670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638461333301227670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_DerivativeLiabilities_638461333301227670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails" xlink:type="extended" xlink:title="40110 - Disclosure - Organization and Significant Accounting Policies - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_StatementTable_638461333301237670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333301237670" xlink:to="us-gaap_IncomeStatementLocationAxis_638461333301237670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638461333301237670" xlink:to="us-gaap_IncomeStatementLocationDomain_638461333301237670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333301237670" xlink:to="us-gaap_CostOfSalesMember_638461333301237670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333301237670" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_638461333301237670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis_638461333301237670" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301237670" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301237670" xlink:to="chrs_YusimryProductMember_638461333301237670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301237670" xlink:to="chrs_UdenycaMember_638461333301237670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333301237670" xlink:to="us-gaap_StatementLineItems_638461333301237670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638461333301237670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333301237670" xlink:to="us-gaap_InventoryWriteDown_638461333301237670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40112 - Disclosure - Organization and Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301247675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301247675" xlink:to="srt_RangeAxis_638461333301247675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333301247675" xlink:to="srt_RangeMember_638461333301247675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301247675" xlink:to="srt_MaximumMember_638461333301247675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301247675" xlink:to="srt_MinimumMember_638461333301247675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301247675" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301247675" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301247675" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301247675" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301247675" xlink:to="us-gaap_ComputerEquipmentMember_638461333301247675" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301247675" xlink:to="us-gaap_FurnitureAndFixturesMember_638461333301247675" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301247675" xlink:to="us-gaap_MachineryAndEquipmentMember_638461333301247675" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301247675" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301247675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638461333301247675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301247675" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638461333301247675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301247675" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638461333301257672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails" xlink:type="extended" xlink:title="40114 - Disclosure - Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_638461333301257672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_638461333301257672" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301257672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301257672" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301257672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301257672" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_638461333301257672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301257672" xlink:to="us-gaap_LicensingAgreementsMember_638461333301257672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_638461333301257672" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_638461333301257672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_638461333301257672" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638461333301257672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638461333301257672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_638461333301257672" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638461333301257672" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails" xlink:type="extended" xlink:title="40116 - Disclosure - Organization and Significant Accounting Policies - Net Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_StatementTable_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333301267670" xlink:to="srt_RangeAxis_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333301267670" xlink:to="srt_RangeMember_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301267670" xlink:to="srt_MaximumMember_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301267670" xlink:to="srt_MinimumMember_638461333301267670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638461333301267670" xlink:to="us-gaap_StatementLineItems_638461333301267670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333301267670" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentTermsPeriodFromDateOfShipment" xlink:label="chrs_PaymentTermsPeriodFromDateOfShipment_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638461333301267670" xlink:to="chrs_PaymentTermsPeriodFromDateOfShipment_638461333301267670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails" xlink:type="extended" xlink:title="40118 - Disclosure - Organization and Significant Accounting Policies - Cost of Goods Sold (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638461333301267670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301267670" xlink:to="us-gaap_TypeOfArrangementAxis_638461333301267670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638461333301267670" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301277671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301277671" xlink:to="chrs_BioeqIPAGMember_638461333301277671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoqtorziMember" xlink:label="chrs_LoqtorziMember_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301277671" xlink:to="chrs_LoqtorziMember_638461333301277671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301267670" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301277671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RoyaltyPaymentTerm" xlink:label="chrs_RoyaltyPaymentTerm_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301277671" xlink:to="chrs_RoyaltyPaymentTerm_638461333301277671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfRoyaltiesOnNetSales" xlink:label="chrs_PercentageOfRoyaltiesOnNetSales_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301277671" xlink:to="chrs_PercentageOfRoyaltiesOnNetSales_638461333301277671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301277671" xlink:to="us-gaap_InventoryWriteDown_638461333301277671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales_638461333301277671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301277671" xlink:to="chrs_PercentageOfGrossProfitsOnSales_638461333301277671" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails" xlink:type="extended" xlink:title="40119 - Disclosure - Organization and Significant Accounting Policies - Operating and Finance Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_638461333301287673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract_4" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_638461333301287673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails" xlink:type="extended" xlink:title="40120 - Disclosure - Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense_638461333301287673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract_3" xlink:to="us-gaap_MarketingAndAdvertisingExpense_638461333301287673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails" xlink:type="extended" xlink:title="40122 - Disclosure - Organization and Significant Accounting Policies - Reclassifications (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_638461333301287673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment_638461333301287673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue - Net Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638461333301297670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638461333301297670" xlink:to="srt_ProductOrServiceAxis_638461333301297670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638461333301297670" xlink:to="srt_ProductsAndServicesDomain_638461333301297670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638461333301297670" xlink:to="us-gaap_ProductMember_638461333301297670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638461333301297670" xlink:to="chrs_UdenycaMember_638461333301297670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliMember" xlink:label="chrs_CimerliMember_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638461333301297670" xlink:to="chrs_CimerliMember_638461333301297670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryMember" xlink:label="chrs_YusimryMember_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638461333301297670" xlink:to="chrs_YusimryMember_638461333301297670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638461333301297670" xlink:to="chrs_ToripalimabMember_638461333301297670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638461333301297670" xlink:to="us-gaap_ProductAndServiceOtherMember_638461333301297670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638461333301297670" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638461333301297670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638461333301297670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638461333301297670" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638461333301297670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638461333301307671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638461333301307671" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638461333301307671" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638461333301307671" xlink:to="us-gaap_SalesRevenueNetMember_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638461333301307671" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638461333301307671" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638461333301307671" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638461333301307671" xlink:to="us-gaap_CustomerConcentrationRiskMember_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638461333301307671" xlink:to="srt_MajorCustomersAxis_638461333301307671" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638461333301307671" xlink:to="srt_NameOfMajorCustomerDomain_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_McKessonMember" xlink:label="chrs_McKessonMember_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638461333301307671" xlink:to="chrs_McKessonMember_638461333301307671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AmeriSourceBergenCorpMember" xlink:label="chrs_AmeriSourceBergenCorpMember_638461333301307671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638461333301307671" xlink:to="chrs_AmeriSourceBergenCorpMember_638461333301307671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CardinalMember" xlink:label="chrs_CardinalMember_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638461333301307671" xlink:to="chrs_CardinalMember_638461333301317674" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638461333301307671" xlink:to="us-gaap_ConcentrationRiskLineItems_638461333301317674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638461333301317674" xlink:to="us-gaap_ConcentrationRiskPercentage1_638461333301317674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638461333301317674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638461333301317674" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638461333301317674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638461333301317674" xlink:to="us-gaap_ReceivableTypeDomain_638461333301317674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="chrs_ChargebacksAndDiscountsForPromptPaymentMember_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638461333301317674" xlink:to="chrs_ChargebacksAndDiscountsForPromptPaymentMember_638461333301317674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RebatesMember" xlink:label="chrs_RebatesMember_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638461333301317674" xlink:to="chrs_RebatesMember_638461333301317674" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OtherFeesCoPayAssistanceAndReturnsMember" xlink:label="chrs_OtherFeesCoPayAssistanceAndReturnsMember_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638461333301317674" xlink:to="chrs_OtherFeesCoPayAssistanceAndReturnsMember_638461333301317674" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_638461333301317674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638461333301317674" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_638461333301317674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638461333301317674" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_638461333301327671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProvisionRelatedToSalesMadeAbstract" xlink:label="chrs_ProvisionRelatedToSalesMadeAbstract_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638461333301317674" xlink:to="chrs_ProvisionRelatedToSalesMadeAbstract_638461333301327671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract_638461333301327671" xlink:to="chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration_638461333301327671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProvisionRelatedToSalesMadeInPriorPeriod" xlink:label="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract_638461333301327671" xlink:to="chrs_ProvisionRelatedToSalesMadeInPriorPeriod_638461333301327671" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_ProvisionRelatedToSalesMadeAbstract_638461333301327671" xlink:to="chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration_638461333301327671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration" xlink:label="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_6384613333013276711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638461333301317674" xlink:to="chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration_6384613333013276711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638461333301327671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638461333301327671" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638461333301327671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638461333301327671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638461333301327671" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638461333301327671" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" xlink:to="us-gaap_FairValueByAssetClassAxis_638461333301337677" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_638461333301337677" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638461333301337677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638461333301337677" xlink:to="us-gaap_CashAndCashEquivalentsMember_638461333301337677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidExpensesMember" xlink:label="chrs_PrepaidExpensesMember_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_638461333301337677" xlink:to="chrs_PrepaidExpensesMember_638461333301337677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" xlink:to="us-gaap_FinancialInstrumentAxis_638461333301337677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638461333301337677" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301337677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301337677" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638461333301337677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301337677" xlink:to="us-gaap_USTreasurySecuritiesMember_638461333301337677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301337677" xlink:to="us-gaap_CorporateNoteSecuritiesMember_638461333301337677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638461333301337677" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638461333301337677" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301337677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638461333301337677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301337677" xlink:to="us-gaap_FairValueInputsLevel1Member_638461333301337677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301337677" xlink:to="us-gaap_FairValueInputsLevel2Member_638461333301347678" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301337677" xlink:to="us-gaap_FairValueInputsLevel3Member_638461333301347678" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638461333301347678" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638461333301347678" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638461333301347678" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContingentConsiderationMember" xlink:label="chrs_ContingentConsiderationMember_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638461333301347678" xlink:to="chrs_ContingentConsiderationMember_638461333301347678" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301327671" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301347678" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301347678" xlink:to="us-gaap_AssetsFairValueDisclosure_638461333301347678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_638461333301347678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301347678" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_638461333301347678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301357678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301357678" xlink:to="us-gaap_FinancialInstrumentAxis_638461333301357678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638461333301357678" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301357678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301357678" xlink:to="us-gaap_MoneyMarketFundsMember_638461333301357678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301357678" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638461333301357678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301357678" xlink:to="us-gaap_USTreasurySecuritiesMember_638461333301357678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638461333301357678" xlink:to="us-gaap_CorporateNoteSecuritiesMember_638461333301357678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301357678" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301357678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301357678" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638461333301357678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301357678" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638461333301357678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638461333301357678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301357678" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638461333301357678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301357678" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638461333301367675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Fair Value Measurements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638461333301367675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_638461333301367675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638461333301367675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity" xlink:label="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity_638461333301367675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition" xlink:label="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition_638461333301367675" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryComponentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventory - Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials_638461333301367675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess_638461333301367675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638461333301367675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods_638461333301367675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryGross_638461333301377674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet_638461333301377674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNoncurrent_638461333301377674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InventoryCurrentAndNoncurrent" xlink:label="chrs_InventoryCurrentAndNoncurrent_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="chrs_InventoryCurrentAndNoncurrent_638461333301377674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Inventory - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable_638461333301377674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638461333301377674" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_638461333301377674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryAxis_638461333301377674" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301377674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_YusimryProductMember" xlink:label="chrs_YusimryProductMember_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301377674" xlink:to="chrs_YusimryProductMember_638461333301377674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UdenycaMember" xlink:label="chrs_UdenycaMember_638461333301377674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301377674" xlink:to="chrs_UdenycaMember_638461333301377674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Chs2020Member" xlink:label="chrs_Chs2020Member_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesInventoryTypeDomain_638461333301377674" xlink:to="chrs_Chs2020Member_638461333301387673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638461333301377674" xlink:to="us-gaap_BalanceSheetLocationAxis_638461333301387673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638461333301387673" xlink:to="us-gaap_BalanceSheetLocationDomain_638461333301387673" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638461333301387673" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember_638461333301387673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638461333301387673" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_638461333301387673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638461333301377674" xlink:to="us-gaap_IncomeStatementLocationAxis_638461333301387673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638461333301387673" xlink:to="us-gaap_IncomeStatementLocationDomain_638461333301387673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333301387673" xlink:to="us-gaap_CostOfSalesMember_638461333301387673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638461333301377674" xlink:to="us-gaap_InventoryLineItems_638461333301387673" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="us-gaap_InventoryWriteDown_638461333301387673" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LongTermAndShortTermPurchaseCommitmentsAmount" xlink:label="chrs_LongTermAndShortTermPurchaseCommitmentsAmount_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="chrs_LongTermAndShortTermPurchaseCommitmentsAmount_638461333301387673" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638461333301387673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638461333301387673" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShortTermPurchaseCommitmentAmount" xlink:label="chrs_ShortTermPurchaseCommitmentAmount_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="chrs_ShortTermPurchaseCommitmentAmount_638461333301397672" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaidManufacturingExpenseCurrent" xlink:label="chrs_PrepaidManufacturingExpenseCurrent_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="chrs_PrepaidManufacturingExpenseCurrent_638461333301397672" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaymentsMadeToCmoForManufacturingServices" xlink:label="chrs_PrepaymentsMadeToCmoForManufacturingServices_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="chrs_PrepaymentsMadeToCmoForManufacturingServices_638461333301397672" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram" xlink:label="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram_638461333301397672" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="us-gaap_GainLossOnContractTermination_638461333301397672" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrCharges" xlink:label="us-gaap_ProductionRelatedImpairmentsOrCharges_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="us-gaap_ProductionRelatedImpairmentsOrCharges_638461333301397672" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638461333301397672" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638461333301397672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638461333301387673" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638461333301397672" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301407674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301407674" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301407674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301407674" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" xlink:to="us-gaap_MachineryAndEquipmentMember_638461333301407674" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" xlink:to="us-gaap_ComputerEquipmentMember_638461333301407674" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" xlink:to="us-gaap_FurnitureAndFixturesMember_638461333301407674" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" xlink:to="us-gaap_LeaseholdImprovementsMember_638461333301407674" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638461333301407674" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301407674" xlink:to="us-gaap_ConstructionInProgressMember_638461333301407674" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638461333301407674" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301407674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638461333301407674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301407674" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638461333301407674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301407674" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638461333301417670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638461333301407674" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638461333301417670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Components - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638461333301417670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638461333301417670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_638461333301417670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301417670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638461333301417670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301417670" xlink:to="us-gaap_TypeOfArrangementAxis_638461333301417670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638461333301417670" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301427674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301427674" xlink:to="chrs_JunshiBiosciencesMember_638461333301427674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301417670" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638461333301427674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638461333301427674" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638461333301427674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_Goodwill_638461333301427674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638461333301427674" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill_638461333301427674" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears" xlink:label="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears_638461333301427674" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638461333301427674" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638461333301427674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638461333301427674" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="us-gaap_GoodwillImpairmentLoss_638461333301437677" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301427674" xlink:to="chrs_UpfrontAndMilestonePayment_638461333301437677" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent" xlink:label="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent_638461333301437677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedCoDevelopmentCostsAndMilestonePayments" xlink:label="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="chrs_AccruedCoDevelopmentCostsAndMilestonePayments_638461333301437677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638461333301437677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638461333301437677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LeaseLiabilitiesOperatingAndFinancing" xlink:label="chrs_LeaseLiabilitiesOperatingAndFinancing_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="chrs_LeaseLiabilitiesOperatingAndFinancing_638461333301437677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638461333301437677" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638461333301437677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638461333301437677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_638461333301447675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638461333301447675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_638461333301447675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638461333301447675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Surface Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_1" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301447675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301447675" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333301447675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333301447675" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301447675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member_638461333301447675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301447675" xlink:to="chrs_SurfaceOncologyInc.Member_638461333301447675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301447675" xlink:to="us-gaap_TypeOfArrangementAxis_638461333301457675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638461333301457675" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301457675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceGlaxosmithklineAgreementMember" xlink:label="chrs_SurfaceGlaxosmithklineAgreementMember_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301457675" xlink:to="chrs_SurfaceGlaxosmithklineAgreementMember_638461333301457675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceNovartisAgreementMember" xlink:label="chrs_SurfaceNovartisAgreementMember_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301457675" xlink:to="chrs_SurfaceNovartisAgreementMember_638461333301457675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember" xlink:label="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301457675" xlink:to="chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_638461333301457675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember" xlink:label="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301457675" xlink:to="chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_638461333301457675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301447675" xlink:to="us-gaap_BusinessAcquisitionLineItems_638461333301457675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree_638461333301457675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="us-gaap_SharesIssuedPricePerShare_638461333301457675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPerShare" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPerShare_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPerShare_638461333301457675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod_638461333301457675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod_638461333301457675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments_638461333301467673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments_638461333301467673" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments" xlink:label="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments_638461333301467673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments_638461333301467673" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638461333301467673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638461333301467673" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares" xlink:label="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares_638461333301467673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares_638461333301467673" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638461333301467673" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="us-gaap_Goodwill_638461333301467673" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram" xlink:label="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram_638461333301537678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram_638461333301537678" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_638461333301547685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_638461333301547685" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:label="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_638461333301547685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_638461333301547685" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_638461333301547685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301457675" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_638461333301547685" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Surface Acquisition - Consideration paid (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301547685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301547685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333301547685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301547685" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333301547685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301547685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333301547685" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301547685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301547685" xlink:to="chrs_SurfaceOncologyInc.Member_638461333301557676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301547685" xlink:to="us-gaap_BusinessAcquisitionLineItems_638461333301557676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301557676" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_638461333301557676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301557676" xlink:to="us-gaap_BusinessAcquisitionSharePrice_638461333301557676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301557676" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders_638461333301557676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301557676" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_638461333301557676" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees" xlink:label="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301557676" xlink:to="chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees_638461333301557676" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301557676" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638461333301557676" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_1" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301557676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333301557676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301557676" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333301557676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333301557676" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301567684" xlink:to="chrs_SurfaceOncologyInc.Member_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301557676" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301567684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301567684" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301567684" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301557676" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638461333301567684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638461333301567684" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301567684" xlink:to="us-gaap_LicensingAgreementsMember_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301557676" xlink:to="us-gaap_BusinessAcquisitionLineItems_638461333301567684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_638461333301567684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_638461333301567684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638461333301567684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_638461333301567684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638461333301577690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_638461333301577690" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301567684" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_638461333301577690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities" xlink:label="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_638461333301577690" xlink:to="chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities_638461333301577690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_638461333301577690" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_638461333301577690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_638461333301577690" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_638461333301577690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_638461333301577690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_638461333301577690" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_638461333301577690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Surface Acquisition - The amount allocated to identifiable intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_2" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301587678" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333301587678" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301587678" xlink:to="chrs_SurfaceOncologyInc.Member_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301587678" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301587678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638461333301587678" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InProcessResearchAndDevelopmentSrf388Member" xlink:label="chrs_InProcessResearchAndDevelopmentSrf388Member_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" xlink:to="chrs_InProcessResearchAndDevelopmentSrf388Member_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InProcessResearchAndDevelopmentSrf114Member" xlink:label="chrs_InProcessResearchAndDevelopmentSrf114Member_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" xlink:to="chrs_InProcessResearchAndDevelopmentSrf114Member_638461333301587678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301587678" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638461333301587678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638461333301587678" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OutLicensesWithGrkMember" xlink:label="chrs_OutLicensesWithGrkMember_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" xlink:to="chrs_OutLicensesWithGrkMember_638461333301587678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OutLicensesWithNovartisInstitutesMember" xlink:label="chrs_OutLicensesWithNovartisInstitutesMember_638461333301587678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638461333301587678" xlink:to="chrs_OutLicensesWithNovartisInstitutesMember_638461333301587678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301587678" xlink:to="us-gaap_BusinessAcquisitionLineItems_638461333301597678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301597678" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_638461333301597678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301597678" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638461333301597678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_2" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301597678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301597678" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333301597678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333301597678" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301597678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceOncologyInc.Member" xlink:label="chrs_SurfaceOncologyInc.Member_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333301597678" xlink:to="chrs_SurfaceOncologyInc.Member_638461333301597678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638461333301597678" xlink:to="us-gaap_BusinessAcquisitionLineItems_638461333301597678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301597678" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_638461333301597678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_638461333301597678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638461333301597678" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_638461333301597678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Collaborations and Other Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAndLicenseAgreementsAbstract" xlink:label="CollaborationAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="srt_StatementScenarioAxis_638461333301607676" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638461333301607676" xlink:to="srt_ScenarioUnspecifiedDomain_638461333301607676" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638461333301607676" xlink:to="us-gaap_ScenarioPlanMember_638461333301607676" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="us-gaap_TypeOfArrangementAxis_638461333301607676" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638461333301607676" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_VaccinexLicenseAgreementMember" xlink:label="chrs_VaccinexLicenseAgreementMember_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" xlink:to="chrs_VaccinexLicenseAgreementMember_638461333301607676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BioeqIPAGMember" xlink:label="chrs_BioeqIPAGMember_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" xlink:to="chrs_BioeqIPAGMember_638461333301607676" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdimabDevelopmentAndOptionAgreementMember" xlink:label="chrs_AdimabDevelopmentAndOptionAgreementMember_638461333301607676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" xlink:to="chrs_AdimabDevelopmentAndOptionAgreementMember_638461333301607676" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NovartisAgreementMember" xlink:label="chrs_NovartisAgreementMember_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" xlink:to="chrs_NovartisAgreementMember_638461333301617677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_GskAgreementMember" xlink:label="chrs_GskAgreementMember_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" xlink:to="chrs_GskAgreementMember_638461333301617677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_JunshiBiosciencesMember" xlink:label="chrs_JunshiBiosciencesMember_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333301607676" xlink:to="chrs_JunshiBiosciencesMember_638461333301617677" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Chs006AntiTigitAntibodyMember" xlink:label="chrs_Chs006AntiTigitAntibodyMember_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_JunshiBiosciencesMember_638461333301617677" xlink:to="chrs_Chs006AntiTigitAntibodyMember_638461333301617677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="us-gaap_IncomeStatementLocationAxis_638461333301617677" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638461333301617677" xlink:to="us-gaap_IncomeStatementLocationDomain_638461333301617677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333301617677" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638461333301617677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="dei_LegalEntityAxis_638461333301617677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638461333301617677" xlink:to="dei_EntityDomain_638461333301617677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SurfaceMember" xlink:label="chrs_SurfaceMember_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638461333301617677" xlink:to="chrs_SurfaceMember_638461333301617677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638461333301617677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="srt_ProductOrServiceAxis_638461333301617677" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638461333301617677" xlink:to="srt_ProductsAndServicesDomain_638461333301627679" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638461333301627679" xlink:to="us-gaap_LicenseMember_638461333301627679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ToripalimabMember" xlink:label="chrs_ToripalimabMember_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638461333301627679" xlink:to="chrs_ToripalimabMember_638461333301627679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AntiTigitAntibodyAndIl2CytokineMember" xlink:label="chrs_AntiTigitAntibodyAndIl2CytokineMember_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638461333301627679" xlink:to="chrs_AntiTigitAntibodyAndIl2CytokineMember_638461333301627679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="us-gaap_BalanceSheetLocationAxis_638461333301627679" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638461333301627679" xlink:to="us-gaap_BalanceSheetLocationDomain_638461333301627679" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638461333301627679" xlink:to="chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_638461333301627679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="chrs_AccruedAndOtherCurrentLiabilitiesMember_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638461333301627679" xlink:to="chrs_AccruedAndOtherCurrentLiabilitiesMember_638461333301627679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember_638461333301627679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638461333301627679" xlink:to="us-gaap_AccountsPayableMember_638461333301627679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638461333301607676" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationCosts" xlink:label="chrs_CollaborationCosts_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationCosts_638461333301637681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales_638461333301637681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds_638461333301637681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementOptionExerciseFeePerProgram" xlink:label="chrs_CollaborationAgreementOptionExerciseFeePerProgram_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementOptionExerciseFeePerProgram_638461333301637681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram" xlink:label="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram_638461333301637681" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram" xlink:label="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram_638461333301637681" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram" xlink:label="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_638461333301637681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram_638461333301637681" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MaximumAmountPaidCoDevelopmentActivities" xlink:label="chrs_MaximumAmountPaidCoDevelopmentActivities_638461333301647678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_MaximumAmountPaidCoDevelopmentActivities_638461333301647678" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638461333301647678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638461333301647678" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts" xlink:label="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_638461333301647678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts_638461333301647678" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssued" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_638461333301647678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssued_638461333301647678" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638461333301647678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="us-gaap_SharePrice_638461333301647678" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue" xlink:label="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_638461333301647678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue_638461333301647678" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock" xlink:label="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock_638461333301657676" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FairValueForDiscountForLackOfMarketability" xlink:label="chrs_FairValueForDiscountForLackOfMarketability_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_FairValueForDiscountForLackOfMarketability_638461333301657676" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_InitialTermOfAgreement" xlink:label="chrs_InitialTermOfAgreement_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_InitialTermOfAgreement_638461333301657676" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_UpfrontAndMilestonePayment" xlink:label="chrs_UpfrontAndMilestonePayment_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_UpfrontAndMilestonePayment_638461333301657676" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones_638461333301657676" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval" xlink:label="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval_638461333301657676" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfGrossProfitsOnSales" xlink:label="chrs_PercentageOfGrossProfitsOnSales_638461333301657676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_PercentageOfGrossProfitsOnSales_638461333301657676" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedMilestonePayment" xlink:label="chrs_AccruedMilestonePayment_638461333301667676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_AccruedMilestonePayment_638461333301667676" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_638461333301667676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_638461333301667676" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption" xlink:label="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption_638461333301667676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption_638461333301667676" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay" xlink:label="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay_638461333301667676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay_638461333301667676" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee" xlink:label="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee_638461333301667676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee_638461333301667676" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade" xlink:label="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade_638461333301677674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade_638461333301677674" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption" xlink:label="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption_638461333301677674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption_638461333301677674" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption" xlink:label="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption_638461333301677674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption_638461333301677674" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementAdditionalPaymentToBeMade" xlink:label="chrs_CollaborationAgreementAdditionalPaymentToBeMade_638461333301677674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementAdditionalPaymentToBeMade_638461333301677674" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl" xlink:label="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl_638461333301677674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl_638461333301677674" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementTerm" xlink:label="chrs_CollaborationAgreementTerm_638461333301687678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementTerm_638461333301687678" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PotentialDevelopmentMilestonesEntitled" xlink:label="chrs_PotentialDevelopmentMilestonesEntitled_638461333301687678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_PotentialDevelopmentMilestonesEntitled_638461333301687678" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SalesMilestonesEntitled" xlink:label="chrs_SalesMilestonesEntitled_638461333301687678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_SalesMilestonesEntitled_638461333301687678" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementMilestonePaymentsEarned" xlink:label="chrs_CollaborationAgreementMilestonePaymentsEarned_638461333301687678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementMilestonePaymentsEarned_638461333301687678" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive" xlink:label="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive_638461333301687678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive_638461333301687678" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive" xlink:label="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive_638461333301697676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive_638461333301697676" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RegulatoryMilestonesEligibleToPay" xlink:label="chrs_RegulatoryMilestonesEligibleToPay_638461333301697676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638461333301637681" xlink:to="chrs_RegulatoryMilestonesEligibleToPay_638461333301697676" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301697676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301697676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301697676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301697676" xlink:to="us-gaap_DebtInstrumentAxis_638461333301697676" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301697676" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301707679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301707679" xlink:to="chrs_TermLoansMember_638461333301707679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301707679" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301707679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301707679" xlink:to="us-gaap_LoansPayableMember_638461333301707679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301697676" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638461333301707679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638461333301707679" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301707679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638461333301707679" xlink:to="us-gaap_FairValueInputsLevel2Member_638461333301707679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638461333301697676" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301707679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301707679" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333301707679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301707679" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301707679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301707679" xlink:to="us-gaap_LongTermDebt_638461333301707679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_638461333301707679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638461333301707679" xlink:to="us-gaap_DebtInstrumentFairValue_638461333301707679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301717678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="us-gaap_DebtInstrumentAxis_638461333301717678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301717678" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301717678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301717678" xlink:to="chrs_TermLoansMember_638461333301717678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheLoanMember" xlink:label="chrs_TrancheLoanMember_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638461333301717678" xlink:to="chrs_TrancheLoanMember_638461333301717678" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheBLoanMember" xlink:label="chrs_TrancheBLoanMember_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638461333301717678" xlink:to="chrs_TrancheBLoanMember_638461333301717678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheCLoanMember" xlink:label="chrs_TrancheCLoanMember_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638461333301717678" xlink:to="chrs_TrancheCLoanMember_638461333301717678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheDLoanMember" xlink:label="chrs_TrancheDLoanMember_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_TermLoansMember_638461333301717678" xlink:to="chrs_TrancheDLoanMember_638461333301717678" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301717678" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301717678" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333301717678" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301717678" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333301717678" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301717678" xlink:to="us-gaap_LoansPayableMember_638461333301727675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TrancheaBAndDLoansMember" xlink:label="chrs_TrancheaBAndDLoansMember_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301717678" xlink:to="chrs_TrancheaBAndDLoansMember_638461333301727675" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_638461333301727675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_638461333301727675" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_638461333301727675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_638461333301727675" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_638461333301727675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_638461333301727675" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_638461333301727675" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="us-gaap_CreditFacilityAxis_638461333301727675" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638461333301727675" xlink:to="us-gaap_CreditFacilityDomain_638461333301727675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638461333301727675" xlink:to="us-gaap_LineOfCreditMember_638461333301727675" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638461333301727675" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="srt_CounterpartyNameAxis_638461333301727675" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638461333301727675" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301737683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301737683" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638461333301737683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301737683" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301737683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="us-gaap_VariableRateAxis_638461333301737683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638461333301737683" xlink:to="us-gaap_VariableRateDomain_638461333301737683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ThreeMonthLiborMember" xlink:label="chrs_ThreeMonthLiborMember_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638461333301737683" xlink:to="chrs_ThreeMonthLiborMember_638461333301737683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638461333301737683" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638461333301737683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="srt_StatementScenarioAxis_638461333301737683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638461333301737683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638461333301737683" xlink:to="srt_ScenarioUnspecifiedDomain_638461333301737683" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638461333301737683" xlink:to="us-gaap_ScenarioPlanMember_638461333301747682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="srt_RangeAxis_638461333301747682" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333301747682" xlink:to="srt_RangeMember_638461333301747682" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301747682" xlink:to="srt_MaximumMember_638461333301747682" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="us-gaap_LongtermDebtTypeAxis_638461333301747682" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638461333301747682" xlink:to="us-gaap_LongtermDebtTypeDomain_638461333301747682" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638461333301747682" xlink:to="us-gaap_ConvertibleDebtMember_638461333301747682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301747682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301717678" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301747682" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333301757679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_638461333301757679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentUncommittedAdditionalFacility" xlink:label="chrs_DebtInstrumentUncommittedAdditionalFacility_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_DebtInstrumentUncommittedAdditionalFacility_638461333301757679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentNumberOfTranches" xlink:label="chrs_DebtInstrumentNumberOfTranches_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_DebtInstrumentNumberOfTranches_638461333301757679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_LongTermDebt_638461333301757679" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301757679" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638461333301757679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638461333301757679" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638461333301767680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_RepaymentsOfDebt_638461333301767680" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638461333301767680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638461333301767680" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodOne" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_638461333301767680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodOne_638461333301767680" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodTwo" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_638461333301767680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodTwo_638461333301767680" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LoanAgreementCovenantsNetSalesForPeriodThree" xlink:label="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_638461333301767680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_LoanAgreementCovenantsNetSalesForPeriodThree_638461333301767680" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MandatoryPrepaymentTerm" xlink:label="chrs_MandatoryPrepaymentTerm_638461333301767680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_MandatoryPrepaymentTerm_638461333301767680" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtDiscountsAndIssuanceCosts" xlink:label="chrs_DebtDiscountsAndIssuanceCosts_638461333301777676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_DebtDiscountsAndIssuanceCosts_638461333301777676" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_638461333301777676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DeferredFinanceCostsGross_638461333301777676" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301777676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301777676" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638461333301777676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentTerm_638461333301777676" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentRemainingTerm" xlink:label="chrs_DebtInstrumentRemainingTerm_638461333301777676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="chrs_DebtInstrumentRemainingTerm_638461333301777676" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301777676" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301777676" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_638461333301787681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301747682" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_638461333301787681" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301787681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_DebtInstrumentTable_638461333301787681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301787681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301787681" xlink:to="us-gaap_DebtInstrumentAxis_638461333301787681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301787681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301787681" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301787681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638461333301787681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301787681" xlink:to="chrs_TermLoansMember_638461333301787681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301787681" xlink:to="srt_CounterpartyNameAxis_638461333301797682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638461333301797682" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301797682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301797682" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638461333301797682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301787681" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301797682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301797682" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301797682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301797682" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333301797682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301797682" xlink:to="us-gaap_InterestExpenseDebt_638461333301797682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_DebtInstrumentTable_638461333301797682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301797682" xlink:to="us-gaap_DebtInstrumentAxis_638461333301797682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301797682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301797682" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301797682" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301797682" xlink:to="chrs_TermLoansMember_638461333301807677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301797682" xlink:to="srt_CounterpartyNameAxis_638461333301807677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638461333301807677" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301807677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BiopharmaCreditInvestmentsVGpLlcMember" xlink:label="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301807677" xlink:to="chrs_BiopharmaCreditInvestmentsVGpLlcMember_638461333301807677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301797682" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301807677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638461333301807677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638461333301807677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638461333301807677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638461333301807677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638461333301807677" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638461333301807677" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoanGross" xlink:label="chrs_TermLoanGross_638461333301807677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="chrs_TermLoanGross_638461333301807677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301817681" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_LongTermDebt_638461333301817681" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301807677" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_638461333301817681" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301817681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301817681" xlink:to="us-gaap_LongtermDebtTypeAxis_638461333301817681" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638461333301817681" xlink:to="us-gaap_LongtermDebtTypeDomain_638461333301817681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638461333301817681" xlink:to="us-gaap_ConvertibleDebtMember_638461333301817681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301817681" xlink:to="us-gaap_DebtInstrumentAxis_638461333301817681" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301817681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301817681" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301817681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301817681" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301827685" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301817681" xlink:to="srt_StatementScenarioAxis_638461333301827685" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638461333301827685" xlink:to="srt_ScenarioUnspecifiedDomain_638461333301827685" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638461333301827685" xlink:to="us-gaap_ScenarioPlanMember_638461333301827685" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301817681" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301827685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333301827685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301827685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638461333301827685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638461333301827685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638461333301827685" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_638461333301827685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="chrs_EquivalentToConversionPricePerCommonShare_638461333301827685" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_638461333301837677" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentMaturityDate_638461333301837677" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote_638461333301837677" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_638461333301837677" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="chrs_NumberOfEventsInDefault_638461333301837677" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_638461333301837677" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentContractualTerm" xlink:label="chrs_DebtInstrumentContractualTerm_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="chrs_DebtInstrumentContractualTerm_638461333301837677" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638461333301837677" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638461333301837677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_SharePrice_638461333301837677" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301847792" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301847792" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301827685" xlink:to="us-gaap_DebtInstrumentTerm_638461333301847792" order="18" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_638461333301847792" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable_638461333301847792" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638461333301847792" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_638461333301847792" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638461333301847792" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638461333301847792" xlink:to="us-gaap_CallOptionMember_638461333301847792" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_638461333301847792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable_638461333301847792" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_638461333301847792" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PaymentForCappedCallTransactions" xlink:label="chrs_PaymentForCappedCallTransactions_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638461333301847792" xlink:to="chrs_PaymentForCappedCallTransactions_638461333301857677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CapPriceOfCapCallTransactions" xlink:label="chrs_CapPriceOfCapCallTransactions_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638461333301847792" xlink:to="chrs_CapPriceOfCapCallTransactions_638461333301857677" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfCapPriceCappedCallTransactions" xlink:label="chrs_PercentageOfCapPriceCappedCallTransactions_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638461333301847792" xlink:to="chrs_PercentageOfCapPriceCappedCallTransactions_638461333301857677" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems_638461333301847792" xlink:to="us-gaap_SharePrice_638461333301857677" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40807 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301857677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301857677" xlink:to="us-gaap_DebtInstrumentAxis_638461333301857677" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301857677" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301857677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301857677" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301857677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301857677" xlink:to="us-gaap_LongtermDebtTypeAxis_638461333301857677" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638461333301857677" xlink:to="us-gaap_LongtermDebtTypeDomain_638461333301857677" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638461333301857677" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638461333301857677" xlink:to="us-gaap_ConvertibleDebtMember_638461333301857677" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301857677" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301867684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301867684" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301867684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301867684" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333301867684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301867684" xlink:to="us-gaap_InterestExpenseDebt_638461333301867684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails" xlink:type="extended" xlink:title="40808 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301867684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301867684" xlink:to="us-gaap_LongtermDebtTypeAxis_638461333301867684" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638461333301867684" xlink:to="us-gaap_LongtermDebtTypeDomain_638461333301867684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638461333301867684" xlink:to="us-gaap_ConvertibleDebtMember_638461333301867684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301867684" xlink:to="us-gaap_DebtInstrumentAxis_638461333301867684" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301867684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301867684" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301867684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301867684" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333301877683" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301867684" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301877683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638461333301877683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638461333301877683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638461333301877683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638461333301877683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638461333301877683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesPrincipalAmount" xlink:label="chrs_ConvertibleNotesPrincipalAmount_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="chrs_ConvertibleNotesPrincipalAmount_638461333301877683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301877683" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638461333301877683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301877683" xlink:to="us-gaap_LongTermDebt_638461333301877683" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails" xlink:type="extended" xlink:title="40809 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301887681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="srt_StatementScenarioAxis_638461333301887681" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638461333301887681" xlink:to="srt_ScenarioUnspecifiedDomain_638461333301887681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638461333301887681" xlink:to="us-gaap_ScenarioPlanMember_638461333301887681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="us-gaap_LongtermDebtTypeAxis_638461333301887681" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638461333301887681" xlink:to="us-gaap_LongtermDebtTypeDomain_638461333301887681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638461333301887681" xlink:to="us-gaap_ConvertibleDebtMember_638461333301887681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="us-gaap_DebtInstrumentAxis_638461333301887681" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301887681" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301887681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301887681" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333301887681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638461333301887681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="srt_CounterpartyNameAxis_638461333301887681" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638461333301887681" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301897686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301897686" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301897686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="srt_RangeAxis_638461333301897686" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333301897686" xlink:to="srt_RangeMember_638461333301897686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301897686" xlink:to="srt_MaximumMember_638461333301897686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638461333301897686" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638461333301897686" xlink:to="us-gaap_RelatedPartyDomain_638461333301897686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_KKRBiosimilarLPMember" xlink:label="chrs_KKRBiosimilarLPMember_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638461333301897686" xlink:to="chrs_KKRBiosimilarLPMember_638461333301897686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_MXIIAssociatesLLCMember" xlink:label="chrs_MXIIAssociatesLLCMember_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638461333301897686" xlink:to="chrs_MXIIAssociatesLLCMember_638461333301897686" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_KMGCapitalPartnersLLCMember" xlink:label="chrs_KMGCapitalPartnersLLCMember_638461333301897686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638461333301897686" xlink:to="chrs_KMGCapitalPartnersLLCMember_638461333301897686" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301887681" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301907685" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333301907685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301907685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_ProceedsFromConvertibleDebt_638461333301907685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DeferredFinanceCostsGross_638461333301907685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_LongTermDebt_638461333301907685" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_638461333301907685" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_638461333301907685" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638461333301907685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentMaturityDate_638461333301907685" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638461333301917682" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_ConvertibleNotesPayable_638461333301917682" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageOfPremiumOnConvertibleNote" xlink:label="chrs_PercentageOfPremiumOnConvertibleNote_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="chrs_PercentageOfPremiumOnConvertibleNote_638461333301917682" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes" xlink:label="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes_638461333301917682" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate" xlink:label="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate_638461333301917682" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquivalentToConversionPricePerCommonShare" xlink:label="chrs_EquivalentToConversionPricePerCommonShare_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="chrs_EquivalentToConversionPricePerCommonShare_638461333301917682" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_638461333301917682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_638461333301917682" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfEventsInDefault" xlink:label="chrs_NumberOfEventsInDefault_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="chrs_NumberOfEventsInDefault_638461333301927679" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638461333301927679" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638461333301927679" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentTerm_638461333301927679" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301927679" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_InterestExpenseDebt_638461333301927679" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301927679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301927679" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333301937681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301907685" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333301937681" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails" xlink:type="extended" xlink:title="40810 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301937681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301937681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638461333301937681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301937681" xlink:to="us-gaap_SubsequentEventTypeAxis_638461333301937681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638461333301937681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638461333301937681" xlink:to="us-gaap_SubsequentEventTypeDomain_638461333301937681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638461333301937681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638461333301937681" xlink:to="us-gaap_SubsequentEventMember_638461333301937681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638461333301937681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301937681" xlink:to="srt_CounterpartyNameAxis_638461333301937681" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638461333301937681" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301947680" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301937681" xlink:to="us-gaap_DebtInstrumentAxis_638461333301947680" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301947680" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301947680" xlink:to="us-gaap_LoansPayableMember_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301937681" xlink:to="srt_RangeAxis_638461333301947680" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333301947680" xlink:to="srt_RangeMember_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333301947680" xlink:to="srt_MaximumMember_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301937681" xlink:to="srt_StatementScenarioAxis_638461333301947680" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638461333301947680" xlink:to="srt_ScenarioUnspecifiedDomain_638461333301947680" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638461333301947680" xlink:to="us-gaap_ScenarioPlanMember_638461333301947680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301947680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301937681" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301947680" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_DebtInstrumentTerm_638461333301957682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333301957682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638461333301957682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_RepaymentsOfDebt_638461333301957682" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638461333301957682" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_638461333301957682" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_DebtInstrumentMaturityDate_638461333301957682" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebtInstrumentPrepaymentPercentage" xlink:label="chrs_DebtInstrumentPrepaymentPercentage_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="chrs_DebtInstrumentPrepaymentPercentage_638461333301957682" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount" xlink:label="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_638461333301957682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount_638461333301957682" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638461333301967684" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301947680" xlink:to="us-gaap_InterestExpenseDebt_638461333301967684" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails" xlink:type="extended" xlink:title="40811 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638461333301967684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301967684" xlink:to="srt_CounterpartyNameAxis_638461333301967684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638461333301967684" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301967684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_HealthcareRoyaltyPartnersIIILPMember" xlink:label="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638461333301967684" xlink:to="chrs_HealthcareRoyaltyPartnersIIILPMember_638461333301967684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301967684" xlink:to="us-gaap_DebtInstrumentAxis_638461333301967684" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333301967684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333301967684" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333301967684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333301967684" xlink:to="us-gaap_LoansPayableMember_638461333301977684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301967684" xlink:to="us-gaap_LongtermDebtTypeAxis_638461333301977684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638461333301977684" xlink:to="us-gaap_LongtermDebtTypeDomain_638461333301977684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638461333301977684" xlink:to="us-gaap_ConvertibleDebtMember_638461333301977684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638461333301967684" xlink:to="us-gaap_DebtInstrumentLineItems_638461333301977684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301977684" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638461333301977684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301977684" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638461333301977684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638461333301977684" xlink:to="us-gaap_InterestExpenseDebt_638461333301977684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_638461333301977684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_638461333301977684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_638461333301987683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="us-gaap_PurchaseObligationDueInThirdYear_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInThirdYear_638461333301987683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligation_638461333301987683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="ContractualObligationFiscalYearMaturityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_LossContingenciesTable_638461333301987683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638461333301987683" xlink:to="us-gaap_BalanceSheetLocationAxis_638461333301987683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638461333301987683" xlink:to="us-gaap_BalanceSheetLocationDomain_638461333301987683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AccruedRebatesFeesAndReservesMember" xlink:label="chrs_AccruedRebatesFeesAndReservesMember_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638461333301987683" xlink:to="chrs_AccruedRebatesFeesAndReservesMember_638461333301987683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638461333301987683" xlink:to="us-gaap_LossContingenciesLineItems_638461333301987683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638461333301987683" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_638461333301987683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_638461333301987683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638461333301987683" xlink:to="us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate_638461333301987683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638461333301997683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638461333301997683" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301997683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638461333301997683" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301997683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CorporateHeadquartersLeaseAgreementMember" xlink:label="chrs_CorporateHeadquartersLeaseAgreementMember_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301997683" xlink:to="chrs_CorporateHeadquartersLeaseAgreementMember_638461333301997683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_LaboratoryFacilitiesLeaseAgreementMember" xlink:label="chrs_LaboratoryFacilitiesLeaseAgreementMember_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301997683" xlink:to="chrs_LaboratoryFacilitiesLeaseAgreementMember_638461333301997683" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NewCamarilloLeaseMember" xlink:label="chrs_NewCamarilloLeaseMember_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301997683" xlink:to="chrs_NewCamarilloLeaseMember_638461333301997683" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_VehiclesLeaseMember" xlink:label="chrs_VehiclesLeaseMember_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638461333301997683" xlink:to="chrs_VehiclesLeaseMember_638461333301997683" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638461333301997683" xlink:to="us-gaap_LeaseContractualTermAxis_638461333301997683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638461333301997683" xlink:to="us-gaap_LeaseContractualTermDomain_638461333301997683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OfficeSpaceRemainingPremisesMember" xlink:label="chrs_OfficeSpaceRemainingPremisesMember_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638461333301997683" xlink:to="chrs_OfficeSpaceRemainingPremisesMember_638461333301997683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638461333301997683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638461333301997683" xlink:to="us-gaap_TypeOfArrangementAxis_638461333301997683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638461333301997683" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333302007685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SixthAmendmentToLeaseMember" xlink:label="chrs_SixthAmendmentToLeaseMember_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333302007685" xlink:to="chrs_SixthAmendmentToLeaseMember_638461333302007685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638461333301997683" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_AreaOfRealEstateProperty_638461333302007685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_LeaseExpirationDate1_638461333302007685" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638461333302007685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638461333302007685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_AreaOfLand_638461333302007685" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfVehiclesLeased" xlink:label="chrs_NumberOfVehiclesLeased_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="chrs_NumberOfVehiclesLeased_638461333302007685" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_638461333302007685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_638461333302007685" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638461333302017683" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638461333302007685" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638461333302017683" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638461333302017683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638461333302017683" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638461333302017683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset_638461333302017683" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638461333302017683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638461333302017683" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638461333302017683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset_638461333302017683" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638461333302017683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="chrs_OperatingAndFinanceLeaseRightOfUseAssets_638461333302017683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638461333302017683" xlink:to="chrs_OperatingAndFinanceLeaseRightOfUseAssets_638461333302017683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingLeaseLiabilitiesAbstract" xlink:label="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638461333302027685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638461333302027685" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638461333302027685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638461333302027685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent_638461333302027685" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638461333302027685" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" xlink:to="us-gaap_OperatingLeaseLiability_638461333302027685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638461333302027685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent_638461333302027685" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638461333302027685" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638461333302027685" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent_638461333302027685" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638461333302027685" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638461333302027685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_OperatingLeaseLiabilitiesAbstract_638461333302027685" xlink:to="us-gaap_FinanceLeaseLiability_638461333302027685" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Leases - Other information related to lease term and discount rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638461333302037687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638461333302037687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638461333302037687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638461333302037687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638461333302037687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638461333302037687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638461333302037687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638461333302037687" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638461333302037687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638461333302037687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638461333302047683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_FinanceLeaseInterestExpense_638461333302047683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_FinanceLeaseCost" xlink:label="chrs_FinanceLeaseCost_638461333302047683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="chrs_FinanceLeaseCost_638461333302047683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638461333302047683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeaseCost_638461333302047683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638461333302047683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LeaseCost_638461333302047683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Leases - Supplemental cash flow information related to leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638461333302107685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeasePayments_638461333302107685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638461333302107685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638461333302107685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_638461333302107685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_638461333302107685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638461333302107685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638461333302107685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638461333302107685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638461333302107685" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638461333302117683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638461333302117683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638461333302117683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638461333302117683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638461333302117683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638461333302117683" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_OperatingLeaseLiability_638461333302117683" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638461333302117683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638461333302117683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638461333302117683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638461333302127684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638461333302127684" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638461333302117683" xlink:to="us-gaap_FinanceLeaseLiability_638461333302127684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockholdersDeficitDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stockholders' Deficit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingTable" xlink:label="chrs_AtMarketOfferingTable_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="chrs_AtMarketOfferingTable_638461333302127684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingTable_638461333302127684" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638461333302127684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638461333302127684" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638461333302127684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_PublicOfferingMember" xlink:label="chrs_PublicOfferingMember_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638461333302127684" xlink:to="chrs_PublicOfferingMember_638461333302127684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingMember" xlink:label="chrs_AtMarketOfferingMember_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638461333302127684" xlink:to="chrs_AtMarketOfferingMember_638461333302127684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638461333302127684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638461333302127684" xlink:to="us-gaap_OverAllotmentOptionMember_638461333302127684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingTable_638461333302127684" xlink:to="srt_RangeAxis_638461333302137683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333302137683" xlink:to="srt_RangeMember_638461333302137683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333302137683" xlink:to="srt_WeightedAverageMember_638461333302137683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333302137683" xlink:to="srt_MaximumMember_638461333302137683" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingTable_638461333302127684" xlink:to="srt_TitleOfIndividualAxis_638461333302137683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638461333302137683" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638461333302137683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ChiefMarketingOfficerMember" xlink:label="chrs_ChiefMarketingOfficerMember_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638461333302137683" xlink:to="chrs_ChiefMarketingOfficerMember_638461333302137683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingTable_638461333302127684" xlink:to="us-gaap_TypeOfArrangementAxis_638461333302137683" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638461333302137683" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333302137683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OptionalStockPurchaseAgreementMember" xlink:label="chrs_OptionalStockPurchaseAgreementMember_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638461333302137683" xlink:to="chrs_OptionalStockPurchaseAgreementMember_638461333302137683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_AtMarketOfferingLineItems" xlink:label="chrs_AtMarketOfferingLineItems_638461333302137683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingTable_638461333302127684" xlink:to="chrs_AtMarketOfferingLineItems_638461333302137683" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638461333302147680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638461333302147680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638461333302147680" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638461333302147680" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock" xlink:label="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock_638461333302147680" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_SharesIssuedPricePerShare_638461333302147680" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingUnderwritersOptionTerm" xlink:label="chrs_SharesOfferingUnderwritersOptionTerm_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_SharesOfferingUnderwritersOptionTerm_638461333302147680" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingAggregateAmount" xlink:label="chrs_SharesOfferingAggregateAmount_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_SharesOfferingAggregateAmount_638461333302147680" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_SharesOfferingAggregateAmountDecrease" xlink:label="chrs_SharesOfferingAggregateAmountDecrease_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_SharesOfferingAggregateAmountDecrease_638461333302147680" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_IncreaseInAmountOfSharesToBeIssuedAndSold" xlink:label="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold_638461333302147680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_IncreaseInAmountOfSharesToBeIssuedAndSold_638461333302147680" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638461333302157689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638461333302157689" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_WeightedAveragePricePerShare" xlink:label="chrs_WeightedAveragePricePerShare_638461333302157689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_WeightedAveragePricePerShare_638461333302157689" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ProceedsFromIssuanceOfCommonStockGross" xlink:label="chrs_ProceedsFromIssuanceOfCommonStockGross_638461333302157689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_ProceedsFromIssuanceOfCommonStockGross_638461333302157689" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638461333302157689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638461333302157689" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6384613333021576891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6384613333021576891" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering" xlink:label="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering_638461333302157689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="chrs_AtMarketOfferingLineItems_638461333302137683" xlink:to="chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering_638461333302157689" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302167683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302167683" xlink:to="us-gaap_PlanNameAxis_638461333302167683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302167683" xlink:to="us-gaap_PlanNameDomain_638461333302167683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember" xlink:label="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302167683" xlink:to="chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_638461333302167683" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandTenPlanMember" xlink:label="chrs_TwoThousandTenPlanMember_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302167683" xlink:to="chrs_TwoThousandTenPlanMember_638461333302167683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmploymentCommencementIncentivePlanMember" xlink:label="chrs_EmploymentCommencementIncentivePlanMember_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302167683" xlink:to="chrs_EmploymentCommencementIncentivePlanMember_638461333302167683" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302167683" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302167683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302167683" xlink:to="chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance_638461333302167683" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302167683" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638461333302167683" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638461333302167683" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302167683" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638461333302167683" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302177687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302177687" xlink:to="us-gaap_AwardTypeAxis_638461333302177687" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638461333302177687" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302177687" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302177687" xlink:to="us-gaap_EmployeeStockOptionMember_638461333302177687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302177687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638461333302177687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638461333302177687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302177687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638461333302177687" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638461333302177687" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638461333302177687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302177687" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638461333302177687" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302187694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302187694" xlink:to="us-gaap_PlanNameAxis_638461333302187694" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302187694" xlink:to="us-gaap_PlanNameDomain_638461333302187694" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302187694" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember_638461333302187694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638461333302187694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638461333302187694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638461333302187694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638461333302187694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638461333302187694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638461333302197684" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638461333302197684" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638461333302197684" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638461333302197684" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638461333302197684" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638461333302197684" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384613333021976841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384613333021976841" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638461333302197684" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638461333302197684" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638461333302197684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638461333302197684" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638461333302207686" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302187694" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638461333302207686" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302207686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302207686" xlink:to="us-gaap_PlanNameAxis_638461333302207686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302207686" xlink:to="us-gaap_PlanNameDomain_638461333302207686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302207686" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember_638461333302207686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302207686" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638461333302207686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638461333302207686" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange1.67To5.44Member" xlink:label="chrs_ExercisePriceRange1.67To5.44Member_638461333302207686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" xlink:to="chrs_ExercisePriceRange1.67To5.44Member_638461333302207686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange5.86To10.05Member" xlink:label="chrs_ExercisePriceRange5.86To10.05Member_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" xlink:to="chrs_ExercisePriceRange5.86To10.05Member_638461333302217686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange10.37To13.63Member" xlink:label="chrs_ExercisePriceRange10.37To13.63Member_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" xlink:to="chrs_ExercisePriceRange10.37To13.63Member_638461333302217686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange14.03To17.17Member" xlink:label="chrs_ExercisePriceRange14.03To17.17Member_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" xlink:to="chrs_ExercisePriceRange14.03To17.17Member_638461333302217686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange17.30To19.40Member" xlink:label="chrs_ExercisePriceRange17.30To19.40Member_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" xlink:to="chrs_ExercisePriceRange17.30To19.40Member_638461333302217686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ExercisePriceRange19.85To46.38Member" xlink:label="chrs_ExercisePriceRange19.85To46.38Member_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638461333302207686" xlink:to="chrs_ExercisePriceRange19.85To46.38Member_638461333302217686" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302207686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638461333302217686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638461333302217686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638461333302217686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638461333302217686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638461333302217686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638461333302217686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638461333302227684" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302217686" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638461333302227684" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302227684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302227684" xlink:to="us-gaap_PlanNameAxis_638461333302227684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302227684" xlink:to="us-gaap_PlanNameDomain_638461333302227684" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EquityPlan2016PlanAnd2014PlanMember" xlink:label="chrs_EquityPlan2016PlanAnd2014PlanMember_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302227684" xlink:to="chrs_EquityPlan2016PlanAnd2014PlanMember_638461333302227684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302227684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302227684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638461333302227684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302227684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638461333302227684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302227684" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638461333302237685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302227684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302237685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302237685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302237685" xlink:to="us-gaap_AwardTypeAxis_638461333302237685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638461333302237685" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302237685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302237685" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638461333302237685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302237685" xlink:to="srt_RangeAxis_638461333302237685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333302237685" xlink:to="srt_RangeMember_638461333302237685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333302237685" xlink:to="srt_MinimumMember_638461333302237685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333302237685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333302237685" xlink:to="srt_MaximumMember_638461333302237685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302237685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638461333302247689" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638461333302247689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638461333302247689" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302247689" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302247689" xlink:to="us-gaap_AwardTypeAxis_638461333302247689" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302247689" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302247689" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638461333302247689" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638461333302257690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638461333302257690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638461333302257690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638461333302257690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384613333022576901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6384613333022576901" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638461333302257690" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302257690" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638461333302257690" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638461333302257690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638461333302257690" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384613333022576901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302247689" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6384613333022576901" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails" xlink:type="extended" xlink:title="41208 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302267684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302267684" xlink:to="us-gaap_AwardTypeAxis_638461333302267684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638461333302267684" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302267684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302267684" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638461333302267684" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302267684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302267684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302267684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638461333302267684" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue" xlink:label="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302267684" xlink:to="chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue_638461333302267684" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302267684" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302267684" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638461333302267684" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41209 - Disclosure - Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302277685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302277685" xlink:to="us-gaap_PlanNameAxis_638461333302277685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302277685" xlink:to="us-gaap_PlanNameDomain_638461333302277685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302277685" xlink:to="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_638461333302277685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302277685" xlink:to="srt_RangeAxis_638461333302277685" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333302277685" xlink:to="srt_RangeMember_638461333302277685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333302277685" xlink:to="srt_MinimumMember_638461333302277685" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302277685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance" xlink:label="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance_638461333302277685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638461333302277685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638461333302277685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne_638461333302277685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne_638461333302277685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo" xlink:label="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo_638461333302287686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638461333302287686" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302277685" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638461333302287686" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails" xlink:type="extended" xlink:title="41210 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302287686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302287686" xlink:to="us-gaap_IncomeStatementLocationAxis_638461333302287686" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638461333302287686" xlink:to="us-gaap_IncomeStatementLocationDomain_638461333302287686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302287686" xlink:to="us-gaap_CostOfSalesMember_638461333302287686" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302287686" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638461333302287686" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638461333302287686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302287686" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638461333302287686" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302287686" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302297686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302297686" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638461333302297686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302297686" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_638461333302297686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails" xlink:type="extended" xlink:title="41211 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302297686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302297686" xlink:to="us-gaap_IncomeStatementLocationAxis_638461333302297686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638461333302297686" xlink:to="us-gaap_IncomeStatementLocationDomain_638461333302297686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302297686" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638461333302297686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302297686" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638461333302297686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638461333302297686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302297686" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638461333302297686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638461333302297686" xlink:to="us-gaap_TypeOfRestructuringDomain_638461333302307688" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638461333302307688" xlink:to="us-gaap_EmployeeSeveranceMember_638461333302307688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638461333302297686" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302307688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302307688" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_638461333302307688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedPaymentArrangementForfeitureCredit" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638461333302307688" xlink:to="chrs_ShareBasedPaymentArrangementForfeitureCredit_638461333302307688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41212 - Disclosure - Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302307688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302307688" xlink:to="us-gaap_AwardTypeAxis_638461333302307688" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638461333302307688" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302307688" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638461333302307688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638461333302307688" xlink:to="us-gaap_EmployeeStockOptionMember_638461333302307688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302307688" xlink:to="us-gaap_PlanNameAxis_638461333302317690" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302317690" xlink:to="us-gaap_PlanNameDomain_638461333302317690" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302317690" xlink:to="chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_638461333302317690" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302307688" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302317690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302317690" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638461333302317690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302317690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638461333302317690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302317690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638461333302317690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302317690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638461333302317690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails" xlink:type="extended" xlink:title="41213 - Disclosure - Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302317690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302317690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302317690" xlink:to="us-gaap_PlanNameAxis_638461333302327687" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638461333302327687" xlink:to="us-gaap_PlanNameDomain_638461333302327687" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_Plan401KMember" xlink:label="chrs_Plan401KMember_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638461333302327687" xlink:to="chrs_Plan401KMember_638461333302327687" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302317690" xlink:to="srt_RangeAxis_638461333302327687" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638461333302327687" xlink:to="srt_RangeMember_638461333302327687" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638461333302327687" xlink:to="srt_MaximumMember_638461333302327687" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638461333302317690" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302327687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302327687" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638461333302327687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302327687" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638461333302327687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302327687" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638461333302327687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638461333302327687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638461333302327687" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638461333302327687" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638461333302337686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638461333302337686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638461333302337686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638461333302337686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638461333302337686" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638461333302337686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638461333302337686" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638461333302337686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638461333302337686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638461333302337686" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638461333302337686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638461333302347690" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638461333302347690" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences_638461333302347690" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch" xlink:label="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch_638461333302347690" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638461333302347690" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638461333302347690" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638461333302347690" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638461333302347690" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638461333302347690" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638461333302347690" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638461333302357688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638461333302357688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638461333302357688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638461333302357688" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_638461333302357688" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_638461333302357688" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638461333302357688" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsGross_638461333302357688" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="chrs_DeferredTaxLiabilitiesRightOfUseAsset_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="chrs_DeferredTaxLiabilitiesRightOfUseAsset_638461333302357688" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638461333302357688" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638461333302357688" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DeferredTaxAssetLiabilityNet" xlink:label="chrs_DeferredTaxAssetLiabilityNet_638461333302357688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="chrs_DeferredTaxAssetLiabilityNet_638461333302357688" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638461333302367687" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638461333302367687" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638461333302357688" xlink:to="us-gaap_DeferredTaxLiabilities_638461333302367687" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638461333302367687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638461333302367687" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638461333302367687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638461333302367687" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638461333302367687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638461333302367687" xlink:to="us-gaap_ResearchMember_638461333302367687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638461333302367687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638461333302367687" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638461333302367687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638461333302367687" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638461333302377686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638461333302377686" xlink:to="us-gaap_DomesticCountryMember_638461333302377686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638461333302377686" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638461333302377686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638461333302367687" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638461333302377686" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="us-gaap_OperatingLossCarryforwards_638461333302377686" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_OperatingLossCarryforwardsExpirationYear" xlink:label="chrs_OperatingLossCarryforwardsExpirationYear_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="chrs_OperatingLossCarryforwardsExpirationYear_638461333302377686" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638461333302377686" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TaxCreditCarryforwardExpirationYear" xlink:label="chrs_TaxCreditCarryforwardExpirationYear_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="chrs_TaxCreditCarryforwardExpirationYear_638461333302377686" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="us-gaap_UnrecognizedTaxBenefits_638461333302377686" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638461333302377686" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638461333302377686" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638461333302377686" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638461333302387687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefits_638461333302387687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638461333302387687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638461333302387687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638461333302387687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638461333302387687" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_638461333302387687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_638461333302387687" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6384613333023876871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefits_6384613333023876871" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638461333302397688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638461333302397688" xlink:to="us-gaap_DebtInstrumentAxis_638461333302397688" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333302397688" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333302397688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333302397688" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333302397688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member" xlink:label="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333302397688" xlink:to="chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_638461333302397688" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638461333302397688" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638461333302397688" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638461333302397688" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638461333302397688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EmployeesAndNonemployeesStockOptionMember" xlink:label="chrs_EmployeesAndNonemployeesStockOptionMember_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638461333302397688" xlink:to="chrs_EmployeesAndNonemployeesStockOptionMember_638461333302397688" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638461333302397688" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638461333302397688" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleNotesMember" xlink:label="chrs_ConvertibleNotesMember_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638461333302397688" xlink:to="chrs_ConvertibleNotesMember_638461333302397688" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638461333302397688" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638461333302397688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638461333302397688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638461333302397688" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638461333302397688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRestructuringChargesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Restructuring Charges (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638461333302407685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638461333302407685" xlink:to="us-gaap_IncomeStatementLocationAxis_638461333302407685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638461333302407685" xlink:to="us-gaap_IncomeStatementLocationDomain_638461333302407685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302407685" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638461333302407685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638461333302407685" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638461333302407685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638461333302407685" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638461333302407685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638461333302407685" xlink:to="us-gaap_TypeOfRestructuringDomain_638461333302407685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638461333302407685" xlink:to="us-gaap_EmployeeSeveranceMember_638461333302407685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638461333302407685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638461333302407685" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638461333302407685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638461333302407685" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638461333302417709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638461333302407685" xlink:to="us-gaap_RestructuringCharges_638461333302417709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638461333302407685" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_638461333302417709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ShareBasedPaymentArrangementForfeitureCredit" xlink:label="chrs_ShareBasedPaymentArrangementForfeitureCredit_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638461333302407685" xlink:to="chrs_ShareBasedPaymentArrangementForfeitureCredit_638461333302417709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638461333302417709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638461333302417709" xlink:to="us-gaap_DebtInstrumentAxis_638461333302417709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333302417709" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333302417709" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConvertibleSeniorNotes8.2PercentDue2022Member" xlink:label="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333302417709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333302417709" xlink:to="chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_638461333302417709" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638461333302417709" xlink:to="us-gaap_RelatedPartyTransactionAxis_638461333302427688" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638461333302427688" xlink:to="us-gaap_RelatedPartyTransactionDomain_638461333302427688" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_ConsultingAgreementWithLanfearAdvisorsMember" xlink:label="chrs_ConsultingAgreementWithLanfearAdvisorsMember_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638461333302427688" xlink:to="chrs_ConsultingAgreementWithLanfearAdvisorsMember_638461333302427688" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638461333302417709" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638461333302427688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333302427688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638461333302427688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638461333302427688" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638461333302427688" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638461333302427688" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses_638461333302427688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638461333302427688" xlink:to="us-gaap_OperatingCostsAndExpenses_638461333302427688" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.coherus.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638461333302437688" xlink:to="us-gaap_BusinessAcquisitionAxis_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638461333302437688" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CoherusOphthalmologyLlcMember" xlink:label="chrs_CoherusOphthalmologyLlcMember_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638461333302437688" xlink:to="chrs_CoherusOphthalmologyLlcMember_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638461333302437688" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638461333302437688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638461333302437688" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_CimerliDivestitureTransactionMember" xlink:label="chrs_CimerliDivestitureTransactionMember_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638461333302437688" xlink:to="chrs_CimerliDivestitureTransactionMember_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638461333302437688" xlink:to="us-gaap_DebtInstrumentAxis_638461333302437688" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638461333302437688" xlink:to="us-gaap_DebtInstrumentNameDomain_638461333302437688" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_TermLoansMember" xlink:label="chrs_TermLoansMember_638461333302437688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638461333302437688" xlink:to="chrs_TermLoansMember_638461333302437688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638461333302437688" xlink:to="us-gaap_SubsequentEventTypeAxis_638461333302447689" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638461333302447689" xlink:to="us-gaap_SubsequentEventTypeDomain_638461333302447689" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638461333302447689" xlink:to="us-gaap_SubsequentEventMember_638461333302447689" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638461333302437688" xlink:to="us-gaap_SubsequentEventLineItems_638461333302447689" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638461333302447689" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638461333302447689" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets" xlink:label="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638461333302447689" xlink:to="chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets_638461333302447689" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_DebInstrumentPartialRepaymentPrincipal" xlink:label="chrs_DebInstrumentPartialRepaymentPrincipal_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638461333302447689" xlink:to="chrs_DebInstrumentPartialRepaymentPrincipal_638461333302447689" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638461333302447689" xlink:to="us-gaap_DebtInstrumentFaceAmount_638461333302447689" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="chrs-20231231.xsd#chrs_EarlyRedemptionFee" xlink:label="chrs_EarlyRedemptionFee_638461333302447689" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638461333302447689" xlink:to="chrs_EarlyRedemptionFee_638461333302447689" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293912848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Coherus BioSciences,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,137,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,714,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Part&#160;III of this annual report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive proxy statement for the 2024 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2023.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296246592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 102,891<span></span>
</td>
<td class="nump">$ 63,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">14,857<span></span>
</td>
<td class="nump">128,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">260,522<span></span>
</td>
<td class="nump">109,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">62,605<span></span>
</td>
<td class="nump">38,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaidManufacturingExpenseCurrent', window );">Prepaid manufacturing</a></td>
<td class="nump">23,657<span></span>
</td>
<td class="nump">17,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other prepaids and current assets</a></td>
<td class="nump">11,099<span></span>
</td>
<td class="nump">22,918<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">475,631<span></span>
</td>
<td class="nump">381,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,119<span></span>
</td>
<td class="nump">8,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">67,495<span></span>
</td>
<td class="nump">76,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">71,673<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, non-current</a></td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">8,668<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">629,604<span></span>
</td>
<td class="nump">480,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">35,219<span></span>
</td>
<td class="nump">11,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedRebatesFeesAndReserveCurrent', window );">Accrued rebates, fees and reserves</a></td>
<td class="nump">169,645<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">21,521<span></span>
</td>
<td class="nump">22,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">105,386<span></span>
</td>
<td class="nump">50,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">331,771<span></span>
</td>
<td class="nump">138,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_TermLoansPayableNoncurrent', window );">Term loans</a></td>
<td class="nump">246,481<span></span>
</td>
<td class="nump">245,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">226,888<span></span>
</td>
<td class="nump">225,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Lease liabilities, non-current</a></td>
<td class="nump">5,328<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">12,561<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">823,029<span></span>
</td>
<td class="nump">618,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 112,215,260 and 78,851,516 at December 31, 2023 and 2022, respectively)</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,386,312<span></span>
</td>
<td class="nump">1,204,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,579,500)<span></span>
</td>
<td class="num">(1,341,608)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(193,425)<span></span>
</td>
<td class="num">(137,418)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 629,604<span></span>
</td>
<td class="nump">$ 480,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedRebatesFeesAndReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued rebates, fees and reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedRebatesFeesAndReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaidManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaidManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_TermLoansPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_TermLoansPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleSubordinatedDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleSubordinatedDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295088960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">112,215,260<span></span>
</td>
<td class="nump">78,851,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">112,215,260<span></span>
</td>
<td class="nump">78,851,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296214320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 257,244<span></span>
</td>
<td class="nump">$ 211,042<span></span>
</td>
<td class="nump">$ 326,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">158,992<span></span>
</td>
<td class="nump">70,083<span></span>
</td>
<td class="nump">57,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">109,436<span></span>
</td>
<td class="nump">199,358<span></span>
</td>
<td class="nump">363,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">192,015<span></span>
</td>
<td class="nump">198,481<span></span>
</td>
<td class="nump">169,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">460,443<span></span>
</td>
<td class="nump">467,922<span></span>
</td>
<td class="nump">590,409<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(203,199)<span></span>
</td>
<td class="num">(256,880)<span></span>
</td>
<td class="num">(263,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(40,542)<span></span>
</td>
<td class="num">(32,474)<span></span>
</td>
<td class="num">(22,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">5,469<span></span>
</td>
<td class="nump">3,822<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(238,272)<span></span>
</td>
<td class="num">(291,754)<span></span>
</td>
<td class="num">(287,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="num">(380)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (237,892)<span></span>
</td>
<td class="num">$ (291,754)<span></span>
</td>
<td class="num">$ (287,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (In dollar per share)</a></td>
<td class="num">$ (2.53)<span></span>
</td>
<td class="num">$ (3.76)<span></span>
</td>
<td class="num">$ (3.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (In dollar per share)</a></td>
<td class="num">$ (2.53)<span></span>
</td>
<td class="num">$ (3.76)<span></span>
</td>
<td class="num">$ (3.81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average number of shares used in computing basic and diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (In shares)</a></td>
<td class="nump">94,162,637<span></span>
</td>
<td class="nump">77,630,020<span></span>
</td>
<td class="nump">75,449,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (In shares)</a></td>
<td class="nump">94,162,637<span></span>
</td>
<td class="nump">77,630,020<span></span>
</td>
<td class="nump">75,449,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293801904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (237,892)<span></span>
</td>
<td class="num">$ (291,754)<span></span>
</td>
<td class="num">$ (287,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available-for-sale securities, net of tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments, net of tax</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (237,891)<span></span>
</td>
<td class="num">$ (291,733)<span></span>
</td>
<td class="num">$ (287,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289544032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Common Stock </div>
<div>At The Market Offering.</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Optional Stock Purchase Agreement</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At The Market Offering.</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Optional Stock Purchase Agreement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>At The Market Offering.</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Optional Stock Purchase Agreement</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,043,991,000<span></span>
</td>
<td class="num">$ (270,000)<span></span>
</td>
<td class="num">$ (762,754,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,974,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,513,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287,100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,410,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodAcquisitions', window );"><strong>Issuance of common stock in connection with Surface Acquisition:(1)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,290,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,903,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,903,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,491,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan ("ESPP")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,002,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,753,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,753,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,147,843,000<span></span>
</td>
<td class="num">(270,000)<span></span>
</td>
<td class="num">(1,049,854,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,726,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,930,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291,754,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(291,754,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodAcquisitions', window );"><strong>Issuance of common stock in connection with Surface Acquisition:(1)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,188,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Offering, net of issuance costs (in shares)</a></td>
<td class="nump">916,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan ("ESPP")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,744,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,744,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(292,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204,431,000<span></span>
</td>
<td class="num">(249,000)<span></span>
</td>
<td class="num">(1,341,608,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (137,418,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,851,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,851,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237,892,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (237,892,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock units ("RSUs") (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodAcquisitions', window );"><strong>Issuance of common stock in connection with Surface Acquisition:(1)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance to Surface shareholders for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,541,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance to Surface shareholders for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,971,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards', window );">Accelerated vesting of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards', window );">Accelerated vesting of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards', window );">Taxes paid related to net share settlement of equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(347,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(347,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,540,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">$ 3,559,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Offering, net of issuance costs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,316,000<span></span>
</td>
<td class="nump">$ 53,624,000<span></span>
</td>
<td class="nump">$ 8,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,317,000<span></span>
</td>
<td class="nump">$ 53,625,000<span></span>
</td>
<td class="nump">$ 8,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,529,411<span></span>
</td>
<td class="nump">2,225,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,559,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan ("ESPP")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan ("ESPP") (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,527,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,527,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(459,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,386,312,000<span></span>
</td>
<td class="num">$ (248,000)<span></span>
</td>
<td class="num">$ (1,579,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (193,425,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,215,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,215,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockIssuedDuringPeriodAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period on acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockIssuedDuringPeriodAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of accelerated vesting of equity awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares settled related to taxes paid related to net share settlement of equity awards during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to accelerated vesting of equity awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock settled related to taxes paid related to net share settlement of equity awards during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294606496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (237,892)<span></span>
</td>
<td class="num">$ (291,754)<span></span>
</td>
<td class="num">$ (287,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,791<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
<td class="nump">3,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">43,110<span></span>
</td>
<td class="nump">50,737<span></span>
</td>
<td class="nump">51,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Write-off of prepaid manufacturing services related to the termination of CHS-2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs, net</a></td>
<td class="nump">52,595<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Non-cash amortization of premium (accretion of discount) on marketable securities, net</a></td>
<td class="num">(3,052)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense from amortization of debt discount and issuance costs</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="nump">6,431<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements', window );">Upfront and option payments to Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">136,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other non-cash adjustments, net</a></td>
<td class="num">(1,493)<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Trade receivables, net</a></td>
<td class="num">(150,683)<span></span>
</td>
<td class="nump">13,052<span></span>
</td>
<td class="nump">34,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(46,734)<span></span>
</td>
<td class="num">(47,348)<span></span>
</td>
<td class="num">(6,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid manufacturing</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="num">(4,214)<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other prepaid, current and non-current assets</a></td>
<td class="nump">16,155<span></span>
</td>
<td class="num">(13,424)<span></span>
</td>
<td class="num">(5,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">23,760<span></span>
</td>
<td class="num">(4,548)<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve', window );">Accrued rebates, fees and reserves</a></td>
<td class="nump">113,105<span></span>
</td>
<td class="num">(24,566)<span></span>
</td>
<td class="num">(2,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_IncreaseDecreaseInAccruedCompensation', window );">Accrued compensation</a></td>
<td class="num">(5,373)<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current and non-current liabilities</a></td>
<td class="nump">10,917<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">17,932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(174,884)<span></span>
</td>
<td class="num">(241,124)<span></span>
</td>
<td class="num">(37,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(2,039)<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments in marketable securities</a></td>
<td class="num">(19,507)<span></span>
</td>
<td class="num">(127,382)<span></span>
</td>
<td class="num">(182,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of investments in marketable securities</a></td>
<td class="nump">144,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments in marketable securities</a></td>
<td class="nump">13,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and cash equivalents acquired from Surface Acquisition</a></td>
<td class="nump">6,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities', window );">Upfront and option payments to Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements', window );">Milestone based license fee payments</a></td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(2,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">144,640<span></span>
</td>
<td class="num">(166,850)<span></span>
</td>
<td class="num">(138,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">10,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from purchase under the employee stock purchase plan</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">3,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement</a></td>
<td class="num">(3,587)<span></span>
</td>
<td class="num">(3,744)<span></span>
</td>
<td class="num">(1,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of 2022 Convertible Notes and premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of 2025 Term Loan, premiums and exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="num">(1,228)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="nump">54,326<span></span>
</td>
<td class="nump">51,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">39,356<span></span>
</td>
<td class="num">(353,648)<span></span>
</td>
<td class="num">(123,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">63,987<span></span>
</td>
<td class="nump">417,635<span></span>
</td>
<td class="nump">541,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">103,343<span></span>
</td>
<td class="nump">63,987<span></span>
</td>
<td class="nump">417,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">37,857<span></span>
</td>
<td class="nump">34,878<span></span>
</td>
<td class="nump">18,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid (refunded), net</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember', window );">At The Market Offering.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">18,093<span></span>
</td>
<td class="nump">$ 6,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 53,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued rebates, fees and reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents upfront and milestone based license fee payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments related to license and collaboration arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront license fee payment related to license and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chrs_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293828976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;"> Coherus BioSciences,&#160;Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span>Organization and Significant Accounting Policies</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Coherus BioSciences,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Coherus&#8221;) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The Company&#8217;s strategy is to build a leading immuno-oncology business funded with cash generated from its diversified portfolio of FDA-approved therapeutics. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company sells UDENYCA <span style="background:#ffffff;">(pegfilgrastim-cbqv)</span>, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. On August 2, 2022, the FDA approved CIMERLI&#174;&#160;<span style="background:#ffffff;">(ranibizumab-eqrn)</span>, a biosimilar to Lucentis, and commercial launch commenced in October 2022 in the United States. The Company launched YUSIMRY&#174;&#160;<span style="background:#ffffff;">(adalimumab-aqvh), a biosimilar to Humira (adalimumab),&#160;</span>in the United States in July 2023. On October 27, 2023, the Company announced that LOQTORZI&#8482; (toripalimab-tpzi) was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a novel PD-1 inhibitor that the Company developed in collaboration with Junshi Biosciences. The Company announced the launch of LOQTORZI in the U.S. on January 2, 2024. On January 19, 2024, the Company entered into the Purchase Agreement by and between the Company and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, the Company completed the Sale Transaction for its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s product pipeline comprises&#160;the following three product candidates: <span style="background:#ffffff;">CHS-1000, an antibody targeting ILT4; casdozokitug (CHS-388, formerly SRF388), an antibody targeting IL-27; and CHS-114 (formerly SRF114), a highly specific afucosylated IgG1 antibody targeting CCR8. In addition to the Company&#8217;s internally developed portfolio of product candidates, the Company has two product candidates, NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes and GSK, respectively.&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of Coherus and its wholly-owned subsidiaries. The Company does not have any significant interest in variable interest entities. All material intercompany transactions and balances have been eliminated upon consolidation.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Reporting and Revenue by Geographic Region</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing human pharmaceutical products. The Company&#8217;s chief executive officer, as the chief operating decision maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the Company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions. Primarily, all revenue is generated and all long-lived assets are maintained in the United States. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash comprise cash and highly liquid investments with original maturities of 90&#160;days or less.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets and which, in aggregate, represent the amount reported in the consolidated statements of cash flows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541,158</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541,598</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,195</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,635</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company classifies the up-front and milestone payments related to licensing arrangements as cash flows used in investing activities in its consolidated statements of cash flows.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Receivables</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are recorded net of allowances for chargebacks, chargeback prepayments, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses and was not material during the periods presented. The Company believes that its allowance for expected credit losses was adequate and immaterial as of December 31, 2023 and 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investments in Marketable Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in marketable securities primarily consist of U.S. Treasury securities, government agency securities, commercial paper, corporate bonds and market money funds. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#8217;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#8217;s investment policy requires that it only invests in highly rated securities and limits its exposure to any single issuer, except for securities issued by the U.S. government. All investments in marketable debt securities are held as &#8220;available-for-sale&#8221; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. The Company regularly reviews its investments for declines in fair value below the amortized cost basis to determine whether the impairment, if any, is due to credit-related or other factors. This review includes the credit worthiness of the security issuers, the severity of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of the amortized cost basis. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an available-for-sale debt investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. There were no impairments related to credit losses during any of the periods presented. Realized gains and losses, if any, on available-for-sale securities </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are included in other income (expense), net, in the consolidated statements of operations based on the specific identification method. During 2023, 2022 and 2021, interest income from marketable securities was $2.8 million, $1.9 million and $1.4 million, respectively, and is included in other income (expense), net, in the consolidated statements of operations.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Risk</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments in marketable securities and trade receivables. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company&#8217;s revenues are in the United States to three&#160;wholesalers. During 2023, the products sold by the Company were UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. During 2022, UDENYCA and CIMERLI were the only products sold by the Company, and in 2021 UDENYCA accounted for all of the Company&#8217;s revenues.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company enters into a strategic commercial supply agreement for each of its products. The Company currently has not engaged back-up suppliers or vendors. If any of the Company&#8217;s current vendors are not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Instruments </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2023, the Company commenced using derivative contracts (foreign exchange option contracts) for the purpose of economically hedging exposure to changes in currency fluctuations between the U.S.&#160;Dollar and the Euro. The Company recognizes all derivatives at fair value on the consolidated balance sheets, and corresponding gains and losses are recognized in other income (expense), net in the consolidated statements of operations. The estimated fair value of derivative financial instruments represents the amount required to enter into similar contracts with similar remaining maturities based on quoted market prices. During the periods presented, the Company did not apply hedge accounting to these instruments. There are no derivative instruments entered into for speculative or trading purposes.&#160;Since the Company's foreign exchange derivatives all matured and settled by December 31, 2023, there were no derivative assets or <span style="-sec-ix-hidden:Hidden_YgjkhDQ6bEeOg5gUe8O-fQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">derivative liabilities</span></span> as of December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combination Accounting &amp; Valuation of Acquired Assets </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations.&#160;Judgment is required in assessing whether the acquired processes or activities, along with their inputs, meet the criteria to constitute a business, as defined by U.S. GAAP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquisition method of accounting requires the recognition of assets acquired and liabilities assumed at their acquisition date fair values.&#160;The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill, or when there is an&#160;excess of the fair values of these identifiable assets and liabilities over the fair value of purchase consideration, a&#160;bargain purchase gain is recorded in&#160;the consolidated statements of operations.&#160;The estimations of fair values based on non-observable inputs that are included in valuation models. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including the estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the measurement period, which occurs before finalization of the purchase price allocation, changes in assumptions and estimates that result in adjustments to the fair values of assets acquired and liabilities assumed, if based on facts and circumstances existing at the acquisition date, are recorded on a retroactive basis as of the acquisition date, with the corresponding offset to goodwill or bargain purchase gain (See Note 6. Surface Acquisition).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in&#160;foreign currencies are remeasured at historical rates.&#160;Translation gains and losses are included in </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accumulated other comprehensive loss in stockholders&#8217; equity (deficit).&#160;Revenue and expense accounts are translated to U.S. dollars at average exchange rates in effect during the period with resulting transaction gains and losses recognized in other income (expense), net in the consolidated statements of operations. The Company has not experienced material foreign currency transaction gains and losses for any of the years presented.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. The Company primarily uses actual costs to determine the cost basis for inventory. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During 2023 and 2022, the Company recorded $52.6 million and $26.0 million in inventory write-downs, respectively, within cost of goods sold in the consolidated statements of operations. The 2023 charge was primarily for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. The 2022 charge was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company believes the assumptions used in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by management, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in the consolidated statements of operations. Adverse developments affecting the Company&#8217;s assumptions of the level and timing of demand for its products include those that are outside of the Company&#8217;s control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the regulatory approval of product candidates, the Company incurs expenses for the manufacture of drug products that could potentially be available to support the commercial launch of the products. I<span style="background:#ffffff;">nventory costs are capitalized when future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment. &#160;A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, viability of commercialization and marketplace trends. Inventory in the consolidated balance sheets as of December 31, 2023 was related to UDENYCA, YUSIMRY, CIMERLI and LOQTORZI.</span> The Company began to capitalize inventory costs associated with UDENYCA, CIMERLI and LOQTORZI after receiving final regulatory approval in November&#160;2018, August 2022, and October 2023, respectively, and capitalization of YUSIMRY inventory costs began in the second quarter of 2022 when sales were deemed probable. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment is stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the capitalized interest costs are amortized as depreciation or amortization expense over the life of the underlying asset. When the Company disposes of property and equipment, it removes the associated cost and accumulated depreciation from the related accounts in the consolidated balance sheets and include any resulting gain or loss in the consolidated statements of operations. Eligible costs of internal use software and implementation costs of certain hosting arrangements are capitalized and amortized over the estimated useful life of the software or associated hosting arrangement, as applicable. Depreciation and amortization are recognized using the straight-line method over the following estimated useful lives:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 - 7 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life</span></span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill and Intangible Assets</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company&#8217;s single reporting unit below its carrying amount.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquired in-process research and development&#160;(&#8220;IPR&amp;D&#8221;) that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company <span style="background:#ffffff;">will commence amortization over the useful life of the intangible asset, which will generally be determined by the period in which the substantial majority of the cash flows are expected to be generated. </span>The Company evaluates IPR&amp;D for impairment on an annual basis, during the fourth quarter, or more frequently if impairment indicators exist.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finite-lived intangible assets are generally amortized on a straight-line basis over their estimated economic life and are reviewed periodically for impairment. The amortization expense related to capitalized milestone payments under license agreements and the amortization expense from out-licenses are recorded as a component of cost of goods sold in the consolidated statements of operations. The estimated life for capitalized milestone payments is&#160;ten years,&#160;and the life for acquired out-licenses is&#160;fifteen years. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Contingent consideration relates to the potential payments to holders of&#160;the CVRs&#160;that are contingent upon the achievement of the Company and certain third-parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within loss from operations in the consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Net Revenues </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sells to wholesalers and distributors, (collectively, &#8220;Customers&#8221;). The Customers then resell to hospitals and clinics (collectively, &#8220;Healthcare Providers&#8221;) pursuant to contracts with the Company. In addition to distribution agreements with Customers and contracts with Healthcare Providers, the Company enters into arrangements with group purchasing organizations (&#8220;GPOs&#8221;) that provide for United States government-mandated or privately negotiated rebates, chargebacks and discounts. The Company also enters into rebate arrangements with payers, which consist primarily of commercial insurance companies and government entities, to cover the reimbursement of products to Healthcare Providers. The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. Revenue from product sales is recognized at the point when a Customer obtains control of the product and the Company satisfies its performance obligation, which generally occurs at the time product is shipped to the Customer. Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Product Sales Discounts and Allowances</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue from product sales is recorded at the net sales price (&#8220;transaction price&#8221;), which includes estimates of variable consideration for which reserves are established and that result from chargebacks, rebates, co-pay assistance, prompt-payment discounts, </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">returns and other allowances that are offered within contracts between the Company and its Customers, Healthcare Providers, payers and GPOs. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions in trade receivables (if the amounts are payable to a Customer) or current and non-current liabilities (if the amounts are payable to a party other than a Customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specifically known market events and trends, industry data and forecasted Customer buying and payment patterns. Overall, these reserves reflect the best estimates of the amount of consideration to which the Company is entitled based on the terms of its contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The actual amount of consideration ultimately received may differ. If actual results in the future vary from the Company&#8217;s estimates, the estimates will be adjusted, which will affect net product revenue in the period that such variances become known.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: </i>Chargebacks are discounts that occur when Healthcare Providers purchase directly from a Customer. Healthcare Providers, which belong to Public Health Service institutions, non-profit clinics, government entities, GPOs, and health maintenance organizations, generally purchase the product at a discounted price. The Customer, in turn, charges back to the Company the difference between the price initially paid by the Customer and the discounted price paid by the Healthcare Providers to the Customer. The allowance for chargebacks is based on an estimate of sales through to Healthcare Providers from the Customer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discounts for Prompt Payment:</i> The Company provides for prompt payment discounts to its Customers, which are recorded as a reduction in revenue in the same period that the related product revenue is recognized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates:</i> Rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with these public sector benefit providers. The accrual for rebates is based on statutory or contractual discount rates and expected utilization. The estimates for the expected utilization of rebates are based on Customer and commercially available payer data, as well as data collected from the Healthcare Providers, Customers, GPOs, and historical utilization rates. Rebates invoiced by payers, Healthcare Providers and GPOs are paid in arrears. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenue in the period of adjustment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Returns:</i> The Company offers its Customers limited product return rights, which are principally based upon whether the product is damaged or defective, or the product&#8217;s expiration date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Allowances:</i> The Company pays fees to Customers and GPOs for account management, data management and other administrative services. To the extent that the services received are distinct from the sale of products to the customer, these payments are classified in selling, general and administrative expense in the Company&#8217;s consolidated statements of operations, otherwise they are included as a reduction in product revenue.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenue from licensees, which is based on sales to third parties of licensed products, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty revenue was immaterial for all periods presented and is included in net revenue. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold consists primarily of third-party manufacturing, distribution, certain overhead costs, royalties on certain products, and charges for inventory write-downs. <span style="background:#ffffff;">Through March 31, 2021, a portion of the costs of producing UDENYCA&#160;sold was expensed as research and development before the FDA approval of UDENYCA&#160;and therefore is not reflected in cost of goods sold. All the inventory expensed prior to approval of UDENYCA was fully utilized by March 31, 2021; thus, the costs of producing UDENYCA&#160;are fully reflected in cost of goods sold beginning April 1, 2021.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;2, 2019, the Company and Amgen settled a trade secret action brought by Amgen. As a result, cost of goods sold reflects a mid-single digit royalty on UDENYCA net product revenue, which began on July&#160;1, 2019. The royalty cost will continue for five years pursuant to the settlement. Additionally, the Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range. The Company incurs royalties on net sales of LOQTORZI in the low- to mid-twenty percent range and on net sales of YUSIMRY in the mid-single digit range. Pursuant to the Genentech Agreement, the Company incurred a royalty that was a low single-digit percentage of net sales of CIMERLI through the end of 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021, cost of goods sold included inventory write-downs, net of $52.6 million, $26.0 million and $5.1 million, respectively. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Research and development expense represents costs incurred to conduct research, such as the discovery and development of product candidates. The Company recognizes all research and development costs as they are incurred. The Company currently tracks research and development costs incurred on a product candidate basis only for external research and development expenses. The Company&#8217;s external research and development expense consists primarily of:</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expense incurred under agreements with collaborators, consultants, third-party CROs, and investigative sites where a substantial portion of the Company&#8217;s preclinical studies and all of its clinical trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with manufacturing process development activities, analytical activities and pre-launch inventory manufactured prior to regulatory approval being obtained or deemed to be probable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">upfront and milestone payments related to licensing and collaboration agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Internal costs are associated with activities performed by the Company&#8217;s research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expense, which include salaries, benefits and stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered and may continue to enter into license agreements to access and utilize certain technology. To determine whether the licensing transactions should be accounted for as a business combination or as an asset acquisition, the Company makes certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an asset acquisition and therefore, any acquired IPR&amp;D that does not have an alternative future use is charged to expense at the acquisition date. To date none of the Company&#8217;s license agreements have been considered to be the acquisition of a business.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Selling, General and Administrative Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expense comprises primarily compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $10.9 million, $10.5 million and $8.7 million in 2023, 2022 and 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s compensation programs include stock-based awards, and the related grants under these programs are accounted for at fair value. The fair values are recognized as compensation expense on a straight-line basis over the vesting period with the related costs recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company&#8217;s common stock on the date of issuance. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as income tax expense.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. The Company does not expect its unrecognized tax benefits from prior years to change significantly in 2024. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Operating and Finance Leases</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:45pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines at an arrangement&#8217;s inception whether it is a lease. The Company does not recognize right-of-use assets and lease liabilities related to short-term leases. The Company also does not separate lease and non-lease components for its facility and vehicle leases. Operating leases are included in accrued and other current liabilities, other assets, non-current, and lease liabilities, non-current in the consolidated balance sheets. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. The Company recognizes operating lease expense for these leases on a straight-line basis over the lease term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of vehicles leased under the Company&#8217;s fleet agreement (&#8220;Vehicle Lease Agreement&#8221;) are 36 months. The vehicles leased under this arrangement were classified as finance leases. Finance leases are included in property and equipment, net, accrued and other current liabilities, and lease liabilities, non-current in the consolidated balance sheets. Assets under finance leases are depreciated to operating expenses on a straight-line basis over the lease term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The operating and finance lease right-of-use assets and the lease liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. The Company uses its incremental borrowing rate based on the information available at the commencement date or the lease modification date, as applicable, in determining the lease liabilities as the Company's leases generally do not provide an implicit rate.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares.</span> <span style="background:#ffffff;">Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive</span> (see Note 14. Net Loss Per Share).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes the following two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that are recorded as an element of stockholders&#8217; equity (deficit), but are excluded from net loss. The Company&#8217;s other comprehensive income (loss) includes unrealized gains on available-for-sale securities and foreign currency translation adjustments in 2023, 2022 and 2021. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain amounts in prior years&#8217; financial statements have been reclassified to conform with the current year presentation in 2023, including amounts in the consolidated statements of cash flows. There were no changes to net cash used in operating activities in the consolidated statements of cash flows for the prior years as a result.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following are recent accounting pronouncements that the Company has not yet adopted:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280) Improvements to Reportable Segment </i><i style="font-style:italic;">Disclosures</i>, which enhances the disclosures required for operating segments by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, among other expanded. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued&#160;ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622299260064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span>Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company launched LOQTORZI and YUSIMRY in the United States in December and July 2023, respectively, and initiated sales of CIMERLI on October 3, 2022. All net product revenue was generated in the United States, and the Company&#8217;s net revenue was as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   UDENYCA</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326,509</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   CIMERLI</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   YUSIMRY</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   LOQTORZI</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 256,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 210,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326,509</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Total net revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326,551</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Gross product revenues by significant customer as a percentage of total gross product revenues were as follows</span>:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cencora (previously known as AmeriSource-Bergen Corporation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Product Sales Discounts and Allowances  </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Provisions that reduce net revenue include chargebacks and discounts for prompt payment, which are recorded as a reduction in trade receivables, and rebates, other fees, co-pay assistance and returns, which are recorded as current liabilities and other liabilities, non-current in the accompanying consolidated balance sheets. The activities and ending reserve balances for each significant category of sales discounts and allowances, which constitute variable consideration, are as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,398</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 679,199</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,876)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,407)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (478,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (93,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (681,467)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 109,723</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 578,699</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,108)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (421,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,640)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (80,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (584,811)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,503</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 590,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 844,325</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,361)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,807</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (558,135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62,370)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (83,245)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (703,750)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244,885</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295904368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span>Fair Value Measurements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of financial instruments are classified into one of the following categories <span style="background:#ffffff;">based upon the lowest level of input that is significant to the fair value measurement</span>:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In connection with the Surface Acquisition on September 8, 2023 (see Note 6. Surface Acquisition), the Company acquired money market funds and marketable securities and recorded&#160;a contingent consideration liability related to the CVRs. At the end of each reporting period, the fair value of the CVR liability is determined using a financial model representing a Level 3 measurement within the fair value hierarchy. Assumptions used in this calculation include estimated revenue, discount rate and various probability factors. If different assumptions were used for the various inputs, the estimated fair value could be significantly higher or lower than the fair value the Company determined. For example, increases in discount rates and the time to payment may result in lower fair value measurements. There is no assurance that any of the conditions for payment of the CVR liability will be met. As of December 31, 2023, the CVR liability was reduced by a fair value adjustment of </span><span style="background:#ffffff;">$0.9</span><span style="background:#ffffff;"> million which was recorded within selling, general and administrative expense in the </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">consolidated statements of operations. The CVR liabilities were recorded in accrued and other current liabilities and other liabilities, non-current on the consolidated balance sheets.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">Financial liabilities related to long-term debt obligations are summarized in Note 8. Debt Obligations. &#160;Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,458</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,195</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,993</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,669</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid financial instrument in Prepaid manufacturing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,940</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,472</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,060</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,964</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,418</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,203</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 191,645</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;">Cash equivalents consist of money market funds, U.S treasury securities, and commercial paper and corporate notes with original maturities of 90 days or less.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;">Relates to Optional Stock Purchase Agreement.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="background:#ffffff;">The cost, unrealized gains or losses, and fair value by investment type are summarized as follows:</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th colspan="11" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Gain</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized (Loss)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Money market funds</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,484</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,484</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. government agency securities</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,200</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,195</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. treasury securities</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,967</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,969</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Commercial paper and corporate notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,673</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,324</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,315</p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,060</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,964</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,418</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,203</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,645</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company held </span><span style="background:#ffffff;">9</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">13</span><span style="background:#ffffff;"> positions that were in unrealized loss positions as of December 31, 2023 and 2022, respectively. </span><span style="background:#ffffff;">No</span><span style="background:#ffffff;"> impairment was recognized in 2023 or 2022. As of December 31, 2023 and 2022, the remaining contractual maturities of available-for-sale securities were less than&#160;</span><span style="background:#ffffff;">one year</span><span style="background:#ffffff;">, and the average maturity of investments upon acquisition was approximately&#160;</span><span style="background:#ffffff;">9</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">7 months</span><span style="background:#ffffff;">, respectively. The accrued interest receivable on available-for-sale marketable securities was immaterial at December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622299139312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span>Inventory</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventory consisted of the following:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,262</p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,712</p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,077</p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115,051</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">During 2023, the Company recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory, inclusive of the related partial recognition of $20.5 million in certain firm purchase commitments in cost of goods sold in the consolidated statements of operations. The Company has presented the partial recognition of these certain firm purchase commitments in the amounts of $11.5 million and $9.0 million in accrued and other current liabilities and other liabilities, non-current, respectively, in the consolidated balance sheets as of December 31, 2023. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current in the consolidated balance sheets. As of December 31, 2023 and 2022, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following table presents the inventory balance sheet classifications: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,791</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,260</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115,051</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Prepaid manufacturing of $23.7 million as of December 31, 2023 includes prepayments of $12.6 million to CMOs for manufacturing services of the Company&#8217;s products, which the Company expects to be converted into inventory during 2024, and prepayments of $11.1 million to various CMOs for research and development pipeline programs<i style="font-style:italic;">.</i> Prepaid manufacturing of $17.9 million </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">as of December 31, 2022 included prepayments of $13.0 million to CMOs for manufacturing services of the Company&#8217;s products and prepayments of $4.9 million to various CMOs for research and development pipeline programs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea as part of a realignment of research and development resources toward other development programs. As a result, the Company recognized $11.2 million within research and development expense in the consolidated statements of operations in 2021, which included an impairment charge of $3.2 million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. No material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301665728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span>Balance Sheet Components</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,944</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,183</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,258</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,198</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,632</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 696</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,911</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (20,651)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (20,157)</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,754</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense related to property and equipment, net was $3.2 million, $3.6 million and $3.5 million in 2023, 2022 and 2021, respectively. There were no material impairments of property and equipment in 2023, 2022 and 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, the net book value of software implementation costs related to hosting arrangements was $3.2 million and $3.5 million, respectively, and the amortization expense was immaterial for all periods presented.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intangible Assets, Net</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Goodwill and intangible assets, net consisted of the following:</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finite-lived assets, net of accumulated amortization of $639 and $61, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite-lived assets - IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,620</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 943</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,931</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization expense related to finite-lived intangible assets was immaterial in all periods presented. As of December 31, 2023, amortization expense related to finite-lived assets for each of the five succeeding fiscal years will be approximately $3.8&#160;million. The weighted average remaining life of the finite-lived assets is 11.4 years on December 31, 2023. No impairment charges were recognized for goodwill or intangible assets during 2023, 2022 or 2021. During 2023, the Company&#8217;s intangible assets increased due to assets acquired in the Surface Acquisition (see Note 6. Surface Acquisition) and capitalized milestone payments, including $25.0 million to Junshi Biosciences (see Note 7. Collaborations and Other Arrangements). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Current Liabilities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Accrued and other current liabilities consisted of the following:</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued commercial and research and development manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,774</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued co-development costs and milestone payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,356</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,015</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,634</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,318</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,097</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Liabilities, Non-current</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other liabilities, non-current consisted of the following:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,365</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Other liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,467</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295710384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Surface Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Surface Acquisition</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">6. Surface Acquisition</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On September 8, 2023, in accordance with Merger Agreement by the Merger Subs, and Surface, the Company completed the Surface Acquisition. Surface is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment&#160;for the development of next-generation cancer therapies. The Surface Acquisition expanded the Company&#8217;s immune-oncology pipeline with the following: casdozokitug (CHS-388,&#160;formerly SRF388), an investigational, novel&#160;IL-27-targeted&#160;antibody currently being evaluated in a Phase 2 clinical trial in HCC, and CHS-114 (formerly SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On the Acquisition Date, and in accordance with the Merger Agreement, the Company issued to the holders of all outstanding Surface common stock (other than treasury shares, any shares of Surface common stock held directly by the Company or the Merger Subs immediately prior to the Acquisition Date and shares of Surface common stock issued and outstanding immediately prior to the Acquisition Date and held by any holder properly demanding appraisal for such shares in accordance with Section 262 of the Delaware General Corporation Law)&#160;0.1960&#160;shares of Coherus common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on a&#160;$5.2831&#160;per share price of Coherus common stock&#160;and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also received&#160;one&#160;CVR for each share of Surface common stock and employee equity award converted.&#160;Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at the Company&#8217;s discretion during the&#160;ten-year&#160;period following September 8, 2023, for the sum of the following, less any permitted deductions in accordance with the CVR Agreement:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">70%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of all milestone- and royalty-based payments actually received by the Company or its affiliates under the GSK Agreement related to the existing program (GSK4381562);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">70%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of all milestone- and royalty-based payments actually received by the Company or its affiliates under the Novartis Agreement related to the existing program (NZV930);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">25%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">50%</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.</span></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">The Company has recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement described above.&#160;The Company is unable to estimate a range of outcomes for potential royalty and milestone payments&#160;for CHS-114 and&#160;casdozokitug.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The total consideration paid for the Surface Acquisition of $64.6&#160;million consisted of the following:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coherus common stock issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,971,460</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coherus common stock share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.89</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value of components of purchase price consideration at closing:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity of combined company owned by Surface equity holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,540</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent CVR liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,290</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity of combined company owned by Surface former employees <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 766</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,596</p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">161,100</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Coherus common stock, net of shares withheld for taxes, issued to Surface&#8217;s former employees on the Acquisition Date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company has accounted for the Surface Acquisition as a business combination which requires, among other things, that the assets acquired and liabilities assumed generally be recognized at their fair value on the Acquisition Date. Fair value estimates are based on management&#8217;s estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company&#8217;s results of operations. The purchase price allocation for the Surface Acquisition is preliminary and subject to revisions as additional information about fair value of assets and liabilities becomes available. This is primarily related to the Company&#8217;s deferred tax liabilities assumed in connection with the Surface Acquisition, as the 2023 short period tax returns have not yet been filed. The following table below sets forth the purchase price allocation to the estimated fair value of the net assets acquired:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amounts Recognized at Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,791</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other prepaids and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,260</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,239</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,530</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,817</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,722</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,499</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,221</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,596</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Company believes that, even after reassessing its identification of all assets acquired and liabilities assumed, it was able to acquire Surface for a price that was completely allocable to identifiable assets acquired and liabilities assumed with&#160;no&#160;residual attributable to goodwill primarily due to Surface&#8217;s need to raise additional capital to finance its operations, the challenging biotech funding environment at the time the transaction was initially announced, and the value of the acquired net assets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The amount allocated to identifiable intangible assets has been attributed to the following assets:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,899</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - CHS-114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-license - GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-license - Novartis Institutes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,024</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total identifiable intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,769</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Surface had&#160;two&#160;out-licensed&#160;partnership programs, with Novartis Institutes (NZV930) and GSK (GSK4381562), to advance certain next-generation cancer therapies. The out-license intangible assets represent potential milestone and royalty-based payments to be received in the future.&#160;Surface shareholders received CVRs for certain percentages of these milestone and royalty-based payments on existing programs with Novartis Institutes (NZV930) and GSK (GSK4381562), as further explained above. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Following the Acquisition Date, the operating results of Surface have been included in the consolidated financial statements. For the period September 8, 2023 through December 31, 2023, there was&#160;no&#160;revenue attributable to Surface and operating losses attributable to Surface for such period were $5.9&#160;million, excluding acquisition-related costs.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unaudited Pro Forma Summary of Operations</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The following table shows the unaudited pro forma summary of operations for the years ended December 31, 2023 and 2022, as if the Surface Acquisition had occurred on January 1, 2022. This pro forma information does not purport to represent what the Company&#8217;s actual results would have been if the acquisition had occurred as of January 1, 2022, and it is not indicative of what such results would be expected for any future period: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 257,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241,042</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (284,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (369,442)</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and Surface. In order to reflect the Surface Acquisition as if it had occurred on January 1, 2022, the summary pro forma financial information includes adjustments to reflect&#160;Surface&#8217;s severance expense, the early termination and related amortization expense of Surface&#8217;s corporate headquarters operating lease, the loss on debt extinguishment and historical interest expense related to the cash settlement of Surface&#8217;s convertible note as if it had occurred on January&#160;1, 2022, and&#160;amortization expense on the acquired finite-lived intangible&#160;assets.&#160;The unaudited pro&#160;forma summary of operations does not reflect the income tax effects, if any, of the pro&#160;forma adjustments, given the combined entity incurred significant losses during the historical periods presented.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;">Acquisition-related costs of $5.1&#160;million were recorded in selling, general and administrative expense in the consolidated statements of operations during the year ended December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295774624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaborations and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">Collaborations and Other Arrangements</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">In-Licensing Agreements</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Junshi Biosciences</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On February 1, 2021, the Company entered into the Collaboration Agreement with Junshi Biosciences for the co-development and commercialization of LOQTORZI, Junshi Biosciences&#8217; anti-PD-1 antibody, in the United States and Canada.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the terms of the Collaboration Agreement, the Company paid&#160;$150.0&#160;million&#160;upfront for exclusive rights to LOQTORZI in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#8217; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to&#160;two&#160;undisclosed preclinical immuno-oncology drug candidates. The Company will have the right to conduct all commercial activities of LOQTORZI in the United States and Canada. The </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Company will be obligated to pay Junshi Biosciences up to a&#160;20% royalty on net sales of LOQTORZI and up to an aggregate&#160;$380.0&#160;million&#160;in one-time payments for the achievement of various regulatory and sales milestones. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In March 2022, the Company paid $35.0 million for the exercise of its option to license CHS-006. Junshi Biosciences and the Company were jointly developing CHS-006 with each party responsible for the associated development costs as set forth in the Collaboration Agreement, however on January 10, 2024, the Company announced that it had delivered a notice of termination of the TIGIT Program (as defined in the Collaboration Agreement) to Junshi Biosciences pursuant to the Collaboration Agreement. The Company plans to continue to wind down work with Junshi Biosciences on the TIGIT Program pursuant to the termination. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay Junshi Biosciences an additional option exercise fee of&#160;$35.0 million and an 18% royalty on net sales, up to $85.0 million&#160;for the achievement of certain regulatory approvals, and up to $170.0 million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of LOQTORZI and the other licensed compounds and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. Research and development expenses recognized for obligations to Junshi Biosciences were $8.0 million, $68.5 million (inclusive of the $35.0 million option fee) and $175.4 million (inclusive of the upfront fee) in 2023, 2022, and 2021 respectively. In the consolidated balance sheets as of December 31, 2023 and 2022, the Company classified $26.3 million and $8.4 million, respectively, in accrued and other current liabilities and $6.3 million and $0 in accounts payable, respectively, related to the co-development, regulatory and technology transfer costs related to these programs. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><span style="background:#ffffff;">On October 27, 2023, LOQTORZI was approved by the FDA in</span><span style="color:#0a0a0a;background:#ffffff;">&#160;combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. </span>As of December 31, 2023, the Company has accrued a<span style="background:#ffffff;"> </span>$25.0 million milestone payment to Junshi Biosciences, of which it expects to pay $12.5 million in the second quarter of 2024 and $12.5 million in the first quarter of 2025. This amount is a non-cash transaction which the Company has recognized in intangible assets, net and accrued and other current liabilities as of December 31, 2023<span style="background:#ffffff;">. The accrued royalty obligation to Junshi Biosciences is immaterial as of December 31, 2023. </span>The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In connection with the Collaboration Agreement, the Company entered into a stock purchase agreement dated February 1, 2021 (the &#8220;Stock Purchase Agreement&#8221;) with Junshi Biosciences agreeing, subject to customary conditions, to acquire certain equity interests in the Company. Pursuant to the Stock Purchase Agreement, on April 16, 2021, the Company issued&#160;2,491,988&#160;unregistered shares of its common stock to Junshi Biosciences, at a price per share of $20.06, for an aggregate amount of approximately $50.0&#160;million in cash. Under the terms of the Stock Purchase Agreement, Junshi Biosciences was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of the common stock for the two-year period following its effective date. The Collaboration Agreement and the Stock Purchase Agreement were negotiated concurrently and were therefore evaluated as a single agreement. The Company used the &#8220;Finnerty&#8221; and &#8220;Asian put&#8221; valuation models and determined the fair value for the discount for lack of marketability (&#8220;DLOM&#8221;) was $9.0 million at the date the shares were issued. The fair value of the DLOM was attributable to the Collaboration Agreement and was included as an offset against the research and development expense in the consolidated statements of operations for the year ended December 31, 2021.<span style="background:#ffffff;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Bioeq</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On November&#160;4, 2019, the Company entered into the Bioeq Agreement with Bioeq for the commercialization of a biosimilar version of ranibizumab (Lucentis) in certain dosage forms in both a vial and pre-filled syringe presentation. Under this agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. Bioeq will supply to the Company the Bioeq Licensed Products in accordance with terms and conditions specified in the agreement and a manufacturing and supply agreement to be executed by the parties in accordance therewith. The agreement&#8217;s initial term continues in effect for ten years after the first commercial sale of a Bioeq Licensed Product in the United States, and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Bioeq will manufacture and supply the Bioeq Licensed Products to the Company in accordance with terms and conditions specified in the Bioeq Agreement and the Bioeq Manufacturing Agreement and will remain in force until the first to occur of the following: (1) the </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">termination of the Bioeq Agreement; (2) the exercise of a right to termination by the Company or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Under the agreement, Bioeq was required to use commercially reasonable efforts to develop and obtain regulatory approval of the Bioeq Licensed Products in the United States in accordance with a development and manufacturing plan, and the Company was required to use commercially reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Additionally, the Company was required to commit certain pre-launch and post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The Company paid Bioeq an upfront and a milestone payment aggregating to &#8364;10&#160;million ($11.1&#160;million), which was recorded as research and development expense in the Company&#8217;s consolidated statements of operations in 2019. The terms of the Bioeq Agreement include an aggregate of up to &#8364;12.5&#160;million in additional milestone payments in connection with the achievement of certain development and regulatory milestones with respect to the Bioeq Licensed Products in the United States including a &#8364;2.5 million milestone related to the FDA approval of the CIMERLI Section 351(k) BLA that was paid in 2022. The Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range. Royalties due to Bioeq were $38.4 million and $2.9 million as of December 31, 2023 and 2022, respectively. The remaining milestone payments are contingent upon future events and, therefore, will be recorded when it becomes probable that a milestone will be achieved. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Adimab Development and Option Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In October 2018, Surface and Adimab entered into the A&amp;R Adimab Agreement, which amended and restated the Original Adimab Agreement, for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the A&amp;R Adimab Agreement, the Company will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. The A&amp;R Adimab Agreement, among other things, extended the discovery term of the Original Adimab Agreement, provided access to additional antibodies, and expanded the Company&#8217;s right to evaluate and use antibodies that were modified or derived using Adimab technology for diagnostic purposes.&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Upon the Company&#8217;s selection of a target, the Company and Adimab will initiate a research plan and the discovery term begins. During the discovery term, Adimab will grant the Company a non-exclusive, non-sublicensable license under its technology with respect to the target, to research, design and preclinically develop and use antibodies that were modified or derived using Adimab technology, solely to evaluate such antibodies, perform the Company&#8217;s responsibilities under the research plan, and use such antibodies for certain diagnostic purposes. The Company also will grant to Adimab a non-exclusive, nontransferable license with respect to the target under the Company&#8217;s technology that covers or relates to such target, solely to perform its responsibilities under the research plan during the discovery period. The Company is required to pay Adimab at an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Adimab granted the Company the Research Option. In addition, Adimab granted the Company the Commercialization Option. Upon the exercise of a Commercialization Option, and payment of the applicable option fee to Adimab, Adimab will assign the Company the patents that cover the antibodies selected by such Commercialization Option. The Company will be required to use commercially reasonable efforts to develop, seek market approval of, and commercialize at least&#160;one&#160;antibody against the target covered by the Commercialization Option in specified markets upon the exercise of a Commercialization Option.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Under the A&amp;R Adimab Agreement, the Company is obligated to make milestone payments and to pay specified fees upon the exercise of the Research Option or Commercialization Option. During the discovery term, the Company may be obligated to pay Adimab up to&#160;$0.3&#160;million&#160;for technical milestones achieved against each biological target. Upon exercise of a Research Option, the Company is obligated to pay a nominal research maintenance fee on each of the next <span style="-sec-ix-hidden:Hidden_RNOKr2yfgEaTSaGdgRnfUQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">four</span></span>&#160;anniversaries of the exercise. Upon the exercise of each Commercialization Option, the Company will be required to pay an option exercise fee of a low seven-digit dollar amount, and the Company may be responsible for milestone payments of up to an aggregate of $13.0&#160;million&#160;for each licensed product that receives marketing approval. For any licensed product that is commercialized, the Company is obligated to pay Adimab tiered royalties of a low to mid single-digit percentage on worldwide net sales of such product. The Company may also partially exercise a Commercialization Option with respect to&#160;ten&#160;antibodies against a biological target by paying&#160;65% of the option fee and later either (i)&#160;paying the balance and choosing additional antibodies for commercialization, up to the maximum number under the Commercialization Option, or (ii)&#160;foregoing the Commercialization Option entirely. For any Adimab diagnostic product that is used with or in connection with any compound or product other than a licensed antibody or licensed product, the Company is obligated to pay Adimab up to a low seven digits in regulatory milestone payments and low </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">single-digit royalties on net sales.&#160;No&#160;additional payment is due with respect to any companion diagnostic or any diagnostic product that does not contain any licensed antibody.&#160;Any payments payable to Adimab as a result of any product candidates being developed pursuant to the GSK Agreement, will be payable to Adimab directly by GSK.&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The A&amp;R Adimab Agreement will remain in effect until (a)&#160;the earlier of (i)&#160;the expiration of the Research and Commercialization Options (if they expire without exercise) and (ii)&#160;12 months&#160;from the effective date without the Company providing materials that pass Adimab&#8217;s quality control; or (b)&#160;if a Research Option is exercised but the Commercialization Option is not, then upon the expiration of the last to expire research license term; or (c)&#160;upon commercialization of a product, until the end of the royalty term, which will vary on a product-by-product and country-by-country basis, ending on the later of (y)&#160;the expiration of the last valid claim covering the licensed product in such country as the product is manufactured or sold, or (z)&#160;ten&#160;years after the first commercial sale of the licensed product in such country.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Either party may terminate the A&amp;R Adimab Agreement for material breach if such breach remains uncured for a specified period of time, however, if a Research Option or Commercialization Option has been exercised and the breach only applies to the applicable target of such Research Option or Commercialization Option, then the termination right will only apply to such target. The Company may also terminate the A&amp;R Adimab Agreement for any reason with prior notice to Adimab. If Adimab is bankrupt, the Company will be entitled to a complete duplicate of, or complete access to, all rights and licenses granted under or pursuant to the A&amp;R Adimab Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Vaccinex License Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On March 23, 2021, Surface and Vaccinex entered into the Vaccinex License Agreement which provides the Company a worldwide, exclusive, sublicensable license to make, have made, use, sell, offer to sell, have sold, import, and otherwise exploit Vaccinex Licensed Products, including the antibody CHS-114 targeting CCR8. Under the Vaccinex License Agreement, the Company is obligated to use commercially reasonable efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at least one Vaccinex Licensed Product.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company is responsible for all costs and expenses of such development, manufacturing and commercialization. Vaccinex is eligible to receive up to an aggregate of $3.5 million based on achievement of certain clinical milestones, up to an aggregate of $11.5 million based on achievement of certain regulatory milestones per Vaccinex Licensed Product, and low single-digit royalties on global net sales of any approved licensed products. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company may terminate the Vaccinex License Agreement for convenience upon the notice period specified in the Vaccinex License Agreement. Either party may terminate the agreement for an uncured material breach by the other party. Vaccinex may terminate the Vaccinex License Agreement if we default on any payments owed to Vaccinex under the agreement, if the Company is in material breach of, and fails to cure, its development obligations, or institute certain actions related to the licensed patents. In the event of termination, all rights in the licensed intellectual property would revert to Vaccinex.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Out-Licensing Agreements Acquired as part of the Surface Acquisition</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;">On September 8, 2023, at the closing of the Surface Acquisition, all the assets, liabilities, rights and obligations of Surface were assumed by the Company&#8217;s direct, wholly-owned subsidiary, Surface Oncology, LLC. See further details in Note 6. Surface Acquisition above.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Novartis Institutes</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;">In January 2016, Surface entered into the&#160;Novartis Agreement. Pursuant to the Novartis Agreement, Surface granted Novartis Institutes a worldwide exclusive license to research, develop, manufacture and commercialize antibodies that target cluster of differentiation 73 (&#8220;CD73&#8221;). Under the Novartis Agreement, the Company is currently entitled to potential development milestones of&#160;$325.0&#160;million&#160;and sales milestones of&#160;$200.0&#160;million, as well as tiered royalties on annual net sales by Novartis Institutes ranging from high single-digit to mid-teens percentages upon the successful commercialization of NZV930. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the Novartis Agreement. The Company did&#160;not&#160;recognize any revenue relating to the Novartis Agreement from September 8, 2023 through December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;">Unless terminated earlier, the Novartis Agreement will continue in effect until neither the Company nor Novartis Institutes is researching, developing, manufacturing or commercializing NZV930. Novartis Institutes may terminate the Novartis Agreement for any or </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">no reason upon prior notice to the Company within a specified time period. Either party may terminate the Novartis Agreement in full if an undisputed material breach is not cured within a certain period of time or upon notice of insolvency of the other party. To the extent Novartis Institutes terminates for convenience, or the Company terminates for Novartis Institutes&#8217; uncured material breach, Novartis Institutes will grant the Company, on mutually agreeable financial terms, an exclusive, worldwide, irrevocable, perpetual and royalty-bearing license with respect to intellectual property controlled by Novartis Institutes that is reasonably necessary to research, develop, manufacture or commercialize NZV930.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">GSK Agreement</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"><span style="color:#231f20;">In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies. GSK is responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee was formed to facilitate information sharing. GSK is responsible for all costs and expenses of such development, manufacturing and commercialization and is obligated to provide the Company with updates on its development, manufacturing and commercialization activities through the joint development committee.&#160;</span>In March 2022, Surface earned a&#160;$30.0&#160;million&#160;milestone payment from GSK upon the dosing of the first patient in the Phase 1 trial of GSK4381562. The Company is eligible to receive up to&#160;$60.0&#160;million&#160;in additional clinical milestones and&#160;$155.0&#160;million&#160;in regulatory milestones. In addition, the Company may receive up to&#160;$485.0&#160;million in sales milestone payments. The Company is also eligible to receive royalties on global net sales of any approved products based on the Licensed Antibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the GSK Agreement.&#160;The Company did&#160;not recognize license-related revenue under the GSK Agreement from September 8, 2023 through December 31, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later of&#160;ten&#160;years&#160;from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. The Company may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, the Company would regain worldwide rights to the terminated program.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295715872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Obligations</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span>Debt Obligations</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s debt obligations, including level within the fair value hierarchy (see Note 3. Fair Value Measurements), is as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2023</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial Liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 Term Loans</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,519)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,481</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,481</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2*</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 Convertible Notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,112)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226,888</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,155</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2**</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December 31, 2022</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial Liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 Term Loans</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,517)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,483</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,483</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2*</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 Convertible Notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,425)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,575</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157,205</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2**</p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:98.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">*</p></td><td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The principal amounts outstanding are subject to variable interest rates, which are based on three-month SOFR starting April 1, 2023 plus fixed percentages. Through March 31, 2023, the variable component was based on the three-month LIBOR. Therefore, the Company believes the carrying amount of these obligations approximates fair value.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr><td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">**</p></td><td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>The fair value is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs.</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2027 Term Loans </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into the Loan Agreement with BioPharma Credit, PLC, BPCR Limited Partnership, and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC that provides for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches: (i) the Tranche A Loan in an aggregate principal amount of $100.0 million that was funded on January 5, 2022; (ii) the Tranche B Loan in an aggregate principal amount of $100.0 million that was funded on March 31, 2022; (iii) the Tranche C Loan in an aggregate principal amount of $50.0 million that was not funded; and (iv) the Tranche D Loan in an aggregate principal amount of $50.0 million that was funded on September 14, 2022. The Company has the right to request an uncommitted additional facility amount of up to $100.0 million that is subject to new terms and conditions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company&#8217;s 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans accrued interest from inception through March 31, 2023 at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.0%; and starting April 1, 2023, accrue interest at 8.25% plus the Adjusted Term SOFR which is the sum of three-month SOFR and 0.26161% per annum, with a floor on Adjusted Term SOFR of 1.0%. The interest rate for the fourth quarter of 2023 was 13.91%. Interest is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The obligations under the Loan Agreement are secured pursuant to customary security documentation, including a guaranty and security agreement among the Credit Parties and the Collateral Agent which provides for a lien on substantially all of the Company&#8217;s tangible and intangible assets and property, including intellectual property.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Loan Agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were used to fund the Company&#8217;s general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to repay in full all amounts outstanding under the 2025 Term Loan, as well as all associated costs and expenses pursuant to which a payoff amount of $81.9&#160;million was outstanding; in March 2022, proceeds of the Tranche B Loan were drawn in connection with the full repayment of all amounts outstanding under the&#160;2022 Convertible Notes, as well as all associated costs and expenses pursuant to which a payoff amount of $111.1 million was outstanding.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Loan Agreement contains certain customary representations and warranties. In addition, the Loan Agreement includes covenants, such as the requirement to maintain minimum trailing twelve-month net sales in an amount that began at $200.0&#160;million for the quarter ending March 31, 2022 and increases to $210.0&#160;million for the quarter ended March 31, 2024. As a result of the Consent and Amendment entered into on February 5, 2024, beginning in the second quarter of 2024 and continuing through the quarter ended December 31, 2026, the requirement is to maintain minimum trailing twelve-month net sales of $125.0 million. In addition, there is a requirement to maintain a minimum trailing twelve-month net sales for LOQTORZI tested quarterly at the end of each quarter commencing with the quarter ended December 31, 2024. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, <span style="background:#ffffff;">make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. The Loan Agreement also contains customary events of default, including among other things, the Company&#8217;s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or its breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#8217;s obligations under the Loan Agreement. A change of control of the Company triggers a mandatory prepayment of the 2027 Term Loans within&#160;</span><span style="-sec-ix-hidden:Hidden_9sZZOOI5Ik6UXQMv7GKoqA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">ten</span></span><span style="background:#ffffff;">&#160;business days. See Note 17. Subsequent Events for further information regarding the Consent and Amendment to the 2027 Term Loans. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company was in full compliance with these covenants and there were no events of default under the 2027 Term Loans.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the closing of Tranche A, the Company incurred $7.8 million&#160;in debt discounts and issuance costs<span style="color:#ff0000;"> </span>of which $6.8 million related to all the tranches of the 2027 Term Loans and was thus allocated pro rata between the tranches. The unamortized debt </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">discount and issuance costs allocated to funded tranches are presented as deductions to the 2027 Term Loan balance and are amortized into interest expense using the effective interest method. The $2.3 million allocated to Tranche B was fully amortized over the commitment period prior to funding and recognized as interest expense in the first quarter of 2022. The associated debt discounts and issuance costs of unfunded tranches were deferred as assets and amortized into interest expense using the straight-line method over the commitment period of the respective tranches. At the closing dates of Tranche B on March 31, 2022 and Tranche D on September 14, 2022, the Company incurred an additional $1.0 million and $0.5 million, respectively,&#160;in debt issuance costs. As of December 31, 2023, the total remaining unamortized debt discount and debt offering costs related to Tranches A, B and D of $3.5 million will be amortized using the effective interest rate over the remaining term of 3.0 years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense related to the 2027 Term Loans: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,243</p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,550</p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,793</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming the fourth quarter of 2023 interest rate of 13.91%, future payments on the 2027 Term Loans as of December 31, 2023, are as follows: </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,345</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,248</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224,607</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,097</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 345,297</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (95,297)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 Term Loans, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,519)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,481</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The table above does not reflect any adjustment for transactions contemplated by the Consent and Amendment entered into on February 5, 2024, including any prepayments to the 2027 Term Loans. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.5%</b><b style="font-weight:bold;"> Convertible Senior Subordinated Notes due 2026</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In April 2020, the Company issued and sold </span><span style="background:#ffffff;">$230.0</span><span style="background:#ffffff;">&#160;million aggregate principal amount of its&#160;2026 Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were </span><span style="background:#ffffff;">$222.2</span><span style="background:#ffffff;">&#160;million after deducting initial purchasers&#8217; fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company&#8217;s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and&#160;structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables.&#160;</span><span style="background:#ffffff;">The 2026 Convertible Notes accrue interest at a rate of&#160;</span><span style="background:#ffffff;">1.5%</span><span style="background:#ffffff;"> per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020</span><span style="background:#ffffff;">, and will mature on&#160;</span><span style="background:#ffffff;">April 15, 2026</span><span style="background:#ffffff;">, unless earlier repurchased or converted.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company&#8217;s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. The initial conversion rate is&#160;51.9224&#160;shares of common stock per $1,000&#160;principal amount of the 2026 Convertible Notes, which represents an initial conversion price of approximately $19.26&#160;per share of common stock. The initial conversion price represents a premium of approximately&#160;30.0% over the last reported sale of $14.82&#160;per share of the Company&#8217;s common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a &#8220;make-whole fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company&#8217;s election before maturity. If a &#8220;fundamental change&#8221; (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The 2026 Convertible Notes have customary provisions relating to the occurrence of &#8220;events of default&#8221; (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">As of December 31, 2023, the Company was in full compliance with these covenants, and there were no events of default under the 2026 Convertible Notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated the features embedded in the 2026 Convertible Notes under the relevant accounting rules&#160;and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. The proceeds received from the issuance of the convertible debt were recorded as a liability in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Capped Call Transactions</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the pricing of the 2026 Convertible Notes, the Company paid </span><span style="background:#ffffff;">$18.2</span><span style="background:#ffffff;">&#160;million to enter into privately negotiated capped call transactions with&#160;one&#160;or a combination of the initial purchasers, their respective affiliates and other financial institutions. The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been </span><span style="background:#ffffff;">$25.93</span><span style="background:#ffffff;">&#160;per share, which represents a premium of approximately&#160;</span><span style="background:#ffffff;">75.0%</span><span style="background:#ffffff;"> over the last reported sale price of the Company&#8217;s common stock of </span><span style="background:#ffffff;">$14.82</span><span style="background:#ffffff;">&#160;per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and&#160;</span><span style="color:#212529;background:#ffffff;">classified as equity instruments.&#160;Therefore, the total&#160;</span><span style="color:#212529;background:#ffffff;">$18.2</span><span style="color:#212529;background:#ffffff;">&#160;million capped call premium paid was recorded as a reduction to additional paid-in capital in the consolidated balance sheets in 2020.</span>&#160;The capped calls will not be subsequently re-measured as long as the conditions for equity classification continue to be met. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred $0.9 million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the notes in the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the six-year contractual term of the notes using the effective interest rate method.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the 2026 Convertible Notes&#160;were converted on December 31, 2023, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $39.8 million based on the Company&#8217;s closing stock price of $3.33 as of December 29, 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents the components of interest expense related to 2026 Convertible Notes:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,259</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,709</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The remaining unamortized debt discount and debt offering costs related to the Company&#8217;s 2026 Convertible Notes&#160;of $3.1 million as of December 31, 2023, will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is 2.1% for the 2026 Convertible Notes.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2026 Convertible Notes&#160;as of December 31, 2023 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0070c0;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 231,725</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 238,625</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,625)</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 Convertible Notes, principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,112)</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226,888</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.2% Convertible Notes due 2022</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On February&#160;29, 2016, the Company issued and sold </span><span style="background:#ffffff;">$100.0</span><span style="background:#ffffff;">&#160;million aggregate principal amount of its </span><span style="background:#ffffff;">8.2%</span><span style="background:#ffffff;"> Convertible Senior Notes due 2022. </span><span style="background:#ffffff;">The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company, bore interest at a fixed coupon rate of 8.2% per annum payable quarterly and matured on March 31, 2022</span><span style="background:#ffffff;">.&#160;In March 2022, the Company fully repaid the 2022 Convertible Notes, and as a result had&#160;</span><span style="background:#ffffff;">no</span><span style="background:#ffffff;">&#160;continuing obligations associated with them thereafter. The payoff amount of </span><span style="background:#ffffff;">$111.1</span><span style="background:#ffffff;">&#160;million included the repayment of the entire outstanding principal amount, the&#160;</span><span style="background:#ffffff;">9.0%</span><span style="background:#ffffff;"> premium of the outstanding principal amount and accrued and unpaid interest. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2022 Convertible Notes&#160;were issued to Healthcare Royalty Partners III,&#160;L.P., for $75.0 million in aggregate principal amount, and to three related party investors, KKR Biosimilar&#160;L.P., MX II Associates LLC, and KMG Capital Partners, LLC, for $20.0 million, $4.0 million, and $1.0 million, respectively, in aggregate principal amount.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense of the 2022 Convertible Notes:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,200</p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,966</p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,166</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2025 Term Loan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On January&#160;7, 2019, the Company entered into the 2025 Term Loan with affiliates of Healthcare Royalty Partners (together, the &#8220;Lender&#8221;). The 2025 Term Loan consisted of a six-year term loan facility for an aggregate principal amount of $75.0 million (the &#8220;Borrowings&#8221;). Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at 6.75%&#160;per annum plus three&#160;month LIBOR. Interest was payable quarterly in arrears.<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Pursuant to the terms of the 2025 Term Loan, the Company was required to begin paying principal on the Borrowings in equal quarterly installments beginning on January 7, 2022, with the outstanding balance to be repaid on&#160;January&#160;7, 2025, the maturity date. In January 2022, pursuant to the Company entering into the 2027 Term Loans, the Company voluntarily prepaid all amounts outstanding under the 2025 Term Loan. The payoff amount of $81.9 million included principal repayment in full, accrued interest, a 5.0% prepayment premium fee of the Borrowings principal amount, and an exit fee of 4.0% of the Borrowings principal amount. The prepayment premium fee and unamortized exit fee, debt discount and debt issuance costs, net from the 2025 Term Loan totaled $6.2 million and was recorded in loss on debt extinguishment in the consolidated statements of operations for 2022. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components of interest expense of the 2025 Term Loan:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,034</p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032</p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,066</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295826224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Commitments and Contingencies</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase Commitments</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of December 31, 2023, the Company&#8217;s non-cancelable purchase commitments under the terms of its agreements are as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,514</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,154</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,410</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,078</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, total obligations excludes certain purchase commitments that were assumed by Sandoz upon their acquisition of the Company&#8217;s CIMERLI ophthalmology franchise (see Note 17. Subsequent Events). The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Guarantees and Indemnifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings and Other Claims</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved. The outcome of such legal proceedings and claims is inherently uncertain. Accruals are recognized for such legal proceedings and claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it&#8217;s determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. As of December 31, 2023 and 2022, the Company had an accrual of $6.4 million and $4.7 million, respectively, related to such matters that was included in accrued rebates, fees and reserves in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (&#8220;Zinc&#8221;) asserting that Zinc was entitled to approximately $14.0 million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. The Company is continuing to evaluate the claims in the letter. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company established an accrual as of December 31, 2023 that represented its estimated liability to resolve the matter. Loss contingencies are inherently unpredictable, the assessment is highly subjective and requires judgments about future events and unfavorable developments or resolutions can occur. The Company regularly reviews litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date<b style="font-weight:bold;">.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other than the matter in connection with the demand letter described in this Note 9, there are no pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries' property is subject.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295800896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span>Leases</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Through December 31, 2023, the Company leased approximately 47,789 square feet of office space for its corporate headquarters in Redwood City, California (the &#8220;Lease Agreement&#8221;). Prior to an amendment to the Lease Agreement entered into on October 24, 2023 (the &#8220;Sixth Amendment&#8221;), the Lease Agreement was set to expire in <span style="-sec-ix-hidden:Hidden_fHNXk8VMLECyy9jYAF_Fdw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">September 2024</span></span> and contained a <span style="-sec-ix-hidden:Hidden_VkjnRAfIcEy-ZaCcc2AiFA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-time option to extend the lease term for five years. Under the terms of the Sixth Amendment, the Company extended the lease term through September 30, 2027 and reduced the amount of office space leased to 27,532&#160;square feet. The remaining&#160;20,257&#160;square feet of office space expired on December 31, 2023, according to the terms of the Sixth Amendment. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also leases approximately&#160;25,017&#160;square feet for its laboratory facilities in Camarillo, California which commenced in January 2020. This lease terminates in&#160;<span style="-sec-ix-hidden:Hidden_2eeuHZDPwkuwZhYvkItgaQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">May 2027</span></span> and contains a <span style="-sec-ix-hidden:Hidden_TfxsXMoIkUuAjOrWK1_x9w;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-time option to extend the lease term for&#160;five years. Both facility leases provide for certain limited rent abatement and annual scheduled rent increases over their respective lease terms.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the above facility leases were operating leases. The options to extend the lease terms, if any, for these leases were not included as part of the right-of-use asset or lease liability as it was not reasonably certain the Company would exercise those options. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2019, the Company entered into the Vehicle Lease Agreement, pursuant to which the Company leased approximately 50 vehicles as of December 31, 2023. The term of each leased vehicle is 36 months and commences upon the delivery of the vehicle. The vehicles leased under this arrangement were classified as finance leases. Beginning in February 2023, the Company no longer enters into these leasing arrangements and began transitioning to a reimbursement program with employees. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental information related to the Company&#8217;s leases is as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-mf-ZxnNGEipJwEpza_71w;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other assets, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,690</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WgpZY07_p0GbKqCO5gEf4g;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Property and equipment, net</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,584</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,274</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_liJO04hsZUOJwgNDIHYjyw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,127</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TFQ5qkqFP0exAVaWIavjVw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,628</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,755</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ieMrVFi9_UGwUiP2AK3LZQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,191</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wCWMjCewb0K1TBEZgR53KQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,418</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,609</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other information related to lease term and discount rate is as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:28.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-Average Remaining Lease Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.2 years</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.7 years</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-Average Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.8%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.0%</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.8%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense were as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 707</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 789</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,066</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,855</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to leases was as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="8" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in measurement of lease liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows from operating leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,560</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,401</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,435</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows from finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financing cash flows from finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,034</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,228</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for lease obligations:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,653</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,694</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 477</p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the maturities of the lease liabilities were as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating&#160;leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance&#160;leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 781</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 358</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,139</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (67)</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,072</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295774624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockholdersDeficitTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;background:#ffffff;">Stockholders&#8217; Deficit</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Public Offering  </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On May&#160;16, 2023, the Company entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company issued and sold the Firm Shares to the Underwriters. Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, for&#160;30 days&#160;from the date of the Underwriting Agreement, to purchase the Option Shares, which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $4.25&#160;per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $3.995&#160;per share.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The Offering was made pursuant to a prospectus supplement and related prospectus filed with the SEC pursuant to the Company&#8217;s Registration Statement under which the Company may offer and sell up to $150.0&#160;million in the aggregate of its common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings. On May&#160;18, 2023, the Company completed the sale and issuance of an aggregate of&#160;13,529,411&#160;Shares, including the exercise in full of the Underwriters&#8217; option to purchase the Option Shares. The Company received net proceeds of approximately $53.6&#160;million, after deducting the Underwriters&#8217; discounts and commissions and offering expenses payable by the Company.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">ATM Offering</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 8, 2022, the Company filed a Registration Statement. Also on November 8, 2022, the Company entered into a Sales Agreement with Cowen, pursuant to which the Company may issue and sell from time to time up to $150.0 million of its common stock through or to Cowen as the Company&#8217;s sales agent or principal in the ATM Offering.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, the Company reduced the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $86.25&#160;million, lowering the aggregate offering price under the Sales Agreement from $150.0&#160;million to $63.75&#160;million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, the Company increased the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $28.75&#160;million, increasing the aggregate offering price under the Sales Agreement from $63.75&#160;million to $92.5&#160;million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The following table summarizes information regarding settlements under the ATM Offering:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of common stock shares sold during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,559,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 916,884</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.30</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,692</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less commissions and fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (168)</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net proceeds after commissions and fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,524</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">As of December 31, 2023, the Company had approximately $66.5 million of its common stock remaining available for sales under the ATM Offering. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Common Stock </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On October 9, 2023, in accordance with the terms of the Optional Stock Purchase Agreement, the Company issued&#160;</span><span style="background:#ffffff;">2,225,513</span><span style="background:#ffffff;">&#160;shares of its common stock to the CMO for a price of </span><span style="background:#ffffff;">$3.675</span><span style="background:#ffffff;">&#160;per share, with a total value of </span><span style="background:#ffffff;">$8.2</span><span style="background:#ffffff;">&#160;million in this non-cash transaction.&#160;The Optional Stock Purchase Agreement gave the Company the option, in its sole discretion, to elect to pay for certain manufacturing services provided by the CMO by either paying cash or a Stock Service Fee Payment. On October 4, 2023, the Company notified the CMO of its election of the Stock Service Fee Payment. The price per share of common stock was equal to the volume-weighted average closing trading price per share of common stock on the Nasdaq Global Market over the&#160;</span><span style="-sec-ix-hidden:Hidden_I67Wh2887EWvSltZhszIEw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">ten</span></span><span style="background:#ffffff;">-trading day period ending on and including October 6, 2023.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockholdersDeficitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure containing information regarding Stockholders' Deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockholdersDeficitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295807008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation and Employee Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation and Employee Benefits</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span>Stock-Based Compensation and Employee Benefits</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2014, the Company&#8217;s board of directors and its stockholders adopted the 2014 Equity Incentive Plan, which became effective upon the closing of the Company&#8217;s IPO on November&#160;6,&#160;2014. The 2014 Plan is subject to automatic annual increases in the number of shares available for issuance on the first business day of each fiscal&#160;year equal to four&#160;percent (4%)&#160;of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors with 2024 being the last calendar year with an automatic annual increase under the 2014 Plan. All remaining shares under the Company&#8217;s 2010 Stock Plan (the &#8220;2010 Plan&#8221;) were transferred to the 2014 Plan upon adoption and any additional shares that would otherwise return to the 2010 Plan as a result of forfeiture, termination or expiration of the awards will return to the 2014 Plan. The 2014 Plan provided for the Company to grant shares and/or options to purchase shares of common stock to employees, directors, consultants and other service providers. While the 2014 Plan allows for non-qualified or incentive stock options, primarily all option grants made since June 2016 have been for non-qualified stock options. Under the 2010 Plan, no awards have been issued since 2014, and there were no shares of common stock available for future issuance as of December 31, 2023. There were 881,231 shares of common stock available for future issuance as of December 31, 2023 under the 2014 Plan.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the Company adopted the 2016 Employment Commencement Incentive Plan. The 2016 Plan is designed to comply with the inducement exemption contained in Nasdaq&#8217;s Rule&#160;5635(c)(4), which provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual&#8217;s entering into employment with the Company. As of December&#160;31, 2023, the Company had 1,773,921 shares of common stock available for future issuance for new employees. The 2016 Plan does not provide for any annual increases in the number of shares available.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option exercises are settled with common stock from the plans&#8217; previously authorized and available pool of shares. If any shares subject to an award granted under the 2014 Plan or the 2016 Plan expire or become forfeited or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool. The annual grant to eligible employees can vary depending on the type of award, and the award size is determined by the employee&#8217;s grade level.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incentive stock options and non-statutory stock options may be granted with exercise prices of not less than the fair value of the common stock on the date of grant. These stock options generally vest over four years, expire in ten years from the date of grant and are generally exercisable after vesting.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the summary of option activities under the 2016 Plan and the 2014 Plan:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Terms</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,691,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted - at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,947,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (430,504)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/Canceled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,549,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,659,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,337</p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,279,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,815</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aggregate intrinsic value represents the value of the Company&#8217;s closing stock price on the last trading day of the year in excess of the exercise price multiplied by the number of options outstanding or exercisable.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information on options outstanding and exercisable as of December&#160;31, 2023 is summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:42.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Terms</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Exercise Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.67</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,288,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,356,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.32</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.86</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,493,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,436,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.45</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.37</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,143,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,317,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.53</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.03</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,436,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,304,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.86</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.30</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,827,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,403,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.95</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.85</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,469,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,461,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,659,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,279,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.20</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional information on options is summarized as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except weighted-average grant-date fair value per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total intrinsic value of options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,726</p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of options vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,365</p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average grant date fair value per share of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.80</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, total unrecognized stock-based compensation expense related to unvested stock options was $37.4 million, which is expected to be recognized over a weighted-average period of 2.3 years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants RSUs primarily to its employees. RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The RSUs cannot be transferred and are subject to forfeiture if the holder&#8217;s employment terminates prior to the release of the vesting restrictions. The Company&#8217;s RSUs generally vest over <span style="-sec-ix-hidden:Hidden_AKrDviHwTEWrO6-oIS4MzA;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to three years from the applicable grant date, provided the employee remains continuously employed with the Company. The estimated fair value of RSUs is based on the closing price of the Company&#8217;s common stock on the grant date.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the summary of RSUs activity, under the 2014 Plan:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Balances at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,333,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.66</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,274,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.93</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,280,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.35</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs canceled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (600,430)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.02</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Balances at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,726,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.93</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additional information on RSUs is summarized as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except weighted-average grant-date fair value per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of RSUs vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,434</p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,869</p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average grant-date fair value per share of RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.86</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, total unrecognized stock-based compensation expense related to unvested RSUs was $10.8 million, which is expected to be recognized over a weighted-average period of 1.5 years.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the ESPP. The ESPP provides for annual increases in the number of shares available for issuance on the first business day of each fiscal&#160;year equal to the lesser of one&#160;percent (1%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. The ESPP had 2,541,769 shares of common stock available for future issuance as of December&#160;31, 2023. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of the Company&#8217;s common stock on the first or last day of the offering period. The offering periods of the ESPP are on <span style="-sec-ix-hidden:Hidden_VnDr0p6zgkaCQAXWjop8Wg;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">May&#160;16</span></span> and <span style="-sec-ix-hidden:Hidden_y3PMsjUAX0CNLgPeFQI8aw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">November&#160;16</span></span>. As of December&#160;31, 2023, there was $0.4 million of unrecognized compensation expense associated with the ESPP, which is expected to be recognized over an estimated weighted-average period of 4.5 months.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the classification of stock-based compensation expense in the Company&#8217;s consolidated statements of operations related to employees and nonemployees:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,099</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,688</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,577</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,364</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The stock-based compensation for the year ended December 31, 2023 includes restructuring charges described in Note 15 of $1.1&#160;million in research and development expense and a net forfeiture credit of $0.1&#160;million in selling, general and administrative expense.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The stock-based compensation expense recorded in connection with the Surface Acquisition that was not included in the consideration transferred was immaterial.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Valuation Assumptions of Awards Granted to Employees<b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of each stock option and awards granted under the ESPP on the date of grant using the Black-Scholes option-pricing model. The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of the awards during the&#160;years ended December 31, 2023, 2022 and 2021:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term: </i>The expected term represents the period for which the stock-based awards are expected to be outstanding and is based on the options&#8217; vesting term and contractual term. Since January 1, 2021, the Company has used historical data to calculate the expected term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility: </i>The expected volatility is calculated based on the Company&#8217;s daily stock closing prices for a period equal to the expected life of the award. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate: </i>The risk-free interest rate is based on the United States Treasury constant maturity rate at the time of grant using a term equal to the expected life.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends: </i>The Company has not paid and does not anticipate paying any dividends in the near future, and therefore used an expected dividend yield of zero in the valuation model.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">401(k)&#160;Retirement Plan </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">In 2019, the Company&#8217;s Compensation Committee approved the Company&#8217;s matching of the employees&#160;401(k)&#160;Plan whereby eligible employees may elect to contribute up to the lesser of&#160;90% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. Beginning January 1, 2021, the Company made matching contributions of 100% of the first 4% of eligible compensation, up to a maximum of $7,500. The Company recorded compensation expense related to the match of $1.8 million, $2.1 million and $1.7&#160;million in 2023, 2022 and 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295855904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></span>Income Taxes </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of loss before income taxes are as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (238,272)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (291,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (287,058)</p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (238,272)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (291,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (287,100)</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">For the periods presented, the income tax provision (benefit) is as follows:<b style="font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Income tax provision (benefit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was no income tax provision in 2022 and 2021 due to the Company&#8217;s history of losses and valuation of allowances against the deferred tax assets. &#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">A reconciliation of the statutory United States federal rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Percent of pre-tax income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">United States federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign rate differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (17.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (22.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (25.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2023 and 2022 consist of the following:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,423</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,164</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,877</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,561</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,864</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,717</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,673</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,279</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,538)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,903)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (6,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (603)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (7,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,506)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 422,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 337,773</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (423,385)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (337,773)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net deferred tax assets (liabilities)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The tax benefit of net operating losses, temporary differences and credit carry forwards is recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its federal net deferred tax assets and certain state net deferred tax assets will not be realized, and therefore, the Company has offset the federal and certain state net deferred tax assets by a valuation allowance as of December 31, 2023 and 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The valuation allowance increased by $85.6 million, $64.4 million and $72.4 million during the years ended December 31, 2023, 2022 and 2021, respectively.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had net operating loss carryforwards for federal income of $774.9 million, which will start to expire in the year 2036, and various states net operating loss carryforwards of $128.0 million, which have various expiration dates beginning in 2031.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2023, the Company had federal research and development credit carryforwards for federal income tax purposes of $60.6 million, which will start to expire in the year 2031, and state research and development credit carryforwards of $26.5 million, which have no expiration date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Utilization of the net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of certain net operating loss and tax credit carryforwards before their utilization. Under the new enacted tax law, the carry forward period of net operating losses generated from 2018 forward is indefinite. However, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. The Company files income tax returns in the United States federal jurisdiction, various United States state jurisdictions, and a foreign jurisdiction with varying statutes of limitations. The tax&#160;years from inception in 2011 forward remain open to examination due to the carryover of unused net operating losses and tax credits. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the Company&#8217;s unrecognized tax benefits during 2023, 2022 and 2021 is as follows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,243</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additions based on tax positions related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,038</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additions (reductions) for tax positions of prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,495</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December&#160;31, 2023, 2022 and 2021, the Company had $17.4 million, $16.8 million and $15.5 million, respectively, of unrecognized benefits, none of which would currently affect the Company&#8217;s effective tax rate if recognized due to the Company&#8217;s deferred tax assets being fully offset by a valuation allowance.&#160;During 2023, 2022 and 2021, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate a material adjustment of unrecognized tax benefits during the next twelve&#160;months from the balance sheet date as reductions for tax positions of prior years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289472784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span>Net Loss Per Share</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, including shares subject to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,083,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,214,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,895,097</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,399,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,811,607</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,078,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473,871</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,291,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,635,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,122,727</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295821504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring Charges.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;">15. </p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;">Restructuring Charges</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">On March 3, 2023, the Company committed to a plan to reduce its workforce to focus resources on strategic priorities including the commercialization of its diversified product portfolio and development of innovative immuno-oncology product candidates. The reduction in force impacted approximately&#160;50&#160;full-time and part-time employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduction in force consisted of $3.9&#160;million in cash expenses related to personnel expenses such as salaries, severance payments and other benefits; and $1.5&#160;million in non-cash stock-based compensation related to acceleration of vesting and extension of the stock option exercise windows for&#160;two&#160;impacted executives; partially offset by $0.5&#160;million in non-cash stock-based compensation forfeiture credits. The reduction in force was completed during the second quarter of 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2023, the consolidated statements of operations include $3.6&#160;million in research and development expense and $1.3&#160;million in selling, general and administrative expense related to the reduction in force.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295861504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">16.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">Related Party Transactions</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consulting services</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2020, the Company entered into a consulting agreement with Lanfear Advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, the Company&#8217;s President, Chief Executive Officer and Chairman of the Board of Directors. Mr. Jonathan Lanfear provided consulting services with respect to the Collaboration Agreement executed with Junshi Biosciences in February 2021 and the Letter Agreement with Junshi Biosciences related to the Collaboration Agreement dated January 9, 2022 (See Note 7. Collaborations and Other Arrangements). In addition to the hourly consulting fee paid to Lanfear Advisors under the consulting agreement, the Company granted fully vested stock options to purchase&#160;65,000&#160;shares of common stock with an exercise price of $17.60&#160;per share to Mr. Jonathan Lanfear in February 2021 upon the execution of the Collaboration Agreement with Junshi Biosciences and recognized stock-based compensation expense of $0.8&#160;million. The Company recorded cash consulting expense of $0.2&#160;million in 2021 with respect to these consulting services. There have been no subsequent material related party expenses. Total liabilities recognized in the consolidated balance sheets with respect to these services were immaterial as of December 31, 2023 and 2022.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295810448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">17.</p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;">Subsequent Events <b style="font-weight:bold;background:#ffff00;"> </b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CIMERLI Sale Transaction</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 19, 2024, the Company entered into the Purchase Agreement by and between the Company and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, the Company completed the Sale Transaction for its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Partial Release and Third Amendment to 2027 Term Loan</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2024, the Company, entered into the Consent and Amendment with the Collateral Agent and the Lenders, pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the 2027 Term Loans and the other loan documents in connection therewith, and the parties thereto agreed to amend the Loan Agreement.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the Purchase Agreement, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the Lenders and the Collateral Agent permitted the Company to make a partial prepayment of the principal of the loans outstanding under the 2027 Term Loans in the amount of $175.0 million upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions including a prepayment premium and makewhole amount calculated pursuant to the Consent and Amendment and (3) the parties thereto agreed to adjust the minimum net sales covenant level under the 2027 Term Loans. Upon the closing of the Sale Transaction the Company became liable to repay $175.0 million of the existing principal balance of $250.0 million of the loans outstanding under the Loan Agreement on April 1, 2024 and the Company plans to repay $175.0 million and the prepayment premium and makewhole amount of $6.8 million to the Lenders on or before April 1, 2024 pursuant to the Consent and Amendment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other terms of the 2027 Term Loans, as amended by the Consent and Amendment, remain generally identical to those under the 2027 Term Loans. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294748944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of Coherus and its wholly-owned subsidiaries. The Company does not have any significant interest in variable interest entities. All material intercompany transactions and balances have been eliminated upon consolidation.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock', window );">Segment Reporting and Revenue by Geographic Region</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Reporting and Revenue by Geographic Region</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing human pharmaceutical products. The Company&#8217;s chief executive officer, as the chief operating decision maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the Company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions. Primarily, all revenue is generated and all long-lived assets are maintained in the United States. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and restricted cash comprise cash and highly liquid investments with original maturities of 90&#160;days or less.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets and which, in aggregate, represent the amount reported in the consolidated statements of cash flows:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541,158</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541,598</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,195</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,635</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current in the consolidated balance sheets.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company classifies the up-front and milestone payments related to licensing arrangements as cash flows used in investing activities in its consolidated statements of cash flows.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Receivables</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Receivables</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade receivables are recorded net of allowances for chargebacks, chargeback prepayments, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses and was not material during the periods presented. The Company believes that its allowance for expected credit losses was adequate and immaterial as of December 31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investments in Marketable Securities</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investments in marketable securities primarily consist of U.S. Treasury securities, government agency securities, commercial paper, corporate bonds and market money funds. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#8217;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#8217;s investment policy requires that it only invests in highly rated securities and limits its exposure to any single issuer, except for securities issued by the U.S. government. All investments in marketable debt securities are held as &#8220;available-for-sale&#8221; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. The Company regularly reviews its investments for declines in fair value below the amortized cost basis to determine whether the impairment, if any, is due to credit-related or other factors. This review includes the credit worthiness of the security issuers, the severity of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of the amortized cost basis. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an available-for-sale debt investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. There were no impairments related to credit losses during any of the periods presented. Realized gains and losses, if any, on available-for-sale securities </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are included in other income (expense), net, in the consolidated statements of operations based on the specific identification method. During 2023, 2022 and 2021, interest income from marketable securities was $2.8 million, $1.9 million and $1.4 million, respectively, and is included in other income (expense), net, in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Risk</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments in marketable securities and trade receivables. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company&#8217;s revenues are in the United States to three&#160;wholesalers. During 2023, the products sold by the Company were UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. During 2022, UDENYCA and CIMERLI were the only products sold by the Company, and in 2021 UDENYCA accounted for all of the Company&#8217;s revenues.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company enters into a strategic commercial supply agreement for each of its products. The Company currently has not engaged back-up suppliers or vendors. If any of the Company&#8217;s current vendors are not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Instruments </b><b style="color:#ff0000;font-weight:bold;"> </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2023, the Company commenced using derivative contracts (foreign exchange option contracts) for the purpose of economically hedging exposure to changes in currency fluctuations between the U.S.&#160;Dollar and the Euro. The Company recognizes all derivatives at fair value on the consolidated balance sheets, and corresponding gains and losses are recognized in other income (expense), net in the consolidated statements of operations. The estimated fair value of derivative financial instruments represents the amount required to enter into similar contracts with similar remaining maturities based on quoted market prices. During the periods presented, the Company did not apply hedge accounting to these instruments. There are no derivative instruments entered into for speculative or trading purposes.&#160;Since the Company's foreign exchange derivatives all matured and settled by December 31, 2023, there were no derivative assets or <span style="-sec-ix-hidden:Hidden_YgjkhDQ6bEeOg5gUe8O-fQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">derivative liabilities</span></span> as of December 31, 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock', window );">Business Combination Accounting &amp; Valuation of Acquired Assets</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combination Accounting &amp; Valuation of Acquired Assets </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations.&#160;Judgment is required in assessing whether the acquired processes or activities, along with their inputs, meet the criteria to constitute a business, as defined by U.S. GAAP.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquisition method of accounting requires the recognition of assets acquired and liabilities assumed at their acquisition date fair values.&#160;The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill, or when there is an&#160;excess of the fair values of these identifiable assets and liabilities over the fair value of purchase consideration, a&#160;bargain purchase gain is recorded in&#160;the consolidated statements of operations.&#160;The estimations of fair values based on non-observable inputs that are included in valuation models. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including the estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the measurement period, which occurs before finalization of the purchase price allocation, changes in assumptions and estimates that result in adjustments to the fair values of assets acquired and liabilities assumed, if based on facts and circumstances existing at the acquisition date, are recorded on a retroactive basis as of the acquisition date, with the corresponding offset to goodwill or bargain purchase gain (See Note 6. Surface Acquisition).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in&#160;foreign currencies are remeasured at historical rates.&#160;Translation gains and losses are included in </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accumulated other comprehensive loss in stockholders&#8217; equity (deficit).&#160;Revenue and expense accounts are translated to U.S. dollars at average exchange rates in effect during the period with resulting transaction gains and losses recognized in other income (expense), net in the consolidated statements of operations. The Company has not experienced material foreign currency transaction gains and losses for any of the years presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. The Company primarily uses actual costs to determine the cost basis for inventory. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During 2023 and 2022, the Company recorded $52.6 million and $26.0 million in inventory write-downs, respectively, within cost of goods sold in the consolidated statements of operations. The 2023 charge was primarily for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. The 2022 charge was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although the Company believes the assumptions used in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by management, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in the consolidated statements of operations. Adverse developments affecting the Company&#8217;s assumptions of the level and timing of demand for its products include those that are outside of the Company&#8217;s control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the regulatory approval of product candidates, the Company incurs expenses for the manufacture of drug products that could potentially be available to support the commercial launch of the products. I<span style="background:#ffffff;">nventory costs are capitalized when future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment. &#160;A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, viability of commercialization and marketplace trends. Inventory in the consolidated balance sheets as of December 31, 2023 was related to UDENYCA, YUSIMRY, CIMERLI and LOQTORZI.</span> The Company began to capitalize inventory costs associated with UDENYCA, CIMERLI and LOQTORZI after receiving final regulatory approval in November&#160;2018, August 2022, and October 2023, respectively, and capitalization of YUSIMRY inventory costs began in the second quarter of 2022 when sales were deemed probable. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment is stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the capitalized interest costs are amortized as depreciation or amortization expense over the life of the underlying asset. When the Company disposes of property and equipment, it removes the associated cost and accumulated depreciation from the related accounts in the consolidated balance sheets and include any resulting gain or loss in the consolidated statements of operations. Eligible costs of internal use software and implementation costs of certain hosting arrangements are capitalized and amortized over the estimated useful life of the software or associated hosting arrangement, as applicable. Depreciation and amortization are recognized using the straight-line method over the following estimated useful lives:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 - 7 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life</span></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill and Intangible Assets</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company&#8217;s single reporting unit below its carrying amount.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquired in-process research and development&#160;(&#8220;IPR&amp;D&#8221;) that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company <span style="background:#ffffff;">will commence amortization over the useful life of the intangible asset, which will generally be determined by the period in which the substantial majority of the cash flows are expected to be generated. </span>The Company evaluates IPR&amp;D for impairment on an annual basis, during the fourth quarter, or more frequently if impairment indicators exist.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finite-lived intangible assets are generally amortized on a straight-line basis over their estimated economic life and are reviewed periodically for impairment. The amortization expense related to capitalized milestone payments under license agreements and the amortization expense from out-licenses are recorded as a component of cost of goods sold in the consolidated statements of operations. The estimated life for capitalized milestone payments is&#160;ten years,&#160;and the life for acquired out-licenses is&#160;fifteen years. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Contingent consideration relates to the potential payments to holders of&#160;the CVRs&#160;that are contingent upon the achievement of the Company and certain third-parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within loss from operations in the consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Net Revenues</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Net Revenues </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sells to wholesalers and distributors, (collectively, &#8220;Customers&#8221;). The Customers then resell to hospitals and clinics (collectively, &#8220;Healthcare Providers&#8221;) pursuant to contracts with the Company. In addition to distribution agreements with Customers and contracts with Healthcare Providers, the Company enters into arrangements with group purchasing organizations (&#8220;GPOs&#8221;) that provide for United States government-mandated or privately negotiated rebates, chargebacks and discounts. The Company also enters into rebate arrangements with payers, which consist primarily of commercial insurance companies and government entities, to cover the reimbursement of products to Healthcare Providers. The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. Revenue from product sales is recognized at the point when a Customer obtains control of the product and the Company satisfies its performance obligation, which generally occurs at the time product is shipped to the Customer. Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Product Sales Discounts and Allowances</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue from product sales is recorded at the net sales price (&#8220;transaction price&#8221;), which includes estimates of variable consideration for which reserves are established and that result from chargebacks, rebates, co-pay assistance, prompt-payment discounts, </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">returns and other allowances that are offered within contracts between the Company and its Customers, Healthcare Providers, payers and GPOs. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions in trade receivables (if the amounts are payable to a Customer) or current and non-current liabilities (if the amounts are payable to a party other than a Customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specifically known market events and trends, industry data and forecasted Customer buying and payment patterns. Overall, these reserves reflect the best estimates of the amount of consideration to which the Company is entitled based on the terms of its contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The actual amount of consideration ultimately received may differ. If actual results in the future vary from the Company&#8217;s estimates, the estimates will be adjusted, which will affect net product revenue in the period that such variances become known.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: </i>Chargebacks are discounts that occur when Healthcare Providers purchase directly from a Customer. Healthcare Providers, which belong to Public Health Service institutions, non-profit clinics, government entities, GPOs, and health maintenance organizations, generally purchase the product at a discounted price. The Customer, in turn, charges back to the Company the difference between the price initially paid by the Customer and the discounted price paid by the Healthcare Providers to the Customer. The allowance for chargebacks is based on an estimate of sales through to Healthcare Providers from the Customer.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discounts for Prompt Payment:</i> The Company provides for prompt payment discounts to its Customers, which are recorded as a reduction in revenue in the same period that the related product revenue is recognized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates:</i> Rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with these public sector benefit providers. The accrual for rebates is based on statutory or contractual discount rates and expected utilization. The estimates for the expected utilization of rebates are based on Customer and commercially available payer data, as well as data collected from the Healthcare Providers, Customers, GPOs, and historical utilization rates. Rebates invoiced by payers, Healthcare Providers and GPOs are paid in arrears. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenue in the period of adjustment.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Returns:</i> The Company offers its Customers limited product return rights, which are principally based upon whether the product is damaged or defective, or the product&#8217;s expiration date. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Allowances:</i> The Company pays fees to Customers and GPOs for account management, data management and other administrative services. To the extent that the services received are distinct from the sale of products to the customer, these payments are classified in selling, general and administrative expense in the Company&#8217;s consolidated statements of operations, otherwise they are included as a reduction in product revenue.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Revenue</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenue from licensees, which is based on sales to third parties of licensed products, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty revenue was immaterial for all periods presented and is included in net revenue. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold consists primarily of third-party manufacturing, distribution, certain overhead costs, royalties on certain products, and charges for inventory write-downs. <span style="background:#ffffff;">Through March 31, 2021, a portion of the costs of producing UDENYCA&#160;sold was expensed as research and development before the FDA approval of UDENYCA&#160;and therefore is not reflected in cost of goods sold. All the inventory expensed prior to approval of UDENYCA was fully utilized by March 31, 2021; thus, the costs of producing UDENYCA&#160;are fully reflected in cost of goods sold beginning April 1, 2021.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;2, 2019, the Company and Amgen settled a trade secret action brought by Amgen. As a result, cost of goods sold reflects a mid-single digit royalty on UDENYCA net product revenue, which began on July&#160;1, 2019. The royalty cost will continue for five years pursuant to the settlement. Additionally, the Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range. The Company incurs royalties on net sales of LOQTORZI in the low- to mid-twenty percent range and on net sales of YUSIMRY in the mid-single digit range. Pursuant to the Genentech Agreement, the Company incurred a royalty that was a low single-digit percentage of net sales of CIMERLI through the end of 2023.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, 2022 and 2021, cost of goods sold included inventory write-downs, net of $52.6 million, $26.0 million and $5.1 million, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Research and development expense represents costs incurred to conduct research, such as the discovery and development of product candidates. The Company recognizes all research and development costs as they are incurred. The Company currently tracks research and development costs incurred on a product candidate basis only for external research and development expenses. The Company&#8217;s external research and development expense consists primarily of:</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expense incurred under agreements with collaborators, consultants, third-party CROs, and investigative sites where a substantial portion of the Company&#8217;s preclinical studies and all of its clinical trials are conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with manufacturing process development activities, analytical activities and pre-launch inventory manufactured prior to regulatory approval being obtained or deemed to be probable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">upfront and milestone payments related to licensing and collaboration agreements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Internal costs are associated with activities performed by the Company&#8217;s research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expense, which include salaries, benefits and stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LicenseAgreementsPolicyTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered and may continue to enter into license agreements to access and utilize certain technology. To determine whether the licensing transactions should be accounted for as a business combination or as an asset acquisition, the Company makes certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an asset acquisition and therefore, any acquired IPR&amp;D that does not have an alternative future use is charged to expense at the acquisition date. To date none of the Company&#8217;s license agreements have been considered to be the acquisition of a business.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Selling, General and Administrative Expense</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative expense comprises primarily compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $10.9 million, $10.5 million and $8.7 million in 2023, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s compensation programs include stock-based awards, and the related grants under these programs are accounted for at fair value. The fair values are recognized as compensation expense on a straight-line basis over the vesting period with the related costs recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company&#8217;s common stock on the date of issuance. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as income tax expense.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. The Company does not expect its unrecognized tax benefits from prior years to change significantly in 2024. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating and Finance Leases</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Operating and Finance Leases</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:45pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines at an arrangement&#8217;s inception whether it is a lease. The Company does not recognize right-of-use assets and lease liabilities related to short-term leases. The Company also does not separate lease and non-lease components for its facility and vehicle leases. Operating leases are included in accrued and other current liabilities, other assets, non-current, and lease liabilities, non-current in the consolidated balance sheets. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. The Company recognizes operating lease expense for these leases on a straight-line basis over the lease term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The terms of vehicles leased under the Company&#8217;s fleet agreement (&#8220;Vehicle Lease Agreement&#8221;) are 36 months. The vehicles leased under this arrangement were classified as finance leases. Finance leases are included in property and equipment, net, accrued and other current liabilities, and lease liabilities, non-current in the consolidated balance sheets. Assets under finance leases are depreciated to operating expenses on a straight-line basis over the lease term.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The operating and finance lease right-of-use assets and the lease liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. The Company uses its incremental borrowing rate based on the information available at the commencement date or the lease modification date, as applicable, in determining the lease liabilities as the Company's leases generally do not provide an implicit rate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares.</span> <span style="background:#ffffff;">Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive</span> (see Note 14. Net Loss Per Share).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes the following two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that are recorded as an element of stockholders&#8217; equity (deficit), but are excluded from net loss. The Company&#8217;s other comprehensive income (loss) includes unrealized gains on available-for-sale securities and foreign currency translation adjustments in 2023, 2022 and 2021. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReclassificationsPolicyPolicyTextBlock', window );">Reclassifications</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassifications</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain amounts in prior years&#8217; financial statements have been reclassified to conform with the current year presentation in 2023, including amounts in the consolidated statements of cash flows. There were no changes to net cash used in operating activities in the consolidated statements of cash flows for the prior years as a result.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following are recent accounting pronouncements that the Company has not yet adopted:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280) Improvements to Reportable Segment </i><i style="font-style:italic;">Disclosures</i>, which enhances the disclosures required for operating segments by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, among other expanded. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued&#160;ASU 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents Information pertaining to Consideration which is contingent upon some future changes in assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LicenseAgreementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LicenseAgreementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ReclassificationsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ReclassificationsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment reporting and revenue by geographic region.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 6<br> -SubTopic 50<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479455/805-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295760672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At beginning of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541,158</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541,598</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,195</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417,635</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property Plant and Equipment</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3 - 7 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life</span></span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293774112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net product revenue in United States, and Company's net revenue</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   UDENYCA</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326,509</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   CIMERLI</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   YUSIMRY</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   LOQTORZI</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 256,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 210,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326,509</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">   Total net revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 326,551</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">McKesson Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cencora (previously known as AmeriSource-Bergen Corporation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cardinal Health, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;Fees,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Discounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Co-pay</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">for&#160;Prompt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rebates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,398</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 679,199</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,876)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,976)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,407)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (478,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (93,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (681,467)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 109,723</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 436,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,435</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 578,699</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,108)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (421,763)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,640)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (80,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (584,811)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100,503</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provision related to sales made in:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 590,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 844,325</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">    Prior period - increase (decrease)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,361)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,807</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments and customer credits issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (558,135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62,370)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (83,245)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (703,750)</p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 121,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244,885</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of product sales discounts and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294094304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,458</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,195</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,993</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,669</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid financial instrument in Prepaid manufacturing<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,940</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,472</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,060</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable debt securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,964</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,418</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,203</p></td></tr><tr><td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 191,645</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;">Cash equivalents consist of money market funds, U.S treasury securities, and commercial paper and corporate notes with original maturities of 90 days or less.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;">Relates to Optional Stock Purchase Agreement.</span></td></tr></table><div style="margin-top:9pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and cash equivalents, marketable securities and restricted cash</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th colspan="11" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized Gain</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized (Loss)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Money market funds</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,484</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,484</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. government agency securities</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,200</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,195</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. treasury securities</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,967</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,969</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Commercial paper and corporate notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,673</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,324</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,315</p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,060</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,964</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,418</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper and corporate notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,203</p></td></tr><tr><td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,645</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301710896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfInventoryTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,262</p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,588</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,712</p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,077</p></td></tr><tr><td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115,051</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock', window );">Schedule of Balance Sheet Classification</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,791</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76,260</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 115,051</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of inventory current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfInventoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfInventoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295100672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,944</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,183</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,258</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,198</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,632</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 696</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,911</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (20,651)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (20,157)</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,754</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Intangible Assets, Net</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finite-lived assets, net of accumulated amortization of $639 and $61, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,368</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite-lived assets - IPR&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,620</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 943</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,931</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued commercial and research and development manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,774</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued co-development costs and milestone payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,356</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,015</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,634</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,318</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 105,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,097</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities, Non-current</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,365</p></td></tr><tr><td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total Other liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,467</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296914048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Surface Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of total consideration paid</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coherus common stock issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,971,460</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Coherus common stock share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.89</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value of components of purchase price consideration at closing:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity of combined company owned by Surface equity holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,540</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent CVR liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,290</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity of combined company owned by Surface former employees <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 766</p></td></tr><tr><td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of total purchase consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,596</p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents </span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">161,100</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Coherus common stock, net of shares withheld for taxes, issued to Surface&#8217;s former employees on the Acquisition Date.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of purchase price allocation to the estimated fair value of the net assets acquired</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amounts Recognized at Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets Acquired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,997</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,791</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other prepaids and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,260</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,239</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,530</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,817</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities Assumed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,722</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,499</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,221</p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,596</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of amount allocated to identifiable intangible assets</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Useful lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at Acquisition Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - casdozokitug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,899</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-process research and development - CHS-114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-license - GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Out-license - Novartis Institutes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,024</p></td></tr><tr><td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total identifiable intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,769</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of pro forma information does not purport to represent what the Company's actual results would have been if the acquisition had occurred as of January 1, 2022</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 257,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241,042</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (284,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (369,442)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622300148448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Company's Debt Obligations</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2023</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial Liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 Term Loans</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,519)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,481</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,481</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2*</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 Convertible Notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,112)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226,888</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,155</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2**</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December 31, 2022</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized Debt Discount and Debt Issuance Costs</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Carrying Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Fair Value</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial Liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 Term Loans</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,517)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,483</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,483</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2*</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 Convertible Notes</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,425)</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225,575</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157,205</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Level 2**</p></th></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:98.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">*</p></td><td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The principal amounts outstanding are subject to variable interest rates, which are based on three-month SOFR starting April 1, 2023 plus fixed percentages. Through March 31, 2023, the variable component was based on the three-month LIBOR. Therefore, the Company believes the carrying amount of these obligations approximates fair value.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr><td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">**</p></td><td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>The fair value is influenced by interest rates, the Company&#8217;s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs.</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,243</p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,550</p></td></tr><tr><td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,793</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Payments on Debt</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,345</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,248</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224,607</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2027 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,097</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 345,297</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (95,297)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027 Term Loans, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,519)</p></td></tr><tr><td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2027 Term Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,481</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,259</p></td></tr><tr><td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,709</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Payments on Debt</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future payments on the 2026 Convertible Notes&#160;as of December 31, 2023 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31,&#160;(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0070c0;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025 - interest only</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,450</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026 - principal and interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 231,725</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 238,625</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less amount representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,625)</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026 Convertible Notes, principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,112)</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 226,888</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,200</p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,966</p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,166</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stated coupon interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,034</p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt discount and debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032</p></td></tr><tr><td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,066</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295810448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentTextBlock', window );">Schedule of Non-cancelable Contractual Obligations</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Year ending December&#160;31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,514</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,154</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,410</p></td></tr><tr><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,078</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293914160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock', window );">Schedule of Balance Sheet Classification of Lease Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-mf-ZxnNGEipJwEpza_71w;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Other assets, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,690</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WgpZY07_p0GbKqCO5gEf4g;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Property and equipment, net</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,584</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,274</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_liJO04hsZUOJwgNDIHYjyw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,127</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_TFQ5qkqFP0exAVaWIavjVw;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,628</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,755</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ieMrVFi9_UGwUiP2AK3LZQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued and other current liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,191</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finance lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wCWMjCewb0K1TBEZgR53KQ;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,418</p></td></tr><tr><td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,609</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock', window );">Other information related to lease term and discount rate</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:28.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-Average Remaining Lease Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.2 years</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.7 years</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-Average Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.8%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.0%</p></td></tr><tr><td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.8%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 707</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total finance lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 789</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,066</p></td></tr><tr><td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,199</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,855</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock', window );">Supplemental cash flow information related to leases</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="8" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in measurement of lease liabilities:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows from operating leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,560</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,401</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,435</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows from finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financing cash flows from finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,034</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,228</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets obtained in exchange for lease obligations:</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,653</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434</p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Finance leases</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,694</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 477</p></th></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating and finance lease liabilities</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31, (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating&#160;leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance&#160;leases</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 781</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 358</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,139</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (67)</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,072</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating and finance leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other information relating to lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information relating to lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294749216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock', window );">Schedule of Settlements Under the ATM Offering</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of common stock shares sold during the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,559,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 916,884</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average price per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.30</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,692</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less commissions and fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (168)</p></td></tr><tr><td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net proceeds after commissions and fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,524</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares offering settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294738448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation and Employee Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activities under 2016 and 2014 Plans</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Terms</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,691,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted - at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,947,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (430,504)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited/Canceled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,549,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,659,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,337</p></td></tr><tr><td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,279,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,815</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of options outstanding and exercisable</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information on options outstanding and exercisable as of December&#160;31, 2023 is summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:42.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual Terms</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of Exercise Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.67</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,288,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,356,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.32</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.86</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,493,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,436,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.45</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.37</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,143,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,317,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.53</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.03</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,436,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,304,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.86</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.30</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,827,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,403,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.95</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.85</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,469,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,461,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.91</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,659,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,279,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.20</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock', window );">Schedule of additional information on options</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except weighted-average grant-date fair value per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total intrinsic value of options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,726</p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of options vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,365</p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average grant date fair value per share of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.80</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity, under 2014 Plan</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Balances at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,333,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.66</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,274,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.93</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,280,901)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.35</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">RSUs canceled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (600,430)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.02</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Balances at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,726,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.93</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except weighted-average grant-date fair value per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of RSUs vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,434</p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant date fair value of RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,869</p></td></tr><tr><td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average grant-date fair value per share of RSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.86</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,099</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,688</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,577</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,364</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense capitalized into inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions for Black-Scholes Option-Pricing Model Used in Determining Fair Value of Awards</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average grant date fair value per share of the options granted, the total intrinsic value of options exercised, the total fair value of options that have vested, and the total cash received from the exercise of stock options during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622300177888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before income taxes</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (238,272)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (291,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (287,058)</p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (42)</p></td></tr><tr><td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (238,272)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (291,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (287,100)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income tax provision (benefit)</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Income tax provision (benefit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (380)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the statutory United States federal rate to the Company's effective tax rate</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Percent of pre-tax income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">United States federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign rate differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (17.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (22.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (25.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's net deferred tax assets</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,423</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,164</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,877</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,561</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,864</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,717</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,673</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 340,279</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,538)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,903)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (6,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (603)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (7,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,506)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total net deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 422,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 337,773</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (423,385)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (337,773)</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net deferred tax assets (liabilities)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Company's unrecognized tax benefits</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,243</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additions based on tax positions related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,038</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Additions (reductions) for tax positions of prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214</p></td></tr><tr><td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,495</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295778048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share</a></td>
<td class="text"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options, including shares subject to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,083,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,214,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,895,097</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,399,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,811,607</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2022 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,078,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,473,871</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares issuable upon conversion of 2026 Convertible Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,942,152</p></td></tr><tr><td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,291,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,635,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,122,727</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294223072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Organization (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>product </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProductPipelineNumberOfDrugCandidates', window );">Product pipeline, number of product candidates | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_NumberOfOperatingAndReportableSegments', window );">Number of reportable and operating segments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_CoherusOphthalmologyLlcMember', window );">Coherus Ophthalmology LLC | CIMERLI Disposition Transaction | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="nump">$ 170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets', window );">Consideration transferred for CIMERLI product inventory and prepaid manufacturing assets</a></td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred for inventory and prepaid manufacturing assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_NumberOfOperatingAndReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating and reportable segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_NumberOfOperatingAndReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProductPipelineNumberOfDrugCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of drug candidates in the product pipeline.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProductPipelineNumberOfDrugCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_CoherusOphthalmologyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_CoherusOphthalmologyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliDivestitureTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliDivestitureTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293804032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 102,891<span></span>
</td>
<td class="nump">$ 63,547<span></span>
</td>
<td class="nump">$ 417,195<span></span>
</td>
<td class="nump">$ 541,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 103,343<span></span>
</td>
<td class="nump">$ 63,987<span></span>
</td>
<td class="nump">$ 417,635<span></span>
</td>
<td class="nump">$ 541,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290880400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Investments in Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income from marketable securities</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Impairments related to credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289430336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Derivative Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Asset</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294698992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 52,595<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 5,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">52,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold | YUSIMRY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold | UDENYCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_YusimryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=chrs_YusimryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_UdenycaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=chrs_UdenycaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293969648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Estimated useful lives, description</a></td>
<td class="text">us-gaap:UsefulLifeTermOfLeaseMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294935392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Goodwill and Intangible Assets and Impairment of Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Long lived assets, material impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Goodwill and Intangible Assets and Impairment of Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Goodwill and Intangible Assets and Impairment of Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296346128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Net Revenues (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Revenue, Performance Obligation, Description of Payment Terms</a></td>
<td class="text">Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentTermsPeriodFromDateOfShipment', window );">Payment terms from date of shipment, period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentTermsPeriodFromDateOfShipment', window );">Payment terms from date of shipment, period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PaymentTermsPeriodFromDateOfShipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment terms from date of shipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PaymentTermsPeriodFromDateOfShipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622286532032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Cost of Goods Sold (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 04, 2019</div></th>
<th class="th"><div>Jul. 01, 2019</div></th>
<th class="th"><div>May 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Cost of Goods Sold</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_RoyaltyPaymentTerm', window );">Royalty payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,595<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 5,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Cost of Goods Sold</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfGrossProfitsOnSales', window );">Percentage of gross profits shared</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_LoqtorziMember', window );">LOQTORZI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Cost of Goods Sold</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfRoyaltiesOnNetSales', window );">Percentage Of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfGrossProfitsOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>percentage of profit shared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfGrossProfitsOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties incurred on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_RoyaltyPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_RoyaltyPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_LoqtorziMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_LoqtorziMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295939392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Operating and Finance Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of leases</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296932688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295796416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Reclassifications (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Changes to net cash used in operating activities in the consolidated statements of cash flows</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293864544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Net Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 257,244<span></span>
</td>
<td class="nump">$ 211,042<span></span>
</td>
<td class="nump">$ 326,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total net product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">256,580<span></span>
</td>
<td class="nump">210,760<span></span>
</td>
<td class="nump">326,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=chrs_UdenycaMember', window );">UDENYCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">127,064<span></span>
</td>
<td class="nump">203,814<span></span>
</td>
<td class="nump">326,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=chrs_CimerliMember', window );">CIMERLI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">125,388<span></span>
</td>
<td class="nump">6,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=chrs_YusimryMember', window );">YUSIMRY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">3,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=chrs_ToripalimabMember', window );">LOQTORZI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_UdenycaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_UdenycaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_CimerliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_CimerliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_YusimryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_YusimryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_ToripalimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_ToripalimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622286695520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details) - Net Product Revenue - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">McKesson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total gross revenue</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Cencora (previously known as AmeriSource-Bergen Corporation)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total gross revenue</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Cardinal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total gross revenue</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=chrs_McKessonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=chrs_McKessonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=chrs_AmeriSourceBergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=chrs_AmeriSourceBergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=chrs_CardinalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=chrs_CardinalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290576384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">$ 100,503<span></span>
</td>
<td class="nump">$ 109,723<span></span>
</td>
<td class="nump">$ 123,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">844,325<span></span>
</td>
<td class="nump">578,699<span></span>
</td>
<td class="nump">679,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period - increase (decrease)</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="num">(3,108)<span></span>
</td>
<td class="num">(11,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(703,750)<span></span>
</td>
<td class="num">(584,811)<span></span>
</td>
<td class="num">(681,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">244,885<span></span>
</td>
<td class="nump">100,503<span></span>
</td>
<td class="nump">109,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">42,677<span></span>
</td>
<td class="nump">29,665<span></span>
</td>
<td class="nump">40,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">590,772<span></span>
</td>
<td class="nump">436,865<span></span>
</td>
<td class="nump">470,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period - increase (decrease)</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="num">(2,090)<span></span>
</td>
<td class="num">(2,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(558,135)<span></span>
</td>
<td class="num">(421,763)<span></span>
</td>
<td class="num">(478,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">73,953<span></span>
</td>
<td class="nump">42,677<span></span>
</td>
<td class="nump">29,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">38,713<span></span>
</td>
<td class="nump">54,004<span></span>
</td>
<td class="nump">54,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">143,370<span></span>
</td>
<td class="nump">68,399<span></span>
</td>
<td class="nump">113,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period - increase (decrease)</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(4,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(62,370)<span></span>
</td>
<td class="num">(82,640)<span></span>
</td>
<td class="num">(108,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">121,137<span></span>
</td>
<td class="nump">38,713<span></span>
</td>
<td class="nump">54,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember', window );">Other Fees, Co-pay Assistance and Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts Notes And Loans Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, beginning balance</a></td>
<td class="nump">19,113<span></span>
</td>
<td class="nump">26,054<span></span>
</td>
<td class="nump">28,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration', window );">Current period</a></td>
<td class="nump">110,183<span></span>
</td>
<td class="nump">73,435<span></span>
</td>
<td class="nump">94,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod', window );">Prior period - increase (decrease)</a></td>
<td class="nump">3,744<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="num">(3,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Payments and customer credits issued</a></td>
<td class="num">(83,245)<span></span>
</td>
<td class="num">(80,408)<span></span>
</td>
<td class="num">(93,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration', window );">Activities and reserve balance, ending balance</a></td>
<td class="nump">$ 49,795<span></span>
</td>
<td class="nump">$ 19,113<span></span>
</td>
<td class="nump">$ 26,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProvisionRelatedToSalesMadeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProvisionRelatedToSalesMadeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProvisionRelatedToSalesMadeInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents provision related to sales made in prior period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProvisionRelatedToSalesMadeInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve for discounts and allowances constitute variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve for sales discounts and allowances constitute variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_RebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=chrs_OtherFeesCoPayAssistanceAndReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622286798320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Commercial paper and corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Commercial paper and corporate notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 104,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">4,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">96,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">7,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Level 3 | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">4,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | U.S. government agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">2,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | U.S. treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">2,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Commercial paper and corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Commercial paper and corporate notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">89,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">88,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Cash equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Prepaid financial instrument in Prepaid manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring Basis | Prepaid financial instrument in Prepaid manufacturing | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets measured at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=chrs_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=chrs_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=chrs_PrepaidExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=chrs_PrepaidExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290451840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Cost, Unrealized Gains or Losses, and Fair Value by Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 104,324<span></span>
</td>
<td class="nump">$ 191,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Loss)</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">104,315<span></span>
</td>
<td class="nump">191,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Cost, Unrealized Gains or Losses, and Fair Value by Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">79,484<span></span>
</td>
<td class="nump">55,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">79,484<span></span>
</td>
<td class="nump">55,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Cost, Unrealized Gains or Losses, and Fair Value by Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">19,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">19,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Cost, Unrealized Gains or Losses, and Fair Value by Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">11,967<span></span>
</td>
<td class="nump">68,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,969<span></span>
</td>
<td class="nump">68,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Commercial paper and corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Cost, Unrealized Gains or Losses, and Fair Value by Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">7,673<span></span>
</td>
<td class="nump">48,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 7,667<span></span>
</td>
<td class="nump">$ 48,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294336464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Adjustment in the CVR liability</a></td>
<td class="num">$ (900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Positions that were in unrealized loss positions | position</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Long lived assets, material impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity', window );">Remaining contractual maturities of available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition', window );">Average maturity of investments upon acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">7 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum remaining period until maturity of the investment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the acquired debt security contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301635488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 12,975<span></span>
</td>
<td class="nump">$ 10,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">82,588<span></span>
</td>
<td class="nump">86,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">34,537<span></span>
</td>
<td class="nump">18,077<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 130,100<span></span>
</td>
<td class="nump">$ 115,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293774368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Balance Sheet Classifications (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 62,605<span></span>
</td>
<td class="nump">$ 38,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">67,495<span></span>
</td>
<td class="nump">76,260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_InventoryCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 130,100<span></span>
</td>
<td class="nump">$ 115,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_InventoryCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_InventoryCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622297007056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 52,595,000<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="nump">$ 5,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaidManufacturingExpenseCurrent', window );">Prepayment made for manufacturing services</a></td>
<td class="nump">23,657,000<span></span>
</td>
<td class="nump">17,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaymentsMadeToCmoForManufacturingServices', window );">Prepayments made to a CMO for manufacturing services for UDENYCA</a></td>
<td class="nump">12,600,000<span></span>
</td>
<td class="nump">13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram', window );">Prepayments made to a CMO For Other Research And Development Pipeline Program</a></td>
<td class="nump">11,100,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Impairment charge within research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,210,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="nump">109,436,000<span></span>
</td>
<td class="nump">199,358,000<span></span>
</td>
<td class="nump">363,105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Expense relating to the discontinuation of CHS-2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LongTermAndShortTermPurchaseCommitmentsAmount', window );">Certain firm purchase commitments</a></td>
<td class="nump">20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ShortTermPurchaseCommitmentAmount', window );">Certain firm purchase commitments, Short-term</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">other liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Certain firm purchase commitments, Long-term</a></td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_YusimryProductMember', window );">YUSIMRY | Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 47,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_UdenycaMember', window );">UDENYCA | Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_Chs2020Member', window );">CHS-2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrCharges', window );">Impairment charge for the write-off of prepaid manufacturing services no longer deemed to have future benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research And Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LongTermAndShortTermPurchaseCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LongTermAndShortTermPurchaseCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaidManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaidManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaymentsMadeToCmoForManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents prepayments made to a CMO for manufacturing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaymentsMadeToCmoForManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents prepayments made to a CMO for other research and development program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ShortTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ShortTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_YusimryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=chrs_YusimryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_UdenycaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=chrs_UdenycaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=chrs_Chs2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=chrs_Chs2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290487744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 25,770<span></span>
</td>
<td class="nump">$ 28,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(20,651)<span></span>
</td>
<td class="num">(20,157)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">5,119<span></span>
</td>
<td class="nump">8,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">13,124<span></span>
</td>
<td class="nump">12,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">3,546<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">5,751<span></span>
</td>
<td class="nump">6,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Finance lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 2,294<span></span>
</td>
<td class="nump">4,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622300275968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense related to property and equipment, net</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Material impairments of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Software implementation costs</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294774224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Goodwill and Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived assets, net of accumulated amortization of $639 and $61, respectively</a></td>
<td class="nump">$ 41,871<span></span>
</td>
<td class="nump">$ 2,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived assets - IPR&amp;D</a></td>
<td class="nump">28,859<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total Goodwill and intangible assets, net</a></td>
<td class="nump">71,673<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears', window );">Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining life of the finite-lived assets</a></td>
<td class="text">11 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestonePayment', window );">Upfront And Milestone Payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in each of five succeeding fiscal years. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontAndMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontAndMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622300156400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent', window );">Accrued commercial and research and development manufacturing</a></td>
<td class="nump">$ 23,470<span></span>
</td>
<td class="nump">$ 21,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedCoDevelopmentCostsAndMilestonePayments', window );">Accrued co-development costs and milestone payments</a></td>
<td class="nump">26,812<span></span>
</td>
<td class="nump">8,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">42,031<span></span>
</td>
<td class="nump">5,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">7,628<span></span>
</td>
<td class="nump">10,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LeaseLiabilitiesOperatingAndFinancing', window );">Lease liabilities, current</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="nump">4,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, current</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued and other current liabilities</a></td>
<td class="nump">$ 105,386<span></span>
</td>
<td class="nump">$ 50,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedCoDevelopmentCostsAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued co-development costs and milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedCoDevelopmentCostsAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued commercial and research and development manufacturing liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LeaseLiabilitiesOperatingAndFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents lease liabilities for both operating and financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LeaseLiabilitiesOperatingAndFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294103520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Other Liabilities, Non-current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, non-current</a></td>
<td class="nump">$ 1,172<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">10,287<span></span>
</td>
<td class="nump">3,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total Other liabilities, non-current</a></td>
<td class="nump">$ 12,561<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289387456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Surface Acquisition (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Surface Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree', window );">Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares</a></td>
<td class="nump">0.1960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price | $ / shares</a></td>
<td class="nump">$ 5.2831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationContingentValueRightPerShare', window );">Contingent value right per share | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod', window );">Contingent value rights payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="nump">$ 64,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares', window );">Business Combination, Number of Shares Issued to Former Employees of Acquiree shares | shares</a></td>
<td class="nump">161,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram', window );">Business Combination, Number of Out Licensed Partnership Program | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of Acquiree since Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Earnings or Loss of Acquiree since Acquisition Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Surface Oncology, Inc. | Surface GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments', window );">Milestone and royalty based CVR payments (as percent)</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Surface Oncology, Inc. | Surface Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments', window );">Milestone and royalty based CVR payments (as percent)</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Surface Oncology, Inc. | Surface's SRF114 proprietary drug product candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments', window );">Upfront payment based CVR payments (as percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Surface Oncology, Inc. | Surface's SRF388 proprietary drug product candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments', window );">Upfront payment based CVR payments (as percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The payment period of contingent value rights under business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of milestone and royalty based payments payable as part of contingent value rights under business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of upfront payments payable as part of contingent value rights under business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationContingentValueRightPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of contingent value rights issuable in consideration for each share under business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationContingentValueRightPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of outlicensed partnership program in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in exchange of each share of acquiree in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued to former employees of acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_SurfaceGlaxosmithklineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_SurfaceGlaxosmithklineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_SurfaceNovartisAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_SurfaceNovartisAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290494128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Surface Acquisition - Consideration paid (Details) - Surface Oncology, Inc.<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Coherus common stock issued | shares</a></td>
<td class="nump">11,971,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders', window );">Equity of combined company owned by Surface equity holders</a></td>
<td class="nump">$ 58,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent CVR liability</a></td>
<td class="nump">5,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees', window );">Equity of combined company owned by Surface former employees (1)</a></td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred, Total</a></td>
<td class="nump">$ 64,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, equity of combined company owned by acquiree equity holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, equity of combined company owned by acquiree former employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293930096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Surface Acquisition - Estimated fair value of the net assets acquired (Details) - Surface Oncology, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets Acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investments in marketable securities</a></td>
<td class="nump">21,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Other prepaids and other assets</a></td>
<td class="nump">5,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">39,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="nump">73,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities Assumed</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="nump">9,221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="nump">64,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Out-licenses</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets Acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">13,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets Acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 26,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294022592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Surface Acquisition - The amount allocated to identifiable intangible assets (Details) - Surface Oncology, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 08, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 39,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Out-license - GSK</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 2,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">Out-license - Novartis Institutes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 11,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">In-process research and development - casdozokitug</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 25,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member', window );">In-process research and development - SRF 114</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithGrkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithGrkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=chrs_OutLicensesWithNovartisInstitutesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=chrs_InProcessResearchAndDevelopmentSrf388Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=chrs_InProcessResearchAndDevelopmentSrf388Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=chrs_InProcessResearchAndDevelopmentSrf114Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=chrs_InProcessResearchAndDevelopmentSrf114Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622299013584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details) - Surface Oncology, Inc. - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Surface Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenues</a></td>
<td class="nump">$ 257,244<span></span>
</td>
<td class="nump">$ 241,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (284,575)<span></span>
</td>
<td class="num">$ (369,442)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622284796960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 04, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>May 02, 2019</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,436<span></span>
</td>
<td class="nump">$ 199,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestonePayment', window );">Upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,400<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember', window );">Vaccinex License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade', window );">Maximum aggregate milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_RegulatoryMilestonesEligibleToPay', window );">Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfGrossProfitsOnSales', window );">Percentage of gross profits shared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG | Licensed Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones', window );">Maximum aggregate milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval', window );">Additional milestone payments related to FDA approval | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember', window );">Bioeq IP AG | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestonePayment', window );">Upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember', window );">Adimab Development and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption', window );">Minimum antibodies to be commercialized under commercialization option | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay', window );">Technical milestone payments obligated to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee', window );">Period for payment of nominal research maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade', window );">Maximum aggregate milestone payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption', window );">Maximum antibodies partially exercised under commercialization option | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption', window );">Percentage of option fee to be paid on partial exercise of commercialization option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementAdditionalPaymentToBeMade', window );">Additional payment to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl', window );">Expiration term from the effective date without providing materials that pass quality control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember', window );">Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PotentialDevelopmentMilestonesEntitled', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SalesMilestonesEntitled', window );">Sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember', window );">GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SalesMilestonesEntitled', window );">Sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive', window );">Additional clinical milestones eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive', window );">Regulatory milestones eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember', window );">GSK Agreement | Surface</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementMilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementOptionExerciseFeePerProgram', window );">License Agreement Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">68,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssued', window );">Unregistered shares | shares</a></td>
<td class="nump">2,491,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 20.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue', window );">Aggregate value</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock', window );">Period before the company can sell, transfer or make any short sale of common stock (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_FairValueForDiscountForLackOfMarketability', window );">Fair value for the discount for lack of marketability (DLOM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Intangible assets, net and accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts', window );">Co-development, regulatory and technology transfer costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts', window );">Co-development, regulatory and technology transfer costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Licensed Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_MaximumAmountPaidCoDevelopmentActivities', window );">Maximum paid amount for co-development activities (per licensed compound)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember', window );">Junshi Biosciences | Toripalimab (LOQTORZI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationCosts', window );">Collaboration Agreement, upfront amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales', window );">Collaboration agreement, royalty on net sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds', window );">Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember', window );">CHS-006 anti-TIGIT antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementOptionExerciseFeePerProgram', window );">License Agreement Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram', window );">Collaboration agreement, royalty on net sales for each exercised option, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram', window );">Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember', window );">CHS-006 anti-TIGIT antibody | Anti-TIGIT Antibody and IL-2 cytokine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram', window );">Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario, Plan | Junshi Biosciences | Toripalimab (LOQTORZI) | Intangible assets, net and accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_UpfrontAndMilestonePayment', window );">Upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments upon achievement of certain development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments upon achievement of with subject to FDA approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents co-development, regulatory and technology transfer costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional clinical milestones eligible to receive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementAdditionalPaymentToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment to be made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementAdditionalPaymentToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration term from the effective date without providing materials that pass quality control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payments to be made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementMilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementMilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementOptionExerciseFeePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of option exercise fee per program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementOptionExerciseFeePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalty on net sales under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of royalty on net sales for each option program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for payment of nominal research maintenance fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory milestones eligible to receive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technical milestone payments obligated to pay</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CollaborationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents costs associated to a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CollaborationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_FairValueForDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value for the discount for lack of marketability (DLOM).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_FairValueForDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_MaximumAmountPaidCoDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum paid amount for co-development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_MaximumAmountPaidCoDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum antibodies partially exercised under commercialization option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum antibodies to be commercialized under commercialization option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfGrossProfitsOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>percentage of profit shared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfGrossProfitsOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of option fee to be paid on partial exercise of commercialization option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PotentialDevelopmentMilestonesEntitled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of potential development milestones entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PotentialDevelopmentMilestonesEntitled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period before the company can sell, transfer or make any short sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_RegulatoryMilestonesEligibleToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory milestones eligible to pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_RegulatoryMilestonesEligibleToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_SalesMilestonesEntitled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales milestones entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_SalesMilestonesEntitled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockPurchaseAgreementSharesAgreedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_UpfrontAndMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_UpfrontAndMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_VaccinexLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_AdimabDevelopmentAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_NovartisAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_GskAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=chrs_SurfaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=chrs_SurfaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_ToripalimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_ToripalimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_Chs006AntiTigitAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290540544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - Summary of Debt Obligations (Details) - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</a></td>
<td class="num">(3,519)<span></span>
</td>
<td class="num">(4,517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Carrying Value</a></td>
<td class="nump">246,481<span></span>
</td>
<td class="nump">245,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">246,481<span></span>
</td>
<td class="nump">245,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</a></td>
<td class="num">(3,112)<span></span>
</td>
<td class="num">(4,425)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Carrying Value</a></td>
<td class="nump">226,888<span></span>
</td>
<td class="nump">225,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">$ 150,155<span></span>
</td>
<td class="nump">$ 157,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622282096688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2027 Term Loan - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 07, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 05, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26161%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodOne', window );">Loan agreement covenants, minimum trailing twelve month net sales for current quarter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodTwo', window );">Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_MandatoryPrepaymentTerm', window );">Mandatory prepayment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtDiscountsAndIssuanceCosts', window );">Debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_LoanAgreementCovenantsNetSalesForPeriodThree', window );">Loan agreement covenants, minimum trailing twelve-month net sales continuing through the quarter ended December 31, 2026</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | Additional facility amount | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentUncommittedAdditionalFacility', window );">Uncommitted additional facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | Through March 31, 2023 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | Starting April 1, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheLoanMember', window );">Tranche A Loan, funded January 5, 2022 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtDiscountsAndIssuanceCosts', window );">Debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheBLoanMember', window );">Tranche B Loan, funded on March 31, 2022 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtDiscountsAndIssuanceCosts', window );">Debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Convertible notes, Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheCLoanMember', window );">Tranche C Loan, not funded between April 1, 2022 and March 17, 2023 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Amount not funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember', window );">Tranche D Loan, funded on September 14, 2022 | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Convertible notes, Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | BioPharma Credit Investments V GP LLC | Scenario, Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan | Lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Total term of the loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TrancheaBAndDLoansMember', window );">Tranches A, B and D | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentRemainingTerm', window );">Remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtDiscountsAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt discounts and issuance costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtDiscountsAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of committed tranches.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to debt instrument remaining term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentUncommittedAdditionalFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of uncommitted additional facility that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentUncommittedAdditionalFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_LoanAgreementCovenantsNetSalesForPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales required under loan agreement for period two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_LoanAgreementCovenantsNetSalesForPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_MandatoryPrepaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mandatory prepayment, term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_MandatoryPrepaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=chrs_ThreeMonthLiborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=chrs_ThreeMonthLiborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TrancheaBAndDLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TrancheaBAndDLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622285553184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2027 Term Loans Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">$ 6,431<span></span>
</td>
<td class="nump">$ 4,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans | BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest</a></td>
<td class="nump">34,289<span></span>
</td>
<td class="nump">20,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">4,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="nump">$ 35,383<span></span>
</td>
<td class="nump">$ 24,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289494416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2027 Term Loan Future Payments (Details) - 2027 Term Loans<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">13.91%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">BioPharma Credit Investments V GP LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024 - interest only</a></td>
<td class="nump">$ 35,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025 - interest only</a></td>
<td class="nump">35,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026 - principal and interest</a></td>
<td class="nump">224,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027 - principal and interest</a></td>
<td class="nump">50,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">345,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less amount representing interest</a></td>
<td class="num">(95,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_TermLoanGross', window );">2027 Term Loans, gross</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</a></td>
<td class="num">(3,519)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Carrying Value</a></td>
<td class="nump">$ 246,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_TermLoanGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_TermLoanGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_BiopharmaCreditInvestmentsVGpLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294987600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_NumberOfEventsInDefault', window );">Number of events in default | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentContractualTerm', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 1.5% Convertible Senior Subordinated Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">$ 230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from offering</a></td>
<td class="nump">$ 222,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes', window );">Initial conversion rate, shares of common stock | shares</a></td>
<td class="nump">51.9224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate', window );">Principal amount of notes converted into shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EquivalentToConversionPricePerCommonShare', window );">Initial conversion price per common share | $ / shares</a></td>
<td class="nump">$ 19.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate description</a></td>
<td class="text">The 2026 Convertible Notes accrue interest at a rate of&#160;1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Apr. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfPremiumOnConvertibleNote', window );">Convertible notes, premium percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Convertible notes, covenant compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of December 31, 2023, the Company was in full compliance with these covenants, and there were no events of default under the 2026 Convertible Notes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Remaining unamortized debt discount and debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 1.5% Convertible Senior Subordinated Notes due 2026 | Scenario, Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes, converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to debt instrument contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible number of shares per thousand of principal amount of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EquivalentToConversionPricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equivalent to conversion price per common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EquivalentToConversionPricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_NumberOfEventsInDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of events in default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_NumberOfEventsInDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfPremiumOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium on convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfPremiumOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount of notes converted into shares of common stock at conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293882320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Capped Call Transactions - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 14.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember', window );">Capped Call Transactions in connection with the 2026 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PaymentForCappedCallTransactions', window );">Payment for capped call transactions</a></td>
<td class="nump">$ 18.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CapPriceOfCapCallTransactions', window );">Initial cap price of capped call transactions.</a></td>
<td class="nump">$ 25.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfCapPriceCappedCallTransactions', window );">Percentage of cap price</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CapPriceOfCapCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cap price of the cap call transactions (per share).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CapPriceOfCapCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PaymentForCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment made for entering into capped call transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PaymentForCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfCapPriceCappedCallTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of premium on cap price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfCapPriceCappedCallTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290524896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">$ 6,431<span></span>
</td>
<td class="nump">$ 4,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
<td class="nump">3,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="nump">$ 4,763<span></span>
</td>
<td class="nump">$ 4,736<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294218992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - 2026 Convertible Notes Future Payments (Details) - Convertible Notes - 1.5% Convertible Senior Subordinated Notes due 2026<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024 - interest only</a></td>
<td class="nump">$ 3,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025 - interest only</a></td>
<td class="nump">3,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026 - principal and interest</a></td>
<td class="nump">231,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">238,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less amount representing interest</a></td>
<td class="num">(8,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ConvertibleNotesPrincipalAmount', window );">2026 Convertible Notes, principal amount</a></td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less unamortized debt discount and debt issuance costs</a></td>
<td class="num">(3,112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net Carrying Value</a></td>
<td class="nump">$ 226,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ConvertibleNotesPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes, principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ConvertibleNotesPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296537200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Convertible Notes due 2022 Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">6,431<span></span>
</td>
<td class="nump">$ 4,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate description</a></td>
<td class="text">The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company, bore interest at a fixed coupon rate of 8.2% per annum payable quarterly and matured on March 31, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | KKR Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | MX II Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | KMGCP Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Lender | KKR Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | 8.2% Convertible Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Outstanding amount payoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageOfPremiumOnConvertibleNote', window );">Convertible notes, premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">10,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
<td class="nump">$ 1,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageOfPremiumOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium on convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageOfPremiumOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chrs_KKRBiosimilarLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chrs_KKRBiosimilarLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chrs_MXIIAssociatesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chrs_MXIIAssociatesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chrs_KMGCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chrs_KMGCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290911984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2025 Term Loan - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 07, 2019</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember', window );">2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Interest rate description</a></td>
<td class="text">Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at 6.75%&#160;per annum plus three&#160;month LIBOR. Interest was payable quarterly in arrears. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember', window );">Lender | 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Total term of the loan</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding amount paid off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebtInstrumentPrepaymentPercentage', window );">Prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount', window );">Percentage required to pay an additional exit fee on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebtInstrumentPrepaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebtInstrumentPrepaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage required to pay an additional exit fee on principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301287616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - 2025 Term Loan Interest Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">$ 6,431<span></span>
</td>
<td class="nump">$ 4,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember', window );">Lender | 2025 Term Loan | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Stated coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">7,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 8,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=chrs_HealthcareRoyaltyPartnersIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295693488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 52,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">19,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total obligations</a></td>
<td class="nump">$ 73,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622286739408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate', window );">Claims related to certain sales of UDENYCA from October 2020 through December 2021</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=chrs_AccruedRebatesFeesAndReservesMember', window );">Accrued rebates, fees and reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrual related to legal Proceedings and Other Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Best estimate of the loss exposure for a reasonably possible liability for product liability damages for which no accrual has been recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=chrs_AccruedRebatesFeesAndReservesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=chrs_AccruedRebatesFeesAndReservesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290589072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>item</div>
</th>
<th class="th">
<div>Oct. 24, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of leases</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease Weighted average discount rate</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease weighted average remaining term</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chrs_SixthAmendmentToLeaseMember', window );">Sixth amendment to lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=chrs_OfficeSpaceRemainingPremisesMember', window );">Remaining Premises | Sixth amendment to lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_CorporateHeadquartersLeaseAgreementMember', window );">Corporate Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space leased</a></td>
<td class="nump">47,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Sep.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of optional lease renewal</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_LaboratoryFacilitiesLeaseAgreementMember', window );">Laboratory Facilities Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space leased</a></td>
<td class="nump">25,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of optional lease renewal</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_NewCamarilloLeaseMember', window );">New Camarillo Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">May  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_VehiclesLeaseMember', window );">Vehicle Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_NumberOfVehiclesLeased', window );">Number of vehicles leased | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_NumberOfVehiclesLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of vehicles leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_NumberOfVehiclesLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_SixthAmendmentToLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_SixthAmendmentToLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=chrs_OfficeSpaceRemainingPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=chrs_OfficeSpaceRemainingPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_CorporateHeadquartersLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_CorporateHeadquartersLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_LaboratoryFacilitiesLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_LaboratoryFacilitiesLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_NewCamarilloLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_NewCamarilloLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_VehiclesLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=chrs_VehiclesLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296724864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases</a></td>
<td class="nump">$ 5,912<span></span>
</td>
<td class="nump">$ 5,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Assets Noncurrent<span></span>
</td>
<td class="text">Other Assets Noncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease</a></td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">$ 2,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
<td class="text">Property, Plant and Equipment, Net<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OperatingAndFinanceLeaseRightOfUseAssets', window );">Total leased assets</a></td>
<td class="nump">$ 6,934<span></span>
</td>
<td class="nump">$ 8,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OperatingLeaseLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 1,424<span></span>
</td>
<td class="nump">$ 3,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Liabilities Current<span></span>
</td>
<td class="text">Accrued Liabilities Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability noncurrent</a></td>
<td class="nump">$ 4,977<span></span>
</td>
<td class="nump">$ 3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Operating and Finance Lease, Liability, Noncurrent<span></span>
</td>
<td class="text">Operating and Finance Lease, Liability, Noncurrent<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 6,401<span></span>
</td>
<td class="nump">$ 6,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">$ 721<span></span>
</td>
<td class="nump">$ 1,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Liabilities Current<span></span>
</td>
<td class="text">Accrued Liabilities Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 1,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities Noncurrent<span></span>
</td>
<td class="text">Other Liabilities Noncurrent<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_OperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_OperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301214160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Other information related to lease term and discount rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease weighted average remaining term</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease Weighted average discount rate</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease Weighted average discount rate</a></td>
<td class="nump">8.70%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301268176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">3,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 4,199<span></span>
</td>
<td class="nump">$ 4,548<span></span>
</td>
<td class="nump">$ 3,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of finance lease cost incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294111264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental cash flow information related to leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 3,560<span></span>
</td>
<td class="nump">$ 3,401<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Operating cash flows from finance leases</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Financing cash flows from finance leases</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 2,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,694<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296971456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 2,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">7,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(1,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">6,401<span></span>
</td>
<td class="nump">$ 6,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 2,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622284383632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 09, 2023</div></th>
<th class="th"><div>Oct. 04, 2023</div></th>
<th class="th"><div>Sep. 11, 2023</div></th>
<th class="th"><div>May 18, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Nov. 08, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=chrs_ChiefMarketingOfficerMember', window );">CMO | Optional Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="nump">2,225,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock', window );">Number of trading days considered for price per share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 3.675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,529,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember', window );">Public Offering | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SharesOfferingAggregateAmount', window );">Shares Offering, Aggregate Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember', window );">At The Market Offering.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,559,761<span></span>
</td>
<td class="nump">916,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,093<span></span>
</td>
<td class="nump">$ 6,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SharesOfferingAggregateAmountDecrease', window );">Shares Offering, Aggregate Amount, Decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_IncreaseInAmountOfSharesToBeIssuedAndSold', window );">Increase in Amount of Shares To be Issued and Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Common stock, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,856<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,339<span></span>
</td>
<td class="nump">6,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Less commissions and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after commissions and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,856<span></span>
</td>
<td class="nump">$ 6,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering', window );">Common stock remaining available for sales under the ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember', window );">At The Market Offering. | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_WeightedAveragePricePerShare', window );">Weighted-average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="nump">$ 7.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember', window );">At The Market Offering. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SharesOfferingAggregateAmount', window );">Shares Offering, Aggregate Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Option to Purchase Additional Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_AtMarketOfferingLineItems', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_SharesOfferingUnderwritersOptionTerm', window );">Term of share offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_AtMarketOfferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent at the market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_AtMarketOfferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the common stock remaining available for sale under the atm offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_IncreaseInAmountOfSharesToBeIssuedAndSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in shares to be issued and sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_IncreaseInAmountOfSharesToBeIssuedAndSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days considered for price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, before stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_SharesOfferingAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of shares to be offered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_SharesOfferingAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_SharesOfferingAggregateAmountDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in aggregate amount of shares to be offered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_SharesOfferingAggregateAmountDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_SharesOfferingUnderwritersOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for exercise of option to purchase additional shares by underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_SharesOfferingUnderwritersOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_WeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_WeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=chrs_ChiefMarketingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=chrs_ChiefMarketingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chrs_OptionalStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chrs_OptionalStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chrs_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chrs_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289420752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">120 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance', window );">Percentage of shares available for issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">881,231<span></span>
</td>
<td class="nump">881,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_TwoThousandTenPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EmploymentCommencementIncentivePlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,773,921<span></span>
</td>
<td class="nump">1,773,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of increase in number of common stock available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_TwoThousandTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_TwoThousandTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_EmploymentCommencementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_EmploymentCommencementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622286686480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses related to stock options</a></td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301199184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details) - 2016 plan and 2014 plan<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning balance | shares</a></td>
<td class="nump">21,691,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted - at fair value | shares</a></td>
<td class="nump">5,947,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised | shares</a></td>
<td class="num">(430,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited/Canceled | shares</a></td>
<td class="num">(3,549,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending balance | shares</a></td>
<td class="nump">23,659,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable | shares</a></td>
<td class="nump">16,279,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted - at fair value | $ / shares</a></td>
<td class="nump">6.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">1.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Canceled | $ / shares</a></td>
<td class="nump">14.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending balance | $ / shares</a></td>
<td class="nump">13.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 15.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options outstanding, Weighted-Average Remaining Contractual Terms, Exercisable</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 2,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options outstanding, Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 1,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296834992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details) - 2016 plan and 2014 plan - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">23,659,240<span></span>
</td>
<td class="nump">21,691,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 13.31<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">16,279,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 15.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember', window );">1.67 - 5.44</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, Lower</a></td>
<td class="nump">1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, Upper</a></td>
<td class="nump">$ 5.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">4,288,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">1,356,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember', window );">5.86 - 10.05</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, Lower</a></td>
<td class="nump">5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, Upper</a></td>
<td class="nump">$ 10.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">4,493,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">2,436,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 9.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember', window );">10.37 - 13.63</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, Lower</a></td>
<td class="nump">10.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, Upper</a></td>
<td class="nump">$ 13.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">4,143,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 12.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">3,317,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 12.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember', window );">14.03 - 17.17</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, Lower</a></td>
<td class="nump">14.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, Upper</a></td>
<td class="nump">$ 17.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">4,436,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 15.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">3,304,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 15.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember', window );">17.30 - 19.40</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, Lower</a></td>
<td class="nump">17.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, Upper</a></td>
<td class="nump">$ 19.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">3,827,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 17.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">3,403,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 17.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember', window );">19.85 - 46.38</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, Lower</a></td>
<td class="nump">19.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, Upper</a></td>
<td class="nump">$ 46.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Options</a></td>
<td class="nump">2,469,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted-Average Remaining Contractual Terms</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise Price</a></td>
<td class="nump">$ 26.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">2,461,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 26.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange1.67To5.44Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange1.67To5.44Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange5.86To10.05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange5.86To10.05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange10.37To13.63Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange10.37To13.63Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange14.03To17.17Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange14.03To17.17Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange17.30To19.40Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange17.30To19.40Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange19.85To46.38Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=chrs_ExercisePriceRange19.85To46.38Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622300237568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details) - 2016 plan and 2014 plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 9,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant date fair value of options vested</a></td>
<td class="nump">$ 30,467<span></span>
</td>
<td class="nump">$ 34,916<span></span>
</td>
<td class="nump">$ 40,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_EquityPlan2016PlanAnd2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296998144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expenses related to unvested RSUs</a></td>
<td class="nump">$ 10.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301258464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details) - Restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, beginning balances</a></td>
<td class="nump">2,333,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted</a></td>
<td class="nump">1,274,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs vested</a></td>
<td class="num">(1,280,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs canceled</a></td>
<td class="num">(600,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, ending balance</a></td>
<td class="nump">1,726,729<span></span>
</td>
<td class="nump">2,333,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, beginning balances</a></td>
<td class="nump">$ 14.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, RSUs granted</a></td>
<td class="nump">8.93<span></span>
</td>
<td class="nump">$ 13.34<span></span>
</td>
<td class="nump">$ 16.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, RSUs Vested</a></td>
<td class="nump">14.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, RSUs canceled</a></td>
<td class="nump">11.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, ending balances</a></td>
<td class="nump">$ 11.93<span></span>
</td>
<td class="nump">$ 14.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622300913168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details) - Restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total grant date fair value of RSUs vested</a></td>
<td class="nump">$ 18,381<span></span>
</td>
<td class="nump">$ 13,598<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue', window );">Total grant date fair value of RSUs granted</a></td>
<td class="nump">$ 11,386<span></span>
</td>
<td class="nump">$ 22,502<span></span>
</td>
<td class="nump">$ 27,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, RSUs granted</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="nump">$ 13.34<span></span>
</td>
<td class="nump">$ 16.86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options grants in period estimated grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294159264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan (ESPP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,541,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of purchase common stock of lesser of fair market value of common stock on first or last day of offering period by eligible employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne', window );">Employee stock purchase plan offering period one</a></td>
<td class="text">--05-16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo', window );">Employee stock purchase plan offering period two</a></td>
<td class="text">--11-16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan (ESPP) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance', window );">Percentage of shares reserve for issuance</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation offering period one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation offering period two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of increase in number of common stock outstanding reserve for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296510896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 43,110<span></span>
</td>
<td class="nump">$ 50,737<span></span>
</td>
<td class="nump">$ 51,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation expense capitalized into inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,596<span></span>
</td>
<td class="nump">18,999<span></span>
</td>
<td class="nump">18,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,882<span></span>
</td>
<td class="nump">$ 31,002<span></span>
</td>
<td class="nump">$ 31,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301181824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Additional Information (Details) - Employee Severance [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Stock-based compensation includes restructuring charges</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ShareBasedPaymentArrangementForfeitureCredit', window );">Forfeiture credit</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Stock-based compensation includes restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ShareBasedPaymentArrangementForfeitureCredit', window );">Forfeiture credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ShareBasedPaymentArrangementForfeitureCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of share based compensation forfeiture credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ShareBasedPaymentArrangementForfeitureCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622286581824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan (ESPP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">5.35%<span></span>
</td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
<td class="nump">0.89%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301708464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details) - 401(k) Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of maximum contribution of annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">First amount of each participant's contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Compensation expense related to match plan</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=chrs_Plan401KMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of maximum contribution of annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer matching contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=chrs_Plan401KMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=chrs_Plan401KMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296980064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (238,272)<span></span>
</td>
<td class="num">$ (291,746)<span></span>
</td>
<td class="num">$ (287,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (238,272)<span></span>
</td>
<td class="num">$ (291,754)<span></span>
</td>
<td class="num">$ (287,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290924320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Subtotal</a></td>
<td class="num">(380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="num">$ (380)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301413536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent of pre-tax income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">United States federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch', window );">Research and development credit</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation costs</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(17.70%)<span></span>
</td>
<td class="num">(22.10%)<span></span>
</td>
<td class="num">(25.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax (expense) and credits research.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622301092144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 170,402<span></span>
</td>
<td class="nump">$ 131,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">65,225<span></span>
</td>
<td class="nump">63,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">37,211<span></span>
</td>
<td class="nump">51,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">30,370<span></span>
</td>
<td class="nump">32,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances', window );">Sales related accruals</a></td>
<td class="nump">38,474<span></span>
</td>
<td class="nump">23,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accruals</a></td>
<td class="nump">42,480<span></span>
</td>
<td class="nump">19,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">46,062<span></span>
</td>
<td class="nump">17,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">430,224<span></span>
</td>
<td class="nump">340,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(1,538)<span></span>
</td>
<td class="num">(1,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-process research and development</a></td>
<td class="num">(6,403)<span></span>
</td>
<td class="num">(603)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(7,941)<span></span>
</td>
<td class="num">(2,506)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DeferredTaxAssetLiabilityNet', window );">Total net deferred tax asset</a></td>
<td class="nump">422,283<span></span>
</td>
<td class="nump">337,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(423,385)<span></span>
</td>
<td class="num">$ (337,773)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (1,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DeferredTaxAssetLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets before valuation allowance net of deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DeferredTaxAssetLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622296833984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 85,600<span></span>
</td>
<td class="nump">$ 64,400<span></span>
</td>
<td class="nump">$ 72,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">17,417<span></span>
</td>
<td class="nump">16,838<span></span>
</td>
<td class="nump">15,495<span></span>
</td>
<td class="nump">$ 13,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, accrued interest and penalties accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 774,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Various states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Federal research and development | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Federal research and development | Various states</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 26,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293841600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 16,838<span></span>
</td>
<td class="nump">$ 15,495<span></span>
</td>
<td class="nump">$ 13,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">865<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 17,417<span></span>
</td>
<td class="nump">$ 16,838<span></span>
</td>
<td class="nump">$ 15,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622295034112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">38,291,761<span></span>
</td>
<td class="nump">37,635,124<span></span>
</td>
<td class="nump">38,122,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember', window );">Stock options, including shares subject to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">24,083,222<span></span>
</td>
<td class="nump">22,214,875<span></span>
</td>
<td class="nump">19,895,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">2,266,387<span></span>
</td>
<td class="nump">2,399,465<span></span>
</td>
<td class="nump">1,811,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member', window );">8.2% Convertible Notes due 2022 | Shares issuable upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,078,632<span></span>
</td>
<td class="nump">4,473,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member', window );">1.5% Convertible Senior Subordinated Notes due 2026 | Shares issuable upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities excluded from computation of EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the calculation of diluted net (loss) income per share</a></td>
<td class="nump">11,942,152<span></span>
</td>
<td class="nump">11,942,152<span></span>
</td>
<td class="nump">11,942,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_EmployeesAndNonemployeesStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorNotes8.2PercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chrs_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290920896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Details) - Employee Severance<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 10, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Employees impacted | employee</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Stock-based compensation includes restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ShareBasedPaymentArrangementForfeitureCredit', window );">Forfeiture credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Stock-based compensation includes restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_ShareBasedPaymentArrangementForfeitureCredit', window );">Forfeiture credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_ShareBasedPaymentArrangementForfeitureCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of share based compensation forfeiture credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_ShareBasedPaymentArrangementForfeitureCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622289392768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,015<span></span>
</td>
<td class="nump">$ 198,481<span></span>
</td>
<td class="nump">$ 169,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 43,110<span></span>
</td>
<td class="nump">$ 50,737<span></span>
</td>
<td class="nump">51,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chrs_ConsultingAgreementWithLanfearAdvisorsMember', window );">Consulting Agreement With Lanfear Advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 17.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Consulting expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chrs_ConsultingAgreementWithLanfearAdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chrs_ConsultingAgreementWithLanfearAdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622294771024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember', window );">2027 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_DebInstrumentPartialRepaymentPrincipal', window );">Partial prepayment of principal</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal Amount</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_EarlyRedemptionFee', window );">Prepayment fees for partial debt repayment</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=chrs_CoherusOphthalmologyLlcMember', window );">Coherus Ophthalmology LLC | CIMERLI Disposition Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets', window );">Consideration transferred for CIMERLI product inventory and prepaid manufacturing assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred for inventory and prepaid manufacturing assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_DebInstrumentPartialRepaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of partial repayment of principal of the loans subject to terms and conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_DebInstrumentPartialRepaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chrs_EarlyRedemptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment fees for paying off debt early.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chrs_EarlyRedemptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chrs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=chrs_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=chrs_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=chrs_CoherusOphthalmologyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=chrs_CoherusOphthalmologyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliDivestitureTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=chrs_CimerliDivestitureTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622293799552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (237,892)<span></span>
</td>
<td class="num">$ (291,754)<span></span>
</td>
<td class="num">$ (287,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139622290917744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>143
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MMSL6)TQH /R_X5R='O0 S7GX_#]02P,$%     @ IXEO6&*9*Z4D P  U@H
M !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM5N]OVC 0_5>LK)HZJ30D
MX5<91"IDTR:M6U76[;-)#N+5L9EMH-U?OW,"&;"05A5?2.S<>_9[-G<W6$OU
MH%, 0QXS+O3028U9]%U7QRED5%_*!0C\,I,JHP:':N[JA0*:Y*",NWZSV7$S
MRH03#O*Y6Q4.Y-)P)N!6$;W,,JJ>1L#E>NAXSG;BCLU38R?<<+"@<YB N5_<
M*ARY)4O",A":24$4S(;.M=>/>C8^#_C!8*UWWHE5,I7RP0X^)T.G:3<$'&)C
M&2@^5C &SBT1;N/WAM,IE[3 W?<M^\=<.VJ94@UCR7^RQ*1#I^>0!&9TR<V=
M7'^"C9ZVY8LEU_DO61>Q75PQ7FHCLPT8QQD3Q9,^;GS8 7B=(P!_ _ / :TC
M@& #"%X*:&T K=R90DKN0T0-#0=*KHFRT<AF7W(S<S3*9\(>^\0H_,H09\*Q
M%%IREE #"9D8?."9&DWDC(QEAC<IM4>\ O)%:DT:Y'X2D?.S=^2,,$&^IW*I
MJ4CTP#6X%\OHQIMU1\6Z_I%U/9_<2&%233Z(!))] A=%E$K\K9*17\L807Q)
M N^"^$T_J-C0^.5POP(>O1SNU:@)RG,)<K[@%.=297]!WZJFM\FDKQ<TAJ&#
M7!K4"ISP[1NOTWQ?9=TIR:(3D>W9VBIM;=6QAU\QD?(CCA7(=HZTV7(5-OR@
MV[O"V[#:-:,J[LKKMEO[<5%57*_K-9MEW)Z$=BFA77LSOID4%(GW+@$3. 9R
M;J6]ZU>):Y_R.IR2+#H1V9Z7G=++3NUUN!=8*CG[@_^Q.99(8@O1BC).IQP:
M6%,;FG(@&N*E8H:!OB "+Q#^!PU]K'*Y6*VS<^2'EZ<BXB DJMWR*PWIEH9T
M:PW!6HJ54F#E40I$_$2,HD)S6M3HY!<6I#P//6=$]S^9#>_ B>=#HMJ]OM*)
M7NE$K]:)_2Q[+&?TCN2,0[%5<9@S@N! <55<5<YP=RI^!FJ>=TX:L\)2F*)D
MEK-E<W:=]R0'\R-LVHH>ZQ]-T?'=4#5G0A,.,Z1L7G9Q5ZKHHHJ!D8N\KYA*
M@UU*_IIBXPG*!N#WF91F.[ +E*UL^!=02P,$%     @ IXEO6-83\ "I$
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M;8A7*ZBC RLHNQ64Q@J*<6 %=;>"VEA!.S2"MEM!:ZP@JP=6T'<KZ(T5=/G
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M+S9 ;#\VB%*8&$= #2&V9J9*7T<T1PP&#(!D6@&=.N I/Z#)Z:?!^4S;^ .
M);E"2#VLC:*78-I%(@73B8&I\@UJMVX+.!+^SZ:W(/MMN5?SI!07M'$!K#'$
MWB,_ &68!D!^-'6Q'03,;)K0U(DSXZP3PE@<XJIAP@!?H#\&WIX)&FD8B]1@
MX%ER9B$P5*.'U6;)!FBP'^O!L;?$B&###4@ZU-3Y6HG=(O-%CKS5@F&/P']
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M%4;Y;MA<XW@4!_6H1S"ST&*:TR%U]5P''VLX0#4Q["MSB^-'R' #!I2BI*"
MB$[T03$OOA>3]:?! 90=9!%6]@O^[8M'<OM=66%6@!M+'KW_%L]7; @$;:E.
M :_+)>9[LIZ@$Q@%I7X"@5/ZZW!_5O\1=O$F^D E6!)NC\)HN6_[F_WKD[[U
M-@D^I.&111R%91="Y++EP*I5DI\%?R6)=RV7 6@1^Y(9.DM%Y*H;'"!0J=M
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MK5XTTW4'MCG/_4;YGA2(WFS2LRV\112Y5LM G9F80^8\E\M@3ET>Z'-!_B]
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M^<\-OF7!$ &>%UJ[;D$*^M?Q\A]02P,$%     @ IXEO6%WJ,LV+!@  6Q,
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M;]$G5TYIJ[M<&ZTD(NH:&IW"XY(\LJKAJ-$U FQ?N6IM(U4H SB\.,U@ IB
M,*V9G*[J^GF =D*R[3MUZPAD;U;0FJB[@,#U@[ *ZA*&JC3$T:X$.'UR!S#E
M5(PK#HYCC[3D]J-2Y0(V=MN(C0Q;R?RW20Z(0%A^4D&HRBW( )1Y;;85.U@[
MRN)1&_CL6:UY79*$-!^&WD1$XRR'0,)U9G=?<D+N[C^]9O7\[':7?G*:IZ,]
MK)1%P28%Z^E1$F\]MUQSMS\Y&WC#D&;#>*OM1_$&_]5WNGK+IYU*>%YID*$#
MA7:@K>AW:65?4+&@.9QD7>7!(ER-BX+S$EMK(DP!:):<:8"(01P#XCDPP9-
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M7R"]'637I)$#12Q42(/R7NJ2$B9Q#@Z8"6C<:BXN]HJIHUI:+94E+9.9^\)
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MX,+W88<O!/J4LM^./40 <B>Y41]7'UC"TD:82(;W6.-*N3?GU!_7$E5T)B6
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M-@!^#E(F1G/R(RV [0YE,N;GR@I! !O(!2"!X?>!FB7Q0.R4V87 36^H-G"
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M^K/:TN*T!&?M'KI>KQ]'T;/9N^?BSVN&V/=Z1O'FWKGMGL$$0>0-QL 9O,8
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MZNK^2'H12WS=L%9CC\D&[\K&K-9F8IGQM?'ZO\1F7U03RL(HZ/3QE^=W5X0
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MMN@Z[-*R2I&#SRDZ^:&*+L2?!*5W,YJ@#? 24$O4&4%HM5/"&<;S??2[V4?
MQL>W?NKH^'5Z+.RDLB(5=34G,;4GVD\PM9]/B-@=:'9YO%] Z'  7RNT;>W5
M)Y57!;S>U 6!-04ASI4O\)HGNXK^,K#R0\4=-PG_RG[-U0IEW'+]!9,8!ZWF
M3"G9ZP81#X%-X<+.1T_H0Y.;(9I!N+%8?90.V+%/!:/.!YP"]-I]IJ(0Q@G4
M?\MIG[9?PJ[]!Z#=<O\9#?FN!9:6'%+<.L;N-&#:?YKR-U:5[G/02EFK"G>9
M 9ZU-"W ]ZE2MKDA >WWP:N_ 5!+ P04    " "GB6]8V$D<[U$0  ""-P
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MFO4)Q:\'5L*B'NIGU)7\SGZ#UKWN-MQZA_I^3Q?$F->AA.+!'&T_81I+;RY
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M6=>TZ= B929NII'&+LC,XTD7PPN62\KVP9I.9*'+@@X&ZQT'LZ&.3@" XSP
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;-5:6V_;.!;^*X0G,W
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MCW !O%\*H;L!"NC_&^+F/U!+ P04    " "GB6]8?2JUGAT#   5!P  &0
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M9 >D1"9Q2W^A\-DTA:E8?5C8J2H+%W\0#-R.\H >UF"#S'!>SGVU8Y]K:]"
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MMSQP2=Y:P#*F+@B9OU^&>G<O8"KN*;G<1>6)A2B/HNX1Y/>RJS+YVIC"1V>
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MQP70/KF-PR0,AM#75,2U,)'=^:<)]:S@Z)94*$FV :EP5=]#3WIX%*+P./5
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M6Y7L8N3M)M@ !X ECG!:H,F7W36= 94#;"L:)9/8J-RA. L4:;=?PC,@G(#
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M%Z]5H=S:U&E,9AS'IZ>ZSA0&TR](L=WT2IJ1R-GH<S5N&S2/&'<)R1NJ^+5
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M//(/ V<<AQ;S!JPP3'B]T',\UZU39Z/=E5F'<-R!\&,S;<-TED&>&LI$TWO
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MH49?APD?4^,EA7:NZ3!A:G>_JP'>#.K&,ZBC$HH\ H4)^BPR/5'H4S9BHV6
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MT1&39@ \OQ&@6K.&6:#ZU#KX!U!+ P04    " "GB6]8.?JUQ6P"  "4!0
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MOVUP;()V 7B^4LIN#5=@&,3%'U!+ P04    " "GB6]809]U![L%  #0%P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S%&-ENVSCP5PCW0 HHMD3=
M:6(@2;?8 BT:)-TM]I&6:%NH)*HDE6._?H>4+=&6K;JMNWT1->1P[AD.>?[
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MERO.H/Y6!'!_(435#I2 [JWNQ=]02P,$%     @ IXEO6!)&) [H!0  9Q0
M !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULU5AM;]LV$/XKA-=V,J#8
M$O7J-#'0).T68-V"I-VPC[1$VT(ETB.IN.FOWY&2)=F1E;18A^V+95*\N^?>
M3SS;<O%)KBE5Z'.1,WD^6BNU.9U.9;*F!9$3OJ$,WBRY*(B"I5A-Y490DAJB
M(I]BQPFG!<G8:'YF]F[$_(R7*L\8O1%(ED5!Q,,%S?GV?.2.=ANWV6JM],9T
M?K8A*WI'U<?-C8#5M.&29@5E,N,,";H\'[UQ3R]B?=X<^#VC6]GYC[0F"\X_
MZ<5U>CYR-"":TT1I#@0>]_22YKEF!##^JGF.&I&:L/M_Q_V=T1UT61!)+WG^
M1Y:J]?DH'J&4+DF9JUN^_9G6^@2:7\)S:7[1MC[KC%!22L6+FA@0%!FKGN1S
M;8?G$.": !O<E2"#\HHH,C\3?(N$/@W<]!^CJJ$&<!G33KE3 MYF0*?FURSA
M!44?R&<JD?6!+'(JQV=3!:SU@6E2L[FHV. C;%R,WG.FUA*]92E-]QE, 5,#
M#.^ 7>!!CE<TF2#/M1%VL#? SVL4]0P_[QF*]NE74?O]U#HU3N6&)/1\!+$O
MJ;BGH_FK']S0>3V S6^P^4/<YY>\V'!&F9*(+U'.I40+"@E'45:A5L=0#_-]
M]4.,'>\U^M[//RD1E>,1N(T6"RJ,ZZR,(;7FI20LE6/C2?V#]8^+KD SJ;*D
M8?,"6=B+;1SA\=[>S+4C/]S?BR/;">(Q@M2$Q&-[D%S<0K/BEL[R@?$'KDC^
M+)&!_TBDZSCC 7\'C;^#0;]<-UY%&\'O,U/AK 5E=)FIWNP;YO??]O-E*03$
M]NE1MN]H2L6>4PZ].+1SIXBB1_U_;/U4W!Q;WY4+=1!!7P/V*0M?T24%:Z5?
M8RS+BYWQ_\-4SX?ZE*&&4^A;1 [D==CD=3B8A[<TX2S)\HR8B0-JN5I3),'J
MI>+B 7UDF8+<,6Z0:%E[4FBG*&[.ZDY V,./$M'EDIJ)Q>BHS_35A6$\_W8=
MV+T_*  W5"10 +0]H'F>:'VJOM9&>;]E6LNU?; R%W8G#GIY\*C"V_1*&S%J
M!.Y8U9&!+'<"I=Z=1 A/PC:IZA WO-,,3 \5*P$DW6@Y?&I"4*T@NG,CP%_(
M1SE@.1-WC)P);M[<PO1 1+)&4"MA?+R'L7A3: 8)I#T ="8S@!?OP;M3//ET
MHH?/%($=8""7580E7*I6J.5-@DZWPQ.OLS)Z[U:_0:P)$!4=5>QR3=A*SQ_H
MGN1E)8WD,,(3L$N':S2)QB *:S4M''2%O&TB^-![VAXO&Y&=?P,Y&#4Y&'W%
M++6?4SHFTKK"&C1$2JIZ!ZMA(?]T0CVOF_ZJ0WH#X:PRMJK&Q(0(\0"3XI:(
MM V$%\B-'-MW<'<'6/O Z8GX:YF$@8UQT"X]VPU]0 HIG-0%3K,@!1<J^U)M
M[ Y[D8U=MUD&KAU'T?$P;L@<VXN<=HGM('31'8%O$O@ S(DN$21)1$GR%B>,
M;W[DM[7'LV/ 647XH\,^MOVXE>#.[,B-T"799-"HLB_ 7QRSSZ'/_-!V0OQH
MVXWL,/+03T*[IR?86GK0%N,6N.?#.IHA\UU\PI<GI:0532?=[,#K#K2N/7,@
MR:_9"31!J%?R:?A6"('1+0RA7O7 A2ZV@%:F,MJI,)$]\]UNC;$#)]P-U?WI
MU;$]MG'LM0I#E$1@JE\T[L$J W%K>W&WMM6T8Y,3?5:V.O#WQ@$7AGC<,Q ,
ME)ZX*3WQ-[3_MOR4#%*'KYB),XVU;DJ]!6A8U/?J[,_M],,3_P7)C0.) A57
M&6.Z7H$Y'C2W3DD*[=B+NQN![<^"[H9G8]]#;U*H3&!2B:KB <8U@Q^7]?:N
M., 4E51?&_NRXK#EZNI0:LN%[0"$5H %<52:"R-0"PKK@2 SPF2PK=EW\@+'
MX<%W9B/ ];OVH)"6/9:(;-^-GC9-7Y!..Y<_!14K<\4%G8&73%7W0,UN<XOV
MIKH\:H]75W#OB0!O2933)9#"> "?G:*ZUJH6BF_,5=*"*\4+\W=-"4Q8^@"\
M7W*N=@LMH+E;G/\-4$L#!!0    ( *>);U@9#G7B/@,  '$'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;*65;6_;-A#'O\I!!8H-4".)DBTYL0TT
M28<.6%LCSC;L)2V=;"Z4J)%4G'W['2E92X#4"[ WXM/=G[\['<GE4>D'<T"T
M\-3(UJR"@[7=9129\H --Q>JPY96:J4;;FFH]Y'I-/+*.S4R8G$\CQHNVF"]
M]',;O5ZJWDK1XD:#Z9N&Z[^O4:KC*DB"T\2=V!^LFXC6RX[O<8OVUVZC:11-
M*I5HL#5"M:"Q7@4?D\OKS-E[@]\$'LVS/KA(=DH]N,'/U2J('1!*+*U3X-0\
MX@U*Z80(XZ]1,YBV=([/^R?UGWSL%,N.&[Q1\G=1V<,J* *HL.:]M'?J^!G'
M>&9.KU32^"\<1]LX@+(W5C6C,Q$THAU:_C3FX2T.;'1@GGO8R%/><LO72ZV.
MH)TUJ;F.#]5[$YQHW4_96DVK@OSL^BO]]U^4,;!!#=L#UP@_W/.=1//C,K*T
M@3.+RE'L>A!CWQ%+&'Q1K3T8^-166+T4B(ALPF,GO&MV5O$6RPM(DQ!8S-(S
M>ND4;NKUTC>'^UJ4@T;VNH8[)I>FXR6N CH'!O4C!NOW[Y)Y?'6&,)L(LW/J
MZRT=NZJ7"*J&;[TUEK>5:/=P*V3O"A@VRF)K!9<#/^7ZJ90]I1MJK1JXX;+L
M)?<E3Q+>C=9<X/(_ S^/=G] J)6D<^R U#.XZ@3737!F@#LB512^(+0D4[ZD
MK$;*]D39$:57@*I'L,HY"0V<M#],FV%=T]F^A/?O"A:G5_^[_0.Y'BH7J.ZP
MV1&$J[W3NJM!]V'ND\#6JO(!5.>","&(U@7ILC&&;OK=G\3GZ#]M-QM@61@7
M:<B</PM9DH5%/H-D$1:+61@O<KA#8[4H72*,U^Y;80V0[7P>ID5.O72Q"+,Y
M>85%DH3S.#\5@3"F=\<6^HY26JKV$;49L^N1;_R4%<[F*_TEX\-*V!5IQ7D1
MSE,&69CE*5$E;U2=?T?5)8OP%AD+DQE[X]2]LE0V:1&R11+F\P32G*!F8<(R
M-YM0SG*6GSQ?.VG1LVNP0;WWE[TA[+ZUPXTXS4[OR<?A&OW7?'B,OG"]%ZT!
MB36YQA?Y+  ]7/##P*K.7ZH[9>F*]MT#O8FHG0&MUXJR,0[<!M,KN_X'4$L#
M!!0    ( *>);UA-?(/-A0,  !4+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;*V646_;-A#'OPJA%4,+=)8LQW:2V@9B.T4#)*L1K]O#T =:.DE$
M)5(A*;LM^N%W)&7-3F4-&?PBB13OS_L=C^1-=D)^41F )E^+G*NIEVE=7ON^
MBC(HJ.J)$CC^280LJ,:F3'U52J"Q-2IR/PR"D5]0QKW9Q/:MY&PB*ITS#BM)
M5%445'Z;0RYV4Z_O[3L>69IIT^'/)B5-80WZ4[F2V/(;E9@5P!43G$A(IMY-
M_WIQ9<;; 7\RV*F#;V)(-D)\,8V[>.H%QB'((=)&@>)K"PO(<R.$;CS5FEXS
MI3$\_-ZKO[?LR+*A"A8B_XO%.IMZEQZ)(:%5KA_%[@/4/$.C%XE<V2?9U6,#
MCT25TJ*HC=&#@G'WIE_K.!P8A.$)@[ V")\;C$\8#&J#@05UGEFL)=5T-I%B
M1Z09C6KFP\;&6B,-XV85UUKB7X9V>O91II2S[]3%E,=D[9:3B(2L6<I9PB+*
M-;F)(E%QS7A*5B)G$0-%?B-'UJ^7H"G+U1ORBC!.'EB>8[>:^!K]-+/Y4>W3
MPOD4GO"I'Y('P76FR"V/(3X6\!&PH0SWE/.P4_&!RAX)^F])&(07Y--Z25Z_
M>M/F6+?,$J(>&3B9 2FEB*M($Z:AZ/!QT*S$P(H/3HC/*X4]2F&HGRJFF(WI
MW_?81^YP!O6YQ=^YD[QHES0GP+4J:013#[>X KD%;_;K+_U1\*X-_DQB1_07
M#?U%E_IL50>S9"68?V\)KXH-2).'^T!C(L8LIAI3[\>^LRTHG3.]-"A.;&3%
MS)&XG0TF_K:%=-B0#CM)?V^X))1":KK)P>X\/)DEM3M,08H'I3:8/R>78^R<
MXZ6,PY\8^^V,HX9QU,FX$!G(2I&/9:8SFA<B%^DW<G^_0*+%W</MX_T=63)5
MBCK-_Y"4*^H.]A]X!&T4/%48 7*[Q6<;?^?\+^4_D]A1J,9-J,;GW_;C<]*?
M2>R(_K*AO^Q,E(8^$L6&<7>11'AKL-AN!FQIDQL)2/G\)G"A</K#P]P=!TWV
M.L).'_XGX55#>/4?6^$$#,$2K-D,S5W"3<(+O'_-B8#NE)3%>-_S*L'M44ES
M.E"E0+==JW/GR=51+'J7SX+1Z>Y+@^$?5!X%R-069&8UL59P14C3V]1\-[;4
M\?\=[@I&O*-3QA7)(4'3H#?&-96N"',-+4I;QVR$QJK(?F98MX(T _!_(H3>
M-\P$324\^P=02P,$%     @ IXEO6/5B7FW1 @  ,0D  !D   !X;"]W;W)K
M<VAE971S+W-H965T-# N>&ULK59=;]HP%/TK5E9-K=0UWQ0ZB-0"T_8P#95V
M>W:3"['JV-0VT.W7SW;2#$C*\L!+8B?GG-QS3V)GN.7B6>8 "KT6E,F1DRNU
MNG%=F>908'G%5\#TG047!59Z*I:N7 G F245U T\K^<6F# G&=IK,Y$,^5I1
MPF FD%P7!1:_[X#R[<CQG;<+]V29*W/!388KO(0YJ,?53.B96ZMDI  F"6=(
MP&+DW/HWT]C@+> G@:W<&2/CY(GS9S/YEHT<SQ0$%%)E%+ ^;6 ,E!HA7<9+
MI>G4CS3$W?&;^A?K77MYPA+&G/XBF<I'3M]!&2SPFJI[OOT*E1];8,JIM$>T
MK;">@]*U5+RHR+J"@K#RC%^K/NP0_.@=0E 1@JZ$L"*$70E118BZ$N**8*V[
MI7?;N E6.!D*OD7"H+6:&=CN6[;N%V'F/9DKH>\2S5/)#['$C/S!96HL0_/R
MA4%\@>9DR<B"I)@I=)NF?,T484LTXY2D!"3ZA,98YI?VB*8O:[+!%)B25N<>
MI!(D59"5]\\GH#"A\D+3'N<3='YV@<X08>@AYVNI&7+H*FW(E.6F5?%W9?'!
M.\5/(+U"H7^) B\(6^CC[O2@A3[I3O=;Z-/N=&^?[NH0ZR2#.LG ZH6G3[*M
M\^7#HO:'F=7K1JYP"B-'+T\2Q :<Y.,'O^=];LOAE&*34XI-3R2VEUA8)Q8>
M4T_L=V&22LT _GU ;7F44K&5,HO_)O&]H#_0+]YFM]--6"^,H^M]U*2)BOQK
M?Q#OPZ9-6!SY?MRO87NVH]IV=-3VSLI@C+>9+05ZN_7%P8'3%DSD'?CL@)D>
MQ^PYC&N'\5&'#UQA:LU=-K*U@8O_MR!NR3L,H_"@"TU8+QST#_-NHG3>^L4X
M:$43IO..!X=YNSO;C?F9^([%DC")*"PTT;NZU@JBW*#+B>(KNP,]<:7W,SO,
M]3\-" /0]Q><J[>)V=3JOZ3D+U!+ P04    " "GB6]8I=AUIK8"  #$!P
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MT.EQ#N:2:_=/-IUMX)%\I5'6'=AX4#/1?NE#%X<=0'CV#"#J -%C0/(,(.X
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MMCYT0V5LZJ.;F,1J8C/;D';:CY_MA)2T(0(I+\1V[CF^Y_AB+J.<LB>>("3
M<Y82/C82(597ILG#!&607] 5(O+-DK(,"CEEL<E7#,%(@[+4="S+,S.(B>&/
M]-J,^2.Z%BDF:,8 7V<99"_7**7YV+"-[<(]CA.A%DQ_M((QFB.Q6,V8G)D5
M2X0S1#BF!#"T'!L3^RH8JG@=\ NCG.^,@5+R2.F3FMQ&8\-2":$4A4(Q0/G8
MH"E*4T4DT_A3<AK5E@JX.]ZR?]':I99'R-&4IK]Q))*Q<6F ""WA.A7W-/^&
M2CU]Q1?2E.M/D)>QE@'"-1<T*\$R@PR3X@F?2Q]V +:W!^"4 .<MH+<'X)8
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M%,B*3K>8"+K2O=\C%;*3U,-$_CE 3 7(]TM*Q7:B-JC^;OC_ 5!+ P04
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MGE+FY56UG$B6F^OAE$EUV33#N;K> ]<;U/N8,;F>Z!MG_8<A_ M02P,$%
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M4)^&1%G,+AN*;XI:Z@M7BF?%Y9K@A(B\@WZ^Y%R]-O(!ZG\I3'X 4$L#!!0
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M)5Y1=<<W7Z"KY\SPY9Q*^X\V76S@H7PE%6\ZL,Z@(<P]\5.GPPX@G+P B#I
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MR-$5ASNM1[JL1D*OC 01N*6%6'!P720DT0E<.>UF[F@[]TMD9,1D>@9\^ M
M'O([)G3U?CCJ@./WPZ$A&[]Y$G[)YYN?1)>P%3#H!JI?AG.^C*=DY,C2YX2M
MB3/^^2<8>;]UB6*3#%LBTP0+&L$"$_M8+5CVNF@5."S!ZM=O/49A#P7!T%WO
MRM$1!J$7(#T,'X;Y* I#V(1I*81-"J$QA4<JX@P4,I$EH\EJ:DS(2'7L*K!)
MABV1:1)&C831J643V13,)AFV1*8)UFL$Z_U(V53@2"N;*.Q[>V73$0:]7K07
MA@_#5-EX@^ZRZ3<I](TI/.'K+\]7%UW3-P*/?>8VR; E,DVP02/8X-0B&=@4
MS"89MD2F"0:]UA=Y/U(F-7IW94/4\Z+]UTM''/+\/MR+PQUQIDJ!._X.&O.X
MNKF]GGR^Z<S!B#SVV5MEP[;8=-50JQHZM6!JI"W5;+)A6VRZ:JV#A4:_]V;-
M^!TU$_K]_G[-',9%@R#:KYC_PWO"UGQ"L_M\?GJXN9T\=^9I1!Z]0FRR85ML
MNFJMWX7AR75EU=]:9<.VV'356HL+C8;PS;J*#M\=8>_@3635P=IBTQ5I/2PT
MF]C/=W\^WDW^Z7ZM&:%'+R2;;-@6FRY;ZYMA_^3RL^J<K;)A6VRZ:JUYAD:K
M^6;Y#0[*+PP/JL^J-;;%IF^[M=X8F;WQG5@0UB6%&7?L(K+*AFVQZ9JU/AS!
M4TL/6?7A5MFP+39=M=:'(Z-C?:OT:O3NMEQT\!>L(PCU]_?W.H)V]@"KV;L[
MV^PY8?/RN(*#*5T5HMJU;GJ;(Y&+\B!@K_\2GN/J8*.EJ<Y9;F,V3PL.,C*3
ME-Y93TZ(54<754/09;F9_T*%H'EYN2!Q0I@*D/=GE(IM0PW0'""-_P-02P,$
M%     @ IXEO6 /<RTY/ P  X0X  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3(N>&ULK5=K;]HP%/TK5B9-G;22%Z]V@%3(7IHZ(=CCLTDN8#6QF>U ^^]G
M.R$E44!4\A<2._><^!SN=7Q'!\:?Q!9 HN<LI6+L;*7<W;NNB+>08=%A.Z#J
MR9KQ#$LUY!M7[#C@Q("RU T\K^]FF%!G,C)S<SX9L5RFA,*<(Y%G&>8O4TC9
M8>SXSG%B039;J2?<R6B'-[ $^7LWYVKD5BP)R8 *PBCBL!X[#_Y]Y!N B?A#
MX"!.[I&6LF+L20^^)V/'TRN"%&*I*;"Z[&$&::J9U#K^E:1.]4X-/+T_LG\Q
MXI68%18P8^E?DLCMV!DZ*($USE.Y8(=O4 KJ:;Z8I<+\HD,9ZSDHSH5D60E6
M*\@(+:[XN33B!.#WSP""$A T =TS@+ $A-<"NB6@:YPII!@?(BSQ9,39 7$=
MK=CTC3'3H)5\0O7_OI1</24*)R<+V /- =VBKYP)@<JQ0*L7M"0;2M8DQE2B
MF5D*<(0%PF@./ 8J56(@MD:_F,1I$W\3@<0D%1\4]4^5OW/.DCR6Z/6%%>6,
M4<W&L<F$!1%/(U<J;7J%;ESJF!8Z@C,Z_  ],BJW GVF"21U E>94CD3')V9
M!A<9(X@[*/0_HL +PI8%S:Z'!RWPZ'JX?T%-6/W/H>'KGN%[C'^ $(RV.7L1
MJ3>>>['#,8P=M;,(X'MP)N_?^7WO4YLK-LDB2V0UQ[J58UW#'IYQ[+JL[-KT
MSB999(FLYEVO\JYW,=OJ^X,T^\/&[ ^\*/\V*PM*WS.<^GNUGWB=[LC=GUK4
M&A0.ZU%1>]1=%543U:]$]2^*F@&-&<?H1AFV)RP7Z0MZHNQ ]9[XH#8RLF2Y
MTGT[!;X!JK8UOF-%^GQHTWOQ;6]-'9MDD26RFLN#RN6!A;(;V/3.)EEDB:SF
MW;#R;FB_[(:M91<VZJX]JE&=46O4N;J[JU3=7:X[S!-"<=JV^(O(M^:!3;+(
M$EG-,=][/=5Y%JJH)+%DGU6VR!9;W<"38[%OOY1*SD;^^[U&+9T)&S2*J3TL
M:!23>W+VS_2'1_=0 L4LI[(X[%:S59_V8+J3QOQ4]V^FIWBE*9J_1\PWA J4
MPEI1>IV!^KSRHI\J!I+M3(>Q8E*=Z,WM5O6@P'6 >KYF3!X'^@555SOY#U!+
M P04    " "GB6]8*$QA=7D&  "8)   &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,RYX;6RUFFMOVS84AO\*X15#"]0U+[IFB8$D:M$!ZQ8DZ_:9D6E;J"QY
M(NTT_W[4I99%4DSC,%\22W[YBN>0/'PDZ_RAK+[Q-6,"?-_D!;^8K(78GLUF
M/%VS#>4?RBTKY#?+LMI0(0^KU8QO*T873:--/L,0!K,-S8K)_+PY=U/-S\N=
MR+."W52 [S8;6CU>L;Q\N)B@R8\3M]EJ+>H3L_GYEJ[8'1-?MS>5/)H=7!;9
MAA4\*PM0L>7%Y!*=)834#1K%/QE[X$>?01W*?5E^JP]^7UQ,8-TCEK-4U!94
M_MNS:Y;GM9/LQW^=Z>1PS;KA\><?[I^:X&4P]Y2SZS+_-UN(]<4DFH %6])=
M+F[+A\^L"\BO_=(RY\U?\-!IX02D.R[*3==8]F"3%>U_^KU+Q%$#%(PTP%T#
MK#;P1AJ0K@'YV09>U\!K,M.&TN0AH8+.SZOR 52U6KK5'YID-JUE^%E1C_N=
MJ.2WF6PGYK=LSXH= U-P68] )C+& 2T6X&.QR(H5N&6<57L&KFA.BU1^)Z<:
M^$C3-;C+5D6VS%):"'!-!5N5U2,HER#)>%KN"M':7.9R9K4MWR9,T"SG[^3%
MOMXEX.V;=^ -R KP][K<<2GFYS,A0ZH[-DN[[E^UW<<CW4<8?"D+L>9U?]EB
M:#"3N3@D!/](R!6V.B8L_0 (>@\PQ,30H>N?;XX-S9.?;XXLT9##\)+&CXSX
M7:;=6/Q9"CD$EW)$_BAIP>6XIBS;T_N<F9+>FGIFT[H4G?$M3=G%1-::9GY,
MYK_^@@+XFREA+LT21V:#9'J'9'HV][FR0KH+R++3+(WWX)ZMLJ*H5TUWRI3:
M]A)^<XFZ*._G"$(?RJFV/TZ:21:'6)$E!ADF)(X.LD&@_B%0WSIK;JIRGW65
M/9=+>P%$"3C-9> ;NF!RS9Z90O-=SAJ79HDCLT$R@T,R ^NLN=Y5%9,U<LNJ
MK%R8\M:V#XX&,?(\@GUE2N@R/XR".%:FA"X+PA@=R091A(<H0FL4-[+S51>#
MK-]9D4K*X R\7;#VTSM39*'6%Q+!4(E+%TT)@I$2ED&%D'=D-@@K.H05V<.B
MCQ)BNKVJW6Y9!61$BTR>S#C?J9M*&UBD]R:$)/2A$IM!YT=>A) 2G4$71,@+
M1L*+#^'%+ZI8K-WD+>4JUCJ&/2^*U+FIRTQ5+3')!E5M$"6"/<1 ^QI;TVK%
M[FGZK0VT9Y :5V0YVVP%Z,;:"!E6^^>6+J=NB2NW86J/^!"]!D%TKJXRZM(M
M<>4VS"CN,XI?'R.Z:QPO)0\'H5I;#3(<!X&R?!.3&_0C.+(N>_I$=OP\$220
M4_YTZI:X<AMFM$=09&?0IVFB,QAP0@S#$*M30]=Y)(CTN6'0A5 BQ<CDZ"$3
M6;'K1*3H3(<@0 *D1F>081A#-3B3+ J#D=AZYD-VZ#N5*Y!.;U/?CQ!1-UR3
MT,,H#-0MUR@,HXB,+>Z>")$="5\.%TB'NI#$OGHO9) 9:EUBD UKW3#.'A&1
MG1%O)5C(K<\8@+7ELPN52[?$E=LP:SUYHOA5N,$*M,_.J$NWQ)7;\+E4#[G8
M#KE.N*&[QO"6+$3JDC/(? ]"3UER9ID_\O@!]]")[=!Y(C=@I]#IU"UQY3;,
M: ^=V Z=3W,#UAD0>82$ZBVM01=$1'L,8;)#TFVD'..>*;&5L$[$ALYT&!WV
MU-ATU11!]:X^,<F\>(P:< ]WV YWIU(#UA%M&F##T!ET$0X\+3Z##L$HC$9N
MU''/?-C.?"]G!JP3&\+US%)CU76&0I<89,-"-PRT!T!L!\"_Q%H.W2?&^'MP
M74ZW]!%<<IYQ4<?5Q'[+Q*XJC%AA]WYV'7/IEKAR&^:UATX<O@968"O*/CNC
M+MT25V[#C/9XB^UXZP8K] >8*$8Z5N@R'$!?PPJ#3-Z4C=RQX)Y)L9U)3\4*
MITSJU"UQY3;\=;%G4O+$@]<GL8+HB(@01)$Z-0RZD'CJ?6]BD,5>"$<V)M(3
M)['RUXE4T9D.-IG04ZG"I,)J7+IF2GQ_A)9(SWW$SGVG(@71\6T:$>RISR&,
M.NAI/]^8=#&)_)&-EAS]P&W'P9<317>!XQ]1)<S%6J2ZS%#B$H-L6.+:.&='
MKVS($5DUK[YPT&QN[<L*A[.'UVLNFY=*E/-7Z"QI7Y+I;=IW=K[02E9N#G*V
ME);P0RC[5+6OP;0'HMPV+X;<ET).B^;CFLDZ6-4"^?VRE'ML=U!?X/ RTOQ_
M4$L#!!0    ( *>);UC+O760+P@  ,Q6   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;+V<;V_;-A#&OPKA%4,';+$ED93<)0::%,4&K$#0M-UKQJ9C
MH;;D2G+2 OOPDV1%)UKRQ71/>I/X'Q_R3D?Y9SZ4+I_BY&NZTCICWS?K*+T:
MK;)L^V8\3N<KO5'I1;S54?[.,DXV*LN?)@_C=)MHM2@;;=9C=S*1XXT*H]'L
MLGSM-IE=QKML'4;Z-F'I;K-1R8]KO8Z?KD;.Z/F%C^'#*BM>&,\NM^I!W^GL
M\_8VR9^-:Y5%N-%1&L812_3R:O36>7,3\*)!^8DOH7Y*&X]9$<I]''\MGOR]
MN!I-BA'IM9YGA83*_SWJ&[U>%TKY.+Y5HJ.ZSZ)A\_&S^OLR^#R8>Y7JFWC]
M;[C(5E>C8,06>JEVZ^QC_/27K@(2A=X\7J?E7_94?78R8O-=FL6;JG$^@DT8
M[?^K[U4B&@T<?J2!6S5P3VW@50V\,M#]R,JPWJE,S2Z3^(DEQ:=SM>)!F9NR
M=1Y-&!6'\2Y+\G?#O%TV>Z_"A'U1ZYUF'[1*=XG.CU&6LC_8^S!2T3Q4:_8V
M377^4O7^@A799Q_U?)<D8?3 KE4:INSU.YVI<)W^EC?]?/>.O7[U&WO%PHA]
M6L6[5$6+]'*<Y0,NNAW/J\%=[P?G'AG<.SV_8)[S.W,GKM?1_.;TYJ[9?)RG
MJ<Z56^?*+?6\8[FJ,Z+V&=D\9T1E;%DD\K%,9)F?I,[/?9&?KN#WO?'NWHKY
M^R;=JKF^&N43--7)HQ[-?OW%D9,_NU)!)&8DQJL3XV'JLT]QEB=E>9">KI!1
M'=N0]V*B%"M.5X\S9^I(+B['CQW!\#H8C@;SCW[4:^9TC1YM:#MZ(C$C1E''
M* :M9$&9&"(Q(S&R3HPDJF14QS;DO9AL5C+W.'>[*]FO@_%/J&2W:_1H0]O1
M$XD9,09UC,&@E1Q0)H9(S$C,M$[,E*B241W;D*>M2N:!._&Z"]F9 *5,T&@^
M7]Q=L(?X42=1P2<L)\QH_H.EQ0$-LU!WPP6J:1L9E9J9@0:G.8,6>M4=57*(
MU,SD )@Y*-Y8%#LN9!VVVSYQ3Z>2'REWX"D'!ZH7RYW]QQ!.P=6M@R12,W,!
M..;P80N?E.*HU,SD ,<Y* W9%#XIHU5JIQ8^X)>#\U=9^%E2'N$73^^D"$:E
M9@8.J.;XPU8Y*>%1J9G) <9S4%*RJ7)2?JO4FE4N ^X$1ZH<T,S!V>Q8E;]P
M5B<%-2HU<R4%@,Z=#+N60LIZ5&IF<H#U7!27+.H=%[(.V[&I=[>Q;H;CV4V\
MV>BD#&6KMCIA*EJP>9QLXT1EFD5QUGV&QV6MH^MCB<P%IG.]82N>%/*HU,SD
M .2Y^**;1<63XENE=N+O51>XS,6Y[)2*K\_VG2LT> ?6<?:QJ.8"UKERV-HG
M13\J-3,Y@'XNODQG4?ND4%>IG5K[0&LN3FLW*ETQ_6T7YL>T\)(Z(R'E-"HU
M,V# .7<Z;'63@AZ5FND, >AY^,J=A3=$BG"56K.ZA9C(27=U>\!F'LYFA]6-
M,SLN9AU3'ZML'F"<-ZS_Z9'B'96:F9R&!4KF@=*:H&T7%*MS(#(/)[)C&P,.
M?/_. $D1C4K-S .0G#>L5>J1<AV5FID<X#J/RBZMA RS?L*G'.JT"J@/%O.
MQ3R<Q4ZL^ORD?Q-'6?Z\6)W/'Z;A0N=D'\919_"DW$:E9J8(\,X;UG'U2%&0
M2LU,#J"@AZ_L-:IB_F)5='BEW'</)T0?^,8!WSB.;Z=/"&S?#"G94:F9&0$
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M\C!*LV17&AAA5+^_4=%NJ>;9KFC=F1;2%4DJ-?/V0T":P;#.=T#*FE1J9G*
M-0.J"YF#CDN/6SM"\-[.C0;@,*"RO<^:*O@V*GQLUG71!Y8&@*7!L*9X0(JC
M5&IF<@!' RI3O!(2^*0AY<=QXU:CQ7U>/ZCD(:]MMM;+7'YR4=!=LK]UZOY)
M%F_+NX_>QUD6;\J'*ZT6.BD^D+^_C./L^4EQ0]/Z!K:S_P%02P,$%     @
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M)Z.;@[&+^@I]IOORL#2WXU36;*%U66MR"&3.(1[N5]<W=P_@/W!<-F&&.W4
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M& <1YJJ ?+]F3#S=J KJ$UR+_P%02P,$%     @ IXEO6'KP.F M!   B!8
M !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULM5A=CYLX%/TK%ENM6FDZ
M8!-(,IM$ZF1VU)6VJZAIM\\>XB16 5/;)-/]]6L3AH_$L0;)?4F W'MRCCG
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M"=X0K@O4[UO&Y,N.'D8VP^?%_U!+ P04    " "GB6]8T.PS@=X"  "D"
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MFF3P0O(LL"+&)#E!H7^, B\(.P*:'^X>=+C'A[O[%C9AO66AP0OWX$&*,_S
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M6I)!2W*AEK=CRI50YJ);(8Q0,*G& ;7XD3UWMGV0;,PM*\+H1,'4JHC3;%Y
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M:W.C-A2&_XK&W6EW9])@Y$OL;>*9V&BW.]U+)FZVGQ60;:: 6$DXZYG^^$I
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MW2<I"Q:989[\##<T6S.SD]!P4QUAULID"L;0?\\/C/.J-[[?NK7[Y_YT;!>
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MX]7XU*1J&X+_:-I(OB)R1<V=95 8RN#DU*B2;<RU'2UJEQ3W0IO<<<W2_!E
MV@(S7PBAMQV[0/^O2?\"4$L#!!0    ( *>);U@/@%F#MQL  '+F 0 9
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M>VZ-DK$"N&*"$PF+H7/M7XW]T#A8BX\,MFJO38R4N1"?3.<V&SJ>800YI-I
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M2IH)4?;:*OEZYN@X(34;U9Q6V_GPO\&9-=Z="Y'#>JCFHUJ :B&J1:@6HYI
M-4EI:E)T==VAOJ[;\Z&"55)63?GVXUV9+8QV+M2;'NB*LZAFHYJ#:BZJ>:CF
MHUJ :B&J1:@6HYI -4EI:L1T)=SAA)WCH U;5+-1S4$U%]4\5/-1+4"U$-4B
M5(M13:":I#0U5KJ&[5"_A.W!<QRT68MJ-JHYJ.:VVJLS)@\=UC]TV  =-D2U
M"-5B5!.H)BE-#8&N#SO4]V&_/2YO;WS<3%_>&-?KS;L#PR1?)^6#,=Y,7JR?
MNI"#UFA1S48U!]5<5/-0S4>U -5"5(M0+48U@6J2TM0@ZMJVPW-VDH.V9E'-
M1C4'U5Q4\U#-1[4 U4)4BU M1C6!:I+2E%@9=:W9D7XMUD,^^$M/'!LEJ&:C
MFH-J+JIYJ.:C6H!J(:I%K?9:1S%&1Q6H)BE-#8FN SOZ#RQ3JS>/3@VT!8MJ
MSFB_!3O=7Z86'=-#-1_5 E0+42U"M1C5!*I)2E,SP^HR0]^!?3IQ\DD]<5+D
M:@?VITZ=Z'?AZ(A!.["HYJ":BVH>JOFH%J!:B&H1JL6H)E!-4IH:15T'=L1V
M8$=H!Q;5;%1S4,U%-0_5?%0+4"U$M0C58E03J"8I38V5K@,[TC;G#CMU0E;Y
M+E'-;K77)L8..JJ+:MZ!/X./CAJ@6HAJ$:K%J"9035*:^O+OBJTC?;'USYT4
M01NMJ&:CFH-J+JIYK;;]T=[6<#\ST*8JJH6H%J%:C&H"U22EJ9G1-55'^N5B
M+XO\/BVKK%E6+2^J=/7&")XRX[+.C-[(0-NJJ&:WVF3GS^_N 03:0D4UK]5V
M#R!VHP!MEZ):B&H1JL6H)E!-4IH:!5V[=*1OESZ='[ULSX_6<?!TCO1[6OU(
MTUQY?XRU.<!X/'5J3G]^^0#]WAV=*FAI%=4<5'-1S4,U']4"5 M1+4*U&-4$
MJDE*4U.JJ[^.SMA3IVB9%=5L5'-0S44U#]5\5 M0+42U"-5B5!.H)BE-C96N
MS#K2+QW[\7%1V.Z8IS=+T 8KJMFHYK3:]C1JW+.*&CJHAVH^J@6H%J):A&HQ
MJ@E4DY2FA,2XJZ:.]=74IQF2O=<@N4KOJL</YS)'/]\BT>_&L3F#:C:J.:CF
MHIJ':CZJ!:@6HEJ$:C&J"523E*;&45>"'9OH5&B,]E]1S48U!]5<5/-0S4>U
M -5"5(M0+48U@6J2TM18L;I8T?=D#VF1Z(FCHP3MN:*:@VHNJGFHYJ-:@&IA
MJVU?%.N9CT;HH#&J"523E*9F1%=@'6N;;'_JLK&>/#HST!(KJCFHYJ*:AVH^
MJ@6H%K;:3F;L)@;:344U@6J2TM3$Z+JI8VWY[<)\._ZKL1T;5VF>%:5QM?Y>
ME/,LWZQL))LH,>;K=//YYL:_E0TVW^P-%K+$=XEJ-JHYJ.:BFH=J/JH%J!:B
M6H1J,:H)5).4IB905X\=C]G3)6@S%M5L5'-0S44U#]5\5 M0+42U"-5B5!.H
M)BE-C96N03O6-V@/.EV"-F91S48U!]5<5/-0S4>U -5"5(M0+1[O]YN;MSKL
MSLP$.JJD-#4DNF[M6-^ME6EES)*R?&A6F;]/%NO>=5OUR-$Q@59@4<U!-;?5
ME%\I:W)V=K:S;"LZJG_@J $Z:HAJ$:K%J"9035*:&@!=;76L7[7UT*6;]<S1
M$8#655'-0347U3Q4\U$M0+40U2)4BUMM=UUL<[Q[I( 642E-#8JNB#K6%U&_
MILLDRYO#A'5>3RC**OM7G1OS[;?V;MYXL[FEN+Y.R^:^+[Z]5S_:T7F"5E91
MS4$UM]6V_[@/3=/:/:! &ZL'C1F@8X:H%J%:C&H"U22E*2DQZ9JH$WT3U:E?
M^+,JNT]?/Z+02\<F *K9J.:@FMMJNW]]+',G ]!1_0-'#=!10U2+4"U&-8%J
MDM+4%.@*H!/]*JA_[IKJ0;7TYE/Q9FF>E%GQQOBR2/+Z!I'\D2W7R]Z00:NE
MJ&:CFH-J+JIYJ.:C6H!J(:I%J!:CFD U26EJ8%E=8%GH)=@)6C-%-1O5'%1S
M4<U#-1_5 E0+42U"M1C5!*I)2E-CI6NC3O1MU$,NP>J)HZ,$;9^BFM-JK[UW
M%QW40S4?U0)4"U$M0K48U02J24I3,Z+KGTZT[;*+L[?67_?KI$_S(NO0KJE^
ME*-CA-1L5'-0S44U#]5\5 M0+42U"-5B5!.H)BE-39NN:SIANZ83M&N*:C:J
M.:CFHIJ':CZJ!:@6HEJ$:C&J"523E*;&2M<UG?Q\UU1/'!TE:-<4U1Q4<U'-
M0S4?U0)4"U$M0K48U02JR4G_.K];\W0U)+JNZ43?-3VT:J9GC@X*M&V*:@ZJ
MN:CFH9J/:@&JA:@6H5J,:@+59*OM5@+.K!>"HNND3O2=U,_K:E4E^;PID#T>
M3QAWR4-Q?=V;%F@Q%=7L5E.BM/[?WK+OZ*@NJGFHYJ-:@&HAJD6H%J.:0#5)
M:6I:=,74B;Z8:@VLL?$M+9>;Q0\//E^*]D]1S48U!]5<5/-0S4>U -5"5(M0
M+48U@6J2TI1PF79]UND /5\Z14NMJ&:CFH-J+JIYJ.:C6H!J(:I%J!:CFD U
M26EJK'0%V:F^(-L[P\GFQ@MS'+UV=*J@+594<UIMNR-R9I[O=43003U4\U$M
M0+40U2)4BU%-H)JD-#4NK"XN]"N?[DUQXC2?IV5O5*#-5%2S4<U!-1?5/%3S
M42U M1#5(E2+44V@FJ0T-5&Z9NITR,YKT)8JJMFHYJ":BVH>JOFH%J!:B&H1
MJL6H)E!-4IH:*UV9=:JMKQW4 ]$31T?):.\2RW2\5RJWT4$=5'-1S4,U']4"
M5 M1+4*U&-4$JDE*4S.BJZ!.M5VT@VL@>N;HG$"KIZCFH)J+:AZJ^:@6H%J(
M:A&JQ:@F6FVWN#&9[BQ@)*EAU:3H6J53?:OTV+.D:,$4U6Q4<Z;[%;W>LZ1H
M<Q35?%0+4"U$M0C58E03J"8I38V+KE\ZU?=+OQ55/?&HFM.DQ;51W:;&HDCR
MWJ1 &Z:O[-;$>$B3LJ^$8J/[X:":BVH>JOFH%J!:B&H1JL6H)E!-4IH:'EWG
M=*KOG+8?H;LR/KXQ/FT6,K1_YI-R]:,=G3!H*Q75'%1S4<U#-1_5 E0+42U"
MM1C5!*I)2E-3I^NN3L_9RS!H:Q75;%1S4,U%-0_5?%0+4"U$M0C58E03J"8I
M38F5LZZU>J9?A15>JUD_VK&I@VHVJCFHYK::LF[RWB<]>NB8_D%C!NB8(:I%
MJ!:CFD U26EJ2G0EU#-]";5+B>:<2>\+'^V=HIJ-:@ZJN:CFH9K_RB_%\,6S
M50&Z'R&J1:@6HYI -4EICZ%QNKI-T\I.JN3B_3(M;]++=+%8&9M#A&:0K5N-
M,KVN0\5\]]$Z.=V[W3;?.6;/[:[YSNN[W3??!9O;3[MA+][?)3>I2,J;+%\9
MB_2ZWH7!V^8B5)G=W#Y_415W'T[J1^%[457%<O//VS29IV5SA_K[UT51/7W1
M#/"C*'_?_)@7_P]02P,$%     @ IXEO6%CSI_]H P  : P  !D   !X;"]W
M;W)K<VAE971S+W-H965T-S,N>&ULO5=MC],X$/XK5D GD+C-:]_VVDC;!KB5
M%EW%+O !W0<WF38625QLI]U#_'C&3C:T:39:4'5?6MN9>3S/8\]D,MUS\46F
M (K<YUDA9U:JU/;2MF6<0D[E!=]"@4_67.14X51L;+D50!/CE&>VYSA#.Z>L
ML,*I65N*<,I+E;$"EH+(,L^I^&\.&=_/+-=Z6'C/-JG2"W8XW=(-W(+ZL%T*
MG-D-2L)R*"3C!1&PGEE7[F4TT?;&X".#O3P8$\UDQ?D7/;E.9I:C X(,8J41
M*/[M8 %9IH$PC*\UIM5LJ1T/QP_H;PQWY+*B$A8\^\02E<ZLL4426-,R4^_Y
M_F^H^0PT7LPS:7[)OK9U+!*74O&\=L8(<E94__2^UN' P1T^XN#5#E[;(7C$
MP:\=_*<Z!+5#8)2IJ!@=(JIH.!5\3X2V1C0],&(:;Z3/"GWLMTK@4X9^*HQ@
MI<@_JXQMJ#X'2?XDGN.-R!V(G-QPBBO7A0(!4I'7]WC9)) %S[>\@$))\B("
M15DF7Z+?A]N(O'C^DCPGK"!W*2\E+1(YM16&J3>SXSJD>162]TA(KD?>\4*E
MDKPN$DB. 6SDUY#T'DC.O5[$".(+XKNO-#6_(Z#%T]V]#O?HZ>YN#QN_.3+?
MX/E]1W9=2"5*S#]%/M^@ ;E6D,M_N]2NT()N-%U6+N66QC"SL&Y($#NPPC^>
MN4/GKRZES@D6G0GL2,6@43'H0P^O<BX4^V9N/>%KK!6H:L)DS$O4%&]NM<*D
M+&D1 XFY5)V7N=IF8+;11787>H$SFMJ[0]E.C8:![QX;1:=&@3?XB71$<]#0
M'/32;"?S=S)G?)E2+)ED(2!A^BKM,+MSD\\?R=LEN;E9=!'MW>A7[]$YP:(S
M@1T)/&P$'IXU&X?G5/&<8-&9P(Y4'#4JCGJOZ0(+OL >H*09OCVJ]TV7>A7*
M\"!%_, ;3UK9=FJ%:1#XK73KC>@W^8X;ON/_I_J,3ZBZSB1HZ7%J% P&3DN.
MWH!_4XY)(\>D5XX[KO#@FT8#JD:CB^_DI$;Z W_<.MK%J947C";M"] ;TZ\R
MM@]ZL!S$QO2RDI@#K3J59K5IEZ],E]A:GV,;776]/V&J'OP=%1N&-3R#-4(Z
M%R,D**J^MIHHOC6=WHHK[!O-,,5/ 1#: )^O.5</$[U!\W$1_@!02P,$%
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MM10<HHJ$O*@8F>4IZE(:3'CS8H+?,*!L!WR^EOA6*2MV@.JK*/P/4$L#!!0
M   ( *>);UC>?/613P,  .L+   9    >&PO=V]R:W-H965T<R]S:&5E=#<W
M+GAM;+U6:V_3,!3]*U9X""18GDW;T4;:%A#[ $SK@,]N<MM:)':QG78@?CS7
M3I;UD94A*KZTMG//\3TGOLX=K87\IA8 FMR6!5=C9Z'U\M1U5;: DJH3L02.
M3V9"EE3C5,Y=M91 <PLJ"S?PO-@M*>-.,K)K5S(9B4H7C,.5)*HJ2RI_G$,A
MUF/'=^X6KME\H<V"FXR6= X3T)^75Q)G;LN2LQ*X8H(3";.Q<^:?ID,3;P.^
M,%BKC3$Q2J9"?#.3RWSL>"8A*"#3AH'BWPHNH"@,$:;QO>%TVBT-<'-\Q_[.
M:D<M4ZK@0A1?6:X78V?@D!QFM"KTM5B_AT9/S_!EHE#VEZR;6,\A6:6T*!LP
M9E R7O_3V\:'#8 ?/P (&D"P"X@> (0-('PL(&H D76FEF)]2*FFR4B*-9$F
M&MG,P)IIT2B?<?/:)UKB4X8XG:0PU>33M&!S:MZ#(J])X 4QN1!\!5*S:0'D
MH]"@R"77($%I\O86SYP"#"F7@@/7BKQ(05-6J)<(_SQ)R8NG+\E3PCBY68A*
M49ZKD:LQ6[.GFS69G=>9!0]DY@?D@^!ZH<A;GD.^3>"BS%9K<*?U/#C(F$)V
M0D+_E5$8=B1T\7AXT %/'P_W#Z@)VS<76K[PT)N[Y$K+"LM0=QE<$T3=!.9"
M.55+FL'8P1M#@5R!DSQ_XL?>FRYSCDF6'HELR[BH-2XZQ)Z<E0(/]D][WHF8
MX2V!1N9,9:+BFN!AK5>84A7E&9!,*-UY?NMM>G8;<[VNDB#R^B-WM6G;?E <
MA?YV4+H?% 6]>Z8MF;U69N^@3/^D]VRKC"? F9!D4DV%S!FG&O*FM/,*ZJK_
MM5_W7<(/;ORWY^J89.F1R+8,CUO#XW\MR/B8QAV3+#T2V99Q_=:X_L&3.M'V
M+&+]X?<$OQKU=Z;+OYHGWJB3,.IY.Q7WF*#T#T%;.@:MCL'_N5@&>\GYH1_N
MR.P("@;QCLRNH-ZP6^:PE3D\*/-&:%K<MP-0MP-=.H;[UUH_WM71%13NZN@*
M\G9UN!MM4 ER;MM)1:S]=9?0KK8=ZYEMU';6S[&3K1O/>YJZ#?Y Y9QAEU3
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M;<EJI\MW6UW6F>[=;[-[5]X%M;5 :0$H+02E15"TMM2UI^:/7YUW05TT4%H
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MTN+EFI(%E?D)YO.E,(-?]28O8+?=</H?4$L#!!0    ( *>);UB2$6!5Z00
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M#>:"L3<\H[=I-'+#%GI'!;Y1ITA6W@E&I1SUJ90]!:LE.BX2';]&*4%<)CX
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M8?MU:4'GM*&: ]5<J.:A-#XS3?U!%O<?6B?SR$_RZ'\/HEW4F2#D)>L'J&9
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MC>4$ P  U0@  !D   !X;"]W;W)K<VAE971S+W-H965T.3(N>&ULQ5;;;MI
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M>@F& ;Q+0ERR Y?L2'N0Y]?L$88\-GV'XIV^=?5.OT?Y3@_U.PU7RG_@CS#
MP)?:/C)QY_+)4*[<%5N9M]Z&:W\/;4?;:_R-O[P>IOMO@'LB5Y0KJ'!I0I.S
M2U-<I;]6^XX6M;O*/@IM+L:NN3:?(BCM!/-\*81^Z=@%VH^;_"]02P,$%
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M]#<+"@/0\PO.U6/'+-!\!26_ 5!+ P04    " "GB6]8':V/.ET$  ! $P
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MH*4^70/)@*D ^7Q)J3A<J!>T>]JS?P%02P,$%     @ IXEO6(9!A]1Q P
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M=@/P_5PI>]=Q$]3WL.%O4$L#!!0    ( *>);U@WH)CYX@,  "42   :
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M);#"FTP\T-V?4"<T5GPQS;C^CW9UK&.A>,,%S6NP[$%.BNH7O]1"' '<X 3
MJP%>!^#Y)P!^#?#/!8QJ@);:KE+1.D18X'#*Z XQ%2W95$&+J=$R?5*H<7\4
M3+XE$B?"1T'CY\N%5"Y!=S27TXGC:D"*!-WG94;W &@!!:R(X.@2?</9IHJ8
M<SE92E7DZ"("@4G&/TYM(7NEN.VX[L&BZH%WH@>NA[[00J0<W1<))&T"6Z;3
MY.2]YK3P>ADCB*^0[_Z./,?S#1VZ.Q_N&>#1^7"W)QN_&2%?\_FG1BC%3([
MVQ&:,X:+-<A%*-!BCX[CEGBOJ^<[S!+T_2])B3X+R/D/T_A4[8_,[2OCN>4E
MCF%F26?AP+9@A1]^<P/GDTG;(<FB@<A:NH\:W4=][.']2RF]28J9D"U)0"Z'
M/8$L,0E8$;F.9E).NPV=J;T]EJ6WK??*,A!92Y9Q(\NX5Q;/<4<'8]#V@98;
M%J=RXJ%EA@MT<?^X7!J-H)?YO1-M2+)H(+*6HD&C:/"+%W@PI.Y#DD4#D;5T
MOVYTOSYO@0M@.;K8 V;F[U<_38!R_?DR:?73R.AGD"T5)HT*D_-4V-),3KN,
MB+U)@\E;BW.OG'''Y0Q1SM5U.R@R!HV\)JJ5QDV3QDUO&@^$/U^NF+0D4LCQ
M!"X0PP),J51$[JC5OC/VN\F8X_SK;C[F.,<9W[3_S FZSF&GYO2/5-MT_]9;
M+^-^JY?GO>M]4+9H*+:VAD>[7?<7>VW=@:'$'Y(M&HJM+;YW$-\;QG#_AR=
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MMZ6WRU=R.&]-7XOAVSV5,?GC5Z0D7S5DZL\V>\OXP_;X9@>\43F-8&'A%J=
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M/;P9B$T@665&Q())-7#,,E??$,!U@CK/&).;0+^@^RJ)_@%02P,$%     @
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M0A#X.](EY=Q$ HY_FZ!.VZ=QO'Q^COYK-7@8S)HHNA3\'[;1^[F3.FA#M^3
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MV'9JV,;S@2_Q8BGS ^9LLJ(+N /Y=77+U9Y94Z(XA4S$+",<'J?&!_LJ<(J
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MH<J)UXU//9"L,JW G$G56)C'7/6*P'6 6E\P)C<#O4';?<9_ 5!+ P04
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M;B(57]Y,9)L;R2HSHUPS*5EA+G<$9X1K ?5^PU2U:&_T MU<?/$_4$L#!!0
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M4P;R_H92\3I1#^C^2(C^ U!+ P04    " "GB6]86!7)J&X#  "Y#@  &@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&ULK9=O;YLZ%,:_BL6=KC9I*X3\
M[TTBM6'3*K5:U:[WOG;@$*P9S&R3K-+]\/?8$!8B2AM=W@"V>9[C\\,V]F(O
MY ^5 &CR*^696CJ)UOFEZZHP@92J"Y%#ABVQD"G56)1;5^42:&1%*7=]SYNX
M*669LUK8NGNY6HA"<Y;!O22J2%,JGZ^!B_W2&3B'B@>V3;2I<%>+G&[A$?13
M?B^QY-8N$4LA4TQD1$*\=*X&E\' ,P+[QM\,]NKHF9A4-D+\,(6;:.EXID?
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M99#]F^]JLT$O..JM@U'@/:03%/HW*/""<(07#N6&EA=>X)TK\P;M7]&&9>1
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ IXEO6+&H;HC;!P  E$L
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M-G[A^PQ9:,9LH3WU/ /#"2FR4,I=^08+>FA:G"(+I<P6PIAT-CU%%DJY%]M
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MK'IG@-Y9]<X O8OJ70!Z%]6[ /0NJG<!Z%U4[P+0NZC>!:!W4;T+0.^B>A>
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MT>#F)U!+ 0(4 Q0    ( *>);U@'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ IXEO6*[VF/?O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ IXEO6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "GB6]8F7'8[Z((  #.-0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ IXEO6)VW-B=G!@  ?!H  !@              ("!YA   'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *>);UB2#+TXP@(  -<)
M   8              " @8,7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "GB6]8)>Q5:F$%   ;%P  &               @(%[&@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ IXEO6&*9*Z4D
M P  U@H  !@              ("!$B   'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( *>);UC6$_  J1   '7V   8              "
M@6PC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "GB6]8
MU5'N*7 +   O0   &               @(%+-   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ IXEO6/4RB<UT*@  N(<  !@
M     ("!\3\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M *>);UB4:1(LF08  *@5   8              " @9MJ  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "GB6]8PF#.MO\(  !,'P  &0
M            @(%J<0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( *>);UB&2=8<CP4  "D/   9              " @:!Z  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ IXEO6%WJ,LV+!@
M6Q,  !D              ("!9H   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "GB6]8?P5/-VD.  !!*@  &0              @($H
MAP  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *>);UB"
M4KX[H!<  "!.   9              " @<B5  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ IXEO6*'/8GXV%P  YU$  !D
M     ("!GZT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *>);U@V--X5]@D  !DA   9              "
M@<ON  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ IXEO
M6'TJM9X= P  %0<  !D              ("!^/@  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "GB6]8FSM_]"0$  !8"0  &0
M        @(%,_   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( *>);UAL?!3:*00  .X)   9              " @:<  0!X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ IXEO6$H;GL9N!0  M@X
M !D              ("!!P4! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "GB6]8.,5<^ZLK   UEP  &0              @(&L"@$
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *>);UBVK1K3
M=@,  +,)   9              " @8XV 0!X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ IXEO6'CK4R["!0  "Q0  !D
M ("!.SH! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "G
MB6]8O>XW5\\$  !C%   &0              @($T0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *>);UC7Y(Y,OP(  %X'   9
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M970S,RYX;6Q02P$"% ,4    " "GB6]809]U![L%  #0%P  &0
M    @(%Y7 $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M *>);U@FQ19 ]0(  )H&   9              " @6MB 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ IXEO6*MS.K7F!P  X1T  !D
M             ("!EV4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "GB6]8$D8D#N@%  !G%   &0              @(&T;0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *>);U@9#G7B/@,
M '$'   9              " @=-S 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ IXEO6$U\@\V% P  %0L  !D              ("!
M2'<! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "GB6]8
M]6)>;=$"   Q"0  &0              @($$>P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( *>);UBEV'6FM@(  ,0'   9
M      " @0Q^ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ IXEO6/7#QQP< @  T00  !D              ("!^8 ! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "GB6]8B*3YB L#  !Z#
M&0              @(%,@P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( *>);UB\B)E/] (  #P,   9              " @8Z& 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ IXEO6*AG&J(N
M P  70P  !D              ("!N8D! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "GB6]8S@XJJMH"  "+!P  &0
M@($>C0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( *>)
M;UANOZ59#00  %X8   9              " @2^0 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ IXEO6)9'<2,% @  ;00  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( *>);U@H3&%U>08  )@D   9
M  " @>^C 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MIXEO6,N]=9 O"   S%8  !D              ("!GZH! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " "GB6]88_[J;6@$   4&   &0
M            @($%LP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( *>);UA.V$&\90,  ,H+   9              " @:2W 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ IXEO6(0K#\QU @
MN08  !D              ("!0+L! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " "GB6]8&T#@HE4"   R!@  &0              @('L
MO0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( *>);UC+
M3L5J]P4  ,TE   9              " @7C  0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ IXEO6'KP.F M!   B!8  !D
M     ("!IL8! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *>);UCKS3/T4P8  /DN   9              "
M@<[8 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ IXEO
M6.24HJ[W @  >0<  !D              ("!6-\! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " "GB6]8,N&*LJ8#  #,#   &0
M        @(&&X@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( *>);UB8>*:5.P,   X-   9              " @6/F 0!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ IXEO6-J0G(Z- @  =P8
M !D              ("!U>D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    " "GB6]8#X!9@[<;  !RY@$ &0              @(&9[ $
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( *>);U@)*6-F
MJ0,  (4-   9              " @8<( @!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ IXEO6/#';_2&%   (5P! !D
M ("!9PP" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " "G
MB6]86/.G_V@#  !H#   &0              @($D(0( >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( *>);UC:NX!#C@,   0+   9
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M970W."YX;6Q02P$"% ,4    " "GB6]8,YNU:=L&  !Z.   &0
M    @(&6.0( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (
M *>);UB2$6!5Z00  "<<   9              " @:A  @!X;"]W;W)K<VAE
M971S+W-H965T.# N>&UL4$L! A0#%     @ IXEO6/)78/I( P  .PP  !D
M             ("!R$4" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"
M% ,4    " "GB6]8PMJB$U,"  ">!0  &0              @(%'20( >&PO
M=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( *>);UC_;08U$ ,
M *0*   9              " @=%+ @!X;"]W;W)K<VAE971S+W-H965T.#,N
M>&UL4$L! A0#%     @ IXEO6#?[#0M=!@  23@  !D              ("!
M&$\" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " "GB6]8
MIY[$4C $  #C$@  &0              @(&L50( >&PO=V]R:W-H965T<R]S
M:&5E=#@U+GAM;%!+ 0(4 Q0    ( *>);UA]EQRIO@(  )@)   9
M      " @1-: @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%
M  @ IXEO6')(_<T1 P  J0D  !D              ("!"%T" 'AL+W=O<FMS
M:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " "GB6]8/;XE0/@"   M"@
M&0              @(%08 ( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+
M 0(4 Q0    ( *>);UBCQ Y)7P,  %\.   9              " @7]C @!X
M;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ IXEO6'I4]+@V
M"P  L8X  !D              ("!%6<" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,"YX;6Q02P$"% ,4    " "GB6]83_$CPF0#  !O#@  &0
M@(&"<@( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( *>)
M;UA[HHWE! ,  -4(   9              " @1UV @!X;"]W;W)K<VAE971S
M+W-H965T.3(N>&UL4$L! A0#%     @ IXEO6.F8Q/-8!   : \  !D
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M=#DW+GAM;%!+ 0(4 Q0    ( *>);U@-Z9=^-@,  !$)   9
M  " @6F1 @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @
MIXEO6!VMCSI=!   0!,  !D              ("!UI0" 'AL+W=O<FMS:&5E
M=',O<VAE970Y.2YX;6Q02P$"% ,4    " "GB6]8<!R@>2\$  #?%@  &@
M            @(%JF0( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"
M% ,4    " "GB6]8AD&'U'$#  "3#0  &@              @('1G0( >&PO
M=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " "GB6]8-Z"8^>(#
M   E$@  &@              @(%ZH0( >&PO=V]R:W-H965T<R]S:&5E=#$P
M,BYX;6Q02P$"% ,4    " "GB6]8#B<ZO+<#  !F$0  &@
M@(&4I0( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " "G
MB6]8Y#J1^;,"  !$"   &@              @(&#J0( >&PO=V]R:W-H965T
M<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " "GB6]81<LN])X"  "A"   &@
M            @(%NK ( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"
M% ,4    " "GB6]8P2W'^K@#  #Q#0  &@              @(%$KP( >&PO
M=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " "GB6]81IP0R14$
M   E#@  &@              @($TLP( >&PO=V]R:W-H965T<R]S:&5E=#$P
M-RYX;6Q02P$"% ,4    " "GB6]83GC.2. $   \(0  &@
M@(&!MP( >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    " "G
MB6]8Y93&#"@#  ")"@  &@              @(&9O ( >&PO=V]R:W-H965T
M<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " "GB6]8)U=.Q5P$   C%P  &@
M            @('YOP( >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q02P$"
M% ,4    " "GB6]8%<?,I. #  !Y%   &@              @(&-Q ( >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " "GB6]8VV<A#*\#
M  !4$   &@              @(&ER ( >&PO=V]R:W-H965T<R]S:&5E=#$Q
M,BYX;6Q02P$"% ,4    " "GB6]86!7)J&X#  "Y#@  &@
M@(&,S ( >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4    " "G
MB6]8-P5,:&4"  "+!@  &@              @($RT ( >&PO=V]R:W-H965T
M<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " "GB6]89#JB:T,"  "*!@  &@
M            @('/T@( >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q02P$"
M% ,4    " "GB6]8*?4248X#  ";&0  #0              @ %*U0( >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *>);UB7BKL<P    !,"   +
M      "  0/9 @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *>);UBQJ&Z(VP<
M )1+   /              "  >S9 @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "GB6]8,)0:5S,#  ""0P  &@              @ 'TX0( >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "GB6]810\$_HD"  #9
M0   $P              @ %?Y0( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    >P![ .0A   9Z (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>365</ContextCount>
  <ElementCount>578</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>132</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Surface Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisition</Role>
      <ShortName>Surface Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stock-Based Compensation and Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureRevenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureInventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Surface Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables</Role>
      <ShortName>Surface Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureSurfaceAcquisition</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Debt Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsTables</Role>
      <ShortName>Debt Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureDebtObligations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31101 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureStockholdersDeficit</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Stock-Based Compensation and Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40103 - Disclosure - Organization and Significant Accounting Policies - Investments in Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Investments in Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40106 - Disclosure - Organization and Significant Accounting Policies - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40110 - Disclosure - Organization and Significant Accounting Policies - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40112 - Disclosure - Organization and Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40114 - Disclosure - Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40116 - Disclosure - Organization and Significant Accounting Policies - Net Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Net Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40118 - Disclosure - Organization and Significant Accounting Policies - Cost of Goods Sold (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Cost of Goods Sold (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40119 - Disclosure - Organization and Significant Accounting Policies - Operating and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Operating and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40120 - Disclosure - Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40122 - Disclosure - Organization and Significant Accounting Policies - Reclassifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails</Role>
      <ShortName>Organization and Significant Accounting Policies - Reclassifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Revenue - Net Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails</Role>
      <ShortName>Revenue - Net Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails</Role>
      <ShortName>Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails</Role>
      <ShortName>Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Inventory - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryComponentsDetails</Role>
      <ShortName>Inventory - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails</Role>
      <ShortName>Inventory - Balance Sheet Classifications (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Inventory - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails</Role>
      <ShortName>Inventory - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails</Role>
      <ShortName>Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails</Role>
      <ShortName>Balance Sheet Components - Other Liabilities, Non-current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Surface Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails</Role>
      <ShortName>Surface Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Surface Acquisition - Consideration paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails</Role>
      <ShortName>Surface Acquisition - Consideration paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails</Role>
      <ShortName>Surface Acquisition - Estimated fair value of the net assets acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Surface Acquisition - The amount allocated to identifiable intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Surface Acquisition - The amount allocated to identifiable intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>40605 - Disclosure - Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails</Role>
      <ShortName>Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails</Role>
      <ShortName>Debt Obligations - Summary of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails</Role>
      <ShortName>Debt Obligations - 2027 Term Loan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2027 Term Loans Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails</Role>
      <ShortName>Debt Obligations - 2027 Term Loan Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails</Role>
      <ShortName>Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>40806 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails</Role>
      <ShortName>Debt Obligations - Capped Call Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>40807 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>40808 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails</Role>
      <ShortName>Debt Obligations - 2026 Convertible Notes Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>40809 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails</Role>
      <ShortName>Debt Obligations - Convertible Notes due 2022 Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>40810 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails</Role>
      <ShortName>Debt Obligations - 2025 Term Loan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>40811 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails</Role>
      <ShortName>Debt Obligations - 2025 Term Loan Interest Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Leases - Other information related to lease term and discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Other information related to lease term and discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Leases - Components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Leases - Supplemental cash flow information related to leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Supplemental cash flow information related to leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockholdersDeficitDetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureStockholdersDeficitTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>41206 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>41207 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>41208 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>41209 - Disclosure - Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>41210 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>41211 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>41212 - Disclosure - Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>41213 - Disclosure - Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails</Role>
      <ShortName>Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>41305 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>41306 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRestructuringChargesDetails</Role>
      <ShortName>Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureRestructuringCharges</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.coherus.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="chrs-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chrs-20231231.xsd</File>
    <File>chrs-20231231_cal.xml</File>
    <File>chrs-20231231_def.xml</File>
    <File>chrs-20231231_lab.xml</File>
    <File>chrs-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="chrs-20231231x10k.htm">chrs-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>chrs-20231231x10k007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1085">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>150
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "chrs-20231231x10k.htm": {
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "chrs-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "chrs-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "chrs-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "chrs-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 438,
   "keyCustom": 140,
   "axisStandard": 43,
   "axisCustom": 0,
   "memberStandard": 50,
   "memberCustom": 77,
   "hidden": {
    "total": 43,
    "http://fasb.org/us-gaap/2023": 29,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://www.coherus.com/20231231": 5,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "contextCount": 365,
   "entityCount": 1,
   "segmentCount": 132,
   "elementCount": 973,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1085,
    "http://xbrl.sec.gov/dei/2023": 42,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.coherus.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "00300 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
     "longName": "00400 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00500 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "10101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.coherus.com/role/DisclosureRevenue",
     "longName": "10201 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurements",
     "longName": "10301 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.coherus.com/role/DisclosureInventory",
     "longName": "10401 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponents",
     "longName": "10501 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisition",
     "longName": "10601 - Disclosure - Surface Acquisition",
     "shortName": "Surface Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements",
     "longName": "10701 - Disclosure - Collaborations and Other Arrangements",
     "shortName": "Collaborations and Other Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations",
     "longName": "10801 - Disclosure - Debt Obligations",
     "shortName": "Debt Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "10901 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.coherus.com/role/DisclosureLeases",
     "longName": "11001 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.coherus.com/role/DisclosureStockholdersDeficit",
     "longName": "11101 - Disclosure - Stockholders' Deficit",
     "shortName": "Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:StockholdersDeficitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:StockholdersDeficitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits",
     "longName": "11201 - Disclosure - Stock-Based Compensation and Employee Benefits",
     "shortName": "Stock-Based Compensation and Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxes",
     "longName": "11301 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.coherus.com/role/DisclosureNetLossPerShare",
     "longName": "11401 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.coherus.com/role/DisclosureRestructuringCharges",
     "longName": "11501 - Disclosure - Restructuring Charges",
     "shortName": "Restructuring Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.coherus.com/role/DisclosureRelatedPartyTransactions",
     "longName": "11601 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.coherus.com/role/DisclosureSubsequentEvents",
     "longName": "11701 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30103 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.coherus.com/role/DisclosureRevenueTables",
     "longName": "30203 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.coherus.com/role/DisclosureInventoryTables",
     "longName": "30403 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:ScheduleOfInventoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:ScheduleOfInventoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables",
     "longName": "30503 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables",
     "longName": "30603 - Disclosure - Surface Acquisition (Tables)",
     "shortName": "Surface Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsTables",
     "longName": "30803 - Disclosure - Debt Obligations (Tables)",
     "shortName": "Debt Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "30903 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:LongTermPurchaseCommitmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:LongTermPurchaseCommitmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.coherus.com/role/DisclosureLeasesTables",
     "longName": "31003 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.coherus.com/role/DisclosureStockholdersDeficitTables",
     "longName": "31101 - Disclosure - Stockholders' Deficit (Tables)",
     "shortName": "Stockholders' Deficit (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables",
     "longName": "31203 - Disclosure - Stock-Based Compensation and Employee Benefits (Tables)",
     "shortName": "Stock-Based Compensation and Employee Benefits (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesTables",
     "longName": "31303 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.coherus.com/role/DisclosureNetLossPerShareTables",
     "longName": "31403 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
     "longName": "40101 - Disclosure - Organization and Summary of Significant Accounting Policies - Organization (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "chrs:ProductPipelineNumberOfDrugCandidates",
      "unitRef": "Unit_Standard_product_SdGd84au20GyPZXZYh-a9w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "chrs:ProductPipelineNumberOfDrugCandidates",
      "unitRef": "Unit_Standard_product_SdGd84au20GyPZXZYh-a9w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "40102 - Disclosure - Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails",
     "longName": "40103 - Disclosure - Organization and Significant Accounting Policies - Investments in Marketable Securities (Details)",
     "shortName": "Organization and Significant Accounting Policies - Investments in Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails",
     "longName": "40106 - Disclosure - Organization and Significant Accounting Policies - Derivative Instruments (Details)",
     "shortName": "Organization and Significant Accounting Policies - Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DerivativesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DerivativesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
     "longName": "40110 - Disclosure - Organization and Significant Accounting Policies - Inventory (Details)",
     "shortName": "Organization and Significant Accounting Policies - Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "40112 - Disclosure - Organization and Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Organization and Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails",
     "longName": "40114 - Disclosure - Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies -Goodwill and Intangible Assets and Impairment of Long-Lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_Pb1Z3ozRJkOA77OkYuNphw",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
     "longName": "40116 - Disclosure - Organization and Significant Accounting Policies - Net Revenues (Details)",
     "shortName": "Organization and Significant Accounting Policies - Net Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails",
     "longName": "40118 - Disclosure - Organization and Significant Accounting Policies - Cost of Goods Sold (Details)",
     "shortName": "Organization and Significant Accounting Policies - Cost of Goods Sold (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2019_To_7_1_2019_peTS_V4r30KWdrPrMS7BCQ",
      "name": "chrs:RoyaltyPaymentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2019_To_7_1_2019_peTS_V4r30KWdrPrMS7BCQ",
      "name": "chrs:RoyaltyPaymentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails",
     "longName": "40119 - Disclosure - Organization and Significant Accounting Policies - Operating and Finance Leases (Details)",
     "shortName": "Organization and Significant Accounting Policies - Operating and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails",
     "longName": "40120 - Disclosure - Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details)",
     "shortName": "Organization and Significant Accounting Policies - Selling, General and Administrative Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:MarketingAndAdvertisingExpense",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:MarketingAndAdvertisingExpense",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails",
     "longName": "40122 - Disclosure - Organization and Significant Accounting Policies - Reclassifications (Details)",
     "shortName": "Organization and Significant Accounting Policies - Reclassifications (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "chrs:ReclassificationsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "chrs:ReclassificationsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails",
     "longName": "40201 - Disclosure - Revenue - Net Revenue (Details)",
     "shortName": "Revenue - Net Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_z6Il8N4kPkqJ7o0Wx5ZYXQ",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails",
     "longName": "40202 - Disclosure - Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)",
     "shortName": "Revenue - Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_bG3CyRk7Ckyq7Y946J92rQ",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_bG3CyRk7Ckyq7Y946J92rQ",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails",
     "longName": "40203 - Disclosure - Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)",
     "shortName": "Revenue - Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ",
      "name": "chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw",
      "name": "chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails",
     "longName": "40301 - Disclosure - Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Financial Assets Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
     "longName": "40302 - Disclosure - Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)",
     "shortName": "Fair Value Measurements - Cost, Unrealized Gains or Losses, and Fair Value by Investment Type (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "th",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "th",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "40303 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_9_8_2023_To_12_31_2023_Oq6suCh5tUWT6TFeG9xafw",
      "name": "us-gaap:LiabilitiesFairValueAdjustment",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_8_2023_To_12_31_2023_Oq6suCh5tUWT6TFeG9xafw",
      "name": "us-gaap:LiabilitiesFairValueAdjustment",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.coherus.com/role/DisclosureInventoryComponentsDetails",
     "longName": "40401 - Disclosure - Inventory - Components (Details)",
     "shortName": "Inventory - Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails",
     "longName": "40402 - Disclosure - Inventory - Balance Sheet Classifications (Details)",
     "shortName": "Inventory - Balance Sheet Classifications (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:InventoryNet",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "chrs:InventoryCurrentAndNoncurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
     "longName": "40403 - Disclosure - Inventory - Additional Information (Details)",
     "shortName": "Inventory - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "chrs:PrepaymentsMadeToCmoForManufacturingServices",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "40501 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "40502 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
     "longName": "40503 - Disclosure - Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)",
     "shortName": "Balance Sheet Components - Goodwill and Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "40504 - Disclosure - Balance Sheet Components - Accrued and Other Current Liabilities (Details)",
     "shortName": "Balance Sheet Components - Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails",
     "longName": "40505 - Disclosure - Balance Sheet Components - Other Liabilities, Non-current (Details)",
     "shortName": "Balance Sheet Components - Other Liabilities, Non-current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails",
     "longName": "40601 - Disclosure - Surface Acquisition (Details)",
     "shortName": "Surface Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ",
      "name": "chrs:BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
     "longName": "40602 - Disclosure - Surface Acquisition - Consideration paid (Details)",
     "shortName": "Surface Acquisition - Consideration paid (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails",
     "longName": "40603 - Disclosure - Surface Acquisition - Estimated fair value of the net assets acquired (Details)",
     "shortName": "Surface Acquisition - Estimated fair value of the net assets acquired (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
     "longName": "40604 - Disclosure - Surface Acquisition - The amount allocated to identifiable intangible assets (Details)",
     "shortName": "Surface Acquisition - The amount allocated to identifiable intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_aK8ibHz1PEqs0z1M6Yn7Sg",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails",
     "longName": "40605 - Disclosure - Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)",
     "shortName": "Surface Acquisition - Unaudited Pro Forma Summary of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
     "longName": "40701 - Disclosure - Collaborations and Other Arrangements (Details)",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
     "longName": "40801 - Disclosure - Debt Obligations - Summary of Debt Obligations (Details)",
     "shortName": "Debt Obligations - Summary of Debt Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "th",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "th",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
     "longName": "40802 - Disclosure - Debt Obligations - 2027 Term Loan - Narrative (Details)",
     "shortName": "Debt Obligations - 2027 Term Loan - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
     "longName": "40803 - Disclosure - Debt Obligations - 2027 Term Loans Interest Expense Components (Details)",
     "shortName": "Debt Obligations - 2027 Term Loans Interest Expense Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
     "longName": "40804 - Disclosure - Debt Obligations - 2027 Term Loan Future Payments (Details)",
     "shortName": "Debt Obligations - 2027 Term Loan Future Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
     "longName": "40805 - Disclosure - Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)",
     "shortName": "Debt Obligations - Convertible Senior Subordinated Notes due 2026 - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_0bsmQzQVxkiRBstBPBwZjw",
      "name": "chrs:NumberOfEventsInDefault",
      "unitRef": "Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtInstrumentCovenantCompliance",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails",
     "longName": "40806 - Disclosure - Debt Obligations - Capped Call Transactions - Narrative (Details)",
     "shortName": "Debt Obligations - Capped Call Transactions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA",
      "name": "chrs:PaymentForCappedCallTransactions",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
     "longName": "40807 - Disclosure - Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)",
     "shortName": "Debt Obligations - 2026 Convertible Notes Interest Expense Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
     "longName": "40808 - Disclosure - Debt Obligations - 2026 Convertible Notes Future Payments (Details)",
     "shortName": "Debt Obligations - 2026 Convertible Notes Future Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
     "longName": "40809 - Disclosure - Debt Obligations - Convertible Notes due 2022 Narrative (Details)",
     "shortName": "Debt Obligations - Convertible Notes due 2022 Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_IYOtI7t0s06IRoQfEZsvfg",
      "name": "us-gaap:DebtInstrumentInterestRateTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
     "longName": "40810 - Disclosure - Debt Obligations - 2025 Term Loan - Narrative (Details)",
     "shortName": "Debt Obligations - 2025 Term Loan - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_7_2019_To_1_7_2019_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ESE6x74w_0eBsyYKVq7Vhw",
      "name": "us-gaap:DebtInstrumentInterestRateTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
     "longName": "40811 - Disclosure - Debt Obligations - 2025 Term Loan Interest Expense Components (Details)",
     "shortName": "Debt Obligations - 2025 Term Loan Interest Expense Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails",
     "longName": "40901 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Non-Cancelable Contractual Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongTermPurchaseCommitmentTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LongTermPurchaseCommitmentTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2022_To_4_30_2022_oL0nzgyjPkiv7bL6dvw4Sw",
      "name": "us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2022_To_4_30_2022_oL0nzgyjPkiv7bL6dvw4Sw",
      "name": "us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "41001 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_24_2023_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_2VupKf10C0ysFKHcmA-N7Q",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails",
     "longName": "41002 - Disclosure - Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails",
     "longName": "41003 - Disclosure - Leases - Other information related to lease term and discount rate (Details)",
     "shortName": "Leases - Other information related to lease term and discount rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails",
     "longName": "41004 - Disclosure - Leases - Components of lease expense (Details)",
     "shortName": "Leases - Components of lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails",
     "longName": "41005 - Disclosure - Leases - Supplemental cash flow information related to leases (Details)",
     "shortName": "Leases - Supplemental cash flow information related to leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "th",
       "tr",
       "table",
       "chrs:ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "th",
       "tr",
       "table",
       "chrs:ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails",
     "longName": "41006 - Disclosure - Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Operating and Finance Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
     "longName": "41101 - Disclosure - Stockholders' Deficit (Details)",
     "shortName": "Stockholders' Deficit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails",
     "longName": "41201 - Disclosure - Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Equity Incentive Plans Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_7crZcL4mN0ypA7JbGnmqqA",
      "name": "chrs:RateOfIncreaseInNumberOfCommonStockAvailableForIssuance",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_7crZcL4mN0ypA7JbGnmqqA",
      "name": "chrs:RateOfIncreaseInNumberOfCommonStockAvailableForIssuance",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails",
     "longName": "41202 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Stock Options Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails",
     "longName": "41203 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Summary of Option Activities Under 2016 and 2014 Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
     "longName": "41204 - Disclosure - Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Options outstanding and exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
     "longName": "41205 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Additional Information Related to Status of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "chrs:ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
     "longName": "41206 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Restricted Stock Units - narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails",
     "longName": "41207 - Disclosure - Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Summary of RSUs Activity, under 2014 Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
     "longName": "41208 - Disclosure - Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Restricted Stock Units - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
     "longName": "41209 - Disclosure - Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails",
     "longName": "41210 - Disclosure - Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Stock-Based Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "Duration_2_1_2021_To_2_28_2021_NvtDoX2JKU-V8xqMiC3p8w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
     "longName": "41211 - Disclosure - Stock-Based Compensation and Employee Benefits - Additional Information (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R102": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails",
     "longName": "41212 - Disclosure - Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
     "longName": "41213 - Disclosure - Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)",
     "shortName": "Stock-Based Compensation and Employee Benefits - 401(k) Retirement Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails",
     "longName": "41301 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails",
     "longName": "41302 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)",
     "shortName": "Income Taxes - Income Tax Provision (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails",
     "longName": "41303 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Statutory U.S. Federal Rate to The Company's Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "longName": "41304 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesDetails",
     "longName": "41305 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "41306 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "41401 - Disclosure - Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
     "longName": "41501 - Disclosure - Restructuring Charges (Details)",
     "shortName": "Restructuring Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "Duration_3_10_2023_To_3_10_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_4wHJPeiz5EGGZlHVcqOJhg",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_AAmVcdTDXkmNakyN2ltl5g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_10_2023_To_3_10_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_4wHJPeiz5EGGZlHVcqOJhg",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_AAmVcdTDXkmNakyN2ltl5g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "41601 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.coherus.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41701 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A",
      "name": "chrs:DebInstrumentPartialRepaymentPrincipal",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A",
      "name": "chrs:DebInstrumentPartialRepaymentPrincipal",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "114",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R115": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "115",
     "firstAnchor": null,
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Notes And Loans Receivable [Line Items]",
        "terseLabel": "Accounts Notes And Loans Receivable",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r834"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts payable",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Non-cash amortization of premium (accretion of discount) on marketable securities, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "chrs_AccruedAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued and other current liabilities.",
        "label": "Accrued and other current liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AccruedCoDevelopmentCostsAndMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedCoDevelopmentCostsAndMilestonePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued co-development costs and milestone payments",
        "label": "The amount represents Accrued co-development costs and milestone payments.",
        "terseLabel": "Accrued co-development costs and milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued commercial and research and development manufacturing liabilities current.",
        "label": "Accrued Commercial and Research and Development Manufacturing Liabilities Current",
        "terseLabel": "Accrued commercial and research and development manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total Accrued and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "chrs_AccruedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for milestone payments.",
        "label": "Accrued Milestone Payment",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AccruedRebatesFeesAndReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedRebatesFeesAndReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued rebates, fees and reserve.",
        "label": "Accrued Rebates Fees And Reserve Current",
        "terseLabel": "Accrued rebates, fees and reserves"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AccruedRebatesFeesAndReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedRebatesFeesAndReservesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued rebates, fees and reserves.",
        "label": "Accrued Rebates, Fees And Reserves [Member]",
        "terseLabel": "Accrued rebates, fees and reserves"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r795"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties",
        "terseLabel": "Royalties due",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r139",
      "r218",
      "r666",
      "r690",
      "r691"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r17",
      "r44",
      "r548",
      "r551",
      "r596",
      "r686",
      "r687",
      "r960",
      "r961",
      "r962",
      "r972",
      "r973",
      "r974"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Useful Lives",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments upon achievement of certain development and regulatory milestones.",
        "label": "Additional Milestone Payments Upon Achievement Of Certain Development And Regulatory Milestones",
        "verboseLabel": "Maximum aggregate milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments upon achievement of with subject to FDA approval",
        "label": "Additional Milestone Payments Upon Achievement With Subject To FDA Approval",
        "terseLabel": "Additional milestone payments related to FDA approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r834",
      "r1071"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r702",
      "r972",
      "r973",
      "r974",
      "r1045",
      "r1073"
     ]
    },
    "chrs_AdimabDevelopmentAndOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AdimabDevelopmentAndOptionAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Adimab Development and Option Agreement.",
        "label": "Adimab Development and Option Agreement [Member]",
        "terseLabel": "Adimab Development and Option Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of RSUs",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r452"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r870",
      "r880",
      "r906"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r873",
      "r883",
      "r909"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r874",
      "r884",
      "r901",
      "r910",
      "r914",
      "r922"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r497"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AmeriSourceBergenCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AmeriSourceBergenCorpMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmeriSource-Bergen Corp.",
        "label": "AmeriSource-Bergen Corp [Member]",
        "terseLabel": "Cencora (previously known as AmeriSource-Bergen Corporation)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Non-cash interest expense from amortization of debt discount and issuance costs",
        "verboseLabel": "Amortization of debt discount and debt issuance costs",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r112",
      "r147",
      "r414"
     ]
    },
    "chrs_AntiTigitAntibodyAndIl2CytokineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AntiTigitAntibodyAndIl2CytokineMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents anti-TIGIT antibody and the IL-2 cytokine.",
        "label": "Anti-TIGIT Antibody and IL-2 cytokine",
        "terseLabel": "Anti-TIGIT Antibody and IL-2 cytokine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "verboseLabel": "Antidilutive securities excluded from the calculation of diluted net (loss) income per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities excluded from computation of EPS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area Of Real Estate Property",
        "terseLabel": "Area of office space leased",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails",
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r217",
      "r248",
      "r282",
      "r291",
      "r295",
      "r333",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r541",
      "r545",
      "r565",
      "r662",
      "r734",
      "r834",
      "r847",
      "r1003",
      "r1004",
      "r1053"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r221",
      "r248",
      "r333",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r541",
      "r545",
      "r565",
      "r834",
      "r1003",
      "r1004",
      "r1053"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total financial assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "chrs_AtMarketOfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AtMarketOfferingLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent at the market offering.",
        "label": "At The Market Offering [Line Items]",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to at the market offering issuance.",
        "label": "At The Market Offering."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_AtMarketOfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "AtMarketOfferingTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "Stockholders' Deficit [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r866"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r866"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r866"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized (Loss)",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r341",
      "r661"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r341",
      "r655",
      "r981"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Components"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "chrs_BioeqIPAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BioeqIPAGMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioeq IP AG.",
        "label": "Bioeq IP AG",
        "terseLabel": "Bioeq IP AG"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BiopharmaCreditInvestmentsVGpLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BiopharmaCreditInvestmentsVGpLlcMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to BioPharma Credit Investments V GP LLC.",
        "label": "BioPharma Credit Investments V GP LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r825",
      "r826"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92",
      "r536",
      "r825",
      "r826"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Coherus common stock issued",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Surface Acquisition",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of pro forma information does not purport to represent what the Company's actual results would have been if the acquisition had occurred as of January 1, 2022",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total revenues",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r535"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationContingentValueRightPaymentPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The payment period of contingent value rights under business combination.",
        "label": "Business Combination, Consideration, Contingent Value Right, Payment Period",
        "terseLabel": "Contingent value rights payment period"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of milestone and royalty based payments payable as part of contingent value rights under business combination.",
        "label": "Business Combination, Consideration, Contingent Value Right Payments, Percent of Milestone and Royalty Based Payments",
        "terseLabel": "Milestone and royalty based CVR payments (as percent)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of upfront payments payable as part of contingent value rights under business combination.",
        "label": "Business Combination, Consideration, Contingent Value Right Payments, Percent of Upfront Payments",
        "terseLabel": "Upfront payment based CVR payments (as percent)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationConsiderationContingentValueRightPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationContingentValueRightPerShare",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of contingent value rights issuable in consideration for each share under business combination.",
        "label": "Business Combination, Consideration, Contingent Value Right Per Share",
        "terseLabel": "Contingent value right per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Business combination consideration transferred",
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r15"
     ]
    },
    "chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, equity of combined company owned by acquiree equity holders.",
        "label": "Business Combination Consideration Transferred, Equity of Combined Company Owned by Acquiree Equity Holders",
        "terseLabel": "Equity of combined company owned by Surface equity holders"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, equity of combined company owned by acquiree former employees.",
        "label": "Business Combination Consideration Transferred, Equity of Combined Company Owned by Acquiree Former Employees",
        "terseLabel": "Equity of combined company owned by Surface former employees (1)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred for inventory and prepaid manufacturing assets.",
        "label": "Business Combination Consideration Transferred, Inventory And Prepaid Manufacturing Assets",
        "terseLabel": "Consideration transferred for CIMERLI product inventory and prepaid manufacturing assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetailss": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Contingent CVR liability",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r96",
      "r538"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r97"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Contingent Consideration Liability Noncurrent",
        "terseLabel": "Contingent consideration, non-current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r97"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Surface Acquisition",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r537"
     ]
    },
    "chrs_BusinessCombinationNumberOfOutLicensedPartnershipProgram": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationNumberOfOutLicensedPartnershipProgram",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of outlicensed partnership program in a business combination.",
        "label": "Business Combination, Number of Out Licensed Partnership Program",
        "terseLabel": "Business Combination, Number of Out Licensed Partnership Program"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in exchange of each share of acquiree in a business combination.",
        "label": "Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree",
        "terseLabel": "Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued to former employees of acquiree.",
        "label": "Business Combination, Number of Shares Issued to Former Employees of Acquiree shares",
        "terseLabel": "Business Combination, Number of Shares Issued to Former Employees of Acquiree shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Earnings or Loss of Acquiree since Acquisition Date",
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of Acquiree since Acquisition Date",
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "chrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued and other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued and Other Current Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Assets Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Investments in marketable securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Other prepaids and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liability",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Identifiable intangible assets",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities Assumed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetailss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total net assets acquired",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Surface Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block]",
        "terseLabel": "Business Combination Accounting &amp; Valuation of Acquired Assets",
        "documentation": "Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1"
     ]
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CallOptionMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capped Call Transactions in connection with the 2026 Convertible Notes",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776"
     ]
    },
    "chrs_CapPriceOfCapCallTransactions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CapPriceOfCapCallTransactions",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the cap price of the cap call transactions (per share).",
        "label": "Cap Price of Cap Call Transactions",
        "terseLabel": "Initial cap price of capped call transactions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedComputerSoftwareNet",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Software implementation costs",
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "chrs_CardinalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CardinalMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal.",
        "label": "Cardinal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash and cash equivalents acquired from Surface Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r213",
      "r793"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r181"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r152",
      "r246"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r152"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "chrs_ChargebacksAndDiscountsForPromptPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge backs and discounts for prompt payment.",
        "label": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ChiefMarketingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ChiefMarketingOfficerMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to chief marketing officer.",
        "label": "Chief Marketing Officer [Member]",
        "terseLabel": "CMO"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_Chs006AntiTigitAntibodyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "Chs006AntiTigitAntibodyMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents CHS-006 anti-TIGIT antibody.",
        "label": "CHS-006 Anti-TIGIT Antibody [Member]",
        "terseLabel": "CHS-006 anti-TIGIT antibody"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_Chs2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "Chs2020Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents CHS-2020, a biosimilar of Eylea.",
        "label": "CHS-2020"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CimerliDivestitureTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CimerliDivestitureTransactionMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to CIMERLI Divestiture transaction.",
        "label": "CIMERLI Divestiture Transaction [Member]",
        "terseLabel": "CIMERLI Disposition Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CimerliMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CimerliMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the product CIMERLI.",
        "label": "CIMERLI"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CoDevelopmentRegulatoryAndTechnologyTransferCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents co-development, regulatory and technology transfer costs.",
        "label": "Co-development, Regulatory And Technology Transfer Costs",
        "terseLabel": "Co-development, regulatory and technology transfer costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "chrs_CoherusOphthalmologyLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CoherusOphthalmologyLlcMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Coherus Ophthalmology LLC Divesture Transaction.",
        "label": "Coherus Ophthalmology LLC [Member]",
        "terseLabel": "Coherus Ophthalmology LLC"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional clinical milestones eligible to receive",
        "label": "Collaboration Agreement, Additional Clinical Milestones Eligible to Receive",
        "terseLabel": "Additional clinical milestones eligible to receive"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementAdditionalPaymentToBeMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementAdditionalPaymentToBeMade",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment to be made",
        "label": "Collaboration Agreement, Additional Payment to be Made",
        "terseLabel": "Additional payment to be made"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration term from the effective date without providing materials that pass quality control",
        "label": "Collaboration Agreement, Expiration Term From the Effective Date Without Providing Materials that Pass Quality Control",
        "terseLabel": "Expiration term from the effective date without providing materials that pass quality control"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payments to be made",
        "label": "Collaboration Agreement, Maximum Aggregate Milestone Payments to be Made",
        "terseLabel": "Maximum aggregate milestone payments to be made"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds",
        "label": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds",
        "terseLabel": "Collaboration agreement, Maximum aggregate one-time payments for the achievement of various regulatory and sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.",
        "label": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program",
        "terseLabel": "Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementMilestonePaymentsEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementMilestonePaymentsEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments earned",
        "label": "Collaboration Agreement, Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementOptionExerciseFeePerProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementOptionExerciseFeePerProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of option exercise fee per program under the collaboration agreement.",
        "label": "Collaboration Agreement, Option Exercise Fee Per Program",
        "terseLabel": "License Agreement Fee"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementPercentageOfRoyaltyOnNetSales",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalty on net sales under the collaboration agreement.",
        "label": "Collaboration Agreement, Percentage Of Royalty On Net Sales",
        "terseLabel": "Collaboration agreement, royalty on net sales, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of royalty on net sales for each option program under the collaboration agreement.",
        "label": "Collaboration Agreement, Percentage Of Royalty On Net Sales For Each Option Program",
        "terseLabel": "Collaboration agreement, royalty on net sales for each exercised option, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for payment of nominal research maintenance fee",
        "label": "Collaboration Agreement, Period for Payment of Nominal Research Maintenance Fee",
        "terseLabel": "Period for payment of nominal research maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementRegulatoryMilestonesEligibleToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementRegulatoryMilestonesEligibleToReceive",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of regulatory milestones eligible to receive",
        "label": "Collaboration Agreement, Regulatory Milestones Eligible to Receive",
        "terseLabel": "Regulatory milestones eligible to receive"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technical milestone payments obligated to pay",
        "label": "Collaboration Agreement, Technical Milestone Payments Obligated to Pay",
        "terseLabel": "Technical milestone payments obligated to pay"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement",
        "label": "Collaboration Agreement, Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.",
        "label": "Collaboration Agreement , Threshold Payments On Achievement Of Various Milestone For Each Option Program",
        "terseLabel": "Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaborations and Other Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_CollaborationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CollaborationCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents costs associated to a collaboration agreement.",
        "label": "Collaboration Costs",
        "terseLabel": "Collaboration Agreement, upfront amount paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r196",
      "r207"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions",
        "verboseLabel": "Cost of Goods Sold",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r119",
      "r664",
      "r721"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r375",
      "r376",
      "r787",
      "r997"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r838",
      "r839",
      "r841",
      "r842",
      "r843",
      "r844",
      "r972",
      "r973",
      "r1045",
      "r1069",
      "r1073"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "chrs_CommonStockRemainingAvailableForSaleUnderAtmOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CommonStockRemainingAvailableForSaleUnderAtmOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the common stock remaining available for sale under the atm offering.",
        "label": "Common Stock Remaining Available For Sale Under The ATM Offering",
        "terseLabel": "Common stock remaining available for sales under the ATM Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r722"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r133",
      "r722",
      "r740",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Value",
        "terseLabel": "Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 112,215,260 and 78,851,516 at December 31, 2023 and 2022, respectively)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r665",
      "r834"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r177",
      "r228",
      "r230",
      "r237",
      "r657",
      "r676"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment and software",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r110",
      "r111",
      "r299",
      "r786"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r110",
      "r111",
      "r299",
      "r692",
      "r786"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r110",
      "r111",
      "r299",
      "r786",
      "r935"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r198"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Percentage of total gross revenue",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r110",
      "r111",
      "r299"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60",
      "r61",
      "r110",
      "r180",
      "r786"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r110",
      "r111",
      "r299",
      "r786"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Basis of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r799"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ConsultingAgreementWithLanfearAdvisorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ConsultingAgreementWithLanfearAdvisorsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consulting agreement with Lanfear advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, our President, Chief Executive Officer and Chairman of our Board of Directors.",
        "label": "Consulting Agreement With Lanfear Advisors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "terseLabel": "Contingent consideration",
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "chrs_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ContingentConsiderationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ContingentConsiderationPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Information pertaining to Consideration which is contingent upon some future changes in assumptions.",
        "label": "Contingent Consideration [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum remaining period until maturity of the investment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Contractual Maturities of Available-for-sale Debt Securities, Remaining Maturity",
        "terseLabel": "Remaining contractual maturities of available-for-sale securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationFiscalYearMaturityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r393",
      "r394",
      "r404",
      "r405",
      "r406",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "chrs_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes.",
        "label": "Shares issuable upon conversion of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r186",
      "r1065"
     ]
    },
    "chrs_ConvertibleNotesPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ConvertibleNotesPrincipalAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes, principal amount.",
        "label": "Convertible Notes Principal Amount",
        "terseLabel": "2026 Convertible Notes, principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ConvertibleSeniorNotes8.2PercentDue2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ConvertibleSeniorNotes8.2PercentDue2022Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 8.2% Convertible Senior Notes due 2022.",
        "label": "8.2% Convertible Notes due 2022"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ConvertibleSeniorSubordinatedNotesDue20261.5Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 1.5% Convertible Senior Subordinated Notes due 2026.",
        "label": "1.5% Convertible Senior Subordinated Notes due 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleSubordinatedDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleSubordinatedDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Subordinated Debt, Noncurrent",
        "terseLabel": "Convertible notes",
        "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "chrs_CorporateHeadquartersLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "CorporateHeadquartersLeaseAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters lease agreement.",
        "label": "Corporate Headquarters Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Commercial paper and corporate notes",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Sold Goods",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r639"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods Sold",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Sales Policy [Text Block]",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r396",
      "r425",
      "r602",
      "r796",
      "r798"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r299"
     ]
    },
    "chrs_DebInstrumentPartialRepaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebInstrumentPartialRepaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of partial repayment of principal of the loans subject to terms and conditions.",
        "label": "Deb Instrument, Partial Repayment, Principal",
        "terseLabel": "Partial prepayment of principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion Converted Instrument Amount1",
        "terseLabel": "Convertible notes, converted amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Obligations",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r247",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r408",
      "r415",
      "r416",
      "r418"
     ]
    },
    "chrs_DebtDiscountsAndIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtDiscountsAndIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt discounts and issuance costs incurred.",
        "label": "Debt Discounts and Issuance Costs",
        "terseLabel": "Debt discounts and issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r127",
      "r128",
      "r183",
      "r186",
      "r254",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r576",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Spread on variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Carrying Amount",
        "totalLabel": "Total minimum payments",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r186",
      "r419"
     ]
    },
    "chrs_DebtInstrumentContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtInstrumentContractualTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debt instrument contractual term.",
        "label": "Debt Instrument Contractual Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument convertible number of shares per thousand of principal amount of notes.",
        "label": "Debt Instrument Convertible Number Of Shares Per Thousand Of Principal Amount Of Notes",
        "terseLabel": "Initial conversion rate, shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCovenantCompliance",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Covenant Compliance",
        "terseLabel": "Convertible notes, covenant compliance",
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r122"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Principal Amount",
        "verboseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r115",
      "r393",
      "r576",
      "r810",
      "r811"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Fair Value",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r564",
      "r810",
      "r811"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r113",
      "r411"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r113",
      "r422",
      "r576"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r394"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Interest Rate Terms",
        "terseLabel": "Interest rate description",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r576",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Debt instrument maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r809",
      "r1046"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r254",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r576",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r969"
     ]
    },
    "chrs_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of committed tranches.",
        "label": "Debt Instrument, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_DebtInstrumentPrepaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtInstrumentPrepaymentPercentage",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment percentage.",
        "label": "Debt Instrument Prepayment Percentage",
        "terseLabel": "Prepayment premium percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Through March 31, 2023",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Starting April 1, 2023",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "chrs_DebtInstrumentRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtInstrumentRemainingTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debt instrument remaining term.",
        "label": "Debt Instrument Remaining Term",
        "terseLabel": "Remaining term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r76",
      "r77",
      "r112",
      "r113",
      "r115",
      "r121",
      "r165",
      "r166",
      "r254",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r576",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r969"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Term",
        "terseLabel": "Total term of the loan",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedTerseLabel": "Less unamortized debt discount and debt issuance costs",
        "terseLabel": "Remaining unamortized debt discount and debt offering costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r404",
      "r420",
      "r810",
      "r811"
     ]
    },
    "chrs_DebtInstrumentUncommittedAdditionalFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DebtInstrumentUncommittedAdditionalFacility",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of uncommitted additional facility that is available to the entity as of the balance sheet date.",
        "label": "Debt Instrument, Uncommitted Additional Facility",
        "terseLabel": "Uncommitted additional facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Amount not funded",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Impairments related to credit losses",
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Positions that were in unrealized loss positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r343"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Finance Costs Gross",
        "terseLabel": "Convertible notes, Issuance Cost",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "terseLabel": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense Benefit",
        "totalLabel": "Subtotal",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r173",
      "r203",
      "r527",
      "r528",
      "r971"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "chrs_DeferredTaxAssetLiabilityNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r184",
      "r517"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r663"
     ]
    },
    "chrs_DeferredTaxAssetLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DeferredTaxAssetLiabilityNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets before valuation allowance net of deferred tax liabilities.",
        "label": "Deferred Tax Asset Liability Net",
        "totalLabel": "Total net deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "chrs_DeferredTaxAssetLiabilityNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Liabilities Net",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Depreciation and amortization",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other",
        "terseLabel": "Other accruals",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances",
        "terseLabel": "Sales related accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1040"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1039"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs",
        "negatedLabel": "In-process research and development",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r1040"
     ]
    },
    "chrs_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Compensation expense related to match plan",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Percentage of employer matching contributions",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "First amount of each participant's contributions",
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent",
        "terseLabel": "Percentage of maximum contribution of annual compensation",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r71"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense related to property and equipment, net",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r287"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r564",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r728",
      "r729",
      "r776",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r798",
      "r839",
      "r1070"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r564",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r735",
      "r737",
      "r738",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r798",
      "r1070"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r100",
      "r101",
      "r102",
      "r105",
      "r253"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net product revenue in United States, and Company's net revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation and Employee Benefits",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r454",
      "r486",
      "r487",
      "r489",
      "r828"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation and Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Expense relating to the discontinuation of CHS-2020",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r866"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r866",
      "r902"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_EarlyRedemptionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EarlyRedemptionFee",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment fees for paying off debt early.",
        "label": "Early Redemption Fee",
        "terseLabel": "Prepayment fees for partial debt repayment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic",
        "terseLabel": "Basic (In dollar per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r270",
      "r272",
      "r274",
      "r275",
      "r276",
      "r280",
      "r555",
      "r556",
      "r658",
      "r677",
      "r803"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Diluted (In dollar per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r272",
      "r274",
      "r275",
      "r276",
      "r280",
      "r555",
      "r556",
      "r658",
      "r677",
      "r803"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]",
        "terseLabel": "Percent of pre-tax income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "United States federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r508",
      "r530"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock based compensation costs",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1043"
     ]
    },
    "chrs_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "terseLabel": "Permanent items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1043"
     ]
    },
    "chrs_EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfStatutoryUsFederalRateToCompanySEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation tax (expense) and credits research.",
        "label": "Effective Income Tax Rate Reconciliation Tax Expense And Credits Research",
        "terseLabel": "Research and development credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount",
        "terseLabel": "Stock-based compensation expense capitalized into inventory",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized share-based compensation related to stock options, RSUs and ESPP, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized stock-based compensation expenses related to unvested RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized stock-based compensation expenses related to stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "chrs_EmployeeServiceShareBasedCompensationOfferingPeriodOne": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationOfferingPeriodOne",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation offering period one.",
        "label": "Employee Service Share Based Compensation Offering Period One",
        "terseLabel": "Employee stock purchase plan offering period one"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_EmployeeServiceShareBasedCompensationOfferingPeriodTwo": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationOfferingPeriodTwo",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation offering period two.",
        "label": "Employee Service Share Based Compensation Offering Period Two",
        "terseLabel": "Employee stock purchase plan offering period two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_EmployeesAndNonemployeesStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EmployeesAndNonemployeesStockOptionMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and non-employees stock option.",
        "label": "Stock options, including shares subject to ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_EmploymentCommencementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EmploymentCommencementIncentivePlanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Employment Commencement Incentive Plan.",
        "label": "2016 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "verboseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "verboseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "verboseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r208",
      "r232",
      "r233",
      "r234",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267",
      "r281",
      "r334",
      "r335",
      "r427",
      "r490",
      "r491",
      "r492",
      "r523",
      "r524",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r596",
      "r686",
      "r687",
      "r688",
      "r702",
      "r765"
     ]
    },
    "chrs_EquityPlan2016PlanAnd2014PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EquityPlan2016PlanAnd2014PlanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 and 2014 Plan.",
        "label": "2016 plan and 2014 plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "chrs_EquivalentToConversionPricePerCommonShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "EquivalentToConversionPricePerCommonShare",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equivalent to conversion price per common share.",
        "label": "Equivalent To Conversion Price Per Common Share",
        "terseLabel": "Initial conversion price per common share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r870",
      "r880",
      "r906"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "chrs_ExercisePriceRange1.67To5.44Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ExercisePriceRange1.67To5.44Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents the exercise price range 1.67 to 5.44.",
        "label": "Exercise Price Range 1.67 To 5.44 [Member]",
        "terseLabel": "1.67 - 5.44"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ExercisePriceRange10.37To13.63Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ExercisePriceRange10.37To13.63Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents the exercise price range 10.37 to 13.63.",
        "label": "Exercise Price Range 10.37 To 13.63 [Member]",
        "terseLabel": "10.37 - 13.63"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ExercisePriceRange14.03To17.17Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ExercisePriceRange14.03To17.17Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents the exercise price range 14.03 to 17.17.",
        "label": "Exercise Price Range 14.03 To 17.17 [Member]",
        "terseLabel": "14.03 - 17.17"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ExercisePriceRange17.30To19.40Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ExercisePriceRange17.30To19.40Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents the exercise price range 17.30 to 19.40.",
        "label": "Exercise Price Range 17.30 To 19.40 [Member]",
        "terseLabel": "17.30 - 19.40"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ExercisePriceRange19.85To46.38Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ExercisePriceRange19.85To46.38Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents the exercise price range 19.85 to 46.38.",
        "label": "Exercise Price Range 19.85 To 46.38 [Member]",
        "terseLabel": "19.85 - 46.38"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ExercisePriceRange5.86To10.05Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ExercisePriceRange5.86To10.05Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "it represents the exercise price range 5.86 to 10.05.",
        "label": "Exercise Price Range 5.86 To 10.05 [Member]",
        "terseLabel": "5.86 - 10.05"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets measured at fair value on a recurring basis",
        "verboseLabel": "Cost, Unrealized Gains or Losses, and Fair Value by Investment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r562"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r562"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r559",
      "r610",
      "r611",
      "r612",
      "r810",
      "r811",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r179"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r561",
      "r563"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "chrs_FairValueForDiscountForLackOfMarketability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "FairValueForDiscountForLackOfMarketability",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value for the discount for lack of marketability (DLOM).",
        "label": "Fair Value for the Discount for Lack of Marketability",
        "terseLabel": "Fair value for the discount for lack of marketability (DLOM)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r440",
      "r445",
      "r559",
      "r610",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r440",
      "r445",
      "r559",
      "r611",
      "r810",
      "r811",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r559",
      "r612",
      "r810",
      "r811",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r610",
      "r611",
      "r612",
      "r810",
      "r811",
      "r822",
      "r823",
      "r824"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements Recurring Basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r563"
     ]
    },
    "chrs_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of finance lease cost incurred during the period.",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "chrs_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r589",
      "r833"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Financing cash flows from finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r591"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails",
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "totalLabel": "Total finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r595"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating and finance lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Operating cash flows from finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r591"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": "chrs_OperatingAndFinanceLeaseRightOfUseAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "chrs_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r589",
      "r833"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease Weighted average discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r833"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance lease weighted average remaining term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r833"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r417",
      "r426",
      "r553",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r675",
      "r807",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Schedule of amount allocated to identifiable intangible assets",
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized in each of five succeeding fiscal years. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, for Each of Five Succeeding Fiscal Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r359"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r359",
      "r361",
      "r640",
      "r641"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived assets, net of accumulated amortization of $639 and $61, respectively",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r640"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining life of the finite-lived assets",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r910"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnContractTermination",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Contract Termination",
        "negatedLabel": "Write-off of prepaid manufacturing services related to the termination of CHS-2020",
        "negatedTerseLabel": "Impairment charge within research and development expenses",
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r73",
      "r74"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r352",
      "r654",
      "r808",
      "r834",
      "r988",
      "r989"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Goodwill Policy",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r355",
      "r808"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill Impairment Loss",
        "terseLabel": "Impairment of goodwill",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r353",
      "r354",
      "r355",
      "r808"
     ]
    },
    "chrs_GskAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "GskAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to GSK Agreement.",
        "label": "GSK Agreement [Member]",
        "terseLabel": "GSK Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_HealthcareRoyaltyPartnersIIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "HealthcareRoyaltyPartnersIIILPMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Royalty Partners III, L.P.",
        "label": "Lender"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r866"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r24"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-lived",
        "verboseLabel": "Long lived assets, material impairments",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r990"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process research and development",
        "terseLabel": "In-process research and development",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_InProcessResearchAndDevelopmentSrf114Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "InProcessResearchAndDevelopmentSrf114Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to In-process research and development - SRF114.",
        "label": "In Process Research and Development SRF 114 [Member]",
        "terseLabel": "In-process research and development - SRF 114"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_InProcessResearchAndDevelopmentSrf388Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "InProcessResearchAndDevelopmentSrf388Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to In-process research and development - SRF388.",
        "label": "In Process Research and Development SRF 388 [Member]",
        "terseLabel": "In-process research and development - casdozokitug"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r529"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r140",
      "r188",
      "r282",
      "r290",
      "r294",
      "r296",
      "r659",
      "r671",
      "r805"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r529"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r367",
      "r749"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r501",
      "r509",
      "r514",
      "r521",
      "r525",
      "r531",
      "r532",
      "r533",
      "r697"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Income tax provision (benefit)",
        "totalLabel": "Income tax provision (benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r204",
      "r266",
      "r267",
      "r288",
      "r507",
      "r526",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r503",
      "r504",
      "r514",
      "r515",
      "r520",
      "r522",
      "r694"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid (refunded), net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accounts Payable Trade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "chrs_IncreaseDecreaseInAccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "IncreaseDecreaseInAccruedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued compensation.",
        "label": "Increase Decrease In Accrued Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued and other current and non-current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "chrs_IncreaseDecreaseInAccruedRebatesFeesAndReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "IncreaseDecreaseInAccruedRebatesFeesAndReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued rebates, fees and reserve.",
        "label": "Increase Decrease In Accrued Rebates Fees And Reserve",
        "terseLabel": "Accrued rebates, fees and reserves"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Other prepaid, current and non-current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Prepaid Expense",
        "negatedLabel": "Prepaid manufacturing",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Receivables",
        "negatedLabel": "Trade receivables, net",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "chrs_IncreaseInAmountOfSharesToBeIssuedAndSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "IncreaseInAmountOfSharesToBeIssuedAndSold",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in shares to be issued and sold.",
        "label": "Increase in Amount of Shares To be Issued and Sold",
        "terseLabel": "Increase in Amount of Shares To be Issued and Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r360"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Goodwill and Intangible Assets and Impairment of Long-Lived Assets",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived assets - IPR&amp;D",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r159"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r874",
      "r884",
      "r901",
      "r910",
      "r914",
      "r922"
     ]
    },
    "chrs_InitialTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "InitialTermOfAgreement",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of agreement.",
        "label": "Initial Term Of Agreement",
        "terseLabel": "Initial term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r926"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r926"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r926"
     ]
    },
    "chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents intangible assets, net and accrued and other current liabilities.",
        "label": "Intangible Assets, Net And Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Intangible assets, net and accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill)",
        "totalLabel": "Total Goodwill and intangible assets, net",
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r190",
      "r235",
      "r286",
      "r575",
      "r750",
      "r845",
      "r1072"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense Debt",
        "positiveLabel": "Interest expense",
        "totalLabel": "Total Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r412",
      "r423",
      "r812",
      "r813"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense Debt Excluding Amortization",
        "terseLabel": "Stated coupon interest",
        "verboseLabel": "Contractual interest",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r413",
      "r812",
      "r813"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income And Interest Expense Disclosure Table [Text Block]",
        "terseLabel": "Schedule of Components of Interest Expense",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r244",
      "r245"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable Current And Noncurrent",
        "negatedLabel": "Less amount representing interest",
        "terseLabel": "Contractual future interest payments due in 2022",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r1064"
     ]
    },
    "chrs_InventoryCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "InventoryCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory current and noncurrent.",
        "label": "Inventory Current And Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Current [Table]",
        "terseLabel": "Inventory Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Finished Goods",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Gross",
        "totalLabel": "Total",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails": {
       "parentTag": "chrs_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Net",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r794",
      "r834"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails": {
       "parentTag": "chrs_InventoryCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryBalanceSheetClassificationsDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Noncurrent",
        "terseLabel": "Inventory, non-current",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r212",
      "r219",
      "r347",
      "r348",
      "r350",
      "r638",
      "r800"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Raw Materials",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Work In Process",
        "terseLabel": "Work in process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write Down",
        "terseLabel": "Inventory write-downs, net",
        "verboseLabel": "Inventory write-downs",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInvestmentsInMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income Interest",
        "terseLabel": "Interest income from marketable securities",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r285"
     ]
    },
    "chrs_JunshiBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "JunshiBiosciencesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Junshi Biosciences.",
        "label": "Junshi Biosciences",
        "terseLabel": "Junshi Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_KKRBiosimilarLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "KKRBiosimilarLPMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KKR Biosimilar L.P.",
        "label": "KKR Member"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_KMGCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "KMGCapitalPartnersLLCMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KMG Capital Partners, LLC.",
        "label": "KMGCP Member"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LaboratoryFacilitiesLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LaboratoryFacilitiesLeaseAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory facilities lease agreement.",
        "label": "Laboratory Facilities Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r833"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LeaseLiabilitiesOperatingAndFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LeaseLiabilitiesOperatingAndFinancing",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents lease liabilities for both operating and financing leases.",
        "label": "Lease Liabilities, Operating and Financing",
        "terseLabel": "Lease liabilities, current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right of use assets",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Term of leases",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Operating and Finance Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "chrs_LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating and finance leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating and Finance Lease, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification of Lease Assets and Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to extend lease",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Term of optional lease renewal",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r248",
      "r333",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r542",
      "r545",
      "r546",
      "r565",
      "r720",
      "r804",
      "r847",
      "r1003",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r187",
      "r668",
      "r834",
      "r970",
      "r987",
      "r1047"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r211",
      "r248",
      "r333",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r542",
      "r545",
      "r546",
      "r565",
      "r834",
      "r1003",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Adjustment in the CVR liability",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LicenseAgreementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LicenseAgreementsPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements policy text block.",
        "label": "License Agreements Policy [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Products",
        "terseLabel": "Licensed Products",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements",
        "verboseLabel": "Out-licenses",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r500",
      "r1036"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional facility amount",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LoanAgreementCovenantsNetSalesForPeriodOne",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period one.",
        "label": "Loan Agreement Covenants, Net Sales For Period One",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve month net sales for current quarter"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LoanAgreementCovenantsNetSalesForPeriodThree",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period three.",
        "label": "Loan Agreement Covenants, Net Sales For Period Three",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve-month net sales continuing through the quarter ended December 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LoanAgreementCovenantsNetSalesForPeriodTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LoanAgreementCovenantsNetSalesForPeriodTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales required under loan agreement for period two.",
        "label": "Loan Agreement Covenants, Net Sales For Period Two",
        "terseLabel": "Loan agreement covenants, minimum trailing twelve month net sales for the quarter ended March 30, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 Term Loan",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_LongTermAndShortTermPurchaseCommitmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LongTermAndShortTermPurchaseCommitmentsAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term and short-term purchase commitment.",
        "label": "Long-Term And Short-Term Purchase Commitments, Amount",
        "totalLabel": "Certain firm purchase commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt",
        "terseLabel": "Net carrying value",
        "totalLabel": "Net Carrying Value",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r186",
      "r405",
      "r421",
      "r810",
      "r811",
      "r1065"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2024 - interest only",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r254",
      "r410"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2027 - principal and interest",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r254",
      "r410"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2026 - principal and interest",
        "verboseLabel": "2026 - principal and interest",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r254",
      "r410"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2025 - interest only",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r254",
      "r410"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails": {
       "parentTag": "chrs_LongTermAndShortTermPurchaseCommitmentsAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Certain firm purchase commitments, Long-term",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Purchase Commitment [Text Block]",
        "terseLabel": "Schedule of Non-cancelable Contractual Obligations",
        "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Longterm Debt Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2026ConvertibleNotesInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Type",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r72"
     ]
    },
    "chrs_LoqtorziMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "LoqtorziMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents LOQTORZI.",
        "label": "LOQTORZI",
        "terseLabel": "LOQTORZI"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r382",
      "r998",
      "r1000"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r382",
      "r998",
      "r1000"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrual related to legal Proceedings and Other Claims",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r929"
     ]
    },
    "chrs_MXIIAssociatesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "MXIIAssociatesLLCMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MX II Associates LLC.",
        "label": "MX II Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r817",
      "r1006",
      "r1067",
      "r1068"
     ]
    },
    "chrs_MandatoryPrepaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "MandatoryPrepaymentTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mandatory prepayment, term.",
        "label": "Mandatory Prepayment, Term",
        "terseLabel": "Mandatory prepayment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities Policy",
        "terseLabel": "Investments in Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesSellingGeneralAndAdministrativeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing And Advertising Expense",
        "terseLabel": "Advertising expenses",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "chrs_MaximumAmountPaidCoDevelopmentActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "MaximumAmountPaidCoDevelopmentActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum paid amount for co-development activities.",
        "label": "Maximum Amount Paid, Co-development Activities",
        "terseLabel": "Maximum paid amount for co-development activities (per licensed compound)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_MaximumAntibodiesPartiallyExericsedUnderCommercializationOption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "MaximumAntibodiesPartiallyExericsedUnderCommercializationOption",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum antibodies partially exercised under commercialization option",
        "label": "Maximum Antibodies Partially Exercised under Commercialization Option",
        "terseLabel": "Maximum antibodies partially exercised under commercialization option"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r448",
      "r637",
      "r685",
      "r712",
      "r713",
      "r771",
      "r772",
      "r773",
      "r774",
      "r784",
      "r788",
      "r789",
      "r806",
      "r814",
      "r827",
      "r836",
      "r1005",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "chrs_McKessonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "McKessonMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson.",
        "label": "McKesson"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "chrs_MinimumAntibodiesToBeCommercializedUnderCommercializationOption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "MinimumAntibodiesToBeCommercializedUnderCommercializationOption",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum antibodies to be commercialized under commercialization option",
        "label": "Minimum Antibodies to be Commercialized under Commercialization Option",
        "terseLabel": "Minimum antibodies to be commercialized under commercialization option"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r448",
      "r637",
      "r685",
      "r712",
      "r713",
      "r771",
      "r772",
      "r773",
      "r774",
      "r784",
      "r788",
      "r789",
      "r806",
      "r814",
      "r827",
      "r836",
      "r1005",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r817",
      "r1006",
      "r1067",
      "r1068"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net loss",
        "totalLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r154",
      "r189",
      "r209",
      "r226",
      "r229",
      "r234",
      "r248",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r273",
      "r282",
      "r290",
      "r294",
      "r296",
      "r333",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r556",
      "r565",
      "r673",
      "r742",
      "r763",
      "r764",
      "r805",
      "r845",
      "r1003"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_NewCamarilloLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NewCamarilloLeaseMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Camarillo Lease.",
        "label": "New Camarillo Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r874",
      "r884",
      "r901",
      "r910"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "chrs_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash operating lease expense.",
        "label": "Noncash Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_NovartisAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NovartisAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Novartis Agreement.",
        "label": "Novartis Agreement [Member]",
        "terseLabel": "Novartis Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_NumberOfEventsInDefault": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NumberOfEventsInDefault",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of events in default.",
        "label": "Number Of Events in Default",
        "terseLabel": "Number of events in default"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_NumberOfOperatingAndReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NumberOfOperatingAndReportableSegments",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating and reportable segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Operating and Reportable Segments",
        "terseLabel": "Number of reportable and operating segments"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_NumberOfTradingDaysConsideredForPricePerShareOfCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NumberOfTradingDaysConsideredForPricePerShareOfCommonStock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days considered for price per share of common stock.",
        "label": "Number of Trading Days Considered for Price per Share of Common Stock",
        "terseLabel": "Number of trading days considered for price per share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_NumberOfVehiclesLeased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "NumberOfVehiclesLeased",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of vehicles leased",
        "label": "Number of Vehicles Leased",
        "terseLabel": "Number of vehicles leased"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_OfficeSpaceRemainingPremisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OfficeSpaceRemainingPremisesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to remaining premises of office space.",
        "label": "Office Space, Remaining Premises [Member]",
        "terseLabel": "Remaining Premises"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease, classified as noncurrent.",
        "label": "Operating and Finance Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, non-current"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_OperatingAndFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OperatingAndFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating and finance lease.",
        "label": "Operating And Finance Lease Right Of Use Assets",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "verboseLabel": "Consulting expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r290",
      "r294",
      "r296",
      "r805"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r833"
     ]
    },
    "chrs_OperatingLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities.",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails",
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Current",
        "verboseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability Noncurrent",
        "verboseLabel": "Operating lease liability noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Payments",
        "verboseLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r591"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "parentTag": "chrs_OperatingAndFinanceLeaseRightOfUseAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesScheduleOfBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating lease Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r833"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesOtherInformationRelatedToLeaseTermAndDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating lease weighted average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r833"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "chrs_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r106",
      "r107",
      "r178"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Equity [Table]",
        "documentation": "Different types of options indexed to an issuer's equity along with the different attributes of those options."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r106",
      "r107",
      "r178"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_OptionalStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OptionalStockPurchaseAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Optional Stock Purchase Agreement.",
        "label": "Optional Stock Purchase Agreement [Member]",
        "terseLabel": "Optional Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Noncurrent",
        "verboseLabel": "Other assets, non-current",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments, net of tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive gain (loss), net of tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r28",
      "r227",
      "r230",
      "r236",
      "r567",
      "r568",
      "r573",
      "r656",
      "r674",
      "r960",
      "r961"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized gain on available-for-sale securities, net of tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r332"
     ]
    },
    "chrs_OtherFeesCoPayAssistanceAndReturnsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OtherFeesCoPayAssistanceAndReturnsMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other fees, co-pay assistance and returns.",
        "label": "Other Fees, Co-pay Assistance and Returns"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities, non-current",
        "totalLabel": "Total Other liabilities, non-current",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities, non-current",
        "verboseLabel": "other liabilities, non-current",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Liabilities, Non-current",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other non-cash adjustments, net",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r185"
     ]
    },
    "chrs_OutLicensesWithGrkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OutLicensesWithGrkMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Out-license - GSK.",
        "label": "Out Licenses with GRK [Member]",
        "terseLabel": "Out-license - GSK"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_OutLicensesWithNovartisInstitutesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "OutLicensesWithNovartisInstitutesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Out-license - Novartis Institutes.",
        "label": "Out Licenses with Novartis Institutes [Member]",
        "terseLabel": "Out-license - Novartis Institutes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r872",
      "r882",
      "r908"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r875",
      "r885",
      "r911"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r875",
      "r885",
      "r911"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters' Option to Purchase Additional Shares",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "chrs_PaymentForCappedCallTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PaymentForCappedCallTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment made for entering into capped call transactions.",
        "label": "Payment for Capped Call Transactions",
        "terseLabel": "Payment for capped call transactions"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PaymentTermsPeriodFromDateOfShipment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PaymentTermsPeriodFromDateOfShipment",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment terms from date of shipment.",
        "label": "Payment Terms, Period from Date of Shipment",
        "terseLabel": "Payment terms from date of shipment, period"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments and customer credits issued from reserve in discounts and allowances constitute variable consideration.",
        "label": "Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration",
        "negatedLabel": "Payments and customer credits issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails": {
       "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Less commissions and fees",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments in marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "chrs_PercentageOfCapPriceCappedCallTransactions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PercentageOfCapPriceCappedCallTransactions",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of premium on cap price.",
        "label": "Percentage of Cap Price, Capped Call Transactions",
        "terseLabel": "Percentage of cap price"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PercentageOfGrossProfitsOnSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PercentageOfGrossProfitsOnSales",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "percentage of profit shared.",
        "label": "Percentage Of Gross Profits On Sales",
        "terseLabel": "Percentage of gross profits shared"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of option fee to be paid on partial exercise of commercialization option",
        "label": "Percentage of Option Fee to be Paid on Partial Exercise of Commercialization Option",
        "terseLabel": "Percentage of option fee to be paid on partial exercise of commercialization option"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PercentageOfPremiumOnConvertibleNote": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PercentageOfPremiumOnConvertibleNote",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium on convertible note.",
        "label": "Percentage Of Premium On Convertible Note",
        "terseLabel": "Convertible notes, premium percentage"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PercentageOfRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties incurred on net sales.",
        "label": "Percentage Of Royalties On Net Sales",
        "terseLabel": "Percentage Of royalties on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage required to pay an additional exit fee on principal amount.",
        "label": "Percentage Required To Pay Additional Exit Fee On Principal Amount",
        "terseLabel": "Percentage required to pay an additional exit fee on principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_Plan401KMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "Plan401KMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401(k) plan.",
        "label": "401(k) Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "chrs_PotentialDevelopmentMilestonesEntitled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PotentialDevelopmentMilestonesEntitled",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of potential development milestones entitled.",
        "label": "Potential Development Milestones Entitled",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r424"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r722"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r424"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r722",
      "r740",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Other prepaids and current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "chrs_PrepaidExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PrepaidExpensesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to prepaid expenses.",
        "label": "Prepaid Expenses [Member]",
        "terseLabel": "Prepaid financial instrument in Prepaid manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PrepaidManufacturingExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PrepaidManufacturingExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Manufacturing current.",
        "label": "Prepaid Manufacturing Expense Current",
        "terseLabel": "Prepaid manufacturing",
        "verboseLabel": "Prepayment made for manufacturing services"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PrepaymentsMadeToCmoForManufacturingServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PrepaymentsMadeToCmoForManufacturingServices",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prepayments made to a CMO for manufacturing services.",
        "label": "Prepayments Made to CMO For Manufacturing Services",
        "terseLabel": "Prepayments made to a CMO for manufacturing services for UDENYCA"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prepayments made to a CMO for other research and development program.",
        "label": "Prepayments made to a CMO For Other Research And Development Pipeline Program",
        "terseLabel": "Prepayments made to a CMO For Other Research And Development Pipeline Program"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount of notes converted into shares of common stock at conversion rate.",
        "label": "Principal Amount Of Notes Converted Into Shares Of Common Stock At Conversion Rate",
        "terseLabel": "Principal amount of notes converted into shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesReclassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Changes to net cash used in operating activities in the consolidated statements of cash flows",
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Convertible Debt",
        "terseLabel": "Proceeds from issuance of 2026 Convertible Notes, net of issuance costs",
        "verboseLabel": "Net proceeds from offering",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "chrs_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails": {
       "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity, before stock issuance costs.",
        "label": "Proceeds from Issuance of Common Stock, Gross",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from 2027 Term Loans, net of debt discount &amp; issuance costs",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r963"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from maturities of investments in marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale of investments in marketable securities",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r239",
      "r300",
      "r331"
     ]
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from disposal of property and equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r23"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from purchase under the employee stock purchase plan",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency, Loss Exposure Not Accrued, Best Estimate",
        "terseLabel": "Claims related to certain sales of UDENYCA from October 2020 through December 2021",
        "documentation": "Best estimate of the loss exposure for a reasonably possible liability for product liability damages for which no accrual has been recorded."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Revenue",
        "terseLabel": "Total net product revenue",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r297",
      "r639",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r792",
      "r815",
      "r835",
      "r940",
      "r1001",
      "r1002",
      "r1006",
      "r1067"
     ]
    },
    "chrs_ProductPipelineNumberOfDrugCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ProductPipelineNumberOfDrugCandidates",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of drug candidates in the product pipeline.",
        "label": "Product pipeline, Number of Drug Candidates",
        "terseLabel": "Product pipeline, number of product candidates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductionRelatedImpairmentsOrCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductionRelatedImpairmentsOrCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Production Related Impairments or Charges",
        "terseLabel": "Impairment charge for the write-off of prepaid manufacturing services no longer deemed to have future benefits",
        "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r297",
      "r639",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r792",
      "r815",
      "r835",
      "r940",
      "r1001",
      "r1002",
      "r1006",
      "r1067"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r226",
      "r229",
      "r242",
      "r248",
      "r258",
      "r266",
      "r267",
      "r282",
      "r290",
      "r294",
      "r296",
      "r333",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r540",
      "r543",
      "r544",
      "r556",
      "r565",
      "r659",
      "r672",
      "r701",
      "r742",
      "r763",
      "r764",
      "r805",
      "r831",
      "r832",
      "r846",
      "r962",
      "r1003"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r939",
      "r994"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r992"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Total property and equipment",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r952",
      "r993"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment By Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r660",
      "r670",
      "r834"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r199",
      "r202",
      "r669"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Estimated useful lives, description",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "chrs_ProvisionRelatedToSalesMadeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ProvisionRelatedToSalesMadeAbstract",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Provision related to sales made in:"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ProvisionRelatedToSalesMadeInPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ProvisionRelatedToSalesMadeInPriorPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents provision related to sales made in prior period.",
        "label": "Provision Related to Sales Made in Prior Period",
        "terseLabel": "Prior period - increase (decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to public offering.",
        "label": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Domain]",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period before the company can sell, transfer or make any short sale of common stock.",
        "label": "Purchase Agreement, Restrictive Requirement on Selling, Transfer and Short Sale of Common Stock",
        "terseLabel": "Period before the company can sell, transfer or make any short sale of common stock (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation",
        "totalLabel": "Total obligations",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation Due In Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation Due In Second Year",
        "terseLabel": "2025",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureCommitmentsAndContingenciesScheduleOfNonCancelableContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation Due In Third Year",
        "terseLabel": "2026",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r439",
      "r448",
      "r480",
      "r481",
      "r482",
      "r613",
      "r637",
      "r685",
      "r712",
      "r713",
      "r771",
      "r772",
      "r773",
      "r774",
      "r784",
      "r788",
      "r789",
      "r806",
      "r814",
      "r827",
      "r836",
      "r839",
      "r995",
      "r1005",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r439",
      "r448",
      "r480",
      "r481",
      "r482",
      "r613",
      "r637",
      "r685",
      "r712",
      "r713",
      "r771",
      "r772",
      "r773",
      "r774",
      "r784",
      "r788",
      "r789",
      "r806",
      "r814",
      "r827",
      "r836",
      "r839",
      "r995",
      "r1005",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "chrs_RateOfIncreaseInNumberOfCommonStockAvailableForIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "RateOfIncreaseInNumberOfCommonStockAvailableForIssuance",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of increase in number of common stock available for issuance.",
        "label": "Rate Of Increase In Number Of Common Stock Available For Issuance",
        "terseLabel": "Percentage of shares available for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of increase in number of common stock outstanding reserve for future issuance.",
        "label": "Rate Of Increase In Number Of Common Stock Outstanding Reserve For Future Issuance",
        "terseLabel": "Percentage of shares reserve for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_RebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "RebatesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables Net Current",
        "terseLabel": "Trade receivables, net",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables Policy [Text Block]",
        "terseLabel": "Trade Receivables",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "chrs_ReclassificationsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ReclassificationsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications.",
        "label": "Reclassifications, Policy [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r867",
      "r877",
      "r903"
     ]
    },
    "chrs_RegulatoryMilestonesEligibleToPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "RegulatoryMilestonesEligibleToPay",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of regulatory milestones eligible to pay.",
        "label": "Regulatory Milestones Eligible to Pay",
        "terseLabel": "Aggregate amount payable for achievement of certain regulatory milestones low single digit royalties on global net sales of any approved licensed products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r600",
      "r601",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r739",
      "r741",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r1052"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r745",
      "r746",
      "r749"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r600",
      "r601",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r739",
      "r741",
      "r770",
      "r1052"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598",
      "r599",
      "r601",
      "r603",
      "r698",
      "r699",
      "r700",
      "r747",
      "r748",
      "r749",
      "r768",
      "r769"
     ]
    },
    "chrs_RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the acquired debt security contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Remaining Contractual Maturities of Available-for-sale Debt Securities, Acquisition",
        "terseLabel": "Average maturity of investments upon acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of 2022 Convertible Notes and premiums",
        "terseLabel": "Outstanding amount payoff",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of 2025 Term Loan, premiums and exit fees",
        "terseLabel": "Outstanding amount paid off",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r396",
      "r425",
      "r602",
      "r797",
      "r798"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r499",
      "r1061"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expense",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Federal research and development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "chrs_ReserveForDiscountsAndAllowancesConstituteVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ReserveForDiscountsAndAllowancesConstituteVariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for discounts and allowances constitute variable consideration.",
        "label": "Reserve For Discounts And Allowances Constitute Variable Consideration",
        "periodEndLabel": "Activities and reserve balance, ending balance",
        "periodStartLabel": "Activities and reserve balance, beginning balance"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for sales discounts and allowances constitute variable consideration.",
        "label": "Reserve For Sales Discounts And Allowances Constitute Variable Consideration",
        "verboseLabel": "Current period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r868",
      "r878",
      "r904"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r869",
      "r879",
      "r905"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r876",
      "r886",
      "r912"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r968",
      "r1062",
      "r1066"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring And Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r366",
      "r369",
      "r374"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Employees impacted",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r370",
      "r371",
      "r996"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost And Reserve [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r371",
      "r372"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost And Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r167",
      "r667",
      "r689",
      "r691",
      "r696",
      "r723",
      "r834"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267",
      "r334",
      "r335",
      "r490",
      "r491",
      "r492",
      "r523",
      "r524",
      "r547",
      "r549",
      "r550",
      "r552",
      "r554",
      "r686",
      "r688",
      "r702",
      "r1073"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer Including Assessed Tax",
        "terseLabel": "Net revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r289",
      "r292",
      "r293",
      "r297",
      "r298",
      "r299",
      "r436",
      "r437",
      "r639"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438"
     ]
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Net Revenues",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r791",
      "r801"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "verboseLabel": "Finance leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r833"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "verboseLabel": "Operating leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r833"
     ]
    },
    "chrs_RoyaltyPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "RoyaltyPaymentTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment term.",
        "label": "Royalty Payment Term",
        "terseLabel": "Royalty payment term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock Consideration Received On Transaction",
        "terseLabel": "Common stock, net proceeds",
        "totalLabel": "Net proceeds after commissions and fees",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SalesMilestonesEntitled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SalesMilestonesEntitled",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales milestones entitled.",
        "label": "Sales Milestones Entitled",
        "terseLabel": "Sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueGrossRevenuesBySignificantCustomerAsPercentageOfTotalGrossRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Product Revenue",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r934"
     ]
    },
    "us-gaap_ScenarioPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScenarioPlanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Plan",
        "documentation": "The scenario under which facts represent plans as distinct from actual."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r449",
      "r929",
      "r975"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueActivitiesAndEndingReserveBalancesForEachSignificantCategoryOfDiscountsAndAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]",
        "terseLabel": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareOutstandingDilutivePotentialSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Outstanding Dilutive Potential Shares Excluded from Calculation of Diluted Net loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92",
      "r536"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of total consideration paid",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Company's Debt Obligations",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and cash equivalents, marketable securities and restricted cash",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Income tax provision (benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of the Company's net deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of the statutory United States federal rate to the Company's effective tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "chrs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property plant and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property Plant and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Components of loss before income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesGoodwillAndIntangibleAssetsAndImpairmentOfLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r159"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill and Intangible Assets, Net",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "chrs_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of inventory current and noncurrent.",
        "label": "Schedule Of Inventory Current And Noncurrent Table [Text Block]",
        "terseLabel": "Schedule of Balance Sheet Classification"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ScheduleOfInventoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfInventoryTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories.",
        "label": "Schedule of Inventory [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Schedule of Future Payments on Debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "chrs_ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other information relating to lease term and discount rate.",
        "label": "Schedule of Other Information Relating To lease Term And Discount Rate [Table Text Block]",
        "terseLabel": "Other information related to lease term and discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of product sales discounts and allowances.",
        "label": "Schedule Of Product Sales Discounts And Allowances Table [Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of purchase price allocation to the estimated fair value of the net assets acquired",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r745",
      "r746",
      "r749"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r181",
      "r1066"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restructuring And Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373"
     ]
    },
    "chrs_ScheduleOfSettlementsUnderSharesOfferingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfSettlementsUnderSharesOfferingTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of shares offering settlements.",
        "label": "Schedule of Settlements Under Shares Offering [Table Text Block]",
        "terseLabel": "Schedule of Settlements Under the ATM Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r453",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of RSU Activity, under 2014 Plan",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of options outstanding and exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activities under 2016 and 2014 Plans",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions for Black-Scholes Option-Pricing Model Used in Determining Fair Value of Awards",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "chrs_ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average grant date fair value per share of the options granted, the total intrinsic value of options exercised, the total fair value of options that have vested, and the total cash received from the exercise of stock options during the period.",
        "label": "Schedule of Share Based Payment Award Stock Options Weighted Average Information [Table Text Block]",
        "terseLabel": "Schedule of additional information on options"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information relating to lease.",
        "label": "Schedule of Supplemental Cash Flow Information Related To Lease [Table Text Block]",
        "terseLabel": "Supplemental cash flow information related to leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Reconciliation of the Company's unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r1038"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60",
      "r61",
      "r110",
      "r180"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "chrs_SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment reporting and revenue by geographic region.",
        "label": "Segment Reporting And Revenue By Geographic Region Policy [Text Block]",
        "terseLabel": "Segment Reporting and Revenue by Geographic Region"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockBasedExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses",
        "terseLabel": "Selling, general and administrative expenses",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "Selling, General and Administrative Expense",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost",
        "verboseLabel": "Stock-based compensation includes restructuring charges",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of RSUs canceled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, RSUs canceled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of RSUs granted",
        "verboseLabel": "Awards issued",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "chrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period estimated grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Estimated Grant Date Fair Value",
        "terseLabel": "Total grant date fair value of RSUs granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, RSUs granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of RSUs, ending balance",
        "periodStartLabel": "Number of RSUs, beginning balances",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, ending balances",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, beginning balances",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of RSUs vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value",
        "terseLabel": "Total grant date fair value of RSUs vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, RSUs Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefits401KRetirementPlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r453",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of Options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Options exercised, aggregate intrinsic value",
        "verboseLabel": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited/Canceled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "netLabel": "Number of options, granted",
        "terseLabel": "Number of Options, Granted - at fair value",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted-average grant-date fair value",
        "verboseLabel": "Weighted-average grant date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options, Ending balance",
        "periodStartLabel": "Number of Options, Beginning balance",
        "verboseLabel": "Options outstanding, Number of Options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning balance",
        "terseLabel": "Options outstanding, Weighted-Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of purchase common stock of lesser of fair market value of common stock on first or last day of offering period by eligible employees",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsRestrictedStockUnitsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfRsusActivityUnder2014PlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Canceled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "netLabel": "Exercise price",
        "terseLabel": "Weighted-Average Exercise Price, Granted - at fair value",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r458",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r493",
      "r494",
      "r495",
      "r496"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price range, Lower",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price range, Upper",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "chrs_ShareBasedPaymentArrangementForfeitureCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ShareBasedPaymentArrangementForfeitureCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of share based compensation forfeiture credit.",
        "label": "Share-Based Payment Arrangement, Forfeiture Credit",
        "verboseLabel": "Forfeiture credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsCappedCallTransactionsNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Closing stock, price per share",
        "verboseLabel": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, Weighted-Average Remaining Contractual Terms, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsOptionsOutstandingAndExercisableDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Options outstanding, Weighted-Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationRelatedToStatusOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total grant date fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Share price",
        "verboseLabel": "Share price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SharesOfferingAggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SharesOfferingAggregateAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of shares to be offered.",
        "label": "Shares Offering, Aggregate Amount",
        "terseLabel": "Shares Offering, Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SharesOfferingAggregateAmountDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SharesOfferingAggregateAmountDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The decrease in aggregate amount of shares to be offered.",
        "label": "Shares Offering, Aggregate Amount, Decrease",
        "terseLabel": "Shares Offering, Aggregate Amount, Decrease"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SharesOfferingUnderwritersOptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SharesOfferingUnderwritersOptionTerm",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for exercise of option to purchase additional shares by underwriters.",
        "label": "Shares Offering, Underwriters Option, Term",
        "terseLabel": "Term of share offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Paid For Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of RSUs (in shares)",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ShortTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ShortTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails": {
       "parentTag": "chrs_LongTermAndShortTermPurchaseCommitmentsAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the short-term purchase commitment.",
        "label": "Short-Term Purchase Commitment, Amount",
        "terseLabel": "Certain firm purchase commitments, Short-term"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SixthAmendmentToLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SixthAmendmentToLeaseMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to sixth amendment to lease.",
        "label": "Sixth Amendment to Lease [Member]",
        "terseLabel": "Sixth amendment to lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Various states",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r41",
      "r208",
      "r232",
      "r233",
      "r234",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267",
      "r281",
      "r334",
      "r335",
      "r427",
      "r490",
      "r491",
      "r492",
      "r523",
      "r524",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r596",
      "r686",
      "r687",
      "r688",
      "r702",
      "r765"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r281",
      "r639",
      "r693",
      "r703",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r743",
      "r744",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r840"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleNotesDue2022NarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsConvertibleSeniorSubordinatedNotesDue2026NarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r449",
      "r929",
      "r930",
      "r975"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesNetRevenuesDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r281",
      "r639",
      "r693",
      "r703",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r743",
      "r744",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r840"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r871",
      "r881",
      "r907"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_StockIssuedDuringPeriodAcquisitions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockIssuedDuringPeriodAcquisitions",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period on acquisitions",
        "label": "Stock Issued During Period, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with Surface Acquisition:(1)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of accelerated vesting of equity awards.",
        "label": "Stock Issued During Period, Shares, Accelerated Vesting of Equity Awards",
        "terseLabel": "Accelerated vesting of equity awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance to Surface shareholders for acquisition (in shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r167"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan (\"ESPP\") (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r133",
      "r167"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Offering, net of issuance costs (in shares)",
        "verboseLabel": "Common stock, shares issued and sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r133",
      "r167",
      "r695",
      "r765",
      "r785"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (\"RSUs\") (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r167"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsSummaryOfOptionActivitiesUnder2016And2014PlansDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r133",
      "r167",
      "r464"
     ]
    },
    "chrs_StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares settled related to taxes paid related to net share settlement of equity awards during the period.",
        "label": "Stock Issued During Period, Shares, Taxes Paid Related to Net Share Settlement of Equity Awards",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to accelerated vesting of equity awards issued during the period.",
        "label": "Stock Issued During Period, Value, Accelerated Vesting of Equity Awards",
        "terseLabel": "Accelerated vesting of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance to Surface shareholders for acquisition",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r41",
      "r167"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan (\"ESPP\")",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r133",
      "r167"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under Offering, net of issuance costs",
        "verboseLabel": "Aggregate offering price",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r133",
      "r167",
      "r702",
      "r765",
      "r785",
      "r846"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "verboseLabel": "Issuance of common stock under ATM Offering, net of issuance costs",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (\"RSUs\")",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r132",
      "r133",
      "r167"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r41",
      "r167"
     ]
    },
    "chrs_StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock settled related to taxes paid related to net share settlement of equity awards during the period.",
        "label": "Stock Issued During Period, Value, Taxes Paid Related to Net Share Settlement of Equity Awards",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_StockPurchaseAgreementSharesAgreedToBeIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockPurchaseAgreementSharesAgreedToBeIssued",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.",
        "label": "Stock Purchase Agreement, Shares Agreed To Be Issued",
        "terseLabel": "Unregistered shares"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockPurchaseAgreementSharesAgreedToBeIssuedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.",
        "label": "Stock Purchase Agreement, Shares Agreed To Be Issued, Value",
        "terseLabel": "Aggregate value"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_StockholdersDeficitTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "StockholdersDeficitTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure containing information regarding Stockholders' Deficit.",
        "label": "Stockholders Deficit",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r136",
      "r137",
      "r156",
      "r724",
      "r740",
      "r766",
      "r767",
      "r834",
      "r847",
      "r970",
      "r987",
      "r1047",
      "r1073"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "verboseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2025TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesOrganizationDetails",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r606"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary Sale Of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SurfaceGlaxosmithklineAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SurfaceGlaxosmithklineAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Surface GSK agreement.",
        "label": "Surface GlaxoSmithKline Agreement [Member]",
        "terseLabel": "Surface GSK Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SurfaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SurfaceMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Surface.",
        "label": "Surface [Member]",
        "terseLabel": "Surface"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SurfaceNovartisAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SurfaceNovartisAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Surface Novartis agreement.",
        "label": "Surface Novartis Agreement [Member]",
        "terseLabel": "Surface Novartis Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SurfaceOncologyInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SurfaceOncologyInc.Member",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionAmountAllocatedToIdentifiableIntangibleAssetsDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionConsiderationPaidDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionEstimatedFairValueOfNetAssetsAcquiredDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionUnauditedProFormaSummaryOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Surface Oncology, Inc.",
        "label": "Surface Oncology, Inc. [Member]",
        "terseLabel": "Surface Oncology, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SurfaceSrf114ProprietaryDrugProductAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Surface's SRF114 proprietary drug product candidate.",
        "label": "Surface SRF114 Proprietary Drug Product Agreement [Member]",
        "terseLabel": "Surface's SRF114 proprietary drug product candidate"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "SurfaceSrf388ProprietaryDrugProductAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Surface's SRF388 proprietary drug product candidate.",
        "label": "Surface SRF388 Proprietary Drug Product Agreement [Member]",
        "terseLabel": "Surface's SRF388 proprietary drug product candidate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Material impairments of property and equipment",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r161"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "chrs_TaxCreditCarryforwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TaxCreditCarryforwardExpirationYear",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "chrs_TermLoanGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TermLoanGross",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan, gross.",
        "label": "Term Loan Gross",
        "terseLabel": "2027 Term Loans, gross"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TermLoansMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanFuturePaymentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails",
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoansInterestExpenseComponentsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsSummaryOfDebtObligationsDetails",
      "http://www.coherus.com/role/DisclosureDebtObligationsTables",
      "http://www.coherus.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans.",
        "label": "2027 Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TermLoansPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TermLoansPayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of term loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Term Loans Payable, Noncurrent",
        "terseLabel": "Term loans"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ThreeMonthLiborMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ThreeMonthLiborMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the London Interbank Offered rate.",
        "label": "Three-month LIBOR [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1051"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_ToripalimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "ToripalimabMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents toripalimab.",
        "label": "Toripalimab",
        "terseLabel": "Toripalimab (LOQTORZI)",
        "verboseLabel": "LOQTORZI"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "verboseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TrancheBLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TrancheBLoanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche B Loan.",
        "label": "Tranche B Loan, funded on March 31, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TrancheCLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TrancheCLoanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche C Loan.",
        "label": "Tranche C Loan, not funded between April 1, 2022 and March 17, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TrancheDLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TrancheDLoanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche D Loan.",
        "label": "Tranche D Loan, funded on September 14, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TrancheLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TrancheLoanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Tranche A Loan.",
        "label": "Tranche A Loan, funded January 5, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TrancheaBAndDLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TrancheaBAndDLoansMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to  tranche A&amp;B &amp; D loans.",
        "label": "Tranche a B And D Loans [Member]",
        "terseLabel": "Tranches A, B and D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r417",
      "r426",
      "r553",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r675",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r983",
      "r984",
      "r985",
      "r986"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEmployeeStockPurchasePlanDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "2014 Employee Stock Purchase Plan (ESPP)"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TwoThousandAndFourteenEquityIncentiveAwardPlanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen equity incentive award plan.",
        "label": "2014 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_TwoThousandTenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "TwoThousandTenPlanMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsEquityIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the company's 2010 stock plan.",
        "label": "2010 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails",
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesCostOfGoodsSoldDetails",
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails",
      "http://www.coherus.com/role/DisclosureSurfaceAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRestructuringChargesDetails",
      "http://www.coherus.com/role/DisclosureStockBasedCompensationAndEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r371",
      "r372"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r822",
      "r1063"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsCostUnrealizedGainsOrLossesAndFairValueByInvestmentTypeDetails",
      "http://www.coherus.com/role/DisclosureFairValueMeasurementsFinancialAssetsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r822",
      "r824",
      "r1063"
     ]
    },
    "chrs_UdenycaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "UdenycaMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails",
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the product UDENYCA.",
        "label": "Udenyca [Member]",
        "terseLabel": "UDENYCA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails",
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r511"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Unrecognized tax benefits, accrued interest and penalties accrued",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "chrs_UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront and milestone based license fee payments.",
        "label": "Upfront And Milestone Based License Fee Payments, Investing Activities",
        "negatedLabel": "Upfront and option payments to Junshi Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_UpfrontAndMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "UpfrontAndMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureBalanceSheetComponentsGoodwillAndIntangibleAssetsNetDetails",
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront and milestone payments.",
        "label": "Upfront And Milestone Payment",
        "terseLabel": "Upfront and milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments related to license and collaboration arrangements.",
        "label": "Upfront And Milestone Payments Related To License And Collaboration Arrangements",
        "negatedLabel": "Milestone based license fee payments"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements",
     "crdr": "debit",
     "calculation": {
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront license fee payment related to license and collaboration agreement.",
        "label": "Upfront License Fee Payments Related To License And Collaboration Arrangements",
        "terseLabel": "Upfront and option payments to Junshi Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.coherus.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r195",
      "r197",
      "r200",
      "r201"
     ]
    },
    "chrs_VaccinexLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "VaccinexLicenseAgreementMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureCollaborationsAndOtherArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Vaccinex License Agreement.",
        "label": "Vaccinex License Agreement [Member]",
        "terseLabel": "Vaccinex License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.coherus.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.coherus.com/role/DisclosureDebtObligations2027TermLoanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "chrs_VehiclesLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "VehiclesLeaseMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vehicles leased.",
        "label": "Vehicle Lease"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r1055",
      "r1057",
      "r1060"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average common shares outstanding - Diluted",
        "terseLabel": "Diluted (In shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r276"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Weighted-average number of shares used in computing basic and diluted net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.coherus.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Basic (In shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r276"
     ]
    },
    "chrs_WeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "WeightedAveragePricePerShare",
     "presentation": [
      "http://www.coherus.com/role/DisclosureStockholdersDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average price per share.",
        "label": "Weighted-average Price Per Share",
        "terseLabel": "Weighted-average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_YusimryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "YusimryMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureRevenueNetRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the product YUSIMRY.",
        "label": "YUSIMRY"
       }
      }
     },
     "auth_ref": []
    },
    "chrs_YusimryProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.coherus.com/20231231",
     "localname": "YusimryProductMember",
     "presentation": [
      "http://www.coherus.com/role/DisclosureInventoryAdditionalInformationDetails",
      "http://www.coherus.com/role/DisclosureOrganizationAndSignificantAccountingPoliciesInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Yusimry product.",
        "label": "Yusimry Product [Member]",
        "terseLabel": "YUSIMRY"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479455/805-10-15-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "6",
   "SubTopic": "50",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-6"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(19)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>151
<FILENAME>0001558370-24-003436-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-003436-xbrl.zip
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MX+=_<1RY_9 @"".Y1/"G],?UF@7S4/T"OZ%P?43./X+8./C'E_OKVBF1(O(
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M>CJ:JGG5W,#(M ]EIIFKKX[L:_8^57.J\,W$E*/#,E.2NJGC['=T2=4HN%I
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M</@Z@,8$O1OJO]>!B3QM%KHV_*X34BL*7JQJTO28$#V?O<T\%.%?"_F%RCW
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MML49UL9B6/E3>QPW?SM>)@[)8HUW29T:W>>W%9K=>GA[V)6]R,D>SBH6C1T
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MQ/Q'\DP%EF3)PA<PCA\_Y=9(/['J@_DU"=HN9JXW8FN$L6&SR4]YA<-??56
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M'HIX'@  P-$! !4   !C:')S+3(P,C,Q,C,Q7V-A;"YX;6SM75EOXSJR?K_
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M6F51I&]MN4@YTPM&S0)SUF0BH.)];&7Y+19]/>R13%5R9G)8$IP0;A".6=!
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MBLOV-=2^$?[#K.LB"@ZK,I87CC(>C,&L9US5*BFY%8(K1U-S56M_;CR?3LV
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M#).BRPCEA=51A:97" &<0Q#IK<VN5+ANL;Z*"KNB&774H(88!72@#GRU5YD
M%WS(S' (D+X2?+;QW#"HKULN\SJ+*HIXB]NN,QMR8@B3BQ#$1^+YU&;?1-M=
MX36F=@<_E4N&,0H^8BZ .'EZ"AC#J%=7^H2[C:YV3_^:89&"SZ7GL(,IL"34
M6SU8NNT!U.O_^*:4,<5M(,T2%9ZP;E9KY("+!#[TK0OP(8@FNM0I7<T<^J;3
M*2]DJV8KVZX5-="+Q#CTK1KKY"/ FQ0T4;7@M[#M*B&)7"3B@!]D\.M!((WP
M:/TO_P]02P,$%     @ J(EO6%@ ._AG<0  B 0( !4   !C:')S+3(P,C,Q
M,C,Q7V1E9BYX;6SMO6ESXSB6*/K]1KS_H)OOPYV)F%SL7&J)KKDA;]F><5I^
MMK-J^E,'34(6.RE"!9).JW[] T!2(BD !+CAT,F(F:ZTB.5L. #.AK_]W^=U
M,'M")/)Q^-NKHS?O7LU0Z&+/#Q]_>Y7$R]<_O_J___G__*^__>_7K__GY/9J
MYF$W6:,PGKD$.3'R9M_]>#6[QYN-$\Z^($+\()B=$-][1+/9T;LW']^\>_/S
M[/7K_^1#G#@1[8+#&1_K^,U1_N$T&PV'O\[>OSWZ^/;XW?&'V2^_OCO^]>C3
M[.9+WNX+A6SIUS4,_/#;K^Q_'NA\,XIA&/WZ'/F_O5K%\>;7MV^_?__^YOO[
M-Y@\TN[OCM[^SY>K.W>%ULYK/XQB)W31JQEM_VO$?[S"KA-S\A2Z/S^0(!_@
M_=O=7-(6[*_7>;/7[*?71\>OWQ^]>8Z\5QF([+/&)'ES]M57M"_@DK8_&#^C
MP=$OO_SREG\M#NW%N[;%<3^^33^^^L__-9O]C>  W:+EC/?^-=YNT&^O(G^]
M"=BL_+<50<O?7KDK$E&LC]\?':<X_[]W,64XDZ13'$8X\#W&_]V/T6)Y%V/W
MVPH''A7.\S\3/]Z>H:7O^O&K&9OUZ^UE"1<7KQ!)(OK?]5OV_6V;"3@5M%CQ
MMF\RG#K1ZB+ WZ.NT"X,.!R:9W[D!CA*"#I##_'B(? ?^9J*[IV' .GB5CN*
M#806Y-$)_;\X(//0NTO6:X=LJ7CYCR'55:X3QG/7Q4D84YUZ0SGB^B@J=CI#
ML>,'YC3H;F((9%,!?1D^4=G%9-L5J<PF@TZ>&X(WB,1;VH[IL0U;Z$-02CDO
M!*)IK8C/&'O?Z:F%=K@,Z8;YZ%-=,H\B%$?LI_7&\0G#;+&\PN'CE?^$O/3K
MH.NV/900&*+"\!K%MX@NO01U1EG3Z:"3Z!1'E,%,%*([>FX9@DRR*6V0*N/7
MGG--"2 ?R"):GPF.HEPD3[8%KIPF48S7B,RC&T1<NLB=1[18WN/8"4J=6I*C
M0P LDG'NQOZ3'U/19=M2R"ZRMRA"Y F=. &[#D47F)P[[JJ('ST=/V*F@]EP
M; 6PSO. GI)YCY:$[14D&Z2^H)O-[TZ0H"_(87_SF\6%'U+(?"=(]YWLD[<(
M;Y&;$$*1IK=_OS$M.YD3#+&86OT:$N0$_E_(^^S0N_J"7-&EQ&5DU^5DRTZC
M4<SZW-/9.R5>6QAL$'-W.)][GL_V+R>X#)>8K%O=I#1'M8%PIB'N5@C1&_UZ
M@T/&.F:M\I* *F'1&9SN:TTIT78Z."12')@[IX_F7#:(<Y>0I>/2+8AR*_+;
M+!+%2# 08P8OWT.$+]H;QV]\/C89&@;JYU'LKYFA;Z>U%TLJ>=G]D+6CNV)W
MY#";#@:)YFMVB&('*)=!?H\O/;ITZ6F+F0ZKJ[8[4C6;%@;)OH9.0O=#Y%&M
M?\%VPYVI8K')UD*'E#*:S0:!3G$0. \X X7J^D5,T9L30GF8GJB:$L-@9  F
M^QU?*K\WQ=YT>  DH*U^ND=D?86=\-HAC'%/C0_G1F,#0SZB*@P1>CLX?]Z@
M,$+[,U$/U-"8#!AY+I*8-KAQMJW4@_D$ ,A CTQ/]*; -K<[%/J8W"54PWGT
MPDY5_#6.4726(#K4IZ[73XN)(9#-V6R0=^H$P3W5_I'C\E\[IY'F+  (PCA5
M8"EGX !*I\&<0(G5EP[2G0@ 6:J0I@K@N$?-HYX& $EHJX\]GF 48P-#?@!=
M8C"7G7O->NUS\RZ[>E A9OX_%#+O7Z=6UL;SV"#*%7*BCO'7&=+*Q;\0!Y=%
MP#6^U2N&LH8:#SIE:XVNN=SG?4['P5N$3E!(P8RS^+_+D#DWJ;*Z"9P.#ET=
MSPZ:@+SA8M/-:;6C66$3;&_=XBUV/N*O(5T]Q^^./M%.]#\?N#3T3\EFX( F
M<288BR1F@=#,[<X:/2/B^A$SO_9.5&T 0)-1N&/=HB"U9[/0XB3*Y:9_06T&
M#6@"W](C(?%='J=-NWP-Z6_#Z5"]V4$3<*>\;J,DRE37-E=<7&,-IS_K00!-
M2I$T='H*[A$2T(3-_^8=;A+BKFBG042S?F;0A-LWS*[-PYPJA3.")I2=93KB
M)<DB%])O492L!SJ_*"<%3:X/[X[^^Q;%?AH^.(CJ4DQI)_J0(H/NG>?F(<&B
M(6R@<HUB%NIY@\C=RB&H<$4Y\X.$6R%PS,P13L ;1.?/;I!XR+L@>'WJ!&X2
M<*:Q^&3:'GF5 9O29S"X[(2HTR--XL8)BTP^I> \MHDM5XQE!SE^![MQ2+PM
M>A6;(U@SGIT@J8<(_9E0 3Q_:N,DD(YCBA2'.\?,6 W3E>40CUGC>8;'_-F/
MSO#:\:F:73I)$$>O6FXM&A-HX+%TH@=.@B1Z_>@XFQ01A+SUV_-GJ@TBYG([
M#Y-U%B=VY4<ZH+/1HSR]_6 .AM-;1$%DO[ )4S0YBFSJ$N0.<7/@LW]6^8"B
MM?,&)01OV'_XG&]1A)9OL_9OO[, T]<AO7GC[XCH05\5D8"0W7ALPM?9'Q3R
MHY]?'QV]/DY95)U+&Y/=3'X8O_7\]6XV)PB:@5PH*<#*(GSD\/'1V@-%_\V$
M X>OO53<.@11,':G /-5T@^\V= =@,M'>KU&ZX>F$BN&M3QN>T!7%";B)@_H
M]8X,'8(K'+T -!40/_13Q11^*\V+F/JBIY=\9@9M2[7'YLUG#K!;FHY'(6/2
M6 VR7_9:,/OAGUG<]P,]D- ].A\\<!Y0\-LK\<?8CQFBU8]OAP<^"RX.'[E[
M]M9_7,6+Y=<HC<BNX*+5-D.MIFT)T[V S$D99RK ^;B9+#=<E4MZ/)8R YNA
MM@?WUUEYQ%F,9S4C)1$= 6]2D\&KV8;XF/CQ]K=7[U[-,*';TF^OCJP(0I[:
MQ&Z9<26_J2('.DTS6JF;0I," \340J >2$,&CNTH QYWGR9NX9"ED%*0*\S7
M:IL1J::M.?OK&%@S887P78C4H3A4I.$>SVJ@REC^OB()%OB?U3^(;IPM\\^R
MC&O7)0GRKGSGP0^X0_Q4*14-1JC(BM$(=FAD2A%3_+6P-5@O;9B#M2 ;9&$U
M0*.X^A3@[S=>VRNP -U>14B.ED9]*E)6T\<<\T,["/ME?[QD*?6\6D$:!YC/
MOY7N,TV[9XB:=V^[NO38@)N -NCR4N+!%I0Y_*KU];>W@DMB^\MC![:_CE9_
M1.+"RJ=_[5<]_>.?ITR7(;)A=MYK9XT8()6EH&J2\5'<I"L%5H/"+=ID;O7Y
M(T%9]<4R/&<E>TZ&EW&_#%F#?GW>,&36M50M*)F&FR-?O'B(YF#7#X.Q*ZJE
M^RMHC>S0FY*7N/&"W"'RY+LB\5<UV5\S!4V&18%%]6?31T)QKVU71D;4SIXX
M*YF ]9$KBJ]HS.SV+!NK=W$U.*NEONQ=;=F\3K) @C5:9N11MH2#HU"^M=JJ
M\;0OYSJLPF:X%D5>,3R3_)IA(4G_#L@T>V.?S"60?ZVV&;5JVEK M *(4/:5
M;3+,)&WLR;H>6[ >=D4I5P[,Y%PRH.W#R&FRYO$S3^A\N41N?(/H=<5;+.=>
M"I3H;&[0)3^K:W4!@K)0VLTZ::)M?ST8\1(W)$/I_*XQ(5LNNA-!VA]8K40*
MX;Z(CV#Q*-MD])*TL6'Y+10DHD?3:\P"2/)?BB%:7TJ6EMP1W*QW[BDV[6UO
M%:F9BMM2HKA^A%.Q!6,\!:25PS+H+T,6WBA9-O(&&8U$#:PC(C4#U343(@7#
MR*/@!-9&K"C1AP,R<98/!$EN6>7]&)$U@Y:M3('DJIIDU! W 8".4';5C20H
MV9=;)1^P)EI%N14-R"17-I#MD_[NAG+G(KHW^%AU:Q6UJ=Y6RVV&PB*;]&L8
M;9#+7P832FEMNQP;>3L MU0A&[ ^=L(;:G%0)K"*P6S+["T[P CD].#WW$VR
M_WU("(6G7\&7(I3V3ZV'1,0JJ(NRM.O*72_%+I!V9UD^R<FV^$4D7L8==VXZ
M_8Z6"2)Q3\H:"!"TKR<;\ EK(%F2=.TI4B_DX="05L3O5,^S *);"J5 [F6?
M,[H<?K:,@E"&Y0T$:-B782G-L08J14FM#L3D430 )'D\)<CSXPO'Y?$S(ENS
MM$%N8A4TL(Z(V(*L:")$QKYL*JB/M1 J67X/!N-V7N$@D&1T_MTAGN1R+_R6
MVR_+WVSX*UGZ\V'2?<%0>++=M\G*N'*P]["''@OHEQJR^IPBOZ'U,H6]1266
M&3P(+4LI'$4X^#VPE_DA+666@^U[OD.V=PY[VXA7I1"90>K:Y:(I;V<#NST,
MC &+9>&\*EZ\VAUR?#4Z6+2:U'(--\"Y9$*1S<"7C\;(D!9#X;FWPAMQ%X07
M*7!%AS&#'AGQM'K8Q%T$E7"M&/2HXJ[J86^UF# 3-\&_N' T)F-+2&L2H&N(
M)[F=!DXDB@:K;7>X7JKM;&*G?FOS:X@?V-NFZ?M6FR2FGW'(#O3\ %%$1;VT
M>IJF2MO.IP&QB"5RA0>CKV2]E^$JK?+.X0&J&G;__+N/".7L:GN%GE"@UA,:
MG0Z5AK(3D'TV.@12>\>M[:O8>Q5]02Q@'89+-F)=LDB6J&)FV:ZLF!'H(MQE
MZ6GLT?*VATM.U-8FIH5<QL::M8R3>G7V/5^5XOW-!T(+*$0/#T]UB<(X!+*D
M)_H##I)N*;^1+DR!DC78900=-K".R*D3HT=,_+\X(X21#?H=A(B*.]C,?Y+R
M"3= MIS[5!TZ37FJ'Q*2I-\D#X'O?HVS-<W #^DL(A.13M,\YU/9%!":TDA(
M_0XU*,.(D-3B'6Z =BD!5C$)3X35&!S4VI"5O3K92K8%@QYU%<6*/2#A+E\Q
M^CWJ< >R9@R8J:JVIK=VZB=35F*#NH9.,7\'+2UI>>M'WTZV)RAT5VN'B+QS
MNLUW=4+JFH- .0=)'#NBV5R*<K6YS2(AFMS#QFB7ZX2HI^&Q)[7# U\EDAU&
MHZ5\;5C=40[@D>XD&BUE.,+8.728)%H"6CN%8G"AX$/*4_GB_ N3M$(5(B)#
MG;Q!1@E1@X& 3SW_)0"$XEO;+D-%T<Z>Z"H8@/51*\KKX8A,3!4C05+,>7%&
M_@(X>_0YVA6(\\/'6^0BG]NY6,AX_F]9/&$'0^7AAZV&LI*<4 1#DIX@;[)+
M4! UL1CMUP5'L1;JI>"^%M.FB0RBZ2"MNA,G8!48[U8(J>I0U37+:"=O!@0U
MX7JH;ZA S_[:J.4--D"Q*/VR@9EDJP:$)-_I>[:7H8>>V3.WEU&4T*TQK2*4
M_J] VLTZ[=XMT.L$C C27<*LDP818.PDAKS%#0E17$=Z4Z9/0.A-!6F%S</8
M][(GYNZ8=Y);G$NOR^'U)HFSU^7.'1+2O7/WKMS)5CR Z%C7_TSYJ:_/F<#P
M2)J.HMM<22T@:2(#R PVIECIC-D?A+R@42UDD)2))$]8/[E</YL<1/IX76Z)
M5ELUGO;7H ZKL!FN&KGEHF1RX+DD>=*7R-TI^)3[]DJ?+((M]E6J$NG@I!,*
MZ8MKP"]Y%0L#</?A0 E\$7+?/.*GMQ[R4U[1?^Q91/_XYQ5Z=()SN@T([SJ2
MKWD!JNK7WJ%-)Q.7RA5\RBODECY9+(\EH2960E^JAU4>@=>\+?6$I+ JK_%*
MS+$UK0I9H,)6,/ 2IW[6M9/C9E]6Z]B"]?&K9G<*AN6YG?+A($GUW/M7D@86
M1A>87*/OF1F8'KMO" [I/]VL0*C@CMJD;WZ/,NMKKS1O5CQ8&-6J:E(NS%MI
M8O&.V(AG6 O7TDW/9!ZV7L3CPUTJIRM6X^ R+.+EAZZ_"81>NB9]A4NEMJ^-
M& PY3,)UH]T^C\>H;P]E1>FR%IM30;Z\:B;E\1OUDT%::^>$4+0P(2BMG<:J
MA+!'T=*:[@7L;U&4%ZEDCLG='UG#T)NO&;Z")=GG%/E)O9<IK*N^"EIBLZI^
M#Z&:D_2PM\Q[%1?<A&!%?= '=-RBJ@.5[?"O AI"XZGPZ\Z06/DZ/,P28ZCD
M^R'<]M>&C,2X'H^R<;,T3&K0/.AN6]IV19$_(_Q(G,W*=QU18GYMNVIQ[,-V
M0V&$'JOSBRT =>URC.3M !3(EK(#ZV,H+))='9A; >0#0CINL65&$C=.6+;M
M*8Y8#@C]#9$G82EMO=8%3:5L;>UN7X),*/&U[4JW?&$[NUI9ATU8'\^JME8,
MO[_3"X>%)/T7#"=TY3\A[S*,Z3W)9P^F\THS)]LTEEA2 *+!"/\\JM"TX1BP
MZ+2'3^H<:SA*$WK)QFG[>'DS-N-6,+=\U5RF(@X7=",DV4OG+9 #](+4+?+0
MFI,YNPK)5WM]1ZG0ZG4%1PSE@M;IVI @W2U=(YYA<_@&7Z8Z"!57IRXB !Z+
MOG>>YTF\PD3LQ5<WEDJ:O#D(1)5+3-;< -GNEE(MW;$>'(,O&1G@Q66B MCV
M(95EXCB!\M'#FM:JPY2LO8WK&0M=6[*TOOQM>WIS6"P%0$;LBA&)/RE75)=3
M2*G:]20=G%]KI +W![R-@ZP8V^)Z[QI+NR%*PG+\_-<HTV=_(>]K2$'D1<?3
M% P6O4>/]N?/B+A^A&Z([R+9*VH]SB1=13W--2[^'.*A5&\]S-0'?U1SM55V
M_8HH[AW_P?5E+P0KZMJ>"&79B$#\)_[H?.%RY4>B(D0Z713W9'4GJZB?8E89
MQ)7'CNITT4!=W*F]:4"+'U@?(@O& !4*93. &G2KB^GOR'MD/@(4^8^A+#U?
MW5@J1?+F(!!5+AM9<P-DNULNM73'>G ,ODAD@!>7API@N[4KDL@/413-W3\3
M/_)KUH:DM51>%.V!X,K^29!Z=ZGM9X3_0<^V"Z>>*=@0HL&7D!2%XAK2 MVR
MF3G#K973UW 4A:W6>!QX-#-P #<8J2GM^G($-V<];@V[!;.Y(;)E>WHC) >/
MZKMGZ"^6%%S_R?<2842?M-V!>"I;VL+H#S]>\01Q%B"\\C?W6)%_VF $/2K4
MC]%T<>JP!S>&:K!EIT"#+:R&X%O=;Z^0$^WNFQ3<>T36BHU5UERZ"Z@Z $%7
MN2/*.QBAW-W^IL$!K O+X/N5'/CBQJ0&VJY-T8\V.'*"SP0G&[XY^DM?6JY0
MLY?<O%;?#Q8-U!;&NGY-Z-"AK5&;2=@0LN%MCG6HE,R..B@ "#W:!?,7:SZR
MK"C/\U/24DS< +,7JNC)MX161(<($H^9CV@;S)(L$^0M-B@MFJV^2@XQ>4VT
MT!#3V]8D=7#67EX;CJ:G=<S&ZR:.:T"ADZDT,[0MA8WU3R>IOC2CCU4M>N\\
MGQ)$*7+J$+)=8O+=(:I0:FE[>4R5J@<4C&O52$TO,^R[50LZ+,%&$ V^8A4H
ME&*_ZD&O+*:_O:U0]8K^R3^4?\H@+"'X_?OW-RY>(9)$]+_KMQRYG5:A-Y$(
M![['RO?M?HP62QX(L<*!MZN->T9G<OT]%3@WT7.,0@]Y%=J\>_?AW;O9ZWV.
M(OUW<:;]AVB&E[/B9/]GEDXW^[=LPG^G8Z^#,"HAM./:\;MW[SEQ'NBUZE4N
M@L-$5>4XW+/B\[* J$JCMW9 3&G*PE]P**FJI-DG1Z#;E,(5[4G<Y &]WBV[
MXB(0Z0LQ^4L!4FI,-JQ0 ?W]MU?'![IB6#95X%-J<$G;?MA2T('9/)H\4<E;
MD442;."PAH*VQB%74,*20HIV/;&$D^CU.IM$S0^E8!7Y(  ?#@_V1]T;Q_<N
MPU-GX\=.H.1'39\A>7/<DC<UJ #BD^LFZX17 E[$],#!<"-HQ30("Q!CMQDU
MS_3[#\F_]VWYIX\6'%[>HIBB@[R\%+J2<;+&0W+I0TLNR7" PQ)6V=/W?(=L
M[QSFAN/:6G60D[<?_A G48(:AS@Y%G:YL8<F??RMKLR\24<@I[DZ@2OQ20.M
M-@QS5R3B7#BB_\<YP7[YYSS^XI!O*%XLEXC5^1#J*65+ ,<T?5EB%%=BTP.)
MTW?.ZPDL;@?@I-6 O&)<>B#N(AN-0W>3$'?E1&C^2!#7BG)BZ_4#<$QJ0'P]
MW.QJ_WS?NJ)GADOZSUIK2J%A/UQQ@D#[>GX M=!LDNW)JA,0@\:+?V7. ?0<
MGP>\WV^OHK3\V/Y[@"/D_?8J)HD%&UC5DBEEU6%#"-I+DVF'P.\9=V@,MV9%
M2=/N%DD<Q4[(?$OU!A5!%PB*38LO:C3@<.@:Q>E5] I',EU6:0/@=J?'@PK<
M<(C.Q8(_0.B=\2IU:5&<WYT@085,U%T6JJ?27&;C#,F\CZT5FQENX!F<:H(.
M.*P<",+%IJF :TB $G?P(L!)P"M4^BYWO;*K-?,#?R9R!=QPK"$%X5-?:UV!
M'WAFIZ+:$;=K!P.^[FO)H+WVAQ )R;5= E<A];#*5?UN0_+OIR;+51\5\"N3
M2Z2":^;=+:X^4\G45;TCXVE6V*4Q4T7]+=H!>N"J"$-+&C,'Q44!"RM%WN]4
MJ?-2:-FK[4RIF^A2W0$M6A":<+0+E"VQ.-,AG7%8<SR+YHFN&:R)L=4E?.\\
MHX@%J&1O0=_C:Q3S3W<HCE/#<,M%W60*BW:.?I9Y$R+87/B]RD7C&2Q>B7M1
M#E:EHLMGWNZQ)-R-(_-0+>)WBU*"H;2&*DI)<HM<_)BRE5-'&B/8][1#BMG/
M;2PO_9,"CK2IUE'N;5XLTSHA#:Z#AT,,*06_]&5_.T1K'!R]1M_YER:L+/0=
M]%K_KB\F%A "S[WTN-.0?0>=@1M%#]#4OL6/B:4<U?/U)L!;A$K1/:S8;H,%
MJAAK4(:WC+=IA"!X;J?R*<6@T8I6C09\B=?*O?:25Q$!CE24'O_-+B7TFL)*
M1K$X)8K3!2;BTMSUYW7S$0>5CE:A7*W0A,/_5%;9#8*"VX[QS88"H \Z6 ,'
M%?^-Z0!')&3I3RPNZYK%LE.<)"*@UW50EK>*"]3#IY9U?WL[8$V 4R=:703X
M^QXA=0V CR8U -C@LWST*=__!TP1:Y[G/Z6(32EB4XI8U5\PI8B]C!2Q_TI8
M;=T3'T>NCT(7B7.QU4TAY$N8DUB*SI3[-5#NU_C2O>CAF1TE;PA^\NFA]&3[
M-6+EW[.J=>'CG K<$R4\BN8/$2_"*^%>DX$@:#+=E!ACY.#<(RG82S]69"H5
M&P#8O)O+9)%G1:3@\*+D.69NW]#U U1*N;K'W:S(?J8"L&:[D8]^R -'TL[0
MAB#73RL]A]Y\C4GL_Z6R&RI[ - +?:Z=\KN!"CK 8;"Y3=BRU5>RG(=B*WR#
M[V=*-(;N(MR]^HC(V@]5C*WI ^ F,Q1_:R@!A\V7X1,E!B;;/R@\Z Q_ES_!
M==@00!KY4 P5H0^'BW/7)8C3O[ _+):\]G?":GB&W@U!:S]91PR1C&"RLUK#
MP0#DI0\E#4U)!$ABRH"CAS@'/@-<)ASU_0#D+ \F!_74Z#N _YKB1A'9 <X?
M*3I_9F>*JJ-+HSV !-:^>:=!A;YY]G5#469F'I?-=X'0C;,M1QIDGZ@>.<4!
M91].WVV8$\(>LA=I[RX'!A#[/H@4=$0N.%J='3LC1AM$3Y[GSXP,B1^MTA02
MIIX4!_>:?@ BX8<\O-=0 P[+>32* ,$\XF-G5%9%Y^CUAQ!(/Y0,&) %CBQ0
M&A"VD9VA]+\%K+-$H!HSK<D  &[SW1A?39"&S&NZ&I#_Q)Q_BC?C5'T F%7-
M)5C-R1)^D)F7VQ=\ ^:5^@ PGG;-O!)^D)E'+WL;Q_?$MR[];@ T:M<LK*(X
M BZ>H24B!.4PTZ,_/PLHDTJ;#@; @-H3QVL0ARP'<S<UXM'+(-LX[HGCZ:]I
M<6< IM&N^2Q&M&_+B1 .DB#O%CW0 WE$[_#,^'J+(D2>A/8OTQ$ 6#.;L:X1
MMM;XIW ;FW0$8+_L@UM0G<12@*]\Y\$/TJM7IOKWMM;]-Q.U:C0L  MF#PK7
MB 1PI$3_FMXZGA/$D:H;LX0)TN!YG7I!.XCA50X$X +5*H97B1P<'N=>DGO,
MBUX11/&@4AEO62([>^"<%:O:*&S.)@, ,$HUE^E2#+ !TH!X3;"+D!==4(JD
M:2!?''=%99ML=1BMVQN ]:HC+NMB#(C%5<%,<\_8K>X.N0E1[<R:?0$HYIX6
ML1A?0,RMR",5PB].S #=,M'49[3Y.'!/8BW7M ;N< 5@L9P_.7[  &:%)YPB
MW(H( ?-A -B\^E+I=:C#X3Y#/]-4'H._4*54PFAE#P#&L&YXJL1RH/ OID;\
M@$*-PS05X# .28"5(NRKZ8  C&;MN-H%$2PPO>.HO_9# [":]2,(8X_KTZ=*
M:VL*B$B_;I2\"=+@>7WAAT[H=F!!4PX$X,S>RH*F1 X.CXM'2E8JDL*,E &Z
MJ@YP+60:,BL[:%>1A,Z[PF.Q1BPL]8-K!>N$DR5<83+4Y&%/C7YP[5XM& K^
MW<X#8%4UBV6- >R$/;$.7+GA@]-YNY*SS8>#:[(RY7EC$L"1BENTR;!@.P<]
MLY/8?PB0XI"D[ '7=&7(6R66,-FGR;/A&65FC6K!*&C<*6X*N;*@6H&'$PG0
MU-@[M4:!:V!JL:EJ80Z']?H$:&U7@&Q+,F2X"=)P>,U 9O_/X@Z>G" ]$N0O
M;W,?"(_]+?Q0:)F^6W$8B.@&"3M$G#^[*V8LO:4GC//E$DGM4$,# > 4IV?#
M&IHP+T0N^Q S$.?# :0&DA#<)9M-6H;6"?*TZLMPB<DZ]<6HK=O:O0&<)S4+
M^.IB!(>%EV&,")4U]JX)W2&EX?R55@ LUH;"5P[-KZ #B1^L",+N15D52PX;
M K ^M^+*(4:#OL'"*C\%.$H(OXHO'@+_D0,=W9=2\I4/K[Q_]_.[][/7L_U8
M[ \ZW*PPWNS?TA'__170UU88P)<A9552]^2*L.70I6F+("@>7!$U!//2BH+D
MY6JRASCL%\FQ]2K!1>C82P/*IU;DS6$\L"*7+#E+BEATQAA)1%+!>'B'0CK7
M7?) ,6)%2I%WC6,4G26(=OMT].:C_-V*)J, V/_K9&T73=0$OR&8Q:?^^<TQ
MO0>Z%(,4B&,#/JD' ' 8:,XB-6I6==P5=L(\9U[(+%5# .YD'::H4.A;J;$R
MRWQ>^4HX: + U:LMZP?  ]JQ#VZWR@W["L#+.C7PR_?I[(2EDN81/+ASYZZ0
ME[",AE.'D*T?/O+GCEEB^7D4^VNVQ5TX/DE_3;U8>QJD%YM[BMQ)( ][ZG@.
M</N2VJ33+?*0# VI#22]=5-T\A^R>C_["ZR6D#0?#MR6J)2'YGC"8?U>IK,D
M.)])[A4.']G>Q(AAJ!=TAP&W36LN?5W\+%FK%N31";,:YE0B[Y+UVB';Q?+.
M?PS]I>^RY/2TUA-[RQX'OLLP*70Z0['C!WH&K@_OCMX=50U<Q<%F3NC-,AC8
MV\(%*&9[,&8Y'-7>_Y8! ]8VMA>+DR2B\A-%A=2SZ&1;^$OY5K'Q,,,J"0%4
M"M.:M#48^UI3MA4U@A1+J^I<!%6:&*FVOFGT@V&&JQ'%.@Y5<.K%M,-U\V*S
MBE=.L,8!?MQ>!:[*E*/L ,"ZIBU4!1N.$B< 7K6=$_?$"5@^P]T*(99D./<\
M/X5KOZE1C4#_V.#("3X3G&RB75P&?Q^$[6$)\K)23E2!*'3C4),/KVIE/L .
M5.U01+-K?#&!M]Z;TG0T&%I^V#5:,@PU)5P?6PFE&@G\,Y]GN,;L'KE_J5NQ
MH>AT ["MM)3X_6:C@Z_EV*B'"/V94$D^9S70[^E4BCU"VGIXI2XKB]>!4I=B
M"8U32CVK: ]#D]:(7@U'NE!N7?-$Z6>3M 6@[6HE2\$*$$I,L-3K7$3J+M;\
M1#J8B(U_NNIN?,ZC'+-3O'[('K8]I<CY7K8!\RTU?03@J(;;>D, </V8RH$9
M@GV7(#* 9O?<;?J2*7O1X8L3)DMZ1$H(2W<1O8;1UR0 ?#RZC.^+!'V+Q@W!
M7N+&-_X&T<;H.F%$62S/2/)XZH2>[['' D3LUNP(P'=CQ$)-M'I_W#6;=U_T
MF^5V;##)"DX^2FN"Z?8$D"QEQ!A=O( XTU0^M-W:-W2@';VK=Z#5>LUVDX_
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MJRA9#N1OK7;KKH7=3F'M0MD'I21O@76V%0Y^G96L\UN\=8)X6SCDB]:ZJ!6
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MB @ .:Q&7L_P6D95[[S4W[S@SECR)204G?XHTWNZ&N:OKU*E6 J&4Z2GJ3M
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M:Z['%$[1+SF"M=&,.CUA^,X,Y%:+E44,X;#RB^.NZ"9%2AI;79I U0. J\U
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MI-$P #3X</S4)8H=AG]QGOUULJ9;$\=^$<[CF%*1_4$5$B+L#P[@/1T\6N'
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M4N38P\G2*</X-736F%X)_D)>GG5_0S6IS^(#/=XTBA(6)<RK(5TC/;XW&!7
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M:A!8"G[O\OOE\ZFS\6,GR ^C2C(KFP.(1]61914*<+3YE"8PZC2!,D[3^^N
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M]8MZ*NF2/$3HSX1.SR^Q-;5%I*W'4M.H%A&[]74.H5(F?2C:P\C]J)&N&H[
MJ'E4ADM=]DC<%D ^2*UD*5AA+4EP9'GXS0H>37GX%O74E(<_Y>%#,!A-99+
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M@C"D^@NES3I92TE:^6Y1&4G8G].T JAEJCK/:JJ6OUNTY=51M0PH[#/:Y#N
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MSAZ!N$=D+<LW[7-" %; 'LMS]$0T.+&EC6FGPO)W'-!A HH@*[C4M8HTF1F
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M-X=A99<+I9PE0^9JG+*WHDGL4UFY0R&=ZYJJU.CG-\=9Y-99@FBG8WDJA^$
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M$?P-O/M_>YM2QD]=XO_Y_P-02P,$%     @ J(EO6+&4YCU?X   )9(. !4
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MG4E5/K_&,[76W4%Y@G&-:@M#W@ 7:[A]>YT\?6O<H-RB9;4,>VU3O%#<)O"
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M@M>W=(+V'7E%0O4I8L<_27U"NH4K$4U.-9E:M%:M69SI)\</8_!L&M^'-U\
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MDY@F'[@1=O V8<NH.%?2NYEA/\1NUT7SP@U-.B%WRTXJC."F,/7I7367)EN
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MK4C)/$-FP7Y%A "8X&AB4S4CTBOG"\;C'[+28%F#T$\X,GWU^/0I_@H3+$D
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MU;K=$($,/U;B*@&2<#[++3$,HGJ2PHU-0^Q3":=ZT,&+1H.TZ1U(R6A)W)0
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M6;N26LPJM;=B8SA:/N''(KV!E[,7T[Q3"&!K(6K/-'*%*4PC,S\4[.4#JT(
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M!UCC)+^9:7>\45X?)09D'E/W!@MV*W"*%SCE];U5?B9NO<"I#0NIB+PO[P;
M+H1^7Y\$T^X0/M$DD> 6?PH]RIYV#H,K !O*8/G;)8[L1@DG>HQ@G;I(L0.9
MY82&?90:.184+/E/DB>)2Y&LA7QS6J42XY6,B>!,)&N2\[8-N7@-!:\VU\\?
M"DO9O<]XLS\$T9'2)\I>?9<*NUQR+3S8<*!A+ M9%IF!U33&#US\R(.]CK@I
MZ]E4O'!"^BP6KK\^.2(CO$'FM.J.<1$SEXMD@DED)$(THLI&2N&@GY+N7,HG
M]C5CJYGD_G]KSPC*XYCXKN5![_A<< /Q1%95(7AD%GC!=RI%^P+!Z,Y_9_G!
M\^_<P'9#W7IK/B4\Y+^7]PK7;N*_FFY?CD(8-W:.9[OZB+4O5;P(.:)N8T1'
M6G<5<I!,$))+@N^=D#TKIOL])!:':T?R#G/&"#914[&0?_?]VS^*+53^PW\7
M9>EQ IS8ZEBGR2YB@,AR_Z.TH!#\\GCSA3+7C^D#U )ZY$8;#H!C,%XX0(YF
M^TX .ICK@@%V/-U[0P>(<"%!-WMM2-:, 1.9!5A*LB*Y$$1(0808MO=-EV1G
M99LU?Q@2I4F<<$S.3[>HY \FG>0\J[!-]D6O/SO,4Z>GOU!_NTNHMWZES-E2
MM3A'E].N,?G@A-3)+5MW4C8:D^6<HXVO\KBG;' \\CD3@3A2!K+EZ)D0#VYR
M*Y4(#SP($X=R>;\<!41SZJW$'V5!6#],F!_&OEM6,<Q;9QA1;5\M>)@W3:",
MC:A1\TICP4$\62MZB?LZC+I4%#^#@2WK*.9 #Z>((O+."7JI."R#1@>Q4+9V
MDHAG7%2.SY0%3#&7@F0G*YA<.)))AZEFTS(LK;Q[5.^:P7\':TF@VJ*0Q^R]
M)Y7V^Q3Z22S,.>I.3G<N.*?8B:W:98G2D<5RUR-]%9UT]Z<4*H-1(58&K$O;
M#)K=PN7.T./3I\)<JW)72&X&_2[N=1@CY_C\EH*A$UEZTCL>2\+5J53&>?L
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MA/$BS+CJ311&/(F5R,FZ@^3L5T0*1*)-\;=)KHZU A<.8Q:4.+8Y"?E,F:A
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M^^"$*3R,3:&0V!-EK[Y[EJNQ3W_$H-?'$@7^=>F,' I[J3+"$=&AY$OVG#&
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M]3.X2](R ;:>$@\E, ?0'V*+8V#7Z3T7\!ZDRW17>">/>'ZE21']^D%@)]:
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M<+NQKMY'N[$=?? ZLK;DTW9D!8<#%_8[=[O1W-QV[/T^70<AO6' LTF>7AD
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M4A(VWL*QHE.2!QNG.E7O^_S2HI.7=7OQ-+CFLJ)NC1LB>K3L6K073?$"1Y_
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MI-Q;;\[$'?UM'Z60?<N <+E:13#8@\W%MRB_I/0FUCA?G$(,,:)-ME%+@L5
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MRSUZ!YA1(A&0(FF)-R1 N%=G3N5E3AZ8=H(\*>F3+]P4G(4'0+&G;NOVI#F
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M(LB7XY-4&GT"\15.$@17L2E5\"64,X:T.<&9!'SFWS%&;A?=7NSRAQ_>_T2
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M68D="?-6YRB=;^1CC=64Y"W.05KVP#[G'*V>Q)VQDYUBK'ZTGAOQTW(;%55
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M7X-N&+FGGVE,TV"SC%?+U3:*HRQ/F5%>Z$51W+GSS8FA-'"B\22+-+82AA!
MO#<P2HW1BWW!;4$*?OQ\K,F1E"S]K-?]F.-),D?0- =M-X<3V%AN.%VY"+V,
MI84U%*;4[HP;*(;90$8(O9YXH6&@_&.=H&*C#B\*5EX0P9$5[GL>7D#[KD]A
M'QY:U:]6B/ *WK/(SH)=E <;^.URF^QCU7.K]KCA!AC+5A[\XLYP5G@AS+;"
M]E=6M7!PN"$]A5.LM+B 1)*0"!'Q/H+CP=Q]X$I"R7Y1G"?L/R^4_7_ZZNU%
MP'V8[V'E""9A<6AQ'K_\%JE>/>OOA1L'-;4^>A=0W04O+ND*/NEMP)*^>$V+
M<:CR4;X DW_Z&-H/C#:XO23>>;(-HL.-09WVN(=SKZ;R0%8VQCN$^T4>G4#+
M*/-4<IFVW_@7[EZS+]ZY/Z9NC7N@]FC9'C\VFN(=I'T"&XC?"L+DBR!]B*JN
M R_;>LXJ*V\90CF$%%;OA\\LFL[7Z6:%&P%LVM=(]ET''[S88U5;?]EVDG3'
M;[;: #\&/(^)I2P[JZ96+3JC.-SL5R+K68K20R;AD\DDN&.5:X/4-6S.4KJ*
M#N%P3'^<&#?:$BW7S?L[(\^T&*7*Z'U]OG=3)?FW)5:L*YXDY$Q]7:YV8 [.
M[-T!HM;\%E)=+2)8.@93]R:Y//S\WH++Q_ZYX_%P[JBN5"^S;+\5U[#A-"AD
MD\D#3;?ONR8K6PQQ@K [6Q^%FU:X(0\Z[>H\"0 ?]2+/QY; LR[<0"0922DD
MX5+ZN^2!T^B5=9@26_+=*PW2;,S]:G]K^"X;_9)L&)E-E+_"Y4;3BX-!G&<
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M'C[SRP#2WX5^-VO^QV$?8A#=64+<<,MI )P^T=G!VPC5S(-;*00II3AH(^2
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MQ,R&8?V(AM&L5_&[7;&PQ+B<JFXS2(;JL:JBRSS0JDO?SHK^4GO\>-(IM6F
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MSIF$X9F'S!/Y4S,]U?]<=RK*72\D"#;TL91LM<,!%"])+3J] 2\+[<C%K.G
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MX0R@OEAJ[DD;WF0>^'Q+S7:17@ EU>D,K+Z8:M(LC*O#H]<7>OU6 M9VD5Z
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M&/;%[R6UP-^BT '>OR# _ >=O**]0%"I\QF(??&'V5@L,NENR6_*#-F<DKV
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M%9 !8RW!$A\B#8_*! W91CC=C\I413?JU]S^H[+TWOTE8 DJ,"3J(2,L6M$
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M94*:"7&,GR%^0P[O"5=9,=M@5L9J [>2B#V%F-KN4M'"TKA)PK*V@*V$5"G
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M=T<T#.QHW8\1ZXC]=\YK-6_DYX5X%1=MUTZU[DN" AV#9&P@C_D/E- B2?:
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MD+W?*:PGR_N*X"Z[!>U#O<F\+R6= 9]^&UP0?B,=@-?!#_ZLOUW06NS%^ F
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M^W,-HDNLPZK$X)QK?@6.0TZU[]M[5[[U65S#-B1UH+%ED*ZA@*ZMTKQ BRB
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M']BXK&@8QO1!(8L+_@CEZ*;<Z@<KS:BPZ4'A2T)>GSWO<[LG[WW@SZ@1CBJ
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MK(_E5>WFAC3"JE01"#\<\_2VT&-?O#60K-TOR@B05B6-6 .:>&/K"O3R(VA
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MMA#W+<.=! 6V:@R7#3*":C)K&3UTT+ =.??L-^@#GV4+> 8>#&\#O'Y9778
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M[-)(ORH,9%*R)+!9I7[^!0'>#3G0I*D])IM( U;%T>R 8R7Q"YHUMN\\X^K
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MVP*R#@CK$(*K@[[QH?+ALESE_O&!BZ :'2I48,ES [K$)E*(7SEO%>L3JA5
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MKF*@*PN,YHWU_HI1$S\>48A^YD=\!2!5>AT.=$1$&[4V>@=+OJ%^\Y@*9MO
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MP1R/2Z8'%FNJZ<RNX.GBFNF]H(#&J8U[$S3F:RTX?6!N!'@KL5,QBG$Y I&
MIL+6!^:I@+<:%><WKD:0$BA6XY=Q-4H=DC,,5'A+465RXSJ$Q_YB$5Z.B_ P
M3XFC/\8R]\OKYB/COAH V0!-$52-+["H)@5\,5>QCO$$RV&E!N@9="QC)QDA
M=FZ]L/2 RMF=:RT4#<22Z9@N8!] 9H6ME"X@!@A<@W5(Z0+V02<&@8UT <#X
M,YPN8!\1O4FW4[H 8(0,)ET  -9ZWO(,<7",YVSC Z?U :!<B=0G VZ=F,&M
MO?L/"7:#*D7$>'FNK\O;FR3UU^04*72>0IG6P:T@T(QWJ_ 0F)")8075', B
M'(8$#J62T:9H%.GPD,7S%>[4IH#19>>[BLW?\IN*<C)CS2)E/_7)>"$A=0:]
M&.J[.B<]7D1<N/BN3J<'X>W!IA]1[T-+R N(/K[.#[W;E[.0[VQ1<0@R("S&
MV?OY9_2\BK($;_G8]KB-LCA%*&3:'.QWX%L-!%6:'-'LG%7UD0WE*87->QT[
M4N:\Y6%?<'VI6S$3.$Z"_L6H_E:,/5&*6=L@A@&LIPYOQ0 0!F=:=7&(R8!H
M@0SFEO%P5*QA#H)Z<H1AE#WB$^9L>1?.8X2)NPOSE&MZ#EU'(34J9EF:I-CH
M\,/71PR%^!W=1O%M1B+R[Y(D\\)YXYV&GI'!0=,,5'9,/8.\<^OH7F'(E??F
MIUY N9\4+%F(D-IZG(/#I5Y.C0$8E/D/*)X3H+SBU5Y9T)2[Q0-LNC=]B4\>
M++9[9^H0+ 2IET1F2SS=S5-5L[#1(F@WTL&A43>ONM:6 @JRYY^1)I#AD>J,
M^X(9=SZ"3(57FLHQ =G0S;U"1DUW2V_.5;Y]<'BWSUU-U9)<7R%#>4MN7#-]
MLMEH62- $5C;AC>_2#ND&'EU?-3]Z;A*AV(28\"5TF"VPJVDUNDTH-.@AMWN
M2J24R85>:?P6%+UJ\O$XT^QRRZM[%V(=BI4F9COA\;>"*YSX+$X/*/#J'Q3[
M@%1E$\1[5 8-W, N;A]H %$5DK28.>0R!=WW=4Z2SI9/7H 2;G[V7KN!R) C
M@::;%ADB@4B.7/]@]JRP37N-WE$0O1&Z"_M1E&LOZNFB=-N2S;PYZ]GJ1 $>
M[O4W?&Z(O0 3,5VL_= GME#JOZ."#OXJ5AK#10QT9P#S @F@-TAHR8@"G31_
MI<[02^N(LFD8]L%:M^[\"V:@13.OBK7+0+)<9V@ [0,D^]#LP"NW3L5ZV%\$
M[9"_3M=1%K+*(!KZVHCIOIG;B]H%X#K7463U^+BS^WRLI:JOEFK_A2K<\J7;
M5Z_= 6#%JZ[7?@ARK0G"3:K#AVX?5OU!H(,/W5T0Z?*UVP>2JC [^=H= $2/
M;EZPX."(5H.;UP&06/8-NP&<[@S0=/"SI6?2.)NG&8D\)ELT9D"18<2Q8 2]
MH,'$IA73AE5#!A2I<DW85J&::\4PV]<X<W*$.?/%*HC:"'(?#FKD0@P+V2XA
M4MHOG/.M$49K:,)5$PO/SR@F<\@6Q_#O'P& S>9VU =K-25;VC&IV\;Z3^=S
M%."UG]9[$G;ISBSF? H:U/N 6X-)WQ=G-:ERO&>\1'W48B]IW7)B^^CG%9ZM
MOXM5Y?Z'#4 ][-)D_HM0!> JD52"SG]+DFR=Y_2IWB1^[GR3N)G%I#*- [M(
M'&HJSI J'UM4AR93;DRPR*V HFX/, +81<T*NR$43<@,B)Z1]KR!]P C -")
M0=#"\M?%%XCXJU4HSBLDR/GF=MM#0T)O4N7X2Z1XY-:VU:5<_\DQ>9/^H#8M
M(2]Z*R/=0L9MR_4#D+.0[VQ1<0@ZR'+]@*3)$<V.OT4?V1 W]:%4LP8 G;X5
MOB$.@JI5J0>_+V(FO>PR:?-27,4I1X)QR"/8SRA>LVI5F?L@.+R;P1\#Z/VQ
MU"TKNK64>,S[/0KP, &FB%0PUZWAY;]\V$O" F_=RNW5RL5'/_GK-D;H+L34
MH20E/#14VUOQ\^,JL<%@!^THW0KGVG_W%RA<]+V)5+\[+HY>.=M+D7( H06G
M1\?_^XA2/Z:L;/&V\O%)Y\ "/(=__>O?)MMIC*\JCY$%1GP4]M3F8"(+G#Q<
M=KJB^7QQ_N7"18^=T._/Y 5$#W#G*QK[<A;R7>V*QIRP&%<T9#+$H&#?O=1;
M0.4_AYD[ERH2]$BP7T]=$>V/&P.02%^:3\R$83]N;%&48M8VB*';>NKG<>/<
MI\)^W+CZ.SAA<*95%X>8#(C&P&"N@P]'Q1KFH%MNS&NTQ-1B#H5I[+]DA!8:
ME)$OQFD89N0UF^V/R0.*2]=*\?@C \ :1@:'8#.(VH>N*=ZY==AF<*E@1/S=
M2[$L26V RN\Y<V9+^J,:<N7''7&KE7-NW;%V6=O<PK7=!QYQJY=U1DV%WFN$
M,IA$/,K;)%TU;-;[CO!3YL[ ;P_S>F'/WB^4$!9'(;']9\MO49)\1<NHUD#M
MNO#D:*^B<3[6A Z&_[G]X"1:3L@G)_DWZPW!7PYN6+0E5E"<F-O#1IU-POQ;
MO/3( O###%L(LS=2]8%HVGT<X/](4G_.):[5B/45=F*]3)J$9/<+<NJCW*W#
M0@ONW.)_^J_\<J]M!CP\G/$(=\NZ;\&<FU^8U9@+?NC%']1LN(_PK]@6B&@E
MS#*^3A\.9;]X>$#MQ!E=YCYY0=JN,;;YSX<X>O<3/&811:5JA.T5@]DQPK;_
MG&P^-?G7XF/_=F#&5__//EP7N-Q,JJBN6PB@:<F('KYH/^* M$WS^PRZ:7?+
M "NY<XL6I+ S@TD"6/$[0T.0;D"P(=>"+VZBJQVL1CQU8(@N YYK]O2_HTL!
M: 1."T:X8R<3[VPX]P._*%9)7C[(,"8_?B2%1B9Y'\\1\35ZX<?3S7*)YN05
M ]R;_*)J3N^E0.R8T_7Y$+_F9D:3'Y^>/DV*64W(QR=I-'E>H4DQN7]))IOI
M48.<MG'( @?D]MPP>C,GPNRF95C\5!>LP ;7-'I][9Y:RVA0//6;I-Z S00!
M>#L<2 LML=$=M<9*H%,:&0K@^D"2+&Z[,] M.U^&2_3]H6FX(,\/!97=N@-R
M64..D-7*.5!W 8S<$QFB'U"\]LC=\K6/6V.AS??0UVFLPX2=?I:!BN7M@+?M
MN0NOM+R2?5(^P-<6=[PQ1_SI95TO83R@]NC[B!QQ,]SL)2C?]&N.M^*\V*+_
M0X<)[)[Y6:#]S C:3R&B?9:N4#Q=_%^6I#2]I0.>=X<:$:N%8P4FSP]' U^M
M2!CK75CZAG&C:9*@ZB,P01#])(_G=8"KPE=&))MF9@'R"Y=!WB2?SG[2$9H=
M^%2@[LOPKWNJ,>KW*-U;AJK7.:=*(>KXBY/RD_2")O^H2U<T,J$WO>N9JM3W
M1"X@1*IO?=6<67_>0\#]?071GDJ];^_:38ZJDUTHQ?"5Q)]>>7'\L8QBDAS$
MVHT41H &F/;R9T>@M&6#T>L.^[#"_Y$[E&J<8/CZ6HYR4/!JP0JCMQ3V(?80
M1WC)I1\D!3$EE3S_SORW-;?0@^0 !P4L-2XXERJ\M\K*OQ4^PUI*;;@HJ[0J
M^X!-?.J@<&J*7T;O-" BFNP9\3M*,,NF\WF<>0'>1M(L#NE?2L>,M/G7^@,'
MCMXN7#)Z,S$0S%)WN5:0TA%'5,JSQ>AEA'T8WH78-L)+<&-E8Z9<HW<41$IF
MIF"8@P)<&UX8O0VPC[+?XBB1WFQIXX-"#)MBH_YZ55PP@J(JY'SSO1?R1I./
MDD?_=97.EC\21&ELBGR2ZN@B$#I27X#BLBTH+G-0A.B5O$( 2EU4.+%[$/+>
M? QB4GVI6:_2UQ3$.J;K%US$8U]L*OW!1ZXA=W-+4V&;;)IKI<LA8$N:[A(L
MK6\/ZF!Y[FD+I,PI:?NX%^Y\>^U=!$$[HDL$F,EFMF\52P=W*<<8G5NOUVC4
M7I8DO\1/:T<^U.UFPXB*#MW7-)*]#@HY$J27J&GM+#>Q[QBRL97,Y0,!BHCB
M$A^M'=,J^.@EE$XU5.Z,&RKG4 @<H"H%[,@;WHN*@EY05K1B58$V5.D-;NM7
M]HUA,9Q7#9GMH<B[BR#WX:!&KG- $#Y_*.@%#11JXI2$@X#<(8.B=,(UODG6
MW&@0(A>(;%_P$C0.OF;,9J><9NF*VHJ<?:"Y,33AZ]D$%&C5%#)J9;'OD\E5
M_:SF=;Y<6*^)IR ]&=%SB!RRIB]?"+@BC]S$'UR%W]@6OM@YDFLXM$O3.&2I
MUXKV_$\6^\G"GY/Y<^4OZ.48$MI0.^1M@+UG?A,\92K1$QHV]!@(;0G7E Q@
M!2;[]R2[?M(RBYW[F)WJ,,,!$%_T^R#2P@FWLN*4<RME<PA=PHTBS:"2VA@A
M#VR2;GZ]^7D-@C_P>;PI_$&VKWN Z$Z^6\EIS<X^WF;$Z>$>7-H2#2K?BZ%
M&FD2ZPZ);N[AH!/E;B52_0CCS3.LF"-E0B1#6S!:NX>0-@2[E=K$H'S[?!K"
MM)&HCFFX*)^.*T*:U< C,^+! :PU4WK)?++R  F#4ZK1-N?*[XQ4/TR+4Y6?
M=BDV1Z+'GR= =%"7S>F+]0LZ 8=;[D%?M-[(8O7F1XNGU(M3^\40V2HR1GA%
MD;S0+"#*F#Z%FL5$  ^4 *(_H\3G%4K4,[BK&-/!!E /'_0+Q@<R3S-09 Q]
M6$!488);CAZF,60,ADI#NPK#[DSHZDJ"ED-CRD0[=@(OS81I\B#E1MI-N(\"
M\Y6#[U%*CKX8]+1TUBQ+D]0+%WA!7/M!1@HJ/T3X");Z7D ;)#>_YD&&3V34
M?O"">184QSK:'BUV!E0[U9T>'>^>ZDA%83+@!(\XH4/B/U:F.2GG.=E,-&^6
M3,JI3@@F)I7)DL-@,5TZ?E ?'_QI\,:+0TSZALF,HR"[6<^1.O,56F0!FBVG
M6#Z+0EY/:)[%-)VH!JEH_9:E!:1V">"E=.C]2'V]7UI+-A9)NA;L8YX#;KW3
M=XU>TKL0,S0CY1DX </[#:'@HT?9-\09RK&% QIK#^+4IRY,%6$UAP8#28F(
M1"D@D"E0'=>?5U'XCF+Z<M,3"C% [O&VGGSY]!DC=([G=ITAW.ES8Y"G^@"P
M!2B0P\X]:'?"+88#RZ+A*7O!L_1#<FBB].54G1]_.E. A' 4IW'1CGJF^Z]?
MS=UQ?_OZT3P 9_<W^$5H,+-B1O3-7XX?VYHIVDR"T"X1=8.&K[Y%+0LVFP;/
MS?HMB#X0#0RXCT)4_O,IC>9_S=Z8&2UJG8>!!+6-K1OQ>H2J(TTYC?TYWHKI
MM'^$Y!W>IQ^BK&5V'\<DW9YF/0:+V#"E)I24\5EIZ9B45"EE7N)!V':E]Z-O
M@J0R7<-# \L0S40^,XU>*@.Q)J59Q<TST#(V-$ ;Q99V*'-XJ,F#@]7X2\1Y
MN-S<?23=YK-YBGD2OEYA:E]5Z["=[=\AU@:=%*/"O^:K31O;N(\H("Z;*7GG
M-C_W\$- I?O_V7NTP78'84R2%LN6N^\3CE!;*:='>*6<6=4V2G+AW?.UHWS(
M11_R> Y:UH X0DE= RHX4;&?QA[0<-%5L/M0427>06A(U %B]($&#U5A2L.!
M0^Z0 ='\"D.1<R-5%8[3<R#@X(BVT<72BNS!5X][0@$>[O4W%*+8"\CS9XNU
M'_ID$R8F>L&!9A]/JS%<1$]W!AA(,+#@R]T<7O!F3;=N^J@>QT(1](*&%?U6
M2AL&#+E*U3,>>X=[_$*UK/;0H-%&D/MP4"-WR!9*>8'UA'?;F%1-XNXPC-;0
M0* FOGWQJY Y>,N#LV)$EPLR7:%AH]>]@\^%(=>OXS#O/B.+9;;<)"_=!/XZ
M#_52\Q(*!JOS]/CBXN@2ZM;#QX$ 4MT8XE9)NR;?O)1RRIL>"F1XY(*J8-?]
MW$R#LKR$+(XU.=X5XHM)K4=RD/SZL6WRX'W0H'1:HFL^1P&IO%+O283 .EX;
M^)3#@.R-79JV4=:%HZ:::ONT;CEQ&\5+Y&.FH[R*6%,,CTI_!U&EAP>:BN^)
MH&+R;IH: @]>G'X\8]H3C];25KR?/F^ZGZ8#3^C(D^K00[BD;F8*XVY:W-S>
M173SS+Y^U'Z1O)*6'@N*NI"5(^LFNAO!8V)I4[X>@-U#GXCWX2-)_9 ]?";R
M3 &@0E)R(I$+"'0USQ2<  5RV#$$NQ,.)O6B4:-QK^J8/>J$?K8>TFI2<:NR
M 6+&'8,&KGKF]H$& %4A28N90ZY$J0=50;/5=U&X:_H:(WH(_8>?KKYYX1)Y
M\73Q[B=1S,_*D>X_$,ERY+*OP;L1+R%G"][I1JZ(K]'XW: )WX)>Y_/"K=09
MN2BF3C%@T!#52NIMX[]4U<D (52WK6^].3^ABM7<49@HD>M6R>&O68*9E217
MT?J%7!K3>Y4P\1<H?ZF$<C4GZY@!%I4A' 509Q8XMF&UO>G+"R0DO^&&I"QS
M7O;VMSA*6):2@2\Y"M&^.*6M!O'^XP"]5^03\BQ18MH_D/^Z(DEU)(CP%5L?
M*)[["7J(_3G3>NMO!H>*>\,<[%J/&=)Z("^ISHE0FIG*/XC(=784A1V(-_KR
M5^\0VCQN1:-J\8FLS,%AH(;9WE&@J-&KZ4$N5OC*F?'PE:?L)4%_9R2E[YWH
M8K6PE8O]L)7M@)-\1/C1*KL\$%108#6W4#"A/A-N&$I#TSJB3ZRO8!YC&^P*
M68J&'"I0GFNG\[\S/P\OY]Q$,EH#ES-;<NQSO@R%@\\#:B*6_&>,^ $CPG[0
M *$B53E,B,F%6-::[M*SMU6Z\H)U%$2O']^".>^ZDM-A"#(62VGOCE*5XL$K
M@9TL_*]>0-(?GU8(I?0Z9>'G%&V-,'R>QO]XBQ(O^"V.LC?RO%J0Y:_W)/,H
MQ,9MAA:%G4N".:7KY!CZ.#2H=MB?+#)LR,GO2AP0!TRV&PT:#"UBJ>&&3B-/
M 6Z]_AK%@7_MOZ,DI2DK%0\"9P,6=X,&*IURW-V<6W)C\%NTMLA^^_#HL/5)
M$C?D%'LC@?OVA2XI.9'(VVM]S6&@SRA>?XNPZF%K[ITFL"6BIH9E2!NR2VQ7
M1>%/<50NHW6=*Z>8*Y8SJMKK714*-67;0I$[5_LRVT.7/4^ 4N+GD.G0PN<7
M7FQJ.P#!<T0G%#V'R,&;V#ND?A/$[[.:0T= >[7/)U'3F^3U:^H#BI,%AQ2^
MN-EW)*U)!U6TBF'W*Q!Y%Q(N1O''-%P\Q.C-\Q??O3!;>F6%KR1!Z:YV,?,1
M1Y#6(W- U<MB8!&?X+8'.!*3Y'O!(Z:21C<^8 +G_AN9\C[ Y'JZA)H.%!L-
MV^\]GL=(DM!@L=&*3$TG7*.ZX<:+@X]'M$!K.KM;M!NTQ6CEB%Q5J--DN/+%
MV2&ZDGXK0?-/K]'[?Z+Y(O_<P_O;]E).*I3R\O+L]/AH-Y;RP?N8O">3!Q0O
MHWA-;O\FM7%EHRD+,ML3=)?OX7C[)I=%U=A]:>I.SW:I*P:=%*-.=H95(>[_
M_6>^?(J__=?_!U!+ P04    " "HB6]8-M$&4AL4!@ S<SX %0   &-H<G,M
M,C R,S$R,S%X,3!K+FAT;>R]67/JR!(N^GY_14>?N+%?KM:2! A8NW>? "%F
MD!C$]*+04$B%1C0 XM=?B<$&##8V8!<V$7OW E,:*O/+J3(KZY__NS"-OV;
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M4VWFG+?DY OQ\08//D@%@LAKK0Y33^AF:I:O@H+0SGEGZ<H=&GP("87 77E
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M*'$S%L!<N3 _%-[5I<S"@>OWC.-58H\0XW)SH&=ZC3I#AV%V,LP5A:(R7P6
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M+G*!K]ENY//LV:25VQ,ID[HMBT8U<*&GP-7B\:$K("[6:W>TZ+KAV'97-N7
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M5\BH/V65'$W!N&G:]"$89Z4^6WFIYVO%G(6#@CWVBF(89HF'6'S3U.<="(7
M=OP<0QH:3C6:16T@FGRX_"DA+R(L/3<?M3K-/MY.N+>+;N\D]+U==,,!S@[;
M:9G10<'11^[ ]#/H[OK>F]WSSKF3T_O6.:CS4Y+=N=W5[, 3+24"?M$.7!\
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M>44^VD!7TIY8?2=A^'JA#_^Z4"?;UKA>1^!T?FIV*A707@XIB)SR_^&AS@X
M\?TERVN$WOAUZFAGY4)[X+GI =\IDSJ'9POA?(D<DA"JHR5P9 HCWVN:BR)T
M>Z(1@'SX]+$<\2.N 0OK<078_B$4VS$5RPE\;S5@&]K4?5F56\34Q@/&(* N
ME[Q\!3F3_/DV\3P2[QQY<9K&=^)U7E#/W0DDVU6@%?<C6\64ZTB2(GZE;H?<
M0)\RW5$BP>&B.I*:M7F$2'1/S3D_*'^3F ]P7Z.1RQ?JW'Z2Y:2,#@&/Z36V
M!Z>I/+GXOJ;Z&\'R]L?-H*US\6+%#_NDKN-!D&YHYHSJL^7[0^Y#YWX"N+,"
MD?S\&HO"3HV%W&WH)9@J)!ERD$FS/2W,<@YR:$5^N>D%86^WN)/%B.2U\)?X
MDAJ?_ [^&EC0;GK+W("!61?+U.N)10N];.*=X"__&?A+H+N,_U:9>OR7ITX(
M'1E88O2Z^RWM-W_<V3US Z]#&C8+HLG+GDYZAN^76^UB04&NPO6+07^[(OSX
M5D=AL-/L_P4.;BB]5W2U$$L=I#[?N.S8%EZJ+"2J2@SQ4D=83G/0J@N9AYA]
MS+9\3ODHGKH>^+ZZ1"^I#$> *Y8K>*!E%G5Q5%#[&>06WQYYJ^=>CWN%5Y<"
M\+G0ZHH(K-N6&MW&C EV[$SEK1V)?S^X],19&%X^W/WE^;UJM79\^!HTH2&Z
M3R]"UEF-*\J"Q(3%GC@)\C55N#M__7- ?8Q7>P=!OV36Y0\]G\L;6AQE\XTD
M[*!6[7H2]@7BT1A4*CG/LV48=_6NU^G-_11CD,M[_5D!#WUON4@%Y6PWBYR
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M(/ >$43?16W76W)!DF&9CXC5[O8YV%84Y J!'B[J0P0_*()WYJ*VB92EJ>D
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M%T1\P.TNSK,EI^ODAGQ_;L\;B[DPE-%MD_G%_M^.$B)B[X^@/D\)7:/8Q1Q
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MT:>=UE+$@V:;';;K$S_C(&O7'BVRSEA9.*SJJZ6Z66<D<:$.:V$M,VDW ]5
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M%^?F;P^&7J4E>6:G(_EU#,,9SNSFXHX[3F0R\<EG+@31O,."&ZB;[-3ANN:
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M]^Q!W8-EEZ?UPUP>Z6@?V,U-,6RU+C:[7>>BT]VP+[8;6YL7C4:KT6X/W>%
M-*2CG7]QYER<)<V_>Q]$=_O\W=O]\_!M<&X?GO4N6A<+3X;>]D'228X^-]Y=
MV9_CH?,ZVKD8P9.MXI/BT(FWMO_9:S?FKSO_?IR]^3":^J.+SN*8[XZ^KO=;
MSN'E>6OT3S(\61]_"K[.,+6T^*1S>O9/\NE\2^R]?C/=:,6[WJ3]MG?1O6@6
MG[R<=[Z>O_\\&5W:SL[VQ>7NH-O8'EULZ+>;K.9V^K3!6#;@S.3Q8;S,X3A;
M/I9IAK,XDME8B$$FD7JK00R_7:>JATHE[W3KK=:?YOTJ:'L&"1J#AS#@T ]G
M*F2C_EY';?_Y(!+VY?H,=N#&@*O^WA[$H9\FDF07EFCN<T$]+:R-+YS\^7:]
MVW["U1F2<W&A]UU@_O"><GGW/CQ2E:\W)F]/H4^DB5YO.,8(=3"-PBL41 _O
M\& 5 %$5(K 8:3 "5Z"&OM%\)W2E1H!\L=??L\/CPU%CH['[YGUGXV3/:<W@
MS8T[.D!\>V9C:M027> !K^4#JA7+SH^5F\7_O<52[G !5X(V'X/TSNPO^S)S
MD[.335L'B.[J<O,TFG7./C:.I]/7_?G5I^ED-L)WWHGH6IM@[#2[6]>8.ZO(
M4!Y<J:7+;8'5'F)FM_4IC;S8]0C0!+3<1P\XW7ZFGLF2:,+1R Z\K_3WL[S#
MY"%XQ5^K<D\?_,CWZZ?U?MW:XR3?:(7..'_QK:.P_JS$$[8ZM_$!DYI*V=3]
MDYI62F1FVW2/37FL/5A]6?O]".5GN%:/KYGT7#?"NF_^OP,O$$W#.7;1'9U]
MW=D_F._9@V9_Z^!X,QXW[A8);+?;UMG,"ZS=T)^.\?\C,(U*]9/;#UK[7G[I
MQ>UIF5D$GTYW3W;=8'(Y:75?VF'[2VOKG[LE._53#U25C4;C$9V&JTUZ._#/
MX^@LG 7&SIY?#K^\[+[;"AK]P67P.GK;^/=0W,WU?RK<61BZ%H[_&.3V)#:L
MW#-2<(^C$W@;J)"F._NT]6IT\-'O_;,G3K>/=E]NOA]_>76WC4/2@L4%GOV-
MV_:=+^E)"$?@?_2FF3U/6]+=W/WLIW\W=\[%>O?L^,1YLWL1WFU+MCN-C>Z/
MY-:76X(^_6D$)((-IBSQ13@I.J;@8]!'1?P(%L9WXE?MC<5H;M,(YRY7,WX1
M/>O);YW=ZWZ--SY$S<9\^WA\_/GEJ[WVW[-5F-G)Q^-PTSWT[89G[X6-P>O+
MH\_O_GXH?O!C\ ?8%0NWY<<R155BRZJ8&*O*,&^W3[<G][5'%^2HI/4B81>N
MJM=)>U_FEXVHD8K=\]/]EWNGX[V[7=6-;KEJ??L1^(ZLDMJ#&!?^R3@,%G-F
MWH9[GSZ/O$YT^?ID%G3_OFIO7%&[E">:3^=@^'GP,=Q]<[[SYI\/L\G^[N&E
M=S<+<J.SO=[NMI=82'<.K:R^['X:'XD3^OCM__[6_NW&G:-0Y??W#]]!P&7Y
M/KCVYN:+V$J$+Z9(I%9 5%JS/ 62;MG >V 'R@7B ^>?W^:P[W"0#Y&#TVPL
MRV#+)YG^&#DY3ULA1;9(YW:9I7TPR"("&Y*I5R(2KC5-HSC%'*PDM. )W ^9
M>-M:&\B46S#L,"6UYR3/-<7*7*1N>ZO3W!QL7PP;@^Y%IV,W+[::K>&%TW('
M[?9F=^"T-XN9._&H-3@XV'#<QGIOX^SO[IOYAW-W)*/>N2<_>J/-]?-P/FL<
MSU\>Q._=:+^QUY.ARMR3X^3TY.UNN#_<:[T_>GWQ=R-\^]+%2'JG^.1T>N)T
M3P^^'NRE@],-=_;A\/V7!/.;U),_3JY03O-K;]8WMN\7C<N-TZQW.M]!3MVV
M3OWA5>1FI[YYC2U1;91:8*=S$T7=;,*5D>A-Z V/+>L1:EA)ENT'-G;/O(21
M.83MC"W'M^/X/GXOIJUE&T6U 5.LUDI6?;.^(9>G[-+^U*03V3CA$@,P_]Q_
M!A%>O1N>XAJCM?NY72OR*V>%/S/Y'<FT?&)<XHLS1@1)*PRLV=B#3S*5\?Y>
MO#S_9[B?[[F%)$^_=0\?T[<A5?1YLS4@0:)S]MZD_W[:<C;2?RZ]Z6[W2_!F
M['QZ^;=,WR_7";BD$$NMX S[2>A<UJP_P/1J-)H67%[KRO93@;5E%B&PW:'H
M< 64HF\]Q.5;]EV\M'EI5EV$A8L@92$+,7T+S@_?OOUW^RST+B>[(CP=A\'D
MX_E,EJ9<>PO>G/8K O^.!)Z7ES\H@5]'46=C8:F]N3Y5 T7IXV1I*&FQ)X5U
MH=CP_>2?Z./H[<;V^4;[XT%SY_CO]-7VWS>LZ\B.7?OSLKMRW2^MUWXXL'WK
MT(XN15+N_7T"YV;G]O2]>J%3PV5WFKGL3JYQV8T677;641B(!ZVB;/_0592/
M"[)V<SBTB :P/ +SVW_W Q=SN84UF%O.6#B7%HQS:7E\ND8%K1=;MC43OK]^
M&80S&$_8,:S>A2^P(W8-2VQ=,?0"+K ]37W!A-)I="U)+ :U =W4+=-@^E?$
M>?N)K\U]L"ZVIB58%]=MPG(CKHS_/D:2QP?8V'>XKWVYK=QGW&"V??$Q;A_N
M^XU&>M$Z>G?67__WT]=2-!!C84?AW1CMLNUXH-/8>&3$TJ>[&D&8P">?4P_9
M)W#-(:).1(3H$E\3 6ECE4S^HPR')..PU4W);LK[T$\#;+^)(!M1G$-!LZ='
M;PX#T9C_>QG]_;*1;H6CV:/?D.IN9'=C-A94HU:X(&M-2=)C$!)X-5S+]GU]
M/\R+,Q#R 1BXY*XL7@]#IB@U%:\,BAR$Z;%<^#88T:/32#B" N3-%H]!R&2Q
MM08C@U9MQ:DSMN)QB+ 0"A0G@2&+ZYG9\>)MIQ_+)3T#<1BXUEK+6/< %'1X
M:/ )5H4_HN?AES@?.1@"0L4T$YJN'2?6=H-'<.UYG&<#W^_*R68R#%"%1G-B
M)ZEY\_9>GP_W_W[OKE^F_L7AU^UWYZ>-RYMDT[\B7KFK=Q_6=Q0^*C?^^;@!
M7@:X!Q,O2>#Z"!_N0Q0&:.C[<TN T3^W]M&LL1W*[MZU$YM1G I\(AO#%+ +
MBB?8-:G/U8K]]3-K#;_<?&&UVJVZ5DT]0H.9(AK,0S",Y":&P5-_]E07VMA>
MW%UYO\VDXN3L\/79EW]'YW9[X]7V]%-/N.^K"[U"%WKK&^_SW:XL&7\^C"4L
MVW'@R@(= B6CW$/++RC]%)3B8+WTBW@"=QW>$BF) E0^@<V9UU#&PW @"7'>
M(POL]5DR5E_70=H+FAM9FF2I4U4(^EI:C1?+9DA?-U^HQVY\8/G\U(,HW>7#
M2^:JGLS9PLW68+VEK&%37:F;*4^=SL9V>Z.S=6%WQ>9%QW8;%UMM=_-BT&ZT
MNAMVUW9;&\6DHSUGYVTO.?]ZUO@P?-/[.';W#T;=WD5C,>7I\' DNO\FX]FY
M/=L/#@\^[1Y_GH[@R04 )">X",-F,)M?BHW1QX_SV6Z\.YK!DPLI3V]WYM[Z
M]L7\=&]CT-]I1_&'V9=I*?C3Z_6KBV[B#K[LO1N\WMLZ>?>QXVWADPMO_SB.
M/WW<&1V^;LP_'6X>M5UQ>3#"B%2[^.35^=M+[VS_X**1OF_L=3_M[^Y'#H(_
MJ2<?*N%*.J0HWXJ</?(#SK>B3VZ=D[6]+5.R;NOQ;K7JFQM/#)QR@!>,2=FX
M1/P!W:0[92RWZ\WF$R_H#FR]E)'?)6+1K;<?>;DK6<6?)^)N?7/KR3?AAG@*
MZ4A$SB@A1V$T?ZP"6/)A[,B7Z"CD>/+2W_Y[%G_>$U\.VY?_;.UUTS/DY>T;
M-+#>DCOY('')=KWQX]W6C>NK!%:#[=[[VK8?\=I^3S9]GPVXA?K]F-OSP[#V
M[[8)J\':GW@3'I])KNY=63W&>J- .2JS4%>,.?Y .NRM*QN^ Z^X<=OZ;.2S
MHJ0M??Y3VO _Y.U_PJ86K-32QKY,8R\0<:R5VFC\=G!QM#7U+C]T#E[N[>Y^
M^;CQ92:KHA[.N79_D,A*Z_L!M+Y*KZOTNDJO>^@]>%CF>#M8UNOYRZTUB56^
MHC^35^U&=6I/AD%8@>)82*5,?;,RI;;U-6WH#F^E5JJ:9]$_KK/?\QOO#B:C
M\\^^,_\<8.3C.RI5JXTGL0*1UN$U$4U$[;AEEB&F35"R!-BIF&Z8A%8:<S04
MIL+-&$MZ>H41O<N?X\MG'KP:7FL%8H:AUDC -I+=&]B!X]D^!D^QC0 ^'"=V
MX-J1&UN( ^FYUV(YM-?L?%Y6+KII?:N-^O-EP,@T.!ECQC)(C"G;22(0>A-/
M$/88VQ1-[, >46K80Z0B$'K,;;(C8LN.8S#@\,4J8BV&0T%9(X%$8\3Y>9A,
M$@#I(/N+0M_"EB(&165!]!1V6:>[6IU&9VWP3*>&V]' AF'7C[_X8DX9?&O-
MKG5>[V,;]\W6!H*%/,/MS?92PHL,?&#-!MT.O6C"63A3>+>-#P&I4YJZ2S.V
M4]=+Y+SJMRRR>516O^\,HQY.*HQZ&0&\\NV1D9,S.#_P#S^+X.I<_+WOCH^_
MV!>7_]RW'61YXNEWP>M]X(LWM.(L Q0.^P;H&8M09ZPLMWHI!S;O;D;-A(O+
M>9KA8B(X(3!Q 03_3&9W#GU*^H2/G#"*A.K=0((ABC#?,T1BO?+"-/;GBE;+
MWGJ;J[L*)*WZF[[R@GXR2?9PE3MZ[072?A=U7[^W3_::>_T/Y\<G4_?B_:Q=
M6DCVD"K,"J@&UU,>"FHBLA#D/--)1CZ*V V"))ZGTPQ1M#@AI5."!/'GL<<L
M.\"B,>#AZP,;13\J!R*(6>1@OB-\1=G7^NTFB6OXL2+Z;A2;B9,1*"I7>"/T
M%*0Z8MY(3L1L=1KU9F-WO0G7LGXG-<&ZNSS\!70+2M6+Q\+WE8YIK2TKS5J:
MCO;L5A4G3VX<]7&9.9N(V,EZH^L[^\?BXZ5],'AYL34\'(Y>/RH[^?8TTWL0
M\W<I(_E6%H=ES/9H! 2*%#RATEV)#+&<N3B,*1$SI@0<,C$D2B<=HDR%H<K$
MKTT?ODT#2=[M!G=KM]888<2+Z1<^UE4,9'S"<NUYOE>HGL4DC(F!P1I!)I,1
M)=#X N(. Y3.L0.B^7/*740M9J?I-&39[_AAC.Q0+GD*=$)+YI1Q7)DEG^2*
MZ'QU,W\'[-R%M=8H?_P/>=]>4>8V?)\&'E^G<_C'15]::Q?G_=V+\_'.Y.V_
M5VY\GKX+@YWC<;0Q<_[^S;RCSX-TXH:)*QQO8ON_6;@8()1&_J;VXHOCX<7&
M1;O!-W.K&7W8G.]_.-J;##8F%]V+\X.++@PLAXG_][?]HU>+%_6$E/17?FB;
M6>:]1N?H*IZ\[NZUFJ]'1^WF_L5;#S3:=JM3:[8W:]O=KKII:M'_K5O8OQK$
MR!2$8JRS]UTX#-CP-(+-(K01^LJD(TU&!#\CA1;97*Z'(A5&'=L@SJA,1WPQ
M%3DX!CHUD&$Q"MX)D,P <Y!![JIB!)5:K.E39PI+N0PT,D$*5(R8C2$\?^3'
MDK_B=+)ZA;BD;K:LQHEJ;V''T050M\YH/P2^#_1'K6FJB9$NF<:J:#$ ^HYC
M._*(Q%%_C4&HUU>(>S"\*5T=?;"WX!M*B<8M#=.$G!F$C4H#O!*#""[NW&IM
M$X_HT!6[Y0WC>5Q\>?GIS==_HL&7<S%S/[T5&\[?O;_O?\E:%ZUMO&2=BXO]
M3UU/C#[Y>QOO/_4NO([[Z3CMW7C)&(F'@'CZ-,/C;-EF%YS#=- /QU>[EQ^N
MXJBY;T^Z7S[/?OMOL]FJ;38[M<[6UN*M>R+X@KOTM=\]WCD_W#LZZUO[1SO'
MIR?'I[VSO5WKY;_6Z=ZKO=.]HYT]C5'PF"4VRO*)LPZ=PGTYA]'!)@7E^PQ>
M]=*'0Y)>W,'%Y<?-\?['?S?"R^.=L[/]Y'RC[<8PI@!RF<*H292*!W/BY_RK
M)R"[9*?O_7W-3.T@2+7C!B41L-R)U6RLO[.R%G]P$8&91FI5%G#3Q,;.V@'3
M/]Z?811.EMU55<%QA656X9=Y9N/J DBZESV>S*$0Y-R!.1*%C^'0@1W7)'C8
MS -]5]>.DINSP#B1#VCFB5<%^ /.$9_UT"W00%4 GALFDB\+Y!Q#:<B3K)\+
M.[+8T[H+?)/X4KO)2@9?D:)B^!3M0Z[WF]\_(+5:'1"ZTP<%$->+ TUBZMMS
MAO:XXTI-/*#[!@T;#[LN XOD_]P*#,7Q@<@Q$C=6%3 MBKV-Q#IWAZ8+\MSV
M9W!;5"U+L][8T* H&GBIC=R[4^]L_FEE_\P 4HS98)&-@=N2*Z+A7^7+:.1G
M-[2HGF1PWZW->ALI)@\.\^ A*Y)7&YF\LDM?<.9-@"$=B9EU&D[L  :G3_ E
M//YOUCA"8?3[V?%.*:'@OX%"@<_Z.6*1'X'B1!5/P+UV0BI=RBHS;9,NC,TR
MSKUX&F7;+$O5MMJ=5K<UZ%QT7,>]Z(@M^V*[N;EU,>PV-IS-;M=INUNR".N)
MV@]<IS+L'+_9.SWO6R_WC_L[^Z@A]&M2'![MU!^PZ^J#S[QW='3>.P#-!M2<
M,^OXR'IU?'HHG3H@IPL@ZDQ&3W0(W,VJ<3LE[JSW\F#/.GYE[1P?G:$RIU?R
M'4'3Z57K( 3 ;N"J/LGFMB@EX3H@]7'9VN2M-#8-7_YB:6K,=KUY;3:'<6N-
MUZ.?=>B',R4.U-_KL\B>/F?>/8-]NY%MZN_M01SZ:2(QL!Z?>RX7BG>!'S?
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M=9B2ADYXJ:Q[ _&H3X&*4S^1H*IH(\#I?P*=6*G3L3T4UMB.!JCU.\#ET3
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M'21N7=^UQ8>R>W=L,)%-)=X7A:Z:^77\'M8^@//,9ND0V'XB<;I&8N* 637
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MIQ"+O$F'G^;LJ,6,45;DT7HSJS7MD5A\-K/3:.[L1L)1U0IR0D-^ULL>U4L
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M52I\OK[  T!8S!(.(299(TYLL#?%GG;D<@-S+ I]#4[.2!#"Z"1OE(L852;
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MA@V;N=[J\,%:L%5B"*)4K- ),WI/_4;DGIV=HPJ#YX?!X%D)TCI3=*-WS);
M<"@7!K9NZ1'3L4HA]?;\9/]L[W2]T9*X#VT9/-">C>.#WNE^/WM  D-0P.*Z
M$6K9@3$-E$H6+-3 FGZ;H2^44;Q49-2X?$9IGI$77^)22@\QDAHTV'N=K3^Y
M[74D&XPL2#?#A"&Z<^&!@)M!NU3\ ;L94ZS%S\V:!:J\GCX6#-E((,/45ZM1
M='C<E_I;1IU\&-3*#+E7>_-/7I[)N?42:2UEAK^<OSP/X\!RR"'F@>06IQP=
MRQJ*Y-2.9=X[OO>A-;0]G\Y/7'EA8:*9^AI2K)>2I50)C=+Y6HUZ]T_,"<_$
M?)!$8:84=E#E9*02*?&/^_AY<[/>4?DB6DW.W#!Y-\L*W5O3'-3.A;*.X'/%
MZ+7_6*%".B1D=?8S694S)%G@ 9'+_L%(9/GKZO9HS?%^##N/LVIZ;HE[YGT6
M^>I7[C\8@3J!*J=V7.9S+J_S[+ RA#9H/*8+"L3G"TJ7,+OW.1AY-/4-2GC8
MJFUMM^J--ME(F#'@BW6$YL LR1\V9+=1A>RJD-VJA^R^*1U%84"_U%F3J\/%
M/R WA&TCB9HWMG0@4,T_@U5G;P8GEE-<(=!6 6IQ<+U<_:M )#K=2@_Y1Q,H
MO:E2LS*8[!R@V!+'-X453U[UZ<T%Y';M=I[=A*=>DN*:?".6^L.B?:\*A>!.
MZSX5QN$X7)&DPSW:%N]N_*FT=.73R.\A!YIUX;U*-D(]%Y1&D_+R S=149*)
M.-22M&Z=1%X8:4>6=C[ESZ%6=,BU]00C,9&&D9$6-<9\=J YU90 A#O\'&A^
ML_.""M 5YGRQ9T!^F=@(F,;I31"L47>0X3_/^SW920AC"1KJ2S79PV>R>K\"
M7;'>I*N]&?5+&3[J6;F@,$N!4X4?^('A[Y,/EJ_ZJ1(.L]+;[Y9R>,,U*9&@
M9@W8$N&W3%KH,M+OE(M]EYR!0#)(6<\*)I$(TG+/?A:@U+<+6'N]I5)&?JX"
MRS/T).*GW&@1+3MN*LY%N(2R"FP^B#.G-_YK+E0:A)A,_1#_S*+M[!STP]DZ
MZOPU"FJM@S3 [(0:67_\R^%06I[:"L\*/ONAGY+/1';0H"K#U@N482J3!H/S
ML)J8G$)8!2"?&=H.)D+POBHOAIR71@^EA$EA3WS\U/"4P]EK*YMB36@:Q; T
MV')8E)J>]N$@I!(FL2LSC>6Z%P'OL?UD3,:>W,UHA23@=ZZK92O9-JWJ@0+O
M#8$,(I8JMRZY795M?"75*K/WC;I#=!TR/I"Y"!C1V)Y3SQS4)K#+<8C0)C*E
M!6F92G,$1OX<I&1-0\8%(Z51,C12$76-OE',%$OO(<6237\"1BFI'#\VT'[5
MFQ'>1Z9N3^Q+\@9\('<99\OXY$C+1=CVL=(^X5QOY37K.8E4_EJY.LS]TU[6
M!)#U["YKJGC?=C5TF*HQ #Z71"G6+LB\-=]3L,TJ4BI_B6AA,?^NX,V42="2
MX7'9$KX[&XI_A7EA##J&O"MF_<(8';86&XD *:,6(J%<^-&!8.AG%>VCN@MU
M=R+X,DYEUC?\6GJ8'/3YI+K"4:T\"5U[3G(@HD!D+;_ B8U]#-?UKN0HQ@@]
M:!U7ABEGUH?>#LL 3,92_J<,8\?4K'!K-9M0AY3E9%&2$L7:@?EK0G[8E(*[
M5'/DJF\R_>K>U>E/L@I5R_.HK_\VEK>H%18=(%7IY5U++[][M>3**>A5Q6%5
M<?C35QSVR0>$>\16/\QVA6X@$IG273U6,%//QWB.JKCP"IGW&=4.4851,66D
M,\ED\9 0#@\I&"]#%".J=P$/LR2^1J5T\5/F)Y)R;Y)7)KZXPDQ'L70D,,EA
M@R@[G1, '#;\LQ:>K0[O%NZ,^(+A;'B/+DDUAB$A(AMVV\.A#<83\#![$DOU
MD/+[BIE#K49##>;%Z@)QXX\M1CS41FZY"T1E&>+;MQO*MXA1?>T0R/)?"*Q2
M+D&YZJ0O-<ZT3#-0'\^!/$:RD+)@0(DOPDFE7(1O?M08X&85 ZQB@*L> [P9
MX:*L8-ZXK,B)R+&#LH)$;NQ0X)^XEN 4ND (-U:*S"*ST\(@5W>$:1,9G$X^
M4U%F(U+( ":3Q9U2[H<T%0Q::_+L%?(:%5"C$PTXA)Y+%#?(WC,U;TQ&$NTT
M[*&4T8@A*,-50,/ 'B+)Y1&S&#:4TYY+8*>E+P[;#;I>!$J7RDO6U83H'57<
M.X/#HVQ35*Y0F>*\DI$=2!.&@/-@5C*+2?@HZ^<8)\4724\QERIR(I3EP+;!
MR45/*N1+(L><"1\8+F%719,,%_*""YI.Y_K]E\<I$1WU<4B/% V ^>B<A.4I
M7VP@1B&&LAF#V72U\*D%"@:?ZSE'LDL/.9^EMX@F++B\7CF8-,VL77FV05VZ
M3V5/$M<NT4@8Q<]J<K6DS<MO=1N@SRD:.GA/80ZVA() AY9'#69J,&O7TPWC
MO,D \\65Y;YD9XIS>T5WY#3WZT.Y#EF<1<LBXD132]X?'4I8/+9Q.I 1FBSB
MH>+Z:FEJOVN%B7/-[3JB2*LSQP,S$K9=[;5=I<QV]%E32A]<P5A:@9C8&%O*
M5X)<7)LJ$V6J %OU*44M%MJ3>XH)D:_8C2RC+Z<TU&DVU 'KP3C63AER'A[5
MB<F;C ^P0:I,5:]+E_%3.1@/37-V=4Y3L:P\$**R=*4F'PM*6N#\35A#P3;/
M<7)=H[%S>!PO8!]F/Q2Y;%NNQL=[X,_5H1IJ0D[V+.*B4U6A@AAA)2)"5PY7
M!Y?,FJ1=R!H&O4I.HU:TG(QFB7)RD?B< D_CW:$ GIS/^F"^KJ8VP%(7FI64
M!R[YW"D603_'JF<JL ;QC7 HF0MD%B$<IQO.).<%"9JJ.F<$'E8-+U' 4!'S
M,(RR_=']$XVUDN4(=].SN90'"[448@W'DM!T5L7%7@#,.:4,7<S52:D:R7)#
M*PB1\;%RA9@SG&^"?ZG1A%NWD#N(+S9ZL6HF##T"J@ EY7-Z.!U4IT?9UA^=
M3<.9Q,O5M)/M#.DQ5"<$[!%>D(493$<2)[,P'Z$"?MD?=11XBG<H9]'0BR9*
M-V$CW&/7$2_H1G9''C9"*)+=2#D>JNOIB7:HW^/]>" :LKVLT^@;3UZ?4T'3
M?\-][O[&$#GY1TZ P$.,G"JFAP_?X7V'>=\;ND.9^G?&\#[%2I\JR!%.IC#B
M0X=9OI&/CK'BOQBE1;I0@>HLSZ!&'3Q\X:)28.8.H%,9"Z434APBH4A*J@'H
MFF87F=H!ZBMR90>(!L%E9=3NQ<EVB/UG=%]=CR+EJ+_PN,2@L-4)7G:J6I -
M$\WQ17#E16% ?D_.<90NV.P5,EP8LX8>*6\ZW/-UZ=C+(US5V+T'2RQ^OI "
MH#"Q:$@O3(0S#K01"18QNH!,)%9%KK($L<SK*(<J1(R4DUC9A+ XD7G8<O)'
MPF84>W-(3]34FU+-TRK9)5GA:>;R1MZ-->"!R@BJ$>W$'.;7QR]MEW(O'_L/
MK2"E5"9,3M18 < U58&Z:O@#$CYF>4@X).6IK,I<9)FA)LNSR/#U8R;K3"_A
M"0-'>VZ]$_,D2EV;DQ.99-=R6&//^->'0#27UO^ K'J1Y8=P_J%DE?1$EFIP
M/'6]JS W;@ ?^,:8+T$T)*&_?D@937V0]8.!&CR#A3[L9X.>T1E$WN?<N+"_
M7PO3?0UW)L +4)BD_CP;<W\R](*O7FY$D,786S,;KX>>@(_P8P?+XAP]GO%Y
M-N)+.+; \?*+A\_, ?<.=ZV^ %X19HF=)T,@X2@_8?XL&_O &R3V/#^T(R8>
M2$P8?#V:^8Y\PRD'7X'EG.380US8$OU<KKM1WP["H6?UZ[WL2?XLFPL!Y0F@
MILCWK#4WQ!0NGL;HBS]7)^';7\(^J CC=U3\8NY>X;LL7[7@M,FNI.Z(K;15
M3<NDR(&F<"F!$2538PV#;P]H9?#9+>[=LFBO##K@&[# .]?!8) FI/7!!GA2
M,7@I/*0W.+0$E+VU<M@/HS,1]3)3+H$,&%T]H;8']J=G5'\6\'Q*&$5I!)^B
M*(8(SJH 79>:35$!K9$B3&@9*<BVA'R,J\2R97O;&I:UJ@U0''I!O$N@$3I0
MLT.C\D'08HL=DTU>BU@/L+O F&K6:P_C=7^]I4*!FM4?PVM ?ZF! CIX[PGD
M!7-,V3NP\12)&#DS&43V:)6J\50H:7'3R@OIB2EBDGG->N_9P)+C/%>1'V;,
M@B/E-<7DB,<@\%J43FY@4.JQ/..A8M4E1]R;! @I=/VP_%".Z;VB)%\/-,=#
M&03<0:X"=U$)OKKU[K7=TV/H'V1S$S:7$+"GB]S).00?,ZQI%S+^#4T+I\/H
M "HOA3-=,YFN<D=+H>^?-):K+,P[T1+=%\Y<Y/9A;#N"B4/&-J=>POYR]<-:
M;_))7'F)_1^P%O/Q(ISW9AT#8"A3UF5@CZ([J@%)L;M'.,4PTN%__H+!_FOV
M7UJWDR1\IJG76GLSC[Q)^/6QW^K:7_FMDS@%GH.M%Z9PP];>V"X*V$=^_6 V
M<_'U\JJN]8!<?/C^L5<]_#K U[X,Q9@:9: J-!(^C IJQ&3P)M,)2Y[0%WEM
M9^ZC0OCH9S28/'MF!M$4'_P+S\LQ^N+RG]D$WZ2^]X#38UVP9(K#RT]3W-">
M?T7&H/4&+A;!))):E^-XDG'9TE244%K(OM";XU/RK2DM.=I!&<$J+=K@7C]J
M'L%6E4=0Y1'\5'D$VN="1H,MD3<8Z5*AC&OTWP5%RBQXD"'ES'^19;(;Q1!K
M4E";W,"PTLCD0.\^FDJ(]\M(H3K1'3,O$02+>]!.&5N!PF.%#/E54GE*PD02
M5!@9:<%G)G*6:;XQDLX1@+5R0UYN!!S+'DKD9Y.XA!0U@6, ;7B"[7G9($8X
MJ!%ZSJGT3#G@BA[V?&R53GJ$@== QUKU:)&[CI.8RS(T3A/+F=VHA^.)<CMM
M,C@UUJP1$=)ZK[1&35V6VM$C:JOKSQG(3U*)'#/W6T0_4Z5^"@"$:#K+;M.3
MTU 9Y.I4G8REFT[=484_-Y/I?9(D2588!:YWB&X8]^B600QK(:JP8_@5>Q*6
MYJG#LCLY]P72R8'L\:73?>.5:>*QZ\%Q>X.4JZ-T CO=J^,H_%(T#ZV7]?>9
M=8A/*(UM=3B+40RK(11:9;WY7'/Q]N+B:]<WV#.8-^418ZA:!IH]=E.ADR2#
M+C1*X+(><@BREV7PPQR-WG%T +GN<4N[Q1GH$0>$QM.;8#C$QF@0HAQ9+R/[
MJ\=1CUZ$<-9>8+./0!?R8CK$&X2&:G:L-4J, R$#K\"?K^T%H*3YCZ./Y^6@
MDL6\^[I:F8J'E3 VE6RN!&L\NVGMR_:<=IE=$!IQ4WS!K8UUH8_'9;5#PBE#
MZ$#9F(7*&Q3_O=5!9<4$NIRA+'2D )$0V8(S\4A,B2A"GLTMXY$/AP,$[Y7T
M4DR%D/D%NL5[)F29ME9+&UA8CE(!%N?/8/>L#"V3G@3^KG\1I@G6=^AFZS;<
M^X&P)7\VJ0;]SRF&3\@K<Z4*@4E#, M\I"<4B5$'ZR*BKU!G7RG^2/V2)6P:
MCIN55V9#8F]H[#ZC%KMXU@+VQI-R%^-L2&>DEC"?L.*QS54](VH#0&!F&2EA
M<D,R@S=)7)DIWFQ$F:.Z4QK'K/!9V/3:#:DIJT-+J'R5<',NUP&=$U,=EJV%
MU4T\_SE^+/\I]<@$T4)P[RBN(1$@R^B/\C,R\F.<2=;$<+B:65UDIV#<<RL&
ML,TD*"XLEM,CD58($(!6 /8 DER,87L8$]-72&=+L" FADW8XOE)H#MB,U>V
M1("F\B^,RZ=3#*L07U7E9S)*3?KH#,MGY#:1-NXEEAN*F*P1^))0!VB";O;[
MXHTK+KEN[7FD[+*>C&JKPB@0A8N 0V'92(3F#7H&G+&Z@*$Q!$^-9^503I)F
MU-G5-%AUG;=P\<V]W)M!QF##=*$3FY81/&&AHPL(7T%;VFRMRXV?$F .'@_L
M$IV: Z;E'J[DYO736 ,[N(S2:>*0F>,%<>A?$0*[POS)=D(#_ETWJ#<A.$0J
MQN'SSTU.:QO>D/_?&8/R(H(1=XPPN(&=<)I:)'.:N"6)\N=G.T\))EHGRDWF
MX8O=[JO]]D62^%GN[**>SMR#W>ZKP^#V2R'"%FM3"1HUO\2%=M2Y)?*E(@U4
MYRJ/_'! R*KYQL4UZCFTJ/#(8 1+.!Y52T#4B@F%*>4$3+B8G'V65Y&D0BH1
M?^GUQC(H(1UO ^/1R[H*T ZG*8IA57-+*348$18YPU./G?5P+N"QZ1?52)-7
MZV(F4AZ;R0KJ0@;-X6.1*,X_'+ES1&.ER%W6HE]'[D:K]<#-D7U>%9#Q&G8Y
MRO:0A6Q_R>-D4H2?*_A17[(7BHE*.@"-J,(SA7_!7;56A@(6CMSH-+]2!Y[!
MO"[A;0N]UXV57&^VVR6&.SFI[, ;R-:1:PK8@:Q*9;.9@ 4:U\ F8%A59U[L
M8I\#KS,19WBB!TJNJG(# XVNU%B]J;_\ I]>;HEF>[@PB\=O.L\O9H ;ME+3
M^*89V=32E=19+@_3N DF4(+60.2+L^LO8:$7$I'E!+('.6V=JWXSZT])D_Q,
M< <$3N=ILPDR<5:X%HID)HA^DL8%G$Q$( H#;I8^1'R)N)@5)IT;2ZR<6]#0
M0GY8\1CMG#='UDP91X1!U$S'+5W&CQI)W:XBJ54D]:>*I)8SE#L)GD7^L"C&
MD2?DA,@2U^=UKV+A>6^Y4E0_;BU="JA / XW<[&YL[>8)E+Y8>"A5HGFD*^G
MT=/(](<S/<<EC_+&,38O+@I.RT'DM\3S#5!$]&\[5"\VS&?0/[?6FL^T \C
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MAT<!-:(Q78_,!"9-2C='62I>S*"4V:EK4ZQP>@,![X9%[V;:9_Z)6FYXAGK
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MB_)-2JP\)RRLJ'P'<5ZH1DW(%M8Z#&(F +E1525Y[0++A"7  #RYLS%$B,'
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MDA,WDV0::;B$LWM<5<L/O9_ I!]Q-0>J"/(&I!!![^3\U9=WZ@#6F.(&,QC
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MN*1'PAB*M*7U\K2<?F<B+60.IZY%5"D5XK$O[:==&C)QY9N6]\4J? %X,97
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ME)\S'>@1QB)-C0?=<"XA^46@UK&+D=#PILS2!35K*@A<5FDH1+%5H=J*1%J
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MBGC#2#00[& U;7,FP3[AX?]'5*]?[YO6;9/-G5Z.96$V>IT/UJT[6U(4WBB
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M#EUT^GSR15IF> U7S7]+"":*TB75(-T,21#TR\1QAX13BWB?5@+3Z0A>4XX
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M=>RU2;LT\8@,& IM0!=44=@! TA@?JN_O.CF?N?K02H>/Z $*&D0_26V* V
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M*&0<?IRL';MA]$CE6)U^O>M8.*T)T.P#%0;Z-'#SR)(WQ %K&W512FED@N+
M(RFH98P09^04((1Q@CN"Q:6(/H:.R4 ]Y6.RTP<;"69 ]^2\2R>I--J:YD'I
MQ<2G11Z3=DQ$<HS!#X;CO8F\OFR8XUN9F.NAWA7F^O/+'$ GBP(IQV#U\;GN
M$MSVA4'H^9,CK*M&"(GB>TRL*%A,CYZ;SQ'.S9C/A,^,T+:VN8P&#^37G"-%
MFA0FC5UTZ%"E#.LII%!;G>/Z&P0? 9L_6_E J8XYU=_BN:-'_>N.@ VO%VL'
MV&?XZ//7(?WJG\>V(O"WLYG_I('!IGL>'_FA*D_TVS3<MD(!O:B;/M[/L>PY
MQ8>3^*"_B0Z [)]#RSLX'?6&SF6O)YE8ZM&#M]8[.^SCE?1HA?N-[U9@['\[
MRPZ]L:=.X+\Q9ZYROXS?>I>XC'P#])O1XVYV+R7:>%$N49-,/_1)],EB3?M0
M";#*;XG);G$(L(\#=*)T7.OB;K!DJ^Q&\+UO7KTX/WOU3')118;NH^F\6/6M
M._4C8M7&J"*)N$;[$N$G.5G-VK[O'.QG@W#Q'6+^#SLL_R*2'@B"MR?6T13$
M>A K7CGE8-HBDE0G#L]=UM4U!&57*3:R:9L!CTO5")V@:Q9UP<V5*/XWIB<(
MP&3985;'<//P?3%KE!$NTN1-GX$,8S"0$G(%UZ/ZBL]WFM"VB<N.$,T0IRZO
MJ#0"W!0KC$%FOM3YRP EI<*\QDKIKR1PDQJ]J)OH_<O4)J/PZ>O-%4,)9Y8O
M_+U*C$$K;"W<0*EH*]#"SQGO(/NUEICIHP4R/)R #!.0X4\%9$B%B7A[EBXJ
MY8C'20;;9 ;<NFEN.49/S;ZG-W,3NC?PPS(:.'2YE,TQBNI7*<[RX-[AE*;6
M#$"S],@CN74H%1:-R0N&F0#NV/M&&7?T!X,,/&:,I0W,\,EH7U()ZAWU*VW^
M7A<-%P-EXBP9)CAP/"0H_CN#633LHZ\@[;?M'[DO7IW=G2SJS: 3,.R#6L")
M#4RHY-(((#CW::@U]*4#]B%H@3&; A[?1"0Z7V17*(EIN,;CWC9*#15Y*\._
MP\5[PTO6[$YG+W$*&S0&[!?3ZMTE@N@'C[/9P_L/'V;Z@F;7/B.7!T!?$5&&
MCWL.$!3A#T+I+]TUJ##8W<SZTI=(G8I2C+ITE]YYY :J$M+/>W._'&4I\;2_
MQ<>?9,+E*'47TIICP4B]CEO:D#?WO]Z)F G1Q'&:,-II'<E]GS(7-9<E^E&4
MMBA:<"8339(42%<^66U1YY?;?O3)U^H:0=S C3&Y?H 87>:[T"H*.8/HSL#5
MZN]L17FP0)]_PO4]O!.FT&Z&'6#\(,W;#O>$0['WNYA'LZ\5-<ZM# P%RHV@
M.R/IE$Z^426SVC'!0=P6E+NH=U5A).JDG,Y^#";Z\ F9Z*-LYF]D%L7MJ,,H
M329JKM+*^V-7[8W:OT,MZ*'IG=*548J"0J_@^ =$9_2[.,R7(,YD+_CGW&"X
M23+)8$_&CYOOM95Y?YI@:(P3/;U3C/AL4!C8;%Q)7'\_KXN-TUI>O@C/CG<N
MZ!ME+PX9]X'11NP=H(/VKL4"\7@N*-G1XX&@-I/!12ZP><(J1Q7:R/:5L6B6
MQ@3<S6OZY5;<9F\!A+>+MPA7*Z1!FN\R?H=(9A,'AE66X@TH.*HM=#E%_IG[
M)TMWY3;53NO!$0Q>_,IUCWE1"4WJ^S\_;W=:/HM3AW?G4!QR<=OP:W1V1OH<
M/*_:GT&3(S73L2G\\:9:]*8&U06DLS7T>N,BL7,S6#B?WBX;;R41!MH$[F+Y
MJFLFS)5J8S*[%[]=V4J]WY%QJ-/(GI[,R-2)-+&![6B2' H2WOEBF(6WJA%9
M7?CXEX9B6.\8F(;-GIAAN5*%MEGI'4B#,Z&9.>U[>W]HM[;(H:$_<KGG6GSC
M,P01$09<ELJ82\;_F268.T[?TS.2744-ZAB>:@7VH9[[1PDWX#/_7R)>41Z/
MN$@812K>EF)\,Y^O7@JUSYSZ5\G\<-:;.",2#%3M"=/*^0^_=YK#+4BS%'UT
M7-"'4TOIM]"*P*Z$:.256UZ#9_N<T"#80WY-RB+/#"'1=5Z#Y>?[9\^>SK[U
M6Y6H1.+(66C-I3'BMWA!LV_T;LYQ%A6;T_<ZJ?@N(3>=V.>RM"]IF.1N>11_
MCK_,:_1F]!2_MI0"9(*H5'%80'A4O-SKJGY+*1I^OJH676-814$#CMZ0#X 6
MC 6Q/=M8X(M./X&T+@N:SV4@BAQ8R-I6U::HI#),QX>&2 * @E46: !7)Z"G
M)!Y;_7M_,"T+L,XT5*#F8(8Y$^BIPI@Q/1-O"]'CJ:M?R"GX[?+Y?3J'3Y!G
M2G)1M_Q?SCN>:N_\4X:) %G8!_=Y95D"O H!46/^Z/T:Z.^DXFZX7; @UJ/9
MHP?&,-;Y<O;H_N.;5\&G)#X\(TR-V??C,V@ES<'SNX_+2'\; &M"<@Z%1&(/
M)L?SL^/J+OG:7P W<A1Y$FK-&ZA?31_48C2=O@?:BMYP^#FN'%/]<_4FY#?I
M/<B0JDI)LY='A"G%6>];=HJ5]X?JNJICT_VR AC /Q;[]%PZ@#XWK+N"92H1
MG%[YMR:XNC)T;B]IZMR[#'YRLRCKBG(JV0!&79P/U&4-N]OX9/ $@:(02A!#
M3V%VY?LVN*1G\.X [?,^M](WPN?R7__QX/']K_\ D/8--VQO#P$PHQ2^6A=+
MOX&4#>;1'W%C[]RA^=D%NZ;L GV")M\0ZIO1:7E1:Y =#N\ /_;7=G5)>*QY
MI6Q91GJEMR>QJ:CH1WOSJG#7;/"Y!&*U0A5_%G+D8.:&\E&IH*C1YJ.8CG//
MN@5T1_A?2*37C/<@&HAM/)WIH1[H8HVGU[/ J$P$S,];XBFMJ;Z'T%?Y,;F0
MY/.ZRW;-O-S_ISALN'_YJ]\SQ5\-$'3NVFN$&X3,+I?V.V@%J -*+?<9XN]V
MWV,1NR;: 5H.C%<S;)[\J";H>,"XF\U:RHD<7PT.:I@-]W["SY6B._RI\7/Q
MPO&TKBCRI,\%5$J@EM/YH+9:O(4 XH>5D.COW+N_4<D>A#/4;$9EKU*6A_#R
MDG$X $"N\D5TDOX-^(AF#]H5IBG<N/R*"1$45E4HRULV\R&VL_\=BYU,+BD;
M1M+]19AG#TUX'H%>;=PO!&9I@F(A\\41I.2S^P_NO?V$K5/*8Y'WIEVLI6-0
MSI[)(_HPP-O2[$*ZB[,+_Y<8Q+-B(-?J2NS?G0EKY&(X'/+L+ ([>*Z%6[ D
M][UB3#=1')+/87R]W49S[SV541W>@<<Z ZN#D$S$"RT=" W?[TYXEP/UEG;_
M,39K'TW-VJE9>]>;M;\S^'U1*O$5/,M3SGW;_13T'CE++UP%,C9*NT I$PD$
M?2I9AJ$WY;,!)2@E1H(^XA("$4M*AD0#XC:LF?U8!DXV>(F0-.XZ'[O*U\OD
M"<_^R7?:&N!\KZ5/Z1U3_-Q6%,SF#!<L^/5?Z?0F#^SB@TPDSO4T&@!3[3WG
M-E1M8168C!]A*3P#K@ST/7-5!6D07]9&?V/;X,5PF*[9 QV5,CB9S]JZ0[MA
M<#MKM]DU@I7D@QV!)X?@\=MDM-C&+V!<]E$WSV56H<@C4U\^"&UD*)]FRER[
M+J$<Z(__4AH']!\FMF%V __TC$15MH,8]:\T:?\9S%9="?@IW7G88_3AN/\T
MD.B'8=*_NQ^!U4M!OW'O:0@;DV*Y3I;X/_[,1S6'ZBK\L%2/U06/WVTK(&DQ
MZI$_DP95$ZJJ5_YF>#>@;/W9D^'G:%&6/)% 4^CEB8SH);0U0;SP>T2/KQ=4
M7R&J=0)_)!_F*B"G@VY3\""2E/IB,VR'P!+#&J50&'B?,P^EE7-O1ZO9,^;[
M]0;U(S@Q$/G1: !&*AHMKWQ381-A?FWIG57%#>WA;?Z;HK)_K[_\G2>.Z2B_
M)OZ1NW:+=_STD29<KT@.*A?C*+4\D6Y-.D)LCVH=WX5PP6Q#DT"'*-)$T*?J
M3$Q#J13&,7'<9 P&24D"J0>,@Z*"[+OT>,]__-N+IR</GOB,TC_@MEA0AI7T
MS6(?3N])J4C&.X$'DU8LQPDZ-2=KS#DEES$SNND:F:]'0!>>5;_S*EZ(W%BD
M<<<0X69C+U=KX]QGS@MX)-&8"8O U25J17"Y8^_/(+[,O*HPB0?QK;:)'XJ3
M>6DE6R?0X>.+AO"ZYTSG0E]R04PMK=:M0:+(4JY;5P?V$YZ!*R\K.C%UR%T>
MO.?!)\<V<&QO9&MD_I2-#2*L_C,"-G'G[6[=]1WW=6],(;(JP:6-,E--F]([
MNI9AA->!J#V=QPRL#N%OMA5&@'I@?T#UY!>SMF"'BB\\KY84A'^C,?4YJX!G
MLZ[<Y->0F%KG=2[J4EQ::HL3C()W/"^@Q$LZ=J-,S!M6*:(!=0F]T%[RN[YU
M/F8+@A]:M"._?6%*R+&5.WMC'?(+. '4Q>./$V(./!9[>+F\4/:LO44 :0"%
MRGG%<W49X_&$&)N";8NW.$Q>?W-R_M<_@OGFAGUPZ[O[]VZ)=^CFQ[JD?\\!
M+7QW.K?>G,CT>E3!ADRLAT!KB(*<,=',EN$NN9'"?\U=3O^%Q6:<G>-T]MH%
M":4?_#'%';L'/IRWJ0&%FH9P3#1&:"I.=JB.C,NWX%IT^/DMWU"A&U_Z/#1W
M7JMP! -_6?_5_RTA-U^\R&8O("#W)2=C_A@]8UV;5X%:YKE_?7*S]T_^FR.2
M^'H35N"ST9]'YT;A  @Y\)5$S!&8PQ'@U:X@!C"2JV>MSHKND[]>[E7NY4P7
M\U71O)T]EQ16%^=.F5KD]=!G]<_YU&V8(J0 4'77DB/E9WMX_\%]<GG1 5M<
MZ8YG#J.DJA(7;;?4N4:?H,"$Y%5ZS<\X=4P_9P&;P*!R6@J@T@]YL\S_-?MV
M4\T)D8-^IQEN;_9;[P3T)9Q_]^JU+O[=6?L?B?:-P >$U])LN:)LF:->!5WX
MD/C1HT>S-]=X-]5FM\;_UG2XO.X*W:^/[]_/^J"LL]F3S^X__IQ;-G@3K=NX
MW1H.0Q"'?I7O/?[\_B>SQY\].7GT^:/['[89^/>J(RCJJ@";)DC"_4GI+6I1
M[0H7FI<B<,4^KQEZ@LQP!!SZT/]D:E[C'_D2EZ%P! D#>RG*OEB\BO]B56QX
M"G'5^="H07&*1F!R%A)XS>F5?.>C>_DG_$__!P\^O[?4_UHIA+P3C-6S7P2[
M&(2;'GVFU99K-V^*E@J7Z[;=-5]]^NGU]?7IHO).JFO\_VYG*_""  A)T\XQ
M $I")8BHY#I>0=N6$?@X4^1W87I:MG50):.K13*5],Z,:C$GE\01@'72(\9=
MAY,B\# "C2DL0HO*'S*8.<(B8(X84SX@*BCFG12I. 9C0O,J86R6LJ[VN]FA
MF5(G(QU?/SL/6B/X4EW4>UA265%_^Z>7U97T'^6 :O35$V'&+\K3$ ^4)IYI
M\:;2$T>Y)0CKKLP/L"1C\,QF%/CEGIW+L->*1IC8/5"-8CFP"[_P%8YKW&J.
M=N?<7XIU35#O%O8DQWP=;,#I%\$U$<1-U"1A1JVPZM#N\R%_FXJIR<!:%0J&
MC%51Z0T>\:&86PLN2H1T)$/@I,^?R@L!9QTP.&5P\8<\,&,YI3#B*6YS;9GC
M)E7'JN0L@D(LK4[R,! 5.'_;-Z@P8,!&RO5(:*KG^OU/:?)^[G245]$YY^*N
MQN(?[ZWH+1+ZT82'_%M&&%0RTMRL*WJ?0NV5-P.&5CY*37$'\TEWJE;Q,3;"
M/YL:X5,C_.-MA-]R9^:S8OG__N4?B^4\GS]Q7_QC]7AU_Q^???;EPW\\>3!_
M^(_ED\>K+Q>/O[S_V1>KO_#3__MK #97.^5_V/][0_GO+W^U>=WPV7'U!V?X
MC'SD'X\^O__YX_L?[''?Y7GT<6[Z$Q^.;/TW_A%MIQN2A@=?1C/%OWMN]CCZ
M\QNWJ:Z9/KGA!S#TE)*,*2N'S,6]18R<RO0.DUKT\3O>C*24YA>40LVB"=\3
MI"2]XZ0H&Y5*58SSG]=A2J!]@3TU%0L$ EUC>O_R!WQIBI69(KVA7\@3Z#=G
M)A(=?E&F, ,FQ9G3 L5<&@- ".A&*AH:PU/?:TU327-'"$-NUT16D\PG$I>.
M;H"!JX.H6&]_M,0SXYP.P-WC;S?6H_&"(HJX%Y3K#&3)]2E4=\#M?//UYS3V
MI3*IQB24)-Y2Q_5MY)2NCWTR?B)BP\:S6$IY$AO0.7Y"A>5=X[[2?WS]/GR]
M!DKF)[@=VHFXB9--OJ^Z]JM5\8M;CFU.<S)IP,%/TM;^_R_U(>1CV+U_^=3^
MXMV.XMXS (F =$GNB6[/W_[7/K%LW4F#R7%_"%_7^>YK<P,2O,B-_M=_/'G\
M!71AVZ6]K_1#QV1F?SL!Q+&0(386B- #=<BBH:E,8E0"TD-P-%G,H\,LC::W
M3I4U]^Q\!.9#+!SB&9#S,,-NH/92()&303Y5'>%+H=Z&74V;.<AJIG^LZN7)
MGWJ#V:  :X>_3L,1@N7_%$;S*1G>'=@$M">G7? A=\&;9,H0&>Q"T-S42E?5
ME6!\DFJ+YF+XL94FZW:"/UJZ2RF5L4V30N2N53G9J <SWP<F+?JR(!"?'5;Y
MI:!"2&$)-[BNMMPZ!&,!"QK7+C)T+?N8^6K>:O<1E1[NZ90!2X<O^92T(P@W
M222Y4'@(>LF?^F]?7U/J;SAN Q]&E8JJ[+Q]UTI0R#)R" S,<#'5#62Z7(=.
MXAF;S,U,6WK:TH>W]%E$XOJ7XD,KUJY8IGB/3U.!0:HST$92:9^,]7LV>Q&E
MJ&HYSAAZXS>6;HIL%O]EA7[H,%,^'=7=]LO>N-BYTEX^,@(KVZY<@!2V#B:4
MP_#7B*Y0,]J%-4%Z6!&_Q>H"C-X$%9JVU+2E#FVI'_LJ4D96RLS-9S, V(A&
M1L*RC$_&VB%>M*05QG#]^=3Y0W8_V>!D@T=L\&G1"&2KD;$*+J<]?WK&_X@>
MSLA0!?KC2- "WFRB4$' P:+TY@^:==>>+*MK9C.Y9 R 2@5 \*4N57MM76@=
M ^/3,G, VM^BCO/ZQ&0$0":-&$/XV$=PZV*7-!6%TEB5OKG#4Y0TOE&(<'=Z
ME/A_B3)6%CA=B(9PQR!2XAPC,HEEPI(A@@5,."!'(K8IHVTYE4I.1BW_Y,IW
MO$77M*8_(!!LU(O!FI0D:7_E4N(8[1=-6WS:XC<<,Y'5RY@LT/*)5KB.1EN6
MGPB>2HXJ^CUOM+%K@U8T85=KXD90*'N3;XGO48F%<F;E$V4@JZIU&I4A5T05
M>/2NI5#9XZ/Q=^G_EW57$YDA_GL7V6-D]+E??+'?*9FG3TR="L!@47PDZM\6
MBS9..W+:D4>*A"MFQP0_F4M,F&K=^:Y (K%8EVRT3'987D;%$L:&R.&HHF!Z
M':0],%\YB:A:GN^"]@X1V?&.S7@64O*B)9]MM=D,K*K@+QZ0W+BPR)N"<% $
M3I/2?92$U*C6G.-2#-)V@SD1#\2_TV::-M.1S031"2IY\>EBYFUI3K)_F&1A
MM/('YW.EAK3H0/!:U'F&)F,(WXC >B42$N3O]>0:7K5'P[FD*@:B2%9!U!'E
MD9.2.#P[8&^G"MQDZ,<,W;"($Y7E-DSCC=")9V180<"""N<%L&K=1L:O282"
MU!J9_X8*UV+I@8 /BMJK*M!8C?MJU*KY& CT]4%#O'&MT>6]42$[X>@=U<F>
M3H-IDQP/K;!!9*HK<BA)\RCH#(I'1O4@@#D;Y1+3ND$*3;CP]E@L=>#MP,0\
M)B#+TA\C+\&56ZX<8BS"&Z]4<9F2BD!*2+N.22EE^$WOS<PC YW"](5V5B9^
M(-;*N6.+07RB;+5/D^PO*B!.Y\ZTI6ZUI;1A0[U'9@/D00.MJA&EA,^UK16&
M_VA:OXGB[J*C2Q03<B";^!"BO)PW0OHU0M:<Y@UY#4A%UTJ=4+E"@4-:=ES
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M->^8%0])[!%%+DFUK/?+6 (90*4(9$)Y5 GZ]1M^AD=D)*JH%EO@#.;#M%@
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MP-XB1EEE.9W!P85G]VY5("4?&\1%H#,6W&*#9A"-(6X2RM *IG12&YV>/^&
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MV"?^!;Q($:8V6M+KFHG3#W^]JJO*-;@Q7S[ZY-,(X/<Q N _.P/@SP#X4P?
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M]R>"CU11X(&;4AC@#G<R5<SK[8:(HN'0:MK%>P)>382Q@4;))(L(%PGJA78
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M31T72.@9+X#@#_ 2_:Q'^'>0%3O3-".X\;HDD)#W.#0O.I[2%9T9^\*@DW'
M'#V!ZW8P?".\8'CK,)4N'EU&+IPL:A*XQ+FG/ >C3#B-IY7CW,>NO3DM!^NE
M<9YH8!X#0P$I#)E3DC<<RP6;5HC8S2'=(,3=\#CG&^2R[I 94[:RI:T$"\WY
M37->!E?N<EBZP!MN(HR;MGM'?=4\MQ?'7WJW=[,  M#67IE +&:0='A,TJE0
M=+VNJQ%'#P$I(\+9;KE;S[?SE]A%7(6J8,R[R=AL241[$8*EJ'FJ'I=6TK,V
M+6#/CA4N4(5@_R]M:(Z+,BD9YAQF7O[\"%V#H^/A155+WJA6\768,(?"80(D
MQ\-4GZN;?NQ0V%A#;]&T\H,98RO^'G\@X^U.ZQS]R&<&^-IY('K) &<[X(?D
MP8A]ATC)H%&+L-CP@4%3!DG(P2FQ1-A5A+V*#J2/^/HQQIS>+F3,=$G'AB]G
M]4'_.UJ?Q  'ZVB,RX]YLENZ#[D]>*?9JR8F.+<2P1Y$J&^+/,MAG<%DY(P*
MJ89H!%&1&U+$4]'8IK@I7A)J*MMV)6A2>(XW7A%^#8<'0/M 7K^X]/H*EPDW
M"1KZ 90_\'"MIM>9::6ID\-GG;N" OFUB[^Y+U?ORDVHV9B]>(O5H9^P@"VG
MLAT';*-&'YCGB2)$$/H:5C1 &/UI#8"HIH,B1)K#GV, .N+WYKR)HX(5K'C8
M!&1$IH:'_BIV9UM,'H*&43MNR()7E#VI=?PL>;_IA$17<;,(06ZLEQ Y#N9>
MB6GS]P!:N."@K$IL"\F90:5]B=]$D T?%[!&CG2L,%&8#'([.0U\%L4(+/P!
M;2BY8%".9ANK&FPL<**2BD2MH,G#\&N+1ZUH)F[BOIUBR'.)YO*IEWM,07SZ
ML."I 'XA8%KLIY]\CMG)!SB@E]BPNH'^9>SH93\1V+Q5((9T5*<D<G5 M)*I
MNVZWUSQ['N_"8T!I>[ #S>Z.6?]8&&B(M,%CN'8?!CA(-\[+V'FT%ZA@_!UD
M=_UF I.)-V9P)<B?[J#+29*>0$I&?#\E)(NHX0_6HCP\&-H'%8 APOQE[DS
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MZ>\@@E/."&_-+6#1A2)YI;7Q&"G%*%!\NABN/?;AQ4G-,5TL_C#V:V/*USO
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M[R=4)!M&JM#NY>-J[<SG/ ;M@'<1;]KN':X#Y!,UY8%YD22+$,@/).FE$R5
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M!U2WHU@6WFJ,"A#I5&]CEN[:_9ED[[H2XD6XTQHU=G2LN)I!;N%DIF'TJ;)
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M5<&1^*JDZVA20-B$-*M@OX.H[I5K)HZ?2P B\.I$EJ%IP96JNQN((!GB!JD
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M?5]95=/"OC4NV#KX$\@:M*K294Y*P<-*"7S#HKB1NMX-J\%UJZFR5D*79E"
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MC=N6A?Y\0514KH6UJZ_-:U :'IL.S!49*<7@#Z4=0SC#\EC704_*EJN,GD\
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M>&ER&>09L-)]*V ^O?)0#F:U,ZN=>ZD=TA*2HHD!E85>.':"'=7/;I%8V?(
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M<6E2N'3^I=.67C9']"FYUWN61)9[BA9_9<[&"9BW%5O!CME<<W\*JW^0-)9
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M*ATGK>R*"GLVNPI 5G/31+M4TE]!*1E>21U3YF&B$%WTDN/F7;*+)VVHBJ4
MJ"E3B(JQF*9[$I(KVTCS^^B=2,>M^QBT^Y'-+NY MX>4K=/H9A45QTWB,PW2
MRM74:R&$DCAPS0Z8E--SXL3AP31X*$F*\K._>9TE&B!F ]$ZP\=[(3HL\U*A
M>BK]84CA^T7T45I/F0_R*R'7XEOOJQZ-_@)#X5:UT'(@2X)K496Z^,5UX:-
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M[B ^#,*#DM(RB6MC86R%\2ZPV@KKRQI$Z/0SA1D*$\0DG*:=96V6M?LD2$)
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M9#18=#Z7TF?K2J\D,71?!GH5;T-S%;EG4L$U%F-O+,,^L)8V-P4Y2&QU;>-
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M?8N1*UU!_B&WGD9L0XYA8'9I-8N^GG5=\'<8^M?0V=S)@8Q7Z&LNM/& E ,
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MG*8K<;JYN$!I%+XTKR>:.QN\J R;YJXNSBD-3[$,'*XOBHO8V@O1W+&@!%R
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M;]]46AD+]579*NF;60_[%#/JDH=Z%> -)_(].<!Q*E?RO;BPBY%9N^0=5:&
MR'O/O";U[1UC!SU'W2;YBYX4WJ[DQB1.NLIN2,L'BQ;ZXXP6FM%"'SI:2 ;5
M9UQF8KH'!>QQ8YFK-?/(\Y*ANH-\OMI!#4:$S!Z=.>L*?;5>H; ;K.;$&;.,
M[* [=,8Q8BG(+2QFE>47W4SX1)DL]]5(M V:#$G %@FL[Y3-D-Z*D*5*;\MJ
M&&W;=/(T2UATX41J0H:06(Q\K\P$OOJSTA-#H+26N&YZSL/)<!L9#?Y5)#-T
M$;@&OS'WY<+9!;V0UC!B0.N;F%:YYS8&),A*#!M^S(;"? IQ(3"[2N,]5RCN
MQB1]AQ;?B(CJE<YY"-IY\?TKEZ5W#=B#QJ9EJC(HW9PO6UEO&F3C(C3)A0*G
MI58"7.G,8XPL+!J@$&XIF<H#:1F[6(A%Q[ >H^3QI;T'65@H*"3___[E__^Z
M>GO^R?F?_OBGSS[^]%_$COV&^1?&S 7-Q\5#Z\4,JN*"Q1*M*(FQPC=&:))Z
M *)3S2%]&%"GH/!9I#"[J6\1:4V^9(@UUF$3IA/1)P2,ZP_\8'FJ)#W7=7QM
MI/#;8)W@=<=C4,F@\60+V!9K,3E!AY"RA">:?7S?Z!1MQ%*X2LM$+A%_."!_
MPD0"LI)B& <A^B-]$2 ]EU8.?N$?^)OT<4N.X:5(0LA&.8SPJ/G:=(--@XP0
MPLAM1*%,LQ"Z))G0H&Z.MP!#R@N#'B<>!3,(IQ[[]PL N_>S?AFZ?7D(AAWR
M0S-YE8>X@^4=B"-R^A('M\W!H*XG;=!QG]%\ '-2(A<//@B*G4L9-,YYQK:+
M Q2O^HKSLC;>!RA6+5T:'P;&#$0Z# GJ2JEX[+B%K%U0/-\#0KIC'#5)UT4?
M\:=Z5E;]181,1,-H-U?X:_SP_K+L+NFXVQ?4W/!#5]Q-N%RP$FEV\F_:(]"_
M;^-K.H26!Z((U0WC5B0EN,8IB'.J<E\]Z_"-[?1+0;BT>3,X+T6+ZT( X" 8
M _VIT^;X["PQKV4L7Y<NX^(,DQZ)J5M=>TN3R>=H8VP0IFSJ(&MX7W?B_9!8
M]W0K(I(-Z1PF:J:#P*CYX<BP$T<JMV2*C7*@$C^?P1^O*[*7QLJ,-THHVHQ/
MX;0&E6[#)AMR=?( "R7+X&32]UN#?6FW "X64_V6:6U&GJ*;&NI&+*1OFO G
M(+N?%T1/<-$6.Z#R37J6.6[90_5&D;$)?+2LW:'?'(6B)[(E5\&:70WXY3]=
MAG$". U!% #%:!"B8.E"(6&49[=T)\FA]+2'02,H!6@+!DYZ58.2/II'P)&7
M49([CD)2#!:- SDP&\][E"-9]VE9V%+XHX/ #JVP/UK6@?_K^[>]<A<SI^<A
MZG;'I:2@5ITB."@4N<X<- 8['2SVV8X=0$*E>-6C R@F]!"K=%KQ>E\+?J.:
MT*"1BRI8"93L51UL\S/*Q*HX5RE/-&WE0'TR8>=.*KZ\Z?R E>:::$93-7AU
ME]S79Q ?P$H"J)<FV$C>NB]EMY2R7]-MJ@2'8_ZA'2D6[C>647HW6<L$R8@,
M-I-%P(QU,"E)[F=_&[@%9SF<%C;*"23/9#S#5H.[H494)>1[57)XE3 U16?,
M_$E%T+(%O6\CR ] "C-W(;[._?E-XDI*#"X6THRDT_ :.*'QD,#6NVRD6AQK
M[6+ARV&3>X"Y@AT-E+';.%$)S?@V@%C@NN:*,Y.99 X-4M.T6378DV?C#2RU
M4Y./T[2J3T[:^5G7WY6'3+4S>F]O"X"R!(9J*)+L;2M%6@J\4VJ3PW2&#@ +
MU#4<,1R,?,?"7G)J#PH0+D#^H4AS/F:2MW-?U,8RY=*CG[C:M;?,2%1C-N#K
MFN$: /1C;&N#U+>H&;8EAY()B#-HO'72D4(YTJ+S9)P6PUY]/?2R<-3A#K@'
MXBS1[W0*N1-H43"+=<1$M)@#5PD-)I+2B5%^] IT8SKTE37(X.<VT$L@NZ'>
M,GO_R]AR(EUT^7DV*YO0;:SYT&4))(6I!U'66L95+1!5[O]E[\V;V\:2?-'_
M[Z= N%WS[ B(Q9V4:[HC5+)=I>KR,I9J.OJ^>.$ @4,1;1!@89',^O0OE[,!
M!+78E A)N#%WQD61P%GRY,GEE[_,R@P3Q'+"CW4Q&&($PE YY:K#-E&0<1#6
M1-RW.6X2M@8W$!:'ND9/,I)!2IEB2TWF,"7-9H-6XCF+!8)3(M6=V9"4>$Z.
M\:S<M8+X!OUC4DHRU6 -G[O-1/)>4A6,LCR5;R]3OR!QZ:ISBW(0-D/&I*/Q
MJ["OO"J,[9&- K''&;8A"A@.&":!(00QY3!;)F.*U<TU;#@90R[ 5,ZU-D>P
M8Q(7M+ @B]3>76RCR^W3DR2R>7UIC70F+!!HFO%^^V'J%TLJ\537@TN/IR:W
M/%WMPS $2W)')K-YD?G4 @]."J@)'^Y5QNRTJOW&U7><C)3=K'B'XG7)R=PT
MD)75:ONGTG&D$RH#4'1>%;]KDI8R+Z#F-.N<V"#I*]FPMO&J68NOM&$EAQ]E
MW$R6CKU LK-+D16T#*TV =<UWZTT.K<JJ\C)I6(J[@CFRG9@&@X?JU<21UTU
M1>E[$DRL.@;4F+KR6;;9C#>@[5!7K7!;K9L-LWYAV=MS-!VK7K?,Z.J%U"5Q
MVRP!)2W*BT>GJZST9D+.E'$Y^FYB(4IM>'5I"O8@RBU#--;+JJ K%YQ=PU>
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M*KF:U"[@]>%C(LO.&KSPL@V+!7YL"@1>2MIX^)"6:YN)HDVR/SK_[-SVKOU
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ML+<S!;!S[# L4Q(5)&F-"T'U6#&"J1CF&8?$&*ZL^*O$[J&[<^1QZ]Y=MFV
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MFE"PY%+GJ-RBO-]85:FL<'&Q3I)>84QM1F,H ZAS_;[5XE>VM4M]YRG"4=>
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M[(NV6Y].*GQT( (+(XR8/@7GO$BB(LX9\,SH041S>E&$J%KX2U:".QNX8)3
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MV;#W,W%/ ,"]S_,NSG[/[8XV'8O&L<'759@_+ 90BW7Z>O[VHPCKX,\7SJ6
M_TD%LC+/0ZZ6"(DAODM%%/UN[]!5_.U('IJ*3'BIOZ"_!N)"1,D*Z=L=(I /
MPIR81OF//E+3.T1%>B%B>,9,P(!CI*_F=_1<?/_"NQ#.N8A%2@35&4PZG,,*
MP4.3%7Z(/XB2+!/$$>]%D>2N1W;H#+X?^X+&AO]8H<WEXC^C(C!O&LC9]/O$
M<DVOG!=$+(V_E.\!:\UBK<\7*2U1YD6&/-5/ELL$US;QO\!KLJQ 9FYZ.KRS
M2%-!HYDCM;<.4.%?<TPJD6V(_U5Z)JQ]4/BY)KIWFB-)'V+G-R\NO'3MH"#
M @YISZC 6."<)9_XQP*$PLN$<W2>"D$2,6."V9G(+X6(G8+%XA3^5_)7!W^
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M5M\5K#A%R($)9?I<.E>0TW)NH8*.54VRK;J64<!@ZS+UV-<XL1::WRV*V))
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MT'1-Q.V.G^#1GA*+\YE=43_ X""GX2?FE&GSC"FW8RP? /,K47PAVFQCS7E
M9HWO9M@M7APC$T+O6F2L1>M-L]9^';!X9ILO2="/!LOM]4;-XM-YI>8+%S]\
M$A\A ?&]0/JA#<1.%>9_3J$S)1V%P0A/A;0U<@-CNQ/D,?%,8*L*/ZOII%4L
M7 1^0 ]G'**9T3] :(YXT(DNQM[Q#5GF/@;E&=$$^F=NLKZ;G>D'G$LBK,2A
MD8:*.64AR#11B)09?P=5SQA3:SIZ1X/+R,:!/R!R^LB<,R10.-'M9]"O\NV,
ML"81]/VD#Y-%.:J.=5:D@L)5#G?+BF.*'R.1\@#P5+N]4-"VQPQSSH% =8NP
MZRI8=70R.;'C6? 7>P>H2)]W.2GL#N@H8\O&9(=O@\"AAB2B!UI..%O=_W*:
M7CVA:P?1XC"RWQR.:X!W%6O\.$A-?1M4$\?BN\WWGG4HHW2P^\#!AA&[0M[F
MNTR5-:14.CI3[^BMAO5]INKQFTZ%^@">)DH4\:/A%*PA)EI@'\^_K9CG#O;.
M<O3 R8FX$7B&2P[ 9BKC%79U8%U!Z2/;%FTVKB5P#1S8YV]>:LUH:+=4+#=
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MVGX9_G)0.R^?5VIH[HUK],-9]?RZ$:LKCX:UZ&U!X/JQ$W'DZ+_9'_BO@@Y
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MJ)>.#+;D*N&P;D*?XJ&(B#$0^F=J )#A5=]#031PQ?V=^BG^HGY8K/<PO$8
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MS._*A1CNU;L$!5)<73V#7E'UW]#,%(S:?W%K,M+@JDW"Q*1'50 !_KH2ST5
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MH1V(()?)Z/S4L@O3<C]3TD[:?:$GF@)Z-()<+DONV<.P*WO-H2%?75:4ULD
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MY1;ID%(JI;/Y>43OA%,33OT&G+KV](OW<>JCJ=QG*KW;=G4Z<4XRT_*)T%&
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MND-UOZ.)A^H.U?V.)OY.U?WB!;3?4^,_)86Z:T0%QP]AU>?[J/I\%<>;H'Y
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MQ&SM^WC)22%H+UA8:1-P??Y (6D#3DQ!8\:$>]+C!0&9[A<'>C;IJ>"I)Z;
M"(/6+N31Q#8P9^=L U[:".E33TQ!,FUV,'_A&L)FU1VO93/B1= M+@\#]D2<
M!-W2;" 8'F-)2TJJZMH.B.;T=64:$AO$55505QYRL"O[>KW'*\2)B47C/3>6
M=F%)-NPMDUC6MC-$=R"?E;?8%>)M_<,V$<3EP4FF+0MI4IEHKJV]F3U-G"[=
ML&E6=D-^E7YFI@TXH0-S7.B4#U5Y;AOE35>+X_5AD62BN:>N'7\[-9>F@AH#
M0>\KS1(V7:4-.*$NC-#95<:$9LKJ;+,0(XH=)&,)B.:>.N/:G!"A-4HPZ(1#
M=IBXVM:SI^;&M3\]4"W1F\UET5Y,FM24-%IV^M032NAVFRS39DJQG/A.&"++
M<(&W>2": R)IV^<$O%&RY7&U5J*9M=<=UDUP%U]^N6X?W"E;1C%A$Z00L.8,
M-2%W0#37UEE-7<NE15RQK7YKO]-,?]^J9E=OY9XZBGIR;;4M[V5$CUQ3+X=#
M-$47XH1J[UQW<6@CSL$>N R"5['YUJ]FM-B\&;:D&CYVPK(].%2K:V2T='0L
MVVW-C4")%$4=J])[N4P$H340TN!DE6V%Y+J%A0LOGBC]1*#])D[2<F<P3?65
M/*':X89*2!<9$S+"V&W*MNC5YF "T5P#RDT+79'C1!1:(<T2EH!24S$3S:F+
MLAS%09=NA[;%R]MQN$FPUC85/6$P^FZH^=VPI @#KV2*8TT(=J@$1'/=.AS<
MF;/>ME<V;?7GS" H84,Z?>H)@^EKRRX_D"H]>R.0AC#=-9<TE8GFVMHH[3Q,
M1A>HT-)"STA=X<8J76-3T5P#QF.M.T'+9@]-/,&*)DZK4TDQBSQA6XEEMB,_
MEM(UMMI0> _IR#LR[=8I*R"-?B]H2"4YV3A>J/H]>]9/&W!"M6LJSB[T90-#
MD6!W0.):I=R;I TXH:\2'C=C8N7O!-K9CP1A:_=8,A/-32RML9760>5&=EG;
M5)SY=AH/1IEH;@38>.[UDHVKV6([H"QJUJA&VU2S3JP%Y3:EN MQ<) 'TW50
M3=R$H1>9:*X!JKG@G0;N>')+9:M*O33==CP3B.8:,*4EQB\YPRWJVMRP%>\K
M:3"3/O6$&0:];A,?((DDE!?=!HET0M2WTG$]889Q3YI+>W$LV+4]006E\7(K
MK'F%.J&O9%GE:AV]>Q!BU"^W0S98R(2D4">4,$[&IE.:\(%-[Q AE#O;&*VE
M_O@)=2D+CCV8BJXG(%0U3O:E5G6%\$ T%SGLA*JQ\SR$D0VDO4S[/<=:1]%<
MZ. 'S+);":2)O:D(U=4\PAMN: +17.R >KVIX569O>"&\V@ZWW03N9.V]802
M3B5=\ =CG93CX53<"8J@)VHZ B>4D$=<J\L,\%@6J^'<[F]5?IXN1A2=[Q85
MM\O+CNO[LMIHE' S$M9+@P>BN6Z)$5J9Z2[KH[A;;X;J(J[-ZYEHKEO+59UT
M#;0\$L8)UG3&RR[>L=,&G/)=S%)K*"O22D[&F+N/AL.]5>*!:*ZMG6 _:MM3
M543+<7T^"S:Q($?94W-ME0*B/JU/IBV[9JSWYEAIT&LJ$WULZQOV;([Y )"?
M?D@J@AR3=LQ-/690LVR?&D?^XP?'7%_VR4\9P6>[CP\RN<V;[(]^3O9%P6-3
M'YJ /6SDO.H4&<5\Q5^\1.99*NW9\_WTF0O'WSUFEQ__C8#=G&_'A.HN';D_
MYC*?;5H]B:KST'?BR+AT5O/W*73LK2GTAY]OW[W.\IK'?N)?&0+.Q#7,!/:5
M>?%.3C@3[S43W%?FQ=II<"8@.MW;3$!TNI:9@.AT+3,!T>E:9@*BT[7,1(I.
M,+([YTR\L4#+'T/K]V2E_\QO!,<N+>TGBDW&/K@<;?T-6/T1P_(/!D'S'?#A
M_WQAO_SE@!#<5^ZZ2D#]S,)[!6EE:JA!6! \W=!_5^;GB<GR1EOZW:B]EWG]
M:5A^KUF?Q)KR!SI>TH3C9.=__CS]S^T&_UN[P;"O%';;=G.L?36'B@ 5 <>A
M(IQ!$4CVYA4!^]NE\OFZ^.$5\%[JI+@V0$E'SRR TUS;-#@PPK-J_T?W_E'#
M_W%WCN'TU1YV?2\OYYAINZYKJWZ!-JB[4'>A[D+=_6RZ>W57:/Y6=Z\O/Y?3
MSZX1%1P_#&_"S;\^=?S3YL(%9NQ_GVT%^%B3.7L1B7>NRMX+_(45@1KL+]62
M4-H)PNWEJBC@=*O<,4-JX,6FDM'7<8(ILER^FM]_H#%"8_QDQHC_9(RXTJ*&
MW'HV[R6VU4I:[*K?C4WG[Z\A>ITQVDU6=PP')^P-6UTU^WMV,0G B4HZ-48.
M*S(4"8WQ[HWQ'5RP#S9&["=CQ!23'7?VHT5W+8PW>D5T[*1I:G]?;>EUQACL
MG*C59Y:V4#/FI+G=U7@%'"D!!SIPEBEBIVNVW782\ME-VX7(+P1&.DV:Y1C9
M;<_ #P>?@M\U4"<@#@V]8'D%_T1V\MNMALC7"E4?K1IGRQ1\2'KGUYWI-Q25
M>]^-::CM4-NAMD-MOUEM?W\OYOVT_=H3ID^EW[*2A%^^5XQUZL)9F7-=2)WR
M@NKZ:7,/V0<P<+R5P/',B]$'1H_Y&UEN_.[+YQ;&>SK_S+Y.Q)26V%]OUIHW
M1S=*A[4519;G54G)"AH0188[=:\3-%)HI)_=2"^<?7V;D<:8$ZV3^2*V:W)M
MJ*QKKM7C0&4Y&A@IS7'02*&1?G@>]OV-],)9V;<9J;Y@=Z5U<T#*%A,L9W,D
MHKDM6$DY8*3DB8V2FT[-_NK89Q<&(',5)&!!56_#"X].OK$'OQLP0(<!^O6D
MHZX.RBX<%&073Y> <9:?V>8)%-M9Y+*>U(B972N5]OL:ML83BU>R^F(D4<2P
M4_=.0\N&E@TM^V,BB5=;MCZID=6%@+."16&K=0-%A$$5%)U.@P@*+3($ RT;
M6O85)]6OSK(O''Z\VK*#Z:%5&DU9Q*X)!KI@AR&/XI*2%?JDL")!GS_T^+@X
M8QP G?07"W W1!J?K55++[BJ%R_2KL4!H'RD3]Q:FA$6LK(6:3P2^85H:10B
M(W M[QB5@(LEZ@,DG3<4YDJN-%=R?7V^QD0HZ"2&G^_\SWW-*-1BJ,6W/Z-W
MJL4PWWU6A[.F6A[@((L>N)H-]&'XPV-ZB9@\<%:-;7NO[5"D12:8U40&(0EN
M*<I2W_B+.:-/D/IN>%O#B_P@*>PRYU3W=UY8!*1D&$#?= !]?<, 4VKOD"Q_
MLN<LUJRDUGP"\T:V=)AB8WDK)R2^E;9H/:9KDI+=,4/A18K+WW<-T0"B 42#
M6TNPOPH--*:,REN>GZ)6>4X)PU8P\3B !N"<)%U$3YS,@F@ T>#3%_KX=#'2
MJ]! F79\3*KZ=5N=U7OFHJ.(:VFG9)?*446,(#Y1/K[K>TAV]/(YD?\A-^]:
ML5OXMZII@?'XJ6Z%6JJ<T7\*Z;_3I]K&PU5-AA8'V3'-\P9.]P4!-\Y?_/Q%
M'2X<N?"/IO:<JR@N*@]&%_*>WCN:90B [.%<]0D$8^93="P$=L6NA7Z9'G2&
M&F?OP'W.V;D E((U6*#-WHG-7CB^.)O-SEUFCD=LWT3=M(%C#S?)K6 "FTV#
M$(9XL38$M-C[L5BX:W+6B."O[?>WVRG=>3-LCQB6$V@DI!JC!&E+9+;XIO$#
M5D1?3"U^@OV4IY#" H6WTQ%[/$-06 2^FPLT=&,>/<45V9EB*PQCU=.,5"W"
MZ'R%&N\^P_#Y6(PP?7KQD.1G5$QM]1$9'U#Q! #6YITJS;?XI:SZ[8YLSA>=
M Y]Z,EA6 [)(HI"J#(T<&OD5Q3!_8>0H8C?9N=<0;36>T?:R,XX:F\S(TW"%
M+I+$!4L/0"/_=$8.MSXN'NC\A9'',Q]-JMN@+"!(7]3JC#(FICM@Y&DH0Q9Q
MZJ65_&:W0GY4GW0,-0U;SGT$^AZQZF:!Z>JHUK<93VC+(/R66A@PL*>[I]K
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MM^'TOXJZ_.<_\!_W=[)&)!/Q=\(7=\L'D[F3%-@R+M&*XO\<!E$YG/G)DNG
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M+*%7KC3N2D4AQ$^"P8(1_3] MC_G9#Q2M;$I 9[.XO)PL?R+TW0,( L88JE
M!9*)\&X01X/G)/Q&,T"+0W\VP!U^K3MPJC68?PAZW >LYJ": 5^/X#'#Q%NF
MR(2N?S@]9;@ PZ8N%)TQD(F0C D8DXO1IP#J@@?U4K5>Z5Q5@0IR:3<G_N6C
MP:[ *'AR9M(P3A:FOO]@5PY*'!4P,8S3<'>.+D_8)T"(]$Z:<)HA,>E>]YPI
M>"-L"?CRKM>MUCMW;SR$I,"]S^@9I,5R\M?VYB^<F6I*0N#)OV)NW0 ][ZX]
MXL8O'6V-ITC12_".E:/7D&+7X)Y"TG78F4PI0+(],@6L3^>3?P-3 O2>X_MA
MG_;\2?U+6$F6?X'#M7>I..[*F U!\%)VP6B2BCI %@K_,9G)*EC80+NTA@!_
M.5)-RXZC(!1L,%]LRH" ."7%T8!XZ2HS8B-V FDB)S2)[)@F/H;TIL%1)64I
MT2,T6B5VT[#%F0%V*B7JM?>RO6_PUHP)CHY,4::.@!B^+_!V6)\]#R*<3OL"
M*(SA<8OR1QV?IM:7P [M -V! )%4VFD><&7F[NC$ S3CX#H 4Q-:Y7@"P#@!
MY+;ICN%"@G?%>33#5J!'SH \:%\ZNC514;Y87+Z$,39XU\0E 8"$OQ>.4"?=
M$SS.)5"_9*XY_:8I-KF?)0KLPS V4?6.[@_P%[]H.2!=$%)%@!-5PQ!E\(J&
MQ%X1HF\@(Z Q_,=X.L%?6@YJ&7PE6'C&^*[E#!_@@MPO ,0*M7] C! ;[QI
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M!9RQ;D$^;@OP6J4!)N]#](+8=,4BB#=@GP!5."#]WO4-VKZNPO8V9+I2\/#
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MY-P"5 8R%&0@:DG585W)(LQ>5"U!U67-4=A\=0/6-@7)LHAMQ02XP3@L9^)
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M8;[;*K2+Z\7A8?9:R^TH859)KBMU4QJVIET-]C0VLZVU5/SC']W8X=M^Z8,
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MA8RHNY8Y5_ < ?C&7#T '@B'CY'T*3\-12,"GE4O*$']5AM!B?!%S Q@T!C
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MKD-"9 PH1>M*7#0)B B.199ER"I]&346-Q/K0V\1J ^85[K0CH 8^=MY*0"
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M,1['$EDD9>WI*'3_"LTH1RO?YIK7W%!U+L0""ZOA+>-[_0Y/-!$K "WT6 :
MY0'!R\O1U)&G^VQN--"CR$\ZMFC.+Y?P.RXTAAV!3 *&C:]!NUR.-2G""]QW
MNUZC,I<+>\[JUW!UZI%B6AYS?[A6"HW98S,T[D%_@Z): 7RGF30,W%3/A@M
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M<'26MN)U/ @V0\#&#;Z$V)!(H?E\.!.1)='0ZKPYK;/Q-NVEP-"LE=CFU,;
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MZ,K0Q_3 #.Q5MQ1A\SZ8ZV)?7K:5%/51):^)TT6CVTV6"XURLGL,>=F!^:'
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M?U+B5AT3<CML O-(U2R Q?L"(%3EM(P[X]0XI>7%F=8<3O)7\KBJORJ0]&^
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MW;[N=2MC3*(_*7S?%)M_ :CFM%K5+%'L5>+&3:KI3-:9!#9]!4!EOG6ZS;^
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MTS]5$F P>.EN8X2MB8D9&Q>U9OXJM\H,,Z^E+#4%G23'-T(0#7M\>1T%>#F
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MM&2>M\S5B5RUQZN8OLP,*PKOR^A4]P7RO,]FIFO@%;V_0K*;9K%:)JFN(K=
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M)\WP6LL@"ELIZQ49^.B*A'9&/$FC5\*!: D MU,T[AX'WHI-^8HP\+PBZ*_
MP'"CV653+ B<UVNMVX2B+92B?V,8F%$<:FH#!4/Z1'NP%9QFMXE"&& >?N(8
MF4PCY\5JOYK[X9W*T.Y)VK>RPWQQ9T3$]B$2%LW;@^ROZ5Q9#:"=H>U 5E^1
M/)X6,@6^W\J7!ICBDF[UUB!;[O?8HF%N9:[0S>96Q3&-I*KP.7B@<Z63.$U?
M3^>*-%]]+X]+##=1A)M?4^U.X6:H$6FTXDPIW<.6U>56Z-2KZUN;> HXU5F3
M$UQ"/-N4E\M:R]C489X*H-J1288@KZ?819JKOI=3*5I@$PD?T3NP)D@(@?WG
M.SAW=OD[8N?.O3MW;B8Z1(QW(Z66##U'F]N;G9S *G."R=(3@6ND^*:DF>Q\
MW+^U6D(U\-5X.3'SNI(;6CT/435N!K/> ;4$3Z:IV!'T=1U!,6:\<-]_F=OO
MFWHV;B7:1IVNOY6I?I^G+K;5?YJM_I;/;**X3R\:UVZ^47<L5'<M6UN J<_%
M\4ZP5OGLLI+.\2E=T8M=<[% 5KY[:P/<FK=S:Z*Q*2+]3L\@TJE.;91N"104
MK-/I*XK5D<:G2-GZ;\Z%,5S=A3P?<]1[#=HW)Y1H<=2+!N^;[]/W,XAW+5>\
MF#+Z"ZK]L='[>QFPHB*?[R3H_1]WXOF6+!ETG=";^K),64A_G1X-!ZT;B^?5
M"JIW4YR3YS;UG&8-.O6TZL J*D \Q])D,DTCL>4[MGS'P/$I4367@:-2][Q5
MCI+77 .;S_SN@"6K[JV!HS<4^K[<JNA(9UPH+'"LQ"D3"!SPS02*)"GR2L 1
M+1$C]BQ\9\]"5%Y87,:-3=LUIT.I6M$UIL%6MV)93@FWM@<V45N3EZD>RI/C
ME. J:9.0T!; C6_TR*(!2TY^#[-,[(AY<9_V621C@V7$]3?6E'=_#1AWCZXY
M=,V1%2.M-[:\,1EX.6M8N;54UIP6+&Z-$1E>Y-P:DO5'A471%QBHSI'7?,T>
M:1"*O2TQ)D44DWY7-;R,22IMI_!"*MW74Z:Y;F:+"Q?KWUKBRU2WRU&=6*_Y
M.3I;#:IV1J07+8!)4%.DL?@!1NRO^AQ,^BINJ(AJG9<AJ5S+5-KJ$JTAY*:)
M\J8T;&+^K1-^*"E^2FPW95'OV*-6U1VQDUD3BDE "25>0Z0[=/B],TSPR2]X
M\ ?&;V'^7"<]018<((ML>;#":R20]0,S(-U^H9'"T/<6/KXM"NJ%[*0XD%.Z
MUUQ3FNWCCH&S HJ$SC\JB1'QLY?KJH<WYYH8'J*@]572768Q&C<WNE;95.A9
MN^Y-C%O;DC:UV40SJ/I2]_*#";YQ,9^;^! > A<?FD1>%96^C+AP0TWMYESS
M.7G3;K_.2*'#<P5L0O=KZYY:7W#]I9QK&/JF/)%NK4+-E[.FXE64A:[T>F9^
MF,>FZ"00'O:.O#3ZEB+UCRN"4_ZY;U;WP/":=(U#G8'%:>HF_$@S =>Z/W#R
MA,"?LWWXEX-1 'L_Z]]D^@%_PEE>@K!CFX<:_ -:%&S+<9Y'@3J)\2;A@#$U
M%4S0=!/2CBP2HI,0$PO%ALG%Q8F2L-2$&^B,D\O]^(JMP"^IEF%8OK/;H!_!
M#IV<]X<(TJ<DWI&FBNP9BM-0 8G#&8>]-M2VYNB9#?QO'M"D97?!P!G#DO0=
M88\%83[RUZ:DY3AELY[J\F29<\J3D&,UL#*9=5]I)\!FZ$-" 0RS #-R;4_Y
M0#@&!+FK;0H0Z57R??HF\G[*#?CQ0#0A*DO@_,2%H_S8_W \*4B#NPG-Q74J
M.$GS -(I0U'=8]1.V>'<P2>G%5-=>S_J4>G6AW>;69BX9F\T:_;"@H9QT=Y(
MGLPC_JIE,CZ8^&#B@SDY&.01>S5@.SZ9F[$,$;-,- ^&I.*#B>+! "S#XY.)
MXLG$6';5@_E5#_Y;JF7$G=>'TM'4[Y:.QNE'YFO5&1\JHIW@3%F1$SE%"L)4
M$CB:_+#2XZ\S\&<0S&NKWX=3'2_VFS'%']DROA C0(OJAU']ZUKK]RPL'N_)
M"TKTUV(B[!M?'5?3#;]46=P_5=2^%K^@WYA??D_4BMI3AII441S',A-9RUY8
MH7/U T6LR)=&>&<$R,*S%2%%>8PO#5U;;_CKMI2Q*==ML+_^5+$FSBQ['Z7A
M/"6"W)_%+N!^'Y5_XO@.W=X9Q92F8%WZ2?A^1S049Q<44E?<M[OI;A:G#P#V
MDSIKN^MK7,"SF[9.9?7-DAHR!%EF,/LDO W[A?B5LU&:AZ $]!"HDL(.D2I,
MO3G-XPUKPVL%L<":HIMGY): "^C#3^)*22KP"+XZ__>77=D-=,&=&/OM@>K2
M^\7[!:K2@M"$2JO2X0ISC:#Y<6;,$Y// JI6N6'4?-QI\,K25PJN*6^-L@^
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M7Q5D-Y7'-9=OC,Q>2:LXO5X=-+U 4FFBMW8ZS'C$SU.UILIUJPN, $TO')5
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MX4IV>*]BF=G&U"9]J76:[99UA(;ZE,L&.2229:4P)J1N 1FF:H'ILZ:<UTS
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MJ?L\1[)Y>S+P-YPFE52GPR[QR>J/W><?"DSE"C?>IC3<X9?;5%TL#ER<,"<
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M@)";6)_^ %UZB$)PG) V>+'(B?.26FQ+HQ9$%YC].4D1,;K$Z!*C2V3,1'_
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M!,\JP>B2:+HP=;M[.O/YT_;N]CY,YQ[ ]V$2X?TM@=F*"T?YL?_A/Q\!%B=
MO/O(M18!.0:S2 &JM3SWAZJM%?G2N>WD2 392QI[_#EU9X3-T@3\VS_'?SA9
M15>;@S.H*WZB;<U%$ZP@^ 2NY.(BG@E$P?3 ]%^1=^DS*>?_^U^&I)C_/)>U
MGHE"9S?:E1AR]]'#SVI 4&CH28%8C6+_2;0\"Q8!6 !X!ONDF0EX_Z\ (8FV
MK@"*!U(+0%% 3G!3$H#RX8?@,P/('A#^ 84_'@#_3%R(R2XFNY#LL%.R*T%,
M X0$56T(;69B1YTASD&<M<90$H9'ETPH6M!0UFQ%<HT-)$  [+O?D@G'DZ:
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M?4X@:CGCL;2.>!@_EXLUNEL8.X-1  W04H0B1)(A7BN3=(]!.?\YKCA=U<0
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M-J>0^7$6L,.BSC;Y(5@I'.+9=LN"H;U*YN?'Z^3?4.'IYX;LA!-JO).C.V;
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MY>T6,"7.E,:&]GY[WJ/RWJ3?->]4I9M=2#9A,I*C9-A'P>KQ+41*> FB)?7
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M,??G$CJL1*>WG5"+-C:4E866;U*B87ZW795!LKG1KD0#%A1&-,-)%7,N('2
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MPL>K>T$7<$\Q9KBT+?(&:W>E63.7E"VIF_6JVV;(2X7 (RB(H"""@N_F*EV
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M6NRL16+3'2;@0F4!-;$%G/'\T.: *_ Q3YN)H%WB?N=CVLLS9K!X#*J(Z7I
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M-G*T4A1AR[.W+_1NLT>Q"HU)O4UW2;1VG4P+Y<.</3-G.A.S#FHRFT_JX\D
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M%Q9T*B6=DX2#@()BEN&\O1+=]>X,F3O'_"2H3W.C/4U@'VJ7Z7$/X0?4I(]
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M%3JP\ <,WA4(^AM:T" L:H85\VL$N#H$H"[#H<^Y-8BIFA7;0HE- 8 3*BE
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M#$OTJ L(.DXDK\E+%P8OVK827J&GZQU4A >M[@CB]T[7#">BWWM6?B"\%S\
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M/^B:+L?7?C@Z,-!9%B?"R?!HEF"/W]07.'8 ]<U"A /[F?[P1'.P5[;A%MX
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M?\39CX\K*1A+6.F#XI#PM[O7/WG%/FTI< > N'?]?>&94IX)M^2\.K*3O"8
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M#_?#GLI1.2QOMYM T/KV[[RMDQ'O"Z_+$NU\ZJJ0U"NSD'1?H9MOKM@Q!<[
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M-@@G;AFOU+NWV<F\8ZG=[/)A58D9\&1@S8$R-MAVRFC/T_*B?X<$N2NEX<D
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M<9=!+$^6M;7Q@T#HH]FF(TR1:,G0%1:;M-"1E>S,R*DBAR$)EIP(&Z:?-L:
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MEQ:-?_S0\!)=_!UHSA9+Y-;[@PBLJ4NJ("UXF4#OU)/_9Z3_]^>+3^7(F.T
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M1PNV:_N1JVA[O]XBULC0Y)B^D%F^V)=[\5UU?#=;@P1,??N9C*1BF6MSD:L
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M?_@E^Z?>LC[^\B)IH2.BQ!$? ^4?N)'W]PDC&?BF'>-_J0*^V$;;P+WKN<;
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MXC"YR')6LEM\;!J+9CKZ]OBL>\$:C;&O,MB7\"(^3](UE- X7IDN[G:3$BM
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M6"P[L4Q/TH>;=LWJ]!I;;,+$;F] 50@G%LSX!#&'(N'H!4'IP$LN$%B 1($
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M[?3U"4KU6L+'^L1]&WT4!Y"I[7;+222[8F_.4#%]1S%]>.7K'1$XB,L/03O
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M4]VB]8VKWF-I6$B*XB^'?9P<2Q#8B= R!!HY&]G)Q[OWOTUGIZ=DY;_HZ50
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M^])\^Y<Z6AG\Z9WFI4YE(N=VI-PIA6[J"=0,;U32=_FPN/U6GY^2?H5XT&7
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MX8#FYNF<8UC#2:D'CWO9E38:W-%M8?+U/CL4V(HP$KL[6IT$AJC*1V%A%DQ
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M'M(NR+0+,?-9:?=>?5U(N[^CW6L:W!6(&)A,N9M,M;T2IP<F[R[X>Q2HY+R
M;5& T_MNMVO[&;"I7[?;02P=2W^O.;$CCM8CI,)R;"3/,=QBRNEN\D4<?3G)
MPGC60^&OYE7_(RH1<Z9:X-:L\=_CW0A!/P3]@&S1SP9][(:@_PVGR,>O#V./
M2S3^*W3_0.YAR&I_PVK8_5@M"'FNY[$NH-#VO=19F.-Y0X7UG>RLH!45PSS!
MB$8#4O*J'J$7X,U,(R(JC&Q!A1\HM@N.-BS=22N$ TQ/)L_\OH_D!K2_T)<*
M\.Z1CQ3NU-/V)@KB3CUNQO8GH?\)[:] S+O_IGL;T"9!3[B3(0*$"/",>QO0
M9CY7LP)#@7]"ICS;)^B'[.U3QHC>']KRVEMW7RYH1'A=7434XZZ[QG<+$'D;
MX%?^N2^:^W$AH2!N2G"#0.?][/<[[0)1X?_@1.+O6.-_UR:Y+7H#O:6&7R.?
M1@/+8&LTB]"V1O6',C;>CN 4\R2L]T_BR+EZ_Z</P=V\_T>(#R$^!+7?SX?Q
M@=EVVS6MP;2IHA!7*HE".;O<V  ?G':W"01]$#X$(6X:XD-@\"$<6G/+AK47
M\&$Q'"HKM<^1Y";%2JMMA4.M+-0?W(9!B?C9AD&W-+J#XUQ[UPX_&JAZ.RL\
M<#L2*!LTB%'J(.Y3&+9^7A]V, [JQT>5'G]VW]CV/YPYU])%A1$U6KYPA">9
MKC76Z$&!PC;1M1R5&LFIW9XDG<&QB4OG]P^/DX>8$F)*4##EQOZ"SV(*(4Z7
MG%5H]"F+SU4FR\16U2<04^# VO--1,/(>X@IP<"4QP?#'X\I-_8Q?!93<A.U
MH,P-W:)H1>C5,SE2,L<VP!3H:DA=<D1^T^"^NX$/="J$EG$8VG_.T/ZYUB.?
MZ3T2.O## -]3. '*,*N.,TSO;&TJ-:]8:N-SRA:3,[DSKG<2B(C8W)(KJ&7:
MLB>XXPUX0>)GYUO^@(2 X"KJ(4I\3Y2XHUG_*92(1I4A*U(#@2Q*>@W)6Z.2
MB68 2D#[_@7#SLX$^@%I 2%*/-YV_UDH<4=#_5,HT;01#>&4-8<L$&+)E"?;
MA#Z#* $M=IS [F6R/UD)? <N,:KR4<O@(K1A<*814:<F+2IN 3RW9F:T(G!.
MA;Q;_JY.P8(=G@C+WP,'O@%++ CP3@4_CR#0OH) [UQ0MBJ8 </GV+LP*!]*
M9"B10=J[,*0=2N1/"8!?;^^^:4"X&=9TAX'?(&Q*&/@-G;5A2.<A@5_'>=CD
M*8/+0,]AT_,;EA72\QH65/VXNNN2!S>5-,FAWA,[$IVC!YF!D"T,FIE)"D:#
ML1<\&0^CP8%2W$+H>"AT0)*CV-T:A(2QSA\O V&L\[JQSNL>G]F9:D9'.):D
ML/)T*Q188E8FX/$) Z")B[E4/Z<VNA!60#_>8@MBH#*(^_0=(I>!;D093"]M
M6,SX.#TW##J&PO.=A.>Y4X8_HB ?)@Q>4H^W)F=)11Z32!RSVXOM/%-$37N2
MAEG$V N>?E2M01A4#1'G><.D/]$D_RCBI+L3K++.&!72ZF6Y5KS68_H3B#B.
M04X0[QGD_V/24YG[L[NL82T >9A;D'5N&:;(;]R/1 5(N/D[CA_Q_1G;:#<3
M#?NX>?20UW?$%KZEQZ89 X[S.IGH&X%1DI>(.>,B@%\LW9GQ!:^$GYP,_XK8
MG Z3I@%[R; >VLV&/J+65:(SYS/D]^Q7=]]VTX,LTP,/S,HJ(WFL.)TD:QA1
M2Q?K46G3&22*[?0,74Z!E'" :35P;U.WN"NB)6",F8M] !LNLM'K-S]A8#MR
ML;N#-YR/ 22@-8/[O?OA\*4@+W@OM*#748<FRNZU7/N>MDQU]X&#<NXG'J*^
M^@!V'[C7P$^\LPE!_@,79^J[%_,>B+J+-MG]:7K)*8+&$A>C^ZRX\KF_"NX)
M*_)WN[;[/0K/C]]3G:.EJ WVZ5]--43(@;]U3@:LN.+>W-,39^?!NTOIJ:'*
MELF]6>C53]8+ ?-/^%[ 8O;_FNP']OV\)8A=C/F$E+@7)8!,H"$E D$))):\
M& 0*21'"TT^C1 A/@:%$"$]7)L5K8/@SZNNCYV4?[\JESODCCM8CG )?86\,
M1J =^(^H )M/M<!#6.._!XWT;XG9=V2*3XW:<]?L,W#]L_*)Q1#T\>QQ:0C<
M>PRS3\=P70:[-(*0/4+V8%_32\XSQQ<!-0 N;_#_N/, #,$25^/VQZ[LRX&.
MO]<7'[[P_W.-I;@*5R"#$C>+2&2,29,_=-OF)EIIQ%6H D+3JV1*ZC4+:_3K
M(8@:9Q@<=R;O;]>R-&]Q#?!"/1ON5AV\W<ROB^E2%"M6M%9>(UPZG1FL451'
MB/8$O#J,>2+IL[V10\$.!3L4["L+MF_@YG,"7>T9P_P$:4C40ANC*%IKDD,Q
M P0:__6'.-^6^,N*QT.UC.1WT*GOB#SW7>71>-J;>FU"8+F2Q@"]'3U;]<&5
MT48I V*LEE038ZK9>86T:B5A$G<5!31]MGM:*)NA;(:R^1>'_GF91%:;F=%J
MTPHECNAE.4I-XXT5E$EPUL>39YN>?ALG Q[:(D]OBUP;B$*#Y&%ZPTSG.+_A
M2Y7"H*,*Q0I")WN;N6 2TW&]/4EXF@.4XM#%$(KU4XOU<072<QK31*BP?T[&
M'AB%NH/ /7IUX:$*#]6":ND^9VJ"*W2'45$<('BV::4G\35M. ,-XW#@03)^
MR<\7"G<HW(]>W?V/UD#9KCW5I&6O6D3S!#Y4>D.E][F4WF]Z[/I-#F&;Y92A
M&64)H_"*3LQH3B;:$QP>M\1+.G&V,CB4YE":0VE^A-?<1XJQ5+L5G5>I',GU
MB1K17&Q[PE0 4HQ#I1F-I[]1<!R"741<:);I#.EQIR2%-D!H SR%#0#QZ)\G
M Z2+Z@6EL*+! .P'XDBN&7!I9@%_\T&I=E&0BNL^JU(;RYQVT[UD<A$5)H1G
MVB=.>]S^-Y3K_\?>ESXIRF3]?G__"J/GG1LS$:7#KO3<VQ&HN.^*VQ<" 15!
M4!91__J;"6AI8=>J55C%$_UT5VF29.8YYY=GR3PGENM8KC]3T7B#/+.XVV^T
MF4R)2ZIBKS@MCM&BT@;R3,&B@\\)\UT[.H)LB;6G&3%BP^@&AM&YS.- YB7#
M@1DPO@;2;GN^^.LG^WVMJM?G$L;R7*G1YA626Y;*4WQ?;V3XX8S/0#6%>B"0
M&T8@8LF/DC#$DO\M)/^U*<N40F4M+@H=F\-VZG0P[FS$\@+*O>=$0?Y>1?F@
MT!QRED7T?ON33&KP=T@&17<$?S91 90?,XYWT5'P^)4O:2J*811-8&D$=/L?
MX7;)U\2Y:?WNVH:HS@T-P)25EZ>*J-CA5&L+7%"TU7;8X9JL);O=)4V2]LP7
M=\!GLL38S[3C83/T5HG90C>6#]G,3M/X_9U6P"I::<+NMZ)KBBXG)W#>9TGW
MX#-!BG+?4?GDLO3'!N[U=,BF>>'R-8JF_,O6/J/\_9[VZ>8S]?X#3Y\2UXM*
MI_^;"(A\O,)])3)<>/]KKYB?[JLK4_92E( G6F"C!/S>G$[!"_59(G'M(1\8
MQ396/I>\.7MD4T_4A9WO#T&ITTR+.6,)"+9+>)?M?8>VX7T!['#9=&$21C E
M9F;*,O3_)US%GI]_#TCVD%@YIN4(X'OP-%@F<7[6N6)90/828%^&'A/)^ZZ@
MF,M$=RZ8LI5X^DK092K!@$E#S! T;?< ]GCPG=<*?+L\IH6\/,KSJ<U, 3H3
M0J\ XTD8*_B*![B9!]ZB5X 8R:/4$<4>?PGV>[[K3"Q%4@1SUP4[?'/J,3>S
M5:QCBR;0VQA-,VPXV*8WA+J7_H0?H=4E7]$;.]5)#IP"15>(CL2<*1N 2<3?
MDF/"K#B6K)^#I+>>!TX\G:S_EAY8.Q\L&X)I\J*FKR8%L5!%FDYVL5E5I:%C
MN;_^X$A"$G;6TRW;7Z&I:2R]M90$6WZ1#@9D#7$.716PG3^,@.X/)ZQR1AA9
MDT6/8D9"WLJFJ("G%3TQ=30ME>B!UBLP'/G -BM?_KRD,7+BJ32Z@I7XW^<U
MQKRR4239TQ<M;V"\C+4MPLQL'%;H\S27G*JN59I=4AO?0GY((MX?WV%X =FS
MO>H"$S?&@L,(1BE4.T-\GSTK#8>]0>'T5[?L"5T+KE1+-KW/CDHG<L($52XS
MD+4A/>&HO&X-,ZI1L*?,KS]$"@M?4?=9 )BR"6^E?&J<"Q4DOA0B?"#I1^8Y
M".<I<#P#.P+X$U =<%Q$Z/FR.*-[NS!#V/&(3=9W^5G1R10P_(RN;S$DWD97
MNUKOD9K=*7&#EIMG&GDY:U=F0+A3](7< T\)^T79@@]9@D_,/<AA9]*\%"3Y
MC&\@9QC6"F"&8R4L9[72 J8!^XV7+0SPXTF+J:*!#XX;69?-A;@PX,Y %;$2
M'7FF6+8/_PE@8-K^"_Q-*;S?+84=8%,P9'_+DS4MX:Q@WR\P[CM-UT>>M4R;
M[\!,V1Y_PM_JPE99.LN 'S^"439-=,J3&4&H:YEBD?1(G,C(>7D!\A7,?&&?
M8F9 SF=@49]X^JD3;E9S6@]M2EL-D2O]7G5(FEUD +8JE$12R%^X&;"K!A<Y
MV!F$PVL@A"BV!59RN32@@@TF#U084P;#@3I0\($D3VQ /#'(1 UV*S 0P"26
M1U5(N0.>*4M_,X+_@I<9.GB%F5@:INRS 9@C4&C.E+#,)24,# CP[D%7L< B
M>*^"ZI-7. N,&^@LI_,X4UI>XJH #+?916D_-"=;3G:E146FQ#;3_EOF=\!;
MF5-=)_/QS8[L<]41PPT  9LUU.E-V.%(=T\9J=PHO 46X3M]5 3#!N\!L*@8
MDL]C#=GUOK(N8F12H+#\GI[I2+*4%QK.KI0GB3;@*OR!Q.@' @W[6OT5/R@P
MBBYJCI?!#E+LJ;(2THY.S!M?\WQ>0?*WUP-WF+(H*QO '+IL0SP3P3[K*<+"
M"OP&Q!RPA+:[.L9\+2N\"E,.G- *%J4 I+(<"$USFO/$W!O.16C!%X.QK.SL
M@BH0YGB@JF[;,0$3D'@J?('N#%D>$L(4T!0,5W)$^\ %EZA]B&GZV &!!P@U
MZ,'__0 2@(%6LFX!/6DE[+P\ZY/=*4!<=5=^T1 .>8K>4T7LJ=//2V]YDK93
MU&3!A([K>?#V@SL$2Z=P<O4TP_OU-9+S-',8$=(_T,-EZ,?\G/]SEGCTN(XP
M#[YA_CZXS$^F%B0\Q3QC?B8G_;RF'O/\%C07V%K!/&G4KVWDN>-_']WN.!P.
MD2+2_TP\_@C7([2>,,7^R9*=I=#WGSI/HA]\]D)RU8 TT %Q4[H\B793CR5Q
MA(LOZ($=UTH C$]TC*6@@\Z]3^!+_/Y_)>8F!+%_])JYB\[/O[FU@H^ ^NG)
M(4#9G.$5+K".["V<YFW]&TN?4^/2,@L'_W^AX-3X$E6=<44QOQ\M 7<.ZRYT
MF ;^U6/+VKJ<1:69DU>3@UIQWTJ7S!4'4XLA3UO:XY(BDUQMS3INL6+5QHL.
M@;B@9:A/+3TM[QS55M7N9+YW^2)M- :P)?FTI8&O)F6]OTVRRRVGY+/;UDH6
M7!X/OWW(#J9CF:MN64%1!'+,HVU'FO%$N&6NW%4IBC8V2'-'[,=859U/LBYH
M&1IG,]-:NVUWFU:;S, $5JN[J!FP96B<4K=1:-I]-\U2:Z."2L4MLT5F8.<*
MO9W,:(0XZ>;VW*Y6S!![!)EN>K!EZ.UH4LJU:)3F$8'AN5FN71Z[(Q>T#+W=
MW6Q1-R,6.4[)5>AUU=B7' P>B0V]O5?M4#U^B"]8I;_A.NF5+:[3#)\.MU36
M-B^+;'*"Y++EW;)8VY![QP4M0^.T9=)%Y%RKBC3)O9+%9)7>)&&?Y*.O_C3X
M\KP#/7",1\$'^^L/TZL?[<%(>EH;QL;/9>SK^-BYCN];G\)?3,I4@M$L U@0
M+_1RYJX5$E#CLIYZ:7.&*^LON6:AJ>JY9Q]-U;!-<QOC]3$HA/*9QX)VQU^N
M9,PR=ETP5=E^HGKFG5JSVRI,&YR@5EUZ9$[9%35[M^KY%R.D+V@PM]Q3&^14
M_2SLEKUL17?VZK)>Z(TRM;QA6^V_6;:)@U%[P88%A 5"-9M#XQ/0RZ,_K)!T
MR:-A>1P#=!' &*#Y"@Q95%:"=C"63Z4L0LX@WX9.H.3!?#[S ^D)!K"_Y(E
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MGHU/S AM\!#"'[5G[U(\W-D]TR-0:RUGN83H#69Z.)<&SZ^"O>CL:-SC-GN
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M@$@\,E1"WL*?Y81W?1!\:1O@03^TZ3]T-*Y=P4K\[Y7]0*$DPSE^51K)%:Z
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M@AX=B"OKB:9H&T=XPQ"4 - VEQ.04(*^@]B,IO]K)28&H"%D6$D!_&T;II4
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M;G+$#E$,+ .T575!C"%<A[#ZG_\^,%V(@8+/G[*YZ(W/9^F$\3A"F$81/NP
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MR+PX8Y5"L8ORZR;1Y-M^;8SSEGAMB2L-7IPA3A;)(MH*[4Y[\.WGX^3%Z91
MTJ3,3_&IQ!,H1O*9C B8,XUFL(F$3T4R)$\9=H/VUS,688LR4V[,FHT.QKM0
M.7C:$C!R=^-LZSJ[QJ0L*;0V94%B+DG>+%N4"WM4<=CB>K^3&97.=!DHH\33
MEM5.GFYMLVV<2TI\76/[+::P;(.6U-.6M#!MS9>#H8LX%MO%F0([G7B2%Z*
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MWGV0E9B A.6Y#HKD0T%)P/\E5"<1?<4RPZ=LG,E03--_)Y8 +A<.#6>!QJ,
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M7J6K]0H]:<:F)G[;1B,/YDG5']JM3O:AI?560!Y-RCQ@00>./)CG6E56^L-
M$#BOO6(>/.@+J L&CCR8IYJENM@PZQH<F$XS95'&>!%#C1\.Y@FP9A9/IY=C
M;&%)$SZ7*O3;-A-U7WF&#D:R^J#"*6PP,!==R*W ,]$S#U;T,)>&.<HH.9RQ
MJN&#A5,5BW7TS .I>ZAZK&>VJD46]'K>RE:%N037GCY<>YD>/_B-3-UC2ZZB
MSC"\F9)F/AQY('7#23'724Y)@POT9;^?(<!$G*"W'U") J4N_&/:P5I3K%V1
M,@$)^<EG#ZG4%=EIPU\,4IBQ+EHZW2+)5C\L_' P=.%6J*(V[F)8LC?&VI-I
MI4Q*S*8ZT?.A>@MW%ZV9-M3LPLJ99OR'1?C4PPUQ2%)Y1:/3;&O)$=W5;/Z0
M:?F;RA//]J29.O7E%8]S0].JK]MC?35?AD,/2.6FY:4$)D83ZWG64LNMK4(.
M;K-PZ &MFLV*-V_6.XH6,&ZWCN/0W1'">W '%.C-9]44S8 !"]89A6@9@9<=
MAQ?%#R2E.R3]]:2L]=B2,:CWR$Z.G8O*YG;=LZV!+A7,(2FU.*$U]JJ9>G&.
M]3IHZ,%<A?ET/"Y,Y18+EF-1J0&IR(U\9+8?S#7M];E<;[C"M<5B6BH."ZTD
MW6!""__YT.6LZKGY$J%H>7/6\+@NV:B*X5,/YEIZH#F_8(]ZV%#5RIAN6P5"
M#)]Z,-?*>-)VEZE"EZ4=SW#-)I^: _C4(UN)/:@MV0S=(;0>UG:Y0;M45=%5
MQ",6S+"UG!-L"I>U15+E"-(U"P,K?.J!9'4G;!W3UBS)@5)IRI@YWS/,\*D'
MR^K,'<]E)HNE-C1D,3O0>O4U$I<CY@[OEPJ=AMSM8-[*]1[,$5;VX;8'AQY0
MH""9B_&ZU>&XO-PKZL:D3:Z;<*Y'E+\OMA:<Y_,]3!"38P_GYP.^$@X]H$#]
M(2\T"L;<Y_+<C$PSZF"EISIHZ $%QA5AZ/53]3%6*@S&HX=%<J)1X5,/*&"6
M'GRC#MJBEAP5EL-67\\X@$%##R@@%?HJ3AB9$BMD^VQ76FM2NZ>@H0<4,-?]
MG%'TU@]LJSL>IQ1QJ"Z&_C'[*%=?-(M=8KS2AM"J(*O+44JQ.L>LGIR!93E_
MW>VQM?Y0HD%GU2ROD:U-/1_I>(!RR%[2Y 1-)M=J:U5:M-'(@]6/*2$SJ2Q[
M/:[5Z&58(8>5YN.CMG;1*M)T45@.-<%VJ60/[YAUB3EF]3A:E2ZTM#;&@CQE
ME7O#XJ#?\X_9,J-)UNQV"],%-F1].M6QQSSK=8[9,LV)%XR&V0<3ZV6KOE>:
M-(FQB9Z9/K!0&)%MCFO% !NV"[*^5'2UMCQN0?<'C+"B4@ML$>B#0F;4&-3(
MSK&='Q!)-U-WEA.LUJ@LDWUS4LL5T<Y_P*,:0_G-<M<9<PO@3T0Y(VN.@D8>
M\*CCD<5@9DV7W*+0KZEM/,48^%$;H9^Q&W@PZ:A8:0'FK@)8M9KI'-OY>X,%
M,-EBM<_16KM.E58@ERMTCNW\Y4)*R?D95M54LLG.:J,Z!*C"9XYL?C;)F!W=
M66,JKO+KK&-():@CC^RHG6ZVP;!V:8CEZX5U#@@E+SGSC^ZH1G>1:?!USM?R
M=<;0+*O2*TXZFY)ES_A),&ML/8:^1BEK>X0SP\5.__@VR20;N)U;I&FMM'3+
M3'=.BN2\<W1#>[!<H\;@;AFK\?T\+W1*V6R..;J?3#H,/O"'P9@%W7%F6":@
M<PB-XV/["3<=C=L"7IZRBS0A ;G8PYUHZSE8ENJGQI7F3.ZP"U8F\_GB--]G
M%#3TT**2J[9;SI,IK31^4,:9&98#UO%=:N:1#;4Y+78YL&XER4&JJY)N.-<M
M3M[?L?R]*3S[4:R**5H&Z NK@NJ@A#K/!GWXAIQNB=JO[0E^@:G74JS"K+B@
M@35 NS.6"5>)PG2JZ0&)<5\9%Y[TX[\2P!&%.7RU:WO@(N?^>Z$<277FNA#\
M5DU=-4%R@A:\%PK"'E-#R.@*QO].3CCC%],UPC6@7)W[__WOY)]-""GB4@*R
M"3B73E'8(2@ZWT#'&989)N-:<@)*D).81&EM:C1I-YPT2KX54)(F.C)V?H=K
M.+=L]\0ID#P=M.2(?KEP7D\2#_\'ERR&135L2'TSS) Y%/]R,E7J9UJ8IQD/
M>'&Z\/-S/L><2Z -U4QNLJRP^]?SP)^^B;T_$ADFJ3^F?(7I62C=2Q?F#OB]
M_65W4D@&-A-"64!BE#VTGY"UDW&_2<?"#C*K7'O[ULW3\&A%[[N!1:?OT_AK
M&?X[>4L[S[?@,V4H<EN2;/^=1'<'?D?9:RAI\<W$L4W,-WSQ=J@P<2S=<\&Y
M4\A>YCO^@9#Z4];?I^_"8*_>A8LY\56<>.O62\R)K^)$^IZ*&7$-C(#**1US
MXAHX 953-N;$-7 B5DY7PHA8.5T+)V+E="V<B)73:1GQP<HF;_K5GU]VYOFJ
M$Y=HAO:ZSWKNZWBOLCOS 79OJ"!:.OKP_WYE?OTA14CLGL"W%_0>4]KFJP04
M?E5*;._^G5LPWJ+8?M!U/T@Z0G=J61-E51> &&9Y1OF2)'ZWK9HQ^>=9E8;K
MAL:KZ_U/>$4U*@7L_+6_MBM&QL$B=^N:O%CCY%'"B3^5\,P]G;EM 4?![M.Q
M^573\Z;9G+UY-A,QFW\"F_%3;$@7KZ.W/3D[V>YS\17]V!ZN_SI)73'JZFI9
M(B_C/U]\>>[MHBE)\@,7C**#ZKKE.$7;,O)1K@4D8FL.HGDXSPZT@;,%)M2Q
MD"CP?8_WC\C'=@KUR<.<EPA&U&IZV:%SO7FO2J/$>1)J*#)S1Z0/NW?^=;*=
MZ>("?Q&D9Z]@X3'23W>=LY;J9^?C23O0U%I0R\RZ34_1.]>&]$&NQZ23PR;&
MT4QS61L/"VIGB2Y1T1#I6?PN31VV3HF1'B/])R/]^>UB)3-LK 9R<\X.%U*A
MI6M!51&5:T-ZR_-H<E2<<2R1\49&S_:X3AHA/0N1GDG?8:G#R_!_77-<[%"H
M-REZ-Q'PNA)==.'@UUDK@5-7L+8+%:(^=X#G2J3WPL&>GRR]/].DWNPPK^VS
MR?ZXU,G5BY;6LZJS% BHGI3THRO:K^ZP,=QCN/]HN%^?7?T.N(]]A1X.B]T)
M5^MD2M.LE%X%)A-53Z!>C9+=:&"_;[F"'D?USQ#5W\<_"?$O61ZZB',9Y7;.
M$,'EEQJ?"SS3=>S*M07(%M44[*#B L-I6F984M72=?C5;4^!UY2AN:@(Q<&$
M7&%>?Y!JY9VDC74W95_B<X.OC"9>'F"Q+OFY;M(I=$D7EP>*W7U@M9I7@2S/
M<9*N=Z+"4.')1.JPTFVL2V)=$NN2[^6#G4*7I/O-UL)@RTLND"8MO=I8.T6"
MB4K'H;./8^7,GWMJV\YM9^J8]FGP7T-#BN*F,4#48<M);'JP 2DJV_]4[2&!
MFE# =4$!_L\$F$!6W;]0&ZK=\@^OI<DE'G/DOJY 1/ZQBL6V6 243S8JSIV+
MUO!"<8A9NU J!L5D'@L6"Z*3-,5ADE/BXA!?6QPB<T_%U[FNXCH7\4:3T9@3
M7W?%D8S+=%P%)^C[;%RFXRHX ;53C(FKX$2LG:Z%$[%VNA9.Q-KI6C@1:Z=K
MX42LG2Y<'^(MU_I+[E5>I&+$ZX[L%[+[(O4AB.P]F;KM"[?GK@_Q-="X>'V(
M<^/@<C?*R0MGYEU5?8C7;<^8S=^D/D3,YBMF\R?K0T0;TL7S&_*>;:,#Q<3)
MMI^++^EDV>"19WGQ]7R]/1TY<M=WI?1%E?09!7MQ_L;R&LMK+*^QO%ZKO%Z?
MJ_V,A]O;NXFH^4\10+/R1'=C+AQ7^J*$T]<#Z->://I6N/FVKXZ?V_>+)2^6
MO%CR8LD[N>3=8B#DF071<P47?)^ R*7@=?&%G\Q3N4J#_=Q[P,79%\MM++>Q
MW,9R>RMR>W.!DA/6Z?LY@9*+EP<Z*^0NO;C8YXW%-Q;?6'QC\;TU\;W%N ^*
M]7@3]V2EU.)PSVMU/"Z-UM,%8*]QJ;'''8M\+/*QR,<B'XO\C<:G_OZ9M\>^
M[8GWB=VCJ\R.B[WV6.QBL8O%[F>(W8T&>0I !K8-I-]QE"<^9+[J0^9S*?R+
MLRV6UUA>8WF-Y?5:Y?7J@R/Q+:>;\PB^1\;_W[??AV=K_V] \T+9\-=*UW-$
MK[>NKLLKK038!5X(\O-\6^%Q#/74(3.OUJV/??48F3=YR!5+7BQY/R@;*+X%
M%CLT-^?0Q(D.L=S&<AO+;2RW5R*W-Q=(BF^!Q?<0OM$]A-CGC<4W%M]8?&/Q
MO1WKY^(V:WP+++X?\-WO!WRC<[P_.,!K=,G,F)^F%QA=E@(6[QL&S?L\3I[_
M "_6!5<$D%@7Q-&W6.1CD;_!P-W?\?6XV*_\GG[EN=*(8[&-Q386VUAL8[']
MSM?[HG! PA56B;EM(0FVS,1_)E%0X*]OU-KL:KT:$LJW9'D3'7Q_M^82:_W>
M8;T_".>M5JU -TU^Q 58.<GH34SQ&QT>3\7AO%@+_$ M$ ?T8J&/A?YH2.^_
MK@ G_,]V1VAZ!GR/>#U2>GHZS3S'5>4@^D@U)=3@EZ3WYAJ2#2<>:=>? ALD
M?,%)G-F4P/=,"9Q7,L/&:B WY^QP(15:NA94%5'9,R52>Z8$7+Z(S D?2J8#
MS/?;$I$)04<F1%.P;;Z05[ *Q_?SV$)9N^T*SE6F#1]R\;PD(/9(0/"U5#\[
M'T_:@:;6@EIFUFUZBM[Y&A*4%;4^Y)H%#1OZF<:D7O>3C:7RZQ_3.K"@#CY(
MJ,?\+M5,H%4E()'0+WA"\N 0*^%.02)O&5#L@Q"GZ;^=Q%1U7,L.$I:<T"W'
M 4[XK:6@>R'!T.>"KEN^8(KH;XJ@FHX;/DG:G 2'+Q?@5UWG/K'CSEX.5-E'
M3#$)&T Y$*$*>%P.FKOC"JX7KAO)$UQ#>-/(2<C1[=0$E)87*09U,H#47T94
M#T>JD#+PRQ8BE!-5N-G3=">Q[/<EK"=.@>3IH"6SV_D\"ET7SJF[M^X^TK]]
M.(.<;HG:QH2?\'*#RN:!Z76QWC!MNFIIY=8"*/8 BND<OLRU/7#"+5,UD].H
MASMV_[K>?OHF^N,[M7BXR6R?L-DU1<@38>Z W]M?=B>%1&<S(4-8)4,FF8^;
M:%('LKN[JR;M:.[PDXUY@F'_1C-W[>U;-T_#HQ6]+X23AL0@7@LX2NKRR/,M
M^$P9RMN6)-M_)Y%-\7MB T%+(NWT]]QR5"0#OVV@"TA.GCUS8UB$+]X.%2:.
MI7LN>+;0L^_7.P/?S_?_PL4\_ORDH4W@,2>N@1/I>SS&Q%5P(L;$M7 BQL2U
M<"+&Q+5P(L;$M7 "O\^^FJ04<^*#G'C_2?"+X'C+LSB]BRY"!PK8[Z)-Y@.T
M.:NV_D)Y^(,U0\<5??A_OU*__G3]J?L+9T-DWB$DD[VW^)&*F%BZ!/\X H*=
M8$T)2(D"$($Q 784:"+QNVW$:7*: X?7E=AI2/%JTLL'$T"^ .,'4[Y("NRY
M,?P"8PY_GF UD=5RRXA$D<H382YF[=6QEHA9^UU9B]_Z3GF:_?+BR11M8"/V
MH0.IN0V2Z"@I.LL[38,$A+N+K_'4R+NN,D3GR#R/V1:S+6;;U[ MVL$NSK8_
M]J6NSU$\7-SQ[(JG[(N=]!7[5*5>OS[8<V+D75,^WSOSL.:>#?ADVLOZXLBU
MM9:_ZHHY.^VZ+>;4:>T?R6I_3VH,XVY*TO>V4KDW^#%E*TD\9K[[\JB<+OIY
MA5MDAJ! ZEFSTO9YBB>@B8W?'V:^WZA<__LL#M1/$N^/YQE>@7BWE,FR*5#E
MA38$@V1!#OH%D>] \:9B\8[%^W.9Q%<@WE5SG1LN4I4F&WB5LN'PRPR]0MJ;
M/I]XGS]:<D2\;SY&$IJ-R#@$SEW"!&&P9&M#;JZ6QN[;S;AO[[XB></&9"BQ
MC"G5+7&GQQ%P#N]1[B@D,5TD&4[.<EC)S*[*7;Q?[D\8/H7,2?R>.-,]RECH
MO]UV?'EK\Q7Y/Q![4"OH;;]0GFF]E,>)BP)% $>!8D\AL4^?S\J,I?Y;2?WE
MC="/2'VADA7TR=1_X C+J]4Q94*FYDCJD?5Y3Y_/^+RXU'_K0.>FA4-T'4Q2
MH=#8 -V8NU'7^!O[Q*>\EA\S)F9,S)CK#H-\\;9S\6VV#:!E8Z+4$L@$XW0;
MT,47]O5)IS=A7I]:;5Z<S]_;._J20-AY @'BU';>Y0\]JJ#"DR'\:@2,L43>
MPA<I5@.46,.FI=%<U#I\&H4"L'L\CH#=JK1_CUC 9P7_0-[Q@<N:V=:4T!8=
M$J?2]=F\,V6@O--(W@\COG$0X":" %W@ ,$6IV$)'0DL@6[-#62)B3:03GA6
M==,:ZB>IH_,<2+U;'3W5GV),*1_*H+.5T6-J29$'2:K5G)+:,&TNC8$S$=<=
MG\^@@RCL/OM=\CYB@;Y5P_*C BU.B/&XGO<<MD:SC50@S_)"O@,%.CQBRL0"
M_>,%^L(&XT<%>M#!)E9G-L^R^?FP3]5T;+WJ(X$^]^G1M[82+VX5]UQ+U)(3
MP0'HOK^!!"(J5RA:CAN'\+Z;5_Q#DJ&:%JK8X,%A$QULU%QO*M@@AP0]OR/G
M>2CFKP:(TBZ;QP IZZR1[.=*#8P3"=;GL\@R)>]3WSE %&/FUN.F%\+,RM'!
M2C67 =9KS@>M7C\O%!\4B!F4QG]/QIB),7.]%O2%,$.N[49]Z?@\1U ,-4YW
MA?ZTCO89^GRIN'%D]OR+:[E38,?>_4_S[B]O X>"QTBH<CTZ"3AZ&E3/%[-M
MDC"Z&-UH$+0K.&7!8W@<B^*N9\R$C@7Y2I,P8L9<'6/B.-CYUYN?"J8"4/^2
MIP8DC]U'8O?D#.[)E?=(_0EALDCH*V9ATT\'#F+";CJ#+0:8+01>]5U2HD6-
M<7\TXKRD2-'C]13:'AT>Q\-[A.DC=L0W\OC/GT;UXY%R^>#8J9#2]H;<=/S0
M&W +B5,[/N<6\9F"D()"8T2<<!@CY<9#8J="2G[2]5J%GCC7\FD_WZ?<2:,B
MAWL*.G!.Q1&QVXR(;3VD!!V^X%&BXGIL;U?\O?(&K-_17L[#^:BF!^G:FH-H
M.D<#:8J6D?O%]M#4/#Z]7%N%V40=^&BVQ-GRJK]/X:J;$O/;#KC%#+SQP-SS
MVEK7WN#Z^;RB-D,[[9-$'0@V(O5T\[*M&!'I>S(U?][Q]-R-@PAJQTB)EHV3
M^/,^2?]OKP'4H[F(FKY:]N^MU.\L;=-XB@B%1 ')J+^4(,,W_Q9T7PB<S3JS
M^#U&;Q'U^Q$Y))H.=4^E_YUX^A71XX">J)_L#LGV6LI&W]IO*KOY[(TF5QO6
MN-;\O'QY9BG2CTSX7^'H"_JJ 9Q$$_B)KF4()GQX^ EZ2?3\7XFIC:R)_^FW
M\D>;(Z'?H81",T&/)K-I7+#YZ-<_80=C5  .&0/H).U1O(5_=N3B)9'>Y\8Q
M,@M;*Z(FC#6=F)!3K?? #!E%I\K#NL*'8;3P;8\C[;0A2LL'=Z0-<4',9D?
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M+?D@[(J*PZE":*BKP EMF3Y\>4ZW1.W7EN6L"_@1)F R"V1E7N/PLK!4X5N
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M^.JLG6SU)Z"N#7V]VVB(ZZ5.0S<=P#UO#E_EVAXXX;FH:B8AW)2I^QN[?_W
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M+1-L_QE*=BL4[$9H*O+YOM]E1ME.21OJ0FM6X'HDL/>2%RK-X@=RISZY-,:
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M,=R'^"*SRHAZ;BB9:5(\<:VU*2T+"H30EP /DU?O00ZJ<:*,1(JK#$TY>6N
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M9.;2)FU#@-6PR\2VAE6Z&%#CQ\1Y+F\ND\1IPN@]RY7V.N$P87\KP91]NUS
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M8*<T')@)2=S'6ZU<#S9I63W:+LVX7Q161/F(>7!S>J"*5VW7C-=E4H%3,LD
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M%Y%'>EQ >@SB=1/%:V2\VPJ*KM?KR6P:S34$1;=8$-AC%?O2XJW<9PF%>*&
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M,-);1![I+4*/]!:1SR&]W3GR.22^%4Q'L;]\=D/1PY47)*,X 3-U>&4"RW5
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M2H6?)$^5"C^"9 <5V2XGC[[ZY5KFG).O?HO+VG;-$?^O&_3L/_\_4$L#!!0
M   ( *B);UC\#1-A,\8  - 9 0 8    8VAR<RTR,#(S,3(S,7@Q,&LP,#<N
M:G!G[+IW5!/O]^\[%"E20N\0$104$.D] 9$F HJ%3I0B34":1 @)B!2I@A]
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M+FLMTY6L"BZ[[;+;1:V]^G15K6$@//SK]W='R465A;^J, '9^ %GT"J,7.
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M&70=ZC74&1PX3C5"4KMB[(>W/=QL<XUT<B@J]J^, ]W>J<;[+79JD<2W>QD
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M(I^GL"6MU*(*EOVZU&65MJ,K44>GU$(@/=#D1<5V<DUUA>:Q/'<%E\S>8/T
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M/#:%7KCL#KF/AJ-TP,>U=F5(IP$TE,Q?(U00JV9T.2T@7M9^T@M9L5F,A?3
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MXLZQGE^?5)REA\ZQ?2W,94AE[V%]PZU&!-CPKXP1 ?9@UKPV=8^VR:8"3_2
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M2';\:X%*F8<+V9H3ZVA+9>?KW_W/1WF1^5.R^Q^49C5/PEKAK'[CH H?*.#
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MV\6VKP7$QM%$0+T4D[E,UXPS%@$R.H#^#4DDT0?GA.>N_](')R7?T=)^89.
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M D9G7')G\S3"QGTF]<5NTQ&" RJ%H3;0D!O!/JB+X\)G;VB8"?Z*+TT)/X@
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MP=?I9UE&25<S0OZ!HRTCQ\E'_RP-#\+PMU6_8)JS37K!<LK=T?#2GVY6'[Q
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M<\D9B3K+PYK\4KW'](,(U/9F/$VFSEW,;Z>?K;XI0_V4N0ZK TV AQLIFXD
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M Q.?P<054ZYYW5@OW;[55)TXN<*5/JMWETM;:-E*^HJR"_B.SQ.<"YS0/RM
M0J/5YIQE]%8<--=NNKSU<[<R^^)F\$;>/MR+/MB*\7E1E5X%P9EG=2)=.DN
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M).4SC8AG/N%_4KY:W!P+:P[/J3 D M*K@4?;)!]0./K57P3K -H?:R.<(8@
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M;T2[Q%,G_B6<ZNTN@^7SP4T J9K-D#?H:*Y=BEE;T6-.JY:1M6)=X& SW$?
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M_A%P/L=M);%#PF=8@%MYE,M0$]?P;@N&W;=7CSKDX/%$ X\HHJL:RO]&E.H
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MK-"BUEMRW+?G?P%^,GBZ "@TO:8M4AFK+I@_QHHN_0(R?1>40XEK8 %I-5A
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ME0  :2UII!\R"JUF(ZJ*+1@GLC*\/ 0JIT0D5AMUTW!#\_.L%7*#J^6XA[C
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MML'ZG 1[SQ:P68G6CN)[6*XT2$C@2+_2DB4<%J+?UA4@&H=HV>$AGJAL(9>
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M">T$N "V.4@8P[Y(Z\ @P",NHZ]<I_IW :)):7)0/M!KGJB[P%<%7HTSBB7
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MX+9=18-2W5.5G-9U.C\.E_@(!TW@A2G2DOYR< Q?KZ L[7!C<09?,*:39=3
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M6"/&8<%F"0-%C2&_V[AR&@(SQO"4P%W=@*S<I"$98T?49"1-7ET1(63@PON
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MYF3D69<]C(3#NF 93)":TM$F!@@K%-,BJRB*#PBKA82E38#5?R7/1N#=X:(
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MP1EHF!M<W0>]^.ZXK71"$=O.&,61+B-::F 1IY,NSNQ+0+XOR<P@B0<5IYM
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MXT7HW:?% !C*AH_2V&3Z$JT8>F]&LB' "NV]7\&_U?'$B?(IZ,H35(+$%7N
M-@ BDVX\?%5Y'RRB)<?2\BG,Z^ F0&/G!2K:/5:$'3 '2F>KJE)U"XW*0GNG
M(JU?BQ:NWK:8Y1&S3,5E+VZ>GKY*Y47.T_%@_^S\ZO3CR?FGT:7S^4.7!J;S
M^?HG>,CU3R<7\#\C9_2_:-]>68_$ 5R-3MG<!?N-3%Y0+P5=PY.-9XEU3];=
MG(YJ/3=@?'_\^/2#^.&OY7<_N?BG\[?SBS/7S,WG2^?\TY>/YR/X[/SB].//
M9^<7/]+OY,I_XG6P=J<PJ]<G[\^1*P^O^G!^?8$W^ #_/G&^G%Q>GY_^_/'D
MTOGR\^67SU<C_ VLQ#7=Z\OEY[.?3Z^OG+/1WT<?/W\9G3D_7YS16IW#J_]X
M.1I] C_$.;D<.1_@#_B?SY]H#2_/?_SI^L//'QV:)OT.<-GE&3WTGZ[S'L=*
MPSR_^' )P^=[T?-'SL?SO]7&\N/ER2>X^AI^!M)Q#C-_?G7U,_WL_<CY^\G'
M\S/\]^@"7NYT=/+^X^A/Q_WX^D5[OK %1I\NSC^<GY+K2P][*1KW]6#X7J>\
MNC:8"NX,K/:91?#.KB[#X+8 (?R/E\RH&5ZIFXR[,LZ\<SVTSMK)B$7H_O_M
M?6M3V]B:[E]19=>9@CK&P4 ((;O[' ><A!D";.Q,=M>I4UVRO&RK(TL>28;V
M_C"_?=9[61?),I".!=BLN70W8$OK]J[W_CQ5^ !AKDEUPM1&("*H$H1R&6D_
MWJ )/-%B*>.6%RT7J^\VTLMF$-+8R?$M8$O- =;PHB23JS3P)U"(0I5_2"AI
M<1ZI5 S6VZOF#E,2S209.BT#!*';3[7$YUC[5]NJRH-&,%K93'K#J2)Q8!>]
MQ ^'I(.PN$*^99"I_@)T?)]H>>SAG>#PZJ.!2D/,VL')H6"$G0)6T0<KH&$\
M1%V&RG[BG$(9Y"92B9\N/.!HALH<OBWTE5=AAT$<H5\U/(+"BH6)-V'4@W-+
MB@FC!+$9BQ&6.,,%-4KEX;-^@S,(HPBZ;R=AQM1A\)Y24@P6PB"M1 "FI< .
M"R7^_%$ZXX]*>U^S4MV32I4OQ]HBX[4-WZN+Q;QD!Q#"A]9[Q7:A0ND2!1.U
M:M8E.NNO05GFGUR!L@C>JPY<'G4S\JB/W593UM+U:U-UZ?RH.@5=6B[,446]
M#4]>,SEB$S)$ 7U'KL)L")V6@!8S@^;!S(=^/+LPH<$7'"=B7N.85>F:HMFN
M+%Y0'[>YH$#Q4L$0?W[G@XC%$-M'K6]2=SM]V,K!42W)!,HO@FVNK=FA4K !
M4G[B53@CWBW*%UCF<Q7MFU]!"DQ7,#*(6CDO /; %\+;!PMOER->P.K6?U2
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MFN)?%_<#W[:P.@L=* _FM]^\2^'M!S_^GLZF>5!#86T;6^)92M&+U2[!PF5
MYQ"NXT(JHJR"3!Q&=]JD7*^.9\4X(4@K K8/B4&#[GK%LF@7Y1R^V8JWE7_V
M-4:OJINC,C*K(WW4@?"VX"./U919>GE='9D-LQER#<P6\30K.WU47$]*.X8"
M]0::'%%K:_]-6R]K:2[%D) %H*]M!^N6$B9?QJ.K]D[YVB>^3GD@(/= -7@F
MFA!%ZCKE1^&5$BF;UMR&=PY8T7-8 \=_H!FEBB45,KR/!(G\+$RL";P]^VBM
MJ#:00M=]Q0!,@$+E%^THIT\HB0):&6;4%P&+UF"SB?[B8U4B]37J(#0*26;?
MHYS>9 *CREXU[M85$XCR:IC]Y=^ @._JGJ970/.[,/QDT:: ^ INB%;_#]T9
M&!%^4^6(%)6@Z>?4Y86\;WB$<&TAY!+&,PHY<[><=>SN(W%J6(6A%,A44[/@
M)2&(WK![1?X0P7*S'6(S$!>7OL*P!-"Z;):YX0#0\#E;(2TE0)$'B'%B+(&!
MZ.=)NA/&.X8D;%L7+W(]+)!]X&;+/X_B0CL@/#=/I2848EM9+TPI@(V;D$\V
M]I069ZN_M@R<F57(N6TQWG.\R18IGLCJ3]\;*VZ8MLO,(AQ>WBF*:/#]0MQN
M10/-QT46MY1:69-(0ZR8.[F E!\+V$ _G5.!1"9=3 @D#*WF/2PDYGVQ[^K"
MPM^[6'3/FB"IA6GJITN"'\B91R^ST\[$6L']W4OO5=-!:P6/D;ISD4G!'I@R
M;8U#^18J:_/QDC^: (Y<U@'#!</];2\@DTT;GA3N23<W-\OB%6/\>ST1C.,D
M2D:%UN@[/G4V03(3/"ORIK\="P*330DR%_9+:7YSJAI*W_-?9E,(;.C?VL%?
M[7#E\IN- @JT32\S$!1_"L(TF$VHD1%%OK#D\A.TH S-CU(.:,"5OD4UPP&O
MXAU+(A_ZP 5SH>J7$ZJNT>DZ,N2D?/!T TD-W8TZS6-\([M80=U1&,F]HRZS
M49)C#@8:3E*>"BD(H'-$LZ<\P4*.<.&/-OA&13D!&W3WQ#B%U[GQHQG]!EM)
ME-J &^=!A4RE[J&&-E(71EP<CCTY1>=:V=-Q1^N'H5]94085AKXDBPIC1&6]
M,$@[O[I]?RCYI;5CMG8WNA_SRUGWI'-^WK[H7'YUI!KWK59KM]D"[(JIB(%V
M"BI!$1]&.CRUUM&M'P0;J0[E%E/NYSZ/& M8K-4-S.JBD8X&8H'+>%GJ%%D;
M,%%'D7$(!!>C]>2XH!*2?QF'F'<")NU9ME#+5R)F5)QGA6]78!^&>9&4@GDD
M&EX Q5N"$1-!<=P2H1@ZP-+\S2G!Z'M_2 <D]R!.CD!/PU!>V"'X9O:K&YC7
MBD6J9@%P<X$F[/P>;B#G A2FGW)U^[7&SUB]"&[:NFWYVV?$=ND]QO(M=*&E
M8LCNH.Y-6)2;<AKJL:+PO"*UX2%R\1?U8?2)E'#&\1F.G9^^5AH%8%#"#&DS
M$R\3<8C%!$C#8ZIT=0QG:ZA=6TK&GW0NL6H!ND<$!.$$]_^:.,[2#U*R'!I-
M=G3#"@]4OO@&-M#T?U!M&,8LP!3.PC\!N^UP=YNZ_AXUC=*E9>J893HU(Z]K
M6QDWRR+Z1AI<;,\P [$B;*8Z1]ODU@)OW%6]U=]FP<I A]-] Q+P0>2W@FEK
MM9FS\@*%HIQ 9'$6J](H%D:J<^?[2-4>85S\KO.D^+1P TO'G@EY1>GZ:ZBR
M(?E:3G'KYOR)D#X G@@:%<;:U;I5IP\XCT%,HA/.:0^)#Q78FM)^F+-+"<Q,
M"UTPI69>SJ1])S<30M2,7$YEKNWV74B"H)"W BD,T&<:1'Z*:0,+14M!\0;?
MX^0V$H.1 N2%B!!%7.'60Z-EX$GO4_?K65UL5$UMS?',KNT?TK-XK]F3C^>E
M\*#]*BXF-F^CTEG]RMMD%@W ,AO+$PW9)P!YUQ3,U+ELT>MR$=W&27"PW39G
MR1E9]ZY7N/*NU[8\QLI@0QM*U<+;0JZ]GV$8(TB(;6QHFE[K"Y4Y&GD5)0!6
M:'(DZ2PR%D=[(H<80$3/>E";^Z@Q,/9H2-;M=GW0^_+J^&,V&%'^F'24O7+^
MK9\.% ^T(L-36=-DEN:J7M3FI:Q%M6,,OH0S_Y,K<B-O;S_.C[.)/$4[@3_-
M2B/8.RIE+([D>R%Y1[A]Q^-P("]H7L_=_?>/(^ UR_3JA;I7.E1V] (BLPJ_
M:.K'(B+Y@R*4K7U +DVFC.*98A_R0"5]^]*<B 51FO?#9 KT-M+8GR%P4*8-
MHC#+9I2E-8[8#1I#61""<AV& 8!/!^,8OE@LR@4 @QR1[=',P>IRG@=\#K 6
MXNH #TV1(LYRBCAO*,A-.07.P-/RKI+;F\ZM"2) ?(AC8X,'0SQ8*V@#FT90
M18SE30J)MGI"9"[I&6FK! ,O4TH\JA;YPAKJP3U@+:?8"EA>+AL$;*NE"Z?,
M$F86EH7*J _4PQ1;3+$1QZ4K7TRZ<H4WD#[U!#3<QX(+.F:1?ZO.;=/[1JZ.
MA>;#:28V[C4_C[G-"L8_-R]@Z10>>RG568*Y1)_:%\WAU\T"7GZ;T/=WZ)L0
M%5V0$7ZH#S=-:G] ^6<+@^98]"V6%$. =6)C$1?>H%ZK6GT7O4CYGJ%TYW$F
M6"*H2[7*XV'IK_I3 ;H&1F1>*8T<2@1,(Y]QL*LTQH<$.DD;WA<_R^2RSP"X
M.:.R7%/MENE+;Q8SGC)6_T#XN'P)%9XN5[$3CZ(P&X-_IU*1F2JFU"S*53.N
MV#)=IEA^87FHJ>#J$;:W"CO*4(YZ3PE7T%K4,#/+N7E1E; &@Z13EECH%Z=:
MQEL(TV:JBI; P[G&C_613HL,50L09+7_"PK3Y,.,[VV=AXIO2$MB,)&V *IV
MB(L,&3F^<+5P16:1#J!TUD@<K6HEC<4T1P'F@(28(,<[9OX-FSJ6ZF$*2?%-
M#!)/X8\.!&7(53TP9ICD+<!$\::^=@-/W<WJ#UT53Y>I0J0ZVV$(M;7J'J!6
M=_:^D/&>\1BDTFK(7XQF$1\4#O#P9W0U,';/!6,_'B'0+9.6E]J%\-3292_/
M%/8$Q86('D.(4/Q'> 7<IP;F*9D3GMB,N#^\<.-5&LDVJGX1P8:!\Y4H6<&[
MS3MJJS]I9Q#\Y%XUQE0M[@:JNC G0#BC6+"U\W8LJ@K^(S$B[PA.&%'<V87_
M%C.-IWH3R:I2>WA:#C7V_=1"%['",)B<IB93TP&L8L.P#K\EZ7<L:-VTL]#:
M;>Y_@L03^HCG_FT=M1;5A00C?"U[XO&@D*)?$CZ3.Z"C95"LE<2WPH]R[.XK
MV&<-"O_C20$E"_><W&RZ*/ I4OKC()3&4O9>>WCAZE89'W0L3Y)\JUP%T_LX
MEBI1SOOOK\.5+C,W5;);@=Q3QME0K1Y:NRY=X&+CUE#(\R]E$"NYVQ;#'):-
M@V]O"#;PG3JK<G_JV;: U7NX3$1PG"]* B:Q*F]NB49$HXW@%:Y!"NT (7Y%
M7D\SB]H%7L(/N_4Q!X5*1[&8A+FI@%>]#M6/M)LX=&\KS4'QKF090$J3;^9'
MQ>=@WI<!H:19[G-93/VG<IBDLPED6@CS&F#WLE4?3!>9W1Q-<=!!4$0CQ;4K
M"ZL= Z[QSI]CN=P  &LP-4%F2=X8:PBSMQ/IER ]J&+8:BB&0<Q?%OD'LX;=
MLHPM743W1AT4 ,^[D$]?:,*NL$/@7N*L:S8#V9?W'*,;&;@GK.5#4]2B _N+
M8Z"$>7$06Z6[*9 7$?3'?)EA9Y.=\P5L(;L39/&% [R0OV"5]][;AK>WVSK8
MA@)">"O1T<G+*P*60/(2?/FH >74E5.0:AR4BNYDK1944DT'?=00V$%-(<A-
M_B.8\*KC$,MLM(G'2X.P'L8#5>RQI4J?36 KED+ZIHV=@?6(YT6Y[H+[$$%'
MWXZ32%5>8MSK#M]K"6U9A??5L""V"D"ZU$EF(F8Q.H<5A7$\PGM@7K4$<Y>E
MPE/%.J(^B"%(2#2WVU"S/ F^D\N<";([5"2D\"X%N%U9R"J];9$"2 O\K-UJ
MX!Q%-VC%0\@3,'AH?0E-#+UZZ?I'G-GB#KV)#CU"!3US?I::34]8HH=4K)U$
MVR68(V[T*.^"RZBXC,I?*-30AYE[@HJ]R=6%7)6.B!:O!H2Z16X8>QMTW(<8
M1$!A-#W$4/HA74; K.)\,)'QD)A,%=#D8&;A(%='H;"[JY\SHR\J:_/P>UTG
MR#UD20D=FF_A8JOVO4T!=W:J62VH2^&K=7^4 H]<0(QN+&(7T@6E6[>YD?V^
MFXXON$J3AP>NR0<4Q_!=S -+J 4V)!I ++V 4/6'99]:N,X/LKL,)UD80QF?
MH@XAW,QRI;1!(K/LKA)L ?/""@U@<$^+>$&'L"<-)[V0H=<RNP5 #5-A2+$@
M^F%_='O!#.#,2<:%W)JCF;EI^0"6J,?N%ZQT@?29H+0,D%0!UL)Z'G%UI,*:
MK:F74./D<(RV]"HP*^#KR)]^/PYOB,C;Z%K)5VDJ7VO[Y<&(9Q&5=MPDX>8E
M_:3A?-@%4:R-(/5LB.EY>3(FB4G96= ,BSU7< H8?FD6BQ@AU3!>K?(QF/8F
M.&GU'+-A_$U@K0^^R\\Q*5!E^Q4=SA)6A$HI,Q3+,F2W33P+;S_B)+_X?PAY
M[ZW^,'RPJJG-CDE/9P;*2-,W\1WA,]O) UO]*KA_Z(Q83T.1QWR-*H4KS%@?
MC#B)^6N&*4HC!K$>RRPJ<3K3^&#MX!>S:81B1%,MU.7A*1L :0"@5JIZ?AV8
M,6U^,)+B:-6WLSO'G?O?19&I>PC>9$;]"I.$VQ7T&QN*)))1-+$+!Q4K0G[(
M6U+%)NQ2?S;'(-S+T(,<C*@8TB:*SM$%'H8:&DY Y?%)TYEI,*&U24'E D /
M<6>-)"4=.&K44,5.S(3%U=U@32Q&IPH*T0#C88H *;Q,):5\"@T$2\F)0X-0
M\Z3)(2_;B.1N&*99#ET=TOF&R!PQ26!B>P3Y;I@C?+H!D$.Y=$!!NH!CLF&!
M6O7G&MN%?SGW@%@])$@GE76P,;Z:WE>*HQDKBE> $BYZ=;!JW:>.%>F:PDL6
M>^1,D16VN@5IV(=A 1/HZH[XXWB94*NFO+?C&L:^:J>8&Q//ST^>_V#?>N<S
MP*/P3E-Y"I__>,]%WX]!#UQ\]G;WWQX>KME9;D-L%:,_WB?ILJ48[I])?S=:
MLXF@T^*;6S](IA!)J$,^'VD_/@M?7N$?5$?!*0%TDY)A;&0?W$^Z<=?N$B6S
M"(L'$\W0<[RZ=K3:1%Y%I2[C )'+&MY9'-2Q_"L>]]X;[R.:$MU<&BOY\Q]P
M=Q;FPMO?W7_^0SWQ)_TT'(R 6*CM[>ZU#EHN@['&&8SZC+$\EU?[R3@40]/9
M[EU2NGD#7;UW)PD7<M?2O%RJ!=$\R>@!@1F &#[1W'++(.C9%Q3S@K\8L"(%
M$5TD96E/^N%(WD18%!)B^7)C*?@1/WSQF<@IQ:3=J17[EJJ/<ATF,K#H-U)A
M M,7^SB>9):9.-PFQ@A:NV#_0%E+/=!>8WXZ.M\8@U&0<WA4.+>VN,_&D9?[
M*KUQ[@0/#"DMM3\"DC+^$//I4_%ZXN6CW<5*8B:JP6Q<W$#&((I28*!/(3-#
MU2N[VL+',"P[V)$?CV;@]9>@N0J)-C4WR)Z)^MJAG_K,M"X2[QO4::;UA)8&
M4K\@P#-%V@FKH]BW<$>J626EL9(T582\]C8I2FR-E<P%6E5 9O*;_"!5K5HY
M$%-VIFJO.$N@<D+WYL>IN(:2VM%<#3O6\215H&/55BV?(4^(F+:MWQM$(TPF
M$W:/*ORNJ,Q2IQ_>M-&QTM;>E163!V8.C5]>PQFWU)!*/F9 <,X!R@=BZWL*
MQD>/=2M#;%-XK@$O7WSP7<*S\$PF+B[ZD2K8Q=5&$$*U4")5&YJFCD<H0(3[
M8]P,\W0%NEVF,RD CN,&-;W/E*.OZ+KEE"[ASV9AG_4+Q*!G/M2:)OHH3XO[
M7,*J-P9,X".O;O'/V*@UF49S4\!BI>D64[\5)23E!! 6:MDZ)![H CW3 D,D
M%B4:3I5-@;Q2*@(!ELY=R$'E!,D=W#2+O2&XGI@R[\\74N6%>D#%%\W$;_2H
M+;BB(&'M#9)9/]]&X[!8$[&$%<"DUE%WX_BK/UK<"C6,-T092VV-T 5)ZR"%
M !!DU!HNK, 6'R V$JG>SFA]G]Z][-OEXTR5&Q6#WE$5,H:#.MLV5T0%G8+>
MFH+1C1ES2"S(3RG8-<I2V@>^2N0W\CK?A_ JV'-R%6LQ;0N[K3!RE#H%Q@NK
MPH#D$6 U FM4?(UIUZ0BG=5'8FYU5+E!!C\<)'B2I,1'\R7?A!&H)"R&,*G7
MEX$ [.)0$#!$!\O,3*A&G#)C?I#)BXCLVJO3CT^$CEU?%=C_NT;U,2![YPJL
M_',QS.4B<908!>N#= &^O_>Z:K'H@P05D/U_+!Q[KI$S_+&BKV9!>%YZH\U#
MU@B#ZM_"'-,%WZBSI+'J*Z:0U"5G6/I%,[CMC9%.Z>3,W#N+2-.*04!3N)Z6
M6_8Q6IIS\RT%3"GL"%>,7 !QK/[#'N6A'"7O&$0)N0^\$ V5 TV*L5#\32%0
M2:%0.TH)O[%BCJ\\/ :_O*+[0>YVGLK_A\13E$EG_I=7^Z_4N&\@:R]O63XY
M>3+E)QT<-M\=_2];N/B=Q[O-O3=TB%8HMH]^'JM3)<=X)C$NG@]PS>Y;IS?-
MH_U[EDD]ZH>6_VVS]7:#E[^0^:^3QJ"THZ]1%-(';NWAX0.W]KY'[3;W'WI*
M[CT9N\UW[U;TK!\XO(_X*+E8!ZM:K-9#'O3CAX*O>U;QK>F?@-PK_;2_#?%_
MEK_3T_\ZT#\\WY30AWFA2.''3OO*U^@')63I^SECN1%[M.S*??7K:[5S*SP/
MV6OOWYO>OXOA,!5S[U,"%$A_Y8#09?%D!Z2FUS_'\_$S,GSPE#+<>B$"+ 55
M2E4OC"+Y:>^32.-1FF39PI:MR' YL%?'^M>*C)E5/+YX?4/UQP.W?A4OO\.,
M68/'WV$YK61G6K5LBS._EN%  Y&IL\">]S8MM\!..I?..'K.6_>3$N;LHV<G
M7LY*<E:2LY)>EI4$V1EG)#WO75I^B[=V7Q^\WMMM'3E3Z3EOX,^)F;.4GEK&
M]JMES-E+SE[:9'OI-19IJ/ZVQZN[>O1\NL*6]<[#+-<I[U5<4VI:3SN_MK>C
M<-+^,1,9%)C%?LC@-JZ/<:W[&)_^='V0I^LC=!1<#H&&6"!"\%7DQ_IX68MT
MSV3WFM;1X-."OY$_6O,7DXHUM8NX\!CCV?SEU=_\7?C?5QZ\XI=7K>8;74&D
M'PEWW^(3X=#M-@_EVZQGJZ7WL+ALL5SLQV[+W1^]+7_.ZH' SW6O?7;AG5Q>
M?#P[[5STSMKGWM7E=>_L\J+K77[T>I_/NE[GGY_//ISUO&^=ZXYW^>6LU^N<
M>NV+4^^Z<W7>/I$_?#OK?5;-%0B,Q'T54$E^<OGEZKS3ZWC_V;GNRN<N//9S
MN^M]Z'0NO(]GY_)9W<Y5^[K=ZYS_1H_M?>[(WYU<=WKMZ]_HR_B+K]=GO;-.
M%P?2^>?)Y_;%IPZ\[,M9%U]S]?6Z^[5]T?-ZE_(S7OOJZOSLI TSD^/^Q]=.
MMW=V\:DX\]YUI]W[(G\H?/GZZWG'.]@]]*ZN+[]\/?_4ANE_O3CM7"\,Y:0'
M VR]V]]O>')6;?FLT\[I&L &_#V<C+PL#>31':?9SM[NWGY+_M^?XD]YS/>:
M?TQ'<+;S7UY]2OWI. RTT #30^3/C\,8!]N/DN"[NOD/WC6A4)/%Y7"ON:^L
MBA4M1WVBL;! 4 P;B[12<];"KER<D#8==FNYVTL%G3;KW.<99-,MN-0/# S:
M2]1BK,9(^J&YKW!G&9^ST+FTXW5](-#SO@'?#ZFO=3RS(^&U2M763O<ZW>MT
MK].]/[ <?TDT?D8[V>H(WS,004)@SB7GL_Q7&.8QMAG"?RW\F3JO,"9BZ?03
M)DL=+-/N=<0 +&567VN9W8$[3V8(3X&]-H [3:"M3$DL_YIZ.4T?&Z?'(IIJ
M[&J!6-N^%\PRJ0BP^\=0TQ)%^(@Z00<B)TS+6]"<\GC&W*Z(#YU%N7Q@+@C1
M/;E5+T"V\8C@!(RE@9W%@"^.@X-! #P*MZX"48NWTK:WUM$CVEB7-X#+*9^P
MTM-U6*NEU".RS EPA@ZIUY[VR&9KU4COPUGDR9,5(   LG*>C3YY4=A/X?M9
MD *\BE^RGBT#I=BIQ1%)I>3AEZ]6USCV@UUA]P3Z)^%@$"DS:%7]%_OW]ZH\
M3_6V!23*/Y[K>M=:UPF##  G,[!<*$)FNM3F^OA7IX]6&&,OSLZ)UH:*UDN6
M+3 W "F)Z* +LC82 %J3&;P,8ZT@=7"6/9H$UJN2OXT!&(&M* #& VS[F"#_
M,Z1=R<44@6/DSS,&'[$N)\AST9V$R'?6^A6!R=)D!'RL8(>I*RS,E FI:?:4
M00T[,Y&F(F YD+D&$'QC'P!Z!#6/RP=/A+0UR0Z >))%("XM.VM* 'F#)F69
MZ0V1K8(TA&?ZB*,'-FOU1*V9 4S1W6?#P@^R+-9(^ ."NK(LG,"?3'TI74S$
MPJ 6/L"M&-/;7IO C[7I3?$-H+I)R,95:R_7]L:/9G 6F_JDUF:+?@/VD G,
M=$K0+9.LM&3D.-Q(RQZ&U-!0=Y7+V #&W# .@&!!$'G#-,DYLL9+IYYOEF_5
M$ ;MC.#+,(X'(_:N>_^QTSDYQ1U ^!_@_29<*,C3P4<^!CO#6<9'(1<AX9W)
M#\CCY8\ D&22Q-*@3<- ?:+![%W$0HG41K.4X/,!U!F(5  F$#R7<0*XDP2H
MAH[37$KG)+.^%/!Y\4=9T['C;49.MD8WLL;8B&)20[&<K63X-8XVHVB]'V>W
MP.=J]!(P3\ %U8]FXN^O9^NX$]M5F?,-L>#?K,B"7UM[%F/UA^__BA'_(#R&
MC78&OD'L*20+@T&QI%EA1S*W1'/4!'!3P(84443XJPFB-2*$X41,I#4;"Z7-
MM_^/<\U7(=BM!_C43KCK%^Y[D62>Y\IU13J;2$_N7_.)< +I-.UF"./Z:MI3
M(*^U%:MRCXFY0+K)0X2/!6[%D5.A*Y'8H]5IT/54 L] 8H\.UU5BSZ0A+! *
M'6C$G% ZNW:S!',]K[23'2J4F&7>YS#;D7+IQ-)9MYLADNMKW;930=5QMW[*
MM4ISI%G>R5,_SB*?4WJ39&#E:))*@Y@C3A<[HV@>)-D\8OZ,R^(O,&DT3C+Y
M_RG_RH6>G(K>I/M@357T!1!7U"Z(+Z399?-JYC?OOG2VT]/?E>MK.YT5XX*^
M%XS#0GV,LH@62FN<O>/LG4V2X;6U=YP8.C6Z&2*XOFIT:8(-JZ_]("?V3J*?
MY+]E$$1 ]E8D!15_BLRI5*=2-TB>UU2E_B8>K[UDH^70Z=2GE\$-TJGBSS#+
MJ5(4*56QKX,;.AK>(,1_Y2G]6^1!TZE3ITXW2)375)UR*TJ86:)KVK"<A#I%
MNQ'2N;Z*MAP#5GVBT'A5:"OU\TR%@[4 L^*%_]"?A?Y'TL N2.Q4\"8)^9JJ
M8!<D=GIV4T1P??7LY^16/HDT:W6TF)4K?"A$Y(O_ZQW\V]]:;P_?GS2\82K$
MOP 8P[_U@GD@GS+P<]]I6*=A-TF\UU3#=NF(^[GWOY7$@LD,=G(^=N%DIWTW
M1#S75_N>8L$W=SP2B%&>>*U=+YXD$4!-Q7D(J*1*"?]WRYN,H)K\[1OO^ZFO
MRY[*& 7\>Z>&G1K>(#E?4S7L4K=.UVZ,#&Z&K@7<GIV^#TB#TAZF"B@_R_QY
M1K#A-O1T/TS\( ]O&/314K-.O3KUND&BO;[J%4%F 4TT+8@V2W08 V= X$!_
MG!+>$$E=7R5\EGE!FF393BH6E.HPA(9H#6LOG6%N)F3G=^&+@/<\2^78Y=_F
M<2)=YM$,"Y@G?N#_UTRPFG;1:*>G-TGZUU1/GRP57\)VES(;^%)Z\W$2)2/Y
M<SSP\\3Q6JQ&>!WRUS,0W,U _F)TW#$HW&0T]_HBOT7>)2;)<.K6J=M-DMKU
MO.^Z4Q$ LA!H6CFW3%K&]##$IP9$>RG'6LDVO8_%/R(Y1Y0E5N6E S#1TW^>
M6_[L23]_E,1R_8@5OB0#0OLB\A]'L^!4DXL#53F#R2P:8#YF(+(@#?N4:YFF
MR1#(QU1(B"FHY:UL18:8BUJ%A11,=,/+C,IK2$46C/TXS"9&'!N**(DK&9^R
M'<"1+ST^^=+F7<+.1W@>%_&:^@AMC;"?>./9Q(^991&#<A0\SXZ]_U KN[(W
MXX\W?AK**_TXF_A1M!-(89(C&JS\7:]^!2URM'OP'NOJON 4OR?#H?[U&VD>
M[QQD.RT7MG!7DKN2GDW8XEC1?]Z()1$,9.N%M(+':05!D$:+:06^S)K2R9],
M12X'A1\$>4B3R)NT^X;@SUT#SCW<B"M@?=U#KM6[#;,Q%N2%63J; A(H%[;O
ME*',(-BB_$%Y&01"3B#=D>L!=X#]H23EWO!_.8!TI_4W3N375.M_$]X@\>(D
M][['R2UTK.7C,),/]T>N;,_IXPT1SK77QXJ9#T'/Y+A-L=X6F]RJFGX;6L)S
MKQ_&@ZQ$:^(TKM.X&R34:ZIQ75.:*ZS;'!E<^\*Z >"*0@94:U34M? ;SH'V
M0ZRV4\E/Y!9+A1<ER7?0Q,,D=8K5*=9-$NKUO ZE*TMF<I0*7\KQI-W/O"!*
M,@%V,!;0WHJRZ#;(7+X5L.ZMM^^CR)ME@@)7,8*3 FX+0/+[:9AA89&3=.<3
M;X"4KZ]/K!@^E1A3G#I(;J"7/#:*W!_Y89Q!\!IB6])YGH9R^L)I:Z>M-TB.
MUU1;.Q!2ITHW10375Y6>2'VY4 LL?PA3,?#(\849 UFV75T/-K'E,P-.FE3"
M\NM*#XN!T[).RVZ0B#LM^Z+%T&G9IQ?!]=6RWR#$I)8N7,E#Z4=XT'&8RY4*
MY&O"V+L)\S3Y^^MPM67<4,KU2,._6?WHI64C1(Q)<X*E\CE^,(W\.%8!A,0+
MXYUQ L$_+%"=SN3C0FD%G8T^999=X_7G'K6M.@O'7:WN:GWJ-%[FM4]/3J"_
M4 2Y%$_R0\+)-$ESZ9XX(75NR 8)ZIJZ(2BB4&2JY=)A6ICI/\\]6T],BZ6[
M7H-5K_;2JW_TCXC1\>K7S]B0VC:QO0]A#->,UTL,KL9#Y[G[T_/\*8^CZ&)\
M2OSH&!V,Q]VJVJ^7&LZBNUB>ZF+IM3^<=[S+C][)Y46O<]'K%C85->.J3$8;
MF,*?Y4D1E@)_\X-6I;)M:9%^K*#SIRLZ"7-C)397T?S=?<BST(*Y<[J6(?>
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MO7Z3R+V[QUQ_#8E6^:]Q/HE^_1]02P,$%     @ J(EO6+KW@30Y'   C;T
M !8   !C:')S+3(P,C,Q,C,Q>&5X,3 N:'1M[5T)DQHYLOXK>I[8'7N#IH$^
M37L=@0%/L]-7--@>QXL7$Z)*@,9%B2E5-69__<M,J:I40%^&OF:8#6]WUZ&2
M4GE\F4JEWOW/UE8['/'0$SX[[IV>,%]YR5B$,?,BP6.X.I7QB/749,)#=BJB
M2 8!^Q!)?R@8JU;*>^5JK5:N;&V]?P=M->U+*JRSG>WJWG:M4MMEE;?U2JV^
M6V$7I^SUIU[S#3W=.F_VOEZTS6<O/GTXZ339JZWM[2\[S>WM5J]E;NR6*U76
MBWBH92Q5R(/M[?;9*_9J%,>3^O;V=#HM3W?**AIN]RZW1_$XV-T.E-*B[,?^
MJ_?O\ K\O^#^^W=C$7/FC7BD1?SO5Y]Z'[<.X8E8QH%X_VX[_6F>[2M_]OZ=
M+Z^8CF>!^/>K,8^&,MR*U:2^4YG$1_#F-MR>>^;[UE3Z\:A>K53^<33AOB_#
MX58@!G&]6BT?[.?7(CD<Y1>5&5P]$@&/Y97 UIUVO4#PJ-Y7\>AH_A/+WIRD
M[PU4&&\-^%@&L_K/C4FL],]'=$W+_PKX. PCD*'8&@G3FW+M\"@6W^,M'LAA
M6/> #41T9$9>AT$S_'=H?N*'^H4/34TK?17X</-___6O?_T?:XHHYC)D,ARH
M:,RQJ_ [BT=2,_%])/LR9B.N65^(D*FQC)%Y^L+CB18,[L%C$Q'9Z[&"6_E3
M,\8GDT!ZO!\(%HEA A10T8P-$^DC0Y??;?=ADB;K(PA-V@_2H_W;<>=#IX<B
ML_-V/3V[OB/X9MKRE=1 YD#&L_I(^KX(X8%__G18J^P<O=O&!U?M2?6MTY/Y
MKQ=;BR0/?B[]?"R"*Q'#S,'O&B1[2XM(#GZ&=UO"$^.^B-A!B8'JV%E/#X%6
M?>Y]&T8J"?WZ3P/Z[X[DN]< G%Z 9H3&'I?X:QO'J_>G7HM?29]U8QE,11"D
MO5VAR7?]Z+UMAI3#6MMZ)&&Z5S<# 8HJVM(3[H'*KV]5RM7'8(E\,#OEZMY:
MN:(%=HA9UBC=WMN>' O-SL247:HQ#Z$YNH+-+LC+4M9V=.\?B8[E8&8NR1#H
M%M</:I,%=5RMK66D7U42@5'1\&ECM0:1&H/=$BPUN0S,5G,DQ8!]E"'8&VB1
MG0\&T@/M-460!+9*# ;"0[/,,L6V4S6:C;W&QG#B:Y5LXI,?ZBV1Q!>>BJBK
M6YX*5%3_J4+_+=Q%(M=!#XH(?UNX31VH:Q5(M%I=,>'F!FL!L'NWG:Q$51IN
M]>A-&09>W:\<]1 '&#%Y&?1H#",A$!ZOBQ)L$BD0)A 3%R(!FN$1XD3BN'$2
M)\!<.I\+T"C?. !PGG:'*>"TR&"DF4H0'#752$2)9A^DTIX4 (ATB75"K_PR
M*-U48_ X9FNCLQZI)/").$0UI!1*M\&BV;R6V5]:K9V'Q%'4EQ'S^8P-5!"H
M*;+:#%4>D@3_4(,YPK#7?(!BNJ#(WI08#_V4CWV+VD,5 Q=?J6]P!11E=A=X
M4LBP]#)XL)VK[S4JOQ(Q868B0G(\27*1)EI<B0C=%^:#NRH#\H=@ADHY#>,1
MCZD-#V0DF!D/'=^%^1EK,W7"86F7HQVO\H=YNG8]"MT")S568_.,O43N[\Y^
M?@%]:&3E6\2 7IEC=U_J2<!G=1E2!_J!\KX=_2A$1]D<0W^,/TV?<[^/79R.
M9"P(P8EZJ*81GT"/JAE%^ZMZ"=B%!6?Q 3GZ@L^LN6!?P(" 16AX7I0 4WT*
MP>7VV47OW,CSAT1#<UJS]O>)"+70QIU>AVM4I7FU$*!]/41R!"6">_C,).__
M%/L/G Y.W7"T[.5) -9OPL&)B8&5T4*RUVO1.'-#><CIZIVOIG46J)[90V[G
MO9_$+#%SG](2M<<<\"LS ,1L#/9")_TQJ'@PS?"J91%A600PC)=$D0G.X-S)
M$+^C(HK'Y'K*VG;L2_7@"(T% )^ Q1&_$@%QGVT1P'8@ ;S@(RS@:'] ^87L
M/SQ,>#1+)WO7L*S3M.$:T)CC20P:$FS.N)]$T"#V"G 6XW [#76BB8+7^00U
MK,@^KE.4VH!G00V,=1:ZZB++ FFJF1HW?&; ET%O 5(&^70DH&,1W1$!O'@M
M\C!?RP'(?'AQH[!_4&'77J["[F9PP*IN;;2S",5 Q@^EE"]2J(%,2[R*'_65
M ^OFN+=$T@WR<8BH$CI)8-%(0YQ$!G9B2]!HCBDMYDF%]@:(Z4(FDC45@C!C
M. )$#&/J9G$ #42)K2?*M$@<5&<L2,;@%B1C]GH8*:W?D 8E87?"T3'_+LQ,
M\20>J0A:,2LI(^ 7P-?ZQ9FB!49\(,-49A^3"!7F6$6BQ.2 IAXM..CQ3'^F
M>,"#9B38 M+&:F!\F)'@03SR>"2 6XR<L EH_X2[+!?2R&BUZGP<RCZZRHD_
M%#&[!!J$G@RD:;;A$=ZHOCW<*Z$OPV'T*!LO;0:;YQ\N&P\T:Z4EQI><R\A,
M"7T;[+$8RV1\/6K;+3^-]:O<U?@]=TNW\X(M70P$8^<3O*7K:[5K+JF ![<L
ML1CK =/RL4J,1Z&I!\KT@)1W)'0<20]UA+F9A*A,,@=\2C&E$<!6=@6/.AAZ
M@;-+1BKP,2;'8^&#=D&5A@![T7?!CY/@B.\B\J1&\!SZ:IK:0&!,?#/%P:GT
M7"L\#B^3/&2KUZM'N):*UZ.$L^9F>:6%E;_RB!>XP<DG2+56C+!E3BM2G@-J
M(3M.4D-.\D$Q2:'0TI8G@N ($ ,.(K ^@VGV^A;2W CBTG)E\OVH#ZZCB$S2
M11FI2,J"_70PV-FKK)CK '/F-%]=TOSUJ]I6[1T J??%T>*G6<L0X^?K5,_.
MS@[K@4BSE@HF")M;$<"9$NLF\#C;KU1*@$+\J5(^:\+TEEBSP=C;W<K^'F.G
M'#K%]O<JY?W=M^6=O9W*LL79I>;(D#Y-7Z&7V \.#&-)0\&6?;K8R*OWU45F
M?*!L@QL&7=VIE _=@3]QDL0#YES<2RVX_S^*TB;R=(DY$^^HCN(-V[5YW5A9
MJE,<J&53H.RE0EK4?,K5!!ANJQ\)_FV+',4Z#Z;@:]H)/M@O[Q[\(Y5IR^ES
M&N:9)&@]-U3[ D,ZNR\7Z)Z:Y=Q+<&:YQK@T:P9<CFTLY^[0[8FXR $W&1<5
M!>GP=K[:JAX^ F,MS&K.:7DG;^.TQ@-SFLTUN88=UA[:>PH7X4<6P7.V*T+H
M@]HZ<GML#@"&,S$:GP#T4A%3&'>:HK<UD(&@-0X/YP*>!LREXV*4 U<1\,>
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MB^RXSD'1<<"^..["4;;O%#P*-36!YRP!-D5Q1>2CT7_/L*S!;P269]F:IT[
M'UC:N_(3P5FGI,C:/NWJ2$<XC5JJW#&#\WXX<:.6GI=:ZC^S-=Y[^FP84M%)
M7UOWB(-*Z2L$N1M7+F1/K^1G+UO%WU.WK;/ $_Z[<W:C540'.^7=:[V/>\EN
M44$>+C$5=\3_&W7_O-2]]\S4/>:ZT8(S55CD/K 5)@BD6M[6?JD_ND N3P!T
M9!0_2D*Z<L+?-9K@)N'[(9SV=Y;&=)*>F33*YRJ-*'V9+<7$K"2PJ4T\S(+\
M(+.(P[*:3-=E=FX<A!?-H\^62;$45<A>'[QQ2SHL9T:S)Y_J0A!.Y.X-&>?U
M6?(W:">K]0^R.HD9^,YOIUO]\[PHMJ0H!BXRIGO]@660X3#;,'<&P&6(96!@
M+?;4LY7T@%+*I\QJ\7TB(^&G=5@Z ]L//5H8G>>)24P=2.NDV>PFXQ>-@3V9
M+P*)N48$@V$@$IX&3T.,N0Q*MI:Q'9L_5]YFKUZIL$EY7(;Q>7(@/=:C"D:F
MBL9!*O@ZN<;^WIDM#LNUO;LRQCRO*UP"B4?OMJ$;C[\V>TWI.I,C"<2]%'WA
M>9QUDU"/@!E*ME;G<3(& E\*#6]XX+C8BIV8I[IT&>0.RNV.7;9U:I]FJ783
M4ULEIK9\ETSZ^-]V,Y8C#:MNLOKPX)NL>DOJCFWV7#W:GJOV=S29A5*@\\74
M=E]_F*LC0RA"&^N;IQ??N&G+R3?-<JP1T/S CJJOU^RHLI.Z+)#JI+K@GQ<<
M3"9&QTS!6?R@.SP]$63=>4 EZH!65U0T:N;&/,=24V&Z222S)*LXXC[",R\2
M,6W#Z(O__C>P=;AN6,RO5?%_]]M2^>H]=&:*2\G:I-[9]"5; 3O"?1&VXA]%
M<POU_7;>@I0U[?OLPL9@([=2EJFK(KY[ 'R&@(B2 +.?UE!N7IDRW)ADMXR&
MZ20,DM#73U$B];FJ\C5OGVVN'7N AW+^B37.6JQY?GK1./O*&LU?S\Z_G+1;
MO[19[[C18_C A_/>,3MN?&ZS#^WV&6NT/G>Z[18[_TBO-B[;[&/CM'/2:5RR
M+QUXM'?<9A>7Y_!4Y_RLB\\U&R>=C^>79YT&:W8^=T[@>ZTVZ[:;/7B"5?=V
M:R7VY;C3/#;OM=I=UNBRC^<G)^=?NO6G4/JW5J:YCX:_(1*>0:6'M=G__#-1
M\5&#_=(^:U\V3MAE^Z3=Z+99ZQQ(?7;>8^W?>FV8S-XY:YXT.J==.QTXE<W+
M=JO3.[_,'T8>87"A^ZE[ 7.(;[5_ZW1[K'/&CCM=O'7<O@2N^ R_ 1-A*[W.
M:1M9H?U;N_FIUSG[A:[:?MC9+['.1VK\C'WX"BV=VI9*[/03M$XL>-KHM2\[
MC9,38-:/'^'KP(G.-[OM7N^D?=H^Z^6\V&I_@.Z7#0VR V,V:8";-,"G3 /<
MV:0!;M( -VF MQVVMAY/[>'=L@]MM&F-+PB'P,QU&YU6 >64"$J!B6J#:6O_
M=G'9[G;!AGUI=,"H(?2Z[/QRW.O24Z>-K\;8]?#Y3V<M-($ B+ZT3T[P)UVA
ME\Y[9/1ZC=ZG7IN,(""Y4\!4)XTO@*4Z9\W.Q4F;,%BW Q@-(%J;K&;Y=@%^
M%+AT/W4UAY96?VLU]+Q77JKI;^A*;:=\</ (B.\AC_*PNPV=V(^[]4D3P'HH
M'+O>L-*UU4R_4K:.'1:%2J8\BJCH\8C']2?P<>]45;Z@N?,*8#<XN<^V*AD6
M=%F[LYLNQYE"ZOE),5F4+ BRWS'( 4 =-\%G&\VUV5'J[B6G#>,J'$@<#AY<
MYAX^Y61^V=4I&"N60RI&K^S6OO28V('-;ILD$7S3;(J;W]B^K)WK:]9N&'-]
MC-E_(,;$&NL8CU539!.S<S'?E*KM7E5WTZ0;0"S9:[3HR373(D8^BD?NRFUU
M"^LA8]+IAE4>@U6\!V"55A*E(7*/RDHMT0XVI5B: +\&FG%;80*WPD881T<=
MDU=8&5/^S-P16H7XM%OT?ZJB;R+*S'_A.=SO_C3,=9<2G7\AWO(?TCXBVTC<
M1LW-B3XS3'<4D>;8(EI&3PAS]H9;V<0MQ.-6]K.7\U(+IE 5569"?IOE2>WI
MF7:A77)(<^.U,FM<@@T2S$LHX3*'704KK/UPS&-($]&7YWBM&$2^_UG7UU:#
M77)0[IWYS6D?N7F1:0J>S[IXQ/QY:[+"?D[ME9V<1_)JSN *$II'8'J188Y
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MG\(VSSP%VN7-CR^]#_G >Y\L8-??Z+C0/MQO,M,9R+1W^KNW]^+5_J[W\?+
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MYBS,GJ'9R/?3>N"-&F4Q$ML*C>>$_V[*B<>ID6G8QTHY:W0,]E8/O8P3+TK
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MTK23%*P>OCW%NZ<K6,*U-+1ZV&NF[H%V"&8QE5+F.::]6PT?AVVUN/BNUJU
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M]R3J(TN>VH(ZDK8EA+OE^DOXB].G)&XA>< >7BWMM^P&J.BG9;6=Q..!NDO
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MLY*?-[ B@U5-GR>@%*ZI\1T;I?PYLZG#=^FU-!=!^QLUR6V(FB15<6;,;Z[
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M>J$,-2^'"OR*:<X<(V6S=8E'?,G0:-"A]/$D6GWWU?MR4MN2[W;#;NRRZ4R
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M)X.@9<@Y<0TO1:4'Q%H:1=,BPL)S"7JZ[>RWI =SZVZL,&7SUMPNK?EWC&_
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M".Z_;OHAUU4J"A"6[:#UZV[^2OU';V;O&VQ_=$,M\^=R(W(FC4KJ=OL$SJQ
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M^L")2E/LZH3N7<*<3,VJ0/A-O000!0V-5>+:Q>V5ZO7(#Q%)=+ENSI2Z&]]
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M[0RL,9JZ+,-=#-@S_Z?=M=K1GX/C2.&BGHV[C$^/XLGJ3N''&?S>FQ]?>A_
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MU^_2^^5B>'#XWCL[]FJ=GSRX!WS:F_F]A(D=G9U>>J\'>UOCE?>.[5';09R
MZ>J;YX(\]&@*]COH'^SC'/QZ<79YZ9T.?ST9_3H\/1SB9[^-3DZ./YYX6#A]
M=GKT$;8X?#HZQ3UURG()UUR];^P^T C##Z>CX]'A 5UT]@O<]8#E^/WP8O@1
MOK_PX6GPX^$%_YB>YOTR]$Y&![^<#&FS7YX/#V';^G##0]K#^'=X^.7P__W(
M.]KW/J :.#\9^M[YQ]/1U>CO\+?A/X8?SD\.+GBWTS/J2LKW#DZ/EHP =,LY
M/&1DAG%R=GGEG5^<'8^N+CWS[XOAWX>G'_%&%\-?#RZ.3H8P?Z!9#DY_]T[/
MKD8XA<?>Y4?00O+(=3RJYCTZJ@[!'@>S%\VD3KR61I!\K&TJVH13XF(^Y@S0
MQ!F-M\7A2?D1&#QQ)G4I4L%$81CB[0.G)POG2!:+6;Q@NNU[)H'$-['V&M()
M4PP)J4'(J>9(J7M9F2 'N^Q:@J"47=8V-\"]:9))L:[V5MPK(2[A-:L7XM]F
M.L;\ :\[F.]%I%(CM.'RP [:_%AI[')3&L0:O(Y?RA&+G7!><;(H*E)I!88.
M@8>E@ZK,3,U5-BEP8KQK[61^W3M,]3R,0Y'86!>(T."+L]IM.;AP"SYN9AK!
MR8U,0SZ\OO(-3(+YCI^,[-H&'@(.:73G-O$+2K($&S6-;,OG\O'F&4E:O7E;
M.KF<=-0G</<,$_$9<?^6!6(( M$JJ/^ AN/\ &Y)+R#/A]\_2]*!&803:\;$
M#E,&59>Z$1AWDC=(4S!3O&[) L/012QA%.$K:JO:YNH\U(>9CJKIH)():Y:$
MB"X3J4AUJ>;BA%A^BOFBY%13\W%X781.Q7O%B:9"5%2^J:9N8-<*9X\3H2G%
M1KX1C<\*-_/_Z3[9>$EM_1#6<:ZN2;2&5CR%(<E9ZV.N:5QU:G)%]27[;^KK
M\J:#94$(!S=\?SL+ SCGWG$'QMWG[S9!Q1X'%3M*$"P14;-N;QXN46MBJ8W(
MX3Q%5^LW="3/COU*X))"^$$1W96&=_W\L@G;H<6T':E\A3G]ECK!_9?[CR\9
M[H;>?21)N>_=.RMIN2D+G4\/!RLJ<%GO';W>;_<EY41BN;?JJM<GNB6_S63\
M\/,O=_V)JS[+GGD?5)&BG_C_J0*;%C-$N[>S?PJ^]MO&._G>^6QPM&+?YAN\
MW568P^IYEIG#^T\U7[SSN QZ2"<_GNNK+H5>;ZVY>;O^OMU7;<3.#+'+CQ?'
M!YCW.#T\.SG[]7<VR#;VV.;MUOGM-@;6PPRL_]%3I.L%7[O7MM7&S&\Q-"MK
MV_,W$N.R:V-R([V;R=A,QA.=C#Z>KED63I1WK(5$M:<SOQ'#UN/57=R>OY*<
MKY<ZQNK0OV-\R@9R?.\XC+'VO^=O^42E^#&2=$_$*]N\ZN95>_VJ]^&&-N^[
M>=_-^SY5Z)OI"=B P#U1Z-O:1V@W;[=YN\[>;H/5[!E6\RGT5>V2'.<?[T>_
MC*Z\7U9.]/P-N]!>#D^&AU?#(^_@]&KTR]G1[][YP=7P],J[&/WZ_FKUS5R_
MX:M*SX2.2+J_(P?JR9\<F[?[3M_N*2B:1SB!#M=)+==/H-%P<^I\\87(!C3O
M\PI>X_5^&7;_1@%WMDL?/^*^CHIL\W;]?;NGH'<>X1 Z^@9:^LD#!HZDRS63
MJB=3[S"9C\T_3?CR[RK"GHLK@Q)\BQKH>O^YQPK6_/7(S$T"*_6%P,RS<1+<
MP1^S?![]_/\#4$L#!!0    ( *B);UB#8:FQ!:L! #:4$  5    8VAR<RTR
M,#(S,3(S,7AE>#(N:'1M[+U[=]LZDB_Z57CWW)FQ9\G:\3.OGE[+D97$>V+'
MQW:Z3]^[SA\0"4G<H4@U'W;4G_[4 P!!BK*=F++!1.?,S(XEB@2!0E6AZE>_
M^LO_L[,SC*<B]F7@?;P^^^0%B5_,9)Q[?BI%#I_>AOG4NT[F<Q%[9S)-PRCR
MWJ5A,)&>M_NB?]C?W=OKO]C9^>M?X%X#]:,D?N/M_[Y[^/O>B[T#[\7K-R]V
MWQP<>A=GWM:7Z\$V77WR>7#]CXLA/_;BR[M/IP/OMYW??__[_N#WWT^N3_B+
M@_Z+7>\Z%7$6YF$2B^CWWX?GOWF_3?-\_N;WWV]O;_NW^_TDG?Q^??G[-)]%
M![]'29+)?I 'O_WU+_@)_%\I@K_^929SX?E3D68R_^_?OER_WWD%5^1A'LF_
M_N5W_5^^=I0$B[_^)0AOO"Q?1/*_?YN)=!+&.WDR?[/_8IZ_A5_^#E_7KOFV
M<QL&^?3-[HL7__YV+H(@C"<[D1SG;W9W^R^/RL_2<#(M/TSXY=ZD,A)Y>"/Q
M[M9]_4B*],THR:=OZX]H^N5<_VZ<Q/G.6,S":/'F/X_G>9+]YUOZ+ O_)>$&
M\!I1&,N=J>31]'=?O^7W?*->$:]NO-MU.).9=RYOO<MD)N+_[/$G\-],IN'X
M/^''@^'E]?'IN3?X?/[^]&1X?GUZ#.O\^?+Z]//YE??YO7?]\?3*&_[OCZ?O
M3J^]OP\OA][GL]/KZ^&)=WQ^XET.+SX=#^"/OY]>?_3^X]]>[>V]>/O__]=_
M_=?_H7_OONU[QW#OLXM/P^NA][?AY17<=^FV'X^OO'?#X;GW_O03W.MJ>'%\
M>7P]_/0/ONWUQR%\-K@<7A]?_H-_3!]\N3R]/AU>T4"&_WOP\?C\PQ ?=G9Z
M18^Y^')Y]>7X_-J[_@S7>,<7%R"]Q_AF,.[_]65X=7UZ_J'ZYM>7P^/K,_BC
M\N/++Y^&WL&+(^_B\O/9ET\?CO'UOYR?#"^7AC*XQ@'NOM[?[WGP5L=PKY/A
M2=_[R^^X,B".\T<N?2Z_Y3LB"B<@3OAI319&/R8(=/4M/V:41 '<:OAM&H["
M'-7'_MY??A^U.W8?M)=,]>#W#N:Y]Z+\WW;?9/#YTZ?C=Y\O>>F//UP.A[3$
M:WZIW;UUOM1HX8DX\$8ROY4R[O:[7'VY? ]:Q/M\#DOU^<,_>M[I^:#?[7?"
MQ>GT"YQ__MLQF($K6 M0E-=?KD&]O?]\Z;T[_7PV/ %%^@FTZ-7P^'+PL;Y>
MEE6\YX7!*9EK%;8#MC-/9J3)9O"G-0=RUF!$+0N+/D3J^4F4I/_]V[^)%_C_
M?_/P$?_]VUY_[_ W/1QU3_P,GK)\3_0<7O2/X'G6W;6&]421)V]_\V@MP.#3
M8A@78V/0-P:]U>W=^HZ^/GX'KPUO S-T#5-R5=FQX&2+423UTT9)&LAT!_94
M).:9?*/_8;_/$8Q0O0JZO#Y\ V^@MS-YU+1EU ?L3M,G%:\;7[3J<N,G]O9>
MVG)Y"O\;Z+'>R#0/?1&I:9R%01!I_;#7?_GRW^TI54^";4XZ /=O'MQQ-]9*
MZFXO^B]W'W6WRMA>[_5W]UT=W(O^[N,FKG*W_?[^,XSM=Y*3M*;]T6[B):T+
M$.R1#$[@8'-^>^#ROSK\WEL?/.C6!_W]H^^8H(=*V /FHD4SV)[FV^T;3?>4
M^PF\B>_8Z4[.W,GP_>GY*3D/SS*%M;L]4B55[O8 E=2-D_KN=Z[,-,SE#F@3
M7[Z)D]M4S#=:=:-5?T#N]C9:]0=G[L-G.#F='Y\/AANEZJA2W7^QT:H;K?H,
MNF%_HU5_<.9T.'*C4QW5J0?[&YVZT:G/H!D.-CKU!V?N\\6UBKP//AY?#7O>
MATN,H7.$?G@Y.+VBB#)?M@D1.*MYCS::=Z-YGT%_'&XT[P]'7O\V_/3Y G.7
M&[7JJ%H]W-NHU8U:?0;E<+11JS\,!CP[0[_U^-/I_T?0D8UR=52Y'KW:*->-
M<GT&%?%RHUQ_. +[X<NGX^O/E__8:%5'M>K+321@HU6?0S>\VFC5'YRYL^/S
M+^^/!]=?+C=P 5?5ZJN-6MVHU>=0#J\W:O4'9^[3Z6!X?C7<)*U<U:FO#S<Z
M=:-3GZ-<X,5&J?[@U%T<_P,S5ANEZJI2W7WQ<J-5-UKU.;3JI@KKQY-694GS
MZ?4_"'[%9#R;%);3RG9O@WC=*-MG4;:;XJP?3V)=8"7!^37IUJN>]_?C2P2]
M:F:*P>>_#<^/-SZNRVIW$XW=J-UG4;N;ZJT?G;K3\Y/AV?GI>^73OO4^G9Z=
ML@[&"H-/I\?O3M'Y?8N$5%\N-\6S+BO@_4V08:. GT4!;TJ]?EP!7P\_?1H.
MKK\@8]SEYXOAY?4&Q^6LBCW8$!2XJ&)_)Q:]ORI22/O_3LW4C83_=9(F11SL
M$&?EFW][0?_OK<4A7?U"\U;61.Z%&I6FSB32:_6136BM/JKP6:O/#%?V7$SD
MSBB5XNN.&.<R?2.B6['(U!R\/.H?P,HI5D E./CF[C%K_U1<AC^'4=Y4 ?XP
M9^?P\HRB3OB/T_--N-]IFWRX.?:X:)-_ 0V[*0C\873UZ=4 SCW'Y\//7S8A
M?6=5Z]&S@ &KWGQ'>+X5"SMGJZX&'X<G7SX-KUKJ1J &?;3<>@!_^6/O4#8;
M.=[9?>.=2)B=61@+=.V]9.P-DMD\B;'?T=]$5,"]6B-?7_?;[+WQSD1<C(6?
M%RD(&;Q*EF?>.$GQI4;J'3OS0N^:7Z<CHQ^\\=XGZ0PEZO.<9&OX3:9^F$GO
M/ $5(KOR(B=++W)1I/Y4=.Y%AF^\TQA.\"+R_K@:>)=RGLH,]CF=Y3LC5^_?
M>->[,/A,"E@%[R(2<5>&_N&-=U6DL)\EOL(U/$OFWO4T3 /O0J3YPCN>I%)B
MJ[G.K,9'-"&#DX.7W5R1CV@S3C_M['5V_/MO/&H8T]7Q'W1Z_*?ECE:VX:?8
MU7\LF;PK&4F?_M4MF_<_Y0)5?:EN+]"G<H%.XYND0PMR]@:N68@(IGT@(K^(
MA/(-Q6P>=<<+.8>#4YCY49(5*>S]$9PT^44<'_^5/Y5!$4D/GM'?/7SU1F_P
M4P2Y"_^KF$@0*3@RS3KX/D<OS?M<)]^Z_3Y[?7!-AM]\.>=#:YY4/';\"+L>
M_EVDJ8CS\ >WSNZ/!$]^_ 5KD\I_XHW>A#D\T*^-9>]5+>7Z"GYT$V:P!:,P
M7[R9AD$@8Q@2MLM[L?^V@VWBUMLN58VZJ7?E8Z24V@^N&OE6/@TSW<Q0KTA[
M$V:,-<W08]Y"]5C<[GFTQ#+PPAAVF<C0K/X!WH)(%][KGK?W8O<(WTJN[Z6&
MXS&Z5S?2.Q&Y;/'-8"4J+U=K9&N<UQ@1$)-%#W2EW^]YPO.3=)ZD*BB83D0,
M0A;0;^6W,,O1A2KB0*8>SLLG<4N3AO^^ NTD\8\3&8E; =9Q:VW3IH;?XGSA
M"YXG-^ 6PLR=QO"B>9%+CB&^"Y,S&6#PVQQ6.C9?^LU:F["^D:#*Q.%;I'(L
M4Y0[D+HP]D@IF+T+GP3A31@4(HH6N./$^O86^?AMO3&])R):>+ORX->J&G#X
M8-W;>H&GZ*6ZW@;CE\/!Z?7QIZLWZ[>1[0WZ[Q^'E\/CJT>O8L]LN ".'\F-
M3+.>ERIM)-DE#"0(9C+/O!@7:")CJ?22F,_31-!U>=*^I'J/?CM?Q#ZHR' V
M*^($=E4JY@MO)#+0(C!\&/P\#66.9CF,,WPTO/ H*7(OAIF(:K_+*1+#4P)*
M!Q=Y@IJ)[7OE43NCD,S?V]:/!UV1JE)UPVR%,&O'XS'XV )MWSS),IF!(_%M
MCLG?3*(^U^('D]K3$H?_=E&L9G;DI^?!TGR5.?T3WS:3482B,9\*."3ZLJ#\
M-DI;4/@P$[=)&@6W82!9^=L2L@&</CW@U$E82_OJO>)/!3(+P:4"3XK M"-T
M-.G/U/BA:@OB[US<@GXRFV'V%]R%?TDP3+=>@ZX'-Z?F@=\F102Z?Y0+4#EP
M.?TW9<T/KX^.5R[]:4S:FWYJMJU64'3R\;+"GUJ3!T+5HB/T)+K^_//?>]XU
MRMG[SXJ:\G&2AC.:@!D-M'N@#B1PU)&3A#1B*F>@[MDHX%>S(@>/W4WYNI&Q
MP @^2)+D5T-AD4&/1JZ\:/H6S\!X$$'7?0PBD=QF;SHF#+M]S^H5O7:P49L#
MW^WS<-NZ)YU" NFK;5TSN?5O\:7?T$$<_[7T-<<BLR0*J2F,'(<Q6:"LU2'_
M]M>^T_BP+W&$_EXVEWXX1F<(CKF9S%$SY%.M=W&#I>B*\X;K*=V!VPEU!X+*
M0)O?3B7J=J_(6 _C11E\7T0B]9+4FT=%*B*X+HPB;RIN)%T!9FVNXF$S*6*X
M/K,&, )#=]O^CEV[W"M&IL>LS!K#JL?'K<5(IBHFHM;.6KH0,\F<1]X]ZN_#
M_^_>,N[U'V^NUK>,O@\'#PHW7N5@MD4:M!8ZHO6$/?WA^/@"=RRLI]JHJ!,L
MQ]5%!^'T_>75\J"UHTG>D!3H(XI,]M SX+@)A2<IY >>4H9%:OC!?!Z%&-F<
MPBEO,L4 A/8Q%CA7NR_?9CH(K'S-(=Z;T0;9%.Z*?NILCC<#YS<<+^@&Y 9K
M+0G^?(SW%3F<QSU_*N*)Y&W5M,;>O$BS0L3T5K?3$)Z&I_@435O  =D9N$/L
M$I5ACN+'IG.--A?FY09<4I"AXK$.KKLO.4UN87G3%MZ1Y$.6PC43"R^)0:P*
M"M. %6;0,PDR2L-$)29*&9JG8>R'!+[8DOU)W^.MPKM<YGY_NX-*>M]M)?W/
M L[S:=N*V<Y+L#]FHYPH(2/AT*T=,1?5=&!<;BI%(*W'10G@;281!^SP+&^]
MF5&Y9<RRIW0I; _6IJ2R?2I3YME06O;!SUO]I$ 54."NHM!R.)O) +^$+0>;
M"[Q<[3)'"?J^> W=<^EQ'=QH!TYOM""<B9'7.F2 -QPK7QV5.N$ '&4W46H8
MA^3B'C/3 ;(+4JK%]H\"Y'6?X X'O3I0@&>RYWWZ-%AC?IJ?TEIVFMY ^:7D
MT]&N$R8)C<9R!+H!_@@P4 2.84X3 EN6],<M)CM2.8\$:LTQN&Q>#@^C_:S_
MBZ[:-W0,O3FJ@1Q_SYE^<]+9@UVRS^$U.PG^8[N]$;'UJ^&SUE;X"!KMT&V-
M%H3LSU44SC%:_;!-G,"=AW@7M9K>;8=P0(<-MR6ZZ+8>=5#V3D0N--1V(WU*
M^H(N2M_+#DH?N%D[IW&KL,F-\#V'\+WJKO!Q2=1&_+HL?J^=3LXTB]]%FLR3
M#!/R3YFXZ;2#M?O":36CPTIM1P;K>0]PV&2:)3'";18J5L:?4%##12WC<X@L
MHYH&]4<$9^W1HH?G=?B03]V(-$IB?06_.4?PZ/WZ6#B)V1+8.3);/I3WS-QP
M3GJ$,4+X)F#TE8X*5J8L'&.*)KF-,>OCE0,-PA3F.UK0^&+]5\^;)0CFPM#D
M.!SG"PP<((#:VSI\\>_;&H8C_UF$F"V2?I'2R<Z$#2O/AM^%><3#NTER:=)'
MNEX7?L5/3M+,VTK2GKX",UT<PEJ^*\P(O&*UK*%'11#U>S,4($792F($_WFP
M?H*QMD4^36#LB^U>-:*BU<P\N944'.4!LNK!7TL319LG4>BO>OF^=VU!>^ $
M$B>W,!43]5KV>R+B5P7J:,;HEJ9,HZS,B%1EAKZ8LB0I75WDB)6BJ[[$(89Y
MJ'0CZZEQ?PMGQ4RO)98=@D# ,*?AW(H,C1;X")I)04BK< *S'=_(#-9'!Z0(
M?;%*/GH*C<4OR+@V?$/Z5T0S:HU!RW!6C%0MBX%AS&'.9<!J'NDW,4;F;LJL
MM;R@)?)+\_\8P22Q6G31).XZ;1(C,(@QE^_#_+>7,WN0K[/'<+6NK:C;$)4X
M+L"1/8?YOA)1BQ%+7,GRM@K[P/I.>)/P1L9(.2 1,.']0XJTBROK=EX;5. H
M"=HKMN,T&[JHS!&CC8"G !0*_P V G.MXYIC9^5?#GL**Y[.]"E-#U8_BV$Y
M%7<OC/VH(),/MP2O#=R>(I(J[S>3D@V##RX.#%S@(^%0I%%!WI;/"2@<%B-R
M^"70__0C@8Y13WVTR0,YF ?:=3NUK<075!JXW9C';1GGQ_B17:_A0;R9W$UP
M*PZFE2._E!,.IC1<86H=/D3)J/F2+MH-MY.:Z#JG19938?P:K,=88I%+U/,R
M+K9/C>L/AS',^T\T#U&2NBC0<"I*I>PI@T3P>I#0CU>7F/CM47G8)&:;!2:2
M&(H8S9"&<'J!UU5O*.&0S-0Q^BBO["5>(XF# JW8+(D3/-_\2\\)WPOQHW3D
M3T4@JYM@4PBY*80LE8W;66S80!@%:9<6XF$E#R_P:-;%FH==MU/#N*0XZYLU
M_9XU=3OCBFN:/'&XI\.+^=KEQ7PGXJ]I,<]]<*.3X&DRY>6B'C)(N6,KNN=T
MIE*OZ'.HW-<,5.K:>CH=9G\7@HL)/Q>I=\RE$GRX;_DHINLP:!VS8J2R8@I'
M_?[DV,73%V<',8.F!'#KZ[8=7]P_W-69T(N/5\>4[,13IXA%E$R2(EO]U@)C
M$7@R2]*%=ZSSI3I#5TDS<A+9I)XY,6DN)9*:+NX*IU,5UJZX8%Z1M0 S. @L
M-'<)QY=_/#+\O OJ=(;BW:?VJMQ9IV'$7R U)&SUT,^\3Z$OXTS:6A0K3ZC.
MS.G*N_<G_R%F\[<##"F9(&@9&<NH8KF()E0@@RI(DE[L>5LCG($S3:JEU9@*
M'MGSL+["H;/VV NVM4H=?B%-SFF<!>%Q;C!]F#/(9S87*=436LJ=0HDAALIT
MX QQ),2A01^0_M9X*ZW!.3SWPXQ$FSS0FL-9>T[G@=ZEH1P_ W/'07\/-GX7
M/0ZG4R'OB@PF)LN\$]%Z&MT+Q,*NBQ;>E<B+%#Y%VKF8OD58V@C.=HXF0GCT
M\V($NL>;(C1,D M\)K),^-,"Y#4G3QGO\H\D_;K2E7XG,AG!>X,#]B^91F#P
MNBC+3D?:#=CF?Q4BS=NF.Z@31<WAJB10B%YD=]O:WR;:%ND7=(&OAS.#QTZ1
M%YTR:0E*#_8=VM_M>7\4L?3V7X!<R'DN9R,0MOT7Y V=2%_]38<]HMSH.IIH
MS^FH?F5V6Y8=6KZL\'U0M:7PD.S<R@@^V-K=VU:"XJ(>)#K-V%?RJWL5[#+7
ML9%K2V:[*)U.YR?\#X.+-2@TF4^1<*_G97Z(B&(X.C#@^Y^%B*@>P# ^I9)8
M9!!3[J*(OC\Y)I0!@Q.(;1FT,<8WZ-^,SC0DS*F<@YM)R(8T%%&F >XW2:0X
M ><(\_?#N>$JG1;P9 RG_0D6(&-^!]M=Q0'8YU?X:&_7&_3?]R_[%+;.O%U0
M^8>@[0\/X'^/>"3[NWMJ1!$==?$VDP(<#00A!XE?4*,POG;$O%VG-L\2<KDH
MHAW<@Q]%"FI$GX:'1V^\#PEHF@%L*Z*9OD@1D@%Z"']'8'=ZZ@=XHL2MQ]'$
MK,)'8=;=IK5!Z$P7=[G3B2O_PZ>V=[E?I"D&$28H!HJ.&*._<R4(N-CV$CL?
M&"\W%6Y1[_ 5;0T$TUK229L1P;,VV@IIFA!GPZ [O<FRGA5^HGG@UGSU&K;[
M)A(C5C+STW!43N2P2),YPL0'"?).$P27L(S#P8FW]=FB["/=-02-E<S@J#%(
MX&>ZBP)Y@V45YB IP!)'VV;4IX./Y?[-?O8-O.]TGM+_<+;6#3RK-)4L16]Y
M$[NX@7%7\B8F9'U&=A),:W5+9_ W'X+V=G>?8W.OFN2'[._&]U/BAM6#EX3H
M_X!,\13QH@Y/84R663')ZWAP@^[X6Q*!/^"!^T!6_:PR4&/:>]YQ',MOWNY^
MS[I$JNZ=,LM5\TAXZ/+C>TS,M??BQ7Y/"^)/KE&<SI0OD?8]0:TV8BQZ*M6$
MG6QDZFA\SC<^K'+22^Y$?B]1H:0D)Q]>M8C*;7:3Y!QY7JI[YM]@'2Z>@?"B
M!J9%3$SEB<G!6[>A_G=<B$.W6WX0\8^/D.X.W@,4@J*"D]^8?3> $XP4Q.!(
MK3=4,TX/WB&"S_.[JKGAP#ZB!*!Z*E>8JB^S(KT);_!C+B+U-#A;D Y<=97]
M]@1EYO<R N)55D,GZO(4I$SX.D&%2\=SK \\U@6T*#QEE84#IRF9,+$[K6JU
M85 /YA#>5_*)5I706B7P\'4LX6 +YSRND<:G-\Y=RJ7R#YE#6RQ6R8[)Y]%T
MBDB:LG1^Z3$7_59E%.Z YBYA!$B.O5:9%1H_'#>1@^H62A9)03DYZBK0WW!8
M_4'MO$GYK3GEM^\T*L7$#J[RHOUB2^]BBG0"NWSWGOISK_KGOOK311MTD63Y
M3@E'4..^*L O(F=33URY^3/Z<ZNLKA%>G,0[1)^-+.SLFM%5A Z@R!,U(%*=
MB4*KP31XP"(U-3H*TF.7[E0O1F>9#0HKI;%D]1K!<9.W4$]W)F.("8Q$,-NC
M]<U7V!W@:B+G"%;S@#(C!@ZNZH'?^ NM)]6 NN@6.HTLJFY*WB9/NC5QL=7F
M='%7JB&+S#J@;&K(-C5DJS:[TZ";@=U(;@U9H$JC.H,M5CQ'FJPH=#(S:1%I
M5:M5RY;95O"T1\$4W1BPC*_6HB2KZK05V#)8BM6\#V4GX=#[3H.3*F*/*S=/
MXM99]9L"( ,Z^:ECK*.Q5,I?6D&/NFP29#0-*7P@X@:1[GNGXWJO"NO%-1M)
M9M''P?0WW(BF*%X?&V6[VL];QP#;EDPFAZ$.*BB1&CXR;5S&[FD=MV%D%:US
M&N^HG?7416>'NJU0UU;7;917J>'60/QAZT^MA^&<5'FH>Z;DFCO8=U'6G,9L
M-4A#ZT?T2@V7,=F6P7=1X(SQXNRNSF>@>[&UN^V)DGY:,-@6U&0J@[#L4*CX
M8IO\&G.%#%7=RPX&P(I(M]H1P2R,L;EB6O94A)E$3RFB=M0SE5*VCA1,1FMH
MU)H?;'M<WBC<T0UMS;7]94JVKM;=[3N-H[)WGM)NK>\\[B&_V.R\\IX;=D%G
M UP'3L.F*OL5 ;FM[]9:O%S+<HW*#-D^7=RV.D]C9UO47UG)CFYE7P)LDL2L
MW];<=M##.W ;G%./)K8EMVL00A"&;DQDZWFL>%&B"*W&=>YM<\:KL#::Z8QR
MCRKA$_YG@-7>X:C@O\*9JF+H>?*;^2>6=,)_DO%8IBK7"TJ"(27P7W9/3:*8
M9L;,BF</@;/-#"T,J?CG>(Y*4D39G9FU;B@6MS$72VF*BPAD^0DZ..^ZN#&:
MIX-'? X""9*?-:1VRHM45]85U]1)>)=BZ<T_ZZ+4NPUJ,-,<+;Q+.)G 2033
M$L,QQD=;E_X5R->N'LD/',]ASXB'JFWKCMOVCP2I@J_@YF3PS*-ZZAN="W95
MM54&6ZWU45^B\>:OEU61=0>%0E8PLV+DF]]CJ^E1%&;3I7;1V%UMOX^EB9TW
MZ8YGLV=SA@B"59FD8M;Z&=<R<M4GD5RX*/RV[:X.N15IW$25UAU5<CR32T)%
M<<S3>(RV@:!";?L1["_<8BF(:MWUU3Z(J4.7=2+#P S6 W GP?(0A^54H+[M
M<H MFT 'OKLB+AKT3LDFJ)YWV%1N7H"%$QF78E2K#*1<"1/!7GECNK/"]DHX
M6V*<;+X,(VFUG\SS6@K7<]1&;K>TBMQ>HPA[UA-=-!/VFR][[2"[2P<VA<LS
M]N5:IBGR>X/(CHK<"Q+)>0S=<DDE[\MI5[:T.NM=](E<SY#?,^6M"3JN\,\A
M[*:=T"JIUWZ@)?08X+A?Z)MU31>EWO7L]#R2[4.0&B,:NH2#,DBZ=&/LYG&@
M+M#:OPC$(O/&:3+C"D_JJ316_7.SW$..'MPL] <EQ<C!HDK)IM??TFWR- :#
M,]K8*A>K6A6R-M//L/"QM8(8RS=;_33D"4HT(6\7&2P/7_0UN-<@7;7</7K)
M37ZV&>O-#)'L"IL/NSB'KJ<QU73_342%;'=Q5P#L]?HZJHKJ)0#>#<Z,.4:5
M+T!DV]CH4_-M"Q^9QHB^BUY\^(T:I'G'.[O][LFMXUFR>!P&DDKDT671=:YK
M3"#[]B,3(GJ!X[',1>HDWLLN_B4?$'$A^EU4F-AB_ING<L=72)F>5_XK-5TC
M>E5VG)Z=IP8+!V*/$X-/\$V@NE*"C!1],(@>QDL4/I/H;7RA>L7?IMQ<"Z,8
M*66"X%\J,L(CGL$/DZ"GF")"XM=%4#U1:9B>O? 3A+4IY@^N=^;?\T<AT6[$
M*@I.6Q6+W#Q34;8I%]V4BZY2BXZG49^&* @VY 7LVI@IL/\G3FYW/B:W#E?,
M91GR[V)G"*U\4$D@)4PV#><]3T56%?F*^JOBYJ,>\LP7Y45ES)7V@S=)18SZ
M; NC372\R!!HB&IE&R.U62'BG+62K7*V^0&&"8:.'YP@H!FGF^"SZ/Y-6HT.
M13RFS!X@+1&-C8@D!%$1DYXN$$3(K#)+:XG>C5&H8^X(5!TQBT52Y)5I:A*5
MLI(*!C87"RY,7!!K4!AHMD-U<24$#H/Q]+/A;%=@F2ZQ]=R$B>:S4-W6,QW-
M%GJ Y<J(%)&35ERE_B!X@/R&A0$QTV*J!<A!D"K$4DD1!=BYW="@F>XD.'Q>
M&KJ^05!ZUCK@4"OKT/?.DQR'9JB%8(@PW\3B49MXO?C$^B/236]WE_-DAXY#
M,V[:8\OOK;,0^(;R9ZT9-MB*ZQVL#%H;:UVE4DVP#IBY:&Y-#$_C=$3.R1>&
MI6O#J2TE1RO!$H,18%TJ,#X7SG2XF@_7RDKQF;P@W<J)5,RMFL1JF5>M,@.N
MBI@3?X/^PX3-T1BSWN=AL>(/56B<OZ(A=C$@Y396YG)X?#W$UF!/W&KH "G"
MN[B<;@,Q+C^W#G9BO\<G/D\"]\&>+^FTN[B$3F,2%"JQQ71LL#[;:T$HUQD*
MU"5E05I,7+3 @84DM4H\5%L,#)'),?&=IHK/M2SXL-O$JIH/KID3*9Y[%#)[
M49*X)GB72(K 8A<,;.*E>2JQ@R$'U'$*J3$M'\?!/)O I!TK7-VQ=JPI:XMT
MC@D_N(,9/!ZWYKJ]!_'ISM5IJNFMDE0/5\PYF(OI12ILQ8<\X*[UXAB;B:I:
M<V1/5XU*$8_9R-E*13Y4E*B"J#&32(RK%8RA17Z.KR/&8Q&F>.)'CR=C"!<V
M!%YD(5V)(]>A5=T"Q?R:'^SYL+ F4FPMSU:560ODZX;XT''2BQP/[YX(X(B6
M*/)U/-$7$5+79K4H*]$EHR?;R3RHTU":*FP\>XIJ">--7\,*2/+)D\S)T)^/
M$\+=JK[-.1RVB9:X&RUQ&KUC;31LH!!&,LLQT32\:=/=>-AQY47_90<5Z9'3
M7 2KUO="+%IU*.]:81=U:->%SFD$CFV]GZS2UZL_U=G4W>6GBX;!UJIVZQ=T
M44B=AMN<A-F\R&5[LOGP]M]=;"AZY#1(X.3S'VNHQ/W2O^K#1L0V7C,%[_NC
MP.-H%^M)CYS.VIT@8C9M;S.N,QGV_ZY!U"(YP:"4I%R12M77VJZ/O>,9W, 7
M710^IQ,T0Y%&BR;#>RW3E@N;>]C65NAG<:AA9[38J7S@C00%N@Q>0W78KC:N
MQF_YW&\UKB[FZAM=5]#1FL8CIU- +#!U/VYMTF)JI$IYJ7WT,(E9+2U=E1*G
MLTS#\9@/*=X);,:G\3.Y2Y$4LVZ27AR],M4YP[/C-=A9TX=4]0J5"$*#':(2
M83%A)!#%YF:+2&ZUJJ(Y90)I*JBU8;7''K?$FB'&,/8[FD8^<CIX.OQG@;-O
M4(PMQSFH9^F5I!:3QSM8IY?X7[T+Q8Q@H59=E-21VE&S!-O(J1I>'>.X,.P.
M$2)4 S1.5_Y4!D6$%8>F#VE ^<42O%K5J&^I*2<XQ7% ]O<\Z>./$]47.$E-
MO\A+AJA:.-\[AQ?JWU,'Y\5WC,=O',_?N.7F0Q^?X3I/82'D#XP@:!P!30#^
MYGV89D@A-2XR5=DR2':N$&3V%*/#>VS);>[&Y(=S3M N/WDD\ULL?[&?K<NY
M[WM*CY#/B"?T<9=LP2;:@6=NXP]F8H%09X$3Q/3I*5))X>VX(!==)TR@PW\[
MJ"U?.IV*&'Y9ISV'PS)A,3+J'CN3LQ'70>@UQS1^'N9%[B:^=$G\>LL.B=YG
M&_HH)Q.]+YW.R0R_^5&14>=31 ##X7 -S@IBC$CU?IXS^[F"4FBV Q=W'A]]
M"_":(](H$L[VX''ES<&33>'DIG"RW/%.)[B&WZ1?D%OT&8GTVRN*T;$IW.W*
M0^N1U1U,0SGVEIY+ILS%K8\O4+J5^ 87X ]203R3CZJ:<@F^!6(D]7NI/@NR
M1)%AU1_9+CRK$>"0?H/*%BGG1$J$*\I^ORVK$!F%&IOR2$2P3A(ND8,-$P:%
MB-AMY6=R1R"I9OJ]*5%7,XWNSS3,?L=1FT'B6Y;%[!JT.1,YZ(2L#X<E5GLW
MIBL*Q9#41M05B-K5KJ\MN%L!%]S+P)3UF60G[1$O3KP(3A(RY8+$S L*J9@S
MIEC#2'C0A*I\,;6?SI$X!8&Y-@:^^DV6IX4JVO<4>#8*OZIN2?!U$97M3&44
MSG0[#O4:UICUB_;J[#A+KPJK'45<*3F/0.8#77?)4E**1V*N_S[I2"K#A?LO
M#:&+9Q*G\\9#%$@4(L.MMX86B1;8WD2*//@_U+(KC&'=1T[2;9@Y(5WH'8\1
M68W[C^6^4FT\3\,2>[Y\(#<(<IP$'9[(K ,X_ZT4)"B(5..S,:G21$1C=,Q>
M_Z"_WZN4H3.51G7XI,)0Q9O7R+32X;6QV!7]:0S.VD31*\IO]NA7-=1L?F[M
M@6&FZ^&[N).=!A"8G:QC1IN-7((=U91T<Q]71G_O-B[I(A^WBZVG_E2;V&T@
MQK>Y# CT<IR.PKRE)MG?#] [Z"1$[Z7;F FSM@IYN5G7AZZKTRB']R?KR--7
ML6_ODR2@@]-)6DR\8]7R-C4<;*#27;2[9>1>,,;@40'\YY5!I\L%WY_\AYC-
MWPY:Y5A8*8P2^9TB$LH>2R3G4;,9UKZZ*(C'U!LOTXG/+LJ?TT 08EQI6? V
M)9W.QOU?.9UGYZAP&:%]\BK.HTYZ6:^<3M\R;J=LE^8A9F<M8.,ZJQ2BC3O!
MS,5D#46<IPL<L_JGC8P>TR1:5+[$KH5!"?B?=&;@8I&,)TB@BPV'A&_2(,N$
M6Y3$L,,G-N%E)5QQJ=(NA'R2E)M@QBTURG$21<DM[JI4^C*<,Y=XF8UH)/NX
M@P?,OGF_VN6(*<(:Q,G+ILCP46^J47;I96=;)<7H!TDD(Z86T6T+D-430:B8
M$XS!WPC,-\1O1OD.(N+  %2A*"1SS+<;[F5,CV'7-(HKQ4F\D\J)<?=QU9@R
MA(A-0Y 3D59^H;\N6U@M3U!&_"=1J)(X20%B,46P BT;I\"0%1J>-K,9HCWD
M7F W'F9_2_\6IBWQ388)4W?8=]ACH@8E"/AZQ;R+5"&OG$YSO[\>K*OT3WOZ
MUZD(N-NNIOA)W8>*=_[(^6K?U *\OQZV3KDV+J)H)P^1#==PQK,N\J=,330G
MHL2>Q=9+B-)D[.)R1\B\RXWUON/5[&N1_Q?,"JKJNW_F+:1(096+-$4%B@J0
M<+LVYQ18A7^"]N0<NYS-HV3!??LL\]A@%WMHKAD/SN<??N(.:%E$&X/=P6?7
M#)K1MWQQ+".;Y$D179DJB(QM(Z&!8]@D,-S(8OOOJ5),I.G'EH<XK1;UU[9E
M)$M(J0<"FG5QBSF=TH-)70_YTUCI;RZ24QX1/.P2?9)9$>4ANP:CA:N@Q;A
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M(A(,S>CJ ?F5VZ E)1*JF\@:6E>5I^;RYEX!ZXRQ'Q?M"*'O, .!=@$&VN/
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M^M]X)(;[6\_V$9N*VZKZ\3R5.X;WQ?H&!0-+D<UWR-)L7ZL)!,$/#=)B@I6
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MAZ-8-.88G&0ELF$-3=R#W0P$.LV,M:I;C#.X@TT*8NW!$+>SL49 9W,VDJJ
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M2A(.^PT4Q'0#;-X FQNJUY4DPUX )9S"%!M=IV44%3;C]W59CM[.!/&O9_U
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M",[@4]=?\7^3V8,^-4.\FZ.JA-X88HA+X$VM%I+MH1 ;O*C$@<Y7%*#5N<B
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M8PJ99#R,/$NB"Y<S6N0+HR&0H6K$Y2']!/\([M=Q[60HU+Q][9@>4OC/W!F
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MWF#WT ;T@[$J?O65W43DKE2S)-(/AM:HXBOY]105JEQ_X?%<_<6=>A_H=.%
M]]*HZ:$$*6!^#$G.U,/Q0Y2&WB9=+2M'Y[3Z.#WW&#?')/&0UWWI*0;=W)Q4
MFXO.D>&Y\.WS2;F&(Y:O;H$82S&)V0/62\H79<)!+U>% 5I<5L42J&>/,O2!
MCF.=KU6AD' :6WE-&ZZ-4TF+6HEKPXG[R9 >YO/M3!#(*A)VX'D;>!CY+.U.
M:XR0S[,V%DW!07U%31Z9MNF$=S@(!QG>APS_]02V8P24 QFV)]NY^='[=$66
MK%3^$R> Q%'*K)"I-?&=?1"@"#JC7* X]F/@:1,?F:L7KL%2I-?B?]BH\_%9
M!?H+V#&4JV^8BXLN]NZXG3^M'F-_$ O_H<.8V/@^&(P>HSM8RW920Y1?NW69
M"1W>UOVMNFQ8%1C,5NVJNFY5U3C @$ /?3W H+I_U[T'QS#$'MK!%:_1P<)!
M<&N!W#*6 $NL8@+E7O4$._U\&>/93J([L53B?5_3F=NTI?&D:3RY%Y34</X"
MY3V3JI E /\63M$S+&1)P3"Q@/?Z4FP]]';,MFMF(/Z?T,V0B5\\+HUM8%S#
M,V3"-Z0S?MV]$T,]% 7[RR>\Z-H.9-,_W>(_OB=#M#?6]6*6"'U-(K%YC<IV
MPFX/3^[S82:,#QRMP?WJP<,)'719A;W[0@]1CJSMX.YC63?,&7'MY_'&U*O<
M,J^1@96_8Q&QSJ$Z^!9@4;/\-I?$K 0=6C5QLQZO]QZ\!*IL5P(D[ >2=CTX
M#'W))C<D,,0[Y*+C]YB$KN7EZ(N/ RLUUG4FK!$<"(&1(B1Q*J3.@N@*0K:+
M9V3KG**D%..F$HR9'-.,OD2R4?9XWC]1\*('5DO,1E!D4-==="D)FFI;=-!P
M'P2%7;&FDJ&ZM S#'7(9@Y&L\H<RQGLHT-RX0*6#XWJH*.&*DL"A=>6XQ_0D
MLW)MN<'6I0,G'';L^HJ<GO5Y1WX^B3Y=_?'7VXN;#Y_^1=M_@,\>X+/&^3A]
M6IG?F]-#UA<VO<MM[U3Y*OWR!AT<LG2NH;8FZ4S='K@V!BB&3ON(TWVX%UJ^
MO,N6C(=S#E>'GL80K34T8A $+O[W^OUKZ%C\^D+\_\9*:->62MQG7/JHOC#)
MQ]6<*D7S>H80&X'49:I;/S<I*@@EE!#DFV8SI,7(%HP%&"%B7CQ\E-XELREL
ME<Q$,*;#?BO$"P&1(-DE(F9+(LO98L+V-;=8%<FBG*;%5@-S&I^X\Q3FX@H$
M%=B7E1C&JBJPFO-B5>\5+;F,-.N;9(&CJ)!8UD]I*6P,"I/<%LD\KC5SE#7!
M979+L1LU.S%3[06K_0_N/(5$@_N^(1NEYT@PQ:/R/Z'L%?@8@*NIH(7+9\;>
M/\(1HA2ZR]S&7*>P9A1D@PARNEJE5O#87AZ;BY+J7JDL&'<&ZXK=W5D?M6M!
MW4:LHM"S%';30DIH3C=]THK@]IQ$;V ;A(.&D"W?+8+'9,5WND2O(G7=\2!9
ML"*HMBDQ. =.*)4(@_=7B#/V3(?ZQ*I"#Z#::'U=14$EG2/0&".,02)R""X9
MMT87)?L<7"(9HCL=1Z\I"T*%MN_T7.E8>BG-?.:K;H0 IWJ$3*=Y9C4Z2,I:
M8UKA5BU6"GPV3^A\2_DO0[R^>PSD*;.OL%G^0',[: MS38Y285 LL.*+?G6%
MEP?"*Z^!U=$0AEX"-^:JY!\C$20>#T2FR#,*1VZ]!&S0?4USPM?1;YO$WZ.(
MLY%P>\ J2.4BQG:?07E L#B-J2?XM% +NCWT8WK(3UGX58DFM,\-W)8GD.3M
M@/Z)6)_4VEF2AK-)/JG6A ;5-PF0>SDV$DXIYZN*TYC9B9LV:OHI-1!V)V,L
M2*H6P$.-.'Z=7".:,;I":!24A/2'FR8I63W1T-:6DF_:KQ#1!PWMX+IS0]&"
MUG0BIS5/TY5*_O4W$L07CH\CL;A?U*M92,D%]4K3W5Y\\,\'ZI_W@-F[M.\>
M'@]]I'JI+^T2<Z6-GL[1"PXFST$MO[X$*KP> G#1SA-9BDE(M"!Y(@3E03,Y
M*9A:7%F^)AYYDI;C(AM16:0TQ*'']LN3TUBFB$9%ED[YJTMI:%\M;F=9>1<;
M1.6+<;:$H@)*3A5)QN6F8'RI7AJ6[->] G84IX&@B&7^0@D>KH6"3/]7)9X+
MI8K@B''Y*U.3&@0^?!7C_G#5_L7I"JSLWG''<R!\!BNXFD"PO@SJR+M1Z.Q2
M31X&%L9IL3!/'WCDV53,"Y@T\7BXQCF?(A69^2WZDCY(/([B0A*6#.7:R^@H
M/;D]B6'7Q!^ $C^9IE"ZFJ'2+KDCK-I\,60L8^&??09?J"HCQ' *#_4*\L!B
M4*FPN6XIYX^/@X$+_2J>/Q:B7TQ@)ANGRG]Z7K@4VX?ERO@,9**;)>,OR"L_
MA548[UOBGZY +\TPM#'#)W!X' >UZJTA.A%K_06;SS84V]+A%Z.Q"R3_H;*O
M%M)0)77S"CI!SZ2CBV]V&0\-EQH\$FC!Q X,Q)/@4CT#39:!%L%[E(_$[) Z
M5PI(Z'PQ D)*#%<HF:5%B7CCL^OWK]6?8J/.3/$-BEMK2K4E52^S9Z0"P!)A
M[U$KAV8-WWF2'3=KP(;P4QUMY1I][XF!TD@\O5C%:#1ADO@5A8\DQ]+_9?=N
MJ*"O)%DP;@+%(1-M!CD]P2857E+QD5".3'>1S<&6P9F8"ALJ@9%U@/E:*^PV
M T_'4::IX8/:4L^7UN'&4(@*&M^ED\JH2Y$.LV*J!"-MC$PD'#*T?^1*%F>!
M-K?5\=[;UC".S2,^UHN(L"%J"P_XDFEIRTXRZZ/_5G ='J,@5E)6)K6$EA:_
MIH4=D)%W@)</1SGC3H5H..5Q"#0,,M#0!])8Q^]Z*/[C:S5$2ZRCVC^<H>L6
M$6"U1(T%OT/6;X/NB',\\#.H!**,)-()$77W8NRV$@J*MM^BH^SX%0EJM94R
MERC#M;G"_Y/><<+VBFC@B%*XF"R%I-"Q:5X=:$9_&)QDE_?&H)NL11S83,FR
M8V)60N+'2$C>C/CE?6>P*1?_2I7V0^K?[!H8 XY:5_C#@.  FZ5P>;&$<XWY
M1>LV$!T"QA#P@V,R-^^A(2=D(">-8Y+!*R)G4]$KS<I R750]&@H,D&Y?#2+
M![B_U5(87OJWTD6()8PG=A+\9L<R*:4LBC<20E1K@PFA@KA"-NA?)E^VAY&0
M7@@]2L4@IP[N=)ID7>0\>=O'^ YQ<(:H--F415^>>DSXJA6 *QW.<4C-M$EV
MK2.]\8 2$MH)(W"^AZ>VAUS2)_11\-0RX*>#P^I :VZ+9$'8(KEA3!1)B!,&
M6@WQ2(MUL24J3L6<B?)VG5HYT#F<;*@O<2S#^@GWCH#."H#RFZ13A+*(\WUV
M&EV>O#GY="(><_I2>(KGI\]/SD%$'S'CL!#& . "\!9ZX/!I E7;58G\D-"=
MXG8A3JW5%0U6_*\%]K[ZO *?^CB.)*@OT2[K.%_"9<(WQ!K!A]TT*O17E7Y)
M5 FL\-$34ZLBX=2[2_M[NA<5?GV>3+!S.W:3@J$6QIMNTT5:)"M->2I+DUB5
M7<H0_N>5>".54PF[B8.89?F_%@EP#,EH_I( H6430*H\E@F5"44^%.4J]'G(
M"_5N%XO4$HID+(^GQ/+81$:536DQ.Q:LH90TX&DU,R.A"C9G0>8BA[S4OQ[-
MI&AVHW0Q6+!85""%0(D%IP'%;R^,)ADN6%*V%Z*^1RBH94]U0Y!S";=M[3!U
MMUNOJD&,UJF"ND\3O5A+%9[OG6XX>UH%26&2WJ=7EG1V*$O:L]T:['[9 ,[]
MV)Q=!@A^[T=+$:31I[<?K?@_<,YQCZ[&KMAQE*KF8UK5*/B]),SP/3ZF-A8(
M+,=NMH8RPO,"5M](_.0^KM5=[ 0A7=.OP^TMIOD3NBJ/*NOOV*Q)[:X <:-!
M75/5E-P]P\^D"GBY!S1/>)>O3RX5W%O\OHW53;%1U-1P[/:FL"E\Q,+E381$
MKM<W-10?M2T/ZK5&R>Q1J%$9^)U-"XX:3STM O1B?(0BB4.=DUOG=#; .J>P
M57Q2:V\9( ,YRE1I0&RU35%% >DCE@3LHAE>46I!%@6D9DF J@=H40RPFW;B
M%$=&]0!6,8"[CG*M=GSG\(VNT7$M;D )4K$8.19OX$'Q22,2\%.D4_UX!WUH
M3Z//!/.$"-"#T;26F<T"!I<EP=1=8#I&*@ZEX*2^LL3!6 B!+9M8K'+ATL:*
MEQ$^!<R%I%J,Y15(*=U$=(LS2Z(U!;)1,V2+9;5B\^)K)M;5R+O$9'=F6H2G
MWT H0 R>- K-QYHL!#^,;'.JR>J3R01ZT$@IRP!@@H ;;_6)+M*(1FC]6H^)
MI"BN0-AL *VI#.!DE']%/% J%KU:()NY-JFYD:_;Q5=9/VYEN#5[-HUXJQHK
M%$V#"?81.3I!N6#E'PSU/BDF+C)@E!J-\WRTA;[<A ;SAZS/=ET)BC2;CRH
M0ZO%Y\@8TCF3EC O ^6L5+[&0+=YF/YU;<$94.)[KR;SNB<,4@B5*3@1-W1R
MS&N!UXQP3'3+2G7-X%/CEDE,.W% RH(K,@A7_%W[/$YR\1.XWO*R&'<%IJ$O
M;,/EA+/I+/Z6HF']43PYH"OV!%UQ0+EUBB8!"&L/<:[F\CD3$GFR>V&78W</
MLO@, &O3!XV[-1RNG0O'T+9NJAP+U"EM&$=@I(SI4TM0$6K1?'H2_25TL8ZP
MN#$$">FK=UO]C5J=6,EJ6!P[QJ.!O IKA&[P3+EG!*KV+D5IK2IASEN^3C8Z
M@8QM)DO?(.&5B5N([Y%>CR3N76&SN@4ASX4U?%L).8TQ2+AP&\QS6HEUVW:2
M9@0#?@AK+!'@,(X6T$AMZ9GQ$XI5X+$,EP.>/7HIX.Z9J>]="UB[DCU4!/8@
M'].3#AH+;%&EV,]43G:>RR-73KIED\1XVP[ON9?9O5ZH5?:@Q#)@Z0QIB$K'
M.QV#6;+ICL.3K^C!:B1_0EF&+0N/['B>76<C@X^A""*T!$3@9!G-,<IBC\U)
M,U#4"Z$W63&NYC#@<>J)_[9H8+AYO:F[KF;=J?.WK>M/W7=T6X?JJZ%BQBQX
M.<4<SSC8N$EQ%9LS:89#QX[B17!-0F=E7<1[N-6>AY+61RYIK8NX%J6M9/BO
MO7)M*EV= E=^"OT> LAW0A_CQ[9L[*D0=L'WSEZ+WBIA0_>Z5A%;;V%0C^1C
M#I&REJ%4I+!P9.1R7:2=0Y>JS ,3YB1P&2>92"0^3T0\KPXT0#5JQ#]WTY\;
M4R)N(A8[4Z$MTBB;JTPS<ZQT90T7LJF2-)^JBH]+<MA1G8'OI:\M6O^;*T9'
M__6ZBWOI"O10KV&4Y [>!8@,>WN([D#-!=BP@I?%'C DK;?DV];[ZK<X-;\<
MQW1%#(_U/BE9)3,.QI+P'RAT>R4S7HHEMOG28?UP[^7#C0!$#YK.RM'V4EW:
M8&)_YQK3\%KU56DZ7'/[X%-L[E.X60^N$'8M?+O4=Z<B87V!]U"%[UV9\)7"
MH)O(<XW<.#]Y$;NUQ-'&A;O"I!XI/EN'W[9-36\8J%B+EOW(!;UGCU/0.V@[
ML58B[(@BLU)XB#:D!&V'PB2J8#@4$SC4#0^D;K@">(#"A/&,+R:3C-O9FK@Y
M84\_NUY$GR2^4LC&E"-RQA.5F".!>Z$D5;QIG7)88+:M5JX!C6.?I([K5<UR
M7</%(-N9N$810*@BY\A?UNNOD6Z(_[0JE2:-YE5?&-!L]%(" 0[>/1DX,I5:
M>0#U[0FHKV>0FZY6D@42_AA*@NEX<>Q*D+XHA63I.I4EQ3)9(-21SA98JM0#
MZO6JBQ=_.[H]/CKWJ8R:MFA4$1CA3EB&QB1BC="'H3RM /V1)1&$"$CAOP#-
M_QD=#KA_Z7'LU[A\D0D4;&&Z7$Q3-(:&[0!+6)' IF>ASD&H0PZ8!0@80 RU
M7+$L8T",#-$8<A&^4JF42;.5NXW(,"K;F 3[TIK!-'I3I.+'"1PFZT^@2*Z^
M@4)P_B"6YDU>I "*UXDET.WK<& *2&<L]"2:5H4,\\@Z.7/IDB(U8^):%&MT
MO+-%$%>3.MG(A,@@O4DIL0L=161$IV L7%1RR=BGV)=!VIROPCVOJOBLM,V7
MJG3JSFIX^7.G(@^>/!)&SS3S:?RON=@)J'+LIQMSSV[2^=/BM@BUH']ZS!;G
MPV5*.#!;>'?KT(QV^,UHN3:*$@#!OBV^[BP!R?0H]>>;]H)-PJ/=$]*$P/@;
M*!,.'6$?N2-L8(L.; DN1.E\@&P)(3NKS\ZPH3O=;W?8YNQ_:$S#;13[_?30
MTVL6>WYH%OLC-(L-";N6#6.S/6X8&YJZ0Q"3/5+7V/!P;*X87VZ]@]ZQ8:VW
MAX+IT%O5&?VAM^JC]%8]W\?>JB$[KYO^JN>'_JJ'_JI/N[_J^:&_ZJ&_ZD#[
MJW;;&[#68#6D6\J[O)I-K"*Z$AR9"61=)T:XS^"7.Y2Q_EB0\T-GUK6=60]0
ML ,4C'BX#@UZMV[0&TS&[*$9N9^]7&D'AFCY;=7/E5+#0VWKVGM99C#_O*[H
M<KN:R\#KOGO%Y9JPR:&SY\"$YQZ7['E;P%@U>YUVUMPF)_3C%N.='[IK'KIK
M'JKDNNRN&1(P7738]"(W FT@?>5B#=;-^EJQ3=MJ;BYI?]#6FN=[V%I3AO3W
MH'3@XUTB!,%8&)"WV2Q!;;-SS<"-;K)!YVF<YTL4&R[_#;/'0:<)PBX,4><(
M?V""IQQL7DI@F?)3 _&L"JX+8<:/\HD0B7 ;)[)>K+G"RRVU<X"JQL43^D2"
MY/ S2A,NHJ6[GP2WD6*9QD_.N*3*0><2'/(%6O9XEQU(#D=B"7D'%5GS=$45
M1'*?RSOXR2*]%2XO;+1X^&TNG%=AY&$^&H"!U)P&I*DLEGH-"D=8LQ2QTJ55
M1[TEA3^_OKKH*@5\;+7T(U.!\J*U32A<\)K!;BASP#)IS&<,E7$JUT9H2N$O
MBOTI::N(0D[CIX_(@02:=K;7(98F[6X-]T5+*$-E>>R":6$'F5YQ)J[HS#Q?
M-KK6@JG:+$,;G_ONI?OI69_B_9>3Z-W%^[_>7%S>_/7IBL3+7NBE7SJMC=H#
MW79SZCV-<*I]7<N?6K7<+\/M*ZQ-8P*X[V.7X:XW2A;*[3+QS]7HWT;K+03H
M2F<84S2?+I4K,$Q3K*0@=KT[+LS)]*C *<<N?<:'D^,H(!.FY*Q)[TI\2P$6
M/I*/&C+/K*\*9>^0OK88$K4)]H_+\U+E9DGX%OI[PJ#>MP :'>NSQSC6KY_H
ML0ZI.O>\-[3'E)&93=\0OBYN:\W#C=GLQIQW<&,^Z!3>^OT?XI79XDC&=M7B
M=[MP%G \5&K8=,2;[EPH-KC-.3_T)JS-M]N[?+8/UC>F,I^BR7W6D<EMPQ'=
M2CS*TG)!K&?EK9J\H,[3W7A#):H8J*%<2<#"/32-_8% A5U?A2[,= = E:"N
ME>=3W0,# +7N.K0P73=5H1:@PE*FU.0$+EDUN4T-2@??N_=2W!T,RYT-RSZE
M?%MGSDMQ\5B69J,NVE.,V"_]U V[QX!H5[HPM4R; RN,=)X/4!XIH%LDI<5
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MY.)D%<69HJ]ZZ?F+"J!..3@"E^D*IX9!)Y0;G,3B_-N;:8'C NN,TI"\NS7
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MVB)H35%>Q4%M5R48,*%"DDO4160L4WMAKDW 3@2-DNC>ML:J"TUH9T=:\</
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M(\),"D'!03B'%"<ID[(J;08]2K=$B#U7V&J',V^[*3!?[)-]?'("1O-G\#+
MJ >' -PG3>>P#7/8(IJ!48I64)875\GRR76T?M%1\V5[$=FRHU^04<>YD8+,
MD\2ME/\[*.AG[[.; =OG?53$5(!B6?F3K,I-=L2K%+&0EVZHTS?5%1+/BJ(U
M8. ^8WW(%+P5TM 8HH7GG40WA>2<^;LXLL1:_X?)X(]">[5#L6PUBJ5CW=9%
MNVW?FP*+ QT3C1^AS ="&QI*TXSSUT?=9JH%'2@*H@(D^WHLN20$!>G>B:C0
M+0:N87J%*DN!XU$//O_YYQ=A</@R^+Q_OG^\'_S[OQV\^N5U</#S(1B.>\\'
MS_ _AX,- P2/SX9'%T,<4W? 0/""4P7S)\6K*(+;"E QG]8$I98V@:33$56<
M2MIO=5+1*AK6*"&\6_.8&7T5Y:K_-GF/\JFMJB1#OGK'(=@EDPUCV'=),CDB
M)"$.[C!;^#*FMPG'@&$!7#U"V$HFT0Z3)#,*K22Y230::+B"A6-)O/8J%(C5
M!W_7 S!.\I0Y94'[,NDS3M4GE*78@A6]\18=@QKI96&ZUCD-@>';2RPK4  F
MUX-M=%Y5OL\IHL!B+'6&_IDEU"16'53U(1%?!%$1)RB;&^[B;Y_IND6L%A]O
MTK@K#\.IYL $.9TV,+9S#>4AC+H$*,&P0&)@<:U1-.?S/EY&RA=@6FVEL"@^
M9"Q<P[&=I.(T*/ ' R0FJ$$2!.Q(>1E" :5.8Z_ @"1"M.!?\F$L88_D%T:]
MUCL8J*BHE':+^>\8]3YCT,.V)NC#.JQHY7"GA; U&:T%*29D!^C'FJCAW'U1
M(NX8T5A'6END4$%;,79]15%UPET\_%7M&V+>15?,E1/#7[E)VZ;N#Y]6MO13
MGB%E+C/9@_1\<),_<@B>8,3*D)AVV-QG](F"U6CM;DE[Z,[7= .KBJT",M4W
M^=&+2IA':Y]4%*V/U@QA1S56U<TCVW0WX%??7&5DQ*?Z@L#OF,C!?C#T4L@1
M. YHZ)/S:8I4W>=J.A]OR:PV,7(O#&<S><*;2-4-,_< 96PSZ66$F=.B&JM\
M#.5E\V"1Y;%"<WL#"%O=U%B_D:#D+EK<]LDTZINRS/O!$<S>F8\_9Q/2L!$,
MB'C$ZQ-1#W$*CFV"2%Q0O=31X-DB^D*!G:J\HC]Q$DIJG6G3DXA^K[UC-YI+
ME[O>(PO=[X[-)G>U!HH%)]<8*=:CI'4#94\?1W !XRBI!#,O9W!!9$AY#B:$
MSK1QAW0<KQ )[=O\!?Y(')N#6XPT;#CV::_H_1ZL69-]C'&HUXGP$N&+82C.
M_BQB:A5"B7C-FD%;ZH^)_6TSJ#U!I+J?,]1?]A1,)RT^0?E 5Q'@DL '9XBK
MP-I5KPL'5MPPKH&(Y%6\PR*)(FH!B8))74QT$V*"E0ML2DP-2*@CE1%3?(+1
MZ'9WE8.']D']48+S?0T4'UJAX@ZOOP\B_!N[^_!T!5$OV<G3&!$'&!9''H@H
MQ]*_BJ^L:67UDM*'@W?A4%4@J(L%3R.=+ H-(@3K.)J#FHGRX+\KT$-QKKNX
MT<5Q@_I3(HAP</%]BW@Q)HVX8A%!G.'9!=<U68Z=Y7C!Q3B'UZ61HN=&_1A'
MW,FGQ&HB4#-QSO%'Q'%EYA<F!EB RSJ/N,%@E4K!=D&%;<OMQ"O0MFW6(L?<
M@RFY3>+N3E0?CXXGGPHPF*3+"H.[EU%NH?H498\?@*ZA;/K?MBD:!-2#)KY$
M]8 I;NT#4]I-?."(4]Y>2J-TR=9T=DI%^@TSF/H3<Q7U?5'&4FC-VD.Q1$:%
M;8A)=L J;=<\8%>Q7ZZN2M.LX[6=.N=%]SKGC?((/I#AV(&6>7#GJU^_W>IZ
MME_C8K_L8K%7V)@__5^$SS]RP;VWX/H/$S_#5\MW=W$%K%S"Q]X(M6G9K6@]
MBX;\::DSF%XSE*BQ)MORLM<"QM$J:F<=?#:^?=;ZQV <%4E1*Y/0E$$K2"WK
MG,9FU_94F2I-1;MS YMTC%J).=6M]>4B1H>YYDC6W&ZU:1C"P5D"-BG</%?!
MWL%+)3M=;.ZO^R]Y=Z^Z?*J(#-(SI$2*2"0<? >\I1R) >D&YU* LGIK@OIU
M*VR;.^^VG][M!GS;!EOK2<;-GV\B;BY-,/9I1?ODFEC4M\R628PM7.#51U?*
MB2X\#]%N'L?E31RG;B"SH=</E;!E\YK]7&9$E5+KF]2(Q6IZ )4'2DM?\/^1
M_$7Y,L?<70Q65WD^L>/WT/?68[F"/;[=*6XB'_LORABX<>O1IP'%Z&MS2:.%
MYQ3L8+5;#:M]S!GR6K%ST%UHHW7?00WIM]F%;5.+K$A*!K&+?ZLI)]8DNE'D
M!6A'<N_#;&95GB:%-9;K)&)2ISQ+DPD63<X#96Z*%QV75QF18W-^ QG*=,30
MT0N3;"F,X)3YBE)*6BV);QH^KA!^5.*032H.^1-;,L),**>2566!X1O%C:&Q
M&:J.8%60PYYXR#F/I@&9=\.(XJG)4^G<DA0/,'EM"X&*?@]I+K-<]LSFJ@G%
M'7:N_E D<3-:CS"0.*"$TB>8>V+4*3R>5Y8?H=[/;3*^" 9;<XU-JYAA/P+
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MHDXGT07@TBPB-7BDMH2)=AW#7)?-64V.@R&A50*&ZYI+/]+];_4BQS^"#MH
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M:#@P(>$DY>-2D3#EEA7U#3W,FJH%V9E5N4J6F>YE,!V,"AA3R"?LL,@ZFAO
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M=T.P2K:/86@@N7,PXL$3IG"!15*FNTQC7/!V52991S/2+$"I%8OR7B<^= +
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M5Z@ PKQ?%@_>0@6-]9Z%OB/D)NFW^/*3R2.-/GP4?K,LO"3X5A*+,%]=M\9
MQ]PBT3+BLNFX$ 1[^G,UQ<RG4> ADX XH 67D>2[4U37-/"8RC51MUX1XH%K
M'XC28:D)$G!P'TNGSC>EARP%6!Y,:9M'&1HS[E'8 #4[C%]R!@I G\+O9DD:
M*&DE:7763,!^TW.>C*8+PT [RK265&_ON1?Y.*D!418MMD#4U,F4%#:"(UY$
M<G C)-8]<Z*QYX]XOB(LGX_U0<!TW5NNG3S<]#T=1;WP8"SA<5.BVIL7!*K'
M5>N8#[F4&.89%8:IC!L9=I+!78_?2UDM;D*(LF#'7.PT27T]?R\1:Z5[@8I6
M>X,X92EK#-[UP_5^XL&35/GD,R2H:M5W!5&M,+2%KL=?W$8+!Y,[ 6>?IA!M
M4E]M;S0 /=-[+%N0ZVC;BMHUO1LK$)]L70&[H\T4L)-,_WX.%/^Q(1J;+^!B
M@@;SP?28#WO'-66*J-!B%J'XCN@(@P%1J0)IFLB*(:8'&@F^3;)<$P81F:AN
M31J#*3LN;4)MKHIYO,9YL6>K\XJ8^.]!S^MW:FDS9;]*L:U2;!>IM,T5+V&&
M/S)M>5BL7[]DK@BQ>LT-#QZXK(DA+:!:49-.E(5&^U?4;D:/;CJCC2MWL_!H
MHN&!A@/_&AS(0)%XH94:VH',;XN'/_4YU?,143^<C[\/6JFIBTM J1=([OQ(
ME8CZ8O(FV9:5Q!)\^A21)*KX610F2)&4ZBM4(S6M!04R.4VC"$%-!#$3?23>
M)H]'@ J#;@+1>NV!>S?BG@0W4\J-(J/Q590Q8J>QDMQ3]!XP=LB4_3@U?Y)]
M&[$ST>3>F?8DBM_2&':(_DDR^JRY>(*J.5$Z*KXAT&:8&DT7MJ^N^8JH4/?S
M5ZCG(8A:PO9^;5NQB+I4*XEH)36<EJ&!.SRAW1+;,Z'5B!S\*9TFE%#$:J :
M6:B2YN.AB1(X6@&ZA ( WWQJ!7/O &MO8CD4183E"23$PXRE@IGC*8)8$(*V
MT/&GPAGCT /%[H4VCQS_YA1>/L)PF=9@4Q)6X]\W6V:FV6SF9QS'69GR%*3I
M)BUZ@^5AZ+X-@0+N6-0'4Y4BDS8S15*UV5 VMPAHQ$C\)^,GBYNY P-2A)FT
M<,V- I.J)UPXV?"TP3LNCP=T<OV)+/CRE(<O./Q1)L+A51\W_4 7:)O?HUN
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M8SO(.$G7D\[('"NC@LH+-C>WIV(#ESP\@=LHHH*:@ _Q$01@!,:LLCMU5;3
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M1&6[I"5*4Y,JB4=>D23#=<^T"@]3!@@!W]!@);RA"FU1T5=J)LTX%R'B/JB
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MDFO[77 IC-S98V65K3Y]%ZX[?K <K/PW0NQ.IW-5Z:NW7A1#@HG8%5Y-;2!
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M9N.6,0M^KSQ9\"T783IQ51KC%Q&Y]R-L7!X)\MU$_3[:!%R\1Q &J@*:14R
M%Q5&)!0Q(D[7]4 6Y@9QE;)TR"@UP]?U05T-GPJA"FQO--]E%/A&>03^G.JV
M7)I_\M#C>?-VUXFGNTCBF['U%+\B"*6LYY.6:(> 647<C:F#<\PG9FC'R'#L
M-P'&B)\NL2$G=!9)J* 78^PD&[>@M8"#Z 9,.@$*SMS7<K9 Q"*>/#K@YYM&
M7L%05A+0RO 0RP1]XL,</\HZ&S'!GN M\%P[JB=$1!N*BQS!*8&@\+,?8])=
MQJ<WL-E=A-D_F C]'HF2/_!##-O''\CZ&-FFM [ ,-DA:@P$52M: L]R$:4_
M0B":0#'+#Y#2XB>^PW9'/]TPB!'ES#9O<.R6'X3>#6H[^-;$\C@6T/&"NW^'
M)CTXL5UW3.6'E7DF.WKACF4-J,1X(^X3:S*O>16KH:C%-!5[&KKMC<*I3]R&
M9/;Y+IH_ODYB.//@O6C":^5[(ZP2+3R5*A8$$-'*\ ER<J2*>(Q"CR_1#5+R
MR)R8Y'\7-8!BJ5O(VUX!P8L+!*\H^#8+?-_;+X]]T=8*\T0%HM>VH-O$Q1KS
M@DFB6CI_,CG2Y4E?Q#-<+UU$9QVH8D4_%)'*BFT(^O#.FCW-!A^18R7PZ CT
M=L!IAL=K[$\JB8@U0>01#0K*&3W6HP:C-B*^*\E +D(%4SH+',EQ(_F;=&)R
MXGCR))>,I'026.^?,%HZ[=!P4,V8D@A:@(6C6H2R;B@<5G$RRU+5R..O9\],
M0485(>V6&M3&R@MNWATJ40D/O 1'(AN0F+QX?^=*&T3,_LB3\^ *MC.TD+1W
M%Y+L-S:O$\AVZ/_5V3E#HC23- H:/'XMXB-+;@#ILIA(>V2!_*'-22S"MAU_
M62MM8MNZ)D-N<45]2!Q\,8M=&7=&B8H>7&EF.BQ_<S(! PJY%//ET=4JCDL&
MOA%&COSX*"2/IXC;(RZ.%3&<H#/C"9X?HG]0U0I3/HY6*NO6,YU U,DB:\!R
M0OQ)AMUT@CC1[LZ">)LE"<70B[4?9;DO-[R]4_3\I'*DOQ4O9ITU4V5#X\]2
MQ1UON,,GEB@KAGZA&*8V%/SM$_U6WNKBJ*%0#)+H4^.3C!^+>AG/9E08(+8.
M([(?Q88C^'V(%-&4/#0:)XG@?%0DF7.%RK4*:WLIIN-Y]F+):*9LD*=8TZA,
M)JC%U"/4V<0:93!+2N-@A>9C/J@%K0L:WH1KCU<R695E-1%)"494!-1/U#[5
MUGU^RJ+2ML)#2U3YW/2^B0MFUMB=^X"\]+(VDZQ<(BKII6L@>WQJ6HXJZ&EA
M;$15.J=X#KU\:OFRXDC<ZPF<?PX5/L?H(X[7PI,S8UN6[VPK4:6'4VF4BZI<
M7Y%&3>2SB#4^)8&&9?+R\5Z;3Y0!L_PB'FWS=.S*C\':,)(D$TT_&0].J8"H
MX*_8VI:G"@+AR&/%F^+>36ODN *]J6OWF!MX3I<@[YDB A:;'_:R\WR7-(66
MU1'._0SBJMBP1;7K$+E<)#B/V@.@&>@0C2CL!/^W")>F@NX9W/JY:8*%>8Z-
M@TWJAC^&WPS6-RZ;[>Z9T6>]<S;\UAZPJ^:%P;XU!^S4,+JL8YP/6;L[-+K#
M=J_;['1^L--.L_N/?PE9K@J"O%F63+O+OK>'76,P8-^_&7VC=YZJX$7%CI2+
M.U^_*5/S):5:BU GF:IDQI#BH\)?_I8?<=:*K%BKT& MRS6U7$[5;OV@D2,1
MUMK-;;!S^_6#'%/;\NU;[HNZG^^B+M6<GF489??O+\KNCS,.#X[K)X>OE]>7
MW_'3[?W>[ _AP&EW!\/V\'IH#-AYK[_RL?),I]/T _D-X+3=NS3.VJUF!T[1
M@='LM[[58#"M>C2$U]P1L42\V59=56R/RRBV@^O^>;-EL%ZWU>OT+GYD+7D>
M4* 5E-JJ8*#=YS7&"YO>KY\<;*;EXQ>(X?+3\9PDKIP'7IYDZ],?+P4_Y:BR
MEC%]UIHO:8U*8W]O]HM1R(&IJ,5FZ&H^^9\077")YUR7#8SVF=%Y^\DNF"FW
M=9MF/>LRN6F>:ZNDF^:,!S:_9Z>68_E__;3X@S7Z:RU<3GE$J]N\-+9!(^>(
M1:TT[/O3L&MN@]+HV/QF;(MUYK ][%1*<S4NSD[OM-EAWXSF68T-AOWFT+AH
MMUBSTVDWNRUCGHR[4J+;MR^V4(M>>=RWQBK]H67T\L0;9]Z ;8[EI(!W8M4,
M5#.PVAUX#GM:UIUES8][F^]O5CY/^+*>;S#1!HQ%S*5PHN0&Q%N[#NJ]WTT[
MY.S_?0HWF^.TSH+^\9__^9__>H7\BSQD[Y_?VJ?M(<A>HY(](7N7IA-.S%$0
M4D'TENL'@M031/!&2J3X19_?4OTTUE%8]RO/'8>8R">S1E7RY!"KJP>N]YB3
MW*XTPULFR:<5_+,D\,]7%Y&LG?T:^;+K]%FF8>>?[)DQ&6NG?ZJ<<$P@QYJT
M)50?K5?H[E&^(G*.*>]@(_5F9"T9"E0B*K7F+^$G&\WZ?()3>YK)J?V"5,]7
MS<CX(Y-RNOC=SN!CSKG/N5LK2M2+9U0*PV^=P=588Y?EJ$PWM ;9I2V+6-EW
MZ6*/!>GOW'X\:!1Q6IM!L+C^7^'%]PP.%C:P"'QQ:8[-:?Y%J7,^_=N+D8<'
M]4;]2"32FP%5ZT;T60LSW6^DFM)R[F\>*::<)HU(;>0/*8.T>*I6=GQMA2N-
MV9TD.<2R5DD))DJ-*;^9BN < K_Q=W Q$-+T&<^NO2/V 6,BA9^6!?LCMUFJ
MQ<*$6*^;"'?L1W0>DO94PL/1/\.9D_9] L<6Q8Z9&02"P T;#=P:B:=@28C>
M-_/XO>6&":RSZ:B&KT*07C-R'&IL%GI^:,;L;1B3C8 Y"Z:ISEKFC&+W?R&L
MAYX0=&X2HCWF$U@#A;%.8<71<<128 I IPADIRJBMO"M:5R0A/Y0G"-'[(\>
MVS'#P%T>#'2P*A;HI+Z;ZP7SYY/\8".?=U]0L&&5_'N*+I7A0O9WCIAW+X0M
M]>C"?JDMRFE9G&W__+PDYO[YJ=F.F?]C(4(G>P'>[TPL1/K\:R-58%903"MB
M'3[O+:FE5LD36Z*[15G'QY<GPZRIW>/I>I%JSV$-BCO:@DA'UYSR>?FH5N&5
M<]:LP%ZT##EF724[_&[ [GKZ9%E6?#1:02MK,GU4CN$EJMZ[5/6>Y2G>&^Y^
MLCY\$0.BAX>)HO!%[&)4)KTI:J,7L8\BKIQ=*'Q3_<VQQ$'+=2:4N&N9-E4[
M2.GT9SK;J&N9)3+9A'X#/VK]Y].,E(RD?KY#WC/;]?[KM[^9N_@_L,SA%6"B
M@V:*K'25[R*TU7R;F+6R6S_BTRQ?B5%D)#J1Q.7W;P53'"VC/VRVNZS5ZYZW
MSY _"-RGJUX?>80&$=N02@OX;O0-UKML#X?&&6MVS\#1NNHT6_##]_;PFPIJ
M4KZ#C/,A0V*K=WG5,88&^]WH#Z#=N68C'J/S=@?:&AA7380Z='Z(9I$!:6"T
M^L:PV?\A'J9?7/?;PS9XN]@1XY^M;\WNA8$ONVP/Z#57U_W!=;,[9,,>?(<U
MKZXZX!WBR*#?_W-M@+O<O4B.?-@WFL-+^"'Q</^Z8["#W2-VU>]=7G<NFCC\
M:^)C2G>E-<0.[GW>WZ\Q&%43VCHSSEZ#AJJPF81Q<#9*^ZNLN#?:[GOSA?/>
MD1$G(OA?6#U7TZWR3(J]ZHUW+=/Q+9GIL[$$!,CB#5\J.<^#;FY9,IR2;)D!
MOW4YNVZSP>/TQK7%I>OGXX.#KR_:)TL4."W(5C$9\I *4F.J^00#TFIQF;,9
M."$DCDUP0 (O]&4-/=A=>"<;L3=7YT>UKZI]]?R^FN(.NL&B96/^W";+=T^]
M8F;9()Q.,7U'%J\1M=IH/CX@+7]R2N!7.:;*O4:F_UD%%*J 0DLA*E*)427C
MV*\0%47I=H6HJ! 5%:*B./VM$!45HF)51 6\MT)4O'!B*T1%A:AX6T0%U@A3
MQOP+(!45(*("1%2 B H04<R9KP 1%2"B D14@(B-C[8@TE$!(HJP"A4@8MO2
MCBI 1 6(6*>'%2"BF("(BOKY11?-Q8NW57GGQ3E-JKSSR@!\;S+]OO/.G[C^
MV]NM[VN7#12JGYF/&)-7EWNFPUQQJ< 5#RO)17SO,.&<N9,J@[W*M*TR;>.,
M.TQIN(3]A#OG#$7+\]F'_SBL@3&$_^U4VZ7:+M5V65R782-1B==(PS9>(6L\
M[YRFMF,ACI_]?=!B?3[SN ^OH[3FXA<4.'>]R(+)/Q6KX 5(-CBGT@#<NBE]
M#1UQ7D(=,=R+\M<P%.N4KZY$QB%3@60JD$R)]<A%"?5(5$-LCPWA#3Q@PSO+
M&[,K.,$?XX0_']-C]XZ.O^[700QK[!#_V*D.H_R%Z-NKE&G<S7>>6V<'QYLZ
MCS;4Y5**QAM545S+F>E\;&Q<-C)J1FV);&S&@RE>QTHTAZ^C"O;+IPI*-,\E
MZFHL$@=O(Q(Y0ICEK.<!67Z-*6^7V."7V*0EC?Y&_0B-_D;]!/_8KVS_C<C3
MWTLH3RDRBP&WY6WV^V&S@-$M)K/X]$<V\+;P=!$+6"X^_?$DSK[HPTJ"[O\0
M+!B?_B#T?<6&4;%A/+<&%1U&18>QF ZC! +\(CJFPJW"$QQ,Q>OK N*EPG54
MB/:[/F:*OT'?&6%-H[Y?$=:\<&*?):QYRO$HP3R]#5]-E5%0XHR"_ Z[PN^.
MS=,61;9@'*3XUW,41I8S)LI=613:C\(YDH:HHC1:-__Z=2F-]@M$0#!':71<
M$>M\K2B-WM!SJRB-GJ TVKY9( XG."NO^^?-EL%ZW5:OT[OXL6%RIV55] O(
MG9[#1+Z$TN:Y[A9D+0M#[K3R(9?#&A1WM 61CES(G:I56!?$4)$[;1FV_YV3
M._U1L3MMN(<5N]/&V9T*>7<5]>GEC>1'^%0=']7QL9'CXYM[:SJLX]YSV_;9
M]:!LY\?)\:%,)6W><R<LY F"'_YPO9\UUOW!8*<TBIJ& EN>V*^:8W/*OM79
MA6N#1EJ#@6_#73XW1[X%W\9"9O4O[$-CK['#/N^=?-R'6?Y7;AVN"/.J$Z0B
MS*L(\RJ9W@["O,Q;; MKMN/];GQ5+6^F;<NG!)$;,*(P3<2LJ/!RX?;:KQ\U
M<HI0'M2/GV,**XKL(8;HA61?1TN%A\O(J?6/$L*45++AI>F$\)<@]%!O/ U[
M.ZD?5C"W#<A/IX3RHV!N;>?>3</::-=N+#THD3RX6L*0T/+JK!$3M)+2/\RQ
M?LD2](<KI \='.56-B?1RV='7)"3J>5.9Z;SR/ B\X7WW&LO2**U91:D('/7
M[O[>:[>,%US_EE)4Y$U)<SSVN.]7PK+:[)TUA\87=@E/W;$S\['&?G#3VQ;1
M:5D!C%A<N/W_]A5KN>-*V[Q,V["_?6'__.>V",[5G>MPMO>+_JDD9L4;"I65
M>M4CH1'_K)6M5!:Y.3=_E4YJ-GDGE[<;<XI8B:&;/^8P#[%?N61[ 0<A$BNB
MH;3@<7,4D)E>^%#"5;U79Z?N+W;X^?-N\7OK>H&-R,E>O\8^'S<:)Q\WTN\,
M-&U^="5]_D4')-US'2[[-$YV$6A4;IG+["W#)Q,$=(G8^#R$LAY3I!0VJH&8
MQ76"&B?UH\/\3HC]^LE26?;+]>UXO][(,:TXW\YA?:*<LME5+^^L@'_T9\AL
M[[@/GCE;;HU8]$?\PPI6S,F&C=\>ZT#KZV>LH:I!LV+]=KKA](;/NZVY2-&B
MQ5CA#5+LI8*1"7E[=52YE$3!5![&JTK$4[%P.@[V<J*$, :M?OMJV.YUUUJA
MQ=,7>*8#N\R+5?%FUE%JB!*MX]KVWF7ONCM\@6^6<23%O 1?_C8:<3BJ2^&S
MS7NF*PGMBH->]@96J91RSND?U[.)!\]\.N/WW'9G9!!>6C;'U'+^:6#"W^*?
M_X5E NDKQ,[B\0F'K0XFX]0<<P6]][C-[Q&*[R<1_6BB>>"C%&@5,W5*.1?R
M/_[YS_KZ8;^"F:Q99W<Q.[>:R9J,WU3D,:]/'O.>G,XB[^"Y<W)SNE2SOFA2
M\\2/]H;-SF:<FE6F<!DE4]BDG.J *NT!E7_.:C%U[]II3(V#^L%Z\/K4%=/N
M>JFPR9#?LIU;Y;YOF1$7Q$+N\ZF%_& OI>M8>S62RF++5^/4='ZR[Y;'6=N9
MN-Z4\$S5TA1F:;*)2UYI.32KL3S3MF;F1(D$I#D:@5\:$/RR$I%*1+)$Y+3Y
MMTHV5I,-]L%U[$=FSF8V# ;-8\DD>CW8V1:Y:9\VNY7<Y" W1NBY,[XU<C/X
MWCX?LE;OS*BD9U7IT03G>D#I/D\*3_&3#[MNP"D]B7^<FI;-_/!F:OF^O(NR
M!++*_S)'Q"Q?]TZ M.O%R;2H8VGRF8F1_.CK\@I &V1>I(CEF:TA6!:FP.HP
M"W;#/,"SPK!76Z_:>IM)WA;E"^19Q":88<&FH1]0F@06MS'CI%LXNT+X\BST
M1G>FSQG)/',HU8Y]N.KM,-<1I0?P\!Z9#A8ON.'L+VLVXV.U)ODE$]<5.MFG
M/! W#*"W5SW5(]49.(!%#V2Y!H%YIRH*T$'*_UUG$EG^ X,Y,T<C/D-B#[0?
M9IX+@_1!ANI1NG)IV10N2XB&[[N/IAT\LI9ICT);5-(P?IG3&6Z7UP .%(_D
M2Y7$VMNM?Z[O141?!:SGE3-C1'E7J5&M4@E6:;_:3259IRW<3X5=&G5"]_DX
M%(LTH.-9/[*W;[GV3G+;5N*--.=4JVPT;[ANE%+TXW5]4%^[6%SABX]6<O"D
M'* 0?&%;M)%?PR/KOI%'5KQ3Y,SR1[;KAQYGO1L8!7W'SU?>2DZ(5[Q%&V (
M*X2C'OI?WSL\R6FY2B[*DAZVW3UC5^;HIWF;R'"K1+I$(GUT7(FT)M)#]U>6
M2$=35.&8MK8(=J4X(L71J#<JK2%<1[Q)(3LN<%F?SSSNPS"D:8<W5=]-SS.=
MP.*O8.GE=TF$*XRAPC6OK[;4(]ZNCFF*_9FN->K:<29/./H-_*CUED\SSH%D
MF@(<O;2+_^NWOYF[^+_?&+[BOWX#N3V,*OJJ0U9<C<^WB4?E;OV(3_76U50Q
MPE7-(Z4*52.J9?2'S7:7M7K=\_:9T1VVFQUVU>LC_<F ]<[9\%M[P)0O_MWH
M&ZQWV1X.C3/6!..];UQUFBWXX7M[^(U1?L/N5UIA^OO>USIK0MN75QUC:+#?
MC?X VIUK]EMSP$X-H\O.VQUH:V!<-?O-H='Y(9H=?C/@=ZV^,6SV?XB'Z1?7
M_?:P;0RH(\8_6]^:W0L#7W;9'M!KKJ[[@^MF=\B&/?@.:UY===JM)HX,^OT_
MU\9@V.Y>)$<^[!O-X27\D'BX?]TQV,'N$;OJ]RZO.Q=-'/YU]\SHSW6E-<0.
M[GW>WZ\Q&%43VCHSSG(DQ]MDR.6\W1\,19]I#F#HK5ZGTSSM]<6T-2_ZAD$?
M%9V/;GAG^6QB>7[ S"EWQL3'\0'SQ*60GM-G3?69%-<=Q<\1$[]],+&ZR03Z
M/68WW'8?=FI8\(3FGI)3X G!WG9I/K(CP=R6>%7T$F9$?&]G9L#5.VOLYI&.
M^J<YYFK,!)WES:0AP5SOUG1@8L?T+/]E^51]A2P/&D/'?/ 5KXA@#88?SD!W
M/9@>Q[(*U#OYLK@S+Z*RVU#G5#]4[_)GF<Q;\+Y_ QW9'-2B14Q,)XYMAG_E
MOI T,V C[E$ND\8\"!,8"^#8Q$R;%#5@4L#4=]4T?2WY-&$U(8^X<N[,>ZY-
MG^^'TW39$+"89V LBU*AEDRWHM_"7L,VAC9K@@%]XXXQ1\896SBCPKB&CSH6
MZ%$?9OC*<_%VSO]*G[R7"23MEU)IH*YFGGMOC6'4=Z#%+*?X^ZK;^U[#T[9O
MG/?Z1@W1&R-<== GIDZ@- V#$+03C<^/G*B1>\\=$S/KQ'AKDH1IQ"WH'G[#
M#R<3:V1Q9_2(33W<6:,[VJ[X .KGT4_'?;#Y^):/%TRZ^B;.,\[Q!#:T^_#N
M4^B?JQZU;&IJ>4J\O;!L87E2;U4JR4F=0KQ,$VY4)V@)/8*.L3D=ZG/?=I@5
MD(4$.B@0IHW'9[8YPF];DA<--Z#8(3@%KU97-V?_7Y[ <NAU4 PW?\IC!P<(
M:L?SL0]*/?V]WU*Z1SNU'O'[\:D&]@_86G3T:;\<[RPZR= R"_T("3F,C3,\
MU&X]<\K\.].V,=T9_G!'9%&DK<V$+L,.^"$V@.6X<)1[QU_C,G_PN%ZM2['6
ML6G<7<_?P0Z9(S +QR;RWT7+GNB@;3IU:;=4BO*=*<H7UL(LJZ)LK*0H&]NK
M*!M+*,HS4)2Q:07F%/[6=^U\5><B)R"M4T4HX8J0)7ML8$YPO09!"*WA-Z56
M6^D-BY6C3C-:Z<=WK!_WMTL_[J^D'_>W5S_NUPNB^G1-A-]ON=,I]T86B.1?
MD=M-=N(+M!^.*AKFD'N>%;C>8Z:R*X@X1WUZ>2/)WC5.4K=92)F.@0NQP%_N
M0#]R1XK'[O[7Z@!X7P? P38= (V5(@F-[8TD-$0D0;CE! 6^T52_+6@[Q#TZ
MJ%]T[),1\9;KPZR)6VKX<7$(W')&H8>W6/ 5/YS-7"]8%$' B.O(#L<BXFY-
M;T+/%]%D>#;2XD]T)[$L51+<MB;!P4SZK@-[\3&6/E !+B'B;_B=:4]0BB*)
M4MZ5;N? YR^.A%6^U#L]2@^WZRA=)=;4V-Y8$Z8AQLHDE[-TB7#0JLZ0SP-\
M#A8@[1:9,[S)Q+4-Q[?B6S(NG_'N2K>]4]UVM%VZ;94X46-[XT0-C!.)!/)$
M2@=,1\J1JN6L M<,IL>I8V\07UK*[*PTZ3O5I,?;HDGW#NN'2RM2]>7MTZ-B
MY/4,7L>"K&<5<JXT8*X"=;)5&O!D%0UXLK4:\*3.VI,HY.R[,.A_AQS,/@$'
MD%XO_X7;D<VX-[4"S $3Z?QZDCYEB;D:.P5:BU&F&&9G"^)+QB,HQ%@F_P?8
MK$./I>U5H9U-YS&1=:;CC"I#[9VIJ<_O74T9O^[@R W8.?N0SH?<T906:2KA
MU"W03$*CX9Z*FS0I<B34'6U>:#"%>*KGJK>VEL5Z^W;FWN[[WYHJIL)_(2#?
MMQ_3(=KY_52CR(F&.Y&)C#'L1N1@>WR*:"_X=Q+"C]"FS+T6)V*^VS)SHE:B
M3+!>-HFB#_BD(F+[[;__&%#N.-[@72$]RKG QZ#;917*YVIW$7C<-08#1C"K
MWODBQ \F6XW,$"-/63*!NO<&[28^"H-(3UN>0J>A^6.&P9WK$532T^@?[C&X
M%0O1 @AI_9W;/6"9KL=\GZA>L[MNX=%$W_8_T]U_,3MW5."^Y;ZHSQTK*_3M
M8-GF]!)1L%?\F0D;:_^W9X_!@T,MS62]8_#D>2VX#J%+K&KIQR2_RX"H7=9N
M_J1^F-W^=?^\V3+R><FB,;#>A@?1;?4ZO8L?FQU%C;4W/HS-CB!5-N*55%*\
M)=],5ZZD-X[JQSF9SV^I-[H;EM7>[\W^L)V3=EJH.#:^XP;#]O!Z:&QZ'!L>
MQGFOO^$!G&YX!.V<CHA% [C<</^-LW:KV=GP(N2TR(L',3":_=:WZAA=Z1B5
M!JIZF]+U#:'@<[?4H[.LL>@L2SM/GY<M +=BTT<;;+FQK*NQ8LO@=GQ>RFI8
MI3)MP9QG+=:YA.>\5BA(!C/D!??>[!<CODVF< /QFRG4M9?/A=HG_Q/K6J.?
M[!2Y9)Q;[KVPRNY[L&U?73C7"P)HAO82;954.+_5V24&+C$_T!IS>ZVZUTLL
M8$'"N5USRE]:\+I,6B_'&:NT6&Y:K"A+NMXF*(UVS6_&ME1;#JW KM3E2E/V
M^U6-M23Y*4_DM/]?<SK[RMI7;!#@9[>/;S^OE2Y]\RVRA<KTPG9O3)M]X^88
M[[3E=K!&K&G;%A(@^5NB7O'6OM*N*V4"$K$VDAZ__;15RO.M-\ 6ZDX4_[V]
M6O86>+7DL#SRZF2]A_,W*NF87WF;X5XR8Y=%L?=-%41=9]X+"V[::,?R6VW5
MS1R7>--]K&KJO)U45S5UJIHZ,1K-@,DX6[VH3D61M;44652[R.<CUQDO*%XT
M$!_F6KWH[Z$-9N8!F9G'5?VBLM0ORAD46HCR137"K\5H7<'_%A?7RD!9+'C[
M^RF$I""P^5<F>E4)J@H3586)*FAF59CHI1&DUP9-IRVM"C5=;<T72>Z[+X7S
MSD'3&[(>7@XU3FNF"FM<88TKK'&%-:ZPQA76>%.C>'<@J>U)(*FPQKG+:H4U
MKK#&N6*-+S6X[@KASF?V6!I%M+$9JG# 13SB*AQPA0,NE&.[%3C@,Q[8_)Z=
M6H[E__73X@_6Z*\J?;E" Q=(1 <C>"=KLE//?7"V!'U108%7G;%*D;U3'$8%
M"%YUQK91859HX)6G[,KCF/T3H7];1N_MYZ]2F&^^%;908R(P_H([W#-MUG)#
MQ]\:%H4*YKOJC"7RS]]^YBJ%^=9[8 OUY?&G/?RW ODNV=V,U/6R8'PWVO42
M E:K/E; WPKX6P%_WPWP%Q:E_P+<;P$1781'%847FYEPU-1G>:!1!WP6\.D-
M]]C>27!7@5++!4I]79!D;JC4>=RIUM+RH%/9N(98E554]>:RTO>?Z>QB@'8:
M0/M^8*\CVX0G!%)+5I"5969U7 /^%3&75,(:Q4 8%; WL DYX_'>TAD:!23L
M-H3ONQZB*:%!T0:5^I4OH3*V>ZSI!-:-.WYD+7C,PF41*$[XJ&/!"8+@C"O/
M'8>CP'\_:Y -/:X(*K:6H**">%<0[V)@MK8/1_KN(=XM&T&.X"KL"#]@1#L,
M7E)O[!YH&&_-3B.X-Y[V<]]>B/_&;UN!..-Q.XK]@A/R:E#2G+TT:0O*H<=*
M-;](DWQ#%!0=<F\J+4X*/ZW3>S;EIN/7V#PC8*6TRJ^TWCWXO<D<^#BA?HX.
M=64U1E6UZ%PNJ98Y.LQ?QRB7]MQRP))JAF,+7=^+SA4;NK\L$;EA@R $'ZS/
M9ZZG7%ZVM@8B!53IGW>I?_:W4?\<O6/]8\L1;M#((?=LX]JE(/(3]>GEC21[
MUSA)Q6\0I(A>,87H'K_<@4+BCISOW?VOY=2XJ:O-O=D*F+KGM+ V"UKS+C0Y
M@1VL)E#]_/'!,V=?1(SK >;@V<A3]+EYX[MV&(C[UT,86>"!J$Y<;_J%_@9/
M\P^[M8_PT4YJ O008(Z'QIN,?'YY7S*Z98Z,H@[O^43,+;<B#MZ[%:'LAWT\
M79<,M<COOG6@90DFO9?/C/:>N=>L<] 5U[ZB555=M=:9-7SRBQ7 KABAG7$&
MLW++G1'_BA?4SMCTQG1CW7(=O#7#L)6U9M9IZ-'%'\A:(E(5!\X_@*AR>\)<
M;Q,C7'L P9WGAK=WM*&:DPE,&-TSNA[NOQF,Q K0)_;#&[1</+RQA/'.0L\/
M37&/K._-XQW8>[;-,*;:<J=3[HTLT[;1?39]UR';R9@@29\?W_6IF:(G1V)I
MJ#_:]6B<=3"7* G:P&2WK@N=Q%N-P)I8(P:C=> !U QT?S*=B<)?0C68,_AQ
M1+WIF _UV.XNHUE8':&+9/MP6X[0PQ6.T,-B'*&O?\K0P.N;4,)#]%S(#%Y;
M'=?9Z2-S7(9^$.H[T&]"26+JEIF5^E%+ZL\9K")>YN*"RJMOU+1Q^A(;>^8D
M8#-4G=@HKG$0#4!=+NM)*_ K/\1S+2/OA$T\=QKU0'\1-(T2AO?SMP['*[;-
MQ4^&>^M?">7?N5@LZ*#2$^#6[.Q0G(.I%]!R<C-[I81T>/S?(:9+Q M6VT!4
M?>WQF3[S71B5B;E5TG  :X2L#W%L1UIIWO3Z0K>Y(JZ >TB7R0GE.,XH\0&9
M?O_A@,_[S7U BS#PH$VA-*/IP1PZ*]$)AX^X[V,:'TPVF#F3D B"%VV8K!PN
M^';65JKA!^X-9H_AN. '9"%6/_;CK+'F##>V*=Z[>&<2"3*/!P]SXUG8 *:4
MC.QP3)K>P=B+R"M!E3%%O0,F6V+,*#7<ES2_JKV:,+S$X_JWS1%2,],JZ7/_
M022:D!C>@*DTXR.PU 1MNAI$2J"1K]F%3D9G$8P;9Y^4E%Q?,K_I>;66.U_9
MAYL=D!U4/$G=YSSJ\W@9C16L6VGGPH; F0<[&'[ ]];23S4%JS&<F>F4O1>L
M.71UM$!6DX+ZX&'_T)+U1/KAF,?6[ 8[2$*A=V!J.91*#/V:<K(LQ'>F?.IZ
MZ&+A)RY"<,'HGH8.[-> DI,VWM6OU(\/X^?G$SKA@CAY">FG_;:L\ O-@.?L
MJZB&)?<RM.TNL6\IAY22Z#''5:9Q8>^T3%;?M;E-B;!@'KHB_]<*^)0.])%G
MW8B-.Z+T&5]H7.E)X@J@QR.R96WHX@;/?7URBV@#M&,)*\+Y#[+M1BM(&R&1
MG;PX'7G1,2,V@CHOZ:@D"X-J6LRXAZ,7QWC6+B+%06F,MA3#,0M!N:EJ&3('
M&Y3D:\E3$65(6^9FM$(Y2I.!(B-4P2K!&[6ZL%!%M"'=&_#KY=DC; $AE.#;
M)H))Z4V$5LT(CMFQF3A@ V@?_55?*S,1J!1;'39719'>613I:%NB2,=U3.78
M6S*.%'U[^R))<NAQUFN.P:3>@\,]_\Z:H:FHF<KGEHVV=GWM"%-\^BI7+,(S
MD5]-S@^\*H4BI"^[#XZHH=/NGH$AV3UKPO]G>E1""FR"DFF I[$["J>B# R(
M4-K(0#V;86/463-@.HQP[_AK9%%HD8 X4#9W3^"YMYXYG0N5N=-9@):'<!4)
M-9?I.MCVXE$*3V+A&!=:[D5,S%G-ZK,BOV3F^N %^-*-&HE8"B74B_D6LL13
M=H;PNFEVA<B!,(&2@<G59S8YG;&/!=T3Y9A$+\4:1B [?1VQA]J-3Z;_^6S$
MJ<9NPB S,CLV'Z&_B/02/8D%<W%TIAY)HM*TLYEKH0<6"YW/-%POB;QYB\.C
M2##,&7@5-%5JF^&$+#+^+>?>M>_3<20Y>K2P%XOI.+[A!(O/<A'C#.(F8E3B
MJ1@374'V*LC>5\'%I"OB.7DD=>",-1G"^(=0*]&%!&Y?&?YZR1GSE%#3B\2S
M3^FY6C;LC0*<OM0[8N-2M<;* WB?'L#QMG@ >[OUXV<= -Q2LEZ\YSZH328%
M5R_!F&JUB%E:<H?FM^_T XA(A!+'#_UFQ:TY1T*T0HW!'%GNEQ#F58K1'2W9
MW/-IHJJ7=U; /_HSL)>^."ZFL2XS"2SZ(_YAA7VYX7I3R9"8%JDU;79IV6!D
MN@Y87_<J]KTBZ^$S2[IH;E9X@USF5-4!9 );6'?@51<HSV)%RRW6E?DXG5NN
ME4AI2T+'2;[1"^DXU]8UB>)R93F$LV>LJO==6:C/R\[)5EFH2Q,SR"]O7X1:
MC'P3N8[R *-,*W\NO6'NH/-SR+$?RIO@1_9PYX+W?6=QJB%>R'SZ[-D@&TU6
MEX^R,F%8(L2I8J(@A2K-QG%ARQ*AGDB$IS$G,DB>>A$V92V*3S[UH!6]:UQG
M37HF'82$76:!1J$D%T4KI/HD>XW$BW' =2<.NXL)4'%?A\*25BIO%#[U Q/V
M*ET]2^^2+IKA+<:O.^L&GNU$T:4X(0HW\Y.R6-=><B<BJ#_YJHTLG-OT7,BQ
MX4L#? 8'-5;^,_2>W[ITRR)'R&G^$]D4L:2S6YARYZF5J[W6V 2;E,WO$?VA
MUD]/ JZB8._4QOC\WFT,I5S.V8<TR&A'LSC(S!#I;PO,"F&.Q,T)=2CL%+J/
MFF>XK;]1Y*O:E27?E6#IO?MMB=<MN(GXKQD<93Z8!8DX<]9^$FD*&C>B/+IB
M:DAQ3'H<D^RQE4EH4[JNY#H4=\OY;LO,B5K("IXWK^0?@_9%MSF\[AOLJGEA
ML/->I]/[/B@D0TB[B_SQ76,P8$3_V3M?Q$1IWH.)@TG(XTPY0'U[ ];5+SX*
M \6SS"U/Y_,UQ3WX7W2-B!(FL@W(\HH%9P$#>/V=VSG+!NJ7+K33R/$68>WF
M-MBY_?I!OD6&<^Q;[HNZG^^B+M6<'C6/"I_O+RI\KH6$C^LGSY5J+V3ME6[O
M]V9_V!ZP=G<P; ^OA\8 E'@_[X(QF[L4.6WW+HVS=JO987UC8#3[K6\U&$RK
M_I+;JWSW_IOMUE4E]Q7KZ^6W\(/K_GFS9;!>M]7K]"Y^9*VZW,[JG;);1[,5
M2*Y64&O1M#<637M:*3VK,U[8]'[]9%FO9<66CU\@A<M/QU+U"E>YV2S/3=WI
MCS4*#:ZGM)*%!I]K:ZWY2MW:SWXMO+-/GQCKS.TG_Q,3I:^S"U^_^CP7S([;
MNOVRGFF9W"_/M57J_=*ZPR#C>B6/RR-3W>:EL0U:.,<K]$JK5CN@A'HU[QVP
M77IRV!YV*D6YTI3]?L4NN,.1PZ3EAHZ?(2N5OMR^G;"%"K,U[)6Z.OS!HLN9
M9SI:%:NNBE57Q:HWMBW5>IR_0G>S;M%SI.9)DQ'G>AF3D1N<7]=5=9!\+X^V
MOH^OA7I?'^)^[UKCYQ#NGY"@#OZX"Z;V?_\O4$L#!!0    ( *B);U@;.  /
MUP,  $X0   8    8VAR<RTR,#(S,3(S,7AE>#(Q9#$N:'1M[5=;3^,X%/XK
MWHYVV9%(G+2%4K=4&M(R9 0MHJEV]]&)W<2+$T>.2^C\^G5NT O,[DJ%>:%2
MD^B<8Y_[9Y_A+X8Q22*<!)2 *^_F&A 1K&*:*!!(BI6FYDQ%P!-IBA-P0Z5D
MG(,+R4A( ; M\\2TVVW3,HS14._EU(M$@D 'VB>P;;6[P.HCJXVZ77![ WY?
M>,[G4GH\<[R_;B>5VMO%Q;7K@)8!X1\=!\*Q-ZX87=.R@2=QDC'%1((YA)-I
M"[0BI5($89[G9MXQA0RA=P<C%?,NY$)DU"2*M$;#@J*?%)/1,*8*@R#",J/J
MO+7P+HTS+:&8XG0TA,V[DO4%68^&A#V 3*TY/6_%6(8L,91(4<=*U4"OA)J]
M(_-HY(RH"-F6]>L@Q82P)#0X72IDVV;O])DF61@]$T7E')*48\4>:+'[#W1O
MZ-"":2.V%(DRECAF?(V./!;3#$QI#NY$C).CXXJBWQF5;'DT**4S]ITBNZWW
MY"RA1D0KLTR[/U#T41F8LU";55 'E16H=KY8WBA^8!GS&6=JC2)&"$VTP&^?
MSMI69S"$A:".5?I"O ).L42^4-%@-W0O1>3G..IO:<VKA;[@1#,G?UZY%ZX'
MVGJC(?0K-W]^/O8L_8\)>GO+ XTL5/Z/",_=KU/WTG6^3#TP7US,W;'[Y<Z=
MS,'L$CBSJ\G=8@XNW-G<<2=39S(_!N[4,=\Q%2\Z=(A<[+=_"2.E!E#J/F\5
ME +!L,]I(^P+2:@T L$Y3C.*FH]-IT[U)K4_1=\%FJ/=J&&EWS?/^B6P**G_
MY*G)J50LP+QV7(-1O>!$]VNM5;>R$C&RTT>0"<X(^&25OX9?(>%KW!H37V,7
M\+?/W(A\C:W%-]#'THE^/7^^(8"\GGS"LI3C-6))N<CG(KBOJH<E.O-5.NLH
M]NI#I2J!UWNB7$YH("0N$++(M)"H"<<NM]"+5EJ9++[VV*425$:T4+[ZH>%"
ME\"2B[RIVWV0WFB,OU>98LOU!LG@.%/;]&=+=FW<B,].X54U-L@CIJB1I3B@
M*!$RQKP.9,?LG96AK)L*-,WUKXFI<[I_PC9MN1I-<4R!6(+YRL\885BNG[ &
M*O+1+F]['+QAZ7];2981%A2L(L$S&>*$?2]%MU,,2UC\@,9#Y'J^DDO=P&"6
M%*D,U\?@^MKYZ*8#1GBLH3G'DN[4+RSO#,V5_-W/Q8,,#.6EJ$[Z^XU%!W*J
M>D;RZ=J&@_M0"@U7.ZBVX?(VHS9JU\BF*+>FSIJT-73N#I4I#O5!J.?W>P,O
M=1TA_" T-%9![9V:W=Y3IU4TJSP:JT&YG+Q'_P!02P,$%     @ J(EO6.5P
M T/ !0   1D  !8   !C:')S+3(P,C,Q,C,Q>&5X,C,N:'1M[5G_;]HX%/]7
M?$RWK1+Y#@$"0^HHW:IK:=523?OI9!)#K#IVSC&EW%]_S_E"0]MQW<9NJG:5
M$OSM?<W[/-NO@]\,8\QCS$,2H8_3LU,4B7"9$*Y0* E6,+JB*D93D::8HS,B
M)64,O9<T6A"$'-MLFX[KFK9A# ? :U02"1X@SW+:EFN[+63W ML-6EUT<8;>
M7D]'!_GJH_/1]//%N!![<?W^]&2$&H9E??)&EG4T/2HF6J;MH*G$/*.*"HZ9
M98TG#=2(E4H#RUJM5N;*,X5<6--+*U8):UE,B(R8D8H:PX$>@3?!T7"0$(51
M&&.9$?6N<3T]-KJP0E'%R'!@5;_%VIF(UL-!1&]1IM:,O&LD6"XH-Y1( \].
M51\H+9A^L.;.6-%(Q8%CV[_W4QQ%E"\,1N8J<!RSX]^/2;J([P=%85P@"<.*
MWA+-?8?L!#HQR3EX/O1K,H$PK<CF@BMCCA/*UL&;*4U(AB9DA2Y%@OF;9C$"
MOQF1=/ZFGZ_.Z-\$& %/1CFIA#BFT^LK<J<,S.@"U-2C_4*KH'3&[$FI(R"8
M20I2/A)V2Q0-L98(7].HBUT5<F:"1<!K?!?3&57(]4QG8,W T>D3S@X9P1)(
M5-Q_Z/>GW+D?K]0\[WBF'JFY)038$/GC_#(ZGUR-)U-T?HQ.)D?CBS&\H'LY
M_G!R-1U?CH\J%!V.1N?7D^G)Y ,Z/KD\V_CP1_F@M-AII0K9]X\V7]-N22WX
MN,4L1APG,//G1W;CN-VNT_;<GD86AD<O?X+!\UW8&'XB*!0\T^E,":1B@B@/
MA4R%Q#I T&R-))D322#_P52^8BX8$RO *+HD"YJI<NF5@L2F$V,6H$HW[=.G
M85H96$2MPC-&T$S(B,AW#;N!0L)8F0DV_2S%8=4O&1841@@:X30C0=7H?TLL
M%8YW-I_+ .@HD12JUE3_0IAK$PR&UV*I@CF](U$]ZQ2*5B&O)#Q1942YK%LZ
M1$7UR6\W1,NZ)5(O8B7^<BB""?U53!4QM$-)P,5*XK1?TZ)T?*GM6^?@H5+;
M"[XG A_H6W0U)U!+)IAMH;P<:@R_$'?H[3&L0%>&AR8B,]$>$/)M^GF>9[AV
MUW?;392W7;O=LZNVZ_>Z381Y5/3]KMMV?YJJ!TC,T4C$1"XS])Z*JY!JK&=-
M=,)#LWF/9!T!E@Y<*X_T%X;9HO\+@=9]<:#M%J ML -X\4J\V)[7]JMVK^=5
M;<?W.[T-ICKV!E^]5K=J>[[M=\MVV^EV*EK?=;Q6'8,]M^<<H!0\CRG76UNY
M&P(B/A .9H<E(I!K.S8:_[6D:JT'P 0X/Z$+ACGPRQ#LUCPB43.G_B*N-)?6
M8RZ'*RRCBA?H]AP>2<K$FA#PJ AOT,52POD](S4F+Q3!]B\.8.]% ]CQ[$ZG
M F3;=RK@N5VWT[H'Z@; G@/GVJK=\FVG!N!V#<"=&F:!7A]-_F7C/)04L^<'
MX3-]\?/.%H]S%.0!O\P#>5UB)))$YXF\LYVB=F[V_1VIXCF'^!]]>7*?<7GZ
MFKL/^$(L)=QOX+8#81SE=9DS# D4.1!SNC#3+(H[DF0I"3=7)'UC$HP6!'/*
M,0\AQD"/#21VN7F3V<E\#DSATW"2Y214WXXY< (!2@J&!&22FH!"4_WE=_*'
M&QQ;PAY4W-=HA@XY7P+Y94Y>PM6QC3]VG_W@GB=S/=<$2Y3O:NB(0%C-0"G/
MR1WDF?6;WO<'P--)?KM>L#_$/:K@W-*,SBB#33F(:101#O)>O^K"$:3_OYU[
M!_0^,&QE%AI+GBGT&B=I'WT62X#'Z>G%?VC'WA/3E2XD0RX13:27 PXYQ?LW
MZ%%8[/&[;*?1NNZ[RY3U$V!>R=UWY=;].L.?B93"J.(=R\TY&8<W"PD1&>FS
MLI#!*SO_Z]=,WIXHE7JHI%UYIEXH+X>VZN0/Z^ I7A!C)@F^,? <-I< WPI:
M'9$[OMGJ5(?DLCQLY]MY4=O/_UDP_ =02P,$%     @ J(EO6*M-\=PI"P
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MZGV..;YH6?U*]%4SK)T?0MZ[13_[R^O\EFXE_1NW 9]_]>^64>^AFW^Y^-^
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M+P[;K5][.H=-7NH@Z\DPY'!9U7O6/4>$*F:! ([-T<O 80G3N&-<1S@"N\5
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MG-88*PJ%\8UV=!)POS*:V-?E:6[DY@OTK37\BM?GL<6A\P!BB0T@I1:E.8K
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M=6YBD7IOUSMX52^O"_ /_@=02P,$%     @ J(EO6,/O)MM !0$ 69P( !4
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M>C>1_KG9=C5HA)JR>@X]\8/1'N)=@^O9LE3KAFYOA378O*YXD\)W'-LX9U=
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M+:FY<V$LBX()%3, =EU.EH?@E9*)-?HY1;FX+WH(K9QX'17(W43+H$Z<YYG
MXR^_B_4Z_H0->;!K#N1W"$X@E^F4PR6@+]Z=Y=6(>ZD1GFIPQ2+U:@G$ZYL4
M6'=%45'?F=X$@WX I6E"II(1BB*FH.D+RVK)-!-;P<SX?:Q"KL: 0BLT$D\,
M2V;7'?7H/?PP:S/6N*?*LJ:\3Z%2XS2*;6'$[JLP[(_RK,CJSK=H]0C?B)U4
M(X71;QPWN,"R_D7##Z[SFF3Y"&=.1^E3/YD/IE<_:==LS(NVNG+/V5HT2\X[
MUV>2 J7I7*8\ ^[$7&/60Y7SQZ<4!GV75U*\DG)7)<4S@*Y4?B$Q2W#!#%JS
M@&L2>O9/CI7Y<;#G^9$].JX2'3WYYQJ@XT20$GZ:J4J1EW_) 8FO+WYQ0E]
MW4(#DGD7^5]3,4/?NL[TU&6CH%$Z&,!_MT/MFM=U-+KU/QB&]71?O#D\/W%&
M8T^8T)AV;*)6*;%R%RB@VM)'QLH6)Q9.CE/['-3H/)NEE-ZJB6>"!*UW1,?E
M0="#X!U!\,"3^*T6!)?("[\YUBP]ZN_-GJ6'O60)EV$GM=P(*0>T^1?%O1B9
M@KQD5OCH-$^[^IRTTH:[;"A'1/-3:%KD'J^7*Z3H!:D$J(<!ERFG3C)93?X)
MI@>P!.T]2+6;: HTVQ_TW7U6.-GC66B?XG]5LJRPW4G>Z3+F:<+;%$>]29N1
MFI,\I=<3+09UKO.@2HF7C9U?YA$8D&5Y-M=*K V\4T^I9%A:<\_=YL*&J**<
ME95,VS_^47-4GBC+NK"YHN:J9C9N/P*#JC"_%K]:PVJ) 4QD=!K-<6<BY:7]
M-&(T$JHHC=W+80>BO-9AJCC\%]KI\6W"<VUJO5;3SB*A?&0,XV6:NR8KF<FI
MR5YW+2@<;6@XIY X"OYJ_MGK1>VP@&I3V\#U5AI[7TG!>/IKPMFWY:<L)&A(
MZ O^H@PYU+[,!).-[KAW;WA5RZM:=U6U/&'H.DA?VM#O5 +2 JGL3JY\21YK
ME'LVV-L:>J.<!\G5@:0G*%U#D#P3,U^YS,.DA\GU0!& 2<_QMEJ8-"16^9+K
MDG>#83%&)%<4_3*<H3-C<8:[CH;FV%Y5!!<VUIE3Y1OB+<,'Q@8!F20]?#'D
MF,@+&[O<&%(*';<#4.UR01,A9L'UP;JAODB3H(JH3K$V$[+)."2?[F!-;31F
MIB[D'[4JR$)#,=)S1W9RU>@Y^0N3X7'7X^Y=<=?S;:T6=W'E%\OCU=H$K\''
MB_]WR3+F8Z90H%Q4!)4QSZE'18^*=T5%S^VU4H1H1Z1\G5.Z]BV)%';D5X .
M7U?"Y\=[+/\:6.[SXU>+Y1\?H)3G28T9R2)#S8]*F/,!.Y7ID/.T31 D\L%6
MJJJKOD#(QN4/!W<,C6C*A'OET0/.70''9]*N%G ,-GR8&L8U-+!%4L;+C,]C
M,/)I]QXL[@46/J-MM6#QF<M^!$?O/GPST.!Y/+\^CZ>'XV\"CGT*W=K <4.9
MM>2R(UYI\RAQ+Y1X['/,5HP2H"E@KLU17GIP\."P1GL'P,%G1:P4'%X='SZ
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MY?1?%.UC:=-B:?KQ<Y;N%RZY)[ N8#42P>2X5C']!306T)K&@N@ID2^2/NO
M;%C8%F914PJ=F[[JK&WG5?0FV[SF7'MU?$C73^HBGV)&X<<,O_,67K,TZRK5
MZ<JZ(5,;@]G?['J'9?#V+ Q>OSOC4;T^.J.&8'F-6&,IF;(3]@3%5]AU&JDB
MJM.2N/1@2DZ/WC@=-5L.)TD4G5'-#:JSM_L7_-?(=O/ZSS>J__CDJM7J R:#
M%J%[F,?+9CM"R@,"4=U\<''^ZOG> 2@!=4$X%),\''(>\/K.T\GGB1HJD*3W
MGI_0<G92!CQ-@IG\(%%E]?U,A9<;7F[<56[X]+/UDAMPCM'63.^V9K?UP>"Y
M1TB/D"M#2)^#MAX(^5!N)SR::\HL\XJ B1;1\)03=,[#=%[,L>:4;'E0Z/DF
M;P<2. ]!5:^+$5K 1&GL&R>CD2:Y.C9T^)4NUYG*(*ZMU_Q2%BG:P0(ID!N.
MF+C,2S(L45D*IDJK2SFJJ>0(DO2((IJ$P;&\DDD^#4&D9#7T &MSDHL+L)_\
M2_1?XN0JL;XF-'.4IZDL(A _L/;^RL@UA],K)9.8J;PR,X!>"K>YKVI,1:6=
MKDZY:D\%U$>-XYE7OS[SZOJO,4^_Y/68.3W&IXRNAQ[S,.%WQD!(;(ZQCK!@
M[PK_W>5I+8V!#*2T,4/]##I(!5H&7.4Z8&$P3>J2Z3%!.S#TH11G@WM49;7Q
M%K7^N0,@0^R*VB%C^"_91*<[4W"(8(2^,8I *12[!)D5,2$U0V7V7T3G:H@N
MNX/,B]XQJAA5!V(]S)UQNBR9,"[3"+:)/2'OC7T3^EC'.87+=!QG1*?9E.LE
M!QKUB_ZV@PRQFE62+F3RFF:N8=GEBN65/N5&N &)BU7R5X/%)#/-USI:T"6C
MMVI/,'/GR@)GW_K#^NRDK3A-5 45A03=K*$6"IDGY[737F57JZFX>.@;LT,M
M3XU ;2FE04/DV:MR(G7K5N,,)K989,I,<V;XU;RB5!2O32WJ..GTBVF$*2QU
M66R3#YL7 G2B3Y\V%,9S2C5^P"]2K 7'.+F*M2TOA1^D.UBL'76[ACVO77O[
MAM<+[J87^,3N-=$+>*<_@'ECVBHC;RF  41&"B,IB) :MY>F6NX_]V]=3UC^
MB00)U[51N<13NF!1T7D/-%7(F'@IF'-9+,+GVYX' 4"4W308Q&(=]!&ZO.#$
M^=W0@CL&!T-Q'L[!:CM*!9OO88SVX.K!]8[@^MSGQ:\'N%["F.6RL96.(AD=
M*[".!=8\A2\ RM[QWM[^.1S)DC*G)((,T>\,^I1?J0+.5.;.'3(KX3DL3>LL
M'R?YL(91 8RE ,4[#B3320')^<_^>7[Z&C37]ZB>9SO[P;EN"Q3Q9WDQVGM"
M^OZ[UT?[CY\>^) RCUUWQBZ?QKXFV&4S?I:,7[BW^)2?N"X9;:#J<](@M.@3
M/C:U]^PE'DSA+(TY0 !/W2Q/>J"5=>H!R0/270')9X^O%I!RS%I<,@;%(H43
M6XGY+9P3F2@N':,D&9;+JG1M?WPA'U&F9UFI<1-O'\L1HA7H1G"JI>Q*"8=;
M;J<2GZ7.J<SH+7@@3=%:BI6 %/,ERJHR]<_:'O?F]84499X1/(@*E*Y,SDH-
MA-IH.X5E:"^-I#7F\HNWV\Y\G:JI3-DPD6D*<H^2'B7OBI(^.WZE*/E._ [@
M8C.7CKB<X9)1T_,U>I"X%TCX=.D5@X1U''Y7:=/-N&'=/ !_"#D22'<,C&E-
M1W!JIX?VO+8\'-K,W\TW;C_1<L G27[M1(>2JYY**EK/;+?Q%UP"%!.1RWK(
M.:7Z#?S0L$X^L2/&E+5$ATEVJVLDY$:G9@SDZJXI^1?: 4U8E1C2P8Z>J8@^
M@;;-$9I43I/+].K*H= -.LRG5*$581NC$;KST@R_F>T7F.2=9124,*V+:")*
M^GLAJ0QH1&UEL2B(2(2J$G-6.L:=#D7VJ7TY%2G6/149W]!\"6K=\><X[I\P
M*&%FY$X]#?4XJ0=S5"T!YMZ6B#ISI"V&&L4]<& P"Q.VX(K"6K@T5;; I7EF
M.VR(5?2-Z/VG*L%8]373?>P^AY=@KR#Y3#E1TRE=NH)NQ?IDTZQH&PSC+&U<
M]/UQ(<3( AM'Z/(=S P#^S+^).64#S,W-C,(SLW7TYST9S!QT"69C6ER<;VT
M-K3;V99C;2*H-#+MH:+W9>ZC<(3"[\KQ)"*XG*@"C5)%Y<,<O,9S9XW')TBO
M5/*_EU5P ?B\-/N1&>KP'M'2U_PMAGF"701P&=ZO:ZR(C*F0L\JN<H7"'4/
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MNI?3"P\I'E+N RD^P6+ED%*(6&*)GF6;')-$5S"2!2;K97%09\Z%RKRWQ+)
M%$03Z'_23T$,(&3_D0EX61@D^3@OL2(/4A\I 7^-H3>@P.G?RUDZS!.\3.1(
M)3/N1'DZU#Q#I ,6,A]YX/+ =1_@\ND=:P!<)@CO*"^K96M"W;*K(CC"*IVQ
M*(+_K4'U03HO/$^>HA4_$PEW(I@F-9\S3SZWKJLLJHN"<V]A7V;Z6&?9R&X,
M+B2:2R(!Z_8!TWKG4MB<%LX2D7FH\U!W'ZCS&1IK!'4/46.:\UZY.C36I)19
M1/2-C"8GHQ&"U97$JH=,5 D0A#?44WU+3+P-HV#$)+_OC^&X&,EI);#,,F+7
MQ?FKYWL'<U6I!\%A-@M@Z#(K23G3=#ISXV6&Q )K)1>2S7AU50-87D-#\'0@
MQH5D:D1H8I@#%N+Q5'T5'_8\^'&C_.>DL+ FHD_C(H>/WED;42)%\0)[_;+]
M@WY+UY^[VW'F'N"K]24"OKV]P;.G9N]IZ&M?@WW*CTW%6.X,"RD^[8@1")07
M(KD6LU)OXF=/!X]A$VM YFN[.$H'WA%^'4QM(;!^:1N$S47-[_F""HW"^NJT
MZ\Q*]Q6W/.D%SF8+')_JLDX"!S1([X3QR2T>'%>/&PB./KEEU6CP,5/$[5UA
MC.32H!&TY/4?^>!B\'T-^.(!3EJM]4/G*0R[K?2A2*$=>TIN.#X3:0MVFF?7
M4B359#5'&B]!OAD)XG.!5@TK_X3)C9<<_VGH-2-LU90 4659RS@,ZDQ^GBHT
M/T\%[BNR.VMK3%-LB7XJF6<3-?4LK[B(DBH*>95C]0U*%J@S,9T"%M&_8U72
M*Z$!S",8 ESE&;X3_D4/3V2"KC^9@:(?2<0%[ _W@U""BIQ<T910> %,FRI-
M'1.L0U54> \G+KS.885F:.D1B5.F"6[%0AR2!O=[7:@R5JRS(WRV!B/B%&U&
MQ $ZE/;5-"ZGDS -15Z/T0= LQ@V(RU"VY]K5?K$*X_']\)CGWBU<CP^O S^
M2Z33EU2@KD"/WZ7XO/3@*D1D )M: @;%")$E%CP%;:\NH@F5=ZKJ(D. 0WR!
M+5?6Z91 K!*?T=.7BAE"EE,+2674JJTGY$(?QDE$24VF>N>UU!B\KQ@SSC$S
M?8*1&0G78E+I-"%C.CYYE-=9I)+@F.8%W0#[N[M/'^WM[3\Z.?+0YZ'O'M!W
MX!.25@U]OX(B.,D3 @F.\?3&7E-N^>F:&7M[U^K"C-+]Q],JV&W^ATMY>+>!
MT-W7_-(A+!9HZO#\\O3H[4EP>@I#'/ZUS-B_-HZE=_WMZ=')^XN3X/7YX?O+
MBY?!R;^.WGZ\./WGZ>5O2QJ+[CDFXG:_P'U6DU,08+#&&T@?*(/76&MAR5MH
M&9_EZ7*_"I8'7M^/<?(95, 2U;9E?Y:+>OB[CHVC<IJR2(VQ$I3HJHGG4&5P
M:,(S0EL0"<-PX;A/!3E*4X]#P#$]VZG0^SB27%1S2W[&4!+2=",89$Q!)10W
MM[ZS;K-:GRR!^VD[#*3]BEOR2F9SP8EN%=DVAT.(15+,=UK_"=M?@H=U.VP*
MP_ 2VK I6$HB-,Q"D<]$4LUVAE)0/5XZJ- :,55S^.S7L@)2("J,:HP%TO/@
M&-9;DD_#X)W(:EAC<$+E97:$@6)%I$!D_^D\?@BGQF$>FSJYW4KNMO;O*X5F
M05JO<T%AZP[XP^W@?5[A'BPKP:%PQ)]"!DHJLF/,EUWP,T7OX<0_S3'12@>\
MF>_!)>C,5X%G-V&YWA_AYH.M83J[2\?6?Q*X]DQ"A_DU#+;4-L=(F\FDF,$\
M2V;:#@+KUOFM_<+6%M!K&&L[9Y6 J:!%2FUW.\4))EL*WJVH>#;"L^YEZZ/"
M(RCQ^-/V#?<#K1X8V33/=!QC[T#OMCT\^<YFDN^LB1G#$<_K?/(XEWJ[&GWH
MG*J^+4'9[>+]'&@W->4 V\L:87Q#M(V]96@;C5ZO([7Q0Y"X W54)J.P1S7E
MK)8\2'(4H&0K0DLVY?.)M@YK*_CAI$X+4$,P77"!W@)M)A)07\,ZA9=7028C
M69:BH.M36<#+4P+>FS-O&@VI$Q-) S+ML.C/0>D<ZS1#^7F*^8O0C4YZCJL0
M+%_5>3B3P\$Z;WQ;KY)U,02 (0IO6BG9V!LA5OMY$!;/S?9=8@7G 0$N(<Y$
M7,DV3+ NW;RM#+:,2S]%<H,I^OB5+,KM3A7G3<?S^ZOC K$Y2?+K\@6IU3#R
MKE7!UA(EM;B995:X&<7IL"<I?8BP'IHU6-]Y2MHGVJ5@=>57JV-#1QKR"8J4
MPS<(:"LB_VG9MDGIA*&4PEJ@L4WX? ?++S:SCG@U7&>\<I;SN;.$EO!93D1[
MMQBLT>6+*<_8)7G9-/!9BNF*$9UBLRC!SPAU<]GL<KP&?\^+&,_(@.:YX7L
M1:"T<6[A7[!/HZ;O?A]Z9:Q2E:D2&BHD',$I8DTF>)$3(F>.YH=-2D7J(']!
MQYCCO,7*K2&>(\A*.=(TO*"R4'A9JDH;!0>77; TEA"8'TS=@R6E;V+ Q'/D
MWK.794LA[>L':]TD$G&*2I'"B"4:^$R[O"Y#K5,Y&OZ\O 6)$$E8RAQ  T)
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MZC'5("L'32%VNDG<II$U7;#!>\.\:+F.@CJ#<U'I!M2TA74;S?1<:N!%G\/
M"34NI$J'E#TY-[#K^37HQ%,[:\AE(=@DG%GKU+MC40DX#51R3$55SW3:U3+
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MGYR!@/8L=*;4(4Q-0"R.<9BA_I<0+EPIV/'K/TYD@'0QV8%BHO%'H:%C3$@
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M<P]/X>%1H1>@"8-C:_F\7<8TIO%R7I5$8XCFPT>7?_]@4(&Q7==Y=ET;'O7
M:*]F39#10S]'"D#6,LFPVLL1TI:ZD;W0]A%\1U,%O,KKPMRD9V+&08LY 6"=
M:1HC0BL+@Q<?SK 6+2YA3?2%\XGJO$I(]VJ$0/.C$=M2)&0*UY<[B&AVB=[R
M304"^X-KE&S5LA54E,<UL#EFL+X%T1,(OB%L1P>#I_<^E#?KW3'7.BO%LJ%Q
MX2L=:X7GK:DH*JV&]&TDC5,WSCRZH5P7#1L,G7#0.5KTAG-1;SY>%EK=I1T?
M@4C.4UF4L 5:);ML-"LJ0B2T,R2RAK^ 9(V,.< YULZ1/G0FIQOA@Y):7!&'
M2S#&@]5(T-*"7J#MU\4]\EB3.5<DS(C-*E0*]]2:EPZ-]?&LX?"SY-YNG[W]
M<KW'^XW;+]>;.=8IW6;3' W)WA+-F;=D/Z O*<GUN2E%)! 8[,_5%'5M09>E
MKTT#2+[L$K%(2^@3>]XZIK!9)SZ^D^3P%_(CD/'/91&]+6GU7J/MQ"W.#]PF
MUSC2 Q\<PI?&8A;79 UNJ!9C6^O'1/KJ*+Q..._\F]JE]LSKW%#?+TBM7<2Q
MV)M>VUDVK@N2CD@X8VUJOZ8ZGIU(X_JB($M8&JTF38RE=.Q@H:/'HMI)Y*6E
M95VB=A:\595N9<IFEEI56T7!4:0.!8?VDB[,5ZYNVIU.P.W<4O01#S[BH2.&
MUIH7LE<,-3"Q;$&D,S?)C3%_<NV&,%A7$>C/\0(8*W7*ZW!A[ON&9(C.LZ7:
M:JS+HTHZ^=>OP=9I%N5\G-S?W=_=-I)O6<+Z4E7Z%%&H\A,N+!"YY0VLL$W5
M6:9+-DN2@O/UBIGQEQX1SB]ZL\7\/&,^^5[IY[ZPA^&V;1CK>NN,X/Y+8K5S
MCG78Q?'LBOV\=68XJL8X3LN*K9'(#89_(Q^+.9N6;%ZYJ34\2S9QF91+%&2-
MSTDG1G*/]<8YO A.+VS6L5LC_)H.OI7>C:@FR +CF2JA.:9AND:JRM#RP?S$
M>#I749T(2W?$W\XZM:-/(&I![Z$0,5/X\88!:0PQI5,TP3]T H^Q< O,5\2C
MQ@G'QC-6T4CCTUY=4[/*ZI!?L%S)3&0U3>OCXHK@95FGC@V4)\.4CD^H0#.3
MJOY>%TQ[W62UJ*J'+$]?X>6G"K?*<&E=9W4IOV2O?4-T2O_<.#:EXY-_GKS]
M</;NY/WE9C F/5YOQB07OH]AMXS1)_FRA>KG[C9<CF:S[LZ>M2:[[OUD2_@H
MY,\P+-4A8R4#8QM,PQN@5/LZ6_$W5BH<N44SSQOP/VG,#,>&SK<)]=!%%MCN
MP =6>'B,+FFL+7-('EF1]-;I_MH4^=\5'_5-&$&?Z\@Z:Y9R&+JM<&X/#4?8
M*KN"X=[,OVY<JW2:HM5\G36')U0TR,G%@0.QR^0CVAE^-YF4%IB09KV:KE6-
MM5I'A=EHY6/K?>N]M;2Y#DUW>=O!&Q\C#K5E]7(JY6KGAA.0P/GMINUN/'\[
MIM/=L10EV# =R.Q*%7G&^G(8E&(D38TXZ%59D?-C,AO#>[7Y[_7;,_AR1_ '
M)]CBLA$8>Q^S'CP%]305$:C98Y50CTP0?6C3?YWNM7(DNE\,9K,R'M=1YSA
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MY.E0.S;AEM$:U!DM$ML6 H.K5_,"'VY9^1R1H[$F&'=IMFSE^*S2N',#1<[
M'.F@5E613NO*&#KXIXX=M;9;]\9&UU&:E57#X')FSC;LYM-%^H_&"(_9I,2-
M9:.'+$[OULRBHJ#+=(>L1G..HBT$U6C7LZTB&[:H#F!Y.*_> -.\KNK"!")+
M(N82=C1F?RLI\%'"" DW"S_&;923L4B7:<5#W!(X["!W=/SH]%'G*"19^<5O
MPJCICD^BV2<4#*)X02)4?$F&K1<8[P(,+!-ZHA@/E<]M?+MUCPNT Y(X?(9
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ML4\4AKR\-@9.;V!UU7@-JM^%^PZSUGQ*//\,#@$!J"LA'[8/05A+9,HH+8+
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M%)0U/6:QR<C$.9NI$H*;LN0A07,1*DC_#1;Z(E\EL0\PQ]1GB#:Q7]Q5HK<
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MP(,CE0!X\N"78)A0 2BN*?V;^HTYSZG!DI3H'KK4\,M&;3PJ$*]'EPE[=9$
MX);?12A#J0$YEGO3GW8 O1U #P%Z))I8Q?24+]G&]0(8)L9C#A%0R4Q:-0"G
MQC1J5,TX_.F^8(LVE9SL=5=S[-N<7PM+2[8)RS8SXN>-(#X?*<[78R;%N;I)
MBUA,UDDV1UA4,A"8;^RQE%$SWYS2=7L&\DM[L5M^J>MS:O("F/@"#185DM0
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M>:D%T.)L\,>:%Q'B6K']<_D#,65@V7+#83![DSXE+T9KFB*&=08SG^99%."
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MA(<NWLJP52I?HMI7C(&"H@-U>LSX3@P[Z:O@ @WH.LU@N,P%1T=QQ.LW;$#
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M-,/#M%@X2. ,_FD8FTPW3N_B^*TZM.%7&"RCGZ,?OXQ,QBPCCS%Z/TND6_:
MW@,WJO>4="0>9T9;B*3*GGJU.8C'2;,>\=5L0(5E@T9PM_P.\K>YXR3^E;QK
M]>M@FHH_O:+!L[.-+-^R> NDKT!,825603,%BZ,A_I46*PO<YZ3@3I>F; J[
M2V&X>6UDHOG^-,H^%?6JP@HI>%F^N$5A .884^:G]9)D3DK5B.J!K%Q,/D#
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M) Z:2[J:Y4=<_].86MLB:9'N&,#J/76%9.P\]<U\7/C]!E$J3\&E\YOE4-)
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M*\3C4-;%+5Z&C=&H'UG^ONV;#78;@AFM/V<^<SEPS T=%;,;&,X6X'\^C5G
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M*.^+,JEX+\ZL\XB8DI&<!71'!#M-V@QHB. %++F9>P O:S#<5'>=B&!S#;=
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M*ZBNHEM[7V24KXG; 0QV]*WP_70\:PVDG0VV\^"Y\X8'/J#KU!I*->)M#A$
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M89J/?Y"^[2YH!'VZAD&P(/[[0MR"_R,:NM/WS3&9?)F%P<IWU-^FX@?IZ<;
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M&&L1H\L'L;9[5"-JE(QJ@-2DC#)0W'!-S/Z;SUW509K(0K6%&.J=:4(_2PG
M+V=)EI)_NN0%P&V3E;A:8KO=O?B@$U'7IS,WMMDTL[L"*!['OM M8('^316!
MI@!LLNZ2,C-QR@PQ=YN<SZQ67D//\QZ**4_!'XB;S\$_X!1KAE,4;5*J]^$0
M #/\]!Y/&T[CKWSHA1BQ'?$)71;&K!6E;3XM4O'1)*>!'I[-PA&E3[C(@983
MVL]$\!(3#P*%,SG2P0J"1>S[]'#2"Z*1#CG D&6%*B$[GB:.'1$'T:YZ<HZQ
M;3_PHEAX%W1_KH/5SYEQ#'2P<7P1X"#A)ND6>VJ-]Y0^A;LK]E#5-#NEQZ5#
M!^.GL(H5<6;<Z!DZY ]NSAG>"_!/:_)CO.9/C:%MXB8M':O':\512?&9E_,X
MQV,CB=F;,&+N/BM= 53_?Z!BCQ2WOO45 +L]PSF).I[I+\Q@:C.#J\R,[##A
MD$H6%34?I6J*SM8K'?&^V.\JP;_MDX@YX\Z83WSC_CDY+A^=1,XJ4V"T<KZS
MCM5-"S_AVOD)U][IGR@C\Y4#'ZEULI0B%\.-%Z#H] .N(ZC;)P]/UU8<@H;E
M4H'H1!YFK/C<*0^LA&"R5]JJ-6/5^D:L5SO2@BD_X<#3VK"V%'T)0^5JZHV=
M<<:F;$_7"W2FPG]":3(5P!S%3.-=&!Q:F['52)]S!YZV1V_3S]F_<D$EASNO
MAOA"045R-.NC966+'N43;UFJ'%8 7S?C*LD%>TQ$A6!DMI\]F74$=YK,<?%=
M6"%=I:N2."AXC+=1^M,R21NH:O^\8OT"ABD.ZD7*93Y'U [7YE1>_L=<<D2U
M#RA^[J,";KD?UYE6Q5]-OLEV))<\8H'-[(29?;(!Z+&R,Z^'E$"R'I"2/>E7
MJ(?#+D.%?V<ED;XT6^6IS)/90\@+HIZV'F%6^BZ.4H=4?3Q0&SJD\,20EXHA
M9!U)RRT5E47_(B_):X!1TC57>3XX)7QA*= ].2D?X608\>UO._AA[ ![EE=+
MDPXI8@:.#C:,7L-:I5U4/ P\@TBG1^7CZB_S7JA9:/-B"*N63^&&J=OS[$\]
M^B_R)QH25<M 1T9RDD6BUERAG8B+OS<.Q<47X#[/^CHAH1)XPV"*=<,P^M<7
M(]#J.O'<Z8@D%@]8E(B>@;:+5^^H7'FW9:NWNL5JN"[:@O=H&L+"L;;.@_CH
M>0';)7)K1P)"JBLXQF_!'M:EX?PP>TX_8 N?EFOUR!I.#BR#&W8N@L'[ WCG
M,J=/)=F8C:"D]@K67&]@^0P?#9P)2ULP:;']@R(AO4RC[X\MTJ)OS1+-?;U@
M!>HDKMGTU]Q7X.=5C9V+N*JV*1%&3N7J^?R9R_HCFO23&ZA8AB>6X<_'1^5:
MI2!QGB2N'IV4:N^.L^A<0$ONT%)?#"W'!=_G"BW'Y>IA0>)<H:5>+9U4ZV4L
M.EU RZJAY7@QM)P4?)\KM)R6J]6"Q/E"RW&I!A!>/WK<CZF3 -<V8+NVY>XR
M7+@GM9>O6X-.E5B#+-]T="R@&^5E//]42=&:L8BFO5HTK59$TQ9%TXQ/_$.R
M$-"B8XJ4CM.*J]0L*DVS?L$X<Q1IKMK1HQ--E^-97/!U;6)Z/Y9W4,3]BKC?
MEKCG-<85090BOE?$]S:7-8OXWE;Y#Q;J9E%QU<5%.0NO3GY>G9-:^5VM('&N
MCK/CD])AM5I^-^\#7K;C+!<?4GYZ_T:XT!::KYOM6<N?0EO.-SL7L^=84Y6R
M2@FVB0[+97@]ICZ'+C;F*%$?9W/Z2M=,0>9)8$QFU8DA*CQXX5]#K(9'"3:F
M!6S6TT[KI9/CXW+E\/&'-<(^$% _KO ';\F1JY6Y>8^VV\F;X\&LAJU;]X"Y
MWA96J("KV:6@&A-Y^WH[B59<B:8^NE@@M? )!CQ(5#GSV<"C%K[LSX='M=+)
MR6&Y4HD*HL^.?K:^5=QY,[8X>"QKZ8RJ+C8Z W^93TZ49P<[1KLR$B%1ZJBM
M"Y("G!Y6X/&3:2W3>#I1Z:X@5"X^(6I>Y%(I3!?&ST<C1\+C9VH4S8U'?+>$
M(+J0"A*-2L^B:&]90/@Z0'B]@/"<('RFXEA[H'VM*D.%7.7IVW4*$F:="6*[
M)&BP!EQ^(<2]N8)P>GEB$8+Y><>UVB]%5_H"@O.&X.,"@G-K?S<2;E0;N<._
MPV\% *\7 !O(C>H19:(R*-@9*_EL;]UYW-BO!);*6 #VE,B&6=2=X.<.F9.O
MZ&^"*YI(QH!CX0*X!S?#A1.\>LXU4XB9;1(S^<B4D[61*1LM0!*USZA(\>M*
MCE=/8'OC:%&D^OX4TFQ]X9RFY_9D/S3J#0K\9M1Z'161>=#(W85K?)93[ZVO
MG;8R0'<M:$XCSX=Q)(M(+N@H0AY?PCY0MK!/,EP[C-J\8-,@WW0O(5T*N\Z@
MYJC$"+0J[*=!1.A.IOY5)?I<1;$VJ; _28)XGIJVK:?W)Y\Z;1(0J9?HI\8)
MQ$^'<8+6"@K8D"6J7.+-W G$]"5R"NPE<M3J#M#8V@ 4-*JW.08:8%\CF(CO
M3%+-H1?51-PLY:W W<W&W>*(!1ANV!U)LRCM]*<5MKRQMP%8(V=&L0!?#5+I
M_B0I<YC24Z1-4YI^AW@XO>?GLE46Y305?0%6V1=@<\)[[ -LP:Q^%<_=INLC
M9@KI,06KT^V6';DV5DZJOF_$LVP$4*S6:]M@S)7B).+(F9J=N($7/J-#TUE<
M6WXO]4JITT@(C'NAP[RQ*Q2=Y'"<Z'4S3F.)V<%X=B79#NP<&_FEGCR \6*5
M?#\$6($KLH<) GC(;4$FA"W]",UQMC[P+%7%UT;+@YB0)$Z5]I]W:<>C0QM#
M2/<<^\9E#(Q-,V^(BJ#?<$N_2RHK'&+*(LK]@;0&;.R%CLWZZ(A7:+90^[<)
MLQPNAR5F@^J!J2]3^ZE$3>D(<F$F5FQZ\=#7K],?<7@8.?-#LK+0;G)QJJXI
MAD]*Q\S\L#/<B'IK9??N.L=6<'J^,$G=V0"4&E^/@#HA3(@$('LR5[+$Z/P@
M6G,.WA(;:^=1>S']=*(OP_@!OB<,XAQ//%NH8(9^G-3IAZ.1[JWI\"X^$A<=
M7B#A#?A,>,#84]]H6%TA7&9[+JVMQ+_QF?2!!+H"Y='@["+)LOA)KU?$>_0P
M8&NT+R-]#U^(/_65? 2JY$AA1U;8;UB5GW;94%@#[DHK)KLCA>O#<Q_$],%>
M%SM_"GM3#=1"H=@<A>)=H5#DI%#<$D3>(:^Y*&WNXF;<;T.WB'UW%"DUEFZ<
M9UHR#<HS,D/GFI.PW=!UA.^#H(9[L)UOXF:\9=?? \@^H$R?D;!D#W>O@^Y*
MNMQ*>/=,OQ?3DSG9V1X3_4U;42.6IGVR^31MUT25BY+BA?MP/?%ZZ\,V+; D
M^A/VQ>?]. T]+ZR[BAO>[IIX!(8NC(:.R-&=E.)CMG"%SI+7M^QA' -!30&>
M %H9AZ()2*@XPB'T?+!A?(@.0AZ8?O(>=JV-$FY*>.-PA \*1Z"68H<P@4>$
M-+J9UD^I/N8PY!)+I/Q/=?V1-B9T]RB1[!V5>@"I\GZ@0D)I&$876TNGHC9:
M5V4]&)M.EX^FIWN2 7ISHU73MWJ2]/KT<802@K(,L+LT!YN"H.7?H=W7D1[I
M3SNBD6\50'\ W/@-AS,*%9AWL, >C1ZL/<OQC#&%PR$\1U'2#2>40J07%(T%
M3P5]X"+FZ [&8=S'F,X*6#0*AX_7.NF_$"&%"/E!$;+U$:@FO!)PQ)6<->6#
M=%C3LP5+]\U^=WB:MPI]%RH_1"P"J,H>$EYW<CX=4>+ $[I)NA,8&"C()DT
MQ4:3.E&BF&A%'07CP%6TZDN=$4TH=F 0A/:U5T4#K\XC@%GA%NSA :R&9:&V
MWT95'F;M@W!M-MJC/;:;Z$[Y&#U8O5ZNU_;*[+4<)/F>\,X5<C>8*#L7#0J<
MPD=XU'KTS-W#<./L8NKR[-[IA4IW:-5[*%%[SFQ0DR_3> [S6EI;TBG)Y)SL
MHOX&&D@B+<<6&.<%LK+Q0-"[,R^U0-.#'4Q^VH3#/*&5H"(%BAGMKWT*4:+F
M2&.+XNKD..7*]HU>0[,D=28*>3N8HP.*:_P-LSVA/9Q&W<)]"[-+;F8SEMDQ
M:X,;!CX4"BF#FA=U+(Y<_XJAC4\NV@F] BX8P%@UM? [0;Y9HYZ11JFU2[+0
MGSN.V#F<<&@K-O*P+!T.:\[//?MFT#9[D7:M0_Q95Y4S3MUJ35QW9H75T\X0
MD_%$(9>^22V(AA@ UQ-;P"8PX1&"\/1,2R9E:J*#%OJ:GA#Q8^:NCV(WEN?3
M#4-.BK+)\.)2P1H+9!6NR"R!384V"GN0GJ/#7WC7#[&8.9ZK#1R]$B;!+(W2
M&PP_!29G8O)5=CY+HAK'XYY"W&YQG))VG;]XMS^BW93T.>^YXRE8U2.Y8\@.
MG=TM5*WCA?F$I5?<<X_097GE0XKSZ=MCC>9E>C[6I.2-G6_9N;C3'JI\K,@D
MLP X[1.[[%R4&<NJR;'H[%\IEL[A4D>78V#-F.FL6G[W_B#,QSY/)8/L8E:#
M"1V-E-1NQIE\F3VJIZ+-BNA:%"R8!J%!W$_'G)Z(+RVJVURKOTK=YG='Y?K)
M#]5MKI<KM5^2V)\N,W@45QD\6L)N3PJ=:J6<D#K5VA,>4DP.@OF>29>>VG4\
MZUOJ>3AV/:=:/-B?9[F9F23R,UU/#;F30A?SD1968(<2QQNN>:DG)T:G>49\
MQO(>'Y7?G:QV>?-)5ID'\PWH8O*R*>]<G!ZST,6,0/6 D&;B*"1*_%(4?U(F
M5O_G"I:%&J$#@3*A\#>J4T>9@[I$$EYJ=&9NXW@Q3H,&/%FXB);FIQ(]![7>
MN9 4Z>Z6UF+I>4O46S?B,,ZZSG#GXB/J"KOU/9;-,9H-!MZ83G=%4UJ6;I5K
ME0GM?OK]A?H9J M&'_CHH4,Q:1&NRUXROIA-8+CE;:E%9V8*.^]5HH[SS<VV
M*^AX*>"K./\O!Q)/DV$VU*([S=N>,U5@$IF'E+CN8(F9>UQ"O/"C5'[ ;C$5
M<8]P^2G;KY2P_6Q<Y!BQ8Q,234%)QKCKQ6&GGJ?T206=[;CQRY>[.3XK7Y/+
MERSP0^?C;T<F$72%*UCD"15Y0F](8M?G$RRV2V0W;!O#/LE2%7D+;PPH\_G7
M,E]0,?L 8U=LZ@*M5O/Q5;Y>$[[M0+1-#?EJ9C7^R&5X(3^%-IXA/#P\9)TQ
ML/:EYXPPJGGG\/_R$KN^;FY>_L#.A77@,3.S.TX'5C"?&_-A)-8>2^RIHHK#
M9E5Q6!T/U>OU]):X5# !T'1#T$58];2R@?OB7MACS[-9DTXP)[+VM/![=U0Y
MKF_@M!I!X$8Y@Q]"J;LJP+6P8]3&36?;A5XQ_6+ZFSW]G_0<Y>@BHK1 RQM)
MJDGX0C_1SL59P5>;-?VMU_,W9#YSRY/6.2N%SKDVTTKJG)]1U42=LPDVHR^<
MC9O.FX#']1.[W+4+6;N9S%3(VK<N:ZN W%7V53K^ $_:??!"1SQP+(6@I>V[
MC92VUY[/&FY?.)A*F!"V,)O:IHM9'6)IV$/I2C_0B+M)F57K?H"FB+Y.0RS5
MRG87:<A1*_HL?61$[@HOS+VN^#H'4-\XG!19'S^'.^M>82R'67?2!0F7$=B.
M#N'S(.#60-A,Z'QS4(M,B5@EHBP,Z0)4C1"MZ& QE0&V30'CN%G*[&GC7*JY
M:'),DTUP!IADAZ4@\,@VD:<K@C$6J@T2Q0^R6O(-.3[?3^2NZ-K)B5P7I '6
MCJ'"MZZ7K,3HF4+!8R7A,>Y,<QHJ]Q4/R2^G*U[KX]^ZHBZ;)@EFE$$66*L8
M72=$]KD3W;H@<P\/JRN=T8]Y,7C4O91H35-*MH[ @?D2EH KADF)WA L%5AA
M',8#9>[K]3=#Q5S_*0FBL3YGJ'%AY35NA+/523Z% 'L= ;;N]<URF'4KA@ -
ML6SHV;I@$<*D3O(K3>M/4AWBTK1GEZY.--^#Q@"IHB8X+'2Q>GG?I M*70+=
M)$%3#]DB"[J DS>VL0!.#K</3JZT<F=Q/VYC@3JJZTL?5#%KDE8!8T1)8X?6
M@.=+Y,Q>GU*]->#T09=2NI,@M7WPG )5"E1Y._L+4"6C>?A;1Y5VV!W*1/?2
MU,9/-AN5N@@AQ^MZNB@U&3]91AKKAG3*&<]C22P=AFX^2YH6IG'%K_A9<5^^
M\FPC@Y31V,7L:UW]+_6V$ PT)U%)$C0N4T;;3M;11CN+[&#SK@*]"O1Z,_L8
MT*N^?>C5XEC>GLK_HXT5>'&A3:DBSQ<Z> !N+*IT:CHQ4\,Q/]&%) P&GH(9
MV[J*0U31GZJ9PJ4\")7P9WJE16XV_>:$!W&*-UUJ-4:>)U%B=Y<?T?2[]*RP
M#0^E_@54R%1^$WMH)U*I01F$@2ZO:H=8LC0>6HE)I<2#1]5FJ==8R)U27%7"
MO'42=8LC_Q3<"0O#'4#I;S,S$40[W2Z,+$7J%S;U Z8@UCBQ8E@E5UB(^(]4
M +.5GH9O)2K$A+71%TA="^*1D.^45D&34M\1>'U=?%??&E,"O:W8.,U).#L+
MY"Z0^^U@&!9'VS[D;O(1=;\ER"4?5XA](U%Q1&TO474^TQ@E[SS%,P3'8M0^
M=6QT4]T-"Y@H8.+M;!B B9/M@XE4[!"WTM"%EY'Z,/ <.]FK")OG*JS-A5EN
M0S'L@FJ#'9JD:\D1=^#WKG !5BS)E<1K4!%QZ2*P0J5%O^G.4![^*H8CQYOH
MIYFF1-3UCE27/@8XIU7=$ZKF](4Z8*P'$GGLM-U+=P.&J2'UV*.R)J3U8 NK
M^-JN\K[AK;N>Z4H 6A30$);BV]ZTVQ5HG@2&<2A6Q 6],^*5,U'&;',[@\Y1
MPZL\J;QRPCY*PZGCX[E4C,JH6W&[8=,#AKI7^>BGI7KLBCI;:>N ONJ;"'5$
MBVB<' CF2%.G[OGCF?;6U=D*U/\7Z\$/AYZM73"Q$P0],VCM4."("NA$C9=U
M6[ A)UN$.B/ 5W[4X-B%%P"O])(C*YD&OQ3RTI/JQ4V;"V&\COGO*<I1:FZ"
M<A;Y]]*$HVO2V6JY5WSY1_OJ]YM&Y\M]J\T:]RUV>\,^WEY?WWZ]NOF=W35^
M;_V3\@5?OY;^$MGHN=3)CZ^**AB;7P4CR:P9>::Y[]RK&_;UJG/3:K?9UT^M
M^];MQ[PR>[,[FI!0)R]:[+B:$97)/LA:W9G BK$>U1OD70_N-[ENFU'[.._\
MWR7U6%[S6>(.7FTQ_VH%*%3_H6K^I^5:=67EWI>U=$N4:S]2<?@YY?,!T4]?
MB9ZY _%UX^;R^O;^\BS6E*8J^)OFMRUEKTT6,05GOF7.S ?X=BX^?;EL@V%(
MYZO!,&27M]=WG^#GW77C[PTZ7UUBG%V"LCW&$*TCAQ+504=RT\,-^WMR=[(<
M4W)I3+)4E>;Y'OMHM%$G'E);9FR;U'?[RAL_^CV^X'P#_/DO/)K\87(V;T0_
M3I1-FM["L_ZPP\IWY=(R#FF][Z)?\.7/X>PS5Q,';;IHMT>^Z($<K=50T:N.
MCECCU%[DAM'_+X!I^<#T2$3R&3MX*V"-;2FN7;G6VN):=$(5CSNNTQ 1S_H"
MD-:D>[FY8MH"O_V33OJZZ9:\EF6-U@@6*>:S$EC4*[(YP+'0W_*FU<"%L_[7
MOS:N3\Z!?\ :NG','V76#KG_TDJHCU G^N]Q+"QV_B;O@1L^%&N_]S=F>^+6
M#&>V9K%KWMZNZ6"!C6+;+*^-*D:[,6GN_Z0EP)P1OK3IK"\F1L,@'ME(A?M]
M>]SORXSC%O&?@@$+!MP@"A8,6#!@P8"OS8#+BX!W6C>-FTZ1X;.-7+0.@;RU
MW!3-VT^M^R]M]N'JMMV\:MTT6^T2N[IIEE/9((DXR@L3E'<NEE?&_TTO<7(Z
MD6DO7;JIZWC6MU0,!^])1$Y?+K>GP]1_DO7L>FK(G107F8_2#OV7Q\=27N#U
M:U&"3O%+X;K29Y_+F%C?$UR]N&E)MO][>UDJ[2E^.5.Q]66H;&;:[N6?<7F^
MZ?5O#J3HL:E7\E:?!)YZ(0M5M5!5"XN[8,#U)M]*&# Z$?\FDSU'LP+:]4!X
MI,X%CV9/J2Y#,%<BN9S3ZA5GI3?KK/2C1_VSZA[D>'IZYZ+UQZ>K#U<=UEA!
M'8-G3FXM0?+5J;*L)<]1U;[]TKF^NFFQQLTEN[YM-CI7MS?L]B.[;UU^:=(?
M[;M&L_56CSFM,)%X,4,TE.0.S.Z3<!X$*D X4^[Z^XLAX!^__OKKM(S)JN3)
MRX7'@P=<]X3L..AZ]@1^#(*A<_'_4$L#!!0    ( *B);UBY!6B3$PL   ),
M   5    8VAR<RTR,#(S,3(S,7AE>#@N:'1M[5P+;]LX$OXK/"]Z30I;?B5-
M*J<!TB1%>^@CV+CH'0Z+!2W1%J^4J"4I.]Y??S.D;$NRF[:QW2:M SB1*8H<
M#F>^>7"4DW\T&I=)1). A>15_^T;$LH@BUEB2* 8-= ZX28B?9FF-"%OF5)<
M"/)"\7#$"&FWO$.OW>EXK4;C] 3&.L\?DHE/NLWV8;/3ZAR0UC._U?$[77+U
MENQ]Z)_OV]X7[\_[_[FZ=-->?7CQYO4YJ36:S8_=\V;SHG_A;AQXK3;I*YIH
M;KA,J&@V+]_52"TR)O6;S<EDXDVZGE2C9O_W9F1B<= 44FKFA2:LG9Y@"_QF
M-#P]B9FA)(BHTLP\KWWHOVP<0P_#C6"G)\W97]=W(,/IZ4G(QT2;J6#/:S%5
M(YXTC$S];BLU/7BR";<K?6X:$QZ:R&^W6H]Z*0U#GHP:@@V-WVY[1T\7;8J/
MHD6C=(OS%1/4\#'#T0OC!H)1Y0^DB7K5*58]F<Z>&\K$-(8TYF+J/SY+C=2/
M>[9-\[\93 [+$#QAC8@Y:KS.4<^P&].@@H]@3&SMN87[L&:"GV/W%^<9K)SG
M'!X>*/ZX_O@5$V-F>$#A6L,&-C13?)B3,*:*T\3X.J9"- *::M<^<;0,I AA
MCLM_OWK]XG4?!:U[=-(< -/3S2TP #EGZL>N\+]/GCSY@YPS92A/"$^&4L44
MMQ2NB8FX)NPFX@-N2$0U&3"6$!ES@THV8 '--"-P#[JE3.7M1L*M1:\IH6DJ
M@,B!8$2Q40:2(M64C#(>HN)[WY^O.-:&65NAY[@WYAK8)KB9^A$/0Y; Q/_\
M[;C3ZO9.FCC*PU]S[?0,H#JT< V;3I.0?*0  HID20B_+V\"D6EH(&\XT >B
M@EW.91PS%7"8]F\G:6<CQ1B.L@W&_"_3A@^GV^%,[;2/*G([&TS$OIT59,\J
M'TI,IS67F.R.=%I^A"R0RD[3"*20RO^M97^6[B([?4L[7BW=MB3X6@H>%D7@
MI)FMR4N[V'9O'^$DIJ'CD95KP!&>(&\UD4/R/C!R (SM'-8)&/ANW8),@HAD
M)HA0U^!1C"+*R;^R1$><O.!2!YP!V&C@N5<G;TSHD;W[SUQ'_P8YZZ0N8BK3
MR)7KG"MU\CH)'@1'<N(WQQ(/=*S]M-6[I$&$PI6+3)%1((Y:@O?&8Y ?Q8;@
MA3HS![<93^H@F^ M\3 #9)S644CI3'&OJ#+3?"H<LTZ %X(%Z"N)*79%="AT
MYDQ[>?]MHJ%M K)!N_SNT_0V-VLKAN,CLHZ"W,T6N=9>6B=FQZ]OY)>5QQW3
MOI9I,S0(F>8*@ #-$=H^J\%A!A\(/0GXSZ#],"K31B:,I'1JS3GBB66[]^.=
MG)#K5-"ISQ,[YD#(X%-Q- P82YN'8[BHSVXCQIYK,_3SV_9.3NK(5$!:J=A&
M]@XA&I 7@GBP,L[3 JC'C<,I1A)"8KM#.D,C@'.3D92A;1M3D=G8I?2\I1",
M0<!X:O)GAT-N[>D4!Y]$',8"TX$+0?\D^)3(B6#AB(7NX1SN"46?#TW!$$R#
MG&B_*"'&3CV0"B9^7FO52,"$R*/X^7>=TF#V/6>1>P(MKP"N,G]VT;N+I.7)
MAX$T1L96&@KI"/QJJ6R 3,G,^$-^P\)5TEE('#CR_%PXC8)/.",][W:<2YH)
MBS?O(F6+E8%3CIU$3IBE$=;0@\TRK(%L9#[LDJ)IKT!%SNZ<VK97I:E\_\Y>
M4X56]]4Z/PD&Y:(4ON=-6_2TP".4*I5E=2F$:NLY8'=9;.W4SYVUOK34 /T.
M6Z<$@H186SU,E<38&Y1UB6A"%0,DL(JL[:,VNXA]Z"R, 5^/&80%N &@D5(%
M^DG32)..';X+489 A+)8L7):'0&:80XDQ&D1&5*F- OATH&!A_$@0]R SBD+
M^!"%$OS!Q=0SU[),OQM9L=@E:\@P@Z_P0)#'2L,AN);VDL-"5I$T0%\5T$XF
M10Q:&"64[";J8]/J]-9-%'YF1F4-<5I*OY0AZW@!638;BIKZE0F:'0#?-P#N
M_"( O,@JW3/P!5(@%D8406^WY/X"I6_GON_E&(E_)SV SA*H]JU.'7O=/;J_
M#-*HA&T(EW]?Y(H1T:XIC+L87<\GO[IHDRLE :7CHK^%W,OSSU8Z<G</72S\
MEK )B8%D<$ %^O+6GL T.3FX-7@=")OCS@F]QL@=H!-(7Z:;QP#V'(8$($_1
M,[2S.C-A%[QGK4UI8B -:)Q+1+CODQT4;SM7OF+]N&[+@*/.!I+"E33:6L<X
MY>.:E\LR;X]/UB+7FV>Z)GBZ&M-/S$X"6M; I-=R.%MQDNYQOK (->LG#9>5
M?B/A:9;F[MB0*PW^6Q!Q-G;C WS--@>V'KVZ,P@S!<*,;;G.!L*=*+"YOPNL
M4$S#F!: %IO'QOF(\ZDV0OWL2"-$B0PS<$!-1 V&RWBFB,G0>8>SQ' \VL8D
M2J#XP.;U*QAK[0D;\H3/ H^EQS>4$[#^,>*OI=<"]2Q=@[9EM2&S*C*PFF!%
M:[YW C$=R=WC&Z%O?S.R10.343'/5 !]=J%.T@HF]BQ%=D#/H9(Q>7EQ9HWN
M1DC8XWQ#B[$9M+H+<$!NJ&:.X?NH"CA-O;R-$YD)>U M8^>DP%[-QM ZB^<&
M^@OLP/U%EH![(0<HU<ZQ< F][Y"N7V&I-V"H[F"IU\#B7;SU0..M[I?BK>\>
MB5B]V_G)FU*A6^2QLM,5.=B$=*VW6U]6U.7M7->[/R@=X=RN&C]B<??0"[^T
MB<G,WEK?"R\F(FBU]&92+;U9^.KHD;(X%32O2S/EVIUJVM9E4[%FA\Y=:W?&
M9YV%B<("MX30@1P7W$";DF4W+,BL^XHDA4P@35,W2&E.2S$W$9@1F\8>9LJ>
M/E&79U#LKXRK&;6+="U9DL#- 6"Y;/1XM9@53P<;[056E4!R9M'N)4BZZEGW
M.U)S+X(&GT9*@O14Q+]0 UN^D1/7J;"R5:&TVZJ0FM?>YDVE>MQJK6]*1ZPQ
M4(Q^:M A!!D^%1,ZU3FF'CWU#HYF#D9>G-NJ5/#>D\K@G6':JF$ZW!FF;R\G
MR["^, 5<W4!-V<(PE4 ^IE,T*\XHN)2'F4@P1XNYZX3E]6>N;J!JBUQ--4T@
MSN7 :"I<$(R=YL\8.6+6>+B'\933<),9F\BSW=&$:+"80($VRKYGX9'W<!.B
MYU@J5B)IA;7*%Y+;,V>6AC30''-,. C#TC8E$QY 7PY$SL]7>8+GK=P:26H6
M)A%&L %XS.C\F#*B8[:@=7:HJ4MVM,"*(M6N;D0.ES5A*Q'"=BOX*Y7ZZR9Z
M"\$5-] [6#6+AF51DRE,<(UFYR5Z"YGL/QY>V7]Q 3^DWO_G?Z/A0:QPYSH^
ML)?*OG/=Z>N$?.0F85J3C\X<U3=ST%*L&K1&<NY25 RU"Q>Y(F&&5>89!)@*
MV!-"0)DJIJ&+9:S>7#'J5EA\5P5=?F]R'AW6B#46SVO8,@])OBJ'[%:/B;^<
M))1;FU-(9N6QSYYYQ\\>+6=XJ_&(G,4=AZU'!=85(Q!RZ!WDS+17GU>";\ZR
MEMG:?E:D8-6&K13RKWK'YI9XY"=D2>'%&EUZL6:U,_J3B,A:;L$O25@Q"P%P
MW+!YB-KIBZE/R)_PLU1.L<4 N*F;Y$)YY!T>A;ZQKYK]6?WYJ=3WWDK%O27L
M5G']WK+Z-KB@8QZ2:\/%A GQ!8'= >TO1M@[&C._C&@[\/JU"',BL P4.TSX
M10GKX[_6\<GYY?L=&/QJA,WV/N)L2%[RA";X[S;(>WQ7DZG/' ^XU-X:^9#C
MK\R'W+.$X_K9Q;$$3^T+R<6F^^=6]K]EG?X?4$L#!!0    ( *B);UA<>41K
ME#,  +1? @ 5    8VAR<RTR,#(S,3(S,7AE>#DN:'1M[7W[<QH[LO^_HJ]/
M[6Y2A3'X%<?.ILJQR1[N36RO3<[>4UO[@Y@1,"?#B#,/$_:O_W:WI'D CIT$
M"7#FUCT;#/.06JU^J?O3;_[?[FXG&O'($S[[M??Q _.EEXU%E#(O%CR%;Z=!
M.F(].9GPB'T4<1R$(7L7!_Y0,-9N-8^:[?W]9FMW]^T;>-:%ODE&I^Q@KWVT
MM]_:/V2MUZ>M_=/](W;SD;WXU+MX25=?7E_T?K_IJ-?>?'KWH7O!=G;W]OYU
M<+&W=]F[5#\<-EMMUHMYE 1I(",>[NUUKG;8SBA-)Z=[>]/IM#D]:,IXN->[
MW1NEX_!P+Y0R$4T_]7?>OL%OX'\%]]^^&8N4,V_$XT2D?]_YU'N_>P)7I$$:
MBK=O]LR_ZMJ^]&=OW_C!/4O262C^OC/F\3"(=E,Y.3UH3=(SN',/?IZ[YLON
M-/#3T6F[U?K+V83[?A -=T,Q2.&;YJN3XKLX&(Z*+Z6:W&DL0IX&]P*?7GJN
M%PH>G_9E.CJ;?\6R.R?FOH&,TMT!'P?A[/1OYY-4)G\[H^^2X+_BM-V&:81!
M)'9'0HVFV7Y]EHHOZ2X/@R$\$[\]4Q,_/9BD[.BD>0+_M-3'5T>*#/VEK^L%
M8Y&P*S%EMW+,H[\UU#?P;R+B8% 9R#X\B/Z<JH'T9>C#DSO_]VOW7;>'7'9P
M\F:O#Q2?K&YV'C"YB!^?'C[2S@RKH]L_T6/9A85.Y?@4QF*^(0YJ%7\K[L$O
M[H,DZ =AD,Y.1X'OBPB&_-=?3O9;!V=O]O"-ZR&:-9ZXN/ZU<_OICKWK7M]=
M=#M7%YV[!NM>730M\T=K8:HGEF?:O;KK7G9N6>_V_+)[]0]V<?WQYD/W'&;,
M;JY!5O[.SJ\NV<WM]47G\M-MY\XR 8Z=$Z S& @/91I[+_IQQN,9VW_58*!1
M#E8SUV)I5[7/CYM'W[G1G[B/ERNDP^9162.EO!\*UI>Q+^*_[[1VF"?"4"N>
M_.]DPCWSMWZBNF/7DV'()XDX-1_.OI^X9HHEV84#QC]IE+LAG\DL/1T$7X1_
M5E)L:BQF;=(8_O/-.-5EQWK*J5_^[8>8\%[$:>#Q4&\ V@LPW+/I*$C%+E),
MG$9R&O.)'NH!TEU35H^UVYP?4O7W-]GJ]@L]"$84CWE8X3K]%4W %YZ,.1H)
MN+(R/OVE1?^W\"LNX6D6 =GQT\+/ZF6)# /<G'>?/GX\O_W]S5ZFEV /UVB/
M%G5U(NB/+$F#P4Q]%<#0HO3TX#CG)2642.DHH=1\O6JEO?/VO0"*\)#Q"%<4
MK%L6\FG")K$<P8Y-61IS7%X61"P="98(+XO!)H.WR $#>U..P7*>,> AV)1P
M$9ALB4@2("E>,(8'Q@$\/@(23[)^&'APT0#7#ZE.;X6;^F!7>R/U1#]+9_@I
MC8$Z3,;PBF@0 &T\T62]D4CT"/_Z2_NX=<;#1!:#A9'(2,!@) L2QJ<\%D\9
MQ2"68WS(?4!334=P<_GW5#(P3D6<T)/'?$94@>&H,?P62+1.X<XD@UG0Z#QP
M)XC9QK#^\+![D:0P%YI4@X&1/M8W(U%C,<G2,D%2,00B$QDN)+PX2]B[0-YY
M 5(A 8L@\IKL12J' H>E?)@@3>#]_03FP., K\)'HY#=;^5"UI(VL[@3+Q2#
MD4I<(=L37=IG+QM$\5@D69@B)_I!,@Z2!'B%F ))J$> K"CN1<3PD1)6Q(L#
M6%R]=;S@/@C)^QK"2/B0!Q%P+]X.^QI^\S-]8>F)Q,[YXV$,(@8VH2O( D:^
M2_EGY&=@8)#>.#HOF #5T%J \1!7LK'@21:+%\E+8 +FBU1Q'?*PX@H)6Q-O
MC85AY[Y@? (</X%MD=*^Q2%,."J(+.0Q [\KH^5HP(]>F-'&P&>$$M^%G#F-
M933T)>T8R882!ABA:\U#PVTK6Z]0I#"I7:W43W?!RE"2D*W\53MO>9:.I))Q
M31M.QB9(_1Z*N&X$P@+XIZ=%/')B&&"PA-W [O-FQ+ WL?2$#VN>@,3!V[9>
MI*C)V9(HN+%"U(^P*7@8PDX9!![HC@9LGQ@L?@EJ!.DJ@-AR)I0BK4@%I1C>
MP_Z>9#'H4W,)T%X-O6'6P#Q;OQMDR #64RL6$!XCN+DD@+3^$D)))E\,@HCB
M*_C\ZB/-$XFF[ X]%;BL?6P&>U?8 9TO(/:BH6#G7HH_MU\?'+(7'&8)TL 7
M_C-11.5IVN*=)NS)8K% F_\!A"<U4"P^0Z,&=N-$PO9%3VB BBD"J:QL%Y["
M"H_[:*VHM0IB-@)])49 (++7PIFR&$H/1554>@,:564V!MT 4DHM-YAC:0RN
MD_!9?U9AKLIX1<ZKA?[ YP!U)YK L"5"4*$84 6QH]Q#;5"2_8+J*()YC())
MPHSQE"B-G6+(E!-7)CB.E S#?) )S!AF"VHNU2%;I!*.ZH$MQ8!? R(7$$?$
M(K^^F" N4OO5&=PY!77I>3*+TJH*1\LP5[]J*2JO*%$4?"85[V43F"%.@I8$
M'@O&<[&#'[%<&\KBY'I5N)(NRF9&BX9':=)DUX])(-BA%5.2K!WZ4PT.)I6
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MTV4X>5RLZE;FA:"I\[2VS [^28 MKR<;E?U_;$O./-S+RCY*H;NL@4F&V43
M^>$S::8$IED<W)..6RRR#NRT/%H+./6\YG"'QUYR *PD"Z!][K+/#-D'VST7
MLP- C^T"-X*\SR)T?K3?86=G.Q54Y W1!I?QD$>4R^>,2109G2*<QD[1U_*
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M->85Y,I1YIJV"FA>;7WLZ]%0%ZQ@/KO79 ?_:/"K'.C<H-C7;]U-PHY[H#N
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M#U!+ 0(4 Q0    ( *B);U@3W%5L7"@   [1 0 1              "  0
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M+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " "HB6]8-M$&4AL4!@ S<SX
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M &-H<G,M,C R,S$R,S%X97@R+FAT;5!+ 0(4 Q0    ( *B);U@;.  /UP,
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M#0!C:')S+3(P,C,Q,C,Q>&5X.3<N:'1M4$L%!@     7 !< $08  )6:#0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>chrs-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:chrs="http://www.coherus.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="chrs-20231231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_-SnhX9CP50mp8ATn7g01-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5guUqMGHzkGsdOQekHmiiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_942S1mhLyka6ZkBmZenXDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IqHD8wCCtk-Oe0InVzTD9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_kZ0HsUuPOkSNL1EUtnGJbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_sWN29oXoPUKV6kz5vOqq8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_e1HpM3V8pkO34aP3JnxjLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_X0KeVsHZyUSbmqBiyMUPOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_DuLOSPFfNUakKw9YrfEp6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">chrs:ChiefMarketingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_sKhnfgNtxkaJ97AXUGzpNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_0oZWQSLFL0e-jivOJv3aGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IWhFYTVSXEG3Qc-xyQ609A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2ZR7usP3sE6lA9rxzLUIRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF-Oa2qAakqTeMwji5pTSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wRFs1JzPGkC_zfkTJLKIXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6C9ecxQ_QEG8bE7IGXl6xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8tkQ9GUbnkaeOclpHWkaYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zxmvh3LGk0mrm79pZRE9ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-x0yoCYUqUKXgofi_PW4rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JlI5BNiMwkCobaOJnCtF4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_js5PyUWww0i7olNWi5CL6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T9fLg1zdZUuTqPJFq3Ewmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EqOtkI14-kOGNRiKyN0UaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OvQzecJ6mUOHxhU6qoAvsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_bovPFj58gkCF6OVAq9cZrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">chrs:ChiefMarketingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_1ztFg0EZYE-MyDgGu8F23A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_BTKj2cvojU24AiFKRX3zBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="As_Of_4_14_2020_lOYMm8IewEGa7ecW7rCQ6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange5.86To10.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange19.85To46.38Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange17.30To19.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange14.03To17.17Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange10.37To13.63Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange1.67To5.44Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange5.86To10.05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange19.85To46.38Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange17.30To19.40Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange14.03To17.17Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange10.37To13.63Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">chrs:ExercisePriceRange1.67To5.44Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EquityPlan2016PlanAnd2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2014_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_9Fk-bFLoyEefRodmTzt7Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gK5gYMN5WUG2uYVdwePLuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZaEeUbUKZ0m5v1ED2M0RTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_z6Il8N4kPkqJ7o0Wx5ZYXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_yD1xE6Kl5kOzUlgXuDoYKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_YusimryMember_Aem49C8g_EO-UPcinAmbWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:YusimryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_UdenycaMember_SS-iB5-1RkODBPDHZukxAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:UdenycaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_ToripalimabMember_fUCqK5DU-kekHTnpp0vwtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_CimerliMember_kv6U35_BGUWQFIX2et6tLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:CimerliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_KNuuvD7dxEO2mjwTXA6LtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_f8r-3G-5Wk-nnxPCHpt2WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_UdenycaMember_OBt5e09w-U23AKziLIjkeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:UdenycaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_CimerliMember_Yi451Ksh7ku2qLqz_SNLxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:CimerliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yRtnhYcLKki9OALzaJd-_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_JMBKRfq1M06yP1UncYP2wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_chrs_UdenycaMember_YyirJnaG_EuVQxR4eipeHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:UdenycaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_PdGnVstbm0yndk6laylDZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_10_2023_To_3_10_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_4wHJPeiz5EGGZlHVcqOJhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iP1gAk8B10WNqliDVtY6VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_tM3Ef_Mpak6Ub3zq_1vXxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_bli3D_4p8Eu4TDVPspP6-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_cWwUSInfWk6DbOgC8phq1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0Z36Will8EWLyeJWTqBk6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_R1ZNIhTdtU6PTDnnezToVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_CmUnXGsYHU-xLi_OavbKiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_6mauAg9SEkCGnWzdOVcIUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_q4XQKvn7hUuMY-hLmFDudw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_YjMCSisOdUGXZi2xqln_Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_XQIUc6d-XUmksooC86ywXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qgwSy_5jP0WkljoCN5grsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lMgSkORl9USZXjMIwMYQHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_0z3z_qR8HkiyEEOaFlpNTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_jucBH5LjrUK46koXbkAVgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_oL0nzgyjPkiv7bL6dvw4Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_NxhQ8-y-vE-qqYM8KM5CLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:Chs2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_5VUKYAUWS0WOL1uTbEXYnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_RpO-Vx6ls0enT64RbZm2Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_chrs_JunshiBiosciencesMember_3vcTLYS0gkekD3G2uhqorw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_drbbzBbCqEO7LriCD-yj_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZLR_IWpbikGexBZ7BUjpdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_S-PFsrc-YEyD32_Z5ut0iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Pnm4g_v2k6bFQvlK9UGDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_PoW1P6R9s0CVYOhvmiJS7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chrs:ConsultingAgreementWithLanfearAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_trchcL8ElUmTtWSY92BZ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsFNWbdr7UWhpxeQGE8rJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VcpbTyhPOkKFIXTOT5V2DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_2TW5nZJ8wUWRYttn81wTMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedRebatesFeesAndReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_u0BIpPgozk2LV-saZBzeXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedRebatesFeesAndReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_l7MKURXDWkyyeEGasiZroA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_12_31_2023_Oq6suCh5tUWT6TFeG9xafw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_IkAU-wbfW06hNr0VdkRc-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:VehiclesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_NewCamarilloLeaseMember_1n1rY0uyP0KFXFjXo3Ns4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:NewCamarilloLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_QSE5TXfKi0yFbPvOeiAHDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:CorporateHeadquartersLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_YusimryProductMember_-J7VNgvVG0G6bkwKupKhUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:YusimryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_UdenycaMember_couIVXZw9U2OdgPC4e_wMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">chrs:UdenycaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_Loyb6ABkV0CqKB-V5_uHvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JoIcCfI8pEKowyCw3vvEBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yPqNV7UizkyOlrp2llCvgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_v9SRmwDa7E2QVcIw31qKkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_Pb1Z3ozRJkOA77OkYuNphw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_s5c_u_nwN0uYnEawr_ZR3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_fo0yiw1iyUiG0i_wC4e7wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_Plan401KMember_GZqVTPVTJESoNA_KLec_Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_Plan401KMember_vkpLaKLvgkiXZssii_XeDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:Plan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember__qTNMulPqkyLxoNEOq3P_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_Z0wbfOYnWk6X7ZFZMIo1Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-u8VFwKaq0W-VpOwOG1Tug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-07</startDate>
            <endDate>2019-01-07</endDate>
        </period>
    </context>
    <context id="Duration_1_7_2019_To_1_7_2019_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ESE6x74w_0eBsyYKVq7Vhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-07</startDate>
            <endDate>2019-01-07</endDate>
        </period>
    </context>
    <context id="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_IYOtI7t0s06IRoQfEZsvfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-29</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4w3mHtTbxUO8oH0eEffh_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_DixWwtQqF0uRVadXYuAfNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2020_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_9RhPVS_PkUqmSIIeRzY6ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_cTMkGi5D4E2X87OVhy9Ppg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_M-uRNszAXEi9r-8LL3xQhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bYNDamUcsk2slttHQRFDdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_UbIxb6J1Y0GS_zqAinL_8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_4dYZePFHI0uh8xLaZDgW8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-07</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_2LOhPFc_bEyFVajuBKg_hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:KKRBiosimilarLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_MXIIAssociatesLLCMember_dlXABsWvD0ytszx5uH9T9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:MXIIAssociatesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KMGCapitalPartnersLLCMember_gM38q0-qfkqM70dI2BG3iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:KMGCapitalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_VEix4k9_P0C5vL3mOkva7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chrs:KKRBiosimilarLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_chrs_ThreeMonthLiborMember_SFCa5VQ500OXf47jZb2Inw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">chrs:ThreeMonthLiborMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mz08bJgB4EaXuGX2fTgvhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pmdNhIdK2kyIctMI_ST38Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hcVA_aikGUy_-SUX6FtLgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">chrs:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dUP-XGp_40W0Jk2_k2_aaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">chrs:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_bG3CyRk7Ckyq7Y946J92rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_JgK6Pnltr0iCDbO6eeuWPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sysHEkDeMUeiH_xQmMEqHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Ip4i_KQKSEGmi48UbBbU4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RLQcDbciHU-31RTWPiRddA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R15nhg7ueUmpYAw1PVmVYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_awtJ_xuQLE-3TKhXeZPfnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_rgJ5WsHKGE6cmgscswHw3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:CardinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_2Jb4uL_RpUq98xojm1NbWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">chrs:AmeriSourceBergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QFSyxqW7LU6FdbrdJ_hL6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_86rzXe3xOEmTHUqRT8IxuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jT2bvCGQeUqvA48e-rmNXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_5TOTwxrkukmWntYx2iyH2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_Hh7T20nqkUe4hvfBDJLy5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EmploymentCommencementIncentivePlanMember_PYQsmuC8gEmAkSzwx_wKQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:EmploymentCommencementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_zLRTOCdaDkGr-Wlc6H94QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_BPCdvDMynEyiPHvB9x6iQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_pOfVd5Rj4Eum4N-4rVrphQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithNovartisInstitutesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_aK8ibHz1PEqs0z1M6Yn7Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithGrkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf388Member_2lO8XAyg6UKhnOMI1Zafnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">chrs:InProcessResearchAndDevelopmentSrf388Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf114Member_MCpWdvb_hUWv00leqUKNEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">chrs:InProcessResearchAndDevelopmentSrf114Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="Duration_9_9_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_rkk2bVd2PEWq4HB48Bymrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-09</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_x0b6Pn8B7UCsaUPMe0v01g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_jcZy0wFZJEaEwLSiKmitHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Q3N2Kq2ULUiYN4xUaP-tWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_GPeCZEn7kE-kP1gzmLw43A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_frQuFnuBxEq5QXwcCjbX7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uqXRAvtuPU-XGMoUQjrc2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LA2YAsqsu0CpSSrrZHjsug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M7126HnRO0qaXeQIsFj8pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uGXcRbQazkuREy28y8WrtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:PrepaidExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_2BjSULWChEWs710kn9cfgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VSDrzPQUwUu7_hzLLjkspg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_mU8Xaof7xEm7Zbk_ZFo9-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__89KIdAh-kybMMe17Uup0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ms9aAG7KIkGkwghMFQVoVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nz62sO_ud0WlWk86bTugEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TO8ess3RJkWPdTQJVaqKPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__TxWSJDseUuXN-WFeLop7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">chrs:PrepaidExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bSSUTn6bQUCMiUY_ocTL-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_8fbTc7hIa0utRNZd1eRxfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_TwVcSvlCtEijskcFydA41w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_prYGlg4f4U63CuX4vjb7Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LQWs2-eMdE2bcCcsGBh6vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_v32YInlozkipoEXkDWXGJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_qVO9cnI0VUC56AJulEuw6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_rEMXEsXhaEWSunlNBcnl4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_LaboratoryFacilitiesLeaseAgreementMember_eWCVJY2d0Uy0fzrMJb295g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:LaboratoryFacilitiesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_4-NTVWKntkKpLY2m9obR2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:CorporateHeadquartersLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_24_2023_us-gaap_LeaseContractualTermAxis_chrs_OfficeSpaceRemainingPremisesMember_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_1ikJXPlaT0qaIZD07NCcJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">chrs:OfficeSpaceRemainingPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SixthAmendmentToLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="As_Of_10_24_2023_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_2VupKf10C0ysFKHcmA-N7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SixthAmendmentToLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_trJKeZ-blEWFIlIsmGdHcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_AYPPQ8ihj0mbo87bSd2xhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_CTwRAY9QGkWlaOjDUS3erA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6-wHjlrUb0eK7XFKJFi0cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lJUaials20Ozgd2f9R3-Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8C3aK0xQf0Go0f8lJiI49A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_w5gYK5ZD10mxWUfBk3mCAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nDHklqDsSkqnJXBtDs4Nbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_7tgQKK_EDUasryLtCO67SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pQgsHAcxhEiHaH9C5c3xTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_yimB1PocVk6HJoJLxYsOcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chrs:EmployeesAndNonemployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jItQvbGTK0Sy8MYmJwHtDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wrjDrMYWnEG3vQ3_hGdwAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_V7Ntz2koqkOY3qfjC84Z6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rdMdgsUj7kOwcgAE94-32g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_yPWVLupjLUC-LrZ0QvW9YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_NvtDoX2JKU-V8xqMiC3p8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_X4a12fHdGkKcfkBHCiHSBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Lv-W7pNdHEiIdf02okAMpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_i6sG_wGq0kGSogKwmLXRFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_08hF26t1CE220LggkCbdaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithNovartisInstitutesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_Db9iHsTjOk2dnST6JR1wPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">chrs:OutLicensesWithGrkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_81rW7yIWNEmb6m_5_UL_5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2024__Ij5iegjlE6VjA_i4djOuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_rO5PqjjHM061tAOT8W_pJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_n-FydJrePEuzzIDzlXSx6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_bjX_QmuqBUiNiIM7YQU9cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_4fiZbKl1c0-rDjVdhAf4iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_7mQuJY0wwEqgj61CikPPcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_oW7u_hLkakKhdnoyoEmKmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_RCrhOsC4rUSwHbQXRXofbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Y1Km_JnNyku-WuF69J4RdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="As_Of_5_15_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_xIobUuv7xkaTn4Q-FI1LMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="As_Of_9_11_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_D_dyxc-7bk6FZ7_nraT6IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_t94RIbg44kqe6E07Ycbe0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="As_Of_5_15_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_f9ef-yFAYEWYmhIzUHYLVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-15</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_N0EdjlOAy0Sqb92Q_d-eKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IQec6wbqNkyXTV-ONWSp-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_1_2019_peTS_V4r30KWdrPrMS7BCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JuDeIjk7WEOxnh8sAqvA9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_CPtilZC0L0K1V6_IsNLFKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_fqcHXPJqtUOZjDirZssjWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_PmryB88z9UeGYuVn9_eCHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fLywbKoRN0OM9lBXBdTjtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ahBUQTlFkUCSXShSrIOSkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUQLjzgmQ0O_aiicO1YWSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_DPP_6bC4Yk26dzFhoz_XuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_Ayc2h31NhkepkMrVbtGURA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUbaaM5xv06IKYj90EnrjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_TQp5WTVb9EWxY7FxWuYu-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_-COT1WJ3EUuvoamMLm5fRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_31_2014_To_10_31_2014_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_Y3ICWQYaSEa4JfXz8gYGiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-31</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_7crZcL4mN0ypA7JbGnmqqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_13eeoeTRfk2iZ3H7ofLzJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_1_31_2016_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_0C2GDS067kqyEScTv50pUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_LoqtorziMember_z2kc3sXj-0-3-XUzY_VHZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:LoqtorziMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-02</instant>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorNotes8.2PercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_2_2019_To_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_iS0ub3fSH06yefAa2ICMew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-02</startDate>
            <endDate>2019-05-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_gVOkBFt9vUSNT22wfjVu6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v-ug3g3l80mlObh8LcgInw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:OtherFeesCoPayAssistanceAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">chrs:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_tLJFKpYaNUKKGQtoFUHYZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Mozz1GcMBEOZ4p50-Yzzeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_AndqifxXsEG2Tfoo9es73w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">chrs:VehiclesLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_4_2023_To_10_4_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_HOqnw3R6o0K280PJUueNGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">chrs:ChiefMarketingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:OptionalStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_0bsmQzQVxkiRBstBPBwZjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rrL79xCbSEKm0OK1XTANMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2024_To_2_5_2024_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_otbpUOnq8EKYMPXpah8q6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_yd1vkuCA00aL3Hm8mfet-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-04</startDate>
            <endDate>2019-11-04</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2023_To_9_11_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_wNY0LcAqy0m5BY-y3yR8Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uXbjzY_AUkS5DM3UL80JAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2014_To_10_31_2014_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_pTatCpQza0uNROYRLjt8pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-10-31</startDate>
            <endDate>2014-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_H5jjpUn1Hkae89daAw6YHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_aM31ORVDHEOXDbOoQGO-Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_OaNk_89S-kO2L5QxklSuhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheaBAndDLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_G4zeUvb2AkiJrpZxrWkJfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:HealthcareRoyaltyPartnersIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wOrFEBBx0kqCfY3Jfb9mmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_F3uuUNoynEGVqfaLmbmpNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_MV06IYXPdkmqFzBkwhBAXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TrancheLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">chrs:BiopharmaCreditInvestmentsVGpLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="Duration_2_5_2024_To_2_5_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_F3gEcw2SlkGZ3F3ZhhXOuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_hK4XJ0wrhk2gRd8IsFyEIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chrs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_hh8Bb6a9E0Co_wILfDg5zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_GKvVg5Ic6ES4-RDKrSHttg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:NovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_K1geY-rGLEiNymNh_P6jTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_-QTpVgOnZUGGQfnOSlwd1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_zOQpf9YQJEWfttgbnzt7Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_HSE0jmg2IUOdXIECBGmidA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_dei_LegalEntityAxis_chrs_SurfaceMember_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_gfCoLb-ssE-NI0WQHzEhdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:GskAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">chrs:SurfaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_QfB80gafZEu1g-1S9zIihw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:AntiTigitAntibodyAndIl2CytokineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:Chs006AntiTigitAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_5YqDtd4hEUeB-HOMwGXqCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">chrs:ToripalimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="Duration_3_23_2021_To_3_23_2021_us-gaap_TypeOfArrangementAxis_chrs_VaccinexLicenseAgreementMember_WDAN8bKZtkOa0CTw_Zz0iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:VaccinexLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:AdimabDevelopmentAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:GskAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_2WiqeL2ms06O_McAP8cV_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_RzvldwJEbE2sTE9gTKsnIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rVWYKaHlykapW6Ik8MkDUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_wPWUD9JeY06Jz0STfXnoNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-08</instant>
        </period>
    </context>
    <context id="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:CoherusOphthalmologyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">chrs:CimerliDivestitureTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_XCQ--7iqDkm-4Cxl9nIn8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceSrf388ProprietaryDrugProductAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_dcELaaK_i0Oi3XQ1ke-MNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceSrf114ProprietaryDrugProductAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceNovartisAgreementMember_gPSalh4re0SjsDIBtluNVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceNovartisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceGlaxosmithklineAgreementMember_HFnWjX4pcU-dEYSrnOgYsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:SurfaceGlaxosmithklineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">chrs:SurfaceOncologyInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-08</startDate>
            <endDate>2023-09-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rKbabCHH6U2-QciM6M39Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_1YkpEyUoQUqaZRiv-_dAXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:BioeqIPAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-04</startDate>
            <endDate>2019-11-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_v--BLMYsNkKl0zxMmYmYEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chrs:JunshiBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_position_Q8MGuTzVYkuWPpfxSr2J5Q">
        <measure>chrs:position</measure>
    </unit>
    <unit id="Unit_Standard_employee_AAmVcdTDXkmNakyN2ltl5g">
        <measure>chrs:employee</measure>
    </unit>
    <unit id="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">
        <measure>chrs:item</measure>
    </unit>
    <unit id="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_tranche_ZKmzrBOMS0eN5e6PQhEzOA">
        <measure>chrs:tranche</measure>
    </unit>
    <unit id="Unit_Standard_product_SdGd84au20GyPZXZYh-a9w">
        <measure>chrs:product</measure>
    </unit>
    <unit id="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_t6jFhJBbhkKHfxOGu1jTgA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_BjE3iFxCZkGPiWaFAMkLBg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_LHX0qd3ip0i6d6fhQPx3CQ">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_Vr8K8LWppE6G3mquOm9drQ">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_Moa6JZuMv0mJTSdRd1DFlg">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_BVLNcymS4EaV3DJ3plJTVg">http://www.coherus.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_c5lAcKOcVkil8kEMNgNApQ">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_11BhQSEL3km5vBJeD_RAsQ">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_DwcuEkqWB0mqmuX8ExLV9w_2_1">0001512762</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_btjtpCePKk2-v5ikv70FRA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_vE_F7BUjlESZrg-lq84LFg_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_QwKca6CpGUSPCfLSDTRSXg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_R-ikeEMa50SHTZi_r4tvbA_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Hidden_--szY9Mda0qUwes4reSEXw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Hidden_OYWDmfmE_EWMGnJd8jiObQ"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Hidden_rRMf5nysqEO0xgC7AyVmnA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Hidden_V9mVERuzDUyFPQ0FF4cI4Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Hidden_ifXNjsyJr0WWF5FEEv1GQg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Hidden_v4oTsv095Ua3rj9SnG6xIw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Hidden_tWVxfTC3cUmEtX68kvPusw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">78851516</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Hidden_mr4oREKsHEmMwylrOmO9ow"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">112215260</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="0"
      id="Hidden_YgjkhDQ6bEeOg5gUe8O-fQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:DerivativeLiabilities>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Hidden_-IH_mKjA6U6bK5tk5yUUQQ">http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <chrs:CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      id="Hidden_RNOKr2yfgEaTSaGdgRnfUQ">P4Y</chrs:CollaborationAgreementPeriodForPaymentOfNominalResearchMaintenanceFee>
    <chrs:MandatoryPrepaymentTerm
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA"
      id="Hidden_9sZZOOI5Ik6UXQMv7GKoqA">P10D</chrs:MandatoryPrepaymentTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_QSE5TXfKi0yFbPvOeiAHDw"
      id="Hidden_fHNXk8VMLECyy9jYAF_Fdw">2024-09-01</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_QSE5TXfKi0yFbPvOeiAHDw"
      id="Hidden_VkjnRAfIcEy-ZaCcc2AiFA">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LeaseExpirationDate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_NewCamarilloLeaseMember_1n1rY0uyP0KFXFjXo3Ns4Q"
      id="Hidden_2eeuHZDPwkuwZhYvkItgaQ">2027-05-01</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_NewCamarilloLeaseMember_1n1rY0uyP0KFXFjXo3Ns4Q"
      id="Hidden_TfxsXMoIkUuAjOrWK1_x9w">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_-mf-ZxnNGEipJwEpza_71w">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_WgpZY07_p0GbKqCO5gEf4g">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_liJO04hsZUOJwgNDIHYjyw">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_TFQ5qkqFP0exAVaWIavjVw">http://www.coherus.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_ieMrVFi9_UGwUiP2AK3LZQ">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Hidden_wCWMjCewb0K1TBEZgR53KQ">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <chrs:NumberOfTradingDaysConsideredForPricePerShareOfCommonStock
      contextRef="Duration_10_4_2023_To_10_4_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_HOqnw3R6o0K280PJUueNGA"
      id="Hidden_I67Wh2887EWvSltZhszIEw">P10D</chrs:NumberOfTradingDaysConsideredForPricePerShareOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_gK5gYMN5WUG2uYVdwePLuA"
      id="Hidden_AKrDviHwTEWrO6-oIS4MzA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <chrs:EmployeeServiceShareBasedCompensationOfferingPeriodOne
      contextRef="Duration_10_31_2014_To_10_31_2014_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_pTatCpQza0uNROYRLjt8pg"
      id="Hidden_VnDr0p6zgkaCQAXWjop8Wg">--05-16</chrs:EmployeeServiceShareBasedCompensationOfferingPeriodOne>
    <chrs:EmployeeServiceShareBasedCompensationOfferingPeriodTwo
      contextRef="Duration_10_31_2014_To_10_31_2014_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_pTatCpQza0uNROYRLjt8pg"
      id="Hidden_y3PMsjUAX0CNLgPeFQI8aw">--11-16</chrs:EmployeeServiceShareBasedCompensationOfferingPeriodTwo>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A"
      id="Hidden_DILPxNagiE2rs6ISbTZ4RA">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A"
      id="Hidden_6muBIslFhk2zKGVekJX6QA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A"
      id="Hidden_YgjPL260ZU2HOBfFy0NsgA">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_N2vZqu7GUkKDvrSo5DbT8A"
      id="Hidden_6Ta87eBqSEq-2bamScPPEQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_PRVSSd-3MUm0WgggZSgpZg">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_8u75Aw1WhkaFjLDwyIZjPA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_4kZe8V7nQ0KYEHHYp0QYnw">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_J9dvC0PieUGUPso3MnIsZg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_9ev_Ep2aJEqyUO4yGWZxtA">001-36721</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_B1ulcpQ_UUCZeLDvbMMnVw">Coherus BioSciences,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_KASEaoOMg060DHV46PEc2w_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_vk7Rrw4TZ0OppGSyvjpmwg_1_2">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr__5gTzCILyEab1S8LO7sh0w">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_8jRDPDdnmkm25Bao3x28Xg">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_UkfxB5K8n0SbknGrJ0YMeA">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_R2FgLZlAXEeR9NDB7VhxFA">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_57DqluQ1CUe-5TOPcHD_oA">94065</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_aA5zs6Wr10y9OhOqBFE3Qw">94065</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_PZOo7dMla0iaEo0bGkNqKQ">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_i4uAxyk0r0ueDURIBERhEQ">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_JoEjqgi4rkGPwn5Qv36vUA">649-3530</dei:LocalPhoneNumber>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_4LfqbZoDHUCHXWwmIDMkiw">649-3530</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_HuYj8c6uXkipD5xnHhcjBQ_2_0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_UMJJY9ToikmDeoRhonmZUw_2_2">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_VmXrZgJ69U63ZL1COQuF9Q">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_SeZs3MIl00u_2NKTS-Yjzg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_8uapNHMne0yYkrQB0u8ogw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_EGUfIQVd-kul_Mz9KUR0kg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_PtTMGTxYgUa36F9pjAedVg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_hmBl9QwsqEexM3kX8E5uTA_0_3">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_rhJb_N8pikW4LBEDDxZ6xw_2_4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tc_1TrXdcIAl0KLmgUqlcyqnw_4_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_bULlMqenvUeQIdhOxa_kXg">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_Kr5GVaPE1ESWUOPpd_Vw3Q">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_-05lcIOeZkaLbB_8fMfgGQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_81rW7yIWNEmb6m_5_UL_5Q"
      decimals="INF"
      id="Narr_A04NvsmG5E21GgN31I_Jig"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">324137955</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_29_2024__Ij5iegjlE6VjA_i4djOuA"
      decimals="INF"
      id="Narr__MubSohvDkWvsr1Iam5xqw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">112714488</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_kZ7hIZY6okOCTTItU63dsA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Part&#160;III of this annual report on Form 10-K incorporates by reference certain information from the registrant&#x2019;s definitive proxy statement for the 2024 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2023.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_VFN7T-MBlUO313tZoD6_Bg">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_A2YIi7VWl0KrOYmInSpdWg">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_Nli90iUWxUOo1y1xKESqUA">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_S4YsZ0wJ50muadCE1zUhlA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">102891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_XtUqqh49dUKAuV11EYvSZA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63547000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_nCFIdHRKF0KfGwQD8ht3bQ_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">14857000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_cl_VBkbgMUGhzGx-gKHqFQ_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">128134000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_92v2oqrGUUK3FdO8sXlfMw_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">260522000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_6sbx5GoaiUu73sFauvp1HQ_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">109964000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_iqQjmLDqi0WJTWGkdcS61A_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">62605000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_CX4kK-RGA0OGdGqg4v_pGA_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">38791000</us-gaap:InventoryNet>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_9s7zkNrAFE-oduuV2HnbVw_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">23657000</chrs:PrepaidManufacturingExpenseCurrent>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_mYsR0zO9JUmKseY4_fPMcQ_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17880000</chrs:PrepaidManufacturingExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_K5CafLcX5UqwwpV4TLaLDw_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11099000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_aI9Gfo2ZAkiwRm9nV2us0Q_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">22918000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_hY4BV_50gUSCDuWjcgHWeA_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">475631000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_u2Hv7saUL0CBVEyKRFTNuw_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">381234000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_K--I-Sk_nk2pscRHZlWYoA_12_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5119000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_pfdWp_1B6k64TA98_Lce5g_12_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8754000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_5fo5cPomxEGGCmLQlNHs5A_13_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">67495000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_f8IcKumQckWklPwfjmK9sw_13_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">76260000</us-gaap:InventoryNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_dGrFGG_W80W1YOBwU0SMug_14_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">71673000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_hfJRq3j640SM1Wf7nwKNdw_14_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5931000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc__7qbwMbzgU2viorUEZn_0A_15_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">9686000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_4SEQ9c1nNEu65cqSahETCw_15_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8668000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_j6YWZCWrkU2uFvrZUQW8Ug_16_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">629604000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_0VhAR2X0zU2C7KyB1K9KAw_16_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">480847000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_eXXeA8Vbb0i4618OpksCKQ_20_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35219000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_kJCrEIimaUOK_dzfW_6iiw_20_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11526000</us-gaap:AccountsPayableCurrent>
    <chrs:AccruedRebatesFeesAndReserveCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_V25S2N1gH0GD0EfEYLpJOA_21_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">169645000</chrs:AccruedRebatesFeesAndReserveCurrent>
    <chrs:AccruedRebatesFeesAndReserveCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_f3rsroLNkkyOIphBCsUFKQ_21_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">54461000</chrs:AccruedRebatesFeesAndReserveCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_lyhQONpLik2rmKQdbqRi2g_22_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21521000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_VCTpIsU-Qk-PzhpmKsmAyw_22_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">22610000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_PN-JgyiIn0y9idFqKhcg_Q_23_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">105386000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_XWcjO8AtQ0K3BS6jgTc1sw_23_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50097000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_xIu7uU3-0kG9yXthUbF-JA_24_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">331771000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_jY-5XFl5I0WgZD9GnUt_rw_24_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">138694000</us-gaap:LiabilitiesCurrent>
    <chrs:TermLoansPayableNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_TxMI-ZKyYEqLaleEvlu-Aw_25_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">246481000</chrs:TermLoansPayableNoncurrent>
    <chrs:TermLoansPayableNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_F9CQiGEgcEaVmgLJ2CQP4Q_25_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">245483000</chrs:TermLoansPayableNoncurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_wBygOSRqHUWvYozBssWQyA_26_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">226888000</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <us-gaap:ConvertibleSubordinatedDebtNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_1sctoLG8X02f3TmI6BCDmw_26_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">225575000</us-gaap:ConvertibleSubordinatedDebtNoncurrent>
    <chrs:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_1HC1apC510OvJeW1_iOZtw_27_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5328000</chrs:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <chrs:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_HUZ30JwWF0eQ-rDPNP_AYw_27_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5046000</chrs:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_4e65xBl4BUey7rXAJXu88w_28_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12561000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_0P2_EcmbqEeb1lBb2DAMSQ_28_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3467000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_rEsyA54NTE2XPfB9ckQJOA_29_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">823029000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_A0XDQtUepECpAEHEZVb2dw_29_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">618265000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_aJiERKpi6UyqczDv1Fkiug"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_g7EmZBo33U2mWgcSEmp7-g"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_P2FLuQd2-Uyi0Dpy73y3Xw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_LYSohQ1bG0K1caCPkHCosA"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_ok6IX3rk9U6c5vKTgCx0Lw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_TaLgHH20fkiakV4AMA3Mfg"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_JIVayFbwaE-MMee3vzKfXQ"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_874vkR9XlEi0k933XLszHw"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_l_0kikA35kmB7rqiSsJvug"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_3PAPHUONIkSMRCRNxg9E9w"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_YdVVzuxV3U6xdT4KVCiHCg"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">112215260</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_URSlstLuFU65ecm3FQRKkw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">78851516</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_Q9mCChbtM0W5IZ-P2U4EHA_33_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_GFu6g05kLkSHHqnnOQHn0A_33_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_yLO5ZrhTwUW8SufDm8mITw_34_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1386312000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_6A_Ap2pAdUmRC8Ny4f_snw_34_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1204431000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_i5V-LzxhPUyOM2I7ToX6oQ_35_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-248000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_ZXIA-J3JyUqzBAcU41PhbA_35_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-249000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_XGxsb5uh1UiLJM7xonrBaQ_36_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1579500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_T7--AeuplkGtN2MfEEefuA_36_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1341608000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_14fmchV7VU6YX99hceVRBQ_37_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-193425000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_KoKIC81-Z0m9vxLeBbjnGQ_37_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-137418000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_WcG_G1N3OUee6av8zjZpZw_38_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">629604000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_OzLsDzRlfUygRzBeJ0vg7w_38_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">480847000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_TtcantlobUWMp7frPhNsVg_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">257244000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_f_egLoShp0GFS5xMlNe58g_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">211042000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_kkQvuhyUskqxeupx7rve9g_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">326551000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_pqvdIT47ZUanvquVwNYmkQ_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">158992000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_TWLnJ30XPEKmQ5ARlLjSXQ_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">70083000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_2gHVUz1yW0u9MZzoBOiuLw_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">57591000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_0eYQR375QEmnVgXr1f2wJg_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">109436000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_ywfERAcTqkSqjYot9b8b_A_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">199358000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_jnaY-ChWbEywsK-yAK0faA_6_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">363105000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_4LdP-f5AxUe-9X_vpm21oA_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">192015000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_hw_0Yb5pxESNevkzIaH0PQ_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">198481000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_UsDQ4LyUPUu1SRsLt9fR9w_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">169713000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_8MpnuQxhtEWH8gO0G5eW1A_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">460443000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_lCI5Ov5bzUCE07wRcxLZDA_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">467922000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Ah_2ZBq2cEuKBnMDeJt62w_8_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">590409000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_h906MC-a2U-fgYu36bv42Q_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-203199000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_cuHXi-q_XEiVBTlnhCntVA_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-256880000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_EkPrsX401E6Y8c-zZeWLrQ_9_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-263858000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_ZmZ4gMgF3US6zN31kA_11g_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40542000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_kwq7h9Esi0WQ5u-TVR8nKA_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">32474000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_05Hu1pt5gky2zmDipJpKPA_10_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">22959000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_yCw10z1Qm0aZN9oNIocWEA_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-6222000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_ScXuC3_5MkysL586mmqRcw_12_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5469000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_gk43YvNveEW_mgmltBjjFA_12_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3822000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_kyud0aduw0i555h5YSS6Rg_12_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-283000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_0EwqDyU4REeeCui6xTK1Ww_13_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-238272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_DJqhH4MAz0aJwBddebO3Kg_13_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_h01HFgJpFU6G2POzKkVIPg_13_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_Lx2sd-d0LEORvkGS9jmTHg_14_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-380000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_WpwvCXIlzEW5S9Ov9NkDVw_15_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-237892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_7YM0lp2enUChJXQoP8gijQ_15_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc__jYIoOHMx0aZ86bnBO8nNg_15_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="2"
      id="Tc_0ygXb8-f_UefKj4QkERu8Q_17_3"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">-2.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="2"
      id="Tc_0ygXb8-f_UefKj4QkERu8Q_17_3_2"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">-2.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="2"
      id="Tc_Y4sX3IWvUUW5Rhs5OXx1YA_17_6"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">-3.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="2"
      id="Tc_Y4sX3IWvUUW5Rhs5OXx1YA_17_6_2"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">-3.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="2"
      id="Tc_p_Tw229Olk2BSkK76q0Q9w_17_9"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">-3.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="2"
      id="Tc_p_Tw229Olk2BSkK76q0Q9w_17_9_2"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">-3.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="0"
      id="Tc_-tGmNMGiE0ep0hMtO-kUqQ_19_3"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">94162637</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="0"
      id="Tc_-tGmNMGiE0ep0hMtO-kUqQ_19_3_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">94162637</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="0"
      id="Tc_S81P8FSU8EGedeqbOpf6yQ_19_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">77630020</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="0"
      id="Tc_S81P8FSU8EGedeqbOpf6yQ_19_6_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">77630020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="0"
      id="Tc_3HvpDOrkHE2A-y7ymLNirw_19_9"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">75449632</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="0"
      id="Tc_3HvpDOrkHE2A-y7ymLNirw_19_9_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">75449632</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_lKL--kYpv0SUFEg72-dkbA_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-237892000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_ky3l7MP5Dk21ktPditamnw_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Sy6UCvkLDk-cd6IB-dn2DQ_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_zA68baDY6EWu2Lrovs1lYQ_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_sep9iVm98UW6lnQid0KuuA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_tElBI1ZjP0GiPxIF-Np9zQ_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_FzSrIFphtke17xGtrGrPHA_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_MhcMe15YNUiI49QFSueKnQ_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-237891000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_DTuW1VKv2U-F1x8OvXYA8w_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291733000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_ZGNLWI8w30CBRP6CA-IHyA_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA"
      decimals="INF"
      id="Tc_LixgjHqC2UCTZUP3Hln0Cw_5_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">72513348</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gzD0VWFXEkOF8_4h8HzkiA"
      decimals="-3"
      id="Tc_EhMBh0kggkCU2PK0gcrq9Q_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EqOtkI14-kOGNRiKyN0UaQ"
      decimals="-3"
      id="Tc_LmRKQY0Ti0-x1Na-8ByaGA_5_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1043991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_OvQzecJ6mUOHxhU6qoAvsg"
      decimals="-3"
      id="Tc_7nwoiIkaaU-9Fr4WE0kITg_5_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T9fLg1zdZUuTqPJFq3Ewmg"
      decimals="-3"
      id="Tc_TGXULbuJYUGHNqmjX9pB6A_5_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-762754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc_Jg4BhQkVxkyx6Oq1IrNV_A_5_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">280974000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VcpbTyhPOkKFIXTOT5V2DQ"
      decimals="-3"
      id="Tc_z7SP4o4QaU2UiRw7mySo2Q_6_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_6qELkY8Z3UWiXGp2W8B5LQ_6_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ"
      decimals="INF"
      id="Tc_USVSrVHQtk2WzY-4GZUm3Q_7_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1316361</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw"
      decimals="-3"
      id="Tc_H1ofS6EpBUa3bKTC7CR31A_7_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10410000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_AX7o94M3tUezkeb7j-zlOQ_7_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10410000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ"
      decimals="INF"
      id="Tc_Hm39PPSPwUmib_38HT_lmQ_8_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">465930</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ"
      decimals="INF"
      id="Tc_yxJwfdh_rUydsRSK6Slcgw_9_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">238934</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw"
      decimals="-3"
      id="Tc__HPHI7rlIEWR1rLEPAriww_9_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3002000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_i8IMbyswN0epwI1uqHxLWg_9_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3002000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ"
      decimals="INF"
      id="Tc_VIhDrfTVD0yddQLDmINGsg_10_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2491988</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw"
      decimals="-3"
      id="Tc_5irjdxskgU-TrAWlGJX9_g_10_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40903000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_s2wVQ_qIXkCZzDVLEZW2nQ_10_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40903000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7SmoUMqG7kGYqo-H2vHGpQ"
      decimals="INF"
      id="Tc_HAotFQ5hTEy4TTgDeqsaUA_11_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">96465</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw"
      decimals="-3"
      id="Tc_F6vK57T-ykOQIIJj9ZpGrQ_11_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1753000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_TCNiUuQyRU295IhjTsP3Kg_11_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1753000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKtZnrKKPEeeTYYQUoOlXw"
      decimals="-3"
      id="Tc_PtzgSrgB4Ui9ElRlWB15lw_12_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Uw_l-R0DtEmJxU0Wlvg4sg_12_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jT2bvCGQeUqvA48e-rmNXw"
      decimals="INF"
      id="Tc_Je5wjN4wYUiLN9hIgxt04A_13_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">76930096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jT2bvCGQeUqvA48e-rmNXw"
      decimals="-3"
      id="Tc_9uRL71DArU6tRHl6tBPWYA_13_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JlI5BNiMwkCobaOJnCtF4Q"
      decimals="-3"
      id="Tc_NnqH4bLN-kSlmaZaC2Xx4A_13_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1147843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_js5PyUWww0i7olNWi5CL6g"
      decimals="-3"
      id="Tc_5kHzKj8nWk6DVdOP-LxYgQ_13_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-x0yoCYUqUKXgofi_PW4rA"
      decimals="-3"
      id="Tc_hXBdaiqzb0q6YT8haHBY8g_13_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1049854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_znvYTcdhYkaoVPp86FFwWg_13_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">97726000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EsFNWbdr7UWhpxeQGE8rJA"
      decimals="-3"
      id="Tc_t0s-Wm8kckujvAtuDjE1sg_15_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_3lDbfEmem0SxfdlNnCeQSg_15_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw"
      decimals="INF"
      id="Tc_3f13j0KS6kC2HsoF_Doo6g_16_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">141897</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw"
      decimals="-3"
      id="Tc_5Wqk3FOZfEKclfvUWTBmag_16_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">691000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_UzIGdYu5hUSpC9c6sE4qlQ_16_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">691000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw"
      decimals="INF"
      id="Tc_zgMDjVcu6kySGwcGipq2Kw_17_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">806854</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw"
      decimals="INF"
      id="Tc_CvPw9SYBJkqM6IFyGCsPDw_18_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">347883</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw"
      decimals="-3"
      id="Tc_1sm_ZSItdkK8yZXS5rxnBQ_18_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2320000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_hKDwjEka9kOqCkaD-klWtw_18_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2320000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IWhFYTVSXEG3Qc-xyQ609A"
      decimals="INF"
      id="Tc_cuhUDvlIOUesgdc_pd-L3Q_19_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">916884</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IWhFYTVSXEG3Qc-xyQ609A"
      decimals="-3"
      id="Tc_wyMrWq-2O0GSzKdf5tE6BA_19_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_942S1mhLyka6ZkBmZenXDw"
      decimals="-3"
      id="Tc_7jN4iY2dRkKiJBPeb_Ro-Q_19_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6133000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"
      decimals="-3"
      id="Tc_bqlBd1Ec30iSMB3gIceu2Q_19_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6134000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_b7uhwC5Vt0mALsxEafyLcw"
      decimals="INF"
      id="Tc_uImW0kjSjEySH88uWcT5FA_20_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">292098</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw"
      decimals="-3"
      id="Tc_juaCEp6x6UOJKPa9wDvj5Q_20_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3744000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_aIaiDVfw5ES5OX_cQ5R4mg_20_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3744000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vQYulgO830W4ghE2f6IfAw"
      decimals="-3"
      id="Tc_o0-oQ7ZVMk2Gvn02VTvO3Q_21_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_tXHMcaJ-8kOfgtFDfgWVGg_21_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZLR_IWpbikGexBZ7BUjpdA"
      decimals="-3"
      id="Tc_k9j6R-MeNEW_g3RijMVqoA_22_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_eMyEQ7cuBEO6xFbcSn0MdA_22_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_86rzXe3xOEmTHUqRT8IxuQ"
      decimals="INF"
      id="Tc_Ek50jG2X8U-iCtppr88yWA_23_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">78851516</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_86rzXe3xOEmTHUqRT8IxuQ"
      decimals="-3"
      id="Tc_RQE87JBrkkugnIiBWUZakw_23_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8tkQ9GUbnkaeOclpHWkaYA"
      decimals="-3"
      id="Tc_xfBwWVuTFkyWikTYIY3AVA_23_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1204431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zxmvh3LGk0mrm79pZRE9ew"
      decimals="-3"
      id="Tc_jMPy3Rk1Q0-_3-jOx1EXPQ_23_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6C9ecxQ_QEG8bE7IGXl6xA"
      decimals="-3"
      id="Tc_JEy2DWoi506htfE6J_hlcw_23_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1341608000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_s-VrK6VuZkCPTPIBiVhbCg_23_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-137418000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_trchcL8ElUmTtWSY92BZ4A"
      decimals="-3"
      id="Tc_By-KSF_iukqHJSiv_5NUmQ_25_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-237892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_fBml9fCg_ke7v-pEOcDyxA_25_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-237892000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_EGwaWadCfEmKTWRl0yrAfA_26_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">430504</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_fRqqpgEnm0WsKEwpegsjjw_26_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">694000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_eURP41SgM0u1_-BYlMyoVQ_26_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">694000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_o47CQscFukmfmu8G64fTDw_27_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1280901</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_jqw8nL-TxEO424nA5EsaPg_28_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">630348</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_YKB3CdrfzEyFkA4H5Jipnw_28_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1809000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_cdZcDecPJk2dgv4TnJeHfA_28_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1809000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_RJkHT2y9QEW_3XsipyBJbQ_30_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">11971460</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="-3"
      id="Tc_XmQLmzfgRUCf8VIamD_yWA_30_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_Sy-TZtCIRU-nns0AB01mqQ_30_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">58540000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_AwxHa_OOp0uZ8PwzYb5aMw_30_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">58541000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <chrs:StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_l5REvHBgnke9SAAtAG64RA_31_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">261239</chrs:StockIssuedDuringPeriodSharesAcceleratedVestingOfEquityAwards>
    <chrs:StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_gy1FCzOR7UC8cVjzBKLqUQ_31_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1053000</chrs:StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards>
    <chrs:StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_oATRrm1N3USgP9fBo26Tlg_31_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1053000</chrs:StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards>
    <chrs:StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_AhIYvlq02kacXyvtnTeZ-g_32_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">65732</chrs:StockIssuedDuringPeriodSharesTaxesPaidRelatedToNetShareSettlementOfEquityAwards>
    <chrs:StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_Qj3agB410EunT3LKEfDD5w_32_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">347000</chrs:StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards>
    <chrs:StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_DAhQQ4K7vkqQkstUNAcH-A_32_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">347000</chrs:StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IqHD8wCCtk-Oe0InVzTD9Q"
      decimals="INF"
      id="Tc_gH8iiRGKW02Gjq89tyZq1w_33_2"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3559761</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_IqHD8wCCtk-Oe0InVzTD9Q"
      decimals="-3"
      id="Tc_Fgr-nnzr_kiuGqHUnfdtkQ_33_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_e1HpM3V8pkO34aP3JnxjLQ"
      decimals="-3"
      id="Tc_X1Y9rcP0VUGFmRSMWPR51Q_33_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18316000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"
      decimals="-3"
      id="Tc_Vpd0Qk05QUuB6BLFYp1Qdg_33_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18317000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_sKhnfgNtxkaJ97AXUGzpNw"
      decimals="INF"
      id="Tc_68BFwSjnDkunaj51V6PtVQ_34_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">13529411</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_sKhnfgNtxkaJ97AXUGzpNw"
      decimals="-3"
      id="Tc_j_ycIz9_XEC0SYrxJE461w_34_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_kZ0HsUuPOkSNL1EUtnGJbQ"
      decimals="-3"
      id="Tc_eD31HLE-YEi5SU2Cv0uPbQ_34_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">53624000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_RpO-Vx6ls0enT64RbZm2Qg"
      decimals="-3"
      id="Tc_wIlvI6s5pkWk9sCmIyqe6g_34_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">53625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_0oZWQSLFL0e-jivOJv3aGw"
      decimals="INF"
      id="Tc_bpdUm2lvRU-lBnryL2z5FQ_35_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2225513</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_sWN29oXoPUKV6kz5vOqq8Q"
      decimals="-3"
      id="Tc_9CvkhziDj0evZGIqppVoKQ_35_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8179000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_OptionalStockPurchaseAgreementMember_X0KeVsHZyUSbmqBiyMUPOQ"
      decimals="-3"
      id="Tc__4oIK36JAUmQHm10rU7WxA_35_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8179000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cdM5DQwKa02zw2tnTRHSbw"
      decimals="INF"
      id="Tc_LZEOl-_KLEG-q_7jMR0oJw_36_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">459661</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_b2Ad0Q2U_02r5N7t8m7gXQ_36_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3527000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_6wHNBI12HUOATcFsVLyKwA_36_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3527000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mXic5B6Q_UiDRQublbY2aw"
      decimals="-3"
      id="Tc_dw8K35Ti0UeUNqYLtkwugg_37_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">43540000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_NIQb4gPy60e00he4dWmYqg_37_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">43540000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_drbbzBbCqEO7LriCD-yj_Q"
      decimals="-3"
      id="Tc_z3NudOV8pkqzREIyWzUKiA_38_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_VXdo0GNY0EegBxRMHHSI7Q_38_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QFSyxqW7LU6FdbrdJ_hL6A"
      decimals="INF"
      id="Tc_YPU_TUTp0EKqFCmGQVYkeQ_39_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">112215260</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QFSyxqW7LU6FdbrdJ_hL6A"
      decimals="-3"
      id="Tc_HKSDrF03p0KJKJGnMtVmXw_39_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF-Oa2qAakqTeMwji5pTSA"
      decimals="-3"
      id="Tc_3J5FxFzRjU-qBjAB-lB29g_39_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1386312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wRFs1JzPGkC_zfkTJLKIXw"
      decimals="-3"
      id="Tc_GizNo7Xtm0eFvkYlKJxNrA_39_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2ZR7usP3sE6lA9rxzLUIRA"
      decimals="-3"
      id="Tc_8EuatHlAwEKaxIaRRZ8ygg_39_14"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1579500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_FHtcecLIpE29yDwQ9wE8bw_39_17"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-193425000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc__Ly-9xUFOE26KCMgs5Snug_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-237892000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_kJ8dlel23kq8FjJRx8fXrQ_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_rwltKR7hkEGeb4gvwGA_Vg_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_iORpqpcnb0q_M8k__UUbFQ_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3791000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_u1ltpybfukGUGT_pGmiP9A_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3699000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_df8wBpJS4Ui7rhZb-t69vQ_6_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3454000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_wi4hHyG3ZkGBBxxG1p2yiA_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">43110000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_dXG4FfE28Ei51jpI0-ESFg_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50737000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_rYzKBVY8-kGEe0f8TsA02Q_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51364000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnContractTermination
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_SljIvLxcw0-K4y1iJ-Ss4w_8_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-3210000</us-gaap:GainLossOnContractTermination>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_VkQzY1WUvUy42vQv0Hu6GQ_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">52595000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_c7C0UvAAY0iCb5ETKrXn9Q_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc__YMo1QFoHkaZHPgfM_OpQw_9_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5133000</us-gaap:InventoryWriteDown>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_7bY0WErkDkGsoC6SMTc9kw_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3052000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_bm7b2t8Rg0mT9pWn2g4vEg_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">730000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_NbJsLV789E6-s5IVy-LQ4w_10_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1095000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_GbMF6AKAhUaoLMUgbfMzAg_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2407000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_0-kJ8bnIOkauZ6khMWtIqg_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6431000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_uZo0yFvrCE--ROcH7_W3Yw_11_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4257000</us-gaap:AmortizationOfDebtDiscountPremium>
    <chrs:NoncashOperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_nqCWGQwhHEmEgvQn3RDzOw_12_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2476000</chrs:NoncashOperatingLeaseExpense>
    <chrs:NoncashOperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_3ATCUvghfki2Y3sZYMJYxQ_12_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2503000</chrs:NoncashOperatingLeaseExpense>
    <chrs:NoncashOperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_gCo1qfg93EGq8GNp5sEOaA_12_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2207000</chrs:NoncashOperatingLeaseExpense>
    <chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_cXZ0Rv2OTUiUNzmQ1EY2fQ_13_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35000000</chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements>
    <chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_ZpSNEMmsgUi8TcUzXeg4Lg_13_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">136000000</chrs:UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_OcO5c2pymkiE0DO4uQ5fmw_14_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-6222000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_1qgNsOaQuEG0BSauZyz69A_15_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1493000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_kZYHDw_riUGoEv6TRHp1qw_15_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">25000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_5p8Bi1noJESiHiC65ZH4nQ_15_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">588000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_UYYpWEPj3kqFjBAxq-3hAQ_17_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">150683000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_VKONCYl_TEutOz2laCJT7g_17_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-13052000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_yGjj2Zk4JEudBCOzWtrR-g_17_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-34062000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_NLr348IimU63Df8oMWANWg_18_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">46734000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_Jv1iXAO0l0-5RQ7B57WBHQ_18_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">47348000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_inAMF5gB2UWJ0ZtQVbgnxg_18_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6253000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_IRWrqJg-XEmqLCzefVmN5Q_19_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-2027000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_dX7ZiTjurEaIf9h5u_WUTw_19_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4214000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_uSa0XFQjY0CzS9mEkGbKBA_19_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-3828000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_z2jySnAYXESc3YD8GUvO-w_20_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-16155000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_HlIRiWlTsE25b5TpxpGAoA_20_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13424000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_6qkWuMWt_0-d0G-cmXDxpw_20_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5351000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_VSQQZdY7o0iNSBfmD9MNzg_21_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">23760000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_LMqzyiDMNkewrEi6KULhEw_21_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-4548000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_ZsZAiHW9UEKr46w0ogHrFw_21_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">874000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_1f9IA5KK6Ee76HYvdJgSPg_22_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">113105000</chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve>
    <chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_GBvC_kknSkCITjfh5nQGmw_22_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-24566000</chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve>
    <chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_FRKCn-MYbkuS8nE0ONR-_A_22_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-2502000</chrs:IncreaseDecreaseInAccruedRebatesFeesAndReserve>
    <chrs:IncreaseDecreaseInAccruedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_pgemMxSkZUarLetqTN4jpA_23_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-5373000</chrs:IncreaseDecreaseInAccruedCompensation>
    <chrs:IncreaseDecreaseInAccruedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_dGtBKwtRakWMLKLIV_31Yg_23_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">596000</chrs:IncreaseDecreaseInAccruedCompensation>
    <chrs:IncreaseDecreaseInAccruedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_5DPiQAPS-EWDoxidNm1c1Q_23_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-230000</chrs:IncreaseDecreaseInAccruedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_irY1w14JS0C8jn2lSI5ptw_24_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10917000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_2JXGi2SOFU-cboPQ4B3O2A_24_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1195000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_c3OwWb10H0enTiuKQ-GwmQ_24_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17932000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_bL-DPGMRik-VgnT_db-5NQ_25_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-174884000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_eEUcvMajxkWZsikBP4DlWw_25_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-241124000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_7LdMcHUTq0CifI4CvHubrw_25_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-37432000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_gZvuREeWP0WZYGAOY7iMew_28_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">286000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_8GXyo_0PIUKD9K3_Rsp12A_28_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2039000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_QzlD5fsB1kKldSlPlpYQBg_28_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1289000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_JjbHOfMTvEmtl8Lyyh26iQ_29_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">845000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_ua59lnUWtE24CQYrsVxjrw_30_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19507000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_8hwNK9yIikuBhppQH-aufw_30_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">127382000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_YjlbhMiUZ02TGc-LIiboUQ_30_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">182485000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_Sc3i0IBPzUWbGL4ZQM6Sow_31_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">144360000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_12DttWyOuEm9jm70UQ-KAA_31_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">99692000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_R9PkVy40kkyFfqY8X7Kgpg_32_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13282000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_m1IMTJmOv0mZlBxEOrTL1A_32_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">81672000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_NA94VrPRzkCfR0k5RW9K5Q_33_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6997000</us-gaap:CashAcquiredFromAcquisition>
    <chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_PYjSBrX-BUCpRrwRWh0k4g_34_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35000000</chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities>
    <chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_unB976Ds8kagh0ff9uRs8g_34_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">136000000</chrs:UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities>
    <chrs:UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_Ujodr_a5ckqpPpZ7zhS7Iw_35_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1051000</chrs:UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements>
    <chrs:UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_MbLNJyRB1kuP7pl3u4CuoA_35_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2429000</chrs:UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_vC-6D4rr_kWT-cuWBvIFbg_36_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">144640000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_5Hq_Ci66wkmsA58wxpbDqw_36_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-166850000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Ol_HSml8_E-3cjYJNqH0hQ_36_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-138410000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_4Mg6m1yZr0ijoM56MKqRJg_39_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">240679000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_chrs_JunshiBiosciencesMember_3vcTLYS0gkekD3G2uhqorw"
      decimals="-3"
      id="Tc_7WcVEYaIH06D-ZBufQMAFw_40_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40903000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"
      decimals="-3"
      id="Tc_QlBj-0uhxU6OiHT3BsaHKg_41_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18093000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"
      decimals="-3"
      id="Tc_NdNUhelPiECZLreAWl2vOw_41_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6358000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_RpO-Vx6ls0enT64RbZm2Qg"
      decimals="-3"
      id="Tc_m1fWtU5La0OWTSec_dwYew_42_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">53625000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_Dp69KyPkPEWHT5oCSLjxxw_43_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">694000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_ok-6jdyguki9qwm7n2hD7g_43_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">691000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_KgEdVYlmCU6oiulM-UIBfg_43_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10399000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_JyUa4P4S-kamVVmNK5A8aA_44_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1809000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_TztGz6ChlUmi4bk45OZSpA_44_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2320000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_BOwdMyNoBES2Hg2Er_N8Hw_44_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3002000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_LApXDlmupkOaM0v60Q74EQ_45_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3587000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_zzHSclcrH0SWrSjADKsgGg_45_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3744000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_AF1w7nmqokqCfVCKZF3ZRQ_45_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1753000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_wFDH3Cmbkkun6sjdOalsrg_46_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">109000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_-O5t1yoR50iDKXf0N-fi8Q_47_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">81750000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_SxICRom8m0K7A2Ia3kurqQ_48_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1034000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_Uv0UHLX_jkKR8z-xqjOkyA_48_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1228000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_QYKS0G_uI0K8ge6li_xOaQ_48_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-672000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_FrF0ug_AX0abp5hjv6dLMw_49_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">69600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_zbeBfYoYVUKocziDEq3S9g_49_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">54326000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_9TIIH-EZZka50eDQuD1h5A_49_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51879000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_eKe-I7EJi0Se_KWJMkVV1A_51_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">39356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_1H3Go8t-oE2WekNcBTQ3nQ_51_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-353648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_8X5yDwO_fkq7fRstdsJG7w_51_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-123963000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_RGpGgwn_9EGE4e_yijQPVw_52_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_4R2r03upWEGrNBHRQmSgIQ_52_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">417635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc__7hVyKHGoEqNHAM8czjAWw_52_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">541598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_597MVqv7CUe1kNrHStuN7w_53_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">103343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_iV-NaibUbUuJ6ujp3K4CXw_53_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_-pktdKOAC0WOmcAaahN8Wg_53_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">417635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_rSaQz015ZU61zCgP53b6vQ_56_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">37857000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_6jdUL2pXBUqUwD4ftS7XMA_56_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">34878000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_t70vg_qYNkix0peKs6e_4g_56_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18684000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_FkBwc4B8qkKcae24zStFXg_57_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-118000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_mV2CWE41GUaDMyW8X02Fwg_57_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_HOFBWV-r7EWlDTfd1DSMnQ_57_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1221000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_XdVJRy2iR0qG9qSEbFS9oA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Coherus BioSciences,&#160;Inc.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Notes&#160;to Consolidated Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/span&gt;Organization and Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Description of the Business&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Coherus BioSciences,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Coherus&#x201d;) is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The Company&#x2019;s strategy is to build a leading immuno-oncology business funded with cash generated from its diversified portfolio of FDA-approved therapeutics. The Company&#x2019;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively. The Company sells UDENYCA &lt;span style="background:#ffffff;"&gt;(pegfilgrastim-cbqv)&lt;/span&gt;, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, in the United States. On August 2, 2022, the FDA approved CIMERLI&#xae;&#160;&lt;span style="background:#ffffff;"&gt;(ranibizumab-eqrn)&lt;/span&gt;, a biosimilar to Lucentis, and commercial launch commenced in October 2022 in the United States. The Company launched YUSIMRY&#xae;&#160;&lt;span style="background:#ffffff;"&gt;(adalimumab-aqvh), a biosimilar to Humira (adalimumab),&#160;&lt;/span&gt;in the United States in July 2023. On October 27, 2023, the Company announced that LOQTORZI&#x2122; (toripalimab-tpzi) was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI is a novel PD-1 inhibitor that the Company developed in collaboration with Junshi Biosciences. The Company announced the launch of LOQTORZI in the U.S. on January 2, 2024. On January 19, 2024, the Company entered into the Purchase Agreement by and between the Company and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, the Company completed the Sale Transaction for its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s product pipeline comprises&#160;the following three product candidates: &lt;span style="background:#ffffff;"&gt;CHS-1000, an antibody targeting ILT4; casdozokitug (CHS-388, formerly SRF388), an antibody targeting IL-27; and CHS-114 (formerly SRF114), a highly specific afucosylated IgG1 antibody targeting CCR8. In addition to the Company&#x2019;s internally developed portfolio of product candidates, the Company has two product candidates, NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes and GSK, respectively.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Consolidation&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of Coherus and its wholly-owned subsidiaries. The Company does not have any significant interest in variable interest entities. All material intercompany transactions and balances have been eliminated upon consolidation.&lt;span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Reporting and Revenue by Geographic Region&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing human pharmaceutical products. The Company&#x2019;s chief executive officer, as the chief operating decision maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of the Company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions. Primarily, all revenue is generated and all long-lived assets are maintained in the United States. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and restricted cash comprise cash and highly liquid investments with original maturities of 90&#160;days or less.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets and which, in aggregate, represent the amount reported in the consolidated statements of cash flows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At beginning of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At end of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company classifies the up-front and milestone payments related to licensing arrangements as cash flows used in investing activities in its consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Trade Receivables&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade receivables are recorded net of allowances for chargebacks, chargeback prepayments, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses and was not material during the periods presented. The Company believes that its allowance for expected credit losses was adequate and immaterial as of December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Investments in Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Investments in marketable securities primarily consist of U.S. Treasury securities, government agency securities, commercial paper, corporate bonds and market money funds. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#x2019;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#x2019;s investment policy requires that it only invests in highly rated securities and limits its exposure to any single issuer, except for securities issued by the U.S. government. All investments in marketable debt securities are held as &#x201c;available-for-sale&#x201d; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. The Company regularly reviews its investments for declines in fair value below the amortized cost basis to determine whether the impairment, if any, is due to credit-related or other factors. This review includes the credit worthiness of the security issuers, the severity of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of the amortized cost basis. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an available-for-sale debt investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. There were no impairments related to credit losses during any of the periods presented. Realized gains and losses, if any, on available-for-sale securities &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;are included in other income (expense), net, in the consolidated statements of operations based on the specific identification method. During 2023, 2022 and 2021, interest income from marketable securities was $2.8 million, $1.9 million and $1.4 million, respectively, and is included in other income (expense), net, in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Risk&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments in marketable securities and trade receivables. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Substantially all of the Company&#x2019;s revenues are in the United States to three&#160;wholesalers. During 2023, the products sold by the Company were UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. During 2022, UDENYCA and CIMERLI were the only products sold by the Company, and in 2021 UDENYCA accounted for all of the Company&#x2019;s revenues.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company enters into a strategic commercial supply agreement for each of its products. The Company currently has not engaged back-up suppliers or vendors. If any of the Company&#x2019;s current vendors are not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative Instruments &lt;/b&gt;&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In January 2023, the Company commenced using derivative contracts (foreign exchange option contracts) for the purpose of economically hedging exposure to changes in currency fluctuations between the U.S.&#160;Dollar and the Euro. The Company recognizes all derivatives at fair value on the consolidated balance sheets, and corresponding gains and losses are recognized in other income (expense), net in the consolidated statements of operations. The estimated fair value of derivative financial instruments represents the amount required to enter into similar contracts with similar remaining maturities based on quoted market prices. During the periods presented, the Company did not apply hedge accounting to these instruments. There are no derivative instruments entered into for speculative or trading purposes.&#160;Since the Company's foreign exchange derivatives all matured and settled by December 31, 2023, there were no derivative assets or &lt;span style="-sec-ix-hidden:Hidden_YgjkhDQ6bEeOg5gUe8O-fQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;derivative liabilities&lt;/span&gt;&lt;/span&gt; as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business Combination Accounting &amp;amp; Valuation of Acquired Assets &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations.&#160;Judgment is required in assessing whether the acquired processes or activities, along with their inputs, meet the criteria to constitute a business, as defined by U.S. GAAP.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The acquisition method of accounting requires the recognition of assets acquired and liabilities assumed at their acquisition date fair values.&#160;The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill, or when there is an&#160;excess of the fair values of these identifiable assets and liabilities over the fair value of purchase consideration, a&#160;bargain purchase gain is recorded in&#160;the consolidated statements of operations.&#160;The estimations of fair values based on non-observable inputs that are included in valuation models. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including the estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the measurement period, which occurs before finalization of the purchase price allocation, changes in assumptions and estimates that result in adjustments to the fair values of assets acquired and liabilities assumed, if based on facts and circumstances existing at the acquisition date, are recorded on a retroactive basis as of the acquisition date, with the corresponding offset to goodwill or bargain purchase gain (See Note 6. Surface Acquisition).&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign Currency&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in&#160;foreign currencies are remeasured at historical rates.&#160;Translation gains and losses are included in &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;accumulated other comprehensive loss in stockholders&#x2019; equity (deficit).&#160;Revenue and expense accounts are translated to U.S. dollars at average exchange rates in effect during the period with resulting transaction gains and losses recognized in other income (expense), net in the consolidated statements of operations. The Company has not experienced material foreign currency transaction gains and losses for any of the years presented.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. The Company primarily uses actual costs to determine the cost basis for inventory. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During 2023 and 2022, the Company recorded $52.6 million and $26.0 million in inventory write-downs, respectively, within cost of goods sold in the consolidated statements of operations. The 2023 charge was primarily for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. The 2022 charge was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes the assumptions used in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by management, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in the consolidated statements of operations. Adverse developments affecting the Company&#x2019;s assumptions of the level and timing of demand for its products include those that are outside of the Company&#x2019;s control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the regulatory approval of product candidates, the Company incurs expenses for the manufacture of drug products that could potentially be available to support the commercial launch of the products. I&lt;span style="background:#ffffff;"&gt;nventory costs are capitalized when future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment. &#160;A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, viability of commercialization and marketplace trends. Inventory in the consolidated balance sheets as of December 31, 2023 was related to UDENYCA, YUSIMRY, CIMERLI and LOQTORZI.&lt;/span&gt; The Company began to capitalize inventory costs associated with UDENYCA, CIMERLI and LOQTORZI after receiving final regulatory approval in November&#160;2018, August 2022, and October 2023, respectively, and capitalization of YUSIMRY inventory costs began in the second quarter of 2022 when sales were deemed probable. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the capitalized interest costs are amortized as depreciation or amortization expense over the life of the underlying asset. When the Company disposes of property and equipment, it removes the associated cost and accumulated depreciation from the related accounts in the consolidated balance sheets and include any resulting gain or loss in the consolidated statements of operations. Eligible costs of internal use software and implementation costs of certain hosting arrangements are capitalized and amortized over the estimated useful life of the software or associated hosting arrangement, as applicable. Depreciation and amortization are recognized using the straight-line method over the following estimated useful lives:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill and Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company&#x2019;s single reporting unit below its carrying amount.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Acquired in-process research and development&#160;(&#x201c;IPR&amp;amp;D&#x201d;) that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, the Company &lt;span style="background:#ffffff;"&gt;will commence amortization over the useful life of the intangible asset, which will generally be determined by the period in which the substantial majority of the cash flows are expected to be generated. &lt;/span&gt;The Company evaluates IPR&amp;amp;D for impairment on an annual basis, during the fourth quarter, or more frequently if impairment indicators exist.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Finite-lived intangible assets are generally amortized on a straight-line basis over their estimated economic life and are reviewed periodically for impairment. The amortization expense related to capitalized milestone payments under license agreements and the amortization expense from out-licenses are recorded as a component of cost of goods sold in the consolidated statements of operations. The estimated life for capitalized milestone payments is&#160;ten years,&#160;and the life for acquired out-licenses is&#160;fifteen years. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued Research and Development Expense&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent Consideration&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Contingent consideration relates to the potential payments to holders of&#160;the CVRs&#160;that are contingent upon the achievement of the Company and certain third-parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within loss from operations in the consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Net Revenues &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells to wholesalers and distributors, (collectively, &#x201c;Customers&#x201d;). The Customers then resell to hospitals and clinics (collectively, &#x201c;Healthcare Providers&#x201d;) pursuant to contracts with the Company. In addition to distribution agreements with Customers and contracts with Healthcare Providers, the Company enters into arrangements with group purchasing organizations (&#x201c;GPOs&#x201d;) that provide for United States government-mandated or privately negotiated rebates, chargebacks and discounts. The Company also enters into rebate arrangements with payers, which consist primarily of commercial insurance companies and government entities, to cover the reimbursement of products to Healthcare Providers. The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. Revenue from product sales is recognized at the point when a Customer obtains control of the product and the Company satisfies its performance obligation, which generally occurs at the time product is shipped to the Customer. Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Revenue from product sales is recorded at the net sales price (&#x201c;transaction price&#x201d;), which includes estimates of variable consideration for which reserves are established and that result from chargebacks, rebates, co-pay assistance, prompt-payment discounts, &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;returns and other allowances that are offered within contracts between the Company and its Customers, Healthcare Providers, payers and GPOs. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions in trade receivables (if the amounts are payable to a Customer) or current and non-current liabilities (if the amounts are payable to a party other than a Customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specifically known market events and trends, industry data and forecasted Customer buying and payment patterns. Overall, these reserves reflect the best estimates of the amount of consideration to which the Company is entitled based on the terms of its contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The actual amount of consideration ultimately received may differ. If actual results in the future vary from the Company&#x2019;s estimates, the estimates will be adjusted, which will affect net product revenue in the period that such variances become known.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Chargebacks: &lt;/i&gt;Chargebacks are discounts that occur when Healthcare Providers purchase directly from a Customer. Healthcare Providers, which belong to Public Health Service institutions, non-profit clinics, government entities, GPOs, and health maintenance organizations, generally purchase the product at a discounted price. The Customer, in turn, charges back to the Company the difference between the price initially paid by the Customer and the discounted price paid by the Healthcare Providers to the Customer. The allowance for chargebacks is based on an estimate of sales through to Healthcare Providers from the Customer.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/i&gt; The Company provides for prompt payment discounts to its Customers, which are recorded as a reduction in revenue in the same period that the related product revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Rebates:&lt;/i&gt; Rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with these public sector benefit providers. The accrual for rebates is based on statutory or contractual discount rates and expected utilization. The estimates for the expected utilization of rebates are based on Customer and commercially available payer data, as well as data collected from the Healthcare Providers, Customers, GPOs, and historical utilization rates. Rebates invoiced by payers, Healthcare Providers and GPOs are paid in arrears. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenue in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Co-payment Assistance:&lt;/i&gt; Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Product Returns:&lt;/i&gt; The Company offers its Customers limited product return rights, which are principally based upon whether the product is damaged or defective, or the product&#x2019;s expiration date. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Other Allowances:&lt;/i&gt; The Company pays fees to Customers and GPOs for account management, data management and other administrative services. To the extent that the services received are distinct from the sale of products to the customer, these payments are classified in selling, general and administrative expense in the Company&#x2019;s consolidated statements of operations, otherwise they are included as a reduction in product revenue.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Revenue&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Royalty revenue from licensees, which is based on sales to third parties of licensed products, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty revenue was immaterial for all periods presented and is included in net revenue. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cost of Goods Sold&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cost of goods sold consists primarily of third-party manufacturing, distribution, certain overhead costs, royalties on certain products, and charges for inventory write-downs. &lt;span style="background:#ffffff;"&gt;Through March 31, 2021, a portion of the costs of producing UDENYCA&#160;sold was expensed as research and development before the FDA approval of UDENYCA&#160;and therefore is not reflected in cost of goods sold. All the inventory expensed prior to approval of UDENYCA was fully utilized by March 31, 2021; thus, the costs of producing UDENYCA&#160;are fully reflected in cost of goods sold beginning April 1, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;2, 2019, the Company and Amgen settled a trade secret action brought by Amgen. As a result, cost of goods sold reflects a mid-single digit royalty on UDENYCA net product revenue, which began on July&#160;1, 2019. The royalty cost will continue for five years pursuant to the settlement. Additionally, the Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range. The Company incurs royalties on net sales of LOQTORZI in the low- to mid-twenty percent range and on net sales of YUSIMRY in the mid-single digit range. Pursuant to the Genentech Agreement, the Company incurred a royalty that was a low single-digit percentage of net sales of CIMERLI through the end of 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, 2022 and 2021, cost of goods sold included inventory write-downs, net of $52.6 million, $26.0 million and $5.1 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expense&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Research and development expense represents costs incurred to conduct research, such as the discovery and development of product candidates. The Company recognizes all research and development costs as they are incurred. The Company currently tracks research and development costs incurred on a product candidate basis only for external research and development expenses. The Company&#x2019;s external research and development expense consists primarily of:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;expense incurred under agreements with collaborators, consultants, third-party CROs, and investigative sites where a substantial portion of the Company&#x2019;s preclinical studies and all of its clinical trials are conducted;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;costs associated with manufacturing process development activities, analytical activities and pre-launch inventory manufactured prior to regulatory approval being obtained or deemed to be probable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;upfront and milestone payments related to licensing and collaboration agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Internal costs are associated with activities performed by the Company&#x2019;s research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;personnel-related expense, which include salaries, benefits and stock-based compensation; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;License Agreements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered and may continue to enter into license agreements to access and utilize certain technology. To determine whether the licensing transactions should be accounted for as a business combination or as an asset acquisition, the Company makes certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an asset acquisition and therefore, any acquired IPR&amp;amp;D that does not have an alternative future use is charged to expense at the acquisition date. To date none of the Company&#x2019;s license agreements have been considered to be the acquisition of a business.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Selling, General and Administrative Expense&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Selling, general and administrative expense comprises primarily compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $10.9 million, $10.5 million and $8.7 million in 2023, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s compensation programs include stock-based awards, and the related grants under these programs are accounted for at fair value. The fair values are recognized as compensation expense on a straight-line basis over the vesting period with the related costs recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company&#x2019;s common stock on the date of issuance. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as income tax expense.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. The Company does not expect its unrecognized tax benefits from prior years to change significantly in 2024. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating and Finance Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:45pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines at an arrangement&#x2019;s inception whether it is a lease. The Company does not recognize right-of-use assets and lease liabilities related to short-term leases. The Company also does not separate lease and non-lease components for its facility and vehicle leases. Operating leases are included in accrued and other current liabilities, other assets, non-current, and lease liabilities, non-current in the consolidated balance sheets. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. The Company recognizes operating lease expense for these leases on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The terms of vehicles leased under the Company&#x2019;s fleet agreement (&#x201c;Vehicle Lease Agreement&#x201d;) are 36 months. The vehicles leased under this arrangement were classified as finance leases. Finance leases are included in property and equipment, net, accrued and other current liabilities, and lease liabilities, non-current in the consolidated balance sheets. Assets under finance leases are depreciated to operating expenses on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The operating and finance lease right-of-use assets and the lease liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. The Company uses its incremental borrowing rate based on the information available at the commencement date or the lease modification date, as applicable, in determining the lease liabilities as the Company's leases generally do not provide an implicit rate.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive&lt;/span&gt; (see Note 14. Net Loss Per Share).&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes the following two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that are recorded as an element of stockholders&#x2019; equity (deficit), but are excluded from net loss. The Company&#x2019;s other comprehensive income (loss) includes unrealized gains on available-for-sale securities and foreign currency translation adjustments in 2023, 2022 and 2021. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Reclassifications&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain amounts in prior years&#x2019; financial statements have been reclassified to conform with the current year presentation in 2023, including amounts in the consolidated statements of cash flows. There were no changes to net cash used in operating activities in the consolidated statements of cash flows for the prior years as a result.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following are recent accounting pronouncements that the Company has not yet adopted:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt; &lt;i style="font-style:italic;"&gt;(Topic 280) Improvements to Reportable Segment &lt;/i&gt;&lt;i style="font-style:italic;"&gt;Disclosures&lt;/i&gt;, which enhances the disclosures required for operating segments by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, among other expanded. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued&#160;ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA"
      decimals="-5"
      id="Narr_BHM7yfVlUUuAXppuPO2ZnQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">170000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <chrs:BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets
      contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA"
      decimals="-5"
      id="Narr_AdxuPe0rP0S0PrSK_YWXuw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17800000</chrs:BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets>
    <chrs:ProductPipelineNumberOfDrugCandidates
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_R83QhID_xECZq6XpIYhhnw"
      unitRef="Unit_Standard_product_SdGd84au20GyPZXZYh-a9w">3</chrs:ProductPipelineNumberOfDrugCandidates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Kh12U6QVdEydDLPI8FurzA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Consolidation&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of Coherus and its wholly-owned subsidiaries. The Company does not have any significant interest in variable interest entities. All material intercompany transactions and balances have been eliminated upon consolidation.&lt;span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_1daHQQKyB0eQ5ONvCs7WzA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <chrs:SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_kmqi1l1y1U2ExwQN7LJbww">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Reporting and Revenue by Geographic Region&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing human pharmaceutical products. The Company&#x2019;s chief executive officer, as the chief operating decision maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of the Company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions. Primarily, all revenue is generated and all long-lived assets are maintained in the United States. &lt;/p&gt;</chrs:SegmentReportingAndRevenueByGeographicRegionPolicyTextBlock>
    <chrs:NumberOfOperatingAndReportableSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="INF"
      id="Narr_1jb4qmkTIUiN710biluIJw"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">1</chrs:NumberOfOperatingAndReportableSegments>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_v_n2Xz8GUEOdr0KYFFb24Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and restricted cash comprise cash and highly liquid investments with original maturities of 90&#160;days or less.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets and which, in aggregate, represent the amount reported in the consolidated statements of cash flows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At beginning of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At end of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of deposits for letters of credit that the Company has provided to secure its obligations under certain leases and is included in other assets, non-current in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company classifies the up-front and milestone payments related to licensing arrangements as cash flows used in investing activities in its consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_GVtZFdPwmEenLWQI_00UcA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At beginning of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 541,598&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;At end of period:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_INGwya90d06CSRtzo8M4-w_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63547000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_CHUkRyQnp0-NZ8JauSgGlQ_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">417195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc_VsxuDgVtf0GeKplz-H8p8w_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">541158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_yGa7Dqq5J0aDiUX2uxcWeQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">440000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_Dqjg_joiFkKBdfp5g6PoAA_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">440000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc_iTHHZ3D8g0iPFTyOxvKUTg_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">440000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_OSLcC37knkCGPAY_3FSSgA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_Bdiq6ouT8kSqIlcqob550Q_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">417635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc_3us_AziQD0CqLPhFS2NVsQ_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">541598000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_cTZrIhThzkSCU7dHQ173Xg_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">102891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_gfVRoTRCMEiep8mbQpxqLQ_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63547000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_zc4dMXlQeUCZw_S28X4Dcg_9_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">417195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_O3kD8vmxNEadnaR0OeUgGw_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">452000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_1rXBK7BdAUaNGyh4qV9E4w_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">440000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_j72IyphJgEOCZG1K5VzndA_10_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">440000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_l1Q3iNdIvUC0qhavI6HsXQ_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">103343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_1gq6emoLWUaXD50VUi465w_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_FzuMnEiG6U-qwniVA8-KLQ_11_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">417635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_JFW0XS8DjEqGDT53hiqmMA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Trade Receivables&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade receivables are recorded net of allowances for chargebacks, chargeback prepayments, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses and was not material during the periods presented. The Company believes that its allowance for expected credit losses was adequate and immaterial as of December 31, 2023 and 2022.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_wxwNFeAavUKPbdMtEfNxQg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Investments in Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Investments in marketable securities primarily consist of U.S. Treasury securities, government agency securities, commercial paper, corporate bonds and market money funds. Management determines the appropriate classification of investments in marketable securities at the time of purchase based upon management&#x2019;s intent with regards to such investment and reevaluates such designation as of each balance sheet date. The Company&#x2019;s investment policy requires that it only invests in highly rated securities and limits its exposure to any single issuer, except for securities issued by the U.S. government. All investments in marketable debt securities are held as &#x201c;available-for-sale&#x201d; and are carried at the estimated fair value as determined based upon quoted market prices or pricing models for similar securities. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company classifies investments in marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date. The Company regularly reviews its investments for declines in fair value below the amortized cost basis to determine whether the impairment, if any, is due to credit-related or other factors. This review includes the credit worthiness of the security issuers, the severity of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that the Company will be required to sell the securities before the recovery of the amortized cost basis. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated comprehensive income (loss), with the exception of unrealized losses believed to be related to credit losses, if any, which are recognized in earnings in the period the impairment occurs. Impairment assessments are made at the individual security level each reporting period. When the fair value of an available-for-sale debt investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is related to a credit loss and, if it is, the portion of the impairment relating to credit loss is recorded as an allowance through net income. There were no impairments related to credit losses during any of the periods presented. Realized gains and losses, if any, on available-for-sale securities &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;are included in other income (expense), net, in the consolidated statements of operations based on the specific identification method. During 2023, 2022 and 2021, interest income from marketable securities was $2.8 million, $1.9 million and $1.4 million, respectively, and is included in other income (expense), net, in the consolidated statements of operations.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="0"
      id="Narr_ihch3Ieg80GCKsBIhwBu4Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="0"
      id="Narr_jx8UAL4MrESCb8SP9QAyqQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="0"
      id="Narr_E2yEMrabPkSlforgr6PyaA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_nfGQLPRXfEyaqhb6Mx52Jw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-5"
      id="Narr_W_zkyK-rfU6hIcTGwIWe3w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-5"
      id="Narr_dZofCyJrSUa65fFCDDHCeA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_hfHPqP0VCUS93zJ8wMXjTQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Risk&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments in marketable securities and trade receivables. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Substantially all of the Company&#x2019;s revenues are in the United States to three&#160;wholesalers. During 2023, the products sold by the Company were UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. During 2022, UDENYCA and CIMERLI were the only products sold by the Company, and in 2021 UDENYCA accounted for all of the Company&#x2019;s revenues.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company enters into a strategic commercial supply agreement for each of its products. The Company currently has not engaged back-up suppliers or vendors. If any of the Company&#x2019;s current vendors are not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_2ffmr95FcE2G81ZmWp_ILA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative Instruments &lt;/b&gt;&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In January 2023, the Company commenced using derivative contracts (foreign exchange option contracts) for the purpose of economically hedging exposure to changes in currency fluctuations between the U.S.&#160;Dollar and the Euro. The Company recognizes all derivatives at fair value on the consolidated balance sheets, and corresponding gains and losses are recognized in other income (expense), net in the consolidated statements of operations. The estimated fair value of derivative financial instruments represents the amount required to enter into similar contracts with similar remaining maturities based on quoted market prices. During the periods presented, the Company did not apply hedge accounting to these instruments. There are no derivative instruments entered into for speculative or trading purposes.&#160;Since the Company's foreign exchange derivatives all matured and settled by December 31, 2023, there were no derivative assets or &lt;span style="-sec-ix-hidden:Hidden_YgjkhDQ6bEeOg5gUe8O-fQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;derivative liabilities&lt;/span&gt;&lt;/span&gt; as of December 31, 2023.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="0"
      id="Narr_LA0djUehLE61pD8ve2CD-Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:DerivativeAssets>
    <us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_VNvtN_nmO0-MZo_z-1HF1g">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business Combination Accounting &amp;amp; Valuation of Acquired Assets &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations.&#160;Judgment is required in assessing whether the acquired processes or activities, along with their inputs, meet the criteria to constitute a business, as defined by U.S. GAAP.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The acquisition method of accounting requires the recognition of assets acquired and liabilities assumed at their acquisition date fair values.&#160;The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill, or when there is an&#160;excess of the fair values of these identifiable assets and liabilities over the fair value of purchase consideration, a&#160;bargain purchase gain is recorded in&#160;the consolidated statements of operations.&#160;The estimations of fair values based on non-observable inputs that are included in valuation models. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including the estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the measurement period, which occurs before finalization of the purchase price allocation, changes in assumptions and estimates that result in adjustments to the fair values of assets acquired and liabilities assumed, if based on facts and circumstances existing at the acquisition date, are recorded on a retroactive basis as of the acquisition date, with the corresponding offset to goodwill or bargain purchase gain (See Note 6. Surface Acquisition).&lt;/p&gt;</us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Y32oWoW2REq4SBLuwB1X1A">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign Currency&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Monetary assets and liabilities denominated in foreign currency are remeasured at period-end exchange rates. Non-monetary assets and liabilities denominated in&#160;foreign currencies are remeasured at historical rates.&#160;Translation gains and losses are included in &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;accumulated other comprehensive loss in stockholders&#x2019; equity (deficit).&#160;Revenue and expense accounts are translated to U.S. dollars at average exchange rates in effect during the period with resulting transaction gains and losses recognized in other income (expense), net in the consolidated statements of operations. The Company has not experienced material foreign currency transaction gains and losses for any of the years presented.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_SXR8CPGCBEK1eBnlaZN23Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. The Company primarily uses actual costs to determine the cost basis for inventory. The determination of excess or obsolete inventory requires judgment including consideration of many factors, such as estimates of future product demand, current and future market conditions, product expiration information, and potential product obsolescence, among others. During 2023 and 2022, the Company recorded $52.6 million and $26.0 million in inventory write-downs, respectively, within cost of goods sold in the consolidated statements of operations. The 2023 charge was primarily for the write-down of slow moving YUSIMRY inventory and the related partial recognition of certain firm purchase commitments. The 2022 charge was due to the competitive environment and lower demand for UDENYCA resulting in certain inventory becoming at risk of expiration.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes the assumptions used in estimating potential inventory write-downs are reasonable, if actual market conditions are less favorable than projected by management, write-downs of inventory, charges related to firm purchase commitments, or both may be required which would be recorded as cost of goods sold in the consolidated statements of operations. Adverse developments affecting the Company&#x2019;s assumptions of the level and timing of demand for its products include those that are outside of the Company&#x2019;s control such as the actions taken by competitors and customers, the direct or indirect effects of the COVID-19 pandemic, and other factors.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the regulatory approval of product candidates, the Company incurs expenses for the manufacture of drug products that could potentially be available to support the commercial launch of the products. I&lt;span style="background:#ffffff;"&gt;nventory costs are capitalized when future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment. &#160;A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, viability of commercialization and marketplace trends. Inventory in the consolidated balance sheets as of December 31, 2023 was related to UDENYCA, YUSIMRY, CIMERLI and LOQTORZI.&lt;/span&gt; The Company began to capitalize inventory costs associated with UDENYCA, CIMERLI and LOQTORZI after receiving final regulatory approval in November&#160;2018, August 2022, and October 2023, respectively, and capitalization of YUSIMRY inventory costs began in the second quarter of 2022 when sales were deemed probable. &lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA"
      decimals="-5"
      id="Narr_76lFkIl1n0KUe6bC9lILgg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">52600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_UdenycaMember_couIVXZw9U2OdgPC4e_wMw"
      decimals="-5"
      id="Narr_XCt6JuV2_kiL8XaOc-pAwg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26000000.0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_3kxyTGQ0FkKL_v-wUY71vg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the capitalized interest costs are amortized as depreciation or amortization expense over the life of the underlying asset. When the Company disposes of property and equipment, it removes the associated cost and accumulated depreciation from the related accounts in the consolidated balance sheets and include any resulting gain or loss in the consolidated statements of operations. Eligible costs of internal use software and implementation costs of certain hosting arrangements are capitalized and amortized over the estimated useful life of the software or associated hosting arrangement, as applicable. Depreciation and amortization are recognized using the straight-line method over the following estimated useful lives:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <chrs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_hI231IkCR0S25ZXlTismuw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3 - 7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-IH_mKjA6U6bK5tk5yUUQQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Shorter&#160;of&#160;lease&#160;term&#160;or&#160;useful&#160;life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_cWwUSInfWk6DbOgC8phq1g"
      id="Narr_9fgELSEmx06Gs1LNmIFbMA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_0Z36Will8EWLyeJWTqBk6Q"
      id="Narr_tfxEulXxzkSNARdD7fBeVg">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA"
      id="Tc_iMXY0L5gN06S5kClx8qFYg_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_R1ZNIhTdtU6PTDnnezToVQ"
      id="Tc_I6Mg3UVRFUqj2i6puowOwg_3_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_d4HuKo249EqSUh2NgRCG-g">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill and Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is not amortized but is evaluated for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company&#x2019;s single reporting unit below its carrying amount.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Acquired in-process research and development&#160;(&#x201c;IPR&amp;amp;D&#x201d;) that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;amp;D project, the Company &lt;span style="background:#ffffff;"&gt;will commence amortization over the useful life of the intangible asset, which will generally be determined by the period in which the substantial majority of the cash flows are expected to be generated. &lt;/span&gt;The Company evaluates IPR&amp;amp;D for impairment on an annual basis, during the fourth quarter, or more frequently if impairment indicators exist.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Finite-lived intangible assets are generally amortized on a straight-line basis over their estimated economic life and are reviewed periodically for impairment. The amortization expense related to capitalized milestone payments under license agreements and the amortization expense from out-licenses are recorded as a component of cost of goods sold in the consolidated statements of operations. The estimated life for capitalized milestone payments is&#160;ten years,&#160;and the life for acquired out-licenses is&#160;fifteen years. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_Pb1Z3ozRJkOA77OkYuNphw"
      id="Narr_5XuQ7osEbkKOXgseCbd-gQ">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_v9SRmwDa7E2QVcIw31qKkg"
      id="Narr_khg3wsyu2UqsW_86tqvoFg">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_s20nfE8l0kqNSS2D9ND2Sg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. If there is an indication of impairment, the Company tests for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <chrs:AccruedResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_BIUsKfR4Y0eNJz_-rVimiQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued Research and Development Expense&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Clinical trial costs are a component of research and development expense. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research and manufacturing organizations and clinical sites. The Company determines the actual costs through monitoring patient enrollment, discussions with internal personnel and external service providers regarding the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.&lt;/p&gt;</chrs:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <chrs:ContingentConsiderationPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_PPyD7qIfRkeXDuOXvXkQig">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent Consideration&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Contingent consideration relates to the potential payments to holders of&#160;the CVRs&#160;that are contingent upon the achievement of the Company and certain third-parties meeting product development or financial performance milestones. For transactions accounted for as business combinations, the Company records contingent consideration at fair value at the date of the acquisition based on the consideration expected to be transferred. Liabilities for contingent consideration are remeasured each reporting period and subsequent changes in fair value are recognized within loss from operations in the consolidated statements of operations. The assumptions utilized in the calculation of the fair values include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from estimated amounts.&lt;/p&gt;</chrs:ContingentConsiderationPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_8YuAv9NQMUWScSH24-seSA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Net Revenues &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells to wholesalers and distributors, (collectively, &#x201c;Customers&#x201d;). The Customers then resell to hospitals and clinics (collectively, &#x201c;Healthcare Providers&#x201d;) pursuant to contracts with the Company. In addition to distribution agreements with Customers and contracts with Healthcare Providers, the Company enters into arrangements with group purchasing organizations (&#x201c;GPOs&#x201d;) that provide for United States government-mandated or privately negotiated rebates, chargebacks and discounts. The Company also enters into rebate arrangements with payers, which consist primarily of commercial insurance companies and government entities, to cover the reimbursement of products to Healthcare Providers. The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. Revenue from product sales is recognized at the point when a Customer obtains control of the product and the Company satisfies its performance obligation, which generally occurs at the time product is shipped to the Customer. Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Product Sales Discounts and Allowances&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Revenue from product sales is recorded at the net sales price (&#x201c;transaction price&#x201d;), which includes estimates of variable consideration for which reserves are established and that result from chargebacks, rebates, co-pay assistance, prompt-payment discounts, &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;returns and other allowances that are offered within contracts between the Company and its Customers, Healthcare Providers, payers and GPOs. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions in trade receivables (if the amounts are payable to a Customer) or current and non-current liabilities (if the amounts are payable to a party other than a Customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as historical experience, current contractual and statutory requirements, specifically known market events and trends, industry data and forecasted Customer buying and payment patterns. Overall, these reserves reflect the best estimates of the amount of consideration to which the Company is entitled based on the terms of its contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The actual amount of consideration ultimately received may differ. If actual results in the future vary from the Company&#x2019;s estimates, the estimates will be adjusted, which will affect net product revenue in the period that such variances become known.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Chargebacks: &lt;/i&gt;Chargebacks are discounts that occur when Healthcare Providers purchase directly from a Customer. Healthcare Providers, which belong to Public Health Service institutions, non-profit clinics, government entities, GPOs, and health maintenance organizations, generally purchase the product at a discounted price. The Customer, in turn, charges back to the Company the difference between the price initially paid by the Customer and the discounted price paid by the Healthcare Providers to the Customer. The allowance for chargebacks is based on an estimate of sales through to Healthcare Providers from the Customer.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Discounts for Prompt Payment:&lt;/i&gt; The Company provides for prompt payment discounts to its Customers, which are recorded as a reduction in revenue in the same period that the related product revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Rebates:&lt;/i&gt; Rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with these public sector benefit providers. The accrual for rebates is based on statutory or contractual discount rates and expected utilization. The estimates for the expected utilization of rebates are based on Customer and commercially available payer data, as well as data collected from the Healthcare Providers, Customers, GPOs, and historical utilization rates. Rebates invoiced by payers, Healthcare Providers and GPOs are paid in arrears. If actual future rebates vary from estimates, the Company may need to adjust its accruals, which would affect net product revenue in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Co-payment Assistance:&lt;/i&gt; Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Product Returns:&lt;/i&gt; The Company offers its Customers limited product return rights, which are principally based upon whether the product is damaged or defective, or the product&#x2019;s expiration date. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Other Allowances:&lt;/i&gt; The Company pays fees to Customers and GPOs for account management, data management and other administrative services. To the extent that the services received are distinct from the sale of products to the customer, these payments are classified in selling, general and administrative expense in the Company&#x2019;s consolidated statements of operations, otherwise they are included as a reduction in product revenue.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Revenue&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Royalty revenue from licensees, which is based on sales to third parties of licensed products, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Royalty revenue was immaterial for all periods presented and is included in net revenue. &lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_lrG1nuGQfEi4lCVGUYNJVA">Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <chrs:PaymentTermsPeriodFromDateOfShipment
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_gVOkBFt9vUSNT22wfjVu6g"
      id="Narr_Iun9rdjIcU2zNQR_ND_30w">P30D</chrs:PaymentTermsPeriodFromDateOfShipment>
    <chrs:PaymentTermsPeriodFromDateOfShipment
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v-ug3g3l80mlObh8LcgInw"
      id="Narr_StOmpgvop0y4Mn_f80Xqpg">P90D</chrs:PaymentTermsPeriodFromDateOfShipment>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_MPXOtx_H_kOJOx5OrjjIpw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cost of Goods Sold&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cost of goods sold consists primarily of third-party manufacturing, distribution, certain overhead costs, royalties on certain products, and charges for inventory write-downs. &lt;span style="background:#ffffff;"&gt;Through March 31, 2021, a portion of the costs of producing UDENYCA&#160;sold was expensed as research and development before the FDA approval of UDENYCA&#160;and therefore is not reflected in cost of goods sold. All the inventory expensed prior to approval of UDENYCA was fully utilized by March 31, 2021; thus, the costs of producing UDENYCA&#160;are fully reflected in cost of goods sold beginning April 1, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;2, 2019, the Company and Amgen settled a trade secret action brought by Amgen. As a result, cost of goods sold reflects a mid-single digit royalty on UDENYCA net product revenue, which began on July&#160;1, 2019. The royalty cost will continue for five years pursuant to the settlement. Additionally, the Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range. The Company incurs royalties on net sales of LOQTORZI in the low- to mid-twenty percent range and on net sales of YUSIMRY in the mid-single digit range. Pursuant to the Genentech Agreement, the Company incurred a royalty that was a low single-digit percentage of net sales of CIMERLI through the end of 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2023, 2022 and 2021, cost of goods sold included inventory write-downs, net of $52.6 million, $26.0 million and $5.1 million, respectively. &lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <chrs:RoyaltyPaymentTerm
      contextRef="Duration_7_1_2019_To_7_1_2019_peTS_V4r30KWdrPrMS7BCQ"
      id="Narr_vcqihw1VlUm1ZuJJlQUWlw">P5Y</chrs:RoyaltyPaymentTerm>
    <chrs:PercentageOfGrossProfitsOnSales
      contextRef="Duration_5_2_2019_To_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_iS0ub3fSH06yefAa2ICMew"
      decimals="2"
      id="Narr_sPovj_MP0kqoL0y3WDWfMA"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.50</chrs:PercentageOfGrossProfitsOnSales>
    <chrs:PercentageOfRoyaltiesOnNetSales
      contextRef="As_Of_5_2_2019_us-gaap_TypeOfArrangementAxis_chrs_LoqtorziMember_z2kc3sXj-0-3-XUzY_VHZg"
      decimals="2"
      id="Narr_NmnIaJ_P_kCNcduafRG_qQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.20</chrs:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_4KVEG243LkuvNze54VMR2A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">52600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-5"
      id="Narr_8BPrKZRCrEuUsjxRunWf-A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26000000.0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-5"
      id="Narr_DoR0wyJ4X0mMDBMacWPZ1Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5100000</us-gaap:InventoryWriteDown>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_qisk_F9wSk-r35eZqu37RA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expense&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Research and development expense represents costs incurred to conduct research, such as the discovery and development of product candidates. The Company recognizes all research and development costs as they are incurred. The Company currently tracks research and development costs incurred on a product candidate basis only for external research and development expenses. The Company&#x2019;s external research and development expense consists primarily of:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;expense incurred under agreements with collaborators, consultants, third-party CROs, and investigative sites where a substantial portion of the Company&#x2019;s preclinical studies and all of its clinical trials are conducted;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;costs of acquiring originator comparator materials and manufacturing preclinical study and clinical trial supplies and other materials from CMOs, and related costs associated with release and stability testing;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;costs associated with manufacturing process development activities, analytical activities and pre-launch inventory manufactured prior to regulatory approval being obtained or deemed to be probable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;upfront and milestone payments related to licensing and collaboration agreements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Internal costs are associated with activities performed by the Company&#x2019;s research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated, internal research and development costs consist primarily of:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;personnel-related expense, which include salaries, benefits and stock-based compensation; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;facilities and other allocated expense, which include direct and allocated expense for rent and maintenance of facilities, depreciation and amortization of leasehold improvements and equipment, laboratory and other supplies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <chrs:LicenseAgreementsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_PbNYNrCETUezC936JHqpeg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;License Agreements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered and may continue to enter into license agreements to access and utilize certain technology. To determine whether the licensing transactions should be accounted for as a business combination or as an asset acquisition, the Company makes certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an asset acquisition and therefore, any acquired IPR&amp;amp;D that does not have an alternative future use is charged to expense at the acquisition date. To date none of the Company&#x2019;s license agreements have been considered to be the acquisition of a business.&lt;/p&gt;</chrs:LicenseAgreementsPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_p4b4mhbGr06-dxiH9hXUUw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Selling, General and Administrative Expense&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Selling, general and administrative expense comprises primarily compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. The Company expenses the cost of advertising, including promotional expenses, as incurred. Advertising expenses were $10.9 million, $10.5 million and $8.7 million in 2023, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_DWhn8AhurUaEg48ntTUSEg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10900000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-5"
      id="Narr_OkIIls00UE-oV3Ouhy51VA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10500000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-5"
      id="Narr_T8SY2rVPTkW1o_koAE6HzA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8700000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_C4eYDCFUXEukSn1tiuOBrw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s compensation programs include stock-based awards, and the related grants under these programs are accounted for at fair value. The fair values are recognized as compensation expense on a straight-line basis over the vesting period with the related costs recorded in cost of goods sold, research and development, and selling, general and administrative expense, as appropriate. The Company accounts for forfeitures as they occur. The Company accounts for stock issued in connection with business combinations based on the fair value of the Company&#x2019;s common stock on the date of issuance. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_nKhefH4xgEKApj6KSZM7vQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as income tax expense.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. The Company does not expect its unrecognized tax benefits from prior years to change significantly in 2024. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_kK7nNR4p8kigJyXi3bduoA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating and Finance Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:45pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines at an arrangement&#x2019;s inception whether it is a lease. The Company does not recognize right-of-use assets and lease liabilities related to short-term leases. The Company also does not separate lease and non-lease components for its facility and vehicle leases. Operating leases are included in accrued and other current liabilities, other assets, non-current, and lease liabilities, non-current in the consolidated balance sheets. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. The Company recognizes operating lease expense for these leases on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The terms of vehicles leased under the Company&#x2019;s fleet agreement (&#x201c;Vehicle Lease Agreement&#x201d;) are 36 months. The vehicles leased under this arrangement were classified as finance leases. Finance leases are included in property and equipment, net, accrued and other current liabilities, and lease liabilities, non-current in the consolidated balance sheets. Assets under finance leases are depreciated to operating expenses on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The operating and finance lease right-of-use assets and the lease liabilities are recognized based on the present value of lease payments over the lease term at the lease commencement date. The Company uses its incremental borrowing rate based on the information available at the commencement date or the lease modification date, as applicable, in determining the lease liabilities as the Company's leases generally do not provide an implicit rate.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Narr_qvqmNUL2zkazaUG5mXjaxg">P36M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_GeyP0OGaRUy3ITXSesp9IQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common shares.&lt;/span&gt; &lt;span style="background:#ffffff;"&gt;Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period, without consideration for any potential dilutive common share equivalents as their effect would be antidilutive&lt;/span&gt; (see Note 14. Net Loss Per Share).&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_2SOItWh6KEGqd7UZpCsisQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes the following two components: net loss and other comprehensive income (loss). Other comprehensive income (loss) refers to gains and losses that are recorded as an element of stockholders&#x2019; equity (deficit), but are excluded from net loss. The Company&#x2019;s other comprehensive income (loss) includes unrealized gains on available-for-sale securities and foreign currency translation adjustments in 2023, 2022 and 2021. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <chrs:ReclassificationsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_mB7E7AoIbU27vflBMuQ5jg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Reclassifications&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain amounts in prior years&#x2019; financial statements have been reclassified to conform with the current year presentation in 2023, including amounts in the consolidated statements of cash flows. There were no changes to net cash used in operating activities in the consolidated statements of cash flows for the prior years as a result.&lt;/p&gt;</chrs:ReclassificationsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="0"
      id="Narr_ydheMdsufkaRbLCsPS0NHQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Xd0bGOoWSkm6_QBpGf72xA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following are recent accounting pronouncements that the Company has not yet adopted:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt; &lt;i style="font-style:italic;"&gt;(Topic 280) Improvements to Reportable Segment &lt;/i&gt;&lt;i style="font-style:italic;"&gt;Disclosures&lt;/i&gt;, which enhances the disclosures required for operating segments by requiring disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, among other expanded. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued&#160;ASU 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The new standard is effective for the Company for annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in this ASU should be applied prospectively; however, retrospective application is also permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business or that no material effect is expected on the consolidated financial statements as a result of future adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_tAlnwL9t70uuZu7lgXnVAg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/span&gt;Revenue&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company launched LOQTORZI and YUSIMRY in the United States in December and July 2023, respectively, and initiated sales of CIMERLI on October 3, 2022. All net product revenue was generated in the United States, and the Company&#x2019;s net revenue was as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   UDENYCA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   CIMERLI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,388&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   YUSIMRY&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   LOQTORZI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 256,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 210,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Total net revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 257,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Gross product revenues by significant customer as a percentage of total gross product revenues were as follows&lt;/span&gt;:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;McKesson Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cencora (previously known as AmeriSource-Bergen Corporation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cardinal Health, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Product Sales Discounts and Allowances  &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Provisions that reduce net revenue include chargebacks and discounts for prompt payment, which are recorded as a reduction in trade receivables, and rebates, other fees, co-pay assistance and returns, which are recorded as current liabilities and other liabilities, non-current in the accompanying consolidated balance sheets. The activities and ending reserve balances for each significant category of sales discounts and allowances, which constitute variable consideration, are as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&#160;Fees,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Co-pay&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Prompt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assistance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 470,791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,703&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 679,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period - increase (decrease)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,876)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,555)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,407)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (478,830)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (93,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (681,467)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 109,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 436,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 578,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period - increase (decrease)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,090)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,050)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (421,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,640)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (80,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (584,811)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 590,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 844,325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period - increase (decrease)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,361)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (558,135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (62,370)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (83,245)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (703,750)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 244,885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_ZYqMiYD8CU-JU5LQCpN31Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   UDENYCA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   CIMERLI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,388&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   YUSIMRY&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   LOQTORZI&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 256,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 210,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Total net revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 257,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211,042&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 326,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_UdenycaMember_SS-iB5-1RkODBPDHZukxAA"
      decimals="-3"
      id="Tc_1nlPkw0AWU2ghP88My6SBA_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">127064000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_UdenycaMember_OBt5e09w-U23AKziLIjkeg"
      decimals="-3"
      id="Tc_pxq9QrS59UiQl4GzcCuH9w_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">203814000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_chrs_UdenycaMember_YyirJnaG_EuVQxR4eipeHw"
      decimals="-3"
      id="Tc_j7E1niXe20W4RXz_sPTP1w_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">326509000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_CimerliMember_kv6U35_BGUWQFIX2et6tLw"
      decimals="-3"
      id="Tc_JWVAHlnzdEGTCDvHb80-Lg_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">125388000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_chrs_CimerliMember_Yi451Ksh7ku2qLqz_SNLxA"
      decimals="-3"
      id="Tc_G37Sx6g3c0urndqqMQlyNQ_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6946000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_YusimryMember_Aem49C8g_EO-UPcinAmbWw"
      decimals="-3"
      id="Tc_7O3vbqgnFkeDYoVu0fiEjA_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3574000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_chrs_ToripalimabMember_fUCqK5DU-kekHTnpp0vwtA"
      decimals="-3"
      id="Tc_xUrDx4OyH0WSVl45-SMZ5Q_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">554000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_z6Il8N4kPkqJ7o0Wx5ZYXQ"
      decimals="-3"
      id="Tc_LK1kT-EsFEyNDioXSN5fsg_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">256580000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_KNuuvD7dxEO2mjwTXA6LtQ"
      decimals="-3"
      id="Tc_VY_WwdQKk0SbGGp32IEegg_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">210760000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yRtnhYcLKki9OALzaJd-_A"
      decimals="-3"
      id="Tc_P1ridq-V1U6b-_te5n4c1Q_8_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">326509000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_yD1xE6Kl5kOzUlgXuDoYKQ"
      decimals="-3"
      id="Tc_PhGoEx24BUaEtM0CwZGpHw_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">664000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_f8r-3G-5Wk-nnxPCHpt2WA"
      decimals="-3"
      id="Tc_BLzqZN4xxUm1jvXLrBa8pQ_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_JMBKRfq1M06yP1UncYP2wg"
      decimals="-3"
      id="Tc_e-Uh4zyJakSrZQLtZAgjPw_9_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">42000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_ekGCgHXd-kuPx7irw3sl3A_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">257244000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_yMjgil7NqkuFXg3yt2wEgw_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">211042000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_mqjPeuKepkeVVnFYF2h1gA_10_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">326551000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb__mZwxnciDEeyxhkdgqDsJg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;McKesson Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cencora (previously known as AmeriSource-Bergen Corporation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cardinal Health, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_bG3CyRk7Ckyq7Y946J92rQ"
      decimals="2"
      id="Tc_9NPhF3OoyUiGaGAnatF9dQ_3_1"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Ip4i_KQKSEGmi48UbBbU4g"
      decimals="2"
      id="Tc_QJOlMw3sOUeqweGtndzlJw_3_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_McKessonMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_awtJ_xuQLE-3TKhXeZPfnQ"
      decimals="2"
      id="Tc_Q2peBtiB8E-K1TZGcAMuew_3_7"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sysHEkDeMUeiH_xQmMEqHg"
      decimals="2"
      id="Tc_rkHfqq1zGE6wQsBmdV31dw_4_1"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R15nhg7ueUmpYAw1PVmVYw"
      decimals="2"
      id="Tc__3b7t4vD7U-YdG8N2hhjgA_4_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_AmeriSourceBergenCorpMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_2Jb4uL_RpUq98xojm1NbWg"
      decimals="2"
      id="Tc_CWR2mFDnSEW9hYd6uVef1Q_4_7"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_JgK6Pnltr0iCDbO6eeuWPw"
      decimals="2"
      id="Tc_hajnRqq16U-FdmKr13-_iA_5_1"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RLQcDbciHU-31RTWPiRddA"
      decimals="2"
      id="Tc_G4_FFg1thkeNMq5MqYQnmA_5_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_chrs_CardinalMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_rgJ5WsHKGE6cmgscswHw3A"
      decimals="2"
      id="Tc_HLLTP0yiN0mf4L4i8zrkNQ_5_7"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.20</us-gaap:ConcentrationRiskPercentage1>
    <chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_mi4-ly2e90albYJFI22Idw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Chargebacks&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&#160;Fees,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Discounts&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Co-pay&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Prompt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assistance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and&#160;Returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 470,791&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 113,705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,703&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 679,199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period - increase (decrease)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,876)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,976)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,555)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,407)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (478,830)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (93,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (681,467)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,004&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 109,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 436,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,435&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 578,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period - increase (decrease)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,090)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,050)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,108)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (421,763)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,640)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (80,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (584,811)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Provision related to sales made in:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 590,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 844,325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Prior period - increase (decrease)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,361)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Payments and customer credits issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (558,135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (62,370)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (83,245)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (703,750)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balances at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 121,137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 244,885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</chrs:ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_-COT1WJ3EUuvoamMLm5fRA"
      decimals="-3"
      id="Tc_zBI8o7CWvU2ily2Gt38ZHA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40580000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUbaaM5xv06IKYj90EnrjA"
      decimals="-3"
      id="Tc_CLximu-u_0Ktr0eB6lNZQA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">54058000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_TQp5WTVb9EWxY7FxWuYu-Q"
      decimals="-3"
      id="Tc_l-O8W7pfTUmV-gHU_dz-tw_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">28760000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc_EsKjtW_gWkCe0SvaZEkZYA_5_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">123398000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg"
      decimals="-3"
      id="Tc_ulBTBPpm4EmjggpqtsUx0w_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">470791000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA"
      decimals="-3"
      id="Tc_JKEbz-i3sUqz-NaHXt34ng_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">113705000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ"
      decimals="-3"
      id="Tc_9xU9ixwhK0u5sd3uxEnhLA_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">94703000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_wVj40XtuqkS3WYu7FrcivQ_7_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">679199000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg"
      decimals="-3"
      id="Tc_PHZym18mekOtN5a0Bfwt8g_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-2876000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA"
      decimals="-3"
      id="Tc_o_vgNQ-0q0qblbUp3BtmvQ_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-4976000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ"
      decimals="-3"
      id="Tc_SyqYjFE0aEW_nwiB15MS0g_8_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-3555000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_6V9HGDZOf0S8cit9BIIqIg_8_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-11407000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_h8HWUcNhEky5qEpRPa6FGg"
      decimals="-3"
      id="Tc_9ClFIR9S2UWU9bqZSH_5Ng_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">478830000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_D6AFrgXwyEicIfsSAq3gvA"
      decimals="-3"
      id="Tc_J3UkKhgTXkuPQa7co0Igsg_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">108783000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_hpnBUOqgoUiC5UMRjc8sIQ"
      decimals="-3"
      id="Tc_FP4exD4WoE6N9NBD7IS9Gg_9_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">93854000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_H9eN5Nbr0UWESTVcfwyzHg_9_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">681467000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_Ayc2h31NhkepkMrVbtGURA"
      decimals="-3"
      id="Tc_ru_bC0rgPEy249HGCLGI8g_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">29665000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_cUQLjzgmQ0O_aiicO1YWSA"
      decimals="-3"
      id="Tc__zDo8NPCUk2SqHau6tuO5Q_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">54004000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_DPP_6bC4Yk26dzFhoz_XuA"
      decimals="-3"
      id="Tc_aNNDpyUTokyoVsCwolVGdg_10_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26054000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_gYQd2w3YD0Cg2NJR8aWGzA_10_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">109723000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g"
      decimals="-3"
      id="Tc_mCe1xCJp5kiyst7_K6otAg_12_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">436865000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog"
      decimals="-3"
      id="Tc_YeuZeq6Bp02K2jRiOXYGLA_12_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">68399000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg"
      decimals="-3"
      id="Tc_dDkZw12G30y62GpTTMwq_w_12_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">73435000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_7TbPIZItXEC1fW8dadPpyA_12_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">578699000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g"
      decimals="-3"
      id="Tc_zTWloSryekO1l9Uxli33Ng_13_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-2090000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog"
      decimals="-3"
      id="Tc_fM2g_myUAU24Zdyh8hhCKA_13_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1050000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg"
      decimals="-3"
      id="Tc_YX7PUZYTYki7kMBEFABQ9w_13_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">32000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_fwqDIRBxj0uW0WDbWBGHiw_13_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-3108000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_hrKGxnhA8kWFCSEYsGf87g"
      decimals="-3"
      id="Tc_Kn63x61KZkWqwVMO5CXOIw_14_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">421763000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_Nlz-7Rh2vUOOwaGBH2ZZog"
      decimals="-3"
      id="Tc_ffzu_8idVEWJCoesrOoQHw_14_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">82640000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_cLGWfWLIW0C04oR8xqRhNg"
      decimals="-3"
      id="Tc_xlofzqnwlUOU3k0xebSgUA_14_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">80408000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_cPmX4ecgWUqckZZ_SfHINQ_14_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">584811000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ahBUQTlFkUCSXShSrIOSkA"
      decimals="-3"
      id="Tc_PahjM9xS1U6ZCT2dilCTRg_15_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">42677000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_PmryB88z9UeGYuVn9_eCHw"
      decimals="-3"
      id="Tc_1UT1khRB7UqP1pBYiJiXqA_15_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">38713000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_fLywbKoRN0OM9lBXBdTjtw"
      decimals="-3"
      id="Tc_z-Zlh3qpnECKo9Vj3aXRLw_15_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19113000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_4CI288hFxkGd-Vel_j1qAg_15_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">100503000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg"
      decimals="-3"
      id="Tc_J7viUmf4NkqqGpn0pdKRaQ_17_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">590772000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw"
      decimals="-3"
      id="Tc_ty1_V0S2KU-oevcOYcV5qg_17_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">143370000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg"
      decimals="-3"
      id="Tc__2EmZ-xNhUOf9nvXwS_89Q_17_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">110183000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_2Wusre3UsEONSfqhK_munA_17_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">844325000</chrs:ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg"
      decimals="-3"
      id="Tc_WFX3mDFC6kCPPSyX30INbg_18_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-1361000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw"
      decimals="-3"
      id="Tc_XJCLRUUDPkWJf9hozn9qBA_18_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1424000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg"
      decimals="-3"
      id="Tc_V0e4EE_5lUaHEamIfHRcZQ_18_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3744000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:ProvisionRelatedToSalesMadeInPriorPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_uFqaG2pdUUi1IWFZ7czLEQ_18_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3807000</chrs:ProvisionRelatedToSalesMadeInPriorPeriod>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_ezfhD7WwVU-Z0D3Q4-ZhOg"
      decimals="-3"
      id="Tc_b8pIWWawj0-_AlnNp0wTwg_19_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">558135000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_ReWGzwo9Jk-W4F3UE_m5gw"
      decimals="-3"
      id="Tc_mAVlkB86UE-z3n9GeKsXTw_19_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">62370000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_nYAvoZEBCU2OZqE5o-Zklg"
      decimals="-3"
      id="Tc_DmHhNpIGv0yjZl4FjES_PQ_19_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">83245000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_-JjsZisEL0WXxuyPM5yHFg_19_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">703750000</chrs:PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_ChargebacksAndDiscountsForPromptPaymentMember_fqcHXPJqtUOZjDirZssjWg"
      decimals="-3"
      id="Tc_6rhBmQXZjU2x0jnioBuhTw_20_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">73953000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_RebatesMember_JuDeIjk7WEOxnh8sAqvA9w"
      decimals="-3"
      id="Tc_omzznJndN0CyNgBJwcnvZg_20_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">121137000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_chrs_OtherFeesCoPayAssistanceAndReturnsMember_CPtilZC0L0K1V6_IsNLFKw"
      decimals="-3"
      id="Tc_-qDTxjz9R0-joyqX9Gslng_20_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">49795000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_iztln31YiUu-LhT2FxqkEg_20_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">244885000</chrs:ReserveForDiscountsAndAllowancesConstituteVariableConsideration>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_AwOS7XAj2UWDT2l1VZH3yg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/span&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of financial instruments are classified into one of the following categories &lt;span style="background:#ffffff;"&gt;based upon the lowest level of input that is significant to the fair value measurement&lt;/span&gt;:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2014; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In connection with the Surface Acquisition on September 8, 2023 (see Note 6. Surface Acquisition), the Company acquired money market funds and marketable securities and recorded&#160;a contingent consideration liability related to the CVRs. At the end of each reporting period, the fair value of the CVR liability is determined using a financial model representing a Level 3 measurement within the fair value hierarchy. Assumptions used in this calculation include estimated revenue, discount rate and various probability factors. If different assumptions were used for the various inputs, the estimated fair value could be significantly higher or lower than the fair value the Company determined. For example, increases in discount rates and the time to payment may result in lower fair value measurements. There is no assurance that any of the conditions for payment of the CVR liability will be met. As of December 31, 2023, the CVR liability was reduced by a fair value adjustment of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million which was recorded within selling, general and administrative expense in the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;consolidated statements of operations. The CVR liabilities were recorded in accrued and other current liabilities and other liabilities, non-current on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;Financial liabilities related to long-term debt obligations are summarized in Note 8. Debt Obligations. &#160;Other financial liabilities and financial assets measured at fair value on a recurring basis are summarized as follows: &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable debt securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Prepaid financial instrument in Prepaid manufacturing&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,940&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable debt securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 191,645&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;Cash equivalents consist of money market funds, U.S treasury securities, and commercial paper and corporate notes with original maturities of 90 days or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;Relates to Optional Stock Purchase Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The cost, unrealized gains or losses, and fair value by investment type are summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="11" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Gain&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized (Loss)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,484&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,484&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,200&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,195&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,967&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,969&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,673&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,324&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,315&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized (Loss)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,645&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company held &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;13&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; positions that were in unrealized loss positions as of December 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;No&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; impairment was recognized in 2023 or 2022. As of December 31, 2023 and 2022, the remaining contractual maturities of available-for-sale securities were less than&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;one year&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, and the average maturity of investments upon acquisition was approximately&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;7 months&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, respectively. The accrued interest receivable on available-for-sale marketable securities was immaterial at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_9_8_2023_To_12_31_2023_Oq6suCh5tUWT6TFeG9xafw"
      decimals="-5"
      id="Narr_CC99ZfTkb0KGqeeIRsM_2Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-900000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_086_rJS1d0OxNpPweXdXYw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable debt securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Prepaid financial instrument in Prepaid manufacturing&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,940&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:52.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable debt securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 191,645&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;Cash equivalents consist of money market funds, U.S treasury securities, and commercial paper and corporate notes with original maturities of 90 days or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;Relates to Optional Stock Purchase Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M7126HnRO0qaXeQIsFj8pQ"
      decimals="-3"
      id="Tc_hyUScfVwCE2f0e5J4JQo2w_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">88460000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LA2YAsqsu0CpSSrrZHjsug"
      decimals="-3"
      id="Tc_bHQnohiW1kOKSPv2xIaaZA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">998000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_TO8ess3RJkWPdTQJVaqKPg"
      decimals="-3"
      id="Tc_PAF_PTktAkyY0HSBqx2RDg_5_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">89458000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uqXRAvtuPU-XGMoUQjrc2Q"
      decimals="-3"
      id="Tc_0V7xOkTu1USNRCbv5aq0Iw_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5195000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_VSDrzPQUwUu7_hzLLjkspg"
      decimals="-3"
      id="Tc_8Hi21q-os0CJqI7WhsG4NQ_7_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5195000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_frQuFnuBxEq5QXwcCjbX7Q"
      decimals="-3"
      id="Tc_jsAo0DepH0OqJpMytnKBCg_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_2BjSULWChEWs710kn9cfgQ"
      decimals="-3"
      id="Tc_MmOh2dWbhU2zWM7g9oATew_8_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_GPeCZEn7kE-kP1gzmLw43A"
      decimals="-3"
      id="Tc_6PAXALrGmkmoNIlZmb389A_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6669000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_mU8Xaof7xEm7Zbk_ZFo9-Q"
      decimals="-3"
      id="Tc_LO1qaiz1BkSPctdmjJwaug_9_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6669000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uGXcRbQazkuREy28y8WrtQ"
      decimals="-3"
      id="Tc_vIwVjo4qE0-KRhBrmRgoAg_10_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">625000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByAssetClassAxis_chrs_PrepaidExpensesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__TxWSJDseUuXN-WFeLop7g"
      decimals="-3"
      id="Tc_Lcn1xdNDh0CXiwXydhaadA_10_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">625000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nz62sO_ud0WlWk86bTugEg"
      decimals="-3"
      id="Tc_SrNGZYeEo06yMnI62h97YA_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">96648000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ms9aAG7KIkGkwghMFQVoVQ"
      decimals="-3"
      id="Tc_RN_BZWaDVUuiLEa9kL-dRg_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7667000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__89KIdAh-kybMMe17Uup0w"
      decimals="-3"
      id="Tc_c3gD3_SqW0iue83WgEryTg_11_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">625000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_bSSUTn6bQUCMiUY_ocTL-A"
      decimals="-3"
      id="Tc_JBuA8k0u2UmdHM8TGbsXZg_11_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">104940000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_hcVA_aikGUy_-SUX6FtLgQ"
      decimals="-3"
      id="Tc_qLcHaKcZeUu_fBntlh6kRA_13_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4472000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByLiabilityClassAxis_chrs_ContingentConsiderationMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_dUP-XGp_40W0Jk2_k2_aaw"
      decimals="-3"
      id="Tc_v8jnzDq11UeRftEG4yPoRg_13_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4472000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_LQWs2-eMdE2bcCcsGBh6vQ"
      decimals="-3"
      id="Tc_kfCEFNcKx02OgD9yMZxrmA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">55060000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_CashAndCashEquivalentsMember_rEMXEsXhaEWSunlNBcnl4Q"
      decimals="-3"
      id="Tc_Q-LUvodUv0ePCgUHDzkNow_5_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">55060000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_prYGlg4f4U63CuX4vjb7Nw"
      decimals="-3"
      id="Tc_SnWS23TgREyeZU3Y-u0M0A_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw"
      decimals="-3"
      id="Tc_nMQf0ixR90S0XMZzwxaW5w_7_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_TwVcSvlCtEijskcFydA41w"
      decimals="-3"
      id="Tc_BhSPiDBKn0iVxi0zh9f0sw_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">68418000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA"
      decimals="-3"
      id="Tc_EtcR0c2iBkuoeggOJEW4pw_8_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">68418000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_8fbTc7hIa0utRNZd1eRxfw"
      decimals="-3"
      id="Tc_xANocsncYECD-dD5PQmBoQ_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">48203000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA"
      decimals="-3"
      id="Tc_2W3hPCOAIEahptvzn8frHA_9_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">48203000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_qVO9cnI0VUC56AJulEuw6A"
      decimals="-3"
      id="Tc_CFOiUibzSUOlBXJNWPd38g_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">143442000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_v32YInlozkipoEXkDWXGJA"
      decimals="-3"
      id="Tc_0OuAofmMhUy-4hErNrjjIQ_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">48203000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_hMudSVa9Ikm-1nYaoNer1Q_10_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">191645000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb__pjmJ2DpUU26DNu73kr17Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="11" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Gain&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized (Loss)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,484&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,484&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,200&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,195&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,967&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,969&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,673&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,324&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,315&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized (Loss)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Commercial paper and corporate notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,645&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_jcZy0wFZJEaEwLSiKmitHg"
      decimals="-3"
      id="Tc_EZ9OPxAQukyroLQU52dq0Q_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">79484000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_jcZy0wFZJEaEwLSiKmitHg"
      decimals="-3"
      id="Tc_EXjXw-iMpU6UtmWpmhjk3g_3_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">79484000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ"
      decimals="-3"
      id="Tc_Wf3zJtHR90eUeERNhXndNQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ"
      decimals="-3"
      id="Tc_s68FND4iPE2jr5HRiF2Icg_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_FiACdicYIkSz8ZxQrb-ELQ"
      decimals="-3"
      id="Tc_KL5DlogwpkKzTcCxxDuLPg_4_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5195000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA"
      decimals="-3"
      id="Tc_5E3PmJxP5kyjFSiuP9hElA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11967000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA"
      decimals="-3"
      id="Tc_eXJB-NJIB02IdND0YxLC6w_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_VbTIMQhd0UCUiHhOsmv8PA"
      decimals="-3"
      id="Tc_aABl4CZAeUWFpUNcWeqlag_5_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg"
      decimals="-3"
      id="Tc_RPnIq_CoHUekRewxF8oGcA_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7673000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg"
      decimals="-3"
      id="Tc_4CR1CBkRlkeBV0X-yOGybw_6_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_HglS7UYcwE2oTinWD6J0lg"
      decimals="-3"
      id="Tc_7RWK3NIQHk6MqCai6IqbLw_6_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7667000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_J98f1Wkkqk--yBPb1DC5Mw_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">104324000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_vPJVjkPRFE6gSsxdLaSlxw_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_o8Oflvx1MUKwsAqw91cY9w_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_pJ6xxc7ECkKORwJIByUTiQ_7_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">104315000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Q3N2Kq2ULUiYN4xUaP-tWg"
      decimals="-3"
      id="Tc_n-eM6HbBZkKVOp7euS_Vnw_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">55060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_Q3N2Kq2ULUiYN4xUaP-tWg"
      decimals="-3"
      id="Tc_XJ4fmHzXhUm_K8Zj8_cM4w_3_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">55060000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw"
      decimals="-3"
      id="Tc_LqFOt7p6gU2xfVJb_KMgMQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19929000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw"
      decimals="-3"
      id="Tc_GeI0nEDFPkm8Z02wb3JeQQ_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_PJYNlpDwe0CDa9h8F9TYpw"
      decimals="-3"
      id="Tc_jYEfkX5ty0GOWX1sRfTRLg_4_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA"
      decimals="-3"
      id="Tc_UF46yOC5DkKo8w0ILv8UrA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">68431000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA"
      decimals="-3"
      id="Tc_Z_ksMgE5SEq_PBhQ6UVDZA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA"
      decimals="-3"
      id="Tc_m76YmKet9Uu2tlwbWYNmLA_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_uopJczGWbE2EyWygfyGptA"
      decimals="-3"
      id="Tc_CDeETeH4g0et8CSXHiUlrA_5_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">68418000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA"
      decimals="-3"
      id="Tc_vNOtehnu-0ibWfefhv7Ffg_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">48203000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateNoteSecuritiesMember_n7Siz-Cm9UKNHnhP2_ZIjA"
      decimals="-3"
      id="Tc_8AgyReVkk0afT5hXtPe0jg_6_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">48203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_F-odSc4SmEqeD-nTVYo5-Q_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">191623000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_XH2TDPUoq0KGHT4a3d0u-Q_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_lPTRacosGEedpkRFfePSiA_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_3D7xLtyt0U-KvCky9Gj4qQ_7_12"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">191645000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="INF"
      id="Narr_bN6u8wVxqECGDux5argEYA"
      unitRef="Unit_Standard_position_Q8MGuTzVYkuWPpfxSr2J5Q">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="INF"
      id="Narr_o_Hz0_IrQ0GHLV53dGHA-g"
      unitRef="Unit_Standard_position_Q8MGuTzVYkuWPpfxSr2J5Q">13</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Narr_4hDr1lriv0it1OEP0N0c1Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Narr_t5jrLErLUUSCBaRjJ78lXQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <chrs:ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_P3Y6yR6jkUmHvvImCCgAuA">P1Y</chrs:ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity>
    <chrs:RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_q5jTpBO7mUeMqLYcxuJU0g">P9M</chrs:RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition>
    <chrs:RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      id="Narr_bKHCjvuG8UqlMftDS1Qstg">P7M</chrs:RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_GducaB4Gbke308921JO0qA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.&lt;/b&gt;&lt;/span&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,588&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;During 2023, the Company recorded a $47.0 million charge for the write-down of slow moving YUSIMRY inventory, inclusive of the related partial recognition of $20.5 million in certain firm purchase commitments in cost of goods sold in the consolidated statements of operations. The Company has presented the partial recognition of these certain firm purchase commitments in the amounts of $11.5 million and $9.0 million in accrued and other current liabilities and other liabilities, non-current, respectively, in the consolidated balance sheets as of December 31, 2023. Inventory expected to be sold more than twelve months from the balance sheet date is classified as inventory, non-current in the consolidated balance sheets. As of December 31, 2023 and 2022, the non-current portion of inventory consisted of raw materials, work in process and a portion of finished goods. The following table presents the inventory balance sheet classifications: &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Prepaid manufacturing of $23.7 million as of December 31, 2023 includes prepayments of $12.6 million to CMOs for manufacturing services of the Company&#x2019;s products, which the Company expects to be converted into inventory during 2024, and prepayments of $11.1 million to various CMOs for research and development pipeline programs&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; Prepaid manufacturing of $17.9 million &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;as of December 31, 2022 included prepayments of $13.0 million to CMOs for manufacturing services of the Company&#x2019;s products and prepayments of $4.9 million to various CMOs for research and development pipeline programs. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In February 2021, the Company announced the discontinuation of the development of CHS-2020, a biosimilar of Eylea as part of a realignment of research and development resources toward other development programs. As a result, the Company recognized $11.2 million within research and development expense in the consolidated statements of operations in 2021, which included an impairment charge of $3.2 million for the write-off of prepaid manufacturing services no longer deemed to have future benefits. No material expense relating to the discontinuation of CHS-2020 was recognized after March 31, 2021.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <chrs:ScheduleOfInventoryTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_csA8wovWF0yQ7FFEDV5fmA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,588&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,077&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfInventoryTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_IiPvU5jAw0u-sULp-jEykw_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12975000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_ZqQBBFAX0EaV3TCZQESJAA_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10262000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_Bb0R2k_Mrk2s98NXXeeduQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">82588000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_uQHF8A8Wp0KSct1LqwEjUA_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">86712000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_nKxWG5adqkmvLheoeFANnw_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">34537000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_iASKZ2-euEi53gQzrb8PWA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18077000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_ekrC40pbB0Gr-zjGMb77Kg_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">130100000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc__04xMKYV-0GqPfZFL0PxBw_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">115051000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PublicUtilitiesInventoryAxis_chrs_YusimryProductMember_-J7VNgvVG0G6bkwKupKhUw"
      decimals="-5"
      id="Narr_MSPBRK8NmEyacYJn1Z889A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">47000000.0</us-gaap:InventoryWriteDown>
    <chrs:LongTermAndShortTermPurchaseCommitmentsAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA"
      decimals="-5"
      id="Narr_UNy5V7X39ECJGACUKlIGAQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">20500000</chrs:LongTermAndShortTermPurchaseCommitmentsAmount>
    <chrs:ShortTermPurchaseCommitmentAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_RCrhOsC4rUSwHbQXRXofbg"
      decimals="-5"
      id="Narr_aCJR1eIrrUCzwpszlCWoxA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11500000</chrs:ShortTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_l7MKURXDWkyyeEGasiZroA"
      decimals="-5"
      id="Narr_5IRAjiu2sEiwl9UXdtScOA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">9000000.0</us-gaap:LongTermPurchaseCommitmentAmount>
    <chrs:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_bBCCLH6gD0W4Br3K1fe4Pg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 115,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</chrs:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_GJvPZjlLq0ukxrFzlptU7w_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">62605000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_g37X-Dybs02Q1YUV6ig0QQ_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">38791000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_GvxwgndMuk-Bs3WF9DbQDw_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">67495000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_nFc-iBI31EiBjrUMifuUkA_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">76260000</us-gaap:InventoryNoncurrent>
    <chrs:InventoryCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_Yo4Kj-VDikiYAd7pZkQP0w_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">130100000</chrs:InventoryCurrentAndNoncurrent>
    <chrs:InventoryCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_6EochILi6U-88S-ZGqadkg_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">115051000</chrs:InventoryCurrentAndNoncurrent>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_NI6ihpnIskSdPzWLRRNBHQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">23700000</chrs:PrepaidManufacturingExpenseCurrent>
    <chrs:PrepaymentsMadeToCmoForManufacturingServices
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_n_nUI9wKz0GNpuqi0tEaAQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12600000</chrs:PrepaymentsMadeToCmoForManufacturingServices>
    <chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_EALxozxTAkyDaZCSbHHHlg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11100000</chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram>
    <chrs:PrepaidManufacturingExpenseCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-5"
      id="Narr_0OwdVCzwkkOUMd-wsph47A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17900000</chrs:PrepaidManufacturingExpenseCurrent>
    <chrs:PrepaymentsMadeToCmoForManufacturingServices
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-5"
      id="Narr_Bgfj_SBxYEaiv1KWH1QpHw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13000000.0</chrs:PrepaymentsMadeToCmoForManufacturingServices>
    <chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-5"
      id="Narr_Za0H6vz-dE-DtMrzxwP9nA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4900000</chrs:PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_NxhQ8-y-vE-qqYM8KM5CLQ"
      decimals="-5"
      id="Narr_5CzJuPgj2kqPnk4CrdvBeA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProductionRelatedImpairmentsOrCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PublicUtilitiesInventoryAxis_chrs_Chs2020Member_NxhQ8-y-vE-qqYM8KM5CLQ"
      decimals="-5"
      id="Narr_Wt2voCUR4U-37-U0d3LFxA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3200000</us-gaap:ProductionRelatedImpairmentsOrCharges>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="0"
      id="Narr_OGTPuU76Qk-JUY0Q2Yfdlw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_YoOCIfxl_UGFJx2q8AbLRA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.&lt;/b&gt;&lt;/span&gt;Balance Sheet Components&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 696&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,651)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,157)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense related to property and equipment, net was $3.2 million, $3.6 million and $3.5 million in 2023, 2022 and 2021, respectively. There were no material impairments of property and equipment in 2023, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, the net book value of software implementation costs related to hosting arrangements was $3.2 million and $3.5 million, respectively, and the amortization expense was immaterial for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets, Net&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Goodwill and intangible assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finite-lived assets, net of accumulated amortization of $639 and $61, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,859&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 943&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total Intangible assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,931&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Amortization expense related to finite-lived intangible assets was immaterial in all periods presented. As of December 31, 2023, amortization expense related to finite-lived assets for each of the five succeeding fiscal years will be approximately $3.8&#160;million. The weighted average remaining life of the finite-lived assets is 11.4 years on December 31, 2023. No impairment charges were recognized for goodwill or intangible assets during 2023, 2022 or 2021. During 2023, the Company&#x2019;s intangible assets increased due to assets acquired in the Surface Acquisition (see Note 6. Surface Acquisition) and capitalized milestone payments, including $25.0 million to Junshi Biosciences (see Note 7. Collaborations and Other Arrangements). &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Accrued and other current liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued commercial and research and development manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued co-development costs and milestone payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,634&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,145&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,318&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contingent consideration, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Liabilities, Non-current&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Other liabilities, non-current consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contingent consideration, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total Other liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,467&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_VtBvd52zwEG28z3zbUsYpw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,751&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 696&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,651)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20,157)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_R1ZNIhTdtU6PTDnnezToVQ"
      decimals="-3"
      id="Tc_MkQ9pSg2dku44pnYuRR3kw_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13124000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_YjMCSisOdUGXZi2xqln_Mw"
      decimals="-3"
      id="Tc_mWfw-0AkrUiCYvooKbQkQQ_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12944000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_q4XQKvn7hUuMY-hLmFDudw"
      decimals="-3"
      id="Tc_qnJox0WZdU22QnMhe4EFaw_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3546000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_jucBH5LjrUK46koXbkAVgg"
      decimals="-3"
      id="Tc_l7a5ItDbUEKxpxTHsyrXmQ_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3183000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_mBjFt7ZwtUuwg4ZjtjCulA"
      decimals="-3"
      id="Tc_1sqZX3sEC0ybe4z7SnzBqQ_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1055000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lMgSkORl9USZXjMIwMYQHQ"
      decimals="-3"
      id="Tc_dOAtgGgGFEe6EeKzhAWj2w_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1258000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_6mauAg9SEkCGnWzdOVcIUw"
      decimals="-3"
      id="Tc_81U4tcLWkke2owFwaOUeuA_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5751000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qgwSy_5jP0WkljoCN5grsA"
      decimals="-3"
      id="Tc_r4UBYzG6eUeDY6EaiIshdA_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6198000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_CmUnXGsYHU-xLi_OavbKiw"
      decimals="-3"
      id="Tc_zVqrmuNhtUuOwO9gCuvjDg_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2294000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_XQIUc6d-XUmksooC86ywXg"
      decimals="-3"
      id="Tc_3b0u7QWkOEKTX4-kpKYLhQ_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4632000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_0z3z_qR8HkiyEEOaFlpNTQ"
      decimals="-3"
      id="Tc_jFBx6UU54UG2NaA876fERA_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">696000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_zjn1M99dcUe-AVg8xc98rg_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">25770000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_Zp2VciFPPU2lmGFa-vtABA_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">28911000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_5zGE5d5iIEaSyIlR6xS9UA_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">20651000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_KKnmojE2IUSbE5THZ8PWGg_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">20157000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_1FoMH743J06ajvFLNr07aQ_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5119000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_FCm_95t4UkekjQoxf5QckA_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8754000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_wGfA-Hg660SHjpUX6TNSMQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-5"
      id="Narr_mjAdY5gGZkK-j8KhwPM3Gw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-5"
      id="Narr_LkxlTk8sy0KaYsGOeM7aUg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Narr_Ohuh8YsMTEWbpk4TOUDqLw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Narr_l7qlIpFYEky1Q2KUmUbCCQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Narr_L9z6DLS3rUeyUwxod7Eytw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_kjRlY0PKWkmfJfym7f1FdA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3200000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-5"
      id="Narr_sjBiVGpYRUmMjVQQloZw9A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3500000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_MMVzH1udA0uBPV_MGn0iqw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finite-lived assets, net of accumulated amortization of $639 and $61, respectively&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,859&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 943&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total Intangible assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,931&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Narr_PRwDrYkAEkeXfGyTP29RpA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">639000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Narr_EbDjRmrTv02lqghs7cc3oQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">61000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_jQrFPAIPs0OcL-uHfVSh1g_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">41871000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_YDCXJ4penkqxocXBhDj1qA_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2368000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc__ZjlN4R79EegxtV2bAnUfg_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">28859000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_vBe8YNYJ606-cINZzu12Ew_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2620000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_lrf1iyFcrUuRifNB3ktiRA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">943000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_9vZeBRzyQkCVwmJYmVRFVw_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">943000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc__XdqB9LYb0yfCghZR6SLgA_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">71673000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_eGbxtkDPt0WounzQU3Ewrw_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5931000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <chrs:FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_3naxq05z7UKLZAc9qHikDw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3800000</chrs:FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Narr_2seIXHRiPE-w5SWfi70Qhg">P11Y4M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Narr_GbocUJydskOC8a1xpcvSGw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Narr_zSdo_rTvEUqRRztlZ1ms5A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Narr_RHH42lUZjU2g80UayUTY5A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_6D1YK9OeyEqVt3G8H0y3GQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">25000000.0</chrs:UpfrontAndMilestonePayment>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_3uYYk1dfg02nxIJVc5--cw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued commercial and research and development manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued co-development costs and milestone payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,031&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,634&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,145&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,318&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contingent consideration, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 105,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_JLJwEoJ7m0S8oWCYT3VNyA_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">23470000</chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent>
    <chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_JGLW1t7jeE2R4DvaaWmpPw_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21774000</chrs:AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent>
    <chrs:AccruedCoDevelopmentCostsAndMilestonePayments
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_y2Qp5q5DY0eLP_gnj8ER1g_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26812000</chrs:AccruedCoDevelopmentCostsAndMilestonePayments>
    <chrs:AccruedCoDevelopmentCostsAndMilestonePayments
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_Jf1tI0TVkkqNlfn91aSzVw_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8356000</chrs:AccruedCoDevelopmentCostsAndMilestonePayments>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_iaWEZ5jwzE-JrJTxdr5rLQ_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">42031000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_gN_odPho7kOtoaUAx-gdqA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5015000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_UV9YaQ2nNk6PrOHYyOCFAw_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7628000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_PT_gUXtAT0GH9h1HLKxy-g_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10634000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <chrs:LeaseLiabilitiesOperatingAndFinancing
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_th3PeZc5cE69QBZEndUH5Q_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2145000</chrs:LeaseLiabilitiesOperatingAndFinancing>
    <chrs:LeaseLiabilitiesOperatingAndFinancing
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_WAFE-rs7P06cZVDlBIC6Pg_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4318000</chrs:LeaseLiabilitiesOperatingAndFinancing>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_TUSXU9FF50CZxhhIQ9YFjw_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_5AIveHiilkOKL4JSBSfGHA_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">105386000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_JUi6KGBGqkOozpttaYVD5Q_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50097000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_pLo0DrfI_Ue7U2aycFvVNA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contingent consideration, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total Other liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,467&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_0nfghXhBT0apFNixNxDKWA_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1172000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_qWmnneJvhEO4IdP29YEtHQ_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">102000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_fUzI9f5Jx0GXUlTzPdx1zw_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1102000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_lZPWaoVqYEqxI2zg1WtFHA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10287000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_YBJySZV0kkuF0P7KQX80Dg_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3365000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_06NblY8XhUOzN0DBx4bUuQ_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12561000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_gRM9_KMm8Euaul9i47-zhA_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3467000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_xiB7_d6_G0eKlhr-Ybed2Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;6. Surface Acquisition&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On September 8, 2023, in accordance with Merger Agreement by the Merger Subs, and Surface, the Company completed the Surface Acquisition. Surface is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment&#160;for the development of next-generation cancer therapies. The Surface Acquisition expanded the Company&#x2019;s immune-oncology pipeline with the following: casdozokitug (CHS-388,&#160;formerly SRF388), an investigational, novel&#160;IL-27-targeted&#160;antibody currently being evaluated in a Phase 2 clinical trial in HCC, and CHS-114 (formerly SRF114), an investigational, CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;On the Acquisition Date, and in accordance with the Merger Agreement, the Company issued to the holders of all outstanding Surface common stock (other than treasury shares, any shares of Surface common stock held directly by the Company or the Merger Subs immediately prior to the Acquisition Date and shares of Surface common stock issued and outstanding immediately prior to the Acquisition Date and held by any holder properly demanding appraisal for such shares in accordance with Section 262 of the Delaware General Corporation Law)&#160;0.1960&#160;shares of Coherus common stock in exchange for each share of outstanding Surface common stock and certain outstanding Surface employee equity awards. The exchange ratio was calculated pursuant to the terms of the Merger Agreement and was based on a&#160;$5.2831&#160;per share price of Coherus common stock&#160;and a nominal total amount of cash in lieu of fractional shares. Surface shareholders also received&#160;one&#160;CVR for each share of Surface common stock and employee equity award converted.&#160;Each CVR entitles the holder to receive quarterly contingent payments in the form of cash, stock or a combination of cash and stock at the Company&#x2019;s discretion during the&#160;ten-year&#160;period following September 8, 2023, for the sum of the following, less any permitted deductions in accordance with the CVR Agreement:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;70%&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of all milestone- and royalty-based payments actually received by the Company or its affiliates under the GSK Agreement related to the existing program (GSK4381562);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;70%&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of all milestone- and royalty-based payments actually received by the Company or its affiliates under the Novartis Agreement related to the existing program (NZV930);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;25%&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for CHS-114; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;50%&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of any upfront payment actually received by the Company or its affiliates pursuant to potential ex-U.S. licensing agreements for casdozokitug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"&gt;The Company has recorded a contingent consideration liability for the fair value of the potential payments under the CVR Agreement described above.&#160;The Company is unable to estimate a range of outcomes for potential royalty and milestone payments&#160;for CHS-114 and&#160;casdozokitug.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The total consideration paid for the Surface Acquisition of $64.6&#160;million consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except share and per share amounts) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of Acquisition Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Coherus common stock issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,971,460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Coherus common stock share price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of components of purchase price consideration at closing:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity of combined company owned by Surface equity holders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contingent CVR liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity of combined company owned by Surface former employees &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of total purchase consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Represents &lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;161,100&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Coherus common stock, net of shares withheld for taxes, issued to Surface&#x2019;s former employees on the Acquisition Date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has accounted for the Surface Acquisition as a business combination which requires, among other things, that the assets acquired and liabilities assumed generally be recognized at their fair value on the Acquisition Date. Fair value estimates are based on management&#x2019;s estimated future cash flows from revenues of acquired assets, the timing and projection of costs and expenses and the related profit margins, tax rates, and discount rate. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company&#x2019;s results of operations. The purchase price allocation for the Surface Acquisition is preliminary and subject to revisions as additional information about fair value of assets and liabilities becomes available. This is primarily related to the Company&#x2019;s deferred tax liabilities assumed in connection with the Surface Acquisition, as the 2023 short period tax returns have not yet been filed. The following table below sets forth the purchase price allocation to the estimated fair value of the net assets acquired:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amounts Recognized at Acquisition Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets Acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investments in marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other prepaids and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,239&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Out-licenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities Assumed&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,722&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;The Company believes that, even after reassessing its identification of all assets acquired and liabilities assumed, it was able to acquire Surface for a price that was completely allocable to identifiable assets acquired and liabilities assumed with&#160;no&#160;residual attributable to goodwill primarily due to Surface&#x2019;s need to raise additional capital to finance its operations, the challenging biotech funding environment at the time the transaction was initially announced, and the value of the acquired net assets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The amount allocated to identifiable intangible assets has been attributed to the following assets:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at Acquisition Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In-process research and development - casdozokitug&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In-process research and development - CHS-114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Out-license - GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Out-license - Novartis Institutes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total identifiable intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,769&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;Surface had&#160;two&#160;out-licensed&#160;partnership programs, with Novartis Institutes (NZV930) and GSK (GSK4381562), to advance certain next-generation cancer therapies. The out-license intangible assets represent potential milestone and royalty-based payments to be received in the future.&#160;Surface shareholders received CVRs for certain percentages of these milestone and royalty-based payments on existing programs with Novartis Institutes (NZV930) and GSK (GSK4381562), as further explained above. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;Following the Acquisition Date, the operating results of Surface have been included in the consolidated financial statements. For the period September 8, 2023 through December 31, 2023, there was&#160;no&#160;revenue attributable to Surface and operating losses attributable to Surface for such period were $5.9&#160;million, excluding acquisition-related costs.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Unaudited Pro Forma Summary of Operations&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table shows the unaudited pro forma summary of operations for the years ended December 31, 2023 and 2022, as if the Surface Acquisition had occurred on January 1, 2022. This pro forma information does not purport to represent what the Company&#x2019;s actual results would have been if the acquisition had occurred as of January 1, 2022, and it is not indicative of what such results would be expected for any future period: &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 257,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (284,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of the Company and Surface. In order to reflect the Surface Acquisition as if it had occurred on January 1, 2022, the summary pro forma financial information includes adjustments to reflect&#160;Surface&#x2019;s severance expense, the early termination and related amortization expense of Surface&#x2019;s corporate headquarters operating lease, the loss on debt extinguishment and historical interest expense related to the cash settlement of Surface&#x2019;s convertible note as if it had occurred on January&#160;1, 2022, and&#160;amortization expense on the acquired finite-lived intangible&#160;assets.&#160;The unaudited pro&#160;forma summary of operations does not reflect the income tax effects, if any, of the pro&#160;forma adjustments, given the combined entity incurred significant losses during the historical periods presented.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;Acquisition-related costs of $5.1&#160;million were recorded in selling, general and administrative expense in the consolidated statements of operations during the year ended December 31, 2023.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <chrs:BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="INF"
      id="Narr_g4NTZ9xGKEi2AqEwbYHiJQ"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0.1960</chrs:BusinessCombinationNumberOfSharesIssuedInExchangeOfEachShareOfAcquiree>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="4"
      id="Narr_zTWwW2Bx40WnIFKHnF6tvw"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">5.2831</us-gaap:SharesIssuedPricePerShare>
    <chrs:BusinessCombinationConsiderationContingentValueRightPerShare
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="INF"
      id="Narr_6ngbuvWiI0GxhPdArTvbTA"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">1</chrs:BusinessCombinationConsiderationContingentValueRightPerShare>
    <chrs:BusinessCombinationConsiderationContingentValueRightPaymentPeriod
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      id="Narr_9Fhmz0kwI0WGjztj-xRW-Q">P10Y</chrs:BusinessCombinationConsiderationContingentValueRightPaymentPeriod>
    <chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceGlaxosmithklineAgreementMember_HFnWjX4pcU-dEYSrnOgYsA"
      decimals="2"
      id="Narr_6UaTdjD4IkiPJplxnggUgA"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.70</chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments>
    <chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceNovartisAgreementMember_gPSalh4re0SjsDIBtluNVw"
      decimals="2"
      id="Narr_k1kErWmqxkCHdz1DQIae4A"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.70</chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments>
    <chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember_dcELaaK_i0Oi3XQ1ke-MNg"
      decimals="2"
      id="Narr_V8x7z4LNv0qBWhcGci33lQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.25</chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments>
    <chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_TypeOfArrangementAxis_chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember_XCQ--7iqDkm-4Cxl9nIn8w"
      decimals="2"
      id="Narr_qEJO0MVYJkOeTgSyhwYEGg"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.50</chrs:BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="-5"
      id="Narr_mWgpt3Edv0m5wpE8HSrv2g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">64600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_gAUR-wi8i0SHsc6JiztGLA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except share and per share amounts) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of Acquisition Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Coherus common stock issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,971,460&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Coherus common stock share price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of components of purchase price consideration at closing:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity of combined company owned by Surface equity holders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contingent CVR liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity of combined company owned by Surface former employees &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 766&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair value of total purchase consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Represents &lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;161,100&lt;/span&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Coherus common stock, net of shares withheld for taxes, issued to Surface&#x2019;s former employees on the Acquisition Date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="INF"
      id="Tc_Q9fPaEK6dkeny3UZyk4ajw_2_3"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">11971460</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="2"
      id="Tc_KCpEN340hE6Y8fKB-r7efg_3_3"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">4.89</us-gaap:BusinessAcquisitionSharePrice>
    <chrs:BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="-3"
      id="Tc_caY4lm4QTEKlTNsgthEy8w_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">58540000</chrs:BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeEquityHolders>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="-3"
      id="Tc_DjEi4lYZ-ES9ICZUre99kQ_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5290000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <chrs:BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="-3"
      id="Tc_ByeR_D4G9UC_0HeDjjKOdg_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">766000</chrs:BusinessCombinationConsiderationTransferredEquityOfCombinedCompanyOwnedByAcquireeFormerEmployees>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_3_lewIe8x0OxIj8aYLy4lQ"
      decimals="-3"
      id="Tc_dTDCTnVFG0eM9Rw2cXcYqQ_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">64596000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <chrs:BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="INF"
      id="Narr_dfuIHoEa4kGxJE39iBZYTg"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">161100</chrs:BusinessCombinationNumberOfSharesIssuedToFormerEmployeesOfAcquireeShares>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Mh1kx0d-4UeZrjo63463Ag">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amounts Recognized at Acquisition Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets Acquired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investments in marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other prepaids and other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,239&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Out-licenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities Assumed&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,722&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net assets acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,596&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_txnsXkrLgE21RQGQXU6uOQ_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6997000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_oxPW-EqNck6ipwyH32cbJg_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">21791000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_LjZtIQ8XSU2CRdp0z_SM1g_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5260000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_BPCdvDMynEyiPHvB9x6iQQ"
      decimals="-3"
      id="Tc_hZv_Dp2fYEm7k611aEdrtg_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26239000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_zLRTOCdaDkGr-Wlc6H94QA"
      decimals="-3"
      id="Tc_3gVhSsS4AE-DA790W_Gf5g_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13530000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_l0avfVyNa0yDb5HXjzsxSw_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">73817000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <chrs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_9_XOl9PcHkGiJgIOrvcRdA_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7722000</chrs:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedAndOtherCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_FgN2X5014EmhSay_mKom0A_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_lTgwlhpIDk2po5VzfjdMfQ_12_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">9221000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_1VwYaSjNk0O350J55WBixA_13_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">64596000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-5"
      id="Narr_LkVyjinDCkilqRh1Vr5SRA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:Goodwill>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Cl6LTCZQ8kGBn7ZOHf6bqw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Useful lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at Acquisition Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In-process research and development - casdozokitug&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In-process research and development - CHS-114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Out-license - GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Out-license - Novartis Institutes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;15 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total identifiable intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,769&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf388Member_2lO8XAyg6UKhnOMI1Zafnw"
      decimals="-3"
      id="Tc_TnNfxFFv10yU7ASX-9qFtg_2_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">25899000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_chrs_InProcessResearchAndDevelopmentSrf114Member_MCpWdvb_hUWv00leqUKNEw"
      decimals="-3"
      id="Tc_UvLRiIQwvkye6cIR3_A8lQ_3_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">340000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_Db9iHsTjOk2dnST6JR1wPA"
      id="Tc_EVRnr5XH6ky-f6VXsBylNw_4_2">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithGrkMember_aK8ibHz1PEqs0z1M6Yn7Sg"
      decimals="-3"
      id="Tc_h3FTHMGPAkKn3wHrwNmA7w_4_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2506000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_9_8_2023_To_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_08hF26t1CE220LggkCbdaQ"
      id="Tc_3ZB4cc9rZEyIZSPfT-QT_A_5_2">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_chrs_OutLicensesWithNovartisInstitutesMember_pOfVd5Rj4Eum4N-4rVrphQ"
      decimals="-3"
      id="Tc_s0aLkyw9NE6MS_iPtA7sVw_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11024000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="-3"
      id="Tc_wyYUenSLA0WfoiJn26c0Tw_6_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">39769000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <chrs:BusinessCombinationNumberOfOutLicensedPartnershipProgram
      contextRef="As_Of_9_8_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_RhKrnufrQ0Gw7mPB4IMG2A"
      decimals="INF"
      id="Narr_momAkZe3jUScVwdzw1_eaw"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">2</chrs:BusinessCombinationNumberOfOutLicensedPartnershipProgram>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="Duration_9_9_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_rkk2bVd2PEWq4HB48Bymrw"
      decimals="-5"
      id="Narr_Gp0yqniICEu7Kg23VZRT2A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="Duration_9_9_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_rkk2bVd2PEWq4HB48Bymrw"
      decimals="-5"
      id="Narr_AN6hNygMz0uWjzzA5lmV8w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-5900000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_1UzZ6ftxxEOEczsEtdoOiA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:28.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:12.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 257,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (284,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (369,442)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw"
      decimals="-3"
      id="Tc_ChvAf39RbUGhUfLt6HPp7Q_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">257244000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_x0b6Pn8B7UCsaUPMe0v01g"
      decimals="-3"
      id="Tc_OKoxqy64NEuHaKI_iYrS2g_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">241042000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw"
      decimals="-3"
      id="Tc_o0JBRnj5OEW7sK6MfcvgmA_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-284575000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_x0b6Pn8B7UCsaUPMe0v01g"
      decimals="-3"
      id="Tc_r7gLEcMya0ei_lxC8tfOeQ_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-369442000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_BusinessAcquisitionAxis_chrs_SurfaceOncologyInc.Member_YM377w7jR0u6ZU0SFq6Yzw"
      decimals="-5"
      id="Narr_KFa2zp62xEOSrxWN_Rrudg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_w_qQcpZTHES3MUqrG0SmdA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"&gt;7.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"&gt;Collaborations and Other Arrangements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In-Licensing Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Junshi Biosciences&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On February 1, 2021, the Company entered into the Collaboration Agreement with Junshi Biosciences for the co-development and commercialization of LOQTORZI, Junshi Biosciences&#x2019; anti-PD-1 antibody, in the United States and Canada.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Under the terms of the Collaboration Agreement, the Company paid&#160;$150.0&#160;million&#160;upfront for exclusive rights to LOQTORZI in&#160;the United States&#160;and&#160;Canada, an option in these territories to Junshi Biosciences&#x2019; anti-TIGIT antibody CHS-006, an option in these territories to a next-generation engineered IL-2 cytokine, and certain negotiation rights to&#160;two&#160;undisclosed preclinical immuno-oncology drug candidates. The Company will have the right to conduct all commercial activities of LOQTORZI in the United States and Canada. The &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Company will be obligated to pay Junshi Biosciences up to a&#160;20% royalty on net sales of LOQTORZI and up to an aggregate&#160;$380.0&#160;million&#160;in one-time payments for the achievement of various regulatory and sales milestones. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In March 2022, the Company paid $35.0 million for the exercise of its option to license CHS-006. Junshi Biosciences and the Company were jointly developing CHS-006 with each party responsible for the associated development costs as set forth in the Collaboration Agreement, however on January 10, 2024, the Company announced that it had delivered a notice of termination of the TIGIT Program (as defined in the Collaboration Agreement) to Junshi Biosciences pursuant to the Collaboration Agreement. The Company plans to continue to wind down work with Junshi Biosciences on the TIGIT Program pursuant to the termination. If the Company exercises its remaining option for the IL-2 cytokine, it will be obligated to pay Junshi Biosciences an additional option exercise fee of&#160;$35.0 million and an 18% royalty on net sales, up to $85.0 million&#160;for the achievement of certain regulatory approvals, and up to $170.0 million for the attainment of certain sales thresholds. Under the Collaboration Agreement, the Company retains the right to collaborate in the development of LOQTORZI and the other licensed compounds and will pay for a portion of these co-development activities up to a maximum of&#160;$25.0 million&#160;per licensed compound per year. Additionally, the Company is responsible for certain associated regulatory and technology transfer costs for LOQTORZI and other licensed compounds and will reimburse Junshi Biosciences for such costs. &#160;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The licensing transaction and the exercise of the option were accounted for as asset acquisitions under the relevant accounting rules. Research and development expenses recognized for obligations to Junshi Biosciences were $8.0 million, $68.5 million (inclusive of the $35.0 million option fee) and $175.4 million (inclusive of the upfront fee) in 2023, 2022, and 2021 respectively. In the consolidated balance sheets as of December 31, 2023 and 2022, the Company classified $26.3 million and $8.4 million, respectively, in accrued and other current liabilities and $6.3 million and $0 in accounts payable, respectively, related to the co-development, regulatory and technology transfer costs related to these programs. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On October 27, 2023, LOQTORZI was approved by the FDA in&lt;/span&gt;&lt;span style="color:#0a0a0a;background:#ffffff;"&gt;&#160;combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. &lt;/span&gt;As of December 31, 2023, the Company has accrued a&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;$25.0 million milestone payment to Junshi Biosciences, of which it expects to pay $12.5 million in the second quarter of 2024 and $12.5 million in the first quarter of 2025. This amount is a non-cash transaction which the Company has recognized in intangible assets, net and accrued and other current liabilities as of December 31, 2023&lt;span style="background:#ffffff;"&gt;. The accrued royalty obligation to Junshi Biosciences is immaterial as of December 31, 2023. &lt;/span&gt;The additional milestone payments, option fee for the IL-2 cytokine and royalties are contingent upon future events and, therefore, will be recorded if and when it becomes probable that a milestone will be achieved, or when an option fee or royalties are incurred.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;In connection with the Collaboration Agreement, the Company entered into a stock purchase agreement dated February 1, 2021 (the &#x201c;Stock Purchase Agreement&#x201d;) with Junshi Biosciences agreeing, subject to customary conditions, to acquire certain equity interests in the Company. Pursuant to the Stock Purchase Agreement, on April 16, 2021, the Company issued&#160;2,491,988&#160;unregistered shares of its common stock to Junshi Biosciences, at a price per share of $20.06, for an aggregate amount of approximately $50.0&#160;million in cash. Under the terms of the Stock Purchase Agreement, Junshi Biosciences was not permitted to sell, transfer, make any short sale of, or grant any option for the sale of the common stock for the two-year period following its effective date. The Collaboration Agreement and the Stock Purchase Agreement were negotiated concurrently and were therefore evaluated as a single agreement. The Company used the &#x201c;Finnerty&#x201d; and &#x201c;Asian put&#x201d; valuation models and determined the fair value for the discount for lack of marketability (&#x201c;DLOM&#x201d;) was $9.0 million at the date the shares were issued. The fair value of the DLOM was attributable to the Collaboration Agreement and was included as an offset against the research and development expense in the consolidated statements of operations for the year ended December 31, 2021.&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Bioeq&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;On November&#160;4, 2019, the Company entered into the Bioeq Agreement with Bioeq for the commercialization of a biosimilar version of ranibizumab (Lucentis) in certain dosage forms in both a vial and pre-filled syringe presentation. Under this agreement, Bioeq granted to the Company an exclusive, royalty-bearing license to commercialize the Bioeq Licensed Products in the field of ophthalmology (and any other approved labelled indication) in the United States. Bioeq will supply to the Company the Bioeq Licensed Products in accordance with terms and conditions specified in the agreement and a manufacturing and supply agreement to be executed by the parties in accordance therewith. The agreement&#x2019;s initial term continues in effect for ten years after the first commercial sale of a Bioeq Licensed Product in the United States, and thereafter renews for an unlimited period of time unless otherwise terminated in accordance with its terms. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;Bioeq will manufacture and supply the Bioeq Licensed Products to the Company in accordance with terms and conditions specified in the Bioeq Agreement and the Bioeq Manufacturing Agreement and will remain in force until the first to occur of the following: (1) the &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;termination of the Bioeq Agreement; (2) the exercise of a right to termination by the Company or Bioeq for a material breach of the other party that is not cured in accordance with the Bioeq Manufacturing Agreement; and (3) the exercise of a right to termination by Bioeq if invoices are not paid in full in accordance with the Bioeq Manufacturing Agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;Under the agreement, Bioeq was required to use commercially reasonable efforts to develop and obtain regulatory approval of the Bioeq Licensed Products in the United States in accordance with a development and manufacturing plan, and the Company was required to use commercially reasonable efforts to commercialize the Bioeq Licensed Products in accordance with a commercialization plan. Additionally, the Company was required to commit certain pre-launch and post-launch resources to the commercialization of the Bioeq Licensed Products for a limited time as specified in the agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;The Company accounted for the licensing transaction as an asset acquisition under the relevant accounting rules. The Company paid Bioeq an upfront and a milestone payment aggregating to &#x20ac;10&#160;million ($11.1&#160;million), which was recorded as research and development expense in the Company&#x2019;s consolidated statements of operations in 2019. The terms of the Bioeq Agreement include an aggregate of up to &#x20ac;12.5&#160;million in additional milestone payments in connection with the achievement of certain development and regulatory milestones with respect to the Bioeq Licensed Products in the United States including a &#x20ac;2.5 million milestone related to the FDA approval of the CIMERLI Section 351(k) BLA that was paid in 2022. The Company shares a&#160;percentage of gross profits on sales of Bioeq Licensed Products in the United States with Bioeq in the low- to mid-fifty&#160;percent range. Royalties due to Bioeq were $38.4 million and $2.9 million as of December 31, 2023 and 2022, respectively. The remaining milestone payments are contingent upon future events and, therefore, will be recorded when it becomes probable that a milestone will be achieved. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adimab Development and Option Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In October 2018, Surface and Adimab entered into the A&amp;amp;R Adimab Agreement, which amended and restated the Original Adimab Agreement, for the discovery and optimization of proprietary antibodies as potential therapeutic product candidates. Under the A&amp;amp;R Adimab Agreement, the Company will select biological targets against which Adimab will use its proprietary platform technology to research and develop antibody proteins using a mutually agreed upon research plan. The A&amp;amp;R Adimab Agreement, among other things, extended the discovery term of the Original Adimab Agreement, provided access to additional antibodies, and expanded the Company&#x2019;s right to evaluate and use antibodies that were modified or derived using Adimab technology for diagnostic purposes.&#160;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Upon the Company&#x2019;s selection of a target, the Company and Adimab will initiate a research plan and the discovery term begins. During the discovery term, Adimab will grant the Company a non-exclusive, non-sublicensable license under its technology with respect to the target, to research, design and preclinically develop and use antibodies that were modified or derived using Adimab technology, solely to evaluate such antibodies, perform the Company&#x2019;s responsibilities under the research plan, and use such antibodies for certain diagnostic purposes. The Company also will grant to Adimab a non-exclusive, nontransferable license with respect to the target under the Company&#x2019;s technology that covers or relates to such target, solely to perform its responsibilities under the research plan during the discovery period. The Company is required to pay Adimab at an agreed upon rate for its full-time employees during the discovery period while Adimab performs research on each target under the applicable research plan.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Adimab granted the Company the Research Option. In addition, Adimab granted the Company the Commercialization Option. Upon the exercise of a Commercialization Option, and payment of the applicable option fee to Adimab, Adimab will assign the Company the patents that cover the antibodies selected by such Commercialization Option. The Company will be required to use commercially reasonable efforts to develop, seek market approval of, and commercialize at least&#160;one&#160;antibody against the target covered by the Commercialization Option in specified markets upon the exercise of a Commercialization Option.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Under the A&amp;amp;R Adimab Agreement, the Company is obligated to make milestone payments and to pay specified fees upon the exercise of the Research Option or Commercialization Option. During the discovery term, the Company may be obligated to pay Adimab up to&#160;$0.3&#160;million&#160;for technical milestones achieved against each biological target. Upon exercise of a Research Option, the Company is obligated to pay a nominal research maintenance fee on each of the next &lt;span style="-sec-ix-hidden:Hidden_RNOKr2yfgEaTSaGdgRnfUQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four&lt;/span&gt;&lt;/span&gt;&#160;anniversaries of the exercise. Upon the exercise of each Commercialization Option, the Company will be required to pay an option exercise fee of a low seven-digit dollar amount, and the Company may be responsible for milestone payments of up to an aggregate of $13.0&#160;million&#160;for each licensed product that receives marketing approval. For any licensed product that is commercialized, the Company is obligated to pay Adimab tiered royalties of a low to mid single-digit percentage on worldwide net sales of such product. The Company may also partially exercise a Commercialization Option with respect to&#160;ten&#160;antibodies against a biological target by paying&#160;65% of the option fee and later either (i)&#160;paying the balance and choosing additional antibodies for commercialization, up to the maximum number under the Commercialization Option, or (ii)&#160;foregoing the Commercialization Option entirely. For any Adimab diagnostic product that is used with or in connection with any compound or product other than a licensed antibody or licensed product, the Company is obligated to pay Adimab up to a low seven digits in regulatory milestone payments and low &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;single-digit royalties on net sales.&#160;No&#160;additional payment is due with respect to any companion diagnostic or any diagnostic product that does not contain any licensed antibody.&#160;Any payments payable to Adimab as a result of any product candidates being developed pursuant to the GSK Agreement, will be payable to Adimab directly by GSK.&#160;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The A&amp;amp;R Adimab Agreement will remain in effect until (a)&#160;the earlier of (i)&#160;the expiration of the Research and Commercialization Options (if they expire without exercise) and (ii)&#160;12 months&#160;from the effective date without the Company providing materials that pass Adimab&#x2019;s quality control; or (b)&#160;if a Research Option is exercised but the Commercialization Option is not, then upon the expiration of the last to expire research license term; or (c)&#160;upon commercialization of a product, until the end of the royalty term, which will vary on a product-by-product and country-by-country basis, ending on the later of (y)&#160;the expiration of the last valid claim covering the licensed product in such country as the product is manufactured or sold, or (z)&#160;ten&#160;years after the first commercial sale of the licensed product in such country.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Either party may terminate the A&amp;amp;R Adimab Agreement for material breach if such breach remains uncured for a specified period of time, however, if a Research Option or Commercialization Option has been exercised and the breach only applies to the applicable target of such Research Option or Commercialization Option, then the termination right will only apply to such target. The Company may also terminate the A&amp;amp;R Adimab Agreement for any reason with prior notice to Adimab. If Adimab is bankrupt, the Company will be entitled to a complete duplicate of, or complete access to, all rights and licenses granted under or pursuant to the A&amp;amp;R Adimab Agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vaccinex License Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On March 23, 2021, Surface and Vaccinex entered into the Vaccinex License Agreement which provides the Company a worldwide, exclusive, sublicensable license to make, have made, use, sell, offer to sell, have sold, import, and otherwise exploit Vaccinex Licensed Products, including the antibody CHS-114 targeting CCR8. Under the Vaccinex License Agreement, the Company is obligated to use commercially reasonable efforts to develop, clinically test, achieve regulatory approval, manufacture, market and commercialize at least one Vaccinex Licensed Product.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The Company is responsible for all costs and expenses of such development, manufacturing and commercialization. Vaccinex is eligible to receive up to an aggregate of $3.5 million based on achievement of certain clinical milestones, up to an aggregate of $11.5 million based on achievement of certain regulatory milestones per Vaccinex Licensed Product, and low single-digit royalties on global net sales of any approved licensed products. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The Company may terminate the Vaccinex License Agreement for convenience upon the notice period specified in the Vaccinex License Agreement. Either party may terminate the agreement for an uncured material breach by the other party. Vaccinex may terminate the Vaccinex License Agreement if we default on any payments owed to Vaccinex under the agreement, if the Company is in material breach of, and fails to cure, its development obligations, or institute certain actions related to the licensed patents. In the event of termination, all rights in the licensed intellectual property would revert to Vaccinex.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Out-Licensing Agreements Acquired as part of the Surface Acquisition&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"&gt;On September 8, 2023, at the closing of the Surface Acquisition, all the assets, liabilities, rights and obligations of Surface were assumed by the Company&#x2019;s direct, wholly-owned subsidiary, Surface Oncology, LLC. See further details in Note 6. Surface Acquisition above.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Novartis Institutes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"&gt;In January 2016, Surface entered into the&#160;Novartis Agreement. Pursuant to the Novartis Agreement, Surface granted Novartis Institutes a worldwide exclusive license to research, develop, manufacture and commercialize antibodies that target cluster of differentiation 73 (&#x201c;CD73&#x201d;). Under the Novartis Agreement, the Company is currently entitled to potential development milestones of&#160;$325.0&#160;million&#160;and sales milestones of&#160;$200.0&#160;million, as well as tiered royalties on annual net sales by Novartis Institutes ranging from high single-digit to mid-teens percentages upon the successful commercialization of NZV930. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the Novartis Agreement. The Company did&#160;not&#160;recognize any revenue relating to the Novartis Agreement from September 8, 2023 through December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"&gt;Unless terminated earlier, the Novartis Agreement will continue in effect until neither the Company nor Novartis Institutes is researching, developing, manufacturing or commercializing NZV930. Novartis Institutes may terminate the Novartis Agreement for any or &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;no reason upon prior notice to the Company within a specified time period. Either party may terminate the Novartis Agreement in full if an undisputed material breach is not cured within a certain period of time or upon notice of insolvency of the other party. To the extent Novartis Institutes terminates for convenience, or the Company terminates for Novartis Institutes&#x2019; uncured material breach, Novartis Institutes will grant the Company, on mutually agreeable financial terms, an exclusive, worldwide, irrevocable, perpetual and royalty-bearing license with respect to intellectual property controlled by Novartis Institutes that is reasonably necessary to research, develop, manufacture or commercialize NZV930.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.8pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;GSK Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;In December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize the Licensed Antibodies. GSK is responsible for the development, manufacturing and commercialization of the Licensed Antibodies and a joint development committee was formed to facilitate information sharing. GSK is responsible for all costs and expenses of such development, manufacturing and commercialization and is obligated to provide the Company with updates on its development, manufacturing and commercialization activities through the joint development committee.&#160;&lt;/span&gt;In March 2022, Surface earned a&#160;$30.0&#160;million&#160;milestone payment from GSK upon the dosing of the first patient in the Phase 1 trial of GSK4381562. The Company is eligible to receive up to&#160;$60.0&#160;million&#160;in additional clinical milestones and&#160;$155.0&#160;million&#160;in regulatory milestones. In addition, the Company may receive up to&#160;$485.0&#160;million in sales milestone payments. The Company is also eligible to receive royalties on global net sales of any approved products based on the Licensed Antibodies, ranging in percentages from high single digits to mid-teens. Due to the uncertainty of pharmaceutical development and the historical failure rates generally associated with drug development, the Company may not receive any milestone payments or any royalty payments under the GSK Agreement.&#160;The Company did&#160;not recognize license-related revenue under the GSK Agreement from September 8, 2023 through December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:28.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Unless terminated earlier, the GSK Agreement expires on a licensed product-by-licensed product and country-by-country basis on the later of&#160;ten&#160;years&#160;from the date of first commercial sale or when there is no longer a valid patent claim or regulatory exclusivity covering such licensed product in such country. Either party may terminate the GSK Agreement for an uncured material breach by the other party or upon the bankruptcy or insolvency of the other party. GSK may terminate the GSK Agreement for its convenience. The Company may terminate the GSK Agreement if GSK institutes certain actions related to the licensed patents or if GSK ceases development activities, other than for certain specified technical or safety reasons. In the event of termination, the Company would regain worldwide rights to the terminated program.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <chrs:CollaborationCosts
      contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_K1geY-rGLEiNymNh_P6jTA"
      decimals="-5"
      id="Narr_PCnZ8wccZkumAb4xQARqWg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">150000000.0</chrs:CollaborationCosts>
    <chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSales
      contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_K1geY-rGLEiNymNh_P6jTA"
      decimals="2"
      id="Narr_g-GR5_x17kmWuMZZGCQujg"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.20</chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSales>
    <chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds
      contextRef="As_Of_2_1_2021_srt_ProductOrServiceAxis_chrs_ToripalimabMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_5YqDtd4hEUeB-HOMwGXqCw"
      decimals="-5"
      id="Narr_YqWb5k4C7EWZBQRj7cxQ-w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">380000000.0</chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholds>
    <chrs:CollaborationAgreementOptionExerciseFeePerProgram
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_zOQpf9YQJEWfttgbnzt7Ag"
      decimals="-5"
      id="Narr_MfrfKiOL80Cfyd8kFXyvsQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35000000.0</chrs:CollaborationAgreementOptionExerciseFeePerProgram>
    <chrs:CollaborationAgreementOptionExerciseFeePerProgram
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_HSE0jmg2IUOdXIECBGmidA"
      decimals="-5"
      id="Narr_l77mpJrU4EO9qTXLgyd1RA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35000000.0</chrs:CollaborationAgreementOptionExerciseFeePerProgram>
    <chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_HSE0jmg2IUOdXIECBGmidA"
      decimals="2"
      id="Narr_JzduuBTFCEC69SoGsnXJ8A"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.18</chrs:CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram>
    <chrs:CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
      contextRef="As_Of_2_1_2021_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_hh8Bb6a9E0Co_wILfDg5zQ"
      decimals="-5"
      id="Narr_tIjbOeH4l0ScZqVinddMBw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">85000000.0</chrs:CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram>
    <chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
      contextRef="As_Of_3_31_2022_srt_ProductOrServiceAxis_chrs_AntiTigitAntibodyAndIl2CytokineMember_us-gaap_TypeOfArrangementAxis_chrs_Chs006AntiTigitAntibodyMember_QfB80gafZEu1g-1S9zIihw"
      decimals="-5"
      id="Narr_zMt26-1A50uKGDb9Rt0YbA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">170000000.0</chrs:CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram>
    <chrs:MaximumAmountPaidCoDevelopmentActivities
      contextRef="Duration_2_1_2021_To_2_1_2021_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rrL79xCbSEKm0OK1XTANMw"
      decimals="-5"
      id="Narr_zOOrOPbM-UWLG030Ss2uzw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">25000000.0</chrs:MaximumAmountPaidCoDevelopmentActivities>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_-QTpVgOnZUGGQfnOSlwd1A"
      decimals="-5"
      id="Narr_YiLYe2ViiUavkrlbja6d4g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_iP1gAk8B10WNqliDVtY6VQ"
      decimals="-5"
      id="Narr_lgO5_fbfoESczyDuaMvSmA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">68500000</us-gaap:ResearchAndDevelopmentExpense>
    <chrs:CollaborationAgreementOptionExerciseFeePerProgram
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_-QTpVgOnZUGGQfnOSlwd1A"
      decimals="-5"
      id="Narr_dM84M1FhMEaoSxAj0y3_KQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35000000.0</chrs:CollaborationAgreementOptionExerciseFeePerProgram>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_tM3Ef_Mpak6Ub3zq_1vXxw"
      decimals="-5"
      id="Narr_M3kNeeWYpkS5_O4lWRd2QQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">175400000</us-gaap:ResearchAndDevelopmentExpense>
    <chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts
      contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_RzvldwJEbE2sTE9gTKsnIg"
      decimals="-5"
      id="Narr_kSmaCp0tXEmkBPjcYiUgBw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26300000</chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts>
    <chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_wPWUD9JeY06Jz0STfXnoNg"
      decimals="-5"
      id="Narr_L6UBUVVKFEO-Xf-nY7DaFg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8400000</chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts>
    <chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts
      contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_2WiqeL2ms06O_McAP8cV_g"
      decimals="-5"
      id="Narr_HkWpDNUlzEqs4N1AAegnng"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6300000</chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts>
    <chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_rVWYKaHlykapW6Ik8MkDUA"
      decimals="-6"
      id="Narr_zRqBIEp7tEyBvKWQtTtZAQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</chrs:CoDevelopmentRegulatoryAndTechnologyTransferCosts>
    <chrs:AccruedMilestonePayment
      contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_v--BLMYsNkKl0zxMmYmYEA"
      decimals="-5"
      id="Narr_t4bxq-yIHEeSflgatoERAQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">25000000.0</chrs:AccruedMilestonePayment>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_4_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_4fiZbKl1c0-rDjVdhAf4iA"
      decimals="-5"
      id="Narr_a0Mv7ZNFuUqKq7OrUURMxQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12500000</chrs:UpfrontAndMilestonePayment>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_chrs_ToripalimabMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_BalanceSheetLocationAxis_chrs_IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_bjX_QmuqBUiNiIM7YQU9cw"
      decimals="-5"
      id="Narr_RY2X1wphrkywjRuNuUkgXg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">12500000</chrs:UpfrontAndMilestonePayment>
    <chrs:StockPurchaseAgreementSharesAgreedToBeIssued
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ"
      decimals="INF"
      id="Narr_u9aYHA4cwEuW-RenjgsW9w"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2491988</chrs:StockPurchaseAgreementSharesAgreedToBeIssued>
    <us-gaap:SharePrice
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ"
      decimals="2"
      id="Narr_oaRRmEbooE6uheOeSOw-Fg"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">20.06</us-gaap:SharePrice>
    <chrs:StockPurchaseAgreementSharesAgreedToBeIssuedValue
      contextRef="As_Of_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_Fw9GpTpAYUWwowMxw_YccQ"
      decimals="-5"
      id="Narr_MWlJYp5a8UWUn0IGnsiBjw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50000000.0</chrs:StockPurchaseAgreementSharesAgreedToBeIssuedValue>
    <chrs:PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock
      contextRef="Duration_4_16_2021_To_4_16_2021_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_13eeoeTRfk2iZ3H7ofLzJg"
      id="Narr_ycIyAQdzs0ajnOX-HIwFlQ">P2Y</chrs:PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock>
    <chrs:FairValueForDiscountForLackOfMarketability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_chrs_JunshiBiosciencesMember_uXbjzY_AUkS5DM3UL80JAA"
      decimals="-5"
      id="Narr_uej47OIMPUKew5UBHjUc9Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">9000000.0</chrs:FairValueForDiscountForLackOfMarketability>
    <chrs:InitialTermOfAgreement
      contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_yd1vkuCA00aL3Hm8mfet-Q"
      id="Narr_G790GjothEe6ivwUR4Vyvw">P10Y</chrs:InitialTermOfAgreement>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_7mQuJY0wwEqgj61CikPPcw"
      decimals="-6"
      id="Narr__Axr2EQq0UGfxCzeep0E_w"
      unitRef="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg">10000000</chrs:UpfrontAndMilestonePayment>
    <chrs:UpfrontAndMilestonePayment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_7mQuJY0wwEqgj61CikPPcw"
      decimals="-5"
      id="Narr_lnXgjpbXxkaroq1wXR4_5g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11100000</chrs:UpfrontAndMilestonePayment>
    <chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
      contextRef="Duration_11_4_2019_To_11_4_2019_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_1YkpEyUoQUqaZRiv-_dAXg"
      decimals="-5"
      id="Narr_mlpn4ycQykS0ECzrkYAwpw"
      unitRef="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg">12500000</chrs:AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones>
    <chrs:AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_rKbabCHH6U2-QciM6M39Sw"
      decimals="-5"
      id="Narr_NSETKAWkSkObraL1pTcFYw"
      unitRef="Unit_Standard_EUR_T0cIGTsCP0aTkGIXcPtYMg">2500000</chrs:AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval>
    <chrs:PercentageOfGrossProfitsOnSales
      contextRef="Duration_11_4_2019_To_11_4_2019_us-gaap_TypeOfArrangementAxis_chrs_BioeqIPAGMember_yd1vkuCA00aL3Hm8mfet-Q"
      decimals="2"
      id="Narr_YWHiogo06UikeP7FoynEbw"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.50</chrs:PercentageOfGrossProfitsOnSales>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_OO5lQg6WOEqa5rle5GaCfQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">38400000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-5"
      id="Narr_RcbOLK6Tr02V9KadOJHYFw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2900000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <chrs:MinimumAntibodiesToBeCommercializedUnderCommercializationOption
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      decimals="INF"
      id="Narr_1oCyBn_yzUC60twQknFsjw"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">1</chrs:MinimumAntibodiesToBeCommercializedUnderCommercializationOption>
    <chrs:CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      decimals="-5"
      id="Narr_q-Th8oUHbk6_Nk9Rab2FTg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">300000</chrs:CollaborationAgreementTechnicalMilestonePaymentsObligatedToPay>
    <chrs:CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      decimals="-5"
      id="Narr_4k8dv76eykyYVnlz-eNaXw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13000000.0</chrs:CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade>
    <chrs:MaximumAntibodiesPartiallyExericsedUnderCommercializationOption
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      decimals="INF"
      id="Narr_1C6JyOhaFE2SECbnJvoHHg"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">10</chrs:MaximumAntibodiesPartiallyExericsedUnderCommercializationOption>
    <chrs:PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      decimals="2"
      id="Narr_vz--7yNCi0WFnuI4-DpQKA"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.65</chrs:PercentageOfOptionFeeToBePaidOnPartialExerciseOfCommercializationOption>
    <chrs:CollaborationAgreementAdditionalPaymentToBeMade
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      decimals="-5"
      id="Narr_5yQmxQUZT0m_uuZqSp6rZw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</chrs:CollaborationAgreementAdditionalPaymentToBeMade>
    <chrs:CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      id="Narr_kv0p4zwYYU6FBvEacynlQg">P12M</chrs:CollaborationAgreementExpirationTermFromEffectiveDateWithoutProvidingMaterialsThatPassQualityControl>
    <chrs:CollaborationAgreementTerm
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_chrs_AdimabDevelopmentAndOptionAgreementMember_RBaVEe3_VUe_gqES6P9K2w"
      id="Narr_ikJCUFBFM06kURL8nPAXuw">P10Y</chrs:CollaborationAgreementTerm>
    <chrs:CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade
      contextRef="Duration_3_23_2021_To_3_23_2021_us-gaap_TypeOfArrangementAxis_chrs_VaccinexLicenseAgreementMember_WDAN8bKZtkOa0CTw_Zz0iA"
      decimals="-5"
      id="Narr_Iv_ui31oU0yJyc6MEddLcw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3500000</chrs:CollaborationAgreementMaximumAggregateMilestonePaymentsToBeMade>
    <chrs:RegulatoryMilestonesEligibleToPay
      contextRef="Duration_3_23_2021_To_3_23_2021_us-gaap_TypeOfArrangementAxis_chrs_VaccinexLicenseAgreementMember_WDAN8bKZtkOa0CTw_Zz0iA"
      decimals="-5"
      id="Narr_yISJa1AYikeVI-RMXOCknw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11500000</chrs:RegulatoryMilestonesEligibleToPay>
    <chrs:PotentialDevelopmentMilestonesEntitled
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_0C2GDS067kqyEScTv50pUg"
      decimals="-5"
      id="Narr_jW9q7N5mX0Clq54sv_Ayhg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">325000000.0</chrs:PotentialDevelopmentMilestonesEntitled>
    <chrs:SalesMilestonesEntitled
      contextRef="Duration_1_1_2016_To_1_31_2016_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_0C2GDS067kqyEScTv50pUg"
      decimals="-5"
      id="Narr_n784x_CcmEq1pdCNtTOqDA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">200000000.0</chrs:SalesMilestonesEntitled>
    <chrs:CollaborationAgreementMilestonePaymentsEarned
      contextRef="Duration_3_1_2022_To_3_31_2022_dei_LegalEntityAxis_chrs_SurfaceMember_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_gfCoLb-ssE-NI0WQHzEhdQ"
      decimals="-5"
      id="Narr_N7FpAsw1M0iv9OR-EbNGvA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">30000000.0</chrs:CollaborationAgreementMilestonePaymentsEarned>
    <chrs:CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA"
      decimals="-5"
      id="Narr_VTIHWcypCkuEf_EzUtaMDw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">60000000.0</chrs:CollaborationAgreementAdditionalClinicalMilestonesEligibleToReceive>
    <chrs:CollaborationAgreementRegulatoryMilestonesEligibleToReceive
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA"
      decimals="-5"
      id="Narr_nN0FwtxS4kKvg1_PlLJjIw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">155000000.0</chrs:CollaborationAgreementRegulatoryMilestonesEligibleToReceive>
    <chrs:SalesMilestonesEntitled
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_GskAgreementMember_6djnCZ4KOk6wZAHemp04FA"
      decimals="-5"
      id="Narr_pzqBmM6gWEWtJtIqf2Ff3g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">485000000.0</chrs:SalesMilestonesEntitled>
    <chrs:CollaborationAgreementTerm
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_chrs_NovartisAgreementMember_GKvVg5Ic6ES4-RDKrSHttg"
      id="Narr_-9Y6rulVnEq0ZNqLenwq2Q">P10Y</chrs:CollaborationAgreementTerm>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_I5mOANR7bUmU7ZGEzLdCkA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/span&gt;Debt Obligations&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of the Company&#x2019;s debt obligations, including level within the fair value hierarchy (see Note 3. Fair Value Measurements), is as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027 Term Loans&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,519)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,481&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,481&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2*&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,112)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226,888&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 150,155&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2**&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027 Term Loans&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,517)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,483&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,483&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2*&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,425)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,575&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 157,205&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2**&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:98.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The principal amounts outstanding are subject to variable interest rates, which are based on three-month SOFR starting April 1, 2023 plus fixed percentages. Through March 31, 2023, the variable component was based on the three-month LIBOR. Therefore, the Company believes the carrying amount of these obligations approximates fair value.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;**&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;The fair value is influenced by interest rates, the Company&#x2019;s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2027 Term Loans &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into the Loan Agreement with BioPharma Credit, PLC, BPCR Limited Partnership, and Biopharma Credit Investments V (Master) LP, acting by its general partner, BioPharma Credit Investments V GP LLC that provides for a senior secured term loan facility of up to $300.0 million to be funded in four committed tranches: (i) the Tranche A Loan in an aggregate principal amount of $100.0 million that was funded on January 5, 2022; (ii) the Tranche B Loan in an aggregate principal amount of $100.0 million that was funded on March 31, 2022; (iii) the Tranche C Loan in an aggregate principal amount of $50.0 million that was not funded; and (iv) the Tranche D Loan in an aggregate principal amount of $50.0 million that was funded on September 14, 2022. The Company has the right to request an uncommitted additional facility amount of up to $100.0 million that is subject to new terms and conditions.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company&#x2019;s 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans accrued interest from inception through March 31, 2023 at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.0%; and starting April 1, 2023, accrue interest at 8.25% plus the Adjusted Term SOFR which is the sum of three-month SOFR and 0.26161% per annum, with a floor on Adjusted Term SOFR of 1.0%. The interest rate for the fourth quarter of 2023 was 13.91%. Interest is payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year. Repayment of outstanding principal of the 2027 Term Loans will be made in five equal quarterly payments of principal commencing March 31, 2026.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company adopted the prospective method to account for future cash payments. Under the prospective method, the effective interest rate is not constant, and any change in the expected cash flows is recognized prospectively as an adjustment to the effective yield. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The obligations under the Loan Agreement are secured pursuant to customary security documentation, including a guaranty and security agreement among the Credit Parties and the Collateral Agent which provides for a lien on substantially all of the Company&#x2019;s tangible and intangible assets and property, including intellectual property.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Loan Agreement, and subject to certain restrictions, proceeds of the 2027 Term Loans were used to fund the Company&#x2019;s general corporate and working capital requirements except for the following: in January 2022, proceeds of the Tranche A Loan were used to repay in full all amounts outstanding under the 2025 Term Loan, as well as all associated costs and expenses pursuant to which a payoff amount of $81.9&#160;million was outstanding; in March 2022, proceeds of the Tranche B Loan were drawn in connection with the full repayment of all amounts outstanding under the&#160;2022 Convertible Notes, as well as all associated costs and expenses pursuant to which a payoff amount of $111.1 million was outstanding.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Loan Agreement contains certain customary representations and warranties. In addition, the Loan Agreement includes covenants, such as the requirement to maintain minimum trailing twelve-month net sales in an amount that began at $200.0&#160;million for the quarter ending March 31, 2022 and increases to $210.0&#160;million for the quarter ended March 31, 2024. As a result of the Consent and Amendment entered into on February 5, 2024, beginning in the second quarter of 2024 and continuing through the quarter ended December 31, 2026, the requirement is to maintain minimum trailing twelve-month net sales of $125.0 million. In addition, there is a requirement to maintain a minimum trailing twelve-month net sales for LOQTORZI tested quarterly at the end of each quarter commencing with the quarter ended December 31, 2024. Further, the Loan Agreement includes certain other affirmative covenants and negative covenants, including, covenants and restrictions that among other things, restrict the Company&#x2019;s ability to incur liens, incur additional indebtedness, &lt;span style="background:#ffffff;"&gt;make investments, engage in certain mergers and acquisitions or asset sales, and declare dividends or redeem or repurchase capital stock. The Loan Agreement also contains customary events of default, including among other things, the Company&#x2019;s failure to make any principal or interest payments when due, the occurrence of certain bankruptcy or insolvency events or its breach of the covenants under the Loan Agreement. Upon the occurrence of an event of default, the Lenders may, among other things, accelerate the Company&#x2019;s obligations under the Loan Agreement. A change of control of the Company triggers a mandatory prepayment of the 2027 Term Loans within&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_9sZZOOI5Ik6UXQMv7GKoqA;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;business days. See Note 17. Subsequent Events for further information regarding the Consent and Amendment to the 2027 Term Loans. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the Company was in full compliance with these covenants and there were no events of default under the 2027 Term Loans.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In connection with the closing of Tranche A, the Company incurred $7.8 million&#160;in debt discounts and issuance costs&lt;span style="color:#ff0000;"&gt; &lt;/span&gt;of which $6.8 million related to all the tranches of the 2027 Term Loans and was thus allocated pro rata between the tranches. The unamortized debt &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;discount and issuance costs allocated to funded tranches are presented as deductions to the 2027 Term Loan balance and are amortized into interest expense using the effective interest method. The $2.3 million allocated to Tranche B was fully amortized over the commitment period prior to funding and recognized as interest expense in the first quarter of 2022. The associated debt discounts and issuance costs of unfunded tranches were deferred as assets and amortized into interest expense using the straight-line method over the commitment period of the respective tranches. At the closing dates of Tranche B on March 31, 2022 and Tranche D on September 14, 2022, the Company incurred an additional $1.0 million and $0.5 million, respectively,&#160;in debt issuance costs. As of December 31, 2023, the total remaining unamortized debt discount and debt offering costs related to Tranches A, B and D of $3.5 million will be amortized using the effective interest rate over the remaining term of 3.0 years.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of interest expense related to the 2027 Term Loans: &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,094&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assuming the fourth quarter of 2023 interest rate of 13.91%, future payments on the 2027 Term Loans as of December 31, 2023, are as follows: &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,345&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 - principal and interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 224,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027 - principal and interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 345,297&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (95,297)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027 Term Loans, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,519)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2027 Term Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The table above does not reflect any adjustment for transactions contemplated by the Consent and Amendment entered into on February 5, 2024, including any prepayments to the 2027 Term Loans. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1.5%&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; Convertible Senior Subordinated Notes due 2026&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In April 2020, the Company issued and sold &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$230.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million aggregate principal amount of its&#160;2026 Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds from the offering were &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$222.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million after deducting initial purchasers&#x2019; fees and offering expenses. The 2026 Convertible Notes are general unsecured obligations and will be subordinated to the Company&#x2019;s designated senior indebtedness (as defined in the indenture for the 2026 Convertible Notes) and&#160;structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables.&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;The 2026 Convertible Notes accrue interest at a rate of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;1.5%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, and will mature on&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;April 15, 2026&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, unless earlier repurchased or converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their 2026 Convertible Notes at their option into shares of the Company&#x2019;s common stock, together, if applicable, with cash in lieu of any fractional share, at the then-applicable conversion rate. The initial conversion rate is&#160;51.9224&#160;shares of common stock per $1,000&#160;principal amount of the 2026 Convertible Notes, which represents an initial conversion price of approximately $19.26&#160;per share of common stock. The initial conversion price represents a premium of approximately&#160;30.0% over the last reported sale of $14.82&#160;per share of the Company&#x2019;s common stock on the Nasdaq Global Market on April&#160;14, 2020, the date the 2026 Convertible Notes were issued. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. If a &#x201c;make-whole fundamental change&#x201d; (as defined in the indenture for the 2026 Convertible Notes) occurs, the Company will, in certain circumstances, increase the conversion rate for a specified period of time for noteholders who convert their 2026 Convertible Notes in connection with that make-whole fundamental change. The 2026 Convertible Notes are not redeemable at the Company&#x2019;s election before maturity. If a &#x201c;fundamental change&#x201d; (as defined in the indenture for the 2026 Convertible Notes) occurs, then, subject to a limited exception, &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;noteholders may require the Company to repurchase their 2026 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The 2026 Convertible Notes have customary provisions relating to the occurrence of &#x201c;events of default&#x201d; (as defined in the Indenture for the 2026 Convertible Notes). The occurrence of such events of default could result in the acceleration of all amounts due under the 2026 Convertible Notes. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;As of December 31, 2023, the Company was in full compliance with these covenants, and there were no events of default under the 2026 Convertible Notes.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated the features embedded in the 2026 Convertible Notes under the relevant accounting rules&#160;and concluded that the embedded features do not meet the requirements for bifurcation, and therefore do not need to be separately accounted for as an equity component. The proceeds received from the issuance of the convertible debt were recorded as a liability in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Capped Call Transactions&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In connection with the pricing of the 2026 Convertible Notes, the Company paid &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$18.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million to enter into privately negotiated capped call transactions with&#160;one&#160;or a combination of the initial purchasers, their respective affiliates and other financial institutions. The capped call transactions are generally expected to reduce the potential dilution upon conversion of the 2026 Convertible Notes in the event that the market price per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the 2026 Convertible Notes, and is subject to anti-dilution adjustments generally similar to those applicable to the conversion rate of the 2026 Convertible Notes. Since inception, the cap price has been &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.93&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per share, which represents a premium of approximately&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;75.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; over the last reported sale price of the Company&#x2019;s common stock of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$14.82&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per share on April 14, 2020, and is subject to certain adjustments under the terms of the capped call transactions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The capped call transactions are accounted for as separate transactions from the 2026 Convertible Notes and&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;classified as equity instruments.&#160;Therefore, the total&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$18.2&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million capped call premium paid was recorded as a reduction to additional paid-in capital in the consolidated balance sheets in 2020.&lt;/span&gt;&#160;The capped calls will not be subsequently re-measured as long as the conditions for equity classification continue to be met. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred $0.9 million of debt issuance costs relating to the issuance of the 2026 Convertible Notes, which were recorded as a reduction to the notes in the consolidated balance sheet. The debt issuance costs are being amortized and recognized as additional interest expense over the six-year contractual term of the notes using the effective interest rate method.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the 2026 Convertible Notes&#160;were converted on December 31, 2023, the holders of the 2026 Convertible Notes&#160;would have received common shares with an aggregate value of $39.8 million based on the Company&#x2019;s closing stock price of $3.33 as of December 29, 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table presents the components of interest expense related to 2026 Convertible Notes:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,709&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The remaining unamortized debt discount and debt offering costs related to the Company&#x2019;s 2026 Convertible Notes&#160;of $3.1 million as of December 31, 2023, will be amortized using the effective interest rate over the remaining term of the 2026 Convertible Notes. The annual effective interest rate is 2.1% for the 2026 Convertible Notes.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Future payments on the 2026 Convertible Notes&#160;as of December 31, 2023 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0070c0;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 - principal and interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 231,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 238,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,625)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026 Convertible Notes, principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,112)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226,888&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.2% Convertible Notes due 2022&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On February&#160;29, 2016, the Company issued and sold &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million aggregate principal amount of its &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;8.2%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; Convertible Senior Notes due 2022. &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company, bore interest at a fixed coupon rate of 8.2% per annum payable quarterly and matured on March 31, 2022&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;.&#160;In March 2022, the Company fully repaid the 2022 Convertible Notes, and as a result had&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;continuing obligations associated with them thereafter. The payoff amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$111.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million included the repayment of the entire outstanding principal amount, the&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;9.0%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; premium of the outstanding principal amount and accrued and unpaid interest. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2022 Convertible Notes&#160;were issued to Healthcare Royalty Partners III,&#160;L.P., for $75.0 million in aggregate principal amount, and to three related party investors, KKR Biosimilar&#160;L.P., MX II Associates LLC, and KMG Capital Partners, LLC, for $20.0 million, $4.0 million, and $1.0 million, respectively, in aggregate principal amount.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of interest expense of the 2022 Convertible Notes:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,966&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2025 Term Loan&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January&#160;7, 2019, the Company entered into the 2025 Term Loan with affiliates of Healthcare Royalty Partners (together, the &#x201c;Lender&#x201d;). The 2025 Term Loan consisted of a six-year term loan facility for an aggregate principal amount of $75.0 million (the &#x201c;Borrowings&#x201d;). Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at 6.75%&#160;per annum plus three&#160;month LIBOR. Interest was payable quarterly in arrears.&lt;span style="text-decoration-line:line-through;text-decoration-style:solid;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Pursuant to the terms of the 2025 Term Loan, the Company was required to begin paying principal on the Borrowings in equal quarterly installments beginning on January 7, 2022, with the outstanding balance to be repaid on&#160;January&#160;7, 2025, the maturity date. In January 2022, pursuant to the Company entering into the 2027 Term Loans, the Company voluntarily prepaid all amounts outstanding under the 2025 Term Loan. The payoff amount of $81.9 million included principal repayment in full, accrued interest, a 5.0% prepayment premium fee of the Borrowings principal amount, and an exit fee of 4.0% of the Borrowings principal amount. The prepayment premium fee and unamortized exit fee, debt discount and debt issuance costs, net from the 2025 Term Loan totaled $6.2 million and was recorded in loss on debt extinguishment in the consolidated statements of operations for 2022. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components of interest expense of the 2025 Term Loan:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_YwWxmFcdhkWpNoTvVvKAKA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027 Term Loans&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,519)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,481&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,481&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2*&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,112)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226,888&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 150,155&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2**&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="13" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:64.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized Debt Discount and Debt Issuance Costs&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial Liabilities:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027 Term Loans&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,517)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,483&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,483&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2*&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 Convertible Notes&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:16.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,425)&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225,575&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 157,205&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Level 2**&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:98.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The principal amounts outstanding are subject to variable interest rates, which are based on three-month SOFR starting April 1, 2023 plus fixed percentages. Through March 31, 2023, the variable component was based on the three-month LIBOR. Therefore, the Company believes the carrying amount of these obligations approximates fair value.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.43%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;**&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:98.56%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;The fair value is influenced by interest rates, the Company&#x2019;s stock price and stock price volatility and is determined by prices observed in market trading. Since the market for trading of the 2026 Convertible Notes is not considered to be an active market, the estimated fair value is based on Level 2 inputs.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw"
      decimals="-3"
      id="Tc_eHMqb11O8keiTbfq-owgSQ_4_2"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw"
      decimals="-3"
      id="Tc_SgLZjfprAk-hpn0KrcmV_Q_4_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3519000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw"
      decimals="-3"
      id="Tc_V4AE93jqSUOUGICRaHxSgQ_4_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">246481000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_LtcgcQ1qo0uEl1ikcGsBIw"
      decimals="-3"
      id="Tc_JD5BjlwBrUCZGQfkTW5UuA_4_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">246481000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA"
      decimals="-3"
      id="Tc_5nEgwbb7cE2QDBJlZrcjug_5_2"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">230000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA"
      decimals="-3"
      id="Tc_CG-l5GMnBkiBTW_lYJPJFg_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3112000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA"
      decimals="-3"
      id="Tc_GMQRlIrfPECTJZBcSvYqFQ_5_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">226888000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_ukqETZ33P0agZbNKwchesA"
      decimals="-3"
      id="Tc_9SexfL9M8UG1Q3DMfXntOA_5_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">150155000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg"
      decimals="-3"
      id="Tc_HPZ7FYE7g0yrS9Zshbbzeg_10_2"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg"
      decimals="-3"
      id="Tc_ubsol1rpl0aDWlU2zLfHjw_10_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4517000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg"
      decimals="-3"
      id="Tc_W4Xohv5LQ0GYIX7nH3B-mw_10_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">245483000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_W4OPb8kieU-kKOViq5B2xg"
      decimals="-3"
      id="Tc_ARMAeoWtBE--ftoWmr_xzg_10_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">245483000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg"
      decimals="-3"
      id="Tc_-ch-sjvNNkmSxk-vOjOYAg_11_2"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">230000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg"
      decimals="-3"
      id="Tc_u4RmDjsnFkCC_bBecVDx6A_11_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4425000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg"
      decimals="-3"
      id="Tc_TxELvigr30amjG55UxBnsQ_11_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">225575000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_0FItyW2kk0uu7Mhmv6WOHg"
      decimals="-3"
      id="Tc__w2bbRPICEqzfZEvMTsL0w_11_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">157205000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wOrFEBBx0kqCfY3Jfb9mmA"
      decimals="-5"
      id="Narr_hEZXPnsghUeVWDpwbJcYZw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">300000000.0</us-gaap:DebtInstrumentFaceAmount>
    <chrs:DebtInstrumentNumberOfTranches
      contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_wOrFEBBx0kqCfY3Jfb9mmA"
      decimals="INF"
      id="Narr_ASjPysY0nkqWfodcNzGEsw"
      unitRef="Unit_Standard_tranche_ZKmzrBOMS0eN5e6PQhEzOA">4</chrs:DebtInstrumentNumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_5_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_UbIxb6J1Y0GS_zqAinL_8Q"
      decimals="-5"
      id="Narr_cLZphGajWkG8nlgaOkUycQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_M-uRNszAXEi9r-8LL3xQhw"
      decimals="-5"
      id="Narr_Y8G3DTEGfkiXiQU7_flc0g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheCLoanMember__qTNMulPqkyLxoNEOq3P_A"
      decimals="-5"
      id="Narr_HV0EaZdJ_0Ogz9TWuJjTFg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50000000.0</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_cTMkGi5D4E2X87OVhy9Ppg"
      decimals="-5"
      id="Narr_R8YPQpnNT0CiwMJmqtNEmw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <chrs:DebtInstrumentUncommittedAdditionalFacility
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_aM31ORVDHEOXDbOoQGO-Eg"
      decimals="-5"
      id="Narr_DHWB-qcJzUq6o6AdcFCy6w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">100000000.0</chrs:DebtInstrumentUncommittedAdditionalFacility>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_bYNDamUcsk2slttHQRFDdQ"
      decimals="-5"
      id="Narr_jlvJ4D7Cy0KuUE8JjarUwQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_DixWwtQqF0uRVadXYuAfNw"
      decimals="4"
      id="Narr_FVX6NmgL7EiXUD2ePDoJbA"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_chrs_ThreeMonthLiborMember_SFCa5VQ500OXf47jZb2Inw"
      decimals="3"
      id="Narr_BqZkSmXxwEWREWdgcO_8og"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4w3mHtTbxUO8oH0eEffh_g"
      decimals="4"
      id="Narr_yBYBf_VPuU-NZ3gJ3rgp2Q"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ"
      decimals="INF"
      id="Narr_Od42J0PXj06d9y-0l6s04g"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0026161</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_80scg5J5akC1Joiw7cWxLQ"
      decimals="3"
      id="Narr_eqjDn0zFdkmGjjeY_jrdCw"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg"
      decimals="4"
      id="Narr_6qRqd2IlxUKyy2ajzKvx0g"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.1391</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_bli3D_4p8Eu4TDVPspP6-w"
      decimals="-5"
      id="Narr_hdZg6Me3oEamhpHzgF0cFg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">81900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ"
      decimals="-5"
      id="Narr_iNYzqa07B0qe7COlXQZa1w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">111100000</us-gaap:RepaymentsOfConvertibleDebt>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodOne
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA"
      decimals="-5"
      id="Narr_35F5vc5d9Ui3lSzXc8qrZQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">200000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodOne>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodTwo
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA"
      decimals="-5"
      id="Narr_I-BA23jajUu0sE2g4JG9bg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">210000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodTwo>
    <chrs:LoanAgreementCovenantsNetSalesForPeriodThree
      contextRef="Duration_2_5_2024_To_2_5_2024_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_otbpUOnq8EKYMPXpah8q6g"
      decimals="-5"
      id="Narr_ZBrjhRuXh0ejMMWroU1MnQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">125000000.0</chrs:LoanAgreementCovenantsNetSalesForPeriodThree>
    <chrs:DebtDiscountsAndIssuanceCosts
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheLoanMember_MV06IYXPdkmqFzBkwhBAXA"
      decimals="-5"
      id="Narr_L1yH75F1ik6gbB4rVqcSKg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7800000</chrs:DebtDiscountsAndIssuanceCosts>
    <chrs:DebtDiscountsAndIssuanceCosts
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_zhZrf0CvXkCw-nDze84sPA"
      decimals="-5"
      id="Narr_yjkkpW2rwUikjsSz1N2-3g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6800000</chrs:DebtDiscountsAndIssuanceCosts>
    <chrs:DebtDiscountsAndIssuanceCosts
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_F3uuUNoynEGVqfaLmbmpNQ"
      decimals="-5"
      id="Narr_HlZy3MYzxE26CAEEBTcRnA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2300000</chrs:DebtDiscountsAndIssuanceCosts>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_3_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheBLoanMember_M-uRNszAXEi9r-8LL3xQhw"
      decimals="-5"
      id="Narr_XjxxPSlMw06f2wct5VLHGA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000000.0</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_9_14_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheDLoanMember_cTMkGi5D4E2X87OVhy9Ppg"
      decimals="-5"
      id="Narr_Qb5IYrPnYkiKySJjUFW7og"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_Z0wbfOYnWk6X7ZFZMIo1Gg"
      decimals="-5"
      id="Narr_UdzNLybWp068_sS81aaXSQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <chrs:DebtInstrumentRemainingTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TrancheaBAndDLoansMember_OaNk_89S-kO2L5QxklSuhw"
      id="Narr_Rr9Fmn2PEEmZxIRxR6YfVw">P3Y</chrs:DebtInstrumentRemainingTerm>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JoIcCfI8pEKowyCw3vvEBg"
      id="Tb_F-ABxmq_j0SFhveWHzXJaQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,094&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ"
      decimals="-3"
      id="Tc_o3Ya2B-88EOw73_sT7CGSA_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">34289000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg"
      decimals="-3"
      id="Tc_07e-GI10u0qHW6fBZNicJA_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">20243000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ"
      decimals="-3"
      id="Tc_7GP2UIBVB0iX1WRRYgy31g_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1094000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg"
      decimals="-3"
      id="Tc_qP-UgXEj8ky0c76m7Cxeeg_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4550000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_hOgxP9sfnUaK-GyVnByWeQ"
      decimals="-3"
      id="Tc_bJUiqnAuAkCMdAu_tHEsbw_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35383000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_haVL-HGiHkCfu0lNo1n3Qg"
      decimals="-3"
      id="Tc_65jHJMCdlk-OisnUFd2l0Q_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">24793000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_vHDRXsr7XUSH2kP09Dywzg"
      decimals="4"
      id="Narr__PUrstQfrEqL8OfZefo_8A"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.1391</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_JoIcCfI8pEKowyCw3vvEBg"
      id="Tb_sP_Ye0zmNEKJTz0ImkzO4g">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#ff0000;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,345&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 - principal and interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 224,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2027 - principal and interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 345,297&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (95,297)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027 Term Loans, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,519)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2027 Term Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_XABaMJ4m-kGuEQBUF7WG1A_2_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35345000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_p5XxgQBWuEi_7c4l-8RfVA_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">35248000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_nORhZFhY50OCmRnrb1zaag_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">224607000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_JkiWdEhj30uwSD8Pmiknig_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50097000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_ojwjT3ikSkOGJ55QioHUjA_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">345297000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_g2kIBYuNhkyVmyVgB-DC0Q_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">95297000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <chrs:TermLoanGross
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_yq3Yc_n-CEaPqW2N_2OeEQ_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">250000000</chrs:TermLoanGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_IhZG4ua2WESIJ-d3X8ux1Q_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3519000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_chrs_BiopharmaCreditInvestmentsVGpLlcMember_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_-QP9bTO7M0G-1o2Sxc2Atw"
      decimals="-3"
      id="Tc_0jEEAEK0zUi4qGSwvKCexQ_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">246481000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A"
      decimals="3"
      id="Narr_l9R3IriyEk6Ur5IPqhRstg"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A"
      decimals="-5"
      id="Narr_s3HPntZDe0SMvUDaBmmzIQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">230000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ"
      decimals="-5"
      id="Narr_VLfvzcNlnEijrSPahAIAMg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">222200000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ"
      id="Narr_Yr-hZg_RukmVKt6CtLtgIw">The 2026 Convertible Notes accrue interest at a rate of&#160;1.5% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, since October 15, 2020</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A"
      decimals="INF"
      id="Narr_vVWNjIjyz0eUFEnWm2Ybxg"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ"
      id="Narr_RCA--MMQaUS_RhrTtbpcWQ">2026-04-15</us-gaap:DebtInstrumentMaturityDate>
    <chrs:DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A"
      decimals="INF"
      id="Narr_TwI0rfpaDU-jcMADrf_CbQ"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">51.9224</chrs:DebtInstrumentConvertibleNumberOfSharesPerThousandOfPrincipalAmountOfNotes>
    <chrs:PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate
      contextRef="As_Of_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_szriiUJ_DUufo1OCKzb9-A"
      decimals="0"
      id="Narr_Wp4LTkyXhEaxJwytGpTIhQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000</chrs:PrincipalAmountOfNotesConvertedIntoSharesOfCommonStockAtConversionRate>
    <chrs:EquivalentToConversionPricePerCommonShare
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ"
      decimals="2"
      id="Narr_nS5CpqS17Uir_xRMuSUOyw"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">19.26</chrs:EquivalentToConversionPricePerCommonShare>
    <chrs:PercentageOfPremiumOnConvertibleNote
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Hs7CLiAov0muMNZ7VlQgCQ"
      decimals="3"
      id="Narr_ZaMqW9VvP0O0bu9Uc78WZg"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.300</chrs:PercentageOfPremiumOnConvertibleNote>
    <us-gaap:SharePrice
      contextRef="As_Of_4_14_2020_lOYMm8IewEGa7ecW7rCQ6Q"
      decimals="2"
      id="Narr_4zuNAzNU0EipdLhkYOB8_A"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">14.82</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw"
      id="Narr_C-EVjBbBfEi9Ik0xac7JCQ">As of December 31, 2023, the Company was in full compliance with these covenants, and there were no events of default under the 2026 Convertible Notes.</us-gaap:DebtInstrumentCovenantCompliance>
    <chrs:NumberOfEventsInDefault
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_0bsmQzQVxkiRBstBPBwZjw"
      decimals="INF"
      id="Narr_CBwXxUMVSUe_bwMUMihq6Q"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">0</chrs:NumberOfEventsInDefault>
    <chrs:PaymentForCappedCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA"
      decimals="-5"
      id="Narr_xB0NBVfuxkiNN3DAkyv-8Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18200000</chrs:PaymentForCappedCallTransactions>
    <chrs:CapPriceOfCapCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA"
      decimals="2"
      id="Narr_V65YhxevjUiRlFwQVY1WDw"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">25.93</chrs:CapPriceOfCapCallTransactions>
    <chrs:PercentageOfCapPriceCappedCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA"
      decimals="3"
      id="Narr_d_0twZckBEW4Xg6afG8pSQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.750</chrs:PercentageOfCapPriceCappedCallTransactions>
    <us-gaap:SharePrice
      contextRef="As_Of_4_14_2020_lOYMm8IewEGa7ecW7rCQ6Q"
      decimals="2"
      id="Narr_3cf-F1k1_Ea_NkfSF7lSLw"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">14.82</us-gaap:SharePrice>
    <chrs:PaymentForCappedCallTransactions
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_CallOptionMember_40jVIES0KUaURigEsjqtKA"
      decimals="-5"
      id="Narr_d9VP0_LNoE6OuW9QHvJ1Sg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18200000</chrs:PaymentForCappedCallTransactions>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-5"
      id="Narr_-Sn50faQD0G_sJIzHF3PJg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">900000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <chrs:DebtInstrumentContractualTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg"
      id="Narr_952OikZP10GPVIK13i64XQ">P6Y</chrs:DebtInstrumentContractualTerm>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_mz08bJgB4EaXuGX2fTgvhQ"
      decimals="-5"
      id="Narr_AdV5T-FpCUGmO4vc4lxm-w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">39800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="2"
      id="Narr_bvMVyrxs-kuOtHMeJa90Lw"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">3.33</us-gaap:SharePrice>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg"
      id="Tb_iuHIGthWmEKmGD7nvhOXGA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,709&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw"
      decimals="-3"
      id="Tc_uSSOlBQt6Uufe7Z0nUYnfQ_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3450000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow"
      decimals="-3"
      id="Tc_97f1oYNCEk6iN7Cl8NGEHg_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3450000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ"
      decimals="-3"
      id="Tc_rQeS6NIwIkq9rSdsm_p2Og_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3450000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw"
      decimals="-3"
      id="Tc_aoWrsEcBvUaldVwV9Y4Vrg_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1313000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow"
      decimals="-3"
      id="Tc_7amQ-dzu5kqGBUhWoeAT3A_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1286000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ"
      decimals="-3"
      id="Tc_RP9jwpcvSU6b9qaXgFNGDQ_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1259000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_1zlV7o3Te0mQYrTq9Hi_Xw"
      decimals="-3"
      id="Tc_akp0aujnAUSMbQf7318J2g_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4763000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember__RMl9mEBKUWYxFwoO-Ytow"
      decimals="-3"
      id="Tc_jmWsuMgCfkScNCrzHP4RUg_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4736000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_RlPMUGWro0uj_sQDUZ6iMQ"
      decimals="-3"
      id="Tc_sxSdtKvhw0u_0nKiVsz8ng_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4709000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-5"
      id="Narr_GCV0KN4R70CMd2dXz7Xqig"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="4"
      id="Narr_T66JZTM1CU291lvWCqa4CA"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.021</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6kqPruJYf0SDQNYio5wgTg"
      id="Tb_-FDhYHxOokSpHHzsD6oPnQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Future payments on the 2026 Convertible Notes&#160;as of December 31, 2023 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31,&#160;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0070c0;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025 - interest only&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026 - principal and interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 231,725&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 238,625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less amount representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,625)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026 Convertible Notes, principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,112)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net carrying amount of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 226,888&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_SWgU862NqEO2AU-obC3Vrw_2_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3450000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_iva8KUVZpk-XbRVr_1UTPg_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3450000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_5W9pDGxTBUa7QvpYEozoFQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">231725000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_rphjv2hw80yyehbexwUFIg_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">238625000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_LsSe2DIW7E-WDrCOguazig_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8625000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <chrs:ConvertibleNotesPrincipalAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_M5vCp_rY4kWanXxDhF5nWA_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">230000000</chrs:ConvertibleNotesPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_lad5XZ1nakGpMisn02YKqA_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3112000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_37e-N3hX0EGieGL7waMM2w"
      decimals="-3"
      id="Tc_ZATBHjxgdUiP0mT8ue-QVQ_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">226888000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA"
      decimals="3"
      id="Narr_zGnX4dH0nEOqcZhByW2h0w"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.082</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA"
      decimals="-5"
      id="Narr_ATzn3ey0pEqH4tZYcWqJBw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_lsc866nVEEqfudMO5QqusA"
      decimals="3"
      id="Narr_tH-nSojjqk6xL5y6FjDVMA"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.082</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="Duration_2_29_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_IYOtI7t0s06IRoQfEZsvfg"
      id="Narr_Vd9VtT9HKEu_IqNe5d8bQg">The 2022 Convertible Notes&#160;constituted general, senior unsubordinated obligations of the Company and were guaranteed by certain subsidiaries of the Company, bore interest at a fixed coupon rate of 8.2% per annum payable quarterly and matured on March 31, 2022</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:ConvertibleNotesPayable
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pmdNhIdK2kyIctMI_ST38Q"
      decimals="-5"
      id="Narr_RGOCGdnSjky34cjD2u_duA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ"
      decimals="-5"
      id="Narr_gdt1MV0JPkKcC2rjWWOZPg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">111100000</us-gaap:RepaymentsOfConvertibleDebt>
    <chrs:PercentageOfPremiumOnConvertibleNote
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_BXJ2Ob0piE25p887v6u7XQ"
      decimals="3"
      id="Narr_2Xci9XnYiEynWBKxv8M00Q"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.090</chrs:PercentageOfPremiumOnConvertibleNote>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_29_2016_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_2LOhPFc_bEyFVajuBKg_hw"
      decimals="-5"
      id="Narr_ybZ_Xv1Wfk6n4E2wr7I_PA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">75000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KKRBiosimilarLPMember_VEix4k9_P0C5vL3mOkva7w"
      decimals="-5"
      id="Narr_QWDCmJYBBEKTC_55lJSVpQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_MXIIAssociatesLLCMember_dlXABsWvD0ytszx5uH9T9w"
      decimals="-5"
      id="Narr_l9m4QWfxq0-sfvRdVsao4w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_29_2016_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_chrs_KMGCapitalPartnersLLCMember_gM38q0-qfkqM70dI2BG3iA"
      decimals="-5"
      id="Narr_uiuw_TiA4Uix3Tq7vhqRQQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_yPqNV7UizkyOlrp2llCvgA"
      id="Tb_5tbLh_rPdEynYWwA6wl4yA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,966&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA"
      decimals="-3"
      id="Tc_HlAAP4HVVEu3v8vXNzUwjQ_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2050000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA"
      decimals="-3"
      id="Tc_CZhYQLAfV0GU7aJ2QpPSVQ_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8200000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA"
      decimals="-3"
      id="Tc_6pW-QGShakKQifHaPTXZQA_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">521000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA"
      decimals="-3"
      id="Tc_DzUB7LTyYUiyJKhCfATSSA_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1966000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_myH3Ooj7ikGRFTA10dD1fA"
      decimals="-3"
      id="Tc_4SwMqGfHW0yfwHNUsXdkzA_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2571000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_f3ogtKUJvkmI7RGNbUFjiA"
      decimals="-3"
      id="Tc_q5sjlQqpnkGS2d_-kwUpgA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10166000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_-u8VFwKaq0W-VpOwOG1Tug"
      id="Narr_f2xrXVQxfEmPnMLl-O84qQ">P6Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_7_2019_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_4dYZePFHI0uh8xLaZDgW8A"
      decimals="-5"
      id="Narr_zP9gatbNsUmIDWGLIApCkg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">75000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="Duration_1_7_2019_To_1_7_2019_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_ESE6x74w_0eBsyYKVq7Vhw"
      id="Narr_DU3a-AJ0tkKdl4w3YbSzgA">Starting January 1, 2020, the Borrowings under the 2025 Term Loan bore interest at 6.75%&#160;per annum plus three&#160;month LIBOR. Interest was payable quarterly in arrears. </us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_1_1_2020_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_9RhPVS_PkUqmSIIeRzY6ig"
      decimals="4"
      id="Narr_gWeqGDakHUCnuHyr1ZK3Cw"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0675</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA"
      decimals="-5"
      id="Narr_v8hB-YJyxkSKZgNeyqEp1A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">81900000</us-gaap:RepaymentsOfDebt>
    <chrs:DebtInstrumentPrepaymentPercentage
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_G4zeUvb2AkiJrpZxrWkJfw"
      decimals="3"
      id="Narr_txatew0Bj0i9XHDacWR5Ug"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.050</chrs:DebtInstrumentPrepaymentPercentage>
    <chrs:PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA"
      decimals="3"
      id="Narr_cfjvKBknUEeReX2UN52SKQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.040</chrs:PercentageRequiredToPayAdditionalExitFeeOnPrincipalAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_t8NV0gJi2U-pp6TOb0gWMA"
      decimals="-5"
      id="Narr_MNtpxMClrkKeCf7bsYO5zQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-6200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_Loyb6ABkV0CqKB-V5_uHvA"
      id="Tb_LIwTxZGfvE6fbGRl2uEbTg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stated coupon interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount and debt issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw"
      decimals="-3"
      id="Tc_IE6aQBozm0OLw69CBiSJ1w_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">154000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ"
      decimals="-3"
      id="Tc_Gr7WojjwpkijnOcg2FeTWw_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7034000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw"
      decimals="-3"
      id="Tc_Sj45RAM0dkimNbQALIx_nQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">16000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ"
      decimals="-3"
      id="Tc_1CGvxOCAsEi4tKAA8BDX7g_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1032000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_WEAmWuZCWk6XYPhHM0OWyw"
      decimals="-3"
      id="Tc_wcz-eLhZ2ESO4RiJIKADIw_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">170000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_chrs_HealthcareRoyaltyPartnersIIILPMember_us-gaap_DebtInstrumentAxis_us-gaap_LoansPayableMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_Xw_oi06xe064VsZdDAP_PQ"
      decimals="-3"
      id="Tc_Yd63eu6xJki30U8Nrv6nOA_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8066000</us-gaap:InterestExpenseDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_4E8U7ybbPk6_-HVIko_OTg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;9.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Commitments and Contingencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Purchase Commitments&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into agreements with certain vendors to secure raw materials and certain CMOs to manufacture its supply of products. As of December 31, 2023, the Company&#x2019;s non-cancelable purchase commitments under the terms of its agreements are as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31, (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,514&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, total obligations excludes certain purchase commitments that were assumed by Sandoz upon their acquisition of the Company&#x2019;s CIMERLI ophthalmology franchise (see Note 17. Subsequent Events). The Company enters into contracts in the normal course of business with contract research organizations for preclinical studies and clinical trials and CMOs for the manufacture of clinical trial materials. The contracts are cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would generally only be obligated for products or services that the Company had received as of the effective date of the termination and any applicable cancellation fees.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Guarantees and Indemnifications&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company assesses the likelihood of any adverse judgments or related claims, as well as ranges of probable losses. In the cases where the Company believes that a reasonably possible or probable loss exists, it will disclose the facts and circumstances of the claims, including an estimate range, if possible.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Legal Proceedings and Other Claims&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved. The outcome of such legal proceedings and claims is inherently uncertain. Accruals are recognized for such legal proceedings and claims to the extent that a loss is both probable and reasonably estimable. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. If it&#x2019;s determined that a material loss is reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. Sometimes it is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and the maximum potential exposure or the range of possible loss cannot be reasonably estimated. As of December 31, 2023 and 2022, the Company had an accrual of $6.4 million and $4.7 million, respectively, related to such matters that was included in accrued rebates, fees and reserves in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In late April of 2022, the Company received a demand letter from Zinc Health Services, LLC (&#x201c;Zinc&#x201d;) asserting that Zinc was entitled to approximately $14.0 million from the Company for claims related to certain sales of UDENYCA from October 2020 through December 2021. The Company is continuing to evaluate the claims in the letter. No legal proceeding has been filed in connection with the claims in the letter and based on currently available information the final resolution of the matter is uncertain. The Company intends to defend any legal proceeding that may be filed. The Company established an accrual as of December 31, 2023 that represented its estimated liability to resolve the matter. Loss contingencies are inherently unpredictable, the assessment is highly subjective and requires judgments about future events and unfavorable developments or resolutions can occur. The Company regularly reviews litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date&lt;b style="font-weight:bold;"&gt;.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Other than the matter in connection with the demand letter described in this Note 9, there are no pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the Company or any of its subsidiaries is a party, or that any of the Company or its subsidiaries' property is subject.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_x-Ft_yU8_ECgyBZ9oycRUA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Year ending December&#160;31, (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,514&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongTermPurchaseCommitmentTextBlock>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_q0VmyIYY8kKVdIQ4fmPucQ_2_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">52514000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_GJiZoBMTnkmWsYQkT05wmw_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19154000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_G-jOw7uq3U2tant8a4fDsg_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1410000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligation
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_tLs7qWSe3UicM423KtTYNw_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">73078000</us-gaap:PurchaseObligation>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_2TW5nZJ8wUWRYttn81wTMg"
      decimals="-5"
      id="Narr_tw8YFgdp-0S5wpNkkS_wCQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_chrs_AccruedRebatesFeesAndReservesMember_u0BIpPgozk2LV-saZBzeXQ"
      decimals="-5"
      id="Narr_QkVmdgPbeEq3HchL1D3V2Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4700000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
      contextRef="Duration_4_1_2022_To_4_30_2022_oL0nzgyjPkiv7bL6dvw4Sw"
      decimals="-6"
      id="Narr_8NV1d1DVeECySp8mF6P37g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">14000000.0</us-gaap:ProductLiabilityContingencyLossExposureNotAccruedBestEstimate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_cFYqaJtE70WJC8hxmj9tGA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/span&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Through December 31, 2023, the Company leased approximately 47,789 square feet of office space for its corporate headquarters in Redwood City, California (the &#x201c;Lease Agreement&#x201d;). Prior to an amendment to the Lease Agreement entered into on October 24, 2023 (the &#x201c;Sixth Amendment&#x201d;), the Lease Agreement was set to expire in &lt;span style="-sec-ix-hidden:Hidden_fHNXk8VMLECyy9jYAF_Fdw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;September 2024&lt;/span&gt;&lt;/span&gt; and contained a &lt;span style="-sec-ix-hidden:Hidden_VkjnRAfIcEy-ZaCcc2AiFA;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-time option to extend the lease term for five years. Under the terms of the Sixth Amendment, the Company extended the lease term through September 30, 2027 and reduced the amount of office space leased to 27,532&#160;square feet. The remaining&#160;20,257&#160;square feet of office space expired on December 31, 2023, according to the terms of the Sixth Amendment. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also leases approximately&#160;25,017&#160;square feet for its laboratory facilities in Camarillo, California which commenced in January 2020. This lease terminates in&#160;&lt;span style="-sec-ix-hidden:Hidden_2eeuHZDPwkuwZhYvkItgaQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;May 2027&lt;/span&gt;&lt;/span&gt; and contains a &lt;span style="-sec-ix-hidden:Hidden_TfxsXMoIkUuAjOrWK1_x9w;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-time option to extend the lease term for&#160;five years. Both facility leases provide for certain limited rent abatement and annual scheduled rent increases over their respective lease terms.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the above facility leases were operating leases. The options to extend the lease terms, if any, for these leases were not included as part of the right-of-use asset or lease liability as it was not reasonably certain the Company would exercise those options. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2019, the Company entered into the Vehicle Lease Agreement, pursuant to which the Company leased approximately 50 vehicles as of December 31, 2023. The term of each leased vehicle is 36 months and commences upon the delivery of the vehicle. The vehicles leased under this arrangement were classified as finance leases. Beginning in February 2023, the Company no longer enters into these leasing arrangements and began transitioning to a reimbursement program with employees. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental information related to the Company&#x2019;s leases is as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-mf-ZxnNGEipJwEpza_71w;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other assets, non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_WgpZY07_p0GbKqCO5gEf4g;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total leased assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,274&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_liJO04hsZUOJwgNDIHYjyw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_TFQ5qkqFP0exAVaWIavjVw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ieMrVFi9_UGwUiP2AK3LZQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wCWMjCewb0K1TBEZgR53KQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,609&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Other information related to lease term and discount rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:28.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-Average Remaining Lease Term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.2 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-Average Discount Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11.8%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.8%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease expense were as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Amortization of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,215&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information related to leases was as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="8" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,560&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,401&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,435&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,228&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 672&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,653&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 434&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Finance leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,694&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 477&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the maturities of the lease liabilities were as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31, (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&#160;leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,072&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_4-NTVWKntkKpLY2m9obR2w"
      decimals="INF"
      id="Narr_G1YBRIzRqUe5gSkuidu6HQ"
      unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A">47789</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_CorporateHeadquartersLeaseAgreementMember_4-NTVWKntkKpLY2m9obR2w"
      id="Narr_srZsoj2VtUiGUpe9TSrneg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="As_Of_10_24_2023_us-gaap_LeaseContractualTermAxis_chrs_OfficeSpaceRemainingPremisesMember_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_1ikJXPlaT0qaIZD07NCcJQ"
      decimals="INF"
      id="Narr_ON5SiDlthEOcJfNyGpeejg"
      unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A">27532</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="As_Of_10_24_2023_us-gaap_TypeOfArrangementAxis_chrs_SixthAmendmentToLeaseMember_2VupKf10C0ysFKHcmA-N7Q"
      decimals="INF"
      id="Narr_DQnzpj0fFUOIygE6a4oaSQ"
      unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A">20257</us-gaap:AreaOfLand>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_LaboratoryFacilitiesLeaseAgreementMember_eWCVJY2d0Uy0fzrMJb295g"
      decimals="INF"
      id="Narr_hjLOBKmoLECO7o8E7plOag"
      unitRef="Unit_Standard_sqft_3YSsBEhsFUiaPtdBq6sk3A">25017</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_LaboratoryFacilitiesLeaseAgreementMember_eWCVJY2d0Uy0fzrMJb295g"
      id="Narr_0X07lifBEEOr1GMSVzIYLA">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <chrs:NumberOfVehiclesLeased
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_AndqifxXsEG2Tfoo9es73w"
      decimals="INF"
      id="Narr_3K3ynSgiNkCv_seyjR3fhQ"
      unitRef="Unit_Standard_item_bE60rjgukkKNKOgiEroVbQ">50</chrs:NumberOfVehiclesLeased>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_chrs_VehiclesLeaseMember_IkAU-wbfW06hNr0VdkRc-A"
      id="Narr_wP0P4Hg0_kOCe7viS3zpJg">P36M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_yeQ14a-AbUebYmWxW8wjjg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-mf-ZxnNGEipJwEpza_71w;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other assets, non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_WgpZY07_p0GbKqCO5gEf4g;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total leased assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,274&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_liJO04hsZUOJwgNDIHYjyw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_TFQ5qkqFP0exAVaWIavjVw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ieMrVFi9_UGwUiP2AK3LZQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wCWMjCewb0K1TBEZgR53KQ;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liabilities, non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,609&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:LesseeOperatingAndFinanceLeaseDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_E0cu3cG6Zky-H5gmK1bepA_3_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5912000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_2ZvlPFqCcEez_bDqziYtCA_3_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">5690000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_UHNyhu8cyUWLSw8i4v7oyA_4_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1022000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_urrpOmnrlky8I0jesqQ9pw_4_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2584000</us-gaap:FinanceLeaseRightOfUseAsset>
    <chrs:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_Q8JDcicdNEKlajnpOzC9EA_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6934000</chrs:OperatingAndFinanceLeaseRightOfUseAssets>
    <chrs:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_0vk6u15w7Em81uv4Aajiwg_5_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8274000</chrs:OperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_kyq3fw7WUUqGM0IKdwGRlA_3_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1424000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_IU7re1Xe-0m0ehBOtzf-gg_3_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3127000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_5Xsn1QCkrE2pDk9FlaPW9A_4_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4977000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_4y73UIRG3EadMiYFbCn3MQ_4_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3628000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_HgwWdkAtAUOUFJey1bodFw_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6401000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_0T_YlMO79UyUU0jCi-Ahrw_5_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6755000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_hBKOIAyPxEOMyEglFvMFBg_7_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">721000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_1CPp94BBS0K2XCyHYnwkdQ_7_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1191000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_jdkw6GhZwEGOQ0Ztfh6J5Q_8_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">351000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_pNNpx_Bj90uFIJbuXXfjwA_8_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1418000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_0XiC4VVg50iFIg5mQ-EpHg_9_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1072000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_XZXmOF61d0KwEZALEO854A_9_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2609000</us-gaap:FinanceLeaseLiability>
    <chrs:ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_TsJztV7Zoke2gwDmUGWKUw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:28.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-Average Remaining Lease Term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.2 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-Average Discount Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11.8%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.8%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfOtherInformationRelatingToLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Narr_6qYUNB7nUkmPLsrYnW3fNw">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Narr_xcp2M-XpRU6GEnTSOT8dwA">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      id="Narr_cq4koSmbZ0qJj7jcJT0OgQ">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      id="Narr_0ZvKk9FKLUKosWNNl4coCQ">P1Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      id="Narr_ZIpav3teqECsnjUylUzYVg">P2Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      id="Narr_rivt9ypXLkS7SUY03cglJQ">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="3"
      id="Tc_QFh4c_BtXEenAz3kPIko1w_7_5"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="3"
      id="Tc_pajx0OojlEmkxAfErRKNjg_7_7"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="3"
      id="Tc_OqLky0zfuEuxUM-nVUq3Wg_7_10"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="3"
      id="Tc_0ponVVnYUEG1RQ4tiskXVA_8_5"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.087</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="3"
      id="Tc_Sgm5rSHN4E26lX53eYtwJQ_8_7"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.084</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="3"
      id="Tc_F-MwJ8dzv0C--YBYXGSLog_8_10"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.058</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_unZF7BQUr0-7rEszpGj7ZQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Amortization of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total finance lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,215&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,199&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_03NRSJ6yz06MDyAv0w78xw_4_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1069000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_f5pX2CiIckOtzMF4bU8Wbg_4_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1228000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_mFmVu-qqC0-S4MhxhRbaAA_4_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">707000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_c1d9zTUg6063HV4QwOG3ZA_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">146000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_AQW9_EVbQUWfNxtyvS1zEw_5_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">166000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_pdvz5tMdPU6GikkYPKqXJg_5_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">82000</us-gaap:FinanceLeaseInterestExpense>
    <chrs:FinanceLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_l53uXcFj3kSAWq--xx0WCQ_6_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1215000</chrs:FinanceLeaseCost>
    <chrs:FinanceLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_h6o2Qtf-REWOpvW41qiHKw_6_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1394000</chrs:FinanceLeaseCost>
    <chrs:FinanceLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_pmNIOOGfNkewaPEixUZj-g_6_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">789000</chrs:FinanceLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_ejYk46wdv0ewg-2MkrIcew_7_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2984000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_L-tZAPfuG0K8NPySjZVV5Q_7_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3154000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_PEP2fcA8lkCBy5bqDaFzuA_7_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3066000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_eFbbB-zJgES57_fFs5SbaA_8_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4199000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_kHfey-ry3kCWlIV0u8KVsQ_8_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">4548000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_dVQMdSt6VEGC8_GaNLF1fQ_8_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3855000</us-gaap:LeaseCost>
    <chrs:ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Xrby58qDbU23ncf6Tofo6w">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="8" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,560&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,401&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,435&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,228&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 672&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,653&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 434&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:51.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Finance leases&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,694&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/th&gt;&lt;th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 477&lt;/p&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfSupplementalCashFlowInformationRelatedToLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_eNN2A2x1B0awpUVXl2ZzYA_4_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3560000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_czSQLpNcQUGg3nJ4FIBqyw_4_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3401000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_mXXnvoVeEEy8dkvzJe1uBA_4_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3435000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_5cSuZpaWFU2y-xl-kN5bwQ_5_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">145000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_7ibqeuFNVUufCJ_q4zor_Q_5_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">155000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_C_oFnjsruUangTMACEktZw_5_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">81000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_G5hlRZMR40i0weqeFoIauw_6_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1034000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_--nXdiUWgEGkrL0DuYHt1A_6_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1228000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Ow0p0enxe0m07qcI_z4rhA_6_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">672000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_85tEXrTiRkaCaWAWgBFWOA_8_5"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2653000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Bhot-Y625U2IbzgFd7hI7A_8_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">434000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_zteukGf2kE62wQmzjAG1tw_9_8"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2694000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_9S_2JxAsJEuTBeP3LTcV_w_9_11"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">477000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_5L27L9GM-kyRW4GQ9h1qbg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31, (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&#160;leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,072&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_qiiJu-LIx0e99AWx11r07Q_2_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2095000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_KTsXD_0NkUmpZ111LOEXiA_2_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">781000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_YynIidtvqUO2cKBjJEuLHg_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2192000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_0vyhsPQanUiYaqI-Ub3Nvg_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">358000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_7JFWRogGJ0a5Tyjgt7bZMQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_4eFSX-iiW06BOu9_3xas_Q_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1531000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_OdOI8spsIk2U6Jr7hael7Q_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_28QP-jKUCEeV7L7OmzTgbg_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1139000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_QGgkGxVdoUyutbS9T55m-g_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1543000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_E3wVNQA8HU-kcTGfGZ1GiQ_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">67000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_2DUHNQ_i5UmHIf3zMN8_Xg_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6401000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_iFJqcjFRtU2ykfWZRvcIjg_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1072000</us-gaap:FinanceLeaseLiability>
    <chrs:StockholdersDeficitTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_j3ailpxXRUOEsewSm955tg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Stockholders&#x2019; Deficit&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Public Offering  &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On May&#160;16, 2023, the Company entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company issued and sold the Firm Shares to the Underwriters. Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, for&#160;30 days&#160;from the date of the Underwriting Agreement, to purchase the Option Shares, which the Underwriters elected to exercise in full. The price to the public in the Public Offering was $4.25&#160;per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $3.995&#160;per share.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;The Offering was made pursuant to a prospectus supplement and related prospectus filed with the SEC pursuant to the Company&#x2019;s Registration Statement under which the Company may offer and sell up to $150.0&#160;million in the aggregate of its common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings. On May&#160;18, 2023, the Company completed the sale and issuance of an aggregate of&#160;13,529,411&#160;Shares, including the exercise in full of the Underwriters&#x2019; option to purchase the Option Shares. The Company received net proceeds of approximately $53.6&#160;million, after deducting the Underwriters&#x2019; discounts and commissions and offering expenses payable by the Company.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ATM Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On November 8, 2022, the Company filed a Registration Statement. Also on November 8, 2022, the Company entered into a Sales Agreement with Cowen, pursuant to which the Company may issue and sell from time to time up to $150.0 million of its common stock through or to Cowen as the Company&#x2019;s sales agent or principal in the ATM Offering.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;On May 15, 2023, pursuant to an Amendment No. 1 to Sales Agreement and in connection with the Public Offering, the Company reduced the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $86.25&#160;million, lowering the aggregate offering price under the Sales Agreement from $150.0&#160;million to $63.75&#160;million.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;On September 11, 2023, pursuant to an Amendment No. 2 to Sales Agreement, the Company increased the number of shares that could be issued and sold pursuant to its&#160;ATM Offering with TD Cowen by $28.75&#160;million, increasing the aggregate offering price under the Sales Agreement from $63.75&#160;million to $92.5&#160;million.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;The following table summarizes information regarding settlements under the ATM Offering:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except share and per share data)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Number of common stock shares sold during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,559,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 916,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average price per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less commissions and fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (168)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net proceeds after commissions and fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;As of December 31, 2023, the Company had approximately $66.5 million of its common stock remaining available for sales under the ATM Offering. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt; &lt;/span&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock &lt;/b&gt;&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-top:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On October 9, 2023, in accordance with the terms of the Optional Stock Purchase Agreement, the Company issued&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2,225,513&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;shares of its common stock to the CMO for a price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$3.675&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per share, with a total value of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million in this non-cash transaction.&#160;The Optional Stock Purchase Agreement gave the Company the option, in its sole discretion, to elect to pay for certain manufacturing services provided by the CMO by either paying cash or a Stock Service Fee Payment. On October 4, 2023, the Company notified the CMO of its election of the Stock Service Fee Payment. The price per share of common stock was equal to the volume-weighted average closing trading price per share of common stock on the Nasdaq Global Market over the&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_I67Wh2887EWvSltZhszIEw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-trading day period ending on and including October 6, 2023.&#160;&lt;/span&gt;&lt;/p&gt;</chrs:StockholdersDeficitTextBlock>
    <chrs:SharesOfferingUnderwritersOptionTerm
      contextRef="Duration_5_16_2023_To_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_Y1Km_JnNyku-WuF69J4RdA"
      id="Narr_clnpbFcFK0OuBjvpKdXusw">P30D</chrs:SharesOfferingUnderwritersOptionTerm>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_BTKj2cvojU24AiFKRX3zBA"
      decimals="2"
      id="Narr_KU8WelX9bU6DnsX8koFtfA"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">4.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_16_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_1ztFg0EZYE-MyDgGu8F23A"
      decimals="3"
      id="Narr_tKMT5ltRHUWPwDANDeBtJg"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">3.995</us-gaap:SharesIssuedPricePerShare>
    <chrs:SharesOfferingAggregateAmount
      contextRef="As_Of_5_16_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_t94RIbg44kqe6E07Ycbe0Q"
      decimals="-5"
      id="Narr_kClT1Odxl0eJVTKX5rS0Ww"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">150000000.0</chrs:SharesOfferingAggregateAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_5VUKYAUWS0WOL1uTbEXYnw"
      decimals="INF"
      id="Narr_-a62Dz9gn0-HDaNuyHD54Q"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">13529411</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_18_2023_To_5_18_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_PublicOfferingMember_5VUKYAUWS0WOL1uTbEXYnw"
      decimals="-5"
      id="Narr_3jWZeiytFka4rZWkkwQurQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">53600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_11_8_2022_To_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_DuLOSPFfNUakKw9YrfEp6g"
      decimals="-5"
      id="Narr_FymTBJnuzkmMFTY8LDotsQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">150000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <chrs:SharesOfferingAggregateAmountDecrease
      contextRef="As_Of_5_15_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_xIobUuv7xkaTn4Q-FI1LMA"
      decimals="-4"
      id="Narr_4dbbaSxfe0-LmInJ0pu4yw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">86250000</chrs:SharesOfferingAggregateAmountDecrease>
    <chrs:SharesOfferingAggregateAmount
      contextRef="As_Of_11_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_N0EdjlOAy0Sqb92Q_d-eKA"
      decimals="-5"
      id="Narr_sr-53FiN8k-N3IpOYghghA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">150000000.0</chrs:SharesOfferingAggregateAmount>
    <chrs:SharesOfferingAggregateAmount
      contextRef="As_Of_5_15_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_f9ef-yFAYEWYmhIzUHYLVw"
      decimals="-4"
      id="Narr_R_5ocpmw6ky-WpXLunBbWg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63750000</chrs:SharesOfferingAggregateAmount>
    <chrs:IncreaseInAmountOfSharesToBeIssuedAndSold
      contextRef="Duration_9_11_2023_To_9_11_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_wNY0LcAqy0m5BY-y3yR8Yg"
      decimals="-4"
      id="Narr_YIFY5BTbskqBahaqGTIH8Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">28750000</chrs:IncreaseInAmountOfSharesToBeIssuedAndSold>
    <chrs:SharesOfferingAggregateAmount
      contextRef="As_Of_5_15_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_f9ef-yFAYEWYmhIzUHYLVw"
      decimals="-4"
      id="Narr_y_tj2lvf30KwBZvm5XYLKA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63750000</chrs:SharesOfferingAggregateAmount>
    <chrs:SharesOfferingAggregateAmount
      contextRef="As_Of_9_11_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_D_dyxc-7bk6FZ7_nraT6IQ"
      decimals="-5"
      id="Narr_ae1IDlHngUy4whTswuRNwg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">92500000</chrs:SharesOfferingAggregateAmount>
    <chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_LFw3xVJYAU-Rv9kpwMzs-w">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except share and per share data)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Number of common stock shares sold during the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,559,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 916,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average price per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less commissions and fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (168)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net proceeds after commissions and fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfSettlementsUnderSharesOfferingTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"
      decimals="INF"
      id="Tc_0vl2xA5fhkei3aThpSxvDw_3_3"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">3559761</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"
      decimals="INF"
      id="Tc_Dx4wNFpUFkOS38bBcEC0fQ_3_5"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">916884</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <chrs:WeightedAveragePricePerShare
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_rO5PqjjHM061tAOT8W_pJg"
      decimals="2"
      id="Tc_rBIq_QMJVUaPwTIzbZmElQ_4_3"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">5.43</chrs:WeightedAveragePricePerShare>
    <chrs:WeightedAveragePricePerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_n-FydJrePEuzzIDzlXSx6Q"
      decimals="2"
      id="Tc_sOZYB0HS_US1BGdBSLrHhw_4_6"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">7.30</chrs:WeightedAveragePricePerShare>
    <chrs:ProceedsFromIssuanceOfCommonStockGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"
      decimals="-3"
      id="Tc_fFVMiLddPESBzMiHUTGKAw_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19339000</chrs:ProceedsFromIssuanceOfCommonStockGross>
    <chrs:ProceedsFromIssuanceOfCommonStockGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"
      decimals="-3"
      id="Tc_IZz4B8kf40mRnqp60yLXWg_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6692000</chrs:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"
      decimals="-3"
      id="Tc_gSZsmFuYV0GzPF6051EfIQ_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">483000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"
      decimals="-3"
      id="Tc_5347coYZIk2A1YKZi5ACyQ_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">168000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_tXB053ze80a7acO6L0S1XQ"
      decimals="-3"
      id="Tc_4w9IS3bnsEW1Z7CiPGBh5w_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18856000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_QvoEU1g7SUKVcjzPYWPjGQ"
      decimals="-3"
      id="Tc_6HEpcuq_00KvNvCxIDXsiQ_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6524000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <chrs:CommonStockRemainingAvailableForSaleUnderAtmOffering
      contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_chrs_AtMarketOfferingMember_hK4XJ0wrhk2gRd8IsFyEIA"
      decimals="-5"
      id="Narr_Q94QacRlkUimnzSRb-ot4Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">66500000</chrs:CommonStockRemainingAvailableForSaleUnderAtmOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww"
      decimals="INF"
      id="Narr_smPtKbH5gUSVAkSL70VxvQ"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2225513</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_bovPFj58gkCF6OVAq9cZrg"
      decimals="3"
      id="Narr_9w9tVB4qg02gLpj38DaQXA"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">3.675</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_10_9_2023_To_10_9_2023_srt_TitleOfIndividualAxis_chrs_ChiefMarketingOfficerMember_us-gaap_TypeOfArrangementAxis_chrs_OptionalStockPurchaseAgreementMember_2COTFZ1VFU61nyxr43OFww"
      decimals="-5"
      id="Narr_lWdideQVm06VN9oRIC8nsQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_COM0rWdBxUeYAqBG44Z5vQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;12.&lt;/b&gt;&lt;/span&gt;Stock-Based Compensation and Employee Benefits&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2014, the Company&#x2019;s board of directors and its stockholders adopted the 2014 Equity Incentive Plan, which became effective upon the closing of the Company&#x2019;s IPO on November&#160;6,&#160;2014. The 2014 Plan is subject to automatic annual increases in the number of shares available for issuance on the first business day of each fiscal&#160;year equal to four&#160;percent (4%)&#160;of the number of shares of the Company&#x2019;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#x2019;s board of directors with 2024 being the last calendar year with an automatic annual increase under the 2014 Plan. All remaining shares under the Company&#x2019;s 2010 Stock Plan (the &#x201c;2010 Plan&#x201d;) were transferred to the 2014 Plan upon adoption and any additional shares that would otherwise return to the 2010 Plan as a result of forfeiture, termination or expiration of the awards will return to the 2014 Plan. The 2014 Plan provided for the Company to grant shares and/or options to purchase shares of common stock to employees, directors, consultants and other service providers. While the 2014 Plan allows for non-qualified or incentive stock options, primarily all option grants made since June 2016 have been for non-qualified stock options. Under the 2010 Plan, no awards have been issued since 2014, and there were no shares of common stock available for future issuance as of December 31, 2023. There were 881,231 shares of common stock available for future issuance as of December 31, 2023 under the 2014 Plan.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the Company adopted the 2016 Employment Commencement Incentive Plan. The 2016 Plan is designed to comply with the inducement exemption contained in Nasdaq&#x2019;s Rule&#160;5635(c)(4), which provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, performance awards, dividend equivalents, deferred stock awards, deferred stock units, stock payment and stock appreciation rights to a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual&#x2019;s entering into employment with the Company. As of December&#160;31, 2023, the Company had 1,773,921 shares of common stock available for future issuance for new employees. The 2016 Plan does not provide for any annual increases in the number of shares available.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock option exercises are settled with common stock from the plans&#x2019; previously authorized and available pool of shares. If any shares subject to an award granted under the 2014 Plan or the 2016 Plan expire or become forfeited or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool. The annual grant to eligible employees can vary depending on the type of award, and the award size is determined by the employee&#x2019;s grade level.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Incentive stock options and non-statutory stock options may be granted with exercise prices of not less than the fair value of the common stock on the date of grant. These stock options generally vest over four years, expire in ten years from the date of grant and are generally exercisable after vesting.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the summary of option activities under the 2016 Plan and the 2014 Plan:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Terms&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,691,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted - at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,947,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (430,504)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited/Canceled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,549,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,659,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,279,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Aggregate intrinsic value represents the value of the Company&#x2019;s closing stock price on the last trading day of the year in excess of the exercise price multiplied by the number of options outstanding or exercisable.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Information on options outstanding and exercisable as of December&#160;31, 2023 is summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:42.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Terms&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of Exercise Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,288,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,356,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,493,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,436,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.45&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,143,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,317,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,436,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,304,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,827,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,403,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,469,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,461,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,659,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,279,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Additional information on options is summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except weighted-average grant-date fair value per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total intrinsic value of options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant date fair value of options vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average grant date fair value per share of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, total unrecognized stock-based compensation expense related to unvested stock options was $37.4 million, which is expected to be recognized over a weighted-average period of 2.3 years.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants RSUs primarily to its employees. RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#x2019;s common stock upon vesting. The RSUs cannot be transferred and are subject to forfeiture if the holder&#x2019;s employment terminates prior to the release of the vesting restrictions. The Company&#x2019;s RSUs generally vest over &lt;span style="-sec-ix-hidden:Hidden_AKrDviHwTEWrO6-oIS4MzA;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to three years from the applicable grant date, provided the employee remains continuously employed with the Company. The estimated fair value of RSUs is based on the closing price of the Company&#x2019;s common stock on the grant date.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the summary of RSUs activity, under the 2014 Plan:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSUs&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Balances at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,333,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;RSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,274,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;RSUs vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,280,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;RSUs canceled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (600,430)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Balances at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,726,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Additional information on RSUs is summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except weighted-average grant-date fair value per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant date fair value of RSUs vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant date fair value of RSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average grant-date fair value per share of RSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, total unrecognized stock-based compensation expense related to unvested RSUs was $10.8 million, which is expected to be recognized over a weighted-average period of 1.5 years.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2014, the Company&#x2019;s board of directors and its stockholders approved the establishment of the ESPP. The ESPP provides for annual increases in the number of shares available for issuance on the first business day of each fiscal&#160;year equal to the lesser of one&#160;percent (1%) of the number of shares of the Company&#x2019;s common stock outstanding as of such date or a number of shares as determined by the Company&#x2019;s board of directors. The ESPP had 2,541,769 shares of common stock available for future issuance as of December&#160;31, 2023. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of the Company&#x2019;s common stock on the first or last day of the offering period. The offering periods of the ESPP are on &lt;span style="-sec-ix-hidden:Hidden_VnDr0p6zgkaCQAXWjop8Wg;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;May&#160;16&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_y3PMsjUAX0CNLgPeFQI8aw;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;November&#160;16&lt;/span&gt;&lt;/span&gt;. As of December&#160;31, 2023, there was $0.4 million of unrecognized compensation expense associated with the ESPP, which is expected to be recognized over an estimated weighted-average period of 4.5 months.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the classification of stock-based compensation expense in the Company&#x2019;s consolidated statements of operations related to employees and nonemployees:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,099&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,688&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,364&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock-based compensation expense capitalized into inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,187&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The stock-based compensation for the year ended December 31, 2023 includes restructuring charges described in Note 15 of $1.1&#160;million in research and development expense and a net forfeiture credit of $0.1&#160;million in selling, general and administrative expense.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The stock-based compensation expense recorded in connection with the Surface Acquisition that was not included in the consideration transferred was immaterial.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Valuation Assumptions of Awards Granted to Employees&lt;b style="color:#ff0000;font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of each stock option and awards granted under the ESPP on the date of grant using the Black-Scholes option-pricing model. The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of the awards during the&#160;years ended December 31, 2023, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term: &lt;/i&gt;The expected term represents the period for which the stock-based awards are expected to be outstanding and is based on the options&#x2019; vesting term and contractual term. Since January 1, 2021, the Company has used historical data to calculate the expected term.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility: &lt;/i&gt;The expected volatility is calculated based on the Company&#x2019;s daily stock closing prices for a period equal to the expected life of the award. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate: &lt;/i&gt;The risk-free interest rate is based on the United States Treasury constant maturity rate at the time of grant using a term equal to the expected life.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividends: &lt;/i&gt;The Company has not paid and does not anticipate paying any dividends in the near future, and therefore used an expected dividend yield of zero in the valuation model.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;401(k)&#160;Retirement Plan &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;In 2019, the Company&#x2019;s Compensation Committee approved the Company&#x2019;s matching of the employees&#160;401(k)&#160;Plan whereby eligible employees may elect to contribute up to the lesser of&#160;90% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. Beginning January 1, 2021, the Company made matching contributions of 100% of the first 4% of eligible compensation, up to a maximum of $7,500. The Company recorded compensation expense related to the match of $1.8 million, $2.1 million and $1.7&#160;million in 2023, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <chrs:RateOfIncreaseInNumberOfCommonStockAvailableForIssuance
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_7crZcL4mN0ypA7JbGnmqqA"
      decimals="2"
      id="Narr_HWEi-dUt1UufrkyRMuuV5Q"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.04</chrs:RateOfIncreaseInNumberOfCommonStockAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2014_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_9Fk-bFLoyEefRodmTzt7Qw"
      decimals="0"
      id="Narr_TqshrS0P6kK8fBkCNrACsw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandTenPlanMember_5TOTwxrkukmWntYx2iyH2g"
      decimals="0"
      id="Narr_PWfaudQSnEK1EchGwub9Sw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEquityIncentiveAwardPlanMember_Hh7T20nqkUe4hvfBDJLy5A"
      decimals="INF"
      id="Narr_s7OJNV_K2keuln-TWTwLHQ"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">881231</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EmploymentCommencementIncentivePlanMember_PYQsmuC8gEmAkSzwx_wKQg"
      decimals="INF"
      id="Narr_wFn8DdLfZ0OdXQTL1A3kLg"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1773921</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ"
      id="Narr_ahD7R902V0CUv6tp7i0KZg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ"
      id="Narr_4mJJLSwH3kqEvpmlNWOo_A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_5oP-UTk6mEOWltiH_rD52Q">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Terms&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,691,321&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted - at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,947,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (430,504)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited/Canceled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,549,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,659,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,279,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A"
      decimals="INF"
      id="Tc_79jf7MP140i3lgc8RT2n0w_7_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">21691321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_JO_0vPTZdUOHBfJ6RknE8A"
      decimals="2"
      id="Tc_TIFJVJYXo0KCesdcVi3Ghw_7_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">15.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="INF"
      id="Tc_0L9lm3isBkKAb28WjCphcQ_8_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">5947607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="2"
      id="Tc_FcpTIQdbCUOsOnh1eZ-AvA_8_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">6.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="INF"
      id="Tc_EOqzHJl4Y0W5sbAeFBx1RQ_9_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">430504</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="2"
      id="Tc_jfOrWYuj_UmN6kQcIZJOkA_9_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">1.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="INF"
      id="Tc_w-ZUCEAv40myYMoIPXojcw_10_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">3549184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="2"
      id="Tc_3N7uqOfNDUmS_7_qoolZxQ_10_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">14.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="INF"
      id="Tc_kpf4rxkygEiFWXQBDVajDg_11_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">23659240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="2"
      id="Tc_jzVzmeJijUCETlgGpEmUhA_11_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">13.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      id="Tc_FpHbOQc9Kki0fvtyvx0ERg_11_7">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="-3"
      id="Tc_VEhYPfUnaUWJV_NBdklSRA_11_10"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2337000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="INF"
      id="Tc_-JYj3Q-7rUCtYj_XhlI5Vw_12_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">16279679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="2"
      id="Tc_wSjGmJZC8kqjJa1dT7WXpg_12_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      id="Tc_uBcUhsg2f0Kr8j5T9mnQqw_12_7">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="-3"
      id="Tc_Doomx5Mms06O1Q-zje_9Cg_12_10"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1815000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_GdddJFxLvk-slm4v3Fn14g">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Information on options outstanding and exercisable as of December&#160;31, 2023 is summarized as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:42.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Terms&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of Exercise Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,288,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,356,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.32&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,493,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,436,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.45&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,143,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,317,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,436,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,304,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,827,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,403,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,469,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,461,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,659,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,279,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg"
      decimals="2"
      id="Tc_mpziosAu40-Nkyimg4HXEg_7_1"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">1.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg"
      decimals="2"
      id="Tc_NnH9FNYHoU6gWEAnvoB_3A_7_4"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">5.44</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A"
      decimals="INF"
      id="Tc_rNbnsIfgpk6Y0c9A419AAA_7_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">4288840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_nXU3FZnIxE2SLT7Xhj7Sdg"
      id="Tc_CFEjMuDq9kWqMIuhOBx0uA_7_8">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A"
      decimals="2"
      id="Tc_tQLrjJZEYkafue92uCK2tw_7_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A"
      decimals="INF"
      id="Tc_edK74OY260C4qIcsGZbYvw_7_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1356589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange1.67To5.44Member_QBbVthFAn0eDofsFayy91A"
      decimals="2"
      id="Tc_dNbcFtMxDU20QsOiWoDXGA_7_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">2.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A"
      decimals="2"
      id="Tc__rmAxzSXckKhASA6_PgP7w_8_1"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">5.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A"
      decimals="2"
      id="Tc_M-Anfoz1B0iCesfDNk5UqA_8_4"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">10.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w"
      decimals="INF"
      id="Tc_yTPdNwypvUunmuV_lZQl4w_8_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">4493996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_U8Rw_6Ax-EODg6nIHz0a-A"
      id="Tc_JzepPIINFk-JUtXdShGwDg_8_8">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w"
      decimals="2"
      id="Tc_QKG09-dxfU6uGHiLHzoq7A_8_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">9.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w"
      decimals="INF"
      id="Tc_iEcNQ4iJCUCrGowWKqxDLA_8_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2436570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange5.86To10.05Member_aulCv_OcsUapcITxPknh9w"
      decimals="2"
      id="Tc_3mseEavT-0eBbh0VQ6JuJA_8_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">9.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA"
      decimals="2"
      id="Tc_7jB-KYQie0Cxp4wst8kXWw_9_1"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">10.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA"
      decimals="2"
      id="Tc_fs4dBBbMh0-aF_wZ5KjHzQ_9_4"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">13.63</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA"
      decimals="INF"
      id="Tc_dSPS-MKZrkmicHkkYsDKiQ_9_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">4143765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_QXIkzJqgk025iWtwxpxKDA"
      id="Tc_doDx4x9mYEWHe-w_960P8A_9_8">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA"
      decimals="2"
      id="Tc_GhWvbejMEkiry26grUrwoA_9_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">12.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA"
      decimals="INF"
      id="Tc_zv32kBSNDEilU0PJrwOLtQ_9_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">3317635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange10.37To13.63Member_LV8NesdKp0uoKuz6tsD8gA"
      decimals="2"
      id="Tc__tnKZxc48ESCpml320039w_9_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">12.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA"
      decimals="2"
      id="Tc_djNXWOomfUKGQMfMBwr1Tw_10_1"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">14.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA"
      decimals="2"
      id="Tc_Yb8aqvyf5keOkjWqZ_HUaQ_10_4"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">17.17</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw"
      decimals="INF"
      id="Tc_UXgiLyC-5EGFaQ1_-viU1Q_10_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">4436113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_JVXED8Y_BkSJs5SObp5nTA"
      id="Tc_R4FsPUTQhE6bb2azJXJBjg_10_8">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw"
      decimals="2"
      id="Tc_Urhe4Oih_UOOhA1Wrt0Vtw_10_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">15.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw"
      decimals="INF"
      id="Tc_twzBWCoSz0uSE4u9nZMf1w_10_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">3304217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange14.03To17.17Member_SWWmfKmL2k6sJreD995UYw"
      decimals="2"
      id="Tc_WetYuo3FXkyrnCCHx8FN0w_10_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">15.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q"
      decimals="2"
      id="Tc_KyJKwlBQDEK23jB_stFA2A_11_1"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">17.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q"
      decimals="2"
      id="Tc_s5ouM9Zu1EGvaX4q_B2UVg_11_4"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">19.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg"
      decimals="INF"
      id="Tc_E01b-3pq3kmY6VAo95YuKQ_11_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">3827172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_oT2XG3V0nEWFXphPaI_k8Q"
      id="Tc_-R6eyKOuoECLdAyw6BbLmA_11_8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg"
      decimals="2"
      id="Tc_SysuWi23i0GJMvDTzjRRGg_11_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">17.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg"
      decimals="INF"
      id="Tc_C-T2DRjtRUiwY87scGu1Zw_11_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">3403068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange17.30To19.40Member_gw3uuMIas0Cihyj39xwiCg"
      decimals="2"
      id="Tc_A2hLlbw02UiP4BwlA-dtEA_11_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">17.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ"
      decimals="2"
      id="Tc_uyO0qchhN0-Tw4dIiS5DvQ_12_1"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">19.85</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ"
      decimals="2"
      id="Tc_pIjpJuJLGEqzAUZzGNcCjw_12_4"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">46.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ"
      decimals="INF"
      id="Tc_9VmTBdKwI0ucKOmCw1m4Ag_12_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2469354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_SKOp4_gxCkuePYYnbj7AZQ"
      id="Tc_Ck1TAXDXtUCgGSif7XrqcA_12_8">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ"
      decimals="2"
      id="Tc_zkel-U6Yf0SFk9WNkb3LHw_12_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">26.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ"
      decimals="INF"
      id="Tc_JmxqPr9bBU-5mvS3BqWXmg_12_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2461600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_chrs_ExercisePriceRange19.85To46.38Member_D2H92im2sUG7zsEdxiEoPQ"
      decimals="2"
      id="Tc_G9rmDL947kSzOOc-9V5J9A_12_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">26.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="INF"
      id="Tc_-47NzdNRdUmfQXvUPxq4Sg_13_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">23659240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      id="Tc_FG68CS3yP0eg6xtVho7h2w_13_8">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="2"
      id="Tc_51d0Lu08KUaYaGv0sYuDUw_13_11"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">13.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="INF"
      id="Tc_UM8LCdLcc02UJQWoeJpSGA_13_13"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">16279679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember__OStAE2lh06MNFhXamUyzQ"
      decimals="2"
      id="Tc_ffSlroOwakyGCiPEtRGAfA_13_16"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <chrs:ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Ir0s1vt5b02LRJ7gLIxWrQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except weighted-average grant-date fair value per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total intrinsic value of options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant date fair value of options vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average grant date fair value per share of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chrs:ScheduleOfShareBasedPaymentAwardStockOptionsWeightedAverageInformationTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="-3"
      id="Tc_lW2kCcn-kEqRX1akvFTn4A_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q"
      decimals="-3"
      id="Tc_kZ5joux6nE2w7sQPzpaPbg_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">914000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg"
      decimals="-3"
      id="Tc_8cK3vn8_zEukSyfbWjzkOQ_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">9726000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="-3"
      id="Tc_ZvWk4WI70EOM7egYVupO3g_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">30467000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q"
      decimals="-3"
      id="Tc_a1UH0VLcHECLn-g-4e1QKg_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">34916000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg"
      decimals="-3"
      id="Tc_-2fZP7daAE6Y6-H_jR5PnQ_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">40365000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_INTNKOY8fUyPNJNJsoLzKQ"
      decimals="2"
      id="Tc_NOHvrxgZ9E6TOGwEfEcH0w_5_3"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_1bjUOrIC90iBhiOmLmte6Q"
      decimals="2"
      id="Tc_7kpUPb_KoUqWpsCurKQ-gw_5_6"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">7.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_EquityPlan2016PlanAnd2014PlanMember_ipgu78sH30aVNNGB4uzyFg"
      decimals="2"
      id="Tc_ab31qecE7021vJUPVhRoLw_5_9"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">9.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_Nms7y8PHtUuzUD__ZMwq1g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">37400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Narr_yafBzMQkG0GR7CMxvilzlA">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZaEeUbUKZ0m5v1ED2M0RTA"
      id="Narr_ULgmyMRl0Eixc5xDBsFOFQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Group_O05y5bB3A0-cvDDfX2duLw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSUs&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Balances at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,333,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;RSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,274,753&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;RSUs vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,280,901)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;RSUs canceled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (600,430)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Balances at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,726,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except weighted-average grant-date fair value per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant date fair value of RSUs vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant date fair value of RSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,386&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average grant-date fair value per share of RSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.86&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg"
      decimals="INF"
      id="Tc_HRPY2CuBBUil2thPMWQoWA_5_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2333307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bGFJ6iJGZEubfp010FpARg"
      decimals="2"
      id="Tc_1N3ascPjfEK0ZUNYHYU-MA_5_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">14.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="INF"
      id="Tc_QcfGVkRX30W_9Y3DKtZrpQ_6_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1274753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="2"
      id="Tc_fSYwir6MN0WJdwRbeOqzFQ_6_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">8.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="INF"
      id="Tc_7tosUKSG50iZMQZgb8WuIg_7_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1280901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="2"
      id="Tc_Bc_gh4rhh0WBej23j3DI5w_7_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">14.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="INF"
      id="Tc_Ipk0fkJjIU6xr5QBrOAePA_8_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">600430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="2"
      id="Tc_NmvV2wGUm0eGDUcLeMZuEA_8_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">11.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA"
      decimals="INF"
      id="Tc_z55qAjKQ4UCOtKyxIQi_PQ_9_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1726729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA"
      decimals="2"
      id="Tc_tCcCSoo_7kKLxj_zepekow_9_5"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">11.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="-3"
      id="Tc_cUVB9Snas0K_VpWZL9ty0Q_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18381000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g"
      decimals="-3"
      id="Tc_vSbr-1ffMUm6CsFA_ZTtMA_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13598000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA"
      decimals="-3"
      id="Tc_ql5a_RT5EEuhBFK6C0jXZQ_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">8434000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="-3"
      id="Tc_WtCVsO1L6UCc4mEK9-advQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">11386000</chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue>
    <chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g"
      decimals="-3"
      id="Tc_GtTtZx8VeUaE7FGM0Sudag_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">22502000</chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue>
    <chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA"
      decimals="-3"
      id="Tc_ehe9p-4-7ka-YMbJbxRDAQ_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">27869000</chrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodEstimatedGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      decimals="2"
      id="Tc_7n3DPcV3nki0yG8EmS-NDA_5_3"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">8.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UPBAfbsddUyCqlLJB9Jp0g"
      decimals="2"
      id="Tc_ZqMpzgYuQ0yr0FhK__GlPQ_5_6"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">13.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lOqku7su4Eyh2AGPdLvcEA"
      decimals="2"
      id="Tc_vSwzjNXAPEirIGrrsUPIGg_5_9"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">16.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Bsz9-YRBxEC-lJXj2d6VNA"
      decimals="-5"
      id="Narr_aMwjkOgCDk6T9W3Qk4N54Q"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">10800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_iU1JCiD6b06IG5pkYwKA4g"
      id="Narr_Zwm_bONmeUum6vu4tSRuiA">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <chrs:RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance
      contextRef="Duration_10_31_2014_To_10_31_2014_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_Y3ICWQYaSEa4JfXz8gYGiQ"
      decimals="2"
      id="Narr_3SvIxvC4y0io28e2Qkj4ZQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.01</chrs:RateOfIncreaseInNumberOfCommonStockOutstandingReserveForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g"
      decimals="INF"
      id="Narr_P0nsKUTu1ESDW7kPniTMTw"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2541769</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg"
      decimals="2"
      id="Narr_vNRcjLnu3UGpHYvMyosgoQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_KubzRY_GBEWMVWbW74ng9g"
      decimals="-5"
      id="Narr_Nk2lU-hUBEeNjbT_R5_2QA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg"
      id="Narr_4oCf78x9CEKcAlwlXLnMCA">P4M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_9_Lc7Swh-EqOZ7QhB29W4g">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 736&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,099&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,688&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,577&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,364&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock-based compensation expense capitalized into inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,187&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Stock-based compensation capitalized into inventory is recognized as cost of goods sold when the related product is sold.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LSAmuuDKZ0ufKpGp1XLrHA"
      decimals="-3"
      id="Tc_XMbrH6JTt0C2lK2IbdxkqA_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">632000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_yPWVLupjLUC-LrZ0QvW9YA"
      decimals="-3"
      id="Tc_SwFPg1Q9m0ydX_1EnHDMaQ_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">736000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_i6sG_wGq0kGSogKwmLXRFg"
      decimals="-3"
      id="Tc_QooXm4GBDEi0pYHGoPUQqw_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wrjDrMYWnEG3vQ3_hGdwAw"
      decimals="-3"
      id="Tc_S6RQ2UJlzkqgQx7b7OjGrQ_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">14596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rdMdgsUj7kOwcgAE94-32g"
      decimals="-3"
      id="Tc_oFl_QJ1-10uyAKAyNVDmIg_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Lv-W7pNdHEiIdf02okAMpQ"
      decimals="-3"
      id="Tc_vlurBlj5wEiJ4y_uphArEw_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">18688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jItQvbGTK0Sy8MYmJwHtDw"
      decimals="-3"
      id="Tc_cvj3VpmHfk-9gNgmTClF-A_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">27882000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_V7Ntz2koqkOY3qfjC84Z6A"
      decimals="-3"
      id="Tc_TtXv7k0r0kaetVfrhqIT-A_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">31002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_X4a12fHdGkKcfkBHCiHSBA"
      decimals="-3"
      id="Tc_Er_h7m-VcE2GLYjXKK_FqQ_6_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">31577000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_n-5BhGCImk-NJFttNlHmcA_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">43110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_d07-i0lz7kqo9Ew-fMnuHA_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">50737000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_EWbWKmK3M0qp5t-83_IdgA_7_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_BqkaWa80H0aUpeWNTP7vOg_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1062000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_srqwsum_GUaB7z3fWZJFrg_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1187000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_-_O8MnufV0q-D5-JQrvkyg_9_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1025000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_PdGnVstbm0yndk6laylDZQ"
      decimals="-5"
      id="Narr_TpTCVSn4xEGs7sOX1PQn8w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <chrs:ShareBasedPaymentArrangementForfeitureCredit
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IQec6wbqNkyXTV-ONWSp-g"
      decimals="-5"
      id="Narr_Vr5NLv-DCUmGjchpLJqZ1w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">100000</chrs:ShareBasedPaymentArrangementForfeitureCredit>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Y45Aq82Jx02ORrlaALyfEQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ"
      id="Tc_A5RPhIW44EyyntZqus5xww_4_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw"
      id="Tc_OgnBrSbosE2Aict459OVkA_4_4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA"
      id="Tc_EEgB6I1dhUmkaNSIlpuuFA_4_6">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg"
      id="Tc_99cId7PsxU-ethwwxR4o5w_5_2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ"
      id="Tc_EI9Qe0mU50q_3zte7_EYww_5_4">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g"
      id="Tc_Rumpuzyz4UGWbvMXhvlXWA_5_6">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ"
      decimals="2"
      id="Tc_YFLDwK5SAUG1JBVpgwT5dg_7_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw"
      decimals="2"
      id="Tc_vyvDxHweHUaRixAqHzVVxg_7_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA"
      decimals="2"
      id="Tc_U8iDmYo8oUmfZpidgX_P0A_7_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg"
      decimals="2"
      id="Tc_ZY94RjWh0U6zPIj_h_b4qA_8_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ"
      decimals="2"
      id="Tc_1g9lkZRddkWdvUWx7KUzRA_8_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g"
      decimals="2"
      id="Tc_cb6ZSnIjRUyacMp7S9y7Kw_8_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_fOI697rLLU6uvonItQg8nQ"
      decimals="4"
      id="Tc_82QpjOJLY0K6ROUZyaBM6w_10_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YX0OYR7cEkeDpkZrXmt8cw"
      decimals="4"
      id="Tc_MrL2WezzpkSyafBqgQQMKA_10_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tYnb39nnYke4BR9M568AzA"
      decimals="4"
      id="Tc_mxunIZBUb0yVomCS3E2Org_10_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_HHPq9QDHNE2KNcQBtavbrg"
      decimals="4"
      id="Tc_Qny2lADHbkmUQVZ7LxULYg_11_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_65J5KnqFFkWtlP8xUs9oaQ"
      decimals="4"
      id="Tc_a0sAMFNGmU-YSGaFaoquCw_11_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_bAoIc9DRfk6o341QVOSx5g"
      decimals="4"
      id="Tc_SB0t8YakTkqvjRZPFBt2WA_11_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.0006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="2"
      id="Narr_y-D3rN7e8k25U0mnRZjvqw"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_s5c_u_nwN0uYnEawr_ZR3A"
      decimals="INF"
      id="Narr_TOh3kDFLLkq6WI1_4hsAHQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw"
      decimals="INF"
      id="Narr_OyFP1Z_MlUylfCLom3PtlQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_chrs_Plan401KMember_fo0yiw1iyUiG0i_wC4e7wg"
      decimals="INF"
      id="Narr_oBDZjdLSM0mfu5Mdhz-NFQ"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw"
      decimals="0"
      id="Narr_olJuRbSk30m5yrswpWCbjQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_chrs_Plan401KMember_GZqVTPVTJESoNA_KLec_Tg"
      decimals="-5"
      id="Narr_kIPrv64o402seZG5t4vBBg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_chrs_Plan401KMember_vkpLaKLvgkiXZssii_XeDQ"
      decimals="-5"
      id="Narr_mttle6d5NkKraTDy6uFIbQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_chrs_Plan401KMember_-xFpBPbxTEufMGxqr-oMgw"
      decimals="-5"
      id="Narr_lNjCDd30AUOs6J6vHJl6RQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_DALK5EgAxUyM0MePQZf2tg">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;13.&lt;/b&gt;&lt;/span&gt;Income Taxes &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of loss before income taxes are as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (238,272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (291,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,058)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (238,272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (291,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,100)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;For the periods presented, the income tax provision (benefit) is as follows:&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Current: &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Income tax provision (benefit) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There was no income tax provision in 2022 and 2021 due to the Company&#x2019;s history of losses and valuation of allowances against the deferred tax assets. &#160;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;A reconciliation of the statutory United States federal rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Percent of pre-tax income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;United States federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign rate differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;The components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2023 and 2022 consist of the following:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,561&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,480&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,717&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340,279&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,538)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,903)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (603)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,941)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,506)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 422,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 337,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (423,385)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (337,773)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,102)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The tax benefit of net operating losses, temporary differences and credit carry forwards is recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its federal net deferred tax assets and certain state net deferred tax assets will not be realized, and therefore, the Company has offset the federal and certain state net deferred tax assets by a valuation allowance as of December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation allowance increased by $85.6 million, $64.4 million and $72.4 million during the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had net operating loss carryforwards for federal income of $774.9 million, which will start to expire in the year 2036, and various states net operating loss carryforwards of $128.0 million, which have various expiration dates beginning in 2031.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2023, the Company had federal research and development credit carryforwards for federal income tax purposes of $60.6 million, which will start to expire in the year 2031, and state research and development credit carryforwards of $26.5 million, which have no expiration date. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Utilization of the net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of certain net operating loss and tax credit carryforwards before their utilization. Under the new enacted tax law, the carry forward period of net operating losses generated from 2018 forward is indefinite. However, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. The Company files income tax returns in the United States federal jurisdiction, various United States state jurisdictions, and a foreign jurisdiction with varying statutes of limitations. The tax&#160;years from inception in 2011 forward remain open to examination due to the carryover of unused net operating losses and tax credits. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits during 2023, 2022 and 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additions based on tax positions related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additions (reductions) for tax positions of prior years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31, 2023, 2022 and 2021, the Company had $17.4 million, $16.8 million and $15.5 million, respectively, of unrecognized benefits, none of which would currently affect the Company&#x2019;s effective tax rate if recognized due to the Company&#x2019;s deferred tax assets being fully offset by a valuation allowance.&#160;During 2023, 2022 and 2021, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate a material adjustment of unrecognized tax benefits during the next twelve&#160;months from the balance sheet date as reductions for tax positions of prior years.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_H-5GT8O0ukmX1FhqwCp_BA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (238,272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (291,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,058)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (238,272)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (291,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,100)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_LbXp_d2AckKlHs6BSpSJ6Q_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-238272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_VBSA7-WN0U6ANvKZWDiQvg_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291746000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Ouu63YFjUE28uYmSruUQ7g_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_-TZGQBLFokSoJj5ey4Sd-w_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-8000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_Zwg6WWFRbUKQ8Gh9d7xynA_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-42000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_nqIaFVb3x0uTV5OCs-r0Rg_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-238272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_R1fVgrRXEkKuIgroBUdllQ_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-291754000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_7TNOqmEHvUydbOlJMzsF2A_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-287100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_jPDGFyF-C0yqq2Q-ncW-Ug">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Current: &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Income tax provision (benefit) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (380)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_U2SSzJzHxkGeEq1DyCpCPg_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-380000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_MR38Z_h7q06HdyE1Tmm6_w_13_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-380000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_xxOylnn_YUy0H-AlN0gwMQ_15_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">-380000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-5"
      id="Narr_DCg0IU_TC0qgztPI1UIhMw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-5"
      id="Narr_HgiLWUNDk0Ww8MbLLw-Mvg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_fM49CenuR0SW7ntiGxtKyQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Percent of pre-tax income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;United States federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign rate differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_wfYH7FwCgUq8WeD3l9nIPw_4_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="3"
      id="Tc_OgbvNa4HqkWeV-DfyTDc_Q_4_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="3"
      id="Tc_JnzBWq5INEyuIHms_v86xw_4_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_c7F3AUf9U0Gn9xHR1THTbA_5_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="3"
      id="Tc_eKDlPwDHjkS5uUcqD42esg_5_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="3"
      id="Tc_DI9albhwXU2ouKL0gb35pg_5_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <chrs:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="3"
      id="Tc_Aoc_o1q5Eke4cK0hGYpckQ_7_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.001</chrs:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <chrs:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="3"
      id="Tc_1VtEn9Oh2kqQ3147LjpQhA_7_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.002</chrs:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_gfV-4ONh3kW7nvmVsbczQw_8_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.009</chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch>
    <chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="3"
      id="Tc_cb2ZZLCusEK6EM5yfjCaCQ_8_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.018</chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch>
    <chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="3"
      id="Tc_VQ0boQjp9ECpWT4Kl0zxTQ_8_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.026</chrs:EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_7tEC0e3flEm-TBGM0Uc2Ew_9_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="3"
      id="Tc_xslexinvy0SNpVOSTCaFXg_9_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="3"
      id="Tc_3zrMLvsw_U24A4Z7RaThLw_9_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_LCF9P32mR06MM26tasHauA_10_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_5co4Z1wYYUu-c46ZzhtheQ_11_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.177</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="3"
      id="Tc_PuWUhZXSVUqdUiQwUtF1jg_11_4"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.221</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="3"
      id="Tc_CbRuODScpkC7wCT4tbMIfQ_11_6"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">-0.252</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="3"
      id="Tc_gk8fTFPWnku_7vzoDjbiVw_12_2"
      unitRef="Unit_Standard_pure_-7u9wcYtrkOwxRcBr7ttOA">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_Ete_Y0a0fEefgpKU1HaviA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63,164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,561&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales related accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,480&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,717&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 340,279&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,538)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,903)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (603)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,941)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,506)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 422,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 337,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (423,385)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (337,773)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,102)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_QJrImlLFiEm9eHO6kpS5Dg_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">170402000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_Pxqv5Rb6DUCCkmxvq3ZXcw_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">131423000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_gZo65qfgMk-MiremWfhBfg_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">65225000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_44N9zfvhv0GScCOQoPw4mQ_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">63164000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_MeCnMbwEgkeY3wzNLa167g_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">37211000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_2ZTPYxNk-k-gP_nKm7Qdng_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">51877000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_ngRdSILoS0Cszapk76KotA_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">30370000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_LHDymo8GoUSYWL2JHSysPg_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">32561000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_-0yFGZkAu0q0Y7yWAINigg_7_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">38474000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_CuKrgMxQ2kOZAWEkrrAR2Q_7_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">23864000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_atM7nC-JREqU3R5uBmKoTA_8_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">42480000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_BS3Hj5KW4UyxJtCDbL83Lg_8_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">19717000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_5sQ44RK5Y0i-nCwV3oIKag_9_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">46062000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_RrKGFY-5nEa6dhJdTTJG_A_9_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17673000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_6BRjSWOkdECd3xhEz4vPKA_10_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">430224000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_JkP_vOWfQU6YtuecMIPk9w_10_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">340279000</us-gaap:DeferredTaxAssetsGross>
    <chrs:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_zhZ1YJLMIky9-kUwessKpQ_11_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1538000</chrs:DeferredTaxLiabilitiesRightOfUseAsset>
    <chrs:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_-KIJBKgoPUa2FR6gPbBNhQ_11_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1903000</chrs:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_lAv2E2RoYU-k3QYOu4A3Lg_12_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6403000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_k1Gc0XVMZEGoW_cgL-7CQw_12_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">603000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_9S8H8Hoq5Uebf2JkNzBCzQ_13_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">7941000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_lORRPNXYJ0Gx1uld0TsJrQ_13_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2506000</us-gaap:DeferredIncomeTaxLiabilities>
    <chrs:DeferredTaxAssetLiabilityNet
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_tiFMRy9G7UKGP4GINcioOA_14_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">422283000</chrs:DeferredTaxAssetLiabilityNet>
    <chrs:DeferredTaxAssetLiabilityNet
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_IOay5U-fi0K_m06UHfVtDA_14_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">337773000</chrs:DeferredTaxAssetLiabilityNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_mM_9gid370CFInQKsFrI9A_15_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">423385000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_-tQJG2ZBgkusx0VaeOIIvA_15_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">337773000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_pb4zL022cUSQGVnRP5KfeA_16_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1102000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-5"
      id="Narr_lsMsSU1eiEyjepGfKzaifQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">85600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-5"
      id="Narr_wzS1FyoG90OxboJD_qbekA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">64400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-5"
      id="Narr__220Vv3mfE2jT7ldxpxW6A"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">72400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6Pnm4g_v2k6bFQvlK9UGDA"
      decimals="-5"
      id="Narr_J2sesIY_wUeCUzPguh866g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">774900000</us-gaap:OperatingLossCarryforwards>
    <chrs:OperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_Mozz1GcMBEOZ4p50-Yzzeg"
      id="Narr_Yes1_pLSUE6jbYjjzK-iMA">2036</chrs:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_S-PFsrc-YEyD32_Z5ut0iQ"
      decimals="-5"
      id="Narr_-l6fF0ZueEWlB0nhTCQAnA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">128000000.0</us-gaap:OperatingLossCarryforwards>
    <chrs:OperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_tLJFKpYaNUKKGQtoFUHYZA"
      id="Narr_pL1TizBE0k2Z88P9vzkZJA">2031</chrs:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_5guUqMGHzkGsdOQekHmiiQ"
      decimals="-5"
      id="Narr_mu6mIElbk0iyU3dlYZJvjg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">60600000</us-gaap:TaxCreditCarryforwardAmount>
    <chrs:TaxCreditCarryforwardExpirationYear
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_oW7u_hLkakKhdnoyoEmKmQ"
      id="Narr_Wh6gA_R2aE6wulg0nMFFvg">2031</chrs:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_-SnhX9CP50mp8ATn7g01-Q"
      decimals="-5"
      id="Narr_BUHK5oYICUeg8QaqI6V-Ww"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">26500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_JjP-OTbeLkWwlRMMczvl6g">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:29.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additions based on tax positions related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Additions (reductions) for tax positions of prior years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_ifWFvOP5ak6vkUp45bMRCg_3_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">16838000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_xAFYS0phtUSexu0Gqgx26Q_3_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">15495000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_1fNj37WUsE-jfLotYFsFPw"
      decimals="-3"
      id="Tc_Zo5evQokuUCyW_gYbRlYDw_3_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">13243000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_5EtNxaULm0GsquUOHPnYTQ_4_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">865000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_Oj4d1W2TZEq5ut9eeMUnfg_4_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1385000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_DZ6k5IIVlUiQO_9vdXP3ew_4_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">2038000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Tc_KHK4Rba-4UGAVSh0P49BMw_5_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">286000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Tc_1lzsyOrcokGrbLNDY_oK9w_5_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">42000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Tc_a159gxf5-EqPPkMckl1qGg_5_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">214000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-3"
      id="Tc_-MaQ7TnA706k9lGl4-Fugg_6_3"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17417000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-3"
      id="Tc_SST8j5-gyEaFVkDdr58TdQ_6_6"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">16838000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-3"
      id="Tc_8ijqT7n2BkuCjQOtpkSNhQ_6_9"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">15495000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_C_pHYeJUF0aav58kTOFx1g"
      decimals="-5"
      id="Narr_Ng5A4V6fjkeyPDbwly854g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022__3mKRueMU0Gyuy41tuoEhQ"
      decimals="-5"
      id="Narr_p2U6JNfIYkqto4CIeUGx2g"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">16800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_AimTCsqYQ0OgiRwsZv-OIA"
      decimals="-5"
      id="Narr_i2Xwb1ZZ702YYk34M_QiVQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">15500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="-3"
      id="Narr_lBfsTh00HU2nZsK3dSAFNQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="-3"
      id="Narr_p6omNC-hQ0SdJLuVaK2LEA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="-3"
      id="Narr_Lrk7RUEky0WsxApi6d4r9w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_FsA6c5y8X0eYE4b_MufqxQ">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;14.&lt;/b&gt;&lt;/span&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock options, including shares subject to ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,083,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,214,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,895,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,399,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,811,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2022 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,078,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,473,871&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,291,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,635,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,122,727&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_AvtcDUbIV0KgKGe7Gy7e9A">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding dilutive potential shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Stock options, including shares subject to ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,083,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,214,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,895,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,399,465&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,811,607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2022 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,078,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,473,871&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares issuable upon conversion of 2026 Convertible Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,942,152&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,291,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,635,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,122,727&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_CTwRAY9QGkWlaOjDUS3erA"
      decimals="INF"
      id="Tc_OXaG-GCGj0WUowgeQ6cpwQ_3_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">24083222</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_w5gYK5ZD10mxWUfBk3mCAQ"
      decimals="INF"
      id="Tc_7gIa2oM8IkeY4XYaEWMDKQ_3_4"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">22214875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_EmployeesAndNonemployeesStockOptionMember_yimB1PocVk6HJoJLxYsOcQ"
      decimals="INF"
      id="Tc_1WVu-N1Kn0-oCCP-D-oETg_3_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">19895097</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_AYPPQ8ihj0mbo87bSd2xhw"
      decimals="INF"
      id="Tc_S6M6Uoti502qHuH5ydIYgA_4_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2266387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_8C3aK0xQf0Go0f8lJiI49A"
      decimals="INF"
      id="Tc_GdSN-KhCPE-p0Qj7vXyraQ_4_4"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">2399465</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pQgsHAcxhEiHaH9C5c3xTg"
      decimals="INF"
      id="Tc_OLPHWOsoN0a8r_I2RCJ45g_4_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1811607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_lJUaials20Ozgd2f9R3-Cg"
      decimals="INF"
      id="Tc_PO_8879LaEa6rGVVyXJQIA_5_4"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">1078632</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorNotes8.2PercentDue2022Member_7tgQKK_EDUasryLtCO67SA"
      decimals="INF"
      id="Tc_N6ID3j71iE-ZsgMMa1hkfw_5_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">4473871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_trJKeZ-blEWFIlIsmGdHcg"
      decimals="INF"
      id="Tc_8H75QqxC50y6E_1I3Z0ymA_6_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_6-wHjlrUb0eK7XFKJFi0cA"
      decimals="INF"
      id="Tc_dbKFn_mj9UG11Q7vhGjGZg_6_4"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_chrs_ConvertibleNotesMember_us-gaap_DebtInstrumentAxis_chrs_ConvertibleSeniorSubordinatedNotesDue20261.5Member_nDHklqDsSkqnJXBtDs4Nbg"
      decimals="INF"
      id="Tc_biYQCSWD3ECIt47zE-zJeQ_6_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">11942152</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      decimals="INF"
      id="Tc_TQ8j6HmUPE-HtcweNqT3CQ_7_2"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">38291761</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_K5T9pZbPykiKyK8jRNuglQ"
      decimals="INF"
      id="Tc_JAj6suswrEW7yytMzetA0w_7_4"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">37635124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_g8WMxVfNpEWqdDOlkyJgcg"
      decimals="INF"
      id="Tc_VAbMw8f270Ssws2EWPr8Bg_7_6"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">38122727</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_o5sZw9LnFUCwqHkU0yYPDA">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;"&gt;15. &lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-top:0pt;"&gt;Restructuring Charges&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;"&gt;On March 3, 2023, the Company committed to a plan to reduce its workforce to focus resources on strategic priorities including the commercialization of its diversified product portfolio and development of innovative immuno-oncology product candidates. The reduction in force impacted approximately&#160;50&#160;full-time and part-time employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduction in force consisted of $3.9&#160;million in cash expenses related to personnel expenses such as salaries, severance payments and other benefits; and $1.5&#160;million in non-cash stock-based compensation related to acceleration of vesting and extension of the stock option exercise windows for&#160;two&#160;impacted executives; partially offset by $0.5&#160;million in non-cash stock-based compensation forfeiture credits. The reduction in force was completed during the second quarter of 2023.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2023, the consolidated statements of operations include $3.6&#160;million in research and development expense and $1.3&#160;million in selling, general and administrative expense related to the reduction in force.&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_3_10_2023_To_3_10_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_4wHJPeiz5EGGZlHVcqOJhg"
      decimals="INF"
      id="Narr_iOK9taw--0acpsqF4af0iw"
      unitRef="Unit_Standard_employee_AAmVcdTDXkmNakyN2ltl5g">50</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q"
      decimals="-5"
      id="Narr_Ylq06wNdZ0yAKyy1iHQz6w"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3900000</us-gaap:RestructuringCharges>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q"
      decimals="-5"
      id="Narr_Pl9JNJGqjkaVhMZXc4qKsA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <chrs:ShareBasedPaymentArrangementForfeitureCredit
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ZFanv3Bd4k2U6RxxuKVX0Q"
      decimals="-5"
      id="Narr_Iz2BYWIFpkejYvPCtmdWAA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">500000</chrs:ShareBasedPaymentArrangementForfeitureCredit>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_PdGnVstbm0yndk6laylDZQ"
      decimals="-5"
      id="Narr_IOwSoNmFVk-wepxLDW20kw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">3600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_IQec6wbqNkyXTV-ONWSp-g"
      decimals="-5"
      id="Narr_pQJjQE0xRUWCU1Wj2i4vUw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">1300000</us-gaap:RestructuringCharges>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_bIJrSTjwD0yDlxAZ8k7CYw">&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"&gt;16.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"&gt;Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consulting services&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2020, the Company entered into a consulting agreement with Lanfear Advisors owned by Mr. Jonathan Lanfear who is the brother of Dennis Lanfear, the Company&#x2019;s President, Chief Executive Officer and Chairman of the Board of Directors. Mr. Jonathan Lanfear provided consulting services with respect to the Collaboration Agreement executed with Junshi Biosciences in February 2021 and the Letter Agreement with Junshi Biosciences related to the Collaboration Agreement dated January 9, 2022 (See Note 7. Collaborations and Other Arrangements). In addition to the hourly consulting fee paid to Lanfear Advisors under the consulting agreement, the Company granted fully vested stock options to purchase&#160;65,000&#160;shares of common stock with an exercise price of $17.60&#160;per share to Mr. Jonathan Lanfear in February 2021 upon the execution of the Collaboration Agreement with Junshi Biosciences and recognized stock-based compensation expense of $0.8&#160;million. The Company recorded cash consulting expense of $0.2&#160;million in 2021 with respect to these consulting services. There have been no subsequent material related party expenses. Total liabilities recognized in the consolidated balance sheets with respect to these services were immaterial as of December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw"
      decimals="INF"
      id="Narr_SA1gdaF6PECwIgEbjQI-6w"
      unitRef="Unit_Standard_shares_xBjHzXrbxUewdjJe6cQAQQ">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_2pnDfpchO0uOLhjBbI12Rw"
      decimals="INF"
      id="Narr_r9LiXWQv1EK3aYnX5Af0uA"
      unitRef="Unit_Divide_USD_shares_e2Qs4r8vuEaV_9U-fkwsHg">17.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_2_1_2021_To_2_28_2021_NvtDoX2JKU-V8xqMiC3p8w"
      decimals="-5"
      id="Narr_Y8c3X8RuFE-tQLaOx-ndSA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_chrs_ConsultingAgreementWithLanfearAdvisorsMember_PoW1P6R9s0CVYOhvmiJS7Q"
      decimals="-5"
      id="Narr_LrS8h5CYVEGDq22FjiyZXg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_Vp6bYDF3WUGYmB2ArdlsjA"
      id="Tb_XjP8QFWt00Ox8Jgx2Z9j8g">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"&gt;17.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"&gt;Subsequent Events &lt;b style="font-weight:bold;background:#ffff00;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CIMERLI Sale Transaction&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On January 19, 2024, the Company entered into the Purchase Agreement by and between the Company and Sandoz. Pursuant to the terms and subject to the conditions set forth in the Purchase Agreement, on March 1, 2024, the Company completed the Sale Transaction for its CIMERLI ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz for upfront, all-cash consideration of $170.0 million plus an additional $17.8 million for CIMERLI product inventory and prepaid manufacturing assets. Such consideration is subject to certain adjustments that will be finalized following the closing pursuant to the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Partial Release and Third Amendment to 2027 Term Loan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 5, 2024, the Company, entered into the Consent and Amendment with the Collateral Agent and the Lenders, pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the 2027 Term Loans and the other loan documents in connection therewith, and the parties thereto agreed to amend the Loan Agreement.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to and subject to terms and conditions in the Consent and Amendment, among other things: (1) the Lenders and the Collateral Agent provided consent to consummation of the transactions contemplated by the Purchase Agreement, and released certain subsidiary of the Company from its obligation and certain assets subject to the transactions contemplated thereby, (2) the Lenders and the Collateral Agent permitted the Company to make a partial prepayment of the principal of the loans outstanding under the 2027 Term Loans in the amount of $175.0 million upon consummation of the transactions contemplated by the Purchase Agreement, subject to certain conditions including a prepayment premium and makewhole amount calculated pursuant to the Consent and Amendment and (3) the parties thereto agreed to adjust the minimum net sales covenant level under the 2027 Term Loans. Upon the closing of the Sale Transaction the Company became liable to repay $175.0 million of the existing principal balance of $250.0 million of the loans outstanding under the Loan Agreement on April 1, 2024 and the Company plans to repay $175.0 million and the prepayment premium and makewhole amount of $6.8 million to the Lenders on or before April 1, 2024 pursuant to the Consent and Amendment.&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Other terms of the 2027 Term Loans, as amended by the Consent and Amendment, remain generally identical to those under the 2027 Term Loans. &lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA"
      decimals="-5"
      id="Narr_ZVXH1ir_FEuJiUoOIlZnWA"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">170000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <chrs:BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets
      contextRef="Duration_3_1_2024_To_3_1_2024_us-gaap_BusinessAcquisitionAxis_chrs_CoherusOphthalmologyLlcMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_chrs_CimerliDivestitureTransactionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eGxr2DI-LEKcEd9onjLQYA"
      decimals="-5"
      id="Narr_VGNqldpk40iN3RLts3Whdw"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">17800000</chrs:BusinessCombinationConsiderationTransferredInventoryAndPrepaidManufacturingAssets>
    <chrs:DebInstrumentPartialRepaymentPrincipal
      contextRef="Duration_2_5_2024_To_2_5_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_F3gEcw2SlkGZ3F3ZhhXOuw"
      decimals="-5"
      id="Narr_MjyL8pZqcU2Npg3quPlukQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">175000000.0</chrs:DebInstrumentPartialRepaymentPrincipal>
    <chrs:DebInstrumentPartialRepaymentPrincipal
      contextRef="Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A"
      decimals="-5"
      id="Narr_Kfpa4oRigki_z06H9APCag"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">175000000.0</chrs:DebInstrumentPartialRepaymentPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_H5jjpUn1Hkae89daAw6YHg"
      decimals="-5"
      id="Narr_c1w0B9CQGEaxb9VfUKPRkQ"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <chrs:DebInstrumentPartialRepaymentPrincipal
      contextRef="Duration_4_1_2024_To_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_VmJTrSd94kOJbeOXhIUV3A"
      decimals="-5"
      id="Narr_RMOdIHLRQk-U9QCOyIYrew"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">175000000.0</chrs:DebInstrumentPartialRepaymentPrincipal>
    <chrs:EarlyRedemptionFee
      contextRef="As_Of_4_1_2024_us-gaap_DebtInstrumentAxis_chrs_TermLoansMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_H5jjpUn1Hkae89daAw6YHg"
      decimals="-5"
      id="Narr_KiVGDO6dI0iMcFzhtsdzIg"
      unitRef="Unit_Standard_USD_UhCmJYvdsUuKonCOhr6wcQ">6800000</chrs:EarlyRedemptionFee>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
